PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Takeuchi, T; Adachi, Y; Sonobe, H; Furihata, M; Ohtsuki, Y				Takeuchi, T.; Adachi, Y.; Sonobe, H.; Furihata, M.; Ohtsuki, Y.			A ubiquitin ligase, skeletrophin, is a negative regulator of melanoma invasion	ONCOGENE			English	Article						melanoma; invasion; ubiquitin; skeletrophin; Notch	METHYLATION-SPECIFIC PCR; T-CADHERIN CDH13; MALIGNANT-MELANOMA; TUMOR PROGRESSION; DYSPLASTIC NEVUS; NOTCH LIGAND; H-CADHERIN; STEM-CELL; MIND BOMB; EXPRESSION	Skeletrophin (mindbomb homolog 2 (MIB2)) is a RING (Really Interesting New Gene) finger-dependent ubiquitin ligase, which targets the intracellular region of Notch ligands. A previous immunohistochemical study demonstrated that skeletrophin was downregulated in many melanomas. In the present study, we have identified a promoter region of skeletrophin on a CpG island and detected aberrant methylation of this region in six of 31 invasive melanomas, but in none of 25 benign nevi or five non-invasive superficial spreading melanomas. Subsequently, we found that a zinc-finger transcriptional factor Snail, which is overexpressed in many melanoma cells, repressed the skeletrophin promoter activity via an E-box-related element and was involved in downregulation of skeletrophin. An activator protein-2, which has a tumor suppressor-like role in melanoma, increased skeletrophin expression. Interestingly, exogenously expressed skeletrophin reduced melanoma cell invasion in vitro and in vivo. Colony formation in soft agar was also reduced in a RING motif-dependent manner, without affecting cell growth. We also found that skeletrophin downregulated transcription of the Met oncogene, which encodes the hepatocyte growth factor receptor and plays a role in the determination of the invasive phenotype of many malignant tumors. Finally, exogenously expressed skeletrophin, but not its RING mutant, increased transcription of Hes1 gene, a downstream effector of Notch pathway in melanoma cells. The present findings indicate that skeletrophin might be a novel suppressor factor for melanoma invasion.	Kochi Med Sch, Dept Pathol, Nankoku, Kochi 7838505, Japan; Natl Hosp Org, Fukuyama Med Ctr, Dept Lab Med & Pathol, Hiroshima, Japan	Kochi University	Takeuchi, T (corresponding author), Kochi Med Sch, Dept Pathol, Nankoku, Kochi 7838505, Japan.	takeutit@med.kochi-ms.ac.jp						BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; Balint K, 2005, J CLIN INVEST, V115, P3166, DOI 10.1172/JCI25001; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Fan X, 2002, ONCOL REP, V9, P181; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; Grichnik JM, 2006, J INVEST DERMATOL, V126, P142, DOI 10.1038/sj.jid.5700017; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hewett PW, 1998, BIOCHEM BIOPH RES CO, V252, P546, DOI 10.1006/bbrc.1998.9690; Hoek K, 2004, CANCER RES, V64, P5270, DOI 10.1158/0008-5472.CAN-04-0731; ISHIHARA T, IN PRESS VIRCHOW ARC; Itoh M, 2003, DEV CELL, V4, P67, DOI 10.1016/S1534-5807(02)00409-4; Jin YJ, 2002, J BIOL CHEM, V277, P46980, DOI 10.1074/jbc.M208585200; Koo BK, 2005, DEVELOPMENT, V132, P3459, DOI 10.1242/dev.01922; Koo BK, 2005, J BIOL CHEM, V280, P22335, DOI 10.1074/jbc.M501631200; LEONGKG, 2006, BLOOD, V107, P2223; MAUHIN V, 1993, NUCLEIC ACIDS RES, V21, P3951, DOI 10.1093/nar/21.17.3951; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758; Nijjar SS, 2002, AM J PATHOL, V160, P1695, DOI 10.1016/S0002-9440(10)61116-9; Parr C, 2004, INT J MOL MED, V14, P779; Pitsouli C, 2005, DEVELOPMENT, V132, P4041, DOI 10.1242/dev.01979; Poetsch M, 2003, MELANOMA RES, V13, P29, DOI 10.1097/00008390-200302000-00006; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Stella MC, 2005, MOL CELL BIOL, V25, P3982, DOI 10.1128/MCB.25.10.3982-3996.2005; Takeuchi T, 2005, AM J PATHOL, V166, P1817, DOI 10.1016/S0002-9440(10)62491-1; Takeuchi T, 2000, J NEUROCHEM, V74, P1489, DOI 10.1046/j.1471-4159.2000.0741489.x; Takeuchi T, 2003, AM J PATHOL, V163, P1395, DOI 10.1016/S0002-9440(10)63497-9; Takeuchi T, 2002, LAB INVEST, V82, P1023, DOI 10.1097/01.LAB.0000025391.35798.F1; Takeuchi T, 1997, J IMMUNOL, V159, P726; Tellez C, 2003, ONCOGENE, V22, P3130, DOI 10.1038/sj.onc.1206453; Wang WD, 2005, DEVELOPMENT, V132, P2883, DOI 10.1242/dev.01860; Zweidler-McKay PA, 2005, BLOOD, V106, P3898, DOI 10.1182/blood-2005-01-0355	35	29	31	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7059	7069		10.1038/sj.onc.1209688	http://dx.doi.org/10.1038/sj.onc.1209688			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16715130				2022-12-25	WOS:000241910500005
J	Westrop, GD; Goodall, G; Mottram, JC; Coombs, GH				Westrop, Gareth D.; Goodall, Gordon; Mottram, Jeremy C.; Coombs, Graham H.			Cysteine biosynthesis in Trichomonas vaginalis involves cysteine synthase utilizing O-phosphoserine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTERIC PROTOZOAN PARASITE; METHIONINE GAMMA-LYASE; ACETYLSERINE SULFHYDRYLASE; ENTAMOEBA-HISTOLYTICA; 3-DIMENSIONAL STRUCTURE; SALMONELLA-TYPHIMURIUM; MECHANISM; DEHYDROGENASE; THIOREDOXIN; CONTAINS	Trichomonas vaginalis is an early divergent eukaryote with many unusual biochemical features. It is an anaerobic protozoan parasite of humans that is thought to rely heavily on cysteine as a major redox buffer, because it lacks glutathione. We report here that for synthesis of cysteine from sulfide, T. vaginalis relies upon cysteine synthase. The enzyme (TvCS1) can use either O-acetylserine or O-phosphoserine as substrates. The Km values of the enzyme for sulfide are very low (0.02mM), suggesting that the enzyme may be a means of ensuring that sulfide in the parasite is maintained at a low level. T. vaginalis appears to lack serine acetyltransferase, the source of O-acetylserine in many cells, but has a functional 3-phosphoglycerate dehydrogenase and an O-phosphoserine aminotransferase that together result in the production of O-phosphoserine, suggesting that this is the physiological substrate. TvCS1 can also use thiosulfate as substrate. Overall, TvCS1 has substrate specificities similar to those reported for cysteine synthases of Aeropyrum pernix and Escherichia coli, and this is reflected by sequence similarities around the active site. We suggest that these enzymes are classified together as type B cysteine synthases, and we hypothesize that the use of O-phosphoserine is a common characteristic of these cysteine synthases. The level of cysteine synthase in T. vaginalis is regulated according to need, such that parasites growing in an environment rich in cysteine have low activity, whereas exposure to propargylglycine results in elevated cysteine synthase activity. Humans lack cysteine synthase; therefore, this parasite enzyme could be an exploitable drug target.	Univ Glasgow, Div Infect & Immun, Inst Biomed & Life Sci, Glasgow Biomed Res Ctr, Glasgow G12 8TA, Lanark, Scotland; Univ Glasgow, Wellcome Ctr Mol Parasitol, Glasgow Biomed Res Ctr, Glasgow G12 8TA, Lanark, Scotland	University of Glasgow; University of Glasgow	Coombs, GH (corresponding author), Univ Glasgow, Div Infect & Immun, Inst Biomed & Life Sci, Glasgow Biomed Res Ctr, Glasgow G12 8TA, Lanark, Scotland.	g.coombs@bio.gla.ac.uk		Westrop, Gareth/0000-0002-8011-6219; Mottram, Jeremy/0000-0001-5574-3766	MRC [G9722968] Funding Source: UKRI; Medical Research Council [G9722968, G9722968(65078)] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Ali V, 2006, MOL BIOCHEM PARASIT, V145, P71, DOI 10.1016/j.molbiopara.2005.09.008; Ali V, 2004, EUR J BIOCHEM, V271, P2670, DOI 10.1111/j.1432-1033.2004.04195.x; Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; BERENDT U, 1995, EUR J BIOCHEM, V233, P347, DOI 10.1111/j.1432-1033.1995.347_1.x; Bonner ER, 2005, J BIOL CHEM, V280, P38803, DOI 10.1074/jbc.M505313200; Burkhard P, 1999, J MOL BIOL, V291, P941, DOI 10.1006/jmbi.1999.3002; Burkhard P, 1998, J MOL BIOL, V283, P121, DOI 10.1006/jmbi.1998.2037; Claus MT, 2005, BIOCHEMISTRY-US, V44, P8620, DOI 10.1021/bi050485+; Coombs GH, 2004, J BIOL CHEM, V279, P5249, DOI 10.1074/jbc.M304359200; Coombs GH, 2001, ANTIMICROB AGENTS CH, V45, P1743, DOI 10.1128/AAC.45.6.1743-1745.2001; Coombs Graham H., 1995, P33, DOI 10.1016/B978-012473345-9/50004-0; Dyall SD, 2004, NATURE, V431, P1103, DOI 10.1038/nature02990; Eliot AC, 2004, ANNU REV BIOCHEM, V73, P383, DOI 10.1146/annurev.biochem.73.011303.074021; ELLIS JE, 1994, MICROBIOL-SGM, V140, P2489, DOI 10.1099/13500872-140-9-2489; FELL DA, 1988, BIOCHEM J, V256, P97, DOI 10.1042/bj2560097; Flint DH, 1996, J BIOL CHEM, V271, P16053, DOI 10.1074/jbc.271.27.16053; GAITONDE MK, 1967, BIOCHEM J, V104, P627, DOI 10.1042/bj1040627; Grant GA, 1996, PROTEIN SCI, V5, P34; Horner DS, 2001, MOL BIOL EVOL, V18, P1970, DOI 10.1093/oxfordjournals.molbev.a003737; Hrdy I, 2004, NATURE, V432, P618, DOI 10.1038/nature03149; KASHIWAMATA S, 1970, BIOCHIM BIOPHYS ACTA, V212, P488, DOI 10.1016/0005-2744(70)90255-X; KNODLER LA, 1994, EXP PARASITOL, V79, P117, DOI 10.1006/expr.1994.1071; Kredich N.M., 1996, ESCHERICHIA COLI SAL, P514; KREDICH NM, 1975, J BIOL CHEM, V250, P7324; KREDICH NM, 1966, J BIOL CHEM, V241, P4955; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096; McKie AE, 1998, J BIOL CHEM, V273, P5549, DOI 10.1074/jbc.273.10.5549; Mino K, 2003, FEBS LETT, V551, P133, DOI 10.1016/S0014-5793(03)00913-X; Minotto L, 1998, EXP PARASITOL, V90, P175, DOI 10.1006/expr.1998.4319; Muller S, 2003, TRENDS PARASITOL, V19, P320, DOI 10.1016/S1471-4922(03)00141-7; NAKAMURA T, 1984, J BACTERIOL, V158, P1122, DOI 10.1128/JB.158.3.1122-1127.1984; Nozaki T, 1999, J BIOL CHEM, V274, P32445, DOI 10.1074/jbc.274.45.32445; Nozaki T, 1998, MOL BIOCHEM PARASIT, V97, P33, DOI 10.1016/S0166-6851(98)00129-7; Nozaki T, 1998, BBA-PROTEIN STRUCT M, V1429, P284, DOI 10.1016/S0167-4838(98)00245-3; Oda Y, 2005, J MOL BIOL, V351, P334, DOI 10.1016/j.jmb.2005.05.064; Petrin D, 1998, CLIN MICROBIOL REV, V11, P300, DOI 10.1128/CMR.11.2.300; Rabeh WM, 2005, BIOCHEMISTRY-US, V44, P5541, DOI 10.1021/bi047479i; Rabeh WM, 2004, J BIOL CHEM, V279, P26803, DOI 10.1074/jbc.R400001200; ROSENBLO.J, 1968, J BIOL CHEM, V243, P2099; SAITO K, 1993, FEBS LETT, V328, P111, DOI 10.1016/0014-5793(93)80976-2; Schumacher MA, 2003, CELL, V115, P413, DOI 10.1016/S0092-8674(03)00887-0; SILVERMAN RB, 1976, BIOCHEMISTRY-US, V15, P4718, DOI 10.1021/bi00666a028; Sorvillo F, 2001, EMERG INFECT DIS, V7, P927, DOI 10.3201/eid0706.010603; TAI CH, 1993, BIOCHEMISTRY-US, V32, P6433, DOI 10.1021/bi00076a017; THONG KW, 1987, PARASITOL RES, V73, P193, DOI 10.1007/BF00578503; Tokoro M, 2003, J BIOL CHEM, V278, P42717, DOI 10.1074/jbc.M212414200; Upcroft P, 2001, CLIN MICROBIOL REV, V14, P150, DOI 10.1128/CMR.14.1.150-164.2001; Vanacova S, 2005, P NATL ACAD SCI USA, V102, P4430, DOI 10.1073/pnas.0407500102; Williams BAP, 2003, ADV PARASIT, V54, P9, DOI 10.1016/S0065-308X(03)54001-5; Williams RAM, 2003, J BIOL CHEM, V278, P1480, DOI 10.1074/jbc.M209395200; World Health Organization, 2001, GLOB PREV INC SEL CU	52	54	60	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25062	25075		10.1074/jbc.M600688200	http://dx.doi.org/10.1074/jbc.M600688200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16735516	Green Accepted, hybrid			2022-12-25	WOS:000240031300008
J	Ahmad, A; Yadav, SP; Asthana, N; Mitra, K; Srivastava, SP; Ghosh, JK				Ahmad, Aqeel; Yadav, Sharada Prasad; Asthana, Neeta; Mitra, Kalyan; Srivastava, Swati Prakash; Ghosh, Jimut Kanti			Utilization of an amphipathic leucine zipper sequence to design antibacterial peptides with simultaneous modulation of toxic activity against human red blood cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDES; MAMMALIAN-CELLS; MOLECULAR-BASIS; ANTIBIOTICS; SELECTIVITY; MEMBRANES; PROTEINS; MOTIF; DIASTEREOMERS; CONFORMATION	The toxicity of naturally occurring or designed antimicrobial peptides is a major barrier for converting them into drugs. To synthesize antimicrobial peptides with reduced toxicity, several amphipathic peptides were designed based on the leucine zipper sequence. The first one was a leucine zipper peptide (LZP); in others, leucine residues at the a- and/or d-position were substituted with single or double alanine residues. The results showed that LZP and its analogs exhibited appreciable and similar antibacterial activity against the tested Gram-positive and Gram-negative bacteria. However, the substitution of alanine progressively lowered the toxicity of LZP against human red blood cells (hRBCs). The substitution of leucine with alanine impaired the binding and localization of LZP to hRBCs, but had little effect on the peptide-induced damage of Escherichia coli cells. Although LZP and its analogs exhibited similar permeability, secondary structures, and localization in negatively charged membranes, significant differences were observed among these peptides in zwitterionic membranes. The results suggest a novel approach for designing antibacterial peptides with modulation of toxicity against hRBCs by employing the leucine zipper sequence. Also, to the best of our knowledge, the results demonstrate that this sequence could be utilized to design novel cell-selective molecules for the first time.	Cent Drug Res Inst, Mol & Struct Biol Div, Lucknow 226001, Uttar Pradesh, India; Cent Drug Res Inst, Electron Microscopy Unit, Lucknow 226001, Uttar Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI)	Ghosh, JK (corresponding author), Cent Drug Res Inst, Mol & Struct Biol Div, Chattar Manzil Palace,Mahatma Gandhi Marg, Lucknow 226001, Uttar Pradesh, India.	jighosh@yahoo.com		Ahmad, Aqeel/0000-0002-6003-9404				ALLEN TM, 1980, BIOCHIM BIOPHYS ACTA, V597, P418, DOI 10.1016/0005-2736(80)90118-2; Asthana N, 2004, J BIOL CHEM, V279, P55042, DOI 10.1074/jbc.M408881200; BARTLETT GR, 1959, J BIOL CHEM, V234, P468; BESSALLE R, 1993, J MED CHEM, V36, P1203, DOI 10.1021/jm00061a011; Blazyk J, 2001, J BIOL CHEM, V276, P27899, DOI 10.1074/jbc.M102865200; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Chen YX, 2005, J BIOL CHEM, V280, P12316, DOI 10.1074/jbc.M413406200; Ghosh JK, 1997, J BIOL CHEM, V272, P31609, DOI 10.1074/jbc.272.50.31609; Ghosh JK, 1998, J BIOL CHEM, V273, P7252, DOI 10.1074/jbc.273.13.7252; Ghosh JK, 1997, BIOCHEMISTRY-US, V36, P15451, DOI 10.1021/bi971152i; Glukhov E, 2005, J BIOL CHEM, V280, P33960, DOI 10.1074/jbc.M507042200; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; Hilpert K, 2005, NAT BIOTECHNOL, V23, P1008, DOI 10.1038/nbt1113; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; Javadpour MM, 1996, J MED CHEM, V39, P3107, DOI 10.1021/jm9509410; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; LEIPPE M, 1994, P NATL ACAD SCI USA, V91, P2602, DOI 10.1073/pnas.91.7.2602; LOEW LM, 1983, BIOCHEMISTRY-US, V22, P837, DOI 10.1021/bi00273a020; Oren Z, 1999, BIOCHEM J, V341, P501, DOI 10.1042/0264-6021:3410501; Oren Z, 1997, BIOCHEMISTRY-US, V36, P1826, DOI 10.1021/bi962507l; Papo N, 2003, J BIOL CHEM, V278, P21018, DOI 10.1074/jbc.M211204200; PEREZPAYA E, 1995, J BIOL CHEM, V270, P1048, DOI 10.1074/jbc.270.3.1048; Porter EA, 2000, NATURE, V404, P565, DOI 10.1038/35007145; Sal-Man N, 2002, BIOCHEMISTRY-US, V41, P11921, DOI 10.1021/bi0260482; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; Shai Y, 1996, J BIOL CHEM, V271, P7305, DOI 10.1074/jbc.271.13.7305; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; Stanger HE, 1998, J AM CHEM SOC, V120, P4236, DOI 10.1021/ja973704q; VICTOR N, 2001, NATURE, V414, P454; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019; Yadav SP, 2003, J BIOL CHEM, V278, P51023, DOI 10.1074/jbc.M310052200; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	34	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22029	22038		10.1074/jbc.M602378200	http://dx.doi.org/10.1074/jbc.M602378200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16717087	hybrid			2022-12-25	WOS:000239387100050
J	Dolcet, X; Llobet, D; Encinas, M; Pallares, J; Cabero, A; Schoenenberger, JA; Comella, JX; Matias-Guiu, X				Dolcet, Xavier; Llobet, David; Encinas, Mario; Pallares, Judit; Cabero, Albert; Schoenenberger, Joan Antoni; Comella, Joan X.; Matias-Guiu, Xavier			Proteasome inhibitors induce death but activate NF-kappa B on endometrial carcinoma cell lines and primary culture explants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-CANCER CELLS; MULTIPLE-MYELOMA CELLS; APOPTOSIS-INDUCTION; MEDIATED APOPTOSIS; DRUG-RESISTANCE; BINDING PROTEIN; IKK-BETA; IN-VIVO; PS-341; PHOSPHORYLATION	Proteasome inhibitors are currently used as chemotherapeutic drugs because of their ability to block NF-kappa B, a transcription factor constitutively activated in many different types of human cancer. In the present study, we demonstrate that proteasome inhibitors induce cell death in endometrial carcinoma cell lines and primary explants but, instead of blocking NF-kappa B, they increase its transcriptional activity. Proteasome inhibitors induce phosphorylation of IKK alpha/beta, phosphorylation and degradation of I kappa B alpha, and phosphorylation of the p65 NF-kappa B subunit on serine 536. Proteasome inhibitor-induced NF-kappa B activity can be blocked by a non-degradable form of I kappa B alpha or dominant negative forms of either IKK alpha or IKK beta. Lentiviral delivery of shRNAs to either IKK alpha or IKK beta cause blockade of NF-kappa B transcriptional activity and inhibit phosphorylation of p65 on serine 536, but has no effect on I kappa Ba degradation. These results suggest a role for p65 phosphorylation in proteasome inhibitor-induced NF-kappa B activation. Accordingly, siRNA knockdown of p65 inhibits proteasome inhibitor-induced NF-kappa B transcriptional activity. Our results demonstrate that proteasome inhibitors, including bortezomib, induce cell death on endometrial carcinoma cells and primary explants. However, they activate NF-kappa B instead of blocking its transcriptional potential. Therefore, the concept that proteasome inhibitors are blockers of NF-kappa B activation should be carefully examined in particular cell types.	Hosp Univ Arnau De Vilanova, Dept Pathol & Mol Genet, Vilanova I La Geltru, Spain; Hosp Univ Arnau De Vilanova, Dept Gynecol, Vilanova I La Geltru, Spain; Hosp Univ Arnau De Vilanova, Dept Pharm, Vilanova I La Geltru, Spain; Univ Lleida, Univ Arnau de Vilanova, Lab Recerca Hosp,Cell Signalling & Apoptosis Grp, Dept Ciencias Med Basiques & Cirurgia, Lleida 25198, Spain	Universitat de Lleida	Dolcet, X (corresponding author), Hosp Univ Arnau De Vilanova, Dept Pathol & Mol Genet, Vilanova I La Geltru, Spain.	dolcet@cmb.udl.es	Schoenenberger-Arnaiz, Joan Antoni/B-5701-2009; Comella, Joan X/D-7333-2012; Llobet-Navas, David/B-5660-2009; Dolcet, Xavi/B-5665-2009; matias-guiu, xavier/C-3039-2009; Encinas, Mario/B-5600-2009; Comella, Joan/GQA-4279-2022; Llobet-Navas, David/AAT-4676-2021	Schoenenberger-Arnaiz, Joan Antoni/0000-0002-8563-8358; Comella, Joan X/0000-0002-6218-0786; Llobet-Navas, David/0000-0003-1443-7003; Dolcet, Xavi/0000-0003-1921-0449; matias-guiu, xavier/0000-0002-7201-6605; Encinas, Mario/0000-0003-3509-7431; 				Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Bottero V, 2001, CANCER RES, V61, P7785; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; Cusack JC, 2001, CANCER RES, V61, P3535; Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9; Farhana L, 2005, CANCER RES, V65, P4909, DOI 10.1158/0008-5472.CAN-04-4124; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; Frankel A, 2000, CLIN CANCER RES, V6, P3719; Fribley A, 2004, MOL CELL BIOL, V24, P9695, DOI 10.1128/MCB.24.22.9695-9704.2004; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Huang TT, 2000, J BIOL CHEM, V275, P9501, DOI 10.1074/jbc.275.13.9501; Huang TT, 2002, MOL CELL BIOL, V22, P5813, DOI 10.1128/MCB.22.16.5813-5825.2002; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Jiang X, 2003, J BIOL CHEM, V278, P919, DOI 10.1074/jbc.M208696200; Jin FS, 2005, CANCER RES, V65, P6354, DOI 10.1158/0008-5472.CAN-04-4061; Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; LeBlanc R, 2002, CANCER RES, V62, P4996; Ling YH, 2003, CLIN CANCER RES, V9, P1145; Mattioli I, 2004, J IMMUNOL, V172, P6336, DOI 10.4049/jimmunol.172.10.6336; Mitsiades N, 2003, BLOOD, V101, P2377, DOI 10.1182/blood-2002-06-1768; Nawrocki ST, 2005, CANCER RES, V65, P11510, DOI 10.1158/0008-5472.CAN-05-2394; Nawrocki ST, 2005, CANCER RES, V65, P11658, DOI 10.1158/0008-5472.CAN-05-2370; Nemeth ZH, 2004, MOL PHARMACOL, V65, P342, DOI 10.1124/mol.65.2.342; O'Mahony AM, 2004, J BIOL CHEM, V279, P18137, DOI 10.1074/jbc.M401397200; Orlowski RZ, 2002, J CLIN ONCOL, V20, P4420, DOI 10.1200/JCO.2002.01.133; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pallares J, 2004, J PATHOL, V204, P569, DOI 10.1002/path.1666; Perez-Galan P, 2006, BLOOD, V107, P257, DOI 10.1182/blood-2005-05-2091; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Tabata M, 2001, J BIOL CHEM, V276, P8029, DOI 10.1074/jbc.M009831200; Teicher BA, 1999, CLIN CANCER RES, V5, P2638; Tergaonkar V, 2003, MOL CELL BIOL, V23, P8070, DOI 10.1128/MCB.23.22.8070-8083.2003; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Yoshida T, 2005, CANCER RES, V65, P5662, DOI 10.1158/0008-5472.CAN-05-0693; Yu J, 2003, CANCER BIOL THER, V2, P694; Zhu HB, 2005, CANCER BIOL THER, V4, P781, DOI 10.4161/cbt.4.7.1897; Zhu HB, 2005, ONCOGENE, V24, P4993, DOI 10.1038/sj.onc.1208683	46	90	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22118	22130		10.1074/jbc.M601350200	http://dx.doi.org/10.1074/jbc.M601350200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16735506	hybrid			2022-12-25	WOS:000239387100059
J	Sato, Y; Miyake, K; Kaneoka, H; Iijima, S				Sato, Yoshitaka; Miyake, Katsuhide; Kaneoka, Hidenori; Iijima, Shinji			Sumoylation of CCAAT/enhancer-binding protein alpha and its functional roles in hepatocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C/EBP-ALPHA; SUMO-1 MODIFICATION; TRANSCRIPTIONAL ACTIVITY; CELL-PROLIFERATION; ADIPOCYTE DIFFERENTIATION; SWI/SNF COMPLEX; GROWTH ARREST; DNA-BINDING; C-MYC; REPRESSION	The sumoylation of CCAAT/ enhancer-binding proteins ( C/EBPs) by small ubiquitin-related modifier-1 ( SUMO-1) has been reported recently. In this study, we investigated the functional role of the sumoylation of C/EBP alpha in the differentiation of hepatocytes. The amount of sumoylated C/EBP alpha gradually decreased during the differentiation, which suggests that the sumoylation is important for the control of growth/differentiation especially in the fetal liver. To analyze the function of the sumoylation of C/EBP alpha in liver-specific gene expression, we studied its effects on the expression of the albumin gene. The C/EBP alpha-mediated transactivation of the albumin gene was reduced by sumoylation of C/EBP alpha in primary fetal hepatocytes. The enhancement of C/EBP alpha-mediated transactivation by BRG1, a core subunit of the SW1/SNF chromatin remodeling complex, was hampered by sumoylation in a luciferase reporter assay. In addition, we discovered that sumoylation of C/EBP alpha blocked its inhibitory effect on cell proliferation by leading to the disruption of a proliferation-inhibitory complex because of a failure of the sumoylated C/EBP alpha to interact with BRG1. BRG1 was recruited to the dihydrofolate reductase promoter in nonproliferating C33a cells but was not detected in proliferating cells where C/EBP alpha, BRG1, and SUMO-1 were overexpressed. This result suggests that BRG1 down-regulates the expression of the dihydrofolate reductase gene. These findings provide the insight that SUMO acts as a space regulator, which affects protein-protein interactions.	Nagoya Univ, Ecotopia Sci Inst, Nagoya, Aichi 4648603, Japan; Nagoya Univ, Dept Biotechnol, Grad Sch Engn, Nagoya, Aichi 4648603, Japan	Nagoya University; Nagoya University	Miyake, K (corresponding author), Nagoya Univ, Ecotopia Sci Inst, Nagoya, Aichi 4648603, Japan.	miyake@proc.nubio.nagoya-u.ac.jp	Sato, Yoshitaka/P-9728-2015	Sato, Yoshitaka/0000-0002-8541-6413; Miyake, Katsuhide/0000-0002-9925-6406				Azuma Y, 2005, EMBO J, V24, P2172, DOI 10.1038/sj.emboj.7600700; Boyer-Guittaut M, 2005, J BIOL CHEM, V280, P9937, DOI 10.1074/jbc.M414149200; Chupreta S, 2005, MOL CELL BIOL, V25, P4272, DOI 10.1128/MCB.25.10.4272-4282.2005; Coisy M, 2004, MOL CELL, V15, P43, DOI 10.1016/j.molcel.2004.06.022; Dahle O, 2003, EUR J BIOCHEM, V270, P1338, DOI 10.1046/j.1432-1033.2003.03504.x; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; Degerny C, 2005, J BIOL CHEM, V280, P24330, DOI 10.1074/jbc.M411250200; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 2005, MOL BIOL CELL, V16, P5115, DOI 10.1091/mbc.E05-06-0536; Dohda T, 2004, J BIOCHEM, V136, P313, DOI 10.1093/jb/mvh123; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gross M, 2004, ONCOGENE, V23, P3059, DOI 10.1038/sj.onc.1207443; GUERTIN M, 1988, MOL CELL BIOL, V8, P1398, DOI 10.1128/MCB.8.4.1398; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Hemelaar J, 2004, MOL CELL BIOL, V24, P84, DOI 10.1128/MCB.24.1.84-95.2004; HERBST RS, 1989, P NATL ACAD SCI USA, V86, P1553, DOI 10.1073/pnas.86.5.1553; Hirano Y, 2003, J BIOL CHEM, V278, P16809, DOI 10.1074/jbc.M212448200; Holmstrom S, 2003, P NATL ACAD SCI USA, V100, P15758, DOI 10.1073/pnas.2136933100; Iakova P, 2003, CELL, V113, P495, DOI 10.1016/S0092-8674(03)00318-0; Inayoshi Y, 2005, J BIOCHEM, V138, P457, DOI 10.1093/jb/mvi147; Inayoshi Y, 2006, J BIOCHEM, V139, P177, DOI 10.1093/jb/mvj015; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Johnson PF, 2005, J CELL SCI, V118, P2545, DOI 10.1242/jcs.02459; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; Kinoshita Y, 2004, J BIOL CHEM, V279, P35879, DOI 10.1074/jbc.M401640200; Le Drean Y, 2002, ENDOCRINOLOGY, V143, P3482, DOI 10.1210/en.2002-220135; Ledl A, 2005, ONCOGENE, V24, P3810, DOI 10.1038/sj.onc.1208539; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Machida Y, 2001, J BIOCHEM, V129, P43, DOI 10.1093/oxfordjournals.jbchem.a002834; Martens JA, 2003, CURR OPIN GENET DEV, V13, P136, DOI 10.1016/S0959-437X(03)00022-4; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Muller C, 2004, J BIOL CHEM, V279, P7353, DOI 10.1074/jbc.M312709200; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Pedersen TA, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; SCHWEIZERGROYER G, 1994, NUCLEIC ACIDS RES, V22, P1583, DOI 10.1093/nar/22.9.1583; Schwienhorst I, 2000, MOL GEN GENET, V263, P771, DOI 10.1007/s004380000254; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Subramanian L, 2003, J BIOL CHEM, V278, P9134, DOI 10.1074/jbc.M210440200; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; Toda Tosifusa, 1997, Japanese Journal of Electrophoresis, V41, P13; Uchimura Y, 2004, ANAL BIOCHEM, V331, P204, DOI 10.1016/j.ab.2004.04.034; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Wang GL, 2005, MOL CELL BIOL, V25, P1325, DOI 10.1128/MCB.25.4.1325-1338.2005; Wang GL, 2004, GENE DEV, V18, P912, DOI 10.1101/gad.1183304; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Wang L, 2004, MOL CELL, V14, P637, DOI 10.1016/j.molcel.2004.05.009; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7	58	27	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21629	21639		10.1074/jbc.M600852200	http://dx.doi.org/10.1074/jbc.M600852200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16735515	hybrid			2022-12-25	WOS:000239387100008
J	Kashino, Y; Inoue-Kashino, N; Roose, JL; Pakrasi, HB				Kashino, Yasuhiro; Inoue-Kashino, Natsuko; Roose, Johnna L.; Pakrasi, Himadri B.			Absence of the PsbQ protein results in destabilization of the PsbV protein and decreased oxygen evolution activity in cyanobacterial photosystem II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS SP PCC-6803; MANGANESE-STABILIZING PROTEIN; BOVINE HEART-MITOCHONDRIA; RED ALGAL PSII; SP. PCC 6803; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; THYLAKOID MEMBRANES; FUNCTIONAL-PROPERTIES; EXTRINSIC COMPONENTS	We have previously reported that cyanobacterial photosystem II ( PS II) contains a protein homologous to PsbQ, the extrinsic 17-kDa protein found in higher plant and green algal PS II ( Kashino, Y., Lauber, W. M., Carroll, J.A., Wang, Q., Whitmarsh, J., Satoh, K., and Pakrasi, H. B. ( 2002) Biochemistry 41, 8004 - 8012) and that it has regulatory role( s) on the water oxidation machinery ( Thornton, L. E., Ohkawa, H., Roose, J. L., Kashino, Y., Keren, N., and Pakrasi, H. B. ( 2004) Plant Cell 16, 2164 - 2175). In this work, the localization and the function of PsbQ were assessed using the cyanobacterium Synechocystis sp. PCC 6803. From the predicted sequence, cyanobacterial PsbQ is expected to be a lipoprotein on the luminal side of the thylakoid membrane. Indeed, experiments in this work show that upon Triton X-114 fractionation of thylakoid membranes, PsbQ partitioned in the hydrophobic phase, and trypsin digestion revealed that PsbQ was highly exposed to the luminal space of thylakoid membranes. Detailed functional assays were conducted on the psbQ deletion mutant ( Delta psbQ) to analyze its water oxidation machinery. PS II complexes purified from Delta psbQ mutant cells had impaired oxygen evolution activity and were remarkably sensitive toNH(2)OH, which indicates destabilization of the water oxidation machinery. Additionally, the cytochrome c(550) ( PsbV) protein partially dissociated from purified Delta psbQ PS II complexes, suggesting that PsbQ contributes to the stability of PsbV in cyanobacterial PS II. Therefore, we conclude that the major function of PsbQ is to stabilize the PsbV protein, thereby contributing to the protection of the catalytic Mn-4-Ca-1-Cl-x cluster of the water oxidation machinery.	Washington Univ, Dept Biol, St Louis, MO 63130 USA; Osaka Univ, Grad Sch Sci, Dept Biol, Toyonaka, Osaka 5600043, Japan	Washington University (WUSTL); Osaka University	Pakrasi, HB (corresponding author), Washington Univ, Dept Biol, Campus Box 1137, St Louis, MO 63130 USA.	pakrasi@wustl.edu						AKABORI K, 1984, FEBS LETT, V173, P36, DOI 10.1016/0014-5793(84)81012-1; ALLEN MM, 1968, J PHYCOL, V4, P1, DOI 10.1111/j.1529-8817.1968.tb04667.x; Balsera M, 2005, J MOL BIOL, V350, P1051, DOI 10.1016/j.jmb.2005.05.044; Biesiadka J, 2004, PHYS CHEM CHEM PHYS, V6, P4733, DOI 10.1039/b406989g; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOWES JM, 1980, BIOCHIM BIOPHYS ACTA, V590, P373, DOI 10.1016/0005-2728(80)90208-X; Bricker TM, 1998, BBA-BIOENERGETICS, V1409, P50, DOI 10.1016/S0005-2728(98)00148-0; BRICKER TM, 1982, FEBS LETT, V149, P197, DOI 10.1016/0014-5793(82)81100-9; Buchanan SK, 1996, BIOCHEM J, V318, P343, DOI 10.1042/bj3180343; BUKHOV NG, 1992, PLANTA, V187, P122, DOI 10.1007/BF00201633; BURNAP RL, 1991, BIOCHEMISTRY-US, V30, P440, DOI 10.1021/bi00216a020; BURNAP RL, 1992, BIOCHEMISTRY-US, V31, P7404, DOI 10.1021/bi00147a027; CAO J, 1990, BIOCHIM BIOPHYS ACTA, V1015, P180, DOI 10.1016/0005-2728(90)90018-Y; CONJEAUD H, 1979, BIOCHIM BIOPHYS ACTA, V546, P280, DOI 10.1016/0005-2728(79)90046-X; De Las Rivas J, 2004, TRENDS PLANT SCI, V9, P18, DOI 10.1016/j.tplants.2003.11.007; Dekker JP, 2005, BBA-BIOENERGETICS, V1706, P12, DOI 10.1016/j.bbabio.2004.09.009; Enami I, 2003, PLANT CELL PHYSIOL, V44, P820, DOI 10.1093/pcp/pcg106; Enami I, 2000, PLANT CELL PHYSIOL, V41, P1354, DOI 10.1093/pcp/pcd069; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; FINEL M, 1992, BIOCHEMISTRY-US, V31, P11425, DOI 10.1021/bi00161a022; Frazao C, 2001, J BIOL INORG CHEM, V6, P324, DOI 10.1007/s007750100208; GHANOTAKIS DF, 1984, BIOCHIM BIOPHYS ACTA, V767, P524, DOI 10.1016/0005-2728(84)90051-3; GHANOTAKIS DF, 1984, FEBS LETT, V167, P127, DOI 10.1016/0014-5793(84)80846-7; GHANOTAKIS DF, 1984, BIOCHIM BIOPHYS ACTA, V765, P388, DOI 10.1016/0005-2728(84)90180-4; GHANOTAKIS DF, 1984, FEBS LETT, V170, P169, DOI 10.1016/0014-5793(84)81393-9; HAUMANN M, 1994, FEBS LETT, V347, P45, DOI 10.1016/0014-5793(94)00495-1; Hong SK, 2001, BBA-BIOENERGETICS, V1504, P262, DOI 10.1016/S0005-2728(00)00255-3; Ifuku K, 2004, EMBO REP, V5, P362, DOI 10.1038/sj.embor.7400113; Inoue-Kashino N, 2005, BIOCHEMISTRY-US, V44, P12214, DOI 10.1021/bi047539k; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Kashino Y, 2003, J CHROMATOGR B, V797, P191, DOI 10.1016/S1570-0232(03)00428-8; Kashino Y, 2002, BIOCHEMISTRY-US, V41, P8004, DOI 10.1021/bi026012+; Kashino Y, 2001, ELECTROPHORESIS, V22, P1004, DOI 10.1002/1522-2683()22:6<1004::AID-ELPS1004>3.0.CO;2-Y; Loll B, 2005, NATURE, V438, P1040, DOI 10.1038/nature04224; Maeda SI, 1997, J BIOL CHEM, V272, P3036, DOI 10.1074/jbc.272.5.3036; MIYAO M, 1984, FEBS LETT, V168, P118, DOI 10.1016/0014-5793(84)80218-5; MIYAO M, 1985, FEBS LETT, V180, P303, DOI 10.1016/0014-5793(85)81091-7; MIYAO M, 1983, BIOCHIM BIOPHYS ACTA, V725, P87, DOI 10.1016/0005-2728(83)90227-X; Ohta H, 2003, EUR J BIOCHEM, V270, P4156, DOI 10.1046/j.1432-1033.2003.03810.x; Okun JG, 2000, BBA-BIOENERGETICS, V1459, P77, DOI 10.1016/S0005-2728(00)00115-8; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Seidler A, 1996, BBA-BIOENERGETICS, V1277, P35, DOI 10.1016/S0005-2728(96)00102-8; SHEN JR, 1995, J BIOL CHEM, V270, P6901, DOI 10.1074/jbc.270.12.6901; Shen JR, 1998, BIOCHEMISTRY-US, V37, P1551, DOI 10.1021/bi971676i; SHEN JR, 1992, FEBS LETT, V301, P145, DOI 10.1016/0014-5793(92)81235-E; SHEN JR, 1993, BIOCHEMISTRY-US, V32, P1825, DOI 10.1021/bi00058a017; Summerfield TC, 2005, BIOCHEMISTRY-US, V44, P805, DOI 10.1021/bi048394k; Thornton LE, 2004, PLANT CELL, V16, P2164, DOI 10.1105/tpc.104.023515; Yamasaki T, 2002, PLANT PHYSIOL, V128, P1087, DOI 10.1104/pp.010919; Zak E, 1999, EUR J BIOCHEM, V261, P311, DOI 10.1046/j.1432-1327.1999.00281.x; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	51	38	38	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20834	20841		10.1074/jbc.M603188200	http://dx.doi.org/10.1074/jbc.M603188200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16723351	hybrid, Green Published			2022-12-25	WOS:000239187300020
J	Kenessey, A; Ojamaa, K				Kenessey, Agnes; Ojamaa, Kaie			Thyroid hormone stimulates protein synthesis in the cardiomyocyte by activating the Akt-mTOR and p70(S6K) pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEFT-VENTRICULAR FUNCTION; IN-VITRO; NUCLEAR; RECEPTOR; HYPERTROPHY; SURVIVAL; HYPERTHYROIDISM; MECHANISMS; EXPRESSION; INDUCTION	Thyroid hormones affect cardiac growth and phenotype; however, the mechanisms by which the hormones induce cardiomyocyte hypertrophy remain uncharacterized. Tri-iodo-L-thyronine ( T3) treatment of cultured cardiomyocytes for 24 h resulted in a 41 +/- 5% ( p < 0.001) increase in [ H-3] leucine incorporation into total cellular protein. This response was abrogated by the phosphatidylinositol 3-kinase ( PI3K) inhibitor, wortmannin. Co-immunoprecipitation studies showed a direct interaction of cytosol-localized thyroid hormone receptor TR alpha 1 and the p85 alpha subunit of PI3K. T3 treatment rapidly increased PI3K activity by 52 +/- 3% ( p < 0.005), which resulted in increased phosphorylation of downstream kinases Akt and mammalian target of rapamycin ( mTOR). This effect was abrogated by pretreatment with wortmannin or LY294002. Phosphorylation of p70(S6K), a known target of mTOR, occurred rapidly following T3 treatment and was inhibited by rapamycin and wortmannin. In contrast, phosphorylation of the p85 variant of S6K in response to T3 was not blocked by LY294002, wortmannin, or rapamycin, thus supporting a T3-activated pathway independent of PI3K and mTOR. 40 S ribosomal protein S6, a target of p70(S6K), and 4E-BP1, a target of mTOR, were both phosphorylated within 15 - 25 min of T3 treatment and could be inhibited by wortmannin and rapamycin. Thus, rapid T3-mediated activation of PI3K by cytosolic TR alpha 1 and subsequent activation of the Akt-mTOR-S6K signaling pathway may underlie one of the mechanisms by which thyroid hormone regulates physiological cardiac growth.	N Shore Long Isl Jewish Hlth Syst, Feinstein Inst Med Res, Manhasset, NY 11030 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA	Northwell Health; New York University; New York University	Ojamaa, K (corresponding author), N Shore Long Isl Jewish Hlth Syst, Feinstein Inst Med Res, 350 Community Dr, Manhasset, NY 11030 USA.	kojamaa@nshs.edu			NHLBI NIH HHS [HL-071623] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071623] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bassett JHD, 2003, MOL CELL ENDOCRINOL, V213, P1, DOI 10.1016/j.mce.2003.10.033; Belke DD, 2002, J CLIN INVEST, V109, P629, DOI 10.1172/JCI200213946; Cao X, 2005, MOL ENDOCRINOL, V19, P102, DOI 10.1210/me.2004-0093; Chang KC, 1997, J CLIN INVEST, V100, P1742, DOI 10.1172/JCI119699; Chowdhury D, 2001, J THORAC CARDIOV SUR, V122, P1023, DOI 10.1067/mtc.2001.116192; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; CRIE JS, 1983, AM J PHYSIOL, V245, pC328, DOI 10.1152/ajpcell.1983.245.5.C328; Davis JM, 2005, EUR PSYCHIAT, V20, P7, DOI 10.1016/j.eurpsy.2004.11.002; Davis PJ, 2002, THYROID, V12, P459, DOI 10.1089/105072502760143827; Dillmann WH, 2002, THYROID, V12, P447, DOI 10.1089/105072502760143809; Farach-Carson MC, 2003, J PHARMACOL EXP THER, V307, P839, DOI 10.1124/jpet.103.055038; FELDMAN T, 1986, J AM COLL CARDIOL, V7, P967, DOI 10.1016/S0735-1097(86)80213-3; FORFAR JC, 1982, NEW ENGL J MED, V307, P1165, DOI 10.1056/NEJM198211043071901; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kato T, 2005, J CLIN INVEST, V115, P2716, DOI 10.1172/JCI24280; Kenessey A, 2006, AM J PHYSIOL-HEART C, V290, pH381, DOI 10.1152/ajpheart.00576.2005; Kenessey A, 2005, AM J PHYSIOL-HEART C, V288, pH813, DOI 10.1152/ajpheart.00804.2004; Khalife WI, 2005, AM J PHYSIOL-HEART C, V289, pH2409, DOI 10.1152/ajpheart.00483.2005; Kinugawa K, 2005, MOL ENDOCRINOL, V19, P1618, DOI 10.1210/me.2004-0503; Klein I, 2001, NEW ENGL J MED, V344, P501, DOI 10.1056/NEJM200102153440707; KLEMPERER JD, 1995, J THORAC CARDIOV SUR, V109, P457, DOI 10.1016/S0022-5223(95)70276-8; KLEMPERER JD, 1995, NEW ENGL J MED, V333, P1522, DOI 10.1056/NEJM199512073332302; Kuzman JA, 2005, J MOL CELL CARDIOL, V39, P251, DOI 10.1016/j.yjmcc.2005.03.020; LADENSON PW, 1992, P NATL ACAD SCI USA, V89, P5251, DOI 10.1073/pnas.89.12.5251; McMullen JR, 2004, J BIOL CHEM, V279, P4782, DOI 10.1074/jbc.M310405200; McMullen JR, 2003, P NATL ACAD SCI USA, V100, P12355, DOI 10.1073/pnas.1934654100; Moruzzi P, 1996, AM J MED, V101, P461, DOI 10.1016/S0002-9343(96)00281-1; Ojamaa K, 2000, AM J PHYSIOL-ENDOC M, V279, pE1319, DOI 10.1152/ajpendo.2000.279.6.E1319; Okumura H, 2004, CIRCULATION, V109, P242, DOI 10.1161/01.CIR.0000109214.30211.7C; Pedram A, 2005, J BIOL CHEM, V280, P26339, DOI 10.1074/jbc.M414409200; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Richardson CJ, 2004, SEMIN CELL DEV BIOL, V15, P147, DOI 10.1016/j.semcdb.2003.12.023; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Shiraishi I, 2004, CIRC RES, V94, P884, DOI 10.1161/01.RES.0000124394.01180.BE; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Tanaka N, 1998, AM J PHYSIOL-HEART C, V275, pH393, DOI 10.1152/ajpheart.1998.275.2.H393; Tee AR, 2005, SEMIN CELL DEV BIOL, V16, P29, DOI 10.1016/j.semcdb.2004.11.005; Wang YG, 2003, J PHYSIOL-LONDON, V546, P491, DOI 10.1113/jphysiol.2002.032847	40	160	167	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20666	20672		10.1074/jbc.M512671200	http://dx.doi.org/10.1074/jbc.M512671200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16717100	hybrid			2022-12-25	WOS:000239187300003
J	Moisan, A; Gaudreau, L				Moisan, Annie; Gaudreau, Luc			The BRCA1 COOH-terminal region acts as an RNA polymerase II carboxyl-terminal domain kinase inhibitor that modulates p21(WAF1/CIP1) expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TEFB; GENE-TRANSCRIPTION; DNA-DAMAGE; CELL-CYCLE; HELA-CELL; PHOSPHORYLATION; PROTEIN; 7SK; P53; ELONGATION	BRCA1 is involved both in positive and negative regulation of gene activity as well as in numerous other processes, such as DNA damage response and repair. We recently reported that BRCA1 inhibits RNA polymerase II carboxyl-terminal domain (CTD) phosphorylation by TFIIH and decreases serine 5 phosphorylation levels when introduced into a BRCA1(-/-) cell line. Regulation of CTD phosphorylation is crucial for proper gene expression and response to cellular stresses, such as DNA damage and transcription arrest. A key player in this process, P-TEFb, phosphorylates the CTD on serine 2 of transcriptionally engaged RNA polymerase II, and its kinase activity was shown to be up-regulated when cells are exposed to transcriptional stress such as UV irradiation. Here, we investigate the effect of BRCA1 on serine 2 phosphorylation and UV-activated P-TEFb kinase activity. We now show that BRCA1 inhibits immunoprecipitated P-TEFb kinase activity from UV-irradiated cells and preferentially decreases UV-induced serine 2 phosphorylation of soluble, rather than chromatin-bound, RNAPII. We further show that BRCA1 rescues the UV-mediated inhibition of transcriptional activity from nuclear extracts and stimulates endogenous p21 gene expression upon UV irradiation, a function that is dependent of the inhibition of CTD kinase activity. Our results suggest that BRCA1 could act as a CTD kinase inhibitor and, as such, contribute to the regulation of p21 gene expression.	Univ Sherbrooke, Fac Sci, Dept Biol, Sherbrooke, PQ J1K 2R1, Canada	University of Sherbrooke	Gaudreau, L (corresponding author), Univ Sherbrooke, Fac Sci, Dept Biol, Sherbrooke, PQ J1K 2R1, Canada.	Luc.Gaudreau@USherbrooke.ca		Moisan, Annie/0000-0002-4944-4548				Aiyar SE, 2004, GENE DEV, V18, P2134, DOI 10.1101/gad.1214104; AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200; Berthiaume M, 2006, DNA CELL BIOL, V25, P124, DOI 10.1089/dna.2006.25.124; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Byers SA, 2005, J BIOL CHEM, V280, P16360, DOI 10.1074/jbc.M500424200; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chiba N, 2001, J BIOL CHEM, V276, P38549, DOI 10.1074/jbc.M105227200; Dahmus ME, 1996, METHOD ENZYMOL, V273, P185; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Gomes NP, 2006, GENE DEV, V20, P601, DOI 10.1101/gad.1398206; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953; Inukai N, 2004, J BIOL CHEM, V279, P8190, DOI 10.1074/jbc.M311412200; Jhanwar-Uniyal M, 2003, FRONT BIOSCI-LANDMRK, V8, pS1107, DOI 10.2741/1131; Kamenski T, 2004, MOL CELL, V15, P399, DOI 10.1016/j.molcel.2004.06.035; Kimura H, 1999, MOL CELL BIOL, V19, P5383; Kleiman FE, 2005, GENE DEV, V19, P1227, DOI 10.1101/gad.1309505; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Krum SA, 2003, J BIOL CHEM, V278, P52012, DOI 10.1074/jbc.M308418200; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; Li HC, 2002, J BIOL CHEM, V277, P20965, DOI 10.1074/jbc.M112231200; Lin PS, 2003, CHEM REC, V3, P235, DOI 10.1002/tcr.10063; Ljungman M, 2001, ONCOGENE, V20, P5964, DOI 10.1038/sj.onc.1204734; Majello B, 1999, ONCOGENE, V18, P4598, DOI 10.1038/sj.onc.1202822; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Moisan A, 2004, MOL CELL BIOL, V24, P6947, DOI 10.1128/MCB.24.16.6947-6956.2004; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Nadeau G, 2000, EMBO REP, V1, P260, DOI 10.1093/embo-reports/kvd059; Narita T, 2003, MOL CELL BIOL, V23, P1863, DOI 10.1128/MCB.23.6.1863-1873.2003; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Oelgeschlager T, 2002, J CELL PHYSIOL, V190, P160, DOI 10.1002/JCP.10058; Rockx DAP, 2000, P NATL ACAD SCI USA, V97, P10503, DOI 10.1073/pnas.180169797; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; STARITA LM, 2005, J BIOL CHEM; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; Whitmarsh AJ, 2001, METHOD ENZYMOL, V332, P319; Williamson EA, 2002, ONCOGENE, V21, P3199, DOI 10.1038/sj.onc.1205461; Wu YB, 1996, EMBO J, V15, P3951, DOI 10.1002/j.1460-2075.1996.tb00769.x; Xiong JB, 2003, MOL CELL BIOL, V23, P8668, DOI 10.1128/MCB.23.23.8668-8690.2003; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Yik JHN, 2003, MOL CELL, V12, P971, DOI 10.1016/S1097-2765(03)00388-5; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298	52	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21119	21130		10.1074/jbc.M600712200	http://dx.doi.org/10.1074/jbc.M600712200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16735508	hybrid			2022-12-25	WOS:000239187300048
J	Pullar, CE; Rizzo, A; Isseroff, RR				Pullar, Christine E.; Rizzo, Amilcar; Isseroff, R. Rivkah			beta-Adrenergic receptor antagonists accelerate skin wound healing - Evidence for a catecholamine synthesis network in the epidermis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PHEOCHROMOCYTOMA CELLS; CORNEAL EPITHELIAL-CELLS; ELECTRIC-FIELDS; HUMAN KERATINOCYTES; DIRECTED MIGRATION; CYCLIC-AMP; FOCAL ADHESIONS; PROTEIN-KINASE; LEG ULCERS; ACTIVATION	The skin is our primary defense against noxious environmental agents. Upon injury, keratinocytes migrate directionally into the wound bed to initiate re-epithelialization, essential for wound repair and restoration of barrier integrity. Keratinocytes express a high level of beta 2-adrenergic receptors (beta 2-ARs) that appear to play a role in cutaneous homeostasis as aberrations in either keratinocyte beta 2-AR function or density are associated with various skin diseases. Here we report the novel finding that beta-AR antagonists promote wound re-epithelialization in a "chronic" human skin wound-healing model. beta-AR antagonists increase ERK phosphorylation, the rate of keratinocyte migration, electric field-directed migration, and ultimately accelerate human skin wound re-epithelialization. We demonstrate that keratinocytes express two key enzymes required for catecholamine (beta-AR agonist) synthesis, tyrosine hydroxylase and phenylethanolamine-N-methyl transferase, both localized within keratinocyte cytoplasmic vesicles. Finally, we confirm the synthesis of epinephrine by measuring the endogenously synthesized catecholamine in keratinocyte extracts. Previously, we have demonstrated that beta-AR agonists delay wound re-epithelialization. Here we report that the mechanism for the beta-AR antagonist-mediated augmentation of wound repair is due to beta 2-AR blockade, preventing the binding of endogenously synthesized epinephrine. Our work describes an endogenous beta-AR mediator network in the skin that can temporally regulate skin wound repair. Further investigation of this network will improve our understanding of both the skin repair process and the multiple modes of action of one of the most frequently prescribed class of drugs, hopefully resulting in a new treatment for chronic wounds.	Univ Calif Davis, Sch Med, Dept Dermatol, Davis, CA 95616 USA; N Calif Hlth Care Syst, Dept Vet Affairs, Dermatol Serv, Mather, CA 95655 USA	University of California System; University of California Davis	Pullar, CE (corresponding author), Univ Calif Davis, Sch Med, Dept Dermatol, TB 192,1 Shields Ave, Davis, CA 95616 USA.	cepullar@ucdavis.edu	Isseroff, Roslyn Rivkah/AAD-8478-2021	Isseroff, Roslyn Rivkah/0000-0001-7813-0858	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR048827, R01AR044518] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44518, AR48827] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahmed N, 2002, ONCOGENE, V21, P1370, DOI 10.1038/sj.onc.1205286; Altizer AM, 2002, J EXP ZOOL, V293, P467, DOI 10.1002/jez.10141; Arbabi S, 2004, J TRAUMA, V56, P265, DOI 10.1097/01.TA.0000109859.91202.C8; Ashcroft GS, 2003, J CLIN INVEST, V111, P1309, DOI 10.1172/KCO200316288; Beningo KA, 2001, J CELL BIOL, V153, P881, DOI 10.1083/jcb.153.4.881; BILSKI AJ, 1983, J CARDIOVASC PHARM, V5, P430, DOI 10.1097/00005344-198305000-00013; BORGENS RB, 1977, P NATL ACAD SCI USA, V74, P4528, DOI 10.1073/pnas.74.10.4528; BORGENS RB, 1984, J EXP ZOOL, V231, P249, DOI 10.1002/jez.1402310209; BURRIDGE K, 1989, BIOESSAYS, V10, P104, DOI 10.1002/bies.950100403; CHIANG MC, 1992, EXP EYE RES, V54, P999, DOI 10.1016/0014-4835(92)90164-N; Coleman A L, 2001, Minerva Med, V92, P365; Cupp Craig L, 2002, Facial Plast Surg, V18, P53, DOI 10.1055/s-2002-19827; Davidoff MS, 2005, HISTOCHEM CELL BIOL, V124, P313, DOI 10.1007/s00418-005-0024-x; Denda M, 2003, J INVEST DERMATOL, V121, P142, DOI 10.1046/j.1523-1747.2003.12310.x; DONALDSON DJ, 1984, COMP BIOCHEM PHYS C, V78, P267, DOI 10.1016/0742-8413(84)90081-1; EEDY DJ, 1990, BRIT J DERMATOL, V122, P477, DOI 10.1111/j.1365-2133.1990.tb14724.x; Feldman RM, 2004, EXPERT OPIN PHARMACO, V5, P909, DOI 10.1517/eoph.5.4.909.30179; Frank DE, 2004, J CELL SCI, V117, P1351, DOI 10.1242/jcs.01003; GABBIANI G, 1978, J CELL BIOL, V76, P561, DOI 10.1083/jcb.76.3.561; Gillbro JM, 2004, J INVEST DERMATOL, V123, P346, DOI 10.1111/j.0022-202X.2004.23210.x; Gilmore AP, 1996, STRUCTURE, V4, P647, DOI 10.1016/S0969-2126(96)00069-X; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; HAAS AF, 1990, J INVEST DERMATOL, V94, P822, DOI 10.1111/1523-1747.ep12874679; Haruta Y, 1997, Eur J Ophthalmol, V7, P334; ISSEROFF RR, 1987, J LIPID RES, V28, P1342; Kano Y, 2005, ENDOCRINOLOGY, V146, P5332, DOI 10.1210/en.2005-0474; Kantor J, 2003, SEMIN CUTAN MED SURG, V22, P212, DOI 10.1016/S1085-5629(03)00043-9; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kratz G, 1998, MICROSC RES TECHNIQ, V42, P345, DOI 10.1002/(SICI)1097-0029(19980901)42:5<345::AID-JEMT5>3.0.CO;2-O; KUBLER MD, 1993, J INVEST DERMATOL, V100, P785, DOI 10.1111/1523-1747.ep12476492; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; Leng J, 1999, J BIOL CHEM, V274, P37855, DOI 10.1074/jbc.274.53.37855; LIU GS, 1990, J OCUL PHARMACOL, V6, P101, DOI 10.1089/jop.1990.6.101; Liu ZX, 2002, J BIOL CHEM, V277, P10452, DOI 10.1074/jbc.M107551200; Lu L, 2001, EXP BIOL MED, V226, P653, DOI 10.1177/153537020222600711; Margolis David J, 2004, Int J Low Extrem Wounds, V3, P4, DOI 10.1177/153473460431002; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Matsubayashi Y, 2004, CURR BIOL, V14, P731, DOI 10.1016/j.cub.2004.03.060; McCaig CD, 1997, BIOESSAYS, V19, P819, DOI 10.1002/bies.950190912; McCaig CD, 2005, PHYSIOL REV, V85, P943, DOI 10.1152/physrev.00020.2004; MCSWIGAN JD, 1981, P NATL ACAD SCI-BIOL, V78, P7670, DOI 10.1073/pnas.78.12.7670; Medeiros FA, 2002, DRUGS TODAY, V38, P563, DOI 10.1358/dot.2002.38.8.704676; *N SUB CARD GROUP, 2001, FACTS HYP; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; NAGATSU T, 1964, BIOCHEM BIOPH RES CO, V14, P543, DOI 10.1016/0006-291X(64)90266-9; Nanmoku T, 2005, J ENDOCRINOL, V186, P233, DOI 10.1677/joe.1.05919; Nishimura KY, 1996, J CELL SCI, V109, P199; Nuccitelli R, 2003, CURR TOP DEV BIOL, V58, P1, DOI 10.1016/S0070-2153(03)58001-2; Ojingwa JC, 2003, J INVEST DERMATOL, V121, P1, DOI 10.1046/j.1523-1747.2003.12454.x; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; PHILLIPS TJ, 1994, J INVEST DERMATOL S, V102, P38; Providence KM, 2004, J CELL PHYSIOL, V200, P297, DOI 10.1002/jcp.20016; Pullar CE, 2006, FASEB J, V20, P76, DOI 10.1096/fj.05-4188com; Pullar CE, 2005, J CELL SCI, V118, P2023, DOI 10.1242/jcs.02330; Pullar CE, 2001, CELL MOTIL CYTOSKEL, V50, P207, DOI 10.1002/cm.10009; Pullar CE, 1996, J IMMUNOL, V157, P1226; Pullar CE, 2003, J BIOL CHEM, V278, P22555, DOI 10.1074/jbc.M300205200; Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389; Reid B, 2005, FASEB J, V19, P379, DOI 10.1096/fj.04-2325com; REIDY JJ, 1994, BRIT J OPHTHALMOL, V78, P377, DOI 10.1136/bjo.78.5.377; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; ROBINSON KR, 1985, J CELL BIOL, V101, P2023, DOI 10.1083/jcb.101.6.2023; Ruckley CV, 1997, ANGIOLOGY, V48, P67, DOI 10.1177/000331979704800111; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; SCHALLREUTER KU, 1993, ARCH DERMATOL RES, V285, P216, DOI 10.1007/BF00372012; SCHALLREUTER KU, 1992, BIOCHEM BIOPH RES CO, V189, P72, DOI 10.1016/0006-291X(92)91527-W; SCHALLREUTER KU, 1995, J INVEST DERMATOL, V104, P953, DOI 10.1111/1523-1747.ep12606218; SCHALLREUTER KU, 1997, J INVEST DERMATOL S, V2, P37; Schulz C, 2004, FRONT HORM RES, V31, P1; Shanley LJ, 2004, INVEST OPHTH VIS SCI, V45, P1088, DOI 10.1167/iovs.03-1064; Sharif NA, 2001, J OCUL PHARMACOL TH, V17, P305, DOI 10.1089/108076801753162726; Sharma GD, 2003, J BIOL CHEM, V278, P21989, DOI 10.1074/jbc.M302650200; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Song B, 2002, P NATL ACAD SCI USA, V99, P13577, DOI 10.1073/pnas.202235299; Sta Iglesia Drina D., 1998, Wound Repair and Regeneration, V6, P531; STEINKRAUS V, 1992, J INVEST DERMATOL, V98, P475, DOI 10.1111/1523-1747.ep12499860; Steinkraus V, 1996, ARCH DERMATOL RES, V288, P549, DOI 10.1007/BF02505253; Stoll SW, 2002, J BIOL CHEM, V277, P26839, DOI 10.1074/jbc.M201108200; Tan AY, 2002, J GLAUCOMA, V11, P134, DOI 10.1097/00061198-200204000-00009; Tseraidis G S, 1972, Vestn Dermatol Venerol, V46, P40; Turchi L, 2002, J INVEST DERMATOL, V119, P56, DOI 10.1046/j.1523-1747.2002.01805.x; Wang ET, 2003, INVEST OPHTH VIS SCI, V44, P244, DOI 10.1167/iovs.02-0456; Wilson SE, 2001, PROG RETIN EYE RES, V20, P625, DOI 10.1016/S1350-9462(01)00008-8; Xu KP, 2004, INVEST OPHTH VIS SCI, V45, P4277, DOI 10.1167/iovs.04-0119; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271; Zhao M, 1996, J CELL SCI, V109, P1405; Zhao M, 1997, CURR EYE RES, V16, P973, DOI 10.1076/ceyr.16.10.973.9014; Zhao M, 1996, INVEST OPHTH VIS SCI, V37, P2548; ZIMMERMAN TJ, 1993, J OCUL PHARMACOL, V9, P373, DOI 10.1089/jop.1993.9.373	90	81	85	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21225	21235		10.1074/jbc.M601007200	http://dx.doi.org/10.1074/jbc.M601007200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16714291	hybrid			2022-12-25	WOS:000239187300058
J	Berghorn, KA; Clark-Campbell, PA; Han, L; McGrattan, M; Weiss, RS; Roberson, MS				Berghorn, Kathie A.; Clark-Campbell, Patricia A.; Han, Li; McGrattan, Michael; Weiss, Robert S.; Roberson, Mark S.			Smad6 represses Dlx3 transcriptional activity through inhibition of DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT GENE; TRICHODENTOOSSEOUS SYNDROME; HOMEODOMAIN PROTEINS; GROWTH-FACTOR; HOMEOBOX; MUTATION; CELLS; ACTIVATION; BETA; MICE	Dlx3 (Distal-less 3) is a homeobox-containing transcription factor required for normal placental development in mice. Here we demonstrate that Dlx3 interacts with Smad6, a member of a larger family of transcriptional regulators generally thought to regulate transforming growth factor beta/bone morphogenetic protein signaling. Immunocytochemical and immunoprecipitation studies demonstrate overlapping nuclear localization and physical interaction between Dlx3 and Smad6 in human choriocarcinoma cells and in differentiated trophoblasts from human placenta. In vitro protein interaction studies mapped the Smad6 interaction domain within Dlx3 to residues 80 - 163, a region of Dlx3 that includes a portion of the homeodomain. Dlx3 and Dlx4 share homology within this region, and Dlx4 was also found to bind Smad6. Using the Esx1 gene promoter as a model for a Dlx3-responsive gene, studies demonstrate two near consensus Dlx3 binding sites within the proximal 2.3 kb of the transcription start site. Interestingly, binding of Dlx3 to one of these two sites was inhibited by interaction with Smad6. Consistent with this result, expression of an Esx1 promoter luciferase reporter was increased by overexpression of Dlx3; this effect was reversed with co-expression of Smad6. Further, small interference RNA-mediated knockdown of endogenous Smad6 increased Dlx3-dependent expression of the Esx1 gene promoter. Thus, Smad6 appears to functionally interact with Dlx3, altering the ability of Dlx3 to bind target gene promoters. Smad6 appears to play a modulatory role in the regulation of Dlx3-dependent gene transcription within placental trophoblasts.	Cornell Univ, Dept Biomed Sci, Ithaca, NY 14853 USA	Cornell University	Roberson, MS (corresponding author), Cornell Univ, Dept Biomed Sci, T3-004d Vet Res Tower, Ithaca, NY 14853 USA.	msr14@cornell.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039354] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD 39354] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Acevedo Hernan F, 2002, J Exp Ther Oncol, V2, P133, DOI 10.1046/j.1359-4117.2002.01031.x; Bai ST, 2000, J BIOL CHEM, V275, P8267, DOI 10.1074/jbc.275.12.8267; Bai ST, 2002, J BIOL CHEM, V277, P4176, DOI 10.1074/jbc.M105105200; Bendall AJ, 2000, GENE, V247, P17, DOI 10.1016/S0378-1119(00)00081-0; Bryan JT, 2000, J CELL SCI, V113, P4013; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Chiba S, 2003, P NATL ACAD SCI USA, V100, P15577, DOI 10.1073/pnas.2536757100; Clouthier David E, 2004, Birth Defects Res C Embryo Today, V72, P190, DOI 10.1002/bdrc.20007; Clouthier DE, 2003, DEV BIOL, V261, P506, DOI 10.1016/S0012-1606(03)00128-3; Clouthier DE, 2000, DEV BIOL, V217, P10, DOI 10.1006/dbio.1999.9527; Dong J, 2005, AM J MED GENET A, V133A, P138, DOI 10.1002/ajmg.a.30521; Feledy JA, 1999, NUCLEIC ACIDS RES, V27, P764, DOI 10.1093/nar/27.3.764; Feledy JA, 1999, DEV BIOL, V212, P455, DOI 10.1006/dbio.1999.9374; France JT, 1996, AUST NZ J OBSTET GYN, V36, P325, DOI 10.1111/j.1479-828X.1996.tb02722.x; GEHRING WJ, 1993, GENE, V135, P215, DOI 10.1016/0378-1119(93)90068-E; Haldeman RJ, 2004, BONE, V35, P988, DOI 10.1016/j.bone.2004.06.003; Hassan MQ, 2004, MOL CELL BIOL, V24, P9248, DOI 10.1128/MCB.24.20.9248-9261.2004; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Holland MP, 2004, ENDOCRINOLOGY, V145, P1096, DOI 10.1210/en.2003-0777; Ivey K, 2003, DEV BIOL, V255, P230, DOI 10.1016/S0012-1606(02)00097-0; Juriloff DM, 2001, MAMM GENOME, V12, P426, DOI 10.1007/s003350010284; Keay SD, 2004, BJOG-INT J OBSTET GY, V111, P1218, DOI 10.1111/j.1471-0528.2004.00412.x; Li YH, 1997, DEV BIOL, V188, P85, DOI 10.1006/dbio.1997.8640; Lin X, 2003, MOL CELL BIOL, V23, P9081, DOI 10.1128/MCB.23.24.9081-9093.2003; Luo T, 2001, INT J DEV BIOL, V45, P681; MacLean JA, 2004, BIOL REPROD, V71, P455, DOI 10.1095/biolreprod.103.025908; Maclean JA, 2003, MOL REPROD DEV, V65, P30, DOI 10.1002/mrd.10262; Miyazono K, 2002, CYTOKINE GROWTH F R, V13, P7, DOI 10.1016/S1359-6101(01)00028-4; Morasso MI, 1999, P NATL ACAD SCI USA, V96, P162, DOI 10.1073/pnas.96.1.162; MORASSO MI, 1995, P NATL ACAD SCI USA, V92, P3968, DOI 10.1073/pnas.92.9.3968; Paria BC, 2001, P NATL ACAD SCI USA, V98, P1047, DOI 10.1073/pnas.98.3.1047; Park GT, 2002, NUCLEIC ACIDS RES, V30, P515, DOI 10.1093/nar/30.2.515; Park GT, 2001, FEBS LETT, V496, P60, DOI 10.1016/S0014-5793(01)02398-5; Price JA, 1998, J MED GENET, V35, P825, DOI 10.1136/jmg.35.10.825; Price JA, 1998, HUM MOL GENET, V7, P563, DOI 10.1093/hmg/7.3.563; Quinn LM, 1997, GENE, V187, P55, DOI 10.1016/S0378-1119(96)00706-8; Roberson MS, 2001, J BIOL CHEM, V276, P10016, DOI 10.1074/jbc.M007481200; Roberson MS, 2000, MOL CELL BIOL, V20, P3331, DOI 10.1128/MCB.20.10.3331-3344.2000; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; TEN DP, 2004, TRENDS BIOCHEM SCI, V29, P265; TEN DP, 2000, TRENDS BIOCHEM SCI, V25, P64; WRIGHT CVE, 1989, TRENDS BIOCHEM SCI, V14, P52, DOI 10.1016/0968-0004(89)90043-1	42	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20357	20367		10.1074/jbc.M603049200	http://dx.doi.org/10.1074/jbc.M603049200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16687405	hybrid			2022-12-25	WOS:000239038200060
J	Fu, XY; Beer, DG; Behar, J; Wands, J; Lambeth, D; Cao, WB				Fu, Xiaoying; Beer, David G.; Behar, Jose; Wands, Jack; Lambeth, David; Cao, Weibiao			cAMP-response element-binding protein mediates acid-induced NADPH oxidase NOX5-S expression in Barrett esophageal adenocarcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; REACTIVE OXYGEN; REFLUX ESOPHAGITIS; SOMATOSTATIN GENE; SUPEROXIDE; CANCER; PATHOGENESIS; PROGRESSION; ACTIVATION; MECHANISM	Gastroesophageal reflux disease complicated by Barrett esophagus (BE) is a major risk factor for esophageal adenocarcinoma(EA). The mechanisms whereby acid reflux may accelerate the progression from BE to EA are not known. We found that NOX1 and NOX5-S were the major isoforms of NADPH oxidase in SEG1-EA cells. The expression of NOX5-S mRNA was significantly higher in these cells than in esophageal squamous epithelial cells. NOX5 mRNA was also significantly higher in Barrett tissues with high grade dysplasia than without dysplasia. Pulsed acid treatment significantly increased H2O2 production in both SEG1-EA cells and BE mucosa, which was blocked by the NADPH oxidase inhibitor apocynin. In SEG1 cells, acid treatment increased mRNA expression of NOX5-S, but not NOX1, and knockdown of NOX5 by NOX5 small interfering RNA abolished acid- induced H2O2 production. In addition, acid treatment increased intracellular Ca2+ and phosphorylation of cAMP-response element-binding protein (CREB). Acid-induced NOX5-S expression and H2O2 production were significantly inhibited by removal of extracellular Ca2+ and by knockdown of CREB using CREB small interfering RNA. Two novel CREB-binding elements TGACGAGA and TGACGCTG were identified in the NOX5-S gene promoter. Overexpression of CREB significantly increased NOX5-S promoter activity. Knockdown of NOX5 significantly decreased [H-3] thymidine incorporation, which was restored by 10(-13) M H2O2. Knockdown of NOX5 also significantly decreased retinoblastoma protein phosphorylation and increased cell apoptosis and caspase-9 expression. In conclusion, in SEG1 EA cells NOX5-S is overexpressed and mediates acid-induced H2O2 production. Acid-induced NOX5-S expression depends on an increase in intracellular Ca2+ and activation of CREB. NOX5-S contributes to increased cell proliferation and decreased apoptosis.	Brown Med Sch, Dept Med, Providence, RI 02903 USA; Rhode Isl Hosp, Dept Med, Providence, RI 02903 USA; Univ Michigan, Sch Med, Sect Gen Thorac Surg, Dept Surg, Ann Arbor, MI 48109 USA; Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; University of Michigan System; University of Michigan; Emory University	Cao, WB (corresponding author), Brown Med Sch, Dept Med, 55 Claverick St,Rm 337, Providence, RI 02903 USA.	wcao@hotmail.com			NCRR NIH HHS [P20 RR17695] Funding Source: Medline; NIDDK NIH HHS [R21 DK073327-01, R21 DK073327] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK073327] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; Banfi B, 2001, J BIOL CHEM, V276, P37594, DOI 10.1074/jbc.M103034200; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; Blot WJ, 1999, SEMIN ONCOL, V26, P2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brar SS, 2003, AM J PHYSIOL-CELL PH, V285, pC353, DOI 10.1152/ajpcell.00525.2002; Cao W, 2001, AM J PHYSIOL-CELL PH, V280, pC980, DOI 10.1152/ajpcell.2001.280.4.C980; CAO W, 2003, AM J PHYSIOL, V285, pC86; Cao WB, 2004, AM J PHYSIOL-GASTR L, V286, pG833, DOI 10.1152/ajpgi.00414.2003; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; El-Serag HB, 2004, AM J GASTROENTEROL, V99, P1877, DOI 10.1111/j.1572-0241.2004.30228.x; Farhadi A, 2002, AM J GASTROENTEROL, V97, P22; Fitzgerald RC, 1996, J CLIN INVEST, V98, P2120, DOI 10.1172/JCI119018; Fitzgerald RC, 2002, GUT, V51, P316, DOI 10.1136/gut.51.3.316; Fountoulakis A, 2004, DIGEST DIS SCI, V49, P914, DOI 10.1023/B:DDAS.0000034548.89117.d6; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gurney AM, 2003, CIRC RES, V93, P957, DOI 10.1161/01.RES.0000099883.68414.61; HAGGITT RC, 1994, HUM PATHOL, V25, P982, DOI 10.1016/0046-8177(94)90057-4; Hamilton CA, 2002, HYPERTENSION, V40, P755, DOI 10.1161/01.HYP.0000037063.90643.0B; Hart B A, 1992, Biotechnol Ther, V3, P119; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Howe HL, 2001, J NATL CANCER I, V93, P824, DOI 10.1093/jnci/93.11.824; Hughes SJ, 1997, CANCER RES, V57, P5571; Kim R, 1997, CANCER EPIDEM BIOMAR, V6, P369; Lagergren J, 1999, NEW ENGL J MED, V340, P825, DOI 10.1056/NEJM199903183401101; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Liu YP, 2003, CIRC RES, V93, P573, DOI 10.1161/01.RES.0000091261.19387.AE; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; Muzaffar S, 2004, CIRCULATION, V110, P1140, DOI 10.1161/01.CIR.0000139851.50067.E4; Naya MJ, 1997, GUT, V40, P175, DOI 10.1136/gut.40.2.175; Ohshima H, 2003, ARCH BIOCHEM BIOPHYS, V417, P3, DOI 10.1016/S0003-9861(03)00283-2; OLYAEE M, 1995, GUT, V37, P168, DOI 10.1136/gut.37.2.168; Ouatu-Lascar R, 1999, GASTROENTEROLOGY, V117, P327, DOI 10.1053/gast.1999.0029900327; OUYANG YB, 1994, BRAIN RES, V646, P65, DOI 10.1016/0006-8993(94)90058-2; Rohra DK, 2003, ACTA PHYSIOL SCAND, V179, P273, DOI 10.1046/j.0001-6772.2003.01174.x; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; Shirvani VN, 2000, GASTROENTEROLOGY, V118, P487, DOI 10.1016/S0016-5085(00)70254-X; Sihvo EIT, 2003, J THORAC CARDIOV SUR, V126, P1952, DOI 10.1016/j.jtcvs.2003.08.014; STOLK J, 1994, AM J RESP CELL MOL, V11, P95, DOI 10.1165/ajrcmb.11.1.8018341; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Tanaka S, 2003, GUT, V52, P775, DOI 10.1136/gut.52.6.775; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Thomas P, 1997, BRIT J SURG, V84, P119; Tobey NA, 1997, GASTROENTEROLOGY, V112, P847, DOI 10.1053/gast.1997.v112.pm9041246; TRIER JS, 1980, METHOD CELL BIOL, P365; Tselepis C, 2003, GUT, V52, P174, DOI 10.1136/gut.52.2.174; Tselepis C, 2002, ONCOGENE, V21, P6071, DOI 10.1038/sj.onc.1205731; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Wetscher G J, 1997, Dis Esophagus, V10, P29; WETSCHER GJ, 1995, DIGEST DIS SCI, V40, P1292, DOI 10.1007/BF02065541; WETSCHER GJ, 1995, AM J SURG, V170, P552, DOI 10.1016/S0002-9610(99)80014-2; Wild CP, 2003, NAT REV CANCER, V3, P676, DOI 10.1038/nrc1166	53	104	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20368	20382		10.1074/jbc.M603353200	http://dx.doi.org/10.1074/jbc.M603353200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16707484	hybrid			2022-12-25	WOS:000239038200061
J	Zelezetsky, I; Pontillo, A; Puzzi, L; Antcheva, N; Segat, L; Pacor, S; Crovella, S; Tossi, A				Zelezetsky, Igor; Pontillo, Alessandra; Puzzi, Luca; Antcheva, Nikolinka; Segat, Ludovica; Pacor, Sabrina; Crovella, Sergio; Tossi, Alessandro			Evolution of the primate cathelicidin - Correlation between structural variations and antimicrobial activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE LL-37; LYTIC PEPTIDES; IDENTIFICATION; NEUTROPHILS; LIKELIHOOD; MEMBRANES; SELECTION; RECEPTOR; DEFENSE; FAMILY	Cathelicidin genes homologous to the human CAMP gene, coding for the host defense peptide LL-37, have been sequenced and analyzed in 20 primate species, including Great Apes, hylobatidae, cercopithecidae, callithricidae, and cebidae. The region corresponding to the putative mature antimicrobial peptide is subject to a strong selective pressure for variation, with evidence for positive selection throughout the phylogenetic tree relating the peptides, which favors alterations in the charge while little affecting overall hydrophobicity or amphipathicity. Selected peptides were chemically synthesized and characterized, and two distinct types of behavior were observed. Macaque and leaf-eating monkey RL- 37 peptides, like other helical antimicrobial peptides found in insect, frog, and mammalian species, were unstructured in bulk solution and had a potent, salt and medium independent antimicrobial activity in vitro, which may be the principal function also in vivo. Human LL-37 and the orangutan, hylobates, and callithrix homologues instead showed a salt-dependent structuring and likely aggregation in bulk solution that affected antimicrobial activity and its medium dependence. The two types of peptides differ also in their interaction with host cells. The evolution of these peptides has thus resulted in distinct mechanisms of action that affect the direct antimicrobial activity and may also modulate accessory antimicrobial functions due to interactions with host cells.	Univ Trieste, Dept Biochem Biophys & Macromol Chem, I-34127 Trieste, Italy; Univ Trieste, Dept Reprod & Dev Sci, I-34127 Trieste, Italy; Univ Trieste, Dept Biomed Sci, I-34127 Trieste, Italy	University of Trieste; University of Trieste; University of Trieste	Tossi, A (corresponding author), Univ Trieste, Dept Biochem Biophys & Macromol Chem, I-34127 Trieste, Italy.	tossi@bbcm.units.it	Tossi, Alessandro/U-2474-2017; Pontillo, Alessandra/AAD-4790-2019; Pontillo, ALESSANDRA/D-4352-2012; Tossi, Alessandro/ABC-9061-2020; Pontillo, Alessandra/ABC-6266-2020; Crovella, Sergio/K-5050-2016	Tossi, Alessandro/0000-0001-9087-5764; Pontillo, Alessandra/0000-0002-7883-0640; Pontillo, ALESSANDRA/0000-0002-7883-0640; Pontillo, Alessandra/0000-0002-7883-0640; Crovella, Sergio/0000-0001-8493-1168; PACOR, SABRINA/0000-0001-8043-6725; Segat, Ludovica/0000-0002-6024-1485; Puzzi, Luca/0000-0001-9296-2263				Antcheva N, 2004, ANTIMICROB AGENTS CH, V48, P685, DOI 10.1128/AAC.48.2.685-688.2004; Bals R, 2003, CELL MOL LIFE SCI, V60, P711, DOI 10.1007/s00018-003-2186-9; Bals R, 2001, CLIN DIAGN LAB IMMUN, V8, P370, DOI 10.1128/CDLI.8.2.370-375.2001; Boniotto M, 2003, BIOCHEM J, V374, P707, DOI 10.1042/BJ20030528; Braff MH, 2005, J IMMUNOL, V174, P4271, DOI 10.4049/jimmunol.174.7.4271; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; Elssner A, 2004, J IMMUNOL, V172, P4987, DOI 10.4049/jimmunol.172.8.4987; Gennaro R, 2000, BIOPOLYMERS, V55, P31, DOI 10.1002/1097-0282(2000)55:1<31::AID-BIP40>3.3.CO;2-0; Giangaspero A, 2001, EUR J BIOCHEM, V268, P5589; Gudmundsson GH, 1996, EUR J BIOCHEM, V238, P325, DOI 10.1111/j.1432-1033.1996.0325z.x; Herasimenka Y, 2005, PEPTIDES, V26, P1127, DOI 10.1016/j.peptides.2005.01.020; Hill W. C. O., 1970, PRIMATES COMP ANATOM; Johansson J, 1998, J BIOL CHEM, V273, P3718, DOI 10.1074/jbc.273.6.3718; Koczulla AR, 2003, DRUGS, V63, P389, DOI 10.2165/00003495-200363040-00005; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Murakami M, 2004, J IMMUNOL, V172, P3070, DOI 10.4049/jimmunol.172.5.3070; Nilsson MF, 1999, INFECT IMMUN, V67, P2561, DOI 10.1128/IAI.67.5.2561-2566.1999; Oren Z, 1998, BIOPOLYMERS, V47, P451; Oren Z, 1999, BIOCHEM J, V341, P501, DOI 10.1042/0264-6021:3410501; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Sorensen OE, 2001, BLOOD, V97, P3951, DOI 10.1182/blood.V97.12.3951; Tiozzo E, 1998, BIOCHEM BIOPH RES CO, V249, P202, DOI 10.1006/bbrc.1998.9114; Tomasinsig L, 2005, CURR PROTEIN PEPT SC, V6, P23, DOI 10.2174/1389203053027520; Tossi A, 1997, EUR J BIOCHEM, V250, P549, DOI 10.1111/j.1432-1033.1997.0549a.x; Tossi A, 2000, BIOPOLYMERS, V55, P4; Tossi A, 1997, Methods Mol Biol, V78, P133; Tossi A, 2002, PEPTIDES 2002, P416; Turner J, 1998, ANTIMICROB AGENTS CH, V42, P2206, DOI 10.1128/AAC.42.9.2206; WALSH PS, 1991, BIOTECHNIQUES, V10, P506, DOI 10.2144/000114018; Wang YQ, 2004, ANTIMICROB AGENTS CH, V48, P2097, DOI 10.1128/AAC.48.6.2097-2100.2004; Wang YQ, 1998, J BIOL CHEM, V273, P33115, DOI 10.1074/jbc.273.50.33115; Wolfheim J, 1983, PRIMATES WORLD DISTR; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Yang ZH, 2000, GENETICS, V155, P431; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; Yang ZH, 1998, MOL BIOL EVOL, V15, P568, DOI 10.1093/oxfordjournals.molbev.a025957; Zaiou M, 2003, J INVEST DERMATOL, V120, P810, DOI 10.1046/j.1523-1747.2003.12132.x; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O; Zanetti M, 2004, J LEUKOCYTE BIOL, V75, P39, DOI 10.1189/jlb.0403147; Zelezetsky I, 2005, BIOCHEM J, V390, P177, DOI 10.1042/BJ20042138; Zelezetsky I, 2005, ARCH BIOCHEM BIOPHYS, V434, P358, DOI 10.1016/j.abb.2004.11.006; Zhao CQ, 2001, ANTIMICROB AGENTS CH, V45, P2695, DOI 10.1128/AAC.45.10.2695-2702.2001	43	88	107	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					19861	19871		10.1074/jbc.M511108200	http://dx.doi.org/10.1074/jbc.M511108200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16720578	hybrid			2022-12-25	WOS:000239038200009
J	Chen, BL; Tsui, S; Boeglin, WE; Douglas, RS; Brash, AR; Smith, TJ				Chen, Beiling; Tsui, Shanli; Boeglin, William E.; Douglas, Raymond S.; Brash, Alan R.; Smith, Terry J.			Interleukin-4 induces 15-lipoxygenase-1 expression in human orbital fibroblasts from patients with graves disease - Evidence for anatomic site-selective actions of Th2 cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-ASSOCIATED OPHTHALMOPATHY; LIPOXYGENASE MESSENGER-RNA; CULTURED HUMAN-FIBROBLASTS; EPITHELIAL-CELLS; UP-REGULATION; ARACHIDONATE 15-LIPOXYGENASE; PROINFLAMMATORY CYTOKINES; LEUKOREGULIN INDUCTION; HYALURONATE SYNTHESIS; DERMAL FIBROBLASTS	Orbital fibroblasts orchestrate tissue remodeling in Graves disease, at least in part, because they exhibit exaggerated responses to proinflammatory cytokines. A hallmark of late stage orbital disease is vision-threatening fibrosis, the molecular basis of which remains uncertain. We report here that the Th2 cytokines, interleukin (IL)-4 and IL-13, can induce in these cells the expression of 15-lipoxygenase-1 (15-LOX-1) and in so doing up-regulate the production of 15-hydroxyeicosatetraenoic acid. IL-4 increases 15-LOX-1 protein levels through pretranslational actions. The increased steady-state 15-LOX-1 mRNA is independent of ongoing protein synthesis and involves very modestly increased gene promoter activity. Importantly, IL-4 substantially enhances 15-LOX-1 transcript stability, activity that localizes to a 293-bp sequence of the 3'-untranslated region. IL-4 activates Jak2 in orbital fibroblasts. Interrupting signaling through that pathway, either with the specific chemical inhibitor, AG490, or by transiently transfecting the cells with a Jak2 dominant negative mutant kinase, attenuates the 15-LOX-1 induction. Interferon gamma, a Th1 cytokine, could block this induction by attenuating IL-4-dependent mRNA stabilization. 15-LOX-1 protein and its mRNA were undetectable in IL-4-treated dermal fibroblasts, despite comparable levels of cell surface IL-4 receptor and phosphorylated Jak2 and STAT6. Our findings suggest that orbital connective tissues may represent a site of localized 15-hydroxyeicosatetraenoic acid generation resulting from cell type-specific 15-LOX-1 mRNA stabilization by IL-4. These results may have relevance to the pathogenesis of orbital Graves disease, an inflammatory autoimmune condition that gives way to extensive fibrosis associated with a Th2 response.	Harbor UCLA Med Ctr, Div Mol Med, Dept Med, Torrance, CA 90502 USA; Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Vanderbilt University	Smith, TJ (corresponding author), Harbor UCLA Med Ctr, Div Mol Med, Dept Med, Bldg C-2,1124 W Carson St, Torrance, CA 90502 USA.	tjsmith@ucla.edu	Smith, Terry/ABG-1360-2020	Douglas, Raymond S./0000-0002-3435-8161; Smith, Terry/0000-0002-6279-9685	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [K23EY016339, R01EY008976, R01EY011708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063121] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431, R01GM053638] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00425] Funding Source: Medline; NEI NIH HHS [EY016339, EY008976, EY011708] Funding Source: Medline; NIDDK NIH HHS [DK063121] Funding Source: Medline; NIGMS NIH HHS [GM15431, GM53638] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aniszewski JP, 2000, J CLIN ENDOCR METAB, V85, P776, DOI 10.1210/jc.85.2.776; BERENSON CS, 1995, J CLIN ENDOCR METAB, V80, P2668, DOI 10.1210/jc.80.9.2668; BETZ M, 1991, J IMMUNOL, V146, P108; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Brinckmann R, 1996, BIOCHEM J, V318, P305, DOI 10.1042/bj3180305; BRYANT RW, 1982, J BIOL CHEM, V257, P6050; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; Conrad DJ, 2000, AM J RESP CELL MOL, V22, P226, DOI 10.1165/ajrcmb.22.2.3786; FLEMING J, 1989, GENE, V79, P181, DOI 10.1016/0378-1119(89)90103-0; Gronert K, 2005, J BIOL CHEM, V280, P15267, DOI 10.1074/jbc.M410638200; Han R, 2002, J BIOL CHEM, V277, P16355, DOI 10.1074/jbc.M111246200; Harada S, 2003, CLIN EXP RHEUMATOL, V21, P753; Heydeck D, 1998, BLOOD, V92, P2503, DOI 10.1182/blood.V92.7.2503.2503_2503_2510; Hiromatsu Y, 2000, J CLIN ENDOCR METAB, V85, P1194, DOI 10.1210/jc.85.3.1194; HUNT T, 1989, TRENDS BIOCHEM SCI, V14, P393, DOI 10.1016/0968-0004(89)90280-6; Jayawickreme SP, 1999, AM J PHYSIOL-LUNG C, V276, pL596, DOI 10.1152/ajplung.1999.276.4.L596; Kamitani H, 2000, FEBS LETT, V467, P341, DOI 10.1016/S0014-5793(00)01155-8; Kazim M, 2002, ARCH OPHTHALMOL-CHIC, V120, P380; Kilty I, 1999, EUR J BIOCHEM, V266, P83, DOI 10.1046/j.1432-1327.1999.00818.x; Koumas L, 2002, EUR J IMMUNOL, V32, P477, DOI 10.1002/1521-4141(200202)32:2<477::AID-IMMU477>3.0.CO;2-U; Kraus J, 2002, FASEB J, V16, P304, DOI 10.1096/fj.02-0482fje; Kritzik MR, 1997, BBA-GENE STRUCT EXPR, V1352, P267, DOI 10.1016/S0167-4781(97)00005-5; Lee YW, 2001, J LIPID RES, V42, P783; LEVY BD, 1993, J CLIN INVEST, V92, P1572, DOI 10.1172/JCI116738; LI TK, 1993, J IMMUNOL, V150, P1680; Liagre B, 1999, J RHEUMATOL, V26, P1044; Liu C, 2004, EXP CELL RES, V297, P61, DOI 10.1016/j.yexcr.2004.02.014; Munger KA, 1999, P NATL ACAD SCI USA, V96, P13375, DOI 10.1073/pnas.96.23.13375; OPREY J, 1995, NUCLEIC ACIDS RES, V23, P3664, DOI 10.1093/nar/23.18.3664; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; Prabhakar BS, 2003, ENDOCR REV, V24, P802, DOI 10.1210/er.2002-0020; RAPOPORT SM, 1986, BIOCHIM BIOPHYS ACTA, V864, P471, DOI 10.1016/0304-4157(86)90006-7; Roy B, 1998, J BIOL CHEM, V273, P32023, DOI 10.1074/jbc.273.48.32023; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Shankaranarayanan P, 2001, J BIOL CHEM, V276, P42753, DOI 10.1074/jbc.M102626200; Shappell SB, 1999, AM J PATHOL, V155, P235, DOI 10.1016/S0002-9440(10)65117-6; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V150, P376, DOI 10.1016/0006-291X(88)90531-1; SMITH TJ, 1989, ENDOCR REV, V10, P366, DOI 10.1210/edrv-10-3-366; SMITH TJ, 1989, J CLIN ENDOCR METAB, V69, P1019, DOI 10.1210/jcem-69-5-1019; Smith TJ, 2003, AUTOIMMUNITY, V36, P409, DOI 10.1080/08916930310001603000; Smith TJ, 2002, J CLIN ENDOCR METAB, V87, P385, DOI 10.1210/jc.87.1.385; SMITH TJ, 1993, AM J PHYSIOL, V265, pC138, DOI 10.1152/ajpcell.1993.265.1.C138; SMITH TJ, 1987, J CLIN INVEST, V79, P1493, DOI 10.1172/JCI112979; SMITH TJ, 1995, J CLIN ENDOCR METAB, V80, P2620, DOI 10.1210/jc.80.9.2620; Spanbroek R, 2001, P NATL ACAD SCI USA, V98, P5152, DOI 10.1073/pnas.091076998; Tang SH, 2002, J BIOL CHEM, V277, P16189, DOI 10.1074/jbc.M111936200; THIELE BJ, 1982, EUR J BIOCHEM, V129, P133, DOI 10.1111/j.1432-1033.1982.tb07031.x; THIELE BJ, 1987, GENE, V57, P111, DOI 10.1016/0378-1119(87)90182-X; THIELE BJ, 1981, ACTA BIOL MED GER, V40, P597; Thiele BJ, 1999, NUCLEIC ACIDS RES, V27, P1828, DOI 10.1093/nar/27.8.1828; Wang HS, 1996, J BIOL CHEM, V271, P22718, DOI 10.1074/jbc.271.37.22718; Wilkie GS, 2003, TRENDS BIOCHEM SCI, V28, P182, DOI 10.1016/S0968-0004(03)00051-3; Xu B, 2004, J BIOL CHEM, V279, P15954, DOI 10.1074/jbc.M400413200; Xu B, 2003, MOL CELL BIOL, V23, P3918, DOI 10.1128/MCB.23.11.3918-3928.2003; Young DA, 1998, P NATL ACAD SCI USA, V95, P8904, DOI 10.1073/pnas.95.15.8904	58	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18296	18306		10.1074/jbc.M603484200	http://dx.doi.org/10.1074/jbc.M603484200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16675443	hybrid			2022-12-25	WOS:000238687300006
J	Mauro, C; Pacifico, F; Lavorgna, A; Mellone, S; Iannetti, A; Acquaviva, R; Formisano, S; Vito, P; Leonardi, A				Mauro, Claudio; Pacifico, Francesco; Lavorgna, Alfonso; Mellone, Stefano; Iannetti, Alessio; Acquaviva, Renato; Formisano, Silvestro; Vito, Pasquale; Leonardi, Antonio			ABIN-1 binds to NEMO/IKK gamma and co-operates with A20 in inhibiting NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ZINC-FINGER PROTEIN; KINASE COMPLEX; IKK-GAMMA; FUNCTIONAL INTERACTION; ENDOTHELIAL-CELLS; ACTIVATION; TNF; UBIQUITINATION; INFLAMMATION	Nuclear factor kappa B (NF-kappa B) plays a pivotal role in inflammation, immunity, stress responses, and protection from apoptosis. Canonical activation of NF-kappa B is dependent on the phosphorylation of the inhibitory subunit I kappa B alpha that is mediated by a multimeric, high molecular weight complex, called I kappa B kinase (IKK) complex. This is composed of two catalytic subunits, IKK alpha and IKK beta, and a regulatory subunit, NEMO/IKK gamma. The latter protein is essential for the activation of IKKs and NF-kappa B, but its mechanism of action is not well understood. Here we identified ABIN-1 (A20 binding inhibitor of NF-kappa B) as a NEMO/IKK gamma-interacting protein. ABIN-1 has been previously identified as an A20-binding protein and it has been proposed to mediate the NF-kappa B inhibiting effects of A20. We find that both ABIN-1 and A20 inhibit NF-kappa B at the level of the IKK complex and that A20 inhibits activation of NF-kappa B by de-ubiquitination of NEMO/IKK gamma. Importantly, small interfering RNA targeting ABIN-1 abrogates A20-dependent de-ubiquitination of NEMO/IKK gamma and RNA interference of A20 impairs the ability of ABIN-1 to inhibit NF-kappa B activation. Altogether our data indicate that ABIN-1 physically links A20 to NEMO/IKK gamma and facilitates A20-mediated de-ubiquitination of NEMO/IKK gamma, thus resulting in inhibition of NF-kappa B.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Sannio, Dipartimento Sci Biol & Ambientali, I-82100 Benevento, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Sannio	Leonardi, A (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.	leonardi@unina.it	Pacifico, Francesco/AAX-3958-2020; vito, pasquale/ABF-5505-2020; leonardi, antonio/A-2887-2009; Mauro, Claudio/AAN-1848-2021; Lavorgna, Alfonso/A-5357-2012	Pacifico, Francesco/0000-0001-9563-3596; leonardi, antonio/0000-0001-8636-9623; Mauro, Claudio/0000-0002-3736-0099; vito, pasquale/0000-0002-5721-7716				Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chariot A, 2002, J BIOL CHEM, V277, P37029, DOI 10.1074/jbc.M205069200; Chariot A, 1999, J BIOL CHEM, V274, P5318, DOI 10.1074/jbc.274.9.5318; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Clevers H, 2004, CELL, V118, P671, DOI 10.1016/j.cell.2004.09.005; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; Evans PC, 2003, J BIOL CHEM, V278, P23180, DOI 10.1074/jbc.M301863200; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Heyninck K, 2003, FEBS LETT, V536, P135, DOI 10.1016/S0014-5793(03)00041-3; Hu XL, 1998, BLOOD, V92, P2759, DOI 10.1182/blood.V92.8.2759.420k29_2759_2765; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Jaattela M, 1996, J IMMUNOL, V156, P1166; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Leonardi A, 2000, J BIOL CHEM, V275, P271, DOI 10.1074/jbc.275.1.271; Leonardi A, 2000, P NATL ACAD SCI USA, V97, P10494, DOI 10.1073/pnas.190245697; Liu YC, 2005, NAT REV IMMUNOL, V5, P941, DOI 10.1038/nri1731; Mauro C, 2003, BIOCHEM BIOPH RES CO, V309, P84, DOI 10.1016/S0006-291X(03)01532-8; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Orange JS, 2005, IMMUNOL REV, V203, P21, DOI 10.1111/j.0105-2896.2005.00221.x; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Saitoh T, 2005, J IMMUNOL, V174, P1507, DOI 10.4049/jimmunol.174.3.1507; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Stilo R, 2004, J BIOL CHEM, V279, P34323, DOI 10.1074/jbc.M402244200; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; Walsh NC, 2005, IMMUNOL REV, V208, P228, DOI 10.1111/j.0105-2896.2005.00338.x; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	43	198	211	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18482	18488		10.1074/jbc.M601502200	http://dx.doi.org/10.1074/jbc.M601502200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16684768	Green Published, hybrid			2022-12-25	WOS:000238687300027
J	Molina, ML; Barrera, FN; Fernandez, AM; Poveda, JA; Renart, ML; Encinar, JA; Riquelme, G; Gonzalez-Ros, JM				Molina, Maria L.; Barrera, Francisco N.; Fernandez, Asia M.; Poveda, Jose A.; Renart, Maria L.; Encinar, Jose A.; Riquelme, Gloria; Gonzalez-Ros, Jose M.			Clustering and coupled gating modulate the activity in KcsA, a potassium channel model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNELS; STREPTOMYCES-LIVIDANS; K+ CHANNEL; ION-CHANNEL; RYANODINE RECEPTORS; ENERGY-TRANSFER; PROTEIN; PORE; FLUORESCENCE; SELECTIVITY	Different patterns of channel activity have been detected by patch clamping excised membrane patches from reconstituted giant liposomes containing purified KcsA, a potassium channel from prokaryotes. The more frequent pattern has a characteristic low channel opening probability and exhibits many other features reported for KcsA reconstituted into planar lipid bilayers, including a moderate voltage dependence, blockade by Na+, and a strict dependence on acidic pH for channel opening. The predominant gating event in this low channel opening probability pattern corresponds to the positive coupling of two KcsA channels. However, other activity patterns have been detected as well, which are characterized by a high channel opening probability (HOP patterns), positive coupling of mostly five concerted channels, and profound changes in other KcsA features, including a different voltage dependence, channel opening at neutral pH, and lack of Na+ blockade. The above functional diversity occurs correlatively to the heterogeneous supramolecular assembly of KcsA into clusters. Clustering of KcsA depends on protein concentration and occurs both in detergent solution and more markedly in reconstituted membranes, including giant liposomes, where some of the clusters are large enough (up to micrometer size) to be observed by confocal microscopy. As in the allosteric conformational spread responses observed in receptor clustering (Bray, D. and Duke, T. (2004) Annu. Rev. Biophys. Biomol. Struct. 33, 53-73) our tenet is that physical clustering of KcsA channels is behind the observed multiple coupled gating and diverse functional responses.	Univ Miguel Hernandez, Inst Biol Mol & Celular, Alicante 03202, Spain; Univ Chile, Programa Fisiol & Biofis, Inst Ciencias Biomed, Fac Med, Santiago 7, Chile	Universidad Miguel Hernandez de Elche; Universidad de Chile	Gonzalez-Ros, JM (corresponding author), Univ Miguel Hernandez, Inst Biol Mol & Celular, Alicante 03202, Spain.	gonzalez.ros@umh.es	Carvajal, Asia Fernandez/G-8877-2015; Gallego, María Luisa Molina/K-4810-2017; Encinar, José Antonio/AAE-9141-2020; Encinar, José A/F-2946-2013; Poveda Larrosa, Jose Antonio/H-5925-2015	Gallego, María Luisa Molina/0000-0001-9190-6948; Encinar, José Antonio/0000-0002-7219-3863; Encinar, José A/0000-0002-7219-3863; Renart, Maria Lourdes/0000-0002-6717-4756; Barrera, Francisco N./0000-0002-5200-7891; Poveda Larrosa, Jose Antonio/0000-0003-0722-3752; Gonzalez Ros, Jose Manuel/0000-0002-4804-6855				Armstrong Clay M, 2003, Sci STKE, V2003, pre10, DOI 10.1126/stke.2003.188.re10; Booth IR, 2003, BIOCHEMISTRY-US, V42, P10045, DOI 10.1021/bi034953w; Bray D, 2004, ANNU REV BIOPH BIOM, V33, P53, DOI 10.1146/annurev.biophys.33.110502.132703; Capeta RC, 2006, J FLUORESC, V16, P161, DOI 10.1007/s10895-005-0036-x; Choi H, 2004, BIOPHYS J, V86, P2137, DOI 10.1016/S0006-3495(04)74273-3; Cole J L, 1999, J Biomol Tech, V10, P163; Cuello LG, 1998, BIOCHEMISTRY-US, V37, P3229, DOI 10.1021/bi972997x; Doyle DA, 2004, MOL MEMBR BIOL, V21, P221, DOI 10.1080/09687680410001716844; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Gonzalez JM, 2005, P NATL ACAD SCI USA, V102, P1895, DOI 10.1073/pnas.0409517102; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Heginbotham L, 1999, J GEN PHYSIOL, V114, P551, DOI 10.1085/jgp.114.4.551; Herrick-Davis K, 2005, J BIOL CHEM, V280, P40144, DOI 10.1074/jbc.M507396200; Horio Y, 1997, J BIOL CHEM, V272, P12885, DOI 10.1074/jbc.272.20.12885; Irizarry SN, 2002, BIOCHEMISTRY-US, V41, P13653, DOI 10.1021/bi026393r; JAMES DR, 1992, REV SCI INSTRUM, V63, P1710, DOI 10.1063/1.1143328; Kenyon JL, 2000, J NEUROSCI METH, V96, P105, DOI 10.1016/S0165-0270(99)00189-2; LACKOWICZ JR, 1999, PRINCIPLES FLUORESCE, P291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laver DR, 2004, J GEN PHYSIOL, V124, P741, DOI 10.1085/jgp.200409092; Liu RH, 2000, BIOCHEMISTRY-US, V39, P14927, DOI 10.1021/bi0018786; MacKinnon R, 2003, FEBS LETT, V555, P62, DOI 10.1016/S0014-5793(03)01104-9; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; Marx SO, 2001, CIRC RES, V88, P1151, DOI 10.1161/hh1101.091268; Meuser D, 1999, FEBS LETT, V462, P447, DOI 10.1016/S0014-5793(99)01579-3; Meuser D, 2001, EUR BIOPHYS J BIOPHY, V30, P385, DOI 10.1007/s002490100147; Misonou H, 2004, NAT NEUROSCI, V7, P711, DOI 10.1038/nn1260; Molina ML, 2004, BIOCHEMISTRY-US, V43, P14924, DOI 10.1021/bi048889+; Nimigean CM, 2002, J GEN PHYSIOL, V120, P323, DOI 10.1085/jgp.20028614; Panchuk-Voloshina N, 1999, J HISTOCHEM CYTOCHEM, V47, P1179, DOI 10.1177/002215549904700910; Pegan S, 2005, NAT NEUROSCI, V8, P279, DOI 10.1038/nn1411; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Reusch RN, 1999, BIOCHEMISTRY-US, V38, P15666, DOI 10.1021/bi991782f; RIQUELME G, 1990, BIOCHEMISTRY-US, V29, P11215, DOI 10.1021/bi00503a009; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Selvin PR, 2002, ANNU REV BIOPH BIOM, V31, P275, DOI 10.1146/annurev.biophys.31.101101.140927; Splitt H, 2000, FEBS LETT, V472, P83, DOI 10.1016/S0014-5793(00)01429-0; Stradner A, 2004, NATURE, V432, P492, DOI 10.1038/nature03109; Tateishi Y, 2005, J BIOL CHEM, V280, P6816, DOI 10.1074/jbc.M405469200; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; WOLBER PK, 1979, BIOPHYS J, V28, P197, DOI 10.1016/S0006-3495(79)85171-1; Wolf M, 2003, J MOL BIOL, V332, P171, DOI 10.1016/S0022-2836(03)00899-4; Yin CC, 2005, J MOL BIOL, V349, P538, DOI 10.1016/j.jmb.2005.04.002; Zakharian E, 2004, BIOCHEM BIOPH RES CO, V322, P1059, DOI 10.1016/j.bbrc.2004.08.027; Zakharian E, 2004, BIOCHEM BIOPH RES CO, V316, P429, DOI 10.1016/j.bbrc.2004.02.069; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009; Zimmer J, 2006, BIOPHYS J, V90, P1752, DOI 10.1529/biophysj.105.071175	48	65	66	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18837	18848		10.1074/jbc.M600342200	http://dx.doi.org/10.1074/jbc.M600342200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16670090	hybrid, Green Submitted			2022-12-25	WOS:000238687300064
J	Ricke, RM; Bielinsky, AK				Ricke, Robin M.; Bielinsky, Anja-Katrin			A conserved Hsp10-like domain in Mcm10 is required to stabilize the catalytic subunit of DNA polymerase-alpha in budding yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL REPLICATION ORIGINS; COMMON FRAGILE SITES; PRIMASE B-SUBUNIT; SACCHAROMYCES-CEREVISIAE; CHROMATIN ASSOCIATION; FISSION YEAST; S-PHASE; COMPLEX-FORMATION; ESCHERICHIA-COLI; PROTEIN COMPLEX	Mcm10 is a conserved eukaryotic DNA replication factor that is required for S phase progression. Recently, Mcm10 has been shown to interact physically with the DNA polymerase-alpha(pol-alpha)(.)primase complex. We show now that Mcm10 is in a complex with pol-alpha throughout the cell cycle. In temperature-sensitive mcm10-1 mutants, depletion of Mcm10 results in degradation of the catalytic subunit of pol-alpha, Cdc17/ Pol1, regardless of whether cells are in G(1), S, or G(2) phase. Importantly, Cdc17 protein levels can be restored upon overexpression of exogenous Mcm10 in mcm10-1 mutants that are grown at the nonpermissive temperature. Moreover, over-expressed Cdc17 that is normally subject to rapid degradation is stabilized by Mcm10 co-overexpression but not by co-overexpression of the B-subunit of pol-alpha, Pol12. These results are consistent with Mcm10 having a role as a nuclear chaperone for Cdc17. Mutational analysis indicates that a conserved heat-shock protein 10 (Hsp10)-like domain in Mcm10 is required to prevent the degradation of Cdc17. Substitution of a single residue in the Hsp10-like domain of endogenous Mcm10 results in a dramatic reduction of steady-state Cdc17 levels. The high degree of evolutionary conservation of this domain implies that stabilizing Cdc17 may be a conserved function of Mcm10.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Bielinsky, AK (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 6-155 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	bielinsk@cbs.umn.edu		Bielinsky, Anja/0000-0003-1783-619X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074917] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM074917] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aparicio OM, 1999, P NATL ACAD SCI USA, V96, P9130, DOI 10.1073/pnas.96.16.9130; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Biswas SB, 2003, NUCLEIC ACIDS RES, V31, P2056, DOI 10.1093/nar/gkg311; Brill SJ, 1998, MOL CELL BIOL, V18, P7225, DOI 10.1128/MCB.18.12.7225; BROOKE RG, 1991, J BIOL CHEM, V266, P10093; BROOKE RG, 1991, J BIOL CHEM, V266, P3005; Burich R, 2003, CURR GENET, V44, P195, DOI 10.1007/s00294-003-0443-y; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Christensen TW, 2003, MOL BIOL CELL, V14, P2206, DOI 10.1091/mbc.E02-11-0706; Cobb JA, 2003, EMBO J, V22, P4325, DOI 10.1093/emboj/cdg391; Cook CR, 2003, J BIOL CHEM, V278, P36051, DOI 10.1074/jbc.M306049200; Desdouets C, 1998, EMBO J, V17, P4139, DOI 10.1093/emboj/17.14.4139; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Douglas NL, 2005, MOL BIOL REP, V32, P197, DOI 10.1007/s11033-005-2312-x; FALCONI MM, 1993, P NATL ACAD SCI USA, V90, P10519, DOI 10.1073/pnas.90.22.10519; Ferrari M, 1996, J BIOL CHEM, V271, P8661, DOI 10.1074/jbc.271.15.8661; Fien K, 2004, J BIOL CHEM, V279, P16144, DOI 10.1074/jbc.M400142200; FOIANI M, 1995, MOL CELL BIOL, V15, P883; Gardner RG, 2005, CELL, V120, P803, DOI 10.1016/j.cell.2005.01.016; Garg P, 2005, CRIT REV BIOCHEM MOL, V40, P115, DOI 10.1080/10409230590935433; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; Gregan J, 2003, MOL BIOL CELL, V14, P3876, DOI 10.1091/mbc.E03-02-0090; Gutierrez PJA, 2003, GENETICS, V165, P65; Hart EA, 2002, CURR GENET, V41, P342, DOI 10.1007/s00294-002-0316-9; HECHT F, 1984, CANCER GENET CYTOGEN, V13, P185, DOI 10.1016/0165-4608(84)90060-8; HOHFELD J, 1994, J CELL BIOL, V126, P305, DOI 10.1083/jcb.126.2.305; Homesley L, 2000, GENE DEV, V14, P913; Izumi M, 2000, NUCLEIC ACIDS RES, V28, P4769, DOI 10.1093/nar/28.23.4769; Kanemaki M, 2003, NATURE, V423, P720, DOI 10.1038/nature01692; Kawasaki Y, 2000, GENES CELLS, V5, P975, DOI 10.1046/j.1365-2443.2000.00387.x; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; Lee JK, 2003, P NATL ACAD SCI USA, V100, P2334, DOI 10.1073/pnas.0237384100; Lee KM, 2005, YEAST, V22, P431, DOI 10.1002/yea.1221; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Lemoine FJ, 2005, CELL, V120, P587, DOI 10.1016/j.cell.2004.12.039; Merchant AM, 1997, MOL CELL BIOL, V17, P3261, DOI 10.1128/MCB.17.6.3261; Mizuno T, 1998, MOL CELL BIOL, V18, P3552, DOI 10.1128/MCB.18.6.3552; Ouali M, 2000, PROTEIN SCI, V9, P1162, DOI 10.1110/ps.9.6.1162; PLEVANI P, 1984, J BIOL CHEM, V259, P7532; PLEVANI P, 1985, J BIOL CHEM, V260, P7102; Raghunathan S, 2000, NAT STRUCT BIOL, V7, P648, DOI 10.1038/77943; Richardson A, 1998, TRENDS BIOCHEM SCI, V23, P138, DOI 10.1016/S0968-0004(98)01193-1; Richardson A, 2001, J BIOL CHEM, V276, P4981, DOI 10.1074/jbc.M008628200; Ricke RM, 2004, MOL CELL, V16, P173, DOI 10.1016/j.molcel.2004.09.017; Sawyer SL, 2004, J MOL BIOL, V340, P195, DOI 10.1016/j.jmb.2004.04.066; Shewmaker F, 2001, J BIOL CHEM, V276, P31257, DOI 10.1074/jbc.M102765200; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; SOLOMON NA, 1992, YEAST, V8, P273, DOI 10.1002/yea.320080405; Takayama Y, 2003, GENE DEV, V17, P1153, DOI 10.1101/gad.1065903; Tanaka S, 2002, NAT CELL BIOL, V4, P198, DOI 10.1038/ncb757; Tanaka TU, 1998, EMBO J, V17, P5182, DOI 10.1093/emboj/17.17.5182; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Theobald DL, 2003, ANNU REV BIOPH BIOM, V32, P115, DOI 10.1146/annurev.biophys.32.110601.142506; Uchiyama M, 2004, MOL CELL BIOL, V24, P7419, DOI 10.1128/MCB.24.17.7419-7434.2004; Voitenleitner C, 1999, MOL CELL BIOL, V19, P646; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Walther AP, 1999, BIOCHEMISTRY-US, V38, P3963, DOI 10.1021/bi982370u; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Yang XW, 2005, BMC MOL BIOL, V6, DOI 10.1186/1471-2199-6-13; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	64	44	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18414	18425		10.1074/jbc.M513551200	http://dx.doi.org/10.1074/jbc.M513551200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16675460	hybrid			2022-12-25	WOS:000238687300020
J	Schlueter, PJ; Royer, T; Farah, MH; Laser, B; Chan, SJ; Steiner, DF; Duan, CM				Schlueter, Peter J.; Royer, Tricia; Farah, Mohamed H.; Laser, Benjamin; Chan, Shu Jin; Steiner, Donald F.; Duan, Cunming			Gene duplication and functional divergence of the zebrafish insulin-like growth factor 1 receptors	FASEB JOURNAL			English	Article						IGF signaling; growth; developmental timing; retina; inner ear; heart; muscle	GROWTH-FACTOR RECEPTOR; IGF-I; INSULIN; MAP; INTRAUTERINE; EXPRESSION; DISTINCT; MUTATIONS	Insulin-like growth factor (IGF) 1 receptor (IGF1R)-mediated signaling plays key roles in growth, development, and physiology. Recent studies have shown that there are two distinct igf1r genes in zebrafish, termed igf1ra and igf1rb. In this study, we tested the hypothesis that zebrafish igf1ra and igf1rb resulted from a gene duplication event at the igf1r locus and that this has led to their functional divergence. The genomic structures of zebrafish igf1ra and igf1rb were determined and their loci mapped. While zebrafish igf1ra has 21 exons and is located on linkage group (LG) 18, zebrafish igf1rb has 22 exons and mapped to LG 7. There is a strong syntenic relationship between the two zebrafish genes and the human IG F1R gene. Using a MO-based loss-of-function approach, we show that both Igf1ra and Igf1rb are required for zebrafish embryo viability and proper growth and development. Although Igf1ra and Igf1rb demonstrated a large degree of functional overlap with regard to cell differentiation in the developing eye, inner ear, heart, and muscle, they also exhibited functional distinction involving a greater requirement for Igf1rb in spontaneous muscle contractility. These findings suggest that the duplicated zebrafish igf1r genes play largely overlapping but not identical functional roles in early development and provide novel insight into the functional evolution of the IGF1R/insulin receptor gene family.-Schlueter, P. J., Royer, T., Mohamed, H. F., Laser, B., Chan, S. J., Steiner, D. F., Duan, C. Gene duplication and functional divergence of the zebrafish insulin-like growth factor 1 receptors.	Univ Michigan, Dept MCDB, Ann Arbor, MI 48109 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Chicago	Schlueter, PJ (corresponding author), Univ Michigan, Dept MCDB, Kraus Nat Sci Bldg, Ann Arbor, MI 48109 USA.	cduan@umich.edu						Abuzzahab MJ, 2003, NEW ENGL J MED, V349, P2211, DOI 10.1056/NEJMoa010107; Amores A, 1998, SCIENCE, V282, P1711, DOI 10.1126/science.282.5394.1711; Ayaso E, 2002, MOL CELL ENDOCRINOL, V191, P137, DOI 10.1016/S0303-7207(02)00083-7; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Barbazuk WB, 2000, GENOME RES, V10, P1351, DOI 10.1101/gr.144700; Chan SJ, 1997, P NATL ACAD SCI USA, V94, P12446, DOI 10.1073/pnas.94.23.12446; Chen C, 1996, ENDOCRINOLOGY, V137, P846, DOI 10.1210/en.137.3.846; De Meyts P, 2002, NAT REV DRUG DISCOV, V1, P769, DOI 10.1038/nrd917; Denley A, 2005, MOL ENDOCRINOL, V19, P711, DOI 10.1210/me.2004-0409; Drapeau P, 2002, PROG NEUROBIOL, V68, P85, DOI 10.1016/S0301-0082(02)00075-8; Duan CM, 1999, P NATL ACAD SCI USA, V96, P15274, DOI 10.1073/pnas.96.26.15274; Easter SS, 2002, RES PRO CEL, V40, P346; Efstratiadis A, 1998, INT J DEV BIOL, V42, P955; Eivers E, 2004, INT J DEV BIOL, V48, P1131, DOI 10.1387/ijdb.041913ee; Ekker SC, 2000, YEAST, V17, P302, DOI 10.1002/1097-0061(200012)17:4<302::AID-YEA53>3.0.CO;2-#; Ekker SC, 2001, GENESIS, V30, P89, DOI 10.1002/gene.1038; Force A, 1999, GENETICS, V151, P1531; Gates MA, 1999, GENOME RES, V9, P334; Geisler R, 1999, NAT GENET, V23, P86, DOI 10.1038/12692; He XL, 2005, GENETICS, V169, P1157, DOI 10.1534/genetics.104.037051; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Hu M, 1999, DEV BIOL, V207, P309, DOI 10.1006/dbio.1998.9031; Hukriede NA, 1999, P NATL ACAD SCI USA, V96, P9745, DOI 10.1073/pnas.96.17.9745; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kawashima Y, 2005, J CLIN ENDOCR METAB, V90, P4679, DOI 10.1210/jc.2004-1947; Kim JJ, 2002, GROWTH HORM IGF RES, V12, P84, DOI 10.1054/ghir.2002.0265; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Klinghoffer RA, 2002, DEV CELL, V2, P103, DOI 10.1016/S1534-5807(01)00103-4; Klinghoffer RA, 2001, MOL CELL, V7, P343, DOI 10.1016/S1097-2765(01)00182-4; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Maures T, 2002, ENDOCRINOLOGY, V143, P1858, DOI 10.1210/en.143.5.1858; Nakae J, 2001, ENDOCR REV, V22, P818, DOI 10.1210/edrv.22.6.0452; Neumann CJ, 2000, SCIENCE, V289, P2137, DOI 10.1126/science.289.5487.2137; Neumann CJ, 2001, SEMIN CELL DEV BIOL, V12, P485, DOI 10.1006/scdb.2001.0272; Ohno S., 1970, P1; Pera EM, 2001, DEV CELL, V1, P655, DOI 10.1016/S1534-5807(01)00069-7; Pera EM, 2003, GENE DEV, V17, P3023, DOI 10.1101/gad.1153603; Pozios KC, 2001, AM J PHYSIOL-REG I, V280, pR1230, DOI 10.1152/ajpregu.2001.280.4.R1230; Richard-Parpaillon L, 2002, DEV BIOL, V244, P407, DOI 10.1006/dbio.2002.0605; Walenkamp MJE, 2005, J CLIN ENDOCR METAB, V90, P2855, DOI 10.1210/jc.2004-1254; Whitfield TT, 2002, DEV DYNAM, V223, P427, DOI 10.1002/dvdy.10073; Wood AW, 2005, INT REV CYTOL, V243, P215, DOI 10.1016/S0074-7696(05)43004-1; Wood AW, 2005, MOL ENDOCRINOL, V19, P1024, DOI 10.1210/me.2004-0392; Woods IG, 2000, GENOME RES, V10, P1903, DOI 10.1101/gr.10.12.1903; Woods KA, 1996, NEW ENGL J MED, V335, P1363, DOI 10.1056/NEJM199610313351805; Zhang JZ, 2003, TRENDS ECOL EVOL, V18, P292, DOI 10.1016/S0169-5347(03)00033-8	47	56	61	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1230	+		10.1096/fj.05-3882fje	http://dx.doi.org/10.1096/fj.05-3882fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16705083	Green Submitted			2022-12-25	WOS:000240210300035
J	Etchegaray, JP; Yang, XM; DeBruyne, JP; Peters, AHFM; Weaver, DR; Jenuwein, T; Reppert, SM				Etchegaray, Jean-Pierre; Yang, Xiaoming; DeBruyne, Jason P.; Peters, Antoine H. F. M.; Weaver, David R.; Jenuwein, Thomas; Reppert, Steven M.			The polycomb group protein EZH2 is required for mammalian circadian clock function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE METHYLTRANSFERASE ACTIVITY; GENE-EXPRESSION; MOUSE DEVELOPMENT; NEGATIVE LIMB; TRANSCRIPTION; METHYLATION; CHROMATIN; CELLS; ENHANCER; COMPLEX	We examined the importance of histone methylation by the polycomb group proteins in the mouse circadian clock mechanism. Endogenous EZH2, a polycomb group enzyme that methylates lysine 27 on histone H3, co-immunoprecipitates with CLOCK and BMAL1 throughout the circadian cycle in liver nuclear extracts. Chromatin immunoprecipitation revealed EZH2 binding and di- and trimethylation of H3K27 on both the Period 1 and Period 2 promoters. A role of EZH2 in cryptochrome-mediated transcriptional repression of the clockwork was supported by overexpression and RNA interference studies. Serum-induced circadian rhythms in NIH 3T3 cells in culture were disrupted by transfection of an RNA interfering sequence targeting EZH2. These results indicate that EZH2 is important for the maintenance of circadian rhythms and extend the activity of the polycomb group proteins to the core clockwork mechanism of mammals.	Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA 01605 USA; Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; Vienna Bioctr, Res Inst Mol Pathol, A-1030 Vienna, Austria	University of Massachusetts System; University of Massachusetts Worcester; Friedrich Miescher Institute for Biomedical Research; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Reppert, SM (corresponding author), Univ Massachusetts, Sch Med, Dept Neurobiol, 364 Plantat St, Worcester, MA 01605 USA.	Steven.Reppert@umassmed.edu	Peters, Antoine/ABA-6283-2020; Hu, Ruogu/B-2203-2008	DeBruyne, Jason/0000-0001-9803-9568; Weaver, David/0000-0001-7941-6719; Peters, Antoine/0000-0002-0311-1887	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM074277] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047141] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM074277] Funding Source: Medline; NINDS NIH HHS [R01 NS047141] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akashi M, 2005, NAT STRUCT MOL BIOL, V12, P441, DOI 10.1038/nsmb925; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Bastow R, 2004, NATURE, V427, P164, DOI 10.1038/nature02269; Brown SA, 2005, SCIENCE, V308, P693, DOI 10.1126/science.1107373; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020; Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904; Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200; Crosio C, 2000, NAT NEUROSCI, V3, P1241, DOI 10.1038/81767; Curtis AM, 2004, J BIOL CHEM, V279, P7091, DOI 10.1074/jbc.M311973200; Emery P, 2004, NEURON, V43, P443, DOI 10.1016/j.neuron.2004.08.009; Erhardt S, 2003, DEVELOPMENT, V130, P4235, DOI 10.1242/dev.00625; Etchegaray JP, 2003, NATURE, V421, P177, DOI 10.1038/nature01314; Faust C, 1998, DEVELOPMENT, V125, P4495; Gil J, 2005, DNA CELL BIOL, V24, P117, DOI 10.1089/dna.2005.24.117; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lee C, 2004, MOL CELL BIOL, V24, P584, DOI 10.1128/MCB.24.2.584-594.2004; Lowrey PL, 2004, ANNU REV GENOM HUM G, V5, P407, DOI 10.1146/annurev.genom.5.061903.175925; Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Nagoshi E, 2004, CELL, V119, P693, DOI 10.1016/j.cell.2004.11.015; Naruse Y, 2004, MOL CELL BIOL, V24, P6278, DOI 10.1128/MCB.24.14.6278-6287.2004; O'Carroll D, 2001, MOL CELL BIOL, V21, P4330, DOI 10.1128/MCB.21.13.4330-4336.2001; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Peters AHFM, 2005, CURR OPIN CELL BIOL, V17, P230, DOI 10.1016/j.ceb.2005.02.006; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; RENDAHL KG, 1992, J NEUROSCI, V12, P390; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Ripperger JRA, 2006, NAT GENET, V38, P369, DOI 10.1038/ng1738; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Sato TK, 2006, NAT GENET, V38, P312, DOI 10.1038/ng1745; Sato TK, 2004, NEURON, V43, P527, DOI 10.1016/j.neuron.2004.07.018; SIBUM S, 2004, NATURE, V427, P159; Travnickova-Bendova Z, 2002, P NATL ACAD SCI USA, V99, P7728, DOI 10.1073/pnas.102075599; Ueda HR, 2002, NATURE, V418, P534, DOI 10.1038/nature00906; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; Wysocka J, 2003, GENE DEV, V17, P896, DOI 10.1101/gad.252103; Yagita K, 2001, SCIENCE, V292, P278, DOI 10.1126/science.1059542; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; Yoo SH, 2005, P NATL ACAD SCI USA, V102, P2608, DOI 10.1073/pnas.0409763102	49	126	138	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21209	21215		10.1074/jbc.M603722200	http://dx.doi.org/10.1074/jbc.M603722200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16717091	hybrid			2022-12-25	WOS:000239187300056
J	Lee, ER; McCool, KW; Murdoch, FE; Fritsch, MK				Lee, Elliot R.; McCool, Kevin W.; Murdoch, Fern E.; Fritsch, Michael K.			Dynamic changes in histone H3 phosphoacetylation during early embryonic stem cell differentiation are directly mediated by mitogen- and stress-activated protein kinase 1 via activation of MAPK pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; PROTEIN-KINASE; SELF-RENEWAL; INDUCED PHOSPHORYLATION; MSK1; PROLIFERATION; PLURIPOTENCY; INHIBITORS; SERINE-10; PATTERNS	Embryonic stem (ES) cells are pluripotent cells capable of unlimited self-renewal and differentiation into the three embryonic germ layers under appropriate conditions. Mechanisms for control of the early period of differentiation, involving exit from the pluripotent state and lineage commitment, are not well understood. An emerging concept is that epigenetic histone modifications may play a role during this early period. We have found that upon differentiation of mouse ES cells by removal of the cytokine leukemia inhibitory factor, there is a global increase in coupled histone H3 phosphorylation (Ser-10)-acetylation (Lys-14) (H3 phosphoacetylation). We show that this occurs through activation of both the extracellular signal-regulated kinase (ERK) and p38 MAPK signaling pathways. Early ES cell differentiation is delayed using pharmacological inhibitors of the ERK and p38 pathways. One common point of convergence of these pathways is the activation of the mitogen- and stress-activated protein kinase 1 (MSK1). We show here that MSK1 is the critical mediator of differentiation-induced H3 phosphoacetylation using both the chemical inhibitor H89 and RNA interference. Interestingly, inhibition of H3 phosphoacetylation also alters gene expression during early differentiation. These results point to an important role for both epigenetic histone modifications and kinase pathways in modulating early ES differentiation.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Canc Biol Grad Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Fritsch, MK (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, MSC 5250,1300 Univ Ave, Madison, WI 53706 USA.	mkfritsch@wisc.edu		MURDOCH, FERN/0000-0001-5724-9681	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064243] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK064243] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Aouadi M, 2006, STEM CELLS, V24, P1399, DOI 10.1634/stemcells.2005-0398; Bain G, 1996, BIOCHEM BIOPH RES CO, V223, P691, DOI 10.1006/bbrc.1996.0957; Baleato RM, 2005, DEV BIOL, V286, P78, DOI 10.1016/j.ydbio.2005.07.009; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Chambeyron S, 2005, DEVELOPMENT, V132, P2215, DOI 10.1242/dev.01813; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Clayton AL, 2003, FEBS LETT, V546, P51, DOI 10.1016/S0014-5793(03)00451-4; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAHLSTRAND J, 1992, J CELL SCI, V103, P589; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Duval D, 2004, CELL DEATH DIFFER, V11, P331, DOI 10.1038/sj.cdd.4401337; Finley MFA, 1999, J NEUROBIOL, V40, P271, DOI 10.1002/(SICI)1097-4695(19990905)40:3<271::AID-NEU1>3.0.CO;2-C; GARDNER RL, 1988, J CELL SCI, P11; Hasegawa Y, 2005, BIOCHEM BIOPH RES CO, V336, P1049, DOI 10.1016/j.bbrc.2005.08.231; Hay DC, 2004, STEM CELLS, V22, P225, DOI 10.1634/stemcells.22-2-225; He ZW, 2003, J BIOL CHEM, V278, P10588, DOI 10.1074/jbc.M208581200; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; Illi B, 2005, CIRC RES, V96, P501, DOI 10.1161/01.RES.0000159181.06379.63; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Keller G, 2005, GENE DEV, V19, P1129, DOI 10.1101/gad.1303605; Kimura H, 2004, MOL CELL BIOL, V24, P5710, DOI 10.1128/MCB.24.13.5710-5720.2004; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Li L, 2004, DEVELOPMENT, V131, P5277, DOI 10.1242/dev.01415; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MacDonald N, 2005, MOL CELL, V20, P199, DOI 10.1016/j.molcel.2005.08.032; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Oberley MJ, 2004, METHOD ENZYMOL, V376, P315; Qi XX, 2004, P NATL ACAD SCI USA, V101, P6027, DOI 10.1073/pnas.0401367101; Sarmento OF, 2004, J CELL SCI, V117, P4449, DOI 10.1242/jcs.01328; Sauter CN, 2005, EXP CELL RES, V311, P251, DOI 10.1016/j.yexcr.2005.09.005; Schratt G, 2001, MOL CELL BIOL, V21, P2933, DOI 10.1128/MCB.21.8.2933-2943.2001; Smith J, 1999, TRENDS GENET, V15, P154, DOI 10.1016/S0168-9525(99)01693-5; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Szutorisz H, 2005, BIOESSAYS, V27, P1286, DOI 10.1002/bies.20330; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Varga AC, 2005, ONCOGENE, V24, P5713, DOI 10.1038/sj.onc.1208919; Yao Y, 2003, P NATL ACAD SCI USA, V100, P12759, DOI 10.1073/pnas.2134254100; Zandstra PW, 2000, BIOTECHNOL BIOENG, V69, P607, DOI 10.1002/1097-0290(20000920)69:6<607::AID-BIT4>3.3.CO;2-6	45	38	45	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21162	21172		10.1074/jbc.M602734200	http://dx.doi.org/10.1074/jbc.M602734200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16728397	hybrid			2022-12-25	WOS:000239187300052
J	Turner, FE; Broad, S; Khanim, FL; Jeanes, A; Talma, S; Hughes, S; Tselepis, C; Hotchin, NA				Turner, Frances E.; Broad, Simon; Khanim, Farhat L.; Jeanes, Alexa; Talma, Sonia; Hughes, Sharon; Tselepis, Chris; Hotchin, Neil A.			Slug regulates integrin expression and cell proliferation in human epidermal keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SLUG; E-CADHERIN EXPRESSION; REPRESSES E-CADHERIN; GENE PROMOTER; MESENCHYMAL TRANSITIONS; DROSOPHILA GASTRULATION; SIGNALING PATHWAY; DIFFERENTIATION; SNAIL; ADHESION	The human epidermis is a self-renewing epithelial tissue composed of several layers of keratinocytes. Within the epidermis there exists a complex array of cell adhesion structures, and many of the cellular events within the epidermis (differentiation, proliferation, and migration) require that these adhesion structures be remodeled. The link between cell adhesion, proliferation, and differentiation within the epidermis is well established, and in particular, there is strong evidence to link the process of terminal differentiation to integrin adhesion molecule expression and function. In this paper, we have analyzed the role of a transcriptional repressor called Slug in the regulation of adhesion molecule expression and function in epidermal keratinocytes. We report that activation of Slug, which is expressed predominantly in the basal layer of the epidermis, results in down-regulation of a number of cell adhesion molecules, including E-cadherin, and several integrins, including alpha 3, beta 1, and beta 4. We demonstrate that Slug binds to the alpha 3 promoter and that repression of alpha 3 transcription by Slug is dependent on an E-box sequence within the promoter. This reduction in integrin expression is reflected in decreased cell adhesion to fibronectin and laminin-5. Despite the reduction in integrin expression and function, we do not observe any increase in differentiation. We do, however, find that activation of Slug results in a significant reduction in keratinocyte proliferation.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Sch Med, Birmingham B15 2TT, W Midlands, England; Canc Res UK, London WC2A 3PX, England	University of Birmingham; University of Birmingham; Cancer Research UK	Hotchin, NA (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	n.a.hotchin@bham.ac.uk		Hotchin, Neil/0000-0002-1844-7607				ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; Akhtar N, 2000, CELL ADHES COMMUN, V7, P465, DOI 10.3109/15419060009040304; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Brakebusch C, 2000, EMBO J, V19, P3990, DOI 10.1093/emboj/19.15.3990; Cai T, 2002, J CELL BIOL, V159, P103, DOI 10.1083/jcb.200205017; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; CARTER BZ, 1991, LAB INVEST, V65, P610; Catalano A, 2004, J BIOL CHEM, V279, P46706, DOI 10.1074/jbc.M406696200; CERVELLA P, 1993, J BIOL CHEM, V268, P5148; Cohen ME, 1998, GENOMICS, V51, P468, DOI 10.1006/geno.1998.5367; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Croft DR, 2004, CANCER RES, V64, P8994, DOI 10.1158/0008-5472.CAN-04-2052; DiPersio CM, 2000, J CELL SCI, V113, P3051; Haase I, 2001, J CLIN INVEST, V108, P527, DOI 10.1172/JCI200112153; Hajra KM, 2002, CANCER RES, V62, P1613; Hemavathy K, 2004, DEV BIOL, V269, P411, DOI 10.1016/j.ydbio.2004.01.029; Hemavathy K, 2000, MOL CELL BIOL, V20, P5087, DOI 10.1128/MCB.20.14.5087-5095.2000; HERTLE MD, 1991, DEVELOPMENT, V112, P193; Hobbs RM, 2004, J INVEST DERMATOL, V123, P503, DOI 10.1111/j.0022-202X.2004.23225.x; Hotchin NA, 1999, J CELL SCI, V112, P2937; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; Kato T, 2002, EUR J BIOCHEM, V269, P4524, DOI 10.1046/j.1432-1033.2002.03146.x; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; Levy L, 2000, MOL BIOL CELL, V11, P453, DOI 10.1091/mbc.11.2.453; Levy L, 1998, GENE THER, V5, P913, DOI 10.1038/sj.gt.3300689; Lin CS, 1997, DNA CELL BIOL, V16, P929, DOI 10.1089/dna.1997.16.929; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Manohar A, 2004, J CELL SCI, V117, P4043, DOI 10.1242/jcs.01277; McMullan R, 2003, CURR BIOL, V13, P2185, DOI 10.1016/S0960-9822(03)00906-0; Nishida K, 1997, BIOCHEM BIOPH RES CO, V241, P258, DOI 10.1006/bbrc.1997.7808; Oda H, 1998, DEV BIOL, V203, P435, DOI 10.1006/dbio.1998.9047; Palmer HG, 2004, NAT MED, V10, P917, DOI 10.1038/nm1095; Parent AE, 2004, J HISTOCHEM CYTOCHEM, V52, P959, DOI 10.1369/jhc.4A6277.2004; Picard Didier, 1994, Current Opinion in Biotechnology, V5, P511, DOI 10.1016/0958-1669(94)90066-3; Raghavan S, 2000, J CELL BIOL, V150, P1149, DOI 10.1083/jcb.150.5.1149; Ray DM, 2005, J IMMUNOL, V174, P4060, DOI 10.4049/jimmunol.174.7.4060; Raymond K, 2005, J CELL SCI, V118, P1045, DOI 10.1242/jcs.01689; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Savagner P, 2005, J CELL PHYSIOL, V202, P858, DOI 10.1002/jcp.20188; Scholl FA, 2004, CANCER RES, V64, P6035, DOI 10.1158/0008-5472.CAN-04-0017; Takaoka AS, 1998, J BIOL CHEM, V273, P33848, DOI 10.1074/jbc.273.50.33848; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Walker JL, 2005, CYTOKINE GROWTH F R, V16, P395, DOI 10.1016/j.cytogfr.2005.03.003; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Xiao JQ, 2003, J BIOL CHEM, V278, P49780, DOI 10.1074/jbc.M308542200; ZUTTER MM, 1994, J BIOL CHEM, V269, P463	52	74	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21321	21331		10.1074/jbc.M509731200	http://dx.doi.org/10.1074/jbc.M509731200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16707493	hybrid			2022-12-25	WOS:000239187300068
J	Imhof, D; Wavreille, AS; May, A; Zacharias, M; Tridandapani, S; Pei, DH				Imhof, Diana; Wavreille, Anne-Sophie; May, Andreas; Zacharias, Martin; Tridandapani, Susheela; Pei, Dehua			Sequence specificity of SHP-1 and SHP-2 Src homology 2 domains - Critical roles of residues beyond the pY+3 position	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PROTEIN-TYROSINE PHOSPHATASES; B-CELL ACTIVATION; FC-GAMMA-RIIB; POTENTIAL BINDING-SITES; NATURAL-KILLER-CELLS; TERMINAL SH2 DOMAIN; INHIBITORY RECEPTOR; NEGATIVE REGULATION; IMMUNOGLOBULIN SUPERFAMILY; ERYTHROPOIETIN RECEPTOR	A combinatorial phosphotyrosyl (pY) peptide library was screened to determine the amino acid preferences at the pY+4 to pY+6 positions for the four SH2 domains of protein-tyrosine phosphatases SHP-1 and SHP-2. Individual binding sequences selected from the library were resynthesized and their binding affinities and specificities to various SH2 domains were further evaluated by SPR studies, stimulation of SHP-1 and SHP-2 phosphatase activity, and in vitro pulldown assays. These studies reveal that binding of a pY peptide to the N-SH2 domain of SHP-2 is greatly enhanced by a large hydrophobic residue (Trp, Tyr, Met, or Phe) at the pY+4 and/or pY+5 positions, whereas binding to SHP-1 N-SH2 domain is enhanced by either hydrophobic or positively charged residues (Arg, Lys, or His) at these positions. Similar residues at the pY+4 to pY+6 positions are also preferred by SHP-1 and SHP-2 C-SH2 domains, although their influence on the overall binding affinities is much smaller compared with the N-SH2 domains. A structural model was generated to qualitatively interpret the contribution of the pY+4 and pY+5 residues to the overall binding affinity. Examination of pY motifs from known SHP-1 and SHP-2-binding proteins shows that many of the pY motifs contain a hydrophobic or positively charged residue(s) at the pY+4 and pY+5 positions.	Ohio State Univ, Dept Chem, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; Int Jacobs Univ Bremen, Sch Sci & Engn, D-28759 Bremen, Germany	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Pei, DH (corresponding author), Ohio State Univ, Dept Chem, 100 W 18th Ave, Columbus, OH 43210 USA.	pei.3@osu.edu	Imhof, Diana/AAD-7491-2019; Pei, Dehua/P-4594-2016; Tridandapani, Susheela/E-4209-2011	Imhof, Diana/0000-0003-4163-7334; Pei, Dehua/0000-0002-2057-6934; 	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062820] Funding Source: NIH RePORTER; NCRR NIH HHS [RR15895] Funding Source: Medline; NIGMS NIH HHS [GM062820] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi T, 2001, J BIOL CHEM, V276, P26648, DOI 10.1074/jbc.M100997200; Alvarez-Errico D, 2004, EUR J IMMUNOL, V34, P3690, DOI 10.1002/eji.200425433; Angata T, 2002, J BIOL CHEM, V277, P24466, DOI 10.1074/jbc.M202833200; Argetsinger LS, 1996, J BIOL CHEM, V271, P29415, DOI 10.1074/jbc.271.46.29415; Avril T, 2005, J BIOL CHEM, V280, P19843, DOI 10.1074/jbc.M502041200; Barrow AD, 2004, J IMMUNOL, V172, P5838, DOI 10.4049/jimmunol.172.10.5838; Bazenet CE, 1996, MOL CELL BIOL, V16, P6926; Beebe KD, 2000, BIOCHEMISTRY-US, V39, P13251, DOI 10.1021/bi0014397; Bellon T, 2002, J IMMUNOL, V168, P3351, DOI 10.4049/jimmunol.168.7.3351; Bjorbaek C, 2000, J BIOL CHEM, V275, P40649, DOI 10.1074/jbc.M007577200; Bone H, 1997, J BIOL CHEM, V272, P14470, DOI 10.1074/jbc.272.22.14470; Bottino C, 2001, J EXP MED, V194, P235, DOI 10.1084/jem.194.3.235; Burshtyn DN, 1997, J BIOL CHEM, V272, P13066, DOI 10.1074/jbc.272.20.13066; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Cantoni C, 1999, EUR J IMMUNOL, V29, P3148, DOI 10.1002/(SICI)1521-4141(199910)29:10<3148::AID-IMMU3148>3.0.CO;2-L; Carretero M, 1998, EUR J IMMUNOL, V28, P1280, DOI 10.1002/(SICI)1521-4141(199804)28:04<1280::AID-IMMU1280>3.0.CO;2-O; CASE D, 2003, AMBER 8; CASE RD, 1994, J BIOL CHEM, V269, P10467; Cella M, 1997, J EXP MED, V185, P1743, DOI 10.1084/jem.185.10.1743; Chauhan D, 2000, J BIOL CHEM, V275, P27845; Chughtai N, 2002, J BIOL CHEM, V277, P31107, DOI 10.1074/jbc.M200156200; Clahsen T, 2005, CELL SIGNAL, V17, P559, DOI 10.1016/j.cellsig.2004.09.016; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; Daigle I, 2002, NAT MED, V8, P61, DOI 10.1038/nm0102-61; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; De Souza D, 2002, BIOCHEMISTRY-US, V41, P9229, DOI 10.1021/bi0259507; de Vet ECJM, 2001, J BIOL CHEM, V276, P42070, DOI 10.1074/jbc.M103214200; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; Falco M, 1999, J EXP MED, V190, P793, DOI 10.1084/jem.190.6.793; Fanger NA, 1998, EUR J IMMUNOL, V28, P3423, DOI 10.1002/(SICI)1521-4141(199811)28:11<3423::AID-IMMU3423>3.0.CO;2-2; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Florio T, 2000, J PHYSIOL-PARIS, V94, P239, DOI 10.1016/S0928-4257(00)00214-X; Fournier N, 2000, J IMMUNOL, V165, P1197, DOI 10.4049/jimmunol.165.3.1197; Frearson JA, 1997, BIOESSAYS, V19, P417, DOI 10.1002/bies.950190509; Fry AM, 1996, J EXP MED, V184, P295, DOI 10.1084/jem.184.1.295; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gavrieli M, 2003, BIOCHEM BIOPH RES CO, V312, P1236, DOI 10.1016/j.bbrc.2003.11.070; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; HAWKINS GD, 1995, CHEM PHYS LETT, V246, P122, DOI 10.1016/0009-2614(95)01082-K; Higashi H, 2002, P NATL ACAD SCI USA, V99, P14428, DOI 10.1073/pnas.222375399; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Huang X, 2001, BIOCHEM BIOPH RES CO, V281, P131, DOI 10.1006/bbrc.2001.4322; Huang ZY, 2003, J LEUKOCYTE BIOL, V73, P823, DOI 10.1189/jlb.0902454; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; HUYER G, 1995, BIOCHEMISTRY-US, V34, P1040, DOI 10.1021/bi00003a039; Huyer G, 1998, BIOCHEMISTRY-US, V37, P2741, DOI 10.1021/bi9722913; Ikehara Y, 2004, J BIOL CHEM, V279, P43117, DOI 10.1074/jbc.M403538200; Imhof D, 2005, J PEPT SCI, V11, P390, DOI 10.1002/psc.631; Ito N, 1998, J BIOL CHEM, V273, P23410, DOI 10.1074/jbc.273.36.23410; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; Kashiwada M, 2001, J IMMUNOL, V167, P6382, DOI 10.4049/jimmunol.167.11.6382; Keilhack H, 2001, J CELL BIOL, V152, P325, DOI 10.1083/jcb.152.2.325; Kim H, 1999, MOL CELL BIOL, V19, P5326; Kitzig F, 2002, BIOCHEM BIOPH RES CO, V296, P355, DOI 10.1016/S0006-291X(02)00885-9; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; Lewis J, 2001, CLIN IMMUNOL, V100, P15, DOI 10.1006/clim.2001.5035; Li LW, 2000, SEMIN IMMUNOL, V12, P75, DOI 10.1006/smim.2000.0209; Lorenz U, 1996, J EXP MED, V184, P1111, DOI 10.1084/jem.184.3.1111; Machida K, 2005, BBA-PROTEINS PROTEOM, V1747, P1, DOI 10.1016/j.bbapap.2004.10.005; Marie-Cardine A, 1999, J EXP MED, V189, P1181, DOI 10.1084/jem.189.8.1181; Mason JM, 2000, J BIOL CHEM, V275, P4398, DOI 10.1074/jbc.275.6.4398; Mousseau DD, 2000, J BIOL CHEM, V275, P4467, DOI 10.1074/jbc.275.6.4467; Muraille E, 2000, IMMUNOL LETT, V72, P7, DOI 10.1016/S0165-2478(00)00162-0; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Okazaki T, 2001, P NATL ACAD SCI USA, V98, P13866, DOI 10.1073/pnas.231486598; Olcese L, 1996, J IMMUNOL, V156, P4531; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Poy F, 1999, MOL CELL, V4, P555, DOI 10.1016/S1097-2765(00)80206-3; Qin CG, 2005, BIOCHEMISTRY-US, V44, P12196, DOI 10.1021/bi050669o; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; Sheppard KA, 2004, FEBS LETT, V574, P37, DOI 10.1016/j.febslet.2004.07.083; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; Sui LL, 2004, BIOCHEM BIOPH RES CO, V319, P920, DOI 10.1016/j.bbrc.2004.05.065; Sweeney MC, 2005, BIOCHEMISTRY-US, V44, P14932, DOI 10.1021/bi051408h; Sweeney MC, 2003, J COMB CHEM, V5, P218, DOI 10.1021/cc020113+; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; Taylor VC, 1999, J BIOL CHEM, V274, P11505, DOI 10.1074/jbc.274.17.11505; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Whitney G, 2001, EUR J BIOCHEM, V268, P6083, DOI 10.1046/j.0014-2956.2001.02543.x; Wolf I, 2002, MOL CELL BIOL, V22, P231, DOI 10.1128/MCB.22.1.231-244.2002; Wong MX, 2004, CURR PHARM DESIGN, V10, P155, DOI 10.2174/1381612043453504; Wu YJ, 1998, CURR BIOL, V8, P1009, DOI 10.1016/S0960-9822(07)00421-6; Xu MJ, 2000, J BIOL CHEM, V275, P17440, DOI 10.1074/jbc.M001313200; Xu MJ, 2001, BIOCHEM BIOPH RES CO, V280, P768, DOI 10.1006/bbrc.2000.4213; Yamasaki S, 2001, J BIOL CHEM, V276, P45175, DOI 10.1074/jbc.M105384200; Yang J, 2003, J BIOL CHEM, V278, P6516, DOI 10.1074/jbc.M210430200; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; Yu WM, 2002, BLOOD, V99, P2351, DOI 10.1182/blood.V99.7.2351; Yu ZB, 2001, J BIOL CHEM, V276, P23816, DOI 10.1074/jbc.M102394200; Zhang JY, 2000, SEMIN IMMUNOL, V12, P361, DOI 10.1006/smim.2000.0223; Zhao RX, 2000, J BIOL CHEM, V275, P5453, DOI 10.1074/jbc.275.8.5453; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	103	48	50	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20271	20282		10.1074/jbc.M601047200	http://dx.doi.org/10.1074/jbc.M601047200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16702225	hybrid			2022-12-25	WOS:000239038200052
J	Martin, DDO; Budamagunta, MS; Ryan, RO; Voss, JC; Oda, MN				Martin, Dale D. O.; Budamagunta, Madhu S.; Ryan, Robert O.; Voss, John C.; Oda, Michael N.			Apolipoprotein A-I assumes a "looped belt" conformation on reconstituted high density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECITHIN-CHOLESTEROL ACYLTRANSFERASE; RESONANCE ENERGY-TRANSFER; ELECTRON-PARAMAGNETIC-RESONANCE; LIPID-BOUND CONFORMATION; C-TERMINAL DOMAIN; APOA-I; SIZE HETEROGENEITY; MASS-SPECTROMETRY; CRYSTAL-STRUCTURE; TRANSGENIC MICE	Apolipoprotein A-I(apoA-I) plays a central role in the reverse cholesterol transport pathway; however, the structural basis for its antiatherogenic effects remains poorly understood. Here we employ EPR spectroscopy and fluorescence resonance energy transfer to elucidate the conformation and relative alignment of apoA-I monomers on discoidal (9.4 nm) reconstituted high density lipoprotein (rHDL). EPR spectroscopy provided evidence for an extended helical secondary structure. Position 139 since it was the only residue examined to display a dynamic motional character consistent with a flexible loop structure. The EPR spectra of nitroxide probes at positions 133 and 146 exhibit spin coupling, indicating that these positions are proximal to an apoA-I paired counterpart on the perimeter of rHDL. fluorescence resonance energy transfer studies employing engineered apoA-I variants possessing a single tryptophan (energy donor) and/or a single cysteine (whose thiol moiety was covalently labeled with an extrinsic energy acceptor) provided evidence that paired apoA-I molecules around the perimeter of rHDL align in an extended antiparallel conformation. Taken together with the observation that the EPR spectra of nitroxide probes positioned at intervening sequence positions (134 - 145) do not exhibit spin coupling, this has led us to propose a "looped belt" model, wherein residues 133 - 146 comprise a flexible loop segment that confers to apoA-I an intrinsic ability to adapt its structure to accommodate changing particle lipid content. Specifically, in the looped belt model, with the exception of amino acids 134 - 145, apoA-I aligns with its counterpart in a helix 5-helix 5 registry, centered at position 139.	Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA; Univ Calif Davis, Dept Biol Chem, Davis, CA 95616 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; University of California System; University of California Davis	Oda, MN (corresponding author), Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA.	moda@chori.org	Martin, Dale/L-6351-2015; Budamagunta, Madhu S/C-4628-2011	Voss, John/0000-0001-9279-209X	NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR012088] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077268, R01HL064159, R37HL064159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG029246] Funding Source: NIH RePORTER; NCRR NIH HHS [C60 RR-12088-01] Funding Source: Medline; NHLBI NIH HHS [HL64159, HL077268] Funding Source: Medline; NIA NIH HHS [R01 AG029246] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ajees AA, 2006, P NATL ACAD SCI USA, V103, P2126, DOI 10.1073/pnas.0506877103; ALTENBACH C, 1989, BIOPHYS J, V56, P1183, DOI 10.1016/S0006-3495(89)82765-1; Bhat S, 2005, J BIOL CHEM, V280, P33015, DOI 10.1074/jbc.M505081200; Bielicki JK, 1997, J LIPID RES, V38, P2314; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; Calabresi L, 1997, BIOCHEM BIOPH RES CO, V232, P345, DOI 10.1006/bbrc.1997.6286; CALABRESI L, 1993, BIOCHEMISTRY-US, V32, P6477, DOI 10.1021/bi00076a023; Calabresi L, 1997, BIOCHEMISTRY-US, V36, P12428, DOI 10.1021/bi970505a; Cho KH, 2001, J LIPID RES, V42, P379; Chomiki N, 2001, EUR J BIOCHEM, V268, P903, DOI 10.1046/j.1432-1327.2001.01946.x; Curtiss LK, 2006, ARTERIOSCL THROM VAS, V26, P12, DOI 10.1161/01.ATV.0000194291.94269.5a; Davidson WS, 2003, J BIOL CHEM, V278, P27199, DOI 10.1074/jbc.M302764200; FORTE TM, 1971, BIOCHIM BIOPHYS ACTA, V248, P381, DOI 10.1016/0005-2760(71)90026-9; Frank PG, 1997, BIOCHEMISTRY-US, V36, P1798, DOI 10.1021/bi962118r; FRONCISZ W, 1982, J MAGN RESON, V47, P515, DOI 10.1016/0022-2364(82)90221-9; Hess JF, 2004, J BIOL CHEM, V279, P44841, DOI 10.1074/jbc.M406257200; HUBBELL WL, 1987, REV SCI INSTRUM, V58, P1879, DOI 10.1063/1.1139536; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; KAMMANN M, 1989, NUCLEIC ACIDS RES, V17, P5404, DOI 10.1093/nar/17.13.5404; Klon AE, 2000, BIOPHYS J, V79, P1679, DOI 10.1016/S0006-3495(00)76417-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li HH, 2000, J BIOL CHEM, V275, P37048, DOI 10.1074/jbc.M005336200; Li HH, 2002, J BIOL CHEM, V277, P39093, DOI 10.1074/jbc.M206770200; Li L, 2004, J MOL BIOL, V343, P1293, DOI 10.1016/j.jmb.2004.09.017; Lindholm EM, 1998, BIOCHEMISTRY-US, V37, P4863, DOI 10.1021/bi972888i; Maiorano JN, 2004, BIOCHEMISTRY-US, V43, P11717, DOI 10.1021/bi0496642; Marcel YL, 2003, CURR OPIN LIPIDOL, V14, P151, DOI 10.1097/00041433-200304000-00006; McManus DC, 2000, J BIOL CHEM, V275, P5043, DOI 10.1074/jbc.275.7.5043; MINNICH A, 1992, J BIOL CHEM, V267, P16553; NICHOLS AV, 1983, BIOCHIM BIOPHYS ACTA, V750, P353, DOI 10.1016/0005-2760(83)90040-1; NICHOLS AV, 1987, J LIPID RES, V28, P719; NOMA A, 1983, ATHEROSCLEROSIS, V49, P1, DOI 10.1016/0021-9150(83)90002-3; Oda MN, 2001, BIOCHEMISTRY-US, V40, P1710, DOI 10.1021/bi001922h; Oda MN, 2003, NAT STRUCT BIOL, V10, P455, DOI 10.1038/nsb931; Roosbeek S, 2001, J LIPID RES, V42, P31; Ryan RO, 2003, PROTEIN EXPRES PURIF, V27, P98, DOI 10.1016/S1046-5928(02)00568-5; Segrest JP, 1999, J BIOL CHEM, V274, P31755, DOI 10.1074/jbc.274.45.31755; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; Silva RAGD, 2005, BIOCHEMISTRY-US, V44, P8600, DOI 10.1021/bi050421z; Sorci-Thomas MG, 2000, J BIOL CHEM, V275, P12156, DOI 10.1074/jbc.275.16.12156; Sorci-Thomas MG, 1998, J BIOL CHEM, V273, P11776, DOI 10.1074/jbc.273.19.11776; SORCITHOMAS M, 1993, J BIOL CHEM, V268, P21403; TALL AR, 1977, J BIOL CHEM, V252, P4701; Tian SM, 2002, BBA-PROTEINS PROTEOM, V1599, P56, DOI 10.1016/S1570-9639(02)00377-1; Tricerri MA, 2000, BIOCHEMISTRY-US, V39, P14682, DOI 10.1021/bi0014251; Tricerri MA, 2001, BIOCHEMISTRY-US, V40, P5065, DOI 10.1021/bi002815q; Voss J, 1997, BIOCHEMISTRY-US, V36, P15055, DOI 10.1021/bi971726j	47	98	106	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20418	20426		10.1074/jbc.M602077200	http://dx.doi.org/10.1074/jbc.M602077200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16698792	hybrid			2022-12-25	WOS:000239038200065
J	Schreiber, S; Stengel, R; Westermann, M; Volkmer-Engert, R; Pop, OI; Muller, JP				Schreiber, Sandra; Stengel, Rayk; Westermann, Martin; Volkmer-Engert, Rudolph; Pop, Ovidiu I.; Mueller, Joerg P.			Affinity of TatC(d) for TatA(d) elucidates its receptor function in the Bacillus subtilis twin arginine translocation (Tat) translocase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEC-INDEPENDENT PROTEIN; ESCHERICHIA-COLI; SIGNAL PEPTIDE; STREPTOMYCES-LIVIDANS; ISOLATED THYLAKOIDS; MEMBRANE-PROTEINS; EXPORT SYSTEM; PATHWAY; COMPLEX; SECRETION	Twin arginine translocation ( Tat) systems catalyze the transport of folded proteins across the bacterial cytosolic membrane or the chloroplast thylakoid membrane. In the Tat systems of Escherichia coli and many other species TatA-, TatB-, and TatC-like proteins have been identified as essential translocase components. In contrast, the Bacillus subtilis phosphodiesterase PhoD-specific system consists only of a pair of TatAd/TatCd proteins and involves a TatAd protein engaged in a cytosolic and a membrane-embedded localization. Because soluble TatAd was able to bind the twin arginine signal peptide of prePhoD prior to membrane integration it could serve to recruit its substrate to the membrane via the interaction with TatCd. By analyzing the distribution of TatAd and studying the mutual affinity with TatCd we have shown here that TatCd assists the membrane localization of TatAd. Besides detergent-solubilized TatCd, membrane-integrated TatCd showed affinity for soluble TatAd. By using a peptide library-specific binding of TatAd to cytosolic loops of membrane protein TatCd was demonstrated. Depletion of TatCd in B. subtilis resulted in a drastic reduction of TatAd, indicating a stabilizing effect of TatCd for TatAd. In addition, the presence of the substrate prePhoD was the prerequisite for appropriate localization in the cytosolic membrane of B. subtilis as demonstrated by freeze-fracture experiments.	Univ Jena, Inst Mol Zellbiol, D-07747 Jena, Germany; Klin Univ Jena, Elektronenmikroskop Zentrum, D-07743 Jena, Germany; Charite, Abt Mol Bibliotheken, D-10117 Berlin, Germany	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Muller, JP (corresponding author), Univ Jena, Inst Mol Zellbiol, Drackendorfer Str 1, D-07747 Jena, Germany.	joerg.mueller2@med.uni-jena.de		Volkmer, Rudolf/0000-0003-4710-1143				Alami M, 2003, MOL CELL, V12, P937, DOI 10.1016/S1097-2765(03)00398-8; Alami M, 2002, J BIOL CHEM, V277, P20499, DOI 10.1074/jbc.M201711200; Allen SCH, 2002, J BIOL CHEM, V277, P10362, DOI 10.1074/jbc.M109135200; Barrett CML, 2005, FEBS J, V272, P2261, DOI 10.1111/j.1742-4658.2005.04654.x; Behrendt J, 2004, FEMS MICROBIOL LETT, V234, P303, DOI 10.1016/j.femsle.2004.03.048; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; Bolhuis A, 2001, J BIOL CHEM, V276, P20213, DOI 10.1074/jbc.M100682200; Buchanan G, 2002, MOL MICROBIOL, V43, P1457, DOI 10.1046/j.1365-2958.2002.02853.x; CLINE K, 1992, J BIOL CHEM, V267, P2688; Cline K, 2001, J CELL BIOL, V154, P719, DOI 10.1083/jcb.200105149; De Keersmaeker S, 2005, BIOCHEM BIOPH RES CO, V335, P973, DOI 10.1016/j.bbrc.2005.07.165; De Keersmaeker S, 2005, FEBS LETT, V579, P797, DOI 10.1016/j.febslet.2004.12.059; de Keyzer J, 2003, CELL MOL LIFE SCI, V60, P2034, DOI 10.1007/s00018-003-3006-y; De Leeuw E, 2001, FEBS LETT, V506, P143, DOI 10.1016/S0014-5793(01)02904-0; Dilks K, 2003, J BACTERIOL, V185, P1478, DOI 10.1128/JB.185.4.1478-1483.2003; Drew D, 2002, P NATL ACAD SCI USA, V99, P2690, DOI 10.1073/pnas.052018199; Economou A, 2002, MOL MEMBR BIOL, V19, P159, DOI 10.1080/09687680210152609; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Fujimoto K, 1997, HISTOCHEM CELL BIOL, V107, P87, DOI 10.1007/s004180050092; Gouffi K, 2004, J BIOL CHEM, V279, P11608, DOI 10.1074/jbc.M313187200; Gouffi K, 2002, FEBS LETT, V525, P65, DOI 10.1016/S0014-5793(02)03069-7; HULETT FM, 1990, J BACTERIOL, V172, P735, DOI 10.1128/jb.172.2.735-740.1990; Jack RL, 2001, J BACTERIOL, V183, P1801, DOI 10.1128/JB.183.5.1801-1804.2001; Jack RL, 2004, EMBO J, V23, P3962, DOI 10.1038/sj.emboj.7600409; Jongbloed JDH, 2002, J BIOL CHEM, V277, P44068, DOI 10.1074/jbc.M203191200; Jongbloed JDH, 2000, J BIOL CHEM, V275, P41350, DOI 10.1074/jbc.M004887200; Jongbloed JDH, 2004, MOL MICROBIOL, V54, P1319, DOI 10.1111/j.1365-2958.2004.04341.x; KLOSGEN RB, 1992, PLANT MOL BIOL, V18, P1031, DOI 10.1007/BF00019226; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mori H, 2001, FEBS LETT, V501, P65, DOI 10.1016/S0014-5793(01)02626-6; MOULD RM, 1991, J BIOL CHEM, V266, P17286; Muller JP, 1996, J BACTERIOL, V178, P6097; Muller JP, 1997, MICROBIOL-SGM, V143, P947, DOI 10.1099/00221287-143-3-947; Muller M, 2001, PROG NUCLEIC ACID RE, V66, P107; Muller M, 2005, MOL MEMBR BIOL, V22, P113, DOI 10.1080/09687860500041809; Oates J, 2003, J MOL BIOL, V330, P277, DOI 10.1016/S0022-2836(03)00621-1; Palmer T, 2003, MICROBIOL-SGM, V149, P547, DOI 10.1099/mic.0.25900-0; Pop O, 2002, J BIOL CHEM, V277, P3268, DOI 10.1074/jbc.M110829200; Pop OI, 2003, J BIOL CHEM, V278, P38428, DOI 10.1074/jbc.M306516200; Robinson C, 2001, NAT REV MOL CELL BIO, V2, P350, DOI 10.1038/35073038; Sargent F, 2001, EUR J BIOCHEM, V268, P3361, DOI 10.1046/j.1432-1327.2001.02263.x; Sargent F, 1999, J BIOL CHEM, V274, P36073, DOI 10.1074/jbc.274.51.36073; Sargent F, 1998, EUR J BIOCHEM, V255, P746, DOI 10.1046/j.1432-1327.1998.2550746.x; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; Swaving J, 1999, J BACTERIOL, V181, P7021, DOI 10.1128/JB.181.22.7021-7027.1999; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; van Dijl JM, 2002, J BIOTECHNOL, V98, P243, DOI 10.1016/S0168-1656(02)00135-9; vanderDoes C, 1996, MOL MICROBIOL, V22, P619, DOI 10.1046/j.1365-2958.1996.d01-1712.x; Walker MB, 1999, J CELL BIOL, V147, P267, DOI 10.1083/jcb.147.2.267; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Wenschuh H, 2000, BIOPOLYMERS, V55, P188, DOI 10.1002/1097-0282(2000)55:3<188::AID-BIP20>3.0.CO;2-T; Wu LF, 2000, J MOL MICROB BIOTECH, V2, P179; Yahr TL, 2001, EMBO J, V20, P2472, DOI 10.1093/emboj/20.10.2472; Yen MR, 2002, ARCH MICROBIOL, V177, P441, DOI 10.1007/s00203-002-0408-4	55	32	36	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					19977	19984		10.1074/jbc.M513900200	http://dx.doi.org/10.1074/jbc.M513900200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16698798	hybrid			2022-12-25	WOS:000239038200021
J	Cordelier, P; Esteve, JP; Najib, S; Moroder, L; Vaysse, N; Pradayrol, L; Susini, C; Buscail, L				Cordelier, Pierre; Esteve, Jean-Pierre; Najib, Souad; Moroder, Luis; Vaysse, Nicole; Pradayrol, Lucien; Susini, Christiane; Buscail, Louis			Regulation of neuronal nitric-oxide synthase activity by somatostatin analogs following SST5 somatostatin receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; TYROSINE PHOSPHATASE SHP-1; GLOMERULAR MESANGIAL CELLS; RINM5F INSULINOMA CELLS; MAP KINASE ACTIVATION; SMOOTH-MUSCLE-CELLS; BETA-GAMMA SUBUNIT; GROWTH-FACTOR; GASTROINTESTINAL-TRACT; IN-VITRO	Somatostatin receptor SST5 is an inhibitory G protein-coupled receptor that exerts a strong cytostatic effect on various cell types. We reported previously that the SST5 anti-proliferative effect results in the inhibition of mitogen-induced increases in intracellular cGMP levels and MAPK activity. This study was conducted to define the early molecular events accountable for the SST5-mediated anti-proliferative effect. Here, we demonstrate that, in Chinese hamster ovary cells expressing SST5 (CHO/SST5 cells), somatostatin inhibited cell proliferation induced by nitric oxide donors and overexpression of the neuronal nitric-oxide synthase (nNOS) protein isoform. Accordingly, nNOS activity and dimerization were strongly inhibited following SST5 activation by the somatostatin analog RC-160. In CHO/SST5 cells, nNOS was dynamically recruited by the SST5 receptor and phosphorylated at tyrosyl residues following RC-160 treatment. RC-160 induced SST5-p60src kinase complex formation and subsequent p60src kinase activation. Coexpression of an inactive p60src kinase mutant with SST5 blocked RC-160-induced nNOS phosphorylation and inactivation and prevented the SST5-mediated anti-proliferative effect. In CHO/SST5 cells, p60(src) kinase associated with nNOS to induce its inactivation by phosphorylation at tyrosyl residues following RC-160 treatment. Using recombinant proteins, we demonstrated that such phosphorylation prevented nNOS homodimerization. Next, surface plasmon resonance and mutation analysis revealed that p60(src) directly associated with nNOS phosphorylated Tyr(604). SST5-mediated inhibition of nNOS activity was demonstrated to be essential to the RC-160 anti-proliferative effect on pancreatic endocrine tumor-derived cells. We therefore identified nNOS as a new p60(src) kinase substrate essential for SST5-mediated anti-proliferative action.	CHU Rangueil, INSERM, U531, Inst Louis Bugnard, F-31432 Toulouse 4, France; Max Planck Inst Biochem, D-82152 Martinsried, Germany	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Max Planck Society	Cordelier, P (corresponding author), CHU Rangueil, INSERM, U531, Inst Louis Bugnard, IFR31,Batiment L3,BP 84225, F-31432 Toulouse 4, France.	pierre.cordelier@toulouse.inserm.fr	Cordelier, Pierre/D-1150-2014	Cordelier, Pierre/0000-0003-2096-7967; Moroder, Luis/0000-0001-9570-5713; Najib, Souad/0000-0001-5509-1411				Alderton F, 2001, BRIT J PHARMACOL, V132, P760, DOI 10.1038/sj.bjp.0703862; Arena S, 2005, MOL ENDOCRINOL, V19, P255, DOI 10.1210/me.2004-0280; Bender AT, 1999, J BIOL CHEM, V274, P1472, DOI 10.1074/jbc.274.3.1472; Bousquet C, 1998, J BIOL CHEM, V273, P7099, DOI 10.1074/jbc.273.12.7099; Brasselet S, 2002, FEBS LETT, V516, P124, DOI 10.1016/S0014-5793(02)02517-6; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; CHEN YH, 1994, J BIOL CHEM, V269, P27372; Chin TY, 2001, EUR J BIOCHEM, V268, P6358, DOI 10.1046/j.0014-2956.2001.02534.x; Christopoulos A., 1999, Life Sciences, V64, P1; Ciani E, 2002, J NEUROCHEM, V81, P218, DOI 10.1046/j.1471-4159.2002.00857.x; Ciani E, 2002, J NEUROCHEM, V82, P1282, DOI 10.1046/j.1471-4159.2002.01080.x; Cordelier P, 1999, FASEB J, V13, P2037, DOI 10.1096/fasebj.13.14.2037; Cordelier P, 1997, P NATL ACAD SCI USA, V94, P9343, DOI 10.1073/pnas.94.17.9343; D'Souza FM, 2003, AM J PHYSIOL-CELL PH, V284, pC191, DOI 10.1152/ajpcell.00179.2002; de Gasparo Marc, 2002, Heart Fail Rev, V7, P347; de Herder WW, 2004, ENDOCR-RELAT CANCER, V11, P19, DOI 10.1677/erc.0.0110019; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Du M, 1997, BIOCHEM MOL BIOL INT, V41, P625; EVERS BM, 1994, ANN NY ACAD SCI, V733, P393, DOI 10.1111/j.1749-6632.1994.tb17289.x; Farinelli SE, 1996, J NEUROSCI, V16, P2325; Ferjoux G, 2003, MOL BIOL CELL, V14, P3911, DOI 10.1091/mbc.E03-02-0069; Florio T, 1999, MOL ENDOCRINOL, V13, P24, DOI 10.1210/me.13.1.24; Florio T, 2003, ENDOCRINOLOGY, V144, P1574, DOI 10.1210/en.2002-220949; Gillies G, 1997, TRENDS PHARMACOL SCI, V18, P87, DOI 10.1016/S0165-6147(96)01032-2; Gu MF, 2000, J BIOL CHEM, V275, P11389, DOI 10.1074/jbc.275.15.11389; Gu MF, 2000, ARTERIOSCL THROM VAS, V20, P27, DOI 10.1161/01.ATV.20.1.27; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; Hajri A, 1998, BRIT J CANCER, V78, P841, DOI 10.1038/bjc.1998.591; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Jaffrey SR, 1998, NEURON, V20, P115, DOI 10.1016/S0896-6273(00)80439-0; Jozkowicz A, 1999, ACTA BIOCHIM POL, V46, P703; Kim YM, 1999, J NEUROSCI, V19, P6740, DOI 10.1523/JNEUROSCI.19-16-06740.1999; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; Komeima K, 2000, J BIOL CHEM, V275, P28139; Kone BC, 2000, ACTA PHYSIOL SCAND, V168, P27; Kone BC, 2003, AM J PHYSIOL-RENAL, V285, pF178, DOI 10.1152/ajprenal.00048.2003; Lahlou H, 2003, J BIOL CHEM, V278, P39356, DOI 10.1074/jbc.M304524200; Lopez F, 2001, FASEB J, V15, P2300, DOI 10.1096/fj.00-0867fje; Lopez F, 1997, J BIOL CHEM, V272, P24448, DOI 10.1074/jbc.272.39.24448; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Matarredona ER, 2004, BRAIN RES, V995, P274, DOI 10.1016/j.brainres.2003.10.010; MCLEOD MK, 1992, J SURG RES, V53, P439, DOI 10.1016/0022-4804(92)90087-G; Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411; Mundell SJ, 2000, J BIOL CHEM, V275, P12900, DOI 10.1074/jbc.275.17.12900; Murillo-Carretero M, 2002, J NEUROCHEM, V83, P119, DOI 10.1046/j.1471-4159.2002.01116.x; OCARROLL AM, 1992, MOL PHARMACOL, V42, P939; Ongini E, 2004, P NATL ACAD SCI USA, V101, P8497, DOI 10.1073/pnas.0401996101; Pittaluga A, 2005, J PHARMACOL EXP THER, V313, P242, DOI 10.1124/jpet.104.079590; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; Ramirez JL, 2004, MOL CELL ENDOCRINOL, V221, P105, DOI 10.1016/j.mce.2004.02.001; Reubi JC, 2001, EUR J NUCL MED, V28, P836, DOI 10.1007/s002590100541; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Rupprecht HD, 2000, KIDNEY INT, V57, P70, DOI 10.1046/j.1523-1755.2000.00828.x; Sandgren K, 2003, J NEUROSCI RES, V72, P595, DOI 10.1002/jnr.10612; Sarkar R, 1997, J HYPERTENS, V15, P275, DOI 10.1097/00004872-199715030-00009; Saur D, 2000, GASTROENTEROLOGY, V118, P849, DOI 10.1016/S0016-5085(00)70171-5; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Sharma RV, 1999, AM J PHYSIOL-HEART C, V276, pH1450, DOI 10.1152/ajpheart.1999.276.5.H1450; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; Stark A, 2002, REGUL PEPTIDES, V108, P97, DOI 10.1016/S0167-0115(02)00152-0; Stetak A, 2001, BIOCHEM BIOPH RES CO, V285, P483, DOI 10.1006/bbrc.2001.5199; Strowski MZ, 2003, MOL ENDOCRINOL, V17, P93, DOI 10.1210/me.2001-0035; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; SULLIVAN SJ, 1988, ENDOCRINOLOGY, V122, P1137, DOI 10.1210/endo-122-3-1137; Tanner FC, 2000, CIRCULATION, V101, P1982, DOI 10.1161/01.CIR.101.16.1982; Thippeswamy T, 1997, BRAIN RES, V774, P116, DOI 10.1016/S0006-8993(97)81694-0; Tomita S, 2001, J CELL BIOL, V153, pF19, DOI 10.1083/jcb.153.5.F19; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Ulibarri JA, 1999, IN VITRO CELL DEV-AN, V35, P215; Vasilaki A, 2004, INVEST OPHTH VIS SCI, V45, P1499, DOI 10.1167/iovs.03-0835; Venema VJ, 1997, J BIOL CHEM, V272, P28187, DOI 10.1074/jbc.272.45.28187; Vezzosi D, 2005, EUR J ENDOCRINOL, V152, P757, DOI 10.1530/eje.1.01901; Wang Y, 1999, CRIT REV NEUROBIOL, V13, P21, DOI 10.1615/CritRevNeurobiol.v13.i1.20; Watanabe Y, 2003, BIOCHEM J, V372, P465, DOI 10.1042/BJ20030380; Wirtz-Brugger F, 2000, NEUROSCIENCE, V99, P737, DOI 10.1016/S0306-4522(00)00243-8; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; Yamazaki M, 2001, J NEUROCHEM, V79, P45, DOI 10.1046/j.1471-4159.2001.00533.x; YASUDA K, 1992, J BIOL CHEM, V267, P20422; Yoshitomi H, 1997, AM J PHYSIOL-ENDOC M, V272, pE769, DOI 10.1152/ajpendo.1997.272.5.E769; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557	91	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19156	19171		10.1074/jbc.M602024200	http://dx.doi.org/10.1074/jbc.M602024200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16690617	hybrid			2022-12-25	WOS:000238847000030
J	Jung, D; Mangelsdorf, DJ; Meyer, UA				Jung, Diana; Mangelsdorf, David J.; Meyer, Urs A.			Pregnane X receptor is a target of farnesoid X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALT EXPORT PUMP; NEGATIVE FEEDBACK-REGULATION; BILE-ACID HOMEOSTASIS; NUCLEAR RECEPTOR; LITHOCHOLIC ACID; DRUG-METABOLISM; RESPONSE ELEMENTS; GENE-EXPRESSION; IDENTIFICATION; INDUCTION	The pregnaneXreceptor (PXR) is an essential component of the body's detoxification system. PXR is activated by a broad spectrum of xenobiotics and endobiotics, including bile acids and their precursors. Bile acids in high concentrations are toxic; therefore, their synthesis is tightly regulated by the farnesoid X receptor, and their catabolism involves several enzymes regulated by PXR. Here we demonstrate that the expression of PXR is regulated by farnesoid X receptor. Feeding mice with cholic acid or the synthetic farnesoid X receptor (FXR) agonist GW4064 resulted in a robust PXR induction. This effect was abolished in FXR knock-out mice. Long time bile acid treatment resulted in an increase of PXR target genes in wild type mice. A region containing four FXR binding sites (IR1) was identified in the mouse Pxr gene. This region was able to trigger an 8-fold induction after GW4064 treatment in transactivation studies. Deletion or mutation of single IR1 sites caused a weakened response. The importance of each individual IR1 element was assessed by cloning a triple or a single copy and was tested in transactivation studies. Two elements were able to trigger a strong response, one a moderate response, and one no response to GW4064 treatment. Mobility shift assays demonstrated that the two stronger responding elements were able to bind FXR protein. This result was confirmed by chromatin immunoprecipitation. These results strongly suggest that PXR is regulated by FXR. Bile acids activate FXR, which blocks synthesis of bile acids and also leads to the transcriptional activation of PXR, promoting breakdown of bile acids. The combination of the two mechanisms leads to an efficient protection of the liver against bile acid induced toxicity.	Univ Basel, Biozentrum, Div Pharmacol & Neurobiol, CH-4056 Basel, Switzerland; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Pharmacol, Dallas, TX 75390 USA	University of Basel; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Jung, D (corresponding author), Univ Basel, Biozentrum, Div Pharmacol & Neurobiol, Kingelbergstr 50-70, CH-4056 Basel, Switzerland.	Diana.jung@unibas.ch		Mangelsdorf, David/0000-0002-4355-0796				Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Chen YH, 2005, TOXICOLOGY, V211, P242, DOI 10.1016/j.tox.2005.03.011; CourjaultGautier F, 1997, EXP CELL RES, V234, P362, DOI 10.1006/excr.1997.3626; Dunn RT, 1999, J PHARMACOL EXP THER, V290, P319; Duran-Sandoval D, 2005, J BIOL CHEM, V280, P29971, DOI 10.1074/jbc.M501931200; Falkner KC, 2001, MOL PHARMACOL, V60, P611; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Fromm MF, 2000, AM J PATHOL, V157, P1575, DOI 10.1016/S0002-9440(10)64794-3; Geick A, 2001, J BIOL CHEM, V276, P14581, DOI 10.1074/jbc.M010173200; Goodwin B, 2001, MOL PHARMACOL, V60, P427; Goodwin B, 2004, TRENDS PHARMACOL SCI, V25, P437, DOI 10.1016/j.tips.2004.06.007; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Goodwin B, 2003, P NATL ACAD SCI USA, V100, P223, DOI 10.1073/pnas.0237082100; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Handschin C, 2003, PHARMACOL REV, V55, P649, DOI 10.1124/pr.55.4.2; HOSOKAWA M, 1993, BIOCHEM PHARMACOL, V45, P2317, DOI 10.1016/0006-2952(93)90205-B; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; Jung D, 2002, GASTROENTEROLOGY, V122, P1954, DOI 10.1053/gast.2002.33583; Jung D, 2001, J BIOL CHEM, V276, P37206, DOI 10.1074/jbc.M103988200; Jung D, 2003, HEPATOLOGY, V37, P622, DOI 10.1053/jhep.2003.50100; Karpen SJ, 2005, HEPATOLOGY, V42, P266, DOI 10.1002/hep.20833; Kast HR, 2002, J BIOL CHEM, V277, P2908, DOI 10.1074/jbc.M109326200; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; Kliewer SA, 2002, ENDOCR REV, V23, P687, DOI 10.1210/er.2001-0038; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Kliewer SA, 2002, J LIPID RES, V43, P359; KLIEWER SA, 2003, J NUTR S7, V133, P244; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; LeCluyse EL, 2001, CHEM-BIOL INTERACT, V134, P283, DOI 10.1016/S0009-2797(01)00163-6; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Li T, 2005, AM J PHYSIOL-GASTR L, V288, P74, DOI DOI 10.1152/AJPGI.00258.2004; Liu L, 1996, BIOCHEM PHARMACOL, V52, P1621, DOI 10.1016/S0006-2952(96)00569-2; MADHU C, 1991, TOXICOL APPL PHARM, V109, P305, DOI 10.1016/0041-008X(91)90177-G; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Marschall HU, 2005, GASTROENTEROLOGY, V129, P476, DOI 10.1053/j.gastro.2005.05.009; Masahiko N, 2000, EUR J PHARM SCI, V11, P259, DOI 10.1016/S0928-0987(00)00112-3; MIYAI K, 1975, LAB INVEST, V32, P527; Owsley E, 2003, BIOCHEM BIOPH RES CO, V304, P191, DOI 10.1016/S0006-291X(03)00551-5; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Pascussi JM, 2000, MOL PHARMACOL, V58, P361, DOI 10.1124/mol.58.2.361; Pascussi JM, 2003, BBA-GEN SUBJECTS, V1619, P243, DOI 10.1016/S0304-4165(02)00483-X; Podvinec M, 2002, MOL ENDOCRINOL, V16, P1269, DOI 10.1210/me.16.6.1269; Prince MI, 2002, GUT, V50, P436, DOI 10.1136/gut.50.3.436; RADOMINSKA A, 1993, SEMIN LIVER DIS, V13, P219, DOI 10.1055/s-2007-1007351; Schuetz EG, 2001, J BIOL CHEM, V276, P39411, DOI 10.1074/jbc.M106340200; Staudinger J, 2001, DRUG METAB DISPOS, V29, P1467; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Sueyoshi T, 2001, ANNU REV PHARMACOL, V41, P123, DOI 10.1146/annurev.pharmtox.41.1.123; Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912; Teng S, 2005, J PHARMACOL EXP THER, V312, P841, DOI 10.1124/jpet.104.076141; Tirona RG, 2005, J PHARM SCI-US, V94, P1169, DOI 10.1002/jps.20324; TUCHWEBER B, 1983, TOXICOL LETT, V19, P107, DOI 10.1016/0378-4274(83)90269-2; Wagner M, 2005, HEPATOLOGY, V42, P420, DOI 10.1002/hep.20784; Wang HB, 2003, CLIN PHARMACOKINET, V42, P1331, DOI 10.2165/00003088-200342150-00003; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Wei P., 2002, Pharmacogenomics Journal, V2, P117, DOI 10.1038/sj.tpj.6500087; Wietholtz H, 1996, J HEPATOL, V24, P713, DOI 10.1016/S0168-8278(96)80268-6; Willson TM, 2002, NAT REV DRUG DISCOV, V1, P259, DOI 10.1038/nrd753; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; Xu DX, 2005, TOXICOL SCI, V87, P38, DOI 10.1093/toxsci/kfi239; Yu JH, 2002, J BIOL CHEM, V277, P31441, DOI 10.1074/jbc.M200474200; Zhang J, 2004, J BIOL CHEM, V279, P49517, DOI 10.1074/jbc.M409041200	64	105	111	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19081	19091		10.1074/jbc.M600116200	http://dx.doi.org/10.1074/jbc.M600116200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16682417	hybrid			2022-12-25	WOS:000238847000022
J	Liu, JG; Ma, XJ				Liu, Jianguo; Ma, Xiaojing			Interferon regulatory factor 8 regulates RANTES gene transcription in cooperation with interferon regulatory factor-1, NF-kappa B, and PU.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-BINDING-PROTEIN; NECROSIS-FACTOR-ALPHA; A VIRUS-INFECTION; INFLUENZA-A; DENDRITIC CELLS; NUCLEAR-FACTOR; IRF FAMILY; IFN-GAMMA; GP91(PHOX) EXPRESSION; FACTOR ACTIVATION	Interferon regulatory factor (IRF)-8 is a member of the IRF family of transcription factors important in interferon-gamma-mediated signaling and in the development and function of dendritic cells. Regulated on activation, normal T cell expressed and secreted (RANTES, or CCL5) is a member of the CC chemokine family of proteins, strongly chemoattractant for several important immune cell types in host defense against infectious agents and cancer. Here we report that RANTES expression in IRF-8-null macrophages stimulated with interferon-gamma and lipopolysaccharide is markedly decreased. IRF-8 can activate RANTES gene transcription in synergism with IRF-1. Interestingly, IRF-8 can activate RANTES transcription independently of IRF-1 through direct physical interactions with NF-kappa B c-Rel and PU.1 via the NF-kappa B element located at -88 to -79 in vitro and in vivo. This study uncovers a novel role of IRF-8 in the regulation of RANTES gene expression and the underlying molecular mechanisms whereby IRF-8 interacts with several other important transcription factors to initiate innate immune responses to pathogenic and inflammatory challenges by activating the RANTES gene.	Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Cornell University	Ma, XJ (corresponding author), Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, 1300 York Ave, New York, NY 10021 USA.	xim2002@med.cornell.edu			NATIONAL CANCER INSTITUTE [R01CA100223] Funding Source: NIH RePORTER; NCI NIH HHS [CA100223] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cappiello MG, 2001, J IMMUNOL, V166, P4498, DOI 10.4049/jimmunol.166.7.4498; Celada A, 1996, J EXP MED, V184, P61, DOI 10.1084/jem.184.1.61; Choi AMK, 1996, AM J PHYSIOL-LUNG C, V271, pL383, DOI 10.1152/ajplung.1996.271.3.L383; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Eklund EA, 1999, J IMMUNOL, V163, P6095; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Fisher RC, 1998, STEM CELLS, V16, P25, DOI 10.1002/stem.160025; Flory E, 2000, J BIOL CHEM, V275, P8307, DOI 10.1074/jbc.275.12.8307; Gri G, 1998, J BIOL CHEM, V273, P6431, DOI 10.1074/jbc.273.11.6431; Hao SX, 2000, MOL CELL BIOL, V20, P1149, DOI 10.1128/MCB.20.4.1149-1161.2000; Himmelmann A, 1997, BLOOD, V90, P3984, DOI 10.1182/blood.V90.10.3984; Hofmann P, 1997, J LEUKOCYTE BIOL, V61, P408, DOI 10.1002/jlb.61.4.408; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kudo T, 2005, INFECT IMMUN, V73, P7602, DOI 10.1128/IAi.73.11.7602-7612.2005; Lee AH, 2000, BIOCHEM J, V350, P131, DOI 10.1042/0264-6021:3500131; Lin RT, 1999, MOL CELL BIOL, V19, P959; Liu JG, 2005, J BIOL CHEM, V280, P24347, DOI 10.1074/jbc.M500973200; Liu JG, 2004, J BIOL CHEM, V279, P55609, DOI 10.1074/jbc.M406565200; Liu JG, 2003, J EXP MED, V198, P1265, DOI 10.1084/jem.20030026; Ma XJ, 1997, J BIOL CHEM, V272, P10389; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Marecki S, 2001, J IMMUNOL, V166, P6829, DOI 10.4049/jimmunol.166.11.6829; Matikainen S, 2000, VIROLOGY, V276, P138, DOI 10.1006/viro.2000.0542; Meraro D, 2002, J IMMUNOL, V168, P6224, DOI 10.4049/jimmunol.168.12.6224; MEURER R, 1993, J EXP MED, V178, P1913, DOI 10.1084/jem.178.6.1913; Morse HC, 2001, LEUKEMIA RES, V25, P719, DOI 10.1016/S0145-2126(01)00022-4; National Research Council, 1985, PUBL NIH, V85-23; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; Ortiz MA, 1999, P NATL ACAD SCI USA, V96, P2740, DOI 10.1073/pnas.96.6.2740; PAHL HL, 1995, J VIROL, V69, P1480, DOI 10.1128/JVI.69.3.1480-1484.1995; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Ronni T, 1997, J IMMUNOL, V158, P2363; RONNI T, 1995, J IMMUNOL, V154, P2764; Rosenbauer F, 2002, EMBO J, V21, P211, DOI 10.1093/emboj/21.3.211; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; Schmidt M, 2004, BLOOD, V103, P4142, DOI 10.1182/blood-2003-01-0285; Schmidt M, 1998, BLOOD, V91, P22, DOI 10.1182/blood.V91.1.22.22_22_29; Schmidt M, 2001, BLOOD, V97, P3648, DOI 10.1182/blood.V97.11.3648; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Sprenger H, 1996, J EXP MED, V184, P1191, DOI 10.1084/jem.184.3.1191; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Tailor P, 2006, CELL RES, V16, P134, DOI 10.1038/sj.cr.7310018; Tamura T, 2005, BLOOD, V106, P1938, DOI 10.1182/blood-2005-01-0080; Tamura T, 2003, BLOOD, V102, P4547, DOI 10.1182/blood-2003-01-0291; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Trinchieri G, 1995, Semin Immunol, V7, P83, DOI 10.1006/smim.1995.0012; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Tsujimura H, 2004, J IMMUNOL, V172, P6820, DOI 10.4049/jimmunol.172.11.6820; Tsujimura H, 2003, J IMMUNOL, V170, P1131, DOI 10.4049/jimmunol.170.3.1131; Wang IM, 2000, J IMMUNOL, V165, P271, DOI 10.4049/jimmunol.165.1.271	56	42	44	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19188	19195		10.1074/jbc.M602059200	http://dx.doi.org/10.1074/jbc.M602059200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16707500	hybrid			2022-12-25	WOS:000238847000033
J	Sala-Valdes, M; Ursa, A; Charrin, S; Rubinstein, E; Hemler, ME; Sanchez-Madrid, F; Yanez-Mo, M				Sala-Valdes, Monica; Ursa, Angeles; Charrin, Stephanie; Rubinstein, Eric; Hemler, Martin E.; Sanchez-Madrid, Francisco; Yanez-Mo, Maria			EWI-2 and EWI-F link the tetraspanin web to the actin cytoskeleton through their direct association with ezrin-radixin-moesin proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; INTERCELLULAR-ADHESION MOLECULE-3; ALPHA-3-BETA-1 INTEGRIN; T-LYMPHOCYTES; ERM PROTEINS; CD9-DEFICIENT MICE; PLASMA-MEMBRANE; GAMETE FUSION; MAJOR CD9; CD81	EWI-2 and EWI-F, two members of a novel subfamily of I-g proteins, are direct partners of tetraspanins CD9 (Tspan29) and CD81 (Tspan28). These EWI proteins contain a stretch of basic charged amino acids in their cytoplasmic domains that may act as binding sites for actin-linking ezrin-radixin-moesin (ERM) proteins. Confocal microscopy analysis revealed that EWI-2 and EWI-F colocalized with ERM proteins at microspikes and microvilli of adherent cells and at the cellular uropod in polarized migrating leukocytes. Immunoprecipitation studies showed the association of EWI-2 and EWI-F with ERM proteins in vivo. Moreover, pulldown experiments and protein-protein binding assays with glutathione S-transferase fusion proteins containing the cytoplasmic domains of EWI proteins corroborated the strong and direct interaction between ERMs and these proteins. The active role of ERMs was further confirmed by double transfections with the N-terminal domain of moesin, which acts as a dominant negative form of ERMs, and was able to delocalize EWIs from the uropod of polarized leukocytes. In addition, direct association of EWI partner CD81 C-terminal domain with ERMs was also demonstrated. Functionally, silencing of endogenous EWI-2 expression by short interfering RNA in lymphoid CEM cells augmented cell migration, cellular polarity, and increased phosphorylation of ERMs. Hence, EWI proteins, through their direct interaction with ERM proteins, act as linkers to connect tetraspanin-associated microdomains to actin cytoskeleton regulating cell motility and polarity.	UAM, Serv Inmunol, Hosp Univ Princesa, Madrid 28006, Spain; Hop Paul Brousse, INSERM, U602, F-94807 Villejuif, France; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Autonomous University of Madrid; Hospital de La Princesa; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Yanez-Mo, M (corresponding author), UAM, Serv Inmunol, Hosp Univ Princesa, Diego Leon 62, Madrid 28006, Spain.	myanez.hlpr@salud.madrid.org	Yáñez-Mó, María/K-8577-2014; YÃÃez-MÃ, Maria/AAI-4544-2020; CHARRIN, Stephanie/B-2892-2019; Rubinstein, Eric/B-4650-2019; Sanchez-Madrid, Francisco/M-7889-2016	Yáñez-Mó, María/0000-0001-7484-2866; YÃÃez-MÃ, Maria/0000-0001-7484-2866; Rubinstein, Eric/0000-0001-7623-9665; Sanchez-Madrid, Francisco/0000-0001-5303-0762; Charrin, Stephanie/0000-0002-4942-3990				Amieva MR, 1999, J CELL SCI, V112, P111; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; Barreiro O, 2005, BLOOD, V105, P2852, DOI 10.1182/blood-2004-09-3606; Barreiro O, 2002, J CELL BIOL, V157, P1233, DOI 10.1083/jcb.200112126; Berditchevski F, 2001, J CELL SCI, V114, P4143; Bost AG, 2003, J VIROL, V77, P4401, DOI 10.1128/JVI.77.7.4401-4408.2003; Bouchard P, 2001, ORG DIVERS EVOL, V1, P17, DOI 10.1078/1439-6092-00003; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Charrin S, 2003, BIOCHEM J, V373, P409, DOI 10.1042/BJ20030343; Charrin S, 2001, J BIOL CHEM, V276, P14329, DOI 10.1074/jbc.M011297200; Clark KL, 2001, J IMMUNOL, V167, P5115, DOI 10.4049/jimmunol.167.9.5115; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gomez-Gaviro MV, 2000, BLOOD, V96, P3592, DOI 10.1182/blood.V96.10.3592.h8003592_3592_3600; He ZY, 2003, DEV BIOL, V254, P226, DOI 10.1016/S0012-1606(02)00043-X; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; HITT AL, 1994, CURR OPIN CELL BIOL, V6, P120, DOI 10.1016/0955-0674(94)90125-2; Inoue N, 2005, NATURE, V434, P234, DOI 10.1038/nature03362; Kaji K, 2000, NAT GENET, V24, P279, DOI 10.1038/73502; Kazarov AR, 2002, J CELL BIOL, V158, P1299, DOI 10.1083/jcb.200204056; Kitadokoro K, 2001, EMBO J, V20, P12, DOI 10.1093/emboj/20.1.12; Kolesnikova TV, 2004, BLOOD, V103, P3013, DOI 10.1182/blood-2003-07-2201; Lammerding J, 2003, P NATL ACAD SCI USA, V100, P7616, DOI 10.1073/pnas.1337546100; Lau LM, 2004, BLOOD, V104, P2368, DOI 10.1182/blood-2003-12-4430; Le Naour F, 2000, SCIENCE, V287, P319, DOI 10.1126/science.287.5451.319; Lee JH, 2004, J CELL BIOL, V167, P327, DOI 10.1083/jcb.200403091; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; Levy S, 2005, NAT REV IMMUNOL, V5, P136, DOI 10.1038/nri1548; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Mittelbrunn M, 2002, J IMMUNOL, V169, P6691, DOI 10.4049/jimmunol.169.12.6691; Miyado K, 2000, SCIENCE, V287, P321, DOI 10.1126/science.287.5451.321; Nishiuchi R, 2005, P NATL ACAD SCI USA, V102, P1939, DOI 10.1073/pnas.0409493102; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; PULIDO R, 1988, J IMMUNOL, V140, P3851; Rosa D, 2005, P NATL ACAD SCI USA, V102, P18544, DOI 10.1073/pnas.0509402102; Rubinstein E, 2006, DEV BIOL, V290, P351, DOI 10.1016/j.ydbio.2005.11.031; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Serrador JM, 1997, J CELL BIOL, V138, P1409, DOI 10.1083/jcb.138.6.1409; Serrador JM, 1998, BLOOD, V91, P4632, DOI 10.1182/blood.V91.12.4632.412k17_4632_4644; Serrador JM, 2002, J BIOL CHEM, V277, P10400, DOI 10.1074/jbc.M110694200; Serrador JM, 2002, EUR J IMMUNOL, V32, P1560, DOI 10.1002/1521-4141(200206)32:6<1560::AID-IMMU1560>3.0.CO;2-U; Stipp CS, 2000, J CELL SCI, V113, P1871; Stipp CS, 2003, J CELL BIOL, V163, P1167, DOI 10.1083/jcb.200309113; Stipp CS, 2001, J BIOL CHEM, V276, P40545, DOI 10.1074/jbc.M107338200; Stipp CS, 2001, J BIOL CHEM, V276, P4853, DOI 10.1074/jbc.M009859200; Tarrant JM, 2003, TRENDS IMMUNOL, V24, P610, DOI 10.1016/j.it.2003.09.011; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Urzainqui A, 2002, IMMUNITY, V17, P401, DOI 10.1016/S1074-7613(02)00420-X; Yanez-Mo M, 2001, MICROCIRCULATION, V8, P153; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Zhang XA, 2003, CANCER RES, V63, P2665; Zhang XA, 2002, MOL BIOL CELL, V13, P1, DOI 10.1091/mbc.01-10-0481; Ziyyat A, 2006, J CELL SCI, V119, P416, DOI 10.1242/jcs.02730	57	145	150	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19665	19675		10.1074/jbc.M602116200	http://dx.doi.org/10.1074/jbc.M602116200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16690612	hybrid			2022-12-25	WOS:000238847000080
J	Smolle, M; Prior, AE; Brown, AE; Cooper, A; Byron, O; Lindsay, JG				Smolle, Michaela; Prior, Alison Elizabeth; Brown, Audrey Elaine; Cooper, Alan; Byron, Olwyn; Lindsay, John Gordon			A new level of architectural complexity in the human pyruvate dehydrogenase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROLIPOYL ACETYLTRANSFERASE COMPONENT; SUBUNIT-BINDING DOMAIN; PRIMARY BILIARY-CIRRHOSIS; X-RAY-SCATTERING; MULTIENZYME COMPLEX; BACILLUS-STEAROTHERMOPHILUS; CRYSTAL-STRUCTURE; GLOBULAR-PROTEINS; SWISS-MODEL; ORGANIZATION	Mammalian pyruvate dehydrogenase multienzyme complex (PDC) is a key metabolic assembly comprising a 60-meric pentagonal dodecahedral E2 ( dihydrolipoamide acetyltransferase) core attached to which are 30 pyruvate decarboxylase E1 heterotetramers and 6 dihydrolipoamide dehydrogenase E3 homodimers at maximal occupancy. Stable E3 integration is mediated by an accessory E3-binding protein (E3BP) located on each of the 12 E2 icosahedral faces. Here, we present evidence for a novel subunit organization in which E3 and E3BP form subcomplexes with a 1:2 stoichiometry implying the existence of a network of E3 "cross-bridges" linking pairs of E3BPs across the surface of the E2 core assembly. We have also determined a low resolution structure for a truncated E3BP/E3 subcomplex using small angle x-ray scattering showing one of the E3BP lipoyl domains docked into the E3 active site. This new level of architectural complexity in mammalian PDC contrasts with the recently published crystal structure of human E3 complexed with its cognate subunit binding domain and provides important new insights into subunit organization, its catalytic mechanism and regulation by the intrinsic PDC kinase.	Univ Glasgow, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Dept Chem, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8TA, Lanark, Scotland	University of Glasgow; University of Glasgow; University of Glasgow	Lindsay, JG (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.	g.lindsay@bio.gla.ac.uk	Cooper, Alan/F-7813-2011	Cooper, Alan/0000-0001-6709-7343; Smolle, Michaela/0000-0001-8900-1541; Byron, Olwyn/0000-0001-7857-4520; Brown, Audrey/0000-0002-0222-4214	Biotechnology and Biological Sciences Research Council [B20089] Funding Source: Medline; Wellcome Trust [065537] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Aral B, 1997, AM J HUM GENET, V61, P1318, DOI 10.1086/301653; Brautigam CA, 2006, STRUCTURE, V14, P611, DOI 10.1016/j.str.2006.01.001; Brautigam CA, 2005, J MOL BIOL, V350, P543, DOI 10.1016/j.jmb.2005.05.014; Bruschi SA, 1998, P NATL ACAD SCI USA, V95, P13413, DOI 10.1073/pnas.95.23.13413; Bubber P, 2005, ANN NEUROL, V57, P695, DOI 10.1002/ana.20474; Ciszak EM, 2006, J BIOL CHEM, V281, P648, DOI 10.1074/jbc.M507850200; de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6; de la Torre JG, 2001, BIOPHYS CHEM, V93, P159, DOI 10.1016/S0301-4622(01)00218-6; Frank RAW, 2005, STRUCTURE, V13, P1119, DOI 10.1016/j.str.2005.04.021; Gibson GE, 1998, ANN NEUROL, V44, P676, DOI 10.1002/ana.410440414; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harding SE, 1999, BIOPHYS J, V76, P2432, DOI 10.1016/S0006-3495(99)77398-4; HIPPS DS, 1994, BIOCHEM J, V297, P137, DOI 10.1042/bj2970137; Hiromasa Y, 2004, J BIOL CHEM, V279, P6921, DOI 10.1074/jbc.M308172200; Howard MJ, 1998, GASTROENTEROLOGY, V115, P139, DOI 10.1016/S0016-5085(98)70375-0; Jones DEJ, 1996, CLIN SCI, V91, P551, DOI 10.1042/cs0910551; Jung HI, 2003, EUR J BIOCHEM, V270, P4488, DOI 10.1046/j.1432-1033.2003.03842.x; Jung HI, 2002, PROTEIN SCI, V11, P1091, DOI 10.1110/ps.4970102; KIM H, 1992, J BIOL CHEM, V267, P5128; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; Kozak M, 2002, ACTA BIOCHIM POL, V49, P509; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lessard IAD, 1996, BIOCHEMISTRY-US, V35, P16863, DOI 10.1021/bi961683r; LESSARD IAD, 1995, BIOCHEM J, V306, P727, DOI 10.1042/bj3060727; Leung PSC, 1996, J AUTOIMMUN, V9, P119, DOI 10.1006/jaut.1996.0015; LEUNG PSC, 1990, HEPATOLOGY, V12, P1321, DOI 10.1002/hep.1840120612; Ling MF, 1998, HUM MOL GENET, V7, P501, DOI 10.1093/hmg/7.3.501; Lissens W, 2000, HUM MUTAT, V15, P209, DOI 10.1002/(SICI)1098-1004(200003)15:3<209::AID-HUMU1>3.0.CO;2-K; LIU SJ, 1995, J BIOL CHEM, V270, P793, DOI 10.1074/jbc.270.2.793; Mande SS, 1996, STRUCTURE, V4, P277, DOI 10.1016/S0969-2126(96)00032-9; Milne JLS, 2002, EMBO J, V21, P5587, DOI 10.1093/emboj/cdf574; Nakasako M, 2001, BIOCHEMISTRY-US, V40, P3069, DOI 10.1021/bi002482x; Nollmann M, 2005, J APPL CRYSTALLOGR, V38, P874, DOI 10.1107/S0021889805026191; Petoukhov MV, 2003, J APPL CRYSTALLOGR, V36, P540, DOI 10.1107/S0021889803000591; Sanderson SJ, 1996, EUR J BIOCHEM, V236, P68, DOI 10.1111/j.1432-1033.1996.00068.x; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Stoops JK, 1997, J BIOL CHEM, V272, P5757, DOI 10.1074/jbc.272.9.5757; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; Svergun DI, 2000, J BIOL CHEM, V275, P297, DOI 10.1074/jbc.275.1.297; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 1997, PROTEINS, V27, P110; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; Toyoda T, 1998, J BIOCHEM-TOKYO, V123, P668; TREWHELLA J, 1988, BIOCHEMISTRY-US, V27, P1121, DOI 10.1021/bi00404a007; Vestergaard B, 2005, MOL CELL, V20, P929, DOI 10.1016/j.molcel.2005.11.022; VIGH R, 1989, ARCH BIOCHEM BIOPHYS, V275, P181, DOI 10.1016/0003-9861(89)90362-7; Wriggers W, 2001, J STRUCT BIOL, V133, P193, DOI 10.1006/jsbi.2000.4350; Wriggers W, 2001, STRUCTURE, V9, P779, DOI 10.1016/S0969-2126(01)00648-7; Yang DQ, 1997, J BIOL CHEM, V272, P6361, DOI 10.1074/jbc.272.10.6361; Zhou ZH, 2001, P NATL ACAD SCI USA, V98, P14802, DOI 10.1073/pnas.011597698; Zhou ZH, 2001, J BIOL CHEM, V276, P21704, DOI 10.1074/jbc.M101765200	53	53	59	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19772	19780		10.1074/jbc.M601140200	http://dx.doi.org/10.1074/jbc.M601140200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16679318	hybrid, Green Accepted			2022-12-25	WOS:000238847000090
J	Zou, TT; Mazan-Mamczarz, K; Rao, JN; Liu, L; Marasa, BS; Zhang, AH; Xiao, L; Pullmann, R; Gorospe, M; Wang, JY				Zou, Tongtong; Mazan-Mamczarz, Krystyna; Rao, Jaladanki N.; Liu, Lan; Marasa, Bernard S.; Zhang, Ai-Hong; Xiao, Lan; Pullmann, Rudolf; Gorospe, Myriam; Wang, Jian-Ying			Polyamine depletion increases cytoplasmic levels of RNA-binding protein HuR leading to stabilization of nucleophosmin and p53 mRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; GASTROINTESTINAL MUCOSAL GROWTH; KAPPA-B ACTIVATION; CARCINOMA-CELLS; C-MYC; STABILITY; INHIBITION; EXPRESSION; APOPTOSIS; PATHWAY	Polyamines are essential for maintaining normal intestinal epithelial integrity, an effect that relies, at least in part, on their ability to keep low levels of nucleophosmin (NPM) and p53 mRNAs. The RNA-binding protein HuR associates with the p53 mRNA, as reported previously, and with the NPM mRNA, computationally predicted to be a target of HuR. Here, we show that HuR binds the NPM and p53 3 '-untranslated regions and stabilizes these mRNAs in polyamine-depleted intestinal epithelial cells. Depletion of cellular polyamines by inhibiting ornithine decarboxylase with alpha-difluoromethylornithine dramatically enhanced the cytoplasmic abundance of HuR, whereas ectopic ornithine decarboxylase overexpression decreased cytoplasmic HuR; neither intervention changed whole-cell HuR levels. HuR was found to specifically bind the 3'-untranslated regions of NPN and p53 mRNAs. HuR silencing rendered the NPM and p53 mRNAs unstable and prevented increases in NPM and p53 mRNA and protein in polyamine-deficient cells. These results indicate that polyamines modulate cytoplasmic HuR levels in intestinal epithelial cells, in turn controlling the stability of the NPM and p53 mRNAs and influencing NPM and p53 protein levels.	Baltimore Vet Affairs Med Ctr, Surg Serv, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Cell Biol Grp, Dept Surg, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; NIA, IRP, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Wang, JY (corresponding author), Baltimore Vet Affairs Med Ctr, Surg Serv, 10 N Greene St, Baltimore, MD 21201 USA.	jwang@smail.umaryand.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061972, R01DK057819, R01DK068491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000511] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-57819, DK-61972, DK-68491] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bashirullah A, 2001, P NATL ACAD SCI USA, V98, P7025, DOI 10.1073/pnas.111145698; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; CELANO P, 1989, J BIOL CHEM, V264, P8922; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Fan JS, 2002, P NATL ACAD SCI USA, V99, P10611, DOI 10.1073/pnas.162212399; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Galban S, 2003, MOL CELL BIOL, V23, P7083, DOI 10.1128/MCB.23.20.7083-7095.2003; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; Gorospe M, 2003, CELL CYCLE, V2, P412, DOI 10.4161/cc.2.5.491; Guo X, 2005, AM J PHYSIOL-GASTR L, V288, pG1159, DOI 10.1152/ajpgi.00407.2004; HARTER HL, 1960, BIOMETRICS, V16, P671, DOI 10.2307/2527770; Heinonen M, 2005, CANCER RES, V65, P2157, DOI 10.1158/0008-5472.CAN-04-3765; JOHNSON LR, 1988, PHYSIOL REV, V68, P456, DOI 10.1152/physrev.1988.68.2.456; Kramer DL, 1999, CANCER RES, V59, P1278; LAEMMLI UK, 1990, NATURE, V227, P680; Li L, 2002, GASTROENTEROLOGY, V123, P764, DOI 10.1053/gast.2002.35386; Li L, 2001, AM J PHYSIOL-GASTR L, V280, pG992, DOI 10.1152/ajpgi.2001.280.5.G992; Li L, 2001, AM J PHYSIOL-CELL PH, V281, pC941, DOI 10.1152/ajpcell.2001.281.3.C941; Li L, 1999, AM J PHYSIOL-CELL PH, V276, pC946, DOI 10.1152/ajpcell.1999.276.4.C946; Liu L, 2005, AM J PHYSIOL-CELL PH, V288, pC89, DOI 10.1152/ajpcell.00326.2004; Liu L, 2003, AM J PHYSIOL-GASTR L, V285, pG1056, DOI 10.1152/ajpgi.00151.2003; Liu L, 2006, BIOCHEM J, V398, P257, DOI 10.1042/BJ20060217; LUK GD, 1980, SCIENCE, V210, P195, DOI 10.1126/science.6774420; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Mazan-Mamczarz K, 2003, P NATL ACAD SCI USA, V100, P8354, DOI 10.1073/pnas.1432104100; MCCORMACK SA, 1991, AM J PHYSIOL, V260, pG795, DOI 10.1152/ajpgi.1991.260.6.G795; Patel AR, 1999, AM J PHYSIOL-GASTR L, V276, pG441, DOI 10.1152/ajpgi.1999.276.2.G441; Patel AR, 1997, AM J PHYSIOL-CELL PH, V273, pC1020, DOI 10.1152/ajpcell.1997.273.3.C1020; Patel AR, 1998, AM J PHYSIOL-CELL PH, V275, pC590, DOI 10.1152/ajpcell.1998.275.2.C590; Paulding WR, 1999, J BIOL CHEM, V274, P2532, DOI 10.1074/jbc.274.4.2532; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Pfeffer LM, 2001, J BIOL CHEM, V276, P45909, DOI 10.1074/jbc.M108097200; POTTEN CS, 1988, J CELL SCI, P45; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; POTTEN CS, 1997, AM J PHYSIOL, V273, P253; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Rao JN, 2000, AM J PHYSIOL-CELL PH, V279, pC1034, DOI 10.1152/ajpcell.2000.279.4.C1034; Seko Y, 2004, J BIOL CHEM, V279, P33359, DOI 10.1074/jbc.M312306200; Shih SC, 1999, J BIOL CHEM, V274, P1359, DOI 10.1074/jbc.274.3.1359; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Tran H, 2003, MOL CELL BIOL, V23, P7177, DOI 10.1128/MCB.23.20.7177-7188.2003; VIELKIND U, 1989, HISTOCHEMISTRY, V91, P81, DOI 10.1007/BF00501916; WANG JY, 1991, AM J PHYSIOL, V261, pG504, DOI 10.1152/ajpgi.1991.261.3.G504; WANG JY, 1993, AM J PHYSIOL, V265, P331; Wang W, 2002, MOL CELL BIOL, V22, P3425, DOI 10.1128/MCB.22.10.3425-3436.2002; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Yang XL, 2004, J BIOL CHEM, V279, P49298, DOI 10.1074/jbc.M407535200; Zhang HFM, 2004, J BIOL CHEM, V279, P22539, DOI 10.1074/jbc.M314337200; Zou TT, 2005, AM J PHYSIOL-CELL PH, V289, pC686, DOI 10.1152/ajpcell.00085.2005	50	103	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19387	19394		10.1074/jbc.M602344200	http://dx.doi.org/10.1074/jbc.M602344200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16690610	hybrid			2022-12-25	WOS:000238847000054
J	Park, GY; Wang, XR; Hu, NN; Pedchenko, TV; Blackwell, TS; Christman, JW				Park, Gye Young; Wang, Xuerong; Hu, Ningning; Pedchenko, Tetyana V.; Blackwell, Timothy S.; Christman, John W.			NIK is involved in nucleosomal regulation by enhancing histone H3 phosphorylation by IKK alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LYMPHOTOXIN-BETA-RECEPTOR; KINASE-ALPHA; GENE-EXPRESSION; MICE LACKING; DEPENDENT TRANSCRIPTION; LIVER DEGENERATION; SIGNALING PATHWAYS; DEFICIENT MICE; MAP KINASE	The exact physiological role of NF-kappa B-inducing kinase (NIK) in the NF-kappa B activation pathway has not been defined, although it is an upstream kinase of IKK alpha. Recent studies have indicated that IKK alpha is a nucleosomal modifier of NF-kappa B signaling. We hypothesized that NIK generates a proximal signal that contributes to IKK alpha modification of nucleosomal structure through phosphorylation of histone H3 and enhancement of target gene expression. By using a chromatin immunoprecipitation assay, our data show that endogenous IKK alpha is recruited to the promoter site of several NF-kappa B-dependent genes in macrophages. Our data show that immunoreactive NIK is rapidly recruited to nuclear compartment in macrophages in response to treatment with endotoxin where it augments phosphorylation of histone H3 by inducing phosphorylation and kinase activity of IKK alpha. A small interfering RNA knockdown of NIK markedly reduces phosphorylation of histone H3 in endotoxin treated macrophages. These data, together, demonstrate a novel role for NIK as a histone H3 modifier, through an accessory pathway from NIK to IKK alpha, that could play an important role in the endotoxin response through modification of nucleosomal structure.	Univ Illinois, Sect Pulm Crit Care & Sleep Med, Chicago, IL 60612 USA; Vanderbilt Univ, Div Allergy Pulm & Crit Care Med, Nashville, TN 37203 USA; Dept Vet Affairs, Nashville, TN 37203 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Vanderbilt University	Christman, JW (corresponding author), Univ Illinois, Sect Pulm Crit Care & Sleep Med, 840 S Wood St,M-C 719, Chicago, IL 60612 USA.	jwc@uic.edu			NHLBI NIH HHS [HL 075557, P01 HL066196, HL 66196, R01 HL075557] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075557, P01HL066196] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Birbach A, 2004, J CELL SCI, V117, P3615, DOI 10.1242/jcs.01224; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Clayton AL, 2003, FEBS LETT, V546, P51, DOI 10.1016/S0014-5793(03)00451-4; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li X, 2002, J BIOL CHEM, V277, P45129, DOI 10.1074/jbc.M205165200; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Park GY, 2004, AM J PHYSIOL-LUNG C, V286, pL956, DOI 10.1152/ajplung.00338.2003; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Sadikot RT, 2003, J IMMUNOL, V170, P1091, DOI 10.4049/jimmunol.170.2.1091; Saito N, 2003, J BIOL CHEM, V278, P46565, DOI 10.1074/jbc.M302549200; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Sil AK, 2004, NATURE, V428, P660, DOI 10.1038/nature02421; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	35	44	46	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18684	18690		10.1074/jbc.M600733200	http://dx.doi.org/10.1074/jbc.M600733200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16675465	Green Accepted, hybrid			2022-12-25	WOS:000238687300049
J	Abdel-Malek, ZA; Kadekaro, AL; Kavanagh, RJ; Todorovic, A; Koikov, LN; McNulty, JC; Jackson, PJ; Millhauser, GL; Schwemberger, S; Babcock, G; Haskell-Luevano, C; Knittel, JJ				Abdel-Malek, Zalfa A.; Kadekaro, Ana Luisa; Kavanagh, Renny J.; Todorovic, Aleksandar; Koikov, Leonid N.; McNulty, Joseph C.; Jackson, Pilgrim J.; Millhauser, Glenn L.; Schwemberger, Sandy; Babcock, George; Haskell-Luevano, Carrie; Knittel, James J.			Melanoma prevention strategy based on using tetrapeptide alpha-MSH analogs that protect human melanocytes from UV-induced DNA damage and cytotoxicity	FASEB JOURNAL			English	Article						melanocortins; photoprotection; melanogenesis; DNA repair; melanomagenesis	NONMELANOMA SKIN-CANCER; MINIMAL ACTIVE SEQUENCE; MELANOCORTIN RECEPTORS; MELANOTROPIN; RISK; STIMULATION; MUTATIONS; VARIANTS; PEPTIDES; AGONISTS	Melanoma is the deadliest form of skin cancer, with no cure for advanced disease. We propose a strategy for melanoma prevention based on using analogs of alpha-melanocyte stimulating hormone (alpha-MSH) that function as melanocortin 1 receptor (MC1R) agonists. Treatment of human melanocytes with alpha-MSH results in stimulation of eumelanin synthesis, reduction of apoptosis that is attributable to reduced hydrogen peroxide generation and enhanced repair of DNA photoproducts. These effects should contribute to genomic stability of human melanocytes, thus preventing their malignant transformation to melanoma. Based on these findings, we synthesized and tested the effects of 3 tetrapeptide alpha-MSH analogs, Ac-His-D-Phe-Arg-Trp-NH2, n-Pentadecanoyl- and 4-Phenylbutyryl-His-D-Phe-Arg-Trp-NH2, on cultured human melanocytes. The latter two analogs were more potent than the former, or alpha-MSH, in stimulating the activity of tyrosinase, thus melanogenesis, reducing apoptosis and release of hydrogen peroxide and enhancing repair of DNA photoproducts in melanocytes exposed to UV radiation (UVR). The above analogs are MC1R agonists, as their effects were abrogated by an analog of agouti signaling protein, the physiological MC1R antagonist, and were absent in melanocytes expressing loss-of-function MC1R. Analogs, such as 4-Phenylbutyryl-His-D-Phe-Arg-Trp-NH2 with prolonged and reversible effects, can potentially be developed into topical agents to prevent skin photocarcinogenesis, particularly melanoma.	Univ Cincinnati, Coll Med, Dept Dermatol, Cincinnati, OH 45267 USA; Univ Florida, Coll Pharm, Dept Med Chem, Gainesville, FL 32611 USA; Univ Cincinnati, Coll Pharm, Cincinnati, OH 45221 USA; Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; Univ Cincinnati, Dept Surg, Coll Med, Cincinnati, OH 45221 USA; Shriners Burn Hosp, Cincinnati, OH USA	University System of Ohio; University of Cincinnati; State University System of Florida; University of Florida; University System of Ohio; University of Cincinnati; University of California System; University of California Santa Cruz; University System of Ohio; University of Cincinnati	Abdel-Malek, ZA (corresponding author), Univ Cincinnati, Coll Med, Dept Dermatol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	abdelmza@email.uc.edu		JACKSON, PILGRIM/0000-0002-2796-5297	NIDDK NIH HHS [DK 57080, DK 064265] Funding Source: Medline; NIEHS NIH HHS [R01 ES-09110] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK057080, R01DK057080, R01DK064265] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009110] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abdel-Malek ZA, 2001, CELL MOL LIFE SCI, V58, P434, DOI 10.1007/PL00000868; ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; ABDELMALEK Z, 1998, PIGMENTARY SYSTEM PH, P115; *AM CANC SOC, 2005, FACTS FIG; BARKER D, 1995, CANCER RES, V55, P4041; Bastiaens MT, 2001, AM J HUM GENET, V68, P884, DOI 10.1086/319500; CASTRUCCI AML, 1989, GEN COMP ENDOCR, V73, P157, DOI 10.1016/0016-6480(89)90066-X; Chakraborty AK, 1996, BBA-MOL CELL RES, V1313, P130, DOI 10.1016/0167-4889(96)00063-8; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Geschwind I.I., 1972, Recent Progress Hormone Res, V28, P91; GREEN A, 1985, BRIT J CANCER, V51, P393, DOI 10.1038/bjc.1985.53; Hadley M.E., 1996, ENDOCRINOLOGY; HRUBY VJ, 1987, J MED CHEM, V30, P2126, DOI 10.1021/jm00394a033; HUNT G, 1994, PIGM CELL RES, V7, P217, DOI 10.1111/j.1600-0749.1994.tb00052.x; Im SB, 1998, CANCER RES, V58, P47; JOSEPH M, 1988, FEBS LETT, V238, P411, DOI 10.1016/0014-5793(88)80522-2; Kadekaro AL, 2005, CANCER RES, V65, P4292, DOI 10.1158/0008-5472.CAN-04-4535; Koikov LN, 2003, BIOORG MED CHEM LETT, V13, P2647, DOI 10.1016/S0960-894X(03)00552-3; KRAEMER KH, 1994, ARCH DERMATOL, V130, P1018, DOI 10.1001/archderm.130.8.1018; Krishnan V, 1999, BIOORG MED CHEM LETT, V9, P3363, DOI 10.1016/S0960-894X(99)00604-6; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; LAN EL, 1994, J PHARM SCI, V83, P1081, DOI 10.1002/jps.2600830805; LEVINE N, 1991, JAMA-J AM MED ASSOC, V266, P2730, DOI 10.1001/jama.266.19.2730; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MARWAN MM, 1985, MOL CELL ENDOCRINOL, V41, P171, DOI 10.1016/0303-7207(85)90020-6; McNulty JC, 2005, J MOL BIOL, V346, P1059, DOI 10.1016/j.jmb.2004.12.030; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Palmer JS, 2000, AM J HUM GENET, V66, P176, DOI 10.1086/302711; Sander CS, 2004, INT J DERMATOL, V43, P326, DOI 10.1111/j.1365-4632.2004.02222.x; Sarkar-Agrawal P, 2004, JNCI-J NATL CANCER I, V96, P1790, DOI 10.1093/jnci/djh307; SAWYER TK, 1982, J MED CHEM, V25, P1022, DOI 10.1021/jm00351a004; Scott MC, 2002, J CELL SCI, V115, P2349; SLEPNEV VI, 1995, BIOCONJUGATE CHEM, V6, P608, DOI 10.1021/bc00035a016; Suzuki I, 1996, ENDOCRINOLOGY, V137, P1627, DOI 10.1210/en.137.5.1627; Suzuki I, 1997, J INVEST DERMATOL, V108, P838, DOI 10.1111/1523-1747.ep12292572; Thomas RK, 2003, MARK HEALTH SERV, V23, P38; Todorovic A, 2005, J MED CHEM, V48, P3328, DOI 10.1021/jm0490843; Tucker MA, 2003, ONCOGENE, V22, P3042, DOI 10.1038/sj.onc.1206444; Veuillez F, 1999, EUR J PHARM BIOPHARM, V48, P21, DOI 10.1016/S0939-6411(99)00025-9; Wei QY, 2003, J NATL CANCER I, V95, P308, DOI 10.1093/jnci/95.4.308	40	60	64	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1561	+		10.1096/fj.05-5655fje	http://dx.doi.org/10.1096/fj.05-5655fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16723376				2022-12-25	WOS:000240266000051
J	He, YY; Pi, J; Huang, JL; Diwan, BA; Waalkes, MP; Chignell, CF				He, YY; Pi, J; Huang, JL; Diwan, BA; Waalkes, MP; Chignell, CF			Chronic UVA irradiation of human HaCaT keratinocytes induces malignant transformation associated with acquired apoptotic resistance	ONCOGENE			English	Article						UVA; transformation; carcinogenesis; AKT; keratinocyte; PTEN	SOLAR ULTRAVIOLET-RADIATION; SQUAMOUS-CELL-CARCINOMA; SKIN-CANCER; IV COLLAGENASE; SUN EXPOSURE; MOUSE SKIN; INDUCTION; PTEN; EXPRESSION; CARCINOGENESIS	Ultraviolet A ( UVA, 315 - 400 nm), constituting about 95% of ultraviolet irradiation in natural sunlight, represents a major environmental challenge to the skin and is clearly associated with human skin cancer. It has proven difficult to show direct actions of UVA as a carcinogen in human cells. Here, we demonstrate that chronic UVA exposures at environmentally relevant doses in vitro can induce malignant transformation of human keratinocytes associated with acquired apoptotic resistance. As evidence of carcinogenic transformation, UVA-long-treated ( 24 J/cm(2) once/week for 18 weeks) HaCaT ( ULTH) cells showed increased secretion of matrix metalloproteinase ( MMP-9), overexpression of keratin 13, altered morphology and anchorage-independent growth. Malignant transformation was established by the production of aggressive squamous cell carcinomas after inoculation of ULTH cells into nude mice ( NCr-nu). ULTH cells were resistant to apoptosis induced not only by UVA but also by UVB and arsenite, two other human skin carcinogens. ULTH cells also became resistant to apoptosis induced by etoposide, staurosporine and doxorubicin hydrochloride. Elevated phosphorylation of protein kinase B ( PKB, also called AKT) and reduced expression of phosphatase and tensin homologue deleted on chromosome 10 ( PTEN) were detected in ULTH cells. The resistance of ULTH cells to UVA-induced apoptosis was reversed by either inhibition of phosphatidylinositol 3-kinase ( PI-3K) or adenovirus expression of PTEN or dominant negative AKT. These data indicate that UVA has carcinogenic potential in human keratinocytes and that the increased AKT signaling and decreased PTEN expression may contribute to this malignant transformation. Further comparisons between the transformed ULTH and control cells should lead to a better understanding of the mechanism of UVA carcinogenesis and may help identify biomarkers for UVA-induced skin malignancies.	NIEHS, Lab Comparat Carcinogenesis, Inorgan Carcinogenesis Sect, Res Triangle Pk, NC USA; Sci Applicat Int Corp, Basic Res Program, NCI, Frederick, MA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	He, YY (corresponding author), NIEHS, Lab Pharmacol & Chem, NIH, 111 TW Alexander Dr,POB 12233,MD F0-06, Res Triangle Pk, NC 27709 USA.	he3@niehs.nih.gov	PI, JINGBO/GWC-2514-2022	PI, JINGBO/0000-0003-0227-8041	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050046] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achanzar WE, 2001, CANCER RES, V61, P455; Agar NS, 2004, P NATL ACAD SCI USA, V101, P4954, DOI 10.1073/pnas.0401141101; Autier P, 1999, JNCI-J NATL CANCER I, V91, P1304, DOI 10.1093/jnci/91.15.1304; Backman SA, 2004, P NATL ACAD SCI USA, V101, P1725, DOI 10.1073/pnas.0308217100; BERNHARD EJ, 1990, CANCER RES, V50, P3872; Borchers AH, 1997, MOL CARCINOGEN, V19, P258, DOI 10.1002/(SICI)1098-2744(199708)19:4<258::AID-MC7>3.0.CO;2-8; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRULS WAG, 1984, PHOTOCHEM PHOTOBIOL, V40, P485, DOI 10.1111/j.1751-1097.1984.tb04622.x; Catani MV, 2001, BIOCHEM J, V356, P77, DOI 10.1042/0264-6021:3560077; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Cokkinides VE, 2001, PREV MED, V33, P141, DOI 10.1006/pmed.2001.0877; COX AD, 1994, METHOD ENZYMOL, V238, P277; Dahle J, 2003, CANCER RES, V63, P1464; Davies MA, 2002, CLIN CANCER RES, V8, P1904; DEGRUIJL FR, 1993, CANCER RES, V53, P53; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Gasparro FP, 2000, ENVIRON HEALTH PERSP, V108, P71, DOI 10.2307/3454633; Geller AC, 2002, PEDIATRICS, V109, P1009, DOI 10.1542/peds.109.6.1009; He YY, 2004, J BIOL CHEM, V279, P53867, DOI 10.1074/jbc.M405781200; He YY, 2003, J BIOL CHEM, V278, P42457, DOI 10.1074/jbc.M303376200; He YY, 2003, J BIOL CHEM, V278, P8058, DOI 10.1074/jbc.M207781200; Huang JH, 2002, J BIOL CHEM, V277, P10760, DOI 10.1074/jbc.M110219200; JEANMOUGIN M, 1987, ANN DERMATOL VENER, V114, P671; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; JUAREZ J, 1993, INT J CANCER, V55, P10, DOI 10.1002/ijc.2910550104; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Minaguchi T, 1999, CANCER RES, V59, P6063; Noonan FP, 2001, NATURE, V413, P271, DOI 10.1038/35095108; Phillipson RP, 2002, FREE RADICAL BIO MED, V32, P474, DOI 10.1016/S0891-5849(01)00829-2; Pi JB, 2005, INT J CANCER, V116, P20, DOI 10.1002/ijc.20990; Rossman TG, 2001, TOXICOL APPL PHARM, V176, P64, DOI 10.1006/taap.2001.9277; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; Slaga T J, 1995, Prog Clin Biol Res, V391, P1; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Suzuki A, 2003, CANCER RES, V63, P674; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WARREN BS, 1993, P SOC EXP BIOL MED, V202, P9; Wyllie A H, 1980, Int Rev Cytol, V68, P251	40	75	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2006	25	26					3680	3688		10.1038/sj.onc.1209384	http://dx.doi.org/10.1038/sj.onc.1209384			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16682958				2022-12-25	WOS:000238448300007
J	Zhang, YM; Bo, J; Taffet, GE; Chang, J; Shi, J; Reddy, AK; Michael, LH; Schneider, MD; Entman, ML; Schwartz, RJ; Wei, L				Zhang, Ying-Min; Bo, Jacqueline; Taffet, George E.; Chang, Jiang; Shi, Jianjian; Reddy, Anilkumar K.; Michael, Lloyd H.; Schneider, Michael D.; Entman, Mark L.; Schwartz, Robert J.; Wei, Lei			Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis	FASEB JOURNAL			English	Article						Rho kinase; pressure overload; fibrosis; hypertrophy; fibrogenic cytokines	TISSUE GROWTH-FACTOR; LEFT-VENTRICULAR HYPERTROPHY; LONG-TERM INHIBITION; RHO-KINASE; CARDIAC-HYPERTROPHY; ANGIOTENSIN-II; MYOCARDIAL HYPERTROPHY; IN-VIVO; FAILURE; MICE	Ventricular myocyte hypertrophy is an important compensatory growth response to pressure overload. However, pathophysiological cardiac hypertrophy is accompanied by reactive fibrosis and remodeling. The Rho kinase family, consisting of ROCK1 and ROCK2, has been implicated in cardiac hypertrophy and ventricular remodeling. However, these previous studies relied heavily on pharmacological inhibitors, and not on gene deletion. Here we used ROCK1 knockout (ROCK1(-/-)) mice to investigate role of ROCK1 in the development of ventricular remodeling induced by transverse aortic banding. We observed that ROCK1 deletion did not impair compensatory hypertrophic response induced by pressure overload. However, ROCK1(-/-) mice exhibited reduced perivascular and interstitial fibrosis, which was observed at 3 wk but not at 1 wk after the banding. The reduced fibrosis in the myocardium of ROCK1(-/-) mice was closely associated with reduced expression of a variety of extracellular matrix (ECM) proteins and fibrogenic cytokines such as TGF beta 2 and connective tissue growth factor. This inhibitory effect of ROCK1 deletion on pathophysiological induction of fibrogenic cytokines was further confirmed in the myocardium of transgenic mice with cardiomyocyte-specific overexpression of G alpha q. Thus, these results indicate that ROCK1 contributes to the development of cardiac fibrosis and induction of fibrogenic cytokines in cardiomyocytes in response to pathological stimuli.	Indiana Univ, Sch Med, Dept Pediat, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Baylor Coll Med, Cardiovasc Sci Sect, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Ctr Cardiovasc Dev, Houston, TX 77030 USA; Texas A&M Univ, Syst Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX USA	Indiana University System; Indiana University-Purdue University Indianapolis; Baylor College of Medicine; Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Wei, L (corresponding author), Indiana Univ, Sch Med, Dept Pediat, Herman B Wells Ctr Pediat Res, R4 Bldg,Rm 370,1044 W Walnut St, Indianapolis, IN 46202 USA.	lewei@iupui.edu	Reddy, Anilkumar/GLS-1391-2022	Schneider, Michael/0000-0001-9645-1938; Chang, Jiang/0000-0003-3707-7557	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049953, P01HL042550, R01HL064356, R01HL072897, P01HL085098] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL072897-04, R01-HL72897, P01 HL085098, R01 HL072897, P01-HL42550, P01-HL49953, P01 HL085098-01A10002, R01-HL64356] Funding Source: Medline; NIA NIH HHS [R01-AG18599] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Ahmed MS, 2005, ACTA PHYSIOL SCAND, V184, P27, DOI 10.1111/j.1365-201X.2005.01416.x; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Barker TH, 2004, EXP CELL RES, V295, P488, DOI 10.1016/j.yexcr.2004.01.026; Begum R, 2004, EXP MOL MED, V36, P358, DOI 10.1038/emm.2004.47; Breitenlechner C, 2003, STRUCTURE, V11, P1595, DOI 10.1016/j.str.2003.11.002; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Dean RG, 2005, J HISTOCHEM CYTOCHEM, V53, P1245, DOI 10.1369/jhc.4A6560.2005; Dorn GW, 2003, CIRC RES, V92, P1171, DOI 10.1161/01.RES.0000077012.11088.BC; Dorn GW, 2005, J CLIN INVEST, V115, P527, DOI 10.1172/JCI200524178; Frey N, 2004, CIRCULATION, V109, P1580, DOI 10.1161/01.CIR.0000120390.68287.BB; Hattori T, 2004, CIRCULATION, V109, P2234, DOI 10.1161/01.CIR.0000127939.16111.58; He ZH, 2005, J BIOL CHEM, V280, P15719, DOI 10.1074/jbc.M413493200; Higashi M, 2003, CIRC RES, V93, P767, DOI 10.1161/01.RES.0000096650.91688.28; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Kallapur S, 1999, MOL REPROD DEV, V52, P341, DOI 10.1002/(SICI)1098-2795(199904)52:4&lt;341::AID-MRD2&gt;3.0.CO;2-N; Kannel W B, 1972, N Engl J Med, V287, P781, DOI 10.1056/NEJM197210192871601; Kemp TJ, 2004, J MOL CELL CARDIOL, V37, P603, DOI 10.1016/j.yjmcc.2004.04.022; Kobayashi N, 2002, CARDIOVASC RES, V55, P757, DOI 10.1016/S0008-6363(02)00457-1; Landerholm TE, 1999, DEVELOPMENT, V126, P2053; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; Lorell BH, 2000, CIRCULATION, V102, P470; Matsui Y, 2004, J MOL CELL CARDIOL, V37, P477, DOI 10.1016/j.yjmcc.2004.05.012; Nakamura A, 2001, AM J PHYSIOL-HEART C, V281, pH1104, DOI 10.1152/ajpheart.2001.281.3.H1104; Nicoletti A, 1999, CARDIOVASC RES, V41, P532, DOI 10.1016/S0008-6363(98)00305-8; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Rikitake Y, 2005, CIRCULATION, V112, P2959, DOI 10.1161/CIRCULATIONAHA.105.584623; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Satoh S, 2003, J MOL CELL CARDIOL, V35, P59, DOI 10.1016/S0022-2828(02)00278-X; Shimizu Y, 2005, J CELL BIOL, V168, P941, DOI 10.1083/jcb.200411179; Taffet GE, 1996, AM J PHYSIOL-HEART C, V270, pH2204; Takaoka H, 2002, AM J PHYSIOL-HEART C, V282, pH2190, DOI 10.1152/ajpheart.00759.2001; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; van Wamel AJET, 2001, MOL CELL BIOCHEM, V218, P113, DOI 10.1023/A:1007279700705; Wakatsuki T, 2004, TRENDS BIOCHEM SCI, V29, P609, DOI 10.1016/j.tibs.2004.09.002; Wang YX, 2005, EUR J PHARMACOL, V512, P215, DOI 10.1016/j.ejphar.2005.02.024; Weber KT, 1995, EUR HEART J, V16, P12, DOI 10.1093/eurheartj/16.suppl_N.12; Wei L, 2004, FASEB J, V18, P857, DOI 10.1096/fj.03-0664fje; Wei L, 2004, J MOL CELL CARDIOL, V36, P465, DOI 10.1016/j.yjmcc.2004.02.006; Wei L, 2002, DEVELOPMENT, V129, P1705; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Zhan GD, 2003, NAT MATER, V2, P38, DOI 10.1038/nmat793; Zhang D, 2000, NAT MED, V6, P556, DOI 10.1038/75037	46	165	174	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					916	925		10.1096/fj.05-5129com	http://dx.doi.org/10.1096/fj.05-5129com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675849				2022-12-25	WOS:000240157700014
J	Patterson, SG; Wei, S; Chen, X; Sallman, DA; Gilvary, DL; Zhong, B; Pow-Sang, J; Yeatman, T; Djeu, JY				Patterson, S. G.; Wei, S.; Chen, X.; Sallman, D. A.; Gilvary, D. L.; Zhong, B.; Pow-Sang, J.; Yeatman, T.; Djeu, J. Y.			Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells	ONCOGENE			English	Article						stat1; clusterin; chemoresistance; prostate cancer; siRNA	CHEMOTHERAPY-INDUCED APOPTOSIS; CANCER-CELLS; IN-VITRO; CLUSTERIN/APOLIPOPROTEIN-J; ANDROGEN INDEPENDENCE; UP-REGULATION; NOBLE RAT; CLUSTERIN; EXPRESSION; PROTEINS	A major obstacle for clinicians in the treatment of advanced prostate cancer is the inevitable progression to chemoresistance, especially to docetaxel. It is essential to understand the molecular events that lead to docetaxel resistance in order to identify means to prevent or interfere with chemoresistance. In initial attempts to detect these events, we analysed genomic differences between non-resistant and docetaxel-resistant prostate tumor cells and, of the genes modulated by docetaxel treatment, we observed Stat1 and clusterin gene expression heightened in the resistant phenotype. In this study, we provide biochemical and biological evidence that these two gene products are related. Stat1 and clusterin protein expression was induced upon docetaxel treatment of DU145 cells and highly overexpressed in the docetaxel-resistant DU145 cells (DU145-DR). The increase in total Stat1 corresponded to an increase in phosphorylated Stat1. Interestingly, there was no detectable difference between DU145 and DU145-DR cells expression of total Stat3 and phosphorylated Stat3. Treatment of DU145-DR cells with small interfering RNA targeted for Stat1 not only resulted in the knockdown of Stat1 expression, but it also caused the inhibition of clusterin expression. Thus, Stat1 appears to play a key role in the regulation of clusterin. Remarkably, inhibition of Stat1 or clusterin expression resulted in the re-sensitization of DU145-DR cells to docetaxel. These results offer the first evidence that Stat1, and its subsequent regulation of clusterin, are essential for docetaxel resistance in prostate cancer. Targeting this pathway could be a potential therapeutic means for intervention of docetaxel resistance.	H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL USA; Genitourinary Oncol Program, Tampa, FL USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Djeu, JY (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, MRC-4 E,12902 Magnolia Dr, Tampa, FL 33612 USA.	djeu@moffitt.usf.edu			NCI NIH HHS [CA98080] Funding Source: Medline; NIAID NIH HHS [AI056213] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056213] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Assikis VJ, 2004, CLIN CANCER RES, V10, P6770, DOI 10.1158/1078-0432.CCR-04-0275; Barton BE, 2004, MOL CANCER THER, V3, P1183; Bettuzzi S, 2000, CANCER RES, V60, P1472; Cochet O, 2006, CELL SIGNAL, V18, P449, DOI 10.1016/j.cellsig.2005.05.010; Culine S, 2000, ANN ONCOL, V11, P1523, DOI 10.1023/A:1008394823889; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; De Marzo AM, 2004, J CELL BIOCHEM, V91, P459, DOI 10.1002/jcb.10747; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; DeMiguel F, 2002, PROSTATE, V52, P123, DOI 10.1002/pros.10110; Dhir R, 2002, PROSTATE, V51, P241, DOI 10.1002/pros.10079; El-Hashemite N, 2004, CANCER RES, V64, P3436, DOI 10.1158/0008-5472.CAN-03-3609; Geney R, 2002, CLIN CHEM LAB MED, V40, P918, DOI 10.1515/CCLM.2002.161; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Ho SM, 1998, AM J PATHOL, V153, P131, DOI 10.1016/S0002-9440(10)65553-8; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; July LV, 2004, MOL CANCER THER, V3, P223; Kominsky SL, 2000, CANCER RES, V60, P3904; Lacroix H, 1998, Expert Opin Investig Drugs, V7, P273, DOI 10.1517/13543784.7.2.273; Lee SO, 2004, PROSTATE, V60, P178, DOI 10.1002/pros.20045; Legrand A, 2004, LIVER INT, V24, P149, DOI 10.1111/j.1478-3231.2004.00899.x; Liu KB, 2005, CANCER RES, V65, P1045; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Makarovskiy AN, 2002, CELL MOL LIFE SCI, V59, P1198, DOI 10.1007/s00018-002-8498-3; Milbank AJ, 2002, UROLOGY, V60, P738, DOI 10.1016/S0090-4295(02)01867-8; Miller ML, 2001, CHEM REC, V1, P195, DOI 10.1002/tcr.1008; Miyake H, 2000, CLIN CANCER RES, V6, P1655; Miyake H, 2000, CANCER RES, V60, P170; Miyake H, 2003, ONCOL REP, V10, P469; Miyake H, 2000, CANCER RES, V60, P3058; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Nickerson T, 1999, CANCER RES, V59, P3392; O'Sullivan J, 2003, CELL DEATH DIFFER, V10, P914, DOI 10.1038/sj.cdd.4401254; Ouyang XS, 2001, CARCINOGENESIS, V22, P965, DOI 10.1093/carcin/22.6.965; Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256; Petrylak DP, 2005, UROLOGY, V65, P3, DOI 10.1016/j.urology.2005.03.053; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Pucci S, 2004, ONCOGENE, V23, P2298, DOI 10.1038/sj.onc.1207404; Stephanou A, 2003, INT J EXP PATHOL, V84, P239, DOI 10.1111/j.0959-9673.2003.00363.x; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Thomas M, 2004, CANCER RES, V64, P8357, DOI 10.1158/0008-5472.CAN-04-1864; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; Trougakos IP, 2004, CANCER RES, V64, P1834, DOI 10.1158/0008-5472.CAN-03-2664; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Zellweger T, 2003, BJU INT, V92, P463, DOI 10.1046/j.1464-410X.2003.04349.x; Zellweger T, 2001, J PHARMACOL EXP THER, V298, P934	48	97	105	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6113	6122		10.1038/sj.onc.1209632	http://dx.doi.org/10.1038/sj.onc.1209632			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16652143				2022-12-25	WOS:000241101200008
J	Yoshida, T; Hisamoto, T; Akiba, J; Koga, H; Nakamura, K; Tokunaga, Y; Hanada, S; Kumemura, H; Maeyama, M; Harada, M; Ogata, H; Yano, H; Kojiro, M; Ueno, T; Yoshimura, A; Sata, M				Yoshida, T.; Hisamoto, T.; Akiba, J.; Koga, H.; Nakamura, K.; Tokunaga, Y.; Hanada, S.; Kumemura, H.; Maeyama, M.; Harada, M.; Ogata, H.; Yano, H.; Kojiro, M.; Ueno, T.; Yoshimura, A.; Sata, M.			Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors	ONCOGENE			English	Article						Ras; Raf-1; ERK; spred; sprouty; HCC	CELL-CYCLE ARREST; PROTEIN-KINASE; MICE LACKING; MAP KINASE; ACTIVATION; EXPRESSION; ERK; PATHWAYS; BINDING; RAS	Aberrant activation of the Ras/Raf-1/extracellular-regulated kinase (ERK) pathway has been shown to be involved in the progression of human hepatocellular carcinoma (HCC). However, the mechanism of dysregulation of ERK activation is poorly understood. Recently, we identified Sprouty-related protein with Ena/vasodilator stimulated phosphoprotein homology-1 domain (Spred) as a physiological inhibitor of the Ras/Raf-1/ERK pathway. In this study, we found that the expression levels of Spred-1 and -2 in human HCC tissue were frequently decreased, comparing with those in adjacent non-tumorous tissue. Moreover, Spred expression levels in HCC tissue were inversely correlated with the incidence of tumor invasion and metastasis. Forced expression of Spred-1 inhibited HCC cell proliferation in vitro and in vivo, which was associated with reduced ERK activation. Spred-1 overexpression also reduced the secretion of matrix metalloproteinase-9 (MMP-9) and MMP-2, which play important roles in tumor invasion and metastasis. In addition, Spred-1 inhibited growth factor-mediated HCC cell motility. These data indicate that the reduction of Spred expression in HCC is one of the causes of the acquisition of malignant features. Thus, Spred could be not only a novel prognostic factor but also a new therapeutic target for human HCC.	Kurume Univ, Dept Med, Sch Med, Liver Canc Div,Res Ctr Innovat Canc Therapy, Kurume, Fukuoka, Japan; Ctr 21st Century Program Med Sci, Kurume, Fukuoka, Japan; Kurume Univ, Dept Pathol, Sch Med, Liver Canc Div,Res Ctr Innovat Canc Therapy, Kurume, Fukuoka, Japan; Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 812, Japan	Kurume University; Kurume University; Kyushu University	Yoshida, T (corresponding author), Kurume Univ, Dept Med, Sch Med, Liver Canc Div,Res Ctr Innovat Canc Therapy, 67 Asahi Machi, Kurume, Fukuoka, Japan.	tayoshi@med.kurume-u.ac.jp	Yoshimura, Akihiko/K-5515-2013					Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; Chen LX, 2004, FASEB J, V18, P914, DOI 10.1096/fj.03-1204fje; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Ehrenreiter K, 2005, J CELL BIOL, V168, P955, DOI 10.1083/jcb.200409162; Inoue H, 2005, J EXP MED, V201, P73, DOI 10.1084/jem.20040616; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kato R, 2003, BIOCHEM BIOPH RES CO, V302, P767, DOI 10.1016/S0006-291X(03)00259-6; Koga H, 2001, HEPATOLOGY, V33, P1087, DOI 10.1053/jhep.2001.24024; Liu JF, 2002, BIOCHEM BIOPH RES CO, V293, P1174, DOI 10.1016/S0006-291X(02)00350-9; Marrero JA, 2004, GASTROENTEROLOGY, V127, pS113, DOI 10.1053/j.gastro.2004.09.024; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Masson V, 2004, FASEB J, V18, P234, DOI 10.1096/fj.04-2140fje; McAllister SS, 2003, MOL CELL BIOL, V23, P216, DOI 10.1128/MCB.23.1.216-228.2003; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Miyoshi K, 2004, ONCOGENE, V23, P5567, DOI 10.1038/sj.onc.1207759; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nonami A, 2004, J BIOL CHEM, V279, P52543, DOI 10.1074/jbc.M405189200; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Schmidt CM, 1997, BIOCHEM BIOPH RES CO, V236, P54, DOI 10.1006/bbrc.1997.6840; Stahl S, 2005, HEPATOLOGY, V42, P353, DOI 10.1002/hep.20768; Tsuboi Y, 2004, LIVER INT, V24, P432, DOI 10.1111/j.1478-3231.2004.0940.x; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Volkman BF, 2002, CELL, V111, P565, DOI 10.1016/S0092-8674(02)01076-0; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; YANO H, 1988, ACTA PATHOL JAPON, V38, P953; Yoshida T, 2004, J EXP MED, V199, P1701, DOI 10.1084/jem.20031675; Zaragoza C, 2002, MOL PHARMACOL, V62, P927, DOI 10.1124/mol.62.4.927; Zhang DL, 2004, J BIOL CHEM, V279, P19683, DOI 10.1074/jbc.M313145200	34	128	140	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6056	6066		10.1038/sj.onc.1209635	http://dx.doi.org/10.1038/sj.onc.1209635			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16652141				2022-12-25	WOS:000241101200003
J	Zheng, R; Iwase, A; Shen, R; Goodman, OB; Sugimoto, N; Takuwa, Y; Lerner, DJ; Nanus, DM				Zheng, R.; Iwase, A.; Shen, R.; Goodman, O. B., Jr.; Sugimoto, N.; Takuwa, Y.; Lerner, D. J.; Nanus, D. M.			Neuropeptide-stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase	ONCOGENE			English	Article						neutral endopeptidase; neuropetide; Rho kinase; RhoGEF; G-protein	NUCLEOTIDE EXCHANGE FACTORS; GTP-BINDING PROTEIN; FOCAL ADHESION KINASE; HETEROTRIMERIC G-PROTEINS; LEUKEMIA-ASSOCIATED RHO; G-BETA-GAMMA; CARCINOMA-CELLS; TYROSINE PHOSPHORYLATION; GROWTH-FACTORS; ALPHA-SUBUNIT	The neuropeptides bombesin and endothelin-1 stimulate prostate cancer (PC) cell migration and invasion (J Clin Invest, 2000; 106: 1399-1407). The intracellular signaling pathways that direct this cell movement are not well delineated. The monomeric GTPase RhoA is required for migration in several cell types including neutrophils, monocytes and. broblasts. We demonstrate that bombesin-stimulated PC cell migration occurs via the heterotrimeric G-protein-coupled receptors (G-protein) G alpha 13 subunit leading to activation of RhoA, and Rho-associated coiled-coil forming protein kinase (ROCK). Using siRNA to suppress expression of the three known G-protein asubunitassociated RhoA guanine nucleotide exchange factors (GEFs), we also show that two of these RhoA GEFs, PDZ-RhoGEF and leukemia-associated RhoGEF (LARG), link bombesin receptors to RhoA in a non-redundant manner in PC cells. We next show that focal adhesion kinase, which activates PDZ-RhoGEF and LARG, is required for bombesin-stimulated RhoA activation. Neutral endopeptidase (NEP) is expressed on normal prostate epithelium whereas loss of NEP expression contributes to PC progression. We also demonstrate that NEP inhibits neuropeptide activation of RhoA. Together, these results establish a contiguous signaling pathway from the bombesin receptor to ROCK in PC cells, and they implicate NEP as a major regulator of neuropeptide-stimulated RhoA in these cells. This work also identifies members of this signaling pathway as potential targets for rational pharmacologic manipulation of neuropeptide-stimulated migration of PC cells.	Cornell Univ, Weill Med Coll, Div Hematol & Med Oncol, Dept Med,Gerintourinary Oncol Res Lab, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Urol, Urol Oncol Res Lab, New York, NY 10021 USA; New York Presbyterian Hosp, New York, NY USA; Kanazawa Univ, Sch Med, Dept Physiol, Kanazawa, Ishikawa 920, Japan; Cornell Univ, Weill Med Coll, Div Cardiol, Dept Med, New York, NY 10021 USA	Cornell University; Cornell University; NewYork-Presbyterian Hospital; Kanazawa University; Cornell University	Nanus, DM (corresponding author), Cornell Univ, Weill Med Coll, Div Hematol & Med Oncol, Dept Med,Gerintourinary Oncol Res Lab, 525 E 68th St,ST-359, New York, NY 10021 USA.	dnanus@med.cornell.edu	Sugimoto, Naotoshi/C-4739-2015	Sugimoto, Naotoshi/0000-0003-1995-5002; Goodman, Oscar/0000-0002-0882-3621	NCI NIH HHS [CA80240] Funding Source: Medline; NHLBI NIH HHS [HL04080] Funding Source: Medline; NIDDK NIH HHS [DK60908] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080240] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060908] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aprikian AG, 1997, INT J CANCER, V72, P498, DOI 10.1002/(SICI)1097-0215(19970729)72:3<498::AID-IJC19>3.3.CO;2-P; Arai K, 2003, MOL PHARMACOL, V63, P478, DOI 10.1124/mol.63.3.478; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Braga V, 2000, NAT CELL BIOL, V2, pE182, DOI 10.1038/35036433; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Dai J, 2001, CLIN CANCER RES, V7, P1370; DELOMBAERT S, 1994, J MED CHEM, V37, P498, DOI 10.1021/jm00030a009; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Grant K, 2003, BRIT J CANCER, V88, P163, DOI 10.1038/sj.bjc.6700750; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hersch E, 2004, AM J PHYSIOL-CELL PH, V287, pC1209, DOI 10.1152/ajpcell.00198.2004; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Iwase A, 2004, J BIOL CHEM, V279, P11898, DOI 10.1074/jbc.M212737200; Jiang YD, 2003, MOL CANCER RES, V1, P453; Kajiyama H, 2005, CLIN CANCER RES, V11, P1798, DOI 10.1158/1078-0432.CCR-04-2395; Karnoub AE, 2004, BREAST CANCER RES TR, V84, P61, DOI 10.1023/B:BREA.0000018427.84929.5c; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; Kitamura K, 1999, AM J PHYSIOL-CELL PH, V276, pC930, DOI 10.1152/ajpcell.1999.276.4.C930; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kurose H, 2003, LIFE SCI, V74, P155, DOI 10.1016/j.lfs.2003.09.003; Leung T, 1996, MOL CELL BIOL, V16, P5313; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Liu B, 2003, J BIOL CHEM, V278, P2384, DOI 10.1074/jbc.M208683200; Lummen G, 1997, N-S ARCH PHARMACOL, V356, P769, DOI 10.1007/PL00005117; LYONS LS, 2005, MOL ENDOCRINOL  1229; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Nagakawa O, 2001, INT J UROL, V8, P65, DOI 10.1046/j.1442-2042.2001.00250.x; Nagakawa O, 1998, CANCER LETT, V133, P27, DOI 10.1016/S0304-3835(98)00186-4; Nakagawa T, 2005, BIOCHEM PHARMACOL, V69, P579, DOI 10.1016/j.bcp.2004.11.003; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050; Radhika V, 2004, J BIOL CHEM, V279, P49406, DOI 10.1074/jbc.M408836200; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; Reuther GW, 2001, J BIOL CHEM, V276, P27145, DOI 10.1074/jbc.M103565200; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rosano L, 2001, CANCER RES, V61, P8340; Rozengurt E, 2002, TRENDS ENDOCRIN MET, V13, P128, DOI 10.1016/S1043-2760(01)00544-6; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Saurin JC, 2002, CANCER RES, V62, P4829; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Shen RQ, 2000, ENDOCRINOLOGY, V141, P1699, DOI 10.1210/en.141.5.1699; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Sugden PH, 2003, J MOL CELL CARDIOL, V35, P871, DOI 10.1016/S0022-2828(03)00153-6; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; Sumitomo M, 2000, J CLIN INVEST, V106, P1399, DOI 10.1172/JCI10536; Sumitomo M, 2005, BBA-PROTEINS PROTEOM, V1751, P52, DOI 10.1016/j.bbapap.2004.11.001; Sumitomo M, 2001, CANCER RES, V61, P3294; Suzuki N, 2003, P NATL ACAD SCI USA, V100, P733, DOI 10.1073/pnas.0234057100; Tangkijvanich P, 2001, HEPATOLOGY, V33, P74, DOI 10.1053/jhep.2001.20677; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VAN AL, 1997, GENE DEV, V11, P2295; Wang Q, 2004, METHOD ENZYMOL, V389, P244; Wang Q, 2004, J BIOL CHEM, V279, P28831, DOI 10.1074/jbc.C400105200; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5; Yuan JZ, 2001, J BIOL CHEM, V276, P38619, DOI 10.1074/jbc.M105530200; Zhao RB, 1997, J BIOL CHEM, V272, P21207, DOI 10.1074/jbc.272.34.21207; Zhou KM, 1998, J BIOL CHEM, V273, P16782, DOI 10.1074/jbc.273.27.16782	76	42	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2006	25	44					5942	5952		10.1038/sj.onc.1209586	http://dx.doi.org/10.1038/sj.onc.1209586			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16652149	Bronze			2022-12-25	WOS:000240826300003
J	Hu, JX; Jiang, JK; Costanzi, S; Thomas, C; Yang, W; Feyen, JHM; Jacobson, KA; Spiegel, AM				Hu, Jianxin; Jiang, Jiankang; Costanzi, Stefano; Thomas, Craig; Yang, Wu; Feyen, Jean H. M.; Jacobson, Kenneth A.; Spiegel, Allen M.			A missense mutation in the seven-transmembrane domain of the human Ca2+ receptor converts a negative allosteric modulator into a positive allosteric modulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-SENSING RECEPTOR; ANTAGONIST; ACTIVATION	G protein-coupled receptors (GPCRs) are the most common targets of drug action. Allosteric modulators bind to the seven-transmembrane domain of family 3 GPCRs and offer enhanced selectivity over orthosteric ligands that bind to the large extracellular N terminus. We characterize a novel negative allosteric modulator of the human Ca2+ receptor, Compound 1, that retains activity against the E837A mutant that lacks a response to previously described positive and negative modulators. A related compound, JKJ05, acts as a negative allosteric modulator on the wild type receptor but as a positive modulator on the E837A mutant receptor. This positive modulation critically depends on the primary amine in JKJ05, which appears to interact with acidic residue Glu(767) in our model of the seven-transmembrane domain of the receptor. Our results suggest the need for identification of possible genetic variation in the allosteric site of therapeutically targeted GPCRs.	NIDCD, Mol Pathophysiol Sect, NIH, Bethesda, MD 20892 USA; NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Computat Quantum Core Lab, NIH, Bethesda, MD 20892 USA; Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Bristol-Myers Squibb	Hu, JX (corresponding author), NIDCD, Mol Pathophysiol Sect, NIH, Bldg 10,Rm 8C-101,9000 Rockville Pike, Bethesda, MD 20892 USA.	jianxinh@intra.niddk.nih.gov	Costanzi, Stefano/G-8990-2013; Jacobson, Kenneth Alan/A-1530-2009	Jacobson, Kenneth Alan/0000-0001-8104-1493; Costanzi, Stefano/0000-0003-3183-7332; Thomas, Craig/0000-0001-9386-9001	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK013025, Z01DK013025, Z01DK070005, ZIADK031115, Z01DK031115] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arey BJ, 2005, ENDOCRINOLOGY, V146, P2015, DOI 10.1210/en.2004-1318; Bessis AS, 2002, P NATL ACAD SCI USA, V99, P11097, DOI 10.1073/pnas.162138699; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Costanzi S, 2005, J MED CHEM, V48, P8108, DOI 10.1021/jm050911p; Edwards PC, 2004, J MOL BIOL, V343, P1439, DOI 10.1016/j.jmb.2004.08.089; Hu JX, 2005, J BIOL CHEM, V280, P5113, DOI 10.1074/jbc.M413403200; Hu JX, 2003, TRENDS ENDOCRIN MET, V14, P282, DOI 10.1016/S1043-2760(03)00104-8; Hu JX, 2002, J BIOL CHEM, V277, P46622, DOI 10.1074/jbc.M207100200; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Malherbe P, 2003, J BIOL CHEM, V278, P8340, DOI 10.1074/jbc.M211759200; May LT, 2004, CURR PHARM DESIGN, V10, P2003, DOI 10.2174/1381612043384303; Nemeth EF, 2004, CELL CALCIUM, V35, P283, DOI 10.1016/j.ceca.2003.10.020; Ott TR, 2002, MOL ENDOCRINOL, V16, P1079, DOI 10.1210/me.16.5.1079; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Patel AB, 2004, P NATL ACAD SCI USA, V101, P10048, DOI 10.1073/pnas.0402848101; Petrel C, 2004, J BIOL CHEM, V279, P18990, DOI 10.1074/jbc.M400724200; Ruprecht JJ, 2004, EMBO J, V23, P3609, DOI 10.1038/sj.emboj.7600374; Steddon S, 2005, LANCET, V365, P2237, DOI 10.1016/S0140-6736(05)66782-7; Tang CM, 2005, EXPERT OPIN THER TAR, V9, P1247, DOI 10.1517/14728222.9.6.1247; Yang W, 2003, ORG LETT, V5, P3131, DOI 10.1021/ol035188g	20	39	41	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21558	21565		10.1074/jbc.M603682200	http://dx.doi.org/10.1074/jbc.M603682200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16735501	hybrid			2022-12-25	WOS:000239187300090
J	Jovanovic, G; Lloyd, LJ; Stumpf, MPH; Mayhew, AJ; Buck, M				Jovanovic, Goran; Lloyd, Louise J.; Stumpf, Michael P. H.; Mayhew, Antony J.; Buck, Martin			Induction and function of the phage shock protein extracytoplasmic stress response in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING PROTEIN; GENE-EXPRESSION; PSP OPERON; SYSTEM; IDENTIFICATION; CATABOLISM; RPOE; ARCB; FNR; TRANSCRIPTION	The phage shock protein (Psp) F regulon response in Escherichia coli is thought to be induced by impaired inner membrane integrity and an associated decrease in proton motive force (pmf). Mechanisms by which the Psp system detects the stress signal and responds have so far remained undetermined. Here we demonstrate that PspA and PspG directly confront a variety of inducing stimuli by switching the cell to anaerobic respiration and fermentation and by down-regulating motility, thereby subtly adjusting and maintaining energy usage and pmf. Additionally, PspG controls iron usage. We show that the Psp-inducing protein IV secretin stress, in the absence of Psp proteins, decreases the pmf in an ArcB-dependent manner and that ArcB is required for amplifying and transducing the stress signal to the PspF regulon. The requirement of the ArcB signal transduction protein for induction of psp provides clear evidence for a direct link between the physiological redox state of the cell, the electron transport chain, and induction of the Psp response. Under normal growth conditions PspA and PspD control the level of activity of ArcB/ArcA system that senses the redox/metabolic state of the cell, whereas under stress conditions PspA, PspD, and PspG deliver their effector functions at least in part by activating ArcB/ArcA through positive feedback.	Imperial Coll London, Div Biol, London SW7 2AZ, England; Imperial Coll London, Ctr Bioinformat, London SW7 2AZ, England	Imperial College London; Imperial College London	Buck, M (corresponding author), Imperial Coll London, Div Biol, Sir Alexander Fleming Bldg,S Kensington Campus, London SW7 2AZ, England.	m.buck@imperial.ac.uk		Jovanovic, Goran/0000-0001-6587-7645	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alexeeva S, 2000, J BACTERIOL, V182, P4934, DOI 10.1128/JB.182.17.4934-4940.2000; Baba T, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100050; Becker LA, 2005, MOL MICROBIOL, V56, P1004, DOI 10.1111/j.1365-2958.2005.04604.x; BRISSETTE JL, 1991, J MOL BIOL, V220, P35, DOI 10.1016/0022-2836(91)90379-K; Darwin AJ, 2005, MOL MICROBIOL, V57, P621, DOI 10.1111/j.1365-2958.2005.04694.x; Dworkin J, 1997, J MOL BIOL, V273, P377, DOI 10.1006/jmbi.1997.1317; Dworkin J, 2000, J BACTERIOL, V182, P311, DOI 10.1128/JB.182.2.311-319.2000; Egler M, 2005, J BACTERIOL, V187, P2297, DOI 10.1128/JB.187.7.2297-2307.2005; Elderkin S, 2005, J BACTERIOL, V187, P3238, DOI 10.1128/JB.187.9.3238-3248.2005; Elderkin S, 2002, J MOL BIOL, V320, P23, DOI 10.1016/S0022-2836(02)00404-7; Georgellis D, 1998, J BIOL CHEM, V273, P32864, DOI 10.1074/jbc.273.49.32864; Georgellis D, 2001, SCIENCE, V292, P2314, DOI 10.1126/science.1059361; Glaser P, 1997, GENE DEV, V11, P1160, DOI 10.1101/gad.11.9.1160; IUCHI S, 1993, MOL MICROBIOL, V9, P9, DOI 10.1111/j.1365-2958.1993.tb01664.x; Jones SE, 2003, J BACTERIOL, V185, P6707, DOI 10.1128/JB.185.22.6707-6711.2003; Jovanovic G, 1997, J BACTERIOL, V179, P5232, DOI 10.1128/jb.179.16.5232-5237.1997; Jovanovic G, 1997, MOL MICROBIOL, V25, P473, DOI 10.1046/j.1365-2958.1997.4791844.x; Kitagawa M, 2005, DNA RES, V12, P291, DOI 10.1093/dnares/dsi012; Kobayashi H, 1998, MICROBIOL-UK, V144, P353, DOI 10.1099/00221287-144-2-353; Lloyd LJ, 2004, J BIOL CHEM, V279, P55707, DOI 10.1074/jbc.M408994200; Malpica R, 2004, P NATL ACAD SCI USA, V101, P13318, DOI 10.1073/pnas.0403064101; Maurer LM, 2005, J BACTERIOL, V187, P304, DOI 10.1128/JB.187.1.304-319.2005; Maxson ME, 2004, J BACTERIOL, V186, P4199, DOI 10.1128/JB.186.13.4199-4208.2004; Mika F, 2005, GENE DEV, V19, P2770, DOI 10.1101/gad.353705; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Model P, 1997, MOL MICROBIOL, V24, P255, DOI 10.1046/j.1365-2958.1997.3481712.x; Perrenoud A, 2005, J BACTERIOL, V187, P3171, DOI 10.1128/JB.187.9.3171-3179.2005; POLARD P, 1995, GENE DEV, V9, P2846, DOI 10.1101/gad.9.22.2846; Ruiz N, 2005, CURR OPIN MICROBIOL, V8, P122, DOI 10.1016/j.mib.2005.02.013; Salmon K, 2003, J BIOL CHEM, V278, P29837, DOI 10.1074/jbc.M213060200; STEWART V, 1988, MICROBIOL REV, V52, P190, DOI 10.1128/MMBR.52.2.190-232.1988; Stewart V, 2003, BIOCHEM SOC T, V31, P1; Unden G, 2002, J MOL MICROB BIOTECH, V4, P263; Wang QF, 2004, MOL MICROBIOL, V52, P169, DOI 10.1111/j.1365-2958.2003.03977.x	34	100	100	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21147	21161		10.1074/jbc.M602323200	http://dx.doi.org/10.1074/jbc.M602323200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16709570	hybrid			2022-12-25	WOS:000239187300051
J	Kampf, JP; Cupp, D; Kleinfeld, AM				Kampf, J. Patrick; Cupp, David; Kleinfeld, Alan M.			Different mechanisms of free fatty acid flip-flop and dissociation revealed by temperature and molecular species dependence of transport across lipid vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE UNILAMELLAR VESICLES; FLUORESCENT-PROBE ADIFAB; BILAYER-MEMBRANES; PHOSPHATIDYLCHOLINE VESICLES; PHOSPHOLIPID-BILAYERS; BIOLOGICAL-MEMBRANES; PERMEANT SIZE; LONG; ALBUMIN; THERMODYNAMICS	The mechanism of free fatty acid (FFA) transport across membranes is a subject of intense investigation. We have demonstrated recently that flip-flop is the rate-limiting step for transport of oleic acid across phospholipid vesicles (Cupp, D., Kampf, J. P., and Kleinfeld, A. M. ( 2004) Biochemistry 43, 4473-4481). To better understand the nature of the flip-flop barrier, we measured the temperature dependence of a series of saturated and monounsaturated FFA. We determined the rate constants for flip-flop and dissociation for small (SUV), large (LUV), and giant (GUV) unilamellar vesicles composed of egg phosphatidylcholine. For all FFA and vesicle types, dissociation was faster than flip-flop, and for all FFA, flip-flop and dissociation were faster in SUV than in LUV or GUV. Rate constants for both flip-flop and dissociation decreased exponentially with increasing FFA size. However, only the flip-flop rate constants increased significantly with temperature; the barrier to flip-flop was virtually entirely due to an enthalpic activation free energy. The barrier to dissociation was primarily entropic. Analysis in terms of a simple free volume (V-f) model revealed Vf values for flip-flop that ranged between similar to 12 and 15 angstrom(3), with larger values for SUV than for LUV or GUV. Vf values increased with temperature, and this temperature dependence generated the enthalpic barrier to flip-flop. The barrier for dissociation and its size dependence primarily reflect the aqueous solubility of FFA. These are the first results to distinguish the energetics of flip-flop and dissociation. This should lead to a better understanding of the mechanisms governing FFA transport across biological membranes.	Torrey Pines Inst Mol Studies, San Diego, CA 92121 USA	Torrey Pines Institute for Molecular Studies, California	Kleinfeld, AM (corresponding author), Torrey Pines Inst Mol Studies, 3550 Gen Atom Ct, San Diego, CA 92121 USA.	akleinfeld@tpims.org		Kampf, James/0000-0003-3050-3998	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058762] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK058762] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brunaldi K, 2005, J LIPID RES, V46, P245, DOI 10.1194/jlr.M400155-JLR200; Cupp D, 2004, BIOCHEMISTRY-US, V43, P4473, DOI 10.1021/bi036335l; DANIELS C, 1985, BIOCHEMISTRY-US, V24, P3286, DOI 10.1021/bi00334a032; Demant EJF, 2002, BIOCHEM J, V363, P809, DOI 10.1042/0264-6021:3630809; DIAMOND JM, 1969, ANNU REV PHYSIOL, V31, P581, DOI 10.1146/annurev.ph.31.030169.003053; DOODY MC, 1980, BIOCHEMISTRY-US, V19, P108, DOI 10.1021/bi00542a017; Falck E, 2005, BIOPHYS J, V89, P745, DOI 10.1529/biophysj.105.065714; FUGLER L, 1985, J BIOL CHEM, V260, P4098; Gomori G, 1942, J LAB CLIN MED, V27, P955; GUTKNECHT J, 1988, J MEMBRANE BIOL, V106, P83, DOI 10.1007/BF01871769; Hamilton JA, 1999, DIABETES, V48, P2255, DOI 10.2337/diabetes.48.12.2255; HAUSER H, 1979, BIOCHEMISTRY-US, V18, P3285, DOI 10.1021/bi00582a014; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HUANG C, 1978, P NATL ACAD SCI USA, V75, P308, DOI 10.1073/pnas.75.1.308; KAMP F, 1995, BIOCHEMISTRY-US, V34, P11928, DOI 10.1021/bi00037a034; KAMP F, 1992, P NATL ACAD SCI USA, V89, P11367, DOI 10.1073/pnas.89.23.11367; Kampf JP, 2004, J BIOL CHEM, V279, P35775, DOI 10.1074/jbc.M403630200; Kleinfeld AM, 2004, J AM SOC MASS SPECTR, V15, P1572, DOI 10.1016/j.jasms.2004.07.010; Kleinfeld AM, 1997, BIOCHEMISTRY-US, V36, P14146, DOI 10.1021/bi971440e; Kleinfeld AM, 1997, BIOCHEMISTRY-US, V36, P5702, DOI 10.1021/bi962007s; Kleinfeld AM, 1998, BIOCHEMISTRY-US, V37, P8011, DOI 10.1021/bi980301+; KLEINFELD AM, 1993, BIOCHEMISTRY-US, V32, P2053, DOI 10.1021/bi00059a024; Kleinfeld AM, 2000, J MEMBRANE BIOL, V175, P79, DOI 10.1007/s002320001056; LIEB WR, 1986, J MEMBRANE BIOL, V92, P111, DOI 10.1007/BF01870701; Massey JB, 1997, BIOPHYS J, V72, P1732, DOI 10.1016/S0006-3495(97)78819-2; MCAULIFFE C, 1966, J PHYS CHEM-US, V70, P1267, DOI 10.1021/j100876a049; MCLEAN LR, 1984, BIOCHIM BIOPHYS ACTA, V776, P21, DOI 10.1016/0005-2736(84)90246-3; NOZAKI Y, 1982, SCIENCE, V217, P366, DOI 10.1126/science.7089571; Pohl EE, 2000, BIOCHEMISTRY-US, V39, P1834, DOI 10.1021/bi9919549; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; RICHIERI GV, 1995, J BIOL CHEM, V270, P15076, DOI 10.1074/jbc.270.25.15076; Richieri GV, 1999, MOL CELL BIOCHEM, V192, P87, DOI 10.1023/A:1006878421990; SEELIG J, 1980, Q REV BIOPHYS, V13, P19, DOI 10.1017/S0033583500000305; SRIVASTAVA A, 1995, J PHYS CHEM-US, V99, P11302, DOI 10.1021/j100029a002; Stein W., 2012, TRANSPORT DIFFUSION; STORCH J, 1986, BIOCHEMISTRY-US, V25, P1717, DOI 10.1021/bi00355a041; Tanford Ch., 1973, HYDROPHOBIC EFFECT F; Thomas RM, 2002, BIOCHEMISTRY-US, V41, P1591, DOI 10.1021/bi011555p; WALTER A, 1986, J MEMBRANE BIOL, V90, P207, DOI 10.1007/BF01870127; Watkins PA, 2001, J MOL NEUROSCI, V16, P87, DOI 10.1385/JMN:16:2-3:87; XIANG TX, 1994, J MEMBRANE BIOL, V140, P111; Xiang TX, 1998, BIOPHYS J, V75, P2658, DOI 10.1016/S0006-3495(98)77711-2; Zakim D, 2000, J MEMBRANE BIOL, V176, P101, DOI 10.1007/s002320001080; Zhang FL, 1996, BIOCHEMISTRY-US, V35, P16055, DOI 10.1021/bi961685b; ZUCKER SD, 1994, J BIOL CHEM, V269, P19262	45	51	54	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21566	21574		10.1074/jbc.M602067200	http://dx.doi.org/10.1074/jbc.M602067200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16737957	hybrid			2022-12-25	WOS:000239187300091
J	Liu, F; Tanner, ME				Liu, Feng; Tanner, Martin E.			PseG of pseudaminic acid biosynthesis - A UDP-sugar hydrolase as a masked glycosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; CAMPYLOBACTER-JEJUNI; HELICOBACTER-PYLORI; IDENTIFICATION; GLYCOSYLATION; GLYCOPROTEINS; MECHANISM; FLAGELLIN; COMPLEX; HOMOLOGY	The flagellin proteins in pathogenic bacteria such as Campylobacter jejuni and Helicobacter pylori are heavily glycosylated with the nine-carbon alpha-keto acid, pseudaminic acid. The presence of this posttranslational modification is absolutely required for assembly of functional flagella. Since motility is required for colonization, pseudaminic acid biosynthesis represents a virulence factor in these bacteria. Pseudaminic acid is generated from UDP-N-acetylglucosamine in five biosynthetic steps. The final step has been shown to involve the condensation of 2,4-diacetamido- 2,4,6-trideoxy-L-altrose ( 6-deoxy-AltdiNAc) with phosphoenolpyruvate as catalyzed by the enzyme pseudaminic acid synthase, NeuB3. The 6-deoxy-AltdiNAc used in this process is generated from its nucleotide-linked form, UDP-6-deoxy-AltdiNAc, by the action of a hydrolase that cleaves the glycosidic bond and releases UDP. This manuscript describes the first characterization of a UDP-6-deoxy-AltdiNAc hydrolase, namely PseG ( Cj1312) from C. jejuni. The activity of this enzyme is independent of the presence of divalent metal ions, and the values of the catalytic constants were found to be k(cat) = 27 s(-1) and K-m = 174 mu M. The enzyme was shown to hydrolyze the substrate with an overall inversion of stereochemistry at C-1 and to utilize a C-O bond cleavage mechanism during catalysis. These results, coupled with homology comparisons, suggest that the closest ancestors to the hydrolase are members of the metal-independent GT-B family of glycosyltransferases that include the enzyme MurG.	Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada	University of British Columbia	Tanner, ME (corresponding author), Univ British Columbia, Dept Chem, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada.	mtanner@chem.ubc.ca						BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butzler JP, 2004, CLIN MICROBIOL INFEC, V10, P868, DOI 10.1111/j.1469-0691.2004.00983.x; Campbell RE, 2000, BIOCHEMISTRY-US, V39, P14993, DOI 10.1021/bi001627x; Chiu CPC, 2004, NAT STRUCT MOL BIOL, V11, P163, DOI 10.1038/nsmb720; Chou WK, 2005, J BIOL CHEM, V280, P35922, DOI 10.1074/jbc.M507483200; Chou WK, 2003, J AM CHEM SOC, V125, P2455, DOI 10.1021/ja021309g; Ciesla WP, 1998, J BIOL CHEM, V273, P16021, DOI 10.1074/jbc.273.26.16021; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Goon S, 2003, MOL MICROBIOL, V50, P659, DOI 10.1046/j.1365-2958.2003.03725.x; GUERRY P, 2006, GLYCOBIOLOGY, V16, pR29; Gunawan J, 2005, J BIOL CHEM, V280, P3555, DOI 10.1074/jbc.M411942200; Hu YN, 2003, P NATL ACAD SCI USA, V100, P845, DOI 10.1073/pnas.0235749100; Josenhans C, 2002, FEMS MICROBIOL LETT, V210, P165, DOI 10.1016/S0378-1097(02)00638-9; KACHMAR JF, 1953, J BIOL CHEM, V200, P669; Lairson LL, 2004, J BIOL CHEM, V279, P28339, DOI 10.1074/jbc.M400451200; Lairson LL, 2004, CHEM COMMUN, P2243, DOI 10.1039/b406490a; Legler PM, 2000, BIOCHEMISTRY-US, V39, P8603, DOI 10.1021/bi000537p; LIAV AL, 1973, CARBOHYD RES, V30, P109, DOI 10.1016/S0008-6215(00)82178-3; Logan SM, 2002, MOL MICROBIOL, V46, P587, DOI 10.1046/j.1365-2958.2002.03185.x; Losey HC, 2001, BIOCHEMISTRY-US, V40, P4745, DOI 10.1021/bi010050w; Messner P, 2004, J BACTERIOL, V186, P2517, DOI 10.1128/JB.186.9.2517-2519.2004; Mildvan AS, 2005, ARCH BIOCHEM BIOPHYS, V433, P129, DOI 10.1016/j.abb.2004.08.017; Mosimann SC, 2001, J BIOL CHEM, V276, P8190, DOI 10.1074/jbc.M007235200; Munster-Kuhnel AK, 2004, GLYCOBIOLOGY, V14, p43R, DOI 10.1093/glycob/cwh113; Murkin AS, 2004, BIOCHEMISTRY-US, V43, P14290, DOI 10.1021/bi048606d; Schirm M, 2003, MOL MICROBIOL, V48, P1579, DOI 10.1046/j.1365-2958.2003.03527.x; Schmidt MA, 2003, TRENDS MICROBIOL, V11, P554, DOI 10.1016/j.tim.2003.10.004; Schoenhofen IC, 2006, J BIOL CHEM, V281, P8907, DOI 10.1074/jbc.M512987200; Schoenhofen IC, 2006, J BIOL CHEM, V281, P723, DOI 10.1074/jbc.M511021200; Soo EC, 2004, ANAL CHEM, V76, P619, DOI 10.1021/ac034875i; Sundaram AK, 2004, BIOCHEM J, V383, P83, DOI 10.1042/BJ20040218; Szymanski CM, 2005, NAT REV MICROBIOL, V3, P225, DOI 10.1038/nrmicro1100; Tanner ME, 2005, BIOORG CHEM, V33, P216, DOI 10.1016/j.bioorg.2005.01.005; Thibault P, 2001, J BIOL CHEM, V276, P34862, DOI 10.1074/jbc.M104529200; Upreti RK, 2003, PROTEOMICS, V3, P363, DOI 10.1002/pmic.200390052; van Amsterdam K, 2006, FEMS MICROBIOL REV, V30, P131, DOI 10.1111/j.1574-6976.2005.00006.x; Vann WF, 2004, J BACTERIOL, V186, P706, DOI 10.1128/JB.186.3.706-712.2004; Wrabl JO, 2001, J MOL BIOL, V314, P365, DOI 10.1006/jmbi.2001.5151; Yuki N, 2005, CURR OPIN IMMUNOL, V17, P577, DOI 10.1016/j.coi.2005.09.004; Zhang YN, 2001, J BIOL CHEM, V276, P11567, DOI 10.1074/jbc.M006530200	40	30	33	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20902	20909		10.1074/jbc.M602972200	http://dx.doi.org/10.1074/jbc.M602972200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16728396	hybrid			2022-12-25	WOS:000239187300027
J	Mauldin, JP; Srinivasan, S; Mulya, A; Gebre, A; Parks, JS; Daugherty, A; Hedrick, CC				Mauldin, Jeremy P.; Srinivasan, Suseela; Mulya, Anny; Gebre, Abraham; Parks, John S.; Daugherty, Alan; Hedrick, Catherine C.			Reduction in ABCG1 in Type 2 diabetic mice increases macrophage foam cell formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCAVENGER RECEPTORS; CHOLESTEROL EFFLUX; EXPRESSION; ATHEROSCLEROSIS; GENE; ABCA1; CD36; TRANSPORTERS; RESISTANCE; ALPHA	Atherosclerosis development is accelerated severalfold in patients with Type 2 diabetes. In the initial stages of disease, monocytes transmigrate into the subendothelial space and differentiate into foam cells. Scavenger receptors and ATP binding cassette (ABC) Transporters play an important role in foam cell formation as they regulate the influx and efflux of oxidized lipids. Here, we show that peritoneal macrophages isolated from Type 2 diabetic db/db mice have decreased expression of the ABC transporter ABCG1 and increased expression of the scavenger receptor CD36. We found a 2-fold increase in accumulation of esterified cholesterol in diabetic db/db macrophages compared with wild-type control macrophages. Diabetic db/db macrophages also had impaired cholesterol efflux to high density lipoprotein but not to lipid-free apo A-I, suggesting that the increased esterified cholesterol in diabetic db/db macrophages was due to a selective loss of ABCG1-mediated efflux to high density lipoprotein. Additionally, we were able to confirm down-regulation of ABCG1 using C57BL/6J peritoneal macrophages cultured in elevated glucose in vitro (25 mM glucose for 7 days), suggesting that ABCG1 expression in diabetic macrophages is regulated by chronic exposure to elevated glucose. Diabetic KKay mice were also studied and were found to have decreased ABCG1 expression without an increase in CD36. These observations demonstrate that ABCG1 plays a major role in macrophage cholesterol efflux and that decreased ABCG1 function can facilitate foam cell formation in Type 2 diabetic mice.	Univ Virginia, Div Endocrinol & Metab, Charlottesville, VA 22908 USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA; Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27106 USA; Univ Kentucky, Div Cardiovasc Med, Gill Heart Inst, Lexington, KY 40506 USA	University of Virginia; University of Virginia; University of Virginia; Wake Forest University; University of Kentucky	Hedrick, CC (corresponding author), Univ Virginia, Div Endocrinol & Metab, 415 Lane Rd,MR-5,Rm G123,POB 801394, Charlottesville, VA 22908 USA.	cch6n@virginia.edu	Hedrick, Catherine/D-1106-2012; Daugherty, Alan/C-8282-2009	Daugherty, Alan/0000-0003-2093-3775	NHLBI NIH HHS [P01 HL49373, P01 HL55798] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049373, P01HL055798] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alberti S, 2001, J CLIN INVEST, V107, P565, DOI 10.1172/JCI9794; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Daugherty A, 2000, J CLIN INVEST, V105, P1605, DOI 10.1172/JCI7818; Fukuhara-Takaki K, 2005, J BIOL CHEM, V280, P3355, DOI 10.1074/jbc.M408715200; Griffin E, 2001, NAT MED, V7, P840, DOI 10.1038/89969; Horiuchi S, 2003, AMINO ACIDS, V25, P283, DOI 10.1007/s00726-003-0029-5; Joseph SB, 2004, CELL, V119, P299, DOI 10.1016/j.cell.2004.09.032; Kashyap SR, 2005, J CLIN ENDOCR METAB, V90, P1100, DOI 10.1210/jc.2004-0745; Kennedy MA, 2005, CELL METAB, V1, P121, DOI 10.1016/j.cmet.2005.01.002; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Kobayashi K, 2000, METABOLISM, V49, P22, DOI 10.1016/S0026-0495(00)90588-2; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200; Li AC, 2004, J CLIN INVEST, V114, P1564, DOI 10.1172/JCI200418730; Li L, 2004, CIRC RES, V94, P892, DOI 10.1161/01.RES.0000124920.09738.26; Liang CP, 2004, J CLIN INVEST, V113, P764, DOI [10.1172/JCI200419528, 10.1172/JCI19528]; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Nakamura M, 1967, Diabetologia, V3, P212, DOI 10.1007/BF01222198; NICHOLS AV, 1976, BIOCHIM BIOPHYS ACTA, V446, P226, DOI 10.1016/0005-2795(76)90113-6; Oram JF, 2001, J LIPID RES, V42, P1173; PARKS JS, 1979, J BIOL CHEM, V254, P6716; Passarelli M, 2005, DIABETES, V54, P2198, DOI 10.2337/diabetes.54.7.2198; Rudel LL, 1998, ARTERIOSCL THROM VAS, V18, P1818, DOI 10.1161/01.ATV.18.11.1818; Schmitz G, 2000, CURR OPIN LIPIDOL, V11, P493, DOI 10.1097/00041433-200010000-00007; Schmitz G, 2001, J LIPID RES, V42, P1513; SHEEHAN DC, 1980, THEORY PRACTICE HIST, P159; Srinivasan S, 2004, DIABETOLOGIA, V47, P1727, DOI 10.1007/s00125-004-1525-1; Steffensen KR, 2004, DIABETES, V53, pS36, DOI 10.2337/diabetes.53.2007.S36; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Vaughan AM, 2003, J LIPID RES, V44, P1373, DOI 10.1194/jlr.M300078-JLR200; Walczak R, 2004, J BIOL CHEM, V279, P9905, DOI 10.1074/jbc.M310587200; Wang N, 2004, P NATL ACAD SCI USA, V101, P9774, DOI 10.1073/pnas.0403506101; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200	34	81	91	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21216	21224		10.1074/jbc.M510952200	http://dx.doi.org/10.1074/jbc.M510952200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16723355	hybrid			2022-12-25	WOS:000239187300057
J	Wang, HC; Liu, YD; Huai, Q; Cai, JW; Zoraghi, R; Francis, SH; Corbin, JD; Robinson, H; Xin, ZC; Lin, GT; Ke, H				Wang, Huanchen; Liu, Yudong; Huai, Qing; Cai, Jiwen; Zoraghi, Roya; Francis, Sharron H.; Corbin, Jackie D.; Robinson, Howard; Xin, Zhongcheng; Lin, Guiting; Ke, Hengming			Multiple conformations of phosphodiesterase-5 - Implications for enzyme function and drug development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; INHIBITOR; PDE4; CGMP; CAMP; SILDENAFIL; SELECTIVITY; MECHANISM	Phosphodiesterase-5 (PDE5) is the target for sildenafil, vardenafil, and tadalafil, which are drugs for treatment of erectile dysfunction and pulmonary hypertension. We report here the crystal structures of a fully active catalytic domain of unliganded PDE5A1 and its complexes with sildenafil or icarisid II. These structures together with the PDE5A1-isobutyl-1-methylxanthine complex show that the H-loop ( residues 660-683) at the active site of PDE5A1 has four different conformations and migrates 7-35 angstrom upon inhibitor binding. In addition, the conformation of sildenafil reported herein differs significantly from those in the previous structures of chimerically hybridized or almost inactive PDE5. Mutagenesis and kinetic analyses confirm that the H-loop is particularly important for substrate recognition and that invariant Gly(659), which immediately precedes the H-loop, is critical for optimal substrate affinity and catalytic activity.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510080, Guangdong, Peoples R China; Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; Peking Univ, Hosp 1, Androl Ctr, Beijing 100034, Peoples R China; Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Sun Yat Sen University; Vanderbilt University; United States Department of Energy (DOE); Brookhaven National Laboratory; Peking University; University of California System; University of California San Francisco	Ke, H (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	hke@med.unc.edu		Wang, Huanchen/0000-0003-2701-7155	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058277, R01DK040029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059791] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58277, DK40029] Funding Source: Medline; NIGMS NIH HHS [GM59791] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barnes S, 2000, BIOFACTORS, V12, P209, DOI 10.1002/biof.5520120133; BROWN DG, 2003, Patent No. 032003038080; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Card GL, 2004, STRUCTURE, V12, P2233, DOI 10.1016/j.str.2004.10.004; Castro A, 2005, MED RES REV, V25, P229, DOI 10.1002/med.20020; Conti M, 2003, J BIOL CHEM, V278, P5493, DOI 10.1074/jbc.R200029200; Corbin JD, 2002, INT J CLIN PRACT, V56, P453; Fink TL, 1999, J BIOL CHEM, V274, P34613, DOI 10.1074/jbc.274.49.34613; Fitzpatrick LA, 2003, MATURITAS, V44, pS21, DOI 10.1016/S0378-5122(02)00345-6; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; Galie N, 2005, NEW ENGL J MED, V353, P2148, DOI 10.1056/NEJMoa050010; Goraya TA, 2005, CELL SIGNAL, V17, P789, DOI 10.1016/j.cellsig.2004.12.017; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/BJ20021698; Huai Q, 2004, P NATL ACAD SCI USA, V101, P9624, DOI 10.1073/pnas.0401120101; Huai Q, 2004, J BIOL CHEM, V279, P13095, DOI 10.1074/jbc.M311556200; Huai Q, 2003, BIOCHEMISTRY-US, V42, P13220, DOI 10.1021/bi034653e; Huai Q, 2003, STRUCTURE, V11, P865, DOI 10.1016/S0969-2126(03)00123-0; Huang Z, 2001, CURR OPIN CHEM BIOL, V5, P432, DOI 10.1016/S1367-5931(00)00224-6; Iffland A, 2005, BIOCHEMISTRY-US, V44, P8312, DOI 10.1021/bi047313h; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Ko WC, 2004, BIOCHEM PHARMACOL, V68, P2087, DOI 10.1016/j.bcp.2004.06.030; Kuroda M, 2000, PLANTA MED, V66, P575, DOI 10.1055/s-2000-8611; Lee ME, 2002, FEBS LETT, V530, P53, DOI 10.1016/S0014-5793(02)03396-3; Li WK, 1996, PHYTOCHEMISTRY, V43, P527, DOI 10.1016/0031-9422(96)00187-2; Limer JL, 2004, BREAST CANCER RES, V6, P119, DOI 10.1186/bcr781; Lipworth BJ, 2005, LANCET, V365, P167, DOI 10.1016/S0140-6736(05)17708-3; Liu YG, 2001, CARDIOVASC DRUG REV, V19, P369, DOI 10.1111/j.1527-3466.2001.tb00076.x; MANGANIELLO VC, 1995, CELL SIGNAL, V7, P445, DOI 10.1016/0898-6568(95)00017-J; Mehats C, 2002, TRENDS ENDOCRIN MET, V13, P29, DOI 10.1016/S1043-2760(01)00523-9; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Nichols MR, 2000, MOL PHARMACOL, V57, P738, DOI 10.1124/mol.57.4.738; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pomeranz HD, 2005, J NEURO-OPHTHALMOL, V25, P9, DOI 10.1097/00041327-200503000-00003; Rotella DP, 2002, NAT REV DRUG DISCOV, V1, P674, DOI 10.1038/nrd893; Scapin G, 2004, BIOCHEMISTRY-US, V43, P6091, DOI 10.1021/bi049868i; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Sung BJ, 2003, NATURE, V425, P98, DOI 10.1038/nature01914; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351, DOI 10.1164/ajrccm.157.2.9708012; Truss MC, 2001, WORLD J UROL, V19, P344, DOI 10.1007/s003450100221; Turko IV, 1999, MOL PHARMACOL, V56, P124, DOI 10.1124/mol.56.1.124; Wang HC, 2005, J BIOL CHEM, V280, P30949, DOI 10.1074/jbc.M504398200; Xin ZC, 2003, ASIAN J ANDROL, V5, P15; Xin ZC, 2001, CHINESE SCI BULL, V46, P1186, DOI 10.1007/BF02900599; Xu RX, 2004, J MOL BIOL, V337, P355, DOI 10.1016/j.jmb.2004.01.040; Xu RX, 2000, SCIENCE, V288, P1822, DOI 10.1126/science.288.5472.1822; Zhang KYJ, 2004, MOL CELL, V15, P279, DOI 10.1016/j.molcel.2004.07.005; Zoraghi R, 2006, J BIOL CHEM, V281, P5553, DOI 10.1074/jbc.M510372200	50	123	130	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21469	21479		10.1074/jbc.M512527200	http://dx.doi.org/10.1074/jbc.M512527200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16735511	hybrid			2022-12-25	WOS:000239187300082
J	Zhu, DH; Paine, ML; Luo, W; Bringas, P; Snead, ML				Zhu, DanHong; Paine, Michael L.; Luo, Wen; Bringas, Pablo, Jr.; Snead, Malcolm L.			Altering biomineralization by protein design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED AMELOGENESIS IMPERFECTA; GENE SPLICE PRODUCTS; ENAMEL MATRIX; DENTAL ENAMEL; CRYSTALS; CELLS; EXPRESSION; TEETH; MICE; RAT	To create a bioceramic with unique materials properties, biomineralization exploits cells to create a tissue-specific protein matrix to control the crystal habit, timing, and position of the mineral phase. The biomineralized covering of vertebrate teeth is enamel, a distinctive tissue of ectodermal origin that is collagen-free. In forming enamel, amelogenin is the abundant protein that undergoes self-assembly to contribute to a matrix that guides its own replacement by mineral. Conserved domains in amelogenin suggest their importance to biomineralization. We used gene targeting in mice to replace native amelogenin with one of two engineered amelogenins. Replacement changed enamel organization by altering protein-to-crystallite interactions and crystallite stacking while diminishing the ability of the ameloblast to interact with the matrix. These data demonstrate that ameloblasts must continuously interact with the developing matrix to provide amelogenin-specific protein to protein, protein to mineral, and protein to membrane interactions critical to biomineralization and enamel architecture while suggesting that mutations within conserved amelogenin domains could account for enamel variations preserved in the fossil record.	Univ So Calif, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA	University of Southern California	Snead, ML (corresponding author), Univ So Calif, Ctr Craniofacial Mol Biol, 2250 Alcazar St,CSA 142, Los Angeles, CA 90033 USA.	mlsnead@usc.edu			NIDCR NIH HHS [DE13404, DE 13045] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE013045] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE013045, R01DE013404] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALVESALO L, 1985, ANN HUM BIOL, V12, P421, DOI 10.1080/03014468500007981; ALVESALO L, 1987, HUM GENET, V77, P345, DOI 10.1007/BF00291424; AOBA T, 1989, J DENT RES, V68, P1331, DOI 10.1177/00220345890680090901; Bartlett JD, 2004, J DENT RES, V83, P909, DOI 10.1177/154405910408301204; Boyde A, 1987, Adv Dent Res, V1, P135; Boyde A, 1997, CIBA F SYMP, V205, P18; Cerny R, 1996, J BONE MINER RES, V11, P883; Collier PM, 1997, ARCH ORAL BIOL, V42, P235, DOI 10.1016/S0003-9969(96)00099-4; DACULSI G, 1984, CALCIFIED TISSUE INT, V36, P550, DOI 10.1007/BF02405364; DENBESTEN PK, 1989, ARCH ORAL BIOL, V34, P399, DOI 10.1016/0003-9969(89)90117-9; DEUTSCH D, 1982, J DENT RES, V61, P1543; Du C, 2005, SCIENCE, V307, P1450, DOI 10.1126/science.1105675; Dumont Elizabeth R., 1996, Scanning Microscopy, V10, P349; Dumont ER, 1996, ARCH ORAL BIOL, V41, P1053, DOI 10.1016/S0003-9969(96)00056-8; FINCHAM AG, 1995, J STRUCT BIOL, V115, P50, DOI 10.1006/jsbi.1995.1029; Fincham AG, 1999, J STRUCT BIOL, V126, P270, DOI 10.1006/jsbi.1999.4130; Fong H, 2003, J BONE MINER RES, V18, P2052, DOI 10.1359/jbmr.2003.18.11.2052; Fukumoto S, 2004, J CELL BIOL, V167, P973, DOI 10.1083/jcb.200409077; GANTT DG, 1979, J BIOL BUCCALE, V7, P149; Gibson CW, 2001, J BIOL CHEM, V276, P31871, DOI 10.1074/jbc.M104624200; Hammarstrom L, 1997, CIBA F SYMP, V205, P246; Hoang AM, 2002, J DENT RES, V81, P497, DOI 10.1177/154405910208100713; Hu CC, 1997, J DENT RES, V76, P648, DOI 10.1177/00220345970760020501; Iijima M, 2004, CALCIFIED TISSUE INT, V74, P522, DOI 10.1007/s00223-002-0011-3; Iijima M, 2002, J DENT RES, V81, P69, DOI 10.1177/154405910208100115; Iwasaki K, 2005, J DENT RES, V84, P1127, DOI 10.1177/154405910508401207; Kirkham J, 2000, J DENT RES, V79, P1943, DOI 10.1177/00220345000790120401; Kobayashi T, 2000, MOL BIOL CELL, V11, P1829, DOI 10.1091/mbc.11.5.1829; Kogaya Y, 1999, J ANAT, V195, P455, DOI 10.1046/j.1469-7580.1999.19530455.x; Landis W J, 1999, Gravit Space Biol Bull, V12, P15; LANDIS WJ, 1995, BONE, V16, P533, DOI 10.1016/8756-3282(95)00076-P; LENCH NJ, 1995, HUM MUTAT, V5, P251, DOI 10.1002/humu.1380050310; LESTER KS, 1989, SCANNING MICROSCOPY, V3, P645; Lyon MF, 2003, SEMIN CELL DEV BIOL, V14, P313, DOI 10.1016/j.semcdb.2003.09.015; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Maycock J, 2002, CONNECT TISSUE RES, V43, P472, DOI 10.1080/03008200290000880; Moradian-Oldak J, 2000, J STRUCT BIOL, V131, P27, DOI 10.1006/jsbi.2000.4237; Moradian-Oldak J, 1998, BIOPOLYMERS, V46, P225, DOI 10.1002/(SICI)1097-0282(19981005)46:4<225::AID-BIP4>3.0.CO;2-R; Paine ML, 2001, MATRIX BIOL, V20, P273, DOI 10.1016/S0945-053X(01)00153-6; Paine ML, 1997, J BONE MINER RES, V12, P221, DOI 10.1359/jbmr.1997.12.2.221; Paine ML, 2002, J BIOL CHEM, V277, P17112, DOI 10.1074/jbc.M110473200; Paine ML, 2000, J STRUCT BIOL, V132, P191, DOI 10.1006/jsbi.2000.4324; Peden AA, 2004, J CELL BIOL, V164, P1065, DOI 10.1083/jcb.200311064; Radlanski RJ, 2004, MED HYPOTHESES, V62, P945, DOI 10.1016/j.mehy.2003.12.038; Ravindranath RMH, 1999, J BIOL CHEM, V274, P2464, DOI 10.1074/jbc.274.4.2464; RISNES S, 1985, SCAND J DENT RES, V93, P135; Robinson C, 1998, EUR J ORAL SCI, V106, P282, DOI 10.1111/j.1600-0722.1998.tb02188.x; ROBINSON C, 1979, J DENT RES, V58, P871, DOI 10.1177/00220345790580024101; Salmivirta K, 1996, DEV DYNAM, V205, P104, DOI 10.1002/(SICI)1097-0177(199602)205:2<104::AID-AJA2>3.0.CO;2-M; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shaw WJ, 2004, J BIOL CHEM, V279, P40263, DOI 10.1074/jbc.C400322200; Simmer JP, 2002, CONNECT TISSUE RES, V43, P441, DOI 10.1080/03008200290001159; SIMMER JP, 1995, CRIT REV ORAL BIOL M, V6, P84, DOI 10.1177/10454411950060020701; SIMMER JP, 1995, DENTAL ENAMEL FORMAT; Smith CE, 2005, J BONE MINER RES, V20, P240, DOI 10.1359/JBMR.041002; SMITH CE, 1995, INT J DEV BIOL, V39, P153; Smith CE, 1998, CRIT REV ORAL BIOL M, V9, P128, DOI 10.1177/10454411980090020101; SMITH CE, 1976, AM J ANAT, V145, P225, DOI 10.1002/aja.1001450206; Smith DA, 1995, MOL IMMUNOL, V32, P1339, DOI 10.1016/0161-5890(95)00113-1; Snead ML, 2003, CONNECT TISSUE RES, V44, P47, DOI 10.1080/03008200390152089; Tompkins K, 2006, BONE, V38, P172, DOI 10.1016/j.bone.2005.08.013; Veis A, 2003, CELL MOL LIFE SCI, V60, P38, DOI 10.1007/s000180300003; Veis A, 2000, J BIOL CHEM, V275, P41263, DOI 10.1074/jbc.M002308200; Wang HJ, 2005, J BONE MINER RES, V20, P1032, DOI 10.1359/JBMR.050111; Wang XP, 2005, J EXP ZOOL PART B, V304B, P177, DOI 10.1002/jez.b.21035; Weiner S, 1999, J STRUCT BIOL, V126, P241, DOI 10.1006/jsbi.1999.4107; Wen HB, 2000, J DENT RES, V79, P1902, DOI 10.1177/00220345000790111501; White SN, 2001, J DENT RES, V80, P321, DOI 10.1177/00220345010800010501; Wright JT, 1997, CIBA F SYMP, V205, P85; Zhou YL, 2000, J BIOL CHEM, V275, P12273, DOI 10.1074/jbc.275.16.12273	70	36	36	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21173	21182		10.1074/jbc.M510757200	http://dx.doi.org/10.1074/jbc.M510757200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16707492	hybrid			2022-12-25	WOS:000239187300053
J	Bairstow, SF; Ling, K; Su, XJ; Firestone, AJ; Carbonara, C; Anderson, RA				Bairstow, Shawn F.; Ling, Kun; Su, Xiaojing; Firestone, Ari J.; Carbonara, Chateen; Anderson, Richard A.			Type I gamma 661 phosphatidylinositol phosphate kinase directly interacts with AP2 and regulates endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER COMPLEX; PLASMA-MEMBRANE; GAMMA; PHOSPHORYLATION; TALIN; AP-2; RECRUITMENT; SIGNALS; BINDING; LIPIDS	Clathrin-coated vesicles mediate sorting and intracellular transport of membrane-bound proteins. The formation of these coats is initiated by the assembly of adaptor proteins (AP), which specifically bind to membrane cargo proteins via recognition of endocytic sorting motifs. The lipid signaling molecule phosphatidylinositol 4,5-bisphosphate (PI(4,5)P-2) is critical for this process, as it serves as both a targeting and regulatory factor. PI( 4,5) P2 is synthesized by type I phosphatidylinositol phosphate kinases (PIPKI). We have discovered a direct interaction between the mu 2-subunit of the AP2 complex and PIPKI gamma 661 via a yeast two-hybrid screen. This interaction was confirmed using both the mu 2-subunit in glutathione S-transferase pulldowns and via coimmunoprecipitation of endogenous PIPKI gamma 661 with the AP2 complex from HEK293 cells. The interaction is mediated, in vivo, by a tyrosine-based motif in the 26-amino acid tail of PIPKI gamma 661. Because AP2 regulates endocytosis of transferrin receptor from the plasma membrane, we also examined a role for PIPKI gamma 661 using a flow cytometry endocytosis assay. We observed that stable expression of wild type PIPKI gamma 661 in Madin-Darby canine kidney cells enhanced transferrin uptake, whereas stable expression of kinase-dead PIPKI gamma 661 had an inhibitory effect. Neither condition affected the overall cellular level of PI(4,5) P2. RNA interference-based knockdown of PIPKI gamma 661 in HeLa cells also had an inhibitory effect on transferrin endocytosis using the same assay system. Collectively, this evidence implies an important role for PIPKI gamma 661 in the AP2-mediated endocytosis of transferrin.	Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Anderson, RA (corresponding author), Univ Wisconsin, Sch Med, Med Sci Ctr 3750, 1300 Univ Ave, Madison, WI 53706 USA.	raanders@wisc.edu		Anderson, Richard/0000-0001-6265-8359; Firestone, Ari/0000-0001-9902-443X	NCI NIH HHS [CA104708] Funding Source: Medline; NIGMS NIH HHS [GM57549, GM08349] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008349] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Bairstow SF, 2005, J BIOL CHEM, V280, P23884, DOI 10.1074/jbc.M500576200; Barbieri MA, 2001, J BIOL CHEM, V276, P47212, DOI 10.1074/jbc.C100490200; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Cockcroft S, 2001, J MEMBRANE BIOL, V180, P187, DOI 10.1007/s002320010069; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Conner SD, 2003, TRAFFIC, V4, P885, DOI 10.1046/j.1398-9219.2003.0142.x; Conner SD, 2002, J CELL BIOL, V156, P921, DOI 10.1083/jcb.200108123; D'Santos CS, 1998, BBA-MOL CELL BIOL L, V1436, P201, DOI 10.1016/S0005-2760(98)00146-5; Di Paolo G, 2004, NATURE, V431, P415, DOI 10.1038/nature02896; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Folsch H, 2001, J CELL BIOL, V152, P595, DOI 10.1083/jcb.152.3.595; Gaidarov I, 1999, J CELL BIOL, V146, P755, DOI 10.1083/jcb.146.4.755; Gan YB, 2002, NAT CELL BIOL, V4, P605, DOI 10.1038/ncb827; Gong LW, 2005, P NATL ACAD SCI USA, V102, P5204, DOI 10.1073/pnas.0501412102; Honing S, 2005, MOL CELL, V18, P519, DOI 10.1016/j.molcel.2005.04.019; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Krauss M, 2003, J CELL BIOL, V162, P113, DOI 10.1083/jcb.200301006; Lee SY, 2005, J CELL BIOL, V168, P789, DOI 10.1083/jcb.200409028; Ling K, 2003, J CELL BIOL, V163, P1339, DOI 10.1083/jcb.200310067; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Morgan JR, 2004, J CELL BIOL, V167, P43, DOI 10.1083/jcb.200406020; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; Padron D, 2003, J CELL BIOL, V162, P693, DOI 10.1083/jcb.200302051; Paleotti O, 2005, J BIOL CHEM, V280, P21661, DOI 10.1074/jbc.m503099200; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Ricotta D, 2002, J CELL BIOL, V156, P791, DOI 10.1083/jcb.200111068; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Rohde G, 2002, J CELL BIOL, V158, P209, DOI 10.1083/jcb.200203103; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Sever S, 2003, DEV CELL, V5, P530, DOI 10.1016/S1534-5807(03)00304-6; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Wenk MR, 2001, NEURON, V32, P79, DOI 10.1016/S0896-6273(01)00456-1; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	40	74	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20632	20642		10.1074/jbc.M601465200	http://dx.doi.org/10.1074/jbc.M601465200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16707488	hybrid			2022-12-25	WOS:000239038200084
J	Ho, WC; Fitzgerald, MX; Marmorstein, R				Ho, William C.; Fitzgerald, Mary X.; Marmorstein, Ronen			Structure of the p53 core domain dimer bound to DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; CONVERTIBLE NUCLEOSIDE APPROACH; BINDING DOMAIN; CRYSTAL-STRUCTURE; COOPERATIVE BINDING; OLIGOMERIZATION DOMAIN; TETRAMERIZATION DOMAIN; REVERSE-TRANSCRIPTASE; CONSENSUS DNA; COMPLEX	The p53 tumor suppressor protein binds to DNA as a dimer of dimers to regulate transcription of genes that mediate responses to cellular stress. We have prepared a cross-linked trapped p53 core domain dimer bound to decamer DNA and have determined its structure by x-ray crystallography to 2.3 angstrom resolution. The p53 core domain subunits bind nearly symmetrically to opposite faces of the DNA in a head-to-head fashion with a loop-helix motif making sequence-specific DNA contacts and bending the DNA by about 20 at the site of protein dimerization. Protein subunit interactions occur over the central DNA minor groove and involve residues from a zinc-binding region. Analysis of tumor derived p53 mutations reveals that the dimerization interface represents a third hot spot for mutation that also includes residues associated with DNA contact and protein stability. Residues associated with p53 dimer formation on DNA are poorly conserved in the p63 and p73 paralogs, possibly contributing to their functional differences. We have used the dimeric protein-DNA complex to model a dimer of p53 dimers bound to icosamer DNA that is consistent with solution bending data and suggests that p53 core domain dimer-dimer contacts are less frequently mutated in human cancer than intra-dimer contacts.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Chem, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania	Marmorstein, R (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St,Rm 327, Philadelphia, PA 19104 USA.	marmor@wistar.org			NIGMS NIH HHS [GM52880] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; Dehner A, 2005, ANGEW CHEM INT EDIT, V44, P5247, DOI 10.1002/anie.200501887; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Huang HF, 2000, CHEM BIOL, V7, P355, DOI 10.1016/S1074-5521(00)00113-7; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Huyen Y, 2004, STRUCTURE, V12, P1237, DOI 10.1016/j.str.2004.05.007; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Joerger AC, 2005, J BIOL CHEM, V280, P16030, DOI 10.1074/jbc.M500179200; Joerger AC, 2004, J BIOL CHEM, V279, P1291, DOI 10.1074/jbc.M309732200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Klein C, 2001, J BIOL CHEM, V276, P49020, DOI 10.1074/jbc.M107516200; Klein C, 2001, J BIOL CHEM, V276, P37390, DOI 10.1074/jbc.M103801200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lebrun A, 2001, PROTEIN ENG, V14, P233, DOI 10.1093/protein/14.4.233; Lu XJ, 2003, NUCLEIC ACIDS RES, V31, P5108, DOI 10.1093/nar/gkg680; Ma BY, 2005, P NATL ACAD SCI USA, V102, P3988, DOI 10.1073/pnas.0500215102; MACMILLAN AM, 1991, TETRAHEDRON, V47, P2603, DOI 10.1016/S0040-4020(01)81793-2; MACMILLAN AM, 1990, J ORG CHEM, V55, P5931, DOI 10.1021/jo00311a005; Nagaich AK, 1999, P NATL ACAD SCI USA, V96, P1875, DOI 10.1073/pnas.96.5.1875; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Rippin TM, 2002, J MOL BIOL, V319, P351, DOI 10.1016/S0022-2836(02)00326-1; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Weinberg RL, 2004, J MOL BIOL, V341, P1145, DOI 10.1016/j.jmb.2004.06.071; XU YZ, 1992, J ORG CHEM, V57, P3839, DOI 10.1021/jo00040a024; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhao KH, 2001, J BIOL CHEM, V276, P12120, DOI 10.1074/jbc.M011644200	42	114	116	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20494	20502		10.1074/jbc.M603634200	http://dx.doi.org/10.1074/jbc.M603634200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16717092	hybrid			2022-12-25	WOS:000239038200072
J	King, DA; Hall, BE; Iwamoto, MA; Win, KZ; Chang, JF; Ellenberger, T				King, Daniel A.; Hall, Brian E.; Iwamoto, Melanie A.; Win, Khine Zar; Chang, Ju Fang; Ellenberger, Tom			Domain structure and protein interactions of the silent information regulator Sir3 revealed by screening a nested deletion library of protein fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TELOMERIC HETEROCHROMATIN; SACCHAROMYCES-CEREVISIAE; COILED-COIL; ADP-RIBOSE; IN-VIVO; DEACETYLASE; COMPLEX; VECTOR; SYSTEM; EXPRESSION	Transcriptional silencing in yeast is mediated by the interactions of silent information regulator ( Sir) proteins with chromatin and with one another. The stable association of Sir3 with Sir4 is mediated by a C-terminal region of Sir3 that has additional functions including the dimerization of Sir3. We have developed a simple, robust expression screening methodology that allows for the unbiased identification of functional protein domains expressed from nested-deletion libraries of full-length genes. Using these methodologies, Sir3 dimerization was shown to be mediated by two separate domains. One of these domains also binds cooperatively to the C-terminal coiled-coil motif of Sir4 and dimerization further increases the affinity of Sir3 for Sir4. The resulting Sir3-Sir4 complexes form progressively higher order assemblies with increasing protein concentration, with implications for the mechanism of gene silencing.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Ellenberger, T (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.	tome@biochem.wustl.edu	Classen, Scott/AAY-8176-2020		NATIONAL CANCER INSTITUTE [P01CA092584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052504] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA92584] Funding Source: Medline; NIGMS NIH HHS [R01 GM52504] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Avalos JL, 2002, MOL CELL, V10, P523, DOI 10.1016/S1097-2765(02)00628-7; Chang JF, 2003, STRUCTURE, V11, P637, DOI 10.1016/S0969-2126(03)00093-5; Cho G, 2000, J MOL BIOL, V297, P309, DOI 10.1006/jmbi.2000.3571; Cockell MM, 2000, GENETICS, V154, P1069; CREIGHTON TE, 1989, PROTEINS STRUCTURES; Daugelat S, 1999, PROTEIN SCI, V8, P644; Dutnall RN, 2001, CELL, V105, P161, DOI 10.1016/S0092-8674(01)00305-1; Enomoto S, 2000, GENETICS, V155, P523; Finnin MS, 2001, NAT STRUCT BIOL, V8, P621, DOI 10.1038/89668; Gartenberg MR, 2000, CURR OPIN MICROBIOL, V3, P132, DOI 10.1016/S1369-5274(00)00064-3; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Gerth ML, 2004, PROTEIN ENG DES SEL, V17, P595, DOI 10.1093/protein/gzh068; Ghidelli S, 2001, EMBO J, V20, P4522, DOI 10.1093/emboj/20.16.4522; Graslund S, 2002, FEMS MICROBIOL LETT, V215, P139, DOI 10.1111/j.1574-6968.2002.tb11383.x; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Hawke NA, 1997, BIOTECHNIQUES, V23, P619, DOI 10.2144/97234bm13; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hill A.V, 1910, J PHYSL, V40, piv, DOI DOI 10.1113/JPHYSIOL.1910.SP001386; Hoppe GJ, 2002, MOL CELL BIOL, V22, P4167, DOI 10.1128/MCB.22.12.4167-4180.2002; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Liou GG, 2005, CELL, V121, P515, DOI 10.1016/j.cell.2005.03.035; Lomakin Aleksey, 2004, V299, P153; Luo KH, 2002, GENE DEV, V16, P1528, DOI 10.1101/gad.988802; Lutz S, 2002, PROTEIN ENG, V15, P1025, DOI 10.1093/protein/15.12.1025; Lutz S, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.4.e16; MARSHALL M, 1987, MOL CELL BIOL, V7, P4441, DOI 10.1128/MCB.7.12.4441; Maxwell KL, 1999, PROTEIN SCI, V8, P1908, DOI 10.1110/ps.8.9.1908; Min JR, 2001, CELL, V105, P269, DOI 10.1016/S0092-8674(01)00317-8; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Moazed D, 1997, P NATL ACAD SCI USA, V94, P2186, DOI 10.1073/pnas.94.6.2186; Moazed D, 2001, CURR OPIN CELL BIOL, V13, P232, DOI 10.1016/S0955-0674(00)00202-7; Moazed Danesh, 2004, Novartis Found Symp, V259, P48; Moradian-Oldak J, 1998, J STRUCT BIOL, V122, P320, DOI 10.1006/jsbi.1998.4008; Moretti P, 2001, MOL CELL BIOL, V21, P8082, DOI 10.1128/MCB.21.23.8082-8094.2001; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; Murphy GA, 2003, J MOL BIOL, V334, P769, DOI 10.1016/j.jmb.2003.09.066; Ostermeier M, 1999, P NATL ACAD SCI USA, V96, P3562, DOI 10.1073/pnas.96.7.3562; Park Y, 1998, GENETICS, V150, P977; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; RINE J, 1987, GENETICS, V116, P9; ROBBEN J, 1993, GENE, V126, P109, DOI 10.1016/0378-1119(93)90597-V; Rusche LN, 2002, MOL BIOL CELL, V13, P2207, DOI 10.1091/mbc.E02-03-0175; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shaw W V, 1975, Methods Enzymol, V43, P737; SHAW WV, 1991, ANNU REV BIOPHYS BIO, V20, P363, DOI 10.1146/annurev.biophys.20.1.363; Sieber V, 2001, NAT BIOTECHNOL, V19, P456, DOI 10.1038/88129; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; Weiss JN, 1997, FASEB J, V11, P835, DOI 10.1096/fasebj.11.11.9285481; Wigley WC, 2001, NAT BIOTECHNOL, V19, P131, DOI 10.1038/84389; Zacchi P, 2003, GENOME RES, V13, P980, DOI 10.1101/gr.861503; Zhao KH, 2003, STRUCTURE, V11, P1403, DOI 10.1016/j.str.2003.09.016	58	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20107	20119		10.1074/jbc.M512588200	http://dx.doi.org/10.1074/jbc.M512588200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16717101	hybrid			2022-12-25	WOS:000239038200035
J	Soni, S; Bala, S; Gwynn, B; Sahr, KE; Peters, LL; Hanspal, M				Soni, Shivani; Bala, Shashi; Gwynn, Babette; Sahr, Kenneth E.; Peters, Luanne L.; Hanspal, Manjit			Absence of erythroblast macrophage protein (Emp) leads to failure of erythroblast nuclear extrusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC-CELL CLUSTERS; ERYTHROPOIESIS IN-VIVO; MOUSE FETAL LIVER; ADHESION MOLECULE-1; BONE-MARROW; DEFINITIVE ERYTHROPOIESIS; INSERTIONAL MUTATIONS; PRECURSOR CELLS; YOLK-SAC; DIFFERENTIATION	In mammals, the functional unit for definitive erythropoiesis is the erythroblastic island, a multicellular structure composed of a central macrophage surrounded by developing erythroblasts. Erythroblast-macrophage interactions play a central role in the terminal maturation of erythroblasts, including enucleation. One possible mediator of this cell-cell interaction is the protein Emp (erythroblast macrophage protein). We used targeted gene inactivation to define the function of Emp during hematopoiesis. Emp null embryos die perinatally and show profound alterations in the hematopoietic system. A dramatic increase in the number of nucleated, immature erythrocytes is seen in the peripheral blood of Emp null fetuses. In the fetal liver virtually no erythroblastic islands are observed, and the number of F4/80-positive macrophages is substantially reduced. Those present lack cytoplasmic projections and are unable to interact with erythroblasts. Interestingly, wild type macrophages can bind Emp-deficient erythroblasts, but these erythroblasts do not extrude their nuclei, suggesting that Emp impacts enucleation in a cell autonomous fashion. Previous studies have implicated the actin cytoskeleton and its reorganization in both erythroblast enucleation as well as in macrophage development. We demonstrate that Emp associates with F-actin and that this interaction is important in the normal distribution of F-actin in both erythroblasts and macrophages. Thus, Emp appears to be required for erythroblast enucleation and in the development of the mature macrophages. The availability of an Emp null model provides a unique experimental system to study the enucleation process and to evaluate the function of macrophages in definitive erythropoiesis.	Tufts Univ, Sch Med, St Elizabeths Med Ctr, Ctr Cell Biol,CBR 406,Dept Med, Brighton, MA 02135 USA; Jackson Lab, Bar Harbor, ME 04609 USA	St. Elizabeth's Medical Center; Tufts University; Jackson Laboratory	Hanspal, M (corresponding author), Tufts Univ, Sch Med, St Elizabeths Med Ctr, Ctr Cell Biol,CBR 406,Dept Med, Brighton, MA 02135 USA.	manjit.hanspal@tufts.edu		Peters, Luanne/0000-0002-0784-0534	NHLBI NIH HHS [HL075714, R01 HL075714] Funding Source: Medline; NIAID NIH HHS [AI50600] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075714] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050600] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN TD, 1982, DIFFERENTIATION, V21, P86, DOI 10.1111/j.1432-0436.1982.tb01201.x; ARKIN S, 1991, BLOOD, V77, P948; ARMEANU S, 1995, J CELL BIOL, V131, P243, DOI 10.1083/jcb.131.1.243; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; Bala S, 2006, BIOCHEM BIOPH RES CO, V342, P1040, DOI 10.1016/j.bbrc.2006.02.060; Bonnesen B, 2005, BLOOD, V106, P3396, DOI 10.1182/blood-2005-04-1739; CAMPBELL FR, 1968, ANAT RECORD, V160, P539, DOI 10.1002/ar.1091600304; Chitu V, 2005, MOL BIOL CELL, V16, P2947, DOI 10.1091/mbc.e04-10-0914; CROCKER PR, 1990, BLOOD, V76, P1131; CROCKER PR, 1986, J EXP MED, V164, P1862, DOI 10.1084/jem.164.6.1862; CROCKER PR, 1985, J EXP MED, V162, P993, DOI 10.1084/jem.162.3.993; DONG L, 2004, CELL BIOL INT, V28, P457; El Nemer W, 1998, J BIOL CHEM, V273, P16686; Hamamura K, 1996, BLOOD, V87, P2513, DOI 10.1182/blood.V87.6.2513.bloodjournal8762513; HANSPAL M, 1994, BLOOD, V84, P3494; Hanspal M, 1998, BLOOD, V92, P2940, DOI 10.1182/blood.V92.8.2940.420k31_2940_2950; HOGAN B, 1994, MANIPULATING MOUSE E, P260; HOUSSAINT E, 1981, CELL DIFFER DEV, V10, P243, DOI 10.1016/0045-6039(81)90007-5; Iavarone A, 2004, NATURE, V432, P1040, DOI 10.1038/nature03068; KANSAS GS, 1990, BLOOD, V76, P2483; Kawane K, 2001, SCIENCE, V292, P1546, DOI 10.1126/science.292.5521.1546; Kingsley PD, 2004, BLOOD, V104, P19, DOI 10.1182/blood-2003-12-4162; KOURY ST, 1989, J CELL BIOL, V109, P3005, DOI 10.1083/jcb.109.6.3005; Krieser RJ, 2002, CELL DEATH DIFFER, V9, P956, DOI 10.1038/sj.cdd.4401056; Lee JCM, 2004, BLOOD, V103, P1912, DOI 10.1182/blood-2003-03-0928; LEWINSOHN DM, 1990, BLOOD, V75, P589; MORIOKA Y, 1994, J LEUKOCYTE BIOL, V55, P642, DOI 10.1002/jlb.55.5.642; Morris RD, 1998, ENVIRON HEALTH PERSP, V106, P649; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Naito M, 1997, MICROSC RES TECHNIQ, V39, P350, DOI 10.1002/(SICI)1097-0029(19971115)39:4<350::AID-JEMT5>3.0.CO;2-L; Palis J, 1999, DEVELOPMENT, V126, P5073; PAPAYANNOPOULOU T, 1992, BLOOD, V79, P1686; Parsons SF, 1999, BEST PRACT RES CL HA, V12, P729, DOI 10.1053/beha.1999.0050; PERRY MM, 1971, EXP CELL RES, V65, P249, DOI 10.1016/S0014-4827(71)80075-7; PETERS LL, 1992, P NATL ACAD SCI USA, V89, P5749, DOI 10.1073/pnas.89.13.5749; REPASKY EA, 1981, RED CELL, P679; ROSEMBLATT M, 1991, J CLIN INVEST, V87, P6, DOI 10.1172/JCI115002; SADAHIRA Y, 1995, J EXP MED, V181, P411, DOI 10.1084/jem.181.1.411; Sasaki K, 1997, MICROSC RES TECHNIQ, V39, P398, DOI 10.1002/(SICI)1097-0029(19971201)39:5<398::AID-JEMT2>3.0.CO;2-D; SCHROEDER TE, 1973, P NATL ACAD SCI USA, V70, P1688, DOI 10.1073/pnas.70.6.1688; SEKI M, 1965, ACTA PATHOL JAPON, V15, P295; SIMMONS PJ, 1992, BLOOD, V80, P388; SIMPSON CF, 1967, J CELL BIOL, V35, P237, DOI 10.1083/jcb.35.1.237; SKUTELSKI E, 1972, ANAT REC, V73, P123; SKUTELSKY E, 1970, EXP CELL RES, V60, P427, DOI 10.1016/0014-4827(70)90536-7; SKUTELSKY E, 1967, J CELL BIOL, V33, P625, DOI 10.1083/jcb.33.3.625; Southcott MJG, 1999, BLOOD, V93, P4425, DOI 10.1182/blood.V93.12.4425.412k22_4425_4435; Stryke D, 2003, NUCLEIC ACIDS RES, V31, P278, DOI 10.1093/nar/gkg064; Townley DJ, 1997, GENOME RES, V7, P293, DOI 10.1101/gr.7.3.293; Trimborn T, 1999, GENE DEV, V13, P112, DOI 10.1101/gad.13.1.112; Yoshida H, 2005, NATURE, V437, P754, DOI 10.1038/nature03964	51	109	121	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20181	20189		10.1074/jbc.M603226200	http://dx.doi.org/10.1074/jbc.M603226200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16707498	hybrid			2022-12-25	WOS:000239038200042
J	Martin, TL; Alquier, T; Asakura, K; Furukawa, N; Preitner, F; Kahn, BB				Martin, Tonya L.; Alquier, Thierry; Asakura, Kenji; Furukawa, Noboru; Preitner, Frederic; Kahn, Barbara B.			Diet-induced obesity alters AMP kinase activity in hypothalamus and skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; LEPTIN SIGNAL-TRANSDUCTION; ACETYL-COA CARBOXYLASE; INSULIN SENSITIVITY; RECOMBINANT LEPTIN; FOOD-INTAKE; RESISTANCE; MICE; EXPRESSION; WEIGHT	AMP-activated protein kinase (AMPK) is a key regulator of cellular energy balance and of the effects of leptin on food intake and fatty acid oxidation. Obesity is usually associated with resistance to the effects of leptin on food intake and body weight. To determine whether diet-induced obesity (DIO) impairs the AMPK response to leptin in muscle and/or hypothalamus, we fed FVB mice a high fat (55%) diet for 10-12 weeks. Leptin acutely decreased food intake by similar to 30% in chow-fed mice. DIO mice tended to eat less, and leptin had no effect on food intake. Leptin decreased respiratory exchange ratio in chow-fed mice indicating increased fatty acid oxidation. Respiratory exchange ratio was low basally in high fat-fed mice, and leptin had no further effect. Leptin (3 mg/kg intraperitoneally) increased alpha 2-AMPK activity 2-fold in muscle in chow-fed mice but not in DIO mice. Leptin decreased acetyl-CoA carboxylase activity 40% in muscle from chow-fed mice. In muscle from DIO mice, acetyl-CoA carboxylase activity was basally low, and leptin had no further effect. In paraventricular, arcuate, and medial hypothalamus of chow-fed mice, leptin inhibited alpha 2-AMPK activity but not in DIO mice. In addition, leptin increased STAT3 phosphorylation 2-fold in arcuate of chow-fed mice, but this effect was attenuated because of elevated basal STAT3 phosphorylation in DIO mice. Thus, DIO in FVB mice alters alpha 2-AMPK in muscle and hypothalamus and STAT3 in hypothalamus and impairs further effects of leptin on these signaling pathways. Defective responses of AMPK to leptin may contribute to resistance to leptin action on food intake and energy expenditure in obese states.	Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Kahn, BB (corresponding author), Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Dept Med, 99 Brookline Ave, Boston, MA 02215 USA.	bkahn@bidmc.harvard.edu	Alquier, Thierry/Z-1917-2019	Alquier, Thierry/0000-0001-8171-802X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK056116, P30DK057521] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30DK57521, R01 DK043051, P30DK56116, DK069026] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersson U, 2004, J BIOL CHEM, V279, P12005, DOI 10.1074/jbc.C300557200; Banks WA, 2004, DIABETES, V53, P1253, DOI 10.2337/diabetes.53.5.1253; Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Bowen H, 2003, AM J PHYSIOL-REG I, V284, pR87, DOI 10.1152/ajpregu.00431.2002; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; El-Haschimi K, 2000, J CLIN INVEST, V105, P1827, DOI 10.1172/JCI9842; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gao Q, 2004, P NATL ACAD SCI USA, V101, P4661, DOI 10.1073/pnas.0303992101; Ghazali A, 2003, NEPHROL DIAL TRANSPL, V18, P1882, DOI 10.1093/ndt/gfg268; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Heymsfield SB, 1999, JAMA-J AM MED ASSOC, V282, P1568, DOI 10.1001/jama.282.16.1568; Hileman SM, 2002, ENDOCRINOLOGY, V143, P775, DOI 10.1210/en.143.3.775; Hojlund K, 2004, AM J PHYSIOL-ENDOC M, V286, pE239, DOI 10.1152/ajpendo.00326.2003; Howard JK, 2004, NAT MED, V10, P734, DOI 10.1038/nm1072; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Kim MS, 2004, NAT MED, V10, P727, DOI 10.1038/nm1061; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Kola B, 2005, J BIOL CHEM, V280, P25196, DOI 10.1074/jbc.C500175200; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Levin BE, 2002, AM J PHYSIOL-REG I, V283, pR941, DOI 10.1152/ajpregu.00245.2002; McLean J., 1987, ANIMAL HUMAN CALORIM; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Mori H, 2004, NAT MED, V10, P739, DOI 10.1038/nm1071; MUNDAY MR, 1991, BIOCHEM J, V280, P733, DOI 10.1042/bj2800733; Munzberg H, 2004, ENDOCRINOLOGY, V145, P4880, DOI 10.1210/en.2004-0726; Muoio DM, 2002, BEST PRACT RES CL EN, V16, P653, DOI 10.1053/beem.2002.0223; Muoio DM, 1997, DIABETES, V46, P1360, DOI 10.2337/diabetes.46.8.1360; Musi N, 2001, DIABETES, V50, P921, DOI 10.2337/diabetes.50.5.921; Musi Nicolas, 2002, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V2, P119; Namkoong C, 2005, DIABETES, V54, P63, DOI 10.2337/diabetes.54.1.63; Prpic V, 2003, ENDOCRINOLOGY, V144, P1155, DOI 10.1210/en.2002-220835; Scarpace PJ, 2000, NEUROPHARMACOLOGY, V39, P1872, DOI 10.1016/S0028-3908(00)00014-9; Spanswick D, 1997, NATURE, V390, P521, DOI 10.1038/37379; Steinberg GR, 2004, J CLIN ENDOCR METAB, V89, P4575, DOI 10.1210/jc.2004-0308; Steinberg GR, 2000, AM J PHYSIOL-ENDOC M, V279, pE1374, DOI 10.1152/ajpendo.2000.279.6.E1374; Steinberg GR, 2003, AM J PHYSIOL-ENDOC M, V284, pE648, DOI 10.1152/ajpendo.00318.2002; Steinberg GR, 2002, AM J PHYSIOL-ENDOC M, V283, pE187, DOI 10.1152/ajpendo.00542.2001; Tanaka T, 2005, DIABETES, V54, P2365, DOI 10.2337/diabetes.54.8.2365; VanHeek M, 1997, J CLIN INVEST, V99, P385, DOI 10.1172/JCI119171; Widdowson PS, 1997, DIABETES, V46, P1782, DOI 10.2337/diabetes.46.11.1782; Wilsey J, 2004, J ENDOCRINOL, V181, P297, DOI 10.1677/joe.0.1810297; WITTERS LA, 1992, J BIOL CHEM, V267, P2864; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Xu AW, 2005, J CLIN INVEST, V115, P951, DOI 10.1172/JCI200524301; Yu HY, 2004, AM J PHYSIOL-CELL PH, V286, pC283, DOI 10.1152/ajpcell.00319.2003; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X	58	211	219	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					18933	18941		10.1074/jbc.M512831200	http://dx.doi.org/10.1074/jbc.M512831200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16687413	hybrid			2022-12-25	WOS:000238847000006
J	Kulbachinskiy, A; Mustaev, A				Kulbachinskiy, Andrey; Mustaev, Arkady			Region 3.2 of the sigma subunit contributes to the binding of the 3 '-initiating nucleotide in the RNA polymerase active center and facilitates promoter clearance during initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; TRANSCRIPTION INITIATION; ANGSTROM RESOLUTION; IN-VITRO; HOLOENZYME; COMPLEX; TFIIB; FLAP	Region 3.2 of the RNA polymerase sigma subunit forms a loop that protrudes toward RNA polymerase active center and partially blocks RNA exit channel. To provide some insights into the functional role of this region, we studied a deletion variant of the Escherichia coli sigma(70) subunit that lacked amino acids 513-519 corresponding to the tip of the loop. The deletion had multiple effects on transcription initiation including: (i) a significant decrease in the amount of short abortive RNAs synthesized during initiation, (ii) defects in promoter escape, (iii) loss of the contacts between the sigma subunit and the nascent RNA during initiation and, finally, (iv) dramatic increase in the K-m value for the 3'-initiating nucleotide. At the same time, the mutation did not impair promoter opening and the binding of the 5'-initiating purine nucleotide. In summary, our data demonstrate an important role of sigma region 3.2 in the binding of initiating substrates mRNA-polymerase active center and in the process of promoter clearance.	Russian Acad Sci, Inst Mol Genet, Moscow 123182, Russia; Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA; Publ Hlth Res Inst, Newark, NJ 07103 USA	Russian Academy of Sciences; Rutgers State University New Brunswick	Mustaev, A (corresponding author), Russian Acad Sci, Inst Mol Genet, 2 Kurchatov Sq, Moscow 123182, Russia.	akulb@img.ras.ru	Kulbachinskiy, Andrey/P-5401-2016	Kulbachinskiy, Andrey/0000-0002-2292-6424	NIGMS NIH HHS [GM64530, GM30717] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064530, R01GM030717] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artsimovitch I, 2005, CELL, V122, P351, DOI 10.1016/j.cell.2005.07.014; Artsimovitch I, 2004, CELL, V117, P299, DOI 10.1016/S0092-8674(04)00401-5; Boeger H, 2005, FEBS LETT, V579, P899, DOI 10.1016/j.febslet.2004.11.027; BORUKHOV S, 1993, PROTEIN EXPRES PURIF, V4, P503, DOI 10.1006/prep.1993.1066; Bushnell DA, 2004, SCIENCE, V303, P983, DOI 10.1126/science.1090838; Campbell EA, 2002, MOL CELL, V9, P527, DOI 10.1016/S1097-2765(02)00470-7; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; Hernandez VJ, 1996, J BIOL CHEM, V271, P18775, DOI 10.1074/jbc.271.31.18775; HSU LM, 1995, P NATL ACAD SCI USA, V92, P11588, DOI 10.1073/pnas.92.25.11588; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; Kuznedelov K, 2002, SCIENCE, V295, P855, DOI 10.1126/science.1066303; Minakhin L, 2003, J BIOL CHEM, V278, P29710, DOI 10.1074/jbc.M304906200; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Murakami KS, 2003, CURR OPIN STRUC BIOL, V13, P31, DOI 10.1016/S0959-440X(02)00005-2; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Naryshkina T, 2001, J BIOL CHEM, V276, P13308, DOI 10.1074/jbc.M011041200; Nickels BE, 2005, P NATL ACAD SCI USA, V102, P4488, DOI 10.1073/pnas.0409850102; Pal M, 2005, MOL CELL, V19, P101, DOI 10.1016/j.molcel.2005.05.024; SEVERINOV K, 1995, J BIOL CHEM, V270, P29428, DOI 10.1074/jbc.270.49.29428; SEVERINOV K, 1994, J BIOL CHEM, V269, P20826; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; Young BA, 2002, CELL, V109, P417, DOI 10.1016/S0092-8674(02)00752-3; Zenkin N, 2004, P NATL ACAD SCI USA, V101, P4396, DOI 10.1073/pnas.0400886101	23	73	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18273	18276		10.1074/jbc.C600060200	http://dx.doi.org/10.1074/jbc.C600060200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16690607	hybrid			2022-12-25	WOS:000238687300003
J	Motyka, SA; Drew, ME; Yildirir, G; Englund, PT				Motyka, Shawn A.; Drew, Mark E.; Yildirir, Gokben; Englund, Paul T.			Overexpression of a cytochrome b(5) reductase-like protein causes kinetoplast DNA loss in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER MOTIF; CRITHIDIA-FASCICULATA; RNA INTERFERENCE; NUCLEOTIDE-SEQUENCE; REDOX REGULATION; VARIABLE REGION; GENE-EXPRESSION; BINDING-PROTEIN; BLOOD-STREAM; MITOCHONDRIAL	The mitochondrial genome of trypanosomes, termed kinetoplast DNA (kDNA), contains thousands of minicircles and dozens of maxicircles topologically interlocked in a network. To identify proteins involved in network replication, we screened an inducible RNA interference-based genomic library for cells that lose kinetoplast DNA. In one cloned cell line with inducible kinetoplast DNA loss, we found that the RNA interference vector had aberrantly integrated into the genome resulting in overexpression of genes downstream of the integration site (Motyka, S. A., Zhao, Z., Gull, K., and Englund, P. T. (2004) Mol. Biochem. Parasitol. 134, 163-167). We now report that the relevant overexpressed gene encodes a mitochondrial cytochrome b(5) reductase-like protein. This overexpression caused kDNA loss by oxidation/inactivation of the universal minicircle sequence-binding protein, which normally binds the minicircle replication origin and triggers replication. The rapid loss of maxicircles suggests that the universal minicircle sequence-binding protein might also control maxicircle replication. Several lines of evidence indicate that the cytochrome b5 reductase-like protein controls the oxidization status of the universal minicircle sequence-binding protein via tryparedoxin, a mitochondrial redox protein. For example, overexpression of mitochondrial tryparedoxin peroxidase, which utilizes tryparedoxin, also caused oxidation of the universal minicircle sequence-binding protein and kDNA loss. Furthermore, the growth defect caused by overexpression of cytochrome b(5) reductase-like protein could be partially rescued by simultaneously overexpressing tryparedoxin.	Johns Hopkins Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	Englund, PT (corresponding author), Johns Hopkins Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.	penglund@jhmi.edu	Drew, Mark/E-2993-2011		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058613] Funding Source: NIH RePORTER; NIAID NIH HHS [AI058613] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bastin P, 1996, MOL BIOCHEM PARASIT, V77, P235, DOI 10.1016/0166-6851(96)02598-4; Borgese N, 1993, Subcell Biochem, V21, P313; BRUN R, 1979, ACTA TROP, V36, P289; CARPENTER LR, 1995, MOL CELL BIOL, V15, P6794; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Colombo S, 2005, J CELL BIOL, V168, P735, DOI 10.1083/jcb.200407082; Downey N, 2005, EUKARYOT CELL, V4, P765, DOI 10.1128/EC.4.4.765-774.2005; Drew ME, 2003, J BIOL CHEM, V278, P46596, DOI 10.1074/jbc.M309320200; Drew ME, 2001, J CELL BIOL, V153, P735, DOI 10.1083/jcb.153.4.735; Gommel DU, 1997, EUR J BIOCHEM, V248, P913, DOI 10.1111/j.1432-1033.1997.t01-1-00913.x; Grams J, 2002, J BIOL CHEM, V277, P16952, DOI 10.1074/jbc.M200662200; KLEIN KG, 1995, MOL BIOCHEM PARASIT, V70, P207, DOI 10.1016/0166-6851(95)00013-Q; Klingbeil MM, 2002, MOL CELL, V10, P175, DOI 10.1016/S1097-2765(02)00571-3; Konstantinov Y, 2001, Dokl Biochem Biophys, V377, P82, DOI 10.1023/A:1011523522080; Lamb JR, 2001, J BIOL CHEM, V276, P21512, DOI 10.1074/jbc.M100235200; Liu BY, 2005, TRENDS PARASITOL, V21, P363, DOI 10.1016/j.pt.2005.06.008; Marchetti MA, 2000, J CELL SCI, V113, P899; MELENDY T, 1988, CELL, V55, P1083, DOI 10.1016/0092-8674(88)90252-8; Morris JC, 2002, EMBO J, V21, P4429, DOI 10.1093/emboj/cdf474; Motyka SA, 2004, MOL BIOCHEM PARASIT, V134, P163, DOI 10.1016/j.molbiopara.2003.11.013; MYLER PJ, 1993, NUCLEIC ACIDS RES, V21, P687, DOI 10.1093/nar/21.3.687; Onn I, 2004, EUKARYOT CELL, V3, P277, DOI 10.1128/EC.3.2.277-287.2004; Rusche LN, 1997, EMBO J, V16, P4069, DOI 10.1093/emboj/16.13.4069; Shen SY, 2001, MOL BIOCHEM PARASIT, V113, P171, DOI 10.1016/S0166-6851(00)00383-2; Shlomai J, 2004, CURR MOL MED, V4, P623, DOI 10.2174/1566524043360096; SLOOF P, 1992, MOL BIOCHEM PARASIT, V56, P289, DOI 10.1016/0166-6851(92)90178-M; SMITH K, 1991, MOL BIOCHEM PARASIT, V48, P109, DOI 10.1016/0166-6851(91)90170-B; Sogin ML, 1998, INT J PARASITOL, V28, P11, DOI 10.1016/S0020-7519(97)00181-1; Stuart KD, 2005, TRENDS BIOCHEM SCI, V30, P97, DOI 10.1016/j.tibs.2004.12.006; Tetaud E, 1998, MOL BIOCHEM PARASIT, V96, P111, DOI 10.1016/S0166-6851(98)00120-0; Tetaud E, 2001, MOL BIOCHEM PARASIT, V116, P171, DOI 10.1016/S0166-6851(01)00320-6; TZFATI Y, 1992, P NATL ACAD SCI USA, V89, P6891, DOI 10.1073/pnas.89.15.6891; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Wang M, 2001, ANTIOXID REDOX SIGN, V3, P657, DOI 10.1089/15230860152543005; Wang ZF, 2001, EMBO J, V20, P4674, DOI 10.1093/emboj/20.17.4674; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Wilkinson SR, 2000, J BIOL CHEM, V275, P8220, DOI 10.1074/jbc.275.11.8220; Wilkinson SR, 2003, J BIOL CHEM, V278, P31640, DOI 10.1074/jbc.M303035200; Wirtz E, 1998, NUCLEIC ACIDS RES, V26, P4626, DOI 10.1093/nar/26.20.4626; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WIRTZ E, 1995, SCIENCE, V268, P1179, DOI 10.1126/science.7761835; You JS, 2000, BIOCHEMISTRY-US, V39, P12953, DOI 10.1021/bi001206f	42	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18499	18506		10.1074/jbc.M602880200	http://dx.doi.org/10.1074/jbc.M602880200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16690608	hybrid			2022-12-25	WOS:000238687300029
J	Rotem, D; Steiner-Mordoch, S; Schuldiner, S				Rotem, Dvir; Steiner-Mordoch, Sonia; Schuldiner, Shimon			Identification of tyrosine residues critical for the function of an ion-coupled multidrug transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON BINDING-SITE; X-RAY-STRUCTURE; ESCHERICHIA-COLI; SUBSTRATE-BINDING; CRYSTAL-STRUCTURE; TRANSCRIPTION ACTIVATOR; STRUCTURAL BASIS; DRUG-BINDING; EMRE; MUTAGENESIS	Aromatic residues may play several roles in integral membrane proteins, including direct interaction with substrates. In this work, we studied the contribution of tyrosine residues to the activity of EmrE, a small multidrug transporter from Escherichia coli that extrudes various drugs across the plasma membrane in exchange with protons. Each of five tyrosine residues was replaced by site-directed mutagenesis. Two of these residues, Tyr-40 and Tyr-60, can be partially replaced with hydroxyamino acids, but in the case of Tyr-40, replacement with either Ser or Thr generates a protein with modified substrate specificity. Replacement of Tyr-4 with either Trp or Phe generates a functional transporter. A Cys replacement at this position generates an uncoupled protein; it binds substrate and protons and transports the substrate downhill but is impaired in uphill substrate transport in the presence of a proton gradient. The role of these residues is discussed in the context of the published structures of EmrE.	Hebrew Univ Jerusalem, Dept Biol Chem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Schuldiner, S (corresponding author), Hebrew Univ Jerusalem, Dept Biol Chem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel.	Shimon.Schuldiner@huji.ac.il	Schuldiner, Shimon/F-7628-2012; Rotem, Dvir/G-1396-2013	Schuldiner, Shimon/0000-0002-4874-6237; Rotem, Dvir/0000-0002-1840-6530	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016708, R56NS016708] Funding Source: NIH RePORTER; NINDS NIH HHS [NS16708] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arkin IT, 1996, BIOCHEMISTRY-US, V35, P7233, DOI 10.1021/bi960094i; Beene DL, 2004, J NEUROSCI, V24, P9097, DOI 10.1523/JNEUROSCI.2429-04.2004; Butler PJG, 2004, J MOL BIOL, V340, P797, DOI 10.1016/j.jmb.2004.05.014; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Elbaz Y, 2005, BIOCHEMISTRY-US, V44, P7369, DOI 10.1021/bi050356t; Elbaz Y, 2004, P NATL ACAD SCI USA, V101, P1519, DOI 10.1073/pnas.0306533101; Godsey MH, 2002, J BIOL CHEM, V277, P40169, DOI 10.1074/jbc.R200018200; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; Gutman N, 2003, J BIOL CHEM, V278, P16082, DOI 10.1074/jbc.M213120200; Heldwein EEZ, 2001, NATURE, V409, P378, DOI 10.1038/35053138; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Klyachko KA, 1997, J BACTERIOL, V179, P2189, DOI 10.1128/jb.179.7.2189-2193.1997; Koteiche HA, 2003, BIOCHEMISTRY-US, V42, P6099, DOI 10.1021/bi0342867; Li Fusheng, 2002, Methods Mol Biol, V182, P19; Ma C, 2004, P NATL ACAD SCI USA, V101, P2852, DOI 10.1073/pnas.0400137101; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Murray DS, 2004, J BIOL CHEM, V279, P14365, DOI 10.1074/jbc.M313870200; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; Neyfakh AA, 2002, MOL MICROBIOL, V44, P1123, DOI 10.1046/j.1365-2958.2002.02965.x; Ninio S, 2004, FEBS LETT, V562, P193, DOI 10.1016/S0014-5793(04)00240-6; Ninio S, 2001, J BIOL CHEM, V276, P48250, DOI 10.1074/jbc.M108231200; Pornillos O, 2005, SCIENCE, V310, P1950, DOI 10.1126/science.1119776; Rotem D, 2001, J BIOL CHEM, V276, P48243, DOI 10.1074/jbc.M108229200; Schuldiner S, 2001, J MOL MICROB BIOTECH, V3, P155; Schuldiner S, 2001, NEWS PHYSIOL SCI, V16, P130; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Schwaiger M, 1998, EUR J BIOCHEM, V254, P610, DOI 10.1046/j.1432-1327.1998.2540610.x; SCHWEIGER U, 1994, BIOCHEMISTRY-US, V33, P535, DOI 10.1021/bi00168a019; Sharoni M, 2005, J BIOL CHEM, V280, P32849, DOI 10.1074/jbc.M504910200; Son MS, 2003, BIOCHEM BIOPH RES CO, V312, P914, DOI 10.1016/j.bbrc.2003.11.018; Soskine M, 2004, J BIOL CHEM, V279, P9951, DOI 10.1074/jbc.M312853200; Soskine M, 2002, P NATL ACAD SCI USA, V99, P12043, DOI 10.1073/pnas.192392899; Steiner-Mordoch S., 1999, J BIOL CHEM, V274, P19480; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Tate CG, 2003, J MOL BIOL, V332, P229, DOI 10.1016/S0022-2836(03)00895-7; Ubarretxena-Belandia I, 2003, EMBO J, V22, P6175, DOI 10.1093/emboj/cdg611; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Yerushalmi H, 2000, BIOCHEMISTRY-US, V39, P14711, DOI 10.1021/bi001892i; Yerushalmi H, 2000, FEBS LETT, V476, P93, DOI 10.1016/S0014-5793(00)01677-X; Yerushalmi H, 2000, J BIOL CHEM, V275, P5264, DOI 10.1074/jbc.275.8.5264; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; Yerushalmi H, 2001, J BIOL CHEM, V276, P12744, DOI 10.1074/jbc.M010979200; Yerushalmi H, 1996, J BIOL CHEM, V271, P31044, DOI 10.1074/jbc.271.49.31044; Zheleznova EE, 2000, TRENDS BIOCHEM SCI, V25, P39, DOI 10.1016/S0968-0004(99)01514-5; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6	48	34	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18715	18722		10.1074/jbc.M602088200	http://dx.doi.org/10.1074/jbc.M602088200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16672221	hybrid			2022-12-25	WOS:000238687300052
J	Terhzaz, S; Southall, TD; Lilley, KS; Kean, L; Allan, AK; Davies, SA; Dow, JAT				Terhzaz, Selim; Southall, Tony D.; Lilley, Kathryn S.; Kean, Laura; Allan, Adrian K.; Davies, Shireen A.; Dow, Julian A. T.			Differential gel electrophoresis and transgenic mitochondrial calcium reporters demonstrate spatiotemporal filtering in calcium control of mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER; NITRIC-OXIDE; EPITHELIAL FUNCTION; MALPIGHIAN TUBULES; H+-ATPASE; CA2+; RESPIRATION; EXPRESSION; PHENOTYPE; RECEPTOR	Mitochondria must adjust both their intracellular location and their metabolism in order to balance their output to the needs of the cell. Here we show by the proteomic technique of time series difference gel electrophoresis that a major result of neuroendocrine stimulation of the Drosophila renal tubule is an extensive remodeling of the mitochondrial matrix. By generating Drosophila that were transgenic for both luminescent and fluorescent mitochondrial calcium reporters, it was shown that mitochondrial calcium tracked the slow (minutes) but not the rapid (< 1 s) changes in cytoplasmic calcium and that this resulted in both increased mitochondrial membrane polarization and elevated cellular ATP levels. The selective V-ATPase inhibitor, bafilomycin, further enhanced ATP levels, suggesting that the apical plasma membrane V-ATPase is a major consumer of ATP. Both the mitochondrial calcium signal and the increase in ATP were abolished by the mitochondrial calcium uniporter blocker Ru360. By using both mitochondrial calcium imaging and the potential sensing dye JC-1, the apical mitochondria of principal cells were found to be selectively responsive to neuropeptide signaling. As the ultimate target is the V-ATPase in the apical plasma membrane, this selective activation of mitochondria is clearly adaptive. The results highlight the dynamic nature and both spatial and temporal heterogeneity of calcium signaling possible in differentiated, organotypic cells and provide a new model for neuroendocrine control of V-ATPase.	Univ Glasgow, Div Mol Genet, Inst Biomed & Life Sci, Glasgow G11 6NU, Lanark, Scotland; Univ Cambridge, Dept Biochem, Cambridge Ctr Proteom, Cambridge CB2 1QW, England	University of Glasgow; University of Cambridge	Dow, JAT (corresponding author), Univ Glasgow, Div Mol Genet, Inst Biomed & Life Sci, Glasgow G11 6NU, Lanark, Scotland.	j.a.t.dow@bio.gla.ac.uk	Dow, Julian/M-2371-2019; Lilley, Kathryn/ABF-5787-2020	Dow, Julian/0000-0002-9595-5146; Lilley, Kathryn/0000-0003-0594-6543; Terhzaz, Selim/0000-0002-6192-6558	Biotechnology and Biological Sciences Research Council [S18917] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Alban A, 2003, PROTEOMICS, V3, P36, DOI 10.1002/pmic.200390006; BERTRAM G, 1991, J INSECT PHYSIOL, V37, P201, DOI 10.1016/0022-1910(91)90070-G; Borutaite V, 1996, BIOCHEM J, V315, P295, DOI 10.1042/bj3150295; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRAND AH, 1993, DEVELOPMENT, V118, P401; Broderick KE, 2004, J BIOL CHEM, V279, P8159, DOI 10.1074/jbc.M304679200; Cox RT, 2003, DEVELOPMENT, V130, P1579, DOI 10.1242/dev.00365; Davies SA, 1995, AM J PHYSIOL-REG I, V269, pR1321, DOI 10.1152/ajpregu.1995.269.6.R1321; Dow JAT, 2003, PHYSIOL REV, V83, P687, DOI 10.1152/physrev.00035.2002; DOW JAT, 1994, AM J PHYSIOL, V266, pR1716, DOI 10.1152/ajpregu.1994.266.5.R1716; DOW JAT, 1994, J EXP BIOL, V197, P421; Dow JAT, 2006, J INSECT PHYSIOL, V52, P365, DOI 10.1016/j.jinsphys.2005.10.007; Dumollard R, 2003, DEVELOPMENT, V130, P683, DOI 10.1242/dev.00296; Hopper RK, 2006, BIOCHEMISTRY-US, V45, P2524, DOI 10.1021/bi052475e; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kean L, 2002, AM J PHYSIOL-REG I, V282, pR1297, DOI 10.1152/ajpregu.00584.2001; Kirichok Y, 2004, NATURE, V427, P360, DOI 10.1038/nature02246; MCCORMACK JG, 1980, BIOCHEM J, V190, P95, DOI 10.1042/bj1900095; Morin X, 2001, P NATL ACAD SCI USA, V98, P15050, DOI 10.1073/pnas.261408198; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; O'Donnell MJ, 1998, AM J PHYSIOL-REG I, V274, pR1039, DOI 10.1152/ajpregu.1998.274.4.R1039; Pollock VP, 2003, J EXP BIOL, V206, P901, DOI 10.1242/jeb.00189; Radford JC, 2002, J BIOL CHEM, V277, P38810, DOI 10.1074/jbc.M203694200; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; Rosay P, 1997, J CELL SCI, V110, P1683; RUTTER GA, 1993, J BIOL CHEM, V268, P22385; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; Skoulakis EMC, 1996, NEURON, V17, P931, DOI 10.1016/S0896-6273(00)80224-X; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; Thyagarajan B, 2002, BRIT J PHARMACOL, V137, P821, DOI 10.1038/sj.bjp.0704949; Torrie LS, 2004, P NATL ACAD SCI USA, V101, P13689, DOI 10.1073/pnas.0403087101; Unlu M, 1997, ELECTROPHORESIS, V18, P2071, DOI 10.1002/elps.1150181133; Villalobos C, 2002, FASEB J, V16, DOI 10.1096/fj.01-0630com; Wang J, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r69; Wessing A., 1978, P1; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; Zimmermann B, 2003, J EXP BIOL, V206, P1867, DOI 10.1242/jeb.00376	40	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18849	18858		10.1074/jbc.M603002200	http://dx.doi.org/10.1074/jbc.M603002200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16670086	hybrid			2022-12-25	WOS:000238687300065
J	Chirakkal, H; Leech, SH; Brookes, KE; Prais, AL; Waby, JS; Corfe, BM				Chirakkal, H.; Leech, S. H.; Brookes, K. E.; Prais, A. L.; Waby, J. S.; Corfe, B. M.			Upregulation of BAK by butyrate in the colon is associated with increased Sp3 binding	ONCOGENE			English	Article						butyrate; colon; BAK; apoptosis; Sp1; Sp3	GENOTOXIN-INDUCED APOPTOSIS; CHAIN FATTY-ACIDS; COLORECTAL-CANCER; DIETARY FIBER; TRANSCRIPTION FACTORS; RESISTANT STARCH; PROMOTER; EXPRESSION; INDUCTION; TRICHOSTATIN	Butyrate is a key bioactive product of dietary fibre fermentation thought to play a key role in cancer prevention. One contributory mechanism in this role is the regulation of apoptosis by butyrate. As butyrate shows lowlevels of toxicity, the mechanisms by which it triggers or regulates apoptosis are of great interest. We and others have shown that the proapoptotic protein BAK is upregulated by butyrate. We show ere that this observation is conserved across multiple cell lines, that it occurs in all cells in a population and is at the transcriptional level. We have used a promoter-reporter construct to identify the regulatory regions of the BAK promoter and found that much of the transcriptional activity occurs via a single Sp1/Sp3 binding site. We have shown that both Sp1 and Sp3 bind, but upon butyrate treatment Sp1 binding decreases in favour of Sp3 binding. We speculate that this may be an acetylation- mediated event.	Univ Sheffield, No Gen Hosp, Human Nutr Unit, Div Clin Sci N, Sheffield S5 7AU, S Yorkshire, England; Univ Manchester, Sch Biol Sci, Manchester, Lancs, England	Northern General Hospital; University of Sheffield; University of Manchester	Corfe, BM (corresponding author), Univ Sheffield, No Gen Hosp, Human Nutr Unit, Div Clin Sci N, Sheffield S5 7AU, S Yorkshire, England.	b.m.corfe@sheffield.ac.uk		Waby, Jennifer/0000-0003-4729-6657; Corfe, Bernard/0000-0003-0449-2228				Arasaradnam RP, 2004, GUT, V53, P155, DOI 10.1136/gut.53.1.155-a; Bingham SA, 2003, LANCET, V361, P1496, DOI 10.1016/S0140-6736(03)13174-1; Blottiere HM, 2003, P NUTR SOC, V62, P101, DOI 10.1079/PNS2002215; Bonithon-Kopp C, 2000, LANCET, V356, P1300, DOI 10.1016/S0140-6736(00)02813-0; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Camarero N, 2003, NUCLEIC ACIDS RES, V31, P1693, DOI 10.1093/nar/gkg262; Chen ZY, 2004, J NUTR, V134, P792, DOI 10.1093/jn/134.4.792; CORFE BM, 1994, MICROBIOL-UK, V140, P3079, DOI 10.1099/13500872-140-11-3079; Della Ragione F, 2001, FEBS LETT, V499, P199, DOI 10.1016/S0014-5793(01)02539-X; Griffiths GJ, 2001, ONCOGENE, V20, P7668, DOI 10.1038/sj.onc.1204995; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Hass R, 1997, GASTROENTEROLOGY, V112, P875, DOI 10.1053/gast.1997.v112.pm9041249; Hill MJ, 1997, EUR J CANCER PREV, V6, P219, DOI 10.1097/00008469-199706000-00002; Hill MJ, 2002, EUR J CANCER PREV, V11, P1, DOI 10.1097/00008469-200202000-00001; Hirose T, 2003, ONCOGENE, V22, P7762, DOI 10.1038/sj.onc.1207091; Le Leu RK, 2003, CARCINOGENESIS, V24, P1347, DOI 10.1093/carcin/bgg098; Le Leu RK, 2002, CARCINOGENESIS, V23, P713, DOI 10.1093/carcin/23.5.713; MacCarthy-Morrogh L, 2000, ONCOGENE, V19, P5534, DOI 10.1038/sj.onc.1203949; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Mariadason JM, 2000, CANCER RES, V60, P4561; MCINTYRE A, 1993, GUT, V34, P386, DOI 10.1136/gut.34.3.386; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Perrin P, 2001, GUT, V48, P53, DOI 10.1136/gut.48.1.53; Potten CS, 1997, STEM CELLS, V15, P82, DOI 10.1002/stem.150082; Ruemmele FM, 1999, CELL DEATH DIFFER, V6, P729, DOI 10.1038/sj.cdd.4400545; Schatzkin A, 2000, NEW ENGL J MED, V342, P1149, DOI 10.1056/NEJM200004203421601; Siavoshian S, 2000, GUT, V46, P507, DOI 10.1136/gut.46.4.507; Sowa Y, 1999, CANCER RES, V59, P4266; Steiner E, 2004, BIOCHEM BIOPH RES CO, V317, P235, DOI 10.1016/j.bbrc.2004.03.029; WELTER C, 1991, J EXP CLIN CANC RES, V10, P75; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	34	56	57	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	54					7192	7200		10.1038/sj.onc.1209702	http://dx.doi.org/10.1038/sj.onc.1209702			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16732318				2022-12-25	WOS:000242046900008
J	Murakami, N; Xie, W; Lu, RC; Chen-Hwang, MC; Wieraszko, A; Hwang, YW				Murakami, Noriko; Xie, Wen; Lu, Renne Chen; Chen-Hwang, Mo-Chou; Wieraszko, Andrzej; Hwang, Yu Wen			Phosphorylation of amphiphysin I by minibrain kinase/dual-specificity tyrosine phosphorylation-regulated kinase, a kinase implicated in Down syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; ACTIVATED PROTEIN-KINASE; SYNDROME CRITICAL REGION; NERVE-TERMINALS; HUMAN HOMOLOG; MEDIATED ENDOCYTOSIS; POTENTIAL ROLE; MAP KINASE; DOMAINS; BINDING	Minibrain kinase/dual-specificity tyrosine phosphorylation-regulated kinase (Mnb/Dyrk1A) is a proline-directed serine/ threonine kinase encoded in the Down syndrome critical region of human chromosome 21. This kinase has been shown to phosphorylate dynamin 1 and synaptojanin 1. Here we report that amphiphysin I (Amph I) is also a Mnb/Dyrk1A substrate. This kinase phosphorylated native Amph I in rodent brains and recombinant human Amph I expressed in Escherichia coli. Serine 293 (Ser-293) was identified as the major site, whereas serine 295 and threonine 310 were found as minor kinase sites. In cultured cells, recombinant Amph I was phosphorylated at Ser-293 by endogenous kinase(s). Because mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) has been suggested to phosphorylate Amph I at Ser-293, our efforts addressed whether Ser-293 is phosphorylated in vivo by MAPK/ERK or by Mnb/Dyrk1A. Overnight serum-withdrawal inactivated MAPK/ERK; nonetheless, Ser-293 was phosphorylated in Chinese hamster ovary and SY5Y cells. Epigallocatechin-3-gallate, a potent Mnb/Dyrk1A inhibitor in vitro, apparently reduced the phosphorylation at Ser-293, whereas PD98059, a potent MAPK/ERK inhibitor, did not. High frequency stimulation of mouse hippocampal slices reduced the phosphorylation at Ser-293, albeit in the midst of MAPK/ERK activation. The endophilin binding in vitro was inhibited by phosphorylating Amph I with Mnb/Dyrk1A. However, phosphorylation at Ser-293 did not appear to alter cellular distribution patterns of the protein. Our results suggest that Mnb/Dyrk1A, not MAPK/ERK, is responsible for in vivo phosphorylation of Amph I at Ser-293 and that phosphorylation changes the recruitment of endophilin at the endocytic sites.	New York State Inst Basic Res Dev Disabil, Dept Mol Biol, Staten Isl, NY 10314 USA; CUNY, CSI IBR, Ctr Dev Neurosci, New York, NY 10016 USA; CUNY, Grad Program Biol, New York, NY 10016 USA; Boston Biomed Res Inst, Dept Muscle & Motil, Watertown, MA 02472 USA	Institute for Basic Research in Developmental Disabilities; City University of New York (CUNY) System; Institute for Basic Research in Developmental Disabilities; City University of New York (CUNY) System; Boston Biomedical Research Institute	Murakami, N (corresponding author), New York State Inst Basic Res Dev Disabil, Dept Mol Biol, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.	Murakami@omr.state.ny.us			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038295] Funding Source: NIH RePORTER; NICHD NIH HHS [HD38295] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; Berisha F, 2002, MOL BIOL CELL, V13, p94A; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Cestra G, 1999, J BIOL CHEM, V274, P32001, DOI 10.1074/jbc.274.45.32001; CHAGGER H, 1987, ANAL BIOCHEM, V166, P367; Chen-Hwang MC, 2002, J BIOL CHEM, V277, P17597, DOI 10.1074/jbc.M111101200; Cohen SL, 1996, ANAL CHEM, V68, P31, DOI 10.1021/ac9507956; Cousin MA, 2001, J NEUROCHEM, V76, P105, DOI 10.1046/j.1471-4159.2001.00049.x; Cousin MA, 2001, TRENDS NEUROSCI, V24, P659, DOI 10.1016/S0166-2236(00)01930-5; El-Sherif Y, 2003, J NEUROSCI RES, V72, P454, DOI 10.1002/jnr.10605; English JD, 1997, J BIOL CHEM, V272, P19103, DOI 10.1074/jbc.272.31.19103; Ermakova S, 2005, J BIOL CHEM, V280, P16882, DOI 10.1074/jbc.M414185200; Farsad K, 2003, NEUROPHARMACOLOGY, V45, P787, DOI 10.1016/S0028-3908(03)00306-X; Floyd SR, 2001, J BIOL CHEM, V276, P8104, DOI 10.1074/jbc.M008932200; Guimera J, 1999, GENOMICS, V57, P407, DOI 10.1006/geno.1999.5775; Guimera J, 1996, HUM MOL GENET, V5, P1305, DOI 10.1093/hmg/5.9.1305; Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431; Huang Y, 2004, BIOCHEMISTRY-US, V43, P10173, DOI 10.1021/bi036060+; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Kojima C, 2004, EMBO J, V23, P4413, DOI 10.1038/sj.emboj.7600442; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SY, 2004, P NATL ACAD SCI USA, V101, P546, DOI 10.1073/pnas.0307813100; Marks B, 1998, CURR BIOL, V8, P740, DOI 10.1016/S0960-9822(98)70297-0; Micheva KD, 1997, FEBS LETT, V414, P308, DOI 10.1016/S0014-5793(97)01016-8; Murakami N, 1998, BIOCHEMISTRY-US, V37, P1989, DOI 10.1021/bi971959a; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; Shang WH, 2004, J BIOL CHEM, V279, P40890, DOI 10.1074/jbc.M404527200; Shindoh N, 1996, BIOCHEM BIOPH RES CO, V225, P92, DOI 10.1006/bbrc.1996.1135; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Song WJ, 1996, GENOMICS, V38, P331, DOI 10.1006/geno.1996.0636; SUNG YJ, 1995, BIOCHEMISTRY-US, V34, P3470, DOI 10.1021/bi00010a040; Tan TC, 2003, NAT CELL BIOL, V5, P701, DOI 10.1038/ncb1020; Tassone F, 1999, J NEURAL TRANSM-SUPP, P179; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; Wegiel J, 2004, BRAIN RES, V1010, P69, DOI 10.1016/j.brainres.2004.03.008; Woods YL, 2001, BIOCHEM J, V355, P609, DOI 10.1042/bj3550609; Yang EJ, 2001, J BIOL CHEM, V276, P39819, DOI 10.1074/jbc.M104091200	41	49	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23712	23724		10.1074/jbc.M513497200	http://dx.doi.org/10.1074/jbc.M513497200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16733250	hybrid			2022-12-25	WOS:000239702900046
J	Boon, EM; Davis, JH; Tran, R; Karow, DS; Huang, SH; Pan, DH; Miazgowicz, MM; Mathies, RA; Marletta, MA				Boon, Elizabeth M.; Davis, Joseph H.; Tran, Rosalie; Karow, David S.; Huang, Shirley H.; Pan, Duohai; Miazgowicz, Michael M.; Mathies, Richard A.; Marletta, Michael A.			Nitric oxide binding to prokaryotic homologs of the soluble guanylate cyclase beta 1 H-NOX domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; CARBON-MONOXIDE; CYTOCHROME-C'; HEME DOMAINS; ACTIVATION; DISSOCIATION; BOND; NITROSYLHEMOGLOBIN; 5-COORDINATE; PROTEINS	The heme cofactor in soluble guanylate cyclase (sGC) is a selective receptor for NO, an important signaling molecule in eukaryotes. The sGC heme domain has been localized to the N-terminal 194 amino acids of the beta 1 subunit of sGC and is a member of a family of conserved hemoproteins, called the H-NOX family (Heme-Nitric Oxide and/or OXygen-binding domain). Three new members of this family have now been cloned and characterized, two proteins from Legionella pneumophila (L1 H-NOX and L2 H-NOX) and one from Nostoc punctiforme (Np H-NOX). Like sGC, L1 H-NOX forms a 5-coordinate Fe-II-NO complex. However, both L2 H-NOX and Np H-NOX form temperature-dependent mixtures of 5- and 6- coordinate Fe-II-NO complexes; at low temperature, they are primarily 6- coordinate, and at high temperature, the equilibrium is shifted toward a 5- coordinate geometry. This equilibrium is fully reversible with temperature in the absence of free NO. This process is analyzed in terms of a thermally labile proximal Fe-II-His bond and suggests that in both the 5- and 6- coordinate Fe-II-NO complexes of L2 H-NOX and Np H-NOX, NO is bound in the distal heme pocket of the H-NOX fold. NO dissociation kinetics for L1 H-NOX and L2 H-NOX have been determined and support a model in which NO dissociates from the distal side of the heme in both 5- and 6- coordinate complexes.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Phys Biosci, Berkeley, CA 94720 USA; Univ Michigan, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Michigan System; University of Michigan	Marletta, MA (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	marletta@berkeley.edu	Boon, Elizabeth/AAR-8229-2020	Davis, Joseph H./0000-0002-8858-8907	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070671] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM070671] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrew CR, 2005, BIOCHEMISTRY-US, V44, P8664, DOI 10.1021/bi050428g; Andrew CR, 2002, BIOCHEMISTRY-US, V41, P2353, DOI 10.1021/bi011419k; Andrew CR, 2001, BIOCHEMISTRY-US, V40, P4115, DOI 10.1021/bi0023652; Boon EM, 2005, J INORG BIOCHEM, V99, P892, DOI 10.1016/j.jinorgbio.2004.12.016; Boon EM, 2005, NAT CHEM BIOL, V1, P53, DOI 10.1038/nchembio704; Cary SPL, 2005, P NATL ACAD SCI USA, V102, P13064, DOI 10.1073/pnas.0506289102; Clark RW, 2006, P NATL ACAD SCI USA, V103, P891, DOI 10.1073/pnas.0505919103; Deinum G, 1996, BIOCHEMISTRY-US, V35, P1540; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; Derbyshire ER, 2005, BIOCHEMISTRY-US, V44, P16257, DOI 10.1021/bi0515671; DIIORIO EE, 1981, HEMOGLOBINS; FERSHT AR, 1970, J AM CHEM SOC, V92, P5432, DOI 10.1021/ja00721a023; Friebe A, 1996, EMBO J, V15, P6863, DOI 10.1002/j.1460-2075.1996.tb01078.x; Huston WM, 2006, BIOCHEMISTRY-US, V45, P4388, DOI 10.1021/bi052605j; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; Iyer LM, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-5; Karow DS, 2005, BIOCHEMISTRY-US, V44, P16266, DOI 10.1021/bi051601b; Karow DS, 2004, BIOCHEMISTRY-US, V43, P10203, DOI 10.1021/bi049374l; Kharitonov VG, 1997, BIOCHEMISTRY-US, V36, P6814, DOI 10.1021/bi970201o; Lawson DM, 2003, BIOCHEM SOC T, V31, P553, DOI 10.1042/BST0310553; LukatRodgers GS, 1997, BIOCHEMISTRY-US, V36, P4178, DOI 10.1021/bi9628230; MOORE EG, 1976, J BIOL CHEM, V251, P2788; Negrerie M, 2001, J BIOL CHEM, V276, P46815, DOI 10.1074/jbc.M102224200; Nioche P, 2004, SCIENCE, V306, P1550, DOI 10.1126/science.1103596; Pellicena P, 2004, P NATL ACAD SCI USA, V101, P12854, DOI 10.1073/pnas.0405188101; Russwurm M, 2004, EMBO J, V23, P4443, DOI 10.1038/sj.emboj.7600422; Schmidt PM, 2004, J BIOL CHEM, V279, P3025, DOI 10.1074/jbc.M310141200; Schotte F, 2003, SCIENCE, V300, P1944, DOI 10.1126/science.1078797; SHARMA VS, 1978, J BIOL CHEM, V253, P6467; Spiro T.G., 1988, BIOL APPL RAMAN SPEC; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; Stone JR, 1998, CHEM BIOL, V5, P255, DOI 10.1016/S1074-5521(98)90618-4; STONE JR, 1995, BIOCHEM BIOPH RES CO, V207, P572, DOI 10.1006/bbrc.1995.1226; Tangen E, 2005, INORG CHEM, V44, P7802, DOI 10.1021/ic050486q; Tomita T, 1997, BIOCHEMISTRY-US, V36, P10155, DOI 10.1021/bi9710131; TSUBAKI M, 1982, BIOCHEMISTRY-US, V21, P1140, DOI 10.1021/bi00535a005; Zhao Y, 1997, BIOCHEMISTRY-US, V36, P15959, DOI 10.1021/bi971825x	37	64	67	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21892	21902		10.1074/jbc.M600557200	http://dx.doi.org/10.1074/jbc.M600557200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16728401	hybrid			2022-12-25	WOS:000239387100036
J	Seleznev, K; Zhao, CY; Zhang, XH; Song, KY; Ma, ZMA				Seleznev, Konstantin; Zhao, Chunying; Zhang, Xu Hannah; Song, Keying; Ma, Zhongmin Alex			Calcium-independent phospholipase A(2) localizes in and protects mitochondria during apoptotic induction by staurosporine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; ARACHIDONIC-ACID INCORPORATION; TRANSFECTED INSULINOMA CELLS; DRUG-INDUCED APOPTOSIS; CASPASE ACTIVATION; LIPID-PEROXIDATION; BIOLOGICAL-SYSTEMS; PANCREATIC-ISLETS; OVEREXPRESS GROUP; OXIDATIVE STRESS	Mitochondria-mediated production of reactive oxygen species (ROS) plays a key role in apoptosis. Mitochondrial phospholipid cardiolipin molecules are likely the main target of ROS because they are particularly rich in polyunsaturated fatty acids. They are also located in the inner mitochondrial membrane near the ROS-producing sites. Under physiological conditions mitochondria can repair peroxidative damage in part through a remodeling mechanism via the deacylation-reacylation cycle mediated by phospholipaseA2 (PLA(2)) and acyl-coenzyme A-dependent monolysocardiolipin acyltransferase. Here we investigate whether group VIA Ca2+-independent PLA(2) (iPLA(2)) plays a role in the protection of mitochondrial function from damage caused by mitochondrially generated ROS during apoptotic induction by staurosporine (STS). We show that iPLA(2)-expressing cells were relatively resistant to STS-induced apoptosis. iPLA2 localized to mitochondria even before apoptotic induction, and most iPLA(2)-associated mitochondria were intact in apoptotic resistant cells. Expression of iPLA(2) in INS-1 cells prevented the loss of mitochondrial membrane potential, attenuated the release of cytochrome c, Smac/DIABLO, and apoptosis inducing factor from mitochondria, and reduced mitochondrial reactive oxygen species production. Inhibition of caspase 8 has little effect on STS-induced apoptosis in INS-1 cells. Finally, we found that STS down-regulated endogenous iPLA(2) transcription in both INS-1 and iPLA(2)-expressing INS-1 cells without affecting the expression of group IV Ca2+-dependent PLA(2). Together, our data indicate that iPLA(2) is important for the protection of mitochondrial function from oxidative damage during apoptotic induction. Down-regulation of endogenous iPLA(2) by STS may result in the loss of mitochondrial membrane repair functions and lead to mitochondrial failure and apoptosis.	Mt Sinai Sch Med, Dept Geriatr & Adult Dev, Div Expt Diabet & Aging, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Ma, ZMA (corresponding author), Mt Sinai Sch Med, Dept Geriatr & Adult Dev, Div Expt Diabet & Aging, New York, NY 10029 USA.	zhongmin.ma@mssm.edu	Seleznev, Konstantin/ABF-3994-2021; Zhang, Xu Hannah/AAI-5409-2021	Zhang, Xu Hannah/0000-0001-9638-0463; Seleznev, Konstantin/0000-0001-6378-7064	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063076] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK063076] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Ahlemeyer B, 2001, FREE RADICAL BIO MED, V30, P1067, DOI 10.1016/S0891-5849(01)00495-6; Atsumi G, 2000, J BIOL CHEM, V275, P18248, DOI 10.1074/jbc.M000271200; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Borutaite V, 2003, FEBS LETT, V541, P1, DOI 10.1016/S0014-5793(03)00278-3; BUCANA C, 1986, J HISTOCHEM CYTOCHEM, V34, P1109, DOI 10.1177/34.9.2426339; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cadenas Enrique, 2004, Molecular Aspects of Medicine, V25, P17, DOI 10.1016/j.mam.2004.02.005; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Chatterjee D, 2001, CANCER RES, V61, P7148; Cristea IM, 2004, CHEM PHYS LIPIDS, V129, P133, DOI 10.1016/j.chemphyslip.2004.02.002; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Gil J, 2003, FREE RADICAL BIO MED, V35, P1500, DOI 10.1016/j.freeradbiomed.2003.08.022; Girotti AW, 1998, J LIPID RES, V39, P1529; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hatch GM, 2004, BIOCHEM CELL BIOL, V82, P99, DOI 10.1139/o03-074; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Johansson AC, 2003, CELL DEATH DIFFER, V10, P1253, DOI 10.1038/sj.cdd.4401290; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Kagan VE, 2004, FREE RADICAL BIO MED, V37, P1963, DOI 10.1016/j.freeradbiomed.2004.08.016; Kruman I, 1998, J NEUROSCI RES, V51, P293, DOI 10.1002/(SICI)1097-4547(19980201)51:3<293::AID-JNR3>3.0.CO;2-B; Kurosu T, 2003, ONCOGENE, V22, P4459, DOI 10.1038/sj.onc.1206755; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Lauber K, 2004, MOL CELL, V14, P277, DOI 10.1016/S1097-2765(04)00237-0; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Ma BJ, 1999, J LIPID RES, V40, P1837; MA Z, 2002, AM J PHYSIOL-ENDOC M, V282, P820; Ma ZM, 2001, LIPIDS, V36, P689, DOI 10.1007/s11745-001-0774-9; Ma ZM, 2001, J BIOL CHEM, V276, P13198, DOI 10.1074/jbc.M010423200; Ma ZM, 2001, PROG NUCLEIC ACID RE, V67, P1, DOI 10.1016/S0079-6603(01)67023-5; Ma ZM, 1997, J BIOL CHEM, V272, P11118; Mancuso DJ, 2003, J BIOL CHEM, V278, P22231, DOI 10.1074/jbc.C300033200; Matsura T, 2002, FEBS LETT, V524, P25, DOI 10.1016/S0014-5793(02)02990-3; Nakagawa Y, 2004, ANN NY ACAD SCI, V1011, P177, DOI 10.1196/annals.1293.018; Nigam S, 2000, BBA-MOL CELL BIOL L, V1488, P167, DOI 10.1016/S1388-1981(00)00119-0; Orrenius S, 2005, NAT CHEM BIOL, V1, P188, DOI 10.1038/nchembio0905-188; Orrenius S, 2004, TOXICOL LETT, V149, P19, DOI 10.1016/j.toxlet.2003.12.017; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Penzo D, 2004, J BIOL CHEM, V279, P25219, DOI 10.1074/jbc.M310381200; Perez R, 2004, J BIOL CHEM, V279, P40385, DOI 10.1074/jbc.M402562200; Petrosillo G, 2003, FASEB J, V17, P2202, DOI 10.1096/fj.03-0012com; Petrosillo G, 2001, FEBS LETT, V509, P435, DOI 10.1016/S0014-5793(01)03206-9; Pong K, 2001, EXP NEUROL, V171, P84, DOI 10.1006/exnr.2001.7747; Ramanadham S, 2004, BIOCHEMISTRY-US, V43, P918, DOI 10.1021/bi035536m; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; SEVANIAN A, 1985, ANNU REV NUTR, V5, P365, DOI 10.1146/annurev.nu.05.070185.002053; Sevanian A., 1988, OXIDATIVE DAMAGE REP, P543; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Song K, 2005, MOL ENDOCRINOL, V19, P504, DOI 10.1210/me.2004-0169; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tsuruga M, 2003, MOL CELL BIOCHEM, V250, P131, DOI 10.1023/A:1024912806686; TURK J, 1986, BIOCHIM BIOPHYS ACTA, V879, P399, DOI 10.1016/0005-2760(86)90232-8; Tyurina YY, 2004, ANTIOXID REDOX SIGN, V6, P209, DOI 10.1089/152308604322899288; van Kuijk F J, 1985, J Free Radic Biol Med, V1, P421, DOI 10.1016/0748-5514(85)90156-4; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Williams SD, 2002, BIOCHEM J, V362, P23, DOI 10.1042/bj3620023; Winstead MV, 2000, BBA-MOL CELL BIOL L, V1488, P28, DOI 10.1016/S1388-1981(00)00107-4; Wissing D, 1997, P NATL ACAD SCI USA, V94, P5073, DOI 10.1073/pnas.94.10.5073; Wu DC, 2002, J BIOL CHEM, V277, P12001, DOI 10.1074/jbc.M109219200; Xu Y, 2003, J BIOL CHEM, V278, P51380, DOI 10.1074/jbc.M307382200; YANG J, 1997, SCIENCE, V275, P1132; Zhang XH, 2006, J CELL SCI, V119, P1005, DOI 10.1242/jcs.02821	72	105	119	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22275	22288		10.1074/jbc.M604330200	http://dx.doi.org/10.1074/jbc.M604330200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16728389	hybrid, Green Accepted			2022-12-25	WOS:000239387100073
J	Cohen, L; Gilles, N; Karbat, I; Ilan, N; Gordon, D; Gurevitz, M				Cohen, Lior; Gilles, Nicolas; Karbat, Izhar; Ilan, Nitza; Gordon, Dalia; Gurevitz, Michael			Direct evidence that receptor site-4 of sodium channel gating modifiers is not dipped in the phospholipid bilayer of neuronal membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; DEPENDENT K+ CHANNEL; BETA-SCORPION TOXIN; VOLTAGE-SENSOR; RAT-BRAIN; MOLECULAR DETERMINANTS; INSECT; NEUROTOXIN; HANATOXIN; DIVERSIFICATION	In a recent note to Nature, R. MacKinnon has raised the possibility that potassium channel gating modifiers are able to partition in the phospholipid bilayer of neuronal membranes and that by increasing their partial concentration adjacent to their receptor, they affect channel function with apparent high affinity ( Lee and MacKinnon ( 2004) Nature 430, 232 - 235). This suggestion was adopted by Smith et al. ( Smith, J. J., Alphy, S., Seibert, A. L., and Blumenthal, K. M. ( 2005) J. Biol. Chem. 280, 11127 - 11133), who analyzed the partitioning of sodium channel modifiers in liposomes. They found that certain modifiers were able to partition in these artificial membranes, and on this basis, they have extrapolated that scorpion beta-toxins interact with their channel receptor in a similar mechanism as that proposed by MacKinnon. Since this hypothesis has actually raised a new conception, we examined it in binding assays using a number of pharmacologically distinct scorpion beta-toxins and insect and mammalian neuronal membrane preparations, as well as by analyzing the rate by which the toxin effect on gating of Drosophila DmNa(v)1 and rat brain rNa(v)1.2a develops. We show that in general, scorpion beta-toxins do not partition in neuronal membranes and that in the case in which a depressant beta-toxin partitions in insect neuronal membranes, this partitioning is unrelated to its interaction with the receptor site and the effect on the gating properties of the sodium channel. These results negate the hypothesis that the high affinity of beta-toxins for sodium channels is gained by their ability to partition in the phospholipid bilayer and clearly indicate that the receptor site for scorpion beta-toxins is accessible to the extracellular solvent.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Plant Sci, IL-69978 Tel Aviv, Israel; CE Saclay, Dept Ingn & Etud Prot, Commissariat Energie Atom, F-91191 Gif Sur Yvette, France	Tel Aviv University; CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite Paris Saclay	Gordon, D (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Plant Sci, IL-69978 Tel Aviv, Israel.	dgordon@post.tau.ac.il; mamgur@post.tau.ac.il						Benzinger GR, 1998, J BIOL CHEM, V273, P80, DOI 10.1074/jbc.273.1.80; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Bosmans F, 2006, MOL PHARMACOL, V69, P419, DOI 10.1124/mol.105.015941; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6; Cestele S, 2000, BIOCHIMIE, V82, P883, DOI 10.1016/S0300-9084(00)01174-3; Cohen L, 2005, J BIOL CHEM, V280, P5045, DOI 10.1074/jbc.M408427200; FELLER DJ, 1985, J BIOL CHEM, V260, P1542; Froy O, 1999, J BIOL CHEM, V274, P5769, DOI 10.1074/jbc.274.9.5769; Garcia ML, 2004, NATURE, V430, P153, DOI 10.1038/430153a; Garcia ML, 2001, TOXICON, V39, P739, DOI 10.1016/S0041-0101(00)00214-2; GERSHON E, 1992, J NEUROSCI, V12, P3743; Gilles N, 2001, BIOCHEMISTRY-US, V40, P14576, DOI 10.1021/bi010973r; Gilles N, 2000, J NEUROCHEM, V75, P1735, DOI 10.1046/j.1471-4159.2000.0751735.x; GORDON D, 1992, BIOCHEMISTRY-US, V31, P7622, DOI 10.1021/bi00148a025; Gordon D, 2003, EUR J BIOCHEM, V270, P2663, DOI 10.1046/j.1432-1033.2003.03643.x; Gordon D, 1996, J BIOL CHEM, V271, P8034, DOI 10.1074/jbc.271.14.8034; Gordon D, 1998, J TOXICOL-TOXIN REV, V17, P131, DOI 10.3109/15569549809009247; GORDON D, 1985, BIOCHIM BIOPHYS ACTA, V821, P130, DOI 10.1016/0005-2736(85)90163-4; Gurevitz M, 2001, FASEB J, V15, P1201, DOI 10.1096/fj.00-0571hyp; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Lee HC, 2003, NEURON, V40, P527, DOI 10.1016/S0896-6273(03)00636-6; Lee SY, 2005, P NATL ACAD SCI USA, V102, P15441, DOI 10.1073/pnas.0507651102; Lee SY, 2004, NATURE, V430, P232, DOI 10.1038/nature02632; Leipold E, 2005, FEBS LETT, V579, P3881, DOI 10.1016/j.febslet.2005.05.077; Leipold E, 2004, MOL PHARMACOL, V65, P685, DOI 10.1124/mol.65.3.685; Li-Smerin Y, 1998, P NATL ACAD SCI USA, V95, P8585, DOI 10.1073/pnas.95.15.8585; Li-Smerin Y, 2000, J GEN PHYSIOL, V115, P673, DOI 10.1085/jgp.115.6.673; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; Marcotte P, 1997, CIRC RES, V80, P363, DOI 10.1161/01.RES.80.3.363; MARTIN MF, 1987, J BIOL CHEM, V262, P4452; Martin-Eauclaire M. F., 1995, Handbook of neurotoxicology., P683; MOSKOWITZ H, 1994, INSECT BIOCHEM MOLEC, V24, P13, DOI 10.1016/0965-1748(94)90118-X; MOSKOWITZ H, 1992, THESIS HEBREW U JERU; Murray D, 1999, BIOPHYS J, V77, P3176, DOI 10.1016/S0006-3495(99)77148-1; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; ROCHAT H, 1977, ANAL BIOCHEM, V82, P532, DOI 10.1016/0003-2697(77)90192-0; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; Ruta V, 2004, BIOCHEMISTRY-US, V43, P10071, DOI 10.1021/bi049463y; Shichor I, 2002, J NEUROSCI, V22, P4364, DOI 10.1523/JNEUROSCI.22-11-04364.2002; Smith JJ, 2005, J BIOL CHEM, V280, P11127, DOI 10.1074/jbc.M412552200; SMITH JJ, 2005, BIOPHYS J; Strugatsky D, 2005, BIOCHEMISTRY-US, V44, P9179, DOI 10.1021/bi050235t; Swartz KJ, 1997, NEURON, V18, P665, DOI 10.1016/S0896-6273(00)80306-2; THOMSEN W, 1995, J NEUROCHEM, V65, P1358; Tsushima RG, 1999, PFLUG ARCH EUR J PHY, V437, P661, DOI 10.1007/s004240050830; Turkov M, 1997, PROTEIN EXPRES PURIF, V10, P123, DOI 10.1006/prep.1997.0724; Veiga AS, 2004, J AM CHEM SOC, V126, P14758, DOI 10.1021/ja0459882; WALLNER M, 1993, FEBS LETT, V336, P535, DOI 10.1016/0014-5793(93)80871-Q; WEILAND GA, 1981, LIFE SCI, V29, P313, DOI 10.1016/0024-3205(81)90324-6; WHEELER KP, 1982, BIOCHEMISTRY-US, V21, P5628, DOI 10.1021/bi00265a037; Wieprecht T, 1999, BIOCHEMISTRY-US, V38, P10377, DOI 10.1021/bi990913+; ZLOTKIN E, 1991, BIOCHEMISTRY-US, V30, P4814, DOI 10.1021/bi00233a025; ZLOTKIN E, 1986, NEUROPHARMACOLOGY PE, P352; Zlotkin E., 1978, ARTHROPOD VENOMS, P317	58	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20673	20679		10.1074/jbc.M603212200	http://dx.doi.org/10.1074/jbc.M603212200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16720570	hybrid			2022-12-25	WOS:000239187300004
J	Camoretti-Mercado, B; Fernandes, DJ; Dewundara, S; Churchill, J; Ma, L; Kogut, PC; McConville, JF; Parmacek, MS; Solway, J				Camoretti-Mercado, Blanca; Fernandes, Darren J.; Dewundara, Samantha; Churchill, Jason; Ma, Lan; Kogut, Paul C.; McConville, John F.; Parmacek, Michael S.; Solway, Julian			Inhibition of transforming growth factor beta-enhanced serum response factor-dependent transcription by SMAD7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE; TGF-BETA; GENE-EXPRESSION; NUCLEAR-LOCALIZATION; DIFFERENTIATION; SM22-ALPHA; COMPLEX; CELLS; SPECIFICITY; MECHANISMS	Transforming growth factor (TGF)-beta is present in large amounts in the airways of patients with asthma and with other diseases of the lung. We show here that TGF beta treatment increased transcriptional activation of SM22 alpha, a smooth muscle-specific promoter, in airway smooth muscle cells, and we demonstrate that this effect stems in part from TGF beta-induced enhancement of serum response factor (SRF) DNA binding and transcription promoting activity. Overexpression of Smad7 inhibited TGF beta-induced stimulation of SRF-dependent promoter function, and chromatin immunoprecipitation as well as co-immunoprecipitation assays established that endogenous or recombinant SRF interacts with Smad7 within the nucleus. The SRF binding domain of Smad7 mapped to the C-terminal half of the Smad7 molecule. TGF beta treatment weakened Smad7 association with SRF, and conversely the Smad7-SRF interaction was increased by inhibition of the TGF beta pathway through overexpression of a dominant negative mutant of TGF beta receptor I or of Smad3 phosphorylation-deficient mutant. Our findings thus reveal that SRF-Smad7 interactions in part mediate TGF beta regulation of gene transcription in airway smooth muscle. This offers potential targets for interventions in treating lung inflammation and asthma.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	University of Chicago; University of Pennsylvania	Camoretti-Mercado, B (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave,MC6026, Chicago, IL 60637 USA.	bcamoret@medicine.bsd.uchicago.edu	Solway, Julian/B-1116-2008	Solway, Julian/0000-0002-0898-8530	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056399] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56399] Funding Source: Medline; NIAID NIH HHS [AI056352] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; Bai ST, 2002, J BIOL CHEM, V277, P4176, DOI 10.1074/jbc.M105105200; Bartram U, 2004, CHEST, V125, P754, DOI 10.1378/chest.125.2.754; Camoretti-Mercado B, 2003, RESP PHYSIOL NEUROBI, V137, P223, DOI 10.1016/S1569-9048(03)00149-6; Camoretti-Mercado B, 1998, GENOMICS, V49, P452, DOI 10.1006/geno.1998.5267; Camoretti-Mercado B, 2000, J BIOL CHEM, V275, P30387, DOI 10.1074/jbc.M000840200; Chen SY, 2003, NUCLEIC ACIDS RES, V31, P1302, DOI 10.1093/nar/gkg224; Ding W, 2001, J CELL SCI, V114, P1011; Evans SE, 2004, CHEST, V125, P1063, DOI 10.1378/chest.125.3.1063; Forsythe SM, 2002, AM J RESP CELL MOL, V26, P298, DOI 10.1165/ajrcmb.26.3.4564; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Halayko AJ, 2004, AM J RESP CELL MOL, V31, P266, DOI 10.1165/rcmb.2003-0272OC; Hanyu A, 2001, J CELL BIOL, V155, P1017, DOI 10.1083/jcb.200106023; Hautmann MB, 1999, ARTERIOSCL THROM VAS, V19, P2049, DOI 10.1161/01.ATV.19.9.2049; Hautmann MB, 1997, J BIOL CHEM, V272, P10948; Holgate ST, 2000, CLIN EXP ALLERGY, V30, P37; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; Liu HW, 2003, AM J RESP CELL MOL, V29, P39, DOI 10.1165/rcmb.2002-0206OC; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; Parmacek MS, 2001, CURR TOP DEV BIOL, V51, P69, DOI 10.1016/S0070-2153(01)51002-9; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Pulaski L, 2001, J BIOL CHEM, V276, P14344, DOI 10.1074/jbc.M011019200; Qiu P, 2003, J MOL CELL CARDIOL, V35, P1407, DOI 10.1016/j.yjmcc.2003.09.002; Reguly T, 2003, TRENDS CELL BIOL, V13, P216, DOI 10.1016/S0962-8924(03)00075-8; Schuster N, 2002, CELL TISSUE RES, V307, P1, DOI 10.1007/s00441-001-0479-6; Silverman EK, 2002, HUM MOL GENET, V11, P623, DOI 10.1093/hmg/11.6.623; Sinha S, 2004, AM J PHYSIOL-CELL PH, V287, pC1560, DOI 10.1152/ajpcell.00221.2004; Solway J, 1998, AM J RESP CRIT CARE, V158, pS100, DOI 10.1164/ajrccm.158.supplement_2.13tac500; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; Wang ZG, 2004, NATURE, V428, P185, DOI 10.1038/nature02382	35	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20383	20392		10.1074/jbc.M602748200	http://dx.doi.org/10.1074/jbc.M602748200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16690609	hybrid			2022-12-25	WOS:000239038200062
J	Feistritzer, C; Schuepbach, RA; Mosnier, LO; Bush, LA; Di Cera, E; Griffin, JH; Riewald, M				Feistritzer, Clemens; Schuepbach, Reto A.; Mosnier, Laurent O.; Bush, Leslie A.; Di Cera, Enrico; Griffin, John H.; Riewald, Matthias			Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BRAIN ENDOTHELIUM; SEVERE SEPSIS; POTENT ANTICOAGULANT; BARRIER PROTECTION; BINDING-SITES; IN-VIVO; THROMBIN; RECEPTOR-1; APOPTOSIS; TRANSACTIVATION	Activated protein C (APC) has endothelial barrier protective effects that require binding to endothelial protein C receptor (EPCR) and cleavage of protease activated receptor-1 (PAR1) and that may play a role in the anti-inflammatory action of APC. In this study we investigated whether protein C (PC) activation by thrombin on the endothelial cell surface may be linked to efficient protective signaling. To minimize direct thrombin effects on endothelial permeability we used the anticoagulant double mutant thrombin W215A/E217A (WE). Activation of PC by WE on the endothelial cell surface generated APC with high barrier protective activity. Comparable barrier protective effects by exogenous APC required a 4-fold higher concentration of APC. To demonstrate conclusively that protective effects in the presence of WE are mediated by APC generation and not direct signaling by WE, we used a PC variant with a substitution of the active site serine with alanine (PC S360A). Barrier protective effects of a low concentration of exogenous APC were blocked by both wildtype PC and PC S360A, consistent with their expected role as competitive inhibitors for APC binding to EPCR. WE induced protective signaling only in the presence of wild type PC but not PC S360A and PAR1 cleavage was required for these protective effects. These data demonstrate that the endogenous PC activation pathway on the endothelial cell surface is mechanistically linked to PAR1-dependent autocrine barrier protective signaling by the generated APC. WE may have powerful protective effects in systemic inflammation through signaling by the endogenously generated APC.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Scripps Research Institute; Scripps Research Institute; Washington University (WUSTL)	Riewald, M (corresponding author), Scripps Res Inst, Dept Immunol, SP30-3040,10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	riewald@scripps.edu	Schuepbach, Reto/AAO-6360-2020; Schuepbach, Reto A/J-9737-2012	Schuepbach, Reto/0000-0002-7058-4377; Schuepbach, Reto A/0000-0002-7058-4377; Griffin, John/0000-0002-4302-2547	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073813, R01HL049413, R37HL052246, R01HL058141, R01HL052246, R29HL049413] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL73813, HL7338, HL58141, HL52246, HL49413] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham E, 2005, NEW ENGL J MED, V353, P1332, DOI 10.1056/NEJMoa050935; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Cantwell AM, 2000, J BIOL CHEM, V275, P39827, DOI 10.1074/jbc.C000751200; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; Dahlback B, 2005, ARTERIOSCL THROM VAS, V25, P1311, DOI 10.1161/01.ATV.0000168421.13467.82; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Domotor E, 2003, BLOOD, V101, P4797, DOI 10.1182/blood-2002-12-3680; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Esmon CT, 1999, THROMB HAEMOSTASIS, V82, P251; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; Faust SN, 2001, NEW ENGL J MED, V345, P408, DOI 10.1056/NEJM200108093450603; Feistritzer C, 2005, J THROMB HAEMOST, V3, P2798, DOI 10.1111/j.1538-7836.2005.01610.x; Feistritzer C, 2005, BLOOD, V105, P3178, DOI 10.1182/blood-2004-10-3985; Finigan JH, 2005, J BIOL CHEM, V280, P17286, DOI 10.1074/jbc.M412427200; Francis K, 1997, P NATL ACAD SCI USA, V94, P12258, DOI 10.1073/pnas.94.23.12258; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; GRUBER A, 1992, BLOOD, V79, P2340; Gruber A, 2002, J BIOL CHEM, V277, P27581, DOI 10.1074/jbc.C200237200; Guo H, 2004, NEURON, V41, P563, DOI 10.1016/S0896-6273(04)00019-4; HANSON SR, 1993, J CLIN INVEST, V92, P2003, DOI 10.1172/JCI116795; HEEB MJ, 1988, THROMB RES, V52, P33, DOI 10.1016/0049-3848(88)90038-2; Hooper WC, 1998, J IMMUNOL, V161, P2567; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Liaw PCY, 2003, J THROMB HAEMOST, V1, P662, DOI 10.1046/j.1538-7836.2003.00153.x; Liaw PCY, 2004, BLOOD, V104, P3958, DOI 10.1182/blood-2004-03-1203; Liaw PCY, 2001, J BIOL CHEM, V276, P8364, DOI 10.1074/jbc.M010572200; LOLLAR P, 1980, J CLIN INVEST, V66, P1222, DOI 10.1172/JCI109973; Ludeman MJ, 2005, J BIOL CHEM, V280, P13122, DOI 10.1074/jbc.M410381200; Mosnier LO, 2004, BLOOD, V104, P1740, DOI 10.1182/blood-2004-01-0110; Mosnier LO, 2003, BIOCHEM J, V373, P65, DOI 10.1042/BJ20030341; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; O'Brien PJ, 2000, J BIOL CHEM, V275, P13502, DOI 10.1074/jbc.275.18.13502; OWEN WG, 1995, BIOCHEMISTRY-US, V34, P9277, DOI 10.1021/bi00029a001; Preston RJS, 2005, FEBS J, V272, P97, DOI 10.1111/j.1432-1033.2004.04401.x; Riewald M, 2005, J BIOL CHEM, V280, P19808, DOI 10.1074/jbc.M500747200; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Riewald M, 2001, P NATL ACAD SCI USA, V98, P7742, DOI 10.1073/pnas.141126698; Sambrano GR, 2001, NATURE, V413, P74, DOI 10.1038/35092573; Stanssens P, 1996, P NATL ACAD SCI USA, V93, P2149, DOI 10.1073/pnas.93.5.2149; TAYLOR FB, 1984, THROMB RES, V36, P177, DOI 10.1016/0049-3848(84)90339-6; Uchiba M, 2004, CIRC RES, V95, P34, DOI 10.1161/01.RES.0000133680.87668.FA; Weiss EJ, 2002, BLOOD, V100, P3240, DOI 10.1182/blood-2002-05-1470; Zeng W, 2004, CRIT CARE MED, V32, pS302, DOI 10.1097/01.CCM.0000128038.49201.8C	44	112	117	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20077	20084		10.1074/jbc.M600506200	http://dx.doi.org/10.1074/jbc.M600506200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16709569	Green Accepted, hybrid			2022-12-25	WOS:000239038200032
J	Radchenko, MV; Tanaka, K; Waditee, R; Oshimi, S; Matsuzaki, Y; Fukuhara, M; Kobayashi, H; Takabe, T; Nakamura, T				Radchenko, Martha V.; Tanaka, Kimihiro; Waditee, Rungaroon; Oshimi, Sawako; Matsuzaki, Yasutomo; Fukuhara, Masahiro; Kobayashi, Hiroshi; Takabe, Teruhiro; Nakamura, Tatsunosuke			Potassium/proton antiport system of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MARINE BACTERIUM; MECHANOSENSITIVE CHANNEL; NA+/H+ ANTIPORTER; CATION-TRANSPORT; PH HOMEOSTASIS; K+; CLONING; SODIUM; GENE; CONSTRUCTION	The intracellular level of potassium (K+) in Escherichia coli is regulated through multiple K+ transport systems. Recent data indicate that not all K+ extrusion system(s) have been identified (15). Here we report that the E. coli Na+(Ca2+)/H+ antiporter ChaA-functions as a K+ extrusion system. Cells expressingChaA mediated K+ efflux against a K+ concentration gradient. E. coli strains lacking the chaA gene were unable to extrude K+ under conditions in which wild- type cells extruded K+. The K+/H+ antiporter activity of ChaA was detected by using invertedmembrane vesicles produced using a French press. Physiological growth studies indicated that E. coli uses ChaA to discard excessive K+, which is toxic for these cells. These results suggest that ChaA K+/H+ antiporter activity enables E. coli to adapt to K+ salinity stress and to maintain K+ homeostasis.	Niigata Univ, Dept Microbiol, Niigata 9502081, Japan; Meijo Univ, Grad Sch Environm & Human Sci, Nagoya, Aichi 4688502, Japan; Meijo Univ, Res Inst, Tenpaku Ku, Nagoya, Aichi 4688502, Japan; Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, Chiba 2608675, Japan	Niigata University; Meijo University; Meijo University; Chiba University	Nakamura, T (corresponding author), Niigata Univ, Dept Microbiol, 5-13-2 Kamishniei Cho, Niigata 9502081, Japan.	tnak@niigata-pharm.ac.jp						BAKKER EP, 1982, FEBS LETT, V140, P177, DOI 10.1016/0014-5793(82)80888-0; BAKKER EP, 1983, BIOCHIM BIOPHYS ACTA, V730, P379, DOI 10.1016/0005-2736(83)90355-3; BAKKER EP, 1987, J BACTERIOL, V169, P3743, DOI 10.1128/jb.169.8.3743-3749.1987; Benito B, 2002, MICROBIOL-SGM, V148, P933, DOI 10.1099/00221287-148-4-933; BOSSEMEYER D, 1989, J BACTERIOL, V171, P2219, DOI 10.1128/jb.171.4.2219-2221.1989; BRACHMANN BJ, 1972, BACTERIOL REV, V36, P525; BREY RN, 1980, J BIOL CHEM, V255, P39; Brown A., 1990, MICROBIAL WATER STRE; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; DOSCH DC, 1991, J BACTERIOL, V173, P687, DOI 10.1128/jb.173.2.687-696.1991; Epstein W, 2003, PROG NUCLEIC ACID RE, V75, P293, DOI 10.1016/S0079-6603(03)75008-9; EPSTEIN W, 1971, J BACTERIOL, V108, P639, DOI 10.1128/JB.108.2.639-644.1971; Ferguson GP, 1999, TRENDS MICROBIOL, V7, P242, DOI 10.1016/S0966-842X(99)01510-3; Fukada-Tanaka S, 2000, NATURE, V407, P581, DOI 10.1038/35036683; Hamada A, 2001, PLANT PHYSIOL, V125, P437, DOI 10.1104/pp.125.1.437; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; IVEY DM, 1993, J BIOL CHEM, V268, P11296; Kakinuma Y, 1999, J BACTERIOL, V181, P4103, DOI 10.1128/JB.181.13.4103-4105.1999; Kuo MMC, 2005, FEMS MICROBIOL REV, V29, P961, DOI 10.1016/j.femsre.2005.03.003; Kuo MMC, 2003, EMBO J, V22, P4049, DOI 10.1093/emboj/cdg409; Levina N, 1999, EMBO J, V18, P1730, DOI 10.1093/emboj/18.7.1730; Lewinson O, 2004, P NATL ACAD SCI USA, V101, P14073, DOI 10.1073/pnas.0405375101; Li YZ, 2002, EMBO J, V21, P5323, DOI 10.1093/emboj/cdf537; Loukin SH, 2005, J GEN PHYSIOL, V125, P521, DOI 10.1085/jgp.200509261; MEURY J, 1982, EMBO J, V1, P339, DOI 10.1002/j.1460-2075.1982.tb01171.x; MEURY J, 1985, EUR J BIOCHEM, V151, P613, DOI 10.1111/j.1432-1033.1985.tb09148.x; MILKMAN R, 1994, P NATL ACAD SCI USA, V91, P3510, DOI 10.1073/pnas.91.9.3510; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; NAKAMURA T, 1982, BIOCHIM BIOPHYS ACTA, V692, P389, DOI 10.1016/0005-2736(82)90389-3; NAKAMURA T, 1984, BIOCHIM BIOPHYS ACTA, V776, P330, DOI 10.1016/0005-2736(84)90222-0; NAKAMURA T, 1992, J GEN MICROBIOL, V138, P1271, DOI 10.1099/00221287-138-6-1271; Numata M, 2001, J BIOL CHEM, V276, P17387, DOI 10.1074/jbc.M101319200; OHYAMA T, 1994, J BACTERIOL, V176, P4311, DOI 10.1128/jb.176.14.4311-4315.1994; Padan E, 2005, BBA-BIOMEMBRANES, V1717, P67, DOI 10.1016/j.bbamem.2005.09.010; PLACK RH, 1980, J BIOL CHEM, V255, P3824; Putnoky P, 1998, MOL MICROBIOL, V28, P1091, DOI 10.1046/j.1365-2958.1998.00868.x; Radchenko MV, 2006, MOL MICROBIOL, V59, P651, DOI 10.1111/j.1365-2958.2005.04966.x; RHOADS DB, 1976, J GEN PHYSIOL, V67, P325, DOI 10.1085/jgp.67.3.325; RHOADS DB, 1978, J GEN PHYSIOL, V72, P283, DOI 10.1085/jgp.72.3.283; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shijuku T, 2002, BBA-BIOENERGETICS, V1556, P142, DOI 10.1016/S0005-2728(02)00345-6; STUMPE S, 1996, HDB BIOL PHYSICS, V2, P474; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; Venema K, 2003, J BIOL CHEM, V278, P22453, DOI 10.1074/jbc.M210794200	44	64	67	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					19822	19829		10.1074/jbc.M600333200	http://dx.doi.org/10.1074/jbc.M600333200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16687400	hybrid			2022-12-25	WOS:000239038200005
J	Ueda, J; Tachibana, M; Ikura, T; Shinkai, Y				Ueda, Jun; Tachibana, Makoto; Ikura, Tsuyoshi; Shinkai, Yoichi			Zinc finger protein Wiz links G9a/GLP histone methyltransferases to the co-repressor molecule CtBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL-BINDING-PROTEIN; LYSINE-9 METHYLATION; H3 METHYLTRANSFERASE; DNA METHYLATION; TRANSCRIPTION; G9A; ASSOCIATION; CHROMATIN; COMPLEX; CHROMODOMAIN	G9a is a SET-domain mammalian histone methyltransferase responsible for mono- and dimethylation of lysine 9 in histone H3 (H3K9) at euchromatic regions. Recently we reported that G9a forms a stoichiometric heteromeric complex with another SET-domain-containing molecule, GLP/Eu-HMTase1. Although G9a and GLP can independently methylate H3K9 in vitro, G9a/GLP heteromeric formation seems to be essential for their function as a euchromatic H3K9 methyltransferase in vivo. To further elucidate how G9a/GLP-mediated histone methylation and transcriptional regulation are controlled, we purified and characterized G9a complexes from mouse embryonic stem cells. We identified a novel G9a/GLP-associating zinc finger molecule named Wiz that can interact with G9a and GLP independently but is more stable in the G9a/GLP heteromeric complexes. Interestingly, Wiz small inhibitory RNA knocks down not only Wiz but also G9a. GLP deficiency also decreases G9a levels, suggesting that the Wiz/G9a/GLP tri-complex may protect G9a from degradation and that Wiz plays a major role in G9a/GLP heterodimer formation. Furthermore, amino acid sequence analysis of Wiz predicted two potential CtBP binding sites, and indeed CtBP binding to Wiz and association of CtBP with the Wiz/G9a/GLP complex was observed. These data indicate that Wiz not only contributes to the stability of G9a but also links the G9a/GLP heteromeric complex to the CtBP co-repressor machinery.	Kyoto Univ, Inst Virus Res, Expt Res Ctr Infect Dis, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Mol & Cellular Biol, Kyoto 6068507, Japan; Tohoku Univ, Grad Sch Med, Dept Biochem, Aoba Ku, Sendai, Miyagi 9808575, Japan	Kyoto University; Kyoto University; Tohoku University	Shinkai, Y (corresponding author), Kyoto Univ, Inst Virus Res, Expt Res Ctr Infect Dis, Shogoin Kawara Cho, Kyoto 6068507, Japan.	yshinkai@virus.kyoto-u.ac.jp	Ueda, Jun/G-1670-2010; Shinkai, Yoichi/N-3909-2014; Ueda, Jun/AAX-9704-2020	Ueda, Jun/0000-0002-9766-203X; Shinkai, Yoichi/0000-0002-6051-2484; Ueda, Jun/0000-0002-9766-203X				Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Carrozza MJ, 2005, CELL, V123, P581, DOI 10.1016/j.cell.2005.10.023; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Czermin B, 2001, EMBO REP, V2, P915, DOI 10.1093/embo-reports/kve210; Duan ZJ, 2005, MOL CELL BIOL, V25, P10338, DOI 10.1128/MCB.25.23.10338-10351.2005; Elgin SCR, 2003, CURR BIOL, V13, pR895, DOI 10.1016/j.cub.2003.11.006; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Gyory I, 2004, NAT IMMUNOL, V5, P299, DOI 10.1038/ni1046; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Iwano T, 2004, J BIOL CHEM, V279, P1442, DOI 10.1074/jbc.M309138200; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Joshi AA, 2005, MOL CELL, V20, P971, DOI 10.1016/j.molcel.2005.11.021; Keogh MC, 2005, CELL, V123, P593, DOI 10.1016/j.cell.2005.10.025; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Lee DY, 2006, J BIOL CHEM, V281, P8476, DOI 10.1074/jbc.M511093200; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Matsumoto K, 1998, MOL BRAIN RES, V61, P179, DOI 10.1016/S0169-328X(98)00216-2; Min JR, 2003, GENE DEV, V17, P1823, DOI 10.1101/gad.269603; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nishio H, 2004, P NATL ACAD SCI USA, V101, P11257, DOI 10.1073/pnas.0401343101; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Roopra A, 2004, MOL CELL, V14, P727, DOI 10.1016/j.molcel.2004.05.026; Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009; Santos-Rosa H, 2003, MOL CELL, V12, P1325, DOI 10.1016/S1097-2765(03)00438-6; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Simpson RJY, 2003, J BIOL CHEM, V278, P28011, DOI 10.1074/jbc.M211146200; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Vakoc CR, 2005, MOL CELL, V19, P381, DOI 10.1016/j.molcel.2005.06.011; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200	45	92	101	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20120	20128		10.1074/jbc.M603087200	http://dx.doi.org/10.1074/jbc.M603087200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16702210	hybrid			2022-12-25	WOS:000239038200036
J	Yan, LJ; Findlay, GM; Jones, R; Procter, J; Cao, YH; Lamb, RF				Yan, Lijun; Findlay, Greg M.; Jones, Rebecca; Procter, Julia; Cao, Yunhong; Lamb, Richard F.			Hyperactivation of mammalian target of rapamycin (mTOR) signaling by a gain-of-function mutant of the Rheb GTPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-GROWTH; TUBEROUS SCLEROSIS; TUMOR-SUPPRESSOR; SOMATIC ACTIVATION; STRUCTURAL BASIS; COMPLEX; GENE; DROSOPHILA; TSC2; PROLIFERATION	Gain-of-function mutants of Ras and Rho family small GTPases have proven to be important tools in analyzing signaling downstream of these small GTPases. The Ras- related GTPase Rheb has emerged as a key player downstream of TSC1-2 in activating signaling to mammalian target of rapamycin ( mTOR) effectors of cell growth such as S6K and 4E-BP1. The TSC1-2 tumor suppressor complex has been shown to act as a RhebGAP, converting Rheb from a GTP-bound to a GDP-bound form. Here we report the identification of a mutant Rheb (S16HRheb) that exhibits gain-of-function properties. At endogenous levels of expression S16HRheb exhibits increased GTP loading in vivo and is resistant to TSC1-2 GAP in vitro. Compared with wild-type Rheb, S16HRheb is more active at promoting the phosphorylation of the mTOR effectors S6K1 and 4E-BP1. Thus S16HRheb will help to identify proximal signaling events downstream of Rheb and allow potential Rheb-independent functions downstream of TSC1-2 to be investigated.	Canc Res UK Ctr Cell & Mol Biol, Inst Canc Res, London SW7 6JB, England	Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Lamb, RF (corresponding author), Canc Res UK Ctr Cell & Mol Biol, Inst Canc Res, 237 Fulham Rd, London SW7 6JB, England.	Richard.Lamb@icr.ac.uk	Jones, Rebecca/C-5244-2011	Yan, Lijun/0000-0001-7863-0449; Findlay, Greg/0000-0002-7222-4965				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Braun BS, 2004, P NATL ACAD SCI USA, V101, P597, DOI 10.1073/pnas.0307203101; Daumke O, 2004, NATURE, V429, P197, DOI 10.1038/nature02505; Findlay GM, 2005, CURR OPIN GENET DEV, V15, P69, DOI 10.1016/j.gde.2004.11.002; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Li Y, 2004, MOL CELL BIOL, V24, P7965, DOI 10.1128/MCB.24.18.7965-7975.2004; Maheshwar MM, 1997, HUM MOL GENET, V6, P1991, DOI 10.1093/hmg/6.11.1991; Patel PH, 2003, J CELL SCI, V116, P3601, DOI 10.1242/jcs.00661; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2005, FEBS LETT, V579, P4763, DOI 10.1016/j.febslet.2005.07.054; Urano J, 2005, MOL MICROBIOL, V58, P1074, DOI 10.1111/j.1365-2958.2005.04877.x; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Yu YD, 2005, J BIOL CHEM, V280, P17093, DOI 10.1074/jbc.M501253200	21	49	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					19793	19797		10.1074/jbc.C600028200	http://dx.doi.org/10.1074/jbc.C600028200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16728407	hybrid			2022-12-25	WOS:000239038200002
J	Balzarini, J; Liekens, S; Solaroli, N; El Omari, K; Stammers, DK; Karlsson, A				Balzarini, Jan; Liekens, Sandra; Solaroli, Nicola; El Omari, Kamel; Stammers, David K.; Karlsson, Anna			Engineering of a single conserved amino acid residue of herpes simplex virus type 1 thymidine kinase allows a predominant shift from pyrimidine to purine nucleoside phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY CRYSTALLOGRAPHY; GENE-THERAPY; GANCICLOVIR; MUTATION; MUTANTS; ACYCLOVIR; SITE	Studies of herpes simplex virus type 1 (HSV-1) thymidine (dThd) kinase (TK) crystal structures show that purine and pyrimidine bases occupy distinct positions in the active site but approximately the same geometric plane. The presence of a bulky side chain, such as tyrosine at position 167, would not be sterically favorable for pyrimidine or pyrimidine nucleoside analogue binding, whereas purine nucleoside analogues would be less affected because they are located further away from the phenylalanine side chain. Site-directed mutagenesis of the conserved Ala-167 and Ala-168 residues in HSV-1 TK resulted in a wide variety of differential affinities and catalytic activities in the presence of the natural substrate dThd and the purine nucleoside analogue drug ganciclovir (GCV), depending on the nature of the amino acid mutation. A168H- and A167F-mutated HSV-1 TK enzymes turned out to have a virtually complete knock-out of dThd kinase activity (at least similar to 4-5 orders of magnitude lower) presumably due to a steric clash between the mutated amino acid and the dThd ring. In contrast, a full preservation of the GCV ( and other purine nucleoside analogues) kinase activity was achieved for A168H TK. The enzyme mutants also markedly lost their binding capacity for dThd and showed a substantially diminished feedback inhibition by thymidine 5'-triphosphate. The side chain size at position 168 seems to play a less important role regarding GCV or dThd selectivity than at position 167. Instead, the nitrogen-containing side chains from A168H and A168K seem necessary for efficient ligand discrimination. This explains why A168H- mutated HSV-1 TK fully preserves its GCV kinase activity (V-max/K-m 4-fold higher than wild- type HSV-1 TK), although still showing a severely compromised dThd kinase activity (V-max/K-m 3-4 orders of magnitude lower than wild-type HSV-1 TK).	Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium; Huddinge Univ Hosp, Karolinska Inst, S-14186 Huddinge, Sweden; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England	KU Leuven; Karolinska Institutet; University of Oxford; Wellcome Centre for Human Genetics	Balzarini, J (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Minderbroedersstr 10, B-3000 Louvain, Belgium.	jan.balzarini@rega.kuleuven.be	Karlsson, Anna/E-7945-2018	Karlsson, Anna/0000-0001-6843-6685; El Omari, Kamel/0000-0003-3506-6045				Balzarini J, 2002, BIOCHEMISTRY-US, V41, P6517, DOI 10.1021/bi0255930; Black ME, 2001, CANCER RES, V61, P3022; Black ME, 1996, P NATL ACAD SCI USA, V93, P3525, DOI 10.1073/pnas.93.8.3525; BOHMAN C, 1994, J BIOL CHEM, V269, P8036; Champness JN, 1998, PROTEINS, V32, P350, DOI 10.1002/(SICI)1097-0134(19980815)32:3<350::AID-PROT10>3.0.CO;2-8; Cohen JL, 1997, BLOOD, V89, P4636, DOI 10.1182/blood.V89.12.4636; Degreve B, 2000, MOL PHARMACOL, V58, P1326, DOI 10.1124/mol.58.6.1326; Degreve B, 2000, GENE THER, V7, P1543, DOI 10.1038/sj.gt.3301278; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FIELD AK, 1983, P NATL ACAD SCI-BIOL, V80, P4139, DOI 10.1073/pnas.80.13.4139; Gambhir SS, 2000, P NATL ACAD SCI USA, V97, P2785, DOI 10.1073/pnas.97.6.2785; Kokoris MS, 2000, ANTICANCER RES, V20, P959; Kokoris MS, 1999, GENE THER, V6, P1415, DOI 10.1038/sj.gt.3300966; Kokoris MS, 2002, PROTEIN SCI, V11, P2267, DOI 10.1110/ps.2460102; Mercer KE, 2002, PROTEIN ENG, V15, P903, DOI 10.1093/protein/15.11.903; Vogt J, 2000, PROTEINS, V41, P545, DOI 10.1002/1097-0134(20001201)41:4<545::AID-PROT110>3.0.CO;2-8	16	25	25	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19273	19279		10.1074/jbc.M600414200	http://dx.doi.org/10.1074/jbc.M600414200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16702226	hybrid			2022-12-25	WOS:000238847000041
J	Chen, IY; Lypowy, J; Pain, J; Sayed, D; Grinberg, S; Alcendor, RR; Sadoshima, J; Abdellatif, M				Chen, Ieng-Yi; Lypowy, Jacqueline; Pain, Jayashree; Sayed, Danish; Grinberg, Stan; Alcendor, Ralph R.; Sadoshima, Junichi; Abdellatif, Maha			Histone H2A.z is essential for cardiac myocyte hypertrophy but opposed by silent information regulator 2 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY MAMMALIAN DEVELOPMENT; RNA-POLYMERASE-II; CELL-SURVIVAL; VARIANT H2A.Z; HETEROCHROMATIN; DEACETYLASE; RAS; UBIQUITINATION; ACTIVATION; SIR2	In this study we have shown that the histone variant H(2)A.z is up-regulated during cardiac hypertrophy. Upon its knockdown with RNA interference, hypertrophy and the underlying increase in growth-related genes, protein synthesis, and cell size were down-regulated. During attempts to understand the mode of regulation of H(2)A.z, we found that overexpression of silent information regulator 2alpha (Sir2 alpha) specifically induced down-regulation of H2A.z via NAD-dependent activity. This effect was reversed by the proteasome inhibitor epoxomicin, suggesting a Sir2 alpha-mediated ubiquitin/proteasome-dependent mechanism for degradation of H2A.z. An increase in Sir2 alpha also resulted in a dose-dependent reduction of the response to hypertrophic stimuli, whereas its inhibition resulted in enhanced hypertrophy and apoptosis. We have shown that Sir2 alpha directly deacetylates H2A.z. Mutagenesis proved that lysines 4, 7, 11, and 13 do not play a role in the stability of H2A.z, whereas Lys-15 was indispensable. Meanwhile, Lys-115 and conserved, ubiquitinatable Lys-121 are critical for Sir2 alpha-mediated degradation. Fusion of the C terminus of H2A.z (amino acids 115-127) to H2A.x or green fluorescence protein conferred Sir2 alpha-inducible degradation to the former protein only. Because H2A.x and H2A.z have conserved N-tails, this implied that both the C and N termini are critical for mediating the effect of Sir2 alpha. In short, the results suggest that H2A.z is required for cardiac hypertrophy, where its stability and the extent of cell growth and apoptosis are moderated by Sir2 alpha. We also propose that Sir2 alpha is involved in deacetylation of H2A.z, which results in ubiquitination of Lys-115 and Lys-121 and its degradation via a ubiquitin/proteasome-dependent pathway.	Univ Med & Dent New Jersey, Cardiovasc Res Inst, Dept Cell Biol & Mol Med, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Abdellatif, M (corresponding author), Univ Med & Dent New Jersey, Cardiovasc Res Inst, Dept Cell Biol & Mol Med, Newark, NJ 07103 USA.	abdellma@umdnj.edu	Sayed, Danish/B-9047-2012	Sadoshima, Junichi/0000-0003-3724-4132	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057970] Funding Source: NIH RePORTER; NHLBI NIH HHS [2R01 HL057970-06] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott DW, 2001, J BIOL CHEM, V276, P41945, DOI 10.1074/jbc.M108217200; ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; Abdellatif M, 1998, MOL CELL BIOL, V18, P6729, DOI 10.1128/MCB.18.11.6729; Adam M, 2001, MOL CELL BIOL, V21, P6270, DOI 10.1128/MCB.21.18.6270-6279.2001; Alcendor RR, 2004, CIRC RES, V95, P971, DOI 10.1161/01.RES.0000147557.75257.ff; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Clarkson MJ, 1999, NATURE, V399, P694, DOI 10.1038/21436; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Faast R, 2001, CURR BIOL, V11, P1183, DOI 10.1016/S0960-9822(01)00329-3; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Gusterson RJ, 2003, J BIOL CHEM, V278, P6838, DOI 10.1074/jbc.M211762200; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jackson JD, 2000, NUCLEIC ACIDS RES, V28, P3811, DOI 10.1093/nar/28.19.3811; Johnatty SE, 2000, J MOL CELL CARDIOL, V32, P805, DOI 10.1006/jmcc.2000.1122; Liu XW, 1996, MOL CELL BIOL, V16, P4305; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Meneghini MD, 2003, CELL, V112, P725, DOI 10.1016/S0092-8674(03)00123-5; Rangasamy D, 2004, NAT STRUCT MOL BIOL, V11, P650, DOI 10.1038/nsmb786; Rangasamy D, 2003, EMBO J, V22, P1599, DOI 10.1093/emboj/cdg160; Ren QH, 2001, MOL CELL, V7, P1329, DOI 10.1016/S1097-2765(01)00269-6; Santisteban MS, 2000, CELL, V103, P411, DOI 10.1016/S0092-8674(00)00133-1; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Suto RK, 2000, NAT STRUCT BIOL, V7, P1121; VANDAAL A, 1992, MOL BIOL CELL, V3, P593, DOI 10.1091/mbc.3.6.593; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Yue YZ, 2004, J BIOL CHEM, V279, P12883, DOI 10.1074/jbc.M312308200; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9	28	73	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19369	19377		10.1074/jbc.M601443200	http://dx.doi.org/10.1074/jbc.M601443200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16687393	hybrid			2022-12-25	WOS:000238847000052
J	Crack, JC; Green, J; Le Brun, NE; Thomson, AJ				Crack, Jason C.; Green, Jeffrey; Le Brun, Nick E.; Thomson, Andrew J.			Detection of sulfide release from the oxygen-sensing [4Fe-4S] cluster of FNR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR FNR; ESCHERICHIA-COLI; ANAEROBIC RESPIRATION; DNA-BINDING; EXPRESSION; PROTEIN; SULFUR; GENES; ARCA; CONVERSION	The Escherichia coli FNR protein regulates the transcription of > 100 genes in response to environmental O-2, thereby coordinating the response to anoxia. Under O-2-limiting conditions, FNR binds a [4Fe-4S](2+) cluster through four cysteine residues (Cys(20), Cys(23), Cys(29), Cys(122)). The acquisition of the [4Fe-4S](2+) cluster converts FNR into the transcriptionally active dimeric form. Upon exposure to O-2, the cluster converts to a [2Fe-2S](2+) form, generating FNR monomers that no longer bind DNA with high affinity. The mechanism of the cluster conversion reaction and the nature of the released iron and sulfur are of considerable current interest. Here, we report the application of a novel in vitro method, involving 5,5'-dithiobis-(2-nitrobenzoic acid), for determining the oxidation state of the sulfur atoms released during FNR cluster conversion following the addition of O-2. Conversion of [4Fe-4S](2+) to [2Fe-2S](2+) clusters by O-2 for both native and reconstituted FNR results in the release of similar to 2 sulfide ions per [4Fe-4S](2+) cluster. This demonstrates that the reaction between O-2 and the [4Fe-4S](2+) cluster does not require sulfide oxidation and hence must entail iron oxidation.	Univ E Anglia, Sch Chem Sci & Pharm, Ctr Met Prot Spect & Biol, Norwich NR4 7TJ, Norfolk, England; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	University of East Anglia; University of Sheffield	Crack, JC (corresponding author), Univ E Anglia, Sch Chem Sci & Pharm, Ctr Met Prot Spect & Biol, Norwich NR4 7TJ, Norfolk, England.	J.Crack@uea.ac.uk; A.Thomson@uea.ac.uk		Crack, Jason C./0000-0002-4979-1910; Le Brun, Nick/0000-0001-9780-4061	Biotechnology and Biological Sciences Research Council [BB/C500836/1] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Achebach S, 2005, FEBS J, V272, P4260, DOI 10.1111/j.1742-4658.2005.04840.x; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Crack J, 2004, J BIOL CHEM, V279, P9278, DOI 10.1074/jbc.M309878200; ELLMAN G, 1979, ANAL BIOCHEM, V93, P98, DOI 10.1016/S0003-2697(79)80122-0; GREEN J, 1993, MOL MICROBIOL, V8, P61, DOI 10.1111/j.1365-2958.1993.tb01203.x; Green J, 2001, ADV MICROB PHYSIOL, V44, P1, DOI 10.1016/S0065-2911(01)44010-0; Green J, 1996, BIOCHEM J, V316, P887, DOI 10.1042/bj3160887; Guest JR, 1995, PHILOS T R SOC B, V350, P189, DOI 10.1098/rstb.1995.0152; Jordan PA, 1997, FEBS LETT, V416, P349, DOI 10.1016/S0014-5793(97)01219-2; Kang YS, 2005, J BACTERIOL, V187, P1135, DOI 10.1128/JB.187.3.1135-1160.2005; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; Kiley PJ, 1998, FEMS MICROBIOL REV, V22, P341, DOI 10.1111/j.1574-6976.1998.tb00375.x; LAMBDEN PR, 1976, J GEN MICROBIOL, V97, P145, DOI 10.1099/00221287-97-2-145; Lazazzera BA, 1996, J BIOL CHEM, V271, P2762, DOI 10.1074/jbc.271.5.2762; LAZAZZERA BA, 1993, GENE DEV, V7, P1993, DOI 10.1101/gad.7.10.1993; NASHEF AS, 1977, ANAL BIOCHEM, V79, P394, DOI 10.1016/0003-2697(77)90413-4; Perrenoud A, 2005, J BACTERIOL, V187, P3171, DOI 10.1128/JB.187.9.3171-3179.2005; PETERSON DA, 1994, BIOCHEM BIOPH RES CO, V200, P1586, DOI 10.1006/bbrc.1994.1632; Popescu CV, 1998, P NATL ACAD SCI USA, V95, P13431, DOI 10.1073/pnas.95.23.13431; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Shalel-Levanon S, 2005, BIOTECHNOL BIOENG, V92, P147, DOI 10.1002/bit.20583; Shalel-Levanon S, 2005, METAB ENG, V7, P364, DOI 10.1016/j.ymben.2005.07.001; SHARROCKS AD, 1991, P ROY SOC B-BIOL SCI, V245, P219, DOI 10.1098/rspb.1991.0113; SHAW DJ, 1983, J MOL BIOL, V166, P241, DOI 10.1016/S0022-2836(83)80011-4; SPIRO S, 1987, J GEN MICROBIOL, V133, P3279; SPIRO S, 1991, TRENDS BIOCHEM SCI, V16, P310, DOI 10.1016/0968-0004(91)90125-F; Sutton VR, 2003, METHOD ENZYMOL, V370, P300; Sutton VR, 2004, J BACTERIOL, V186, P8018, DOI 10.1128/JB.186.23.8018-8025.2004; Unden G, 1997, BBA-BIOENERGETICS, V1320, P217, DOI 10.1016/S0005-2728(97)00034-0; UNDEN G, 1991, ANTON LEEUW INT J G, V59, P65, DOI 10.1007/BF00445650; Vogel A. I., 1989, TXB PRACTICAL ORGANI, P395	33	49	51	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					18909	18913		10.1074/jbc.C600042200	http://dx.doi.org/10.1074/jbc.C600042200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16717103	hybrid			2022-12-25	WOS:000238847000002
J	Cheng, JCH; Chou, CH; Kuo, ML; Hsieh, CY				Cheng, J. C-H; Chou, C. H.; Kuo, M. L.; Hsieh, C-Y			Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappa B signal transduction pathway	ONCOGENE			English	Article						radiation; hepatocellular carcinoma; invasion; signal transduction	INDUCED MATRIX-METALLOPROTEINASE-9 EXPRESSION; FACTOR-KAPPA-B; INDUCED INCREASE; GENE-EXPRESSION; DOWN-REGULATION; MELANOMA-CELLS; KINASE PATHWAY; CANCER; MIGRATION; RADIOTHERAPY	This study is to investigate the molecular mechanism of radiation-enhanced cell invasiveness of hepatocellular carcinoma (HCC) correlating with clinical patients undergoing radiotherapy and subsequently developing metastasis. Three HCC cell lines (HepG2, Hep3B and Huh7) and normal hepatocyte cell line (CL-48) were irradiated with different doses. The effect of radiation on cell invasiveness was determined using the Boyden chamber assay. Radiation-enhanced invasion capability was evident in HCC cells but not in normal hepatocytes. Invasion was observed in gelatin-coated but not fibronectin-coated or type I collagen-coated membranes. Radiation upregulated matrix metalloproteinase-9 (MMP-9) mRNA level, MMP-9 protein level and MMP-9 activity. MMP-9 antisense oligonucleotides inhibited radiation-induced MMP-9 expression and thereby significantly inhibited radiation-induced HCC invasion. Furthermore, phosphatidylinositol 3-kinase (PI3K)/Akt chemical inhibitors LY294002 and wortmannin suppressed radiation-induced MMP-9 mRNA expression. Transient transfection with dominant-negative Akt plasmid also showed that the PI3K/Akt-signaling pathway was involved in this radiation-induced MMP-9 expression. Moreover, nuclear factor-kappa B (NF-kappa B) decoy oligodeoxynucleotide suppressed radiation enhanced MMP-9 promoter activity completely. PI3K/Akt chemical inhibitors inhibited radiation-induced NF-kappa B-driven luciferase promoter activity. Taken together, our results indicated that sublethal dose of radiation could enhance HCC cell invasiveness by MMP-9 expression through the PI3K/Akt/NF-kappa B signal transduction pathway.	Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Oncol, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Hsieh, CY (corresponding author), Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, 7 Chung Shan S Rd, Taipei 100, Taiwan.	cheng38@ms15.hinet.net	Kuo, Min-Liang/C-4872-2009	KUO, MIN-LIANG/0000-0002-7139-0144; CHENG, JASON CHIA-HSIEN/0000-0002-2007-0220				Agarwal A, 2005, ONCOGENE, V24, P1021, DOI 10.1038/sj.onc.1208296; Aguayo A, 2001, SEMIN ONCOL, V28, P503, DOI 10.1053/sonc.2001.26953; Akimoto T, 1998, INT J RADIAT ONCOL, V41, P1171, DOI 10.1016/S0360-3016(98)00176-X; Amin ARMR, 2003, GENES CELLS, V8, P515, DOI 10.1046/j.1365-2443.2003.00652.x; Camphausen K, 2001, CANCER RES, V61, P2207; Cheng JCH, 2001, INT J CANCER, V96, P243, DOI 10.1002/ijc.1022; Chung TW, 2004, FASEB J, V18, P1123, DOI 10.1096/fj.03-1429fje; Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; FU KK, 1991, HEMATOL ONCOL CLIN N, V5, P737, DOI 10.1016/S0889-8588(18)30413-1; Hegedus B, 2004, J NEURO-ONCOL, V67, P147, DOI 10.1023/B:NEON.0000021826.73020.f3; Huang SC, 2005, BIOCHEM PHARMACOL, V69, P221, DOI 10.1016/j.bcp.2004.09.019; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Kuyvenhoven JP, 2003, THROMB HAEMOSTASIS, V89, P718, DOI 10.1055/s-0037-1613578; Liang SX, 2005, CANCER-AM CANCER SOC, V103, P2181, DOI 10.1002/cncr.21012; London CA, 2003, CANCER GENE THER, V10, P823, DOI 10.1038/sj.cgt.7700642; Moon SK, 2004, J CELL PHYSIOL, V198, P417, DOI 10.1002/jcp.10435; Murawaki Y, 2000, RES COMMUN MOL PATH, V108, P351; Nakashio A, 2002, INT J CANCER, V98, P36, DOI 10.1002/ijc.10166; Nirmala C, 2000, INT J CANCER, V88, P766, DOI 10.1002/1097-0215(20001201)88:5<766::AID-IJC13>3.0.CO;2-Y; O-Charoenrat P, 2004, INT J CANCER, V111, P174, DOI 10.1002/ijc.20228; ONODA JM, 1992, RADIAT RES, V130, P281, DOI 10.2307/3578372; Qian LW, 2002, CLIN CANCER RES, V8, P1223; SATO H, 1993, ONCOGENE, V8, P395; Steinle JJ, 2002, J BIOL CHEM, V277, P43830, DOI 10.1074/jbc.M207221200; Sugioka Y, 2004, INT J CANCER, V109, P867, DOI 10.1002/ijc.20095; Susskind H, 2003, INT J RADIAT ONCOL, V56, P1161, DOI 10.1016/S0360-3016(03)00161-5; Thant AA, 2001, CLIN EXP METASTAS, V18, P423, DOI 10.1023/A:1010921730952; Wang JL, 2000, MOL CARCINOGEN, V27, P252, DOI 10.1002/(SICI)1098-2744(200004)27:4<252::AID-MC2>3.0.CO;2-3; Wei LH, 2005, ONCOGENE, V24, P390, DOI 10.1038/sj.onc.1208192; Wild-Bode C, 2001, CANCER RES, V61, P2744; Woo JH, 2003, CANCER RES, V63, P3430; Yao JHS, 2004, CIRC RES, V95, P364, DOI 10.1161/01.RES.0000138581.04174.2f; Zijlstra A, 2002, CANCER RES, V62, P7083	34	264	280	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7009	7018		10.1038/sj.onc.1209706	http://dx.doi.org/10.1038/sj.onc.1209706			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16732316				2022-12-25	WOS:000241910500001
J	Baillat, D; Leprivier, G; Regnier, D; Vintonenko, N; Begue, A; Stehelin, D; Aumercier, M				Baillat, D.; Leprivier, G.; Regnier, D.; Vintonenko, N.; Begue, A.; Stehelin, D.; Aumercier, M.			Stromelysin-1 expression is activated in vivo by Ets-1 through palindromic head-to-head Ets binding sites present in the promoter	ONCOGENE			English	Article						Ets-1; MMP-3; gene regulation; synovial fibroblasts cell transcription	TRANSCRIPTION FACTOR EXPRESSION; MATRIX-METALLOPROTEINASE GENES; DNA-BINDING; RHEUMATOID-ARTHRITIS; ANGIOGENESIS; FUMAGILLIN; PROTEIN; ELEMENTS; RAS; INHIBITION	Regulation of the gene expression of Stromelysin-1 (matrix metalloproteinase-3), a member of the matrix metalloproteinase family, is critical for tissue homeostasis. The Stromelysin-1 promoter is known to be transactivated by Ets proteins through palindromic head-to-head Ets binding sites (EBS), an unusual configuration among metalloproteinase promoters. Patterns of increased co-expression of Stromelysin-1 and Ets-1 genes have been observed in pathological processes such as rheumatoid arthritis, glomerulonephritis and tumor invasion. In this context, we show in a synovial fibroblastic model cell line (HIG-82), which is able to co-express Stromelysin-1 and Ets-1, that the EBS palindrome is essential for the expression of Stromelysin-1. More precisely, using electrophoretic mobility shift assays, DNA affinity purification and chromatin immunoprecipitation, we demonstrate that endogenous Ets-1, but not Ets-2, is present on this palindrome. The use of a dominant-negative form of Ets-1 and the decrease of Ets-1 amount either by fumagillin, an antiangiogenic compound, or by short interfering RNA show that the activation rate of the promoter and the expression of Stromelysin-1 correlate with the level of endogenous Ets-1. Thus, it is the first demonstration, using this cellular model, that endogenously expressed Ets-1 is actually a main activator of the Stromelysin-1 promoter through its effective binding to the EBS palindrome.	Univ Lille 2, Inst Biol Lille, UMR 8526, Inst Pasteur Lille,CNRS, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Aumercier, M (corresponding author), Univ Lille 2, Inst Biol Lille, UMR 8526, Inst Pasteur Lille,CNRS, 1 Rue Prof Calmette,BP 447, F-59021 Lille, France.	marc.aumercier@ibl.fr		Aumercier, Marc/0000-0002-0370-3452				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baillat D, 2002, J BIOL CHEM, V277, P29386, DOI 10.1074/jbc.M200088200; Barrett JM, 2002, BREAST CANCER RES TR, V72, P227, DOI 10.1023/A:1014993006190; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; Bernier SG, 2004, P NATL ACAD SCI USA, V101, P10768, DOI 10.1073/pnas.0404105101; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Calmels TPG, 1995, BIOL CELL, V84, P53, DOI 10.1016/0248-4900(96)81318-9; Catalano A, 2001, AM J PATHOL, V159, P721, DOI 10.1016/S0002-9440(10)61743-9; CHEN JH, 1990, ONCOGENE RES, V5, P277; Chen YF, 2005, DNA CELL BIOL, V24, P126, DOI 10.1089/dna.2005.24.126; Constantin A, 2002, ARTHRITIS RHEUM, V46, P1754, DOI 10.1002/art.10336; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; Datta B, 2004, BIOCHEMISTRY-US, V43, P14821, DOI 10.1021/bi049172p; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, P1; FRISCH SM, 1987, P NATL ACAD SCI USA, V84, P2600, DOI 10.1073/pnas.84.9.2600; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gaire M, 1996, MOL CARCINOGEN, V15, P124, DOI 10.1002/(SICI)1098-2744(199602)15:2<124::AID-MC5>3.0.CO;2-J; GALANG CK, 1994, ONCOGENE, V9, P2913; GEORGESCU HI, 1988, IN VITRO CELL DEV B, V24, P1015; Ghilardi G, 2002, CLIN CANCER RES, V8, P3820; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Hodge DR, 1996, ONCOGENE, V12, P11; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Kirstein M, 1996, J BIOL CHEM, V271, P18231, DOI 10.1074/jbc.271.30.18231; Kria L, 1998, CURR EYE RES, V17, P986, DOI 10.1076/ceyr.17.10.986.5245; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin CW, 1996, EXP CELL RES, V223, P117, DOI 10.1006/excr.1996.0064; Lowther WT, 2000, BBA-PROTEIN STRUCT M, V1477, P157, DOI 10.1016/S0167-4838(99)00271-X; MAJERUS MA, 1992, NUCLEIC ACIDS RES, V20, P2699, DOI 10.1093/nar/20.11.2699; MALEMUD CJ, 1999, FRONT BIOSCI, V4, P762; Man AK, 2003, MOL CELL BIOL, V23, P8614, DOI 10.1128/MCB.23.23.8614-8625.2003; Maroulakou IG, 2000, ONCOGENE, V19, P6432, DOI 10.1038/sj.onc.1204039; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; Mukherjee T, 2003, J CANCER RES CLIN, V129, P430, DOI 10.1007/s00432-003-0457-3; Naito T, 2000, J AM SOC NEPHROL, V11, P2243, DOI 10.1681/ASN.V11122243; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Ozaki I, 2003, HEPATOL RES, V27, P288, DOI 10.1016/S1386-6346(03)00268-7; Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297; Pufall MA, 2005, SCIENCE, V309, P142, DOI 10.1126/science.1111915; Pufall MA, 2002, ANNU REV CELL DEV BI, V18, P421, DOI 10.1146/annurev.cellbio.18.031502.133614; QUINONES S, 1994, BIOCHEM J, V302, P471, DOI 10.1042/bj3020471; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Redlich K, 2001, ARTHRITIS RHEUM, V44, P266, DOI 10.1002/1529-0131(200102)44:2<266::AID-ANR43>3.3.CO;2-7; Rekdal C, 2000, J BIOL CHEM, V275, P40288, DOI 10.1074/jbc.M006978200; Rodriguez-Nieto S, 2001, ANTICANCER RES, V21, P3457; Rothhammer T, 2004, CELL MOL LIFE SCI, V61, P118, DOI 10.1007/s00018-003-3337-8; Sato Y, 2000, ADV EXP MED BIOL, V476, P109; Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099; Singh S, 2002, CURR DRUG TARGETS, V3, P359, DOI 10.2174/1389450023347489; Span PN, 2002, ONCOGENE, V21, P8506, DOI 10.1038/sj.onc.1206040; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Sternlicht MD, 1999, GUIDEBOOK EXTRACELLU, P505; Sun HB, 2001, BONE, V28, P303, DOI 10.1016/S8756-3282(00)00454-3; Terashima M, 1999, CIRCULATION, V99, P2717, DOI 10.1161/01.CIR.99.21.2717; Tokuhara K, 2003, INT SURG, V88, P25; Trojanowska M, 2000, ONCOGENE, V19, P6464, DOI 10.1038/sj.onc.1204043; Vetter M, 2005, ONCOGENE, V24, P650, DOI 10.1038/sj.onc.1208234; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; Wang JY, 2000, J CELL BIOCHEM, V77, P465, DOI 10.1002/(SICI)1097-4644(20000601)77:3<465::AID-JCB11>3.3.CO;2-D; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; Wernert N, 1999, ANGEW CHEM INT EDIT, V38, P3228, DOI 10.1002/(SICI)1521-3773(19991102)38:21<3228::AID-ANIE3228>3.0.CO;2-8; WERNERT N, 1994, CANCER RES, V54, P5683; Yamamoto H, 1998, GENE DEV, V12, P1315, DOI 10.1101/gad.12.9.1315; Yang BS, 1996, MOL CELL BIOL, V16, P538; Ye S, 1999, FEBS LETT, V450, P268, DOI 10.1016/S0014-5793(99)00509-8; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P6427, DOI 10.1073/pnas.97.12.6427; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	72	23	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5764	5776		10.1038/sj.onc.1209583	http://dx.doi.org/10.1038/sj.onc.1209583			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16652151				2022-12-25	WOS:000240765800007
J	Joshi, HK; Etzkorn, C; Chatwell, L; Bitinaite, J; Horton, NC				Joshi, Hemant K.; Etzkorn, Christopher; Chatwell, Lorentz; Bitinaite, Jurate; Horton, Nancy C.			Alteration of sequence specificity of the type II restriction endonuclease HincII through an indirect readout mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DNA RECOGNITION; ESCHERICHIA-COLI; TRP REPRESSOR; BINDING; OPERATOR; SITE; COMPLEX; AFFINITY; PROGRAM; VIII	The functional and structural consequences of a mutation of the DNA intercalating residue of HincII, Q138F, are presented. Modeling has suggested that the DNA intercalation by Gln-138 results in DNA distortions potentially used by HincII in indirect readout of its cognate DNA, GTYRAC ( Y = C or T, R = A or G) ( Horton, N. C., Dorner, L. F., and Perona, J. J. ( 2002) Nat. Struct. Biol. 9, 42 - 47). Kinetic data presented here indicate that the mutation of glutamine 138 to phenylalanine ( Q138F) results in a change in sequence specificity at the center two base pairs of the cognate recognition site. We show that the preference of HincII for cutting, but not binding, the three cognate sites differing in the center two base pairs has been altered by the mutation Q138F. Five new crystal structures are presented including Q138F HincII bound to GTTAAC and GTCGAC both with and without Ca2+ as well as the structure of wild type HincII bound to GTTAAC. The Q138F HincII/DNA structures show conformational changes in the protein, bound DNA, and at the protein-DNA interface, consistent with the formation of adaptive complexes. Analysis of these structures and the effect of Ca2+ binding on the protein-DNA interface illuminates the origin of the altered specificity by the mutation Q138F in the HincII enzyme.	Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA; New England Biolabs Inc, Beverly, MA 01915 USA	University of Arizona	Horton, NC (corresponding author), Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA.	nhorton@u.arizona.edu	Horton, Nancy C/E-7881-2011	Horton, Nancy C/0000-0003-2710-8284; Bitinaite, Jurate/0000-0002-9190-6355	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066805] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM066805-01A1, R01 GM066805-03, R01 GM066805-04, R01 GM066805-05, R01 GM066805-02, R01 GM066805, 1 R01 GM066805-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL A K, 1990, Methods (Orlando), V1, P83, DOI 10.1016/S1046-2023(05)80150-1; Bareket-Samish A, 1998, J MOL BIOL, V277, P1071, DOI 10.1006/jmbi.1998.1638; Bareket-Samish A, 2000, J MOL BIOL, V299, P965, DOI 10.1006/jmbi.2000.3797; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen SF, 2001, J MOL BIOL, V314, P75, DOI 10.1006/jmbi.2001.5090; Etzkorn C, 2004, J MOL BIOL, V343, P833, DOI 10.1016/j.jmb.2004.08.082; Etzkorn C, 2004, BIOCHEMISTRY-US, V43, P13256, DOI 10.1021/bi0490082; FASMAN GD, 1975, CRC HDB BIOCH MOL BI, P589; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Garvie CW, 2000, STRUCTURE, V8, P905, DOI 10.1016/S0969-2126(00)00182-9; Gromiha MM, 2005, GENE, V364, P108, DOI 10.1016/j.gene.2005.07.022; Horton NC, 1999, ACTA CRYSTALLOGR D, V55, P1943, DOI 10.1107/S0907444999010574; Horton NC, 2002, NAT STRUCT BIOL, V9, P42, DOI 10.1038/nsb741; JenJacobson L, 1996, EMBO J, V15, P2870, DOI 10.1002/j.1460-2075.1996.tb00648.x; JenJacobson L, 1997, BIOPOLYMERS, V44, P153; Jiang DY, 1997, J BIOL CHEM, V272, P32230, DOI 10.1074/jbc.272.51.32230; JORDAN SR, 1985, SCIENCE, V230, P1383; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LINDAHL T, 1977, J BIOL CHEM, V252, P3286; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; Little EJ, 2005, J MOL BIOL, V351, P76, DOI 10.1016/j.jmb.2005.05.063; Luscombe NM, 2000, GENOME BIOL, V1; Martin AM, 1999, NAT STRUCT BIOL, V6, P269; Martin AM, 1999, BIOCHEMISTRY-US, V38, P8430, DOI 10.1021/bi9905359; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MELAMEDE RJ, 1994, BIOCHEMISTRY-US, V33, P1255, DOI 10.1021/bi00171a028; Moore M, 2001, P NATL ACAD SCI USA, V98, P1432, DOI 10.1073/pnas.98.4.1432; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; Pingoud A, 2005, CELL MOL LIFE SCI, V62, P685, DOI 10.1007/s00018-004-4513-1; Reid SL, 2001, BIOCHEMISTRY-US, V40, P2484, DOI 10.1021/bi001956p; Schumacher MA, 2001, NATURE, V409, P215, DOI 10.1038/35051623; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; TAYLOR JD, 1991, BIOCHEMISTRY-US, V30, P8743, DOI 10.1021/bi00100a005; THIELKING V, 1991, BIOCHEMISTRY-US, V30, P6416, DOI 10.1021/bi00240a011; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P1113, DOI 10.1021/bi00004a002	39	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23852	23869		10.1074/jbc.M512339200	http://dx.doi.org/10.1074/jbc.M512339200			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16675462	hybrid			2022-12-25	WOS:000239702900061
J	Conte, M; Arcaro, A; D'Angelo, D; Gnata, A; Mamone, G; Ferranti, P; Formisano, S; Gentile, F				Conte, Marisa; Arcaro, Alessia; D'Angelo, Daniela; Gnata, Ariele; Mamone, Gianfranco; Ferranti, Pasquale; Formisano, Silvestro; Gentile, Fabrizio			A single chondroitin 6-sulfate oligosaccharide unit at Ser-2730 of human thyroglobulin enhances hormone formation and limits proteolytic accessibility at the carboxyl terminus - Potential insights into thyroid homeostasis and autoimmunity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; PROTEOGLYCAN CORE PROTEIN; SODIUM DODECYL-SULFATE; ORBITAL TISSUES; CARBOHYDRATE UNITS; RAT THYROGLOBULIN; INVARIANT-CHAIN; CARTILAGE PROTEOGLYCAN; BINDING; IDENTIFICATION	We localized the site of type D (chondroitin 6-sulfate) oligosaccharide unit addition to human thyroglobulin (hTg). hTg was chromatographically separated into chondroitin 6-sulfate-containing (hTg-CS) and chondroitin 6-sulfate-devoid (hTg-CS0) molecules on the basis of their D-glucuronic acid content. In an ample number of hTg preparations, the fraction of hTg-CS in total hTg ranged from 32.0 to 71.6%. By exploiting the electrophoretic mobility shift and metachromasia conferred by chondroitin 6-sulfate upon the products of limited proteolysis of hTg, chondroitin 6-sulfate was first restricted to a carboxyl-terminal region, starting at residue 2514. A single chondroitin 6-sulfate-containing nonapeptide was isolated in pure form from the products of digestion of hTg with endoproteinase Glu-C, and its sequence was determined as LTAGXGLRE (residues 2726-2734, X being Ser(2730) linked to the oligosaccharide chain). In an in vitro assay of enzymatic iodination, hTg-CS produced higher yields of 3,5,5'-triiodothyronine (T-3) (171%) and 3,5,3', 5'-tetraiodothyronine (T-4) (134%) than hTg-CS0. Unfractionated hTg behaved as hTg-CS. Thus, chondroitin 6-sulfate addition to a subset of hTg molecules enhanced the overall level of T-4 and, in particular, T-3 formation. Furthermore, the chondroitin 6-sulfate oligosaccharide unit of hTg-CS protected peptide bond Lys(2714)-Gly(2715) from proteolysis, during the limited digestion of hTg-CS with trypsin. These findings provide insights into the molecular mechanism of regulation of the hormonogenic efficiency and of the T-4/T-3 ratio in hTg. The potential implications in the ability of hTg to function as an autoantigen and into the pathogenesis of thyroidal and extra-thyroidal manifestations of autoimmune thyroid disease are discussed.	Univ Molise, Dipartimento Sci Salute, Via F De Sancits, I-86100 Campobasso, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellularte & Mol, I-80131 Naples, Italy; CNR, Ist Sci Alimentaz, I-83100 Avellino, Italy; Univ Naples Federico II, Dipartimento Sci Alimenti, I-80055 Portici, Italy	University of Molise; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze dell' Alimentazione (ISA-CNR); University of Naples Federico II	Gentile, F (corresponding author), Univ Molise, Dipartimento Sci Salute, Via F De Sancits, I-86100 Campobasso, Italy.	gentilefabrizio@unimol.it	Ferranti, Pasquale/ABF-8111-2021; Gentile, Fabrizio/K-2475-2012; D'Angelo, Daniela/GVT-9143-2022; Arcaro, Alessia/D-9383-2017; Mamone, Gianfranco/AAX-8690-2020	Gentile, Fabrizio/0000-0002-6704-3115; Mamone, Gianfranco/0000-0002-0394-7617; FERRANTI, Pasquale/0000-0002-6250-6512				Anderton SM, 2004, CURR OPIN IMMUNOL, V16, P753, DOI 10.1016/j.coi.2004.09.001; ARIMA T, 1972, J BIOL CHEM, V247, P1836; ARIMA T, 1972, J BIOL CHEM, V247, P1825; BADER JP, 1972, BIOCHIM BIOPHYS ACTA, V264, P73, DOI 10.1016/0304-4165(72)90118-3; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; Brinkmann T, 1997, J BIOL CHEM, V272, P11171; DAHLBERG AE, 1969, J MOL BIOL, V41, P139, DOI 10.1016/0022-2836(69)90131-4; DEME D, 1978, BIOCHIM BIOPHYS ACTA, V540, P73, DOI 10.1016/0304-4165(78)90436-1; DUNN JT, 1983, J BIOL CHEM, V258, P9093; DUNN JT, 1982, J BIOL CHEM, V257, P88; Duthoit C, 2000, ENDOCRINOLOGY, V141, P2518, DOI 10.1210/en.141.7.2518; FASSLER CA, 1988, J BIOL CHEM, V263, P17366; FENOUILLET E, 1986, J BIOL CHEM, V261, P5153; FOGELFELD L, 1990, ENDOCRINOLOGY, V126, P1064, DOI 10.1210/endo-126-2-1064; Fujimoto T, 2001, INT IMMUNOL, V13, P359, DOI 10.1093/intimm/13.3.359; Gahring LC, 2001, J IMMUNOL, V166, P1433, DOI 10.4049/jimmunol.166.3.1433; Gentile F, 2004, IMMUNOLOGY, V112, P13, DOI 10.1111/j.1365-2567.2004.01861.x; Gentile F, 1997, ANAL BIOCHEM, V244, P228, DOI 10.1006/abio.1996.9863; GENTILE F, 1993, EUR J BIOCHEM, V218, P603, DOI 10.1111/j.1432-1033.1993.tb18414.x; Gentile F., 1995, ENDOCRINOLOGY, P517; Glant TT, 1998, J IMMUNOL, V160, P3812; Hanisch FG, 2003, EUR J IMMUNOL, V33, P3242, DOI 10.1002/eji.200324189; HASCALL VC, 1972, J BIOL CHEM, V247, P4521; Hollander CS, 1974, NUCL MED IN VITRO, P136; HOSHIOKA A, 1993, IMMUNOL LETT, V37, P235, DOI 10.1016/0165-2478(93)90036-2; HUFNAGEL TJ, 1984, OPHTHALMOLOGY, V91, P1411; Kahaly G, 1998, THYROID, V8, P429, DOI 10.1089/thy.1998.8.429; LAMAS L, 1986, ENDOCRINOLOGY, V118, P2131, DOI 10.1210/endo-118-5-2131; LAMAS L, 1989, J BIOL CHEM, V264, P13541; Lisi S, 2002, THYROID, V12, P351, DOI 10.1089/105072502760043413; MALLET B, 1995, J BIOL CHEM, V270, P29881; Malsch R, 1996, J CHROMATOGR B, V685, P223, DOI 10.1016/S0378-4347(96)00185-5; Marino M, 2000, THYROID, V10, P551, DOI 10.1089/thy.2000.10.551; Marino M, 2000, J BIOL CHEM, V275, P7125, DOI 10.1074/jbc.275.10.7125; Marino M, 1999, J BIOL CHEM, V274, P30377, DOI 10.1074/jbc.274.43.30377; Marino M, 2003, THYROID, V13, P851, DOI 10.1089/105072503322401041; Marino M, 2001, THYROID, V11, P177, DOI 10.1089/105072501300042929; MILLER J, 1988, P NATL ACAD SCI USA, V85, P1359, DOI 10.1073/pnas.85.5.1359; NAUJOKAS MF, 1993, CELL, V74, P257, DOI 10.1016/0092-8674(93)90417-O; PALUMBO G, 1982, ANAL BIOCHEM, V123, P183, DOI 10.1016/0003-2697(82)90641-8; PITTRIVE.R, 1968, BIOCHEM J, V109, P825, DOI 10.1042/bj1090825; Prabhakar BS, 2003, ENDOCR REV, V24, P802, DOI 10.1210/er.2002-0020; RAWITCH AB, 1968, BIOCHIM BIOPHYS ACTA, V160, P360, DOI 10.1016/0005-2795(68)90208-0; Reed larsen P, 2003, WILLIAMS TXB ENDOCRI, P331; Segrest J P, 1971, Biochem Biophys Res Commun, V44, P390; ROSAMOND S, 1987, J IMMUNOL, V139, P1946; SANT AJ, 1985, J IMMUNOL, V135, P416; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNEIDER AB, 1988, ENDOCRINOLOGY, V122, P2428, DOI 10.1210/endo-122-6-2428; SPIRO MJ, 1977, J BIOL CHEM, V252, P5424; SPIRO RG, 1988, J BIOL CHEM, V263, P14351; ToyamaSorimachi N, 1997, J BIOL CHEM, V272, P26714, DOI 10.1074/jbc.272.42.26714; TOYAMASORIMACHI N, 1995, J BIOL CHEM, V270, P7437, DOI 10.1074/jbc.270.13.7437; van de Graaf SAR, 2001, J ENDOCRINOL, V170, P307, DOI 10.1677/joe.0.1700307; Veneziani BM, 1999, BIOCHIMIE, V81, P517, DOI 10.1016/S0300-9084(99)80104-7; Vlad AM, 2002, J EXP MED, V196, P1435, DOI 10.1084/jem.20020493; WARREN L, 1963, METHOD ENZYMOL, V6, P463, DOI 10.1016/0076-6879(63)06207-8; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wood P, 1998, J EXP MED, V188, P773, DOI 10.1084/jem.188.4.773; Yang SX, 1996, ARCH BIOCHEM BIOPHYS, V327, P61, DOI 10.1006/abbi.1996.0093	60	9	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22200	22211		10.1074/jbc.M513382200	http://dx.doi.org/10.1074/jbc.M513382200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16679516	hybrid			2022-12-25	WOS:000239387100067
J	Lukov, GL; Baker, CM; Ludtke, PJ; Hu, T; Carter, MD; Hackett, RA; Thulin, CD; Willardson, BM				Lukov, Georgi L.; Baker, Christine M.; Ludtke, Paul J.; Hu, Ting; Carter, Michael D.; Hackett, Ryan A.; Thulin, Craig D.; Willardson, Barry M.			Mechanism of assembly of G protein beta gamma subunits by protein kinase CK2-phosphorylated phosducin-like protein and the cytosolic chaperonin complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTORS; CRYSTAL-STRUCTURE; CCT; BINDING; IDENTIFICATION; CK2	Phosducin-like protein (PhLP) is a widely expressed binding partner of the G protein beta gamma subunit complex (G beta gamma) that has been recently shown to catalyze the formation of the G beta gamma dimer from its nascent polypeptides. Phosphorylation of PhLP at one or more of three consecutive serines (Ser-18, Ser-19, and Ser-20) is necessary for G beta gamma dimer formation and is believed to be mediated by the protein kinase CK2. Moreover, several lines of evidence suggest that the cytosolic chaperonin complex (CCT) may work in concert with PhLP in the G beta gamma-assembly process. The results reported here delineate a mechanism for G beta gamma assembly in which a stable ternary complex is formed between PhLP, the nascent G beta subunit, and CCT that does not include G gamma. PhLP phosphorylation permits the release of a PhLP(.)G beta intermediate from CCT, allowing G gamma to associate with G beta in this intermediate complex. Subsequent interaction of G beta gamma with membranes releases PhLP for another round of assembly.	Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA	Brigham Young University	Willardson, BM (corresponding author), Brigham Young Univ, Dept Chem & Biochem, C-100 BNSN, Provo, UT 84602 USA.	barry_willardson@byu.edu	Lukov, Georgi/AAI-8544-2021	Willardson, Barry/0000-0002-8503-2268	NEI NIH HHS [EY12287] Funding Source: Medline; NIGMS NIH HHS [R01 GM078550] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012287] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078550] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blaauw M, 2003, EMBO J, V22, P5047, DOI 10.1093/emboj/cdg508; Cabrera-Vera TM, 2003, ENDOCR REV, V24, P765, DOI 10.1210/er.2000-0026; Camasses A, 2003, MOL CELL, V12, P87, DOI 10.1016/S1097-2765(03)00244-2; Carter Michael D, 2004, J Biomol Tech, V15, P257; Flanary PL, 2000, J BIOL CHEM, V275, P18462, DOI 10.1074/jbc.M002163200; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; Garzon J, 2002, NEUROPHARMACOLOGY, V42, P813, DOI 10.1016/S0028-3908(02)00027-8; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Gensse M, 2000, FEBS LETT, V480, P184, DOI 10.1016/S0014-5793(00)01926-8; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Humrich J, 2005, J BIOL CHEM, V280, P20042, DOI 10.1074/jbc.M409233200; Humrich J, 2003, J BIOL CHEM, V278, P4474, DOI 10.1074/jbc.M206347200; Kasahara S, 2000, P NATL ACAD SCI USA, V97, P412, DOI 10.1073/pnas.97.1.412; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Lukov GL, 2005, EMBO J, V24, P1965, DOI 10.1038/sj.emboj.7600673; Lukov GL, 2004, BIOCHEMISTRY-US, V43, P5651, DOI 10.1021/bi035903u; Martin-Benito J, 2004, P NATL ACAD SCI USA, V101, P17410, DOI 10.1073/pnas.0405070101; Martin-Benito J, 2002, EMBO J, V21, P6377, DOI 10.1093/emboj/cdf640; McLaughlin JN, 2002, P NATL ACAD SCI USA, V99, P7962, DOI 10.1073/pnas.112075699; McLaughlin JN, 2002, J BIOL CHEM, V277, P34885, DOI 10.1074/jbc.M205583200; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Michaelson D, 2002, MOL BIOL CELL, V13, P3294, DOI 10.1091/mbc.E02-02-0095; MILES MF, 1993, P NATL ACAD SCI USA, V90, P10831, DOI 10.1073/pnas.90.22.10831; Pappenberger G, 2002, J MOL BIOL, V318, P1367, DOI 10.1016/S0022-2836(02)00190-0; Rockman HA, 2002, NATURE, V415, P206, DOI 10.1038/415206a; Savage JR, 2000, J BIOL CHEM, V275, P30399, DOI 10.1074/jbc.M005120200; Schoneberg T, 2004, PHARMACOL THERAPEUT, V104, P173, DOI 10.1016/j.pharmthera.2004.08.008; Schroder S, 1996, P NATL ACAD SCI USA, V93, P2100, DOI 10.1073/pnas.93.5.2100; Siegers K, 2003, EMBO J, V22, P5230, DOI 10.1093/emboj/cdg483; Simonds WF, 2003, J INVEST MED, V51, P194, DOI 10.1136/jim-51-04-18; Thibault C, 1997, J BIOL CHEM, V272, P12253, DOI 10.1074/jbc.272.19.12253; Valpuesta JM, 2002, FEBS LETT, V529, P11, DOI 10.1016/S0014-5793(02)03180-0	32	54	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22261	22274		10.1074/jbc.M601590200	http://dx.doi.org/10.1074/jbc.M601590200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16717095	hybrid			2022-12-25	WOS:000239387100072
J	Abramova, MV; Pospelova, TV; Nikulenkov, FP; Hollander, CM; Fornace, AJ; Pospelov, VA				Abramova, Maria V.; Pospelova, Tatiana V.; Nikulenkov, Fedor P.; Hollander, Christine M.; Fornace, Albert J., Jr.; Pospelov, Valery A.			G(1)/S arrest induced by histone deacetylase inhibitor sodium butyrate in E1A+Ras-transformed cells is mediated through down-regulation of E2F activity and stabilization of beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REPRESSOR; DEPENDENT TRANSCRIPTION; COLORECTAL-CANCER; COLON-CANCER; PATHWAY; EXPRESSION; APOPTOSIS; P300; DIFFERENTIATION; ACTIVATION	Tumor cells are often characterized by a high and growth factor-independent proliferation rate. We have previously shown that REF cells transformed with oncogenes E1A and c-Ha-Ras do not undergo G(1)/S arrest of the cell cycle after treatment with genotoxic factors. In this work, we used sodium butyrate, a histone deacetylase inhibitor, to show that E1A + Ras transformants were able to stop proliferation and undergo G(1)/S arrest. Apart from inducing G1/S arrest, sodium butyrate was shown to change expression of a number of cell cycle regulatory genes. It down-regulated cyclins D1, E, andAas well as c-myc and cdc25A and up-regulated the cyclin-kinase inhibitor p21(waf1). Accordingly, activities of cyclin E-Cdk2 and cyclin A-Cdk2 complexes in sodium butyrate-treated cells were decreased substantially. Strikingly, E2F1 expression was also down-modulated at the levels of gene transcription, the protein content, and the E2F transactivating capability. To further study the role of p21waf1 in the sodium butyrate-induced G(1)/S arrest and the E2F1 down-modulation, we established E1A + Ras transformants from mouse embryo fibroblast cells with deletion of the cdkn1a ( p21waf1) gene. Despite the absence of p21(waf1), sodium butyrate-treated mERas transformants reveal a slightly delayed G(1)/S arrest as well as down-modulation of E2F1 activity, implying that the observed effects are mediated through an alternative p21(waf1)-independent signaling pathway. Subsequent analysis showed that sodium butyrate induced accumulation of beta-catenin, a downstream component of the Wnt signaling. The results obtained indicate that the antiproliferative effect of histone deacetylase inhibitors on E1A + Ras-transformed cells can be mediated, alongside other mechanisms, through down-regulation of E2F activity and stabilization of beta-catenin.	Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia; NCI, Gene Response Unit, NIH, Bethesda, MD 20892 USA	Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pospelov, VA (corresponding author), Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia.	Pospelov_v@mail.ru	Fornace, Albert J/A-7407-2008; Igotti, Maria V/U-4868-2017; Nikulenkov, Fedor/AAJ-2304-2021	Fornace, Albert J/0000-0001-9695-085X; Igotti, Maria/0000-0001-9596-5195	PHS HHS [G-3-00-336] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abramova MV, 2003, BIOCHEM BIOPH RES CO, V306, P483, DOI 10.1016/S0006-291X(03)00996-3; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Araki K, 2003, ONCOGENE, V22, P7632, DOI 10.1038/sj.onc.1206840; Baek SH, 2003, P NATL ACAD SCI USA, V100, P3245, DOI 10.1073/pnas.0330217100; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bordonaro M, 2002, INT J CANCER, V97, P42, DOI 10.1002/ijc.1577; Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007; Brembeck FH, 2004, GENE DEV, V18, P2225, DOI 10.1101/gad.317604; Bulavin DV, 1999, ONCOGENE, V18, P5611, DOI 10.1038/sj.onc.1202945; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chen RH, 2000, J BIOL CHEM, V275, P17894, DOI 10.1074/jbc.M905336199; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Dai Y, 2003, CELL CYCLE, V2, P467, DOI 10.4161/cc.2.5.465; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153; Holnthoner W, 2002, J BIOL CHEM, V277, P45847, DOI 10.1074/jbc.M209354200; Hughes TA, 2005, EXP CELL RES, V303, P32, DOI 10.1016/j.yexcr.2004.09.014; Iwamoto M, 2004, CANCER BIOL THER, V3, P395, DOI 10.4161/cbt.3.4.733; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kuphal F, 2006, EXP CELL RES, V312, P457, DOI 10.1016/j.yexcr.2005.11.007; Lazarova DL, 2004, INT J CANCER, V110, P523, DOI 10.1002/ijc.20152; Levy L, 2004, MOL CELL BIOL, V24, P3404, DOI 10.1128/MCB.24.8.3404-3414.2004; Lu ZM, 2004, CELL CYCLE, V3, P571; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Muraoka M, 1996, ONCOGENE, V12, P1565; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Onda M, 2004, J HUM GENET, V49, P312, DOI 10.1007/s10038-004-0146-3; Papkoff J, 1998, BIOCHEM BIOPH RES CO, V247, P851, DOI 10.1006/bbrc.1998.8888; Park CS, 2004, J BIOL CHEM, V279, P19592, DOI 10.1074/jbc.M314208200; PEART MJ, 2000, GENE DEV, V14, P1837; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; Piekarz R, 2004, CURR PHARM DESIGN, V10, P2289, DOI 10.2174/1381612043383980; Place RF, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-37; POSPELOV VA, 1994, CELL GROWTH DIFFER, V5, P187; Pospelova TV, 1999, GENE EXPRESSION, V8, P19; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Sampson EM, 2001, EMBO J, V20, P4500, DOI 10.1093/emboj/20.16.4500; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Sparks AB, 1998, CANCER RES, V58, P1130; Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; VanLint C, 1996, GENE EXPRESSION, V5, P245; Vaziri C, 1998, CELL GROWTH DIFFER, V9, P465; Vincan E, 2000, ONCOL RES, V12, P193; WATERHOUSE NI, 2003, CANCER RES, V63, P4460; Weidle UH, 2000, ANTICANCER RES, V20, P1471; Wolffe AP, 2001, ONCOGENE, V20, P2988, DOI 10.1038/sj.onc.1204322; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yee AS, 2004, GENE, V336, P1, DOI 10.1016/j.gene.2004.04.004	55	50	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21040	21051		10.1074/jbc.M511059200	http://dx.doi.org/10.1074/jbc.M511059200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16717102	hybrid			2022-12-25	WOS:000239187300041
J	Hoashi, T; Muller, J; Vieira, WD; Rouzaud, F; Kikuchi, K; Tamaki, K; Hearing, VJ				Hoashi, Toshihiko; Muller, Jacqueline; Vieira, Wilfred D.; Rouzaud, Francois; Kikuchi, Kanako; Tamaki, Kunihiko; Hearing, Vincent J.			The repeat domain of the melanosomal matrix protein PMEL17/GP100 is required for the formation of organellar fibers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERMANSKY-PUDLAK-SYNDROME; HUMAN MELANOCYTES; SILVER LOCUS; IDENTIFICATION; TYROSINASE; CELLS; GLYCOPROTEIN; ANTIBODIES; SIGNALS; CANCER	Over 125 pigmentation-related genes have been identified to date. Of those, PMEL17/GP100 has been widely studied as a melanoma-specific antigen as well as a protein required for the formation of fibrils in melanosomes. PMEL17 is synthesized, glycosylated, processed, and delivered to melanosomes, allowing them to mature from amorphous round vesicles to elongated fibrillar structures. In contrast to other melanosomal proteins such as TYR and TYRP1, the processing and sorting of PMEL17 is highly complex. Monoclonal antibody HMB45 is commonly used for melanoma detection, but has the added advantage that it specifically reacts with sialylated PMEL17 in the fibrillar matrix in melanosomes. In this study, we generated mutant forms of PMEL17 to clarify the subdomain of PMEL17 required for formation of the fibrillar matrix, a process critical to pigmentation. The internal proline/serine/threonine-rich repeat domain (called the RPT domain) of PMEL17 undergoes variable proteolytic cleavage. Deletion of the RPT domain abolished its recognition by HMB45 and its capacity to form fibrils. Truncation of the C-terminal domain did not significantly affect the processing or trafficking of PMEL17, but, in contrast, deletion of the N-terminal domain abrogated both. We conclude that the RPT domain is essential for its function in generating the fibrillar matrix of melanosomes and that the luminal domain is necessary for its correct processing and trafficking to those organelles.	Tokai Univ, Fac Med, Dept Dermatol, Tokyo 1138655, Japan; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; US FDA, Div Viral Prod, Rockville, MD 20852 USA	Tokai University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA)	Hoashi, T (corresponding author), Tokai Univ, Fac Med, Dept Dermatol, Tokyo 1138655, Japan.	thoashi-tky@umin.ac.jp; hearingv@nih.gov			DIVISION OF BASIC SCIENCES - NCI [Z01BC009100] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ADEMA GJ, 1994, J BIOL CHEM, V269, P20126; Adema GJ, 1996, BRIT J CANCER, V73, P1044, DOI 10.1038/bjc.1996.202; Angles-Cano E, 2002, BIOL CHEM, V383, P93, DOI 10.1515/BC.2002.009; Balch CM, 2004, CA-CANCER J CLIN, V54, P131, DOI 10.3322/canjclin.54.3.131; Basrur V, 2003, J PROTEOME RES, V2, P69, DOI 10.1021/pr025562r; Berson JF, 2003, J CELL BIOL, V161, P521, DOI 10.1083/jcb.200302072; Berson JF, 2001, MOL BIOL CELL, V12, P3451, DOI 10.1091/mbc.12.11.3451; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; Bycroft M, 1999, EMBO J, V18, P297, DOI 10.1093/emboj/18.2.297; Calvo PA, 1999, J BIOL CHEM, V274, P12780, DOI 10.1074/jbc.274.18.12780; Chiamenti AM, 1996, MELANOMA RES, V6, P291, DOI 10.1097/00008390-199608000-00003; de Vries TJ, 2001, J PATHOL, V193, P13; Fowler DM, 2006, PLOS BIOL, V4, P100, DOI 10.1371/journal.pbio.0040006; Fredriksson L, 2005, J BIOL CHEM, V280, P26856, DOI 10.1074/jbc.M503388200; GOWN AM, 1986, AM J PATHOL, V123, P195; Hoashi T, 2005, J BIOL CHEM, V280, P14006, DOI 10.1074/jbc.M413692200; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; KAPUR RP, 1992, J HISTOCHEM CYTOCHEM, V40, P207, DOI 10.1177/40.2.1552165; Kawakami Y, 1998, J IMMUNOTHER, V21, P237, DOI 10.1097/00002371-199807000-00001; Kushimoto T, 2001, P NATL ACAD SCI USA, V98, P10698, DOI 10.1073/pnas.191184798; KWON BS, 1991, P NATL ACAD SCI USA, V88, P9228, DOI 10.1073/pnas.88.20.9228; Le Borgne R, 2001, J CELL SCI, V114, P2831; Lepage S, 2006, CANCER RES, V66, P2423, DOI 10.1158/0008-5472.CAN-05-2516; LOCKER JK, 1992, J BIOL CHEM, V267, P14094; MARESH GA, 1994, ARCH BIOCHEM BIOPHYS, V311, P95, DOI 10.1006/abbi.1994.1213; Nguyen T, 2004, J INVEST DERMATOL, V122, P452, DOI 10.1046/j.0022-202X.2004.22117.x; Nguyen T, 2002, J INVEST DERMATOL, V119, P1156, DOI 10.1046/j.1523-1747.2002.19535.x; Nichols SE, 2003, J INVEST DERMATOL, V121, P821, DOI 10.1046/j.1523-1747.2003.12474.x; ORLOW SJ, 1995, J INVEST DERMATOL, V105, P3, DOI 10.1111/1523-1747.ep12312291; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; Raposo G, 2001, J CELL BIOL, V152, P809, DOI 10.1083/jcb.152.4.809; Rich JN, 2003, J BIOL CHEM, V278, P15951, DOI 10.1074/jbc.M211498200; SCANU AM, 1995, BBA-LIPID LIPID MET, V1256, P1, DOI 10.1016/0005-2760(95)00012-2; SEIJI M, 1963, NATURE, V197, P1082, DOI 10.1038/1971082a0; Shikano S, 2001, J BIOL CHEM, V276, P8125, DOI 10.1074/jbc.M008539200; Solano F, 2000, PIGM CELL RES, V13, P118, DOI 10.1111/j.0893-5785.2000.130821.x; Spanknebel K, 2005, AM J SURG PATHOL, V29, P305, DOI 10.1097/01.pas.0000152134.36030.b7; Theos AC, 2006, DEV CELL, V10, P343, DOI 10.1016/j.devcel.2006.01.012; Theos AC, 2005, PIGM CELL RES, V18, P322, DOI 10.1111/j.1600-0749.2005.00269.x; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; THOMSON W, 1989, J AM ACAD DERMATOL, V21, P1280, DOI 10.1016/S0190-9622(89)70344-3; Valencia JC, 2006, J CELL SCI, V119, P1080, DOI 10.1242/jcs.02804; VENNEGOOR C, 1988, AM J PATHOL, V130, P179; Vigneron N, 2004, SCIENCE, V304, P587, DOI 10.1126/science.1095522; VIJAYASARADHI S, 1995, J CELL BIOL, V130, P807, DOI 10.1083/jcb.130.4.807; VOGEL AM, 1988, CANCER RES, V48, P1286; Watabe H, 2004, J BIOL CHEM, V279, P7971, DOI 10.1074/jbc.M309714200; WETERMAN MAJ, 1995, INT J CANCER, V60, P73, DOI 10.1002/ijc.2910600111; Whitehouse C, 1997, J CELL BIOL, V137, P1229, DOI 10.1083/jcb.137.6.1229; Yasumoto K, 2004, J BIOL CHEM, V279, P28330, DOI 10.1074/jbc.M401269200	52	85	91	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21198	21208		10.1074/jbc.M601643200	http://dx.doi.org/10.1074/jbc.M601643200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16682408	hybrid			2022-12-25	WOS:000239187300055
J	Kim, BJ; Ryu, SW; Song, BJ				Kim, Bong-Jo; Ryu, Seung-Wook; Song, Byoung-Joon			JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; BCL-2 PROTEIN FAMILY; SELECTIVE ACTIVATION; NEURONAL APOPTOSIS; CANCER CELLS; KINASE-C; DEATH; PATHWAY; ALPHA; LOCALIZATION	Mitochondrial translocation of pro-apoptotic Bax prior to apoptosis is well established after treatment with many cell death stimulants or under apoptosis-inducing conditions. The mechanism of mitochondrial translocation of Bax is, however, still unknown. The aim of this work was to investigate the mechanism of Bax activation and mitochondrial translocation to initiate apoptosis of human hepatoma HepG2 and porcine kidney LLC-PK1 cells exposed to various cell death agonists. Phosphorylation of Bax by JNK and p38 kinase activated after treatment with staurosporine, H2O2, etoposide, and UV light was demonstrated by the shift in the pI value of Bax on two-dimensional gels and confirmed by metabolic labeling with inorganic [P-32] phosphate in HepG2 cells. Specific inhibitors of JNK and p38 kinase significantly inhibited Bax phosphorylation and mitochondrial translocation and apoptosis of HepG2 cells. A specific small interfering RNA to MAPKK4 (the upstream protein kinase of JNK and p38 kinase) markedly decreased the levels of MAPKK4 and MAPKK3/6, blocked the activation of JNK or p38 kinase, and inhibited Bax phosphorylation. However, the negative control small interfering RNA did not cause these changes. Confocal microscopy of various Bax mutants showed differential rates of mitochondrial translocation of Bax before and after staurosporine treatment. Among the Bax mutants, T167D did not translocate to mitochondria after staurosporine exposure, suggesting that Thr(167) is a potential phosphorylation site. In conclusion, our results demonstrate, for the first time, that Bax is phosphorylated by stress-activated JNK and/or p38 kinase and that phosphorylation of Bax leads to mitochondrial translocation prior to apoptosis.	NIAAA, Lab Membrane Biochem & Biophys, NIH, Bethesda, MD 20892 USA; NINDS, Surg Neurol Branch, Biochem Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Song, BJ (corresponding author), NIAAA, Lab Membrane Biochem & Biophys, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	bjs@mail.nih.gov			Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Ahmad KA, 2004, CANCER RES, V64, P7867, DOI 10.1158/0008-5472.CAN-04-0648; Bae MA, 2001, MOL PHARMACOL, V60, P847; Bae MA, 2003, MOL PHARMACOL, V63, P401, DOI 10.1124/mol.63.2.401; Boldt S, 2002, CARCINOGENESIS, V23, P1831, DOI 10.1093/carcin/23.11.1831; Chua BT, 2003, NAT CELL BIOL, V5, P1083, DOI 10.1038/ncb1070; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Figueroa-Masot XA, 2001, J NEUROSCI, V21, P4657, DOI 10.1523/JNEUROSCI.21-13-04657.2001; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Jaeschke H, 2003, GASTROENTEROLOGY, V125, P1246, DOI 10.1016/S0016-5085(03)01209-5; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kavallaris M, 1999, BRIT J CANCER, V80, P1020, DOI 10.1038/sj.bjc.6690507; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; Kirchhoff SR, 2002, CIRCULATION, V105, P2899, DOI 10.1161/01.CIR.0000019403.35847.23; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Li D, 2002, J BIOL CHEM, V277, P31416, DOI 10.1074/jbc.M204818200; Linseman DA, 2004, J NEUROSCI, V24, P9993, DOI 10.1523/JNEUROSCI.2057-04.2004; Longuet M, 2004, INT J ONCOL, V25, P309; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; McJilton MA, 2003, ONCOGENE, V22, P7958, DOI 10.1038/sj.onc.1206795; Molton SA, 2003, ONCOGENE, V22, P4690, DOI 10.1038/sj.onc.1206692; Morris EJ, 2001, J NEUROSCI, V21, P5017, DOI 10.1523/JNEUROSCI.21-14-05017.2001; Nadkarni V, 1999, J BIOL CHEM, V274, P20185, DOI 10.1074/jbc.274.29.20185; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087; Pastorino JG, 2003, AM J PHYSIOL-GASTR L, V285, pG503, DOI 10.1152/ajpgi.00442.2002; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Schinzel A, 2004, J CELL BIOL, V164, P1021, DOI 10.1083/jcb.200309013; Schroeter H, 2003, BIOCHEM J, V372, P359, DOI 10.1042/BJ20030201; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Soh YJ, 2000, MOL PHARMACOL, V58, P535, DOI 10.1124/mol.58.3.535; Suh SK, 2004, PROTEOMICS, V4, P3401, DOI 10.1002/pmic.200400971; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Tsuruta F, 2002, J BIOL CHEM, V277, P14040, DOI 10.1074/jbc.M108975200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao DH, 2003, CANCER RES, V63, P6825; Xin MG, 2005, J BIOL CHEM, V280, P10781, DOI 10.1074/jbc.M500084200; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Yu WP, 2003, CANCER RES, V63, P2483; Zimmerman TL, 2006, J BIOL CHEM, V281, P15434, DOI 10.1074/jbc.M508277200; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	59	364	379	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21256	21265		10.1074/jbc.M510644200	http://dx.doi.org/10.1074/jbc.M510644200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16709574	hybrid			2022-12-25	WOS:000239187300061
J	Liu, HG; Tang, JR; Choi, YH; Napolitano, M; Hockman, S; Taira, M; Degerman, E; Manganiello, VC				Liu, Hanguan; Tang, Jing Rong; Choi, Young Hun; Napolitano, Maria; Hockman, Steven; Taira, Masato; Degerman, Eva; Manganiello, Vincent C.			Importance of cAMP-response element-binding protein in regulation of expression of the murine cyclic nucleotide phosphodiesterase 3B (Pde3b) gene in differentiating 3T3-L1 preadipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOCYTE DIFFERENTIATION; TRANSCRIPTIONAL ACTIVATION; CARDIOMYOCYTE APOPTOSIS; INSULIN-SECRETION; ADIPOSE-TISSUE; FACTOR CREB; PROMOTER; CELL; AMP; ADIPOGENESIS	Incubation of 3T3-L1 preadipocytes with isobutylmethylxanthine (IBMX), dexamethasone, and insulin, alone or in combination, demonstrated that IBMX, which increased cAMP-response element-binding protein (CREB) phosphorylation, was the predominant regulator of Pde3b expression. Real time PCR and immunoblotting indicated that in 3T3-L1 preadipocytes, IBMX-stimulated induction of Pde3b mRNA and protein was markedly inhibited by dominant-negative CREB proteins. By transfecting preadipocytes, differentiating preadipocytes, and HEK293A cells with luciferase reporter vectors containing different fragments of the 5'- flanking region of the Pde3b gene, we identified a distal promoter that contained canonical cis-acting cAMP-response elements (CRE) and a proximal, GC-rich promoter region, which contained atypical CRE. Mutation of the CRE sequences dramatically reduced distal promoter activity; H89 inhibited IBMX-stimulated CREB phosphorylation and proximal and distal promoter activities. Distal promoter activity was stimulated by IBMX and phorbol ester (PMA) in Raw264.7 monocytes, but only by IBMX in 3T3-L1 preadipocytes. Chromatin immunoprecipitation analyses with specific antibodies against CREB, phospho-CREB, and CBP/p300 (CREB-binding protein) showed that these proteins associated with both distal and proximal promoters and that interaction of phospho-CREB, the active form of CREB, with both Pde3b promoter regions was increased in IBMX-treated preadipocytes. These results indicate that CRE in distal and proximal promoter regions and activation of CREB proteins play a crucial role in transcriptional regulation of Pde3b expression during preadipocyte differentiation.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA; Lund Univ, Dept Cell & Mol Biol, Sect Mol Signaling, S-22100 Lund, Sweden	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Lund University	Manganiello, VC (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Bldg 10,Rm 5N307,10 Ctr Dr, Bethesda, MD 20892 USA.	manganiv@nhlbi.nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002540, ZIAHL002540] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bradley D, 2000, DRUG DISCOV TODAY, V5, P131, DOI 10.1016/S1359-6446(00)01473-2; Cha-Molstad H, 2004, P NATL ACAD SCI USA, V101, P13572, DOI 10.1073/pnas.0405587101; Chung TW, 2005, GLYCOBIOLOGY, V15, P233, DOI 10.1093/glycob/cwh156; Cowan MJ, 2004, BBA-GENE STRUCT EXPR, V1680, P145, DOI 10.1016/j.bbaexp.2004.09.006; DEGERMAN E, 2004, DIABETES MELLITUS FU, P373; Ding B, 2005, P NATL ACAD SCI USA, V102, P14771, DOI 10.1073/pnas.0506489102; Ding B, 2005, CIRCULATION, V111, P2469, DOI 10.1161/01.CIR.0000165128.39715.87; DiPolo A, 1997, NUCLEIC ACIDS RES, V25, P3863, DOI 10.1093/nar/25.19.3863; ELKS ML, 1985, J CELL PHYSIOL, V124, P191, DOI 10.1002/jcp.1041240204; ERIKSSON H, 1995, BBA-MOL CELL RES, V1266, P101, DOI 10.1016/0167-4889(94)00237-9; Farmer SR, 2005, INT J OBESITY, V29, pS13, DOI 10.1038/sj.ijo.0802907; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Harndahl L, 2002, J BIOL CHEM, V277, P37446, DOI 10.1074/jbc.M205401200; IMPEY S, 2001, SCI STKE, pE1; Kalkhoven E, 2004, BIOCHEM PHARMACOL, V68, P1145, DOI 10.1016/j.bcp.2004.03.045; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Klemm DJ, 2001, J BIOL CHEM, V276, P28430, DOI 10.1074/jbc.M103382200; Klemm DJ, 1998, J BIOL CHEM, V273, P917, DOI 10.1074/jbc.273.2.917; Kwon EM, 2000, BLOOD, V95, P2552, DOI 10.1182/blood.V95.8.2552.008k30_2552_2558; Le Jeune IR, 2002, J BIOL CHEM, V277, P35980, DOI 10.1074/jbc.M204832200; Leahy P, 1999, J BIOL CHEM, V274, P8813, DOI 10.1074/jbc.274.13.8813; Lerner LE, 2005, J BIOL CHEM, V280, P20642, DOI 10.1074/jbc.M500957200; LIJAM N, 1995, GENOME RES, V5, P116, DOI 10.1101/gr.5.2.116; Liu H, 1998, BRIT J PHARMACOL, V125, P1501, DOI 10.1038/sj.bjp.0702227; Liu Hanguan, 2005, V307, P109; Lomvardas S, 2002, CELL, V110, P261, DOI 10.1016/S0092-8674(02)00822-X; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; MANGANIELLO VC, 1983, J CYCLIC NUCL PROT, V9, P143; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; McKnight GS, 1998, RECENT PROG HORM RES, V53, P139; Nagaoka T, 1998, DIABETES, V47, P1135, DOI 10.2337/diabetes.47.7.1135; Nagaoka Tadasu, 1998, Cell Biochemistry and Biophysics, V29, P49, DOI 10.1007/BF02737828; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; Niiya T, 2001, FEBS LETT, V505, P136, DOI 10.1016/S0014-5793(01)02807-1; OMATSUKANBE M, 1995, FEBS LETT, V374, P187, DOI 10.1016/0014-5793(95)01112-R; Otto TC, 2005, CRIT REV BIOCHEM MOL, V40, P229, DOI 10.1080/10409230591008189; Palacios VG, 2001, PROSTAG LEUKOTR ESS, V65, P215, DOI 10.1054/plef.2001.0314; Parker JC, 1997, BIOCHEM BIOPH RES CO, V236, P665, DOI 10.1006/bbrc.1997.7034; Pyne NJ, 2003, DIABETOLOGIA, V46, P1179, DOI 10.1007/s00125-003-1176-7; RAHN LT, 2000, BIOCHEM J, V346, P337; REINHARDT RR, 1995, J CLIN INVEST, V95, P1528, DOI 10.1172/JCI117825; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; Robidoux J, 2004, ANNU REV PHARMACOL, V44, P297, DOI 10.1146/annurev.pharmtox.44.101802.121659; Roesler WJ, 2000, MOL CELL ENDOCRINOL, V162, P1, DOI 10.1016/S0303-7207(00)00198-2; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; RUTTIMANN Y, 1994, CRIT CARE MED, V22, P1235, DOI 10.1097/00003246-199408000-00006; Sasaki T, 2004, J NEUROCHEM, V89, P474, DOI 10.1111/j.1471-4159.2004.02354.x; SCHMITZPEIFFER C, 1992, CELL SIGNAL, V4, P37, DOI 10.1016/0898-6568(92)90006-T; Shakur Y, 2001, PROG NUCLEIC ACID RE, V66, P241; SNYDER PB, 1999, EMERGING THERAPEUTIC, V3, P587; TAIRA M, 1993, J BIOL CHEM, V268, P18573; Tang QQ, 1999, MOL CELL BIOL, V19, P4855; Tilley DG, 2005, MOL PHARMACOL, V68, P596, DOI 10.1124/mol.105.014126; Valet P, 2002, J LIPID RES, V43, P835; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; WERNER T, 2002, BIOINFORMATICS GENOM, V1, P113; Zambon AC, 2005, P NATL ACAD SCI USA, V102, P8561, DOI 10.1073/pnas.0503363102; Zhang JW, 2004, J BIOL CHEM, V279, P4471, DOI 10.1074/jbc.M311327200; Zhao AZ, 2000, J BIOL CHEM, V275, P11348, DOI 10.1074/jbc.275.15.11348; Zhao AZ, 1998, J CLIN INVEST, V102, P869, DOI 10.1172/JCI3920; Zhao AZ, 1997, P NATL ACAD SCI USA, V94, P3223, DOI 10.1073/pnas.94.7.3223; Zilberfarb V, 2001, DIABETOLOGIA, V44, P377, DOI 10.1007/s001250051630	63	9	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21096	21113		10.1074/jbc.M601307200	http://dx.doi.org/10.1074/jbc.M601307200			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16702214	hybrid			2022-12-25	WOS:000239187300046
J	Qin, JZ; Yao, JH; Cui, G; Xiao, H; Kim, TW; Fraczek, J; Wightman, P; Sato, S; Akira, S; Puel, A; Casanova, JL; Su, B; Li, XX				Qin, Jinzhong; Yao, Jianhong; Cui, Grace; Xiao, Hui; Kim, Tae Whan; Fraczek, Jerzy; Wightman, Paul; Sato, Shintaro; Akira, Shizuo; Puel, Anne; Casanova, Jean-Laurent; Su, Bing; Li, Xiaoxia			TLR8-mediated NF-kappa B and JNK activation are TAK1-independent and MEKK3-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-ASSOCIATED KINASE; TOLL-LIKE RECEPTOR; INTERLEUKIN-1 RECEPTOR; MAP KINASE; IKK-BETA; TAK1; ALPHA; COMPLEX; IRAK; TAB2	TLR8-mediated NF-kappa B and IRF7 activation are abolished in human IRAK-deficient 293 cells and IRAK4-deficient fibroblast cells. Both wild-type and kinase-inactive mutants of IRAK and IRAK4, respectively, restored TLR8-mediated NF-kappa B and IRF7 activation in the IRAK- and IRAK4-deficient cells, indicating that the kinase activity of IRAK and IRAK4 is probably redundant for TLR8-mediated signaling. We recently found that TLR8 mediates a unique NF-kappa B activation pathway in human 293 cells and mouse embryonic fibroblasts, accompanied only by I kappa B alpha phosphorylation and not I kappa B alpha degradation, whereas interleukin (IL)-1 stimulation causes both I kappa B alpha phosphorylation and degradation. The intermediate signaling events mediated by IL-1 ( including IRAK modifications and degradation and TAK1 activation) were not detected in cells stimulated by TLR8 ligands. TLR8 ligands trigger similar levels of I kappa B alpha phosphorylation and NF-kappa B and JNK activation in TAK1(-/-) mouse embryo fibroblasts (MEFs) as compared with wild-type MEFs, whereas lack of TAK1 results in reduced IL-1-mediated NF-kappa B activation and abolished IL-1-induced JNK activation. The above results indicate that although TLR8-mediated NF-kappa B and JNK activation are IRAK- dependent, they do not require IRAK modification and are TAK1-independent. On the other hand, TLR8-mediated I kappa B alpha phosphorylation, NF-kappa B, and JNK activation are completely abolished in MEKK3(-/-) MEFs, whereas IL-1-mediated signaling was only moderately reduced in these deficient MEFs as compared with wild-type cells. The differences between IL-1R- and TLR8-mediated NF-kappa B activation are also reflected at the level of I kappa B kinase (IKK) complex. TLR8 ligands induced IKK gamma phosphorylation, whereas IKK alpha/beta phosphorylation and IKK gamma ubiquitination that can be induced by IL-1 were not detected in cells treated with TLR8 ligands. We postulate that TLR8-mediated MEKK3-dependent IKK gamma phosphorylation might play an important role in the activation of IKK complex, leading to I kappa B alpha phosphorylation.	3M Co, St Paul, MN 55144 USA; Cleveland Clin Fdn, Dept Immunol, Cleveland, OH 44195 USA; Osaka Univ, Japan Sci & Technol Agcy, Suita, Osaka 5650871, Japan; Univ Paris 05, Lab Human Genet Infect Dis, INSERM, U550,Necker Med Sch, F-75015 Paris, France; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77054 USA	3M; Cleveland Clinic Foundation; Japan Science & Technology Agency (JST); Osaka University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Texas System; UTMD Anderson Cancer Center	Li, XX (corresponding author), Cleveland Clin Fdn, Dept Immunol, Cleveland, OH 44195 USA.		Akira, Shizuo/C-3134-2009; Puel, Anne/H-7305-2017; Casanova, Jean-Laurent/I-3418-2017	Puel, Anne/0000-0003-2603-0323; Casanova, Jean-Laurent/0000-0002-7782-4169; Sato, Shintaro/0000-0001-5156-3354				Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chuang TH, 2000, EUR CYTOKINE NETW, V11, P372; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Honda K, 2004, P NATL ACAD SCI USA, V101, P15416, DOI 10.1073/pnas.0406933101; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Li QT, 2000, GENE DEV, V14, P1729; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li XX, 1999, MOL CELL BIOL, V19, P4643; Li XX, 2001, P NATL ACAD SCI USA, V98, P4461, DOI 10.1073/pnas.071054198; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Peng GY, 2005, SCIENCE, V309, P1380, DOI 10.1126/science.1113401; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Qian YC, 2001, J BIOL CHEM, V276, P41661, DOI 10.1074/jbc.M102262200; Qin JZ, 2004, J BIOL CHEM, V279, P26748, DOI 10.1074/jbc.M400785200; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xiao CC, 2003, GENE DEV, V17, P2933, DOI 10.1101/gad.1145603; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	44	77	83	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21013	21021		10.1074/jbc.M512908200	http://dx.doi.org/10.1074/jbc.M512908200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16737960	hybrid			2022-12-25	WOS:000239187300038
J	Rajgopal, R; Butcher, M; Weitz, JI; Shaughnessy, SG				Rajgopal, Raghav; Butcher, Martin; Weitz, Jeffrey I.; Shaughnessy, Stephen G.			Heparin synergistically enhances interleukin-11 signaling through up-regulation of the MAPK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT HEPARIN; FIBROBLAST-GROWTH-FACTOR; BONE-MINERAL DENSITY; OSTEOCLAST DIFFERENTIATION; SERINE PHOSPHORYLATION; TYROSINE PHOSPHORYLATION; UNFRACTIONATED HEPARIN; VENOUS THROMBOEMBOLISM; INHIBITORY FACTOR; STAT3 ACTIVATION	Using an animal model of heparin-induced osteoporosis we previously demonstrated that heparin causes bone loss, in part, by increasing osteoclast number and activity. Furthermore, we found that, although heparin alone has no effect, it is able to synergistically enhance Interleukin-11 ( IL-11)-induced signal transducer and activator of transcription 3 ( STAT3) activation and thus increase osteoclast formation in vitro. In the present study, we examine the effect of various serine kinase inhibitors on the ability of heparin to act synergistically with IL-11. Inhibition of the c-Jun N-terminal kinase ( JNK), p38 mitogen-activated protein kinase ( MAPK), or the phosphatidylinositol 3- kinase pathways had no effect on the ability of heparin to promote either IL-11-induced STAT3 (.) DNA complex formation or osteoclast formation in vitro. In contrast, PD098059, a MAPK kinase inhibitor, completely abolished the synergy between heparin and IL-11. In an attempt to resolve the mechanism by which this was occurring, we examined the effect of heparin on STAT3 Ser-727 phosphorylation and extracellular signal-regulated kinases 1 and 2 ( Erk1/2) activation, either in the presence or absence of IL-11. Heparin alone was found to have no effect on Ser-727 phosphorylation, nor did heparin alter the phosphorylation status of Ser-727 in the presence of IL-11. Heparin was, however, found to increase Erk1/2 activation in both a time- and dose-dependent manner. When taken together, these findings suggest that heparin enhances IL-11-induced STAT3 activation and thus osteoclast formation, by a mechanism that is independent of STAT3 Ser-727 phosphorylation but that involves up-regulation of the MAPK pathway.	Henderson Res Ctr, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Dept Pathol, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Dept Mol Med, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Dept Med, Hamilton, ON L8V 1C3, Canada	McMaster University; McMaster University; McMaster University	Shaughnessy, SG (corresponding author), Henderson Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.	sshaughnessy@thrombosis.hhscr.org	Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550				BARBOUR LA, 1994, AM J OBSTET GYNECOL, V170, P862, DOI 10.1016/S0002-9378(94)70299-3; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DAHLMAN TC, 1993, AM J OBSTET GYNECOL, V168, P1265, DOI 10.1016/0002-9378(93)90378-V; DAHLMAN TC, 1994, AM J OBSTET GYNECOL, V170, P1315; El-Sheikh A, 2002, CANCER RES, V62, P7118; ELIAS JA, 1995, ENDOCRINOLOGY, V136, P489, DOI 10.1210/en.136.2.489; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HURLEY MM, 1992, ENDOCRINOLOGY, V130, P2675, DOI 10.1210/en.130.5.2675; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MONREAL M, 1994, THROMB HAEMOSTASIS, V71, P7; MONREAL M, 1991, LANCET, V338, P706, DOI 10.1016/0140-6736(91)91292-3; Muir JM, 1997, BLOOD, V89, P3236, DOI 10.1182/blood.V89.9.3236; Muir JM, 1996, BLOOD, V88, P1314, DOI 10.1182/blood.V88.4.1314.bloodjournal8841314; MURPHY MS, 1992, LANCET, V340, P1098; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Nojiri S, 2004, BIOCHEM BIOPH RES CO, V314, P97, DOI 10.1016/j.bbrc.2003.12.054; O'Brien CA, 1999, J BIOL CHEM, V274, P19301, DOI 10.1074/jbc.274.27.19301; O'Brien CA, 2000, J CELL BIOCHEM, V79, P532, DOI 10.1002/1097-4644(20001215)79:4<532::AID-JCB20>3.0.CO;2-U; OBrien CA, 1997, J BIOL CHEM, V272, P15003, DOI 10.1074/jbc.272.23.15003; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; Pettila V, 2002, THROMB HAEMOSTASIS, V87, P182; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; Raman R, 2003, P NATL ACAD SCI USA, V100, P2357, DOI 10.1073/pnas.0437842100; Richards CD, 2000, CYTOKINE, V12, P613, DOI 10.1006/cyto.1999.0635; Rodel B, 2000, EMBO J, V19, P5845, DOI 10.1093/emboj/19.21.5845; Romas E, 1996, J EXP MED, V183, P2581, DOI 10.1084/jem.183.6.2581; Rupp W M, 1982, Curr Surg, V39, P419; Schuringa JJ, 2000, BIOCHEM J, V347, P89, DOI 10.1042/0264-6021:3470089; Shaughnessy SG, 1999, BLOOD, V93, P1231, DOI 10.1182/blood.V93.4.1231.404k03_1231_1236; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; Tenney R, 2005, J CELL PHYSIOL, V202, P160, DOI 10.1002/jcp.20100; Walton KJ, 2002, BLOOD, V100, P2530, DOI 10.1182/blood.V100.7.2530; Wawrzynska L, 2003, PATHOPHYSIOL HAEMO T, V33, P64, DOI 10.1159/000073848; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wong BR, 1999, J LEUKOCYTE BIOL, V65, P715, DOI 10.1002/jlb.65.6.715; Yamamoto T, 2003, BIOCHEM BIOPH RES CO, V306, P610, DOI 10.1016/S0006-291X(03)01026-X; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	48	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20780	20787		10.1074/jbc.M600169200	http://dx.doi.org/10.1074/jbc.M600169200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16720575	hybrid			2022-12-25	WOS:000239187300014
J	Schweppe, RE; Cheung, TH; Ahn, NG				Schweppe, Rebecca E.; Cheung, Tom Hiu; Ahn, Natalie G.			Global gene expression analysis of ERK5 and ERK1/2 signaling reveals a role for HIF-1 in ERK5-mediated responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; ENDOTHELIAL GROWTH-FACTOR; TRANSCRIPTION FACTOR AP-1; FACTOR-I; EPITHELIAL-CELLS; MESSENGER-RNA; UP-REGULATION; PFKFB3 GENE	ERK5 is a recently characterized MAPK, which is most similar to the well studied ERK1/2 subfamily but uses distinct mechanisms to elicit responses. To understand the specificity of signaling through ERK5 versus ERK1/2, we examined global gene expression changes in response to each pathway. Microarray measurements in retinal pigment epithelial cells revealed 36 genes regulated by ERK5, all which were novel targets for this pathway. 39 genes were regulated by ERK1/2, which included 11 known genes. Of these genes, 19 were regulated by both pathways. Inspection of the 17 genes uniquely regulated by ERK5 revealed that 14 genes (82%) were previously associated with hypoxia via regulation by HIF-1. In contrast, 16 genes (84%) regulated by either ERK5 or ERK1/2 were implicated in hypoxia, most through mechanisms independent of HIF-1. Of the 20 genes regulated by ERK1/2, only 9 were implicated in hypoxia and were not well characterized hypoxia targets. Thus, unlike ERK5, a mechanistic link between ERK1/2 and HIF-1/HRE could not be established on the basis of gene regulation. Activation of both pathways enhanced transcription from a hypoxia-response element and increased HIF-1 alpha protein expression. In contrast, ERK5 but not ERK1/2 elevated transcription through GAL4-HIF-1. Most interestingly, ERK5 is not significantly activated by hypoxia in retinal pigment epithelial cells, indicating that ERK5 regulation of these genes is relevant in normoxia rather than hypoxia. Thus, ERK5 and ERK1/2 differ in their mechanisms of gene regulation, and indicate that ERK5 may control hypoxia-responsive genes by a mechanism independent of HIF-1 alpha expression control.	Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Boulder, CO 80309 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Ahn, NG (corresponding author), Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Boulder, CO 80309 USA.	Natalie.Ahn@Colorado.edu		Schweppe, Rebecca/0000-0001-7502-0151				Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; *AFF INC, 2004, GEN EXPR AN TECHN MA; Aklilu F, 2000, CANCER RES, V60, P1753; Barros JC, 2005, J CELL SCI, V118, P1663, DOI 10.1242/jcs.02308; Berra E, 2000, CANCER METAST REV, V19, P139, DOI 10.1023/A:1026506011458; Bi WZ, 1999, DEV BIOL, V211, P255, DOI 10.1006/dbio.1999.9307; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Bobrovnikova-Marjon EV, 2004, CANCER RES, V64, P4858, DOI 10.1158/0008-5472.CAN-04-0682; Bogoyevitch MA, 2004, CELL SIGNAL, V16, P1345, DOI 10.1016/j.cellsig.2004.05.004; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Brahimi-Horn C, 2005, CELL SIGNAL, V17, P1, DOI 10.1016/j.cellsig.2004.04.010; Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055; Cangul H, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-27; CHAO TH, 1999, J BIOL CHEM, V274, P36305; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Combe C, 1997, KIDNEY INT, V51, P1703, DOI 10.1038/ki.1997.235; Cunha-Vaz JG, 2004, EXP EYE RES, V78, P715, DOI 10.1016/S0014-4835(03)00213-6; Defoe DM, 2004, EXP EYE RES, V79, P51, DOI 10.1016/j.exer.2004.02.017; Dinev D, 2001, EMBO REP, V2, P829, DOI 10.1093/embo-reports/kve177; Dwivedi PP, 2002, J BIOL CHEM, V277, P29643, DOI 10.1074/jbc.M204561200; English JM, 1999, J BIOL CHEM, V274, P31588, DOI 10.1074/jbc.274.44.31588; Guillonneau X, 1998, J BIOL CHEM, V273, P22367, DOI 10.1074/jbc.273.35.22367; Hatano N, 2003, GENES CELLS, V8, P847, DOI 10.1046/j.1365-2443.2003.00680.x; Hayashi M, 2004, J CLIN INVEST, V113, P1138, DOI 10.1172/JCI200419890; Hecquet C, 2002, INVEST OPHTH VIS SCI, V43, P3091; Hecquet C, 2002, ONCOGENE, V21, P6101, DOI 10.1038/sj.onc.1205765; Hii CS, 2004, J BIOL CHEM, V279, P49825, DOI 10.1074/jbc.M406892200; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Ji YS, 1998, CIRC RES, V83, P295, DOI 10.1161/01.RES.83.3.295; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Karhausen J, 2004, J CLIN INVEST, V114, P1098, DOI 10.1172/JCI200421086; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kawaguchi M, 2003, J PHARMACOL EXP THER, V307, P1213, DOI 10.1124/jpet.103.056341; Kopacek J, 2005, BBA-GENE STRUCT EXPR, V1729, P41, DOI 10.1016/j.bbaexp.2005.03.003; Lal A, 2001, JNCI-J NATL CANCER I, V93, P1337, DOI 10.1093/jnci/93.17.1337; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lee E, 2002, MOL CELLS, V14, P9; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Lee MH, 2004, PHARM RES-DORDR, V21, P736, DOI 10.1023/B:PHAM.0000026421.09367.b3; Leonard MO, 2003, J BIOL CHEM, V278, P40296, DOI 10.1074/jbc.M302560200; Li J, 2002, AM J PHYSIOL-LUNG C, V283, pL690, DOI 10.1152/ajplung.00060.2002; Lukiw WJ, 2003, INVEST OPHTH VIS SCI, V44, P4163, DOI 10.1167/iovs.02-0655; Luo GJ, 2003, AM J PHYSIOL-REG I, V284, pR1249, DOI 10.1152/ajpregu.00490.2002; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Mansour SJ, 1996, CELL GROWTH DIFFER, V7, P243; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Matsui H, 1999, CARDIOVASC RES, V42, P104, DOI 10.1016/S0008-6363(98)00285-5; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Minchenko A, 2002, J BIOL CHEM, V277, P6183, DOI 10.1074/jbc.M110978200; Minchenko O, 2004, FEBS LETT, V576, P14, DOI 10.1016/j.febslet.2004.08.053; Miyazaki K, 2002, J BIOL CHEM, V277, P47014, DOI 10.1074/jbc.M204938200; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; Muller JN, 1997, J BIOL CHEM, V272, P23435, DOI 10.1074/jbc.272.37.23435; Muraoka K, 1997, TRANSPLANTATION, V63, P466, DOI 10.1097/00007890-199702150-00023; Ni CW, 2003, J CELL PHYSIOL, V195, P428, DOI 10.1002/jcp.10259; Nishihara H, 2004, J BIOL CHEM, V279, P26176, DOI 10.1074/jbc.M313346200; Obach M, 2004, J BIOL CHEM, V279, P53562, DOI 10.1074/jbc.M406096200; ORourke JF, 1996, EUR J BIOCHEM, V241, P403, DOI 10.1111/j.1432-1033.1996.00403.x; Pearson G, 2001, J BIOL CHEM, V276, P7927, DOI 10.1074/jbc.M009764200; Pi XC, 2005, CIRC RES, V96, P1145, DOI 10.1161/01.RES.0000168802.43528.e1; Pi XC, 2004, CIRC RES, V94, P362, DOI 10.1161/01.RES.0000112406.27800.6F; Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980; PRUSINER SB, 1982, BIOCHEMISTRY-US, V21, P6942, DOI 10.1021/bi00269a050; Regan CP, 2002, P NATL ACAD SCI USA, V99, P9248, DOI 10.1073/pnas.142293999; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Salnikow K, 2002, MOL CELL BIOL, V22, P1734, DOI 10.1128/MCB.22.6.1734-1741.2002; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; Scheurer SB, 2004, PROTEOMICS, V4, P1737, DOI 10.1002/pmic.200300689; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Shi QA, 1999, J INTERF CYTOK RES, V19, P1363, DOI 10.1089/107999099312821; Sodhi A, 2001, BIOCHEM BIOPH RES CO, V287, P292, DOI 10.1006/bbrc.2001.5532; Sohn SJ, 2002, J BIOL CHEM, V277, P43344, DOI 10.1074/jbc.M207573200; Sonna LA, 2003, PHYSIOL GENOMICS, V12, P195, DOI 10.1152/physiolgenomics.00104.2002; Su YQ, 2003, DEV BIOL, V263, P126, DOI 10.1016/S0012-1606(03)00437-8; Sun WY, 2003, MOL CELL BIOL, V23, P2298, DOI 10.1128/MCB.23.7.2298-2308.2003; Takaya K, 2003, AM J PHYSIOL-RENAL, V284, pF1037, DOI 10.1152/ajprenal.00230.2002; Treins C, 2001, J BIOL CHEM, V276, P43836, DOI 10.1074/jbc.M106534200; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang V, 2005, CANCER RES, V65, P3299, DOI 10.1158/0008-5472.CAN-04-4130; Wang Zhi-qiu, 2004, Chin Med Sci J, V19, P270; Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547; Wanner RM, 2000, BLOOD, V96, P1558, DOI 10.1182/blood.V96.4.1558.h8001558_1558_1565; Watson FL, 2001, NAT NEUROSCI, V4, P981, DOI 10.1038/nn720; Weigel AL, 2002, FREE RADICAL BIO MED, V33, P1419, DOI 10.1016/S0891-5849(02)01082-1; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wykoff CC, 2000, CANCER RES, V60, P7075; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; Yan SF, 1997, J BIOL CHEM, V272, P4287, DOI 10.1074/jbc.272.7.4287; Yan ZP, 2004, CELL IMMUNOL, V232, P116, DOI 10.1016/j.cellimm.2005.03.001; Yang CC, 1998, NUCLEIC ACIDS RES, V26, P4771, DOI 10.1093/nar/26.20.4771; Yang JH, 2000, NAT GENET, V24, P309, DOI 10.1038/73550; Zampetaki A, 2004, FASEB J, V18, P1090, DOI 10.1096/fj.03-0991fje; Zhao M, 1999, MOL CELL BIOL, V19, P21; Zheng QL, 2004, J BIOL CHEM, V279, P8787, DOI 10.1074/jbc.M310212200; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	103	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20993	21003		10.1074/jbc.M604208200	http://dx.doi.org/10.1074/jbc.M604208200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16735500	hybrid			2022-12-25	WOS:000239187300036
J	Winkler, A; Hartner, F; Kutchan, TM; Glieder, A; Macheroux, P				Winkler, Andreas; Hartner, Franz; Kutchan, Toni M.; Glieder, Anton; Macheroux, Peter			Biochemical evidence that berberine bridge enzyme belongs to a novel family of flavoproteins containing a bi-covalently attached FAD cofactor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROLOGOUS EXPRESSION; GLUCOOLIGOSACCHARIDE OXIDASE; TRIMETHYLAMINE DEHYDROGENASE; STRUCTURAL-CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; ALKALOID BIOSYNTHESIS; MOLECULAR-CLONING; PURIFICATION; PROTEINS; SYNTHASE	Berberine bridge enzyme (BBE) is involved in the transformation of (S)-reticuline to (S)-scoulerine in benzophenanthridine alkaloid biosynthesis of plants. In this report, we describe the high level expression of BBE encoded by the gene from Eschscholzia californica (California poppy) in the methylotrophic yeast Pichia pastoris employing the secretory pathway of the host organism. Using a two-step chromatographic purification protocol, 120 mg of BBE could be obtained from 1 liter of fermentation culture. The purified protein exhibits a turnover number for substrate conversion of 8.2 s(-1). The recombinant enzyme is glycosylated and carries a covalently attached FAD cofactor. In addition to the previously known covalent attachment of the 8 alpha-position of the flavin ring system to a histidine (His-104), we could also demonstrate that a covalent linkage between the 6-position and a thiol group of a cysteine residue (Cys-166) is present in BBE. The major evidence for the occurrence of a bi-covalently attached FAD cofactor is provided by N-terminal amino acid sequencing and mass spectrometric analysis of the isolated flavin-containing peptide. Furthermore, it could be shown that anaerobic photoirradiation leads to cleavage of the linkage between the 6-cysteinyl group yielding 6-mercaptoflavin and a peptide with the cysteine residue replaced by alanine due to breakage of the C - S bond. Overall, BBE is shown to exhibit typical flavoprotein oxidase properties as exemplified by the occurrence of an anionic flavin semiquinone species and formation of a flavin N(5)-sulfite adduct.	Graz Univ Technol, Inst Biochem, A-8010 Graz, Austria; Graz Univ Technol, Inst Mol Biotechnol, Res Ctr Appl Biocatalysis, A-8010 Graz, Austria; Leibniz Inst Pflanzenbiochem, Abt Naturstoff Biotechnol, D-06120 Halle, Germany	Graz University of Technology; Graz University of Technology; Leibniz Institut fur Pflanzenbiochemie	Macheroux, P (corresponding author), Graz Univ Technol, Inst Biochem, Petersgasse 12-2, A-8010 Graz, Austria.	peter.macheroux@tugraz.at	Kutchan, Toni/L-4625-2013; Macheroux, Peter/AAB-5157-2019	Macheroux, Peter/0000-0002-0242-454X; glieder, anton/0000-0002-5986-9689; Winkler, Andreas/0000-0001-6221-9671	Austrian Science Fund (FWF) [W 901] Funding Source: researchfish; Austrian Science Fund FWF [W 901] Funding Source: Medline	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Austrian Science Fund FWF(Austrian Science Fund (FWF))		AMANN M, 1988, EUR J BIOCHEM, V175, P17, DOI 10.1111/j.1432-1033.1988.tb14160.x; BARTON DHR, 1963, P CHEM SOC LONDON, P267; BATTERSBY AR, 1963, P CHEM SOC LONDON, V268; Bird DA, 2001, PLANTA, V213, P888, DOI 10.1007/s004250100582; Cheney R. H., 1964, Q J CRUD DRUGS, V3, P413; Chivian D, 2003, PROTEINS, V53, P524, DOI 10.1002/prot.10529; DeWitt AM, 2006, CLIN EXP ALLERGY, V36, P77, DOI 10.1111/j.1365-2222.2006.02399.x; DITTRICH H, 1991, P NATL ACAD SCI USA, V88, P9969, DOI 10.1073/pnas.88.22.9969; Fraaije MW, 2000, TRENDS BIOCHEM SCI, V25, P126, DOI 10.1016/S0968-0004(99)01533-9; GHISLA S, 1980, BIOCHEMISTRY-US, V19, P2537, DOI 10.1021/bi00553a001; GHISLA S, 1986, BIOCHEM J, V239, P1; GHISLA S, 1991, CHEM BIOCH FLAVOENZY, V2; Groen BW, 1997, EUR J BIOCHEM, V244, P858, DOI 10.1111/j.1432-1033.1997.00858.x; Huang CH, 2005, J BIOL CHEM, V280, P38831, DOI 10.1074/jbc.M506078200; KASPRZAK AA, 1983, BIOCHEM J, V211, P535, DOI 10.1042/bj2110535; KUTCHAN TM, 1994, PHYTOCHEMISTRY, V35, P353, DOI 10.1016/S0031-9422(00)94763-0; KUTCHAN TM, 1995, J BIOL CHEM, V270, P24475, DOI 10.1074/jbc.270.41.24475; Kutchan TM, 1996, GENE, V179, P73, DOI 10.1016/S0378-1119(96)00426-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MH, 2005, APPL ENVIRON MICROB, V71, P8881, DOI 10.1128/AEM.71.12.8881-8887.2005; Liaw SH, 2001, BIOCHEM BIOPH RES CO, V280, P738, DOI 10.1006/bbrc.2000.4203; MACHEROUX P, 1991, BIOCHEMISTRY-US, V30, P4612, DOI 10.1021/bi00232a036; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1969, J BIOL CHEM, V244, P3999; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Sirikantaramas S, 2004, J BIOL CHEM, V279, P39767, DOI 10.1074/jbc.M403693200; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2818; STEFFENS P, 1985, PHYTOCHEMISTRY, V24, P2577, DOI 10.1016/S0031-9422(00)80672-X; WALKER WH, 1972, EUR J BIOCHEM, V26, P279, DOI 10.1111/j.1432-1033.1972.tb01766.x; Weis R, 2004, FEMS YEAST RES, V5, P179, DOI 10.1016/j.femsyr.2004.06.016; ZSEBO KM, 1986, J BIOL CHEM, V261, P5858	31	90	93	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21276	21285		10.1074/jbc.M603267200	http://dx.doi.org/10.1074/jbc.M603267200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16728404	hybrid			2022-12-25	WOS:000239187300063
J	Cao, Y; Espinola, JA; Fossale, E; Massey, AC; Cuervo, AM; MacDonald, ME; Cotman, SL				Cao, Yi; Espinola, Janice A.; Fossale, Elisa; Massey, Ashish C.; Cuervo, Ana Maria; MacDonald, Marcy E.; Cotman, Susan L.			Autophagy is disrupted in a knock-in mouse model of juvenile neuronal ceroid lipofuscinosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ATP SYNTHASE; BATTEN-DISEASE; SUBUNIT-C; SACCHAROMYCES-CEREVISIAE; ALZHEIMERS-DISEASE; CARDIAC MYOCYTES; CELL-DEATH; STORAGE; AUTOPHAGOCYTOSIS; VACUOLES	Juvenile neuronal ceroid lipofuscinosis is caused by mutation of a novel, endosomal/lysosomal membrane protein encoded by CLN3. The observation that the mitochondrial ATPase subunit c protein accumulates in this disease suggests that autophagy, a pathway that regulates mitochondrial turnover, may be disrupted. To test this hypothesis, we examined the autophagic pathway in Cln3(Delta ex7/8) knock-in mice and CbCln3(Delta ex7/8) cerebellar cells, accurate genetic models of juvenile neuronal ceroid lipofuscinosis. In homozygous knock-in mice, we found that the autophagy marker LC3-II was increased, and mammalian target of rapamycin was down-regulated. Moreover, isolated autophagic vacuoles and lysosomes from homozygous knock-in mice were less mature in their ultrastructural morphology than the wild-type organelles, and subunit c accumulated in autophagic vacuoles. Intriguingly, we also observed subunit c accumulation in autophagic vacuoles in normal aging mice. Upon further investigation of the autophagic pathway in homozygous knock-in cerebellar cells, we found that LC3-positive vesicles were altered and overlap of endocytic and lysosomal dyes was reduced when autophagy was stimulated, compared with wildtype cells. Surprisingly, however, stimulation of autophagy did not significantly impact cell survival, but inhibition of autophagy led to cell death. Together these observations suggest that autophagy is disrupted in juvenile neuronal ceroid lipofuscinosis, likely at the level of autophagic vacuolar maturation, and that activation of autophagy may be a prosurvival feedback response in the disease process.	Massachusetts Gen Hosp, Mol Neurogenet Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA; Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Yeshiva University; Albert Einstein College of Medicine	Cotman, SL (corresponding author), Massachusetts Gen Hosp, Mol Neurogenet Unit, Boston, MA 02114 USA.	cotman@helix.mgh.harvard.edu		Cuervo, Ana Maria/0000-0002-0771-700X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033648] Funding Source: NIH RePORTER; NIA NIH HHS [AG02194] Funding Source: Medline; NINDS NIH HHS [NS33648, R01 NS033648] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Chen RM, 2004, J BIOL CHEM, V279, P21883, DOI 10.1074/jbc.M402074200; Cotman SL, 2002, HUM MOL GENET, V11, P2709, DOI 10.1093/hmg/11.22.2709; Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002; Cuervo AM, 2005, AUTOPHAGY, V1, P131, DOI 10.4161/auto.1.3.2017; Cutler NS, 1999, MOL CELL ENDOCRINOL, V155, P135, DOI 10.1016/S0303-7207(99)00121-5; Elleder M, 1997, ACTA NEUROPATHOL, V93, P379, DOI 10.1007/s004010050629; Ezaki J, 2003, J NEUROCHEM, V87, P1296, DOI 10.1046/j.1471-4159.2003.02132.x; Fossale E, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-57; Goebel HH, 2004, BRAIN PATHOL, V14, P61, DOI 10.1111/j.1750-3639.2004.tb00499.x; Hofman I L, 2001, Eur J Paediatr Neurol, V5 Suppl A, P213; Holopainen JM, 2001, EUR J BIOCHEM, V268, P5851, DOI 10.1046/j.0014-2956.2001.02530.x; Jager S, 2004, J CELL SCI, V117, P4837, DOI 10.1242/jcs.01370; Jolly RD, 2002, NEUROCHEM INT, V40, P565, DOI 10.1016/S0197-0186(01)00128-0; Kegel KB, 2000, J NEUROSCI, V20, P7268, DOI 10.1523/jneurosci.20-19-07268.2000; Koike M, 2005, AM J PATHOL, V167, P1713, DOI 10.1016/S0002-9440(10)61253-9; KOMINAMI E, 1992, J BIOCHEM, V111, P278, DOI 10.1093/oxfordjournals.jbchem.a123749; KOVACS J, 1989, RBC-CELL BIOL REV, V20, P63; LERNER TJ, 1995, CELL, V82, P949, DOI 10.1016/0092-8674(95)90274-0; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Luiro K, 2004, HUM MOL GENET, V13, P3017, DOI 10.1093/hmg/ddh321; MARZELLA L, 1982, J CELL BIOL, V93, P144, DOI 10.1083/jcb.93.1.144; Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005; Mizushima N, 2005, CELL DEATH DIFFER, V12, P1535, DOI 10.1038/sj.cdd.4401728; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Mole SE, 2004, BRAIN PATHOL, V14, P70, DOI 10.1111/j.1750-3639.2004.tb00500.x; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; PALMER DN, 1992, AM J MED GENET, V42, P561, DOI 10.1002/ajmg.1320420428; Pearce DA, 1999, NAT GENET, V22, P55, DOI 10.1038/8861; Persaud-Sawin DA, 2005, APOPTOSIS, V10, P973, DOI 10.1007/s10495-005-0733-6; Petersen A, 2001, HUM MOL GENET, V10, P1243, DOI 10.1093/hmg/10.12.1243; Ramirez-Montealegre D, 2005, HUM MOL GENET, V14, P3759, DOI 10.1093/hmg/ddi406; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Stefanis L, 2001, J NEUROSCI, V21, P9549, DOI 10.1523/JNEUROSCI.21-24-09549.2001; Terman A, 2004, ANN NY ACAD SCI, V1019, P70, DOI 10.1196/annals.1297.015; Terman A, 2003, EXP GERONTOL, V38, P863, DOI 10.1016/S0531-5565(03)00114-1; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Vella F, 2002, IUBMB LIFE, V54, P89, DOI 10.1080/15216540214307; Wisniewski KE, 2001, NEUROLOGY, V57, P576, DOI 10.1212/WNL.57.4.576; Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765; Yu WH, 2005, J CELL BIOL, V171, P87, DOI 10.1083/jcb.200505082; Yu WH, 2004, INT J BIOCHEM CELL B, V36, P2531, DOI 10.1016/j.biocel.2004.05.010	45	201	207	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20483	20493		10.1074/jbc.M602180200	http://dx.doi.org/10.1074/jbc.M602180200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16714284	hybrid			2022-12-25	WOS:000239038200071
J	Eisinger, AL; Nadauld, LD; Shelton, DN; Peterson, PW; Phelps, RA; Chidester, S; Stafforini, DM; Prescott, SM; Jones, DA				Eisinger, Annie L.; Nadauld, Lincoln D.; Shelton, Dawne N.; Peterson, Peter W.; Phelps, Reid A.; Chidester, Stephanie; Stafforini, Diana M.; Prescott, Stephen M.; Jones, David A.			The adenomatous polyposis coli tumor suppressor gene regulates expression of cyclooxygenase-2 by a mechanism that involves retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT/ENHANCER-BINDING-PROTEIN; GLYCOGEN-SYNTHASE KINASE-3; MAMMARY EPITHELIAL-CELLS; CARCINOMA-CELLS; TRANSCRIPTIONAL REGULATION; DIFFERENTIAL EXPRESSION; INTESTINAL DEVELOPMENT; BETA-CATENIN; CANCER; ZEBRAFISH	Mutations in the adenomatous polyposis coli (APC) gene result in uncontrolled proliferation of intestinal epithelial cells and are associated with the earliest stages of colorectal carcinogenesis. Cyclooxygenase-2 (COX-2) is elevated in human colorectal cancers and plays an important role in colorectal tumorigenesis; however, the mechanisms by which APC mutations result in increased COX-2 expression remain unclear. We utilized APC mutant zebrafish and human cancer cells to investigate how APC modulates COX-2 expression. We report that COX-2 is up-regulated in APC mutant zebrafish because of a deficiency in retinoic acid biosynthesis. Treatment of both APC mutant zebrafish and human carcinoma cell lines with retinoic acid significantly reduces COX-2 expression. Retinoic acid regulates COX-2 levels by a mechanism that involves participation of the transcription factor C/EBP-beta. APC mutant zebrafish express higher levels of C/EBP-beta than wild-type animals, and retinoic acid supplementation reduces C/EBP-beta expression to basal levels. Both morpholino knockdown of C/EBP-beta in APC mutant zebrafish and silencing of C/EBP-beta using small interfering RNA in HT29 colon cancer cells robustly decrease COX-2 expression. Our findings support a sequence of events in which mutations in APC result in impaired retinoic acid biosynthesis, elevated levels of C/EBP-beta, up-regulation of COX-2, increased prostaglandin E-2 accumulation, and activation of Wnt target genes.	Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Jones, DA (corresponding author), Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, 2000 Circle Of Hope, Salt Lake City, UT 84112 USA.	david.jones@hci.utah.edu		Chidester, Stephanie/0000-0003-4163-3480				Araki Y, 2003, CANCER RES, V63, P728; Buchanan FG, 2006, CANCER CELL, V9, P6, DOI 10.1016/j.ccr.2005.12.029; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chen JJ, 2005, MOL BIOL CELL, V16, P5579, DOI 10.1091/mbc.E05-08-0778; Clevers H, 2006, NEW ENGL J MED, V354, P761, DOI 10.1056/NEJMcibr055457; Delaunay F, 2000, SCIENCE, V289, P297, DOI 10.1126/science.289.5477.297; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Elizondo G, 2000, J BIOL CHEM, V275, P39747, DOI 10.1074/jbc.M004987200; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Grosser T, 2002, P NATL ACAD SCI USA, V99, P8418, DOI 10.1073/pnas.112217799; Haertel-Wiesmann M, 2000, J BIOL CHEM, V275, P32046, DOI 10.1074/jbc.M000074200; Haramis APG, 2006, EMBO REP, V7, P444, DOI 10.1038/sj.embor.7400638; Heckman CA, 2003, ONCOGENE, V22, P7891, DOI 10.1038/sj.onc.1206639; Hsi LC, 1999, CARCINOGENESIS, V20, P2045, DOI 10.1093/carcin/20.11.2045; Hull MA, 1999, BRIT J CANCER, V79, P1399, DOI 10.1038/sj.bjc.6690224; Jacoby RF, 2000, CANCER RES, V60, P5040; Jette C, 2004, J BIOL CHEM, V279, P34397, DOI 10.1074/jbc.M314021200; Kawamori T, 1998, CANCER RES, V58, P409; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Li M, 2002, ONCOGENE, V21, P411, DOI 10.1038/sj.onc.1205106; Mahmoud NN, 1998, CARCINOGENESIS, V19, P87, DOI 10.1093/carcin/19.1.87; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; Mestre JR, 1997, CANCER RES, V57, P1081; Mestre JR, 1997, CANCER RES, V57, P2890; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Nadauld LD, 2005, J BIOL CHEM, V280, P30490, DOI 10.1074/jbc.M504973200; Nadauld LD, 2004, J BIOL CHEM, V279, P51581, DOI 10.1074/jbc.M408830200; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; Shao JY, 2005, J BIOL CHEM, V280, P26565, DOI 10.1074/jbc.M413056200; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Shattuck-Brandt RL, 1999, MOL CARCINOGEN, V24, P177, DOI 10.1002/(SICI)1098-2744(199903)24:3<177::AID-MC4>3.0.CO;2-6; Shattuck-Brandt RL, 2000, GASTROENTEROLOGY, V118, P337, DOI 10.1016/S0016-5085(00)70216-2; Sinicrope FA, 1999, GASTROENTEROLOGY, V117, P350, DOI 10.1053/gast.1999.0029900350; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Sonoshita M, 2002, CANCER RES, V62, P6846; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Subbaramaiah K, 2002, CANCER RES, V62, P2522; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Tamamura Y, 2005, J BIOL CHEM, V280, P19185, DOI 10.1074/jbc.M414275200; Wardlaw SA, 2002, MOL PHARMACOL, V62, P326, DOI 10.1124/mol.62.2.326; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	47	52	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20474	20482		10.1074/jbc.M602859200	http://dx.doi.org/10.1074/jbc.M602859200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16699180	hybrid			2022-12-25	WOS:000239038200070
J	Ghosh-Choudhury, N; Singha, PK; Woodruff, K; St Clair, P; Bsoul, S; Werner, SL; Choudhury, GG				Ghosh-Choudhury, Nandini; Singha, Prajjal K.; Woodruff, Kathleen; St Clair, Patricia; Bsoul, Sameer; Werner, Sherry L.; Choudhury, Goutam Ghosh			Concerted action of Smad and CREB-binding protein regulates bone morphogenetic protein-2-stimulated osteoblastic colony-stimulating factor-1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCLAST DIFFERENTIATION FACTOR; GROWTH-FACTOR-BETA; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTIONAL REGULATION; SIGNAL-TRANSDUCTION; HISTONE ACETYLTRANSFERASES; FAMILY-MEMBERS; CELL-FORMATION; STROMAL CELLS; OP/OP MICE	Bone remodeling depends upon proper osteoblast and osteoclast function. Bone morphogenetic protein-2 (BMP-2) stimulates differentiation of osteoblasts from pluripotent precursors. Osteoclast formation depends on the concerted action of osteoblast-derived receptor activator of NF-kappa B ligand and colony-stimulating factor-1 (CSF-1). BMP-2 stimulates receptor activator of NF-kappa B ligand expression. However, the effect of BMP-2 on CSF-1 expression has not been studied. We investigated the role of BMP-2 in CSF-1 expression in osteogenic C2C12 cells. Incubation of C2C12 cells with BMP-2 supported osteoclastogenesis of spleen cells with a concomitant increase in expression of CSF-1 mRNA and protein. To determine the mechanism, we identified a BMP-responsive element between -627 bp and -509 bp in the CSF-1 promoter. DNase I footprint analysis revealed the presence of consensus Smad binding motif in this region. Electrophoretic mobility shift assay showed BMP-2-stimulated binding of proteins to this motif. Mutation of core sequence as well as its 5'- and 3'-flanking sequences abolished the DNA-protein interaction resulting in inhibition of CSF-1 transcription. Supershift analysis detects the presence of Smads 1, 5, and 4 and the transcriptional coactivator CREB-binding protein in the BMP-responsive element-protein complex. In addition, Smads 1 and 5 alone or in combination with Smad 4 increased CSF-1 transcription. Furthermore, CREB-binding protein markedly increased transcription of CSF-1. These data represent the first evidence that BMP-2 increases the osteoclas-togenic CSF-1 expression by a transcriptional mechanism using the canonical Smad pathway and provide a mechanism for BMP-2-induced osteoclast differentiation.	Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Dent Diagnost Sci, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA; Audie L Murphy Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Choudhury, GG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	choudhury@uthscsa.edu			NIAMS NIH HHS [R01 AR042306, R01-AR52425] Funding Source: Medline; NIDDK NIH HHS [DK 55815, R01 DK 50190, P50 DK061597] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042306, R01AR052425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK061597, R01DK050190, R01DK055815] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abboud SL, 2002, ENDOCRINOLOGY, V143, P1942, DOI 10.1210/en.143.5.1942; ABBOUD SL, 1991, BLOOD, V78, P103; Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663; AONO A, 1995, BIOCHEM BIOPH RES CO, V210, P670, DOI 10.1006/bbrc.1995.1712; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Choudhury GG, 2004, J BIOL CHEM, V279, P27399, DOI 10.1074/jbc.M403530200; Choudhury GG, 1998, J CLIN INVEST, V101, P2751, DOI 10.1172/JCI1044; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Felix R, 1996, J CELL PHYSIOL, V166, P311, DOI 10.1002/(SICI)1097-4652(199602)166:2<311::AID-JCP9>3.0.CO;2-S; FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo-127-5-2592; Ghosh-Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200; Ghosh-Choudhury NG, 2003, J BIOL CHEM, V278, P21998, DOI 10.1074/jbc.M302277200; GhoshChoudhury N, 1996, ENDOCRINOLOGY, V137, P331, DOI 10.1210/en.137.1.331; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Harrington M, 1997, MOL REPROD DEV, V46, P39, DOI 10.1002/(SICI)1098-2795(199701)46:1<39::AID-MRD7>3.0.CO;2-S; Hong YH, 1997, J IMMUNOL, V159, P2418; Itoh K, 2001, ENDOCRINOLOGY, V142, P3656, DOI 10.1210/en.142.8.3656; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KANATANI M, 1995, J BONE MINER RES, V10, P1681, DOI 10.1002/jbmr.5650101110; Kaneko H, 2000, BONE, V27, P479, DOI 10.1016/S8756-3282(00)00358-6; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601-0825.2002.01829.x; Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359-6101(97)00036-1; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KODAMA H, 1991, J EXP MED, V173, P269, DOI 10.1084/jem.173.1.269; Koide M, 1999, BIOCHEM BIOPH RES CO, V259, P97, DOI 10.1006/bbrc.1999.0715; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lewis BA, 2003, J CELL SCI, V116, P3667, DOI 10.1242/jcs.00734; Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Matsuzaki K, 1998, BIOCHEM BIOPH RES CO, V246, P199, DOI 10.1006/bbrc.1998.8586; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Otsuka E, 2003, CALCIFIED TISSUE INT, V73, P72, DOI 10.1007/s00223-002-1071-0; Pearson KL, 1999, BBA-GENE STRUCT EXPR, V1489, P354, DOI 10.1016/S0167-4781(99)00166-9; Persengiev SP, 2003, APOPTOSIS, V8, P225, DOI 10.1023/A:1023633704132; Reddi A. Hari, 1997, Cytokine and Growth Factor Reviews, V8, P11, DOI 10.1016/S1359-6101(96)00049-4; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Roth JF, 2003, EMBO J, V22, P5186, DOI 10.1093/emboj/cdg473; Rubin J, 2000, MOL CELL ENDOCRINOL, V160, P193, DOI 10.1016/S0303-7207(99)00212-9; Sakou T, 1998, BONE, V22, P591, DOI 10.1016/S8756-3282(98)00053-2; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; TAKAHASHI N, 1991, ENDOCRINOLOGY, V128, P1792, DOI 10.1210/endo-128-4-1792; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Wozney JM, 1998, CLIN ORTHOP RELAT R, P26; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; Yamaguchi A, 1996, BIOCHEM BIOPH RES CO, V220, P366, DOI 10.1006/bbrc.1996.0411; Yao GQ, 2000, ENDOCRINOLOGY, V141, P2914, DOI 10.1210/en.141.8.2914; Yao GQ, 1998, J BIOL CHEM, V273, P4119, DOI 10.1074/jbc.273.7.4119; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zou HY, 1997, GENE DEV, V11, P2191, DOI 10.1101/gad.11.17.2191	69	41	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20160	20170		10.1074/jbc.M511071200	http://dx.doi.org/10.1074/jbc.M511071200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16707491	hybrid			2022-12-25	WOS:000239038200040
J	Shi, DH; Morizono, H; Cabrera-Luque, J; Yu, XL; Roth, L; Malamy, MH; Allewell, N; Tuchman, M				Shi, Dashuang; Morizono, Hiroki; Cabrera-Luque, Juan; Yu, Xiaolin; Roth, Lauren; Malamy, Michael H.; Allewell, NormaM.; Tuchman, Mendel			Structure and catalytic mechanism of a novel N-succinyl-L-ornithine transcarbamylase in arginine biosynthesis of Bacteroides fragilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESOLUTION CRYSTAL-STRUCTURE; ASPARTATE-TRANSCARBAMYLASE; ACETYLORNITHINE TRANSCARBAMYLASE; XANTHOMONAS-CAMPESTRIS; ESCHERICHIA-COLI; PROTEIN; CARBAMOYLTRANSFERASE; ENZYME; PROGRAM; BINDING	A Bacteroides fragilis gene (argF' (bf)), the disruption of which renders the bacterium auxotrophic for arginine, was expressed and its recombinant protein purified and studied. The novel protein catalyzes the carbamylation of N-succinyl-L-ornithine but not L-ornithine or N-acetyl-L-ornithine, forming N-succinyl-L-citrulline. Crystal structures of this novel transcarbamylase complexed with carbamyl phosphate and N-succinyl-L-norvaline, as well as sulfate and N-succinyl-L-norvaline have been determined and refined to 2.9 and 2.8 A resolution, respectively. They provide structural evidence that this protein is a novel N-succinyl-L-ornithine transcarbamylase. The data provided herein suggest that B. fragilis uses N-succinyl-L-ornithine rather than N-acetyl-L-ornithine for de novo arginine biosynthesis and therefore that this pathway in Bacteroides is different from the canonical arginine biosynthetic pathway of most organisms. Comparison of the structures of the new protein with those recently reported for N-acetyl-L-ornithine transcarbamylase indicates that amino acid residue 90 (B. fragilis numbering) plays an important role in conferring substrate specificity for N-succinyl-L-ornithine versus N-acetyl-L-ornithine. Movement of the 120 loop upon substrate binding occurs in N-succinyl-L-ornithine transcarbamylase, while movement of the 80 loop and significant domain closure take place as in other transcarbamylases. These findings provide new information on the putative role of succinylated intermediates in arginine biosynthesis and on the evolution of transcarbamylases.	George Washington Univ, Childrens Res Inst, Childrens Natl Med Ctr, Washington, DC 20010 USA; Univ Maryland, Coll Chem & Life Sci, Dept Chem & Biochem, College Pk, MD 20742 USA; Tufts Univ, Sch Med, Dept Microbiol & Mol Biol, Boston, MA 02111 USA	Children's National Health System; George Washington University; University System of Maryland; University of Maryland College Park; Tufts University	Shi, DH (corresponding author), George Washington Univ, Childrens Res Inst, Childrens Natl Med Ctr, 111 Michigan Ave,NW, Washington, DC 20010 USA.	dshi@cnmcresearch.org	; Morizono, Hiroki/E-9737-2013	Shi, Dashuang/0000-0002-5491-1104; Morizono, Hiroki/0000-0002-9678-5564	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019497, R21AI019497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK067935] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-019497] Funding Source: Medline; NIDDK NIH HHS [DK067935] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Baughn AD, 2002, P NATL ACAD SCI USA, V99, P4662, DOI 10.1073/pnas.052710199; Beernink PT, 1999, P NATL ACAD SCI USA, V96, P5388, DOI 10.1073/pnas.96.10.5388; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Collaborative Computational Project, 1997, ACTA CRYSTALLOGR D, V50, P760; CUNIN R, 1986, MICROBIOL REV, V50, P314, DOI 10.1128/MMBR.50.3.314-352.1986; De Vos D, 2004, J MOL BIOL, V339, P887, DOI 10.1016/j.jmb.2004.03.079; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Endrizzi JA, 2000, P NATL ACAD SCI USA, V97, P5077, DOI 10.1073/pnas.090087197; Ha Y, 1997, P NATL ACAD SCI USA, V94, P9550, DOI 10.1073/pnas.94.18.9550; Huang JW, 2004, BIOCHEMISTRY-US, V43, P6415, DOI 10.1021/bi030213b; Jin L, 1997, NAT STRUCT BIOL, V4, P622, DOI 10.1038/nsb0897-622; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIPSCOMB WN, 1994, ADV ENZYMOL RAMB, V68, P67; Massant J, 2003, ACTA CRYSTALLOGR D, V59, P2140, DOI 10.1107/S0907444903019231; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Morizono H, 2006, J BACTERIOL, V188, P2974, DOI 10.1128/JB.188.8.2974-2982.2006; Morizono H, 1997, BIOCHEM J, V322, P625, DOI 10.1042/bj3220625; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Shi DS, 2006, PROTEINS, V64, P532, DOI 10.1002/prot.21013; Shi DS, 1998, J BIOL CHEM, V273, P34247, DOI 10.1074/jbc.273.51.34247; Shi DS, 2000, PROTEINS, V39, P271, DOI 10.1002/(SICI)1097-0134(20000601)39:4<271::AID-PROT10>3.3.CO;2-5; Shi DS, 2005, J BIOL CHEM, V280, P14366, DOI 10.1074/jbc.C500005200; Shi DS, 2002, J MOL BIOL, V320, P899, DOI 10.1016/S0022-2836(02)00539-9; Shi DS, 2001, BIOCHEM J, V354, P501, DOI 10.1042/0264-6021:3540501; STALON V, 1967, BIOCHIM BIOPHYS ACTA, V99, P9509; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Tang YXP, 2000, INFECT IMMUN, V68, P415, DOI 10.1128/IAI.68.1.415-419.2000; Van Boxstael S, 2003, J MOL BIOL, V326, P203, DOI 10.1016/S0022-2836(02)01228-7; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; VILLERET V, 1995, P NATL ACAD SCI USA, V92, P10762, DOI 10.1073/pnas.92.23.10762; Villeret V, 1998, P NATL ACAD SCI USA, V95, P2801, DOI 10.1073/pnas.95.6.2801	38	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20623	20631		10.1074/jbc.M601229200	http://dx.doi.org/10.1074/jbc.M601229200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16704984	hybrid			2022-12-25	WOS:000239038200083
J	Violin, JD; Ren, XR; Lefkowitz, RJ				Violin, Jonathan D.; Ren, Xiu-Rong; Lefkowitz, Robert J.			G-protein-coupled receptor kinase specificity for beta-arrestin recruitment to the beta(2)-adrenergic receptor revealed by fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-II RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; ACTIVATION; PHOSPHORYLATION; DESENSITIZATION; BINDING; TRAFFICKING; ENDOCYTOSIS; CELLS; INTERNALIZATION	The small family of G-protein-coupled receptor kinases (GRKs) regulate cell signaling by phosphorylating heptahelical receptors, thereby promoting receptor interaction with beta-arrestins. This switches a receptor from G-protein activation to G-protein desensitization, receptor internalization, and beta-arrestin-dependent signal activation. However, the specificity of GRKs for recruiting beta-arrestins to specific receptors has not been elucidated. Here we use the beta(2)-adrenergic receptor (beta(2)AR), the archetypal nonvisual heptahelical receptor, as a model to test functional GRK specificity. We monitor endogenous GRK activity with a fluorescence resonance energy transfer assay in live cells by measuring kinetics of the interaction between the beta(2)AR and beta-arrestins. We show that beta(2)AR phosphorylation is required for high affinity beta-arrestin binding, and we use small interfering RNA silencing to show that HEK-293 and U2-OS cells use different subsets of their expressed GRKs to promote beta-arrestin recruitment, with significant GRK redundancy evident in both cell types. Surprisingly, the GRK specificity for beta-arrestin recruitment does not correlate with that for bulk receptor phosphorylation, indicating that beta-arrestin recruitment is specific for a subset of receptor phosphorylations on specific sites. Moreover, multiple members of the GRK family are able to phosphorylate the beta(2)AR and induce beta-arrestin recruitment, with their relative contributions largely determined by their relative expression levels. Because GRK isoforms vary in their regulation, this partially redundant system ensures beta-arrestin recruitment while providing the opportunity for tissue-specific regulation of the rate of beta-arrestin recruitment.	Duke Univ, Ctr Med, Dept Med, Durham, NC 27710 USA; Duke Univ, Ctr Med, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Ctr Med, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Howard Hughes Medical Institute	Lefkowitz, RJ (corresponding author), Duke Univ, Ctr Med, Dept Med, Durham, NC 27710 USA.	lefko001@receptor-biol.duke.edu	Lefkowitz, Robert/AAW-2649-2021		NHLBI NIH HHS [HL 70631, HL 16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070631, R01HL016037, R37HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn SK, 2004, J BIOL CHEM, V279, P35518, DOI 10.1074/jbc.M405878200; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Azzi M, 2003, P NATL ACAD SCI USA, V100, P11406, DOI 10.1073/pnas.1936664100; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; COLLINS S, 1991, VITAM HORM, V46, P1; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Fong AM, 2002, P NATL ACAD SCI USA, V99, P7478, DOI 10.1073/pnas.112198299; Gainetdinov RR, 1999, NEURON, V24, P1029, DOI 10.1016/S0896-6273(00)81048-X; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Gurevich VV, 2004, TRENDS PHARMACOL SCI, V25, P105, DOI 10.1016/j.tips.2003.12.008; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hoffmann C, 2005, NAT METHODS, V2, P171, DOI 10.1038/NMETH742; Iaccarino G, 1999, Expert Opin Investig Drugs, V8, P545, DOI 10.1517/13543784.8.5.545; Jaber M, 1996, P NATL ACAD SCI USA, V93, P12974, DOI 10.1073/pnas.93.23.12974; Jala VR, 2005, J BIOL CHEM, V280, P4880, DOI 10.1074/jbc.M409821200; Johnson M, 1998, AM J RESP CRIT CARE, V158, pS146, DOI 10.1164/ajrccm.158.supplement_2.13tac110; Kim J, 2005, P NATL ACAD SCI USA, V102, P1442, DOI 10.1073/pnas.0409532102; Kim YM, 2002, J BIOL CHEM, V277, P16340, DOI 10.1074/jbc.M200678200; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Krasel C, 2005, J BIOL CHEM, V280, P9528, DOI 10.1074/jbc.M413078200; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Liapakis G, 2004, MOL PHARMACOL, V65, P1181, DOI 10.1124/mol.65.5.1181; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Peppel K, 1997, J BIOL CHEM, V272, P25425, DOI 10.1074/jbc.272.41.25425; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Ren XR, 2005, P NATL ACAD SCI USA, V102, P1448, DOI 10.1073/pnas.0409534102; Seibold A, 2000, MOL PHARMACOL, V58, P1162, DOI 10.1124/mol.58.5.1162; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; Shenoy SK, 2006, J BIOL CHEM, V281, P1261, DOI 10.1074/jbc.M506576200; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Tran TM, 2004, MOL PHARMACOL, V65, P196, DOI 10.1124/mol.65.1.196; Trester-Zedlitz M, 2005, BIOCHEMISTRY-US, V44, P6133, DOI 10.1021/bi0475469; Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976	42	111	114	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20577	20588		10.1074/jbc.M513605200	http://dx.doi.org/10.1074/jbc.M513605200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16687412	hybrid			2022-12-25	WOS:000239038200079
J	Yusa, A; Kitajima, K; Habuchi, O				Yusa, Akiko; Kitajima, Ken; Habuchi, Osami			N-linked oligosaccharides on chondroitin 6-sulfotransferase-1 are required for production of the active enzyme, golgi localization, and sulfotransferase activity toward keratan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLGALACTOSAMINE 4-SULFATE 6-O-SULFOTRANSFERASE; MOLECULAR-CLONING; MONOCLONAL-ANTIBODIES; ENDOPLASMIC-RETICULUM; GLYCOSAMINOGLYCAN; EXPRESSION; GLYCOSYLATION; BIOSYNTHESIS; PURIFICATION; CARTILAGE	We have shown previously that purified chondroitin 6-sulfotransferase-1 (C6ST-1) was a glycoprotein abundant in N-linked oligosaccharides and could sulfate both chondroitin (C6ST activity) and keratan sulfate (KSST activity); however, functional roles of the N-glycans have remained unclear. In the present study, we show essential roles of N-glycans attached to C6ST-1 in the generation of the active enzyme and in its KSST activity. Treatment with tunicamycin of COS-7 cells transfected with C6ST-1 cDNA totally abolished production of the active C6ST-1. A nearly complete removal of N-glycans of the recombinant C6ST-1 by peptide N-glycosidase F increased the C6ST activity but decreased the KSST activity. Among six potential N-glycosylation sites, deletion of the fourth or sixth site from the amino terminus inhibited production of the active C6ST-1, whereas deletion of the fifth site resulted in a marked loss of the KSST activity. Wild-Type recombinant C6ST-1 showed a typical Golgi localization, whereas M-4 recombinant C6ST-1, in which the fourth N-glycosylation site was deleted, colocalized with calnexin, an endoplasmic reticulum-resident protein. Unlike wild-type recombinant C6ST-1, M-4 recombinant C6ST-1 showed a weak affinity toward wheat germ agglutinin and was converted completely to the nonglycosylated form by endoglycosidase H. These observations suggest that N-glycan attached to the fourth N-glycosylation site may function in the proper processing of N-glycans required for the Golgi localization, thereby causing the production of the active C6ST-1, and that N-glycan attached to the fifth N-glycosylation site may contribute to the KSST activity of C6ST-1.	Aichi Univ Educ, Dept Chem, Kariya, Aichi 4488542, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Biosci & Biotechnol Ctr, Nagoya, Aichi 4648601, Japan	Aichi University Education; Nagoya University; Nagoya University	Habuchi, O (corresponding author), Aichi Univ Educ, Dept Chem, Kariya, Aichi 4488542, Japan.	ohabuchi@auecc.aichi-edu.ac.jp						CATERSON B, 1983, J BIOL CHEM, V258, P8848; DELFERT DM, 1985, ANAL BIOCHEM, V148, P303, DOI 10.1016/0003-2697(85)90233-7; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; Fukuta M, 1997, J BIOL CHEM, V272, P32321, DOI 10.1074/jbc.272.51.32321; Habuchi H, 2004, GLYCOCONJUGATE J, V21, P47, DOI 10.1023/B:GLYC.0000043747.87325.5e; Habuchi O, 1996, GLYCOBIOLOGY, V6, P51, DOI 10.1093/glycob/6.1.51; HABUCHI O, 1980, BIOCHIM BIOPHYS ACTA, V616, P208, DOI 10.1016/0005-2744(80)90139-4; Habuchi O, 2000, BBA-GEN SUBJECTS, V1474, P115, DOI 10.1016/S0304-4165(00)00016-7; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; HASHIMOTO N, 1990, 15 INT CARB S YOK JA, P271; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hiraoka N, 2000, J BIOL CHEM, V275, P20188, DOI 10.1074/jbc.M002443200; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Ito Y, 2000, J BIOL CHEM, V275, P34728, DOI 10.1074/jbc.M909633199; Jones J, 2005, BBA-GEN SUBJECTS, V1726, P121, DOI 10.1016/j.bbagen.2005.07.003; Kang HG, 2002, J BIOL CHEM, V277, P34766, DOI 10.1074/jbc.M204907200; Kitagawa H, 2000, J BIOL CHEM, V275, P21075, DOI 10.1074/jbc.M002101200; Kluppel M, 2005, DEVELOPMENT, V132, P3989, DOI 10.1242/dev.01948; Kobayashi M, 1999, J BIOL CHEM, V274, P10474, DOI 10.1074/jbc.274.15.10474; Kusche-Gullberg M, 2003, CURR OPIN STRUC BIOL, V13, P605, DOI 10.1016/j.sbi.2003.08.002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Martina JA, 1998, J BIOL CHEM, V273, P3725, DOI 10.1074/jbc.273.6.3725; MEHMET H, 1986, EUR J BIOCHEM, V157, P385, DOI 10.1111/j.1432-1033.1986.tb09680.x; Mikami T, 2003, J BIOL CHEM, V278, P36115, DOI 10.1074/jbc.M306044200; Nagai K, 1997, GLYCOBIOLOGY, V7, P769, DOI 10.1093/glycob/7.6.769; Nakazawa K., 1989, KERATAN SULPHATE CHE, P99; Ohtake S, 2005, J BIOL CHEM, V280, P39115, DOI 10.1074/jbc.M508816200; Ohtake S, 2003, J BIOL CHEM, V278, P38443, DOI 10.1074/jbc.M306132200; Ohtake S, 2001, J BIOL CHEM, V276, P43894, DOI 10.1074/jbc.M104922200; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; SHAKLEE PN, 1986, BIOCHEM J, V235, P225, DOI 10.1042/bj2350225; Shi XH, 2004, J VIROL, V78, P5414, DOI 10.1128/JVI.78.10.5414-5422.2004; Thiele H, 2004, P NATL ACAD SCI USA, V101, P10155, DOI 10.1073/pnas.0400334101; Trombetta ES, 2003, GLYCOBIOLOGY, V13, p77R, DOI 10.1093/glycob/cwg075; Uchimura K, 1998, GLYCOBIOLOGY, V8, P489, DOI 10.1093/glycob/8.5.489; Uchimura K, 2002, J BIOL CHEM, V277, P1443, DOI 10.1074/jbc.M104719200; Yamada T, 2004, BIOCHEM J, V384, P567, DOI 10.1042/BJ20040965; Yamauchi S, 1999, J BIOL CHEM, V274, P2456, DOI 10.1074/jbc.274.4.2456; Yamauchi S, 2000, J BIOL CHEM, V275, P8975, DOI 10.1074/jbc.275.12.8975; Yusa A, 2005, BIOCHEM J, V388, P115, DOI 10.1042/BJ20041573	41	16	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20393	20403		10.1074/jbc.M600140200	http://dx.doi.org/10.1074/jbc.M600140200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16720579	hybrid			2022-12-25	WOS:000239038200063
J	Bruck, S; Huber, TB; Ingham, RJ; Kim, K; Niederstrasser, H; Allen, PM; Pawson, T; Cooper, JA; Shaw, AS				Bruck, Serawit; Huber, Tobias B.; Ingham, Robert J.; Kim, Kyoungtae; Niederstrasser, Hanspeter; Allen, Paul M.; Pawson, Tony; Cooper, John A.; Shaw, Andrey S.			Identification of a novel inhibitory actin-capping protein binding motif in CD2-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN; CYTOSKELETON; MORPHOLOGY; INTERACTS; CLEAVAGE; NEPHRIN; CLONING; CIN85; ARF; CMS	CD2-associated protein (CD2AP) is a scaffold molecule that plays a critical role in the maintenance of the kidney filtration barrier. Little, however, is understood about its mechanism of function. We used mass spectrometry to identify CD2AP-interacting proteins. Many of the proteins that we identified suggest a role for CD2AP in endocytosis and actin regulation. To address the role of CD2AP in regulation of the actin cytoskeleton, we focused on characterizing the interaction of CD2AP with actin-capping protein CP. We identified a novel binding motif LXHXTXXRPK(X)(6)P present in CD2AP that is also found in its homolog Cin85 and other capping protein-associated proteins such as CARMIL and CKIP-1. CD2AP inhibits the function of capping protein in vitro. Therefore, our results support a role of CD2AP in the regulation of the actin cytoskeleton.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Grad Program Mol Biophys, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Shaw, AS (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.	shaw@pathology.wustl.edu	Pawson, Tony J/E-4578-2013; Cooper, John/E-9389-2012; Cooper, John/D-4448-2014	Huber, Tobias B./0000-0001-7175-5062; Cooper, John/0000-0002-0933-4571	NIDDK NIH HHS [R01 DK066428, DK066428] Funding Source: Medline; NIGMS NIH HHS [T32 GM08492, R01 GM038542, T32 GM008492, R01 GM038542-19] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK066428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008492, R01GM038542] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOWCOCK AM, 1993, BREAST CANCER RES TR, V28, P121, DOI 10.1007/BF00666425; Brett TJ, 2002, STRUCTURE, V10, P797, DOI 10.1016/S0969-2126(02)00784-0; Canton DA, 2005, MOL CELL BIOL, V25, P3519, DOI 10.1128/MCB.25.9.3519-3534.2005; CICCHETTI P, 1995, EMBO J, V14, P3127, DOI 10.1002/j.1460-2075.1995.tb07315.x; COOPER JA, 1984, J CELL BIOL, V99, P217, DOI 10.1083/jcb.99.1.217; Cooper JA, 2000, CURR OPIN CELL BIOL, V12, P97, DOI 10.1016/S0955-0674(99)00062-9; Cormont M, 2003, TRAFFIC, V4, P97, DOI 10.1034/j.1600-0854.2003.40205.x; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Gout I, 2000, EMBO J, V19, P4015, DOI 10.1093/emboj/19.15.4015; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Harris ES, 2004, CURR BIOL, V14, pR520, DOI 10.1016/j.cub.2004.06.043; Hart MC, 1999, J CELL BIOL, V147, P1287, DOI 10.1083/jcb.147.6.1287; HOUTHAEVE T, 1995, FEBS LETT, V376, P91, DOI 10.1016/0014-5793(95)01242-7; Huber TB, 2003, MOL CELL BIOL, V23, P4917, DOI 10.1128/MCB.23.14.4917-4928.2003; Hutchings NJ, 2003, J BIOL CHEM, V278, P22396, DOI 10.1074/jbc.M302540200; Ingham RJ, 2005, MOL CELL BIOL, V25, P7092, DOI 10.1128/MCB.25.16.7092-7106.2005; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; Kowanetz K, 2004, MOL BIOL CELL, V15, P3155, DOI 10.1091/mbc.E03-09-0683; Lehtonen S, 2002, AM J PHYSIOL-RENAL, V283, pF734, DOI 10.1152/ajprenal.00312.2001; Liu YH, 2005, J BIOL CHEM, V280, P8884, DOI 10.1074/jbc.M412200200; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; Lynch DK, 2003, J BIOL CHEM, V278, P21805, DOI 10.1074/jbc.M211407200; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Mejillano MR, 2004, CELL, V118, P363, DOI 10.1016/j.cell.2004.07.019; Miura K, 2002, MOL CELL, V9, P109, DOI 10.1016/S1097-2765(02)00428-8; Pollard TD, 2002, CURR OPIN STRUC BIOL, V12, P768, DOI 10.1016/S0959-440X(02)00396-2; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shih NY, 2001, AM J PATHOL, V159, P2303, DOI 10.1016/S0002-9440(10)63080-5; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Take H, 2000, BIOCHEM BIOPH RES CO, V268, P321, DOI 10.1006/bbrc.2000.2147; Taoka M, 2003, J BIOL CHEM, V278, P5864, DOI 10.1074/jbc.M211509200; Uruno T, 2006, J BIOL CHEM, V281, P10635, DOI 10.1074/jbc.M513186200; Wear MA, 2003, CURR BIOL, V13, P1531, DOI 10.1016/S0960-9822(03)00559-1; Yang CS, 2005, DEV CELL, V9, P209, DOI 10.1016/j.devcel.2005.06.008	36	56	57	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19196	19203		10.1074/jbc.M600166200	http://dx.doi.org/10.1074/jbc.M600166200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16707503	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000238847000034
J	Jafri, F; El-Shewy, HM; Lee, MH; Kelly, M; Luttrell, DK; Luttrell, LM				Jafri, Farahdiba; El-Shewy, Hesham M.; Lee, Mi-Hye; Kelly, Margaret; Luttrell, Deirdre K.; Luttrell, Louis M.			Constitutive ERK1/2 activation by a chimeric neurokinin 1 receptor-beta-arrestin1 fusion protein - Probing the composition and function of the G protein-coupled receptor "signalsome"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ARRESTIN; MAP KINASE; REGULATED KINASES; VISUAL ARRESTIN; EGF RECEPTOR; SUBSTANCE-P; DESENSITIZATION; ENDOCYTOSIS; TRAFFICKING; PATHWAYS	The beta-arrestins, a small family of G protein-coupled receptor (GPCR)-binding proteins involved in receptor desensitization, have been shown to bind extracellular signal-regulated kinases 1 and 2 (ERK1/2) and function as scaffolds for GPCR-stimulated ERK1/2 activation. To better understand the mechanism of beta-arrestin-mediated ERK1/2 activation, we compared ERK1/2 activation by the wild-type neurokinin 1 (NK1) receptor with a chimeric NK1 receptor having beta-arrestin1 fused to the receptor C terminus (NK1- beta Arr1). The NK1 receptor couples to both Gs and G(q/11), resides on the plasma membrane, and mediates rapid ERK1/2 activation and nuclear translocation in response to neurokinin A. In contrast, NK1-beta Arr1 is a G protein-uncoupled "constitutively desensitized" receptor that resides almost entirely in an intracellular endosomal compartment. Despite its inability to respond to neurokinin A, we found that NK1-beta Arr1 expression caused robust constitutive activation of cytosolic ERK1/2 and that endogenous Raf, MEK1/2, and ERK1/2 coprecipitated in a complex with NK1-beta Arr1. While agonist- dependent ERK1/2 activation by the NK1 receptor was independent of protein kinase A(PKA) or PKC activity, NK1-beta Arr1-mediated ERK1/2 activation was completely inhibited when basal PKA and PKC activity were blocked. In addition, the rate of ERK1/ 2 dephosphorylation was slowed in NK1-beta Arr1-expressing cells, suggesting that beta-arrestin-bound ERK1/2 is protected from mitogen-activated protein kinase phosphatase activity. These data suggest that beta-arrestin binding to GPCRs nucleates the formation of a stable "signalsome" that functions as a passive scaffold for the ERK1/2 cascade while confining ERK1/2 activity to an extranuclear compartment.	Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Luttrell, LM (corresponding author), Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, 96 Jonathan Lucas St,816 CSB,POB 250624, Charleston, SC 29425 USA.	luttrell@musc.edu		Luttrell, Louis/0000-0003-2805-6949	NIDDK NIH HHS [DK55524] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK055524, R01DK055524] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn S, 2004, J BIOL CHEM, V279, P7807, DOI 10.1074/jbc.C300443200; Ahn SK, 2004, J BIOL CHEM, V279, P35518, DOI 10.1074/jbc.M405878200; Azzi M, 2003, P NATL ACAD SCI USA, V100, P11406, DOI 10.1073/pnas.1936664100; Brady AE, 2002, CELL SIGNAL, V14, P297, DOI 10.1016/S0898-6568(01)00239-X; Collins SP, 1999, J BIOL CHEM, V274, P8391, DOI 10.1074/jbc.274.13.8391; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; Fong AM, 2002, P NATL ACAD SCI USA, V99, P7478, DOI 10.1073/pnas.112198299; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Ge L, 2004, J BIOL CHEM, V279, P55419, DOI 10.1074/jbc.M410312200; Ge L, 2003, J BIOL CHEM, V278, P34418, DOI 10.1074/jbc.M300573200; Gesty-Palmer D, 2005, J BIOL CHEM, V280, P32157, DOI 10.1074/jbc.M507460200; Grewal SS, 2000, J BIOL CHEM, V275, P34433, DOI 10.1074/jbc.M004728200; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hall RA, 2002, CIRC RES, V91, P672, DOI 10.1161/01.RES.0000037000.74258.03; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Holst B, 2001, J BIOL CHEM, V276, P19793, DOI 10.1074/jbc.M100621200; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Luttrell LM, 2005, CONTEMPORARY CLIN NE, P159; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 2003, J MOL ENDOCRINOL, V30, P117, DOI 10.1677/jme.0.0300117; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Martin NP, 2003, J BIOL CHEM, V278, P45954, DOI 10.1074/jbc.M308285200; Martini L, 2002, MOL PHARMACOL, V62, P30, DOI 10.1124/mol.62.1.30; McConalogue K, 1999, J BIOL CHEM, V274, P16257, DOI 10.1074/jbc.274.23.16257; McConalogue K, 1998, MOL BIOL CELL, V9, P2305, DOI 10.1091/mbc.9.8.2305; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Pouyssegur J, 2003, EUR J BIOCHEM, V270, P3291, DOI 10.1046/j.1432-1033.2003.03707.x; Schubert C, 1999, J BIOL CHEM, V274, P21186, DOI 10.1074/jbc.274.30.21186; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; Shenoy SK, 2005, J BIOL CHEM, V280, P15315, DOI 10.1074/jbc.M412418200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Shi M, 2003, BIOCHEMISTRY-US, V42, P7283, DOI 10.1021/bi0341657; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Storez H, 2005, J BIOL CHEM, V280, P40210, DOI 10.1074/jbc.M508001200; Terrillon S, 2004, EMBO J, V23, P3950, DOI 10.1038/sj.emboj.7600387; Theodosiou A, 2002, GENOME BIOL, V3; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	50	30	31	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19346	19357		10.1074/jbc.M512643200	http://dx.doi.org/10.1074/jbc.M512643200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16670094	hybrid			2022-12-25	WOS:000238847000050
J	Keppetipola, N; Shuman, S				Keppetipola, Niroshika; Shuman, Stewart			Distinct enzymic functional groups are required for the phosphomonoesterase and phosphodiesterase activities of Clostridium thermocellum polynucleotide kinase/phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATASE; MECHANISM	The central phosphatase domain of Clostridium thermocellum polynucleotide kinase/phosphatase (CthPnkp) belongs to the dinuclear metallophosphoesterase superfamily. Prior mutational studies of CthPnkp identified 7 individual active site side chains (Asp-187, His-189, Asp-233, Asn-263, His-323, His-376, and Asp-392) required for Ni2(+)-dependent hydrolysis of p-nitrophenyl phosphate. Here we find that Mn2(+)-dependent phosphomonoesterase activity requires two additional residues, Arg-237 and His-264. We report that CthPnkp also converts bis-p-nitrophenyl phosphate to p-nitrophenol and inorganic phosphate via a processive two-step mechanism. The Ni2+-dependent phosphodiesterase activity of CthPnkp requires the same seven side chains as the Ni2+-dependent phosphomonoesterase. However, the Mn2+-dependent phosphodiesterase activity does not require His-189, Arg-237, or His-264, each of which is critical for the Mn2+-dependent phosphomonoesterase. Mutations H189A, H189D, and D392N transform the metal and substrate specificity of CthPnkp such that it becomes a Mn2+-dependent phosphodiesterase. The H189E change results in a Mn2+/Ni2+-dependent phosphodiesterase. Mutations H376N, H376D, and D392E convert the enzyme into a Mn2+-dependent phosphodiesterase-monoesterase. The phosphodiesterase activity is strongly stimulated compared with wild-type CthPnkp when His-189 is changed to Asp, Arg-237 is replaced by Ala or Gln, and His-264 is replaced by Ala, Asn, or Gln. Steady-state kinetic analysis of wild-type and mutated enzymes illuminates the structural features that affect substrate affinity and k(cat). Our results highlight CthPnkp as an "undifferentiated" diesterase-monoesterase that can evolve toward narrower metal and substrate specificities via alterations of the active site milieu.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org			NIGMS NIH HHS [GM42498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andreeva AV, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-47; Chen SF, 2004, J BIOL CHEM, V279, P31854, DOI 10.1074/jbc.M401059200; Funhoff EG, 2005, FEBS J, V272, P2968, DOI 10.1111/j.1742-4658.2005.04686.x; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Hoff RH, 1999, J AM CHEM SOC, V121, P6382, DOI 10.1021/ja990667p; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; Keppetipola N, 2006, RNA, V12, P73, DOI 10.1261/rna.2196406; Khalid MF, 2005, NUCLEIC ACIDS RES, V33, P6349, DOI 10.1093/nar/gki934; Klabunde T, 1996, J MOL BIOL, V259, P737, DOI 10.1006/jmbi.1996.0354; Knofel T, 1999, NAT STRUCT BIOL, V6, P448; Knofel T, 2001, J MOL BIOL, V309, P239, DOI 10.1006/jmbi.2001.4656; KOONIN EV, 1994, PROTEIN SCI, V3, P356; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Martins A, 2005, RNA, V11, P1271, DOI 10.1261/rna.2690505; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Schenk G, 2005, P NATL ACAD SCI USA, V102, P273, DOI 10.1073/pnas.0407239102; Shenoy AR, 2005, BIOCHEMISTRY-US, V44, P15695, DOI 10.1021/bi0512391; Voegtli WC, 2000, BIOCHEMISTRY-US, V39, P15365, DOI 10.1021/bi0021030; ZHUO S, 1993, J BIOL CHEM, V268, P17754	19	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19251	19259		10.1074/jbc.M602549200	http://dx.doi.org/10.1074/jbc.M602549200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16675457	hybrid			2022-12-25	WOS:000238847000039
J	Kwak, E; Kim, TD; Kim, KT				Kwak, Eunyee; Kim, Tae-Don; Kim, Kyong-Tai			Essential role of 3 '-untranslated region-mediated mRNA decay in circadian oscillations of mouse Period3 mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; E-BOX; IN-VIVO; CLOCK; TRANSCRIPTION; RHYTHMS; MAMMALS; CELLS; FIBROBLASTS; COMPONENT	Daily oscillations in mRNA levels are a general feature of most clock genes. Although mRNA oscillations largely depend on transcriptional regulation, it has been suggested that post-transcriptional controls also contribute to mRNA oscillations in Drosophila. Currently, however, there is no direct evidence for post-transcriptional regulation of mammalian clock genes. To investigate the roles of post-transcriptional regulations, we focused on the 3'-untranslated region (3'-UTR) of mouse Period3 (mPer3) mRNA, one of the clock genes. Insertion of the entire mPer3 3'-UTR downstream of a reporter gene resulted in a dramatic decrease in mRNA stability. Deletion and point mutation analyses led to the identification of critical sequences responsible for mRNA decay. To explore the effects of the mPer3 3'-UTR-mediated mRNA decay on circadian oscillations, we established NIH3T3 stable cell lines that express luciferase mRNA with wild-type or mutant mPer3 3'-UTR. Interestingly, a stabilizing mutation of 3'-UTR induced a significant alteration in the oscillation profile of luciferase mRNA. Above all, the peak time, during which the mRNAs reached their highest levels, was significantly delayed (for 12 h). In addition, the luciferase mRNA level with mutant 3'-UTR began to increase earlier than that in the presence of wild-type 3'-UTR. Consequently, luciferase mRNA with mutant 3'-UTR displayed oscillation patterns with a prolonged rising phase. Our results indicate that mPer3 3'-UTR- mediated mRNA decay plays an essential role in mRNA cycling and provide direct evidence for post- transcriptional control of circadian mRNA oscillations.	Pohang Univ Sci & Technol, Dept Life Sci, Div Mol & Life Sci, Syst Biodynam Natl Core Res Ctr, Pohang 790784, Kyungbuk, South Korea	Pohang University of Science & Technology (POSTECH)	Kim, KT (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Div Mol & Life Sci, Syst Biodynam Natl Core Res Ctr, San 31,Hyoja Dong, Pohang 790784, Kyungbuk, South Korea.	ktk@postech.ac.kr		KIM, KYONG-TAI/0000-0001-7292-2627; Kim, Tae-Don/0000-0002-5910-4264; KWAK, EUNYEE/0000-0001-8336-9986				Akashi M, 2000, GENE DEV, V14, P645; Albrecht U, 2001, J BIOL RHYTHM, V16, P100, DOI 10.1177/074873001129001791; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Bell-Pedersen D, 2005, NAT REV GENET, V6, P544, DOI 10.1038/nrg1633; Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; Chen YF, 1998, J BIOL RHYTHM, V13, P364, DOI 10.1177/074873098129000192; Cheng YZ, 1998, J NEUROSCI, V18, P741; Darlington TK, 2000, J BIOL RHYTHM, V15, P462, DOI 10.1177/074873000129001576; Forger DB, 2004, J THEOR BIOL, V230, P533, DOI 10.1016/j.jtbi.2004.04.041; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; Hardin PE, 2004, J BIOL RHYTHM, V19, P348, DOI 10.1177/0748730404268052; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; Kim TD, 2005, MOL CELL BIOL, V25, P3232, DOI 10.1128/MCB.25.8.3232-3246.2005; Kojima S, 2003, BIOCHEM BIOPH RES CO, V301, P1, DOI 10.1016/S0006-291X(02)02938-8; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lee JH, 2004, J NEUROCHEM, V91, P634, DOI 10.1111/j.1471-4159.2004.02770.x; Nagoshi E, 2004, CELL, V119, P693, DOI 10.1016/j.cell.2004.11.015; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Reppert SM, 2000, J BIOL RHYTHM, V15, P357, DOI 10.1177/074873000129001459; Sato TK, 2004, NEURON, V43, P527, DOI 10.1016/j.neuron.2004.07.018; So WV, 1997, EMBO J, V16, P7146, DOI 10.1093/emboj/16.23.7146; Stanewsky R, 2002, J BIOL RHYTHM, V17, P293, DOI 10.1177/074873002129002609; Takumi T, 1998, EMBO J, V17, P4753, DOI 10.1093/emboj/17.16.4753; Ueda HR, 2005, NAT GENET, V37, P187, DOI 10.1038/ng1504; Ueda HR, 2002, NATURE, V418, P534, DOI 10.1038/nature00906; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Wang GK, 2001, J NEUROBIOL, V47, P161, DOI 10.1002/neu.1024; Yagita K, 2001, SCIENCE, V292, P278, DOI 10.1126/science.1059542; Yamamoto T, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-18; Yamamoto Y, 2005, MOL CELL BIOL, V25, P1912, DOI 10.1128/MCB.25.5.1912-1921.2005; Yoo SH, 2005, P NATL ACAD SCI USA, V102, P2608, DOI 10.1073/pnas.0409763102; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	34	33	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19100	19106		10.1074/jbc.M511927200	http://dx.doi.org/10.1074/jbc.M511927200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16684777	hybrid			2022-12-25	WOS:000238847000024
J	Nevins, AK; Thurmond, DC				Nevins, Angela K.; Thurmond, Debbie C.			Caveolin-1 functions as a novel Cdc42 guanine nucleotide dissociation inhibitor in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; INSULIN-SECRETING CELLS; LIPID RAFTS; MEMBRANE-FUSION; NULL MICE; IN-VIVO; GLUT4 TRANSLOCATION; SIGNAL-TRANSDUCTION; SNARE PROTEINS; MAP KINASE	The cycling of the small Rho family GTPase Cdc42 is required for insulin granule exocytosis, although the regulatory proteins involved in Cdc42 cycling in pancreatic beta-cells are unknown. Here we demonstrate that the caveolar protein caveolin-1 (Cav-1) is a Cdc42-binding protein in beta-cells. Cav-1 associated with Cdc42-VAMP2-bound granules present near the plasma membrane under basal conditions. However, stimulation with glucose induced the dissociation of Cav-1 from Cdc42- VAMP2 complexes, coordinate with the timing of Cdc42 activation. Analyses of the Cav-1 scaffolding domain revealed a motif conserved in guanine nucleotide dissociation inhibitors (GDIs), which suggested a novel role for Cav-1 as a Cdc42 GDI in beta-cells. The novel role was further supported by: 1) in vitro binding analyses that demonstrated a direct interaction between Cav-1 and Cdc42; 2) GST-Cdc42 interaction assays showing preferential Cav-1 binding to GDP-Cdc42 over that of GTP-Cdc42;3) Cav-1 depletion studies resulting in an inappropriate 40% induction of activated Cdc42 in the absence of stimuli and also a 40% increase in basal insulin release from both MIN6 cells and islets. Expression of wild-type Cav-1 in Cav-1-depleted cells restored basal level secretion to normal, whereas expression of a scaffolding domain mutant of Cav-1 failed to normalize secretion. Taken together, these data suggest that Cav-1 functions as a Cdc42 GDI in beta-cells, maintaining Cdc42 in an inactive state and regulating basal secretion in the absence of stimuli. Through its interaction with the Cdc42-VAMP2-bound insulin granule complex, Cav-1 may contribute to the specific targeting of granules to "active sites" of exocytosis organized by caveolae.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Diabet Res Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Thurmond, DC (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Diabet Res Ctr, Indianapolis, IN 46202 USA.	dthurmon@iupui.edu			NIDDK NIH HHS [T32 DK064466] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK064466] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andrikopoulos S, 2005, J ENDOCRINOL, V187, P45, DOI 10.1677/joe.1.06333; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Bourmeyster N, 1996, BIOCHEM BIOPH RES CO, V218, P54, DOI 10.1006/bbrc.1996.0011; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Cho KA, 2004, J BIOL CHEM, V279, P42270, DOI 10.1074/jbc.M402352200; Cohen AW, 2003, AM J PHYSIOL-CELL PH, V285, pC222, DOI 10.1152/ajpcell.00006.2003; Cohen AW, 2003, AM J PHYSIOL-CELL PH, V284, pC457, DOI 10.1152/ajpcell.00380.2002; COOK S, 1994, NATURE, V369, P361, DOI 10.1038/369361a0; Daniel S, 2002, BIOCHEMISTRY-US, V41, P9663, DOI 10.1021/bi025604p; DerMardirossian C, 2004, MOL CELL, V15, P117, DOI 10.1016/j.molcel.2004.05.019; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fujita Y, 2004, KIDNEY INT, V66, P1794, DOI 10.1111/j.1523-1755.2004.00954.x; Gingras D, 1998, BIOCHEM BIOPH RES CO, V247, P888, DOI 10.1006/bbrc.1998.8885; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; HUBBARD AL, 1983, J CELL BIOL, V96, P230, DOI 10.1083/jcb.96.1.230; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Kashima Y, 2001, J BIOL CHEM, V276, P46046, DOI 10.1074/jbc.M108378200; Kowluru A, 1996, BIOCHEM J, V313, P97, DOI 10.1042/bj3130097; Kowluru A, 1996, J CLIN INVEST, V98, P540, DOI 10.1172/JCI118822; KOWLURU A, 1994, BBA-MOL CELL RES, V1222, P360, DOI 10.1016/0167-4889(94)90041-8; KOWLURU A, 1994, BBA-MOL CELL RES, V1222, P348, DOI 10.1016/0167-4889(94)90040-X; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; Lammert E, 2003, CURR BIOL, V13, P1070, DOI 10.1016/S0960-9822(03)00378-6; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Li GD, 1996, BIOCHEM J, V316, P345, DOI 10.1042/bj3160345; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Mitchell KJ, 2004, DIABETES, V53, P393, DOI 10.2337/diabetes.53.2.393; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Mulder H, 2001, J BIOL CHEM, V276, P6479, DOI 10.1074/jbc.M010364200; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Nevins AK, 2005, J BIOL CHEM, V280, P1944, DOI 10.1074/jbc.M409528200; Nevins AK, 2003, AM J PHYSIOL-CELL PH, V285, pC698, DOI 10.1152/ajpcell.00093.2003; Nomura R, 1999, MOL BIOL CELL, V10, P975, DOI 10.1091/mbc.10.4.975; Nystrom FH, 1999, MOL ENDOCRINOL, V13, P2013, DOI 10.1210/me.13.12.2013; Ohkawara H, 2005, J BIOL CHEM, V280, P10182, DOI 10.1074/jbc.M409547200; Okamoto CT, 1998, ADV DRUG DELIVER REV, V29, P215, DOI 10.1016/S0169-409X(97)00080-X; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; PALADE GE, 1968, J CELL BIOL, V37, P633, DOI 10.1083/jcb.37.3.633; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; Razani B, 2001, J BIOL CHEM, V276, P38121; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; RHODES CJ, 2000, DIABETES MELLITUS FU; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; Rorsman P, 2000, NEWS PHYSIOL SCI, V15, P72; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Saito T, 2003, J BIOL CHEM, V278, P36718, DOI 10.1074/jbc.M305114200; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Saslowsky DE, 2003, J MEMBRANE BIOL, V194, P153, DOI 10.1007/s00232-003-2035-7; SATIN LS, 1985, PFLUG ARCH EUR J PHY, V404, P385, DOI 10.1007/BF00585354; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Schlegel A, 2000, J BIOL CHEM, V275, P21605, DOI 10.1074/jbc.M002558200; Schlegel A, 1998, CELL SIGNAL, V10, P457, DOI 10.1016/S0898-6568(98)00007-2; Schubert W, 2002, J BIOL CHEM, V277, P40091, DOI 10.1074/jbc.M205948200; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; Shisheva A, 1999, BIOCHEMISTRY-US, V38, P11711, DOI 10.1021/bi990200r; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Spurlin BA, 2006, MOL ENDOCRINOL, V20, P183, DOI 10.1210/me.2005-0157; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Thurmond DC, 2003, MOL ENDOCRINOL, V17, P732, DOI 10.1210/me.2002-0333; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Tu S, 2003, J BIOL CHEM, V278, P49293, DOI 10.1074/jbc.M307021200; Usui I, 2003, J BIOL CHEM, V278, P13765, DOI 10.1074/jbc.M208904200; VAN AL, 1997, GENE DEV, V11, P2295; Veluthakal R, 2005, DIABETES, V54, P2576, DOI 10.2337/diabetes.54.9.2576; Wasmeier C, 1999, BIOCHEM J, V341, P563, DOI 10.1042/0264-6021:3410563; Wheeler MB, 1996, ENDOCRINOLOGY, V137, P1340, DOI 10.1210/en.137.4.1340; Xia FZ, 2004, J BIOL CHEM, V279, P24685, DOI 10.1074/jbc.M314314200; Zalcman G, 1996, J BIOL CHEM, V271, P30366, DOI 10.1074/jbc.271.48.30366; Zhao YY, 2002, P NATL ACAD SCI USA, V99, P11375, DOI 10.1073/pnas.172360799; Zong H, 1999, J BIOL CHEM, V274, P4551, DOI 10.1074/jbc.274.8.4551; Zuckerbraun BS, 2005, J SURG RES, V124, P256, DOI 10.1016/j.jss.2004.10.022	75	78	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					18961	18972		10.1074/jbc.M603604200	http://dx.doi.org/10.1074/jbc.M603604200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16714282	hybrid			2022-12-25	WOS:000238847000009
J	Sakamoto, Y; Ogita, H; Hirota, T; Kawakatsu, T; Fukuyama, T; Yasumi, M; Kanzaki, N; Ozaki, M; Takai, Y				Sakamoto, Yasuhisa; Ogita, Hisakazu; Hirota, Takeshi; Kawakatsu, Tomomi; Fukuyama, Taihei; Yasumi, Masato; Kanzaki, Noriyuki; Ozaki, Misa; Takai, Yoshimi			Interaction of integrin alpha(v)beta(3) with nectin - Implication in cross-talk between cell-matrix and cell-cell junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SMALL G-PROTEINS; CANINE KIDNEY-CELLS; C-TERMINAL DOMAIN; ADHERENS JUNCTIONS; TIGHT JUNCTIONS; E-CADHERIN; TYROSINE PHOSPHORYLATION; INTERCELLULAR-JUNCTIONS; EXTRACELLULAR-MATRIX	Cell-matrix and cell-cell junctions cross-talk together, and these two junctions cooperatively regulate cell movement, proliferation, adhesion, and polarization. However, the mechanism of this cross-talk remains unknown. An immunoglobulin-like cell-cell adhesion molecule nectin first trans-interacts with each other to form cell-cell adhesion and induces activation of Rap1, Cdc42, and Rac small G proteins through c-Src. Trans-interacting nectin then recruits another cell-cell adhesion molecule cadherin to the nectin-based cell-cell adhesion sites and forms adherens junctions (AJs). Here, we show that integrin alpha(v)beta(3) functionally and physically associates with nectin. Integrin alpha(v)beta(3) colocalized with nectin at the nectin-based cell-cell adhesion sites. The association of integrin alpha(v)beta(3) with nectin was direct and was mediated through their extracellular regions. This interaction was necessary for the nectin-induced signaling. Focal adhesion kinase, which relays the integrin-initiated outside-in signals to the intracellular signaling molecules, was also involved in the nectin-induced signaling. During the formation of AJs, the high affinity form of integrin alpha(v)beta(3) co-localized with nectin at the primordial cell-cell contact sites, and then after the establishment of AJs, this high affinity form of integrin alpha(v)beta(3) was converted to the low affinity form, which continued to co-localize with nectin. Thus, integrin alpha(v)beta(3) and nectin play pivotal roles in the cross-talk between cell-matrix and cell-cell junctions and the formation of cadherin-based AJs.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp	Ogita, Hisakazu/AAE-4416-2020	Sakamoto, Yasuhisa/0000-0003-1833-6197; Ogita, Hisakazu/0000-0001-6750-1668				ABERCROMBIE M, 1953, EXP CELL RES, V5, P111, DOI 10.1016/0014-4827(53)90098-6; Calderwood DA, 2004, J CELL SCI, V117, P657, DOI 10.1242/jcs.01014; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; FISHER HW, 1967, SCIENCE, V155, P581, DOI 10.1126/science.155.3762.581; FUHUHARA T, 2004, J CELL BIOL, V166, P393; Fujito T, 2005, J CELL BIOL, V171, P165, DOI 10.1083/jcb.200501090; Fukuhara A, 2003, J BIOL CHEM, V278, P51885, DOI 10.1074/jbc.M308015200; Fukuhara A, 2002, ONCOGENE, V21, P7642, DOI 10.1038/sj.onc.1205875; Fukuhara A, 2002, GENES CELLS, V7, P1059, DOI 10.1046/j.1365-2443.2002.00578.x; Fukuyama T, 2005, J BIOL CHEM, V280, P815, DOI 10.1074/jbc.M411099200; GAILIT J, 1988, J BIOL CHEM, V263, P12927; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Honda T, 2003, BIOCHEM BIOPH RES CO, V306, P104, DOI 10.1016/S0006-291X(03)00919-7; Honda T, 2003, GENES CELLS, V8, P481, DOI 10.1046/j.1365-2443.2003.00649.x; Honda T, 2003, GENES CELLS, V8, P51, DOI 10.1046/j.1365-2443.2003.00616.x; Hoshino T, 2005, J BIOL CHEM, V280, P24095, DOI 10.1074/jbc.M414447200; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; Ikeda W, 2004, J BIOL CHEM, V279, P18015, DOI 10.1074/jbc.M312969200; Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576; Kakunaga S, 2004, J BIOL CHEM, V279, P36419, DOI 10.1074/jbc.M406340200; Kawakatsu T, 2005, J BIOL CHEM, V280, P4940, DOI 10.1074/jbc.M408710200; Kawakatsu T, 2002, J BIOL CHEM, V277, P50749, DOI 10.1074/jbc.M209846200; Kiosses WB, 2001, NAT CELL BIOL, V3, P316, DOI 10.1038/35060120; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; Luo BH, 2004, J BIOL CHEM, V279, P10215, DOI 10.1074/jbc.M312732200; Luo BH, 2003, P NATL ACAD SCI USA, V100, P2403, DOI 10.1073/pnas.0438060100; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Marcinkiewicz C, 1997, BLOOD, V90, P1565, DOI 10.1182/blood.V90.4.1565.1565_1565_1575; MonierGavelle F, 1997, J CELL BIOL, V137, P1663, DOI 10.1083/jcb.137.7.1663; Mueller S, 2003, J BIOL CHEM, V278, P31251, DOI 10.1074/jbc.M304166200; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pignatelli M, 1998, J PATHOL, V186, P1, DOI 10.1002/(SICI)1096-9896(199809)186:1<1::AID-PATH135>3.0.CO;2-T; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Sato T, 2006, J BIOL CHEM, V281, P5288, DOI 10.1074/jbc.M510070200; Sato T, 2004, GENES CELLS, V9, P791, DOI 10.1111/j.1365-2443.2004.00763.x; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schreider C, 2002, J CELL SCI, V115, P543; Shimizu K, 2003, J BIOCHEM, V134, P631, DOI 10.1093/jb/mvg198; Siu MKY, 2004, BIOESSAYS, V26, P978, DOI 10.1002/bies.20099; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Takekuni K, 2003, J BIOL CHEM, V278, P5497, DOI 10.1074/jbc.C200707200; Thibault G, 2000, MOL PHARMACOL, V58, P1137, DOI 10.1124/mol.58.5.1137; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wozniak MA, 2004, BBA-MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007; Yano H, 2004, J CELL BIOL, V166, P283, DOI 10.1083/jcb.200312013	54	65	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19631	19644		10.1074/jbc.M600301200	http://dx.doi.org/10.1074/jbc.M600301200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16679515	hybrid			2022-12-25	WOS:000238847000077
J	van de Wijngaart, DJ; van Royen, ME; Hersmus, R; Pike, ACW; Houtsmuller, AB; Jenster, G; Trapman, J; Dubbink, HJ				van de Wijngaart, Dennis J.; van Royen, Martin E.; Hersmus, Remko; Pike, Ashley C. W.; Houtsmuller, Adriaan B.; Jenster, Guido; Trapman, Jan; Dubbink, Hendrikus J.			Novel FXXFF and FXXMF motifs in androgen receptor cofactors mediate high affinity and specific interactions with the ligand-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COOH-TERMINAL INTERACTION; NUCLEAR RECEPTOR; PROSTATE-CANCER; COACTIVATOR INTERACTIONS; MOLECULAR-MECHANISMS; P21-ACTIVATED KINASE; PEPTIDE ANTAGONISTS; TRANSCRIPTIONAL ACTIVATION; ESTROGEN-RECEPTOR; PHAGE DISPLAY	Upon hormone binding, a hydrophobic coactivator binding groove is induced in the androgen receptor (AR) ligand-binding domain (LBD). This groove serves as high affinity docking site for alpha-helical FXXLF motifs present in the AR N-terminal domain and in AR cofactors. Study of the amino acid requirements at position + 4 of the AR FXXLF motif revealed that most amino acid substitutions strongly reduced or completely abrogated AR LBD interaction. Strong interactions were still observed following substitution of Leu + 4 by Phe or Met residues. Leu + 4 to Met or Phe substitutions in the FXXLF motifs of AR cofactors ARA54 and ARA70 were also compatible with strong AR LBD binding. Like the corresponding FXXLF motifs, interactions of FXXFF and FXXMF variants of AR and ARA54 motifs were AR specific, whereas variants of the less AR-selective ARA70 motif displayed increased AR specificity. A survey of currently known AR-binding proteins revealed the presence of an FXXFF motif in gelsolin and an FXXMF motif in PAK6. In vivo fluorescence resonance energy transfer and functional protein-protein interaction assays showed direct, efficient, and specific interactions of both motifs with AR LBD. Mutation of these motifs abrogated interaction of gelsolin and PAK6 proteins with AR. In conclusion, we have demonstrated strong interaction of FXXFF and FXXMF motifs to the AR coactivator binding groove, thereby mediating specific binding of a subgroup of cofactors to the AR LBD.	Erasmus MC, Josephine Nefkens Inst, Dept Pathol, NL-3000 DR Rotterdam, Netherlands; Erasmus MC, Josephine Nefkens Inst, Dept Urol, NL-3000 DR Rotterdam, Netherlands; Univ York, Dept Chem, Struct Biol Lab, York YO10 5DD, N Yorkshire, England	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University of York - UK	Dubbink, HJ (corresponding author), Erasmus MC, Josephine Nefkens Inst, Dept Pathol, POB 1738, NL-3000 DR Rotterdam, Netherlands.	h.dubbink@erasmusmc.nl	Hersmus, Remko/AAE-9953-2019	van Royen, Martin/0000-0002-6814-0996; Hersmus, Remko/0000-0001-5250-3572				Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Bastiaens PIH, 1996, EMBO J, V15, P4246, DOI 10.1002/j.1460-2075.1996.tb00799.x; Bastiaens PIH, 1996, P NATL ACAD SCI USA, V93, P8407, DOI 10.1073/pnas.93.16.8407; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; Callewaert L, 2003, J BIOL CHEM, V278, P8212, DOI 10.1074/jbc.M210744200; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; Chang CY, 2002, MOL ENDOCRINOL, V16, P647, DOI 10.1210/me.16.4.647; Chang CY, 2005, MOL ENDOCRINOL, V19, P2478, DOI 10.1210/me.2005-0072; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; Dubbink HJ, 2004, MOL ENDOCRINOL, V18, P2132, DOI 10.1210/me.2003-0375; DUBBINK HJ, 2006, IN PRESS MOL ENDOCIN; Estebanez-Perpina E, 2005, J BIOL CHEM, V280, P8060, DOI 10.1074/jbc.M407046200; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Gottlieb B, 2004, HUM MUTAT, V23, P527, DOI 10.1002/humu.20044; Greschik I, 2003, CURR TOP MED CHEM, V3, P1573, DOI 10.2174/1568026033451736; Hall JM, 2000, MOL ENDOCRINOL, V14, P2010, DOI 10.1210/me.14.12.2010; He B, 2002, J BIOL CHEM, V277, P25631, DOI 10.1074/jbc.M202809200; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 2004, MOL CELL, V16, P425, DOI 10.1016/j.molcel.2004.09.036; He B, 2002, J BIOL CHEM, V277, P10226, DOI 10.1074/jbc.M111975200; He B, 2001, J BIOL CHEM, V276, P42293, DOI 10.1074/jbc.M107492200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Hsu CL, 2003, J BIOL CHEM, V278, P23691, DOI 10.1074/jbc.M211908200; Hu YC, 2004, J BIOL CHEM, V279, P33438, DOI 10.1074/jbc.M401781200; Hur E, 2004, PLOS BIOL, V2, P1303, DOI 10.1371/journal.pbio.0020274; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Jenster G, 1999, SEMIN ONCOL, V26, P407; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kinyamu HK, 2004, BBA-GENE STRUCT EXPR, V1677, P30, DOI 10.1016/j.bbaexp.2003.09.015; Lee DK, 2003, J CLIN ENDOCR METAB, V88, P4043, DOI 10.1210/jc.2003-030261; Lee SR, 2002, MOL ENDOCRINOL, V16, P85, DOI 10.1210/me.16.1.85; Lee YH, 2004, MOL CELL BIOL, V24, P2103, DOI 10.1128/MCB.24.5.2103-2117.2004; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Needham M, 2000, J STEROID BIOCHEM, V72, P35, DOI 10.1016/S0960-0760(00)00027-3; Nishimura K, 2003, CANCER RES, V63, P4888; Patterson GH, 2000, ANAL BIOCHEM, V284, P438, DOI 10.1006/abio.2000.4708; Pike ACW, 2000, J STEROID BIOCHEM, V74, P261, DOI 10.1016/S0960-0760(00)00102-3; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Schrantz N, 2004, J BIOL CHEM, V279, P1922, DOI 10.1074/jbc.M311145200; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Steketee K, 2002, INT J CANCER, V100, P309, DOI 10.1002/ijc.10495; Steketee K, 2002, EUR J BIOCHEM, V269, P5780, DOI 10.1046/j.1432-1033.2002.03276.x; Ting HJ, 2002, P NATL ACAD SCI USA, V99, P661, DOI 10.1073/pnas.022469899; Trapman J, 2001, EUR J CANCER, V37, pS119; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Wang L, 2004, MOL CELL BIOL, V24, P2202, DOI 10.1128/MCB.24.5.2202-2213.2004; Warnmark A, 2003, MOL ENDOCRINOL, V17, P1901, DOI 10.1210/me.2002-0384; Yang F, 2001, J BIOL CHEM, V276, P15345, DOI 10.1074/jbc.M010311200	53	50	52	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19407	19416		10.1074/jbc.M602567200	http://dx.doi.org/10.1074/jbc.M602567200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16690616	hybrid			2022-12-25	WOS:000238847000056
J	Yan, W; Shao, R				Yan, Wei; Shao, Rong			Transduction of a mesenchyme-specific gene periostin into 293T cells induces cell invasive activity through epithelial-mesenchymal transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; BREAST-CANCER CELLS; TUMOR PROGRESSION; ALPHA(V)BETA(3) INTEGRIN; N-CADHERIN; TYROSINE PHOSPHORYLATION; MOLECULAR-MECHANISMS; ADHESION MOLECULE; FACTOR RECEPTOR-2; CARCINOMA CELLS	Tumor metastasis is a multistep pathological process involved in the final phase of tumor development. During this process, epithelium-derived tumor cells undergo fibroblast-like transformation, referred to as epithelial-mesenchymal transition (EMT), which contributes to aggressive behavior of tumors. We identify periostin, a mesenchyme-specific gene product, as a contributor to EMT and metastatic potential. Stable expression of a periostin transgene in tumorigenic but non-metastatic 293T cells caused cells to undergo fibroblast-like transformation accompanied by increased expressions of vimentin, epidermal growth factor receptor (EGFR), and matrix metalloproteinase-9. The cells expressing ectopic periostin increased cell migration, invasion, and adhesion by 2-9-fold. Invasive characteristics required signaling through integrin alpha(v)beta(5) and EGFR. In addition, periostin-engineered 293T cells formed metastases in immunodeficient mice following either cardiac inoculation or injection into mammary fat pad. These data demonstrate an active role for periostin in EMT and metastasis that requires cross-talk between integrin and EGFR signaling pathways.	Univ Massachusetts Amherst, Baystate Med Ctr, Pioneer Valley Life Sci Inst, Springfield, MA 01107 USA; Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA	Baystate Medical Center; University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst	Shao, R (corresponding author), Univ Massachusetts Amherst, Baystate Med Ctr, Pioneer Valley Life Sci Inst, Springfield, MA 01107 USA.	rong.shao@bhs.org						Bagnato A, 2004, CANCER RES, V64, P1436, DOI 10.1158/0008-5472.CAN-03-2344; Bill HM, 2004, MOL CELL BIOL, V24, P8586, DOI 10.1128/MCB.24.19.8586-8599.2004; Birchmeier C, 1996, ACTA ANAT, V156, P217; Blystone SD, 1996, J BIOL CHEM, V271, P31458, DOI 10.1074/jbc.271.49.31458; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; Boyer B, 1996, ACTA ANAT, V156, P227; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; CHEN WC, 1991, J CELL BIOL, V114, P319, DOI 10.1083/jcb.114.2.319; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Gillan L, 2002, CANCER RES, V62, P5358; Gonzalez HE, 2003, ARCH OTOLARYNGOL, V129, P754, DOI 10.1001/archotol.129.7.754; Hazan RB, 2004, ANN NY ACAD SCI, V1014, P155, DOI 10.1196/annals.1294.016; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Jensen BV, 2003, CLIN CANCER RES, V9, P4423; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Kiemer AK, 2001, ONCOGENE, V20, P6679, DOI 10.1038/sj.onc.1204872; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Kupferman ME, 2000, AM J PATHOL, V157, P1777, DOI 10.1016/S0002-9440(10)64815-8; Lakka SS, 2004, ONCOGENE, V23, P4681, DOI 10.1038/sj.onc.1207616; Max R, 1997, INT J CANCER, V71, P320, DOI 10.1002/(SICI)1097-0215(19970502)71:3<320::AID-IJC2>3.3.CO;2-3; Mizejewski GJ, 1999, P SOC EXP BIOL MED, V222, P124, DOI 10.1046/j.1525-1373.1999.d01-122.x; NYZOVA TV, 2000, MOL CELL, V6, P851; Pulyaeva H, 1997, CLIN EXP METASTAS, V15, P111, DOI 10.1023/A:1018444609098; Putz E, 1999, CANCER RES, V59, P241; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; Sasaki H, 2003, BREAST CANCER RES TR, V77, P245, DOI 10.1023/A:1021899904332; Sasaki H, 2001, CANCER-AM CANCER SOC, V92, P843, DOI 10.1002/1097-0142(20010815)92:4<843::AID-CNCR1391>3.0.CO;2-P; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Senger DR, 1996, AM J PATHOL, V149, P293; Shao R, 2004, MOL CELL BIOL, V24, P3992, DOI 10.1128/MCB.24.9.3992-4003.2004; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 1999, CANCER METAST REV, V18, P31, DOI 10.1023/A:1006256219004; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; Yokota J, 2000, CARCINOGENESIS, V21, P497, DOI 10.1093/carcin/21.3.497	48	136	148	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19700	19708		10.1074/jbc.M601856200	http://dx.doi.org/10.1074/jbc.M601856200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16702213	hybrid			2022-12-25	WOS:000238847000083
J	Lutzelberger, M; Reinert, LS; Das, AT; Berkhout, B; Kjems, J				Lutzelberger, Martin; Reinert, Line S.; Das, Atze T.; Berkhout, Ben; Kjems, Jorgen			A novel splice donor site in the gag-pol gene is required for HIV-1 RNA stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PRE-MESSENGER-RNA; HNRNP A/B PROTEINS; NUCLEAR EXPORT; SR PROTEINS; SILENCER ELEMENT/; FUSION PROTEIN; REV PROTEIN; TAT; ENV	Productive infection and successful replication of human immunodeficiency virus 1 (HIV-1) requires the balanced expression of all viral genes. This is achieved by a combination of alternative splicing events and regulated nuclear export of viral RNA. Because viral splicing is incomplete and intron-containing RNAs must be exported from the nucleus where they are normally retained, it must be ensured that the unspliced HIV-1 RNA is actively exported from the nucleus and protected from degradation by processes such as nonsense-mediated decay. Here we report the identification of a novel 178-nt-long exon located in the gag-pol gene of HIV-1 and its inclusion in at least two different mRNA species. Although efficiently spliced in vitro, this exon appears to be tightly repressed and infrequently used in vivo. The splicing is activated or repressed in vitro by the splicing factors ASF/SF2 and heterogeneous nuclear ribonucleoprotein A1, respectively, suggesting that splicing is controlled by these factors. Interestingly, mutations in the 5'-splice site resulted in a dramatic reduction in the steady-state level of HIV-1 RNA, and this effect was partially reversed by expression of U1small nuclear RNA harboring the compensatory mutation. This implies that U1 small nuclear RNA binding to optimal but non-functional splice sites might have a role in protecting unspliced HIV-1 mRNA from degradation.	Aarhus Univ, Dept Biol Mol, DK-8000 Aarhus C, Denmark; Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1100 DD Amsterdam, Netherlands	Aarhus University; University of Amsterdam; Academic Medical Center Amsterdam	Kjems, J (corresponding author), Aarhus Univ, Dept Biol Mol, CF Mollers Alle 130, DK-8000 Aarhus C, Denmark.	jk@mb.au.dk	Kjems, Jorgen/I-3490-2016	Kjems, Jorgen/0000-0003-4128-9317; Reinert, Line/0000-0002-8317-0886				BENKO DM, 1990, J VIROL, V64, P2505, DOI 10.1128/JVI.64.6.2505-2518.1990; Bilodeau PS, 2001, J VIROL, V75, P8487, DOI 10.1128/JVI.75.18.8487-8497.2001; Blanchette M, 1999, EMBO J, V18, P1939, DOI 10.1093/emboj/18.7.1939; Bohne J, 2005, NUCLEIC ACIDS RES, V33, P825, DOI 10.1093/nar/gki185; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; Domsic JK, 2003, MOL CELL BIOL, V23, P8762, DOI 10.1128/MCB.23.23.8762-8772.2003; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; Fischer U, 1999, NUCLEIC ACIDS RES, V27, P4128, DOI 10.1093/nar/27.21.4128; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; FURTADO MR, 1991, VIROLOGY, V185, P258, DOI 10.1016/0042-6822(91)90773-5; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; Huang YQ, 1996, MOL CELL BIOL, V16, P6046; Jacquenet S, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-33; Jacquenet S, 2001, J BIOL CHEM, V276, P40464, DOI 10.1074/jbc.M104070200; Kammler S, 2001, RNA, V7, P421, DOI 10.1017/S1355838201001212; Kwek KY, 2002, NAT STRUCT BIOL, V9, P800, DOI 10.1038/nsb862; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LU XB, 1990, P NATL ACAD SCI USA, V87, P7598, DOI 10.1073/pnas.87.19.7598; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; Marchand V, 2002, J MOL BIOL, V323, P629, DOI 10.1016/S0022-2836(02)00967-1; MUESING MA, 1985, NATURE, V313, P450, DOI 10.1038/313450a0; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; NASIOULAS G, 1994, J VIROL, V68, P2986, DOI 10.1128/JVI.68.5.2986-2993.1994; Powell DM, 1997, P NATL ACAD SCI USA, V94, P973, DOI 10.1073/pnas.94.3.973; PURCELL DFJ, 1993, J VIROL, V67, P6365, DOI 10.1128/JVI.67.11.6365-6378.1993; ROBERTGUROFF M, 1990, J VIROL, V64, P3391, DOI 10.1128/JVI.64.7.3391-3398.1990; Ropers D, 2004, J BIOL CHEM, V279, P29963, DOI 10.1074/jbc.M404452200; SALFELD J, 1990, EMBO J, V9, P965, DOI 10.1002/j.1460-2075.1990.tb08195.x; SCHWARTZ S, 1990, J VIROL, V64, P2519, DOI 10.1128/JVI.64.6.2519-2529.1990; SMITH J, 1992, J GEN VIROL, V73, P1825, DOI 10.1099/0022-1317-73-7-1825; Tange TO, 2001, EMBO J, V20, P5748; Verhoef K, 2001, J VIROL, V75, P3495, DOI 10.1128/JVI.75.7.3495-3500.2001; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yue B G, 2000, Nucleic Acids Res, V28, pE14, DOI 10.1093/nar/28.5.e14; Zahler AM, 2004, J BIOL CHEM, V279, P10077, DOI 10.1074/jbc.M312743200; Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9	39	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18644	18651		10.1074/jbc.M513698200	http://dx.doi.org/10.1074/jbc.M513698200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16675444	hybrid			2022-12-25	WOS:000238687300044
J	Majumder, P; Gomez, JA; Boss, JM				Majumder, Parimal; Gomez, Jorge A.; Boss, Jeremy M.			The human major histocompatibility complex class IIHLA-DRB1 and HLA-DQA1 genes are separated by a CTCF-binding enhancer-blocking element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II; X-BOX; HISTONE ACETYLATION; CHROMATIN DOMAINS; PROTEIN CTCF; INSULATOR; EXPRESSION; METHYLATION; TRANSCRIPTION; SITES	The human major histocompatibility complex class II (MHC-II) region encodes a cluster of polymorphic heterodimeric glycoproteins HLA-DR, -DQ, and -DP that functions in antigen presentation. Separated by similar to 44 kb of DNA, the HLA-DRB1 and HLA-DQA1 encode MHC-II proteins that function in separate MHC-II heterodimers and are diametrically transcribed. A region of high acetylation located in the intergenic sequences between HLA-DRB1 and HLA-DQA1 was discovered and termed XL9. The peak of acetylation coincided with sequences that bound the insulator protein CCCTC-binding factor as determined by chromatin immunoprecipitations and in vitro DNA binding studies. XL9 was also found to be associated with the nuclear matrix. The activity of the XL9 region was examined and found to be a potent enhancer-blocking element. These results suggest that the XL9 region may have evolved to separate the transcriptional units of the HLA-DR and HLA-DQ genes.	Emory Univ, Dept Microbiol & Immunol, Sch Med, Atlanta, GA 30322 USA	Emory University	Boss, JM (corresponding author), Emory Univ, Dept Microbiol & Immunol, Sch Med, 1510 Clifton Rd, Atlanta, GA 30322 USA.	boss@microbio.emory.edu			NIGMS NIH HHS [GM47310, T32 GM008490] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047310, T32GM008490] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Ausubel F.M., 2006, CURRENT PROTOCOLS MO; Beck S, 1999, NATURE, V401, P921, DOI 10.1038/44853; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Beresford GW, 2001, NAT IMMUNOL, V2, P652, DOI 10.1038/89810; Boss JM, 2003, CURR OPIN IMMUNOL, V15, P105, DOI 10.1016/S0952-7915(02)00015-8; Burgess-Beusse B, 2002, P NATL ACAD SCI USA, V99, P16433, DOI 10.1073/pnas.162342499; Byrd K, 2003, J CELL BIOL, V162, P565, DOI 10.1083/jcb.200305013; Cerrato F, 2005, NAT GENET, V37, P786, DOI 10.1038/ng0805-786; Coiras MT, 2002, TISSUE ANTIGENS, V60, P505, DOI 10.1034/j.1399-0039.2002.600606.x; Daujat S, 2002, CURR BIOL, V12, P2090, DOI 10.1016/S0960-9822(02)01387-8; Farrell CM, 2002, MOL CELL BIOL, V22, P3820, DOI 10.1128/MCB.22.11.3820-3831.2002; Filippova GN, 2001, NAT GENET, V28, P335, DOI 10.1038/ng570; Gerasimova TI, 2000, MOL CELL, V6, P1025, DOI 10.1016/S1097-2765(00)00101-5; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GERMAIN RN, 1986, ANNU REV IMMUNOL, V4, P281, DOI 10.1146/annurev.iy.04.040186.001433; GEYER PK, 1992, GENE DEV, V6, P1865, DOI 10.1101/gad.6.10.1865; Gomez JA, 2005, J IMMUNOL, V175, P1030, DOI 10.4049/jimmunol.175.2.1030; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P6269, DOI 10.1093/nar/19.22.6269; Kalkhoven E, 2004, BIOCHEM PHARMACOL, V68, P1145, DOI 10.1016/j.bcp.2004.03.045; Krawczyk M, 2004, J IMMUNOL, V173, P6200, DOI 10.4049/jimmunol.173.10.6200; Labrador M, 2002, CELL, V111, P151, DOI 10.1016/S0092-8674(02)01004-8; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Li QL, 2002, BLOOD, V100, P3077, DOI 10.1182/blood-2002-04-1104; Long AB, 2006, MOL IMMUNOL, V43, P395, DOI 10.1016/j.molimm.2005.03.008; LouisPlence P, 1997, J IMMUNOL, V159, P3899; Magdinier F, 2004, J BIOL CHEM, V279, P25381, DOI 10.1074/jbc.M403121200; Masternak K, 2003, NAT IMMUNOL, V4, P132, DOI 10.1038/ni883; Muczynski KA, 2001, KIDNEY INT, V59, P488, DOI 10.1046/j.1523-1755.2001.059002488.x; Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6; Pikaart MI, 1998, GENE DEV, V12, P2852, DOI 10.1101/gad.12.18.2852; Prawitt D, 2005, P NATL ACAD SCI USA, V102, P4085, DOI 10.1073/pnas.0500037102; Quitschke WW, 2000, NUCLEIC ACIDS RES, V28, P3370, DOI 10.1093/nar/28.17.3370; Redondo M, 1998, EUR J IMMUNOGENET, V25, P385, DOI 10.1046/j.1365-2370.1998.00116.x; REITH W, 1994, J BIOL CHEM, V269, P20020; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; Sparago A, 2004, NAT GENET, V36, P958, DOI 10.1038/ng1410; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Szabo PE, 2004, MOL CELL BIOL, V24, P4791, DOI 10.1128/MCB.24.11.4791-4800.2004; Ting JPY, 2002, CELL, V109, pS21, DOI 10.1016/S0092-8674(02)00696-7; VANEWIJK W, 1988, CELL, V53, P357, DOI 10.1016/0092-8674(88)90156-0; Weber DA, 1996, SCIENCE, V274, P618, DOI 10.1126/science.274.5287.618; West AG, 2004, MOL CELL, V16, P453, DOI 10.1016/j.molcel.2004.10.005; West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702; Yusufzai TM, 2004, P NATL ACAD SCI USA, V101, P8620, DOI 10.1073/pnas.0402938101; Yusufzai TM, 2004, MOL CELL, V13, P291, DOI 10.1016/S1097-2765(04)00029-2; Zhu XS, 2000, MOL CELL BIOL, V20, P6051, DOI 10.1128/MCB.20.16.6051-6061.2000	52	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18435	18443		10.1074/jbc.M601298200	http://dx.doi.org/10.1074/jbc.M601298200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16675454	hybrid			2022-12-25	WOS:000238687300022
J	Rodriguez, E; Roland, SK; Plaas, A; Roughley, PJ				Rodriguez, Elida; Roland, Samantha Kim; Plaas, Anna; Roughley, Peter J.			The glycosaminoglycan attachment regions of human aggrecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE CODING SEQUENCE; CHONDROITIN SULFATE PROTEOGLYCAN; HYALURONAN-BINDING REGION; DEDUCED PRIMARY-STRUCTURE; SKELETAL KERATAN SULFATE; CARTILAGE PROTEOGLYCAN; CORE PROTEIN; LINKED OLIGOSACCHARIDES; OSTEOARTHRITIS; ASSOCIATION	Aggrecan possesses both chondroitin sulfate (S) and keratan sulfate (KS) chains attached to its core protein, which reside mainly in the central region of the molecule termed the glycosaminoglycan-attachment region. This region is further subdivided into the KS-rich domain and two adjacent CS-rich domains (CS1 and CS2). The CS1 domain of the human is unique in exhibiting length polymorphism due to a variable number of tandem amino acid repeats. The focus of this work was to determine how length polymorphism affects the structure of the CS1 domain and whether CS and KS chains can coexist in the different glycosaminoglycan-attachment domains. The CS1 domain possesses several amino acid repeat sequences that divide it into three sub-domains. Variation in repeat number may occur in any of these domains, with the consequence that CS1 domains of the same length may possess different amino acid sequences. There was no evidence to support the presence of KS in either the CS1 or the CS2 domains nor the presence of CS in the KS-rich domain. The structure of the CS chains was shown to vary between the CS1 and CS2 domains, particularly in the adult, with variation occurring in chain length and the sulfation of the non-reducing terminal N-acetylgalactosamine residue. CS chains in the adult CS2 domain were shorter than those in the CS1 domain and possessed disulfated terminal residues in addition to monosulfated residues. There was, however, no change in the sulfation pattern of the disaccharide repeats in the CS chains from the two domains.	Shriners Hosp Children, Genet Unit, Montreal, PQ H3G 1A6, Canada; Univ S Florida, Coll Med, Dept Internal Med, Tampa, FL 33612 USA	McGill University; State University System of Florida; University of South Florida	Roughley, PJ (corresponding author), Shriners Hosp Children, Genet Unit, 1529 Cedar Ave, Montreal, PQ H3G 1A6, Canada.	proughley@shriners.mcgill.ca						BARRY FP, 1994, MATRIX BIOL, V14, P323, DOI 10.1016/0945-053X(94)90198-8; BARRY FP, 1995, J BIOL CHEM, V270, P20516, DOI 10.1074/jbc.270.35.20516; BARRY FP, 1992, BIOCHEM J, V286, P761, DOI 10.1042/bj2860761; BJORNSSON S, 1993, ANAL BIOCHEM, V210, P292, DOI 10.1006/abio.1993.1198; Calabro A, 2001, OSTEOARTHR CARTILAGE, V9, pS16, DOI 10.1053/joca.2001.0439; CATERSON B, 1990, J CELL SCI, V97, P411; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; Doege KJ, 1997, J BIOL CHEM, V272, P13974, DOI 10.1074/jbc.272.21.13974; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FOSANG AJ, 1989, BIOCHEM J, V261, P801, DOI 10.1042/bj2610801; HASCALL VC, 1969, J BIOL CHEM, V244, P2384; HASCALL VC, 1988, ISI ATLAS-BIOCHEM, V1, P189; HEINEGARD D, 1974, ARCH BIOCHEM BIOPHYS, V165, P427, DOI 10.1016/0003-9861(74)90182-9; HEINEGARD D, 1977, J BIOL CHEM, V252, P1971; Hering TM, 1997, ARCH BIOCHEM BIOPHYS, V345, P259, DOI 10.1006/abbi.1997.0261; HOLLANDER AP, 1991, CLIN EXP IMMUNOL, V83, P52; Horton WE, 1998, OSTEOARTHR CARTILAGE, V6, P245, DOI 10.1053/joca.1998.0117; HUGHES CE, 1992, J BIOL CHEM, V267, P16011; Karlsson M, 2000, ANAL BIOCHEM, V286, P51, DOI 10.1006/abio.2000.4767; Kawaguchi Y, 1999, SPINE, V24, P2456, DOI 10.1097/00007632-199912010-00006; Kirk KM, 2003, TWIN RES, V6, P62, DOI 10.1375/136905203762687915; KRUEGER RC, 1990, J BIOL CHEM, V265, P12075; NILSSON B, 1982, J BIOL CHEM, V257, P920; OEGEMA TR, 1993, CLIN SPORT MED, V12, P419; Plaas AH, 2001, J BIOL CHEM, V276, P39788, DOI 10.1074/jbc.M103227200; Plaas AHK, 1997, J BIOL CHEM, V272, P20603, DOI 10.1074/jbc.272.33.20603; POOLE AR, 1989, BIOCHEM J, V260, P849, DOI 10.1042/bj2600849; RIZKALLA G, 1992, J CLIN INVEST, V90, P2268, DOI 10.1172/JCI116113; ROUGHLEY PJ, 1980, J BIOL CHEM, V255, P217; Roughley PJ, 1996, OSTEOARTHR CARTILAGE, V4, P153, DOI 10.1016/S1063-4584(96)80011-2; ROUGHLEY PJ, 1978, CONNECT TISSUE RES, V6, P145, DOI 10.3109/03008207809152624; Roughley PJ, 2002, BIOCHEM SOC T, V30, P869, DOI 10.1042/BST0300869; SANTER V, 1982, BIOCHIM BIOPHYS ACTA, V716, P277, DOI 10.1016/0304-4165(82)90017-4; WALCZ E, 1994, GENOMICS, V22, P364, DOI 10.1006/geno.1994.1396; Watanabe H, 1998, J BIOCHEM, V124, P687, DOI 10.1093/oxfordjournals.jbchem.a022166	36	22	23	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18444	18450		10.1074/jbc.M512531200	http://dx.doi.org/10.1074/jbc.M512531200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16679517	hybrid			2022-12-25	WOS:000238687300023
J	Zhu, MH; Rhee, I; Liu, Y; Zhang, WG				Zhu, Minghua; Rhee, Inmoo; Liu, Yan; Zhang, Weiguo			Negative regulation of Fc epsilon RI-mediated signaling and mast cell function by the adaptor protein LAX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY IGE RECEPTOR; ALLERGIC RESPONSE; TYROSINE KINASE; ACTIVATION; AGGREGATION; ANTIGEN; SLP-76; GADS	LAX is a transmembrane adaptor protein that is expressed in both T and B cells. Upon stimulation via the antigen receptors, it is tyrosine-phosphorylated and binds Grb2 and the p85 subunit of phosphatidylinositol 3-kinase. Disruption of the Lax gene causes hyperresponsiveness in T and B lymphocytes. Here, we showed that LAX was also expressed in mast cells. Upon engagement of the Fc epsilon RI, LAX was also phosphorylated and interacted with Grb2 and p85. LAX-deficient mast cells were hyperresponsive to stimulation via the Fc epsilon RI, as evidenced by enhanced degranulation, p38 MAPK, Akt, and phosphatidylinositol 3-kinase activation. This hyperresponsiveness was likely a consequence of reduced LAB expression after sensitization of mast cells with anti-dinitrophenyl IgE. In addition, Fc epsilon RI-mediated cytokine production and cell survival were also enhanced. These data suggested that LAX negatively regulates mast cell function.	Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Duke University	Zhang, WG (corresponding author), Duke Univ, Med Ctr, Dept Immunol, Box 3010, Durham, NC 27710 USA.	zhang033@mc.duke.edu	Zhu, Minghua/ABH-2671-2020		NIAID NIH HHS [AI056156, AI08674, R01 AI048674] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056156, R56AI056156, R01AI048674] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		EISEMAN E, 1992, NATURE, V355, P78; ElHillal O, 1997, P NATL ACAD SCI USA, V94, P1919, DOI 10.1073/pnas.94.5.1919; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Kawakami T, 2005, J IMMUNOL, V175, P4167, DOI 10.4049/jimmunol.175.7.4167; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Manetz TS, 2001, MOL CELL BIOL, V21, P3763, DOI 10.1128/MCB.21.11.3763-3774.2001; MINOGUCHI K, 1994, J BIOL CHEM, V269, P16902; Nadler M J, 2000, Adv Immunol, V76, P325; Nadler MJS, 2002, NAT IMMUNOL, V3, P707, DOI 10.1038/ni0802-707; Ott VL, 2000, J ALLERGY CLIN IMMUN, V106, P429, DOI 10.1067/mai.2000.109428; Parravicini V, 2002, NAT IMMUNOL, V3, P741, DOI 10.1038/ni817; Pivniouk VI, 1999, J CLIN INVEST, V103, P1737; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; Rivera J, 2002, CURR OPIN IMMUNOL, V14, P688, DOI 10.1016/S0952-7915(02)00396-5; Saitoh S, 2000, IMMUNITY, V12, P525, DOI 10.1016/S1074-7613(00)80204-6; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhu MH, 2004, J EXP MED, V200, P991, DOI 10.1084/jem.20041223; Zhu MH, 2002, J BIOL CHEM, V277, P46151, DOI 10.1074/jbc.M208946200; Zhu MH, 2005, J IMMUNOL, V174, P5612, DOI 10.4049/jimmunol.174.9.5612	22	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18408	18413		10.1074/jbc.M601535200	http://dx.doi.org/10.1074/jbc.M601535200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16672218	hybrid			2022-12-25	WOS:000238687300019
J	Jia, XM; Olson, DJH; Ross, ARS; Wu, LY				Jia, Xuming; Olson, Douglas J. H.; Ross, Andrew R. S.; Wu, Lingyun			Structural and functional changes in human insulin induced by methylglyoxal	FASEB JOURNAL			English	Article						MG-insulin adduct; mass spectrometry; glucose uptake; insulin release	GLYCATION END-PRODUCTS; RESISTANCE; PROTEINS; PREVENTION; GLUCOSE; OBESITY	Elevated methylglyoxal (MG) levels have been reported in insulin-resistance syndrome. The present study investigated whether MG, a highly reactive metabolite of glucose, induced structural and functional changes of insulin. Incubation of human insulin with MG in vitro yielded MG-insulin adducts, as evidenced by additional peaks observed on mass spectrometric (MS) analysis of the incubates. Tandem MS analysis of insulin B-chain adducts confirmed attachment of MG at an arginine residue. [H-3]-2-deoxyglucose uptake by 3T3-L1 adipocytes was significantly and concentration-dependently decreased after the treatment with MG-insulin adducts, in comparison with the effect of native insulin at the same concentrations. A significant decrease of glucose uptake induced by MG-insulin adducts was also observed in L8 skeletal muscle cells. MG alone had no effect on glucose uptake or the transcriptional expression of insulin receptor. Unlike native insulin, MG-insulin adducts did not inhibit insulin release from pancreatic beta-cells. The degradation of MG-insulin through liver cells was also decreased. In conclusion, MG modifies insulin by attaching to internal arginine residue in beta-chain of insulin. The formation of this MG-insulin adduct decreases insulin-mediated glucose uptake, impairs autocrine control of insulin secretion, and decreases insulin clearance. These structural and functional abnormalities of insulin molecule may contribute to the pathogenesis of insulin resistance.	Univ Saskatchewan, Coll Med, Dept Pharmacol, Saskatoon, SK S7N 5E5, Canada; Natl Res Council Canada, Inst Plant Biotechnol, Saskatoon, SK S7N 0W9, Canada	University of Saskatchewan; National Research Council Canada	Wu, LY (corresponding author), Univ Saskatchewan, Coll Med, Dept Pharmacol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	liw070@duke.usask.ca						Ahmed N, 2002, BIOCHEM J, V364, P1; Alzaid AA, 1996, ACTA DIABETOL, V33, P87; Babaei-Jadidi R, 2003, DIABETES, V52, P2110, DOI 10.2337/diabetes.52.8.2110; Bradley M, 1999, Health Technol Assess, V3, P1; Chaplen FWR, 1998, P NATL ACAD SCI USA, V95, P5533, DOI 10.1073/pnas.95.10.5533; DEFRONZO RA, 1979, AM J PHYSIOL, V236, pE328, DOI 10.1152/ajpendo.1979.236.4.E328; Du J, 2003, J CELL BIOCHEM, V88, P1235, DOI 10.1002/jcb.10478; GLOMB MA, 1995, J BIOL CHEM, V270, P10017, DOI 10.1074/jbc.270.17.10017; GORDEN P, 1978, SCIENCE, V200, P782, DOI 10.1126/science.644321; Iezzi M, 1999, MOL ENDOCRINOL, V13, P202, DOI 10.1210/me.13.2.202; Jana CK, 2002, ARCH BIOCHEM BIOPHYS, V397, P433, DOI 10.1006/abbi.2001.2690; Jones CNO, 2000, AM J PHYSIOL-ENDOC M, V278, pE501, DOI 10.1152/ajpendo.2000.278.3.E501; Kalapos MP, 1999, TOXICOL LETT, V110, P145, DOI 10.1016/S0378-4274(99)00160-5; KLIP A, 1994, FASEB J, V8, P43, DOI 10.1096/fasebj.8.1.8299889; Li YM, 1996, P NATL ACAD SCI USA, V93, P3902, DOI 10.1073/pnas.93.9.3902; LiCalzi S, 1997, AM J PHYSIOL-ENDOC M, V273, pE801, DOI 10.1152/ajpendo.1997.273.4.E801; LO TWC, 1994, J BIOL CHEM, V269, P32299; Mizutani K, 1999, J HYPERTENS, V17, P481, DOI 10.1097/00004872-199917040-00005; Nagaraj RH, 2002, ARCH BIOCHEM BIOPHYS, V402, P110, DOI 10.1016/S0003-9861(02)00067-X; OLEFSKY JM, 1981, AM J MED, V70, P151, DOI 10.1016/0002-9343(81)90422-8; Permutt MA, 2005, J CLIN INVEST, V115, P1431, DOI 10.1172/JCI24758; Poggioli S, 2002, EXP GERONTOL, V37, P1207, DOI 10.1016/S0531-5565(02)00145-6; Portero-Otin M, 2002, DIABETES, V51, P1535, DOI 10.2337/diabetes.51.5.1535; Rett K, 1999, DIABETES OBES METAB, V1, pS8, DOI 10.1046/j.1463-1326.1999.0010s1008.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591; THORNALLEY PJ, 1989, DIABETES RES CLIN PR, V7, P115, DOI 10.1016/0168-8227(89)90101-0; VanderJagt DL, 1997, BIOCHEM PHARMACOL, V53, P1133, DOI 10.1016/S0006-2952(97)00090-7; Wang XX, 2005, J HYPERTENS, V23, P1565, DOI 10.1097/01.hjh.0000173778.85233.1b; Wang XX, 2004, KIDNEY INT, V66, P2315, DOI 10.1111/j.1523-1755.2004.66034.x; WHITE MF, 1994, J BIOL CHEM, V269, P1; Wu LY, 2002, HYPERTENSION, V39, P809, DOI 10.1161/hy0302.105207; Wu LY, 2005, CAN J PHYSIOL PHARM, V83, P63, DOI 10.1139/Y04-112; [No title captured]	34	88	94	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1555	+		10.1096/fj.05-5478fje	http://dx.doi.org/10.1096/fj.05-5478fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16723378				2022-12-25	WOS:000240266000049
J	Lopez-Lazaro, M				Lopez-Lazaro, Miguel			HIF-1: hypoxia-inducible factor or dysoxia-inducible factor?	FASEB JOURNAL			English	Article						oxygen; ATP; glycolysis; hydrogen peroxide; cancer	MITOCHONDRIAL COMPLEX-III; HEPATIC STELLATE CELLS; INTRACELLULAR PH; HYDROGEN-PEROXIDE; NA+/H+ EXCHANGER; GROWTH-FACTOR; CANCER; ACTIVATION; EXPRESSION; HIF-1-ALPHA	Hypoxia-inducible factor 1 (HIF-1) activates the transcription of genes involved in diverse aspects of cellular and integrative physiology, including energy metabolism, cell growth, survival, invasion, migration or angiogenesis. The activity of this transcription factor is known to be increased by hypoxia, but also by a growing number of apparently unrelated factors that can activate it even in nonhypoxic conditions. Here I propose a model in which an alteration in oxygen metabolism is the key cellular event involved in HIF-1 activation under hypoxic and nonhypoxic conditions. This new perspective unifies previously unrelated observations and predicts cellular processes and therapeutic strategies that may modify HIF-1 activity. This may have relevance, for instance, to cancer, as HIF-1 overexpression is observed in many human cancers and has been associated with increased patient mortality.	Univ Seville, Fac Pharm, Dept Pharmacol, Seville 41011, Spain	University of Sevilla	Lopez-Lazaro, M (corresponding author), Univ Seville, Fac Pharm, Dept Pharmacol, C Prof Garcia Gonzalez, Seville 41011, Spain.	mlopezlazaro@us.es						Alberts B, 2002, MOL BIOL CELL; Brunelle JK, 2005, CELL METAB, V1, P409, DOI 10.1016/j.cmet.2005.05.002; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Cao Q, 2004, J BIOL CHEM, V279, P4292, DOI 10.1074/jbc.M308351200; Cardone RA, 2005, NAT REV CANCER, V5, P786, DOI 10.1038/nrc1713; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chou WC, 2004, P NATL ACAD SCI USA, V101, P4578, DOI 10.1073/pnas.0306687101; Cuezva JM, 2002, CANCER RES, V62, P6674; Dalgard CL, 2004, BIOCHEM J, V380, P419, DOI 10.1042/BJ20031647; Di Sario A, 2001, J HEPATOL, V34, P378, DOI 10.1016/S0168-8278(00)00062-3; DiGiammarino EL, 2002, NAT STRUCT BIOL, V9, P12, DOI 10.1038/nsb730; ERECINSKA M, 1995, J NEUROCHEM, V65, P2765; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001; Haddad JJ, 2001, FEBS LETT, V505, P269, DOI 10.1016/S0014-5793(01)02833-2; Harguindey S, 2005, BBA-REV CANCER, V1756, P1, DOI 10.1016/j.bbcan.2005.06.004; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Isidoro A, 2004, BIOCHEM J, V378, P17, DOI 10.1042/BJ20031541; Jung YJ, 2003, FASEB J, V17, P2115, DOI 10.1096/fj.03-0329fje; Kamat CD, 2005, TOXICOL SCI, V86, P248, DOI 10.1093/toxsci/kfi190; Kim M, 2005, CARCINOGENESIS, V26, P1553, DOI 10.1093/carcin/bgi104; Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851; Lee M, 2003, J BIOL CHEM, V278, P39653, DOI 10.1074/jbc.M306104200; LU H, 2005, J BIOL CHEM; Lu HS, 2002, J BIOL CHEM, V277, P23111, DOI 10.1074/jbc.M202487200; Mansfield KD, 2005, CELL METAB, V1, P393, DOI 10.1016/j.cmet.2005.05.003; Mekhail K, 2004, NAT CELL BIOL, V6, P642, DOI 10.1038/ncb1144; PERONA R, 1988, NATURE, V334, P438, DOI 10.1038/334438a0; Pirkebner D, 2004, J CELL PHYSIOL, V198, P295, DOI 10.1002/jcp.10408; Reshkin SJ, 2000, FASEB J, V14, P2185, DOI 10.1096/fj.00-0029com; ROTHENBERG P, 1983, J BIOL CHEM, V258, P2644; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; SIMCHOWITZ L, 1985, J CLIN INVEST, V76, P1079, DOI 10.1172/JCI112061; Srinivas V, 2001, J BIOL CHEM, V276, P21995, DOI 10.1074/jbc.C100177200; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Thomas R, 2005, BIOCHEM BIOPH RES CO, V334, P543, DOI 10.1016/j.bbrc.2005.06.114; Thomas SR, 2002, J BIOL CHEM, V277, P6017, DOI 10.1074/jbc.M109107200; TRIVEDI B, 1966, J BIOL CHEM, V241, P4110; van der Logt EMJ, 2005, FREE RADICAL BIO MED, V39, P182, DOI 10.1016/j.freeradbiomed.2005.03.003; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang FS, 2004, J BIOL CHEM, V279, P10331, DOI 10.1074/jbc.M308013200; Xu RH, 2005, CANCER RES, V65, P613; Zhong H, 2002, CANCER LETT, V181, P233, DOI 10.1016/S0304-3835(02)00053-8	47	68	79	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					828	832		10.1096/fj.05-5168hyp	http://dx.doi.org/10.1096/fj.05-5168hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675839				2022-12-25	WOS:000240157700004
J	Chen, SY; Cai, C; Fisher, CJ; Zheng, Z; Omwancha, J; Hsieh, CL; Shemshedini, L				Chen, S-Y; Cai, C.; Fisher, C. J.; Zheng, Z.; Omwancha, J.; Hsieh, C-L; Shemshedini, L.			c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation	ONCOGENE			English	Article						androgen receptor; c-Jun; coactivation proliferation	TRANSCRIPTIONAL ACTIVITY; RESPONSE ELEMENT; SERINE-PROTEASE; AMINO-TERMINUS; TMPRSS2 GENE; EXPRESSION; PROGRESSION; ACTIVATION; LNCAP; DIMERIZATION	Androgens and the androgen receptor (AR) are involved in the growth and progression of prostate cancer. Our previous studies suggest that the proto-oncoprotein c-Jun is an AR coactivator that stimulates AR transactivation by mediating receptor dimerization and subsequent DNA binding. To study the physiological relevance of this c-Jun activity on AR, we have generated stable LNCaP cell lines expressing different levels of c-Jun. These cell lines exhibit a direct correlation between endogenous c-Jun levels and AR transcriptional activity and expression of endogenous androgen-regulated genes. Disruption by antisense RNA of endogenous c-Jun expression in LNCaP cells strongly compromises the androgen-dependent proliferation of these cells. In contrast, expression of a c-Jun mutant, which is fully active in coactivation of AR but deficient in AP-1 transactivation, significantly enhances androgen-dependent proliferation. This. nding indicates that the coactivation function of c-Jun is sufficient for regulating androgen-induced growth of LNCaP cells. c-Jun also enhances AR transactivtion in androgen-independent LNCaP cells, which closely mimic hormone-refractory prostate cancer cells in gene expression and growth behavior. Importantly, siRNA-mediated repression of endogenous c-Jun expression results in markedly reduced growth of these cells, strongly suggesting an important biological role for c-Jun in hormone-efractory prostate cancer.	Univ Toledo, Dept Sci Biol, Toledo, OH 43603 USA	University System of Ohio; University of Toledo	Shemshedini, L (corresponding author), Univ Toledo, Dept Sci Biol, 2801,W Bancroft Ave, Toledo, OH 43603 USA.	lshemsh@utnet.utoledo.edu	CHEN, Shaoyong/ABF-3357-2021; Cai, Changmeng/AAE-6835-2020	Cai, Changmeng/0000-0002-8701-2586				Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Acevedo ML, 2004, ESSAYS BIOCHEM, V40, P73, DOI 10.1042/bse0400073; Ameyar M, 2003, BIOCHIMIE, V85, P747, DOI 10.1016/j.biochi.2003.09.006; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Arnold JT, 2002, ENDOCR-RELAT CANCER, V9, P61, DOI 10.1677/erc.0.0090061; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Belandia B, 2005, MOL CELL BIOL, V25, P1425, DOI 10.1128/MCB.25.4.1425-1436.2005; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bubulya A, 2001, J BIOL CHEM, V276, P44704, DOI 10.1074/jbc.M107346200; Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583; Bubulya A, 2000, ENDOCRINE, V13, P55, DOI 10.1385/ENDO:13:1:55; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Culig Z, 2000, MICROSC RES TECHNIQ, V51, P447; Culig Z, 2004, J STEROID BIOCHEM, V92, P265, DOI 10.1016/j.jsbmb.2004.10.003; Debes JD, 2002, CANCER RES, V62, P5632; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; GLEAVE ME, 1992, CANCER RES, V52, P1598; Gross M, 2004, ONCOGENE, V23, P3059, DOI 10.1038/sj.onc.1207443; Haelens A, 2003, BIOCHEM J, V369, P141, DOI 10.1042/BJ20020912; Han GZ, 2005, P NATL ACAD SCI USA, V102, P1151, DOI 10.1073/pnas.0408925102; Heisler LE, 1997, MOL CELL ENDOCRINOL, V126, P59, DOI 10.1016/S0303-7207(96)03970-6; Henttu P, 1998, BIOCHEM BIOPH RES CO, V244, P167, DOI 10.1006/bbrc.1998.8238; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Isaacs JT, 1999, UROL CLIN N AM, V26, P263, DOI 10.1016/S0094-0143(05)70066-5; Jenster G, 1999, SEMIN ONCOL, V26, P407; Korkmaz CG, 2004, J ENDOCRINOL, V182, P377, DOI 10.1677/joe.0.1820377; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; Lin BY, 1999, CANCER RES, V59, P4180; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; Linja MJ, 2004, J STEROID BIOCHEM, V92, P255, DOI 10.1016/j.jsbmb.2004.10.012; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; MURTHA P, 1993, BIOCHEMISTRY-US, V32, P6459, DOI 10.1021/bi00076a020; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; PaoloniGiacobino A, 1997, GENOMICS, V44, P309, DOI 10.1006/geno.1997.4845; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Salas TR, 2004, J BIOL CHEM, V279, P19191, DOI 10.1074/jbc.M309560200; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUURMANS ALG, 1988, PROSTATE, V12, P55, DOI 10.1002/pros.2990120108; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Song LN, 2004, MOL ENDOCRINOL, V18, P70, DOI 10.1210/me.2003-0189; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Tillman K, 1998, ENDOCRINE, V9, P193, DOI 10.1385/ENDO:9:2:193; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Vaarala MH, 2001, INT J CANCER, V94, P705, DOI 10.1002/ijc.1526; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Wise SC, 1998, ONCOGENE, V16, P2001, DOI 10.1038/sj.onc.1201697; Yeap BB, 1999, ENDOCRINOLOGY, V140, P3282, DOI 10.1210/en.140.7.3282; Zheng Z, 2006, J BIOL CHEM, V281, P4002, DOI 10.1074/jbc.M509260200; Zhou HJ, 2005, CANCER RES, V65, P7976, DOI 10.1158/0008-5472.CAN-04-4076	60	51	52	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	54					7212	7223		10.1038/sj.onc.1209705	http://dx.doi.org/10.1038/sj.onc.1209705			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16732317				2022-12-25	WOS:000242046900010
J	Doig, J; Anderson, C; Lawrence, NJ; Selfridge, J; Brownstein, DG; Melton, DW				Doig, J.; Anderson, C.; Lawrence, N. J.; Selfridge, J.; Brownstein, D. G.; Melton, D. W.			Mice with skin-specific DNA repair gene (Ercc1) inactivation are hypersensitive to ultraviolet irradiation-induced skin cancer and show more rapid actinic progression	ONCOGENE			English	Article						Ercc1; nucleotide; excision repair; skin cancer; ultraviolet irradiation	TRANSCRIPTION-COUPLED REPAIR; STEM-CELLS; HPRT GENE; DEFICIENCY; EXPRESSION; LACKING; TUMORS; CARCINOGENESIS; SUSCEPTIBILITY; DISRUPTION	Ercc1 has an essential role in the nucleotide excision repair (NER) pathway that protects against ultraviolet (UV)-induced DNA damage and is also involved in additional repair pathways. The premature death of simple Ercc1 mouse knockouts meant that we were unable to study the role of Ercc1 in the skin. To do this, we have used the Cre-lox system to generate a skin-specific Ercc1 knockout. With a Cre transgene under control of the bovine keratin 5 promoter we achieved 100% recombination of the Ercc1 gene in the epidermis. Hairless mice with Ercc1-deficient skin were hypersensitive to the short-term effects of UV irradiation, showing a very low minimal erythemal dose and a dramatic hyperproliferative response. Ultraviolet-irradiated mice with Ercc1-deficient skin developed epidermal skin tumours much more rapidly than controls. These tumours appeared to arise earlier in actinic progression and grew more rapidly than tumours on control mice. These responses are more pronounced than have been reported for other NER-deficient mice, demonstrating that Ercc1 has a keyrole in protecting against UV-induced skin cancer.	Univ Edinburgh, Western Gen Hosp, Sir Alastair Currie Canc Res UK Labs, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland; Royal Infirm Edinburgh NHS Trust, Dept Pathol, Edinburgh, Midlothian, Scotland; Univ Edinburgh, Queens Med Res Inst, Res Anim Pathol Core Lab, Edinburgh, Midlothian, Scotland	University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh	Melton, DW (corresponding author), Univ Edinburgh, Western Gen Hosp, Sir Alastair Currie Canc Res UK Labs, Mol Med Ctr, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	David.Melton@ed.ac.uk		SELFRIDGE, JIM/0000-0003-2473-4386				Berg RJW, 2000, CANCER RES, V60, P2858; Berg RJW, 1997, CANCER RES, V57, P581; CANFIELD PJ, 1988, PATHOLOGY, V20, P109, DOI 10.3109/00313028809066620; Chipchase MD, 2002, DNA REPAIR, V1, P335, DOI 10.1016/S1568-7864(02)00010-1; de Boer J, 1999, CANCER RES, V59, P3489; de Vries A, 1998, ONCOGENE, V16, P2205, DOI 10.1038/sj.onc.1201744; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; GALLAGHER CH, 1984, J INVEST DERMATOL, V83, P169, DOI 10.1111/1523-1747.ep12263512; Hsia KT, 2003, DEVELOPMENT, V130, P369, DOI 10.1242/dev.00221; Itoh T, 2004, P NATL ACAD SCI USA, V101, P2052, DOI 10.1073/pnas.0306551101; Kuhn Ralf, 2002, Methods Mol Biol, V180, P175; MAGIN TM, 1992, GENE, V122, P289, DOI 10.1016/0378-1119(92)90217-D; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; MOORE RC, 1995, BIO-TECHNOL, V13, P999, DOI 10.1038/nbt0995-999; NAKANE H, 1995, NATURE, V377, P165, DOI 10.1038/377165a0; Nunez F, 2000, FASEB J, V14, P1073, DOI 10.1096/fasebj.14.9.1073; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Ramirez A, 2004, GENESIS, V39, P52, DOI 10.1002/gene.20025; Remenyik E, 2003, ONCOGENE, V22, P6369, DOI 10.1038/sj.onc.1206657; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; Selbert S, 1998, TRANSGENIC RES, V7, P387, DOI 10.1023/A:1008848304391; SELFRIDGE J, 1992, SOMAT CELL MOLEC GEN, V18, P325, DOI 10.1007/BF01235756; Selfridge J, 2001, NUCLEIC ACIDS RES, V29, P4541, DOI 10.1093/nar/29.22.4541; STACEY A, 1994, MOL CELL BIOL, V14, P1009, DOI 10.1128/MCB.14.2.1009; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; van Schanke A, 2005, J INVEST DERMATOL, V124, P241, DOI 10.1111/j.0022-202X.2004.23551.x; vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8	29	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2006	25	47					6229	6238		10.1038/sj.onc.1209642	http://dx.doi.org/10.1038/sj.onc.1209642			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16682947				2022-12-25	WOS:000241218200001
J	Lin, SS; Bassik, MC; Suh, H; Nishino, M; Arroyo, JD; Hahn, WC; Korsmeyer, SJ; Roberts, TM				Lin, Stephen S.; Bassik, Michael C.; Suh, Heikyung; Nishino, Mari; Arroyo, Jason D.; Hahn, William C.; Korsmeyer, Stanley J.; Roberts, Thomas M.			PP2A regulates BCL-2 phosphorylation and proteasome-mediated degradation at the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; SERINE/THREONINE PHOSPHATASES; PROAPOPTOTIC BAX; APOPTOSIS; CA2+; DEPHOSPHORYLATION; IDENTIFICATION; SUBUNIT; ER	Anti-apoptotic activity of BCL-2 is mediated by phosphorylation at the endoplasmic reticulum (ER), but how this phosphorylation is regulated and the mechanism(s) by which it regulates apoptosis are unknown. We purified macromolecular complexes containing BCL-2 from ER membranes and found that BCL-2 co-purified with the main two subunits of the serine/threonine phosphatase, PP2A. The association of endogenous PP2A and BCL-2 at the ER was verified by co-immunoprecipitation and microcystin affinity purification. Knock down or pharmacological inhibition of PP2A caused degradation of phosphorylated BCL-2 and led to an overall reduction in BCL-2 levels. We found that this degradation was due to the action of the proteasome acting selectively at the ER. Conversely, overexpression of PP2A caused elevation in endogenous BCL-2. Most importantly, we found that PP2A knock down sensitized cells to several classes of death stimuli (including ER stress), but this effect was abolished in a genetic background featuring knock in of a non-phosphorylatable BCL-2 allele. These studies support the hypothesis that PP2A-mediated dephosphorylation of BCL-2 is required to protect BCL-2 from proteasome-dependent degradation, affecting resistance to ER stress.	Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Howard Hughes Med Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Howard Hughes Med Inst, Dept Med Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Howard Hughes Medical Institute	Roberts, TM (corresponding author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.	thomas_roberts@dfci.harvard.edu						Annis MG, 2001, ONCOGENE, V20, P1939, DOI 10.1038/sj.onc.1204288; Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Chen R, 2004, J CELL BIOL, V166, P193, DOI 10.1083/jcb.200309146; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Deng XM, 1998, J BIOL CHEM, V273, P34157, DOI 10.1074/jbc.273.51.34157; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Gotz J, 1998, P NATL ACAD SCI USA, V95, P12370, DOI 10.1073/pnas.95.21.12370; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; MOORHEAD G, 1994, FEBS LETT, V356, P46, DOI 10.1016/0014-5793(94)01232-6; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Ruvolo PP, 2002, J BIOL CHEM, V277, P22847, DOI 10.1074/jbc.M201830200; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Simizu S, 2004, CANCER SCI, V95, P266, DOI 10.1111/j.1349-7006.2004.tb02214.x; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Strack S, 2004, J BIOL CHEM, V279, P47732, DOI 10.1074/jbc.M408015200; Tamura Y, 2004, FEBS LETT, V569, P249, DOI 10.1016/j.febslet.2004.06.003; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wei G, 2004, J IMMUNOL, V173, P1374, DOI 10.4049/jimmunol.173.2.1374; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469	31	80	82	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23003	23012		10.1074/jbc.M602648200	http://dx.doi.org/10.1074/jbc.M602648200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16717086	Green Published, hybrid			2022-12-25	WOS:000239542600062
J	Dai, FHF; Zhang, Y; Kang, YH; Wang, QH; Gaisano, HY; Braunewell, KH; Chan, CB; Wheeler, MB				Dai, Feihan F.; Zhang, Yi; Kang, Youhou; Wang, Qinghua; Gaisano, Herbert Y.; Braunewell, Karl-Heinz; Chan, Catherine B.; Wheeler, Michael B.			The neuronal Ca2+ sensor protein visinin-like protein-1 is expressed in pancreatic islets and regulates insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CELLS; CALCIUM SENSOR-1; CYCLIC-AMP; GENE-EXPRESSION; CAMP; KINASE; ACTIVATION; EXOCYTOSIS; VILIP; CHANNELS	Visinin-like protein-1 (VILIP-1) is a member of the neuronal Ca2+ sensor protein family that modulates Ca2+-dependent cell signaling events. VILIP-1, which is expressed primarily in the brain, increases cAMP formation in neural cells by modulating adenylyl cyclase, but its functional role in other tissues remains largely unknown. In this study, we demonstrate that VILIP-1 is expressed in murine pancreatic islets and beta-cells. To gain insight into the functions of VILIP-1 in beta-cells, we used both overexpression and small interfering RNA knockdown strategies. Overexpression of VILIP-1 in the MIN6 beta-cell line or isolated mouse islets had no effect on basal insulin secretion but significantly increased glucose-stimulated insulin secretion. cAMP accumulation was elevated in VILIP-1-overexpressing cells, and the protein kinase A inhibitor H-89 attenuated increased glucose-stimulated insulin secretion. Overexpression of VILIP-1 in isolated mouse beta-cells increased cAMP content accompanied by increased cAMP-responsive element-binding protein gene expression and enhanced exocytosis as detected by cell capacitance measurements. Conversely, VILIP-1 knockdown by small interfering RNA caused a reduction in cAMP accumulation and produced a dramatic increase in preproinsulin mRNA, basal insulin secretion, and total cellular insulin content. The increase in preproinsulin mRNA in these cells was attributed to enhanced insulin gene transcription. Taken together, we have shown that VILIP-1 is expressed in pancreatic beta-cells and modulates insulin secretion. Increased VILIP-1 enhanced insulin secretion in a cAMP-associated manner. Downregulation of VILIP-1 was accompanied by decreased cAMP accumulation but increased insulin gene transcription.	Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Med Berlin, Signal Transduct Res Grp, Ctr Res Neurosci, Charite, D-10117 Berlin, Germany; Univ Prince Edward Isl, Dept Biomed Sci, Charlottetown, PE C1A 4P3, Canada	University of Toronto; University of Toronto; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Prince Edward Island	Wheeler, MB (corresponding author), Univ Toronto, Dept Physiol, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	michael.wheeler@utoronto.ca	Wang, Qinghua/GVT-3252-2022; Chan, Catherine/C-1162-2011	Chan, Catherine/0000-0003-3882-0592; Wheeler, Michael B./0000-0002-7480-7267				Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Bernstein HG, 1999, J NEUROCYTOL, V28, P655, DOI 10.1023/A:1007056731551; Boekhoff I, 1997, EUR J CELL BIOL, V72, P151; Brackmann M, 2005, J CELL SCI, V118, P2495, DOI 10.1242/jcs.02376; Braunewell KH, 1997, J NEUROCHEM, V68, P2129; Braunewell KH, 1999, CELL TISSUE RES, V295, P1, DOI 10.1007/s004410051207; Braunewell KH, 2001, J NEUROCHEM, V78, P1277, DOI 10.1046/j.1471-4159.2001.00506.x; Braunewell KH, 1997, NEUROSCI LETT, V234, P139, DOI 10.1016/S0304-3940(97)00696-4; BRUBAKER PL, 1992, J BIOL CHEM, V267, P20728; Burgoyne RD, 2004, TRENDS NEUROSCI, V27, P203, DOI 10.1016/j.tins.2004.01.010; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Chan CB, 1999, DIABETES, V48, P1482, DOI 10.2337/diabetes.48.7.1482; Chen XL, 2001, J PHYSIOL-LONDON, V532, P649, DOI 10.1111/j.1469-7793.2001.0649e.x; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Georgia S, 2004, J CLIN INVEST, V114, P963, DOI 10.1172/JCI200422098; Gierke P, 2004, BIOCHEM BIOPH RES CO, V323, P38, DOI 10.1016/j.bbrc.2004.08.055; Gromada J, 2005, P NATL ACAD SCI USA, V102, P10303, DOI 10.1073/pnas.0504487102; Harndahl L, 2002, J BIOL CHEM, V277, P37446, DOI 10.1074/jbc.M205401200; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; Islam MS, 1998, P NATL ACAD SCI USA, V95, P6145, DOI 10.1073/pnas.95.11.6145; Iype T, 2005, J BIOL CHEM, V280, P16798, DOI 10.1074/jbc.M414381200; Joseph JW, 2004, J BIOL CHEM, V279, P51049, DOI 10.1074/jbc.M409189200; Kang GX, 2001, J PHYSIOL-LONDON, V536, P375, DOI 10.1111/j.1469-7793.2001.0375c.xd; Kang YH, 2004, J BIOL CHEM, V279, P47125, DOI 10.1074/jbc.M404954200; Kanno T, 1998, PFLUG ARCH EUR J PHY, V435, P578, DOI 10.1007/s004240050556; Kashima Y, 2001, J BIOL CHEM, V276, P46046, DOI 10.1074/jbc.M108378200; KUNO T, 1992, BIOCHEM BIOPH RES CO, V184, P1219, DOI 10.1016/S0006-291X(05)80012-9; Kushner JA, 2005, MOL CELL BIOL, V25, P3752, DOI 10.1128/MCB.25.9.3752-3762.2005; LALLI E, 1994, J BIOL CHEM, V269, P17359; Leung YM, 2003, J BIOL CHEM, V278, P17532, DOI 10.1074/jbc.M213088200; Lin L, 2002, BIOCHEM BIOPH RES CO, V296, P827, DOI 10.1016/S0006-291X(02)00943-9; Lin L, 2002, J BIOL CHEM, V277, P41872, DOI 10.1074/jbc.M206857200; Liu DM, 2006, DIABETES, V55, P1043, DOI 10.2337/diabetes.55.04.06.db05-1089; MacDonald PE, 2002, MOL ENDOCRINOL, V16, P2452, DOI 10.1210/me.2002-0058; Mahloogi H, 2003, CANCER RES, V63, P4997; MALAISSE WJ, 1984, ENDOCRINOLOGY, V115, P2015, DOI 10.1210/endo-115-5-2015; Mathisen PM, 1999, J BIOL CHEM, V274, P31571, DOI 10.1074/jbc.274.44.31571; Mitchell KJ, 2004, DIABETES, V53, P393, DOI 10.2337/diabetes.53.2.393; NIELSEN DA, 1985, J BIOL CHEM, V260, P3585; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; PHILIPPE J, 1990, J BIOL CHEM, V265, P1465; POLYMEROPOULOS MH, 1995, GENOMICS, V29, P273, DOI 10.1006/geno.1995.1244; Rajebhosale M, 2003, J BIOL CHEM, V278, P6075, DOI 10.1074/jbc.M204702200; Renstrom E, 1997, J PHYSIOL-LONDON, V502, P105, DOI 10.1111/j.1469-7793.1997.105bl.x; Rorsman P, 2003, DIABETOLOGIA, V46, P1029, DOI 10.1007/s00125-003-1153-1; Salapatek AMF, 1999, MOL ENDOCRINOL, V13, P1305, DOI 10.1210/me.13.8.1305; Sherr CJ, 2000, CANCER RES, V60, P3689; Spilker C, 1997, NEUROSCI LETT, V225, P126, DOI 10.1016/S0304-3940(97)00201-2; Spilker C, 2002, J NEUROSCI, V22, P7331; Wang XL, 2004, DIABETES, V53, P129, DOI 10.2337/diabetes.53.1.129; Wang XL, 2001, ENDOCRINOLOGY, V142, P1820, DOI 10.1210/en.142.5.1820; Weiss JL, 2000, J BIOL CHEM, V275, P40082, DOI 10.1074/jbc.M008603200; Xia FZ, 2004, J BIOL CHEM, V279, P24685, DOI 10.1074/jbc.M314314200; Yaney GC, 2001, DIABETES, V50, P56, DOI 10.2337/diabetes.50.1.56; Zhang XQ, 2005, P NATL ACAD SCI USA, V102, P892, DOI 10.1073/pnas.0408936102; Zheng Q, 2005, J NEUROCHEM, V92, P442, DOI 10.1111/j.1471-4159.2004.02897.x	60	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21942	21953		10.1074/jbc.M512924200	http://dx.doi.org/10.1074/jbc.M512924200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16731532	hybrid			2022-12-25	WOS:000239387100041
J	Parfenova, LV; Crane, BM; Rothberg, BS				Parfenova, Lyubov V.; Crane, Brittany M.; Rothberg, Brad S.			Modulation of MthK potassium channel activity at the intracellular entrance to the pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNEL; ESCHERICHIA-COLI; RCK DOMAIN; RING; CONDUCTANCE; ACTIVATION; CALCIUM; CA2+; GATE	We used a bacterial complementation screen with the LB2003 K+ uptake-deficient strain of Escherichia coli to analyze residues that are critical to Methanobacterium thermoautotrophicum potassium channel (MthK) function. Channel expression and relative structural integrity of mutants were analyzed by SDS-PAGE and Western blot, and mechanisms underlying altered mutant channel function were analyzed using single-channel recording. We observed that wild-type MthK expression complements K uptake deficiency. Although MthK function was previously thought to require Ca2+ in the millimolar range, we demonstrate that at elevated temperatures the requirement for Ca2+ becomes much lower. Mutations at the cytoplasmic mouth of the MthK pore can blunt complementation, indicating that those mutant channels cannot support K+ uptake. In contrast, substitutions at the Ca2+-binding site in the MthK RCK domain did not decrease complementation compared with wild-type MthK. We focused on mutations to residues Glu-92 and Glu-96, which may form the narrowest part of the pore in the channel's closed state. Mutations at these residues can yield slight changes in single-channel conductance that do not necessarily correlate with effects on bacterial complementation. However, mutations at Glu-92 could also change channel open probability, and these changes correlated with complementation effects. The most striking of these mutations was E92A, which nearly eliminated bacterial complementation by decreasing the open probability of MthK. Our results suggest that the small, hydrophobic alanine side chain at the K+ channel bundle crossing may generate an intrinsically stable structure, which in turn shifts the closed-to-open-state equilibrium toward the closed state.	Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Rothberg, BS (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Physiol, 7703 Floyd Curl Dr,MC7756, San Antonio, TX 78229 USA.	rothberg@uthscsa.edu	Rothberg, Brad/AAD-1260-2022	Rothberg, Brad/0000-0003-1982-2269	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068523] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM068523, GM68523] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brelidze TI, 2003, P NATL ACAD SCI USA, V100, P9017, DOI 10.1073/pnas.1532257100; del Camino D, 2001, NEURON, V32, P649, DOI 10.1016/S0896-6273(01)00487-1; Dong JB, 2005, J BIOL CHEM, V280, P41716, DOI 10.1074/jbc.M508144200; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Hellmer J, 2003, FEBS LETT, V547, P165, DOI 10.1016/S0014-5793(03)00706-3; HORN R, 1991, BIOPHYS J, V60, P433, DOI 10.1016/S0006-3495(91)82069-0; Irizarry SN, 2002, BIOCHEMISTRY-US, V41, P13653, DOI 10.1021/bi026393r; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Jones HE, 1999, CELL CALCIUM, V25, P265, DOI 10.1054/ceca.1999.0028; Kitaguchi T, 2004, J GEN PHYSIOL, V124, P319, DOI 10.1085/jgp.200409098; Krishnamoorthy G, 2005, J GEN PHYSIOL, V126, P227, DOI 10.1085/jgp.200509321; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; Nimigean CM, 2003, BIOCHEMISTRY-US, V42, P9263, DOI 10.1021/bi0348720; Niu XW, 2004, NEURON, V42, P745, DOI 10.1016/j.neuron.2004.05.001; Parfenova Lyubov V., 2006, V337, P157; Ptak CP, 2005, BIOCHEMISTRY-US, V44, P62, DOI 10.1021/bi048390f; Stumpe S, 1997, ARCH MICROBIOL, V167, P126, DOI 10.1007/s002030050425; Sukhareva M, 2003, J GEN PHYSIOL, V122, P541, DOI 10.1085/jgp.200308905	19	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21131	21138		10.1074/jbc.M603109200	http://dx.doi.org/10.1074/jbc.M603109200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16728395	hybrid			2022-12-25	WOS:000239187300049
J	Ahn, KS; Sethi, G; Jain, AK; Jaiswal, AK; Aggarwal, BB				Ahn, Kwang Seok; Sethi, Gautam; Jain, Abhinav K.; Jaiswal, Anil K.; Aggarwal, Bharat B.			Genetic deletion of NAD(P)H: Quinone oxidoreductase 1 abrogates activation of nuclear factor-kappa B, I kappa B alpha kinase, c-Jun N-terminal kinase, Akt, p38, and p44/42 mitogen-activated protein kinases and potentiates apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; NAD(P)H-QUINONE OXIDOREDUCTASE; DT-DIAPHORASE; CYCLIN D1; NQO1 GENE; SKIN CARCINOGENESIS; PANCREATIC-CANCER; TRANSFORMED-CELLS; TNF SUPERFAMILY	The NAD(P)H: quinone oxidoreductase 1 (NQO1) is a phase II enzyme that reduces and detoxifies quinones and their derivatives. Although overexpressed in tumor cells, the NQO1 has been linked with the suppression of carcinogenesis, and the effect of NQO1 on tumor necrosis factor (TNF), a cytokine that mediates tumorigenesis through proliferation, invasion, angiogenesis, and metastasis of tumors, is currently unknown. The purpose of our study was to determine the role of NQO1 in TNF cell signaling by using keratinocytes derived from wild-type and NQO1 gene-deleted mice. TNF induced nuclear factor (NF)-kappa B activation in wild-type but not in NQO1-deleted cells. The treatment of wild-type cells with dicoumarol, a known inhibitor of NQO1, also abolished TNF-induced NF-kappa B activation. NF-kappa B activation induced by lipopolysaccharide, phorbol ester, and cigarette smoke, was also abolished in NQO1- deleted cells. The suppression of NF-kappa B activation was mediated through the inhibition of I kappa B alpha kinase activation, I kappa B alpha phosphorylation, and I kappa B alpha degradation. Further, the deletion of NQO1 abolished TNFinduced c-Jun N-terminal kinase, Akt, p38, and p44/p42 mitogen-activated protein kinase activation. TNF also induced the expression of various NF-kappa B-regulated gene products involved in cell proliferation, antiapoptosis, and invasion in wild-type NQO1 keratinocytes but not in NQO1-deleted cells. The suppression of these antiapoptotic gene products increased TNF-induced apoptosis in NQO1- deleted cells. We also found that TNF activated NQO1, and NQO1-specific small interfering RNA abolished the TNF-induced NQO1 activity and NF-kappa B activation. Overall, our results indicate that NQO1 plays a pivotal role in signaling activated by TNF and other inflammatory stimuli and that its suppression is a potential therapeutic strategy to inhibit the proliferation, survival, invasion, and metastasis of tumor cells.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA; Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Sethi, Gautam/F-2372-2011; Aggarwal, Bharat B/G-3388-2013; Jain, Abhinav K/A-2540-2013; Ahn, Kwang Seok/G-4249-2013	Sethi, Gautam/0000-0002-8677-8475; 	NATIONAL CANCER INSTITUTE [P01CA091844] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA91844] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2005, CANC TREAT, V126, P103, DOI 10.1007/0-387-24361-5_5; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Aggarwal BB, 2006, CURR SIGNAL TRANSD T, V1, P25, DOI 10.2174/157436206775269235; Ahn KS, 2005, ANN NY ACAD SCI, V1056, P218, DOI 10.1196/annals.1352.026; Alpert D, 1999, J BIOL CHEM, V274, P22176, DOI 10.1074/jbc.274.32.22176; Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511; Arlt VM, 2005, CANCER RES, V65, P2644, DOI 10.1158/0008-5472.CAN-04-3544; Asher G, 2002, P NATL ACAD SCI USA, V99, P3099, DOI 10.1073/pnas.052706799; Bauer AK, 2003, CANCER RES, V63, P929; BENSON AM, 1980, P NATL ACAD SCI-BIOL, V77, P5216, DOI 10.1073/pnas.77.9.5216; Blonska M, 2005, J BIOL CHEM, V280, P43056, DOI 10.1074/jbc.M507807200; Brar SS, 2001, AM J PHYSIOL-CELL PH, V280, pC659, DOI 10.1152/ajpcell.2001.280.3.C659; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585; Chen HW, 1999, CANCER RES, V59, P3045; CRESTEIL T, 1991, BIOCHEM PHARMACOL, V42, P1021, DOI 10.1016/0006-2952(91)90284-C; Cross JV, 1999, J BIOL CHEM, V274, P31150, DOI 10.1074/jbc.274.44.31150; Cullen JJ, 2003, CANCER RES, V63, P5513; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Dinkova-Kostova LT, 2000, FREE RADICAL BIO MED, V29, P231, DOI 10.1016/S0891-5849(00)00300-2; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Garg AK, 2002, MOL IMMUNOL, V39, P509, DOI 10.1016/S0161-5890(02)00207-9; Gaur U, 2003, BIOCHEM PHARMACOL, V66, P1403, DOI 10.1016/S0006-2952(03)00490-8; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Iskander K, 2005, CANCER RES, V65, P2054, DOI 10.1158/0008-5472.CAN-04-3157; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; Jing YW, 2004, ACTA BIOCH BIOPH SIN, V36, P235, DOI 10.1093/abbs/36.3.235; JOSEPH P, 1994, ONCOL RES, V6, P525; Kumar A, 2004, J MOL MED, V82, P434, DOI 10.1007/s00109-004-0555-y; Larson RA, 1999, BLOOD, V94, P803, DOI 10.1182/blood.V94.2.803.414k44_803_807; Lee YY, 2005, FREE RADICAL BIO MED, V39, P257, DOI 10.1016/j.freeradbiomed.2005.03.013; Lin PP, 1999, J TOXICOL ENV HEAL A, V58, P187, DOI 10.1080/009841099157287; Logsdon CD, 2003, CANCER RES, V63, P2649; Long DJ, 2000, CANCER RES, V60, P5913; Long DJ, 2002, CANCER RES, V62, P3030; Long DJ, 2001, JNCI-J NATL CANCER I, V93, P1166, DOI 10.1093/jnci/93.15.1166; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MALKINSON AM, 1992, CANCER RES, V52, P4752; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811; MORRE DJ, 1995, P NATL ACAD SCI USA, V92, P1831, DOI 10.1073/pnas.92.6.1831; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; ODONNELL VB, 1994, MOL PHARMACOL, V46, P778; Ozes ON, 1999, NATURE, V401, P82; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382; Rauth AM, 1997, ONCOL RES, V9, P339; Rothman N, 1997, CANCER RES, V57, P2839; SCHLAGER JJ, 1990, INT J CANCER, V45, P403, DOI 10.1002/ijc.2910450304; SHAW PM, 1991, EUR J BIOCHEM, V195, P171, DOI 10.1111/j.1432-1033.1991.tb15691.x; Sieger D, 2000, FREE RADICAL BIO MED, V29, P246, DOI 10.1016/S0891-5849(00)00310-5; Siemankowski LM, 2000, CANCER RES, V60, P3638; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Singh S, 1996, J IMMUNOL, V157, P4412; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; Takada Y, 2004, J BIOL CHEM, V279, P39541, DOI 10.1074/jbc.M403449200; Takada Y, 2004, J BIOL CHEM, V279, P4750, DOI 10.1074/jbc.M304546200; Talalay P, 1995, TOXICOL LETT, V82-3, P173, DOI 10.1016/0378-4274(95)03553-2; Tsvetkov P, 2005, P NATL ACAD SCI USA, V102, P5535, DOI 10.1073/pnas.0501828102; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Winski SL, 2002, CANCER RES, V62, P1420; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769	68	108	113	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					19798	19808		10.1074/jbc.M601162200	http://dx.doi.org/10.1074/jbc.M601162200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16682409	hybrid			2022-12-25	WOS:000239038200003
J	Galas, MC; Dourlen, P; Begard, S; Ando, K; Blum, D; Hamdane, M; Buee, L				Galas, Marie-Christine; Dourlen, Pierre; Begard, Severine; Ando, Kunie; Blum, David; Hamdane, Malika; Buee, Luc			The peptidylprolyl cis/trans-isomerase Pin1 modulates stress-induced dephosphorylation of tau in neurons - Implication in a pathological mechanism related to Alzheimer disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WW DOMAIN; PHOSPHORYLATION; PROTEIN; INHIBITORS; APOPTOSIS; JUGLONE; BINDING; NEURODEGENERATION; ISOFORMS; CLEAVAGE	Deregulation of Tau phosphorylation is a key question in Alzheimer disease pathogenesis. Recently, Pin1, a peptidylprolyl cis/trans-isomerase, was proposed to be a new modulator in Tau phosphorylation in Alzheimer disease. In vitro, Pin1 was reported to present a high affinity for both Thr(P)-231, a crucial site for microtubule binding, and Thr(P)-212. In fact, Pin1 may facilitate Thr(P)-231 dephosphorylation by protein phosphatase 2A through trans isomerization of the Thr(P)-Pro peptide bound. However, whether Pin1 binding to Tau leads to isomerization of a single site or of multiple Ser/Thr(P)-Pro sites in vivo is still unknown. In the present study, Pin1 involvement was investigated in stress-induced Tau dephosphorylation with protein phosphatase 2A activation. Both oxidative (H2O2) and heat stresses induced hypophosphorylation of a large set of phospho-Tau epitopes in primary cortical cultures. In both cases, juglone, a Pin1 pharmacological inhibitor, partially prevented dephosphorylation of Tau at Thr-231 among a set of phosphoepitopes tested. Moreover, Pin1 is physiologically found in neurons and partially co-localized with Tau. Furthermore, in Pin1-deficient neuronal primary cultures, H2O2 stress-induced Tau dephosphorylation at Thr(P)-231 was significantly lower than in wild type neurons. Finally, Pin1 transfection in Pin1-deficient neuronal cell cultures allowed for rescuing the effect of H2O2 stress-induced Tau dephosphorylation, whereas a Pin1 catalytic mutant did not. This is the first demonstration of an in situ Pin1 involvement in a differential Tau dephosphorylation on the full-length multiphosphorylated substrate.	INSERM, U815, Inst Med Predict & Rech Therapeut, F-59045 Lille, France; Univ Lille 2, Sch Med, F-59000 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Franche-Comte; Universite de Lille - ISITE; CHU Lille; Universite de Lille	Buee, L (corresponding author), INSERM, U815, Inst Med Predict & Rech Therapeut, F-59045 Lille, France.	buee@lille.inserm.fr	Blum, David/E-9901-2016; BUEE, Luc/B-3126-2010; Galas, Marie-Christine/AAL-9812-2020; Blum, David/O-2924-2019	Blum, David/0000-0001-5691-431X; BUEE, Luc/0000-0002-6261-4230; Blum, David/0000-0001-5691-431X; Ando, Kunie/0000-0003-3822-175X; Dourlen, Pierre/0000-0002-3562-1080; Hamdane, Malika/0000-0001-7971-8696; Galas, Marie-Christine/0000-0002-3766-7103				Bayer E, 2005, CHEM COMMUN, P516, DOI 10.1039/b414037k; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Canu N, 1998, J NEUROSCI, V18, P7061; Chao SH, 2001, NUCLEIC ACIDS RES, V29, P767, DOI 10.1093/nar/29.3.767; Cho JH, 2004, J NEUROCHEM, V88, P349, DOI 10.1046/j.1471-4159.2003.02155.x; Cho JH, 2003, J BIOL CHEM, V278, P187, DOI 10.1074/jbc.M206236200; Davis DR, 1997, J NEUROCHEM, V68, P1590; De Castro E, 2004, FREE RADICAL BIO MED, V37, P139, DOI 10.1016/j.freeradbiomed.2004.04.021; Delobel P, 2002, J NEUROCHEM, V83, P412, DOI 10.1046/j.1471-4159.2002.01143.x; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; Goldbaum O, 2002, GLIA, V40, P271, DOI 10.1002/glia.10119; Hamdane M, 2003, J BIOL CHEM, V278, P34026, DOI 10.1074/jbc.M302872200; Hamdane M, 2002, J MOL NEUROSCI, V19, P275, DOI 10.1385/JMN:19:3:275; Hamdane M, 2006, MOL CELL NEUROSCI, V32, P155, DOI 10.1016/j.mcn.2006.03.006; Hennig L, 1998, BIOCHEMISTRY-US, V37, P5953, DOI 10.1021/bi973162p; Hoffmann R, 1997, BIOCHEMISTRY-US, V36, P8114, DOI 10.1021/bi970380+; Jiang M, 2004, GENE THER, V11, P1303, DOI 10.1038/sj.gt.3302305; Jicha GA, 1997, J NEUROCHEM, V69, P2087; Liou YC, 2003, NATURE, V424, P556, DOI 10.1038/nature01832; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; Liu F, 2005, EUR J NEUROSCI, V22, P1942, DOI 10.1111/j.1460-9568.2005.04391.x; Lu PJ, 1999, NATURE, V399, P784; Lu PJ, 2002, J BIOL CHEM, V277, P2381, DOI 10.1074/jbc.C100228200; Mailliot C, 1998, FEBS LETT, V433, P201, DOI 10.1016/S0014-5793(98)00910-7; Noble W, 2005, P NATL ACAD SCI USA, V102, P6990, DOI 10.1073/pnas.0500466102; Papasozomenos S.C., 1999, J Alzheimers Dis, V1, P147; Paulsen MT, 2005, TOXICOL APPL PHARM, V209, P1, DOI 10.1016/j.taap.2005.03.005; Rametti A, 2004, J BIOL CHEM, V279, P54518, DOI 10.1074/jbc.M408186200; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Smet C, 2005, J MED CHEM, V48, P4815, DOI 10.1021/jm0500119; Smet C, 2005, FEBS LETT, V579, P4159, DOI 10.1016/j.febslet.2005.06.048; Smet C, 2004, BIOCHEMISTRY-US, V43, P2032, DOI 10.1021/bi035479x; Tanimukai H, 2005, AM J PATHOL, V166, P1761, DOI 10.1016/S0002-9440(10)62486-8; Uchida T, 2003, CHEM BIOL, V10, P15, DOI 10.1016/S1074-5521(02)00310-1; VOS RME, 1989, CHEM-BIOL INTERACT, V71, P381, DOI 10.1016/0009-2797(89)90112-9; Wintjens R, 2001, J BIOL CHEM, V276, P25150, DOI 10.1074/jbc.M010327200; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Zambrano CA, 2004, FREE RADICAL BIO MED, V36, P1393, DOI 10.1016/j.freeradbiomed.2004.03.007; Zhang YX, 2002, BIOCHEMISTRY-US, V41, P11868, DOI 10.1021/bi0262395; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	40	71	74	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19296	19304		10.1074/jbc.M601849200	http://dx.doi.org/10.1074/jbc.M601849200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16675464	hybrid			2022-12-25	WOS:000238847000044
J	Narayanan, K; Gajjeraman, S; Ramachandran, A; Hao, JJ; George, A				Narayanan, Karthikeyan; Gajjeraman, Sivakumar; Ramachandran, Amsaveni; Hao, Jianjun; George, Anne			Dentin matrix protein 1 regulates dentin sialophosphoprotein gene transcription during early odontoblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DSPP GENE; GENOMIC ORGANIZATION; EXPRESSION PATTERNS; SPATIAL EXPRESSION; IN-VITRO; SIALOPROTEIN; PHOSPHOPROTEIN; MUTATION; DMP1; PREDENTIN	Dentin mineralization requires transcriptional mechanisms to induce a cascade of gene expression for progressive development of the odontoblast phenotype. During cytodifferentiation of odontoblasts there is a constant change of actively transcribed genes. Thus, tissue-specific matrix genes that are silenced in early differentiation are expressed during the terminal differentiation process. Dentin sialophosphoprotein (DSPP) is an extracellular matrix, prototypical dentin, and a bone-specific gene, however, the molecular mechanisms by which it is temporally and spatially regulated are not clear. In this report, we demonstrate that dentin matrix protein 1 (DMP1), which is localized in the nucleus during early differentiation of odontoblasts, is able to bind specifically with the DSPP promoter and activate its transcription. We have identified the specific promoter sequence that binds specifically to the carboxyl end of DMP1. The DNA binding domain in DMP1 resides between amino acids 420 and 489. A chromatin immunoprecipitation assay confirmed the in vivo association of DMP1 with the DSPP promoter. Interactions between DMP1 and DSPP promoter thus provide the foundation to understand how DMP1 regulates the expression of the DSPP gene.	Univ Illinois, Dept Oral Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	George, A (corresponding author), Univ Illinois, Dept Oral Biol, 801 S Paulina, Chicago, IL 60612 USA.	anneg@uic.edu	Narayanan, Karthikeyan/D-1957-2010	Narayanan, Karthikeyan/0000-0001-5136-2296; GEORGE, ANNE/0000-0002-9008-7642	NIDCR NIH HHS [DE11657, DE13836] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R56DE011657, R01DE013836] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Baba O, 2004, MATRIX BIOL, V23, P371, DOI 10.1016/j.matbio.2004.07.008; Begue-Kirn C, 1998, EUR J ORAL SCI, V106, P963, DOI 10.1046/j.0909-8836.1998.eos106510.x; Bleicher F, 1999, MATRIX BIOL, V18, P133, DOI 10.1016/S0945-053X(99)00007-4; Burke LJ, 2000, FASEB J, V14, P1876, DOI 10.1096/fj.99-0943rev; Butler WT, 1998, EUR J ORAL SCI, V106, P204, DOI 10.1111/j.1600-0722.1998.tb02177.x; Chen S, 2005, J BIOL CHEM, V280, P29717, DOI 10.1074/jbc.M502929200; Chen S, 2002, CONNECT TISSUE RES, V43, P338, DOI 10.1080/03008200290000691; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; Dong J, 2005, AM J MED GENET A, V132A, P305, DOI 10.1002/ajmg.a.30460; DSouza RN, 1997, J BONE MINER RES, V12, P2040, DOI 10.1359/jbmr.1997.12.12.2040; Feng JQ, 1998, J BIOL CHEM, V273, P9457, DOI 10.1074/jbc.273.16.9457; George A, 1999, CONNECT TISSUE RES, V40, P49, DOI 10.3109/03008209909005277; GEORGE A, 1994, J HISTOCHEM CYTOCHEM, V42, P1527, DOI 10.1177/42.12.7983353; GEORGE A, 1993, J BIOL CHEM, V268, P12624; Hao JJ, 2004, BONE, V34, P921, DOI 10.1016/j.bone.2004.01.020; Hao JJ, 2002, J BIOL CHEM, V277, P19976, DOI 10.1074/jbc.M112223200; He G, 2003, NAT MATER, V2, P552, DOI 10.1038/nmat945; Kim JW, 2004, HUM GENET, V115, P248, DOI 10.1007/s00439-004-1143-5; Kornberg RD, 1999, TRENDS GENET, V15, pM46, DOI 10.1016/S0168-9525(99)01901-0; Kosak ST, 2004, GENE DEV, V18, P1371, DOI 10.1101/gad.1209304; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; MacDougall M, 1998, J BONE MINER RES, V13, P422, DOI 10.1359/jbmr.1998.13.3.422; McKinsey TA, 2002, CURR OPIN CELL BIOL, V14, P763, DOI 10.1016/S0955-0674(02)00389-7; Narayanan K, 2004, J BIOL CHEM, V279, P45423, DOI 10.1074/jbc.M405031200; Narayanan K, 2003, J BIOL CHEM, V278, P17500, DOI 10.1074/jbc.M212700200; Narayanan K, 2001, P NATL ACAD SCI USA, V98, P4516, DOI 10.1073/pnas.081075198; Qin CL, 2003, CONNECT TISSUE RES, V44, P179, DOI 10.1080/03008200390152296; Ritchie HH, 2000, BBA-GENE STRUCT EXPR, V1493, P27, DOI 10.1016/S0167-4781(00)00150-0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sreenath T, 2003, J BIOL CHEM, V278, P24874, DOI 10.1074/jbc.M303908200; Sreenath TL, 1999, INT J DEV BIOL, V43, P509; Thotakura SR, 2000, J BIOL CHEM, V275, P10272, DOI 10.1074/jbc.275.14.10272; Thotakura SR, 2000, J DENT RES, V79, P835, DOI 10.1177/00220345000790030901; Thyagarajan T, 2001, J BIOL CHEM, V276, P11016, DOI 10.1074/jbc.M010502200; VALENTINHANSEN P, 1989, MOL MICROBIOL, V3, P1385, DOI 10.1111/j.1365-2958.1989.tb00120.x; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Xiao SX, 2001, NAT GENET, V27, P201, DOI 10.1038/84848; Ye L, 2005, J BIOL CHEM, V280, P6197, DOI 10.1074/jbc.M412911200; Ye L, 2004, J BIOL CHEM, V279, P19141, DOI 10.1074/jbc.M400490200; Zhang XH, 2001, NAT GENET, V27, P151, DOI 10.1038/84765	40	100	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19064	19071		10.1074/jbc.M600714200	http://dx.doi.org/10.1074/jbc.M600714200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16679514	hybrid			2022-12-25	WOS:000238847000020
J	Cohen, B				Cohen, Bernard			Inner ear troubles: the roar in the forest?	FASEB JOURNAL			English	Editorial Material							PAROXYSMAL POSITIONAL VERTIGO; EYE MOVEMENTS; STIMULATION		Mt Sinai Sch Med, Dept Neurol, New York, NY USA	Icahn School of Medicine at Mount Sinai	Cohen, B (corresponding author), Mt Sinai Sch Med, Dept Neurol, New York, NY USA.	bernard.cohen@mssm.edu						Bladin PF, 1998, EPILEPSIA, V39, P442, DOI 10.1111/j.1528-1157.1998.tb01398.x; BRANDT T, 1991, BRAIN, V114, P2159, DOI 10.1093/brain/114.5.2159; Clarke AH, 2005, J VESTIBUL RES-EQUIL, V15, P65; COHEN B, 1964, ANN OTO RHINOL LARYN, V73, P153, DOI 10.1177/000348946407300116; Desai SS, 2005, J NEUROPHYSIOL, V93, P251, DOI 10.1152/jn.00746.2003; EPLEY JM, 1992, OTOLARYNG HEAD NECK, V107, P399, DOI 10.1177/019459989210700310; Gizzi M, 1998, ACTA OTO-LARYNGOL, V118, P774, DOI 10.1080/00016489850182422; GRAF W, 1984, J COMP NEUROL, V227, P569, DOI 10.1002/cne.902270408; Janensch W, 1935, PALAEONTOGRAPHICA S, V7, P145; Koehler P J, 2001, J Hist Neurosci, V10, P253, DOI 10.1076/jhin.10.3.253.9089; Nunn JF, 1996, ANCIENT EGYPTIAN MED; Paffenholz R, 2004, GENE DEV, V18, P486, DOI 10.1101/gad.1172504; PARNES LS, 1990, ANN OTO RHINOL LARYN, V99, P330, DOI 10.1177/000348949009900502; RAPHAN T, 1979, EXP BRAIN RES, V35, P229; ROSS MD, 1976, ANN OTO RHINOL LARYN, V85, P310, DOI 10.1177/000348947608500302; SCHUCKNECHT HF, 1991, PATHOLOGY EAR, P529; SEMONT A, 1989, ANN OTOLARYNGOL CHIR, V105, P473; SPIELBERG S, 1992, JURASSIC PARK; SUZUKI J, 1964, EXP NEUROL, V9, P137, DOI 10.1016/0014-4886(64)90013-5; SUZUKI JI, 1964, EXP NEUROL, V10, P393, DOI 10.1016/0014-4886(64)90031-7; TOKUMASU K, 1965, ARCH OPHTHALMOL-CHIC, V73, P851; Weissmann G, 2005, FASEB J, V19, P1581, DOI 10.1096/fj.05-1001ufm	22	0	0	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					806	808		10.1096/fj.06-0502ufm	http://dx.doi.org/10.1096/fj.06-0502ufm			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675836				2022-12-25	WOS:000240157700002
J	Xi, JH; Bai, F; McGaha, R; Andley, UP				Xi, Jing-Hua; Bai, Fang; McGaha, Rebecca; Andley, Usha P.			Alpha-crystallin expression affects microtubule assembly and prevents their aggregation	FASEB JOURNAL			English	Article						tubulin; lens; cytoskeleton; chaperone	LENS EPITHELIAL-CELLS; B-CRYSTALLIN; A-CRYSTALLIN; CHAPERONE; TUBULIN; PROTEIN; HYPERPROLIFERATION; TAU	The molecular chaperones alpha A- and alpha B-crystallins are important for cell survival and genomic stability and associate with the tubulin cytoskeleton. The mitotic spindle is abnormally assembled in a number of alpha A-/- and alpha B-/- lens epithelial cells. However, no report to date has studied the effect of alpha-crystallin expression on tubulin/microtubule assembly in lens epithelial cells. In the current work we tested the hypothesis that the absence of alpha A- and alpha B-crystallins alters microtubule assembly. Microtubules were reconstituted from freshly dissected explants of wildtype, alpha A-/-, alpha B-/-, and alpha(A/B) -/- (DKO) mouse lens epithelia and examined by electron microscopic and biochemical analyses. The wild-type microtubules were 4 mu m long and similar to 25 nm wide and had a characteristic protofilament structure, but alpha B-/- microtubules were 2.5-fold longer. Microtubule-associated proteins (MAPs) extracted from microtubules by washing with salt included transketolase, alpha-enolase, and beta B2-crystallin. In DKO lens epithelial microtubules but not in wild-type, alpha A-/- or alpha B-/- microtubules, extraction of the MAPs gave very long (14 - 20 mu m) "polyfilament" assemblies that were tightly bundled. Addition of exogenous alpha-crystallin (alpha A+ alpha B) was ineffective in preventing polyfilament formation. However, normal microtubule structure could be restored by including MAPs derived from wild-type lens epithelial cells during microtubule reconstitution. Intriguingly, these data suggest that alpha-crystallin may interact with MAPs to inhibit aggregation of microtubules in lens epithelial cells. Sedimentation analysis and 90 degrees light scattering measurements showed that alpha-crystallin suppressed tubulin assembly in vitro. alpha-Crystallin did not have a strong effect on the GTPase activity of purified tubulin. SDS-PAGE analysis showed that alpha-crystallin prevented heat-induced aggregation of tubulin, suggesting that alpha-crystallin may affect microtubule assembly by maintaining the pool of unassembled tubulin.	Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Andley, UP (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S Euclid Ave,Campus Box 8096, St Louis, MO 63110 USA.	andley@vision.wustl.edu		Andley, Usha/0000-0001-7049-7591	NATIONAL EYE INSTITUTE [R01EY005681, P30EY002687] Funding Source: NIH RePORTER; NEI NIH HHS [EY05681, EY02687] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; Andley UP, 1998, J BIOL CHEM, V273, P31252, DOI 10.1074/jbc.273.47.31252; Andley UP, 2002, J BIOL CHEM, V277, P10178, DOI 10.1074/jbc.M109211200; Andley UP, 2001, FASEB J, V15, P221, DOI 10.1096/fj.00-0296com; Bai F, 2004, MOL CELL BIOCHEM, V265, P115, DOI 10.1023/B:MCBI.0000044365.48900.82; Bai F, 2003, J BIOL CHEM, V278, P36876, DOI 10.1074/jbc.M304010200; BEEBE DC, 1979, SCIENCE, V206, P836, DOI 10.1126/science.493982; Bhat SP, 2001, BIOSCIENCE REP, V21, P537, DOI 10.1023/A:1017952128502; BLOEMENDAL H, 1977, SCIENCE, V197, P127, DOI 10.1126/science.877544; Bluhm WF, 1998, AM J PHYSIOL-HEART C, V275, pH2243, DOI 10.1152/ajpheart.1998.275.6.H2243; Boyle Daniel L, 2003, BMC Ophthalmol, V3, P3, DOI 10.1186/1471-2415-3-3; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; Brady JP, 2001, INVEST OPHTH VIS SCI, V42, P2924; Dammermann A, 2003, CURR BIOL, V13, pR614, DOI 10.1016/S0960-9822(03)00530-X; Das KP, 1999, J BIOL CHEM, V274, P33209, DOI 10.1074/jbc.274.47.33209; Dou F, 2003, P NATL ACAD SCI USA, V100, P721, DOI 10.1073/pnas.242720499; Downing KH, 1998, CURR OPIN STRUC BIOL, V8, P785, DOI 10.1016/S0959-440X(98)80099-7; Downing KH, 1998, CURR OPIN CELL BIOL, V10, P16, DOI 10.1016/S0955-0674(98)80082-3; Dunn AY, 2001, J STRUCT BIOL, V135, P176, DOI 10.1006/jsbi.2001.4380; Fujita Y, 2004, J CELL SCI, V117, P1719, DOI 10.1242/jcs.01021; GOPALAKRISHNAN S, 1992, CURR EYE RES, V11, P929, DOI 10.3109/02713689209033490; Haeusser DP, 2004, MOL MICROBIOL, V52, P801, DOI 10.1111/j.1365-2958.2004.04016.x; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; Inaguma Y, 2001, EUR J CELL BIOL, V80, P741, DOI 10.1078/0171-9335-00203; Kato K, 1996, J BIOL CHEM, V271, P26989, DOI 10.1074/jbc.271.43.26989; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Liang P, 1997, J CELL SCI, V110, P1431; Lim JN, 2005, BBA-MOL BASIS DIS, V1739, P311, DOI 10.1016/j.bbadis.2004.10.003; Lo WK, 2003, EXP EYE RES, V77, P615, DOI 10.1016/S0014-4835(03)00176-3; MACCIONI RB, 1983, BIOCHEM BIOPH RES CO, V110, P463, DOI 10.1016/0006-291X(83)91172-5; Martin JL, 1997, CIRCULATION, V96, P4343; Muchowski PJ, 1999, INVEST OPHTH VIS SCI, V40, P951; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; PACHTER JS, 1987, CELL, V51, P283, DOI 10.1016/0092-8674(87)90155-3; Piatigorsky Joram, 2003, Journal of Structural and Functional Genomics, V3, P131; PRESCOTT AR, 1991, EXP EYE RES, V52, P743, DOI 10.1016/0014-4835(91)90026-B; Quinlan Roy, 2002, Prog Mol Subcell Biol, V28, P219; Rusan NM, 2001, MOL BIOL CELL, V12, P971, DOI 10.1091/mbc.12.4.971; Sakurai T, 2005, FASEB J, V19, P1199, DOI 10.1096/fj.04-3060fje; Sun TX, 1998, J BIOL CHEM, V273, P286, DOI 10.1074/jbc.273.1.286; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; WANG KY, 1995, INVEST OPHTH VIS SCI, V36, P311; Wang KY, 1996, EUR J BIOCHEM, V242, P56, DOI 10.1111/j.1432-1033.1996.0056r.x; Weart RB, 2005, MOL MICROBIOL, V57, P238, DOI 10.1111/j.1365-2958.2005.04673.x; Westermann S, 2005, MOL CELL, V17, P277, DOI 10.1016/j.molcel.2004.12.019; Xi JH, 2003, J CELL SCI, V116, P1073, DOI 10.1242/jcs.00325; Xu ZP, 2002, MOL CELL BIOL, V22, P6142, DOI 10.1128/MCB.22.17.6142-6147.2002; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0	49	65	67	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					846	857		10.1096/fj.05-5532com	http://dx.doi.org/10.1096/fj.05-5532com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675842				2022-12-25	WOS:000240157700007
J	Mitra, SK; Mikolon, D; Molina, JE; Hsia, DA; Hanson, DA; Chi, A; Lim, ST; Bernard-Trifilo, JA; Ilic, D; Stupack, DG; Cheresh, DA; Schlaepfer, DD				Mitra, S. K.; Mikolon, D.; Molina, J. E.; Hsia, D. A.; Hanson, D. A.; Chi, A.; Lim, S-T; Bernard-Trifilo, J. A.; Ilic, D.; Stupack, D. G.; Cheresh, D. A.; Schlaepfer, D. D.			Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors	ONCOGENE			English	Article						FAK; FRNK; VEGF; tumor growth; angiogenesis	FOCAL-ADHESION KINASE; ENDOTHELIAL GROWTH-FACTOR; HUMAN BREAST; CELL MOTILITY; IN-VIVO; ONCOGENIC TRANSFORMATION; PROTEIN-KINASE; CANCER; SRC; PATHWAYS	Elevated focal adhesion kinase (FAK) expression occurs in advanced cancers, yet a signaling role for FAK in tumor progression remains undefined. Here, we suppressed FAK activity in 4T1 breast carcinoma cells resulting in reduced FAK Y925 phosphorylation, Grb2 adaptor protein binding to FAK, and signaling to mitogen-activated protein (MAP) kinase (MAPK). Loss of a FAK-Grb2-MAPK linkage did not affect 4T1 cell proliferation or survival in culture, yet FAK inhibition reduced vascular endothelial growth factor (VEGF) expression and resulted in small avascular tumors in mice. This FAK-Grb2-MAPK linkage was essential in promoting angiogenesis as reconstitution experiments using Src-transformed FAK-null fibroblasts revealed that point mutations affecting FAK catalytic activity (R454) or Y925 phosphorylation (F925) disrupted the ability of FAK to promote MAPK- and VEGF-associated tumor growth. Notably, in both FAK- inhibited 4T1 and Src-transformed FAK- null cells, constitutively activated (CA) mitogen-activated protein kinase kinase 1 (MEK1) restored VEGF production and CA-MEK1 or added VEGF rescued tumor growth and angiogenesis. These studies provide the first biological support for Y925 FAK phosphorylation and de. ne a novel role for FAK activity in promoting a MAPK- associated angiogenic switch during tumor progression.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; StemLifeLine Inc, San Carlos, CA USA	Scripps Research Institute; University of California System; University of California San Diego	Schlaepfer, DD (corresponding author), Scripps Res Inst, Dept Immunol, IMM 21,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dschlaep@scripps.edu		Lim, Steve/0000-0003-0323-8607; ILIC, DUSKO/0000-0003-1647-0026	NATIONAL CANCER INSTITUTE [K01CA087652, R01CA095262, R01CA045726, P01CA078045, R37CA050286, R01CA107263, R01CA050286, R01CA102310] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R24EY014174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007606] Funding Source: NIH RePORTER; NCI NIH HHS [CA45726, CA50286, CA78045, CA95262, CA102310, CA087652, CA107263] Funding Source: Medline; NEI NIH HHS [EY14174] Funding Source: Medline; NIAID NIH HHS [T32 AI07606] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barberis L, 2000, J BIOL CHEM, V275, P36532, DOI 10.1074/jbc.M002487200; Barr MP, 2005, BRIT J CANCER, V92, P328, DOI 10.1038/sj.bjc.6602308; Benlimame N, 2005, J CELL BIOL, V171, P505, DOI 10.1083/jcb.200504124; Boudreau N, 2003, BREAST CANCER RES, V5, P140, DOI 10.1186/bcr589; Cance WG, 2000, CLIN CANCER RES, V6, P2417; De S, 2005, P NATL ACAD SCI USA, V102, P7589, DOI 10.1073/pnas.0502935102; Ding Q, 2005, J BIOL CHEM, V280, P6802, DOI 10.1074/jbc.M409180200; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Ghiso JAA, 2002, ONCOGENE, V21, P2513, DOI 10.1038/sj/onc/1205342; Golubovskaya V, 2002, J BIOL CHEM, V277, P38978, DOI 10.1074/jbc.M205002200; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; Haskell H, 2003, CLIN CANCER RES, V9, P2157; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Hecker TP, 2003, FRONT BIOSCI-LANDMRK, V8, pS705, DOI 10.2741/1115; Heppner GH, 2000, BREAST CANCER RES, V2, P331; Hood JD, 2003, J CELL BIOL, V162, P933, DOI 10.1083/jcb.200304105; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Ilic D, 2003, CIRC RES, V92, P300, DOI 10.1161/01.RES.0000055016.36679.23; Ilic D, 1998, J CELL BIOL, V143, P547; ILLC D, 1995, NATURE, V377, P539; Jiang BH, 1997, CANCER RES, V57, P5328; Kornberg LJ, 2004, INVEST OPHTH VIS SCI, V45, P4463, DOI 10.1167/iovs.03-1201; Kranenburg O, 2004, BBA-REV CANCER, V1654, P23, DOI 10.1016/j.bbcan.2003.09.004; LARK AL, 2005, MOD PATHOL; Li N, 2005, EMBO J, V24, P1942, DOI 10.1038/sj.emboj.7600674; Lightfoot HM, 2004, BREAST CANCER RES TR, V88, P109, DOI 10.1007/s10549-004-1022-8; McLean GW, 2004, GENE DEV, V18, P2998, DOI 10.1101/gad.316304; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mitra SK, 2006, ONCOGENE, V25, P4429, DOI 10.1038/sj.onc.1209482; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Moissoglu K, 2003, J BIOL CHEM, V278, P47946, DOI 10.1074/jbc.M302720200; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Pages G, 2005, CARDIOVASC RES, V65, P564, DOI 10.1016/j.cardiores.2004.09.032; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Peng X, 2004, CARDIOVASC RES, V64, P421, DOI 10.1016/j.cardiores.2004.07.012; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Seko Y, 1999, BIOCHEM BIOPH RES CO, V262, P290, DOI 10.1006/bbrc.1999.1185; Shen TL, 2005, J CELL BIOL, V169, P941, DOI 10.1083/jcb.200411155; Sieg DJ, 1999, J CELL SCI, V112, P2677; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Storgard Chris, 2004, V294, P123; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tschan MP, 2003, J BIOL CHEM, V278, P42750, DOI 10.1074/jbc.M307067200; van Nimwegen MJ, 2005, CANCER RES, V65, P4698, DOI 10.1158/0008-5472.CAN-04-4126; Wang DY, 2000, J CELL SCI, V113, P4221; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199	59	128	140	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2006	25	44					5969	5984		10.1038/sj.onc.1209588	http://dx.doi.org/10.1038/sj.onc.1209588			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16682956				2022-12-25	WOS:000240826300006
J	Reed-Inderbitzin, E; Moreno-Miralles, I; Vanden-Eynden, SK; Xie, J; Lutterbach, B; Durst-Goodwin, KL; Luce, KS; Irvin, BJ; Cleary, ML; Brandt, SJ; Hiebert, SW				Reed-Inderbitzin, E.; Moreno-Miralles, I.; Vanden-Eynden, S. K.; Xie, J.; Lutterbach, B.; Durst-Goodwin, K. L.; Luce, K. S.; Irvin, B. J.; Cleary, M. L.; Brandt, S. J.; Hiebert, S. W.			RUNX1 associates with histone deacetylases and SUV39H1 to repress transcription	ONCOGENE			English	Article						Suv39h1; RUNX1; AML1; histone; deacetylase	ACUTE MYELOID-LEUKEMIA; MYOSIN HEAVY-CHAIN; SYNERGISTICALLY ACTIVATE; DEPENDENT ACTIVATION; AUTO-INHIBITION; NUCLEAR-MATRIX; FUSION PROTEIN; N-COR; GENE; T(8-21)	RUNX1 (AML1) is a gene that is frequently disrupted by chromosomal translocations in acute leukemia. Like its Drosophila homolog Runt, RUNX1 both activates and represses transcription. Both Runt and RUNX1 are required for gene silencing during development and a central domain of RUNX1, termed repression domain 2 (RD2), was defined as being required for transcriptional repression and for the silencing of CD4 during T-cell maturation in thymic organ cultures. Although transcriptional co-repressors are known to contact other repression domains in RUNX1, the factors that bind to RD2 had not been defined. Therefore, we tested whether RD2 contacts histone-modifying enzymes that may mediate both repression and gene silencing. We found that RD2 contacts SUV39H1, a histone methyltransferase, via two motifs and that endogenous Suv39h1 associates with a Runx1-regulated repression element in murine erythroleukemia cells. In addition, one of these SUV39H1-binding motifs is also sufficient for binding to histone deacetylases 1 and 3, and both of these domains are required for full RUNX1-mediated transcriptional repression. The association between RUNX1, histone deacetylases and SUV39H1 provides a molecular mechanism for repression and possibly gene silencing mediated by RUNX1.	Vanderbilt Univ, Sch Med, Dept Biochem, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; Tennessee Valley VA Healthcare Syst, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Hiebert, SW (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, Vanderbilt Ingram Canc Ctr, Preston Res Bldg,Rm 512,23rd & Pierce, Nashville, TN 37232 USA.	scott.hiebert@vanderbilt.edu	Hiebert, Scott W/C-9979-2010		NCI NIH HHS [R01-CA64140, R01-CA77274, CA68485] Funding Source: Medline; NHLBI NIH HHS [R01-HL49118] Funding Source: Medline; PHS HHS [R01-87549] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064140, P30CA068485, R01CA077274] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049118] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chakraborty S, 2003, ONCOGENE, V22, P5229, DOI 10.1038/sj.onc.1206600; Durst KL, 2003, MOL CELL BIOL, V23, P607, DOI 10.1128/MCB.23.2.607-619.2003; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ERICKSON PF, 1994, CANCER RES, V54, P1782; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Firestein R, 2000, MOL CELL BIOL, V20, P4900, DOI 10.1128/MCB.20.13.4900-4909.2000; GERGEN JP, 1985, DEV BIOL, V109, P321, DOI 10.1016/0012-1606(85)90459-2; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; Guidez F, 2000, BLOOD, V96, P2557; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; Imai Y, 2004, MOL CELL BIOL, V24, P1033, DOI 10.1128/MCB.24.3.1033-1043.2004; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Javed A, 2000, J CELL SCI, V113, P2221; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; LENNY N, 1995, ONCOGENE, V11, P1761; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Lutterbach B, 1999, P NATL ACAD SCI USA, V96, P12822, DOI 10.1073/pnas.96.22.12822; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Nishimura M, 2004, BLOOD, V103, P562, DOI 10.1182/blood-2003-06-2109; NUCIFORA G, 1995, P NATL ACAD SCI USA, V92, P4917; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; RAYNAUD S, 1995, GENE, V159, P245; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Swantek D, 2004, DEVELOPMENT, V131, P2281, DOI 10.1242/dev.01109; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Telfer JC, 2004, J IMMUNOL, V172, P4359, DOI 10.4049/jimmunol.172.7.4359; van Wijnen AJ, 2004, ONCOGENE, V23, P4209, DOI 10.1038/sj.onc.1207758; Wheeler JC, 2002, NAT GENET, V32, P206, DOI 10.1038/ng942; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	46	60	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5777	5786		10.1038/sj.onc.1209591	http://dx.doi.org/10.1038/sj.onc.1209591			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16652147				2022-12-25	WOS:000240765800008
J	Pesho, MM; Bledzka, K; Michalec, L; Cierniewski, CS; Plow, EF				Pesho, Michelle M.; Bledzka, Kamila; Michalec, Lidia; Cierniewski, Czeslaw S.; Plow, Edward F.			The specificity and function of the metal-binding sites in the integrin beta(3) A-domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED PLATELET-AGGREGATION; GLYCOPROTEIN-IIB-IIIA; LIGAND-BINDING; CATION-BINDING; BETA-3-INTEGRIN-DEFICIENT MICE; EXTRACELLULAR SEGMENT; DEPENDENT ADHESION; FIBRINOGEN BINDING; CRYSTAL-STRUCTURE; CALCIUM-BINDING	The A-domains within integrin beta subunits contain three metal sites termed the metal ion-dependent adhesion site (MIDAS), site adjacent to the metal ion-dependent adhesion site (ADMIDAS), and ligand-induced metal-binding site (LIMBS), and these sites are involved in ligand engagement. The selectivity of these metal sites and their role in ligand binding have been investigated by expressing a fragment corresponding to the beta(3) A-domain, beta(3)-(109-352), and single point mutants in which each of the cation-binding sites has been disabled. Equilibrium dialysis experiments identified three Mn2+- and two Ca2+-binding sites with the LIMBS being the site that did not bind Ca2+. Although the ADMIDAS could bind Ca2+, it did not bind Mg2+. These results indicate that the Ca2+-specific site that inhibits ligand binding is the ADMIDAS. Two different assay systems, surface plasmon resonance and a microtiter plate assay, demonstrated that the beta(3) A-domain fragment bound fibrinogen in the presence of 0.1 mM Ca2+ but not in 3 mM Ca2+. This behavior recapitulated the effects of Ca2+ on fibrinogen binding to alpha(v)beta(3) but not alpha(IIb)beta(3). Disabling any of the three cation-binding sites abrogated fibrinogen binding. These results indicate that the specificities of the three metal-binding sites for divalent cations are distinct and that each site can regulate the ligand binding potential of the beta(3) A-domain.	Cleveland Clin, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA; Cleveland Clin, Dept Mol Cardiol, Cleveland, OH 44195 USA; Med Univ Lodz, Dept Mol & Med Biophys, PL-92215 Lodz, Poland	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Medical University Lodz	Plow, EF (corresponding author), Cleveland Clin, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, 9500 Euclid Ave,Mail Code NB50, Cleveland, OH 44195 USA.	plowe@ccf.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL073311] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01HL073311] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRIEUX A, 1991, J BIOL CHEM, V266, P14202; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; Byzova TV, 1998, THROMB HAEMOSTASIS, V80, P726; CHARO IF, 1991, J BIOL CHEM, V266, P1415; Chen JF, 2004, J BIOL CHEM, V279, P55556, DOI 10.1074/jbc.M407773200; Chen JF, 2003, NAT STRUCT BIOL, V10, P995, DOI 10.1038/nsb1011; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; Cierniewska-Cieslak A, 2002, J BIOL CHEM, V277, P11126, DOI 10.1074/jbc.M112388200; Cierniewski CS, 1999, J BIOL CHEM, V274, P16923, DOI 10.1074/jbc.274.24.16923; D'Andrea G, 2002, THROMB HAEMOSTASIS, V87, P1034, DOI 10.1055/s-0037-1613129; DSOUZA SE, 1988, J BIOL CHEM, V263, P3943; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FARRELL DH, 1994, J BIOL CHEM, V269, P226; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; Gonzalez-Manchon C, 2004, THROMB HAEMOSTASIS, V92, P1377, DOI 10.1160/TH04-06-0380; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; Hu DD, 1996, J BIOL CHEM, V271, P21745, DOI 10.1074/jbc.271.36.21745; HU DD, 1995, J BIOL CHEM, V270, P9917, DOI 10.1074/jbc.270.17.9917; HUBER W, 1995, EUR J BIOCHEM, V227, P647, DOI 10.1111/j.1432-1033.1995.tb20184.x; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; LAM SCT, 1987, J BIOL CHEM, V262, P947; Lin ECK, 1997, J BIOL CHEM, V272, P14236, DOI 10.1074/jbc.272.22.14236; Liu QD, 1998, BBA-PROTEIN STRUCT M, V1385, P33, DOI 10.1016/S0167-4838(98)00039-9; MARGUERIE G, 1977, BIOCHIM BIOPHYS ACTA, V490, P94, DOI 10.1016/0005-2795(77)90109-X; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; Mihalyi E, 2004, BIOPHYS CHEM, V112, P131, DOI 10.1016/j.bpc.2004.07.012; Mould AP, 2003, J BIOL CHEM, V278, P51622, DOI 10.1074/jbc.M306655200; MUSTARD JF, 1978, BLOOD, V52, P453; PHILLIPS DR, 1983, J BIOL CHEM, V258, P240; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; PLOW EF, 2001, HEMOSTASIS THROMBOSI, P479; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RIVAS GA, 1991, BIOCHEM J, V276, P35, DOI 10.1042/bj2760035; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SMITH JW, 1990, J BIOL CHEM, V265, P12267; SMITH JW, 1994, J BIOL CHEM, V269, P960; Smyth SS, 2001, BLOOD, V98, P1055, DOI 10.1182/blood.V98.4.1055; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; Suehiro K, 1996, J BIOL CHEM, V271, P10365, DOI 10.1074/jbc.271.17.10365; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2003, J THROMB HAEMOST, V1, P1642, DOI 10.1046/j.1538-7836.2003.00277.x; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yokoyama K, 1999, BIOCHEMISTRY-US, V38, P5872, DOI 10.1021/bi9827619	48	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23034	23041		10.1074/jbc.M602856200	http://dx.doi.org/10.1074/jbc.M602856200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16723352	hybrid			2022-12-25	WOS:000239542600066
J	Dao, KK; Teigen, K; Kopperud, R; Hodneland, E; Schwede, F; Christensen, AE; Martinez, A; Dskeland, SO				Dao, Khanh Kim; Teigen, Knut; Kopperud, Reidun; Hodneland, Erlend; Schwede, Frank; Christensen, Anne E.; Martinez, Aurora; Doskeland, Stein Ove			Epac1 and cAMP-dependent protein kinase holoenzyme have similar cAMP affinity, but their cAMP domains have distinct structural features and cyclic nucleotide recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT; BINDING-SITES; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURE; AMP; ANALOGS; ACTIVATION; BIOLOGY; PKA; MUTATIONS	The cAMP-dependent protein kinase (PKA I and II) and the cAMP-stimulated GDP exchange factors (Epac1 and -2) are major cAMP effectors. The cAMP affinity of the PKA holoenzyme has not been determined previously. We found that cAMP bound to PKA I with a Kd value (2.9 mu M) similar to that of Epac1. In contrast, the free regulatory subunit of PKA type I (RI) had Kd values in the low nanomolar range. The cAMP sites of RI therefore appear engineered to respond to physiological cAMP concentrations only when in the holoenzyme form, whereas Epac can respond in its free form. Epac is phylogenetically younger than PKA, and its functional cAMP site has presumably evolved from site B of PKA. A striking feature is the replacement of a conserved Glu in PKA by Gln (Epac1) or Lys (Epac2). We found that such a switch (E326Q) in site B of human RI alpha led to a 280-fold decreased cAMP affinity. A similar single switch early in Epac evolution could therefore have decreased the high cAMP affinity of the free regulatory subunit sufficiently to allow Epac to respond to physiologically relevant cAMP levels. Molecular dynamics simulations and cAMP analog mapping indicated that the E326Q switch led to flipping of Tyr-373, which normally stacks with the adenine ring of cAMP. Combined molecular dynamics simulation, GRID analysis, and cAMP analog mapping of wild-type and mutated BI and Epac1 revealed additional differences, independent of the Glu/Gln switch, between the binding sites, regarding space (roominess), hydrophobicity/polarity, and side chain flexibility. This helped explain the specificity of current cAMP analogs and, more importantly, lays a foundation for the generation of even more discriminative analogs.	Univ Bergen, Dept Biomed, N-5009 Bergen, Norway; BioLog Life Sci Inst, D-28071 Bremen, Germany; Haukeland Univ Hosp, N-5009 Bergen, Norway	University of Bergen; University of Bergen; Haukeland University Hospital	Dskeland, SO (corresponding author), Univ Bergen, Dept Biomed, N-5009 Bergen, Norway.	stein.doskeland@biomed.uib.no	Martinez, Aurora/M-3088-2019; Teigen, Knut/K-3934-2012	Martinez, Aurora/0000-0003-1643-6506; Teigen, Knut/0000-0002-7031-9215; Doskeland, Stein Ove/0000-0002-4009-4756				Baillie GS, 2005, CURR OPIN CELL BIOL, V17, P129, DOI 10.1016/j.ceb.2005.01.003; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Berman HM, 2005, P NATL ACAD SCI USA, V102, P45, DOI 10.1073/pnas.0408579102; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; BUBIS J, 1988, BIOCHEMISTRY-US, V27, P1570, DOI 10.1021/bi00405a026; Case D. A., 2004, AMBER VERSION 8; Chen L, 2005, FEBS J, V272, P2746, DOI 10.1111/j.1742-4658.2005.04694.x; Christensen AE, 2003, J BIOL CHEM, V278, P35394, DOI 10.1074/jbc.M302179200; CHRISTENSEN AE, 2003, HDB CELL SIGNALING, V2, P549; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; Diller TC, 2001, STRUCTURE, V9, P73, DOI 10.1016/S0969-2126(00)00556-6; DOSKELAND SO, 1988, METHOD ENZYMOL, V159, P147; DOSKELAND SO, 1993, BIOCHIM BIOPHYS ACTA, V1178, P249, DOI 10.1016/0167-4889(93)90201-Y; DOSKELAND SO, 1981, INT J BIOCHEM, V13, P1, DOI 10.1016/0020-711X(81)90131-2; Dremier S, 2003, FEBS LETT, V546, P103, DOI 10.1016/S0014-5793(03)00561-1; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Francis SH, 2005, FRONT BIOSCI-LANDMRK, V10, P2097, DOI 10.2741/1684; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; GORMAN KB, 1994, SOMAT CELL MOLEC GEN, V20, P301, DOI 10.1007/BF02254719; Hofmann F, 2005, J BIOL CHEM, V280, P1, DOI 10.1074/jbc.R400035200; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; Ji HT, 2003, J MED CHEM, V46, P5700, DOI 10.1021/jm030301u; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; Kapphahn MA, 1997, ARCH BIOCHEM BIOPHYS, V348, P347, DOI 10.1006/abbi.1997.0431; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; Kim C, 2005, SCIENCE, V307, P690, DOI 10.1126/science.1104607; Kopperud R, 2003, FEBS LETT, V546, P121, DOI 10.1016/S0014-5793(03)00563-5; Kopperud R, 2002, J BIOL CHEM, V277, P13443, DOI 10.1074/jbc.M109869200; Kraemer A, 2001, J MOL BIOL, V306, P1167, DOI 10.1006/jmbi.2001.4444; OGREID D, 1989, EUR J BIOCHEM, V181, P19; OGREID D, 1983, J BIOL CHEM, V258, P1041; OGREID D, 1985, EUR J BIOCHEM, V150, P219, DOI 10.1111/j.1432-1033.1985.tb09010.x; Perrin CL, 1997, ANNU REV PHYS CHEM, V48, P511, DOI 10.1146/annurev.physchem.48.1.511; Rangarajan S, 2003, J CELL BIOL, V160, P487, DOI 10.1083/jcb.200209105; Rehmann H, 2006, NATURE, V439, P625, DOI 10.1038/nature04468; Rehmann H, 2003, NAT STRUCT BIOL, V10, P26, DOI 10.1038/nsb878; Rehmann H, 2003, J BIOL CHEM, V278, P38548, DOI 10.1074/jbc.M306292200; RINGHEIM GE, 1990, J BIOL CHEM, V265, P19472; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Schwede F, 2000, BIOCHEMISTRY-US, V39, P8803, DOI 10.1021/bi000304y; Shabb JB, 2001, CHEM REV, V101, P2381, DOI 10.1021/cr000236l; Shimomura H, 2004, ARCH BIOCHEM BIOPHYS, V431, P124, DOI 10.1016/j.abb.2004.07.021; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; Viste K, 2005, J BIOL CHEM, V280, P13279, DOI 10.1074/jbc.M413065200; Vriend G, 1990, J MOL GRAPHICS, V8, P29; Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F; Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035; Wu J, 2004, STRUCTURE, V12, P1057, DOI 10.1016/j.str.2004.03.022	50	116	120	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21500	21511		10.1074/jbc.M603116200	http://dx.doi.org/10.1074/jbc.M603116200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16728394	hybrid			2022-12-25	WOS:000239187300085
J	Bitto, E; Bingman, CA; Wesenberg, GE; McCoy, JG; Phillips, GN				Bitto, Eduard; Bingman, Craig A.; Wesenberg, Gary E.; McCoy, Jason G.; Phillips, George N., Jr.			Structure of pyrimidine 5 '-nucleotidase type 1 - Insight into mechanism of action and inhibition during lead poisoning	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOSERINE PHOSPHATASE; HEMOLYTIC-ANEMIA; MOLECULAR CHARACTERIZATION; EXPOSURE; 5-NUCLEOTIDASE; NUCLEOTIDASE; ASPARTATE; PROTEINS; WORKERS; FOCUS	Eukaryotic pyrimidine 5'-nucleotidase type 1 (P5N-1) catalyzes dephosphorylation of pyrimidine 5'-mononucleotides. Deficiency of P5N-1 activity in red blood cells results in nonspherocytic hemolytic anemia. The enzyme deficiency is either familial or can be acquired through lead poisoning. We present the crystal structure of mouse P5N-1 refined to 2.35 angstrom resolution. The mouse P5N-1 has a 92% sequence identity to its human counterpart. The structure revealed that P5N-1 adopts a fold similar to enzymes of the haloacid dehydrogenase superfamily. The active site of this enzyme is structurally highly similar to those of phosphoserine phosphatases. We propose a catalytic mechanism for P5N-1 that is also similar to that of phosphoserine phosphatases and provide experimental evidence for the mechanism in the form of structures of several reaction cycle states, including: 1) P5N-1 with bound Mg(II) at 2.25 angstrom, 2) phosphoenzyme intermediate analog at 2.30 angstrom, 3) product-transition complex analog at 2.35 A, and 4) product complex at 2.1 angstrom resolution with phosphate bound in the active site. Furthermore the structure of Pb(II)-inhibited P5N-1 (at 2.35 angstrom) revealed that Pb(II) binds within the active site in a way that compromises function of the cationic cavity, which is required for the recognition and binding of the phosphate group of nucleotides.	Univ Wisconsin, Ctr Eukaryot Struct Gen, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Phillips, GN (corresponding author), Univ Wisconsin, Ctr Eukaryot Struct Gen, Madison, WI 53706 USA.	phillips@biochem.wisc.edu			NIGMS NIH HHS [P50GM64598, U54 GM074901] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM074901, P50GM064598] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allegrin S, 2001, J BIOL CHEM, V276, P33526, DOI 10.1074/jbc.M104088200; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amici A, 1997, FEBS LETT, V419, P263, DOI 10.1016/S0014-5793(97)01464-6; Amici A, 2005, CELL MOL LIFE SCI, V62, P1613, DOI 10.1007/s00018-005-5135-y; Amici A, 2002, ARCH BIOCHEM BIOPHYS, V397, P184, DOI 10.1006/abbi.2001.2676; Amici A, 2002, METHOD ENZYMOL, V354, P149; AMICI A, 1994, BIOCHEM J, V304, P987, DOI 10.1042/bj3040987; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Balta G, 2003, BLOOD, V102, P1900, DOI 10.1182/blood-2003-02-0628; Bianchi P, 2003, BRIT J HAEMATOL, V122, P847, DOI 10.1046/j.1365-2141.2003.04532.x; BISHOP C, 1959, J BIOL CHEM, V234, P1233; Chiarelli LR, 2005, BLOOD, V105, P3340, DOI 10.1182/blood-2004-10-3895; Cho H, 2001, P NATL ACAD SCI USA, V98, P8525, DOI 10.1073/pnas.131213698; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gough J, 2001, J MOL BIOL, V313, P903, DOI 10.1006/jmbi.2001.5080; Grosse-Kunstleve RW, 2003, ACTA CRYSTALLOGR D, V59, P1966, DOI 10.1107/S0907444903018043; HIRONO A, 1988, MEDICINE, V67, P110, DOI 10.1097/00005792-198803000-00004; HIRONO A, 1987, BRIT J HAEMATOL, V65, P35, DOI 10.1111/j.1365-2141.1987.tb06132.x; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hunsucker SA, 2005, PHARMACOL THERAPEUT, V107, P1, DOI 10.1016/j.pharmthera.2005.01.003; Jaroszewski L, 2005, NUCLEIC ACIDS RES, V33, pW284, DOI 10.1093/nar/gki418; Jeon Won Bae, 2005, Journal of Structural and Functional Genomics, V6, P143, DOI 10.1007/s10969-005-1908-7; Kanno H, 2004, BRIT J HAEMATOL, V126, P265, DOI 10.1111/j.1365-2141.2004.05029.x; Kim HY, 2002, J BIOL CHEM, V277, P46651, DOI 10.1074/jbc.M204866200; Kim Y, 2002, SCI TOTAL ENVIRON, V286, P181, DOI 10.1016/S0048-9697(01)00976-7; KIM Y, 1995, OCCUP ENVIRON MED, V52, P484, DOI 10.1136/oem.52.7.484; Kim Y, 2002, IND HEALTH, V40, P23, DOI 10.2486/indhealth.40.23; Kurtz JE, 1999, CURR GENET, V36, P130, DOI 10.1007/s002940050482; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; MADEJ T, 1995, PROTEINS, V23, P356, DOI 10.1002/prot.340230309; Marinaki AM, 2001, BLOOD, V97, P3327, DOI 10.1182/blood.V97.11.3327; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAGLIA DE, 1984, P NATL ACAD SCI-BIOL, V81, P588, DOI 10.1073/pnas.81.2.588; Paglia DE, 1999, CLIN BIOCHEM, V32, P193, DOI 10.1016/S0009-9120(99)00003-X; PAGLIA DE, 1975, J BIOL CHEM, V250, P7973; PAGLIA DE, 1975, J CLIN INVEST, V56, P1164, DOI 10.1172/JCI108192; Peeraer Y, 2003, ACTA CRYSTALLOGR D, V59, P971, DOI 10.1107/S0907444903005407; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rees DC, 2003, BRIT J HAEMATOL, V120, P375, DOI 10.1046/j.1365-2141.2003.03980.x; Sakai T, 2000, IND HEALTH, V38, P127, DOI 10.2486/indhealth.38.127; Schlichting I, 1999, NAT STRUCT BIOL, V6, P721, DOI 10.1038/11485; Sreenath HK, 2005, PROTEIN EXPRES PURIF, V40, P256, DOI 10.1016/j.pep.2004.12.022; Thao Sandy, 2004, Journal of Structural and Functional Genomics, V5, P267, DOI 10.1007/s10969-004-7148-4; Uson I, 1999, CURR OPIN STRUC BIOL, V9, P643, DOI 10.1016/S0959-440X(99)00020-2; VALENTINE WN, 1974, J CLIN INVEST, V54, P866, DOI 10.1172/JCI107826; VALENTINE WN, 1976, J CLIN INVEST, V58, P926, DOI 10.1172/JCI108545; Wang WR, 2001, STRUCTURE, V9, P65, DOI 10.1016/S0969-2126(00)00558-X; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8; Yan D, 1999, P NATL ACAD SCI USA, V96, P14789, DOI 10.1073/pnas.96.26.14789; Zolnai Zsolt, 2003, Journal of Structural and Functional Genomics, V4, P11, DOI 10.1023/A:1024684404761	57	25	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20521	20529		10.1074/jbc.M602000200	http://dx.doi.org/10.1074/jbc.M602000200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16672222	hybrid			2022-12-25	WOS:000239038200074
J	Bruder, S; Schultz, A; Schultz, JE				Bruder, Sandra; Schultz, Anita; Schultz, Joachim E.			Characterization of the tandem GAF domain of human phosphodiesterase 5 using a cyanobacterial adenylyl cyclase as a reporter enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CGMP-SPECIFIC PHOSPHODIESTERASE; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; BINDING PHOSPHODIESTERASE; REGULATORY DOMAIN; PDE5; PHOSPHORYLATION; DIMERIZATION; INHIBITION; ACTIVATION; SITES	We analyzed cGMP signaling by the human phosphodiesterase 5 (hPDE5) tandem GAF domain based on a functional activation assay. The C-terminal catalytic domain of the cyanobacterial adenylyl cyclase (AC) cyaB1 was used as a reporter enzyme. We demonstrate functional coupling between the hPDE5 GAF ensemble and the AC resulting in a chimera stimulated 10-fold by cGMP. The hPDE5 GAF domain has an inhibitory effect on AC activity, which is released upon cGMP activation. Removal of 109 amino acids from the N terminus resulted in partial disengagement of the GAF domain and AC, i.e. in a 10-fold increase in basal activity, and affected cGMP affinity. The Ser-102 phosphorylation site of hPDE5 increased cGMP affinity, as shown by a 5-fold lower KD for cGMP in a S102D mutant, which mimicked complete modification. The function of the NKFDE motif, which is a signature of all GAF domains with known cyclic nucleotide binding capacity, was elucidated by targeted mutations. Data with either single and double mutants in either GAF A or GAF B or a quadruple mutant affecting both subdomains simultaneously indicated that it is impossible to functionally assign cGMP binding and intramolecular signaling to either GAF A or B of hPDE5. Both subdomains are structurally and functionally interdependent and act in concert in regulating cycaB1 AC and, most likely, also hPDE5.	Univ Tubingen, Fak Chem & Pharm, Abt Pharmazeut Biochem, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Schultz, JE (corresponding author), Univ Tubingen, Fak Chem & Pharm, Abt Pharmazeut Biochem, Morgenstelle 8, D-72076 Tubingen, Germany.	joachim.schultz@uni-tuebingen.de						Anantharaman V, 2001, J MOL BIOL, V307, P1271, DOI 10.1006/jmbi.2001.4508; Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911; Bruder S, 2005, P NATL ACAD SCI USA, V102, P3088, DOI 10.1073/pnas.0409917102; Corbin JD, 2000, EUR J BIOCHEM, V267, P2760, DOI 10.1046/j.1432-1327.2000.01297.x; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; Francis SH, 2002, J BIOL CHEM, V277, P47581, DOI 10.1074/jbc.M206088200; Granovsky AE, 1998, J BIOL CHEM, V273, P24485, DOI 10.1074/jbc.273.38.24485; Gross-Langenhoff M, 2006, J BIOL CHEM, V281, P2841, DOI 10.1074/jbc.M511468200; Ho YSJ, 2000, EMBO J, V19, P5288, DOI 10.1093/emboj/19.20.5288; Kanacher T, 2002, EMBO J, V21, P3672, DOI 10.1093/emboj/cdf375; Little R, 2003, J BIOL CHEM, V278, P28711, DOI 10.1074/jbc.M301992200; Liu L, 2002, CELL SIGNAL, V14, P45, DOI 10.1016/S0898-6568(01)00216-9; Martinez SE, 2005, P NATL ACAD SCI USA, V102, P3082, DOI 10.1073/pnas.0409913102; Martinez SE, 2002, P NATL ACAD SCI USA, V99, P13260, DOI 10.1073/pnas.192374899; McAllisterLucas LM, 1995, J BIOL CHEM, V270, P30671, DOI 10.1074/jbc.270.51.30671; Mullershausen F, 2004, MOL BIOL CELL, V15, P4023, DOI 10.1091/mbc.E03-12-0890; Mullershausen F, 2004, CIRCULATION, V109, P1711, DOI 10.1161/01.CIR.0000126286.47618.BD; Mullershausen F, 2003, J CELL BIOL, V160, P719, DOI 10.1083/jcb.200211041; Okada D, 2002, BIOCHEMISTRY-US, V41, P9672, DOI 10.1021/bi025727+; Rybalkin SD, 2003, EMBO J, V22, P469, DOI 10.1093/emboj/cdg051; Rybalkin SD, 2002, J BIOL CHEM, V277, P3310, DOI 10.1074/jbc.M106562200; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Sopory S, 2003, FEBS LETT, V539, P161, DOI 10.1016/S0014-5793(03)00219-9; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; Turko IV, 1996, J BIOL CHEM, V271, P22240, DOI 10.1074/jbc.271.36.22240; Turko IV, 1998, BIOCHEM J, V329, P505; Wu AY, 2004, J BIOL CHEM, V279, P37928, DOI 10.1074/jbc.M404287200; Zoraghi R, 2004, MOL PHARMACOL, V65, P267, DOI 10.1124/mol.65.2.267; Zoraghi R, 2005, J BIOL CHEM, V280, P12051, DOI 10.1074/jbc.M413611200	30	18	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					19969	19976		10.1074/jbc.M603374200	http://dx.doi.org/10.1074/jbc.M603374200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16690614	hybrid			2022-12-25	WOS:000239038200020
J	Aharon, R; Bar-Shavit, Z				Aharon, Refael; Bar-Shavit, Zvi			Involvement of aquaporin 9 in osteoclast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; LIGAND; TESTIS; LIVER	Aquaporins (water channels) selectively enhance water permeability of membranes. Since osteoclast differentiation includes a dramatic increase in cell volume, we hypothesize that aquaporin(s) is/are critical for the formation of the multinucleated osteoclast from its mononuclear precursor. Our studies employ two cell models, bone marrow macrophages (BMMs) and the murine macrophage-like cell line, RAW264.7, as osteoclast precursors. Receptor activator of nuclear factor kappa B (NF-kappa B) ligand (RANKL) and macrophage-colony-stimulating factor or RANKL alone were used to induce osteoclast differentiation in BMMs or RAW264.7 cells, respectively. We first used qualitative reverse transcription (RT)-PCR to examine which of the aquaporins are expressed in osteoclasts and in their precursor cells. Out of the 10 aquaporins examined, only aquaporin 9 (AQP9) was expressed in osteoclast-lineage cells. AQP9 has unique aqueous pore properties mediating the passage of a wide variety of non-charged solutes in addition to water. Western analyses using specific antibodies revealed a higher AQP9 level in RANKL-treated than in untreated cells. Quantitative real-time RT-PCR analyses also demonstrated higher AQP9 mRNA levels in RANKL-treated cells. Finally, we examined the effect of phloretin, an AQP9 inhibitor, on RANKL-induced osteoclast differentiation. Cells were incubated with RANKL for 5 days, and phloretin was added for the last 2 days, when most fusion occurs. A dramatic reduction in osteoclast size and in the number of nuclei per osteoclast was observed in cultures containing phloretin. The inhibitor did not have a significant effect on the number and size of mononuclear phagocytes in cultures not treated with RANKL. Our results suggest a role for AQP9 in osteoclast differentiation, specifically in the fusion process.	Hebrew Univ Jerusalem, Humphrey Ctr Expt Med & Canc Res, Fac Med, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Bar-Shavit, Z (corresponding author), Hebrew Univ Jerusalem, Humphrey Ctr Expt Med & Canc Res, Fac Med, IL-91120 Jerusalem, Israel.	Zvi.Bar-Shavit@huji.ac.il			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR048818] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01 AR48818] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Amcheslavsky A, 2006, J CELL PHYSIOL, V207, P244, DOI 10.1002/jcp.20563; Aoki-Yoshino K, 2005, ACTA NEUROPATHOL, V110, P281, DOI 10.1007/s00401-005-1052-2; Barcroft LC, 2003, DEV BIOL, V256, P342, DOI 10.1016/S0012-1606(02)00127-6; Calamita G, 2001, BIOCHEM BIOPH RES CO, V288, P619, DOI 10.1006/bbrc.2001.5810; Cheung KH, 2003, BIOL REPROD, V68, P1505, DOI 10.1095/biolreprod.102.010017; Elkjaer ML, 2000, BIOCHEM BIOPH RES CO, V276, P1118, DOI 10.1006/bbrc.2000.3505; Fan HT, 2001, BRIT J PHARMACOL, V133, P1096, DOI 10.1038/sj.bjp.0704159; GOLDMAN R, 1979, J NATL CANCER I, V63, P1009; King LS, 2004, NAT REV MOL CELL BIO, V5, P687, DOI 10.1038/nrm1469; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lloyd DJ, 2005, PLOS GENET, V1, P171, DOI 10.1371/journal.pgen.0010020; Macnamara E, 2004, MOL VIS, V10, P51; Maurel C, 1997, ANNU REV PLANT PHYS, V48, P399, DOI 10.1146/annurev.arplant.48.1.399; Mobasheri A, 2004, VET J, V168, P143, DOI 10.1016/j.tvjl.2003.08.001; Okada S, 2003, FEBS LETT, V540, P157, DOI 10.1016/S0014-5793(03)00256-4; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Talbot NC, 2003, CELLS TISSUES ORGANS, V174, P117, DOI 10.1159/000071152; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Tsukaguchi H, 1998, J BIOL CHEM, V273, P24737, DOI 10.1074/jbc.273.38.24737; Tsukaguchi H, 1999, AM J PHYSIOL-RENAL, V277, pF685, DOI 10.1152/ajprenal.1999.277.5.F685; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	26	27	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19305	19309		10.1074/jbc.M601728200	http://dx.doi.org/10.1074/jbc.M601728200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16698796	hybrid			2022-12-25	WOS:000238847000045
J	Girzalsky, W; Hoffmann, LS; Schemenewitz, A; Nolte, A; Kunau, WH; Erdmann, R				Girzalsky, Wolfgang; Hoffmann, Linda S.; Schemenewitz, Andreas; Nolte, Andreas; Kunau, Wolf-Hubert; Erdmann, Ralf			Pex19p-dependent targeting of Pex17p, a peripheral component of the peroxisomal protein import machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR DOCKING COMPLEX; SACCHAROMYCES-CEREVISIAE; MEMBRANE-PROTEIN; BIOGENESIS; YEAST; PEX3P; IDENTIFICATION; LOCALIZATION; STABILITY; INTERACTS	Pex19p is required for the topogenesis of peroxisomal membrane proteins (PMPs). Here we have demonstrated that Pex19p is also required for the peroxisomal targeting and stability of Pex17p, a peripheral component of the docking complex of the peroxisomal protein import machinery. We have demonstrated that Pex17p is associated with the peroxisomal Pex13p-Pex14p complex as well as with Pex19p. We have identified the corresponding binding sites for Pex14p and Pex19p and demonstrated that a specific loss of the Pex19p interaction resulted in mistargeting of Pex17p. We have shown that a construct consisting only of the Pex19p- and Pex14p-binding sites of Pex17p is sufficient to direct an otherwise cytosolic reporter protein to the peroxisomal membrane in a Pex19p- dependent manner. Our data show that the function of Pex19p as chaperone or import receptor is not restricted to integral membrane proteins but may also include peripheral PMPs. As a consequence of our data, the previous definition of a targeting signal for PMPs (mPTS) as a Pex19p-binding motif in conjunction with a transmembrane segment should be extended to regions comprising a Pex19p- binding motif and a peroxisomal anchor sequence.	Ruhr Univ Bochum, Inst Physiol Chem, Abt Systembiochem, D-44780 Bochum, Germany	Ruhr University Bochum	Erdmann, R (corresponding author), Ruhr Univ Bochum, Inst Physiol Chem, Abt Systembiochem, Univ Str 150, D-44780 Bochum, Germany.	Ralf.Erdmann@ruhr-uni-bochum.de						Agne B, 2003, MOL CELL, V11, P635, DOI 10.1016/S1097-2765(03)00062-5; Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Albertini M, 2001, EUR J CELL BIOL, V80, P257, DOI 10.1078/0171-9335-00164; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Baerends RJS, 2000, J BIOL CHEM, V275, P9986, DOI 10.1074/jbc.275.14.9986; Baerends RJS, 1996, J BIOL CHEM, V271, P8887, DOI 10.1074/jbc.271.15.8887; Baker A, 2005, CURR OPIN PLANT BIOL, V8, P640, DOI 10.1016/j.pbi.2005.09.009; Brocard C, 1997, EMBO J, V16, P5491, DOI 10.1093/emboj/16.18.5491; Brown LA, 2003, J CELL MOL MED, V7, P388, DOI 10.1111/j.1582-4934.2003.tb00241.x; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; Dyer JM, 1996, J CELL BIOL, V133, P269, DOI 10.1083/jcb.133.2.269; Eckert JH, 2003, REV PHYSIOL BIOCH P, V147, P75, DOI 10.1007/s10254-003-0007-z; Elgersma Y, 1997, EMBO J, V16, P7326, DOI 10.1093/emboj/16.24.7326; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; ENTIAN KD, 1988, FEBS LETT, V236, P195, DOI 10.1016/0014-5793(88)80313-2; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; Fang Y, 2004, J CELL BIOL, V164, P863, DOI 10.1083/jcb.200311131; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fransen M, 2004, J BIOL CHEM, V279, P12615, DOI 10.1074/jbc.M304941200; Ghaedi K, 2000, MOL BIOL CELL, V11, P2085, DOI 10.1091/mbc.11.6.2085; Gietz R.D., 1994, MOL GENETICS YEAST P, P121; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; Gotte K, 1998, MOL CELL BIOL, V18, P616; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; Halbach A, 2005, J BIOL CHEM, V280, P21176, DOI 10.1074/jbc.M501750200; Harper CC, 2002, J BIOL CHEM, V277, P16498, DOI 10.1074/jbc.M111728200; Hazra PP, 2002, TRAFFIC, V3, P560, DOI 10.1034/j.1600-0854.2002.30806.x; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; Holroyd C, 2001, FEBS LETT, V501, P6, DOI 10.1016/S0014-5793(01)02617-5; Huhse B, 1998, J CELL BIOL, V140, P49, DOI 10.1083/jcb.140.1.49; Johnson MA, 2001, YEAST, V18, P621, DOI 10.1002/yea.711; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Lazarow PB, 2003, CURR OPIN CELL BIOL, V15, P489, DOI 10.1016/S0955-0674(03)00082-6; MARSHALL PA, 1995, J CELL BIOL, V129, P345, DOI 10.1083/jcb.129.2.345; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; Otzen M, 2004, J BIOL CHEM, V279, P19181, DOI 10.1074/jbc.M314275200; Pause B, 2000, FEBS LETT, V471, P23, DOI 10.1016/S0014-5793(00)01332-6; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; Rehling P, 1996, EMBO J, V15, P2901, DOI 10.1002/j.1460-2075.1996.tb00653.x; Rehling P, 2001, CRIT REV BIOCHEM MOL, V36, P291, DOI 10.1080/20014091074200; Rottensteiner H, 2004, MOL BIOL CELL, V15, P3406, DOI 10.1091/mbc.E04-03-0188; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; Schliebs W, 2004, CURR BIOL, V14, pR397, DOI 10.1016/j.cub.2004.05.017; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; Snyder WB, 1999, MOL BIOL CELL, V10, P4005, DOI 10.1091/mbc.10.12.4005; Sparkes IA, 2002, MOL MEMBR BIOL, V19, P171, DOI 10.1080/09687680210159422; Stein K, 2002, MOL CELL BIOL, V22, P6056, DOI 10.1128/MCB.22.17.6056-6069.2002; Subramani S, 2000, ANNU REV BIOCHEM, V69, P399, DOI 10.1146/annurev.biochem.69.1.399; van der Zand A, 2006, J CELL SCI, V119, P989, DOI 10.1242/jcs.02893; Vizeacoumar FJ, 2006, J BIOL CHEM, V281, P12817, DOI 10.1074/jbc.M600365200; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895	57	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19417	19425		10.1074/jbc.M603344200	http://dx.doi.org/10.1074/jbc.M603344200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16679311	hybrid			2022-12-25	WOS:000238847000057
J	Xie, T; Plagge, A; Gavrilova, O; Pack, S; Jou, W; Lai, EW; Frontera, M; Kelsey, G; Weinstein, LS				Xie, Tao; Plagge, Antonius; Gavrilova, Oksana; Pack, Stephanie; Jou, William; Lai, Edwin W.; Frontera, Marga; Kelsey, Gavin; Weinstein, Lee S.			The alternative stimulatory G protein alpha-subunit XL alpha s is a critical regulator of energy and glucose metabolism and sympathetic nerve activity in adult mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHITE ADIPOSE-TISSUE; INCREASED INSULIN SENSITIVITY; G(S)ALPHA KNOCKOUT MICE; II GENE-EXPRESSION; MELANOCORTIN-4 RECEPTOR; ADRENERGIC AGONIST; SYSTEM; GNAS; RESISTANCE; OBESITY	The complex imprinted Gnas locus encodes several gene products including G(s)alpha, the ubiquitously expressed G protein alpha-subunit required for receptor-stimulated cAMP generation, and the neuroendocrine-specific G(s)alpha isoform XL alpha s. XL alpha s is only expressed from the paternal allele, whereas G(s)alpha is biallelically expressed in most tissues. XL alpha s knock-out mice (Gnasxl (m+/p-)) have poor suckling and perinatal lethality, implicating XL alpha s as critical for postnatal feeding. We have now examined the metabolic phenotype of adult Gnasxl(m+/p-) mice. Gnasxl(m+/p-) mice had reduced fat mass and lipid accumulation in adipose tissue, with increased food intake and metabolic rates. Gene expression profiling was consistent with increased lipid metabolism in adipose tissue. These changes likely result from increased sympathetic nervous system activity rather than adipose cell-autonomous effects, as we found that XL alpha s is not normally expressed in adult adipose tissue, and Gnasxl(m+/p-) mice had increased urinary norepinephrine levels but not increased metabolic responsiveness to a beta 3-adrenergic agonist. Gnasxl(m+/p-) mice were hypolipidemic and had increased glucose tolerance and insulin sensitivity. The similar metabolic profile observed in some prior paternal Gnas knock- out models results from XL alpha s deficiency (or deficiency of the related alternative truncated protein XLN1). XL alpha s ( or XLN1) is a negative regulator of sympathetic nervous system activity in mice.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Mouse Metab Core Lab, NIH, Bethesda, MD 20892 USA; NICHD, Reprod Biol & Med Branch, NIH, Bethesda, MD 20892 USA; NINDS, Clin Neurocardiol Sect, NIH, Bethesda, MD 20892 USA; Babraham Inst, Lab Dev Genet & Imprinting, Cambridge CB2 4AT, England	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Weinstein, LS (corresponding author), NIDDK, Metab Dis Branch, NIH, Bldg 10 Rm,8C101, Bethesda, MD 20892 USA.	leew@amb.niddk.nih.gov	Plagge, Antonius/AAH-3877-2019; Weinstein, Lee S/I-5575-2015	Plagge, Antonius/0000-0001-6592-1343; Frontera Borrueco, Marga/0000-0001-8670-9106; Kelsey, Gavin/0000-0002-9762-5634; Weinstein, Lee/0000-0002-1899-5152	Biotechnology and Biological Sciences Research Council [BBS/E/B/0000M147, BBS/E/B/0000C169, BBS/E/B/00001169] Funding Source: Medline; Intramural NIH HHS Funding Source: Medline; Medical Research Council [G0400155] Funding Source: Medline; MRC [G0400155] Funding Source: UKRI; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK070002, ZIADK043313, Z01DK043313, ZIADK043302, Z01DK043302, ZICDK070002] Funding Source: NIH RePORTER	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abramowitz J, 2004, P NATL ACAD SCI USA, V101, P8366, DOI 10.1073/pnas.0308758101; Bartness TJ, 2005, P NUTR SOC, V64, P53, DOI 10.1079/PNS2004409; Bastepe M, 2002, MOL ENDOCRINOL, V16, P1912, DOI 10.1210/me.2002-0054; BLOOM JD, 1992, J MED CHEM, V35, P3081, DOI 10.1021/jm00094a025; Cattanach BM, 2000, HUM MOL GENET, V9, P2263, DOI 10.1093/oxfordjournals.hmg.a018917; CATTANACH BM, 1985, NATURE, V315, P496, DOI 10.1038/315496a0; Cederberg A, 2001, CELL, V106, P563, DOI 10.1016/S0092-8674(01)00474-3; Chen HC, 2003, J CLIN INVEST, V111, P1715, DOI [10.1172/JCI15859, 10.1172/JCI200315859]; Chen M, 2005, P NATL ACAD SCI USA, V102, P7386, DOI 10.1073/pnas.0408268102; Chen M, 2004, ENDOCRINOLOGY, V145, P4094, DOI 10.1210/en.2004-0038; Chin CH, 2004, GENE DEV, V18, P1970, DOI 10.1101/gad.1213104; Chu CA, 1997, J CLIN INVEST, V99, P1044, DOI 10.1172/JCI119232; EISENHOFER G, 1986, CLIN CHEM, V32, P2030; Ellacott KLJ, 2004, RECENT PROG HORM RES, V59, P395, DOI 10.1210/rp.59.1.395; Gavrilova O, 2000, DIABETES, V49, P1910, DOI 10.2337/diabetes.49.11.1910; Genevieve D, 2005, EUR J HUM GENET, V13, P1033, DOI 10.1038/sj.ejhg.5201448; Haig D, 2004, ANNU REV GENET, V38, P553, DOI 10.1146/annurev.genet.37.110801.142741; Haque MS, 1999, DIABETES, V48, P1706, DOI 10.2337/diabetes.48.9.1706; KEHLENBACH RH, 1994, NATURE, V372, P804; Kim JK, 2005, DIABETES, V54, P1657, DOI 10.2337/diabetes.54.6.1657; Klemke M, 2000, J BIOL CHEM, V275, P33633, DOI 10.1074/jbc.M006594200; LEE JE, 1990, DEVELOPMENT, V110, P151; Li T, 2000, GENOMICS, V69, P295, DOI 10.1006/geno.2000.6337; Liu J, 2000, J CLIN INVEST, V106, P1167, DOI 10.1172/JCI10431; LIU XL, 1994, AM J PHYSIOL, V266, pR914, DOI 10.1152/ajpregu.1994.266.3.R914; Martinez JA, 2001, J PHYSIOL BIOCHEM, V57, P287, DOI 10.1007/BF03179821; Matsumura K, 2002, BRAIN RES, V948, P145, DOI 10.1016/S0006-8993(02)03045-7; MOORE T, 1991, TRENDS GENET, V7, P45, DOI 10.1016/0168-9525(91)90230-N; Pasolli HA, 2000, J BIOL CHEM, V275, P33622, DOI 10.1074/jbc.M001335200; Pasolli HA, 2001, NEUROSCI LETT, V301, P119, DOI 10.1016/S0304-3940(01)01620-2; PENNYCUIK PR, 1967, AUST J EXP BIOL MED, V45, P331, DOI 10.1038/icb.1967.33; Plagge A, 2004, NAT GENET, V36, P818, DOI 10.1038/ng1397; Plagge A, 2005, MOL CELL BIOL, V25, P3019, DOI 10.1128/MCB.25.8.3019-3026.2005; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Rayner DV, 2001, P NUTR SOC, V60, P357, DOI 10.1079/PNS2001101; Shimizu Y, 1996, BIOCHEM J, V314, P485, DOI 10.1042/bj3140485; SINGH JS, 1991, BIOL NEONATE, V60, P7; Skinner JA, 2002, GENOMICS, V80, P373, DOI 10.1006/geno.2002.6842; Song CK, 2005, AM J PHYSIOL-REG I, V289, pR1467, DOI 10.1152/ajpregu.00348.2005; Weinstein LS, 2004, ENDOCRINOLOGY, V145, P5459, DOI 10.1210/en.2004-0865; Weinstein LS, 2001, ENDOCR REV, V22, P675, DOI 10.1210/er.22.5.675; Yang Q, 2005, NATURE, V436, P356, DOI 10.1038/nature03711; Yu SH, 2000, J CLIN INVEST, V105, P615, DOI 10.1172/JCI8437; Yu SH, 1998, P NATL ACAD SCI USA, V95, P8715, DOI 10.1073/pnas.95.15.8715; Yu SH, 2001, J BIOL CHEM, V276, P19994, DOI 10.1074/jbc.M010313200; ZARORBEHRENS G, 1983, AM J PHYSIOL, V244, pE361, DOI 10.1152/ajpendo.1983.244.4.E361; Zhang Y, 2002, BBA-MOL CELL BIOL L, V1584, P115, DOI 10.1016/S1388-1981(02)00298-6	47	79	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					18989	18999		10.1074/jbc.M511752200	http://dx.doi.org/10.1074/jbc.M511752200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16672216	Green Accepted, hybrid			2022-12-25	WOS:000238847000012
J	Arck, PC; Overall, R; Spatz, K; Liezman, C; Handjiski, B; Klapp, BF; Birch-Machin, MA; Peters, EMJ				Arck, Petra Clara; Overall, Rupert; Spatz, Katharina; Liezman, Christiane; Handjiski, Bori; Klapp, Burghard F.; Birch-Machin, Mark A.; Peters, Eva Milena Johanne			Towards a "free radical theory of graying": melanocyte apoptosis in the aging human hair follicle is an indicator of oxidative stress induced tissue damage	FASEB JOURNAL			English	Article						gray hair; premature aging	MITOCHONDRIAL-DNA; STEM-CELLS; MELANOGENESIS; MICE; SKIN; DIFFERENTIATION; INVOLVEMENT; DISRUPTION; REGRESSION; DELETIONS	Oxidative stress is generated by a multitude of environmental and endogenous challenges such as radiation, inflammation, or psychoemotional stress. It also speeds the aging process. Graying is a prominent but little understood feature of aging. Intriguingly, the continuous melanin synthesis in the growing (anagen) hair follicle generates high oxidative stress. We therefore hypothesize that hair bulb melanocytes are especially susceptible to free radical-induced aging. To test this hypothesis, we subjected human scalp skin anagen hair follicles from graying individuals to macroscopic and immunohistomorphometric analysis and organ culture. We found evidence of melanocyte apoptosis and increased oxidative stress in the pigmentary unit of graying hair follicles. The "common" deletion, a marker mitochondrial DNA-deletion for accumulating oxidative stress damage, occurred most prominently in graying hair follicles. Cultured unpigmented hair follicles grew better than pigmented follicles of the same donors. Finally, cultured pigmented hair follicles exposed to exogenous oxidative stress (hydroquinone) showed increased melanocyte apoptosis in the hair bulb. We conclude that oxidative stress is high in hair follicle melanocytes and leads to their selective premature aging and apoptosis. The graying hair follicle, therefore, offers a unique model system to study oxidative stress and aging and to test antiaging therapeutics in their ability to slow down or even stop this process.	Humboldt Univ, Ctr Biomed Res, Cutaneous Neuroimmunol, D-13353 Berlin, Germany; Humboldt Univ, Ctr Biomed Res, Psychoneuroimmunol, D-13353 Berlin, Germany; Univ Newcastle, Sch Med, Newcastle, NSW 2308, Australia	Humboldt University of Berlin; Humboldt University of Berlin; University of Newcastle	Arck, PC (corresponding author), Humboldt Univ, Ctr Biomed Res, Cutaneous Neuroimmunol, Rm Nr 2-0549,Univ Med Charite,Virchow Campus,Augu, D-13353 Berlin, Germany.	eva.peters@charite.de	Overall, Rupert W/P-3102-2016; Arck, Petra C/D-7094-2013	Overall, Rupert W/0000-0002-3882-6073; Arck, Petra/0000-0002-2932-926X				Akar A, 2002, J DERMATOL SCI, V29, P85, DOI 10.1016/S0923-1811(02)00015-4; Bahmer FA, 2002, HAUTARZT, V53, P492, DOI 10.1007/s00105-002-0375-3; Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016; Birch-Machin MA, 2000, CLIN EXP DERMATOL, V25, P141, DOI 10.1046/j.1365-2230.2000.00605.x; BOTCHKAREVA NV, 2001, FASEB J, V15, P3; Bowers RR, 1999, CELL MOL BIOL, V45, P1065; Brierley EJ, 1997, MOL CELL BIOCHEM, V174, P325, DOI 10.1023/A:1006847319162; Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x; Cernak I, 2000, MAGNESIUM RES, V13, P29; Commo S, 2004, BRIT J DERMATOL, V150, P435, DOI 10.1046/j.1365-2133.2004.05787.x; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; DAWBER R, 1995, HAIR SCALP DISORDERS; Emerit I, 2004, PHOTOCHEM PHOTOBIOL, V80, P579, DOI 10.1562/2004-06-22-RA-212.1; Epel ES, 2004, P NATL ACAD SCI USA, V101, P17312, DOI 10.1073/pnas.0407162101; FLUGEL B, 1971, Z ALTERNSFORSCHUNG, V23, P397; Fuchs J, 2001, FREE RADICAL BIO MED, V30, P337, DOI 10.1016/S0891-5849(00)00482-2; Gould L, 1996, AM HEART J, V132, P1317, DOI 10.1016/S0002-8703(96)90496-2; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Irie M, 2001, JPN J CANCER RES, V92, P367, DOI 10.1111/j.1349-7006.2001.tb01104.x; Irie M, 2001, INT ARCH OCC ENV HEA, V74, P153, DOI 10.1007/s004200000209; Ito M, 2004, DIFFERENTIATION, V72, P548, DOI 10.1111/j.1432-0436.2004.07209008.x; Jimenez-Cervantes C, 2001, J CELL SCI, V114, P2335; Kadekaro AL, 2003, PIGM CELL RES, V16, P434, DOI 10.1034/j.1600-0749.2003.00088.x; Kao SH, 1997, BIOCHEM MOL BIOL INT, V42, P285; KLIGMAN AM, 1959, J INVEST DERMATOL, V33, P307, DOI 10.1038/jid.1959.156; Kokoszka JE, 2001, P NATL ACAD SCI USA, V98, P2278, DOI 10.1073/pnas.051627098; Lee JW, 2005, MECH AGEING DEV, V126, P79, DOI 10.1016/j.mad.2004.09.011; Legue E, 2005, DEVELOPMENT, V132, P4143, DOI 10.1242/dev.01975; Lindner G, 1997, AM J PATHOL, V151, P1601; Liu CS, 2001, NEPHROL DIAL TRANSPL, V16, P561, DOI 10.1093/ndt/16.3.561; Lu CY, 1999, MUTAT RES-FUND MOL M, V423, P11, DOI 10.1016/S0027-5107(98)00220-6; Melov S, 2002, INT J BIOCHEM CELL B, V34, P1395, DOI 10.1016/S1357-2725(02)00086-9; Meyskens FL, 1999, CLIN CANCER RES, V5, P1197; Moller P, 1996, CHEM-BIOL INTERACT, V102, P17, DOI 10.1016/0009-2797(96)03729-5; MOSLEY JG, 1996, BR MED J, V313; Muller-Rover S, 1999, J INVEST DERM SYMP P, V4, P272, DOI 10.1038/sj.jidsp.5640228; Muller-Rover S, 2000, AM J PATHOL, V156, P1395, DOI 10.1016/S0002-9440(10)65008-0; NAGL W, 1995, BRIT J DERMATOL, V132, P94, DOI 10.1111/j.1365-2133.1995.tb08631.x; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; Nappi AJ, 1996, MELANOMA RES, V6, P341, DOI 10.1097/00008390-199610000-00001; Nishimura EK, 2005, SCIENCE, V307, P720, DOI 10.1126/science.1099593; Nishimura EK, 2002, NATURE, V416, P854, DOI 10.1038/416854a; NORDLUND JJ, 1998, PIGMENTARY SYSTEM, P1106; OrrWalker BJ, 1997, J CLIN ENDOCR METAB, V82, P3580, DOI 10.1210/jc.82.11.3580; PAUS R, 1993, YALE J BIOL MED, V66, P541; Paus R, 1999, J INVEST DERM SYMP P, V4, P338, DOI 10.1038/sj.jidsp.5640241; PAVEL S, 1993, J INVEST DERMATOL, V100, pS162, DOI 10.1111/1523-1747.ep12465095; Peters EMJ, 2002, J HISTOCHEM CYTOCHEM, V50, P751, DOI 10.1177/002215540205000602; Philpott M, 1999, Exp Dermatol, V8, P317; PHILPOTT MP, 1990, J CELL SCI, V97, P463; Porteous WK, 1998, EUR J BIOCHEM, V257, P192, DOI 10.1046/j.1432-1327.1998.2570192.x; RILEY PA, 1988, ANN NY ACAD SCI, V551, P111, DOI 10.1111/j.1749-6632.1988.tb22325.x; ROSEN CJ, 1994, J CLIN ENDOCR METAB, V79, P854, DOI 10.1210/jc.79.3.854; Slominski A, 2005, J INVEST DERMATOL, V124, P13, DOI 10.1111/j.0022-202X.2004.23528.x; SLOMINSKI A, 1993, J INVEST DERMATOL, V101, pS90, DOI 10.1111/1523-1747.ep12362991; SPERLING LC, 1991, J AM ACAD DERMATOL, V25, P1, DOI 10.1016/0190-9622(91)70167-Z; Sun LQ, 2004, GENE DEV, V18, P1035, DOI 10.1101/gad.1176104; Tobin DJ, 2000, J PATHOL, V191, P407; Tobin DJ, 2001, EXP GERONTOL, V36, P29, DOI 10.1016/S0531-5565(00)00210-2; Tobin DJ, 1999, J INVEST DERM SYMP P, V4, P323, DOI 10.1038/sj.jidsp.5640239; TOBIN DJ, 2000, ATLAS HAIR NAILS, P157; Van Neste D, 2004, MICRON, V35, P193, DOI 10.1016/j.micron.2003.11.006; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Yamamura K, 1996, CANCER RES, V56, P3546; YANG JH, 1994, ARCH DERMATOL RES, V286, P386, DOI 10.1007/BF00371798; YOHN JJ, 1991, J INVEST DERMATOL, V97, P405, DOI 10.1111/1523-1747.ep12480983; Zhai S, 1996, EXP CELL RES, V224, P335, DOI 10.1006/excr.1996.0143	68	145	156	2	45	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1567	+		10.1096/fj.05-4039fje	http://dx.doi.org/10.1096/fj.05-4039fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16723385				2022-12-25	WOS:000240266000053
J	Wang, S; Teschemacher, AG; Paton, JFR; Kasparov, S				Wang, Sheng; Teschemacher, Anja G.; Paton, Julian F. R.; Kasparov, Sergey			Mechanism of nitric oxide action on inhibitory GABAergic signaling within the nucleus tractus solitarii	FASEB JOURNAL			English	Article						ryanodine; cADPR; [Ca2+](i); patch clamp	CYCLIC ADP-RIBOSE; CA2+-INDUCED CA2+ RELEASE; CALCIUM-RELEASE; ANGIOTENSIN-II; INTRACELLULAR CALCIUM; VENTROLATERAL MEDULLA; BARORECEPTOR REFLEX; GLUTAMATE RELEASE; HEART-RATE; NEURONS	The cellular mechanisms mediating nitric oxide (NO) modulation of the inhibitory transmission in the nucleus tractus solitarii (NTS) remain unclear, even though this could be extremely important for various physiological and pathological processes. Specifically, in the NTS NO-evoked glutamate and gamma-aminobutyric acid (GABA) release might contribute to pathological hypertension. In cultured rat brainstem slices, NTS GABAergic neurons were targeted using an adenoviral vector to express enhanced green fluorescent protein and studied with a combination of patch clamp and confocal microscopy. Low nanomolar concentrations of NO increased intracellular Ca2+ concentration ([Ca2+](i)) in somata, dendrites, and putative axons of GABAergic neurons, with axons being the most sensitive compartment. This effect was cGMP mediated and not related to depolarization or indirect presynaptic effects on glutamatergic transmission. Blockade of the cyclic adenosine diphosphate ribose (cADPR)/ryanodine-sensitive stores but not the inositol triphosphate-sensitive stores, inhibited NO effect. Since cADPR/ryanodine-sensitive stores are implicated in the Ca2+-induced Ca2+ release, NO can be expected to potentiate GABA release. In support of this notion, a cADPR antagonist abolished the NO-induced potentiation of GABAergic inhibitory postsynaptic potentials in the NTS. Thus, the NO-cGMP-cADPR-Ca2+ pathway, previously described in sea urchin eggs, also operates in mammalian GABAergic neurons. Potentiation of GABA release by NO may have implications for numerous brain functions.	Univ Bristol, Sch Med Sci, Dept Physiol, Bristol BS8 1TD, Avon, England; Univ Bristol, Sch Med Sci, Dept Pharmacol, Bristol BS8 1TD, Avon, England	University of Bristol; University of Bristol	Kasparov, S (corresponding author), Univ Bristol, Sch Med Sci, Dept Physiol, Bristol BS8 1TD, Avon, England.	sergey.kasparov@bristol.ac.uk	Paton, Julian/AAM-2121-2020; Kasparov, Sergey/AAH-5286-2019; Kasparov, Sergey/C-4932-2014	Kasparov, Sergey/0000-0002-1824-1764; Kasparov, Sergey/0000-0002-1824-1764; Wang, Sheng/0000-0001-9579-4808; Paton, Julian/0000-0001-7410-2913	Wellcome Trust [069061] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abudara V, 2002, J NEUROPHYSIOL, V88, P497, DOI 10.1152/jn.2002.88.1.497; ANDRESEN MC, 1990, AM J PHYSIOL, V259, pH1307, DOI 10.1152/ajpheart.1990.259.4.H1307; Bains JS, 1997, NEUROSCIENCE, V79, P149, DOI 10.1016/S0306-4522(96)00670-7; Bellamy TC, 2001, J BIOL CHEM, V276, P4287, DOI 10.1074/jbc.M006677200; BROOKS PA, 1992, J PHYSIOL-LONDON, V457, P115, DOI 10.1113/jphysiol.1992.sp019367; Bruzzone S, 2003, BIOCHEM J, V375, P395, DOI 10.1042/BJ20030556; Butcher JW, 1999, J AUTONOM NERV SYST, V77, P90, DOI 10.1016/S0165-1838(99)00036-3; Chini EN, 2005, BIOCHEM J, V389, P269, DOI 10.1042/BJ20041971; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; Clementi E, 1996, J BIOL CHEM, V271, P17739, DOI 10.1074/jbc.271.30.17739; Cohen AS, 1997, J PHYSIOL-LONDON, V499, P315, DOI 10.1113/jphysiol.1997.sp021929; Dias ACR, 2005, AM J PHYSIOL-HEART C, V288, pH256, DOI 10.1152/ajpheart.01149.2003; Empson RM, 1997, J BIOL CHEM, V272, P20967, DOI 10.1074/jbc.272.34.20967; Esplugues JV, 2002, BRIT J PHARMACOL, V135, P1079, DOI 10.1038/sj.bjp.0704569; Fernandez SF, 2003, HYPERTENSION, V41, P56, DOI 10.1161/01.HYP.0000047513.75459.7E; Galione A, 2002, CELL CALCIUM, V32, P343, DOI 10.1016/S0143416002001902; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Genazzani AA, 1996, BIOCHEM J, V315, P721, DOI 10.1042/bj3150721; Griffiths C, 2002, EUR J NEUROSCI, V15, P962, DOI 10.1046/j.1460-9568.2002.01930.x; Guse AH, 2004, CURR MOL MED, V4, P239, DOI 10.2174/1566524043360771; Hashii M, 2000, BIOCHEM J, V345, P207, DOI 10.1042/0264-6021:3450207; Hirooka Y, 2003, J CARDIOVASC PHARM, V42, pS111, DOI 10.1097/00005344-200312001-00023; Horn TFW, 2002, FASEB J, V16, P1611, DOI 10.1096/fj.02-0126com; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; Huang CC, 2003, MOL PHARMACOL, V64, P521, DOI 10.1124/mol.64.2.521; Kasparov S, 2004, PROG BIOPHYS MOL BIO, V84, P251, DOI 10.1016/j.pbiomolbio.2003.11.011; Kasparov S, 1999, J PHYSIOL-LONDON, V521, P227, DOI 10.1111/j.1469-7793.1999.00227.x; Kishi T, 2001, HYPERTENSION, V38, P896, DOI 10.1161/hyp.38.4.896; Koh HY, 2001, EUR J NEUROSCI, V13, P553, DOI 10.1046/j.0953-816x.2000.01416.x; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Li Y, 2003, NEUROSCIENCE, V118, P585, DOI 10.1016/S0306-4522(03)00042-3; Lin HC, 2000, EUR J PHARMACOL, V407, P83, DOI 10.1016/S0014-2999(00)00684-1; LINDEN DJ, 1995, J NEUROSCI, V15, P5098; Llano I, 2000, NAT NEUROSCI, V3, P1256, DOI 10.1038/81781; Looms DK, 2001, BIOCHEM J, V355, P87, DOI 10.1042/bj3550087; Lu YF, 2002, J NEUROPHYSIOL, V88, P1270, DOI 10.1152/jn.2002.88.3.1270; Maeda M, 1999, NEUROREPORT, V10, P1957, DOI 10.1097/00001756-199906230-00030; Matsumura K, 1998, BRAIN RES, V798, P232, DOI 10.1016/S0006-8993(98)00420-X; Matsuo I, 2001, AM J PHYSIOL-REG I, V280, pR1285, DOI 10.1152/ajpregu.2001.280.5.R1285; MORRISSETTE J, 1993, FEBS LETT, V330, P270, DOI 10.1016/0014-5793(93)80886-Y; Ohkuma S, 1996, MOL BRAIN RES, V36, P137, DOI 10.1016/0169-328X(95)00256-R; OHKUMA S, 1995, J NEUROCHEM, V65, P1109; OHTA H, 1994, AM J PHYSIOL-REG I, V267, pR1065, DOI 10.1152/ajpregu.1994.267.4.R1065; Oliva AA, 2000, J NEUROSCI, V20, P3354, DOI 10.1523/JNEUROSCI.20-09-03354.2000; PAPE HC, 1992, NEURON, V9, P441, DOI 10.1016/0896-6273(92)90182-D; Paton JFR, 2002, TRENDS NEUROSCI, V25, P626, DOI 10.1016/S0166-2236(02)02261-0; Paton JFR, 2001, J PHYSIOL-LONDON, V531, P445, DOI 10.1111/j.1469-7793.2001.0445i.x; PATON JFR, 2005, ADV VAGAL AFFERENT N, P209; Pontieri V, 1998, J HYPERTENS, V16, P1993, DOI 10.1097/00004872-199816121-00021; Reyes-Harde M, 1999, J NEUROPHYSIOL, V82, P1569, DOI 10.1152/jn.1999.82.3.1569; Sistiaga A, 1997, EUR J PHARMACOL, V321, P247, DOI 10.1016/S0014-2999(96)00937-5; Stern JE, 2005, J PHYSIOL-LONDON, V562, P725, DOI 10.1113/jphysiol.2004.077735; Talman WT, 2004, HYPERTENSION, V43, P820, DOI 10.1161/01.HYP.0000120848.76987.ef; Talman WT, 2001, ANN NY ACAD SCI, V940, P169; Teggatz EG, 2005, MICROVASC RES, V70, P65, DOI 10.1016/j.mvr.2005.06.004; Teschemacher AG, 2005, EXP PHYSIOL, V90, P61, DOI 10.1113/expphysiol.2004.028191; Trabace L, 2000, J NEUROCHEM, V75, P1664, DOI 10.1046/j.1471-4159.2000.0751664.x; Vacher CM, 2003, EUR J NEUROSCI, V17, P455, DOI 10.1046/j.1460-9568.2003.02467.x; Verkhratsky A, 2005, PHYSIOL REV, V85, P201, DOI 10.1152/physrev.00004.2004; Waki H, 2003, J PHYSIOL-LONDON, V546, P233, DOI 10.1113/jphysiol.2002.030270; WHITE AM, 1993, FEBS LETT, V318, P259, DOI 10.1016/0014-5793(93)80524-X; Willmott N, 1996, J BIOL CHEM, V271, P3699; Willmott NJ, 2000, J NEUROSCI, V20, P1767; Yusufi ANK, 2002, EXP BIOL MED, V227, P36, DOI 10.1177/153537020222700107; ZANZINGER J, 1995, NEUROSCI LETT, V197, P199, DOI 10.1016/0304-3940(95)11929-Q	66	36	37	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1537	+		10.1096/fj.05-5547fje	http://dx.doi.org/10.1096/fj.05-5547fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16720728				2022-12-25	WOS:000240266000043
J	Wang, X; Wang, TT; White, JH; Studzinski, GP				Wang, X.; Wang, T-T; White, J. H.; Studzinski, G. P.			Induction of kinase suppressor of RAS-1( KSR-1) gene by 1, alpha 25-dihydroxyvitamin D-3 in human leukemia HL60 cells through a vitamin D response element in the 5 '-flanking region	ONCOGENE			English	Article						KSR; differentiation; vitamin D; vitamin D receptor; VDRE; RXRalfa; MAPK	ACTIVATED PROTEIN-KINASE; 1,25-DIHYDROXYVITAMIN D-3; MONOCYTIC DIFFERENTIATION; SIGNAL-TRANSDUCTION; HL-60 CELLS; D-RECEPTOR; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; TRANSCRIPTIONAL ACTIVATION; MYELOID-LEUKEMIA; BINDING PROTEINS	Differentiation therapy is being developed as an additional therapeutic option for the treatment of several forms of cancer, including myeloid leukemia. In model systems, the physiologically active form of vitamin D, 1, alpha 25-dihydroxyvitamin D-3 (1,25D), induces monocytic differentiation of human myeloid cells, but the mechanism is not clear. We report here, the first direct connection between the signal provided by 1,25D and the molecular circuitry known to be involved in monocytic differentiation. Specifically, we show that 1,25D selectively increases the expression of the gene encoding kinase suppressor of Ras-1 (KSR-1) in HL60 cells, while other differentiation-inducing agents such as 12-O-tetradecanoylphorbol-13-acetate, retinoic acid or dimethyl sulfoxide do not significantly increase KSR-1 expression. Further, the upregulation of KSR-1 gene by 1,25D is competed by ZK159222, an antagonist of vitamin D receptor (VDR) action, and can occur in the presence of protein synthesis inhibitor cycloheximide, showing that the effect is direct. Most importantly, we have identified a vitamin D responsive element (VDRE) in the promoter region of the human KSR-1 gene, to which VDR binds in a 1,25D-dependent manner, in vitro and in vivo. This binding is paralleled by increased association of RNA polymerase II with the transcription start site of KSR-1 gene, and the VDRE is functional in reporter assays. Our findings offer a potential mechanism for a signaling pathway that contributes to 1,25D-induced monocytic differentiation of human myeloid leukemia cells.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pathol & Lab Med, Newark, NJ 07103 USA; McGill Univ, Dept Physiol, Montreal, PQ, Canada	Rutgers State University New Brunswick; Rutgers State University Medical Center; McGill University	Studzinski, GP (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pathol & Lab Med, 185 S Orange Ave,C543, Newark, NJ 07103 USA.	studzins@umdnj.edu	white, john h/N-9782-2013	white, john h/0000-0002-4785-2687	NCI NIH HHS [R01 CA044722-16, R01 CA044722, R01-CA44722-16] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044722] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE E, 1981, P NATL ACAD SCI-BIOL, V78, P4990, DOI 10.1073/pnas.78.8.4990; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BIELAWSKA A, 1992, FEBS LETT, V307, P211, DOI 10.1016/0014-5793(92)80769-D; BUNCE CM, 1983, EXP HEMATOL, V11, P828; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; CHOMIENNE C, 1990, BLOOD, V76, P1710; Christakos S, 2003, J CELL BIOCHEM, V88, P238, DOI 10.1002/jcb.10349; Dhawan P, 2005, MOL CELL BIOL, V25, P472, DOI 10.1128/MCB.25.1.472-487.2005; FERRARA J, 1994, J BIOL CHEM, V269, P2971; FRETZ JA, 2006, MOL ENDOCRINOL; Herdick M, 2000, J BIOL CHEM, V275, P16506, DOI 10.1074/jbc.M910000199; Ikezoe T, 2005, CANCER RES, V65, P4762, DOI 10.1158/0008-5472.CAN-03-3619; Ji Y, 2004, CANCER RES, V64, P370, DOI 10.1158/0008-5472.CAN-03-3029; Kolesnick R, 2004, J CLIN INVEST, V114, P1233, DOI 10.1172/JCI200423441; KOLLA SS, 1994, CANCER RES, V54, P1418; Lamkin TJ, 2006, J CELL BIOCHEM, V97, P1328, DOI 10.1002/jcb.20745; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Lin R, 2004, BIOESSAYS, V26, P21, DOI 10.1002/bies.10368; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Marcinkowska E, 2001, ANTICANCER RES, V21, P499; Ory S, 2004, CURR BIOL, V14, pR277, DOI 10.1016/j.cub.2004.03.023; Pan Z, 1999, J BIOL CHEM, V274, P23242, DOI 10.1074/jbc.274.33.23242; Qi XM, 2002, J BIOL CHEM, V277, P25884, DOI 10.1074/jbc.M203039200; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; Roy F, 2002, CURR BIOL, V12, pR325, DOI 10.1016/S0960-9822(02)00831-X; SIEGEL MR, 1963, NATURE, V200, P675, DOI 10.1038/200675a0; Song XD, 1998, ENDOCRINOLOGY, V139, P457, DOI 10.1210/en.139.2.457; Studzinski GP, 2005, J STEROID BIOCHEM, V97, P47, DOI 10.1016/j.jsbmb.2005.06.010; STUDZINSKI GP, 1985, P SOC EXP BIOL MED, V179, P288; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Wang Q, 2005, J CELL PHYSIOL, V204, P962, DOI 10.1002/jcp.20355; Wang Q, 2003, J CELL BIOCHEM, V89, P1087, DOI 10.1002/jcb.10595; Wang QM, 1996, CANCER RES, V56, P264; Wang TT, 2005, MOL ENDOCRINOL, V19, P2685, DOI 10.1210/me.2005-0106; Wang XN, 2004, J CELL PHYSIOL, V198, P333, DOI 10.1002/jcp.10443; Wang XN, 2001, J CELL BIOCHEM, V80, P471, DOI 10.1002/1097-4644(20010315)80:4<471::AID-JCB1001>3.0.CO;2-J; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	37	29	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7078	7085		10.1038/sj.onc.1209697	http://dx.doi.org/10.1038/sj.onc.1209697			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16732322	Green Accepted			2022-12-25	WOS:000241910500007
J	Lin, YT; Chen, Y; Wu, G; Lee, WH				Lin, Y-T; Chen, Y.; Wu, G.; Lee, W-H			Hec1 sequentially recruits Zwint-1 and ZW10 to kinetochores for faithful chromosome segregation and spindle checkpoint control	ONCOGENE			English	Article						mitosis; kinetochores; spindle checkpoint; chromosome segregation and microtubule	MITOTIC CHECKPOINT; BUDDING YEAST; CELL-CYCLE; MICROTUBULE ATTACHMENT; MAMMALIAN-CELLS; NDC80 COMPLEX; MOLECULAR ANALYSIS; OUTER KINETOCHORE; DROSOPHILA ZW10; GENE-PRODUCT	Faithful chromosome segregation is essential for maintaining the genomic integrity, which requires coordination among chromosomes, kinetochores, centrosomes and spindles during mitosis. Previously, we discovered a novel coiled-coil protein, highly expressed in cancer 1 (Hec1), which is indispensable for this process. However, the precise underlying mechanism remains unclear. Here, we show that Hec1 directly interacts with human ZW10 interacting protein (Zwint-1), a binding partner of Zeste White 10 ( ZW10) that is required for chromosome motility and spindle checkpoint control. In mitotic cells, Hec1 transiently forms complexes with Zwint-1 and ZW10 in a temporal and spatial manner. Although the three proteins have variable cell cycle-dependent expression profiles, they can only be co-immunoprecipitated during M phase. Immunofluorescent study showed that Hec1 and Zwint-1 co-localize at kinetochores beginning at prophase and that ZW10 joins them later at prometaphase. Depletion of Hec1 impairs the recruitment of both Zwint-1 and ZW10 to kinetochores, while depletion of Zwint-1 abrogates the kinetochore localization of ZW10 but not Hec1. The results suggest that the localization of Hec1 at kinetochores is required for the sequential recruitment of Zwint-1 and ZW10. Disrupting this recruitment by inhibiting the expression of Hec1 or Zwint-1 causes chromosome missegregation, spindle checkpoint failure, and eventually cell death upon cytokinesis. Taken together, these results, at least in part, provide a molecular basis to explain how Hec1 plays a crucial role for spindle checkpoint control and faithful chromosome segregation.	Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX USA	University of California System; University of California Irvine; University of Texas System; University of Texas Health San Antonio	Lee, WH (corresponding author), Univ Calif Irvine, Dept Biol Chem, 124 Sprague Hall, Irvine, CA 92697 USA.	whlee@uci.edu			NCI NIH HHS [CA 107568] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA107568] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Basto R, 2000, NAT CELL BIOL, V2, P939, DOI 10.1038/35046592; Bharadwaj R, 2004, J BIOL CHEM, V279, P13076, DOI 10.1074/jbc.M310224200; Biggins S, 2001, GENE DEV, V15, P3118, DOI 10.1101/gad.934801; BRINKLEY BR, 1966, CHROMOSOMA, V19, P28, DOI 10.1007/BF00332792; Chan GK, 2005, TRENDS CELL BIOL, V15, P589, DOI 10.1016/j.tcb.2005.09.010; Chan GKT, 2000, NAT CELL BIOL, V2, P944, DOI 10.1038/35046598; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Cheeseman IM, 2002, J CELL BIOL, V157, P199, DOI 10.1083/jcb.200201052; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen Y, 1997, J BIOL CHEM, V272, P24081, DOI 10.1074/jbc.272.38.24081; Chen YM, 1997, MOL CELL BIOL, V17, P6049, DOI 10.1128/MCB.17.10.6049; Chen YM, 2002, J BIOL CHEM, V277, P49408, DOI 10.1074/jbc.M207069200; Ciferri C, 2005, J BIOL CHEM, V280, P29088, DOI 10.1074/jbc.M504070200; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Craig JM, 1999, EXP CELL RES, V246, P249, DOI 10.1006/excr.1998.4278; De Wulf P, 2003, GENE DEV, V17, P2902, DOI 10.1101/gad.1144403; DeLuca JG, 2005, MOL BIOL CELL, V16, P519, DOI 10.1091/mbc.E04-09-0852; Desai A, 2003, GENE DEV, V17, P2421, DOI 10.1101/gad.1126303; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; EARNSHAW WC, 1987, J CELL BIOL, V104, P817, DOI 10.1083/jcb.104.4.817; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Emanuele MJ, 2005, MOL BIOL CELL, V16, P4882, DOI 10.1091/mbc.E05-03-0239; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; He XW, 2001, CELL, V106, P195, DOI 10.1016/S0092-8674(01)00438-X; Hori T, 2003, J CELL SCI, V116, P3347, DOI 10.1242/jcs.00645; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Janke C, 2001, EMBO J, V20, P777, DOI 10.1093/emboj/20.4.777; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kitagawa K, 2001, NAT REV MOL CELL BIO, V2, P678, DOI 10.1038/35089568; Kniola B, 2001, MOL BIOL CELL, V12, P2767, DOI 10.1091/mbc.12.9.2767; Kops GJPL, 2005, J CELL BIOL, V169, P49, DOI 10.1083/jcb.200411118; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Lou Y, 2004, J BIOL CHEM, V279, P20049, DOI 10.1074/jbc.M314205200; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; McCleland ML, 2004, CURR BIOL, V14, P131, DOI 10.1016/j.cub.2003.12.058; McCleland ML, 2003, GENE DEV, V17, P101, DOI 10.1101/gad.1040903; McEwen BF, 1998, CHROMOSOMA, V107, P366, DOI 10.1007/s004120050320; Meraldi P, 2004, DEV CELL, V7, P45, DOI 10.1016/j.devcel.2004.06.006; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Mikami Y, 2005, MOL CELL BIOL, V25, P1958, DOI 10.1128/MCB.25.5.1958-1970.2005; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Obuse C, 2004, NAT CELL BIOL, V6, P1135, DOI 10.1038/ncb1187; PALMER DK, 1987, J CELL BIOL, V104, P805, DOI 10.1083/jcb.104.4.805; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Savoian MS, 2000, NAT CELL BIOL, V2, P948, DOI 10.1038/35046605; Sharp DJ, 2000, NAT CELL BIOL, V2, P922, DOI 10.1038/35046574; Starr DA, 2000, J CELL SCI, V113, P1939; Starr DA, 1998, J CELL BIOL, V142, P763, DOI 10.1083/jcb.142.3.763; Starr DA, 1997, J CELL BIOL, V138, P1289, DOI 10.1083/jcb.138.6.1289; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Wang HM, 2004, J BIOL CHEM, V279, P54590, DOI 10.1074/jbc.M407588200; Wei RR, 2005, P NATL ACAD SCI USA, V102, P5363, DOI 10.1073/pnas.0501168102; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; Wigge PA, 2001, J CELL BIOL, V152, P349, DOI 10.1083/jcb.152.2.349; Wigge PA, 1998, J CELL BIOL, V141, P967, DOI 10.1083/jcb.141.4.967; Williams BC, 2003, MOL BIOL CELL, V14, P1379, DOI 10.1091/mbc.E02-09-0624; WILLIAMS BC, 1992, J CELL BIOL, V118, P759, DOI 10.1083/jcb.118.4.759; WILLIAMS BC, 1994, J CELL SCI, V107, P785; Xiao J, 2001, J BIOL CHEM, V276, P6105, DOI 10.1074/jbc.M008893200; Zheng L, 1999, MOL CELL BIOL, V19, P5417; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091	73	51	59	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	52					6901	6914		10.1038/sj.onc.1209687	http://dx.doi.org/10.1038/sj.onc.1209687			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16732327				2022-12-25	WOS:000241732300001
J	Huang, Y; Zhao, Q; Zhou, CX; Gu, ZM; Li, D; Xu, HZ; Sims, PJ; Zhao, KW; Chen, GQ				Huang, Y.; Zhao, Q.; Zhou, C-X; Gu, Z-M; Li, D.; Xu, H-Z; Sims, P. J.; Zhao, K-W; Chen, G-Q			Antileukemic roles of human phospholipid scramblase 1 gene, evidence from inducible PLSCR1-expressing leukemic cells	ONCOGENE			English	Article						PLSCR1; proliferation; differentiation; apoptosis; leukemia; gene regulation	KINASE-C-DELTA; GROWTH-FACTOR RECEPTOR; UV-INDUCED APOPTOSIS; PLASMA-MEMBRANE; MYELOID-LEUKEMIA; RETINOIC ACID; C/EBP-ALPHA; INDUCED-DIFFERENTIATION; TRANSBILAYER MOVEMENT; MEDIATED DEGRADATION	Phospholipid scramblase 1 (PLSCR1) is a multiply palmitoylated protein which is localized in either the cell membrane or nucleus depending on its palmitoylated state. The increasing evidence showed the biological roles of PLSCR1 in cell signaling, maturation and apoptosis. To investigate the functions of PLSCR1 in leukemic cells, we generated an inducible PLSCR1-expressing cell line using myeloid leukemic U937 cells. In this cell line, PLSCR1 was tightly regulated and induced upon tetracycline withdrawal. Our results showed that inducible PLSCR1 expression arrested the proliferation of U937 cells at G(1) phase. Meanwhile, PLSCR1-overexpressing U937 cells also underwent granulocyte-like differentiation with increased sensitivity to etoposide-induced apoptosis. Furthermore, we also found that PLSCR1 induction increased cyclin-dependent kinase inhibitors p27(Kip1) and p21(Cip1) proteins, together with downregulation of S phase kinase-associated protein 2 (SKP2), an F-box subunit of the ubiquitin-ligase complex that targets proteins for degradation. Additionally, PLSCR1 induction significantly decreased c-Myc protein and antiapoptotic Bcl-2 protein. Although the exact mechanism by which PLSCR1 regulates these cellular events and gene expression remains unresolved, our results suggest that PLSCR1 plays the antagonistic role regarding leukemia development. These data will shed new insights into understanding the biochemical and biological functions of PLSCR1 protein.	Shanghai Jiao Tong Univ, Sch Med, Key Lab Cell Differentiat & Apoptosis Chinese Min, Dept Pathophysiol, Shanghai 200025, Peoples R China; Shanghai Jiao Tong Univ, Sch Med, Inst Hlth Sci, Shanghai Inst Biol Sci, Shanghai 200030, Peoples R China; Shanghai Jiao Tong Univ, Sch Med, Grad Sch, Chinese Acad Sci, Shanghai 200030, Peoples R China; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA USA	Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Jiao Tong University; Scripps Research Institute	Chen, GQ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Key Lab Cell Differentiat & Apoptosis Chinese Min, Dept Pathophysiol, 280,Chong Qing S Rd, Shanghai 200025, Peoples R China.	chengq@shsmu.edu.cn	Li, Dong/C-7344-2011	chen, guo qiang/0000-0003-4936-2363	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036946, R01HL076215] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL076215, HL036946] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bailey K, 2005, BBA-MOL CELL BIOL L, V1733, P199, DOI 10.1016/j.bbalip.2004.12.013; Basse F, 1996, J BIOL CHEM, V271, P17205, DOI 10.1074/jbc.271.29.17205; Ben-Efraim I, 2004, BIOCHEMISTRY-US, V43, P3518, DOI 10.1021/bi0356911; Boer J, 1998, MOL CELL BIOL, V18, P1236, DOI 10.1128/MCB.18.3.1236; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chen MH, 2005, J BIOL CHEM, V280, P10599, DOI 10.1074/jbc.M413194200; Cheng T, 2000, NAT MED, V6, P1235, DOI 10.1038/81335; COLBY WW, 1983, NATURE, V301, P722, DOI 10.1038/301722a0; Coleman ML, 2003, EMBO J, V22, P2036, DOI 10.1093/emboj/cdg189; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; Friedman AD, 2002, J CELL BIOCHEM, V86, P624, DOI 10.1002/jcb.10271; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; Jiang Y, 2005, LEUKEMIA, V19, P1239, DOI 10.1038/sj.leu.2403734; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Kasukabe T, 1998, BIOCHEM BIOPH RES CO, V249, P449, DOI 10.1006/bbrc.1998.9190; Kasukabe T, 1997, BLOOD, V89, P2975, DOI 10.1182/blood.V89.8.2975; Kikuchi J, 1997, BLOOD, V89, P3980, DOI 10.1182/blood.V89.11.3980; Koschmieder S, 2005, INT J HEMATOL, V81, P368, DOI 10.1532/IJH97.05051; LARSSON LG, 1994, ONCOGENE, V9, P1247; Li LW, 1999, MOL CELL BIOL, V19, P8547; Matassa AA, 2001, J BIOL CHEM, V276, P29719, DOI 10.1074/jbc.M100273200; Mitani K, 2004, ONCOGENE, V23, P4263, DOI 10.1038/sj.onc.1207777; Munoz-Alonso MJ, 2005, J BIOL CHEM, V280, P18120, DOI 10.1074/jbc.M500758200; Nakajima H, 1996, LEUKEMIA RES, V20, P665, DOI 10.1016/0145-2126(96)00020-3; Nakamaki T, 2002, EXP HEMATOL, V30, P421, DOI 10.1016/S0301-472X(02)00779-8; Nanjundan M, 2003, J BIOL CHEM, V278, P37413, DOI 10.1074/jbc.M306182200; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Rots NY, 1999, BLOOD, V93, P2721, DOI 10.1182/blood.V93.8.2721.408k28_2721_2729; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Silverman RH, 2002, CANCER RES, V62, P397; Song MG, 2005, BLOOD, V105, P3714, DOI 10.1182/blood-2004-10-4011; Stegmaier K, 2004, NAT GENET, V36, P257, DOI 10.1038/ng1305; Steinman RA, 2002, ONCOGENE, V21, P3403, DOI 10.1038/sj.onc.1205325; Sun J, 2002, BIOCHEMISTRY-US, V41, P6338, DOI 10.1021/bi025610l; Sun J, 2001, J BIOL CHEM, V276, P28984, DOI 10.1074/jbc.M102505200; Wang ZL, 1998, EXP CELL RES, V244, P105, DOI 10.1006/excr.1998.4191; Wiedmer T, 2003, BIOCHEMISTRY-US, V42, P1227, DOI 10.1021/bi026679w; Yamanaka R, 1998, INT J MOL MED, V1, P213; Yokoyama A, 2004, LEUKEMIA RES, V28, P149, DOI 10.1016/S0145-2126(03)00189-9; Yu A, 2003, J BIOL CHEM, V278, P9706, DOI 10.1074/jbc.M204614200; Zhao J, 1998, BIOCHEMISTRY-US, V37, P6361, DOI 10.1021/bi980218m; Zhao KW, 2005, J BIOL CHEM, V280, P42707, DOI 10.1074/jbc.M506178200; Zhao KW, 2004, BLOOD, V104, P3731, DOI 10.1182/blood-2004-04-1630; Zhou QS, 2005, J BIOL CHEM, V280, P35062, DOI 10.1074/jbc.M504821200; Zhou QS, 2002, BLOOD, V99, P4030, DOI 10.1182/blood-2001-12-0271; ZHU J, 1995, LEUKEMIA, V9, P302	49	48	55	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6618	6627		10.1038/sj.onc.1209677	http://dx.doi.org/10.1038/sj.onc.1209677			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16702944				2022-12-25	WOS:000241569700006
J	Yeh, AH; Bohula, EA; Macaulay, VM				Yeh, A. H.; Bohula, E. A.; Macaulay, V. M.			Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs	ONCOGENE			English	Article						IGF1R; melanoma; B-RAF; siRNA; apoptosis; chemosensitization	GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; BREAST-CANCER CELLS; METASTATIC MELANOMA; ONCOGENIC MUTATIONS; SIGNALING PATHWAY; BRAF; IGF-1; B-V599E-RAF; SENSITIVITY	The type 1 insulin-like growth factor receptor (IGF1R) is overexpressed by malignant melanomas compared with benign naevi, and mediates proliferation, motility and protection from apoptosis. However, the utility of IGF1R targeting as anti-cancer therapy may be limited by activating mutations in downstream signaling intermediates. We previously showed that IGF1R knockdown blocked survival of prostate cancer cells in which Akt activation was deregulated by PTEN loss. The current study investigated effects of IGF1R targeting in cells harboring activating RAS-RAF mutations, found in 70-80% of human melanomas. We assembled a panel of eight human melanoma cell lines: two expressing wild-type (WT) B-RAF and N-RAS, two with activating N-RAS mutations and four harboring V600E B-RAF. We also generated isogenic cell populations overexpressing WT or V600E BRAF. Cells expressing V600E B-RAF were relatively resistant to apoptosis. However, IGF1R gene silencing was capable of inducing significant inhibition of survival, enhancement of apoptosis, and similar to two-fold sensitization to cisplatin and temozolomide. These effects were independent of mutation status and were associated with reduced activation of Akt and also, unexpectedly, of ERKs. These results support development of IGF1R targeting as therapy for melanoma, regardless of the presence of activating mutations in the RAS-RAF pathway.	Univ Oxford, Weatherall Inst Mol Med, ICF Grp, Canc Res UK Labs, Oxford OX1 2JD, England	Cancer Research UK; University of Oxford	Macaulay, VM (corresponding author), Weatherall Inst Mol Med, ICF Grp, Mol Oncol Labs, Oxford OX3 9DS, England.	macaulay@cancer.org.uk	Bohula, Erin/AAW-7276-2020					Benini S, 2004, INT J CANCER, V108, P358, DOI 10.1002/ijc.11576; Bohula EA, 2003, ANTI-CANCER DRUG, V14, P669, DOI 10.1097/01.cad.0000092782.37568.04; Bohula EA, 2003, J BIOL CHEM, V278, P15991, DOI 10.1074/jbc.M300714200; BOS JL, 1989, CANCER RES, V49, P4682; Brose MS, 2002, CANCER RES, V62, P6997; Camp ER, 2005, CLIN CANCER RES, V11, P397; Danson S, 2003, J CLIN ONCOL, V21, P2551, DOI 10.1200/JCO.2003.10.039; Danson S J, 2001, Expert Rev Anticancer Ther, V1, P13, DOI 10.1586/14737140.1.1.13; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dong JL, 2003, CANCER RES, V63, P3883; Dunn SE, 1997, CANCER RES, V57, P2687; Garber K, 2005, J NATL CANCER I, V97, P790, DOI 10.1093/jnci/97.11.790; GEIER A, 1995, J CELL PHYSIOL, V163, P570, DOI 10.1002/jcp.1041630318; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Gorden A, 2003, CANCER RES, V63, P3955; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hellawell GO, 2003, BJU INT, V91, P271, DOI 10.1046/j.1464-410X.2003.04061.x; Hingorani SR, 2003, CANCER RES, V63, P5198; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kanter-Lewensohn L, 2000, GROWTH FACTORS, V17, P193, DOI 10.3109/08977190009001068; Kumar R, 2003, CLIN CANCER RES, V9, P3362; LeRoith D, 2000, ENDOCRINOLOGY, V141, P1287, DOI 10.1210/en.141.4.1287; Macaluso M, 2002, J CELL PHYSIOL, V192, P125, DOI 10.1002/jcp.10109; Macaulay VM, 2001, ONCOGENE, V20, P4029, DOI 10.1038/sj.onc.1204565; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; McMenamin ME, 1999, CANCER RES, V59, P4291; Min YF, 2003, CANCER RES, V63, P6432; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; O'Connor R, 2003, HORM METAB RES, V35, P771; Park S, 2005, ONCOGENE, V24, P3535, DOI 10.1038/sj.onc.1208435; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; RESNICOFF M, 1994, CANCER RES, V54, P4848; Rochester MA, 2005, CANCER GENE THER, V12, P90, DOI 10.1038/sj.cgt.7700775; Sato S, 2004, J BIOL CHEM, V279, P33759, DOI 10.1074/jbc.M402055200; SELL C, 1995, CANCER RES, V55, P303; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao D, 2005, MOL CARCINOGEN, V43, P130, DOI 10.1002/mc.20099	45	46	48	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6574	6581		10.1038/sj.onc.1209674	http://dx.doi.org/10.1038/sj.onc.1209674			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16715137				2022-12-25	WOS:000241569700002
J	Jackson-Fisher, AJ; Bellinger, G; Shum, E; Duong, JK; Perkins, AS; Gassmann, M; Muller, W; Lloyd, KCK; Stern, DF				Jackson-Fisher, A. J.; Bellinger, G.; Shum, E.; Duong, J. K.; Perkins, A. S.; Gassmann, M.; Muller, W.; Lloyd, K. C. Kent; Stern, D. F.			Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4	ONCOGENE			English	Article						ErbB; HER-4; breast cancer; MMTV-Neu; carcinoma	GROWTH-FACTOR RECEPTOR; BREAST-CANCER CELLS; CONSTITUTIVELY ACTIVE ERBB4; TRANSGENIC MICE; NEU PROTOONCOGENE; TYROSINE KINASES; PROGNOSTIC-SIGNIFICANCE; ACTIVATING MUTATIONS; NEUREGULIN RECEPTOR; MESSENGER-RNA	The four members of the ErbB family of receptor tyrosine kinases are involved in development and tumorigenesis of the mammary gland. Whereas the epidermal growth factor receptor, ErbB2 and ErbB3 are positively associated with various cancers, clinical studies of ErbB4 in breast cancer are contradictory. Results from tissue culture analyses and some clinical studies suggested that ErbB4 is either a tumor suppressor or is a negative regulator of ErbB2-driven tumors. Neu-Cre-ErbB4(flox/null) mice in which ErbB4 was inactivated by Cre-lox-mediated recombination in the mammary gland developed MMTV-Neu-driven mammary tumors with a similar latency period to mice with one or two wild-type ErbB4 alleles. Moreover, there was no difference in the histologies of tumors that developed, nor in the propensity to form lung metastases. Taken together these results suggest that ErbB4 is not a potent, highly penetrant tumor suppressor, nor is it a factor in Neu-mediated tumorigenesis in this model.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Columbia Univ, Sch Publ Hlth, New York, NY USA; Univ Basel, Dept Physiol, Biozentrum, Pharmazentrum, Basel, Switzerland; McGill Univ, Royal Univ Hosp, Mol Oncol Grp, Montreal, PQ, Canada; Univ Calif Davis, Sch Vet Med, Ctr Comparat Med, Davis, CA 95616 USA	Yale University; Columbia University; University of Basel; McGill University; University of Saskatchewan; University of California System; University of California Davis	Stern, DF (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St,Room BML 342,POB 208023, New Haven, CT 06520 USA.	df.stern@yale.edu		Lloyd, David/0000-0002-5656-0571; Gassmann, Martin/0000-0001-6201-3032	NATIONAL CANCER INSTITUTE [R01CA080065] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA80065] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abd El-Rehim DM, 2004, BRIT J CANCER, V91, P1532, DOI 10.1038/sj.bjc.6602184; Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Bacus SS, 1996, AM J PATHOL, V148, P549; Barnes NLP, 2005, CLIN CANCER RES, V11, P2163, DOI 10.1158/1078-0432.CCR-04-1633; Bieche I, 2003, INT J CANCER, V106, P758, DOI 10.1002/ijc.11273; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Cohen BM, 1996, J BIOL CHEM, V271, P4813; DiGiovanna MP, 2005, J CLIN ONCOL, V23, P1152, DOI 10.1200/JCO.2005.09.055; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Elenius K, 1999, ONCOGENE, V18, P2607, DOI 10.1038/sj.onc.1202612; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Gilbertson RJ, 1997, CANCER RES, V57, P3272; Gullick WJ, 2003, J PATHOL, V200, P279, DOI 10.1002/path.1335; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Haugen DRF, 1996, CANCER RES, V56, P1184; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Junttila TT, 2003, CLIN CANCER RES, V9, P5346; Kew TY, 2000, BRIT J CANCER, V82, P1163, DOI 10.1054/bjoc.1999.1057; Knowlden JM, 1998, ONCOGENE, V17, P1949, DOI 10.1038/sj.onc.1202107; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Lodge AJ, 2003, J CLIN PATHOL, V56, P300, DOI 10.1136/jcp.56.4.300; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maatta JA, 2006, MOL BIOL CELL, V17, P67, DOI 10.1091/mbc.E05-05-0402; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pawlowski V, 2000, CLIN CANCER RES, V6, P4217; Penington DJ, 2002, CELL GROWTH DIFFER, V13, P247; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Sartor CI, 2001, MOL CELL BIOL, V21, P4265, DOI 10.1128/MCB.21.13.4265-4275.2001; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; Soung YH, 2006, INT J CANCER, V118, P1426, DOI 10.1002/ijc.21507; Srinivasan R, 2000, CANCER RES, V60, P1483; Srinivasan R, 1998, J PATHOL, V185, P236, DOI 10.1002/(SICI)1096-9896(199807)185:3<236::AID-PATH118>3.0.CO;2-7; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Stern DF, 2000, BREAST CANCER RES, V2, P176, DOI 10.1186/bcr51; Suo Z, 2002, J PATHOL, V196, P17, DOI 10.1002/path.1003; Suo ZH, 2001, VIRCHOWS ARCH, V439, P62, DOI 10.1007/s004280000392; Tang CK, 1999, CANCER RES, V59, P5315; Tang CK, 1998, CANCER RES, V58, P3415; Thor AD, 2002, HUM PATHOL, V33, P628, DOI 10.1053/hupa.2002.124034; Thuret S, 2004, J NEUROCHEM, V91, P1302, DOI 10.1111/j.1471-4159.2004.02809.x; Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; von Mehren M, 2005, J CLIN ONCOL, V23, P8, DOI 10.1200/JCO.2005.09.961; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Williams EE, 2003, CANCER LETT, V192, P67, DOI 10.1016/S0304-3835(02)00690-0; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215	55	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2006	25	41					5664	5672		10.1038/sj.onc.1209574	http://dx.doi.org/10.1038/sj.onc.1209574			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16652155				2022-12-25	WOS:000240599100008
J	Oved, S; Mosesson, Y; Zwang, Y; Santonico, E; Shtiegman, K; Marmor, MD; Kochupurakkal, BS; Katz, M; Lavi, S; Cesareni, G; Yarden, Y				Oved, Shlomo; Mosesson, Yaron; Zwang, Yaara; Santonico, Elena; Shtiegman, Keren; Marmor, Mina D.; Kochupurakkal, Bose S.; Katz, Menachem; Lavi, Sara; Cesareni, Gianni; Yarden, Yosef			Conjugation to Nedd8 instigates ubiquitylation and down-regulation of activated receptor tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; C-CBL; PROTEIN NEDD8; RING FINGER; CELL-CYCLE; UBIQUITIN; PATHWAY; ENDOCYTOSIS; LIGASE; SUPPRESSION	When appended to the epidermal growth factor receptor ( EGFR), ubiquitin serves as a sorting signal for lysosomal degradation. Here we demonstrate that the ubiquitin ligase of EGFR, namely c-Cbl, also mediates receptor modification with the ubiquitin-like molecule Nedd8. EGF stimulates receptor neddylation, which enhances subsequent ubiquitylation, as well as sorting of EGFR for degradation. Multiple lysine residues, located within the tyrosine kinase domain of EGFR, serve as attachment sites for Nedd8. A set of clathrin coat-associated binders of ubiquitin also bind Nedd8, but they undergo ubiquitylation, not neddylation. We discuss the emerging versatility of the concerted action of ubiquitylation and neddylation in the process that desensitizes growth factor-activated receptor tyrosine kinases.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy	Weizmann Institute of Science; University of Rome Tor Vergata	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	Yosef.yarden@weizmann.ac.il	YARDEN, YOSEF/K-1467-2012; Santonico, Elena/ABB-8919-2020; Cesareni, Gianni/AAW-1382-2020	Santonico, Elena/0000-0002-3897-8990; 	NATIONAL CANCER INSTITUTE [R37CA072981, R01CA072981] Funding Source: NIH RePORTER; NCI NIH HHS [CA72981] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Chen YZ, 2000, J BIOL CHEM, V275, P8929, DOI 10.1074/jbc.275.12.8929; Dharmasiri S, 2003, EMBO J, V22, P1762, DOI 10.1093/emboj/cdg190; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Dunn R, 2001, J BIOL CHEM, V276, P25974, DOI 10.1074/jbc.M104113200; Fisher RD, 2003, J BIOL CHEM, V278, P28976, DOI 10.1074/jbc.M302596200; Gray WM, 2002, PLANT CELL, V14, P2137, DOI 10.1105/tpc.003178; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liakopoulos D, 1999, P NATL ACAD SCI USA, V96, P5510, DOI 10.1073/pnas.96.10.5510; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Morimoto M, 2000, BIOCHEM BIOPH RES CO, V270, P1093, DOI 10.1006/bbrc.2000.2576; Morimoto M, 2003, BIOCHEM BIOPH RES CO, V301, P392, DOI 10.1016/S0006-291X(02)03051-6; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Ohh M, 2002, EMBO REP, V3, P177, DOI 10.1093/embo-reports/kvf028; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; Pan ZQ, 2004, ONCOGENE, V23, P1985, DOI 10.1038/sj.onc.1207414; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; SORKIN A, 1993, ONCOGENE, V8, P3021; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Wada H, 2000, J BIOL CHEM, V275, P17008, DOI 10.1074/jbc.275.22.17008; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Whitby FG, 1998, J BIOL CHEM, V273, P34983, DOI 10.1074/jbc.273.52.34983; Wu K, 2002, J BIOL CHEM, V277, P516, DOI 10.1074/jbc.M108008200; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zhao C, 2004, P NATL ACAD SCI USA, V101, P7578, DOI 10.1073/pnas.0402528101; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	46	114	123	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21640	21651		10.1074/jbc.M513034200	http://dx.doi.org/10.1074/jbc.M513034200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16735510	hybrid			2022-12-25	WOS:000239387100009
J	Kitao, H; Yamamoto, K; Matsushita, N; Ohzeki, M; Ishiai, M; Takata, M				Kitao, Hiroyuki; Yamamoto, Kazuhiko; Matsushita, Nobuko; Ohzeki, Mioko; Ishiai, Masamichi; Takata, Minoru			Functional interplay between BRCA2/FancD1 and FancC in DNA repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; NUCLEAR RAD51 FOCI; HOMOLOGOUS RECOMBINATION; ANEMIA PROTEIN; FANCONIS ANEMIA; HELICASE BRIP1; S-PHASE; BRCA1; SUSCEPTIBILITY; PATHWAY	A rare hereditary disorder, Fanconi anemia (FA), is caused by mutations in an array of genes, which interact in a common FA pathway/network. These genes encode components of the FA "core" complex, a key factor FancD2, the familial breast cancer suppressor BRCA2/FancD1, and Brip1/FancJ helicase. Although BRCA2 is known to play a pivotal role in homologous recombination repair by regulating Rad51 recombinase, the precise functional relationship between BRCA2 and the other FA genes is unclear. Here we show that BRCA2-dependent chromatin loading of Rad51 after mitomycin C treatment was not compromised by disruption of FANCC or FANCD2. Rad51 and FancD2 form co-localizing subnuclear foci independently of each other. Furthermore, we created a conditional BRCA2 truncating mutation lacking the C-terminal conserved domain (CTD) (brca2 Delta CTD), and disrupted the FANCC gene in this background. The fancc/brca2 Delta CTD double mutant revealed an epistatic relationship between FANCC and BRCA2 CTD in terms of x-ray sensitivity. In contrast, levels of cisplatin sensitivity and mitomycin C-induced chromosomal aberrations were increased in fancc/brca2 Delta CTD cells relative to either single mutant. Taken together, these results indicate that FA proteins work together with BRCA2/Rad51-mediated homologous recombination in double strand break repair, whereas the FA pathway plays a role that is independent of the CTD of BRCA2 in interstrand cross-link repair. These results provide insights into the functional interplay between the classical FA pathway and BRCA2.	Kawasaki Med Sch, Dept Immunol & Mol Genet, Kurashiki, Okayama 7010192, Japan	Kawasaki Medical School	Takata, M (corresponding author), Kawasaki Med Sch, Dept Immunol & Mol Genet, 577 Matsushima, Kurashiki, Okayama 7010192, Japan.	mtakata@med.kawasaki-m.ac.jp		Takata, Minoru/0000-0002-4926-3675				Bridge WL, 2005, NAT GENET, V37, P953, DOI 10.1038/ng1627; Bruun D, 2003, DNA REPAIR, V2, P1007, DOI 10.1016/S1568-7864(03)00112-5; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; de Oca RM, 2005, BLOOD, V105, P1003, DOI 10.1182/blood-2003-11-3997; Digweed M, 2002, CARCINOGENESIS, V23, P1121, DOI 10.1093/carcin/23.7.1121; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Godthelp BC, 2006, MUTAT RES-FUND MOL M, V594, P39, DOI 10.1016/j.mrfmmm.2005.07.008; Godthelp BC, 2002, ONCOGENE, V21, P5002, DOI 10.1038/sj.onc.1205656; Gupta R, 2005, J BIOL CHEM, V280, P25450, DOI 10.1074/jbc.M501995200; Hatanaka A, 2005, MOL CELL BIOL, V25, P1124, DOI 10.1128/MCB.25.3.1124-1134.2005; Hirano S, 2005, EMBO J, V24, P418, DOI 10.1038/sj.emboj.7600534; Hirsch B, 2004, BLOOD, V103, P2554, DOI 10.1182/blood-2003-06-1970; Houghtaling S, 2003, GENE DEV, V17, P2021, DOI 10.1101/gad.1103403; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Hussain S, 2003, HUM MOL GENET, V12, P2503, DOI 10.1093/hmg/ddg266; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Komori K, 2004, J BIOL CHEM, V279, P53175, DOI 10.1074/jbc.M409243200; Komori K, 2002, GENES GENET SYST, V77, P227, DOI 10.1266/ggs.77.227; Levitus M, 2004, BLOOD, V103, P2498, DOI 10.1182/blood-2003-08-2915; Levitus M, 2005, NAT GENET, V37, P934, DOI 10.1038/ng1625; Levran O, 2005, NAT GENET, V37, P931, DOI 10.1038/ng1624; Litman R, 2005, CANCER CELL, V8, P255, DOI 10.1016/j.ccr.2005.08.004; Matsushita N, 2005, MOL CELL, V19, P841, DOI 10.1016/j.molcel.2005.08.018; McHugh PJ, 2001, LANCET ONCOL, V2, P483, DOI 10.1016/S1470-2045(01)00454-5; Meetei AR, 2003, MOL CELL BIOL, V23, P3417, DOI 10.1128/MCB.23.10.3417-3426.2003; Meetei AR, 2005, NAT GENET, V37, P958, DOI 10.1038/ng1626; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Mosedale G, 2005, NAT STRUCT MOL BIOL, V12, P763, DOI 10.1038/nsmb981; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Niedzwiedz W, 2004, MOL CELL, V15, P607, DOI 10.1016/j.molcel.2004.08.009; Nojima K, 2005, CANCER RES, V65, P11704, DOI 10.1158/0008-5472.CAN-05-1214; Ohashi A, 2005, J BIOL CHEM, V280, P14877, DOI 10.1074/jbc.M414669200; SASAKI MS, 1973, CANCER RES, V33, P1829; SASAKI MS, 1975, NATURE, V257, P501, DOI 10.1038/257501a0; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Simpson LJ, 2003, EMBO J, V22, P1654, DOI 10.1093/emboj/cdg161; Taniguchi T, 2002, BLOOD, V100, P2414, DOI 10.1182/blood-2002-01-0278; Tebbs RS, 2005, DNA REPAIR, V4, P11, DOI 10.1016/j.dnarep.2004.06.013; Thiriet C, 2005, MOL CELL, V18, P617, DOI 10.1016/j.molcel.2005.05.008; Thompson LH, 2005, NAT GENET, V37, P921, DOI 10.1038/ng0905-921; Thompson LH, 2005, ENVIRON MOL MUTAGEN, V45, P128, DOI 10.1002/em.20109; Venkitaraman AR, 2004, NAT REV CANCER, V4, P266, DOI 10.1038/nrc1321; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wagner JE, 2004, BLOOD, V103, P3226, DOI 10.1182/blood-2003-09-3138; Wang XZ, 2004, MOL CELL BIOL, V24, P5850, DOI 10.1128/MCB.24.13.5850-5862.2004; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yamamoto K, 2005, MOL CELL BIOL, V25, P34, DOI 10.1128/MCB.25.1.34-43.2005; Yamamoto K, 2003, MOL CELL BIOL, V23, P5421, DOI 10.1128/MCB.23.15.5421-5430.2003; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yang YG, 2005, CARCINOGENESIS, V26, P1731, DOI 10.1093/carcin/bgi134	52	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21312	21320		10.1074/jbc.M603290200	http://dx.doi.org/10.1074/jbc.M603290200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16687415	hybrid			2022-12-25	WOS:000239187300067
J	Roth, AL; Marzola, E; Rizzi, A; Arduin, M; Trapella, C; Corti, C; Vergura, R; Martinelli, P; Salvadori, S; Regoli, D; Corsi, M; Cavanni, P; Calo, G; Guerrini, R				Roth, Adelheid L.; Marzola, Erika; Rizzi, Anna; Arduin, Marika; Trapella, Claudio; Corti, Corrado; Vergura, Raffaella; Martinelli, Prisca; Salvadori, Severo; Regoli, Domenico; Corsi, Mauro; Cavanni, Paolo; Calo, Girolamo; Guerrini, Remo			Structure-activity studies on neuropeptide S - Identification of the amino acid residues crucial for receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEORPHANIZATIONS; AROUSAL; MICE	Neuropeptide S ( NPS) has been recently recognized as the endogenous ligand for the previous orphan G-protein-coupled receptor GPR154, now referred to as the NPS receptor ( NPSR). The NPS-NPSR receptor system regulates important biological functions such as sleeping/wakening, locomotion, anxiety, and food intake. To collect information on the mechanisms of interaction between NPS and its receptor, a classical structure-activity relationship study was performed. Human ( h) NPS derivatives obtained by Ala and D-scan and N- and C-terminal truncation were assessed for their ability to stimulate calcium release in HEK293 cells expressing the human recombinant NPSR. The results of this study indicate that ( i) the effect of hNPS is mimicked by the fragment hNPS( 1 - 10); ( ii) Phe(2), Arg(3), and Asn(4) are crucial for biological activity; ( iii) the sequence Thr(8)-Gly(9)-Met(10) is important for receptor activation, although with non-stringent chemical requirements; and ( iv) the sequence Val(6)-Gly(7) acts as a hinge region between the two above-mentioned domains. However, the stimulatory effect of hNPS given intracerebroventricularly on mouse locomotor activity was not fully mimicked by hNPS-( 1 - 10), suggesting that the C-terminal region of the peptide maintains importance for in vivo activity. In conclusion, this study identified the amino acid residues of this peptide most important for receptor activation.	Univ Ferrara, Dept Expt & Clin Med, Pharmacol Sect, I-44100 Ferrara, Italy; Univ Ferrara, Ctr Neurosci, I-44100 Ferrara, Italy; GlaxoSmithKline Pharmaceut, Psychiat Ctr Excellence Drug Discovery, Dept Biol, I-37135 Verona, Italy; Univ Ferrara, Dept Pharmaceut Sci, I-44100 Ferrara, Italy; Univ Ferrara, Ctr Biotechnol, I-44100 Ferrara, Italy	University of Ferrara; University of Ferrara; GlaxoSmithKline; University of Ferrara; University of Ferrara	Calo, G (corresponding author), Univ Ferrara, Dept Expt & Clin Med, Pharmacol Sect, Via Fossato Mortara 19, I-44100 Ferrara, Italy.	g.calo@unife.it	Trapella, Claudio/I-2128-2012	Trapella, Claudio/0000-0002-6666-143X; Guerrini, Remo/0000-0002-7619-0918; SALVADORI, Severo/0000-0002-8224-2358; Corti, Corrado/0000-0002-7876-9114; Marzola, Erika/0000-0002-1428-1363				Beck B, 2005, BIOCHEM BIOPH RES CO, V332, P859, DOI 10.1016/j.bbrc.2005.05.029; Benoiton N. L., 2005, CHEM PEPTIDE SYNTHES, P125, DOI DOI 10.1201/9781420027693.CH5; Civelli O, 2005, TRENDS PHARMACOL SCI, V26, P15, DOI 10.1016/j.tips.2004.11.005; Gilchrist A, 2004, EXPERT OPIN THER TAR, V8, P495, DOI 10.1517/14728222.8.5.495; HALL JM, 1993, TRENDS PHARMACOL SCI, V14, P376, DOI 10.1016/0165-6147(93)90096-3; Koob GF, 2004, NEURON, V43, P441, DOI 10.1016/j.neuron.2004.08.007; Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; LAURSEN SE, 1986, J PHARMACOL METHOD, V16, P355, DOI 10.1016/0160-5402(86)90038-0; LEONARD SK, 2005, SOC NEUR ABSTR; Neubig RR, 2003, PHARMACOL REV, V55, P597, DOI 10.1124/pr.55.4.4; Reinscheid RK, 2005, J PHARMACOL EXP THER, V315, P1338, DOI 10.1124/jpet.105.093427; Reinscheid RK, 2005, FEBS J, V272, P5689, DOI 10.1111/j.1742-4658.2005.04982.x; Rizzi A, 2001, N-S ARCH PHARMACOL, V363, P161, DOI 10.1007/s002100000358; RUFFOLO RR, 2000, IUPHAR COMPENDIUM RE, P7; Saito Y, 2005, INT REV NEUROBIOL, V65, P179, DOI 10.1016/S0074-7742(04)65007-0; SATO S, 2002, Patent No. 0231145; SOLE NA, 1992, J ORG CHEM, V57, P5399, DOI 10.1021/jo00046a022; Vassilatis DK, 2003, P NATL ACAD SCI USA, V100, P4903, DOI 10.1073/pnas.0230374100; Xu YL, 2004, NEURON, V43, P487, DOI 10.1016/j.neuron.2004.08.005	19	87	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20809	20816		10.1074/jbc.M601846200	http://dx.doi.org/10.1074/jbc.M601846200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16720571	hybrid			2022-12-25	WOS:000239187300017
J	Dietz, ML; Bernaciak, TM; Vendetti, F; Kielec, JM; Hildebrand, JD				Dietz, Megan L.; Bernaciak, Teresa M.; Vendetti, Frank; Kielec, Joseph M.; Hildebrand, Jeffrey D.			Differential actin-dependent localization modulates the evolutionarily conserved activity of Shroom family proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCULAR ALBINISM TYPE-1; XENOPUS-LAEVIS; MYOSIN-II; GENE; CELLS; MOTILITY; CLONING; RAB27A	Shroom is an actin-associated determinant of cell morphology that is required for neural tube closure in both mice and frogs. Shroom regulates this process by causing apical constriction of epithelial cells via a pathway involving myosin II. Here we report on characterization of the Shroom-related proteins Apxl and KIAA1202 and their role in cell architecture. Shroom, Apxl, and KIAA1202 exhibit differing abilities to interact with the actin cytoskeleton. In fibroblasts, Shroom readily associates with actin stress fibers and induces bundling, Apxl is found on cortical actin, and KIAA1202 is localized to a cytoplasmic population of F-actin. In epithelial cells, Apxl and KIAA1202 do not induce apical constriction as Shroom does, but have the capacity to do so if targeted to the apical junctional complex. To determine whether the activity of Shroom-like proteins is conserved in invertebrates, we have tested the ability of the lone Shroom-related protein in Drosophila, CG8603, to activate the constriction pathway. A chimeric protein consisting of the Shroom targeting domain and the Drosophila protein elicits constriction. Finally, we show that Apxl is involved in regulating the cytoskeletal organization and architecture of endothelial cells. We predict that the ability of Shroom-like proteins to regulate cellular morphology is conserved in evolution and is regulated in part by subcellular localization.	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hildebrand, JD (corresponding author), 4249 5th Ave, Pittsburgh, PA 15260 USA.	jeffh@pitt.edu			NIGMS NIH HHS [R01 GM067525] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067525] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASSI MT, 1995, NAT GENET, V10, P13, DOI 10.1038/ng0595-13; Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049; Fuchs E, 2001, GENE DEV, V15, P1, DOI 10.1101/gad.861501; Futter CE, 2004, MOL BIOL CELL, V15, P2264, DOI 10.1091/mbc.E03-10-0772; Galjart N, 2005, NAT REV MOL CELL BIO, V6, P487, DOI 10.1038/nrm1664; Gibbs D, 2004, J CELL SCI, V117, P6473, DOI 10.1242/jcs.01580; HAGENS O, 2005, HUM GENET, P1; Haigo SL, 2003, CURR BIOL, V13, P2125, DOI 10.1016/j.cub.2003.11.054; Hildebrand JD, 2005, J CELL SCI, V118, P5191, DOI 10.1242/jcs.02626; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; Hildebrand JD, 1999, CELL, V99, P485, DOI 10.1016/S0092-8674(00)81537-8; Linz-McGillem LA, 2003, EXP EYE RES, V76, P543, DOI 10.1016/S0014-4835(03)00031-9; McNeil EL, 2004, CELL MOTIL CYTOSKEL, V58, P71, DOI 10.1002/cm.10179; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Raychowdhury MK, 2004, J BIOL CHEM, V279, P20137, DOI 10.1074/jbc.M311946200; SCHIAFFINO MV, 1995, HUM MOL GENET, V4, P373, DOI 10.1093/hmg/4.3.373; SCHIAFFINO MV, 1995, HUM MOL GENET, V4, P2319, DOI 10.1093/hmg/4.12.2319; Schiaffino MV, 1996, P NATL ACAD SCI USA, V93, P9055, DOI 10.1073/pnas.93.17.9055; Seong KH, 2001, BIOGERONTOLOGY, V2, P209, DOI 10.1023/A:1011517325711; STAUB O, 1992, J CELL BIOL, V119, P1497, DOI 10.1083/jcb.119.6.1497; Stockton RA, 2004, J BIOL CHEM, V279, P46621, DOI 10.1074/jbc.M408877200; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; Wang SJ, 1996, IN VITRO CELL DEV-AN, V32, P292; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760	24	46	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20542	20554		10.1074/jbc.M512463200	http://dx.doi.org/10.1074/jbc.M512463200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16684770	hybrid			2022-12-25	WOS:000239038200076
J	Marz, P; Stetefeld, J; Bendfeldt, K; Nitsch, C; Reinstein, J; Shoeman, RL; Dimitriades-Schmutz, B; Schwager, M; Leiser, D; Ozcan, S; Otten, U; Ozbek, S				Maerz, Pia; Stetefeld, Joerg; Bendfeldt, Kerstin; Nitsch, Cordula; Reinstein, Jochen; Shoeman, Robert L.; Dimitriades-Schmutz, Beatrice; Schwager, Martine; Leiser, Dominic; Ozcan, Sabire; Otten, Uwe; Ozbek, Suat			Ataxin-10 interacts with O-linked beta-N-acetylglucosamine transferase in the brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLCNAC-MODIFIED PROTEINS; TETRATRICOPEPTIDE REPEATS; NUCLEOCYTOPLASMIC GLYCOSYLATION; SUBSTRATE-SPECIFICITY; CEREBELLAR NEURONS; ALZHEIMERS-DISEASE; INSULIN-RESISTANCE; CELL LINE; NUCLEAR; EXPRESSION	Modification by O-GlcNAc involves a growing number of eucaryotic nuclear and cytosolic proteins. Glycosylation of intracellular proteins is a dynamic process that in several cases competes with and acts as a reciprocal modification system to phosphorylation. O-Linked beta-N-acetylglucosamine transferase (OGT) levels are highest in the brain, and neurodegenerative disorders such as Alzheimer disease have been shown to involve abnormally phosphorylated key proteins, probably as a result of hypoglycosylation. Here, we show that the neurodegenerative disease protein ataxin-10 (Atx-10) is associated with cytoplasmic OGT p110 in the brain. In PC12 cells and pancreas, this association is competed by the shorter OGT p78 splice form, which is down-regulated in brain. Overexpression of Atx-10 in PC12 cells resulted in the reconstitution of the Atx-10-OGT p110 complex and enhanced intracellular glycosylation activity. Moreover, in an in vitro enzyme assay using PC12 cell extracts, Atx-10 increased OGT activity 2-fold. These data indicate that Atx-10 might be essential for the maintenance of a critical intracellular glycosylation level and homeostasis in the brain.	Univ Basel, Inst Physiol, CH-4056 Basel, Switzerland; Univ Basel, Biozentrum, CH-4056 Basel, Switzerland; Univ Basel, Inst Anat, CH-4056 Basel, Switzerland; Max Planck Inst Med Res, Dept Biomol Mech, D-69120 Heidelberg, Germany; Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Heidelberg Univ, Inst Zool, D-69130 Heidelberg, Germany	University of Basel; University of Basel; University of Basel; Max Planck Society; University of Kentucky; Ruprecht Karls University Heidelberg	Ozbek, S (corresponding author), Univ Basel, Inst Physiol, Pestalozzistr 20, CH-4056 Basel, Switzerland.	soezbek@zoo.uni-heidelberg.de	Stetefeld, Joerg/H-7630-2017; bendfeldt, kerstin/AAZ-2197-2020; Özbek, Suat/D-3701-2014	Stetefeld, Joerg/0000-0003-1478-3248; Ozbek, Suat/0000-0003-2569-3942	NIDDK NIH HHS [R21DK065730] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK065730] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akimoto Y, 2003, BRAIN RES, V966, P194, DOI 10.1016/S0006-8993(02)04158-6; Akimoto Y, 2003, INVEST OPHTH VIS SCI, V44, P3802, DOI 10.1167/iovs.03-0227; Andrali SS, 2005, BIOCHEM BIOPH RES CO, V337, P149, DOI 10.1016/j.bbrc.2005.09.026; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Gao Y, 2003, ARCH BIOCHEM BIOPHYS, V415, P155, DOI 10.1016/S0003-9861(03)00234-0; Griffith LS, 1999, EUR J BIOCHEM, V262, P824, DOI 10.1046/j.1432-1327.1999.00439.x; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Hanover JA, 2003, ARCH BIOCHEM BIOPHYS, V409, P287, DOI 10.1016/S0003-9861(02)00578-7; Iyer SPN, 2003, J BIOL CHEM, V278, P24608, DOI 10.1074/jbc.M300036200; Iyer SPN, 2003, BIOCHEMISTRY-US, V42, P2493, DOI 10.1021/bi020685a; Jinek M, 2004, NAT STRUCT MOL BIOL, V11, P1001, DOI 10.1038/nsmb833; Khidekel N, 2004, P NATL ACAD SCI USA, V101, P13132, DOI 10.1073/pnas.0403471101; Kreppel LK, 1999, J BIOL CHEM, V274, P32015, DOI 10.1074/jbc.274.45.32015; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; Lazarus BD, 2006, GLYCOBIOLOGY, V16, P415, DOI 10.1093/glycob/cwj078; Liu F, 2004, P NATL ACAD SCI USA, V101, P10804, DOI 10.1073/pnas.0400348101; Love DC, 2003, J CELL SCI, V116, P647, DOI 10.1242/jcs.00246; Lubas WA, 2000, J BIOL CHEM, V275, P10983, DOI 10.1074/jbc.275.15.10983; Lubas WA, 1997, J BIOL CHEM, V272, P9316; Marshall S, 2003, ANAL BIOCHEM, V319, P304, DOI 10.1016/S0003-2697(03)00329-4; Marz P, 2004, J BIOL CHEM, V279, P35542, DOI 10.1074/jbc.M405865200; Matsuura T, 2000, NAT GENET, V26, P191, DOI 10.1038/79911; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; O'Donnell N, 2004, MOL CELL BIOL, V24, P1680, DOI 10.1128/MCB.24.4.1680-1690.2004; Parker GJ, 2003, J BIOL CHEM, V278, P10022, DOI 10.1074/jbc.M207787200; Robertson LA, 2004, J ALZHEIMERS DIS, V6, P489; TORRES CR, 1984, J BIOL CHEM, V259, P3308; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; Vosseller K, 2001, BIOCHIMIE, V83, P575, DOI 10.1016/S0300-9084(01)01295-0; Zachara Natasha Elizabeth, 2004, Methods Mol Biol, V284, P175; Zachara NE, 2004, BBA-GEN SUBJECTS, V1673, P13, DOI 10.1016/j.bbagen.2004.03.016; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7	32	33	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20263	20270		10.1074/jbc.M601563200	http://dx.doi.org/10.1074/jbc.M601563200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16714295	hybrid, Green Published			2022-12-25	WOS:000239038200051
J	Wells, CA; Dingus, J; Hildebrandt, JD				Wells, Christopher A.; Dingus, Jane; Hildebrandt, John D.			Role of the chaperonin CCT/TRiC complex in G protein beta gamma-dimer assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSDUCIN-LIKE PROTEIN; CYTOSOLIC CHAPERONIN; WD-REPEAT; NASCENT CHAIN; SUBUNIT; CCT; IDENTIFICATION; UBIQUITYLATION; HETEROTRIMER; SELECTIVITY	G beta gamma dimer formation occurs early in the assembly of heterotrimeric G proteins. On nondenaturing (native) gels, in vitro translated, S-35-labeled G gamma subunits traveled primarily according to their pI and apparently were not associated with other proteins. In contrast, in vitro translated, S-35-labeled G beta subunits traveled at a high apparent molecular mass (similar to 700 kDa) and co-migrated with the chaperonin CCT complex ( also called TRiC). Different FLAG-G beta isoforms coprecipitated CCT/TRiC to a variable extent, and this correlated with the ability of the different G beta subunits to efficiently form dimers with G gamma. When translated G gamma was added to translated G gamma, a new band of low apparent molecular mass (similar to 50 kDa) was observed, which was labeled by either S-35-labeled G gamma or G gamma, indicating that it is a dimer. Formation of the G beta gamma dimer was ATP-dependent and inhibited by either adenosine 5'-O-(thiotriphosphate) or aluminum fluoride in the presence of Mg2+. This inhibition led to increased association of G gamma with CCT/TRiC. Although G gamma did not bind CCT/TRiC, addition of G gamma to previously synthesized G beta caused its release from the CCT/TRiC complex. We conclude that the chaperonin CCT/TRiC complex binds to and folds G beta subunits and that CCT/TRiC mediates G beta gamma dimer formation by an ATP-dependent reaction.	Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29425 USA	Medical University of South Carolina	Hildebrandt, JD (corresponding author), Med Univ S Carolina, Dept Pharmacol, 303 BSB,173 Ashley Ave, Charleston, SC 29425 USA.	hildebjd@musc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037219] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37219] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; Camasses A, 2003, MOL CELL, V12, P87, DOI 10.1016/S1097-2765(03)00244-2; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Cook LA, 2006, MOL CELL PROTEOMICS, V5, P671, DOI 10.1074/mcp.M500223-MCP200; Cowan NJ, 2002, ADV PROTEIN CHEM, V59, P73; Dingus J, 2005, BIOCHEMISTRY-US, V44, P11882, DOI 10.1021/bi0504254; Dunn AY, 2001, J STRUCT BIOL, V135, P176, DOI 10.1006/jsbi.2001.4380; Farr GW, 1997, CELL, V89, P927, DOI 10.1016/S0092-8674(00)80278-0; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Garcia-Higuera I, 1998, J BIOL CHEM, V273, P9041, DOI 10.1074/jbc.273.15.9041; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Guenther MG, 2002, GENE DEV, V16, P3130, DOI 10.1101/gad.1037502; Hamilton MH, 2003, P NATL ACAD SCI USA, V100, P5081, DOI 10.1073/pnas.0831228100; Hansen WJ, 1999, J CELL BIOL, V145, P265, DOI 10.1083/jcb.145.2.265; Hansen WJ, 2002, MOL CELL BIOL, V22, P1947, DOI 10.1128/MCB.22.6.1947-1960.2002; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hildebrandt JD, 1997, BIOCHEM PHARMACOL, V54, P325, DOI 10.1016/S0006-2952(97)00269-4; HILDEBRANDT JD, 1984, J BIOL CHEM, V259, P2039; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Humrich J, 2005, J BIOL CHEM, V280, P20042, DOI 10.1074/jbc.M409233200; Hynes GM, 2000, J BIOL CHEM, V275, P18985, DOI 10.1074/jbc.M910297199; INANOBE A, 1994, J BIOCHEM, V115, P486, DOI 10.1093/oxfordjournals.jbchem.a124363; Jones MB, 2004, MOL INTERV, V4, P200, DOI 10.1124/mi.4.4.4; Krumins AM, 2006, J BIOL CHEM, V281, P10250, DOI 10.1074/jbc.M511551200; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Llorca O, 1999, NATURE, V402, P693, DOI 10.1038/45294; Llorca O, 2000, EMBO J, V19, P5971, DOI 10.1093/emboj/19.22.5971; Lukov GL, 2005, EMBO J, V24, P1965, DOI 10.1038/sj.emboj.7600673; Martin-Benito J, 2004, P NATL ACAD SCI USA, V101, P17410, DOI 10.1073/pnas.0405070101; McLaughlin JN, 2002, P NATL ACAD SCI USA, V99, P7962, DOI 10.1073/pnas.112075699; MENDE U, 1995, J BIOL CHEM, V270, P15892, DOI 10.1074/jbc.270.26.15892; MULLIKINKILPATRICK D, 1995, MOL PHARMACOL, V47, P997; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; Obin M, 2002, J BIOL CHEM, V277, P44566, DOI 10.1074/jbc.M205308200; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Roobol A, 1999, EUR J CELL BIOL, V78, P21, DOI 10.1016/S0171-9335(99)80004-1; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; Siegers K, 2003, EMBO J, V22, P5230, DOI 10.1093/emboj/cdg483; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Valpuesta JM, 2002, FEBS LETT, V529, P11, DOI 10.1016/S0014-5793(02)03180-0; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Won KA, 1998, MOL CELL BIOL, V18, P7584, DOI 10.1128/MCB.18.12.7584	49	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20221	20232		10.1074/jbc.M602409200	http://dx.doi.org/10.1074/jbc.M602409200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16702223	hybrid			2022-12-25	WOS:000239038200047
J	Andrews-Zwilling, YS; Kawabe, H; Reim, K; Varoqueaux, F; Brose, N				Andrews-Zwilling, Yaisa S.; Kawabe, Hiroshi; Reim, Kerstin; Varoqueaux, Frederique; Brose, Nils			Binding to Rab3A-interacting molecule RIM regulates the presynaptic recruitment of Munc13-1 and ubMunc13-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; SYNAPTIC-VESICLE FUSION; ZONE PROTEIN RIM1-ALPHA; ACTIVE-ZONE; NEUROTRANSMITTER RELEASE; FUNCTIONAL INTERACTION; TRANSMITTER RELEASE; CHROMAFFIN CELLS; UNC-13; FAMILY	Transmitter release at synapses between nerve cells is spatially restricted to active zones, where synaptic vesicle docking, priming, and Ca2+-dependent fusion take place in a temporally highly coordinated manner. Munc13s are essential for priming synaptic vesicles to a fusion competent state, and their specific active zone localization contributes to the active zone restriction of transmitter release and the speed of excitation-secretion coupling. However, the molecular mechanism of the active zone recruitment of Munc13s is not known. We show here that the active zone recruitment of Munc13 isoforms Munc13-1 and ubMunc13-2 is regulated by their binding to the Rab3A-interacting molecule RIM1 alpha, a key determinant of long term potentiation of synaptic transmission at mossy fiber synapses in the hippocampus. We identify a single point mutation in Munc13-1 and ubMunc13-2 (I121N) that, depending on the type of assay used, strongly perturbs or abolishes RIM1 alpha binding in vitro and in cultured fibroblasts, and we demonstrate that RIM1 alpha binding-deficient ubMunc13-2(I121) is not efficiently recruited to synapses. Moreover, the levels of Munc13-1 and ubMunc13-2 levels are decreased in RIM1 alpha-deficient brain, and Munc13-1 is not properly enriched at active zones of mossy fiber terminals of the mouse hippocampus if RIM1 alpha is absent. We conclude that one function of the Munc13/RIM1 alpha interaction is the active zone recruitment of Munc13-1 and ubMunc13-2.	Max Planck Inst Expt Med, Dept Mol Neurobiol, D-37075 Gottingen, Germany	Max Planck Society	Brose, N (corresponding author), Max Planck Inst Expt Med, Dept Mol Neurobiol, Hermann Rein Str 3, D-37075 Gottingen, Germany.	brose@em.mpg.de	Varoqueaux, Frederique/AAC-1834-2021; Kawabe, Hiroshi/U-7325-2018	Varoqueaux, Frederique/0000-0002-3614-3121; Kawabe, Hiroshi/0000-0001-5650-8696				Altrock WD, 2003, NEURON, V37, P787, DOI 10.1016/S0896-6273(03)00088-6; Aravamudan B, 1999, NAT NEUROSCI, V2, P965, DOI 10.1038/14764; Ashery U, 2000, EMBO J, V19, P3586, DOI 10.1093/emboj/19.14.3586; Ashery U, 1999, EUR J CELL BIOL, V78, P525, DOI 10.1016/S0171-9335(99)80017-X; Augustin I, 1999, BIOCHEM J, V337, P363, DOI 10.1042/0264-6021:3370363; Augustin I, 1999, NATURE, V400, P457, DOI 10.1038/22768; Basu J, 2005, NAT STRUCT MOL BIOL, V12, P1017, DOI 10.1038/nsmb1001; Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; Betz A, 1998, NEURON, V21, P123, DOI 10.1016/S0896-6273(00)80520-6; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; Brose N, 2000, CURR OPIN NEUROBIOL, V10, P303, DOI 10.1016/S0959-4388(00)00105-7; BROSE N, 1994, J BIOL CHEM, V269, P16780; Calakos N, 2004, NEURON, V42, P889, DOI 10.1016/j.neuron.2004.05.014; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; Castillo PE, 2002, NATURE, V415, P327, DOI 10.1038/415327a; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Deguchi-Tawarada M, 2004, GENES CELLS, V9, P15, DOI 10.1111/j.1356-9597.2004.00697.x; Dick O, 2003, NEURON, V37, P775, DOI 10.1016/S0896-6273(03)00086-2; Dieck ST, 2005, J CELL BIOL, V168, P825, DOI 10.1083/jcb.200408157; Dieck ST, 1998, J CELL BIOL, V142, P499, DOI 10.1083/jcb.142.2.499; Dresbach T, 2001, CELL MOL LIFE SCI, V58, P94, DOI 10.1007/PL00000781; Dulubova I, 2005, EMBO J, V24, P2839, DOI 10.1038/sj.emboj.7600753; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; Follenzi Antonia, 2002, Methods Mol Med, V69, P259; Gerber SH, 2001, EMBO J, V20, P1605, DOI 10.1093/emboj/20.7.1605; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; JONES DH, 1974, BIOCHIM BIOPHYS ACTA, V356, P276, DOI 10.1016/0005-2736(74)90268-5; Khimich D, 2005, NATURE, V434, P889, DOI 10.1038/nature03418; Ko J, 2003, J BIOL CHEM, V278, P42377, DOI 10.1074/jbc.M307561200; Koushika SP, 2001, NAT NEUROSCI, V4, P997, DOI 10.1038/nn732; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lonart G, 2003, CELL, V115, P49, DOI 10.1016/S0092-8674(03)00727-X; Madison JM, 2005, CURR BIOL, V15, P2236, DOI 10.1016/j.cub.2005.10.049; Monier S, 2002, TRAFFIC, V3, P289, DOI 10.1034/j.1600-0854.2002.030406.x; Ohara-Imaizumi M, 2005, MOL BIOL CELL, V16, P3289, DOI 10.1091/mbc.E04-09-0816; Ohtsuka T, 2002, J CELL BIOL, V158, P577, DOI 10.1083/jcb.200202083; Powell CM, 2004, NEURON, V42, P143, DOI 10.1016/S0896-6273(04)00146-1; Rhee JS, 2002, CELL, V108, P121, DOI 10.1016/S0092-8674(01)00635-3; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; Richmond JE, 1999, NAT NEUROSCI, V2, P959, DOI 10.1038/12160; Rosenmund C, 2003, CURR OPIN NEUROBIOL, V13, P509, DOI 10.1016/j.conb.2003.09.011; Schoch S, 2002, NATURE, V415, P321, DOI 10.1038/415321a; Serra-Pages C, 1998, J BIOL CHEM, V273, P15611, DOI 10.1074/jbc.273.25.15611; Stevens DR, 2005, CURR BIOL, V15, P2243, DOI 10.1016/j.cub.2005.10.055; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Takao-Rikitsu E, 2004, J CELL BIOL, V164, P301, DOI 10.1083/jcb.200307101; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Varoqueaux F, 2002, P NATL ACAD SCI USA, V99, P9037, DOI 10.1073/pnas.122623799; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang XL, 1999, J CELL BIOL, V147, P151, DOI 10.1083/jcb.147.1.151; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Wang Y, 2003, GENOMICS, V81, P126, DOI 10.1016/S0888-7543(02)00024-1; Wang Y, 2002, P NATL ACAD SCI USA, V99, P14464, DOI 10.1073/pnas.182532999; Wang Y, 2000, J BIOL CHEM, V275, P20033, DOI 10.1074/jbc.M909008199; Zhai RG, 2001, NEURON, V29, P131, DOI 10.1016/S0896-6273(01)00185-4	55	73	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19720	19731		10.1074/jbc.M601421200	http://dx.doi.org/10.1074/jbc.M601421200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16704978	hybrid			2022-12-25	WOS:000238847000085
J	Haller, C; Rauch, S; Michel, N; Hannemann, S; Lehmann, MJ; Keppler, OT; Fackler, OT				Haller, Claudia; Rauch, Susanne; Michel, Nico; Hannemann, Sebastian; Lehmann, Maik J.; Keppler, Oliver T.; Fackler, Oliver T.			The HIV-1 pathogenicity factor Nef interferes with maturation of stimulatory T-lymphocyte contacts by modulation of N-wasp activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-RECEPTOR MICROCLUSTERS; ACTIN CYTOSKELETON; IMMUNOLOGICAL SYNAPSE; P21-ACTIVATED KINASE; DEPENDENT MANNER; DENDRITIC CELLS; PROTEIN COMPLEX; TCR ENGAGEMENT; ZETA-CHAIN; ACTIVATION	The Nef protein is a key determinant of human immunodeficiency virus (HIV) pathogenicity that, among other activities, sensitizes T-lymphocytes for optimal virus production. The initial events by which Nef modulates the T-cell receptor (TCR) cascade are poorly understood. TCR engagement triggers actin rearrangements that control receptor clustering for signal initiation and dynamic organization of signaling protein complexes to form an immunological synapse. Here we report that Nef potently interferes with cell spreading and formation of actin-rich circumferential rings in T-lymphocytes upon surface-supported TCR stimulation. These effects were conserved among Nef proteins from different lentiviruses and occurred in HIV1-infected primary human T-lymphocytes. This novel Nef activity critically depended on its Src homology 3 domain binding motif and required efficient association with Pak2 activity. Notably, whereas overall signaling microcluster formation immediately following TCR engagement occurred normally in Nef-expressing cells, the viral protein inhibited the concomitant activation of the actin organizer N-Wasp. During the subsequent maturation phase of the stimulatory contact, Nef interfered with the translocation of N-Wasp to the cell periphery, the overall induction of tyrosine phosphorylation, and the selective recruitment of phosphorylated LAT to stimulatory contacts. Consistent with such a critical role of N-Wasp in this process, Nef also blocked morphological changes induced by the known N-Wasp regulators Rac1 and Cdc42. Together, our results demonstrate that Nef alters both the amount and composition of signaling microclusters. We propose modulation of actin dynamics as an important mechanism for Nef-induced alterations of TCR signaling.	Heidelberg Univ, Dept Virol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Fackler, OT (corresponding author), Heidelberg Univ, Dept Virol, Neuenheimer Feld 324, D-69120 Heidelberg, Germany.	oliver_fackler@med.uni-heidelberg.de		Fackler, Oliver Till/0000-0003-2982-4209				Arora VK, 2002, MICROBES INFECT, V4, P189, DOI 10.1016/S1286-4579(01)01527-1; Barda-Saad M, 2005, NAT IMMUNOL, V6, P80, DOI 10.1038/ni1143; Baur AS, 1997, IMMUNITY, V6, P283, DOI 10.1016/S1074-7613(00)80331-3; Bunnell SC, 2002, J CELL BIOL, V158, P1263, DOI 10.1083/jcb.200203043; Bunnell SC, 2001, IMMUNITY, V14, P315, DOI 10.1016/S1074-7613(01)00112-1; Campbell EM, 2004, J VIROL, V78, P5745, DOI 10.1128/JVI.78.11.5745-5755.2004; Campi G, 2005, J EXP MED, V202, P1031, DOI 10.1084/jem.20051182; Choi J, 2005, J VIROL, V79, P264, DOI 10.1128/JVI.79.1.264-276.2005; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; Douglass AD, 2005, CELL, V121, P937, DOI 10.1016/j.cell.2005.04.009; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Fackler OT, 2000, MOL CELL BIOL, V20, P2619, DOI 10.1128/MCB.20.7.2619-2627.2000; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; Fackler OT, 2001, CURR BIOL, V11, P1294, DOI 10.1016/S0960-9822(01)00373-6; Faure S, 2004, NAT IMMUNOL, V5, P272, DOI 10.1038/ni1039; Fenard D, 2005, J IMMUNOL, V175, P6050, DOI 10.4049/jimmunol.175.9.6050; Fortin JF, 2004, J BIOL CHEM, V279, P39520, DOI 10.1074/jbc.M407477200; Friedl P, 2004, CURR OPIN IMMUNOL, V16, P389, DOI 10.1016/j.coi.2004.05.022; Gasteier JE, 2003, J BIOL CHEM, V278, P38902, DOI 10.1074/jbc.M306229200; Geyer M, 2001, EMBO REP, V2, P580, DOI 10.1093/embo-reports/kve141; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; Hao SL, 2005, MOL BIOL CELL, V16, P2275, DOI 10.1091/mbc.e04-10-0881; Janardhan A, 2004, PLOS BIOL, V2, P65, DOI 10.1371/journal.pbio.0020006; Keppler OT, 2006, J LEUKOCYTE BIOL, V79, P616, DOI 10.1189/jlb.0805461; Keppler OT, 2005, J VIROL, V79, P1655, DOI 10.1128/JVI.79.3.1655-1665.2005; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; Krautkramer E, 2004, J VIROL, V78, P4085, DOI 10.1128/JVI.78.8.4085-4097.2004; Lee KH, 2003, SCIENCE, V302, P1218, DOI 10.1126/science.1086507; Messmer D, 2000, J VIROL, V74, P2406, DOI 10.1128/JVI.74.5.2406-2413.2000; Michel N, 2005, CURR BIOL, V15, P714, DOI 10.1016/j.cub.2005.02.058; Muller B, 2004, J VIROL, V78, P10803, DOI 10.1128/JVI.78.19.10803-10813.2004; Nolz JC, 2006, CURR BIOL, V16, P24, DOI 10.1016/j.cub.2005.11.036; PARSEY MV, 1993, J IMMUNOL, V151, P1881; Peterson JR, 2004, NAT STRUCT MOL BIOL, V11, P747, DOI 10.1038/nsmb796; Quaranta MG, 2003, FASEB J, V17, P2025, DOI 10.1096/fj.03-0272com; Renkema GH, 1999, CURR BIOL, V9, P1407, DOI 10.1016/S0960-9822(00)80086-X; Rivas FV, 2004, MOL CELL BIOL, V24, P1628, DOI 10.1128/MCB.24.4.1628-1639.2004; ROZDZIAL MM, 1995, IMMUNITY, V3, P623, DOI 10.1016/1074-7613(95)90133-7; Sancho D, 2002, J IMMUNOL, V169, P292, DOI 10.4049/jimmunol.169.1.292; Schrager JA, 1999, P NATL ACAD SCI USA, V96, P8167, DOI 10.1073/pnas.96.14.8167; Sechi AS, 2004, TRENDS IMMUNOL, V25, P257, DOI 10.1016/j.it.2004.03.003; Simmons A, 2005, IMMUNITY, V23, P621, DOI 10.1016/j.immuni.2005.11.003; Simmons A, 2001, IMMUNITY, V14, P763, DOI 10.1016/S1074-7613(01)00158-3; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; Vicente-Manzanares M, 2005, J CELL SCI, V118, DOI 10.1242/jcs.02662; Wang JK, 2000, P NATL ACAD SCI USA, V97, P394, DOI 10.1073/pnas.97.1.394; Williams M, 2005, J VIROL, V79, P632, DOI 10.1128/JVI.79.1.632-636.2005; Xu XN, 1999, J EXP MED, V189, P1489, DOI 10.1084/jem.189.9.1489; Yokosuka T, 2005, NAT IMMUNOL, V6, P1253, DOI 10.1038/ni1272; Zipfel PA, 2006, CURR BIOL, V16, P35, DOI 10.1016/j.cub.2005.12.024	53	74	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19618	19630		10.1074/jbc.M513802200	http://dx.doi.org/10.1074/jbc.M513802200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16687395	hybrid			2022-12-25	WOS:000238847000076
J	Rayala, SK; den Hollander, P; Manavathi, B; Talukder, AH; Song, CY; Peng, SH; Barnekow, A; Kremerskothen, J; Kumar, R				Rayala, Suresh K.; den Hollander, Petra; Manavathi, Bramanandam; Talukder, Amjad H.; Song, Chunying; Peng, Shaohua; Barnekow, Angelika; Kremerskothen, Joachim; Kumar, Rakesh			Essential role of KIBRA in co-activator function of dynein light chain 1 in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR; HISTONE; SUBSTRATE; CHROMATIN; PROTEIN; ACTIVATION; PELP1	Recently dynein light chain 1 (DLC1), a cytoskeleton signaling component, has been shown to interact with and transactivate estrogen receptor-alpha (ER), leading to increased expression of ER target genes and growth stimulation of breast cancer cells. However, the molecular mechanism by which DLC1 regulates the ER pathway remains poorly understood. To gain insights into the putative mechanism, here we set out to identify novel DLC1-interacting proteins. We identified KIBRA, a WW domain- and a glutamic acid stretch-containing protein, as a DLC1-binding protein and showed that it interacts with DLC1 both in vitro and in vivo. We found that KIBRA-DLC1 complex is recruited to ER-responsive promoters. We also found that KIBRA-DLC1 interaction is mandatory for the recruitment and transactivation functions of ER or DLC1 to the target chromatin. Finally we found that KIBRA interacts with histone H3 via its glutamic acid-rich region and that such interaction might play a mechanistic role in conferring an optimal ER transactivation function as well as the proliferation of ligand-stimulated breast cancer cells. Together these findings indicate that DLC1-KIBRA interaction is essential for ER transactivation in breast cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Houston, TX 77030 USA; Univ Munster, Dept Expt Tumor Biol, D-48149 Munster, Germany	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Munster	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org	Kumar, Rakesh/ABD-1065-2020	Kumar, Rakesh/0000-0001-7664-0803; Rayala, Suresh/0000-0003-4394-4450; Manavathi, Bramanandam/0000-0002-1797-398X	NCI NIH HHS [CA65746, CA80066] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA065746, R01CA065746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; Barnes CJ, 2004, CELL MOL LIFE SCI, V61, P281, DOI 10.1007/s00018-003-3222-5; Bednarek AK, 2000, CANCER RES, V60, P2140; Bjornstrom Linda, 2004, Nucl Recept, V2, P3, DOI 10.1186/1478-1336-2-3; Buther K, 2004, BIOCHEM BIOPH RES CO, V317, P703, DOI 10.1016/j.bbrc.2004.03.107; CHEN H, 1994, EMBO J, V13, P380, DOI 10.1002/j.1460-2075.1994.tb06272.x; EARNSHAW WC, 1987, J CELL BIOL, V105, P1479, DOI 10.1083/jcb.105.4.1479; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Jensen EV, 2003, CLIN CANCER RES, V9, P1980; Kremerskothen J, 2003, BIOCHEM BIOPH RES CO, V300, P862, DOI 10.1016/S0006-291X(02)02945-5; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; Nair SS, 2004, CANCER RES, V64, P6416, DOI 10.1158/0008-5472.CAN-04-1786; Rayala SK, 2006, MOL CANCER THER, V5, P230, DOI 10.1158/1535-7163.MCT-05-0276; Rayala SK, 2006, J BIOL CHEM, V281, P4395, DOI 10.1074/jbc.M510368200; Rayala SK, 2006, CANCER RES, V66, P1694, DOI 10.1158/0008-5472.CAN-05-2922; Rayala SK, 2005, EMBO REP, V6, P538, DOI 10.1038/sj.embor.7400417; Shao WL, 2004, BREAST CANCER RES, V6, P39, DOI 10.1186/bcr742; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Vadlamudi RK, 2004, CANCER CELL, V5, P575, DOI 10.1016/j.ccr.2004.05.022; Woodcock CL, 2001, CURR OPIN GENET DEV, V11, P130, DOI 10.1016/S0959-437X(00)00169-6	23	54	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19092	19099		10.1074/jbc.M600021200	http://dx.doi.org/10.1074/jbc.M600021200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16684779	hybrid			2022-12-25	WOS:000238847000023
J	Chou, YT; Yang, YC				Chou, Yu-Ting; Yang, Yu-Chung			Post-transcriptional control of Cited2 by transforming growth factor beta - Regulation via Smads and Cited2 coding region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYC MESSENGER-RNA; MARROW STROMAL CELLS; BREAST-CANCER CELLS; OPEN READING FRAME; C-MYC; GENE-EXPRESSION; PROTEIN-SYNTHESIS; BINDING-PROTEIN; MYOGENIC DIFFERENTIATION; 3-UNTRANSLATED REGION	Cited2 is a transcription factor without typical DNA binding domains. Cited2 interacts with cAMP-responsive element-binding protein-binding protein (CBP)/p300, TFAP2, Lhx2, and nuclear receptors, such as peroxisome proliferator-activated receptor and estrogen receptor to function as a transcriptional modulator. Overexpression of Cited2 in Rat1 cells leads to tumor formation in nude mice, suggesting that Cited2 is a transforming gene. Through microarray analysis, Cited2 was found to be down-regulated by transforming growth factor beta 1 (TGF-beta) in various cell lines. In this study, we confirmed that both mRNA and protein levels of Cited2 are down-regulated in MDA-MB-231 breast cancer cells. Overexpression of Smad7 or knockdown of Smad4 in MDA-MB-231 cells showed that the Smad pathway is involved in the down-regulation of Cited2. Based on nuclear run-on analysis and Cited2 promoter/reporter assay, Cited2 transcription was not affected by TGF-beta, supporting that down-regulation of Cited2 by TGF-beta is most likely through post-transcriptional regulation. By using transcriptional inhibitors, we demonstrated that the turnover of Cited2 transcripts appears to be accelerated during TGF-beta stimulation. Pharmacologic inhibition of translation with cycloheximide attenuated Cited2 down-regulation by TGF-beta. We examined the expression of recombinant Cited2 gene introduced into MDA-MB-231 cells by stable transfection, and we found that mRNA containing the Cited2 protein-coding region controlled by a heterologous promoter indeed responds to TGF-beta-mediated down-regulation. Study from Cited2 deletion mutants showed that the C-terminal conserved region of Cited2 coding sequence is essential for the down-regulation. This is the first demonstration that TGF-beta-mediated down-regulation of Cited2 is post-transcriptional, through the Smad pathway, and requires the presence of its coding sequence.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Canc, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Yang, YC (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 2109 Adelbert Rd,W353, Cleveland, OH 44106 USA.	yxy36@cwru.edu		Chou, Yu-Ting/0000-0001-9274-8603	NCI NIH HHS [R01 CA78433] Funding Source: Medline; NHLBI NIH HHS [R01 HL48819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078433] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048819] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amara FM, 1996, J BIOL CHEM, V271, P15279, DOI 10.1074/jbc.271.25.15279; AMARA FM, 1993, NUCLEIC ACIDS RES, V21, P4803, DOI 10.1093/nar/21.20.4803; AMARA FM, 1995, NUCLEIC ACIDS RES, V23, P1461, DOI 10.1093/nar/23.9.1461; Baer C, 2004, INT J CANCER, V110, P687, DOI 10.1002/ijc.20171; Bamforth SD, 2004, NAT GENET, V36, P1189, DOI 10.1038/ng1446; Bamforth SD, 2001, NAT GENET, V29, P469, DOI 10.1038/ng768; Bandyopadhyay A, 1999, CANCER RES, V59, P5041; Barbera JPM, 2002, HUM MOL GENET, V11, P283, DOI 10.1093/hmg/11.3.283; Bashirullah A, 2001, P NATL ACAD SCI USA, V98, P7025, DOI 10.1073/pnas.111145698; BEAUCHAMP RD, 1992, MOL ENDOCRINOL, V6, P1789, DOI 10.1210/me.6.11.1789; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Braganca J, 2003, J BIOL CHEM, V278, P16021, DOI 10.1074/jbc.M208144200; Braganca J, 2002, J BIOL CHEM, V277, P8559, DOI 10.1074/jbc.M110850200; Charlesworth A, 2002, EMBO J, V21, P2798, DOI 10.1093/emboj/21.11.2798; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; CHOU YT, 2006, ONCOGENE, V17, P17; Dumont N, 2000, BREAST CANCER RES, V2, P125, DOI 10.1186/bcr44; Dunwoodie SL, 1998, MECH DEVELOP, V72, P27, DOI 10.1016/S0925-4773(98)00011-2; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; Fernandez CA, 2005, CLIN CANCER RES, V11, P5390, DOI 10.1158/1078-0432.CCR-04-2391; Futaki S, 2003, J BIOL CHEM, V278, P50691, DOI 10.1074/jbc.M304985200; Glenn DJ, 1999, J BIOL CHEM, V274, P36159, DOI 10.1074/jbc.274.51.36159; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hen BG, 2001, J BIOL CHEM, V276, P7937, DOI 10.1074/jbc.M007470200; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; HUA JL, 1992, MOL ENDOCRINOL, V6, P1418, DOI 10.1210/me.6.9.1418; Jeong JW, 2005, ENDOCRINOLOGY, V146, P3490, DOI 10.1210/en.2005-0016; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kash JC, 1999, BIOCHEMISTRY-US, V38, P16889, DOI 10.1021/bi9915770; Kucich U, 2002, AM J RESP CELL MOL, V26, P183, DOI 10.1165/ajrcmb.26.2.4666; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; Lafont J, 2002, J BIOL CHEM, V277, P41220, DOI 10.1074/jbc.M204405200; Lee CH, 1998, J BIOL CHEM, V273, P25261, DOI 10.1074/jbc.273.39.25261; Lemm I, 2002, MOL CELL BIOL, V22, P3959, DOI 10.1128/MCB.22.12.3959-3969.2002; Luo XP, 2005, ENDOCRINOLOGY, V146, P1097, DOI 10.1210/en.2004-1377; Martinez-Carpio PA, 1999, CELL SIGNAL, V11, P753, DOI 10.1016/S0898-6568(99)00048-0; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nguyen VT, 1998, EUR J IMMUNOL, V28, P2537, DOI 10.1002/(SICI)1521-4141(199808)28:08<2537::AID-IMMU2537>3.0.CO;2-1; PARKER R, 1990, P NATL ACAD SCI USA, V87, P2780, DOI 10.1073/pnas.87.7.2780; Selvamurugan N, 2004, J BIOL CHEM, V279, P27764, DOI 10.1074/jbc.M312870200; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Shioda T, 1997, GENE, V204, P235, DOI 10.1016/S0378-1119(97)00551-9; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Sun HB, 1998, P NATL ACAD SCI USA, V95, P13555, DOI 10.1073/pnas.95.23.13555; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Tien ES, 2004, J BIOL CHEM, V279, P24053, DOI 10.1074/jbc.M401489200; Weninger WJ, 2005, DEVELOPMENT, V132, P1337, DOI 10.1242/dev.01696; WISDOM R, 1990, J BIOL CHEM, V265, P19015; Yahata T, 2000, J BIOL CHEM, V275, P8825, DOI 10.1074/jbc.275.12.8825; Yahata T, 2001, GENE DEV, V15, P2598, DOI 10.1101/gad.906301; Yan L, 2001, J BIOL CHEM, V276, P37258, DOI 10.1074/jbc.M106089200; Yang F, 2004, MOL CELL, V14, P435, DOI 10.1016/j.molcel.2004.05.001; YANG L, 1994, J BIOL CHEM, V269, P32732; Yang L, 1996, MOL CELL BIOL, V16, P3300; Yeilding NM, 1998, J BIOL CHEM, V273, P15749, DOI 10.1074/jbc.273.25.15749; Yeilding NM, 1997, MOL CELL BIOL, V17, P2698, DOI 10.1128/MCB.17.5.2698; Yin Z, 2002, P NATL ACAD SCI USA, V99, P10488, DOI 10.1073/pnas.162371799; Zhang MC, 1999, MOL CELL BIOL, V19, P7314; Zimmerman CM, 2000, GENE, V249, P17, DOI 10.1016/S0378-1119(00)00162-1	67	31	32	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18451	18462		10.1074/jbc.M601720200	http://dx.doi.org/10.1074/jbc.M601720200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16675452	hybrid			2022-12-25	WOS:000238687300024
J	Ha, JY; Min, JY; Lee, SK; Kim, HS; Kim, DJ; Kim, KH; Lee, HH; Kim, HK; Yoon, HJ; Suh, SW				Ha, Jun Yong; Min, Ji Young; Lee, Su Kyung; Kim, Hyoun Sook; Kim, Do Jin; Kim, Kyoung Hoon; Lee, Hyung Ho; Kim, Hye Kyung; Yoon, Hye-Jin; Suh, Se Won			Crystal structure of 2-nitropropane dioxygenase complexed with FMN and substrate - Identification of the catalytic base	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HANSENULA-MRAKII; NITROALKANES; OXIDATION; 1-NITROPROPANE; PARTICIPATION; DEHYDROGENASE; MECHANISM; ALIGNMENT; SEQUENCE; RESCUE	Nitroalkane compounds are widely used in chemical industry and are also produced by microorganisms and plants. Some nitroalkanes have been demonstrated to be carcinogenic, and enzymatic oxidation of nitroalkanes is of considerable interest. 2-Nitropropane dioxygenases from Neurospora crassa and Williopsis mrakii ( Hansenula mrakii), members of one family of the nitroalkane-oxidizing enzymes, contain FMN and FAD, respectively. The enzymatic oxidation of nitroalkanes by 2-nitropropane dioxygenase operates by an oxidase-style catalytic mechanism, which was recently shown to involve the formation of an anionic flavin semiquinone. This represents a unique case in which an anionic flavin semiquinone has been experimentally observed in the catalytic pathway for oxidation catalyzed by a flavin-dependent enzyme. Here we report the first crystal structure of 2-nitropropane dioxygenase from Pseudomonas aeruginosa in two forms: a binary complex with FMN and a ternary complex with both FMN and 2-nitropropane. The structure identifies His(152) as the proposed catalytic base, thus providing a structural framework for a better understanding of the catalytic mechanism.	Seoul Natl Univ, Coll Nat Sci, Dept Chem, Seoul 151742, South Korea	Seoul National University (SNU)	Suh, SW (corresponding author), Seoul Natl Univ, Coll Nat Sci, Dept Chem, Seoul 151742, South Korea.	sewonsuh@snu.ac.kr	Suh, Won/H-8306-2013; Kim, Do Jin/I-7675-2014	Suh, Won/0000-0002-1768-4635; 				Ballini R, 2003, J ORG CHEM, V68, P9173, DOI 10.1021/jo0351163; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CONAWAY CC, 1991, CANCER RES, V51, P3143; DAVIS R, 1993, PATTYS IND HYGIENE T, V2, P559; DAYAL R, 1989, FUND APPL TOXICOL, V13, P341, DOI 10.1016/0272-0590(89)90270-4; FIALA ES, 1987, CARCINOGENESIS, V8, P1947, DOI 10.1093/carcin/8.12.1947; Fraaije MW, 2000, TRENDS BIOCHEM SCI, V25, P126, DOI 10.1016/S0968-0004(99)01533-9; Francis K, 2005, J BIOL CHEM, V280, P5195, DOI 10.1074/jbc.M411249200; Gadda G, 2001, J ENZYM INHIB, V16, P157, DOI 10.1080/14756360109162365; Gorlatova N, 1998, APPL ENVIRON MICROB, V64, P1029; HAASJOBELIUS M, 1992, ECOTOX ENVIRON SAFE, V23, P253, DOI 10.1016/0147-6513(92)90075-E; Hanessian S, 2000, ORG LETT, V2, P2975, DOI 10.1021/ol000170g; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIDO T, 1984, AGR BIOL CHEM TOKYO, V48, P2549, DOI 10.1080/00021369.1984.10866530; KIDO T, 1984, ARCH BIOCHEM BIOPHYS, V234, P468, DOI 10.1016/0003-9861(84)90294-7; KIDO T, 1978, J BIOL CHEM, V253, P226; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lehoux IE, 1999, BIOCHEMISTRY-US, V38, P9948, DOI 10.1021/bi9907532; LEWIS TR, 1979, J ENVIRON PATHOL TOX, V2, P233; LITTLE HN, 1951, J BIOL CHEM, V193, P347; Massey V, 2000, BIOCHEM SOC T, V28, P283, DOI 10.1042/0300-5127:0280283; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Nagano N, 2002, J MOL BIOL, V321, P741, DOI 10.1016/S0022-2836(02)00649-6; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Sakano K, 2001, MUTAT RES-FUND MOL M, V479, P101, DOI 10.1016/S0027-5107(01)00158-0; SITTIG M, 1991, HDB TOXIC HAZARDOUS, P1198; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; TCHORZEWSKI M, 1994, EUR J BIOCHEM, V226, P841, DOI 10.1111/j.1432-1033.1994.00841.x; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Valley MP, 2003, J AM CHEM SOC, V125, P8738, DOI 10.1021/ja036045s; Whitby FG, 1997, BIOCHEMISTRY-US, V36, P10666, DOI 10.1021/bi9708850	36	39	41	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18660	18667		10.1074/jbc.M601658200	http://dx.doi.org/10.1074/jbc.M601658200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16682407	hybrid			2022-12-25	WOS:000238687300046
J	Liu, L; Li, F; Cardelli, JA; Martin, KA; Blenis, J; Huang, S				Liu, L.; Li, F.; Cardelli, J. A.; Martin, K. A.; Blenis, J.; Huang, S.			Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways	ONCOGENE			English	Article						rapamycin; mTOR; S6K1; 4E-BP1; eIF4E; motility	TOP MESSENGER-RNAS; MAMMALIAN TARGET; ACTIN CYTOSKELETON; SIGNALING PATHWAY; INDUCED APOPTOSIS; INDUCED MIGRATION; BINDING PARTNER; GROWTH; PHOSPHORYLATION; TRANSLATION	Rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), inhibits tumor cell motility. However, the underlying mechanism is poorly understood. Here, we show that rapamycin inhibited type I insulin-like growth factor (IGF-I)-stimulated motility of a panel of cell lines. Expression of a rapamycin-resistant mutant of mTOR (mTORrr) prevented rapamycin inhibition of cell motility. However, cells expressing a kinase-dead mTORrr remained sensitive to rapamycin. Downregulation of raptor or rictor by RNA interference (RNAi) decreased cell motility. However, only downregulation of raptor mimicked the effect of rapamycin, inhibiting phosphorylation of S6 kinase 1 (S6K1) and 4E-BP1. Cells infected with an adenovirus expressing constitutively active and rapamycin-resistant mutant of p70 S6K1, but not with an adenovirus expressing wild-type S6K1, or a control virus, conferred to resistance to rapamycin. Further, IGF-I failed to stimulate motility of the cells, in which S6K1 was downregulated by RNAi. Moreover, downregulation of eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) by RNAi-attenuated rapamycin inhibition of cell motility. In contrast, expression of constitutively active 4E-BP1 dramatically inhibited IGF-I-stimulated cell motility. The results indicate that both S6K1 and 4E-BP1 pathways, regulated by TORC1, are required for cell motility. Rapamycin inhibits IGF-I-stimulated cell motility, through suppression of both S6K1 and 4E-BP1/ eIF4E-signaling pathways, as a consequence of inhibition of mTOR kinase activity.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol & Immunol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, FeistWeiller Canc Ctr, Shreveport, LA 71130 USA; Dartmouth Med Sch, Dept Surg, Lebanon, NH USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Dartmouth College; Harvard University; Harvard Medical School	Huang, S (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.	shuan1@lsuhsc.edu	Huang, Shile/I-1632-2019	Huang, Shile/0000-0002-3239-1072; Martin, Kathleen/0000-0002-1748-0034				Andre F, 1999, INT J CANCER, V83, P497, DOI 10.1002/(SICI)1097-0215(19991112)83:4<497::AID-IJC11>3.3.CO;2-4; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Berven LA, 2004, EXP CELL RES, V296, P183, DOI 10.1016/j.yexer.2003.12.032; Beuvink I, 2005, CELL, V120, P747, DOI 10.1016/j.cell.2004.12.040; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Boffa DJ, 2004, CLIN CANCER RES, V10, P293, DOI 10.1158/1078-0432.CCR-0629-3; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Cartwright JE, 2002, EXP CELL RES, V279, P219, DOI 10.1006/excr.2002.5616; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; Erbay E, 2001, J BIOL CHEM, V276, P36079, DOI 10.1074/jbc.C100406200; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Gallicchio MA, 2003, J CELL PHYSIOL, V197, P131, DOI 10.1002/jcp.10352; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Gomez-Cambronero J, 2003, FEBS LETT, V550, P94, DOI 10.1016/S0014-5793(03)00828-7; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hassid A, 1999, AM J PHYSIOL-HEART C, V277, pH1014, DOI 10.1152/ajpheart.1999.277.3.H1014; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; Hosoi H, 1999, CANCER RES, V59, P886; Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097-2765(03)00180-1; Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kwon YS, 2005, INVEST OPHTH VIS SCI, V46, P454, DOI 10.1167/iovs.04-0753; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Luan FL, 2003, KIDNEY INT, V63, P917, DOI 10.1046/j.1523-1755.2003.00805.x; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; Martin KA, 2004, AM J PHYSIOL-CELL PH, V286, pC507, DOI 10.1152/ajpcell.00201.2003; Meyer GE, 2001, ONCOGENE, V20, P7542, DOI 10.1038/sj.onc.1204927; MINNITI CP, 1992, J BIOL CHEM, V267, P9000; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Poon M, 1996, J CLIN INVEST, V98, P2277, DOI 10.1172/JCI119038; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rodriguez Luis G., 2004, V294, P23; Rowinsky EK, 2004, CURR OPIN ONCOL, V16, P564, DOI 10.1097/01.cco.0000143964.74936.d1; Sakakibara K, 2005, AM J PHYSIOL-HEART C, V288, pH2861, DOI 10.1152/ajpheart.00561.2004; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schalm SS, 2005, J BIOL CHEM, V280, P11101, DOI 10.1074/jbc.M413995200; Sekulic A, 2000, CANCER RES, V60, P3504; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; Shu LL, 2002, J BIOL CHEM, V277, P16726, DOI 10.1074/jbc.M112285200; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; Sun J, 2001, CIRCULATION, V103, P2967, DOI 10.1161/01.CIR.103.24.2967; Tai YT, 2003, CANCER RES, V63, P5850; TAKAISHI K, 1995, METHOD ENZYMOL, V256, P336; Tang H, 2001, MOL CELL BIOL, V21, P8671, DOI 10.1128/MCB.21.24.8671-8683.2001; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008-5472.CAN-04-3135; Wong AST, 2004, EXP CELL RES, V299, P248, DOI 10.1016/j.yexcr.2004.06.002; Yuan Q, 2000, AM J PHYSIOL-GASTR L, V278, pG49, DOI 10.1152/ajpgi.2000.278.1.G49; Zhang DL, 2003, ONCOGENE, V22, P974, DOI 10.1038/sj.onc.1206197	60	153	166	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7029	7040		10.1038/sj.onc.1209691	http://dx.doi.org/10.1038/sj.onc.1209691			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16715128				2022-12-25	WOS:000241910500003
J	Alchanati, I; Nallar, SC; Sun, P; Gao, L; Hu, J; Stein, A; Yakirevich, E; Konforty, D; Alroy, I; Zhao, X; Reddy, SP; Resnick, MB; Kalvakolanu, DV				Alchanati, I.; Nallar, S. C.; Sun, P.; Gao, L.; Hu, J.; Stein, A.; Yakirevich, E.; Konforty, D.; Alroy, I.; Zhao, X.; Reddy, S. P.; Resnick, M. B.; Kalvakolanu, D. V.			A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas	ONCOGENE			English	Article						cell growth; cancer; cytokines; tumor suppression; transcription	ACID-ACTIVATED REGULATOR; TUMOR-SUPPRESSOR GENE; RETINOIC ACID; IN-VIVO; C-MET; GROWTH-SUPPRESSION; SIGNAL TRANSDUCER; CANCER-CELLS; COMPLEX-I; IFN-BETA	Gene associated with retinoid interferon-induced mortality (GRIM)-19, an inhibitor of transcription factor STAT3, was originally identified as a critical regulatory protein in a genetic screen that was designed to identify the gene products necessary for Interferon (IFN)-beta-and retinoic acid-induced cell death. Over expression of GRIM-19 activates cell death. Conversely, inactivation of its expression promotes cell growth. STAT3 is a transcription factor that regulates gene expression in response to multiple extra cellular growth factors. In contrast to its normal feedback inhibition, a constitutive activation of STAT3 has been documented in several tumors. Although many STAT3-inhibitors are described, their relevance to human cancer is unclear. In an attempt to de. ne the molecular alterations associated with human renal cell carcinoma (RCC) using mass spectrometry, we have discovered that expression of GRIM-19 is lost or severely depressed in a number of primary RCC and in some urinogenital tumors. Using an RCC cell line, we show that down regulation of GRIM-19 promotes tumor growth via an augmentation of STAT3-dependent gene expression. These studies for the. rst time show a tumor-suppressor like activity of GRIM-19.	Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Proteol Ltd, Rehovot, Israel; Jilin Univ, Sch Basic Med, Dept Pathophysiol, Changchun 130023, Peoples R China; Carmel Hosp, Dept Urol, Haifa, Israel; Rhode Isl Hosp, Dept Pathol, Providence, RI 02902 USA; Brown Univ, Sch Med, Providence, RI 02912 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA	University System of Maryland; University of Maryland Baltimore; Jilin University; Clalit Health Services; Carmel Medical Center; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Kalvakolanu, DV (corresponding author), Univ Maryland, Sch Med, Greenebaum Canc Ctr, 660 W Redwood St,Howard Hall Room 324, Baltimore, MD 21201 USA.	dkalvako@umaryland.edu	Resnick, Murray/U-2986-2019		NATIONAL CANCER INSTITUTE [R01CA105005] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R56ES011863, R01ES011863] Funding Source: NIH RePORTER; NCI NIH HHS [CA105005, CA78286] Funding Source: Medline; NHLBI NIH HHS [HL66109] Funding Source: Medline; NIEHS NIH HHS [ES11863] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Angell JE, 2000, J BIOL CHEM, V275, P33416, DOI 10.1074/jbc.M003929200; BAGGETTO LG, 1992, BIOCHIMIE, V74, P959, DOI 10.1016/0300-9084(92)90016-8; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; Chidambaram NV, 2000, J INTERF CYTOK RES, V20, P661, DOI 10.1089/107999000414844; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; Fearnley IM, 2001, J BIOL CHEM, V276, P38345, DOI 10.1074/jbc.C100444200; Fischer J, 1998, ONCOGENE, V17, P733, DOI 10.1038/sj.onc.1201983; Gao AC, 1999, PROSTATE, V38, P46, DOI 10.1002/(SICI)1097-0045(19990101)38:1<46::AID-PROS6>3.0.CO;2-9; Gao LF, 2005, CLIN CANCER RES, V11, P6333, DOI 10.1158/1078-0432.CCR-05-0148; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gresser I, 2002, CYTOKINE GROWTH F R, V13, P111, DOI 10.1016/S1359-6101(01)00035-1; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hu JD, 2002, J INTERF CYTOK RES, V22, P1017, DOI 10.1089/107999002760624242; Huang GC, 2004, MOL CELL BIOL, V24, P8447, DOI 10.1128/MCB.24.19.8447-8456.2004; Ikeda H, 2002, CYTOKINE GROWTH F R, V13, P95, DOI 10.1016/S1359-6101(01)00038-7; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Kalvakolanu DV, 2004, CYTOKINE GROWTH F R, V15, P169, DOI 10.1016/j.cytogfr.2004.01.002; Kalvakolanu DV, 2001, MOL BASIS CANC, P503; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; Klosek SK, 2004, ONCOL REP, V12, P293; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lindner DJ, 2002, CLIN CANCER RES, V8, P3210; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Lubensky IA, 1999, AM J PATHOL, V155, P517, DOI 10.1016/S0002-9440(10)65147-4; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; Maximo V, 2005, BRIT J CANCER, V92, P1892, DOI 10.1038/sj.bjc.6602547; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MOORE DM, 1994, SEMIN HEMATOL, V31, P31; Morris MR, 2004, J CLIN PATHOL, V57, P706, DOI 10.1136/jcp.2003.011767; Pingoud-Meier C, 2003, CLIN CANCER RES, V9, P6401; Pollard PJ, 2003, ANN MED, V35, P632, DOI 10.1080/07853890310018458; Pollard PJ, 2005, HUM MOL GENET, V14, P2231, DOI 10.1093/hmg/ddi227; Radaeva S, 2002, GASTROENTEROLOGY, V122, P1020, DOI 10.1053/gast.2002.32388; Schmidt PR, 1997, J ANTHROPOL ARCHAEOL, V16, P73, DOI 10.1006/jaar.1997.0305; Seo T, 2002, J VIROL, V76, P8797, DOI 10.1128/JVI.76.17.8797-8807.2002; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Simpson RJ, 2003, PROTEINS PROTEOMICS; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; Thacher SM, 2000, CURR PHARM DESIGN, V6, P25, DOI 10.2174/1381612003401415; Trovato M, 2004, EUR J HISTOCHEM, V48, P291; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Xu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719; Yang J, 2005, CANCER RES, V65, P939; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zhang J, 2003, P NATL ACAD SCI USA, V100, P9342, DOI 10.1073/pnas.1633516100; Zhang XW, 2004, CANCER RES, V64, P2474, DOI 10.1158/0008-5472.CAN-03-3443; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	62	83	97	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	54					7138	7147		10.1038/sj.onc.1209708	http://dx.doi.org/10.1038/sj.onc.1209708			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16732315				2022-12-25	WOS:000242046900003
J	Brocke-Heidrich, K; Ge, B; Cvijic, H; Pfeifer, G; Loffler, D; Henze, C; McKeithan, TW; Horn, F				Brocke-Heidrich, K.; Ge, B.; Cvijic, H.; Pfeifer, G.; Loeffler, D.; Henze, C.; McKeithan, T. W.; Horn, F.			BCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription	ONCOGENE			English	Article						BCL3; IL-6; Stat3; myeloma	NF-KAPPA-B; CANDIDATE PROTOONCOGENE BCL-3; MULTIPLE-MYELOMA CELLS; ONCOPROTEIN BCL-3; GENE-EXPRESSION; P50 HOMODIMERS; ENCODES; PHOSPHORYLATION; ACTIVATION; INDUCTION	BCL3 is a proto-oncogene affected by chromosomal translocations in some patients with chronic lymphocytic leukemia. It is an IKB family protein that is involved in transcriptional regulation of a number of NF-KB target genes. In this study, interleukin (IL)-6-induced BCL3 expression and its effect on survival of multiple myeloma ( MM) cells were examined. We demonstrate the upregulation of BCL3 by IL-6 in INA-6 and other MM cell lines. Sequence analysis of the BCL3 gene locus revealed four potential signal transducer and activator of transcription (Stat) binding sites within two conserved intronic enhancers regions: one located within enhancer HS3 and three within HS4. Chromatin immunoprecipitation experiments showed increased Stat3 binding to both enhancers upon IL-6 stimulation. Silencing Stat3 expression by small interfering RNA ( siRNA) abrogated BCL3 expression by IL-6. Using reporter gene assays, we demonstrate that BCL3 transcription depends on HS4. Mutation of the Stat motifs within HS4 abolished IL-6-dependent BCL3 induction. Furthermore, BCL3 transcription was inhibited by its own gene product. This repressive feedback is mediated by NF-KB sites within the promoter and HS3. Finally, we show that overexpression of BCL3 increases apoptosis, whereas BCL3-specific siRNA does not affect the viability of INA-6 cells suggesting that BCL3 is not essential for the survival of these cells.	Univ Leipzig, Inst Clin Immunol & Transfus Med, D-04103 Leipzig, Germany; Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68182 USA	Leipzig University; University of Nebraska System; University of Nebraska Medical Center	Brocke-Heidrich, K (corresponding author), Univ Leipzig, Inst Clin Immunol & Transfus Med, Johannisallee 30, D-04103 Leipzig, Germany.	kheid@medizin.uni-leipzig.de		McKeithan, Timothy/0000-0003-2242-3074				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Brasier AR, 2001, J BIOL CHEM, V276, P32080, DOI 10.1074/jbc.M102949200; Brocke-Heidrich K, 2004, BLOOD, V103, P242, DOI 10.1182/blood-2003-04-1048; Bundy DL, 1997, J BIOL CHEM, V272, P33132, DOI 10.1074/jbc.272.52.33132; Burger R, 2001, Hematol J, V2, P42, DOI 10.1038/sj.thj.6200075; Chatterjee M, 2004, BLOOD, V104, P3712, DOI 10.1182/blood-2004-04-1670; CHEN HM, 1995, ONCOGENE, V11, P1549; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Elliott SF, 2002, ARTHRITIS RHEUM-US, V46, P3230, DOI 10.1002/art.10675; Feinman R, 1999, BLOOD, V93, P3044; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Ge BS, 2003, J IMMUNOL, V171, P4210, DOI 10.4049/jimmunol.171.8.4210; Holtick U, 2005, LEUKEMIA, V19, P936, DOI 10.1038/sj.leu.2403750; INOUE J, 1993, ONCOGENE, V8, P2067; Jamaluddin M, 2005, J VIROL, V79, P15302, DOI 10.1128/JVI.79.24.15302-15313.2005; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; Kordula T, 1998, J BIOL CHEM, V273, P4112, DOI 10.1074/jbc.273.7.4112; Kuwata H, 2003, BLOOD, V102, P4123, DOI 10.1182/blood-2003-04-1228; MCKEITHAN TW, 1990, GENE CHROMOSOME CANC, V1, P247, DOI 10.1002/gcc.2870010310; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; Mitchell TC, 2001, NAT IMMUNOL, V2, P397, DOI 10.1038/87692; Nishikori M, 2003, BLOOD, V101, P2789, DOI 10.1182/blood-2002-08-2464; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; Ong ST, 1998, ONCOGENE, V16, P2333, DOI 10.1038/sj.onc.1201771; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; Richard M, 1999, BLOOD, V93, P4318, DOI 10.1182/blood.V93.12.4318.412k09_4318_4327; Thornburg NJ, 2003, CANCER RES, V63, P8293; Viatour P, 2004, MOL CELL, V16, P35, DOI 10.1016/j.molcel.2004.09.004; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; Yamazaki S, 2005, J BIOL CHEM, V280, P1678, DOI 10.1074/jbc.M409983200	35	54	57	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	55					7297	7304		10.1038/sj.onc.1209711	http://dx.doi.org/10.1038/sj.onc.1209711			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16732314				2022-12-25	WOS:000242244700008
J	Davies, GC; Ryan, PE; Rahman, L; Zajac-Kaye, M; Lipkowitz, S				Davies, G. C.; Ryan, P. E.; Rahman, L.; Zajac-Kaye, M.; Lipkowitz, S.			EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteins	ONCOGENE			English	Article						EGFRvIII; Cbl proteins; ubiquitin; cancer	EPIDERMAL-GROWTH-FACTOR; MUTANT EGF-RECEPTOR; CONFERS ENHANCED TUMORIGENICITY; HUMAN GLIOBLASTOMA CELLS; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; KINASE INHIBITORS; RING FINGER; CANCER; EXPRESSION	The overexpression or mutation of tyrosine kinases (TKs), such as the epidermal growth factor receptor (EGFR), can lead to the development of cancer. The most common mutation of the EGFR in glioblastomas is the deletion of exons 2-7 known as the EGFRvIII. This mutant receptor cannot bind EGF but, instead, is constitutively active. The Cbl family of ubiquitin ligases (Cbl, Cbl-b, and Cbl-c) targets the activated EGFR for degradation. As the EGFRvIII is transforming, we investigated whether it could be downregulated by the Cbl proteins. The overexpression of all three Cbl proteins resulted in the ubiquitination and degradation of the EGFRvIII. As with the wild-type EGFR, the TK-binding domain and the RING finger of Cbl-b are sufficient for the downregulation of the EGFRvIII. Also, we found that Cbl-b is recruited to the EGFRvIII and inhibits the transformation of NIH 3T3 cells by the EGFRvIII. Mutation of the Cbl-binding site (Y1045F) in the EGFRvIII inhibits its ubiquitination and downregulation by Cbl-b and enhances its ability to transform. Furthermore, the EGFR TK inhibitor, AG 1478, prevents the downregulation of the EGFRvIII by the Cbl proteins and antagonizes the ability of an immunotoxin directed against the EGFRvIII to kill cells expressing this receptor. In conclusion, the EGFRvIII does not transform by escaping regulation by Cbl proteins and this activation-induced downregulation of the EGFRvIII has an important role in mediating the toxicity of anti-EGFRvIII immunotoxins.	NCI, LCMB, CCR, NIH, Bethesda, MD 20892 USA; George Washington Univ, Inst Biomed Sci, Washington, DC USA; NCI, Mol Therapeut Program, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); George Washington University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lipkowitz, S (corresponding author), NCI, LCMB, CCR, NIH, Bldg 37,Rm 2066,37 Convent Dr, Bethesda, MD 20892 USA.	LipkowiS@mail.nih.gov			Intramural NIH HHS [Z99 CA999999] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01SC007263] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abulrob A, 2004, ONCOGENE, V23, P6967, DOI 10.1038/sj.onc.1207911; Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; Beers R, 2000, CLIN CANCER RES, V6, P2835; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Damstrup L, 2002, INT J CANCER, V97, P7, DOI 10.1002/ijc.1572; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; Ettenberg S A, 1999, Mol Cell Biol Res Commun, V2, P111, DOI 10.1006/mcbr.1999.0157; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Ettenberg SA, 2001, J BIOL CHEM, V276, P27677, DOI 10.1074/jbc.M102641200; Fernandes H, 2001, J BIOL CHEM, V276, P5375, DOI 10.1074/jbc.M005599200; GARCIA DP, 1993, CANCER RES, V53, P3217; Han YC, 1996, CANCER RES, V56, P3859; Heimberger AB, 2005, CLIN CANCER RES, V11, P1462, DOI 10.1158/1078-0432.CCR-04-1737; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Johns TG, 2003, P NATL ACAD SCI USA, V100, P15871, DOI 10.1073/pnas.2036503100; Keane MM, 1996, CANCER RES, V56, P4791; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; Kuan CT, 2000, INT J CANCER, V88, P962, DOI 10.1002/1097-0215(20001215)88:6<962::AID-IJC20>3.0.CO;2-U; Kuan CT, 2001, ENDOCR-RELAT CANCER, V8, P83, DOI 10.1677/erc.0.0080083; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Luwor RB, 2004, ONCOGENE, V23, P6095, DOI 10.1038/sj.onc.1207870; Mancini A, 2002, J BIOL CHEM, V277, P14635, DOI 10.1074/jbc.M109214200; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Montgomery RB, 2002, INT J CANCER, V101, P111, DOI 10.1002/ijc.10560; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Moscatello DK, 1996, ONCOGENE, V13, P85; Nagane M, 1996, CANCER RES, V56, P5079; Nau MM, 2003, GENE, V308, P103, DOI 10.1016/S0378-1119(03)00471-2; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; O'Rourke DM, 1998, ONCOGENE, V16, P1197, DOI 10.1038/sj.onc.1201635; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; Pedersen MW, 2004, INT J CANCER, V108, P643, DOI 10.1002/ijc.11566; Pedersen MW, 2001, ANN ONCOL, V12, P745, DOI 10.1023/A:1011177318162; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; REIST CJ, 1995, CANCER RES, V55, P4375; Schmidt MHH, 2003, P NATL ACAD SCI USA, V100, P6505, DOI 10.1073/pnas.1031790100; Shinojima N, 2003, CANCER RES, V63, P6962; Tang CK, 2000, CANCER RES, V60, P3081; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707	49	25	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2006	25	49					6497	6509		10.1038/sj.onc.1209662	http://dx.doi.org/10.1038/sj.onc.1209662			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16702950	Green Accepted			2022-12-25	WOS:000241395100006
J	Siddiqi, SA; Siddiqi, S; Mahan, J; Peggs, K; Gorelick, FS; Mansbach, CM				Siddiqi, Shadab A.; Siddiqi, Shahzad; Mahan, James; Peggs, Kiffany; Gorelick, Fred S.; Mansbach, Charles M., II			The identification of a novel endoplasmic reticulum to Golgi SNARE complex used by the prechylomicron transport vesicle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V-SNARES; MEMBRANE; PROTEINS; FUSION; ER; EXIT; LOCALIZATION; CONTRIBUTES; SPECIFICITY; COMPARTMENT	Dietary long chain fatty acids are absorbed in the intestine, esterified to triacylglycerol, and packaged in the unique lipoprotein of the intestine, the chylomicron. The rate-limiting step in the transit of chylomicrons through the enterocyte is the exit of chylomicrons from the endoplasmic reticulum in prechylomicron transport vesicles (PCTV) that transport chylomicrons to the cis-Golgi. Because chylomicrons are 250 nm in average diameter and lipid absorption is intermittent, we postulated that a unique SNARE pairing would be utilized to fuse PCTV with their target membrane, cis-Golgi. PCTV loaded with [3H] triacylglycerol were incubated with cis-Golgi and were separated from the Golgi by a sucrose step gradient. PCTV-chylomicrons acquire apolipoprotein-AI (apoAI) only after fusion with the Golgi. PCTV became isodense with Golgi upon incubation and were considered fused when their cargo chylomicrons acquired apoAI but docked when they did not. PCTV, docked with cis-Golgi, were solubilized in 2% Triton X-100, and proteins were immunoprecipitated using VAMP7 or rBet1 antibodies. In both cases, a 112-kDa complex was identified in nonboiled samples that dissociated upon boiling. The constituents of the complex were VAMP7, syntaxin 5, vti1a, and rBet1. Antibodies to each SNARE component significantly inhibited fusion of PCTV with cis-Golgi. Membrin, Sec22b, and Ykt6 were not found in the 112-kDa complex. We conclude that the PCTV-cis-GolgiSNAREcomplex is composed of VAMP7, syntaxin 5, Bet1, and vti1a.	Univ Tennessee, Ctr Hlth Sci, Div Gastroenterol, Memphis, TN 38163 USA; Vet Affairs Med Ctr, Memphis, TN 38104 USA; Yale Univ, Sch Med, Dept Med, Vet Affairs Healthcare, West Haven, CT 06516 USA	University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University	Mansbach, CM (corresponding author), Univ Tennessee, Ctr Hlth Sci, Div Gastroenterol, 920 Madison Ave,Suite 240, Memphis, TN 38163 USA.	cmansbach@utmem.edu	Eckhardt, Erik/G-1567-2010	Gorelick, Fred/0000-0001-8293-6803	NCRR NIH HHS [RR1052] Funding Source: Medline; NIDDK NIH HHS [R01 DK054021, R01 DK054021-02, T35DK07405, DK54201, T35 DK007405, DK38760, R01 DK038760-12, R01 DK038760] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054021, T35DK007405, R01DK038760] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Advani RJ, 1999, J CELL BIOL, V146, P765, DOI 10.1083/jcb.146.4.765; Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; Aridor M, 2001, J CELL BIOL, V152, P213, DOI 10.1083/jcb.152.1.213; Berriot-Varoqueaux N, 2001, GASTROENTEROLOGY, V121, P1101, DOI 10.1053/gast.2001.29331; Castillo-Flores A, 2005, J BIOL CHEM, V280, P34033, DOI 10.1074/jbc.M507142200; COUVE A, 1994, J BIOL CHEM, V269, P23391; Galli T, 1998, MOL BIOL CELL, V9, P1437, DOI 10.1091/mbc.9.6.1437; Gusarova V, 2003, J BIOL CHEM, V278, P48051, DOI 10.1074/jbc.M306898200; HAG JC, 1997, J NEUROSCI, V17, P1596; Hasegawa H, 2003, MOL BIOL CELL, V14, P698, DOI 10.1091/mbc.E02-09-0556; Hay JC, 1998, J CELL BIOL, V141, P1489, DOI 10.1083/jcb.141.7.1489; Hay JC, 2001, EXP CELL RES, V271, P10, DOI 10.1006/excr.2001.5368; Hsu KT, 1996, J BIOL CHEM, V271, P13317, DOI 10.1074/jbc.271.23.13317; Husain M, 2003, J VIROL, V77, P11754, DOI 10.1128/JVI.77.21.11754-11766.2003; Joglekar AP, 2003, J BIOL CHEM, V278, P14121, DOI 10.1074/jbc.M300659200; JOHNSTON PA, 1990, J BIOL CHEM, V265, P8869; Katz L, 1998, EMBO J, V17, P6200, DOI 10.1093/emboj/17.21.6200; Kumar NS, 1997, AM J PHYSIOL-GASTR L, V273, pG18, DOI 10.1152/ajpgi.1997.273.1.G18; Kumar NS, 1999, AM J PHYSIOL-GASTR L, V276, pG378, DOI 10.1152/ajpgi.1999.276.2.G378; Levy E, 2002, J BIOL CHEM, V277, P16470, DOI 10.1074/jbc.M102385200; MANSBACH CM, 1986, AM J PHYSIOL, V251, pG263, DOI 10.1152/ajpgi.1986.251.2.G263; Mansbach CM, 2000, J LIPID RES, V41, P605; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Miller EA, 2003, CELL, V114, P497, DOI 10.1016/S0092-8674(03)00609-3; Mironov AA, 2003, DEV CELL, V5, P583, DOI 10.1016/S1534-5807(03)00294-6; Morsomme P, 2003, J CELL BIOL, V162, P403, DOI 10.1083/jcb.200212101; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; Muniz M, 2000, J CELL BIOL, V148, P925, DOI 10.1083/jcb.148.5.925; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; OLOFSSON SO, 1987, ATHEROSCLEROSIS, V68, P1, DOI 10.1016/0021-9150(87)90088-8; Peng RW, 2002, J CELL BIOL, V157, P645, DOI 10.1083/jcb.200202006; Rashid KA, 2002, J BIOL CHEM, V277, P22010, DOI 10.1074/jbc.M112448200; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Siddiqi SA, 2006, J CELL SCI, V119, P943, DOI 10.1242/jcs.02803; Siddiqi SA, 2003, J CELL SCI, V116, P415, DOI 10.1242/jcs.00215; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sollner TH, 1996, CELL STRUCT FUNCT, V21, P407; Stephens DJ, 2002, J CELL SCI, V115, P1149; STRALFORS P, 1990, FEBS LETT, V263, P153, DOI 10.1016/0014-5793(90)80726-Y; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tisdale EJ, 1997, J CELL BIOL, V137, P581, DOI 10.1083/jcb.137.3.581; TRABER MG, 1987, J LIPID RES, V28, P1350; TROTTER PJ, 1991, J LIPID RES, V32, P293; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; Xu DL, 2000, J BIOL CHEM, V275, P39631, DOI 10.1074/jbc.M007684200; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649; Zhang T, 2001, J BIOL CHEM, V276, P27480, DOI 10.1074/jbc.M102786200	49	62	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20974	20982		10.1074/jbc.M601401200	http://dx.doi.org/10.1074/jbc.M601401200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16735505	Green Accepted, hybrid			2022-12-25	WOS:000239187300034
J	Zheng, J; Du, GG; Anderson, CT; Keller, JP; Orem, A; Dallos, P; Cheatham, MA				Zheng, Jing; Du, Guo-Guang; Anderson, Charles T.; Keller, Jacob P.; Orem, Alex; Dallos, Peter; Cheatham, MaryAnn			Analysis of the oligomeric structure of the motor protein prestin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER HAIR CELL; GUINEA-PIG; SPLIT-UBIQUITIN; MEMBRANE; SALICYLATE; ELECTROMOTILITY; DIMERIZATION; EXPRESSION; MOTILITY; DENSITY	Prestin, a member of the solute carrier family 26, is expressed in the basolateral membrane of outer hair cells. This protein provides the molecular basis for outer hair cell somatic electromotility, which is crucial for the frequency selectivity and sensitivity of mammalian hearing. It has long been known that there are abundantly expressed similar to 11-nM protein particles present in the basolateral membrane. These particles were hypothesized to be the motor proteins that drive electromotility. Because the calculated size of a prestin monomer is too small to form an similar to 11-nM particle, the possibility of prestin oligomerization was examined. We investigated possible quaternary structures of prestin by lithium dodecyl sulfate-PAGE, perfluoro-octanoate-PAGE, a membrane-based yeast two-hybrid system, and chemical cross-linking experiments. Prestin, obtained from different host or native cells, is resistant to dissociation by lithium dodecyl sulfate and behaves as a stable oligomer on lithium dodecyl sulfate-PAGE. In the membrane-based yeast two-hybrid system, homo-oligomeric interactions between prestin-bait/prestin-prey suggest that prestin molecules can associate with each other. Chemical cross-linking experiments, perfluoro-octanoate-PAGE/Western blot, and affinity purification experiments all indicate that prestin exists as a higher order oligomer, such as a tetramer, in prestin-expressing yeast, mammalian cell lines and native outer hair cells. Our data from experiments using hydrophobic and hydrophilic reducing reagents suggest that the prestin dimer is connected by a disulfide bond embedded in the prestin hydrophobic core. This stable dimer may act as the building block for producing the higher order oligomers that form the similar to 11-nM particles in the outer hair cell's basolateral membrane.	Northwestern Univ, Dept Commun Sci & Disorders, Evanston, IL 60208 USA; Northwestern Univ, Inst Neurosci, Dept Physiol & Neurobiol, Evanston, IL 60208 USA	Northwestern University; Northwestern University	Zheng, J (corresponding author), Northwestern Univ, Dept Commun Sci & Disorders, 2240 Campus Dr, Evanston, IL 60208 USA.	jzh215@northwestern.edu	Dallos, Peter/Q-9360-2019; Zheng, Jing/F-5273-2017	Dallos, Peter/0000-0002-9731-6591; Zheng, Jing/0000-0003-2790-1143; Anderson, Charles/0000-0003-3353-0182; Keller, Jacob/0000-0001-7487-4104	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006412] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC00089, DC006412] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Ashmore J F, 1990, Neurosci Res Suppl, V12, pS39, DOI 10.1016/0921-8696(90)90007-P; Belyantseva IA, 2000, J NEUROSCI, V20, part. no.; BROGLIE RM, 1980, P NATL ACAD SCI-BIOL, V77, P87, DOI 10.1073/pnas.77.1.87; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; Cheatham MA, 2004, J PHYSIOL-LONDON, V560, P821, DOI 10.1113/jphysiol.2004.069559; CREIGHTON TE, 1975, J MOL BIOL, V96, P777, DOI 10.1016/0022-2836(75)90152-7; Dallos P, 2002, NAT REV MOL CELL BIO, V3, P104, DOI 10.1038/nrm730; DALLOS P, 1992, J NEUROSCI, V12, P4575; Dawson PA, 2005, CURR MED CHEM, V12, P385, DOI 10.2174/0929867053363144; Deak L, 2005, J PHYSIOL-LONDON, V563, P483, DOI 10.1113/jphysiol.2004.078857; FORGE A, 1991, CELL TISSUE RES, V265, P473, DOI 10.1007/BF00340870; GLOCKER MO, 1993, BIOCHEMISTRY-US, V32, P482, DOI 10.1021/bi00053a012; GULLEY RL, 1977, ANAT RECORD, V189, P109, DOI 10.1002/ar.1091890108; He DZZ, 1999, P NATL ACAD SCI USA, V96, P8223, DOI 10.1073/pnas.96.14.8223; HOLLEY MC, 1996, COCHLEA SPRINGER HDB; HOLLEY MC, 1996, SPR HDB AUD, V8, P386; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hudspeth AJ, 1997, NEURON, V19, P947, DOI 10.1016/S0896-6273(00)80385-2; JOHNSSON N, 1994, P NATL ACAD SCI USA, V91, P10340, DOI 10.1073/pnas.91.22.10340; Jorgensen CS, 2003, EUR J BIOCHEM, V270, P4140, DOI 10.1046/j.1432-1033.2003.03808.x; Kakehata S, 1996, J NEUROSCI, V16, P4881; KALINEC F, 1992, P NATL ACAD SCI USA, V89, P8671, DOI 10.1073/pnas.89.18.8671; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Koppl C, 2004, J COMP NEUROL, V479, P149, DOI 10.1002/cne.20311; Kroeger KM, 2003, FRONT NEUROENDOCRIN, V24, P254, DOI 10.1016/j.yfrne.2003.10.002; Le Grimellec C, 2002, J COMP NEUROL, V451, P62, DOI 10.1002/cne.10338; Liberman MC, 2002, NATURE, V419, P300, DOI 10.1038/nature01059; Liu XZ, 2003, HUM MOL GENET, V12, P1155, DOI 10.1093/hmg/ddg127; Ludwig J, 2001, P NATL ACAD SCI USA, V98, P4178, DOI 10.1073/pnas.071613498; Matsuda K, 2004, J NEUROCHEM, V89, P928, DOI 10.1111/j.1471-4159.2004.02377.x; Mitic LL, 2003, PROTEIN SCI, V12, P218, DOI 10.1110/ps.0233903; Mount DB, 2004, PFLUG ARCH EUR J PHY, V447, P710, DOI 10.1007/s00424-003-1090-3; Muallem D, 2006, BIOPHYS J, V90, P4035, DOI 10.1529/biophysj.105.073254; MURAKOSHI MTG, 2005, 28 M ASS RES OT NEW, P216; Oliver D, 2001, SCIENCE, V292, P2340, DOI 10.1126/science.1060939; Ramjeesingh M, 1999, BIOCHEM J, V342, P119, DOI 10.1042/0264-6021:3420119; Ramjeesingh M, 1997, BIOCHEM J, V327, P17, DOI 10.1042/bj3270017; Rybalchenko V, 2003, J PHYSIOL-LONDON, V547, P873, DOI 10.1113/jphysiol.2002.036434; Santos-Sacchi J, 2001, J PHYSIOL-LONDON, V531, P661, DOI 10.1111/j.1469-7793.2001.0661h.x; Santos-Sacchi J, 1998, NEUROSCI LETT, V256, P155, DOI 10.1016/S0304-3940(98)00788-5; SHEHATA WE, 1991, ACTA OTO-LARYNGOL, V111, P707, DOI 10.3109/00016489109138403; SHEPHERD FH, 1995, ANAL BIOCHEM, V224, P21, DOI 10.1006/abio.1995.1003; Souter M, 1995, HEARING RES, V91, P43, DOI 10.1016/0378-5955(95)00163-8; Stagljar I, 1998, P NATL ACAD SCI USA, V95, P5187, DOI 10.1073/pnas.95.9.5187; TUNSTALL MJ, 1995, J PHYSIOL-LONDON, V485, P739, DOI 10.1113/jphysiol.1995.sp020765; Weber T, 2002, P NATL ACAD SCI USA, V99, P2901, DOI 10.1073/pnas.052609899; Xu JK, 2004, J BIOL CHEM, V279, P19781, DOI 10.1074/jbc.M310785200; Zheng J, 2000, NATURE, V405, P149, DOI 10.1038/35012009; Zheng J, 2003, MAMM GENOME, V14, P87, DOI 10.1007/s00335-002-2227-y; Zheng J, 2001, NEUROREPORT, V12, P1929, DOI 10.1097/00001756-200107030-00032	50	78	82	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					19916	19924		10.1074/jbc.M513854200	http://dx.doi.org/10.1074/jbc.M513854200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16682411	hybrid			2022-12-25	WOS:000239038200015
J	Kovaleski, BJ; Kennedy, R; Hong, MK; Datta, SA; Kleiman, L; Rein, A; Musier-Forsyth, K				Kovaleski, Brandie J.; Kennedy, Robert; Hong, Minh K.; Datta, Siddhartha A.; Kleiman, Lawrence; Rein, Alan; Musier-Forsyth, Karin			In vitro characterization of the interaction between HIV-1 Gag and human lysyl-tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PRIMER TRANSFER-RNAS; ROUS-SARCOMA-VIRUS; ESCHERICHIA-COLI; CAPSID PROTEIN; FLUORESCENCE POLARIZATION; REVERSE TRANSCRIPTION; DIMERIZATION DOMAIN; RECOGNITION; IDENTIFICATION	Human immunodeficiency virus type 1 (HIV-1) viral assembly is mediated by multiple protein-protein and protein-nucleic acid interactions. Humant RNA(Lys3) is used as the primer for HIV reverse transcription, and HIV Gag and GagPol are required for packaging of the tRNA into virions. Human lysyl-t-RNA synthetase (LysRS) is also specifically packaged into HIV, suggesting a role for LysRS in tRNA packaging. Gag alone is sufficient for packaging of LysRS, and these two proteins have been shown to interact in vitro using glutathione S-transferase pull-down assays. In vitro pull-down assays using truncated constructs have also revealed that residues important for homodimerization of Gag and LysRS are critical for the Gag/LysRS interaction. In this work, we report further in vitro characterization of the interaction between HIV Gag and human LysRS using affinity pull-down assays, fluorescence anisotropy measurements and gel chromatography. An equilibrium binding constant of 310 +/- 80 nM was measured for the Gag/LysRS interaction. We also show that capsid alone binds to LysRS with a similar affinity as full-length Gag. Point mutations that disrupt the homodimerization of LysRS and Gag in vitro do not affect their interaction. These results suggest that dimerization of each protein per se is not required for the interaction but that residues involved in forming the homodimer interfaces contribute to heterodimer formation. Gel chromatography studies further support the formation of a Gag/ LysRS heterodimer.	Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA; NCI, Retrovirus Assembly Sect, HIV Drug Resistance Program, NIH, Ft Detrick, MD 21702 USA; Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; Jewish Gen Hosp, McGill Aids Ctr, Montreal, PQ H3T 1E2, Canada	University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Lady Davis Institute; McGill University; McGill University	Musier-Forsyth, K (corresponding author), Univ Minnesota, Dept Chem, 207 Pleasant St SE, Minneapolis, MN 55455 USA.	musier@chem.umn.edu		Datta, Siddhartha/0000-0002-4098-7490	Intramural NIH HHS Funding Source: Medline; NIAID NIH HHS [AI054145] Funding Source: Medline; NIGMS NIH HHS [T32-GM08700, GM069339, T32-GM08277] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010512] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM069339, T32GM008700, T32GM008277] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burniston MT, 1999, J VIROL, V73, P8527, DOI 10.1128/JVI.73.10.8527-8540.1999; Campbell S, 1999, J VIROL, V73, P2270, DOI 10.1128/JVI.73.3.2270-2279.1999; Campbell S, 1997, J VIROL, V71, P4425, DOI 10.1128/JVI.71.6.4425-4435.1997; Cen S, 2002, J VIROL, V76, P13111, DOI 10.1128/JVI.76.24.13111-13115.2002; Cen S, 2001, J VIROL, V75, P5043, DOI 10.1128/JVI.75.11.5043-5048.2001; CUSACK S, 1995, NAT STRUCT BIOL, V2, P824, DOI 10.1038/nsb1095-824; Cusack S, 1996, EMBO J, V15, P6321, DOI 10.1002/j.1460-2075.1996.tb01022.x; Ellinger T, 1998, BIOTECHNIQUES, V24, P718, DOI 10.2144/98245bm03; ERIANI G, 1990, NUCLEIC ACIDS RES, V18, P7109, DOI 10.1093/nar/18.23.7109; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849; Halwani R, 2004, J VIROL, V78, P7553, DOI 10.1128/JVI.78.14.7553-7564.2004; Heacock D, 1996, BIOORG CHEM, V24, P273, DOI 10.1006/bioo.1996.0025; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Ivanov D, 2005, MOL CELL, V17, P137, DOI 10.1016/j.molcel.2004.12.015; Javanbakht H, 2003, J BIOL CHEM, V278, P27644, DOI 10.1074/jbc.M301840200; JIANG M, 1993, J VIROL, V67, P3246, DOI 10.1128/JVI.67.6.3246-3253.1993; Kleiman L, 2004, CURR HIV RES, V2, P163, DOI 10.2174/1570162043484988; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; MAK J, 1994, J VIROL, V68, P2065, DOI 10.1128/JVI.68.4.2065-2072.1994; Mak J, 1997, J VIROL, V71, P8087, DOI 10.1128/JVI.71.11.8087-8095.1997; MULLER B, 1991, BIOCHEMISTRY-US, V30, P3709, DOI 10.1021/bi00229a017; ONESTI S, 1995, STRUCTURE, V3, P163, DOI 10.1016/S0969-2126(01)00147-2; Reid SL, 2001, BIOCHEMISTRY-US, V40, P2484, DOI 10.1021/bi001956p; SAWYER RC, 1973, J VIROL, V12, P1226, DOI 10.1128/JVI.12.6.1226-1237.1973; Shiba K, 1997, J BIOL CHEM, V272, P22809, DOI 10.1074/jbc.272.36.22809; Swanstrom R., 1997, P263; Vogt V. M., 1997, P27; von Schwedler UK, 2003, J VIROL, V77, P5439, DOI 10.1128/JVI.77.9.5439-5450.2003; Waters L C, 1977, Prog Nucleic Acid Res Mol Biol, V20, P131; Worthylake DK, 1999, ACTA CRYSTALLOGR D, V55, P85, DOI 10.1107/S0907444998007689; Yoo SH, 1997, J MOL BIOL, V269, P780, DOI 10.1006/jmbi.1997.1051	33	55	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19449	19456		10.1074/jbc.M601189200	http://dx.doi.org/10.1074/jbc.M601189200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16702215	hybrid			2022-12-25	WOS:000238847000060
J	Lu, J; Daly, CM; Parker, MD; Gill, HS; Piermarini, PM; Pelletier, MF; Boron, WF				Lu, Jing; Daly, Christopher M.; Parker, Mark D.; Gill, Harindarpal S.; Piermarini, Peter M.; Pelletier, Marc F.; Boron, Walter F.			Effect of human carbonic anhydrase II on the activity of the human electrogenic Na/HCO3 cotransporter NBCe1-A in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-BICARBONATE COTRANSPORTER; PROXIMAL TUBULE CELLS; NA+-HCO3-COTRANSPORTER; FUNCTIONAL EXPRESSION; TRANSPORT METABOLON; BINDING-SITE; RAT-KIDNEY; CLONING; STOICHIOMETRY; EXCHANGER	Others report that carbonic anhydrase II (CA II) binds to the C termini of the anion exchanger AE1 and the electrogenic Na/HCO3 cotransporter NBCe1-A, enhancing transport. After injecting oocytes with NBCe1-A cRNA (Day 0), we measured NBC current (I-NBC) by two-electrode voltage clamp (Day 3), injected CA II protein + Tris or just Tris (Day 3), measured I-NBC or the initial rate at which the intracellular pH fell (dpH(i)/dt) upon applying 5% CO2 (Day 4), exposed oocytes to the permeant CA inhibitor ethoxzolamide (EZA), and measured I-NBC or dpH(i)/dt (Day 4). Because dpH(i)/dt was greater in CA II than Tris oocytes, and EZA eliminated the difference, injected CA II was functional. INBC slope conductance was unaffected by injecting CA II. Moreover, EZA had identical effects in CA II versus Tris oocytes. Thus, injected CA II does not enhance NBC activity. In a second protocol, we made a fusion protein with enhanced green fluorescent protein (EGFP) at the 5' end of NBCe1-A and CA II at the 3' end (EGFP-e1-CAII). We measured I-NBC or dpH(i)/dt (days 3 - 4), exposed oocytes to EZA, and measured I-NBC or dpH(i)/dt (Day 3 - 4). dpH(i)/dt was greater in oocytes expressing EGFP-e1-CAII versus EGFP-e1, and EZA eliminated the difference. Thus, fused CA II was functional. Slope conductances of EGFP-e1-CAII versus EGFP-e1 oocytes were indistinguishable, and EZA had no effect. Thus, even when fused to NBCe1-A, CA II does not enhance NBCe1-A activity.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University	Lu, J (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06520 USA.	Jing.Lu@Yale.edu	Boron, Walter/ABI-1564-2020; Parker, Mark/AAH-5575-2020; Piermarini, Peter/AAO-5666-2021	Piermarini, Peter/0000-0003-1020-5774; Boron, Walter/0000-0003-4741-7287	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030344, R37DK030344, K01DK082646, F32DK075258] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-30344, K01 DK082646, F32 DK075258] Funding Source: Medline; PHS HHS [P30-34989] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abuladze N, 1998, J BIOL CHEM, V273, P17689, DOI 10.1074/jbc.273.28.17689; Bevensee MO, 2000, AM J PHYSIOL-CELL PH, V278, pC1200, DOI 10.1152/ajpcell.2000.278.6.C1200; Choi I, 1999, AM J PHYSIOL-CELL PH, V276, pC576, DOI 10.1152/ajpcell.1999.276.3.C576; Ducoudret O, 2001, PFLUG ARCH EUR J PHY, V442, P709, DOI 10.1007/s004240100594; Grichtchenko I, 2002, FASEB J, V16, pA795; Gross E, 2002, J PHYSIOL-LONDON, V544, P679, DOI 10.1113/jphysiol.2002.029777; Gross E, 2001, J PHYSIOL-LONDON, V537, P659; Gross E, 2001, J PHYSIOL-LONDON, V531, P597, DOI 10.1111/j.1469-7793.2001.0597h.x; HOROWITZ SB, 1970, J CELL BIOL, V47, P120, DOI 10.1083/jcb.47.1.120; Pushkin A, 2004, J PHYSIOL-LONDON, V559, P55, DOI 10.1113/jphysiol.2004.065110; Reid R.C., 1987, PROPERTIES GASES LIQ; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; Romero MF, 1998, AM J PHYSIOL-RENAL, V274, pF425, DOI 10.1152/ajprenal.1998.274.2.F425; Schmitt BM, 1999, AM J PHYSIOL-RENAL, V276, pF27, DOI 10.1152/ajprenal.1999.276.1.F27; Sciortino CM, 1999, AM J PHYSIOL-RENAL, V277, pF611, DOI 10.1152/ajprenal.1999.277.4.F611; SIEBENS AW, 1987, J GEN PHYSIOL, V90, P799, DOI 10.1085/jgp.90.6.799; SLY WS, 1995, ANNU REV BIOCHEM, V64, P375, DOI 10.1146/annurev.bi.64.070195.002111; SOLEIMANI M, 1987, J CLIN INVEST, V79, P1276, DOI 10.1172/JCI112948; Sterling D, 2002, J BIOL CHEM, V277, P25239, DOI 10.1074/jbc.M202562200; Sterling D, 2001, J BIOL CHEM, V276, P47886, DOI 10.1074/jbc.M105959200; Swietach P, 2003, PROG BIOPHYS MOL BIO, V83, P69, DOI 10.1016/S0079-6107(03)00027-0; TANHAUSER SM, 1992, GENE, V117, P113, DOI 10.1016/0378-1119(92)90498-E; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Vince JW, 2000, BIOCHEMISTRY-US, V39, P5527, DOI 10.1021/bi992564p; Vince JW, 2000, BIOCHEMISTRY-US, V39, P13344, DOI 10.1021/bi0015111; Vince JW, 1998, J BIOL CHEM, V273, P28430, DOI 10.1074/jbc.273.43.28430; WHITNEY PL, 1974, ANAL BIOCHEM, V57, P467, DOI 10.1016/0003-2697(74)90102-X; ZHAO JH, 1995, NATURE, V374, P636, DOI 10.1038/374636a0	28	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19241	19250		10.1074/jbc.M602181200	http://dx.doi.org/10.1074/jbc.M602181200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16687407	hybrid			2022-12-25	WOS:000238847000038
J	Johar, S; Cave, AC; Narayanapanicker, A; Grieve, DJ; Shah, AM				Johar, Sofian; Cave, Alison C.; Narayanapanicker, Anilkumar; Grieve, David J.; Shah, Ajay M.			Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase	FASEB JOURNAL			English	Article						oxidative stress; matrix metalloproteinase; mineralocorticoid receptor	FACTOR-KAPPA-B; MESSENGER-RNA EXPRESSION; TISSUE GROWTH-FACTOR; MYOCARDIAL FIBROSIS; OXIDATIVE STRESS; HEART-FAILURE; CARDIOVASCULAR INJURY; SUPEROXIDE GENERATION; PRESSURE-OVERLOAD; CONVERTING-ENZYME	Angiotensin (ANG) II (AngII) and aldosterone contribute to the development of interstitial cardiac fibrosis. We investigated the potential role of a Nox2-containing NADPH oxidase in aldosterone-induced fibrosis and the involvement of this mechanism in AngII-induced effects. Nox2(-/-) mice were compared with matched wild-type controls (WT). In WT mice, subcutaneous (s.c.) AngII (1.1 mg/kg/day for 2 wk) significantly increased NADPH oxidase activity, interstitial fibrosis (11.5 +/- 1.0% vs. 7.2 +/- 0.7%; P < 0.05), expression of fibronectin, procollagen I, and connective tissue growth factor mRNA, MMP-2 activity, and NF-kB activation. These effects were all inhibited in Nox(-/-) hearts. The mineralocorticoid receptor antagonist spironolactone inhibited AngII-induced increases in NADPH oxidase activity and the increase in interstitial fibrosis. In a model of mineralocorticoiddependent hypertension involving chronic aldosterone infusion (0.2 mg/kg/day) and a 1% Na Cl diet ("ALDO"), WT animals exhibited increased NADPH oxidase activity, pro-fibrotic gene expression, MMP-2 activity, NF-kB activation, and significant interstitial cardiac fibrosis (12.0 +/- 1.7% with ALDO vs. 6.3 +/- 0.3% without; P < 0.05). These effects were inhibited in Nox2(-/-) ALDO mice (e.g., fibrosis 6.8 +/- 0.8% with ALDO vs. 5.8 +/- 1.0% without ALDO; P=NS). These results suggest that aldosterone-dependent activation of a Nox2-containing NADPH oxidase contributes to the profibrotic effect of AngII in the heart as well as the fibrosis seen in mineralocorticoid-dependent hypertension.	Kings Coll London, Sch Med, Div Cardiovasc, London SE5 9PJ, England	University of London; King's College London	Shah, AM (corresponding author), Kings Coll London, Sch Med, Div Cardiovasc, New Med Sch Bldg,Bessemer Rd, London SE5 9PJ, England.	ajay.shah@kcl.ac.uk	Grieve, David/F-5035-2010; Johar, Sofian/AAX-7450-2021	Johar, Sofian/0000-0002-5962-6492; Shah, Ajay/0000-0002-6547-0631				Ahmed MS, 2004, J MOL CELL CARDIOL, V36, P393, DOI 10.1016/j.yjmcc.2003.12.004; Bataller R, 2003, J CLIN INVEST, V112, P1383, DOI 10.1172/JCI200318212; Bendall JK, 2002, CIRCULATION, V105, P293, DOI 10.1161/hc0302.103712; BRILLA CG, 1993, J MOL CELL CARDIOL, V25, P563, DOI 10.1006/jmcc.1993.1066; Brilla CG, 2000, CIRCULATION, V102, P1388, DOI 10.1161/01.CIR.102.12.1388; BRILLA CG, 1990, CIRC RES, V67, P1355, DOI 10.1161/01.RES.67.6.1355; Byrne JA, 2003, CIRC RES, V93, P802, DOI 10.1161/01.RES.0000099504.30207.F5; Callera GE, 2005, HYPERTENSION, V45, P773, DOI 10.1161/01.HYP.0000154365.30593.d3; Chen K, 2004, HYPERTENSION, V44, P655, DOI 10.1161/01.HYP.0000144400.49062.6b; Chen K, 2004, CIRC RES, V95, P1167, DOI 10.1161/01.RES.0000150369.68826.2f; Diez J, 2002, CIRCULATION, V105, P2512, DOI 10.1161/01.CIR.0000017264.66561.3D; Ferri N, 2003, J BIOL CHEM, V278, P19757, DOI 10.1074/jbc.M212714200; Fiebeler A, 2001, HYPERTENSION, V37, P787, DOI 10.1161/01.HYP.37.2.787; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Griendling KK, 2003, CIRCULATION, V108, P1912, DOI 10.1161/01.CIR.0000093660.86242.BB; Griendling KK, 2004, HEART, V90, P491, DOI 10.1136/hrt.2003.029397; Griendling KK, 2003, CIRCULATION, V108, P2034, DOI 10.1161/01.CIR.0000093661.90582.c4; Grote K, 2003, CIRC RES, V92, pE80, DOI 10.1161/01.RES.0000077044.60138.7C; Gunaruwan P, 2005, AM J CARDIOL, V95, P412, DOI 10.1016/j.amjcard.2004.09.047; Haendeler J, 2000, REGUL PEPTIDES, V95, P1, DOI 10.1016/S0167-0115(00)00133-6; Harada E, 2001, CIRCULATION, V104, P137, DOI 10.1161/01.CIR.104.2.137; Jayasankar V, 2004, CIRCULATION, V110, pII180, DOI 10.1161/01.CIR.0000138946.29375.49; Kawano H, 2000, CIRCULATION, V101, P1130, DOI 10.1161/01.CIR.101.10.1130; Keidar S, 2004, CIRCULATION, V109, P2213, DOI 10.1161/01.CIR.0000127949.05756.9D; Landmesser U, 2002, CIRCULATION, V106, P3073, DOI 10.1161/01.CIR.0000041431.57222.AF; Li JM, 2003, J BIOL CHEM, V278, P12094, DOI 10.1074/jbc.M209793200; Li LX, 2003, CIRCULATION, V107, P1053, DOI 10.1161/01.CIR.0000051459.74466.46; Lijnen P, 2000, J MOL CELL CARDIOL, V32, P865, DOI 10.1006/jmcc.2000.1129; Lu L, 2004, BIOCHEM BIOPH RES CO, V321, P879, DOI 10.1016/j.bbrc.2004.07.048; Manoury B, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-11; Maytin M, 2004, CIRCULATION, V109, P1168, DOI 10.1161/01.CIR.0000117229.60628.2F; Mazak I, 2004, CIRCULATION, V109, P2792, DOI 10.1161/01.CIR.0000131860.80444.AB; McEwan PE, 1998, CIRCULATION, V98, P2765, DOI 10.1161/01.CIR.98.24.2765; Meiners S, 2004, HYPERTENSION, V44, P471, DOI 10.1161/01.HYP.0000142772.71367.65; Mulrow PJ, 1999, REGUL PEPTIDES, V80, P27, DOI 10.1016/S0167-0115(99)00004-X; Neumann S, 2002, HYPERTENSION, V39, P756, DOI 10.1161/hy0302.105295; Ogata T, 2004, J AM COLL CARDIOL, V43, P1481, DOI 10.1016/j.jacc.2003.11.043; Pagano PJ, 1998, HYPERTENSION, V32, P331, DOI 10.1161/01.HYP.32.2.331; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Pu Q, 2003, HYPERTENSION, V42, P49, DOI 10.1161/01.HYP.0000078357.92682.EC; Ramires FJA, 1998, J MOL CELL CARDIOL, V30, P475, DOI 10.1006/jmcc.1997.0612; Robert V, 1999, HYPERTENSION, V33, P981, DOI 10.1161/01.HYP.33.4.981; Ruperez M, 2003, CIRCULATION, V108, P1499, DOI 10.1161/01.CIR.0000089129.51288.BA; Schwartzkopff B, 2000, HYPERTENSION, V36, P220, DOI 10.1161/01.HYP.36.2.220; Silvestre JS, 1998, J BIOL CHEM, V273, P4883, DOI 10.1074/jbc.273.9.4883; Stockand JD, 2003, AM J PHYSIOL-HEART C, V284, pH176, DOI 10.1152/ajpheart.00421.2002; Sun Y, 2002, AM J PATHOL, V161, P1773, DOI 10.1016/S0002-9440(10)64454-9; Swynghedauw B, 1999, PHYSIOL REV, V79, P215, DOI 10.1152/physrev.1999.79.1.215; Touyz RM, 2003, ARTERIOSCL THROM VAS, V23, P981, DOI 10.1161/01.ATV.0000069236.27911.68; Vellaichamy E, 2005, J BIOL CHEM, V280, P19230, DOI 10.1074/jbc.M411373200; Wang TL, 2004, J MOL CELL CARDIOL, V37, P785, DOI 10.1016/j.yjmcc.2004.06.016; Weber KT, 1997, CIRCULATION, V96, P4065	53	240	246	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1546	+		10.1096/fj.05-4642fje	http://dx.doi.org/10.1096/fj.05-4642fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16720735				2022-12-25	WOS:000240266000046
J	Pasder, O; Shpungin, S; Salem, Y; Makovsky, A; Vilchick, S; Michaeli, S; Malovani, H; Nir, U				Pasder, O.; Shpungin, S.; Salem, Y.; Makovsky, A.; Vilchick, S.; Michaeli, S.; Malovani, H.; Nir, U.			Downregulation of Fer induces PP1 activation and cell-cycle arrest in malignant cells	ONCOGENE			English	Article						malignant cells; Fer kinase; cell; cycle; PP1; pRB	TYROSINE KINASE FER; SERINE/THREONINE PROTEIN PHOSPHATASES; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; CATALYTIC SUBUNIT; G(1)/S TRANSITION; CANCER-CELLS; HELPER-FREE; HIGH-TITER; IN-VIVO	Fer is a nuclear and cytoplasmic intracellular tyrosine kinase. Herein we show that Fer is required for cell-cycle progression in malignant cells. Decreasing the level of Fer using the RNA interference (RNAi) approach impeded the proliferation of prostate and breast carcinoma cells and led to their arrest at the G0/G1 phase. At the molecular level, knockdown of Fer resulted in the activation of the retinoblastoma protein (pRB), and this was reflected by profound hypo-phosphorylation of pRB on both cyclin-dependent kinase CDK4 and CDK2 phosphorylation sites. Dephosphorylation of pRB was not seen upon the direct targeting of either CDK4 or CDK2 expression, and was only partially achieved by the simultaneous depletion of these two kinases. Amino-acid sequence analysis revealed two protein phosphatase 1 (PP1) binding motifs in the kinase domain of Fer and the association of Fer with the pRB phosphatase PP1 alpha was verified using co-immunoprecipitation analysis. Downregulation of Fer potentiated the activation of PP1 alpha and overexpression of Fer decreased the enzymatic activity of that phosphatase. Our findings portray Fer as a regulator of cell-cycle progression in malignant cells and as a potential target for cancer intervention.	Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-52900 Ramat Gan, Israel	Bar Ilan University	Nir, U (corresponding author), Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-52900 Ramat Gan, Israel.	nir@mail.biu.ac.il	SILVERSTEIN, ADAR MAKOVSKI/P-1300-2019; Michaeli, Shulamit/AAC-8255-2022					ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; Allard P, 2000, MOL CELL ENDOCRINOL, V159, P63, DOI 10.1016/S0303-7207(99)00205-1; Ayllon V, 2002, EUR J IMMUNOL, V32, P1847, DOI 10.1002/1521-4141(200207)32:7<1847::AID-IMMU1847>3.0.CO;2-7; Ben-Dor I, 1999, CELL GROWTH DIFFER, V10, P113; Bennett D, 2002, NAT GENET, V31, P419, DOI 10.1038/ng938; Berndt N, 1997, CURR BIOL, V7, P375, DOI 10.1016/S0960-9822(06)00185-0; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Ceulemans H, 2002, BIOESSAYS, V24, P371, DOI 10.1002/bies.10069; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chow JPH, 2003, MOL BIOL CELL, V14, P3989, DOI 10.1091/mbc.E03-03-0168; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Craig AWB, 2002, MOL CELL BIOL, V22, P6363, DOI 10.1128/MCB.22.18.6363-6374.2002; Craig AWB, 2001, MOL CELL BIOL, V21, P603, DOI 10.1128/MCB.21.2.603-613.2001; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; Garcia A, 2003, BIOCHIMIE, V85, P721, DOI 10.1016/j.biochi.2003.09.004; Greer P, 2002, NAT REV MOL CELL BIO, V3, P278, DOI 10.1038/nrm783; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Honkanen RE, 2002, CURR MED CHEM, V9, P2055, DOI 10.2174/0929867023368836; Iwanishi M, 2000, J BIOL CHEM, V275, P38995, DOI 10.1074/jbc.M006665200; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kogata N, 2003, MOL BIOL CELL, V14, P3553, DOI 10.1091/mbc.E03-02-0080; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; LETWIN K, 1988, ONCOGENE, V3, P621; Liu CWY, 1999, J BIOL CHEM, V274, P29470, DOI 10.1074/jbc.274.41.29470; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; Lunter PC, 2002, BIOCHEM BIOPH RES CO, V296, P904, DOI 10.1016/S0006-291X(02)02007-7; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Miravet S, 2003, MOL CELL BIOL, V23, P7391, DOI 10.1128/MCB.23.20.7391-7402.2003; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Orlovsky K, 2000, BIOCHEMISTRY-US, V39, P11084, DOI 10.1021/bi0005153; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Pan WJ, 1998, CARCINOGENESIS, V19, P765, DOI 10.1093/carcin/19.5.765; PENHALLOW RC, 1995, J BIOL CHEM, V270, P23362, DOI 10.1074/jbc.270.40.23362; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Priel-Halachmi S, 2000, J BIOL CHEM, V275, P28902, DOI 10.1074/jbc.M003402200; Reed SI, 1997, CANCER SURV, V29, P7; Rosato R, 1998, MOL CELL BIOL, V18, P5762, DOI 10.1128/MCB.18.10.5762; Rubin E, 2001, ONCOGENE, V20, P3776, DOI 10.1038/sj.onc.1204518; Salem Y, 2005, CELL SIGNAL, V17, P341, DOI 10.1016/j.cellsig.2004.08.001; Sellin JH, 2001, CANCER RES, V61, P2899; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sugiyama K, 2002, ONCOGENE, V21, P3103, DOI 10.1038/sj.onc.1205432; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Wang RH, 2001, ONCOGENE, V20, P6111, DOI 10.1038/sj.onc.1204829; Yamasaki Lili, 2003, Cancer Treat Res, V115, P209; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	60	37	39	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	30					4194	4206		10.1038/sj.onc.1209695	http://dx.doi.org/10.1038/sj.onc.1209695			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16732323				2022-12-25	WOS:000239004800007
J	Carlson, CR; Lygren, B; Berge, T; Hoshi, N; Wong, W; Tasken, K; Scott, JD				Carlson, Cathrine Rein; Lygren, Birgitte; Berge, Torunn; Hoshi, Naoto; Wong, Wei; Tasken, Kjetil; Scott, John D.			Delineation of type I protein kinase A-selective signaling events using an RI anchoring disruptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-ACTIVATION; MOLECULAR CHARACTERIZATION; REGULATORY SUBUNITS; CAMP; IDENTIFICATION; CLONING; ALPHA; INHIBITION; RECEPTOR; DOMAINS	Control of specificity in cAMP signaling is achieved by A-kinase anchoring proteins (AKAPs), which assemble cAMP effectors such as protein kinase A (PKA) into multiprotein signaling complexes in the cell. AKAPs tether the PKA holoenzymes at subcellular locations to favor the phosphorylation of selected substrates. PKA anchoring is mediated by an amphipathic helix of 14-18 residues on each AKAP that binds to the R subunit dimer of the PKA holoenzymes. Using a combination of bioinformatics and peptide array screening, we have developed a high affinity-binding peptide called RIAD ( RI anchoring disruptor) with > 1000-fold selectivity for type I PKA over type II PKA. Cell-soluble RIAD selectively uncouples cAMP-mediated inhibition of T cell function and inhibits progesterone synthesis at the mitochondria in steroid-producing cells. This study suggests that these processes are controlled by the type I PKA holoenzyme and that RIAD can be used as a tool to define anchored type I PKA signaling events.	Univ Oslo, Biotechnol Ctr Oslo, N-0317 Oslo, Norway; Oregon Hlth & Sci Univ, Vollum Inst, Howard Hughes Med Inst, Portland, OR 97239 USA	University of Oslo; Howard Hughes Medical Institute; Oregon Health & Science University	Carlson, CR (corresponding author), Ullevaal Univ Hosp, Expt Med Res Inst, Kirkeveien 166, N-0407 Oslo, Norway.	cathrine.carlson@biotek.uio.no		Tasken, Kjetil/0000-0003-2841-4697	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK054441] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54441] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aandahl EM, 2002, J IMMUNOL, V169, P802, DOI 10.4049/jimmunol.169.2.802; Aandahl EM, 1998, FASEB J, V12, P855, DOI 10.1096/fasebj.12.10.855; Abrahamsen H, 2003, J BIOL CHEM, V278, P17170, DOI 10.1074/jbc.M211426200; Alto N, 2002, DIABETES, V51, pS385, DOI 10.2337/diabetes.51.2007.S385; Angelo R, 1998, J BIOL CHEM, V273, P14633, DOI 10.1074/jbc.273.23.14633; Arakane F, 1997, J BIOL CHEM, V272, P32656, DOI 10.1074/jbc.272.51.32656; BAILEY TL, 1994, P 2 INT C INT SYST M, P28; Baillie GS, 2005, FEBS LETT, V579, P3264, DOI 10.1016/j.febslet.2005.03.089; Banky P, 2000, J BIOL CHEM, V275, P35146, DOI 10.1074/jbc.M003961200; Birkemo GA, 2004, BBA-PROTEINS PROTEOM, V1699, P221, DOI 10.1016/j.bbapap.2004.03.001; Burns-Hamuro LL, 2003, P NATL ACAD SCI USA, V100, P4072, DOI 10.1073/pnas.2628038100; Carnegie GK, 2004, MOL CELL, V15, P889, DOI 10.1016/j.molcel.2004.09.015; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARRERA A, 1994, DEV BIOL, V165, P272, DOI 10.1006/dbio.1994.1252; CLEGG CH, 1992, BIOCHEMISTRY-US, V31, P3720, DOI 10.1021/bi00129a023; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Corbin J D, 1974, Methods Enzymol, V38, P287; Diviani D, 2001, J BIOL CHEM, V276, P44247, DOI 10.1074/jbc.M106629200; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; Dodge-Kafka KL, 2005, NATURE, V437, P574, DOI 10.1038/nature03966; DURGERIAN S, 1989, J BIOL CHEM, V264, P9807; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Futaki S, 2005, ADV DRUG DELIVER REV, V57, P547, DOI 10.1016/j.addr.2004.10.009; Gronholm M, 2003, J BIOL CHEM, V278, P41167, DOI 10.1074/jbc.M306149200; Hausken ZE, 1998, METH MOL B, V88, P47; Herberg FW, 2000, J MOL BIOL, V298, P329, DOI 10.1006/jmbi.2000.3662; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Jo Y, 2005, BIOL REPROD, V73, P244, DOI 10.1095/biolreprod.104.037721; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Li H, 2001, MOL ENDOCRINOL, V15, P2211, DOI 10.1210/me.15.12.2211; Li HW, 2003, P NATL ACAD SCI USA, V100, P1627, DOI 10.1073/pnas.0337678100; Liu J, 2003, J STEROID BIOCHEM, V85, P275, DOI 10.1016/S0960-0760(03)00213-9; Lygren B, 2005, J IMMUNOL METHODS, V305, P199, DOI 10.1016/j.jim.2005.06.011; Miki E, 1998, J BIOL CHEM, V273, P34384, DOI 10.1074/jbc.273.51.34384; Mustelin T, 2003, BIOCHEM J, V371, P15, DOI 10.1042/BJ20021637; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; Sewer M B, 2001, Rev Endocr Metab Disord, V2, P269, DOI 10.1023/A:1011516532335; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; Stocco DM, 2001, ANNU REV PHYSIOL, V63, P193, DOI 10.1146/annurev.physiol.63.1.193; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Tasken KA, 2001, J BIOL CHEM, V276, P21999, DOI 10.1074/jbc.C000911200; Torgersen KM, 2001, J BIOL CHEM, V276, P29313, DOI 10.1074/jbc.C100014200; Trendelenburg G, 1996, BIOCHEM BIOPH RES CO, V225, P313, DOI 10.1006/bbrc.1996.1172; Vang T, 2003, J BIOL CHEM, V278, P17597, DOI 10.1074/jbc.C300077200; Vang T, 2001, J EXP MED, V193, P497, DOI 10.1084/jem.193.4.497; Wang L, 2001, P NATL ACAD SCI USA, V98, P3220, DOI 10.1073/pnas.051633398; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; Witczak O, 1999, EMBO J, V18, P1858, DOI 10.1093/emboj/18.7.1858; Wong W, 2004, NAT REV MOL CELL BIO, V5, P959, DOI 10.1038/nrm1527; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	52	120	123	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21535	21545		10.1074/jbc.M603223200	http://dx.doi.org/10.1074/jbc.M603223200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16728392	Green Submitted, hybrid			2022-12-25	WOS:000239187300088
J	Hegde, NR; Chevalier, MS; Wisner, TW; Dentono, MC; Shire, K; Frappier, L; Johnson, DC				Hegde, Nagendra R.; Chevalier, Mathieu S.; Wisner, Todd W.; Dentono, Michael C.; Shire, Kathy; Frappier, Lori; Johnson, David C.			The role of BiP in endoplasmic reticulum-associated degradation of major histocompatibility complex class I heavy chain induced by cytomegalovirus proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ER-ASSOCIATED DEGRADATION; INHIBITS ANTIGEN PRESENTATION; IMMUNOGLOBULIN LIGHT-CHAINS; MISFOLDED SECRETORY PROTEIN; MOLECULAR CHAPERONES; MEMBRANE-PROTEIN; RETRO-TRANSLOCATION; QUALITY-CONTROL; ATPASE ACTIVITY; DNAJ HOMOLOG	Human cytomegalovirus (HCMV1) US11 and US2 proteins cause rapid degradation of major histocompatibility complex (MHC) molecules, apparently by ligating cellular endoplasmic reticulum (ER)-associated degradation machinery. Here, we show that US11 and US2 bind the ER chaperone BiP. Four related HCMV proteins, US3, US7, US9, and US10, which do not promote degradation of MHC proteins, did not bind BiP. Silencing BiP reduced US11- and US2-mediated degradation of MHC class I heavy chain (HC) without altering the synthesis or translocation of HC into the ER or the stability of HC in the absence of US11 or US2. Induction of the unfolded protein response (UPR) did not affect US11- mediated HC degradation and could not explain the stabilization of HC when BiP was silenced. Unlike in yeast, BiP did not act by maintaining substrates in a retrotranslocation-competent form. Our studies go beyond previous observations in mammalian cells correlating BiP release with degradation, demonstrating that BiP is functionally required for US2- and US11- mediated HC degradation. Further, US2 and US11 bound BiP even when HC was absent and degradation of US2 depended on HC. These data were consistent with a model in which US2 and US11 bridge HC onto BiP promoting interactions with other ER-associated degradation proteins.	Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada	Oregon Health & Science University; University of Toronto	Johnson, DC (corresponding author), Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	johnsoda@ohsu.edu	Hegde, Nagendra/J-5920-2014; Hegde, Nagendra R/H-3132-2019	Hegde, Nagendra/0000-0001-5260-2159; Hegde, Nagendra R/0000-0001-5260-2159	NEI NIH HHS [EY11245] Funding Source: Medline; NIAID NIH HHS [AI055051] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011245] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055051] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahn K, 1997, IMMUNITY, V6, P613, DOI 10.1016/S1074-7613(00)80349-0; Ahn KS, 1996, P NATL ACAD SCI USA, V93, P10990, DOI 10.1073/pnas.93.20.10990; Ahner A, 2004, TRENDS CELL BIOL, V14, P474, DOI 10.1016/j.tcb.2004.07.013; Alder NN, 2005, J CELL BIOL, V168, P389, DOI 10.1083/jcb.200409174; Barel MT, 2003, J IMMUNOL, V171, P6757, DOI 10.4049/jimmunol.171.12.6757; Barel MT, 2003, EUR J IMMUNOL, V33, P1707, DOI 10.1002/eji.200323912; Bays NW, 2001, MOL BIOL CELL, V12, P4114, DOI 10.1091/mbc.12.12.4114; Beggah A, 1996, J BIOL CHEM, V271, P20895, DOI 10.1074/jbc.271.34.20895; Bhamidipati A, 2005, MOL CELL, V19, P741, DOI 10.1016/j.molcel.2005.07.027; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Chevalier MS, 2003, J VIROL, V77, P4731, DOI 10.1128/JVI.77.8.4731-4738.2003; Chevalier MS, 2002, J VIROL, V76, P8265, DOI 10.1128/JVI.76.16.8265-8275.2002; Chillaron J, 2000, MOL BIOL CELL, V11, P217, DOI 10.1091/mbc.11.1.217; Chung KT, 2002, J BIOL CHEM, V277, P47557, DOI 10.1074/jbc.M208377200; de Virgilio M, 1999, MOL BIOL CELL, V10, P4059, DOI 10.1091/mbc.10.12.4059; Elkabetz Y, 2004, J BIOL CHEM, V279, P3980, DOI 10.1074/jbc.M309938200; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Furman MH, 2002, J VIROL, V76, P11753, DOI 10.1128/JVI.76.22.11753-11756.2002; Furman MH, 2002, J BIOL CHEM, V277, P3258, DOI 10.1074/jbc.M109765200; Gao B, 2002, IMMUNITY, V16, P99, DOI 10.1016/S1074-7613(01)00260-6; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; Gewurz BE, 2001, P NATL ACAD SCI USA, V98, P6794, DOI 10.1073/pnas.121172898; Gillece P, 1999, J CELL BIOL, V147, P1443, DOI 10.1083/jcb.147.7.1443; Gruhler A, 2000, TRAFFIC, V1, P306, DOI 10.1034/j.1600-0854.2000.010403.x; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; Hegde NR, 2003, J VIROL, V77, P9287, DOI 10.1128/JVI.77.17.9287-9294.2003; Hegde NR, 2003, TRENDS IMMUNOL, V24, P278, DOI 10.1016/S1471-4906(03)00099-1; Hegde NR, 2002, J VIROL, V76, P10929, DOI 10.1128/JVI.76.21.10929-10941.2002; Hendershot LM, 2004, MT SINAI J MED, V71, P289; HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Holowaty MN, 2003, J BIOL CHEM, V278, P29987, DOI 10.1074/jbc.M303977200; Huber MT, 2002, J VIROL, V76, P5748, DOI 10.1128/JVI.76.11.5748-5758.2002; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Johnson AE, 2000, CELL, V102, P709, DOI 10.1016/S0092-8674(00)00059-3; Jones TR, 1997, J VIROL, V71, P2970, DOI 10.1128/JVI.71.4.2970-2979.1997; JONES TR, 1995, J VIROL, V69, P4830, DOI 10.1128/JVI.69.8.4830-4841.1995; Kabani M, 2003, MOL BIOL CELL, V14, P3437, DOI 10.1091/mbc.E02-12-0847; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Kikkert M, 2001, BIOCHEM J, V358, P369, DOI 10.1042/0264-6021:3580369; Kim W, 2005, MOL CELL, V19, P753, DOI 10.1016/j.molcel.2005.08.010; Kimata Y, 2003, MOL BIOL CELL, V14, P2559, DOI 10.1091/mbc.E02-11-0708; KNITTLER MR, 1995, P NATL ACAD SCI USA, V92, P1764, DOI 10.1073/pnas.92.5.1764; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Lee RJ, 2004, EMBO J, V23, P2206, DOI 10.1038/sj.emboj.7600232; Lilley BN, 2005, P NATL ACAD SCI USA, V102, P14296, DOI 10.1073/pnas.0505014102; Lilley BN, 2004, NATURE, V429, P834, DOI 10.1038/nature02592; Lilley BN, 2003, MOL BIOL CELL, V14, P3690, DOI 10.1091/mbc.E03-03-0192; Mancini R, 2000, FASEB J, V14, P769, DOI 10.1096/fasebj.14.5.769; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Nishikawa S, 2005, J BIOCHEM, V137, P551, DOI 10.1093/jb/mvi068; Nishikawa S, 2001, J CELL BIOL, V153, P1061, DOI 10.1083/jcb.153.5.1061; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Paulsson K, 2003, BBA-MOL CELL RES, V1641, P1, DOI 10.1016/S0167-4889(03)00048-X; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Rehm A, 2002, J VIROL, V76, P5043, DOI 10.1128/JVI.76.10.5043-5050.2002; Romisch K, 2005, ANNU REV CELL DEV BI, V21, P435, DOI 10.1146/annurev.cellbio.21.012704.133250; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; Shamu CE, 2001, MOL BIOL CELL, V12, P2546, DOI 10.1091/mbc.12.8.2546; Shen Y, 2005, MOL BIOL CELL, V16, P40, DOI 10.1091/mbc.E04-05-0434; Shen Y, 2002, J BIOL CHEM, V277, P15947, DOI 10.1074/jbc.M112214200; Skowronek MH, 1998, P NATL ACAD SCI USA, V95, P1574, DOI 10.1073/pnas.95.4.1574; Streblow DN, 1999, CELL, V99, P511, DOI 10.1016/S0092-8674(00)81539-1; Szathmary R, 2005, MOL CELL, V19, P765, DOI 10.1016/j.molcel.2005.08.015; Tirabassi RS, 2002, J VIROL, V76, P6832, DOI 10.1128/JVI.76.13.6832-6835.2002; Tirosh B, 2005, J VIROL, V79, P2768, DOI 10.1128/JVI.79.5.2768-2779.2005; Tomazin R, 1999, NAT MED, V5, P1039, DOI 10.1038/12478; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; Tortorella D, 1998, J CELL BIOL, V142, P365, DOI 10.1083/jcb.142.2.365; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; Walter J, 2001, EMBO J, V20, P3124, DOI 10.1093/emboj/20.12.3124; Wang QQ, 2003, EMBO J, V22, P3792, DOI 10.1093/emboj/cdg378; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wilkinson BM, 2000, J BIOL CHEM, V275, P521, DOI 10.1074/jbc.275.1.521; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656; Yewdell JW, 2002, NAT IMMUNOL, V3, P1019, DOI 10.1038/ni1102-1019; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1	95	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20910	20919		10.1074/jbc.M602989200	http://dx.doi.org/10.1074/jbc.M602989200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16731524	hybrid			2022-12-25	WOS:000239187300028
J	Johansson, H; Nordling, K; Weaver, TE; Johansson, J				Johansson, Hanna; Nordling, Kerstin; Weaver, Timothy E.; Johansson, Jan			The Brichos domain-containing C-terminal part of pro-surfactant protein C binds to an unfolded poly-Val transmembrane segment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERSTITIAL LUNG-DISEASE; RAT TYPE-II; PULMONARY SURFACTANT; TRANSGENIC MICE; BIOPHYSICAL ACTIVITY; AGGRESOME FORMATION; GENE; MUTATION; BIOSYNTHESIS; PROPROTEIN	Native lung surfactant protein C (SP-C) is a 4.2-kDa acylpeptide that associates with alveolar surfactant phospholipids via a transmembrane alpha-helix. This helix contains mainly Val, although poly-Val is inefficient in helix formation, and helical SP-C can spontaneously convert to beta-sheet aggregates and amyloid-like fibrils. SP-C is cleaved out from a 21-kDa integral membrane protein, proSP-C, in the alveolar type II cell. Recently several mutations localized in the endoplasmic reticulum-lumenal (C-terminal) part of proSP-C (CTproSP-C) have been associated with intracellular accumulation of toxic forms of proSP-C, low levels of mature SP-C, and development of interstitial lung disease. CTproSP-C contains a similar to 100-residue Brichos domain of unknown function that is also found in other membrane proteins associated with amyloid formation, dementia, and cancer. Here we find that recombinant CTproSP-C binds lipid-associated SP-C, which is in beta-strand conformation, and that this interaction results in an increased helical content. In contrast, CTproSP-C does not bind alpha-helical SP-C. Recombinant CTproSP-C(L188Q), a mutation associated with interstitial lung disease, shows secondary and quaternary structures similar to those of wild type CTproSP-C but is unable to bind lipid-associated beta-strand SP-C. Transfection of CTproSP-C into HEK293 cells that express proSP-C(L188Q) increases the amount of proSP-C protein, whereas no effect is seen on cells expressing wild type proSP-C. These findings suggest that CTproSP-C binds nonhelical SP-C and thereby prevents beta-sheet aggregation and that mutations in CTproSP-C can interfere with this function.	Swedish Univ Agr Sci, Dept Mol Biosci, Biomed Ctr, S-75123 Uppsala, Sweden; Cincinnati Childrens Res Fdn, Div Pulm Biol, Cincinnati, OH 45229 USA	Swedish University of Agricultural Sciences; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Johansson, J (corresponding author), Swedish Univ Agr Sci, Dept Mol Biosci, Biomed Ctr, Box 575, S-75123 Uppsala, Sweden.	jan.johansson@vmk.slu.se		Johansson, Jan/0000-0002-8719-4703				BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; Beers MF, 1995, AM J PHYSIOL-LUNG C, V269, pL744, DOI 10.1152/ajplung.1995.269.6.L744; Beers MF, 2005, ANNU REV PHYSIOL, V67, P663, DOI 10.1146/annurev.physiol.67.040403.101937; Beers MF, 1998, J BIOL CHEM, V273, P15287, DOI 10.1074/jbc.273.24.15287; Brasch F, 2004, EUR RESPIR J, V24, P30, DOI 10.1183/09031936.04.00000104; Bridges JP, 2006, J CELL BIOL, V172, P395, DOI 10.1083/jcb.200508016; Bridges JP, 2003, J BIOL CHEM, V278, P52739, DOI 10.1074/jbc.M309599200; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; Conkright JJ, 2002, AM J RESP CELL MOL, V26, P85, DOI 10.1165/ajrcmb.26.1.4686; Conkright JJ, 2001, J BIOL CHEM, V276, P14658, DOI 10.1074/jbc.M011770200; CURSTEDT T, 1987, EUR J BIOCHEM, V168, P255, DOI 10.1111/j.1432-1033.1987.tb13414.x; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; Gustafsson M, 1999, FEBS LETT, V464, P138, DOI 10.1016/S0014-5793(99)01692-0; JOHANSSON J, 1995, BIOCHEM J, V307, P535, DOI 10.1042/bj3070535; Johnson AL, 2001, AM J RESP CELL MOL, V24, P253, DOI 10.1165/ajrcmb.24.3.4312; Kabore AF, 2001, J CELL SCI, V114, P293; Kallberg Y, 2001, J BIOL CHEM, V276, P12945, DOI 10.1074/jbc.M010402200; Li J, 2004, J MOL BIOL, V338, P857, DOI 10.1016/j.jmb.2004.03.051; Mingarro I, 2000, BMC Cell Biol, V1, P3, DOI 10.1186/1471-2121-1-3; Mulugeta S, 2005, AM J RESP CELL MOL, V32, P521, DOI 10.1165/rcmb.2005-0009OC; Nogee LM, 2002, CHEST, V121, p20S, DOI 10.1378/chest.121.3_suppl.20S; Nogee LM, 2001, NEW ENGL J MED, V344, P573, DOI 10.1056/NEJM200102223440805; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; Russo SJ, 1999, AM J PHYSIOL-LUNG C, V277, pL1034, DOI 10.1152/ajplung.1999.277.5.L1034; Sanchez-Pulido L, 2002, TRENDS BIOCHEM SCI, V27, P329, DOI 10.1016/S0968-0004(02)02134-5; Stark M, 1998, ANAL BIOCHEM, V265, P97, DOI 10.1006/abio.1998.2856; Stevens PA, 2005, PEDIATR RES, V57, P89, DOI 10.1203/01.PDR.0000147567.02473.5A; Szyperski T, 1998, PROTEIN SCI, V7, P2533, DOI 10.1002/pro.5560071206; Thomas AQ, 2002, AM J RESP CRIT CARE, V165, P1322, DOI 10.1164/rccm.200112-123OC; Vorbroker DK, 1995, AM J PHYSIOL-LUNG C, V269, pL727, DOI 10.1152/ajplung.1995.269.6.L727; Wang WJ, 2003, J CELL SCI, V116, P683, DOI 10.1242/jcs.00267; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Westley BR, 2005, BIOCHEMISTRY-US, V44, P7967, DOI 10.1021/bi047287n; Whitsett JA, 2002, NEW ENGL J MED, V347, P2141, DOI 10.1056/NEJMra022387	34	43	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21032	21039		10.1074/jbc.M603001200	http://dx.doi.org/10.1074/jbc.M603001200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16709565	hybrid			2022-12-25	WOS:000239187300040
J	Koch, M; Veit, G; Stricker, S; Bhatt, P; Kutsch, S; Zhou, P; Reinders, E; Hahn, RA; Song, R; Burgeson, RE; Gerecke, DR; Mundlos, S; Gordon, MK				Koch, Manuel; Veit, Guido; Stricker, Sigmar; Bhatt, Pinaki; Kutsch, Stefanie; Zhou, Peihong; Reinders, Elina; Hahn, Rita A.; Song, Rich; Burgeson, Robert E.; Gerecke, Donald R.; Mundlos, Stefan; Gordon, Marion K.			Expression of type XXIII collagen mRNA and protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASE INDUCER; BENIGN EPIDERMOLYSIS-BULLOSA; XIII COLLAGEN; STIMULATORY FACTOR; OLIGOMERIZATION DOMAINS; ALPHA-1 CHAIN; MOUSE EMBRYO; AVIAN CORNEA; CLONING; CELLS	Collagen XXIII is a member of the transmembranous subfamily of collagens containing a cytoplasmic domain, a membrane-spanning hydrophobic domain, and three extracellular triple helical collagenous domains interspersed with non-collagenous domains. We cloned mouse, chicken, and human alpha 1( XXIII)collagen cDNAs and showed that this non-abundant collagen has a limited tissue distribution in non-tumor tissues. Lung, cornea, brain, skin, tendon, and kidney are the major sites of expression. In contrast, five transformed cell lines were tested for collagen XXIII expression, and all expressed the mRNA. In vivo the alpha 1( XXIII) mRNA is found in mature and developing organs, the latter demonstrated using stages of embryonic chick cornea and mouse embryos. Polyclonal antibodies were generated in guinea pig and rabbit and showed that collagen XXIII has a transmembranous form and a shed form. Comparison of collagen XXIII with its closest relatives in the transmembranous subfamily of collagens, types XIII and XXV, which have the same number of triple helical and non-collagenous regions, showed that there is a discontinuity in the alignment of domains but that striking similarities remain despite this.	Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmacol & Toxicol, Piscataway, NJ 08854 USA; Rutgers State Univ, Environm & Occupat Hlth Sci Inst, Piscataway, NJ 08854 USA; Univ Cologne, Ctr Biochem, D-50931 Cologne, Germany; Univ Cologne, Dept Dermatol, D-50931 Cologne, Germany; Univ Cologne, Ctr Mol Med, D-50931 Cologne, Germany; Max Planck Inst Mol Genet, Dev & Dis Grp, D-14195 Berlin, Germany; Tech Univ Berlin, Charite, Inst Med Genet, D-13353 Berlin, Germany	Rutgers State University New Brunswick; Rutgers State University New Brunswick; University of Cologne; University of Cologne; University of Cologne; Max Planck Society; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Technical University of Berlin	Gordon, MK (corresponding author), Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmacol & Toxicol, 170 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	magordon@eohsi.rutgers.edu	Mundlos, Stefan/ABH-9585-2020; Koch, Manuel/AAG-9914-2021; Stricker, Sigmar/B-9169-2009; Veit, Guido/C-9596-2009	Koch, Manuel/0000-0002-2962-7814; Stricker, Sigmar/0000-0002-7174-5363; Veit, Guido/0000-0002-6758-2696; Mundlos, Stefan/0000-0002-9788-3166	NATIONAL EYE INSTITUTE [R01EY009056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K01HL067708] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY009056, EY09056] Funding Source: Medline; NHLBI NIH HHS [HL67708] Funding Source: Medline; NIEHS NIH HHS [ES05022] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARAKISASAKI K, 1995, INVEST OPHTH VIS SCI, V36, P614; Banyard J, 2003, J BIOL CHEM, V278, P20989, DOI 10.1074/jbc.M210616200; Boardman PE, 2002, CURR BIOL, V12, P1965, DOI 10.1016/S0960-9822(02)01296-4; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; DIAZ LA, 1990, J CLIN INVEST, V86, P1088, DOI 10.1172/JCI114812; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Franzke CW, 2005, J BIOL CHEM, V280, P4005, DOI 10.1074/jbc.R400034200; FUJIKAWA LS, 1984, J CELL BIOL, V98, P128, DOI 10.1083/jcb.98.1.128; GIPSON IK, 1989, INVEST OPHTH VIS SCI, V30, P425; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; Gordon MK, 1996, DEV DYNAM, V206, P49, DOI 10.1002/(SICI)1097-0177(199605)206:1<49::AID-AJA5>3.3.CO;2-T; Gordon MK, 1997, INVEST OPHTH VIS SCI, V38, P153; Gordon MK, 2000, INVEST OPHTH VIS SCI, V41, pS752; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Haug C, 2004, ARTERIOSCL THROM VAS, V24, P1823, DOI 10.1161/01.ATV.0000142806.59283.11; Hay E D, 1969, Monogr Dev Biol, V1, P1; Hirako Y, 2003, J INVEST DERMATOL, V121, P1554, DOI 10.1046/j.1523-1747.2003.12607.x; JONKMAN MF, 1995, J CLIN INVEST, V95, P1345, DOI 10.1172/JCI117785; JUVONEN M, 1992, J BIOL CHEM, V267, P24700; JUVONEN M, 1993, LAB INVEST, V69, P541; KATAOKA H, 1993, CANCER RES, V53, P3154; KNIGHT DP, 2000, J CELL SCI, V113, P4141; Koch M, 2004, J BIOL CHEM, V279, P22514, DOI 10.1074/jbc.M400536200; Koch M, 2003, J BIOL CHEM, V278, P43236, DOI 10.1074/jbc.M302112200; Koch M, 2001, J BIOL CHEM, V276, P23120, DOI 10.1074/jbc.M009912200; Koch M, 1999, J CELL BIOL, V145, P605, DOI 10.1083/jcb.145.3.605; Kvist AP, 2001, AM J PATHOL, V159, P1581, DOI 10.1016/S0002-9440(10)62542-4; Latvanlehto A, 2003, J BIOL CHEM, V278, P37590, DOI 10.1074/jbc.M305974200; LINSENMAYER TF, 1986, J CELL BIOL, V103, P1587, DOI 10.1083/jcb.103.4.1587; MASON IJ, 1986, EMBO J, V5, P1465, DOI 10.1002/j.1460-2075.1986.tb04383.x; McAlinden A, 2003, J BIOL CHEM, V278, P42200, DOI 10.1074/jbc.M302429200; MCGRATH JA, 1995, NAT GENET, V11, P83, DOI 10.1038/ng0995-83; Menashi S, 2003, CANCER RES, V63, P7575; MURAOKA K, 1993, INT J CANCER, V55, P19, DOI 10.1002/ijc.2910550105; Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255; Peltonen S, 1997, DNA CELL BIOL, V16, P227, DOI 10.1089/dna.1997.16.227; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P16922; PIHLAJANIEMI T, 1987, P NATL ACAD SCI USA, V84, P940, DOI 10.1073/pnas.84.4.940; PIHLAJANIEMI T, 1995, PROG NUCLEIC ACID RE, V50, P225, DOI 10.1016/S0079-6603(08)60816-8; Polette M, 1997, J HISTOCHEM CYTOCHEM, V45, P703, DOI 10.1177/002215549704500508; Schwabe GC, 2004, DEV DYNAM, V229, P400, DOI 10.1002/dvdy.10466; Sidhu SS, 2004, ONCOGENE, V23, P956, DOI 10.1038/sj.onc.1207070; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; Sund M, 2001, EMBO J, V20, P5153, DOI 10.1093/emboj/20.18.5153; Tasanen K, 2000, J INVEST DERMATOL, V115, P207, DOI 10.1046/j.1523-1747.2000.00049.x; TIKKA L, 1988, P NATL ACAD SCI USA, V85, P7491, DOI 10.1073/pnas.85.20.7491; Veit G, 2006, J BIOL CHEM, V281, P3494, DOI 10.1074/jbc.M509333200; Visel A, 2004, NUCLEIC ACIDS RES, V32, pD552, DOI 10.1093/nar/gkh029	50	48	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21546	21557		10.1074/jbc.M604131200	http://dx.doi.org/10.1074/jbc.M604131200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16728390	hybrid, Green Published			2022-12-25	WOS:000239187300089
J	Li, XN; Wang, SY; Wang, HT; Gupta, D				Li, Xinna; Wang, Shiyong; Wang, Haitao; Gupta, Dipika			Differential expression of peptidoglycan recognition protein 2 in the skin and liver requires different transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ALANINE AMIDASE; TOLL-LIKE RECEPTOR-2; NF-KAPPA-B; INNATE IMMUNITY; P38 MAPK; BACTERIAL PEPTIDOGLYCAN; STAPHYLOCOCCUS-AUREUS; HUMAN KERATINOCYTES; BINDING PROTEIN; HUMAN-SERUM	Human peptidoglycan recognition protein 2 ( PGLYRP2) is an N-acetylmuramoyl-L-alanine amidase that hydrolyzes bacterial peptidoglycan and is differentially expressed in the two major organs in the human body, liver and skin. PGLYRP2 has a high constitutive expression in the liver but is not expressed in healthy human skin. PGLYRP2 mRNA is also not expressed in cultured human keratinocytes but is highly induced upon exposure to bacteria. In this study we identified the transcription start site for pglyrp2 and demonstrated that the differential expression of PGLYRP2 in hepatocytes and keratinocytes is regulated by different transcription factors whose binding sequences are located in different regions of the pglyrp2 promoter. Induction of pglyrp2 in keratinocytes is regulated by sequences in the distal region of the promoter and requires transcription factors NF-kappa B and Sp1, whereas constitutive expression of pglyrp2 in a hepatocyte cell line is regulated by sequences in the proximal region of the promoter and requires transcription factors c-Jun and ATF2. Regulation of constitutive and inducible expression of pglyrp2 is important for systemic and local innate immune responses to bacterial infections.	Indiana Univ, Sch Med NW, Gary, IN 46408 USA	Indiana University System; Indiana University Northwest	Gupta, D (corresponding author), Indiana Univ, Sch Med NW, Gary, IN 46408 USA.	dgupta@iun.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028797, U01AI056395] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28797, AI56395] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		D'Addario M, 2002, J BIOL CHEM, V277, P47541, DOI 10.1074/jbc.M207681200; Dziarski R, 2005, INFECT IMMUN, V73, P5212, DOI 10.1128/IAI.73.8.5212-5216.2005; Dziarski R, 2003, BLOOD, V102, P689, DOI 10.1182/blood-2002-12-3853; Dziarski R, 2004, MOL IMMUNOL, V40, P877, DOI 10.1016/j.molimm.2003.10.011; Eckert RL, 2004, J INVEST DERMATOL, V123, P13, DOI 10.1111/j.0022-202X.2004.22723.x; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; Filipe SR, 2005, EMBO REP, V6, P327, DOI 10.1038/sj.embor.7400371; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200; Gupta D, 1996, J BIOL CHEM, V271, P23310, DOI 10.1074/jbc.271.38.23310; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hoijer MA, 1997, EUR CYTOKINE NETW, V8, P375; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jang SI, 2002, J BIOL CHEM, V277, P42268, DOI 10.1074/jbc.M205593200; Jijon H, 2004, CELL SIGNAL, V16, P1023, DOI 10.1016/j.cellsig.2004.02.005; JONATHAN H, 1995, NEURON, V14, P927; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kao SJ, 2005, IMMUNOLOGY, V115, P366, DOI 10.1111/j.1365-2567.2005.02160.x; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kawai K, 2002, J DERMATOL SCI, V30, P185, DOI 10.1016/S0923-1811(02)00105-6; Leung TH, 2004, CELL, V118, P453, DOI 10.1016/j.cell.2004.08.007; Liu C, 2000, J BIOL CHEM, V275, P24490, DOI 10.1074/jbc.M001239200; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Lu XF, 2006, J BIOL CHEM, V281, P5895, DOI 10.1074/jbc.M511631200; Mellroth P, 2003, J BIOL CHEM, V278, P7059, DOI 10.1074/jbc.M208900200; Mempel M, 2003, J INVEST DERMATOL, V121, P1389, DOI 10.1111/j.1523-1747.2003.12630.x; MOLLNER S, 1984, ARCH MICROBIOL, V140, P171, DOI 10.1007/BF00454921; Ronai Z, 1998, ONCOGENE, V16, P523, DOI 10.1038/sj.onc.1201566; Sang YM, 2005, INFECT IMMUN, V73, P7133, DOI 10.1128/IAI.73.11.7133-7141.2005; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Tydell CC, 2006, J IMMUNOL, V176, P1154, DOI 10.4049/jimmunol.176.2.1154; Tydell CC, 2002, J BIOL CHEM, V277, P19658, DOI 10.1074/jbc.M200659200; VALINGER Z, 1982, BIOCHIM BIOPHYS ACTA, V701, P63, DOI 10.1016/0167-4838(82)90313-2; VANDERWINKEL E, 1990, BIOCHIM BIOPHYS ACTA, V1039, P331, DOI 10.1016/0167-4838(90)90267-J; Wang HT, 2005, INFECT IMMUN, V73, P7216, DOI 10.1128/IAI.73.11.7216-7225.2005; Wang QL, 2001, INFECT IMMUN, V69, P2270, DOI 10.1128/IAI.69.4.2270-2276.2001; Wang ZM, 2003, J BIOL CHEM, V278, P49044, DOI 10.1074/jbc.M307758200; Wu XQ, 2004, J BIOL CHEM, V279, P36158, DOI 10.1074/jbc.M402454200; Xu ZJ, 2001, J IMMUNOL, V167, P6975, DOI 10.4049/jimmunol.167.12.6975; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854; Zhang YO, 2005, BBA-PROTEINS PROTEOM, V1752, P34, DOI 10.1016/j.bbapap.2005.07.001	42	30	30	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20738	20748		10.1074/jbc.M601017200	http://dx.doi.org/10.1074/jbc.M601017200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16714290	hybrid			2022-12-25	WOS:000239187300010
J	Samuels, NM; Klinman, JP				Samuels, Nicole M.; Klinman, Judith P.			Investigation of Cu(I)-dependent 2,4,5-trihydroxyphenylalanine quinone biogenesis in Hansenula polymorpha amine oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPA QUINONE; COPPER; DIOXYGEN; MECHANISM; YEAST; SPECTROSCOPY; REACTIVITY; ACTIVATION; COMPLEXES; PROTEINS	Copper, a mediator of redox chemistries in biology, is often found in enzymes that bind and reduce dioxygen. Among these, the copper amine oxidases catalyze the oxidative deamination of primary amines utilizing a type(II) copper center and 2,4,5-trihydroxyphenylalanine quinone (TPQ), a covalent cofactor derived from the post-translational modification of an active site tyrosine. Previous studies established the dependence of TPQ biogenesis on Cu(II); however, the dependence of cofactor formation on the biologically relevant Cu(I) ion has remained untested. In this study, we demonstrate that the apoform of the Hansenula polymorpha amine oxidase readily binds Cu(I) under anaerobic conditions and produces the quinone cofactor at a rate of 0.28 h(-1) upon subsequent aeration to yield a mature enzyme with kinetic properties identical to the protein product of the Cu(II)-dependent reaction. Because of the change in magnetic properties associated with the oxidation of copper, electron paramagnetic resonance spectroscopy was employed to investigate the nature of the rate-limiting step of Cu(I)-dependent cofactor biogenesis. Upon aeration of the unprocessed enzyme prebound with Cu(I), an axial Cu(II) electron paramagnetic resonance signal was found to appear at a rate equivalent to that for the cofactor. These data provide strong evidence for a rate-limiting release of superoxide from a Cu(II)(O-2(.-)) complex as a prerequisite for the activation of the precursor tyrosine and its transformation for TPQ. As copper is trafficked to intracellular protein targets in the reduced, Cu(I) state, these studies offer possible clues as to the physiological significance of the acquisition of Cu(I) by nascent H. polymorpha amine oxidase.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Klinman, JP (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	klinman@berkeley.edu			NIGMS NIH HHS [GM039296] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039296] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAI DY, 1994, BIOCHEMISTRY-US, V33, P7647, DOI 10.1021/bi00190a019; Dooley DM, 1998, J AM CHEM SOC, V120, P2599, DOI 10.1021/ja970312a; Dove JE, 2000, BIOCHEMISTRY-US, V39, P3690, DOI 10.1021/bi992225w; DuBois JL, 2005, ARCH BIOCHEM BIOPHYS, V433, P255, DOI 10.1016/j.abb.2004.08.036; Finney LA, 2003, SCIENCE, V300, P931, DOI 10.1126/science.1085049; Heiland I, 2005, FEBS J, V272, P2362, DOI 10.1111/j.1742-4658.2005.04690.x; Hirota S, 1999, BIOCHEMISTRY-US, V38, P14256, DOI 10.1021/bi991129s; Lewis EA, 2004, CHEM REV, V104, P1047, DOI 10.1021/cr020633r; Mirica LM, 2004, CHEM REV, V104, P1013, DOI 10.1021/cr020632z; Mure M, 2002, BIOCHEMISTRY-US, V41, P9269, DOI 10.1021/bi020246b; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Ruggiero CE, 1997, BIOCHEMISTRY-US, V36, P1953, DOI 10.1021/bi9628836; Samuels NM, 2005, BIOCHEMISTRY-US, V44, P14308, DOI 10.1021/bi051176m; SAWYER DT, 1985, PHILOS T ROY SOC B, V311, P483, DOI 10.1098/rstb.1985.0159; Schwartz B, 2000, BIOCHEMISTRY-US, V39, P3699, DOI 10.1021/bi9922244; Schwartz B, 2001, BIOCHEMISTRY-US, V40, P2954, DOI 10.1021/bi0021378; Solomon EI, 2001, ANGEW CHEM INT EDIT, V40, P4570, DOI 10.1002/1521-3773(20011217)40:24<4570::AID-ANIE4570>3.0.CO;2-4; Su QJ, 1998, BIOCHEMISTRY-US, V37, P12513, DOI 10.1021/bi981103l	19	9	9	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21114	21118		10.1074/jbc.M601501200	http://dx.doi.org/10.1074/jbc.M601501200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16717088	hybrid			2022-12-25	WOS:000239187300047
J	Scheuner, D; Patel, R; Wang, F; Lee, K; Kumar, K; Wu, J; Nilsson, A; Karin, M; Kaufman, RJ				Scheuner, Donalyn; Patel, Rupali; Wang, Feng; Lee, Kuei; Kumar, Kotlo; Wu, Jun; Nilsson, Anders; Karin, Michael; Kaufman, Randal J.			Double-stranded RNA-dependent protein kinase phosphorylation of the alpha-subunit of eukaryotic translation initiation factor 2 mediates apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-KAPPA-B; VIRUS-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR P53; MALIGNANT-TRANSFORMATION; MAMMALIAN-CELLS; GENE-EXPRESSION; IKK-BETA; PKR; ACTIVATION; INTERFERON	As the molecular processes of complex cell stress signaling pathways are defined, the subsequent challenge is to elucidate how each individual event influences the final biological outcome. Phosphorylation of the translation initiation factor 2 (eIF2 alpha) at Ser(51) is a molecular signal that inhibits translation in response to activation of any of four diverse eIF2 alpha stress kinases. We used gene targeting to replace the wild-type Ser51 allele with an Ala in the eIF2 alpha gene to test the hypothesis that translational control through eIF2 alpha phosphorylation is a central death stimulus in eukaryotic cells. Homozygous eIF2 alpha mutant mouse embryo fibroblasts were resistant to the apoptotic effects of dsRNA, tumor necrosis factor-alpha, and serum deprivation. TNF alpha treatment induced eIF2 alpha phosphorylation and activation of caspase 3 primarily through the dsRNA-activated eIF2 alpha kinase PKR. In addition, expression of a phospho-mimetic Ser51 to Asp mutant eIF2 alpha-activated caspase 3, indicating that eIF2 alpha phosphorylation is sufficient to induce apoptosis. The proapoptotic effects of PKR-mediated eIF2 alpha phosphorylation contrast with the anti-apoptotic response upon activation of the PKR-related endoplasmic reticulum eIF2 alpha kinase, PERK. Therefore, divergent fates of death and survival can be mediated through phosphorylation at the same site within eIF2 alpha. We propose that eIF2 alpha phosphorylation is fundamentally a death signal, yet it may promote either death or survival, depending upon coincident signaling events.	Univ Michigan, Sch Med, Howard Hughes Med Inst, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Howard Hughes Med Inst, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of California System; University of California San Diego	Kaufman, RJ (corresponding author), Univ Michigan, Sch Med, Howard Hughes Med Inst, Dept Biol Chem, Ann Arbor, MI 48109 USA.	kaufmanr@umich.edu	Lee, Kuei/AAF-9272-2021		NHLBI NIH HHS [HL52173] Funding Source: Medline; NIDDK NIH HHS [DK42394] Funding Source: Medline; NIEHS NIH HHS [ES04151] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK042394, R01DK042394] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES004151, R01ES004151] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Balachandran S, 2000, J VIROL, V74, P1513, DOI 10.1128/JVI.74.3.1513-1523.2000; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; Barber GN, 2005, CELL DEATH DIFFER, V12, P563, DOI 10.1038/sj.cdd.4401643; Bonnet MC, 2000, MOL CELL BIOL, V20, P4532, DOI 10.1128/MCB.20.13.4532-4542.2000; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; Deb A, 2001, EMBO J, V20, P2487, DOI 10.1093/emboj/20.10.2487; DeGracia DJ, 2002, J CEREBR BLOOD F MET, V22, P127, DOI 10.1097/00004647-200202000-00001; Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004; Deng J, 2002, CURR BIOL, V12, P1279, DOI 10.1016/S0960-9822(02)01037-0; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Donze O, 2004, EMBO J, V23, P564, DOI 10.1038/sj.emboj.7600078; Donze O, 1999, VIROLOGY, V256, P322, DOI 10.1006/viro.1999.9618; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Gil J, 1999, MOL CELL BIOL, V19, P4653; Goh KC, 2000, EMBO J, V19, P4292, DOI 10.1093/emboj/19.16.4292; Han AP, 2001, EMBO J, V20, P6909, DOI 10.1093/emboj/20.23.6909; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; Horn TL, 2000, TOXICOL SCI, V54, P262, DOI 10.1093/toxsci/54.1.262; Hsu LC, 2004, NATURE, V428, P341, DOI 10.1038/nature02405; Ishii T, 2001, ONCOGENE, V20, P1900, DOI 10.1038/sj.onc.1204267; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; Kaufman RJ, 2004, TRENDS BIOCHEM SCI, V29, P152, DOI 10.1016/j.tibs.2004.01.004; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; Kaufman RJ, 1999, P NATL ACAD SCI USA, V96, P11693, DOI 10.1073/pnas.96.21.11693; Kazemi S, 2004, MOL CELL BIOL, V24, P3415, DOI 10.1128/MCB.24.8.3415-3429.2004; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; LENGYEL P, 1987, J INTERFERON RES, V7, P511, DOI 10.1089/jir.1987.7.511; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Marques JT, 2005, J VIROL, V79, P11105, DOI 10.1128/JVI.79.17.11105-11114.2005; Martin SJ, 1996, ADV EXP MED BIOL, V406, P29; Minagawa H, 2004, J GEN VIROL, V85, P343, DOI 10.1099/vir.0.19627-0; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Perkins DJ, 2004, MOL CELL BIOL, V24, P2025, DOI 10.1128/MCB.24.5.2025-2040.2004; Peschon JJ, 1998, J IMMUNOL, V160, P943; Ramana CV, 2000, ONCOGENE, V19, P2619, DOI 10.1038/sj.onc.1203525; Ron D, 2000, COLD SPRING HARBOR M, V39, P547; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Scheuner D, 2003, VIROLOGY, V317, P263, DOI 10.1016/j.virol.2003.08.010; Shimizu S, 2005, HEPATOL RES, V31, P136, DOI 10.1016/j.hepres.2004.11.012; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Sun M, 2004, CIRCULATION, V110, P3221, DOI 10.1161/01.CIR.0000147233.10318.23; Suresh M, 2004, J VIROL, V78, P3906, DOI 10.1128/JVI.78.8.3906-3918.2004; Torchinsky A, 2004, DIABETOLOGIA, V47, P132, DOI 10.1007/s00125-003-1283-5; von Holzen U, 2005, SURGERY, V138, P261, DOI 10.1016/j.surg.2005.04.011; Wang S, 2006, J BIOL CHEM, V281, P9439, DOI 10.1074/jbc.M504977200; Weaver BK, 2001, FASEB J, V15, P501, DOI 10.1096/fj.00-0222com; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; Wu SY, 2004, J BIOL CHEM, V279, P34898, DOI 10.1074/jbc.M405616200; Wu SY, 1996, J BIOL CHEM, V271, P1756, DOI 10.1074/jbc.271.3.1756; Xu Z, 2000, MOL CELL BIOL, V20, P5285, DOI 10.1128/MCB.20.14.5285-5299.2000; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; Yeung MC, 1998, J BIOL CHEM, V273, P25198, DOI 10.1074/jbc.273.39.25198; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593	72	107	111	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21458	21468		10.1074/jbc.M603784200	http://dx.doi.org/10.1074/jbc.M603784200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16717090	hybrid			2022-12-25	WOS:000239187300081
J	Gomez, MI; O'Seaghdha, M; Magargee, M; Foster, TJ; Prince, AS				Gomez, Marisa I.; O'Seaghdha, Maghnus; Magargee, Mariah; Foster, Timothy J.; Prince, Alice S.			Staphylococcus aureus protein A activates TNFR1 signaling through conserved IgG binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY EPITHELIAL-CELLS; PSEUDOMONAS-AERUGINOSA; IMMUNE EVASION; B-LYMPHOCYTES; GENE; IMMUNOGLOBULIN; FIBRINOGEN; RECEPTOR; EXPRESSION; FRAGMENT	Staphylococcus aureus continues to be a major cause of infection in normal as well as immunocompromised hosts, and the increasing prevalence of highly virulent community-acquired methicillin-resistant strains is a public health concern. A highly expressed surface component of S. aureus, proteinA(SpA), contributes to its success as a pathogen by both activating inflammation and by interfering with immune clearance. SpA is known to bind to IgG Fc, which impedes phagocytosis. SpA is also a potent activator of tumor necrosis factor alpha(TNF-alpha) receptor 1 (TNFR1) signaling, inducing both chemokine expression and TNF-converting enzyme-dependent soluble TNFR1 (sTNFR1) shedding, which has anti-inflammatory consequences, particularly in the lung. Using a collection of glutathione S-transferase fusions to the intact IgG binding region of SpA and to each of the individual binding domains, we found that the SpA IgG binding domains also mediate binding to human airway cells. TNFR1-dependent CXCL8 production could be elicited by any one of the individual SpA IgG binding domains as efficiently as by either the entire SpA or the intact IgG binding region. SpA induction of sTNFR1 shedding required the entire IgG binding region and tolerated fewer substitutions in residues known to interact with IgG. Each of the repeated domains of the IgG binding domain can affect multiple immune responses independently, activating inflammation through TNFR1 and thwarting opsonization by trapping IgG Fc domains, while the intact IgG binding region can limit further signaling through sTNFR1 shedding.	Columbia Univ, Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Univ Dublin Trinity Coll, Moyne Inst Prevent Med, Dept Microbiol, Dublin 2, Ireland	Columbia University; Columbia University; Trinity College Dublin	Gomez, MI (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pediat, 650 W 168th St,Black Bldg 4-416, New York, NY 10032 USA.	asp7@columbia.edu		O'Seaghdha, Maghnus/0000-0002-0232-0556	NHLBI NIH HHS [R01 HL079395] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079395] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cheung AL, 1997, INFECT IMMUN, V65, P2243, DOI 10.1128/IAI.65.6.2243-2249.1997; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DiMango E, 1998, J CLIN INVEST, V101, P2598, DOI 10.1172/JCI2865; Fitzgerald JR, 2006, MOL MICROBIOL, V59, P212, DOI 10.1111/j.1365-2958.2005.04922.x; FLOCK JI, 1987, EMBO J, V6, P2351, DOI 10.1002/j.1460-2075.1987.tb02511.x; Foster TJ, 2005, NAT REV MICROBIOL, V3, P948, DOI 10.1038/nrmicro1289; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; Gillet Y, 2002, LANCET, V359, P753, DOI 10.1016/S0140-6736(02)07877-7; Goerke C, 2000, INFECT IMMUN, V68, P1304, DOI 10.1128/IAI.68.3.1304-1311.2000; Gomez MI, 2004, NAT MED, V10, P842, DOI 10.1038/nm1079; Goodyear CS, 2004, P NATL ACAD SCI USA, V101, P11392, DOI 10.1073/pnas.0404382101; GOUDA H, 1992, BIOCHEMISTRY-US, V31, P9665, DOI 10.1021/bi00155a020; Gouda H, 1998, BIOCHEMISTRY-US, V37, P129, DOI 10.1021/bi970923f; Graille M, 2000, P NATL ACAD SCI USA, V97, P5399, DOI 10.1073/pnas.97.10.5399; Jansson B, 1998, FEMS IMMUNOL MED MIC, V20, P69, DOI 10.1016/S0928-8244(97)00108-9; LANGONE JJ, 1982, ADV IMMUNOL, V32, P157; Loughman A, 2005, MOL MICROBIOL, V57, P804, DOI 10.1111/j.1365-2958.2005.04731.x; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; MCDEVITT D, 1994, MOL MICROBIOL, V11, P237, DOI 10.1111/j.1365-2958.1994.tb00304.x; MOKS T, 1986, EUR J BIOCHEM, V156, P637, DOI 10.1111/j.1432-1033.1986.tb09625.x; Peacock SJ, 1999, MICROBIOL-SGM, V145, P3477, DOI 10.1099/00221287-145-12-3477; Peacock SJ, 2002, INFECT IMMUN, V70, P4987, DOI 10.1128/IAI.70.9.4987-4996.2002; Rajan S, 2000, AM J RESP CELL MOL, V23, P304, DOI 10.1165/ajrcmb.23.3.4098; Ratner AJ, 2001, J BIOL CHEM, V276, P19267, DOI 10.1074/jbc.M007703200; ROBEN PW, 1995, J IMMUNOL, V154, P6437; Roche FM, 2004, J BIOL CHEM, V279, P38433, DOI 10.1074/jbc.M402122200; Said-Salim B, 2003, INFECT CONT HOSP EP, V24, P451, DOI 10.1086/502231; SASSO EH, 1989, J IMMUNOL, V142, P2778; Shopsin B, 1999, J CLIN MICROBIOL, V37, P3556, DOI 10.1128/JCM.37.11.3556-3563.1999; Sinha B, 1999, CELL MICROBIOL, V1, P101, DOI 10.1046/j.1462-5822.1999.00011.x; Starovasnik MA, 1996, BIOCHEMISTRY-US, V35, P15558, DOI 10.1021/bi961409x; SWITALSKI LM, 1989, J BIOL CHEM, V264, P21080; UHLEN M, 1984, J BIOL CHEM, V259, P1695; Viau M, 2005, J IMMUNOL, V175, P7719, DOI 10.4049/jimmunol.175.11.7719	34	98	108	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20190	20196		10.1074/jbc.M601956200	http://dx.doi.org/10.1074/jbc.M601956200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16709567	hybrid			2022-12-25	WOS:000239038200043
J	N'Diaye, M; Le Ferrec, E; Lagadic-Gossmann, D; Corre, S; Gilot, D; Lecureur, V; Monteiro, P; Rauch, C; Galibert, MD; Fardel, O				N'Diaye, Monique; Le Ferrec, Eric; Lagadic-Gossmann, Dominique; Corre, Sebastien; Gilot, David; Lecureur, Valerie; Monteiro, Patricia; Rauch, Claudine; Galibert, Marie-Dominique; Fardel, Olivier			Aryl hydrocarbon receptor-and calcium-dependent induction of the chemokine CCL1 by the environmental contaminant benzo[a] pyrene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; PROTEIN-KINASE-C; CYP1A1 GENE-EXPRESSION; HUMAN-MONOCYTES; AH RECEPTOR; CONTACT HYPERSENSITIVITY; INTERLEUKIN-1 PRODUCTION; CELL CHEMOTAXIS; EXPOSURE; I-309	Polycyclic aromatic hydrocarbons (PAHs) are widely distributed immunotoxic environmental contaminants well known to regulate expression of pro-inflammatory cytokines such as interleukine-1 beta and tumor necrosis factor-alpha. In the present study, we demonstrated that the chemokine CCL1, notably involved in cardiovascular diseases and inflammatory or allergic processes, constitutes a new molecular target for PAHs. Indeed, exposure to PAHs such as benzo[a] pyrene (BP) markedly increased mRNA expression and secretion of CCL1 in primary human macrophage cultures. Moreover, intranasal administration of BP to mice enhanced mRNA levels of TCA3, the mouse orthologue of CCL1, in lung. CCL1 induction in cultured human macrophages was fully prevented by targeting the aryl hydrocarbon receptor (AhR) through chemical inhibition or small interfering RNA-mediated down-modulation of its expression. In addition, BP and the potent AhR agonist 2,3,7,8-tetrachlorodibenzop-dioxin were found to enhance activity of a CCL1 promoter sequence containing a consensus xenobiotic-responsive element known to specifically interact with AhR. Moreover, 2,3,7,8-tetrachlorodibenzo-p-dioxin triggered AhR binding to this CCL1 promoter element as revealed by chromatin immunoprecipitation experiments and electrophoretic mobility shift assays. In an attempt to further characterize the mechanism of CCL1 induction, we demonstrated that BP was able to induce an early and transient increase of intracellular calcium concentration in human macrophages. Inhibition of this calcium increase, using the calcium chelator 1,2-bis(o-aminophenoxy) ethane-N, N, N',N'-tetraacetic acid tetra( acetoxymethyl) ester or the calcium store-operated channel inhibitor 2-aminoethoxydiphenyl borate, fully blocked CCL1 up-regulation. Taken together, these results bring the first demonstration that PAHs induce expression of the chemokine CCL1 in an AhR- and calcium-dependent manner.	Univ Rennes 1, INSERM U620, F-35043 Rennes, France; Univ Rennes 1, Fac Med, CNRS, UMR 6061,Lab Genet & Dev, F-35043 Rennes, France; CHU Rennes, Dept Hematol Immunol & Therapie Cellulaire, F-35033 Rennes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes; CHU Rennes	Le Ferrec, E (corresponding author), Univ Rennes 1, INSERM U620, IFR140,2 Ave Pr Leon Bernard, F-35043 Rennes, France.	eric.leferrec@univ-rennes1.fr	LAGADIC-GOSSMANN, Dominique/I-5079-2015; CORRE, Sebastien/B-7069-2018; Fardel, Olivier/J-8560-2015; N'DIAYE, Monique MND/K-6209-2015; LECUREUR, Valérie/J-9095-2015; Le FERREC, Eric/K-1374-2015	LAGADIC-GOSSMANN, Dominique/0000-0002-4888-236X; CORRE, Sebastien/0000-0003-1532-5660; N'DIAYE, Monique MND/0000-0001-8867-0778; Le FERREC, Eric/0000-0002-2015-2779				Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; ANDERSON C, 1995, J IMMUNOL, V155, P3530; Arend WP, 2000, ARTHRITIS RES, V2, P245, DOI 10.1186/ar94; Bishop B, 2003, J IMMUNOL, V170, P4810, DOI 10.4049/jimmunol.170.9.4810; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Burchiel SW, 2001, CLIN IMMUNOL, V98, P2, DOI 10.1006/clim.2000.4934; Chen YH, 1996, J BIOL CHEM, V271, P26261, DOI 10.1074/jbc.271.42.26261; Corre S, 2004, J BIOL CHEM, V279, P51226, DOI 10.1074/jbc.M409768200; Curfs DMJ, 2004, AM J PATHOL, V164, P101, DOI 10.1016/S0002-9440(10)63101-X; DAVILA DR, 1995, J TOXICOL ENV HEALTH, V45, P101, DOI 10.1080/15287399509531985; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, P573, DOI 10.1289/ehp.02110s4573; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gao J, 2005, TOXICOL SCI, V87, P419, DOI 10.1093/toxsci/kfi265; Gombert M, 2005, J IMMUNOL, V174, P5082, DOI 10.4049/jimmunol.174.8.5082; Goya I, 1998, J IMMUNOL, V160, P1975; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Haque NS, 2000, CIRCULATION, V102, P786, DOI 10.1161/01.CIR.102.7.786; Haque NS, 2004, BLOOD, V103, P1296, DOI 10.1182/blood-2002-05-1480; Haque NS, 2001, BLOOD, V97, P39, DOI 10.1182/blood.V97.1.39; HATTEMERFREY HA, 1991, TOXICOL IND HEALTH, V7, P141, DOI 10.1177/074823379100700303; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Heist EK, 1998, CELL CALCIUM, V23, P103; Henley DV, 2004, ARCH BIOCHEM BIOPHYS, V422, P42, DOI 10.1016/j.abb.2003.11.022; Hestermann EV, 2003, MOL CELL BIOL, V23, P7920, DOI 10.1128/MCB.23.21.7920-7925.2003; Jeon MS, 2000, J IMMUNOL, V165, P6975, DOI 10.4049/jimmunol.165.12.6975; Jigorel E, 2005, DRUG METAB DISPOS, V33, P1418, DOI 10.1124/dmd.105.004762; Kadkhoda K, 2005, TOXICOL LETT, V157, P31, DOI 10.1016/j.toxlet.2005.01.002; Kangsadalampai K, 1997, FOOD CHEM TOXICOL, V35, P213, DOI 10.1016/S0278-6915(96)00067-1; KARRAS JG, 1995, TOXICOL LETT, V75, P225, DOI 10.1016/0378-4274(94)03185-A; Kim MS, 2005, CYTOKINE, V32, P226, DOI 10.1016/j.cyto.2005.10.001; KLEMME JC, 1987, CANCER RES, V47, P6074; Knize M G, 1999, Adv Exp Med Biol, V459, P179; KRIEGER JA, 1994, TOXICOL APPL PHARM, V127, P268, DOI 10.1006/taap.1994.1161; Laupeze W, 2002, J IMMUNOL, V168, P2652, DOI 10.4049/jimmunol.168.6.2652; Le Ferrec E, 2002, J BIOL CHEM, V277, P24780, DOI 10.1074/jbc.M111319200; Lecureur V, 2005, FEBS LETT, V579, P1904, DOI 10.1016/j.febslet.2005.01.081; LIJINSKY W, 1991, MUTAT RES, V259, P251, DOI 10.1016/0165-1218(91)90121-2; Long WP, 1998, MOL PHARMACOL, V53, P691, DOI 10.1124/mol.53.4.691; LU YF, 1995, ARCH BIOCHEM BIOPHYS, V316, P470, DOI 10.1006/abbi.1995.1062; LYTE M, 1986, LIFE SCI, V38, P1163, DOI 10.1016/0024-3205(86)90170-0; LYTE M, 1986, INT J IMMUNOPHARMACO, V8, P377, DOI 10.1016/0192-0561(86)90120-7; Ma Q, 2001, CURR DRUG METAB, V2, P149, DOI 10.2174/1389200013338603; Maasch C, 2000, FASEB J, V14, P1653, DOI 10.1096/fj.14.11.1653; Machemer DEW, 2005, TOXICOL SCI, V87, P27, DOI 10.1093/toxsci/kfi220; Mandal PK, 2005, J COMP PHYSIOL B, V175, P221, DOI 10.1007/s00360-005-0483-3; Matikainen T, 2001, NAT GENET, V28, P355, DOI 10.1038/ng575; Morel Y, 1998, J BIOL CHEM, V273, P26969, DOI 10.1074/jbc.273.41.26969; Nazarenko DA, 2001, TOXICOL SCI, V61, P256, DOI 10.1093/toxsci/61.2.256; Roos RS, 1997, J BIOL CHEM, V272, P17251, DOI 10.1074/jbc.272.28.17251; Ruckes T, 2001, BLOOD, V98, P1150, DOI 10.1182/blood.V98.4.1150; Selvan RS, 1997, EUR J IMMUNOL, V27, P687, DOI 10.1002/eji.1830270317; Sorensen M, 2003, MUTAT RES-REV MUTAT, V544, P255, DOI 10.1016/j.mrrev.2003.06.010; STERLING K, 1994, TOXICOL APPL PHARM, V128, P18, DOI 10.1006/taap.1994.1175; Sun YV, 2004, NUCLEIC ACIDS RES, V32, P4512, DOI 10.1093/nar/gkh782; Swanson HI, 2002, CHEM-BIOL INTERACT, V141, P63, DOI 10.1016/S0009-2797(02)00066-2; Tamaki A, 2004, BIOL PHARM BULL, V27, P407, DOI 10.1248/bpb.27.407; Tan ZQ, 2004, TOXICOL SCI, V82, P80, DOI 10.1093/toxsci/kfh228; Tauchi M, 2005, MOL CELL BIOL, V25, P9360, DOI 10.1128/MCB.25.21.9360-9368.2005; van Grevenynghe J, 2003, J IMMUNOL, V170, P2374, DOI 10.4049/jimmunol.170.5.2374; Vandebriel RJ, 1998, TOXICOL APPL PHARM, V148, P126, DOI 10.1006/taap.1997.8294; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Wogan GN, 2004, SEMIN CANCER BIOL, V14, P473, DOI 10.1016/j.semcancer.2004.06.010; Wu MT, 2003, ENVIRON MOL MUTAGEN, V42, P98, DOI 10.1002/em.10176; Yim S, 2004, BIOCHEM BIOPH RES CO, V322, P9, DOI 10.1016/j.bbrc.2004.07.072	65	92	94	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					19906	19915		10.1074/jbc.M601192200	http://dx.doi.org/10.1074/jbc.M601192200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16679317	hybrid			2022-12-25	WOS:000239038200014
J	Bernad, R; Engelsma, D; Sanderson, H; Pickersgill, H; Fornerod, M				Bernad, Rafael; Engelsma, Dieuwke; Sanderson, Helen; Pickersgill, Helen; Fornerod, Maarten			Nup214-Nup88 nucleoporin subcomplex is required for CRM1-mediated 60 S preribosomal nuclear export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPORT; 60S RIBOSOMAL-SUBUNITS; PORE COMPLEX STRUCTURE; NUCLEOCYTOPLASMIC TRANSPORT; PROTEIN IMPORT; MOLECULAR-MECHANISM; PROTEOMIC ANALYSIS; DEK-CAN; CRM1; SIGNAL	The nuclear pore complex (NPC) conducts macromolecular transport to and from the nucleus and provides a kinetic/hydrophobic barrier composed of phenylalanine-glycine (FG) repeats. Nuclear transport is achieved through permeation of this barrier by transport receptors. The transport receptor CRM1 facilitates export of a large variety of cargoes. Export of the preribosomal 60 S subunit follows this pathway through the adaptor protein NMD3. Using RNA interference, we depleted two FG-containing cytoplasmically oriented NPC complexes, Nup214-Nup88 and Nup358, and investigated CRM1-mediated export. A dramatic defect in NMD3-mediated export of preribosomes was found in Nup214-Nup88-depleted cells, whereas only minor export defects were evident in other CRM1 cargoes or upon depletion of Nup358. We show that the large C-terminal FG domain of Nup214 is not accessible to freely diffusing molecules from the nucleus, indicating that it does not conduct 60 S preribosomes through the NPC. Consistently, derivatives of Nup214 lacking the FG-repeat domain rescued the 60 S export defect. We show that the coiled-coil region of Nup214 is sufficient for 60 S nuclear export, coinciding with recruitment of Nup88 to the NPC. Our data indicate that Nup214 plays independent roles in NPC function by participating in the kinetic/hydrophobic barrier through its FG-rich domain and by enabling NPC gating through association with Nup88.	Netherlands Canc Inst, Dept Tumor Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Fornerod, M (corresponding author), Netherlands Canc Inst, Dept Tumor Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	m.fornerod@nki.nl	Fornerod, Maarten/A-7503-2010	Fornerod, Maarten/0000-0002-6166-3030; Sanderson, Helen/0000-0002-0701-219X				Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; AKEY CW, 1990, BIOPHYS J, V58, P341, DOI 10.1016/S0006-3495(90)82381-X; Allen NPC, 2001, J BIOL CHEM, V276, P29268, DOI 10.1074/jbc.M102629200; Allen TD, 2000, J CELL SCI, V113, P1651; Askjaer P, 1999, MOL CELL BIOL, V19, P6276; Bastos R, 1996, J CELL BIOL, V134, P1141, DOI 10.1083/jcb.134.5.1141; Bastos R, 1997, J CELL BIOL, V137, P989, DOI 10.1083/jcb.137.5.989; Bayliss R, 2000, TRAFFIC, V1, P448, DOI 10.1034/j.1600-0854.2000.010602.x; Beck M, 2004, SCIENCE, V306, P1387, DOI 10.1126/science.1104808; Becskei A, 2005, CURR OPIN CELL BIOL, V17, P27, DOI 10.1016/j.ceb.2004.12.010; Belgareh N, 1998, MOL BIOL CELL, V9, P3475, DOI 10.1091/mbc.9.12.3475; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; Bernad R, 2004, MOL CELL BIOL, V24, P2373, DOI 10.1128/MCB.24.6.2373-2384.2004; Boer J, 1998, MOL CELL BIOL, V18, P1236, DOI 10.1128/MCB.18.3.1236; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; Del Priore V, 1997, J CELL SCI, V110, P2987; Denning DP, 2003, P NATL ACAD SCI USA, V100, P2450, DOI 10.1073/pnas.0437902100; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; Engelsma D, 2004, EMBO J, V23, P3643, DOI 10.1038/sj.emboj.7600370; Fahrenkrog B, 2003, NAT REV MOL CELL BIO, V4, P757, DOI 10.1038/nrm1230; Fahrenkrog B, 2002, J STRUCT BIOL, V140, P254, DOI 10.1016/S1047-8477(02)00524-5; FELDHERR CM, 1990, ELECTRON MICROSC REV, V3, P73, DOI 10.1016/0892-0354(90)90014-J; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FORNEROD M, 1995, ONCOGENE, V10, P1739; Fornerod M, 1996, ONCOGENE, V13, P1801; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gadal O, 2001, MOL CELL BIOL, V21, P3405, DOI 10.1128/MCB.21.10.3405-3415.2001; Gleizes PE, 2001, J CELL BIOL, V155, P923, DOI 10.1083/jcb.200108142; Goldberg MW, 1996, J MOL BIOL, V257, P848, DOI 10.1006/jmbi.1996.0206; GORSCH LC, 1995, J CELL BIOL, V129, P939, DOI 10.1083/jcb.129.4.939; GRANDI P, 1995, J CELL BIOL, V130, P1263, DOI 10.1083/jcb.130.6.1263; Hedges J, 2005, EMBO J, V24, P567, DOI 10.1038/sj.emboj.7600547; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Hurwitz ME, 1998, P NATL ACAD SCI USA, V95, P11241, DOI 10.1073/pnas.95.19.11241; HURWITZ ME, 1995, J CELL BIOL, V130, P1275, DOI 10.1083/jcb.130.6.1275; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Kiseleva E, 1998, J CELL SCI, V111, P223; Klemm JD, 1997, CURR BIOL, V7, P638, DOI 10.1016/S0960-9822(06)00290-9; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; Matos P, 2003, J BIOL CHEM, V278, P50442, DOI 10.1074/jbc.M308215200; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; NEHRBASS U, 1990, CELL, V61, P979, DOI 10.1016/0092-8674(90)90063-K; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Paulillo SM, 2005, J MOL BIOL, V351, P784, DOI 10.1016/j.jmb.2005.06.034; Ribbeck K, 2001, EMBO J, V20, P1320, DOI 10.1093/emboj/20.6.1320; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; Roth P, 2003, J CELL BIOL, V163, P701, DOI 10.1083/jcb.200304046; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; Schmitt C, 1999, EMBO J, V18, P4332, DOI 10.1093/emboj/18.15.4332; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stewart M, 2001, FEBS LETT, V498, P145, DOI 10.1016/S0014-5793(01)02489-9; Stoffler D, 1999, CURR OPIN CELL BIOL, V11, P391, DOI 10.1016/S0955-0674(99)80055-6; Strawn LA, 2004, NAT CELL BIOL, V6, P197, DOI 10.1038/ncb1097; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; Thomas F, 2003, J CELL SCI, V116, P2409, DOI 10.1242/jcs.00464; Trotta CR, 2003, EMBO J, V22, P2841, DOI 10.1093/emboj/cdg249; vanDeursen J, 1996, EMBO J, V15, P5574, DOI 10.1002/j.1460-2075.1996.tb00942.x; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; Walther TC, 2002, J CELL BIOL, V158, P63, DOI 10.1083/jcb.200202088; Walther TC, 2001, EMBO J, V20, P5703, DOI 10.1093/emboj/20.20.5703; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yang WD, 2004, P NATL ACAD SCI USA, V101, P12887, DOI 10.1073/pnas.0403675101; Zeitler B, 2004, J CELL BIOL, V167, P583, DOI 10.1083/jcb.200407156	69	61	62	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19378	19386		10.1074/jbc.M512585200	http://dx.doi.org/10.1074/jbc.M512585200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16675447	hybrid			2022-12-25	WOS:000238847000053
J	Boanca, G; Sand, A; Barycki, JJ				Boanca, Gina; Sand, Aaron; Barycki, Joseph J.			Uncoupling the enzymatic and autoprocessing activities of Helicobacter pylori gamma-glutamyltranspeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; DEFICIENT MICE; TRANSFERASE TRANSPEPTIDASE; GENE-EXPRESSION; IN-VIVO; CATALYTIC MECHANISM; SUBUNIT; PROTEIN; KIDNEY; RAT	gamma-Glutamyltranspeptidase (gamma GT), a member of the N-terminal nucleophile hydrolase superfamily, initiates extracellular glutathione reclamation by cleaving the gamma-glutamyl amide bond of the tripeptide. This protein is translated as an inactive proenzyme that undergoes autoprocessing to become an active enzyme. The resultant N terminus of the cleaved proenzyme serves as a nucleophile in amide bond hydrolysis. Helicobacter pylori gamma-glutamyltranspeptidase (HpGT) was selected as a model system to study the mechanistic details of autoprocessing and amide bond hydrolysis. In contrast to previously reported gamma GT, large quantities of HpGT were expressed solubly in the inactive precursor form. The 60-kDa proenzyme was kinetically competent to form the mature 40- and 20-kDa subunits and exhibited maximal autoprocessing activity at neutral pH. The activated enzyme hydrolyzed the gamma-glutamyl amide bond of several substrates with comparable rates, but exhibited limited transpeptidase activity relative to mammalian gamma GT. As with autoprocessing, maximal enzymatic activity was observed at neutral pH, with hydrolysis of the acyl-enzyme intermediate as the rate-limiting step. Coexpression of the 20- and 40-kDa subunits of HpGT uncoupled autoprocessing from enzymatic activity and resulted in a fully active heterotetramer with kinetic constants similar to those of the wild- type enzyme. The specific contributions of a conserved threonine residue (Thr(380)) to autoprocessing and hydrolase activities were examined by mutagenesis using both the standard and coexpression systems. The results of these studies indicate that the gamma-methyl group of Thr(380) orients the hydroxyl group of this conserved residue, which is required for both the processing and hydrolase reactions.	Univ Nebraska, Dept Biochem, Beadle Ctr N222, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Barycki, JJ (corresponding author), Univ Nebraska, Dept Biochem, Beadle Ctr N222, 1901 Vine St, Lincoln, NE 68588 USA.	jbarycki2@unl.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM077289] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR017675, P20RR-17675] Funding Source: Medline; NIGMS NIH HHS [R01 GM077289, 1R01GM077289-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTT WA, 1983, J BIOL CHEM, V258, P6193; ALLISON RD, 1985, METHOD ENZYMOL, V113, P419; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Bjorkholm B, 2003, J INTERN MED, V253, P102, DOI 10.1046/j.1365-2796.2003.01119.x; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; BURTSCHER H, 1992, EUR J BIOCHEM, V205, P77, DOI 10.1111/j.1432-1033.1992.tb16753.x; Busiello I, 2004, CELL MICROBIOL, V6, P255, DOI 10.1046/j.1462-5822.2004.00366.x; Carter BZ, 1998, J BIOL CHEM, V273, P28277, DOI 10.1074/jbc.273.43.28277; Castonguay R, 2003, BIOCHEMISTRY-US, V42, P11504, DOI 10.1021/bi035064b; Chevalier C, 1999, MOL MICROBIOL, V31, P1359, DOI 10.1046/j.1365-2958.1999.01271.x; Chevez-Barrios P, 2000, EXP EYE RES, V71, P575, DOI 10.1006/exer.2000.0913; Comtois SL, 2003, MICROBIOL-SGM, V149, P121, DOI 10.1099/mic.0.25896-0; ELVING PJ, 1956, ANAL CHEM, V28, P1179, DOI 10.1021/ac60115a034; Gallagher BC, 1998, CARCINOGENESIS, V19, P1251, DOI 10.1093/carcin/19.7.1251; Habib GM, 2000, HEPATOLOGY, V32, P556, DOI 10.1053/jhep.2000.9715; Hanigan MH, 1999, CARCINOGENESIS, V20, P553, DOI 10.1093/carcin/20.4.553; Hanigan MH, 2001, AM J PATHOL, V159, P1889, DOI 10.1016/S0002-9440(10)63035-0; Hanigan MH, 1999, HUM PATHOL, V30, P300, DOI 10.1016/S0046-8177(99)90009-6; HASHIMOTO W, 1995, J BIOCHEM-TOKYO, V118, P75, DOI 10.1093/oxfordjournals.jbchem.a124894; HASHIMOTO W, 1995, J BIOCHEM, V118, P1216, DOI 10.1093/oxfordjournals.jbchem.a125010; Ikeda Y, 2005, METHOD ENZYMOL, V401, P408, DOI 10.1016/S0076-6879(05)01025-6; IKEDA Y, 1995, P NATL ACAD SCI USA, V92, P126, DOI 10.1073/pnas.92.1.126; IKEDA Y, 1995, J BIOL CHEM, V270, P22223, DOI 10.1074/jbc.270.38.22223; Inoue M, 2000, BIOCHEMISTRY-US, V39, P7764, DOI 10.1021/bi000220p; Keillor JW, 2005, METHOD ENZYMOL, V401, P449, DOI 10.1016/S0076-6879(05)01027-X; Keillor JW, 2004, J PHYS ORG CHEM, V17, P529, DOI 10.1002/poc.777; Kinlough CL, 2005, METHOD ENZYMOL, V401, P426, DOI 10.1016/S0076-6879(05)01026-8; Kumar TR, 2000, ENDOCRINOLOGY, V141, P4270, DOI 10.1210/en.141.11.4270; Li Y, 1999, EUR J BIOCHEM, V262, P713, DOI 10.1046/j.1432-1327.1999.00417.x; Lieberman MW, 1996, P NATL ACAD SCI USA, V93, P7923, DOI 10.1073/pnas.93.15.7923; McGovern KJ, 2001, INFECT IMMUN, V69, P4168, DOI 10.1128/IAI.69.6.4168-4173.2001; Minami H, 2003, FEMS MICROBIOL LETT, V224, P169, DOI 10.1016/S0378-1097(03)00456-7; Oinonen C, 2000, PROTEIN SCI, V9, P2329, DOI 10.1110/ps.9.12.2329; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Rojas E, 2000, MUTAT RES-FUND MOL M, V447, P305, DOI 10.1016/S0027-5107(99)00191-8; Sharma P, 2003, ALIMENT PHARM THER, V17, P297, DOI 10.1046/j.1365-2036.2003.01428.x; Shi ZZ, 1995, GENE, V167, P233, DOI 10.1016/0378-1119(95)00618-4; Shibayama K, 2003, MOL MICROBIOL, V47, P443, DOI 10.1046/j.1365-2958.2003.03305.x; SUZUKI H, 1988, BIOCHEM BIOPH RES CO, V150, P33, DOI 10.1016/0006-291X(88)90482-2; Suzuki H, 2002, J BIOL CHEM, V277, P43536, DOI 10.1074/jbc.M207680200; SUZUKI H, 1986, J BACTERIOL, V168, P1325, DOI 10.1128/jb.168.3.1325-1331.1986; Taniguchi N, 1998, ADV ENZYMOL RAMB, V72, P239; TATE SS, 1981, MOL CELL BIOCHEM, V39, P357, DOI 10.1007/BF00232585; TATE SS, 1985, METHOD ENZYMOL, V113, P400; THOMPSON GA, 1977, J BIOL CHEM, V252, P6792; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Will Y, 2000, HEPATOLOGY, V32, P740, DOI 10.1053/jhep.2000.17913	47	66	73	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19029	19037		10.1074/jbc.M603381200	http://dx.doi.org/10.1074/jbc.M603381200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16672227	hybrid			2022-12-25	WOS:000238847000016
J	Hu, KQ; Liu, C; Ernst, H; Krinsky, NI; Russell, RM; Wang, XD				Hu, Kang-Quan; Liu, Chun; Ernst, Hansgeorg; Krinsky, Norman I.; Russell, Robert M.; Wang, Xiang-Dong			The biochemical characterization of ferret carotene-9 ', 10 '-monooxygenase catalyzing cleavage of carotenoids in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CAROTENE; VITAMIN-A; OXIDATIVE CLEAVAGE; EXCENTRIC CLEAVAGE; EXPRESSION; LYCOPENE; IDENTIFICATION; BIOSYNTHESIS; CLONING; ACID	Previous studies have shown that beta-carotene 15,15'-monooxygenase catalyzes the cleavage of beta-carotene at the central carbon 15,15'-double bond but cleaves lycopene with much lower activity. However, expressing the mouse carotene 9', 10'-monooxygenase (CMO2) in beta-carotene/lycopene-synthesizing and -accumulating Escherichia coli strains leads to both a color shift and formation of apo-10'-carotenoids, suggesting the oxidative cleavage of both carotenoids at their 9', 10'-double bond. Here we provide information on the biochemical characterization of CMO2 of the ferret, a model for human carotenoid metabolism, in terms of the kinetic analysis of beta-carotene/lycopene cleavage into beta-apo-10'-carotenal/apo-10'-lycopenal in vitro and the formation of apo-10'-lycopenoids in ferrets in vivo. We demonstrate that the recombinant ferret CMO2 catalyzes the excentric cleavage of both all-trans-beta-carotene and the 5-cis- and 13-cis-isomers of lycopene at the 9', 10'-double bond but not all-trans-lycopene. The cleavage activity of ferret CMO2 was higher toward lycopene cis-isomers as compared with beta-carotene as substrate. Iron was an essential co-factor for the reaction. Furthermore, all-trans-lycopene supplementation in ferrets resulted in significant accumulation of cis-isomers of lycopene and the formation of apo-10'-lycopenol, as well as upregulation of the CMO2 expression in lung tissues. In addition, in vitro incubation of apo-10'-lycopenal with the post-nuclear fraction of hepatic homogenates of ferrets resulted in the production of both apo-10'-lycopenoic acid and apo-10'-lycopenol, respectively, depending upon the presence of NAD(+) or NADH as cofactors. Our finding of bioconversion of cis-isomers of lycopene into apo-10'-lycopenoids by CMO2 is significant because cis-isomers of lycopene are a predominant form of lycopene in mammalian tissues and apo-lycopenoids may have specific biological activities related to human health.	Tufts Univ, Human Nutr Res Ctr Aging, Nutrit & Canc Biol Lab, Jean Mayer US Dept Agr, Boston, MA 02111 USA; BASF Inc, D-67056 Ludwigshafen, Germany; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Tufts University; United States Department of Agriculture (USDA); BASF; Tufts University	Wang, XD (corresponding author), Tufts Univ, Human Nutr Res Ctr Aging, Nutrit & Canc Biol Lab, Jean Mayer US Dept Agr, 711 Washington St, Boston, MA 02111 USA.	xiang-dong.wang@tufts.edu			NCI NIH HHS [R01 CA104932, R01CA104932] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104932] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boileau AC, 1999, J NUTR, V129, P1176, DOI 10.1093/jn/129.6.1176; Boulanger A, 2003, FASEB J, V17, P1304, DOI 10.1096/fj.02-0690fje; Giovannucci E, 2002, EXP BIOL MED, V227, P852, DOI 10.1177/153537020222701003; GOODMAN DS, 1965, SCIENCE, V149, P879, DOI 10.1126/science.149.3686.879; HAMEL CP, 1993, J BIOL CHEM, V268, P15751; Kiefer C, 2001, J BIOL CHEM, V276, P14110, DOI 10.1074/jbc.M011510200; Kloer DP, 2005, SCIENCE, V308, P267, DOI 10.1126/science.1108965; Leuenberger MG, 2001, ANGEW CHEM INT EDIT, V40, P2614, DOI 10.1002/1521-3773(20010716)40:14<2613::AID-ANIE2613>3.0.CO;2-Z; Lian F, 2005, FASEB J, V19, pA1458; Lindqvist A, 2002, J BIOL CHEM, V277, P23942, DOI 10.1074/jbc.M202756200; Lindqvist A, 2005, J HISTOCHEM CYTOCHEM, V53, P1403, DOI 10.1369/jhc.5A6705.2005; Liu C, 2006, J NUTR, V136, P106, DOI 10.1093/jn/136.1.106; Liu C, 2003, CANCER RES, V63, P3138; OLSON JA, 1965, P NATL ACAD SCI USA, V54, P1364, DOI 10.1073/pnas.54.5.1364; Paik J, 2001, J BIOL CHEM, V276, P32160, DOI 10.1074/jbc.M010086200; Poliakov E, 2005, J BIOL CHEM, V280, P29217, DOI 10.1074/jbc.M500409200; Prakash P, 2004, J NUTR, V134, P667, DOI 10.1093/jn/134.3.667; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; Ruch S, 2005, MOL MICROBIOL, V55, P1015, DOI 10.1111/j.1365-2958.2004.04460.x; Schwartz SH, 1997, SCIENCE, V276, P1872, DOI 10.1126/science.276.5320.1872; SHARMA RV, 1977, BIOCHIM BIOPHYS ACTA, V486, P183, DOI 10.1016/0005-2760(77)90083-2; Suzuki T, 1995, J NUTR SCI VITAMINOL, V41, P575, DOI 10.3177/jnsv.41.575; TANG GW, 1991, BIOCHEMISTRY-US, V30, P9829, DOI 10.1021/bi00105a003; Tibaduiza EC, 2002, J NUTR, V132, P1368, DOI 10.1093/jn/132.6.1368; von Lintig J, 2001, ARCH BIOCHEM BIOPHYS, V385, P47, DOI 10.1006/abbi.2000.2096; Wang XD, 1996, J BIOL CHEM, V271, P26490, DOI 10.1074/jbc.271.43.26490; Wang XD, 2004, OXIDAT STRESS DIS, V13, P313; WANG XD, 1991, ARCH BIOCHEM BIOPHYS, V285, P8, DOI 10.1016/0003-9861(91)90322-A; WANG XD, 1995, GASTROENTEROLOGY, V108, P719, DOI 10.1016/0016-5085(95)90444-1; Wang XD, 1999, J NATL CANCER I, V91, P60, DOI 10.1093/jnci/91.1.60; WANG XD, 1992, AM J PHYSIOL, V263, pG480, DOI 10.1152/ajpgi.1992.263.4.G480; WANG XD, 2005, CAROTENOIDS RETINOID, P168; Winum JY, 1997, FARMACO, V52, P39; Wyss A, 2000, BIOCHEM BIOPH RES CO, V271, P334, DOI 10.1006/bbrc.2000.2619	34	175	178	1	19	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19327	19338		10.1074/jbc.M512095200	http://dx.doi.org/10.1074/jbc.M512095200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16672231	Green Accepted, hybrid			2022-12-25	WOS:000238847000048
J	Vila-Carriles, WH; Kovacs, GG; Jovov, B; Zhou, ZH; Pahwa, AK; Colby, G; Esimai, O; Gillespie, GY; Mapstone, TB; Markert, JM; Fuller, CM; Bubien, JK; Benos, DJ				Vila-Carriles, Wanda H.; Kovacs, Gergely Gy; Jovov, Biljana; Zhou, Zhen-Hong; Pahwa, Amit K.; Colby, Garrett; Esimai, Ogenna; Gillespie, G. Yancey; Mapstone, Timothy B.; Markert, James M.; Fuller, Catherine M.; Bubien, James K.; Benos, Dale J.			Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSING ION CHANNELS; EPITHELIAL SODIUM-CHANNELS; CYSTIC-FIBROSIS; MALIGNANT GLIOMA; PHENYLBUTYRATE; CONTRIBUTES; 4-PHENYLBUTYRATE; DELTA-F508-CFTR; TRAFFICKING; CONDUCTANCE	Gliomas are primary brain tumors with a complex biology characterized by antigenic and genomic heterogeneity and a propensity for invasion into normal brain tissue. High grade glioma cells possess a voltage-independent, amiloride-inhibitable, inward Na+ current. This current does not exist in normal astrocytes or low grade tumor cells. Inhibition of this conductance decreases glioma growth and cell migration making it a potential therapeutic target. Our previous results have shown that the acid-sensing ion channels (ASICs), members of the epithelial Na+ channel (ENaC)/degenerin (DEG) family of ion channels are part of this current pathway. We hypothesized that one member of the ENaC/DEG family, ASIC2, is retained intracellularly and that it is the lack of functional expression of ASIC2 at the cell surface that results in hyperactivity of this conductance in high grade gliomas. In this study we show that the chemical chaperone, glycerol, and the transcriptional regulator, sodium 4-phenylbutyrate, inhibit the constitutively activated inward current and reduce cell growth and migration in glioblastoma multiforme. The results suggest that these compounds induce the movement of ASIC2 to the plasma membrane, and once there, the basally active inward current characteristic of glioma cells is abolished by inherent negative regulatory mechanisms. This in turn compromises the ability of the glioma cell to migrate and proliferate. These results support the hypothesis that the conductance pathway in high grade glioma cells is comprised of ENaC/DEG subunits and that abolishing this channel activity promotes a reversion of a high grade glioma cell to a phenotype resembling that of normal astrocytes.	Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama, Dept Surg, Birmingham, AL 35294 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Neurosurg, Oklahoma City, OK 73104 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Oklahoma System; University of Oklahoma Health Sciences Center	Benos, DJ (corresponding author), Univ Alabama, Dept Physiol & Biophys, 1918 Univ Blvd,MCLM 704, Birmingham, AL 35294 USA.	benos@physiology.uab.edu	Fuller, Cathy/B-4046-2011	Gillespie, George/0000-0001-6436-9542	NCI NIH HHS [CA101952, P50 CA97247] Funding Source: Medline; NIDDK NIH HHS [DK37206, R01 DK037206] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA097247, R01CA101952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037206, R56DK037206] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baker MJ, 2002, J NEURO-ONCOL, V59, P239, DOI 10.1023/A:1019905127442; Baron A, 2002, J PHYSIOL-LONDON, V539, P485, DOI 10.1113/jphysiol.2001.014837; Berdiev BK, 2003, J BIOL CHEM, V278, P15023, DOI 10.1074/jbc.M300991200; Brown CR, 1997, J BIOENERG BIOMEMBR, V29, P491, DOI 10.1023/A:1022491124939; Brown CR, 1997, J CLIN INVEST, V99, P1432, DOI 10.1172/JCI119302; Bubien JK, 2004, AM J PHYSIOL-CELL PH, V287, pC1282, DOI 10.1152/ajpcell.00077.2004; Bubien JK, 1999, AM J PHYSIOL-CELL PH, V276, pC1405, DOI 10.1152/ajpcell.1999.276.6.C1405; Carducci MA, 1996, CLIN CANCER RES, V2, P379; CHENG SH, 1995, AM J PHYSIOL-LUNG C, V268, pL615, DOI 10.1152/ajplung.1995.268.4.L615; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; Engelhard HH, 1998, J NEURO-ONCOL, V37, P97, DOI 10.1023/A:1005865125588; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Jovov B, 2003, HISTOCHEM CELL BIOL, V119, P437, DOI 10.1007/s00418-003-0525-4; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Leonard AS, 2003, P NATL ACAD SCI USA, V100, P2029, DOI 10.1073/pnas.252782799; Loffing J, 1999, AM J PHYSIOL-LUNG C, V277, pL700, DOI 10.1152/ajplung.1999.277.4.L700; Paukert M, 2004, J BIOL CHEM, V279, P18783, DOI 10.1074/jbc.M401477200; Price MP, 2004, J BIOL CHEM, V279, P53886, DOI 10.1074/jbc.M407708200; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rubenstein RC, 1997, J CLIN INVEST, V100, P2457, DOI 10.1172/JCI119788; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Skach WR, 2000, KIDNEY INT, V57, P825, DOI 10.1046/j.1523-1755.2000.00921.x; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Tamarappoo BK, 1999, J BIOL CHEM, V274, P34825, DOI 10.1074/jbc.274.49.34825; Valentijn JA, 1998, J BIOL CHEM, V273, P30344, DOI 10.1074/jbc.273.46.30344; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Yermolaieva O, 2004, P NATL ACAD SCI USA, V101, P6752, DOI 10.1073/pnas.0308636100; Zeitlin PL, 2002, MOL THER, V6, P119, DOI 10.1006/mthe.2002.0639	30	73	73	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19220	19232		10.1074/jbc.M603100200	http://dx.doi.org/10.1074/jbc.M603100200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16704974	hybrid			2022-12-25	WOS:000238847000036
J	Wang, TG; Zhang, W; Pei, Z; Block, M; Wilson, B; Reece, JM; Miller, DS; Hong, JS				Wang, Tongguang; Zhang, Wei; Pei, Zhong; Block, Michelle; Wilson, Belinda; Reece, Jeffrey M.; Miller, David S.; Hong, Jau-Shyong			Reactive microgliosis participates in MPP+-induced dopaminergic neurodegeneration: role of 67 kDa laminin receptor	FASEB JOURNAL			English	Article						laminin receptor; extracellular matrix; microglia; neuron; MPP; Parkinson's disease	LIPOPOLYSACCHARIDE-INDUCED NEUROTOXICITY; PARKINSONS-DISEASE; EXTRACELLULAR-MATRIX; ALPHA-6-BETA-1 INTEGRIN; NADPH OXIDASE; ACTIVATION; CELLS; INFLAMMATION; EXPRESSION; PROTEIN	It has been reported that extracellular matrix (ECM) molecules regulate monocyte activation by binding with a 67 kDa nonintegrin laminin receptor (LR). As microgliosis is a pivotal factor in propelling the progress of chronic neurodegeneration in the brain, we hypothesized that LR may regulate the microgliosis and subsequent neurotoxicity. Using 1-methyl-4-phenylpyridinium (MPP+)- treated C57 mice primary mesencephalic neuron-glia cultures as an in vitro Parkinson's disease (PD) model, we observed that MPP+ treatment increased LR expression only in the mixed neuron-glia but not in microglia-enriched or microglia-depleted cultures, indicating that MPP+-induced increase of LR expression is associated with neuron-microglia interaction. Using confocal microscopic examination, we found that LR was localized in the microglia, which were F4/80 positive. Treatment with the antibody ( Ab) against LR (LR-Ab) or YIGSR, a synthetic pentapeptide inhibitor for LR, significantly attenuated the MPP+-increased F4/80 immunoreactivity ( 24 h) and dopaminergic (DA) neurotoxicity. LR-Ab also attenuated MPP+-increased microglial phagocytotic activity ( 48 h) and the superoxide production ( 4 days). Further study demonstrated that exogenous laminin (1 - 10 mu g/ml) treatment induced microglial activation and DA neurotoxicity, in a dose-dependent manner, which was partially attenuated by the LR-Ab. We concluded that by regulating cell-ECM interaction, LR plays important roles in mediating microgliosis and subsequent DA neurotoxicity. Laminin is a potential ligand for activating this LR receptor. This study also suggests that laminin/LR is a potential target for developing new therapeutic drugs against neurodegenerative disorders such as PD.	Natl Inst Environm Hlth Sci, Neuropharmacol Sect, Lab Pharmacol & Chem, Natl Inst Hlth, Res Triangle Pk, NC USA; Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Hand Surg, Union Hosp, Wuhan 430074, Peoples R China; Natl Inst Environm Hlth Sci, Conofocal Microscopy Ctr, Lab Signal Transduct, Natl Inst Hlth, Res Triangle Pk, NC USA; Natl Inst Environm Hlth Sci, Lab Pharmacol & Chem, Natl Inst Hlth, Res Triangle Pk, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Huazhong University of Science & Technology; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wang, TG (corresponding author), Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21287 USA.	twang40@jhmi.edu	Hong, Jau-shyong/F-1920-2019	Hong, Jau-shyong/0000-0002-3056-8401; Block, Michelle/0000-0001-8303-7914	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090082, ZIAES080060, ZIAES080048, Z01ES080060, Z01ES080048, Z01ES090082] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ardini E, 1997, J BIOL CHEM, V272, P2342; Ardini E, 2002, CANCER RES, V62, P1321; Baloui H, 2004, EUR J NEUROSCI, V20, P2605, DOI 10.1111/j.1460-9568.2004.03728.x; Canfield SM, 1999, J IMMUNOL, V163, P3430; CHAMAK B, 1991, NEUROSCIENCE, V45, P513, DOI 10.1016/0306-4522(91)90267-R; Chen J, 2003, P NATL ACAD SCI USA, V100, P14000, DOI 10.1073/pnas.2334584100; Cherepanova O A, 2003, Tsitologiia, V45, P271; Cho BP, 2003, CELL MOL NEUROBIOL, V23, P551, DOI 10.1023/A:1025024129946; Conant K, 1999, ANN NEUROL, V46, P391, DOI 10.1002/1531-8249(199909)46:3<391::AID-ANA15>3.0.CO;2-0; Donaldson Elaine A., 2000, Molecular Cell Biology Research Communications, V3, P53, DOI 10.1006/mcbr.2000.0191; Gao HM, 2003, FASEB J, V17, DOI 10.1096/fj.03-0109fje; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; GIULIAN D, 1993, GLIA, V7, P102, DOI 10.1002/glia.440070116; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Kohutnicka M, 1998, IMMUNOPHARMACOLOGY, V39, P167, DOI 10.1016/S0162-3109(98)00022-8; Liu B, 2000, NEUROSCIENCE, V97, P749, DOI 10.1016/S0306-4522(00)00057-9; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Lorenzl S, 2002, EXP NEUROL, V178, P13, DOI 10.1006/exnr.2002.8019; MARTIGNONE S, 1993, J NATL CANCER I, V85, P398, DOI 10.1093/jnci/85.5.398; MCGEER PL, 1988, ANN NEUROL, V24, P574, DOI 10.1002/ana.410240415; McGeer PL, 2001, ADV NEUROL, V86, P83; MECHAM RP, 1989, J BIOL CHEM, V264, P16652; Milner R, 2003, J IMMUNOL, V170, P3850, DOI 10.4049/jimmunol.170.7.3850; Milner R, 2002, J NEUROSCI, V22, P1562, DOI 10.1523/JNEUROSCI.22-05-01562.2002; MONNING U, 1995, J BIOL CHEM, V270, P7104, DOI 10.1074/jbc.270.13.7104; Montuori N, 1999, CLIN CANCER RES, V5, P1465; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Peterszegi G, 1997, ATHEROSCLEROSIS, V135, P103, DOI 10.1016/S0021-9150(97)00155-X; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Ringheim GE, 2004, J NEUROIMMUNOL, V147, P43, DOI 10.1016/j.jneuroim.2003.10.013; ROMANOV V, 1994, CELL ADHES COMMUN, V2, P201, DOI 10.3109/15419069409004438; Schneider B, 2003, P NATL ACAD SCI USA, V100, P13326, DOI 10.1073/pnas.2235648100; Simoneau S, 2003, BIOL CHEM, V384, P243, DOI 10.1515/BC.2003.027; SINGER II, 1989, J CELL BIOL, V109, P3169, DOI 10.1083/jcb.109.6.3169; Tan AS, 2000, J IMMUNOL METHODS, V238, P59, DOI 10.1016/S0022-1759(00)00156-3; Wang TG, 2004, J NEUROIMMUNOL, V147, P68, DOI 10.1016/j.jneuroim.2003.10.040; Wang TG, 2004, J PHARMACOL EXP THER, V308, P975, DOI 10.1124/jpet.103.059683; Wang TG, 2004, J NEUROCHEM, V88, P939, DOI 10.1046/j.1471-4159.2003.02242.x; Zhang W, 2005, FASEB J, V19, P533, DOI 10.1096/fj.04-2751com	40	30	33	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					906	915		10.1096/fj.05-5053com	http://dx.doi.org/10.1096/fj.05-5053com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675848				2022-12-25	WOS:000240157700013
J	Wen, XF; Yang, G; Mao, W; Thornton, A; Liu, J; Bast, RC; Le, XF				Wen, X-F; Yang, G.; Mao, W.; Thornton, A.; Liu, J.; Bast, R. C., Jr.; Le, X-F			HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy	ONCOGENE			English	Article						HER2; trastuzumab; TSP-1; IL-8; VEGF; p38; PI3K; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; METASTATIC BREAST-CANCER; KINASE INHIBITOR P27(KIP1); RECEPTOR TYROSINE KINASES; CELL-CYCLE ARREST; P38 MAP KINASE; TUMOR-GROWTH; ANTI-HER2 ANTIBODY; UP-REGULATION; IN-VITRO	We determined the impact of HER2 signaling on two proangiogenic factors, vascular endothelial growth factor ( VEGF) and interleukin-8(IL-8), and on an antiangiogenic factor, thrombospondin-1 (TSP-1). Re-expression of HER2 in MCF-7 and T-47D breast cancer cells that endogenously express low levels of HER2 resulted in elevated expression of VEGF and IL-8 and decreased expression of TSP-1. Inhibition of HER2 with a humanized anti-HER2 antibody ( trastuzumab, or Herceptin (R)) or a retrovirus-mediated small interfering RNA against HER2 (siHER2) decreased VEGF and IL-8 expression, but increased TSP-1 expression in BT474 breast cancer cells that express high levels of HER2. These in vitro results were further evaluated by treatment of BT474 xenografts in immunosuppressed mice with trastuzumab. Trastuzumab inhibited growth of BT474 xenografts and decreased microvascular density associated with down-regulation of VEGF and IL-8 and with upregulation of TSP-1 expression. Inhibiting the PI3K-AKT pathway decreased VEGF and IL-8 expression. AKT1 overexpession increased VEGF and IL-8 expression, but did not increase TSP- 1 expression. A p38 kinase inhibitor, SB203580, instead blocked TSP- 1 expression and a p38 activator, MKK6, increased TSP- 1 expression. Trastuzumab stimulated sustained p38 activation and SB203580 attenuated the TSP- 1 upregulation induced by trastuzumab. HER2 signaling therefore influences the equilibrium between pro- and antiangiogenic factors via distinct signaling pathways. Trastuzumab inhibits angiogenesis and tumor growth, at least in part, through activation of the HER2-p38-TSP-1 pathway and inhibition of the HER2-PI3K-AKT-VEGF/IL-8 pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Div Canc Med,Unit 355, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Le, XF (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Div Canc Med,Unit 355, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rbast@mdanderson.org; xfle@mdanderson.org	Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	NCI NIH HHS [CA39930, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA039930] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bagheri-Yarmand R, 2000, J BIOL CHEM, V275, P39451, DOI 10.1074/jbc.M006150200; Bar-Eli M, 1999, PATHOBIOLOGY, V67, P12, DOI 10.1159/000028045; Baselga J, 2004, SEMIN ONCOL, V31, P51, DOI 10.1053/j.seminoncol.2004.07.022; Baselga J, 1998, CANCER RES, V58, P2825; Benoy IH, 2004, CLIN CANCER RES, V10, P7157, DOI 10.1158/1078-0432.CCR-04-0812; Bulavin DV, 2004, ADV CANCER RES, V92, P95, DOI 10.1016/S0065-230X(04)92005-2; Chelouche-Lev D, 2004, EUR J CANCER, V40, P2509, DOI 10.1016/j.ejca.2004.05.024; Chen JJW, 2003, CLIN CANCER RES, V9, P729; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Crown J, 2003, BREAST CANCER RES TR, V79, pS11; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; De Larco JE, 2001, AM J PATHOL, V158, P639, DOI 10.1016/S0002-9440(10)64005-9; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Finn Richard S, 2003, Cancer Chemother Biol Response Modif, V21, P223; Freund A, 2003, ONCOGENE, V22, P256, DOI 10.1038/sj.onc.1206113; Green AR, 1997, INT J CANCER, V72, P937; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harmey JH, 2002, BIOESSAYS, V24, P280, DOI 10.1002/bies.10043; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kos KS, 2003, CANCER-AM CANCER SOC, V98, P1377, DOI 10.1002/cncr.11656; Kumar R, 2001, SEMIN ONCOL, V28, P27, DOI 10.1016/S0093-7754(01)90279-9; Le XF, 2005, CELL CYCLE, V4, P87, DOI 10.4161/cc.4.1.1360; Le XF, 2005, J BIOL CHEM, V280, P2092, DOI 10.1074/jbc.M403080200; Le XF, 2003, J BIOL CHEM, V278, P23441, DOI 10.1074/jbc.M300848200; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Le XF, 2000, CANCER RES, V60, P3522; Loureiro RMB, 2005, BIOCHEM BIOPH RES CO, V326, P455, DOI 10.1016/j.bbrc.2004.11.053; Marmor MD, 2004, INT J RADIAT ONCOL, V58, P903, DOI 10.1016/j.ijrobp.2003.06.002; Miller KD, 2005, J CLIN ONCOL, V23, P792, DOI 10.1200/JCO.2005.05.098; Nahta R, 2003, CLIN CANCER RES, V9, P5078; Naito T, 2004, AM J PHYSIOL-RENAL, V286, pF278, DOI 10.1152/ajprenal.00139.2003; Pegram MD, 2002, SEMIN ONCOL, V29, P29, DOI 10.1053/sonc.2002.34053; Petit AMV, 1997, AM J PATHOL, V151, P1523; Price DJ, 2001, CELL GROWTH DIFFER, V12, P129; Ribatti D, 1998, INT J CANCER, V77, P449; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Rofstad EK, 2002, BRIT J CANCER, V86, P301, DOI 10.1038/sj.bjc.6600052; Sargiannidou I, 2001, EXP BIOL MED, V226, P726, DOI 10.1177/153537020222600803; Shahied LS, 2004, J BIOL CHEM, V279, P53907, DOI 10.1074/jbc.M407888200; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Spiridon CI, 2004, CLIN CANCER RES, V10, P3542, DOI 10.1158/1078-0432.CCR-03-0549; Stein Steven, 2004, Clin Breast Cancer, V4 Suppl 3, pS117, DOI 10.3816/CBC.2004.s.005; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Xiong SB, 2001, CANCER RES, V61, P1727; Yang G, 2004, J BIOL CHEM, V279, P4339, DOI 10.1074/jbc.M311153200; Yen L, 2002, MOL BIOL CELL, V13, P4029, DOI 10.1091/mbc.e02-02-0084; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Zhang HT, 2003, CANCER BIOL THER, V2, pS122	55	131	135	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	52					6986	6996		10.1038/sj.onc.1209685	http://dx.doi.org/10.1038/sj.onc.1209685			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16715132				2022-12-25	WOS:000241732300009
J	Palacios, G; Moll, UM				Palacios, G.; Moll, U. M.			Mitochondrially targeted wild-type p53 suppresses growth of mutant p53 lymphomas in vivo	ONCOGENE			English	Article						p53; apoptosis; mitochondria; E mu-Myc lymphoma	MEMBRANE PERMEABILIZATION; GENE-THERAPY; APOPTOSIS; TRANSLOCATION; DEATH; PROTEIN; CELLS; BAX; DISRUPTION; ACTIVATION	The complex apoptotic functions of the p53 tumor suppressor are central to its antineoplastic activity in vivo. Besides its well-known action as a transcriptional activator of apoptotic genes, p53 exerts a direct proapoptotic role at the mitochondria via protein-protein interactions with Bcl2 family members, thus executing the shortest known circuitry of p53 death signaling. We recently reported that exclusive delivery of p53 to mitochondria exerts a significant in vivo tumor suppressor activity in p53-null lymphomas. However, it was unknown whether mitochondrially targeted p53 has suppressor activities in tumors harboring missense mutants, which constitute the vast majority of p53 alterations in human tumors. Here, we show that targeting p53 to mitochondria does confer a significant growth disadvantage in B-lymphomas expressing various point mutants of p53, resulting in efficient apoptosis induction in vitro and in vivo in mice.	SUNY Stony Brook, Stony Brook Univ, Dept Pathol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Moll, UM (corresponding author), SUNY Stony Brook, Stony Brook Univ, Dept Pathol, BSTL9,Room 134, Stony Brook, NY 11794 USA.	umoll@notes.cc.sunysb.edu						Arima Y, 2005, J BIOL CHEM, V280, P19166, DOI 10.1074/jbc.M410691200; Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Erster S, 2005, BIOCHEM BIOPH RES CO, V331, P843, DOI 10.1016/j.bbrc.2005.03.187; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Essmann F, 2005, J BIOL CHEM, V280, P37169, DOI 10.1074/jbc.M502052200; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Lim DS, 2006, HUM GENE THER, V17, P347, DOI 10.1089/hum.2006.17.347; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Nemajerova A, 2005, FEBS LETT, V579, P6079, DOI 10.1016/j.febslet.2005.09.074; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Peng ZH, 2005, HUM GENE THER, V16, P1016, DOI 10.1089/hum.2005.16.1016; PETROS AM, 2004, FEBS LETT, P1; Roth JA, 2006, EXPERT OPIN BIOL TH, V6, P55, DOI 10.1517/14712598.6.1.55; Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1; Sauthoff H, 2006, CANCER GENE THER, V13, P686, DOI 10.1038/sj.cgt.7700936; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Talos F, 2005, CANCER RES, V65, P9971, DOI 10.1158/0008-5472.CAN-05-1084; Yin SM, 2006, INT J ONCOL, V28, P781; Zhao YF, 2005, CANCER RES, V65, P3745, DOI 10.1158/0008-5472.CAN-04-3835	30	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6133	6139		10.1038/sj.onc.1209641	http://dx.doi.org/10.1038/sj.onc.1209641			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16682948				2022-12-25	WOS:000241101200011
J	An, BS; Selva, DM; Hammond, GL; Rivero-Muller, A; Rahman, N; Leung, PCK				An, Beum-Soo; Selva, David M.; Hammond, Geoffrey L.; Rivero-Muller, Adolfo; Rahman, Nafis; Leung, Peter C. K.			Steroid receptor coactivator-3 is required for progesterone receptor trans-activation of target genes in response to gonadotropin-releasing hormone treatment of pituitary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDEPENDENT ACTIVATION; NUCLEAR-RECEPTOR; PROTEIN-KINASE; SIGNALING PATHWAYS; TRANSCRIPTIONAL ACTIVATION; PHOSPHORYLATION SITES; CROSS-TALK; GNRH-II; A-FORM; BINDING	Regulation of gonadotropin production involves interplay between steroids and neuropeptides, and we have examined the effects of gonadotropin-releasing hormones ( GnRH I and GnRH II) on progesterone receptor ( PR) activation in alpha T3-1 pituitary cells. Treatment with GnRHs activated a progesterone response element ( PRE)-luciferase reporter gene, and this was blocked by protein kinase C and protein kinase A inhibitors but not by RU486. Treatment with GnRHs phosphorylated the PR at Ser(294) and increased PR translocation to the nucleus within 1 h. Interactions between the PR and several coactivators were examined, and treatment with GnRHs specifically induced PR-steroid receptor coactivator-3 ( SRC-3) interactions within 8 h. In chromatin immunoprecipitation assays, recruitment of PR and SRC-3 by the PREs of the luciferase reporter gene or the gonadotopin alpha-subunit gene promoter was also increased by GnRHs within 8 h, while progesterone-induced recruitment of PR to the PREs occurred in association with much less SRC-3. A small interfering RNA knockdown of type I GnRH receptor levels reduced PR activation by GnRHs, while progesterone-dependent PR activation was unaffected. Moreover, small interfering RNA knockdown of SRC-3 abolished PRE-luciferase trans-activation by the PR in response to GnRHs. Collectively, these data indicate that PR activation by GnRHs in alpha T3-1 cells is type I GnRH receptor-mediated and that trans-activation of PR-responsive genes requires SRC-3 in this context.	Univ British Columbia, Dept Obstet & Gynecol, Child & Family Res Inst, Vancouver, BC V6H 3V5, Canada; Univ Turku, Inst Biomed, Dept Physiol, FIN-20520 Turku, Finland	Child & Family Research Institute; University of British Columbia; University of Turku	Leung, PCK (corresponding author), Univ British Columbia, Dept Obstet & Gynecol, Child & Family Res Inst, 2H-30,4490 Oak St, Vancouver, BC V6H 3V5, Canada.	peleung@interchange.ubc.ca	Selva, David Martínez/O-6444-2016; Rivero-Muller, Adolfo/A-5120-2008	Rivero-Muller, Adolfo/0000-0002-9794-802X; Hammond, Geoffrey/0000-0002-4639-7336; Leung, Peter/0000-0003-3152-3800				Alen P, 1999, MOL ENDOCRINOL, V13, P117, DOI 10.1210/me.13.1.117; Chappell PE, 1999, ENDOCRINOLOGY, V140, P3653, DOI 10.1210/en.140.8.3653; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cheng CK, 2005, ENDOCR REV, V26, P283, DOI 10.1210/er.2003-0039; FINK G, 1995, FRONT NEUROENDOCRIN, V16, P183, DOI 10.1006/frne.1995.1006; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Islami D, 2001, MOL HUM REPROD, V7, P3, DOI 10.1093/molehr/7.1.3; Kaiser UB, 1997, ENDOCR REV, V18, P46, DOI 10.1210/er.18.1.46; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Labriola L, 2003, MOL CELL BIOL, V23, P1095, DOI 10.1128/MCB.23.3.1095-1111.2003; Lange CA, 2004, MOL ENDOCRINOL, V18, P269, DOI 10.1210/me.2003-0331; MANI SK, 1994, SCIENCE, V265, P1246, DOI 10.1126/science.7915049; MATKOVITS T, 1995, MOL ENDOCRINOL, V9, P232, DOI 10.1210/me.9.2.232; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; MCDONNELL DP, 1994, J STEROID BIOCHEM, V48, P425, DOI 10.1016/0960-0760(94)90190-2; Millar R, 2001, P NATL ACAD SCI USA, V98, P9636, DOI 10.1073/pnas.141048498; MILLAR RP, 1986, ENDOCRINOLOGY, V119, P224, DOI 10.1210/endo-119-1-224; Morgan K, 2004, GEN COMP ENDOCR, V139, P191, DOI 10.1016/j.ygcen.2004.09.015; Neill JD, 2001, BIOCHEM BIOPH RES CO, V282, P1012, DOI 10.1006/bbrc.2001.4678; Pierson-Mullany LK, 2004, MOL CELL BIOL, V24, P10542, DOI 10.1128/MCB.24.24.10542-10557.2004; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; Qiu M, 2003, MOL ENDOCRINOL, V17, P628, DOI 10.1210/me.2002-0378; Qutob MS, 2002, MOL CELL BIOL, V22, P6611, DOI 10.1128/MCB.22.18.6611-6626.2002; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; SARTORIUS CA, 1994, MOL ENDOCRINOL, V8, P1347, DOI 10.1210/me.8.10.1347; Shupnik MA, 1996, BIOL REPROD, V54, P279, DOI 10.1095/biolreprod54.2.279; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Stanislaus D, 1998, MOL CELL ENDOCRINOL, V144, P1, DOI 10.1016/S0303-7207(98)00126-9; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TURGEON JL, 1994, MOL ENDOCRINOL, V8, P860, DOI 10.1210/me.8.7.860; TURGEON JL, 1986, ENDOCRINOLOGY, V118, P2053, DOI 10.1210/endo-118-5-2053; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; WARING DW, 1992, ENDOCRINOLOGY, V130, P3275, DOI 10.1210/en.130.6.3275; Weck J, 1998, MOL ENDOCRINOL, V12, P451, DOI 10.1210/me.12.3.451; Wu RC, 2005, ENDOCR REV, V26, P393, DOI 10.1210/er.2004-0018; Wu RC, 2004, MOL CELL, V15, P937, DOI 10.1016/j.molcel.2004.08.019; Yi P, 2005, MOL CELL BIOL, V25, P9687, DOI 10.1128/MCB.25.21.9687-9699.2005; Zhang YX, 1997, MOL ENDOCRINOL, V11, P823, DOI 10.1210/me.11.6.823; ZHANG YX, 1995, MOL ENDOCRINOL, V9, P1029, DOI 10.1210/me.9.8.1029	41	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20817	20824		10.1074/jbc.M600743200	http://dx.doi.org/10.1074/jbc.M600743200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16728408	hybrid			2022-12-25	WOS:000239187300018
J	Protchenko, O; Rodriguez-Suarez, R; Androphy, R; Bussey, H; Philpott, CC				Protchenko, Olga; Rodriguez-Suarez, Roberto; Androphy, Rachel; Bussey, Howard; Philpott, Caroline C.			A screen for genes of heme uptake identifies the FLC family required for import of FAD into the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; GPI-ANCHORED PROTEINS; SACCHAROMYCES-CEREVISIAE; CANDIDA-ALBICANS; IRON-SOURCE; YEAST; GOLGI; TRANSPORT; GLYCOSYLATION; PATHWAY	Although Candida albicans and Saccharomyces cerevisiae express very similar systems of iron uptake, these species differ in their capacity to use heme as a nutritional iron source. Whereas C. albicans efficiently takes up heme, S. cerevisiae grows poorly on media containing heme as the sole source of iron. We identified a gene from C. albicans that would enhance heme uptake when expressed in S. cerevisiae. Overexpression of CaFLC1 ( for flavin carrier 1) stimulated the growth of S. cerevisiae on media containing heme iron. In C. albicans, deletion of both alleles of CaFLC1 resulted in a decrease in heme uptake activity, whereas overexpression of CaFLC1 resulted in an increase in heme uptake. The S. cerevisiae genome contains three genes with homology to CaFLC1, and two of these, termed FLC1 and FLC2, also stimulated growth on heme when overexpressed in S. cerevisiae. The S. cerevisiae Flc proteins were detected in the endoplasmic reticulum and the FLC genes encoded an essential function, as strains deleted for either FLC1 or FLC2 were viable, but deletion of both FLC1 and FLC2 was synthetically lethal. FLC gene deletion resulted in pleiotropic phenotypes related to defects in cell wall integrity. High copy suppressors of this synthetic lethality included three mannosyl-transferases, VAN1, KTR4, and HOC1. FLC deletion strains exhibited loss of cell wall mannose phosphates, defects in cell wall assembly, and delayed maturation of carboxypeptidase Y. Permeabilized cells lacking FLC proteins exhibited dramatic loss of FAD import activity. We propose that the FLC genes are required for import of FAD into the lumen of the endoplasmic reticulum, where it is required for disulfide bond formation.	NIDDK, Liver Dis Branch, NIH, Bethesda, MD 20892 USA; McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); McGill University	Philpott, CC (corresponding author), Bldg 10,Rm 9B-16,10 Ctr Dr,MSC 1800, Bethesda, MD 20892 USA.	carolinep@intra.niddk.nih.gov	Protchenko, Olga/AAU-9237-2021	Protchenko, Olga/0000-0002-4688-4214	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK054507, Z01DK054507] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Adams A, 1997, METHODS YEAST GENETI; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Bafunno V, 2004, J BIOL CHEM, V279, P95, DOI 10.1074/jbc.M308230200; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; Baxter BK, 1996, MOL CELL BIOL, V16, P6444; Bulik DA, 2003, EUKARYOT CELL, V2, P886, DOI 10.1128/EC.2.5.886-900.2003; Calderone RA, 2001, TRENDS MICROBIOL, V9, P327, DOI 10.1016/S0966-842X(01)02094-7; Care RS, 1999, MOL MICROBIOL, V34, P792, DOI 10.1046/j.1365-2958.1999.01641.x; Conde R, 2003, YEAST, V20, P1189, DOI 10.1002/yea.1032; Cullen PJ, 2000, GENETICS, V155, P1005; Davis D, 2000, INFECT IMMUN, V68, P5953, DOI 10.1128/IAI.68.10.5953-5959.2000; Dean N, 1997, J BIOL CHEM, V272, P31908, DOI 10.1074/jbc.272.50.31908; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; Eakanunkul S, 2005, BIOCHEMISTRY-US, V44, P13179, DOI 10.1021/bi050422r; Flandez M, 2004, J BIOL CHEM, V279, P11027, DOI 10.1074/jbc.M306412200; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; FRIIS J, 1970, CR TRAV LAB CARLSB, V37, P327; GALBRAITH RA, 1985, J BIOL CHEM, V260, P2198; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Griffith DA, 2003, FEBS LETT, V553, P45, DOI 10.1016/S0014-5793(03)00952-9; Hashimoto H, 1997, BIOCHEM BIOPH RES CO, V241, P682, DOI 10.1006/bbrc.1997.7888; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; Hsiang T, 2005, J MOL EVOL, V60, P475, DOI 10.1007/s00239-004-0218-1; JITSURONG S, 1993, MYCOPATHOLOGIA, V123, P95, DOI 10.1007/BF01365086; Jungmann J, 1998, EMBO J, V17, P423, DOI 10.1093/emboj/17.2.423; Kaiser CA, 2002, METHOD ENZYMOL, V351, P325; KAISER CA, 1997, MOL CELLULAR BIOL YE, P91; Lussier M, 1999, BBA-GEN SUBJECTS, V1426, P323, DOI 10.1016/S0304-4165(98)00133-0; Luz JM, 1998, BIOCHEM BIOPH RES CO, V248, P621, DOI 10.1006/bbrc.1998.8992; MANNS JM, 1994, INFECT IMMUN, V62, P5154, DOI 10.1128/IAI.62.11.5154-5156.1994; Mazmanian SK, 2003, SCIENCE, V299, P906, DOI 10.1126/science.1081147; Mills M, 1997, INFECT IMMUN, V65, P5358, DOI 10.1128/IAI.65.12.5358-5363.1997; Mnaimneh S, 2004, CELL, V118, P31, DOI 10.1016/j.cell.2004.06.013; Munro S, 2001, FEBS LETT, V498, P223, DOI 10.1016/S0014-5793(01)02488-7; Orlean P., 1997, MOL CELLULAR BIOL YE, P229; Palmer CP, 2005, BIOCHEM J, V387, P211, DOI 10.1042/BJ20041710; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Pendrak ML, 2004, ARCH BIOCHEM BIOPHYS, V426, P148, DOI 10.1016/j.abb.2004.02.006; Pendrak ML, 2004, J BIOL CHEM, V279, P3426, DOI 10.1074/jbc.M311550200; Philpott CC, 1998, EMBO J, V17, P5026, DOI 10.1093/emboj/17.17.5026; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Portnoy ME, 2000, MOL CELL BIOL, V20, P7893, DOI 10.1128/MCB.20.21.7893-7902.2000; Protchenko O, 2003, J BIOL CHEM, V278, P36582, DOI 10.1074/jbc.M306584200; Quigley JG, 2004, CELL, V118, P757, DOI 10.1016/j.cell.2004.08.014; Rao AU, 2005, P NATL ACAD SCI USA, V102, P4270, DOI 10.1073/pnas.0500877102; Reilly BA, 2001, MOL BIOL CELL, V12, P3783, DOI 10.1091/mbc.12.12.3783; Saito H, 2004, J BIOCHEM, V136, P267, DOI 10.1093/jb/mvh135; Santos R, 2004, MOL MICROBIOL, V54, P507, DOI 10.1111/j.1365-2958.2004.04281.x; Santos R, 2003, MICROBIOL-SGM, V149, P579, DOI 10.1099/mic.0.26108-0; Schneider BL, 1996, YEAST, V12, P129, DOI 10.1002/(SICI)1097-0061(199602)12:2<129::AID-YEA891>3.0.CO;2-O; Shayeghi M, 2005, CELL, V122, P789, DOI 10.1016/j.cell.2005.06.025; SHERMAN F, 1991, P3; Skaar EP, 2004, SCIENCE, V305, P1626, DOI 10.1126/science.1099930; Stearman R, 1998, GENE, V212, P197, DOI 10.1016/S0378-1119(98)00179-6; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; Sutterlin C, 1997, J CELL SCI, V110, P2703; Ter Linde JJM, 2002, YEAST, V19, P825, DOI 10.1002/yea.879; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Van Ho A, 2002, ANNU REV MICROBIOL, V56, P237, DOI 10.1146/annurev.micro.56.012302.160847; Varsanyi M, 2004, J BIOL CHEM, V279, P3370, DOI 10.1074/jbc.M307783200; Wang QQ, 1999, EMBO J, V18, P5972, DOI 10.1093/emboj/18.21.5972; Weissman Z, 2004, MOL MICROBIOL, V53, P1209, DOI 10.1111/j.1365-2958.2004.04199.x; Weissman Z, 2002, MOL MICROBIOL, V44, P1551, DOI 10.1046/j.1365-2958.2002.02976.x; Wilson RB, 2000, YEAST, V16, P65, DOI 10.1002/(SICI)1097-0061(20000115)16:1&lt;65::AID-YEA508&gt;3.0.CO;2-M; Wilson RB, 1999, J BACTERIOL, V181, P1868, DOI 10.1128/JB.181.6.1868-1874.1999; Yun CW, 2000, J BIOL CHEM, V275, P10709, DOI 10.1074/jbc.275.14.10709	73	55	62	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21445	21457		10.1074/jbc.M512812200	http://dx.doi.org/10.1074/jbc.M512812200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16717099	hybrid			2022-12-25	WOS:000239187300080
J	Chong, YH; Shin, YJ; Lee, EO; Kayed, R; Glabe, CG; Tenner, AJ				Chong, Young Hae; Shin, Yoo Jeong; Lee, Eun Ok; Kayed, Rakez; Glabe, Charles G.; Tenner, Andrea J.			ERK1/2 activation mediates A beta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; AMYLOID-INDUCED NEURODEGENERATION; HUMAN MONOCYTIC THP-1; ALZHEIMERS-DISEASE; IN-VIVO; CELL-DEATH; PROTEIN-KINASE; MAP KINASE; COGNITIVE DECLINE; NEURONS	In this study, we investigated the molecular basis for the altered signal transduction associated with soluble amyloid beta-protein (A beta) oligomer-mediated neurotoxicity in the hippocampus, which is primarily linked to cognitive dysfunction in Alzheimer disease (AD). As measured by media lactate dehydrogenase levels, and staining with propidium iodide, acute exposure to low micromolar concentrations of the A beta 1-42 oligomer significantly induced cell death. This was accompanied by activation of the ERK1/2 signal transduction pathway in rat organo-typic hippocampal slices. Notably, this resulted in caspase-3 activation by a process that led to proteolytic cleavage of Tau, which was recently confirmed to occur in AD brains. Tau cleavage likely occurred in the absence of overt synaptic loss, as suggested by the preserved levels of synaptophysin, a presynaptic marker. Moreover, among the pharmacological agents tested to inhibit several kinase cascades, only the ERK inhibitor significantly attenuated A beta 1-42 oligomer-induced toxicity concomitant with the reduction of activation of ERK1/2 and caspase-3 to a lesser extent. Importantly, the caspase-3 inhibitor also decreased A beta oligomer-induced cell death, with no appreciable effect on the ERK signaling pathway, although such treatment was effective in reducing caspase-3 activation and Tau cleavage. Therefore, these results suggest that local targeting of the ERK1/2 signaling pathway to reduce Tau cleavage, as occurs with the inhibition of caspase-3 activation, may modulate the neurotoxic effects of soluble A beta oligomer in the hippocampus and provide the rationale for symptomatic treatment of AD.	Ewha Womans Univ, Dept Microbiol, Coll Med, Div Mol Biol & Neurosci,Ewha Med Res Inst, Seoul 158710, South Korea; Univ Calif Irvine, Ctr Immunol, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	Ewha Womans University; University of California System; University of California Irvine	Chong, YH (corresponding author), Ewha Womans Univ, Dept Microbiol, Coll Med, Div Mol Biol & Neurosci,Ewha Med Res Inst, 911-1,Mok 6 Dong, Seoul 158710, South Korea.	younghae@ewha.ac.kr			NINDS NIH HHS [NS35144] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035144] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Backman L, 2001, BRAIN, V124, P96, DOI 10.1093/brain/124.1.96; Barr RK, 2002, J BIOL CHEM, V277, P10987, DOI 10.1074/jbc.M107565200; Bell KA, 2004, J NEUROCHEM, V91, P349, DOI 10.1111/j.1471-4159.2004.02722.x; Belmadani A, 2004, NEUROREPORT, V15, P2093, DOI 10.1097/00001756-200409150-00019; Braak E, 1997, ACTA NEUROPATHOL, V93, P323, DOI 10.1007/s004010050622; Chang L, 2003, J MOL NEUROSCI, V20, P305, DOI 10.1385/JMN:20:3:305; Chong YH, 2001, J BIOL CHEM, V276, P23511, DOI 10.1074/jbc.M009466200; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; Dineley KT, 2001, J NEUROSCI, V21, P4125, DOI 10.1523/JNEUROSCI.21-12-04125.2001; Ekinci FJ, 1999, J BIOL CHEM, V274, P30322, DOI 10.1074/jbc.274.42.30322; Fan R, 2004, EXP NEUROL, V185, P241, DOI 10.1016/j.expneurol.2003.09.023; Fasulo L, 2005, J ALZHEIMERS DIS, V7, P3; Ferreira A, 1997, MOL CELL NEUROSCI, V9, P220, DOI 10.1006/mcne.1997.0615; Funato H, 1999, AM J PATHOL, V155, P23, DOI 10.1016/S0002-9440(10)65094-8; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; Gandy S, 2005, J CLIN INVEST, V115, P1121, DOI 10.1172/JCI200525100; Georganopoulou DG, 2005, P NATL ACAD SCI USA, V102, P2273, DOI 10.1073/pnas.0409336102; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; Harwood SM, 2005, ANN CLIN BIOCHEM, V42, P415, DOI 10.1258/000456305774538238; Higuchi M, 2005, J BIOL CHEM, V280, P15229, DOI 10.1074/jbc.M500939200; Holopainen IE, 2003, NEUROSCIENCE, V118, P967, DOI 10.1016/S0306-4522(03)00046-0; Ivins KJ, 1999, J BIOL CHEM, V274, P2107, DOI 10.1074/jbc.274.4.2107; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kelly BL, 2005, J BIOL CHEM, V280, P31746, DOI 10.1074/jbc.M503259200; Kim HJ, 2004, NEUROREPORT, V15, P503, DOI 10.1097/00001756-200403010-00024; Kim HJ, 2002, FASEB J, V16, P118, DOI 10.1096/fj.01-0987fje; Klyubin I, 2004, EUR J NEUROSCI, V19, P2839, DOI 10.1111/j.1460-9568.2004.03389.x; Klyubin I, 2005, NAT MED, V11, P556, DOI 10.1038/nm1234; Kokubo H, 2005, BRAIN RES, V1031, P222, DOI 10.1016/j.brainres.2004.10.041; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lee EO, 2005, J BIOL CHEM, V280, P7845, DOI 10.1074/jbc.M409101200; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Li M, 2004, J NEUROCHEM, V91, P623, DOI 10.1111/j.1471-4159.2004.02765.x; Ma QL, 2006, J NEUROSCI RES, V83, P374, DOI 10.1002/jnr.20734; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Medina MG, 2005, EMBO J, V24, P1706, DOI 10.1038/sj.emboj.7600650; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; Noraberg J, 2005, CNS NEUROL DISORD-DR, V4, P435, DOI 10.2174/1568007054546108; NOVAK M, 1993, EMBO J, V12, P365, DOI 10.1002/j.1460-2075.1993.tb05665.x; Oddo S, 2006, J BIOL CHEM, V281, P1599, DOI 10.1074/jbc.M507892200; Paivio A, 2004, J MOL BIOL, V339, P145, DOI 10.1016/j.jmb.2004.03.028; Papucci L, 2004, CELL TISSUE RES, V316, P197, DOI 10.1007/s00441-004-0872-z; Park SY, 2005, J NEUROSCI, V25, P5365, DOI 10.1523/JNEUROSCI.1125-05.2005; Rapoport M, 2002, P NATL ACAD SCI USA, V99, P6364, DOI 10.1073/pnas.092136199; Rapoport M, 2000, J NEUROCHEM, V74, P125, DOI 10.1046/j.1471-4159.2000.0740125.x; Rissman RA, 2004, J CLIN INVEST, V114, P121, DOI 10.1172/JCI200420640; Sabbagh MN, 1999, ARCH NEUROL-CHICAGO, V56, P1458, DOI 10.1001/archneur.56.12.1458; Selcher JC, 2001, LEARN MEMORY, V8, P11, DOI 10.1101/lm.37001; Selcher JC, 2003, LEARN MEMORY, V10, P26, DOI 10.1101/lm.51103; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Stadelmann C, 1999, AM J PATHOL, V155, P1459, DOI 10.1016/S0002-9440(10)65460-0; Stine WB, 2003, J BIOL CHEM, V278, P11612, DOI 10.1074/jbc.M210207200; Takahashi RH, 2004, J NEUROSCI, V24, P3592, DOI 10.1523/JNEUROSCI.5167-03.2004; Tiraboschi P, 2000, NEUROLOGY, V55, P1278, DOI 10.1212/WNL.55.9.1278; Veeranna, 2004, AM J PATHOL, V165, P795, DOI 10.1016/S0002-9440(10)63342-1; Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010; Walsh DM, 2005, J NEUROSCI, V25, P2455, DOI 10.1523/JNEUROSCI.4391-04.2005; Wang QW, 2004, J NEUROSCI, V24, P3370, DOI 10.1523/JNEUROSCI.1633-03.2004; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P801, DOI 10.1001/archneur.57.6.801; Yao PJ, 2005, BIOCHEM BIOPH RES CO, V330, P34, DOI 10.1016/j.bbrc.2005.02.121; Zou JY, 2005, BRAIN RES, V1034, P11, DOI 10.1016/j.brainres.2004.11.014	64	146	154	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20315	20325		10.1074/jbc.M601016200	http://dx.doi.org/10.1074/jbc.M601016200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16714296	hybrid			2022-12-25	WOS:000239038200056
J	Schiavon, E; Sacco, T; Cassulini, RR; Gurrola, G; Tempia, F; Possani, LD; Wanke, E				Schiavon, Emanuele; Sacco, Tiziana; Cassulini, Rita Restano; Gurrola, Georgina; Tempia, Filippo; Possani, Lourival D.; Wanke, Enzo			Resurgent current and voltage sensor trapping enhanced activation by a beta-scorpion toxin solely in Na(v)1.6 channel - Significance in mice Purkinje neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTHRESHOLD SODIUM CURRENTS; CENTRUROIDES-NOXIUS HOFFMANN; MOLECULAR-MECHANISMS; SUBTHALAMIC NUCLEUS; FUNCTIONAL-ANALYSIS; ISOFORM NACH6; ANTIBODY BCF2; DOMAIN-II; SCULPTURATUS; EXPRESSION	Resurgent currents are functionally crucial in sustaining the high frequency firing of cerebellar Purkinje neurons expressing Na(V)1.6 channels. beta-Scorpion toxins, such as CssIV, induce a left shift in the voltage-dependent activation of Na(V)1.2 channels by "trapping" the IIS4 voltage sensor segment. We found that the dangerous Cn2 beta-scorpion peptide induces both the left shift voltage-dependent activation and a transient resurgent current only in human Nav1.6 channels (among 1.1 - 1.7), whereas CssIV did not induce the resurgent current. Cn2 also produced both actions in mouse Purkinje cells. These findings suggest that only distinct beta-toxins produce resurgent currents. We suggest that the novel and unique selectivity of Cn2 could make it a model drug to replace deep brain stimulation of the subthalamic nucleus in patients with Parkinson disease.	Univ Milan, Dipartimento Biotecnol & Biosci, I-20126 Milan, Italy; Univ Turin, Dept Neurosci, I-10126 Turin, Italy; Univ Nacl Autonoma Mexico, Inst Biotechnol, Dept Mol Med & Bioproc, Cuernavaca 62271, Morelos, Mexico	University of Milan; University of Turin; Universidad Nacional Autonoma de Mexico	Wanke, E (corresponding author), Univ Milan, Dipartimento Biotecnol & Biosci, Piazza Sci 2U3, I-20126 Milan, Italy.	enzo.wanke@unimib.it	Possani, Lourival D/J-2397-2013; Tempia, Filippo/A-5883-2012	Tempia, Filippo/0000-0003-2778-0943; Schiavon, Emanuele/0000-0002-4592-6961				Beurrier C, 2001, J NEUROPHYSIOL, V85, P1351, DOI 10.1152/jn.2001.85.4.1351; Boiko T, 2001, NEURON, V30, P91, DOI 10.1016/S0896-6273(01)00265-3; Burbidge SA, 2002, MOL BRAIN RES, V103, P80, DOI 10.1016/S0169-328X(02)00188-2; CAHALAN MD, 1975, J PHYSIOL-LONDON, V244, P511, DOI 10.1113/jphysiol.1975.sp010810; Calderon-Aranda ES, 1999, EUR J BIOCHEM, V264, P746, DOI 10.1046/j.1432-1327.1999.00620.x; Caldwell JH, 2000, P NATL ACAD SCI USA, V97, P5616, DOI 10.1073/pnas.090034797; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6; Cestele S, 2001, J GEN PHYSIOL, V118, P291, DOI 10.1085/jgp.118.3.291; Cestele S, 2000, BIOCHIMIE, V82, P883, DOI 10.1016/S0300-9084(00)01174-3; Cha A, 1999, NEURON, V22, P73, DOI 10.1016/S0896-6273(00)80680-7; Cohen L, 2005, J BIOL CHEM, V280, P5045, DOI 10.1074/jbc.M408427200; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; Do MTH, 2003, NEURON, V39, P109, DOI 10.1016/S0896-6273(03)00360-X; Do MTH, 2004, J NEUROPHYSIOL, V92, P726, DOI 10.1152/jn.00186.2004; Drouot' X, 2004, NEURON, V44, P769, DOI 10.1016/j.neuron.2004.11.023; Goldin AL, 2001, ANNU REV PHYSIOL, V63, P871, DOI 10.1146/annurev.physiol.63.1.871; Grieco TM, 2005, NEURON, V45, P233, DOI 10.1016/j.neuron.2004.12.035; Gullo F, 2002, FASEB J, V16, P330, DOI 10.1096/fj.02-0200fje; Herzog RI, 2003, J PHYSIOL-LONDON, V551, P741, DOI 10.1113/jphysiol.2003.047357; Hille B., 2001, ION CHANNELS EXCITAB, P635; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; KLUGBAUER N, 1995, EMBO J, V14, P1084, DOI 10.1002/j.1460-2075.1995.tb07091.x; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krack P, 1998, BRAIN, V121, P451, DOI 10.1093/brain/121.3.451; Krzemien DM, 2000, J COMP NEUROL, V420, P70; KUO CC, 1994, NEURON, V12, P819, DOI 10.1016/0896-6273(94)90335-2; Licea AF, 1996, TOXICON, V34, P843, DOI 10.1016/0041-0101(96)00043-8; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P171, DOI 10.1113/jphysiol.1980.sp013357; Mantegazza M, 2005, J PHYSIOL-LONDON, V568, P13, DOI 10.1113/jphysiol.2005.093484; MARTIN MF, 1987, J BIOL CHEM, V262, P4452; MEVES H, 1982, PFLUG ARCH EUR J PHY, V393, P56, DOI 10.1007/BF00582392; Moran O, 2000, FEBS LETT, V473, P132, DOI 10.1016/S0014-5793(00)01518-0; Oliveira JS, 2004, J BIOL CHEM, V279, P33323, DOI 10.1074/jbc.M404344200; Pintar A, 1999, J MOL BIOL, V287, P359, DOI 10.1006/jmbi.1999.2611; Raman IM, 1997, NEURON, V19, P881, DOI 10.1016/S0896-6273(00)80969-1; Raman IM, 1997, J NEUROSCI, V17, P4517, DOI 10.1523/jneurosci.17-12-04517.1997; Raman IM, 2001, BIOPHYS J, V80, P729, DOI 10.1016/S0006-3495(01)76052-3; ROCHAT H, 1984, J PHYSIOL-PARIS, V79, P334; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; Sacco T, 2002, J PHYSIOL-LONDON, V543, P505, DOI 10.1113/jphysiol.2002.022525; Schaller KL, 2000, J COMP NEUROL, V420, P84; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Selisko B, 1999, PROTEINS, V37, P130, DOI 10.1002/(SICI)1097-0134(19991001)37:1&lt;130::AID-PROT13&gt;3.0.CO;2-S; Smith MR, 1998, J NEUROSCI, V18, P6093; WANG GK, 1983, MOL PHARMACOL, V23, P519; ZAMUDIO F, 1992, EUR J BIOCHEM, V204, P281, DOI 10.1111/j.1432-1033.1992.tb16635.x	47	79	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20326	20337		10.1074/jbc.M600565200	http://dx.doi.org/10.1074/jbc.M600565200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16702217	hybrid			2022-12-25	WOS:000239038200057
J	Hao, B; Miao, X; Li, Y; Zhang, X; Sun, T; Liang, G; Zhao, Y; Zhou, Y; Wang, H; Chen, X; Zhang, L; Tan, W; Wei, Q; Lin, D; He, F				Hao, B.; Miao, X.; Li, Y.; Zhang, X.; Sun, T.; Liang, G.; Zhao, Y.; Zhou, Y.; Wang, H.; Chen, X.; Zhang, L.; Tan, W.; Wei, Q.; Lin, D.; He, F.			A novel T-77C polymorphism in DNA repair gene XRCC1 contributes to diminished promoter activity and increased risk of non-small cell lung cancer	ONCOGENE			English	Article						base excision repair; non-small cell lung cancer; single nucleotide polymorphism; transcription regulation	ACID SUBSTITUTION VARIANTS; LINKAGE PHASE; ASSOCIATIONS; TRANSCRIPTION; ADDUCTS; XPD; SUSCEPTIBILITY; IDENTIFICATION; CARCINOGENS; BIOMARKERS	X-ray repair cross-complementing 1 (XRCC1) plays a key role in DNA base excision repair and cells lacking its activity are hypersensitive to DNA damage. Recently, we reported a SNP (rs3213245, -77T > C) in the XRCC1 gene 5' untranslated region (UTR) was significantly associated with the risk of developing esophageal squamous-cell carcinoma. Computer analysis predicted that this SNP was in the core of Sp1-binding motif, which suggested its functional significance. Gel shift and super shift assays confirmed that -77T > C polymorphic site in the XRCC1 promoter was within the Sp1-binding motif and the T > C substitution greatly enhanced the binding affinity of Sp1 to this region. Luciferase assays indicated that the Sp1-high-affinity C-allelic XRCC1 promoter was associated with a reduced transcriptional activity. The association between -77T > C and three other amino-acid substitution-causing polymorphisms in XRCC1 and risk of lung cancer was examined in 1024 patients and 1118 controls and the results showed that only the -77T > C polymorphism was significantly associated with an increased risk of developing lung cancer. Multivariate logistic regression analysis found that an increased risk of lung cancer was associated with the variant XRCC1 -77 genotypes (TC and CC) compared with the TT genotype (OR 1.46, 95% CI 1.18-1.82; P = 0.001) and the increased risk was more pronounced in smokers (OR 1.63, 95% CI 1.20-2.21) than in non-smokers (OR 1.28, 95% CI 0.94-1.76). Taken together, these results showed that the functional SNP -77T > C in XRCC1 5'UTR was associated with cancer development owing to the decreased transcriptional activity of C-allele-containing promoter with higher affinity to Sp1 binding.	Chinese Acad Med Sci, Dept Etiol & Carcinogenesis, Canc Inst & Hosp, Beijing 100037, Peoples R China; Peking Union Med Coll, Beijing, Peoples R China; Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China; Beijing Inst Radiat Med, Lab Syst Biol, Beijing, Peoples R China; Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Tsinghua University; Academy of Military Medical Sciences - China; University of Texas System; UTMD Anderson Cancer Center	Lin, D (corresponding author), Chinese Acad Med Sci, Dept Etiol & Carcinogenesis, Inst Canc, Beijing 100021, Peoples R China.	dlin@public.bta.net.cn; hefc@nic.bmi.ac.cn	miao, xiaoping/C-4336-2011; Zhao, Yanlin/L-2773-2013; Wang, Weili/D-1546-2011; zhang, xuemei/F-3818-2010; Zhao, Yanlin/M-2360-2013; hao, Bingtao/G-6648-2011	miao, xiaoping/0000-0002-6818-9722; Zhao, Yanlin/0000-0002-0278-7543; Zhao, Yanlin/0000-0002-0278-7543; hao, Bingtao/0000-0003-1997-9338				Caldecott KW, 2003, DNA REPAIR, V2, P955, DOI 10.1016/S1568-7864(03)00118-6; Dean G, 2000, J BIOL CHEM, V275, P32664, DOI 10.1074/jbc.275.42.32664; Ding KY, 2003, BIOINFORMATICS, V19, P2147, DOI 10.1093/bioinformatics/btg276; Duell EJ, 2000, CARCINOGENESIS, V21, P965, DOI 10.1093/carcin/21.5.965; GONZALEZ FJ, 1995, CANCER RES, V55, P710; Goode EL, 2002, CANCER EPIDEM BIOMAR, V11, P1513; Hao BT, 2004, CANCER RES, V64, P4378, DOI 10.1158/0008-5472.CAN-04-0372; Hecht SS, 2003, NAT REV CANCER, V3, P733, DOI 10.1038/nrc1190; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hu JJ, 2001, CARCINOGENESIS, V22, P917, DOI 10.1093/carcin/22.6.917; Hu ZB, 2005, PHARMACOGENET GENOM, V15, P457, DOI 10.1097/01.fpc.0000167329.85163.0d; Ioannidis JPA, 2003, LANCET, V361, P567, DOI 10.1016/S0140-6736(03)12516-0; Kelsey KT, 2004, CANCER EPIDEM BIOMAR, V13, P1337; Lake SL, 2003, HUM HERED, V55, P56, DOI 10.1159/000071811; Li J, 2001, J VIROL, V75, P8400, DOI 10.1128/JVI.75.18.8400-8406.2001; Liang G, 2003, INT J CANCER, V105, P669, DOI 10.1002/ijc.11136; Lunn RM, 1999, CANCER RES, V59, P2557; Matullo G, 2001, INT J CANCER, V92, P562, DOI 10.1002/ijc.1228; Matullo G, 2001, CARCINOGENESIS, V22, P1437, DOI 10.1093/carcin/22.9.1437; Mohrenweiser HW, 2002, CANCER EPIDEM BIOMAR, V11, P1054; NAKACHI K, 1993, CANCER RES, V53, P2994; Pagliuca A, 1998, J BIOL CHEM, V273, P7668, DOI 10.1074/jbc.273.13.7668; Palli D, 2001, INT J CANCER, V94, P121, DOI 10.1002/ijc.1433; Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688; Shen MR, 1998, CANCER RES, V58, P604; Shou YP, 1998, J BIOL CHEM, V273, P5716, DOI 10.1074/jbc.273.10.5716; Shu XO, 2003, CANCER EPIDEM BIOMAR, V12, P1462; Sturgis EM, 1999, CARCINOGENESIS, V20, P2125, DOI 10.1093/carcin/20.11.2125; Sun T, 2004, JNCI-J NATL CANCER I, V96, P1030, DOI 10.1093/jnci/djh187; Tebbs RS, 1999, DEV BIOL, V208, P513, DOI 10.1006/dbio.1999.9232; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; Vineis P, 1997, INT J CANCER, V71, P1, DOI 10.1002/(SICI)1097-0215(19970328)71:1<1::AID-IJC1>3.0.CO;2-Y; Wang HJ, 2003, CANCER RES, V63, P8057; Wang YF, 2003, DNA REPAIR, V2, P901, DOI 10.1016/S1568-7864(03)00085-5; WEINFELD M, 2001, CELL, V104, P107; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Xing DY, 2002, INT J CANCER, V100, P600, DOI 10.1002/ijc.10528; Zhou W, 2003, CANCER EPIDEM BIOMAR, V12, P359	39	99	107	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3613	3620		10.1038/sj.onc.1209355	http://dx.doi.org/10.1038/sj.onc.1209355			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16652158				2022-12-25	WOS:000238448200014
J	Dias, SS; Milne, DM; Meek, DW				Dias, S. S.; Milne, D. M.; Meek, D. W.			c-Abl phosphorylates Hdm2 at tyrosine 276 in response to DNA damage and regulates interaction with ARF	ONCOGENE			English	Article						Hdm2; p53; c-Abl; ARF; phosphorylation; DNA damage	POSTTRANSLATIONAL MODIFICATIONS; P53; MDM2; ACTIVATION	The p53 tumour-suppressor protein is tightly regulated through its association with the Hdm2 E3 ligase. Activation of p53 by DNA strand breaks is orchestrated by the ataxia-telangiectasia mutated (ATM) protein kinase and involves interruption of Hdm2-mediated p53 degradation. As part of this mechanism ATM itself, and the ATM-activated protein tyrosine kinase, c-Abl, inhibit Hdm2 function through phosphorylation of serine 395 and tyrosine 394 (Y394), respectively. In the present study, we have identified a novel target of c-Abl in the Hdm2 protein, tyrosine 276 (Y276). We show that c-Abl phosphorylates this residue in vitro and confirm that Y394 is a target of c-Abl. We also show that Y276 is phosphorylated in a c-Abl-dependent manner in cultured cells and provide evidence that Y276 is phosphorylated in response to DNA damage coincident with the activation of c-Abl. Finally, we show that Y276 phosphorylation stimulates interaction with ARF, leading to increased levels of nucleolar Hdm2 and decreased turnover of p53. These data establish Y276 as a physiological target of c-Abl that contributes functionally to the induction of p53.	Univ Dundee, Ninewells Hosp & Med Sch, Mol Signalling Grp, Biomed Res Ctr, Dundee DD1 9SY, Scotland	University of Dundee	Meek, DW (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Mol Signalling Grp, Biomed Res Ctr, Dundee DD1 9SY, Scotland.	david.meek@cancer.org.uk						Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Lu X, 2005, CURR OPIN GENET DEV, V15, P27, DOI 10.1016/j.gde.2004.12.008; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Meek DW, 2003, MOL CANCER RES, V1, P1017; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Shaul Y, 2005, CELL RES, V15, P33, DOI 10.1038/sj.cr.7290261; Sionov RV, 2001, MOL CELL BIOL, V21, P5869; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Wu JJ, 2002, COMB CHEM HIGH T SCR, V5, P83, DOI 10.2174/1386207023330516	16	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6666	6671		10.1038/sj.onc.1209671	http://dx.doi.org/10.1038/sj.onc.1209671			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16702947				2022-12-25	WOS:000241569700011
J	Kostenko, O; Tsacoumangos, A; Crooks, D; Kil, SJ; Carlin, C				Kostenko, O.; Tsacoumangos, A.; Crooks, D.; Kil, S. J.; Carlin, C.			Gab1 signaling is regulated by EGF receptor sorting in early endosomes	ONCOGENE			English	Article						EGF receptor; endocytosis; Gab1; MAPK	EPIDERMAL-GROWTH-FACTOR; PLECKSTRIN HOMOLOGY DOMAIN; ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASES; DOCKING PROTEIN; GRB2-ASSOCIATED BINDER-1; TRANSFERRIN RECEPTORS; ENDOCYTIC PATHWAY; NOONAN-SYNDROME	Although combinatorial signaling through the ErbB network is implicated in certain types of human cancer, the specifics of how particular receptors contribute to the transformed phenotype are not well understood. The goal of this study was to identify epidermal growth factor (EGF) receptor-dependent cell signaling abnormalities specifically associated with mutations in a previously described 679-LL lysosomal sorting signal, which restrict ligand-dependent receptor downregulation by promoting recycling. Importantly, the 679-LL signal is not conserved in any of the other members of the ErbB receptor family suggesting its physiological function may be tightly regulated during EGF receptor-dependent signaling. Our data indicate that cells expressing receptors with an inactive 679-AA signal are rapidly transported to Rab4(+) early endosomes after they are internalized in contrast to wild-type receptors that are localized to early endocytic antigen 1 (EEA1)(+) early endosomes. Divergent trafficking in early endosomes is associated with prolonged activation of p44/42 mitogen-activated protein kinases (MAPK) but not Akt. Gab1 appears to be the critical signaling molecule facilitating prolonged MAPK signaling, and activated Gab1 is recruited to early endosomes in 679-AA receptor-expressing cells. Activated Gab1 is also recruited to early endosomes in breast cancer cells characterized by high levels of EGF receptor-ErbB2 heterodimers, suggesting 679-AA expressing cells recapitulate certain aspects of EGF receptor signaling and transformation by activated ErbB2. Phosphatidylinositol 3-kinase (PI3K)-dependent membrane translocation known to be important for maintaining Gab1 activity in other settings was dispensable. We conclude that 679-LL has dual functions in EGF receptor trafficking and threshold signaling through a subset of signaling molecules including p44/42 MAPK and Gab1.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Canc, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Carlin, C (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.	cathleen.carlin@case.edu			NIGMS NIH HHS [R01 GM64243] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Baulida J, 1996, J BIOL CHEM, V271, P5251; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Cai T, 2002, J CELL BIOL, V159, P103, DOI 10.1083/jcb.200205017; Chakraborty A, 2002, HOSP MED, V63, P743, DOI 10.12968/hosp.2002.63.12.1896; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Chen XM, 2001, EMBO REP, V2, P842, DOI 10.1093/embo-reports/kve179; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014-4827(02)00101-5; Crooks D, 2000, MOL BIOL CELL, V11, P3559, DOI 10.1091/mbc.11.10.3559; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; Fragale A, 2004, HUM MUTAT, V23, P267, DOI 10.1002/humu.20005; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; Hendriks BS, 2003, J BIOL CHEM, V278, P23343, DOI 10.1074/jbc.M300477200; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Jones SM, 2002, AM J PHYSIOL-CELL PH, V282, pC420, DOI 10.1152/ajpcell.00253.2001; Kameda H, 2001, MOL CELL BIOL, V21, P6895, DOI 10.1128/MCB.21.20.6895-6905.2001; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kil SJ, 1999, J BIOL CHEM, V274, P3141, DOI 10.1074/jbc.274.5.3141; Kil SJ, 2000, J CELL PHYSIOL, V185, P47, DOI 10.1002/1097-4652(200010)185:1<47::AID-JCP4>3.3.CO;2-F; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; Krendel M, 2005, PHYSIOLOGY, V20, P239, DOI 10.1152/physiol.00014.2005; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB JE, 1983, J BIOL CHEM, V258, P8751; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; MARGOLIS B, 1994, J AM SOC NEPHROL, V5, P1288; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Maroun CR, 1999, J BIOL CHEM, V274, P31719, DOI 10.1074/jbc.274.44.31719; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsacoumango A, 2005, J CELL SCI, V118, P3959, DOI 10.1242/jcs.02527; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; Wang ZX, 1999, MOL BIOL CELL, V10, P1621, DOI 10.1091/mbc.10.5.1621; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; WEIDNER KM, 1996, NATURE, V173, P384; WEIEL JE, 1984, BIOCHEM BIOPH RES CO, V119, P598, DOI 10.1016/S0006-291X(84)80291-0; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; Wilson JM, 2000, MOL BIOL CELL, V11, P2657, DOI 10.1091/mbc.11.8.2657; Wolf I, 2002, MOL CELL BIOL, V22, P231, DOI 10.1128/MCB.22.1.231-244.2002; Yamasaki S, 2003, ONCOGENE, V22, P1546, DOI 10.1038/sj.onc.1206284; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	71	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6604	6617		10.1038/sj.onc.1209675	http://dx.doi.org/10.1038/sj.onc.1209675			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16715136				2022-12-25	WOS:000241569700005
J	Vakifahmetoglu, H; Olsson, M; Orrenius, S; Zhivotovsky, B				Vakifahmetoglu, H.; Olsson, M.; Orrenius, S.; Zhivotovsky, B.			Functional connection between p53 and caspase-2 is essential for apoptosis induced by DNA damage	ONCOGENE			English	Article						apoptosis; caspase-2; PIDDosome complex; p53; 5-FU	CYTOCHROME-C RELEASE; CELL-DEATH; ACTIVATION; PROTEIN; PIDD; TRANSCRIPTION; LOCALIZATION; MITOCHONDRIA; REQUIREMENT; INHIBITOR	Recent findings have established caspase-2 as an important apical regulator in apoptotic pathways leading from DNA damage to release of mitochondrial cytochrome c and subsequent activation of effector caspases. Yet, the molecular map connecting the embarking stimuli of genotoxic stress with caspase-2 activation remains to be elucidated. Here, we address the question of potential caspase-2 regulators by examining 5-fluorouracil (5-FU)-induced apoptosis in wild-type and p53-deficient human colon carcinoma cells. Apoptosis was observed only in p53(+/+) cells and was preceded by caspase-2 activation. Hence, although no direct interaction between p53 and caspase-2 was observed in the cell system used, our data clearly demonstrate that a functional connection between these two proteins is essential for initiation of the 5-FU-induced apoptotic process. Proposed mediators of caspase-2 activation include PIDDosome complex proteins PIDD and RAIDD. Surprisingly, the presence of a complex encompassing at least RAIDD, PIDD and caspase-2 was verified in both p53(+/+) and p53(-/-) cells, also in the absence of 5-FU treatment. Thus, our results confirm the participation of PIDD and RAIDD in PIDDosome complex formation but question their role as sole mediators of caspase-2 activation. This assumption was further supported by siRNA transfections targeting PIDD or RAIDD. In conclusion, our findings support the hypothesis of p53 as an upstream regulator of caspase activity and provide data concerning caspase-2 processing mechanisms. As suppression of caspase-2 expression in 5-FU-treated cells also affects the level of the p53 protein, possibilities of a reciprocal interaction between these proteins are discussed.	Karolinska Inst, Inst Environm Med, Div Toxicol, SE-17177 Stockholm, Sweden	Karolinska Institutet	Zhivotovsky, B (corresponding author), Karolinska Inst, Inst Environm Med, Div Toxicol, Box 210, SE-17177 Stockholm, Sweden.	Boris.Zhivotovsky@imm.ki.se	Zhivotovsky, Boris/A-4346-2014; Olsson, Magnus/E-3140-2012	Zhivotovsky, Boris/0000-0002-2238-3482; Olsson, Magnus/0000-0002-6370-8423				Baliga BC, 2004, CELL DEATH DIFFER, V11, P1234, DOI 10.1038/sj.cdd.4401492; Baliga BC, 2003, J BIOL CHEM, V278, P4899, DOI 10.1074/jbc.M211512200; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Berube C, 2005, P NATL ACAD SCI USA, V102, P14314, DOI 10.1073/pnas.0506475102; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; Enoksson M, 2004, J BIOL CHEM, V279, P49575, DOI 10.1074/jbc.C400374200; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; Ho PK, 2005, FEBS J, V272, P1401, DOI 10.1111/j.1742-4658.2005.04573.x; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Jiang M, 2003, GENE DEV, V17, P832, DOI 10.1101/gad.252603; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Levav-Cohen Y, 2005, BIOCHEM BIOPH RES CO, V331, P737, DOI 10.1016/j.bbrc.2005.03.152; Lin CF, 2005, J BIOL CHEM, V280, P23758, DOI 10.1074/jbc.M412292200; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Marsden VS, 2004, J CELL BIOL, V165, P775, DOI 10.1083/jcb.200312030; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Park HH, 2006, J MOL BIOL, V357, P358, DOI 10.1016/j.jmb.2005.12.082; Paroni G, 2001, J BIOL CHEM, V276, P21907, DOI 10.1074/jbc.M011565200; Ren JY, 2005, P NATL ACAD SCI USA, V102, P565, DOI 10.1073/pnas.0408744102; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Robertson JD, 2004, EMBO REP, V5, P643, DOI 10.1038/sj.embor.7400153; Rotter B, 2004, BIOCHEM J, V378, P161, DOI 10.1042/BJ20030955; Scholz C, 2005, ONCOGENE, V24, P1904, DOI 10.1038/sj.onc.1208233; Schuler M, 2005, TRENDS GENET, V21, P182, DOI 10.1016/j.tig.2005.01.001; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Seth R, 2005, J BIOL CHEM, V280, P31230, DOI 10.1074/jbc.M503305200; Shearwin-Whyatt LM, 2000, CELL DEATH DIFFER, V7, P155, DOI 10.1038/sj.cdd.4400632; Shikama Y, 2001, EXP CELL RES, V264, P315, DOI 10.1006/excr.2000.5153; Tang J, 2005, CANCER BIOL THER, V4, P645, DOI 10.4161/cbt.4.6.1729; Telliez JB, 2000, BBA-PROTEIN STRUCT M, V1478, P280, DOI 10.1016/S0167-4838(00)00029-7; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; Wang Q, 2006, CELL DEATH DIFFER, V13, P75, DOI 10.1038/sj.cdd.4401690; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378	44	84	89	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2006	25	41					5683	5692		10.1038/sj.onc.1209569	http://dx.doi.org/10.1038/sj.onc.1209569			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16652156				2022-12-25	WOS:000240599100010
J	Lauberth, SM; Rauchman, M				Lauberth, Shannon M.; Rauchman, Michael			A conserved 12-amino acid motif in Sall1 recruits the nucleosome remodeling and deacetylase corepressor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOWNES-BROCKS-SYNDROME; INDUCED VULVAL DEVELOPMENT; ZINC-FINGER PROTEIN; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; CAENORHABDITIS-ELEGANS; DNA-BINDING; NURD-COMPLEX; IN-VIVO; GENE	Sall1 is a multi-zinc finger transcription factor that represses gene expression and regulates organogenesis. In this report, we further characterize the domain of Sall1 necessary for repression. We show that endogenous Sall1 binds to the nucleosome remodeling and deacetylase corepressor complex ( NuRD) and confirm the functionality of the Sall1-associating macromolecular complex by showing that the complex possesses HDAC activity. NuRD is involved in global transcriptional repression and regulation of specific developmental processes. The mechanism by which sequence-specific DNA-binding proteins associate with NuRD is not well understood. We have identified a highly conserved 12-amino acid motif in the transcription factor Sall1 that is sufficient for the recruitment of NuRD. Single amino acid substitutions defined the critical amino acid peptide motif as RRKQXK-PXXF. This motif probably exhibits a more general role in regulating gene expression, since other proteins containing this domain, including all Sall family members and an unrelated zinc finger protein Ebfaz, mediate transcriptional repression and associate with NuRD. These results also have important implications for the pathogenesis of Townes-Brocks, a syndrome caused by SALL1 mutations.	St Louis Univ, St Louis Vet Affairs Med Ctr, Dept Biochem & Mol Biol, St Louis, MO 63106 USA; St Louis Univ, St Louis Vet Affairs Med Ctr, Dept Internal Med, St Louis, MO 63106 USA	Saint Louis University; Saint Louis University	Rauchman, M (corresponding author), St Louis Univ, St Louis Vet Affairs Med Ctr, Dept Biochem & Mol Biol, 657-111B-JC,915 N Grand Blvd, St Louis, MO 63106 USA.	rauchman@slu.edu		Lauberth, Shannon/0000-0003-4131-8536	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067222] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK067222] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Avram D, 2002, BIOCHEM J, V368, P555, DOI 10.1042/BJ20020496; Boube M, 2000, MECH DEVELOP, V91, P271, DOI 10.1016/S0925-4773(99)00315-9; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brehm A, 2000, EMBO J, V19, P4332, DOI 10.1093/emboj/19.16.4332; Cantor AB, 2005, SEMIN CELL DEV BIOL, V16, P117, DOI 10.1016/j.semcdb.2004.10.006; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Cismasiu VB, 2005, ONCOGENE, V24, P6753, DOI 10.1038/sj.onc.1208904; de Celis JF, 2000, MECH DEVELOP, V91, P31, DOI 10.1016/S0925-4773(99)00261-0; Durum SK, 2003, NAT IMMUNOL, V4, P512, DOI 10.1038/ni0603-512; Feng Q, 2001, GENE DEV, V15, P827; FERGUSON EL, 1989, GENETICS, V123, P109; Hong W, 2005, EMBO J, V24, P2367, DOI 10.1038/sj.emboj.7600703; JOHN A, 1995, DEVELOPMENT, V121, P1801; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kiefer SM, 2003, HUM MOL GENET, V12, P2221, DOI 10.1093/hmg/ddg233; Kiefer SM, 2002, J BIOL CHEM, V277, P14869, DOI 10.1074/jbc.M200052200; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Kohlhase J, 1999, AM J HUM GENET, V64, P435, DOI 10.1086/302238; Kohlhase J, 1998, NAT GENET, V18, P81, DOI 10.1038/ng0198-81; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; Kon C, 2005, GENETICS, V169, P2087, DOI 10.1534/genetics.104.034595; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Leight ER, 2005, DEVELOPMENT, V132, P1047, DOI 10.1242/dev.01664; Lin AC, 2004, J BIOL CHEM, V279, P55017, DOI 10.1074/jbc.M411240200; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; Ma YP, 2001, J BIOL CHEM, V276, P48223, DOI 10.1074/jbc.M106468200; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Mollereau B, 2001, NATURE, V412, P911, DOI 10.1038/35091076; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Nishinakamura R, 2001, DEVELOPMENT, V128, P3105; Onai T, 2004, DEV CELL, V7, P95, DOI 10.1016/j.devcel.2004.06.004; Poulin G, 2005, EMBO J, V24, P2613, DOI 10.1038/sj.emboj.7600726; Rodriguez P, 2005, EMBO J, V24, P2354, DOI 10.1038/sj.emboj.7600702; Solari F, 2000, CURR BIOL, V10, P223, DOI 10.1016/S0960-9822(00)00343-2; Svensson EC, 2000, J BIOL CHEM, V275, P20762, DOI 10.1074/jbc.M001522200; Tan PBO, 1999, TRENDS GENET, V15, P145, DOI 10.1016/S0168-9525(99)01694-7; Toker AS, 2003, DEVELOPMENT, V130, P3831, DOI 10.1242/dev.00398; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Tsai RYL, 1997, J NEUROSCI, V17, P4159; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wang WD, 1998, P NATL ACAD SCI USA, V95, P492, DOI 10.1073/pnas.95.2.492; Warming S, 2003, BLOOD, V101, P1934, DOI 10.1182/blood-2002-08-2652; XUE Y, 1998, MOL CELL, V2, P51861; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	48	97	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23922	23931		10.1074/jbc.M513461200	http://dx.doi.org/10.1074/jbc.M513461200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16707490	Green Submitted, hybrid			2022-12-25	WOS:000239702900067
J	Estecio, MRH; Youssef, EM; Rahal, P; Fukuyama, EE; Gois, JF; Maniglia, JV; Goloni-Bertollo, EM; Issa, JPJ; Tajara, EH				Estecio, M. R. H.; Youssef, E. M.; Rahal, P.; Fukuyama, E. E.; Gois-Filho, J. F.; Maniglia, J. V.; Goloni-Bertollo, E. M.; Issa, J-P J.; Tajara, E. H.			LHX6 is a sensitive methylation marker in head and neck carcinomas	ONCOGENE			English	Article						DNA methylation; head and neck cancer; solid tumors; early diagnosis; circulating DNA	DNA METHYLATION; PROMOTER HYPERMETHYLATION; CELL CARCINOMAS; CANCER PATIENTS; GENOMIC DNA; GENES; IDENTIFICATION; EXPRESSION; SEQUENCES; FREQUENT	Head and neck cancer remains a morbid and often fatal disease and at the present time few effective molecular markers have been identified. The purpose of the present work was to identify new molecular markers for head and neck squamous cell carcinoma (HNSCC). We applied methylation-sensitive arbitrarily primed PCR (MS/APPCR) to isolate sequences differentially methylated in HNSCC. The most frequently hypermethylated fragment we found maps close to a cytosine guanine dinucleotide (CpG) island on chromosome 9q33.2, and hypermethylation of this CpG island was associated with transcriptional silencing of an alternative transcript of the LHX6 gene. Using combined bisulfite restriction analysis (COBRA), hypermethylation of this fragment was detected in 13 of 14 (92.8%) HNSCC cell lines studied and 21 of 32 (65.6%) primary tumors, whereas little or no methylation was seen in 10 normal oral mucosa samples. We extended this investigation to other cancer cell lines and methylation was found in those derived from colon, breast, leukemia and lung, and methylation was also found in 12/14 primary colon tumors. These findings suggest that differentially methylated (DIME)-6 hypermethylation is a good cancer marker in HNSCC as well as in other kinds of neoplasias and confirm the importance of searching for markers of epigenetic dysregulation in cancer.	Sch Med, FAMERP, Dept Mol Biol, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil; Sch Med, FAMERP, Dept Surg, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil; Sch Med, FAMERP, Dept Mol Biol, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil; UNESP, IBILCE, Dept Biol, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil; Arnaldo Vieira Carvalho Hosp, Dept Head & Neck & Skull Base Surg, Sao Paulo, Brazil; Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA	Universidade de Sao Paulo; Faculdade de Medicina de Sao Jose do Rio Preto (FAMERP); Universidade de Sao Paulo; Faculdade de Medicina de Sao Jose do Rio Preto (FAMERP); Universidade de Sao Paulo; Faculdade de Medicina de Sao Jose do Rio Preto (FAMERP); Universidade Estadual Paulista; University of Texas System; UTMD Anderson Cancer Center	Tajara, EH (corresponding author), Sch Med, FAMERP, Dept Mol Biol, Av Brig Faria Lima 5416, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil.	tajara@famerp.br	Goloni-Bertollo, Eny Maria/B-8405-2012; Maniglia, José V/K-3129-2016; Tajara, Eloiza H/G-7586-2012; Rahal, Paula/D-3871-2012	Goloni-Bertollo, Eny Maria/0000-0002-2622-4673; Maniglia, José V/0000-0002-9765-2659; Tajara, Eloiza H/0000-0002-2603-2057; Rahal, Paula/0000-0001-5693-6148; Estecio, Marcos/0000-0002-6874-7413; Issa, Jean-Pierre/0000-0003-2258-5030	NCI NIH HHS [R33CA89837] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R33CA089837] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alves G, 1996, GENE, V176, P39, DOI 10.1016/0378-1119(96)00205-3; Casiglia Jeffrey, 2001, General Dentistry, V49, P72; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Esteller M, 1999, CANCER RES, V59, P67; Florl AR, 1999, BRIT J CANCER, V80, P1312, DOI 10.1038/sj.bjc.6690524; Gonzalgo ML, 1997, CANCER RES, V57, P594; Grati FR, 2000, CANCER GENET CYTOGEN, V118, P57, DOI 10.1016/S0165-4608(99)00199-5; Grigoriou M, 1998, DEVELOPMENT, V125, P2063; International Union Against Cancer, 1992, UICC TNM ATL ILL GUI, V3rd, P50; Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; KAWAI J, 1993, NUCLEIC ACIDS RES, V21, P5604, DOI 10.1093/nar/21.24.5604; Li J, 2005, CANCER-AM CANCER SOC, V104, P771, DOI 10.1002/cncr.21215; Macluskey M, 2000, Dent Update, V27, P148; Reichart P A, 2001, Clin Oral Investig, V5, P207, DOI 10.1007/s00784-001-0132-5; Shintani S, 2001, ORAL ONCOL, V37, P498, DOI 10.1016/S1368-8375(00)00142-1; Toyota M, 1999, CANCER RES, V59, P2307; Viswanathan M, 2003, INT J CANCER, V105, P41, DOI 10.1002/ijc.11028; Wong DTW, 1996, CRIT REV ORAL BIOL M, V7, P319, DOI 10.1177/10454411960070040201; Wong IHN, 1999, CANCER RES, V59, P71; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Xu J, 1998, CANCER-AM CANCER SOC, V83, P204, DOI 10.1002/(SICI)1097-0142(19980715)83:2<204::AID-CNCR2>3.0.CO;2-Q; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	23	42	44	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					5018	5026		10.1038/sj.onc.1209509	http://dx.doi.org/10.1038/sj.onc.1209509			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16732332				2022-12-25	WOS:000239921300007
J	Liwosz, A; Lei, TL; Kukuruzinska, MA				Liwosz, Aneta; Lei, Tianlei; Kukuruzinska, Maria A.			N-glycosylation affects the molecular organization and stability of E-cadherin junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED OLIGOSACCHARIDES; TYROSINE PHOSPHORYLATION; DIFFERENTIAL EXPRESSION; MEDIATED ADHESION; CELL-ADHESION; VINCULIN; CATENIN; BINDING; CYTOSKELETON; TRANSFERASE	Epithelial cell-cell adhesion is mediated by E-cadherin, an intercellular N-glycoprotein adhesion receptor that functions in the assembly of multiprotein complexes anchored to the actin cytoskeleton named adherens junctions (AJs). E-cadherin ectodomains 4 and 5 contain three potential N-glycan addition sites, although their significance in AJ stability is unclear. Here we show that sparse cells lacking stable AJs produced E-cadherin that was extensively modified with complex N-glycans. In contrast, dense cultures with more stable AJs had scarcely N-glycosylated E-cadherin modified with high mannose/hybrid and limited complex N-glycans. This suggested that variations in AJ stability were accompanied by quantitative and qualitative changes in E-cadherin N-glycosylation. To further examine the role of N-glycans in AJ function, we generated E-cadherin N-glycosylation variants lacking selected N-glycan addition sites. Characterization of these variants in CHO cells, lacking endogenous E-cadherin, revealed that site 1 on ectodomain 4 was modified with a prominent complex N-glycan, site 2 on ectodomain 5 did not have a substantial oligosaccharide, and site 3 on ectodomain 5 was decorated with a high mannose/hybrid N-glycan. Removal of complex N-glycan from ectodomain 4 led to a dramatically increased interaction of E-cadherin-catenin complexes with vinculin and the actin cytoskeleton. The latter effect was further enhanced by the deletion of the high mannose/hybrid N-glycan from site 3. In MDCK cells, which produce E-cadherin, a variant lacking both complex and high mannose/hybrid N-glycans functioned like a dominant positive displaying increased interaction with gamma-catenin and vinculin compared with the endogenous E-cadherin. Collectively, our studies show that N-glycans, and complex oligosaccharides in particular, destabilize AJs by affecting their molecular organization.	Boston Univ, Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA	Boston University	Kukuruzinska, MA (corresponding author), Boston Univ, Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA.	mkukuruz@bu.edu		Kukukruzinska, Maria/0000-0001-5314-1454	NIDCR NIH HHS [R01DE10183] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010183] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Causeret M, 2005, MOL BIOL CELL, V16, P2168, DOI 10.1091/mbc.E04-09-0829; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; Cullen PJ, 2000, GENETICS, V155, P1005; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; ELBEIN AD, 1991, TRENDS BIOTECHNOL, V9, P346, DOI 10.1016/0167-7799(91)90117-Z; Fernandes RP, 1999, HISTOCHEM CELL BIOL, V111, P153, DOI 10.1007/s004180050345; Geng F, 2004, CELL RES, V14, P423, DOI 10.1038/sj.cr.7290243; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Guo HB, 2003, J BIOL CHEM, V278, P52412, DOI 10.1074/jbc.M308837200; Guo HB, 2002, CANCER RES, V62, P6837; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Kitada T, 2001, J BIOL CHEM, V276, P475, DOI 10.1074/jbc.M006689200; KLEBL B, 2001, BIOCHEM BIOPH RES CO, V286, P575; Kowalczyk AP, 1998, J CELL SCI, V111, P3045; KUKURUZINSKA MA, 1994, GLYCOBIOLOGY, V4, P437, DOI 10.1093/glycob/4.4.437; Kukuruzinska MA, 1998, CRIT REV ORAL BIOL M, V9, P415, DOI 10.1177/10454411980090040301; KUKURUZINSKA MA, 1995, BBA-PROTEIN STRUCT M, V1247, P51, DOI 10.1016/0167-4838(94)00201-Q; Lampugnani MG, 1997, J CELL SCI, V110, P2065; Lee BN, 1999, P NATL ACAD SCI USA, V96, P12679, DOI 10.1073/pnas.96.22.12679; Leong L, 2000, INVEST OPHTH VIS SCI, V41, P3503; Lickert H, 2000, J BIOL CHEM, V275, P5090, DOI 10.1074/jbc.275.7.5090; LifschitzMercer B, 1997, HUM PATHOL, V28, P1230, DOI 10.1016/S0046-8177(97)90195-7; Mendelsohn RD, 2005, BBA-GEN SUBJECTS, V1723, P33, DOI 10.1016/j.bbagen.2005.01.017; Menko AS, 2002, DEV DYNAM, V224, P321, DOI 10.1002/dvdy.10111; Nathke Inke S., 1995, Seminars in Developmental Biology, V6, P89, DOI 10.1016/S1044-5781(06)80018-6; Nemade RV, 2004, MECH DEVELOP, V121, P91, DOI 10.1016/j.mod.2003.09.007; Palovuori R, 2000, EUR J CELL BIOL, V79, P961, DOI 10.1078/0171-9335-00120; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; RAJPUT B, 1994, J BIOL CHEM, V269, P16054; RAZ A, 1982, CANCER RES, V42, P5183; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHIRAYOSHI Y, 1986, CELL STRUCT FUNCT, V11, P245, DOI 10.1247/csf.11.245; Spear ED, 2005, J CELL BIOL, V169, P73, DOI 10.1083/jcb.200411136; Straub BK, 2003, J CELL SCI, V116, P4985, DOI 10.1242/jcs.00815; Subauste MC, 2005, J BIOL CHEM, V280, P5676, DOI 10.1074/jbc.M405561200; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Walker JL, 1999, DEV BIOL, V210, P497, DOI 10.1006/dbio.1999.9277; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; Wheelock MJ, 2003, CURR OPIN CELL BIOL, V15, P509, DOI 10.1016/S0955-0674(03)00101-7; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0; Yoshida A, 2001, DEV CELL, V1, P717, DOI 10.1016/S1534-5807(01)00070-3; Zhu B, 2003, BIOPHYS J, V84, P4033, DOI 10.1016/S0006-3495(03)75129-7; Zhu WJ, 2001, EMBO J, V20, P5999, DOI 10.1093/emboj/20.21.5999	52	97	102	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23138	23149		10.1074/jbc.M512621200	http://dx.doi.org/10.1074/jbc.M512621200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16682414	hybrid			2022-12-25	WOS:000239542600078
J	Zhang, SB; Malmersjo, S; Li, J; Ando, H; Aizman, O; Uhlen, P; Mikoshiba, K; Aperia, A				Zhang, Songbai; Malmersjo, Seth; Li, Juan; Ando, Hideaki; Aizman, Oleg; Uhlen, Per; Mikoshiba, Katsuhiko; Aperia, Anita			Distinct role of the N-terminal tail of the Na,K-ATPase catalytic subunit as a signal transducer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; SMOOTH-MUSCLE-CELLS; NA+-K+-ATPASE; CALCIUM OSCILLATIONS; KAPPA-B; INDUCED PROLIFERATION; SERUM DEPRIVATION; ALPHA-2 ISOFORM; IP3 RECEPTOR; OUABAIN	Mounting evidence suggests that the ion pump, Na, K-ATPase, can, in the presence of ouabain, act as a signal transducer. A prominent binding motif linking the Na, K-ATPase to intracellular signaling effectors has, however, not yet been identified. Here we report that the N-terminal tail of the Na, K-ATPase catalytic alpha-subunit (alpha NT-t) binds directly to the N terminus of the inositol 1,4,5-trisphosphate receptor. Three amino acid residues, LKK, conserved in most species and most alpha-isoforms, are essential for the binding to occur. In wild-type cells, low concentrations of ouabain trigger low frequency calcium oscillations that activate NF-kappa B and protect from apoptosis. All of these effects are suppressed in cells overexpressing a peptide corresponding to alpha NT-t but not in cells overexpressing a peptide corresponding to alpha NT- t Delta LKK. Thus we have identified a well conserved Na, K-ATPase motif that binds to the inositol 1,4,5-trisphosphate receptor and can trigger an anti-apoptotic calcium signal.	Astrid Lindgren Childrens Hosp, Dept Woman & Child Hlth, Karolinska Inst, SE-17176 Stockholm, Sweden; Univ Tokyo, Inst Med Sci, Div Mol Neurobiol, Tokyo 1088639, Japan; Inst Phys & Chem Res, Dev Neurobiol Lab, Brain Sci Inst, Wako, Saitama 3510198, Japan	Karolinska Institutet; University of Tokyo; RIKEN	Aperia, A (corresponding author), Astrid Lindgren Childrens Hosp, Dept Woman & Child Hlth, Karolinska Inst, Q2-09, SE-17176 Stockholm, Sweden.	anita.aperia@ki.se	Malmersjö, Seth/D-2454-2010; Ando, Hideaki/D-3876-2017; Mikoshiba, Katsuhiko/N-7943-2015	Malmersjö, Seth/0000-0002-1519-8916; Uhlen, Per/0000-0003-1446-1062; Zhang, Songbai/0000-0002-2033-8389				Abramowitz J, 2003, CIRCULATION, V108, P3048, DOI 10.1161/01.CIR.0000101919.00548.86; Aizman O, 2001, P NATL ACAD SCI USA, V98, P13420, DOI 10.1073/pnas.221315298; Ando H, 2003, J BIOL CHEM, V278, P10602, DOI 10.1074/jbc.M210119200; Barwe SP, 2005, MOL BIOL CELL, V16, P1082, DOI 10.1091/mbc.E04-05-0427; Beguin P, 1998, J BIOL CHEM, V273, P24921, DOI 10.1074/jbc.273.38.24921; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Bosanac I, 2005, MOL CELL, V17, P193, DOI 10.1016/j.molcel.2004.11.047; Bosanac I, 2002, NATURE, V420, P696, DOI 10.1038/nature01268; CHENG XJ, 1997, AM J PHYSIOL, V273, P893; DALY SE, 1994, J BIOL CHEM, V269, P23944; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Harwood S, 2005, FRONT BIOSCI-LANDMRK, V10, P2011, DOI 10.2741/1676; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; Kawamura A, 2001, BIOCHEMISTRY-US, V40, P5835, DOI 10.1021/bi0101751; Li JA, 2006, J AM SOC NEPHROL, V17, P1848, DOI 10.1681/ASN.2005080894; Lingrel J, 2003, ANN NY ACAD SCI, V986, P354, DOI 10.1111/j.1749-6632.2003.tb07214.x; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Liu LJ, 2004, AM J PHYSIOL-HEART C, V287, pH2173, DOI 10.1152/ajpheart.00352.2004; Miyakawa-Naito A, 2003, J BIOL CHEM, V278, P50355, DOI 10.1074/jbc.M305378200; Mogi M, 2004, BONE, V35, P507, DOI 10.1016/j.bone.2004.03.003; Moseley AE, 2003, J BIOL CHEM, V278, P5317, DOI 10.1074/jbc.M211315200; Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588; OHTA T, 1991, BIOCHIM BIOPHYS ACTA, V1059, P157, DOI 10.1016/S0005-2728(05)80200-2; Pressley TA, 1996, AM J PHYSIOL-CELL PH, V271, pC825, DOI 10.1152/ajpcell.1996.271.3.C825; Scheiner-Bobis G, 2001, NAT MED, V7, P1288, DOI 10.1038/nm1201-1288; Schoner W, 2002, EUR J BIOCHEM, V269, P2440, DOI 10.1046/j.1432-1033.2002.02911.x; Segall L, 2003, J BIOL CHEM, V278, P9027, DOI 10.1074/jbc.M211636200; SHANBAKY NM, 1994, AM J PHYSIOL, V267, pC590, DOI 10.1152/ajpcell.1994.267.2.C590; Skou JC, 1998, BIOSCIENCE REP, V18, P155, DOI 10.1023/A:1020196612909; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; UHLEN P, 2004, SCI STKE, P115; Wang XQ, 2005, J NEUROCHEM, V93, P1515, DOI 10.1111/j.1471-4159.2005.03147.x; Xie Zijian, 2003, Mol Interv, V3, P157, DOI 10.1124/mi.3.3.157; Yuan ZK, 2005, MOL BIOL CELL, V16, P4034, DOI 10.1091/mbc.E05-04-0295; Zhang SB, 2003, J BIOL CHEM, V278, P4048, DOI 10.1074/jbc.M209960200	38	96	103	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21954	21962		10.1074/jbc.M601578200	http://dx.doi.org/10.1074/jbc.M601578200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16723354	hybrid			2022-12-25	WOS:000239387100042
J	Belliveau, DJ; Bani-Yaghoub, M; McGirr, B; Naus, CCG; Rushlow, WJ				Belliveau, Daniel J.; Bani-Yaghoub, Mahmud; McGirr, Becky; Naus, Christian C. G.; Rushlow, Walter J.			Enhanced neurite outgrowth in PC12 cells mediated by connexin hemichannels and ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; EMBRYONAL CARCINOMA-CELLS; GAP-JUNCTIONAL HEMICHANNELS; NTERA2/CLONE D1 CELLS; RADIAL GLIAL-CELLS; NEURONAL DIFFERENTIATION; DEVELOPMENTAL REGULATION; PROTEIN CONNEXIN36; BRAIN-DEVELOPMENT; TYROSINE KINASE	Gap junctions have traditionally been described as transmembrane channels that facilitate intercellular communication via the passage of small molecules. Connexins, the basic building blocks of gap junctions, are expressed in most mammalian tissues including the developing and adult central nervous system. During brain development, connexins are temporally and spatially regulated suggesting they play an important role in the proper formation of the central nervous system. In the current study, connexins 32 and 43 were overexpressed in PC12 cells to determine whether connexins are involved in neuronal differentiation. Both connexin 32 and 43 were appropriately trafficked to the cell membrane following overexpression and resulted in the formation of functional gap junctions. Connexin overexpression was found to cause enhanced neurite outgrowth in PC12 cells treated with nerve growth factor to initiate neuritogenesis. Surprisingly, however, enhanced neurite outgrowth was found to be the consequence of functional hemichannel formation as opposed to traditional intercellular communication. Additional analysis revealed that ATP was released into the media likely through hemichannels and acted on purinergic receptors to cause enhanced neurite outgrowth. Collectively, the results of the current study suggest that connexins may play an important role in neuronal differentiation by non-traditional mechanisms.	Univ Western Ontario, Dept Psychiat, London N6A 5A5, England; Univ Western Ontario, Dept Anat & Cell Biol, London N6A 5A5, England; Univ British Columbia, Dept Cellular & Physiol Sci, Vancouver, BC V6T 1Z3, Canada; Natl Res Council Canada, Neurogenesis & Brain Repair Grp, Ottawa, ON K1A 0R6, Canada	University of British Columbia; National Research Council Canada	Rushlow, WJ (corresponding author), London Hlth Sci Ctr, Dept Psychiat, Univ Campus,Rm B9-144,339 Windermere Rd, London, ON N6A 5A5, Canada.	wrushlow@uwo.ca						Altevogt BM, 2002, J NEUROSCI, V22, P6458; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Bani-Yaghoub M, 1999, DEV GENET, V24, P69, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<69::AID-DVG8>3.0.CO;2-M; Bani-Yaghoub M, 1999, EXP NEUROL, V156, P16, DOI 10.1006/exnr.1998.6950; BaniYaghoub M, 1997, J NEUROSCI RES, V49, P19, DOI 10.1002/(SICI)1097-4547(19970701)49:1<19::AID-JNR3>3.0.CO;2-G; Bannerman P, 2000, J NEUROSCI RES, V61, P605, DOI 10.1002/1097-4547(20000915)61:6<605::AID-JNR4>3.0.CO;2-U; Belliveau DJ, 1997, DEV GENET, V21, P187, DOI 10.1002/(SICI)1520-6408(1997)21:3<187::AID-DVG2>3.0.CO;2-3; BELLIVEAU DJ, 1991, DEV GENET, V12, P308, DOI 10.1002/dvg.1020120408; BELLIVEAU DJ, 1995, DEV NEUROSCI-BASEL, V17, P81, DOI 10.1159/000111277; Bittman K, 2002, J COMP NEUROL, V443, P201, DOI 10.1002/cne.2121; Bittman KS, 1999, CEREB CORTEX, V9, P188, DOI 10.1093/cercor/9.2.188; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; Burnstock G, 2004, INT REV CYTOL, V240, P31, DOI 10.1016/S0074-7696(04)40002-3; Chang Q, 1999, J NEUROSCI, V19, P10813, DOI 10.1523/JNEUROSCI.19-24-10813.1999; Cushing P, 2005, J NEUROSCI RES, V82, P788, DOI 10.1002/jnr.20689; D'Ambrosi N, 2001, NEUROSCIENCE, V108, P527, DOI 10.1016/S0306-4522(01)00431-6; Deans MR, 2002, NEURON, V36, P703, DOI 10.1016/S0896-6273(02)01046-2; Frisch C, 2005, BEHAV BRAIN RES, V157, P177, DOI 10.1016/j.bbr.2004.06.023; Galipeau J, 1997, HUM GENE THER, V8, P1773, DOI 10.1089/hum.1997.8.15-1773; Goodenough DA, 2003, NAT REV MOL CELL BIO, V4, P285, DOI 10.1038/nrm1072; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Gysbers JW, 1996, NEUROSCI LETT, V220, P175, DOI 10.1016/S0304-3940(96)13253-5; Gysbers JW, 2000, NEUROSCIENCE, V96, P817, DOI 10.1016/S0306-4522(99)00588-6; Honma S, 2004, SYNAPSE, V52, P258, DOI 10.1002/syn.20022; Kamermans M, 2001, SCIENCE, V292, P1178, DOI 10.1126/science.1060101; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; Lai A, 2006, J CELL SCI, V119, P532, DOI 10.1242/jcs.02770; Leung DSY, 2002, INT J DEV NEUROSCI, V20, P63, DOI 10.1016/S0736-5748(01)00056-9; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; LYNN BD, 1995, NEUROSCI LETT, V199, P21, DOI 10.1016/0304-3940(95)12028-3; Malatesta P, 2000, DEVELOPMENT, V127, P5253; Malatesta P, 2003, NEURON, V37, P751, DOI 10.1016/S0896-6273(03)00116-8; Mao AJ, 2000, J BIOL CHEM, V275, P34407, DOI 10.1074/jbc.M003917200; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Maxeiner S, 2005, J NEUROSCI, V25, P566, DOI 10.1523/JNEUROSCI.3232-04.2005; Maxeiner S, 2003, NEUROSCIENCE, V119, P689, DOI 10.1016/S0306-4522(03)00077-0; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MEAKIN SO, 1992, P NATL ACAD SCI USA, V89, P2374, DOI 10.1073/pnas.89.6.2374; Nadarajah B, 1997, J NEUROSCI, V17, P3096; Nagy JI, 2003, GLIA, V44, P205, DOI 10.1002/glia.10278; Noctor SC, 2001, NATURE, V409, P714, DOI 10.1038/35055553; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Quist AP, 2000, J CELL BIOL, V148, P1063, DOI 10.1083/jcb.148.5.1063; Rash JE, 2001, CELL COMMUN ADHES, V8, P315, DOI 10.3109/15419060109080745; Roscoe W, 2005, J BIOL CHEM, V280, P11458, DOI 10.1074/jbc.M409564200; Sasagawa S, 2005, NAT CELL BIOL, V7, P365, DOI 10.1038/ncb1233; Sohl G, 2005, NAT REV NEUROSCI, V6, P191, DOI 10.1038/nrn1627; Sohl G, 2003, CELL COMMUN ADHES, V10, P173, DOI 10.1080/15419060390262877; Sohl G, 1998, FEBS LETT, V428, P27, DOI 10.1016/S0014-5793(98)00479-7; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; Srinivas M, 1999, J NEUROSCI, V19, P9848; Stout CE, 2002, J BIOL CHEM, V277, P10482, DOI 10.1074/jbc.M109902200; Theis M, 2005, TRENDS NEUROSCI, V28, P188, DOI 10.1016/j.tins.2005.02.006; Trexler EB, 1996, P NATL ACAD SCI USA, V93, P5836, DOI 10.1073/pnas.93.12.5836; Weissman TA, 2004, NEURON, V43, P647, DOI 10.1016/j.neuron.2004.08.015; Xiao JN, 2006, NEUROSCI LETT, V392, P231, DOI 10.1016/j.neulet.2005.09.024; Yasui H, 2001, J BIOL CHEM, V276, P15298, DOI 10.1074/jbc.M008546200; Ye ZC, 2003, J NEUROSCI, V23, P3588, DOI 10.1523/jneurosci.23-09-03588.2003; Yip PM, 2001, J NEUROCHEM, V76, P1552, DOI 10.1046/j.1471-4159.2001.00152.x	59	63	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20920	20931		10.1074/jbc.M600026200	http://dx.doi.org/10.1074/jbc.M600026200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16731531	hybrid			2022-12-25	WOS:000239187300029
J	Dahl, LD; Wieden, HJ; Rodnina, MV; Knudsen, CR				Dahl, Louise D.; Wieden, Hans-Joachim; Rodnina, Marina V.; Knudsen, Charlotte R.			The importance of P-loop and domain movements in EF-Tu for guanine nucleotide exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-TU; AMINOACYL-TRANSFER-RNA; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; FACTOR TS; TERNARY COMPLEX; GTP HYDROLYSIS; THERMUS-THERMOPHILUS; ANGSTROM RESOLUTION; HISTIDINE-RESIDUES	Elongation factor Ts (EF-Ts) is the guanine nucleotide exchange factor for elongation factor Tu (EF-Tu). An important feature of the nucleotide exchange is the structural rearrangement of EF-Tu in the EF-Tu.EF-Ts complex caused by insertion of Phe-81 of EF-Ts between His-84 and His-118 of EF-Tu. In this study, the contribution of His-118 to nucleotide release was studied by pre-steady state kinetic analysis of nucleotide exchange in EF-Tu mutants in which His-118 was replaced by Ala or Glu. Intrinsic as well as EF-Ts-catalyzed release of GDP/ GTP was affected by the mutations, resulting in an similar to 10-fold faster spontaneous nucleotide release and a 10-50-fold slower EF-Ts-catalyzed nucleotide release. The effects are attributed to the interference of the mutations with the EF-Ts-induced movements of the P-loop of EF-Tu and changes at the domain 1/3 interface, leading to the release of the beta-phosphate group of GTP/GDP. The K-d for GTP is increased by more than 40 times when His-118 is replaced with Glu, which may explain the inhibition by His-118 mutations of aminoacyl-tRNA binding to EF-Tu. The mutations had no effect on EF-Tu-dependent delivery of aminoacyl-tRNA to the ribosome.	Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark; Univ Witten Herdecke, Inst Phys Biochem, D-58448 Witten, Germany	Aarhus University; Witten Herdecke University	Knudsen, CR (corresponding author), Aarhus Univ, Dept Mol Biol, Gustav Wieds Vej 10C, DK-8000 Aarhus C, Denmark.	crk@bioxray.dk	Rodnina, Marina V./AAD-4667-2019	Rodnina, Marina V./0000-0003-0105-3879; Knudsen, Charlotte/0000-0003-2356-4821				ANDERSEN C, 1994, EUR J BIOCHEM, V220, P739, DOI 10.1111/j.1432-1033.1994.tb18674.x; Azuma Y, 1999, J MOL BIOL, V289, P1119, DOI 10.1006/jmbi.1999.2820; Azuma Y, 1996, J BIOCHEM-TOKYO, V120, P82; BLOCK W, 1981, ANAL BIOCHEM, V114, P112, DOI 10.1016/0003-2697(81)90460-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cetin R, 1996, EMBO J, V15, P2604, DOI 10.1002/j.1460-2075.1996.tb00618.x; Cochella L, 2005, SCIENCE, V308, P1178, DOI 10.1126/science.1111408; Daviter T, 2003, J MOL BIOL, V332, P689, DOI 10.1016/S0022-2836(03)00947-1; Diaconu M, 2005, CELL, V121, P991, DOI 10.1016/j.cell.2005.04.015; FERSHT A, 1998, STRUCTURE MECH PROTE, P122; Gromadski KB, 2006, MOL CELL, V21, P369, DOI 10.1016/j.molcel.2005.12.018; Gromadski KB, 2004, MOL CELL, V13, P191, DOI 10.1016/S1097-2765(04)00005-X; Gromadski KB, 2002, BIOCHEMISTRY-US, V41, P162, DOI 10.1021/bi015712w; JACQUET E, 1989, EUR J BIOCHEM, V185, P341, DOI 10.1111/j.1432-1033.1989.tb15121.x; JACQUET E, 1988, EMBO J, V7, P2861, DOI 10.1002/j.1460-2075.1988.tb03142.x; JAMESON DM, 1987, BIOCHEMISTRY-US, V26, P3894, DOI 10.1021/bi00387a023; Jeppesen MG, 2005, J BIOL CHEM, V280, P5071, DOI 10.1074/jbc.M411782200; JONAK J, 1994, FEBS LETT, V343, P94, DOI 10.1016/0014-5793(94)80614-4; JONAK J, 1984, EUR J BIOCHEM, V144, P295, DOI 10.1111/j.1432-1033.1984.tb08463.x; Karring H, 2003, EUR J BIOCHEM, V270, P4294, DOI 10.1046/j.1432-1033.2003.03822.x; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; KNUDSEN CR, 1995, EUR J BIOCHEM, V228, P176; KNUDSEN CR, 1992, BIOCHEM INT, V28, P353; Lounsbury KM, 1996, J BIOL CHEM, V271, P32834, DOI 10.1074/jbc.271.51.32834; Miller D L, 1974, Methods Enzymol, V30, P219; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; NEUHARD J, 1987, ESCHERICHIA COLI SAL, V1, P445; Nissen P, 1999, STRUCTURE, V7, P143, DOI 10.1016/S0969-2126(99)80021-5; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Pape T, 1998, EMBO J, V17, P7490, DOI 10.1093/emboj/17.24.7490; PARMEGGIANI A, 1987, P NATL ACAD SCI USA, V84, P3141, DOI 10.1073/pnas.84.10.3141; Piepenburg O, 2000, BIOCHEMISTRY-US, V39, P1734, DOI 10.1021/bi992331y; POWERS T, 1994, J MOL BIOL, V235, P156, DOI 10.1016/S0022-2836(05)80023-3; Renault L, 2001, CELL, V105, P245, DOI 10.1016/S0092-8674(01)00315-4; Rodnina MV, 2005, FEBS LETT, V579, P938, DOI 10.1016/j.febslet.2004.11.048; RODNINA MV, 1995, EMBO J, V14, P2613, DOI 10.1002/j.1460-2075.1995.tb07259.x; RODNINA MV, 1995, P NATL ACAD SCI USA, V92, P1945, DOI 10.1073/pnas.92.6.1945; RODNINA MV, 1994, BIOCHEMISTRY-US, V33, P12267, DOI 10.1021/bi00206a033; Rodnina MV, 2001, ANNU REV BIOCHEM, V70, P415, DOI 10.1146/annurev.biochem.70.1.415; Song HW, 1999, J MOL BIOL, V285, P1245, DOI 10.1006/jmbi.1998.2387; TAPPRICH WE, 1990, EMBO J, V9, P2649, DOI 10.1002/j.1460-2075.1990.tb07447.x; TONAK J, 1998, FEBS LETT, V442, P189; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; WAGNER A, 1995, BIOCHEMISTRY-US, V34, P12535, DOI 10.1021/bi00039a007; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650; Wieden HJ, 2002, J BIOL CHEM, V277, P6032, DOI 10.1074/jbc.M110888200; Zhang YL, 1996, FEBS LETT, V391, P330, DOI 10.1016/0014-5793(96)00789-2; Zhang YL, 1998, J BIOL CHEM, V273, P4556, DOI 10.1074/jbc.273.8.4556	50	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21139	21146		10.1074/jbc.M602068200	http://dx.doi.org/10.1074/jbc.M602068200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16717093	hybrid, Green Published			2022-12-25	WOS:000239187300050
J	Kozlov, SA; Vassilevski, AA; Feofanov, AV; Surovoy, AY; Karpunin, DV; Grishin, EV				Kozlov, Sergey A.; Vassilevski, Alexander A.; Feofanov, Alexei V.; Surovoy, Andrey Y.; Karpunin, Dmitry V.; Grishin, Eugene V.			Latarcins, antimicrobial and cytolytic peptides from the venom of the spider Lachesana tarabaevi (Zodariidae) that exemplify biomolecular diversity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE PRECURSOR; CYSTINE KNOT; IN-VITRO; ANTIBACTERIAL; IDENTIFICATION; PROTEIN; FAMILY; MEMBRANES; DROSOPHILA; DEFENSINS	Seven novel short linear antimicrobial and cytolytic peptides named latarcins were purified from the venom of the spider Lachesana tarabaevi. These peptides were found to produce lytic effects on cells of diverse origin (Gram-positive and Gram-negative bacteria, erythrocytes, and yeast) at micromolar concentrations. In addition, five novel peptides that share considerable structural similarity with the purified latarcins were predicted from the L. tarabaevi venom gland expressed sequence tag data base. Latarcins were shown to adopt amphipathic alpha-helical structure in membrane-mimicking environment by CD spectroscopy. Planar lipid bilayer studies indicated that the general mode of action was scaled membrane destabilization at the physiological membrane potential consistent with the "carpet-like" model. Latarcins represent seven new structural groups of lytic peptides and share little homology with other known peptide sequences. For every latarcin, a precursor protein sequence was identified. On the basis of structural features, latarcin precursors were split into three groups: simple precursors with a conventional prepropeptide structure; binary precursors with a typical modular organization; and complex precursors, which were suggested to be cleaved into mature chains of two different types.	Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences	Kozlov, SA (corresponding author), Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Miklukho Maklaya 16-10, Moscow 117997, Russia.	serg@ibch.ru	Kozlov, Sergey A/D-1548-2012; Vassilevski, Alexander/S-3824-2016; Feofanov, Alexey V/K-3082-2012	Kozlov, Sergey A/0000-0002-0242-4240; Vassilevski, Alexander/0000-0002-1359-0076; Feofanov, Alexey V/0000-0002-1596-9506				ABIDOR IG, 1979, BIOELECTROCH BIOENER, V6, P37; ADAMS ME, 1989, J COMP PHYSIOL A, V164, P333, DOI 10.1007/BF00612993; Bals R, 2003, CELL MOL LIFE SCI, V60, P711, DOI 10.1007/s00018-003-2186-9; Brogden KA, 2005, NAT REV MICROBIOL, V3, P238, DOI 10.1038/nrmicro1098; Budnik BA, 2004, J MASS SPECTROM, V39, P193, DOI 10.1002/jms.577; CASTEELSJOSSON K, 1994, J BIOL CHEM, V269, P28569; CASTEELSJOSSON K, 1993, EMBO J, V12, P1569, DOI 10.1002/j.1460-2075.1993.tb05801.x; CHAN TK, 1975, TOXICON, V13, P61, DOI 10.1016/0041-0101(75)90159-2; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Conde R, 2000, FEBS LETT, V471, P165, DOI 10.1016/S0014-5793(00)01384-3; Corzo G, 2002, J BIOL CHEM, V277, P23627, DOI 10.1074/jbc.M200511200; Cotter PD, 2005, NAT REV MICROBIOL, V3, P777, DOI 10.1038/nrmicro1273; Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4; DALY JW, 1992, P NATL ACAD SCI USA, V89, P10960, DOI 10.1073/pnas.89.22.10960; Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1; Dimarcq JL, 1998, BIOPOLYMERS, V47, P465, DOI 10.1002/(SICI)1097-0282(1998)47:6<465::AID-BIP5>3.0.CO;2-#; Egorov TA, 2005, PEPTIDES, V26, P2064, DOI 10.1016/j.peptides.2005.03.007; Escoubas P, 2004, TOXICON, V43, P555, DOI 10.1016/j.toxicon.2004.02.007; FLORACK DEA, 1994, PLANT MOL BIOL, V24, P83, DOI 10.1007/BF00040576; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Giangaspero A, 2001, EUR J BIOCHEM, V268, P5589; He K, 1996, BIOPHYS J, V70, P2659, DOI 10.1016/S0006-3495(96)79835-1; Herbst R, 2004, J BIOL CHEM, V279, P25955, DOI 10.1074/jbc.M401965200; Imler Jean-Luc, 2005, V86, P1, DOI 10.1159/000086648; Kozlov S, 2005, TOXICON, V46, P672, DOI 10.1016/j.toxicon.2005.07.009; Kozlov S, 2005, PROTEINS, V59, P131, DOI 10.1002/prot.20390; KREIL G, 1973, FEBS LETT, V33, P241, DOI 10.1016/0014-5793(73)80202-9; Kuhn-Nentwig L, 2003, CELL MOL LIFE SCI, V60, P2651, DOI 10.1007/s00018-003-3106-8; Kuhn-Nentwig L, 2002, J BIOL CHEM, V277, P11208, DOI 10.1074/jbc.M111099200; Ludtke SJ, 1996, BIOCHEMISTRY-US, V35, P13723, DOI 10.1021/bi9620621; Marcus JP, 1999, PLANT J, V19, P699, DOI 10.1046/j.1365-313x.1999.00569.x; Moerman L, 2002, EUR J BIOCHEM, V269, P4799, DOI 10.1046/j.1432-1033.2002.03177.x; MUELLER P, 1962, NATURE, V194, P979, DOI 10.1038/194979a0; Orivel J, 2001, J BIOL CHEM, V276, P17823, DOI 10.1074/jbc.M100216200; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; Peschel A, 2002, TRENDS MICROBIOL, V10, P179, DOI 10.1016/S0966-842X(02)02333-8; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rabel D, 2004, J BIOL CHEM, V279, P14853, DOI 10.1074/jbc.M313608200; Satchell DP, 2003, J BIOL CHEM, V278, P13838, DOI 10.1074/jbc.M212115200; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Shin SY, 2000, BIOCHEM BIOPH RES CO, V275, P904, DOI 10.1006/bbrc.2000.3269; Tailor RH, 1997, J BIOL CHEM, V272, P24480, DOI 10.1074/jbc.272.39.24480; Terlau H, 2004, PHYSIOL REV, V84, P41, DOI 10.1152/physrev.00020.2003; TERRY AS, 1988, J BIOL CHEM, V263, P5745; TOSSI A, 1994, FEBS LETT, V339, P108, DOI 10.1016/0014-5793(94)80395-1; Tossi A, 2000, BIOPOLYMERS, V55, P4; Vanhoye D, 2003, EUR J BIOCHEM, V270, P2068, DOI 10.1046/j.1432-1033.2003.03584.x; Wullschleger B, 2005, J EXP BIOL, V208, P2115, DOI 10.1242/jeb.01594; Yamada K, 1999, J BIOL CHEM, V274, P2563, DOI 10.1074/jbc.274.4.2563; Yang L, 2001, BIOPHYS J, V81, P1475, DOI 10.1016/S0006-3495(01)75802-X; Yans LZ, 1998, J BIOL CHEM, V273, P2059, DOI 10.1074/jbc.273.4.2059; Zeng XC, 2004, PEPTIDES, V25, P143, DOI 10.1016/j.peptides.2003.12.003	53	140	161	0	17	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20983	20992		10.1074/jbc.M602168200	http://dx.doi.org/10.1074/jbc.M602168200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16735513	hybrid			2022-12-25	WOS:000239187300035
J	Kim, J; Kil, IS; Seok, YM; Yang, ES; Kim, DK; Lim, DG; Park, JW; Bonventre, JV; Park, KM				Kim, Jinu; Kil, In Sup; Seok, Young Mi; Yang, Eun Sun; Kim, Dae Kyong; Lim, Dong Gun; Park, Jeen-Woo; Bonventre, Joseph V.; Park, Kwon Moo			Orchiectomy attenuates post-ischemic oxidative stress and ischemia/reperfusion injury in mice - A role for manganese superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIA-REPERFUSION INJURY; INDUCED FUNCTIONAL INJURY; MAPK KINASE ACTIVATION; NITRIC-OXIDE SYNTHASE; ANTIOXIDANT ACTION; CHRONIC REJECTION; RENAL ISCHEMIA; KIDNEY; RAT; GENDER	Males are much more susceptible to ischemia/reperfusion (I/R)-induced kidney injury when compared with females. Recently we reported that the presence of testosterone, rather than the absence of estrogen, plays a critical role in gender differences in kidney susceptibility to I/R injury in mice. Although reactive oxygen species and antioxidant defenses have been implicated in I/R injury, their roles remain to be defined. Here we report that the orchiectomized animal had significantly less lipid peroxidation and lower hydrogen peroxide levels in the kidney 4 and 24 h after 30 min of bilateral renal ischemia when compared with intact or dihydrotestosterone-treated orchiectomized males. The post-ischemic kidney expression and activity of manganese superoxide dismutase (MnSOD) in orchiectomized mice was much greater than in intact or dihydrotestosterone-administered orchiectomized mice. Four hours after 30 min of bilateral ischemia, superoxide formation was significantly lower in orchiectomized mice than in intact mice. In Madin-Darby canine kidney cells, a kidney epithelial cell line, 1 mM H2O2 decreased MnSOD activity, an effect that was potentiated by pretreatment with dihydrotestosterone. Orchiectomy prevented the post-ischemic decrease of catalase activity. Treatment of male mice with manganese(III) tetrakis(1-methyl-4-pyridyl) porphyrin (MnTMPyP), a SOD mimetic, reduced the post-ischemic increase of plasma creatinine, lipid peroxidation, and tissue hydrogen peroxide. These results suggest that orchiectomy accelerates the post-ischemic activation of MnSOD and reduces reactive oxygen species and lipid peroxidation, resulting in reduced kidney susceptibility to I/R injury.	Kyungpook Natl Univ, Sch Med, Dept Anat, Taegu 700422, South Korea; Kyungpook Natl Univ, Sch Med, Dept Anesthesiol & Pain Med, Taegu 700422, South Korea; Kyungpook Natl Univ, Coll Nat Sci, Dept Biochem, Taegu 700422, South Korea; Chung Ang Univ, Coll Pharm, Dept Environm & Hlth Chem, Seoul 156756, South Korea; Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Kyungpook National University; Kyungpook National University; Kyungpook National University; Chung Ang University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Park, KM (corresponding author), Kyungpook Natl Univ, Sch Med, Dept Anat, 101 Dongin 2Ga, Taegu 700422, South Korea.	kmpark@knu.ac.kr		Kim, Jinu/0000-0002-1313-4791	NIDDK NIH HHS [DK-39773] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039773, R01DK039773] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Actis-Goretta L, 2004, CLIN CHIM ACTA, V349, P97, DOI 10.1016/j.cccn.2004.06.009; Aragno M, 2003, KIDNEY INT, V64, P836, DOI 10.1046/j.1523-1755.2003.00152.x; Arnal JF, 1996, P NATL ACAD SCI USA, V93, P4108, DOI 10.1073/pnas.93.9.4108; BONVENTRE JV, 1993, KIDNEY INT, V43, P1160, DOI 10.1038/ki.1993.163; Borras C, 2003, FREE RADICAL BIO MED, V34, P546, DOI 10.1016/S0891-5849(02)01356-4; Camper-Kirby D, 2001, CIRC RES, V88, P1020, DOI 10.1161/hh1001.090858; Chen ZY, 1998, J MOL CELL CARDIOL, V30, P2281, DOI 10.1006/jmcc.1998.0789; Chien CT, 2001, J AM SOC NEPHROL, V12, P973, DOI 10.1681/ASN.V125973; Cruthirds DL, 2003, ARCH BIOCHEM BIOPHYS, V412, P27, DOI 10.1016/S0003-9861(03)00039-0; Deng Huazhao, 1999, Hunan Yike Daxue Xuebao, V24, P343; Dobashi K, 2000, MOL CELL BIOCHEM, V205, P1, DOI 10.1023/A:1007047505107; Eltzschig HK, 2004, BRIT MED BULL, V70, P71, DOI 10.1093/bmb/ldh025; Fukuda K, 2000, STROKE, V31, P155, DOI 10.1161/01.STR.31.1.155; Gurel A, 2004, CLIN CHIM ACTA, V339, P33, DOI 10.1016/j.cccn.2003.09.013; Inal M, 2002, CELL BIOCHEM FUNCT, V20, P291, DOI 10.1002/cbf.953; Jain M, 2004, CIRCULATION, V109, P898, DOI 10.1161/01.CIR.0000112605.43318.CA; Kaminski KA, 2002, INT J CARDIOL, V86, P41, DOI 10.1016/S0167-5273(02)00189-4; LAND W, 1994, TRANSPLANTATION, V57, P211, DOI 10.1097/00007890-199401001-00010; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; Lee JH, 2004, FREE RADICAL BIO MED, V37, P272, DOI 10.1016/j.freeradbiomed.2004.04.029; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; MacMillan-Crow LA, 2001, FREE RADICAL BIO MED, V31, P1603, DOI 10.1016/S0891-5849(01)00750-X; MacMillan-Crow LA, 2001, FREE RADICAL RES, V34, P325, DOI 10.1080/10715760100300281; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; MARKLUND S, 1974, European Journal of Biochemistry, V47, P469, DOI 10.1111/j.1432-1033.1974.tb03714.x; MOORADIAN AD, 1993, J STEROID BIOCHEM, V45, P509, DOI 10.1016/0960-0760(93)90166-T; Muller V, 2002, KIDNEY INT, V62, P1364, DOI 10.1111/j.1523-1755.2002.kid590.x; Park KM, 2004, J BIOL CHEM, V279, P52282, DOI 10.1074/jbc.M407629200; Park KM, 2005, BIOCHEM BIOPH RES CO, V328, P312, DOI 10.1016/j.bbrc.2004.12.177; Park KM, 2003, J BIOL CHEM, V278, P27256, DOI 10.1074/jbc.M301778200; Park KM, 2002, J BIOL CHEM, V277, P2040, DOI 10.1074/jbc.M107525200; Park KM, 2001, J BIOL CHEM, V276, P11870, DOI 10.1074/jbc.M007518200; Reckelhoff JF, 1999, CLIN EXP PHARMACOL P, V26, P127, DOI 10.1046/j.1440-1681.1999.02996.x; Reckelhoff JF, 1999, HYPERTENSION, V34, P920, DOI 10.1161/01.HYP.34.4.920; RUIZLARREA B, 1995, STEROIDS, V60, P780, DOI 10.1016/0039-128X(95)00119-B; RuizLarrea MB, 1997, J PHYSIOL BIOCHEM, V53, P225; Sam F, 2005, J CARD FAIL, V11, P473, DOI 10.1016/j.cardfail.2005.01.007; SILBIGER SR, 1995, AM J KIDNEY DIS, V25, P515, DOI 10.1016/0272-6386(95)90119-1; Silbiger SR, 2003, ADV RENAL REPLACE TH, V10, P3, DOI 10.1053/jarr.2003.50001; Squadrito F, 1997, EUR J PHARMACOL, V335, P185, DOI 10.1016/S0014-2999(97)01201-6; Strehlow K, 2003, CIRC RES, V93, P170, DOI 10.1161/01.RES.0000082334.17947.11; Toyokuni S, 1999, PATHOL INT, V49, P91, DOI 10.1046/j.1440-1827.1999.00829.x	42	94	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20349	20356		10.1074/jbc.M512740200	http://dx.doi.org/10.1074/jbc.M512740200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16682413	hybrid			2022-12-25	WOS:000239038200059
J	Snabaitis, AK; D'Mello, R; Dashnyam, S; Avkiran, M				Snabaitis, Andrew K.; D'Mello, Richard; Dashnyam, Semjidmaa; Avkiran, Metin			A novel role for protein phosphatase 2A in receptor-mediated regulation of the cardiac sarcolemmal Na+/H+ exchanger NHE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRICULAR MYOCYTES; SODIUM-HYDROGEN EXCHANGE; HEART-FAILURE; H+ EXCHANGE; CARDIOMYOCYTE HYPERTROPHY; ANGIOTENSIN-II; OKADAIC ACID; KINASE-C; ACTIVATION; INHIBITION	G(q) protein-coupled receptor stimulation increases sarcolemmal Na+/H+ exchanger (NHE1) activity in cardiac myocytes by an ERK/RSK-dependent mechanism, most likely via RSK-mediated phosphorylation of the NHE1 regulatory domain. Adenosine A(1) receptor stimulation inhibits this response through a G(i) protein-mediated pathway, but the distal inhibitory signaling mechanisms are unknown. In cultured adult rat ventricular myocytes (ARVM), the A1 receptor agonist cyclopentyladenosine (CPA) inhibited the increase in NHE1 phosphorylation induced by the alpha(1)-adrenoreceptor agonist phenylephrine, without affecting activation of the ERK/RSK pathway. CPA also induced significant accumulation of the catalytic subunit of type 2A protein phosphatase (PP2A(c)) in the particulate fraction, which contained the cellular NHE1 complement; this effect was abolished by pretreatment with pertussis toxin to inactivate G(i) proteins. Confocal immunofluorescence microscopic imaging of CPA-treated ARVM revealed significant co-localization of PP2A(c) and NHE1, in intercalated disc regions. In an in vitro assay, purified PP2A(c) dephosphorylated a GST-NHE1 fusion protein containing aa 625-747 of the NHE1 regulatory domain, which had been pre-phosphorylated by recombinant RSK; such dephosphorylation was inhibited by the PP2A-selective phosphatase inhibitor endothall. In intact ARVM, the ability of CPA to attenuate the phenylephrine-induced increase in NHE1 phosphorylation and activity was lost in the presence of endothall. These studies reveal a novel role for the PP2A holoenzyme in adenosine A1 receptor-mediated regulation of NHE1 activity in ARVM, the mechanism of which appears to involve G(i) protein-mediated translocation of PP2Ac and NHE1 dephosphorylation.	Kings Coll London, St Thomas Hosp, Div Cardiovasc, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Avkiran, M (corresponding author), Kings Coll London, St Thomas Hosp, Div Cardiovasc, London SE1 7EH, England.	metin.avkiran@kcl.ac.uk		Avkiran, Metin/0000-0003-2392-6343; snabaitis, andrew/0000-0003-0061-1111				Ai X, 2005, CIRC RES, V96, P54, DOI 10.1161/01.RES.0000152325.07495.5a; Aker S, 2004, CARDIOVASC RES, V63, P273, DOI 10.1016/j.cardiores.2004.04.014; Alvarez BV, 1999, CIRC RES, V85, P716, DOI 10.1161/01.RES.85.8.716; Avkiran M, 2000, BRIT J PHARMACOL, V131, P659, DOI 10.1038/sj.bjp.0703647; Avkiran M, 1999, AM J CARDIOL, V83, p10G; Avkiran M, 2002, J AM COLL CARDIOL, V39, P747, DOI 10.1016/S0735-1097(02)01693-5; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Boyce SW, 2003, J THORAC CARDIOV SUR, V126, P420, DOI 10.1016/S0022-5223(03)00209-5; Carr AN, 2002, MOL CELL BIOL, V22, P4124, DOI 10.1128/MCB.22.12.4124-4135.2002; de Hurtado MCC, 2002, CARDIOVASC RES, V53, P862; Engelhardt S, 2002, CIRC RES, V90, P814, DOI 10.1161/01.RES.0000014966.97486.C0; Fahimi-Vahid M, 2002, J MOL CELL CARDIOL, V34, P441, DOI 10.1006/jmcc.2002.1525; FLIEGEL L, 1995, CARDIOVASC RES, V29, P155, DOI 10.1016/S0008-6363(96)88563-4; GAMBASSI G, 1992, CIRC RES, V71, P870, DOI 10.1161/01.RES.71.4.870; Gan XHT, 2005, J PHARMACOL EXP THER, V312, P27, DOI 10.1124/jpet.104.073122; Gunasegaram S, 1999, CIRC RES, V85, P919; Haworth RS, 2003, J BIOL CHEM, V278, P31676, DOI 10.1074/jbc.M304400200; Hoque N, 2000, J PHARMACOL EXP THER, V294, P770; Karmazyn M, 1999, CIRC RES, V85, P777, DOI 10.1161/01.RES.85.9.777; KRAMER BK, 1991, CIRC RES, V68, P269, DOI 10.1161/01.RES.68.1.269; Leem CH, 1999, J PHYSIOL-LONDON, V517, P159, DOI 10.1111/j.1469-7793.1999.0159z.x; Lehoux S, 2001, J BIOL CHEM, V276, P15794, DOI 10.1074/jbc.M100410200; LI YM, 1993, BIOCHEM PHARMACOL, V46, P1435, DOI 10.1016/0006-2952(93)90109-A; Liu QH, 2003, AM J PHYSIOL-HEART C, V285, pH97, DOI 10.1152/ajpheart.00956.2002; Liu QH, 2002, AM J PHYSIOL-HEART C, V283, pH1314, DOI 10.1152/ajpheart.00343.2002; Louttit JB, 1999, J CARDIOVASC PHARM, V33, P285, DOI 10.1097/00005344-199902000-00016; MATSUI H, 1995, CARDIOVASC RES, V29, P215, DOI 10.1016/S0008-6363(96)88573-7; Mentzer RM, 2003, CIRCULATION, V108; Misik AJ, 2005, BIOCHEMISTRY-US, V44, P5842, DOI 10.1021/bi047659s; Moor AN, 1999, J BIOL CHEM, V274, P22985, DOI 10.1074/jbc.274.33.22985; Moor AN, 2001, J BIOL CHEM, V276, P16113, DOI 10.1074/jbc.M100519200; Orlowski J, 2004, PFLUG ARCH EUR J PHY, V447, P549, DOI 10.1007/s00424-003-1110-3; Petrecca K, 1999, AM J PHYSIOL-HEART C, V276, pH709, DOI 10.1152/ajpheart.1999.276.2.H709; Roberts NA, 2005, BRIT J PHARMACOL, V145, P477, DOI 10.1038/sj.bjp.0706210; Sabri A, 1998, CIRC RES, V82, P1053, DOI 10.1161/01.RES.82.10.1053; SARDET C, 1991, J BIOL CHEM, V266, P19166; SIM ATR, 1994, J NEUROCHEM, V62, P1552; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Snabaitis AK, 2000, CIRC RES, V86, P214, DOI 10.1161/01.RES.86.2.214; Snabaitis AK, 2005, CELL SIGNAL, V17, P655, DOI 10.1016/j.cellsig.2004.10.008; Snabaitis AK, 2002, CARDIOVASC RES, V53, P470, DOI 10.1016/S0008-6363(01)00464-3; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Takahashi E, 1999, J BIOL CHEM, V274, P20206, DOI 10.1074/jbc.274.29.20206; Tolstykh T, 2000, EMBO J, V19, P5682, DOI 10.1093/emboj/19.21.5682; von Lewinski D, 2004, CIRC RES, V94, P1392, DOI 10.1161/01.RES.0000129181.48395.ff; Yasutake M, 1996, CIRC RES, V79, P705, DOI 10.1161/01.RES.79.4.705; Yoshida H, 2000, AM J PHYSIOL-HEART C, V278, pH300, DOI 10.1152/ajpheart.2000.278.1.H300	47	62	62	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20252	20262		10.1074/jbc.M600268200	http://dx.doi.org/10.1074/jbc.M600268200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16707501	hybrid			2022-12-25	WOS:000239038200050
J	Thambirajah, AA; Dryhurst, D; Ishibashi, T; Li, A; Maffey, AH; Ausio, J				Thambirajah, Anita A.; Dryhurst, Deanna; Ishibashi, Toyotaka; Li, Andra; Maffey, Allison H.; Ausio, Juan			H2A.Z stabilizes chromatin in a way that is dependent on core histone acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY MAMMALIAN DEVELOPMENT; ESSENTIAL CHARGE PATCH; N-TERMINAL TAIL; NUCLEOSOME CORE; VARIANT H2A.Z; TETRAHYMENA-THERMOPHILA; DROSOPHILA-MELANOGASTER; CRYSTAL-STRUCTURE; INACTIVE GENES; IONIC-STRENGTH	The functional and structural chromatin roles of H2A. Z are still controversial. This work represents a further attempt to resolve the current functional and structural dichotomy by characterizing chromatin structures containing native H2A. Z. We have analyzed the role of this variant in mediating the stability of the histone octamer in solution using gel-filtration chromatography at different pH. It was found that decreasing the pH from neutral to acidic conditions destabilized the histone complex. Furthermore, it was shown that the H2A. Z-H2B dimer had a reduced stability. Sedimentation velocity analysis of nucleosome core particles (NCPs) reconstituted from native H2A. Z-containing octamers indicated that these particles exhibit a very similar behavior to that of native NCPs consisting of canonical H2A. Sucrose gradient fractionation of native NCPs under different ionic strengths indicated that H2A. Z had a subtle tendency to fractionate with more stabilized populations. Anextensive analysis of the salt-dependent dissociation of histones from hydroxyapatite-adsorbed chromatin revealed that, whereas H2A. Z co-elutes with H3-H4, hyperacetylation of histones (by treatment of chicken MSB cells with sodium butyrate) resulted in a significant fraction of this variant eluting with the canonical H2A. These studies also showed that the late elution of this variant (correlated to enhanced binding stability) was independent of the chromatin size and of the presence or absence of linker histones.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada	University of Victoria	Ausio, J (corresponding author), Univ Victoria, Dept Biochem & Microbiol, POB 3055,Petch Bldg 220, Victoria, BC V8W 3P6, Canada.	jausio@uvic.ca	Ishibashi, Toyotaka/AAW-2687-2020	Ishibashi, Toyotaka/0000-0001-8015-2319				Abbott DW, 2005, J BIOL CHEM, V280, P16437, DOI 10.1074/jbc.M500170200; Abbott DW, 2004, BIOCHEMISTRY-US, V43, P1352, DOI 10.1021/bi035859i; Abbott DW, 2001, J BIOL CHEM, V276, P41945, DOI 10.1074/jbc.M108217200; Adam M, 2001, MOL CELL BIOL, V21, P6270, DOI 10.1128/MCB.21.18.6270-6279.2001; AKIYAMA Y, 1974, BIKEN J, V17, P105; Ausio J, 2002, BIOCHEMISTRY-US, V41, P5945, DOI 10.1021/bi020059d; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; Ausio J, 1998, METHODS, V15, P333, DOI 10.1006/meth.1998.0637; Ausio J, 2000, BIOPHYS CHEM, V86, P141, DOI 10.1016/S0301-4622(00)00144-7; BRADBURY EM, 1975, BIOCHEMISTRY-US, V14, P1876, DOI 10.1021/bi00680a012; Bruce K, 2005, NUCLEIC ACIDS RES, V33, P5633, DOI 10.1093/nar/gki874; Clarkson MJ, 1999, NATURE, V399, P694, DOI 10.1038/21436; Dhillon N, 2000, MOL CELL, V6, P769, DOI 10.1016/S1097-2765(00)00076-9; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; Dryhurst D, 2004, BIOCHEM CELL BIOL, V82, P490, DOI 10.1139/O04-043; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; Faast R, 2001, CURR BIOL, V11, P1183, DOI 10.1016/S0960-9822(01)00329-3; Fan JY, 2004, MOL CELL, V16, P655, DOI 10.1016/j.molcel.2004.10.023; Farris SD, 2005, J BIOL CHEM, V280, P25298, DOI 10.1074/jbc.M501784200; FAULHABER I, 1967, BIOCHIM BIOPHYS ACTA, V140, P561, DOI 10.1016/0005-2795(67)90538-7; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; Gloss LM, 2002, BIOCHEMISTRY-US, V41, P14951, DOI 10.1021/bi026282s; GLOVER CVC, 1978, BIOCHEMISTRY-US, V17, P5705, DOI 10.1021/bi00619a016; Guillemette B, 2005, PLOS BIOL, V3, P2100, DOI 10.1371/journal.pbio.0030384; HATCH CL, 1995, DNA CELL BIOL, V14, P257, DOI 10.1089/dna.1995.14.257; HIROSE M, 1988, J BIOCHEM-TOKYO, V103, P31, DOI 10.1093/oxfordjournals.jbchem.a122234; Karantza V, 1996, BIOCHEMISTRY-US, V35, P2037, DOI 10.1021/bi9518858; KARANTZA V, 1995, BIOCHEMISTRY-US, V34, P5988, DOI 10.1021/bi00017a028; Karantza V, 2001, BIOCHEMISTRY-US, V40, P13114, DOI 10.1021/bi0110140; Kobor MS, 2004, PLOS BIOL, V2, P587, DOI 10.1371/journal.pbio.0020131; Larochelle M, 2003, EMBO J, V22, P4512, DOI 10.1093/emboj/cdg427; Leach TJ, 2000, J BIOL CHEM, V275, P23267, DOI 10.1074/jbc.M910206199; Lee KM, 1997, P NATL ACAD SCI USA, V94, P8959, DOI 10.1073/pnas.94.17.8959; Li A, 2005, BIOCHEMISTRY-US, V44, P2529, DOI 10.1021/bi048061n; LI W, 1993, BIOCHEM J, V296, P737, DOI 10.1042/bj2960737; Liu XW, 1996, MOL CELL BIOL, V16, P4305; Lowell JE, 2005, J CELL SCI, V118, P5721, DOI 10.1242/jcs.02688; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Marino-Ramirez L, 2005, EXPERT REV PROTEOMIC, V2, P719, DOI 10.1586/14789450.2.5.719; Meneghini MD, 2003, CELL, V112, P725, DOI 10.1016/S0092-8674(03)00123-5; Myers FA, 2003, J BIOL CHEM, V278, P36315, DOI 10.1074/jbc.M305822200; Myers FA, 2001, J BIOL CHEM, V276, P20197, DOI 10.1074/jbc.M009472200; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; OLINS AL, 1976, NUCLEIC ACIDS RES, V3, P3271, DOI 10.1093/nar/3.12.3271; Park YJ, 2004, J BIOL CHEM, V279, P24274, DOI 10.1074/jbc.M313152200; Placek BJ, 2005, PROTEIN SCI, V14, P514, DOI 10.1110/ps.041026405; Placek BJ, 2002, BIOCHEMISTRY-US, V41, P14960, DOI 10.1021/bi026283k; Rabbani A, 1999, J BIOL CHEM, V274, P18401, DOI 10.1074/jbc.274.26.18401; Raisner RM, 2005, CELL, V123, P233, DOI 10.1016/j.cell.2005.10.002; Rangasamy D, 2003, EMBO J, V22, P1599, DOI 10.1093/emboj/cdg160; Ren QH, 2003, MOL CELL BIOL, V23, P2778, DOI 10.1128/MCB.23.8.2778-2789.2003; Ren QH, 2001, MOL CELL, V7, P1329, DOI 10.1016/S1097-2765(01)00269-6; Santisteban MS, 2000, CELL, V103, P411, DOI 10.1016/S0092-8674(00)00133-1; Suto RK, 2000, NAT STRUCT BIOL, V7, P1121; Swaminathan J, 2005, GENE DEV, V19, P65, DOI 10.1101/gad.1259105; VANDAAL A, 1992, MOL BIOL CELL, V3, P593, DOI 10.1091/mbc.3.6.593; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; Wang XY, 2000, J BIOL CHEM, V275, P35013, DOI 10.1074/jbc.M004998200; Zhang HY, 2005, CELL, V123, P219, DOI 10.1016/j.cell.2005.08.036; Zheng CY, 2003, J BIOL CHEM, V278, P24217, DOI 10.1074/jbc.M302817200	60	55	56	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20036	20044		10.1074/jbc.M601975200	http://dx.doi.org/10.1074/jbc.M601975200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16707487	hybrid			2022-12-25	WOS:000239038200028
J	Ausar, SF; Foubert, TR; Hudson, MH; Vedvick, TS; Middaugh, CR				Ausar, Salvador F.; Foubert, Thomas R.; Hudson, Mary H.; Vedvick, Thomas S.; Middaugh, C. Russell			Conformational stability and disassembly of Norwalk virus-like particles - Effect of pH and temperature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM; OUTBREAKS; GASTROENTERITIS; SPECTROSCOPY; TRYPTOPHAN; PEPTIDES; RESIDUES; TYROSINE; SPECTRA	Greater than 99% of the Norwalk virus (NV) capsid consists of 180 copies of a single 58-kDa protein. Recombinantly expressed monomers self-assemble into virus-like particles (VLPs) with a well defined icosahedral structure. NV-VLPs are an appropriate vaccine antigen since the antigenic determinants of the parent virion are preserved. They also constitute very simple models to study the mechanisms of assembly and disassembly of viral capsids. This work examines the inherent stability of NV-VLPs over a range of pH and temperature values and provides detailed insight into structural perturbations that accompany disassembly. The NV-VLP structure was monitored using a variety of biophysical techniques including intrinsic and extrinsic fluorescence, high resolution second-derivative UV absorption spectroscopy, circular dichroism (CD), dynamic light scattering, differential scanning calorimetry, and direct observation employing transmission electron microscopy. The data demonstrate that NV-VLPs are highly stable over a pH range of 3-7 and up to 55 degrees C. At pH 8, however, reversible capsid dissociation was correlated with increased solvent exposure of tyrosine residues and subtle changes in secondary structure. Above 60 degrees C NV-VLPs undergo distinct phase transitions arising from secondary-, tertiary-, and quaternary-level protein structural perturbations. By combining the spectroscopic data employing a multidimensional eigenvector phase space approach, an empirical phase diagram for NV-VLP was constructed. This strategy of visualization provides a comprehensive description of the physical stability of NV-VLP over a broad range of pH and temperature. Complementary, differential scanning calorimetric analyses suggest that the two domains of VP1 unfold independently in a pH-dependent manner.	Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA; LigoCyte Pharmaceut Inc, Bozeman, MT 59718 USA	University of Kansas	Middaugh, CR (corresponding author), Univ Kansas, Dept Pharmaceut Chem, Multidisciplinary Res Bldg,2030 Becker Dr, Lawrence, KS 66047 USA.	middaugh@ku.edu		Ausar, Salvador/0000-0001-7001-7615				BROWN JC, 1975, J CHEM PHYS, V62, P1136, DOI 10.1063/1.430557; Carreira A, 2004, J BIOL CHEM, V279, P6517, DOI 10.1074/jbc.M307662200; Chakravarty S, 2005, J VIROL, V79, P554, DOI 10.1128/JVI.79.1.554-568.2005; Chernysh S, 2002, P NATL ACAD SCI USA, V99, P12628, DOI 10.1073/pnas.192301899; Culver JN, 2002, ANNU REV PHYTOPATHOL, V40, P287, DOI 10.1146/annurev.phyto.40.120301.102400; Doultree JC, 1999, J HOSP INFECT, V41, P51, DOI 10.1016/S0195-6701(99)90037-3; Fan HH, 2005, J PHARM SCI-US, V94, P1893, DOI 10.1002/jps.20410; Fankhauser RL, 2002, J INFECT DIS, V186, P1, DOI 10.1086/341085; GREENBERG HB, 1979, J INFECT DIS, V139, P564, DOI 10.1093/infdis/139.5.564; HARDY ME, 1995, J VIROL, V69, P1693, DOI 10.1128/JVI.69.3.1693-1698.1995; HYAMS KC, 1993, J INFECT DIS, V167, P986, DOI 10.1093/infdis/167.4.986; Jiang G, 2006, J PHARM SCI-US, V95, P80, DOI 10.1002/jps.20484; JIANG X, 1993, VIROLOGY, V195, P51, DOI 10.1006/viro.1993.1345; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; Krell T, 2005, BIOTECHNOL APPL BIOC, V41, P241, DOI 10.1042/BA20040113; Kueltzo LA, 2003, J PHARM SCI-US, V92, P1805, DOI 10.1002/jps.10439; Lopman BA, 2003, EMERG INFECT DIS, V9, P71; MACH H, 1993, BIOTECHNIQUES, V15, P240; MACH H, 1994, ANAL BIOCHEM, V222, P323, DOI 10.1006/abio.1994.1499; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; McCarthy M, 2000, J INFECT DIS, V181, pS387, DOI 10.1086/315582; Oliveira AC, 2000, J BIOL CHEM, V275, P16037, DOI 10.1074/jbc.M910145199; Pirtle E C, 1991, Rev Sci Tech, V10, P733; Prasad BVV, 1999, SCIENCE, V286, P287, DOI 10.1126/science.286.5438.287; PRASAD BVV, 1994, J VIROL, V68, P5117, DOI 10.1128/JVI.68.8.5117-5125.1994; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rexroad J, 2006, J PHARM SCI-US, V95, P237, DOI 10.1002/jps.20496; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; Singh S, 2003, J BIOL CHEM, V278, P18249, DOI 10.1074/jbc.M211408200; Sreerama N, 2003, PROTEIN SCI, V12, P384, DOI 10.1110/ps.0235003; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Stark M, 2002, ANTIMICROB AGENTS CH, V46, P3585, DOI 10.1128/AAC.46.11.3585-3590.2002; Tacket CO, 2005, VACCINE, V23, P1866, DOI 10.1016/j.vaccine.2004.11.019; Tacket CO, 2003, CLIN IMMUNOL, V108, P241, DOI 10.1016/S1521-6616(03)00120-7; White LJ, 1997, J VIROL, V71, P8066, DOI 10.1128/JVI.71.10.8066-8072.1997; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; XI JA, 1992, J VIROL, V66, P6527, DOI 10.1128/JVI.66.11.6527-6532.1992	37	167	183	2	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19478	19488		10.1074/jbc.M603313200	http://dx.doi.org/10.1074/jbc.M603313200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16675449	hybrid			2022-12-25	WOS:000238847000063
J	Babbin, BA; Lee, WY; Parkos, CA; Winfree, LM; Akyildiz, A; Perretti, M; Nusrat, A				Babbin, Brian A.; Lee, Winston Y.; Parkos, Charles A.; Winfree, L. Matthew; Akyildiz, Adil; Perretti, Mauro; Nusrat, Asma			Annexin I regulates SKCO-15 cell invasion by signaling through formyl peptide receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOXIN A(4) RECEPTOR; METASTASIS-ASSOCIATED PROTEINS; MATRIX METALLOPROTEINASES MMPS; LIPOCORTIN-DERIVED PEPTIDES; ALVEOLAR EPITHELIAL-CELLS; CHEMOATTRACTANT RECEPTOR; PHOSPHOINOSITIDE HYDROLYSIS; FORMYLPEPTIDE RECEPTOR; EXTRACELLULAR-MATRIX; ENDOGENOUS LIGAND	Annexin 1 (AnxA1) is a multifunctional phospholipid-binding protein associated with the development of metastasis in some invasive epithelial malignancies. However, the role of AnxA1 in the migration/invasion of epithelial cells is not known. In this study, experiments were performed to investigate the role of AnxA1 in the invasion of a model epithelial cell line, SKCO-15, derived from colorectal adenocarcinoma. Small interfering RNA-mediated knockdown of AnxA1 expression resulted in a significant reduction in invasion through Matrigel-coated filters. Localization studies revealed a translocation of AnxA1 to the cell surface upon the induction of cell migration, and functional inhibition of cell surface AnxA1 using antiserum (LCO1) significantly reduced cell invasion. Conversely, SKCO-15 cell invasion was increased by similar to 2-fold in the presence of recombinant full-length AnxA1 and the AnxA1 N-terminal-derived peptide mimetic, Ac2-26. Because extracellular AnxA1 has been shown to regulate leukocyte migratory events through interactions with n-formyl peptide receptors (nFPRs), we examined the expression of FPR-1, FPRL-1, and FPRL-2 in SKCO-15 cells by reverse transcriptase-PCR and identified expression of all three receptors in this cell line. Treatment of SKCO-15 cells with AnxA1, Ac2-26, and the classical nFPR agonist, formylmethionylleucylphenylalanine, induced intracellular calcium release consistent with nFPR activation. Furthermore, the nFPR antagonist, Boc2, abrogated the AnxA1 and Ac2-26-induced intracellular calcium release and increase in SKCO-15cell invasion. Together, these results support an autocrine/paracrine role for membrane AnxA1 in stimulating SKCO-15 cell migration through nFPR activation. The findings in this study suggest that activation of nFPRs stimulates epithelial cell motility important in the development of metastasis as well as wound healing.	Emory Univ, Dept Pathol & Lab Med, Epithelial Pathobiol Res Unit, Atlanta, GA 30322 USA; Barts & London Queen Marys Sch Med & Dent, William Harvey Res Inst, London EC1M 6BQ, England	Emory University; University of London; Queen Mary University London	Babbin, BA (corresponding author), Emory Univ, Dept Pathol & Lab Med, Epithelial Pathobiol Res Unit, Whitehead Biomed Bldg 115,615 Micheal St, Atlanta, GA 30322 USA.	bbabbin@emory.edu	Parkos, Charles a/B-3896-2009; Nusrat, Asma/B-3887-2009		NIGMS NIH HHS [T32 GM008169] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008169] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alfonso P, 2005, PROTEOMICS, V5, P2602, DOI 10.1002/pmic.200401196; Alldridge LC, 2003, EXP CELL RES, V290, P93, DOI 10.1016/S0014-4827(03)00310-0; Alldridge LC, 1999, J BIOL CHEM, V274, P37620, DOI 10.1074/jbc.274.53.37620; AMBROSE MP, 1990, AM J RESP CELL MOL, V3, P349, DOI 10.1165/ajrcmb/3.4.349; Bae YS, 2004, J IMMUNOL, V173, P607, DOI 10.4049/jimmunol.173.1.607; Baek SH, 1996, J BIOL CHEM, V271, P8170, DOI 10.1074/jbc.271.14.8170; Bai XF, 2004, WORLD J GASTROENTERO, V10, P1466; Becker EL, 1998, CELL TISSUE RES, V292, P129, DOI 10.1007/s004410051042; Chodniewicz D, 2003, BLOOD, V101, P1181, DOI 10.1182/blood-2002-05-1435; Chou CL, 2000, J BIOL CHEM, V275, P36839, DOI 10.1074/jbc.M005552200; Christensen PJ, 2004, AM J PHYSIOL-LUNG C, V286, pL68, DOI 10.1152/ajplung.00079.2003; Cicek M, 2004, CLIN EXP METASTAS, V21, P149, DOI 10.1023/B:CLIN.0000024729.19084.f0; CIRINO G, 1987, PROSTAGLANDINS, V34, P59, DOI 10.1016/0090-6980(87)90262-0; CROXTALL J, 1993, J LIPID MEDIATOR, V6, P295; CROXTALL JD, 1992, P NATL ACAD SCI USA, V89, P3571, DOI 10.1073/pnas.89.8.3571; Croxtall JD, 1996, BIOCHEM PHARMACOL, V52, P351, DOI 10.1016/0006-2952(95)02442-5; CUPO JF, 1989, BIOCHIM BIOPHYS ACTA, V982, P31, DOI 10.1016/0005-2736(89)90170-3; Dahlgren C, 2000, BLOOD, V95, P1810, DOI 10.1182/blood.V95.5.1810.005k06_1810_1818; de Paulis A, 2004, J IMMUNOL, V173, P5739, DOI 10.4049/jimmunol.173.9.5739; DURSTIN M, 1994, BIOCHEM BIOPH RES CO, V201, P174, DOI 10.1006/bbrc.1994.1685; Emoto K, 2001, ANTICANCER RES, V21, P1339; Ernst S, 2004, J IMMUNOL, V172, P7669, DOI 10.4049/jimmunol.172.12.7669; Fenteany G, 2000, CURR BIOL, V10, P831, DOI 10.1016/S0960-9822(00)00579-0; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; Gavins FNE, 2003, BLOOD, V101, P4140, DOI 10.1182/blood-2002-11-3411; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; GOULDING NJ, 1990, BIOCHEM SOC T, V18, P306, DOI 10.1042/bst0180306; Gronert K, 1998, J EXP MED, V187, P1285, DOI 10.1084/jem.187.8.1285; Hayes MJ, 2004, BIOCHEM BIOPH RES CO, V322, P1166, DOI 10.1016/j.bbrc.2004.07.124; Hayhoe RPG, 2006, BLOOD, V107, P2123, DOI 10.1182/blood-2005-08-3099; Hopkins AM, 2004, AM J PHYSIOL-GASTR L, V287, pG886, DOI 10.1152/ajpgi.00065.2004; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Huber E, 2004, J VIROL, V78, P7478, DOI 10.1128/JVI.78.14.7478-7489.2004; HULLIN F, 1989, J BIOL CHEM, V264, P3506; Ivanov AI, 2004, MOL BIOL CELL, V15, P2639, DOI 10.1091/mbc.E04-02-0163; Jackson M, 1996, EASTERN EUR ECON, V34, P3, DOI 10.1080/00128775.1996.11648587; Jiang DF, 2003, PROTEOMICS, V3, P724, DOI 10.1002/pmic.200300411; Katanaev VL, 2001, BIOCHEMISTRY-MOSCOW+, V66, P351, DOI 10.1023/A:1010293809553; Kirfel G, 2004, EUR J CELL BIOL, V83, P717, DOI 10.1078/0171-9335-00421; Kucharzik T, 2003, AM J PHYSIOL-CELL PH, V284, pC888, DOI 10.1152/ajpcell.00507.2001; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Le YY, 2001, CYTOKINE GROWTH F R, V12, P91, DOI 10.1016/S1359-6101(01)00003-X; Le YY, 2002, TRENDS IMMUNOL, V23, P541, DOI 10.1016/S1471-4906(02)02316-5; Le YY, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-02-j0003.2001; Li S, 2005, ANNU REV BIOMED ENG, V7, P105, DOI 10.1146/annurev.bioeng.7.060804.100340; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; Liu Y, 2000, J CELL SCI, V113, P2363; Mandell KJ, 2005, J BIOL CHEM, V280, P11665, DOI 10.1074/jbc.M412650200; MCCOY R, 1995, J EXP MED, V182, P207, DOI 10.1084/jem.182.1.207; Mercurio AM, 2004, SEMIN CANCER BIOL, V14, P115, DOI 10.1016/j.semcancer.2003.09.016; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; Oliani SM, 2001, AM J PATHOL, V158, P603, DOI 10.1016/S0002-9440(10)64002-3; Panaro MA, 1999, IMMUNOPHARM IMMUNOT, V21, P397, DOI 10.3109/08923979909007117; Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786; Perretti M, 2001, AM J PATHOL, V158, P1969, DOI 10.1016/S0002-9440(10)64667-6; PERRETTI M, 1993, J IMMUNOL, V151, P4306; Perretti M, 1996, BRIT J PHARMACOL, V118, P605, DOI 10.1111/j.1476-5381.1996.tb15444.x; PERRETTI M, 1995, AGENT ACTION SUPPL, V46, P131; PERRETTI M, 1993, J IMMUNOL, V150, P992; PERRETTI M, 1994, BIOCHEM PHARMACOL, V47, P931, DOI 10.1016/0006-2952(94)90402-2; Perretti M, 1996, NAT MED, V2, P1259, DOI 10.1038/nm1196-1259; Prossnitz ER, 1999, BIOCHEMISTRY-US, V38, P2240, DOI 10.1021/bi982274t; Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3; Rescher U, 2002, J IMMUNOL, V169, P1500, DOI 10.4049/jimmunol.169.3.1500; Rhee NJ, 2000, EUR J BIOCHEM, V267, P3220, DOI 10.1046/j.1432-1327.2000.01345.x; Ryan JS, 1999, J PHYSIOL-LONDON, V520, P745, DOI 10.1111/j.1469-7793.1999.00745.x; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Sampey AV, 2000, ARTHRITIS RHEUM, V43, P2537, DOI 10.1002/1529-0131(200011)43:11<2537::AID-ANR22>3.0.CO;2-M; Seifert R, 2001, J BIOL CHEM, V276, P42043, DOI 10.1074/jbc.M106621200; SENGELOV H, 1994, BIOCHEM J, V299, P473, DOI 10.1042/bj2990473; Seo JK, 1997, J IMMUNOL, V158, P1895; Shi T, 2004, MOL CARCINOGEN, V40, P47, DOI 10.1002/mc.20015; SILICIANO JD, 1988, J CELL BIOL, V107, P2389, DOI 10.1083/jcb.107.6.2389; Singh AB, 2005, CELL SIGNAL, V17, P1183, DOI 10.1016/j.cellsig.2005.03.026; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Solito E, 1998, CELL GROWTH DIFFER, V9, P327; Srivastava M, 2004, CLIN CANCER RES, V10, P2344, DOI 10.1158/1078-0432.CCR-03-0278; Srivastava M, 2001, DIS MARKERS, V17, P115, DOI 10.1155/2001/239602; Steffensen B, 2001, CRIT REV ORAL BIOL M, V12, P373, DOI 10.1177/10454411010120050201; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; THEOBALD J, 1995, BRIT J CANCER, V71, P786, DOI 10.1038/bjc.1995.152; VanCompernolle SE, 2003, J IMMUNOL, V171, P2050, DOI 10.4049/jimmunol.171.4.2050; Vergnolle N, 2004, INFLAMM BOWEL DIS, V10, P584, DOI 10.1097/00054725-200409000-00013; VERGNOLLE N, 1995, EUR J BIOCHEM, V232, P603, DOI 10.1111/j.1432-1033.1995.603zz.x; von der Weid PY, 2004, CIRCULATION, V110, P1320, DOI 10.1161/01.CIR.0000140985.89766.CB; Walther A, 2000, MOL CELL, V5, P831, DOI 10.1016/S1097-2765(00)80323-8; Wang Y, 2004, BIOCHEM BIOPH RES CO, V314, P565, DOI 10.1016/j.bbrc.2003.12.117; Wenzel-Seifert K, 2003, BIOCHEM BIOPH RES CO, V301, P693, DOI 10.1016/S0006-291X(03)00023-8; White IJ, 2006, EMBO J, V25, P1, DOI 10.1038/sj.emboj.7600759; WU CC, 1995, P NATL ACAD SCI USA, V92, P3473, DOI 10.1073/pnas.92.8.3473; Wu WG, 2002, CLIN EXP METASTAS, V19, P319, DOI 10.1023/A:1015515119300; Yang D, 2002, J LEUKOCYTE BIOL, V72, P598; Zigrino P, 2005, BIOCHIMIE, V87, P321, DOI 10.1016/j.biochi.2004.10.025	93	121	125	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19588	19599		10.1074/jbc.M513025200	http://dx.doi.org/10.1074/jbc.M513025200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16675446	hybrid			2022-12-25	WOS:000238847000073
J	Oresic, K; Noriega, V; Andrews, L; Tortorella, D				Oresic, Kristina; Noriega, Vanessa; Andrews, Laura; Tortorella, Domenico			A structural determinant of human cytomegalovirus US2 dictates the down-regulation of class I major histocompatibility molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX CLASS-I; MHC CLASS-I; VIRAL IMMUNE EVASION; ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEIN; ANTIGEN PRESENTATION; HEAVY-CHAINS; N-GLYCANASE; ER; DEGRADATION	Human cytomegalovirus down-regulates cell surface class I major histocompatibility (MHC) molecules, thus allowing the virus to proliferate while avoiding detection by CD8(+) T lymphocytes. The unique short gene product US2 is a 199-amino acid type I endoplasmic reticulum glycoprotein that modulates surface expression of class I MHC products by targeting class I heavy chains for dislocation from the endoplasmic reticulum to the cytosol, where they undergo proteasomal degradation. Although the mechanism by which this viral protein targets class I heavy chains for destruction remains unclear, the putative US2 cytoplasmic tail comprised of only 14 residues is known to play a functional role. To determine the specific residues critical for mediating class I degradation, a mutagenesis analysis of the cytoplasmic tail of US2 was performed. Using truncation mutants, the removal of only 4 residues (mutant US2(195)) from the US2 carboxyl terminus completely abolishes class I destruction. Furthermore, site-directed mutagenesis of the US2 cytoplasmic tail revealed that the most critical residues for class I-induced destruction, cysteine 187, serine 190, tryptophan 193, and phenylalanine 196, occurs every third residue. This experimental data supports a model that the US2 cytoplasmic tail is in a 310 helical configuration. Such a secondary structure would predict that one side of the 310 helical cytoplasmic tail would interact with the extraction apparatus to facilitate the dislocation and subsequent destruction of class I heavy chains.	Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; Jozef Stefan Inst, Dept Biochem & Mol Biol, Ljubljana 1000, Slovenia	Icahn School of Medicine at Mount Sinai; Slovenian Academy of Sciences & Arts (SASA); Jozef Stefan Institute	Tortorella, D (corresponding author), 1 Gustave L Levy Pl,Box 1124, New York, NY 10029 USA.	Domenico.Tortorella@mssm.edu		Tortorella, Domenico/0000-0003-0961-3535	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060905] Funding Source: NIH RePORTER; NIAID NIH HHS [AI060905, AI07647] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahn K, 1997, IMMUNITY, V6, P613, DOI 10.1016/S1074-7613(00)80349-0; Ahn KS, 1996, P NATL ACAD SCI USA, V93, P10990, DOI 10.1073/pnas.93.20.10990; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; Biron Z, 2002, BIOCHEMISTRY-US, V41, P12687, DOI 10.1021/bi026261y; Blom D, 2004, EMBO J, V23, P650, DOI 10.1038/sj.emboj.7600090; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; Chevalier MS, 2002, J VIROL, V76, P8265, DOI 10.1128/JVI.76.16.8265-8275.2002; Demarest SJ, 1999, J MOL BIOL, V294, P213, DOI 10.1006/jmbi.1999.3228; Ferreon JC, 2005, J BIOL CHEM, V280, P20483, DOI 10.1074/jbc.M500422200; Furman MH, 2003, J BIOL CHEM, V278, P34804, DOI 10.1074/jbc.M300913200; Furman MH, 2002, J BIOL CHEM, V277, P3258, DOI 10.1074/jbc.M109765200; Gewurz BE, 2001, P NATL ACAD SCI USA, V98, P6794, DOI 10.1073/pnas.121172898; Gewurz BE, 2001, J VIROL, V75, P5197, DOI 10.1128/JVI.75.11.5197-5204.2001; Hashimoto Y, 1998, J BIOL CHEM, V273, P16544, DOI 10.1074/jbc.273.26.16544; Hengel H, 1997, IMMUNITY, V6, P623, DOI 10.1016/S1074-7613(00)80350-7; Hewitt EW, 2003, IMMUNOLOGY, V110, P163, DOI 10.1046/j.1365-2567.2003.01738.x; Hirsch C, 2003, EMBO J, V22, P1036, DOI 10.1093/emboj/cdg107; Jones TR, 1997, J VIROL, V71, P2970, DOI 10.1128/JVI.71.4.2970-2979.1997; Jones TR, 1996, P NATL ACAD SCI USA, V93, P11327, DOI 10.1073/pnas.93.21.11327; Lilley BN, 2004, NATURE, V429, P834, DOI 10.1038/nature02592; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Pal L, 1999, PROTEIN ENG, V12, P811, DOI 10.1093/protein/12.10.811; Pal L, 2003, J MOL BIOL, V326, P273, DOI 10.1016/S0022-2836(02)01338-4; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; PARHAM P, 1979, J IMMUNOL, V123, P342; Peti W, 2005, J VIROL, V79, P12905, DOI 10.1128/JVI.79.20.12905-12913.2005; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Rape M, 2004, BBA-MOL CELL RES, V1695, P209, DOI 10.1016/j.bbamcr.2004.09.022; Sayeed A, 2005, CRIT REV BIOCHEM MOL, V40, P75, DOI 10.1080/10409230590918685; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Shamu CE, 2001, MOL BIOL CELL, V12, P2546, DOI 10.1091/mbc.12.8.2546; Suzuki T, 2000, J CELL BIOL, V149, P1039, DOI 10.1083/jcb.149.5.1039; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; Vossen MTM, 2002, IMMUNOGENETICS, V54, P527, DOI 10.1007/s00251-002-0493-1; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Worthylake DK, 1999, ACTA CRYSTALLOGR D, V55, P85, DOI 10.1107/S0907444998007689; Xu RM, 1997, STRUCTURE, V5, P559, DOI 10.1016/S0969-2126(97)00211-6; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656	42	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19395	19406		10.1074/jbc.M601026200	http://dx.doi.org/10.1074/jbc.M601026200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16687410	hybrid			2022-12-25	WOS:000238847000055
J	Terao, M; Kurosaki, M; Barzago, MM; Varasano, E; Boldetti, A; Bastone, A; Fratelli, M; Garattini, E				Terao, Mineko; Kurosaki, Mami; Barzago, Maria Monica; Varasano, Emanuela; Boldetti, Andrea; Bastone, Antonio; Fratelli, Maddalena; Garattini, Enrico			Avian and canine aldehyde oxidases - Novel insights into the biology and evolution of molybdo-flavoenzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER XANTHINE DEHYDROGENASE; DINUCLEOTIDE-BINDING-SITE; MOLECULAR-CLONING; ADENINE-DINUCLEOTIDE; CRYSTAL-STRUCTURE; CDNA CLONING; GENE-CLUSTER; TISSUE DISTRIBUTION; IN-VIVO; OXIDOREDUCTASE	Aldehyde oxidases are molybdo-flavoenzymes structurally related to xanthine oxidoreductase. They catalyze the oxidation of aldehydes or N-heterocycles of physiological, pharmacological, and toxicological relevance. Rodents are characterized by four aldehyde oxidases as follows: AOX1 and aldehyde oxidase homologs 1-3 (AOH1, AOH2, and AOH3). Humans synthesize a single functional aldehyde oxidase, AOX1. Here we define the structure and the characteristics of the aldehyde oxidase genes and proteins in chicken and dog. The avian genome contains two aldehyde oxidase genes, AOX1 and AOH, mapping to chromosome 7. AOX1 and AOH are structurally very similar and code for proteins whose sequence was deduced from the corresponding cDNAs. AOX1 is the ortholog of the same gene in mammals, whereas AOH represents the likely ancestor of rodent AOH1, AOH2, and AOH3. The dog genome is endowed with two structurally conserved and active aldehyde oxidases clustering on chromosome 37. Cloning of the corresponding cDNAs and tissue distribution studies demonstrate that they are the orthologs of rodent AOH2 and AOH3. The vestiges of dog AOX1 and AOH1 are recognizable upstream of AOH2 and AOH3 on the same chromosome. Comparison of the complement and the structure of the aldehyde oxidase and xanthine oxidoreductase genes in vertebrates and other animal species indicates that they evolved through a series of duplication and inactivation events. Purification of the chicken AOX1 protein to homogeneity from kidney demonstrates that the enzyme possesses retinaldehyde oxidase activity. Unlike humans and most other mammals, dog and chicken are devoid of liver aldehyde oxidase activity.	Univ Milan, Ist Ric Farmacol Mario Negri, Mol Biol Lab, Ctr Catullo & Deniela Borgomainerio, I-20157 Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Milan	Garattini, E (corresponding author), Univ Milan, Ist Ric Farmacol Mario Negri, Mol Biol Lab, Ctr Catullo & Deniela Borgomainerio, Via Eritrea 62, I-20157 Milan, Italy.	egarattini@marionegri.it	Terao, Mineko/AAA-6415-2020; Garattini, Enrico/AAI-1998-2019; Barzago, Maria Monica/AAA-6402-2020; Fratelli, Maddalena/AAA-6446-2020; KUROSAKI, Mami/ABG-2224-2020; terao, mineko/AAU-8089-2020	Terao, Mineko/0000-0002-9976-9869; Barzago, Maria Monica/0000-0002-6952-0069; Fratelli, Maddalena/0000-0002-1769-3427; KUROSAKI, Mami/0000-0001-8231-713X; Garattini, Enrico/0000-0001-8983-886X				Attwood TK, 1997, NUCLEIC ACIDS RES, V25, P212, DOI 10.1093/nar/25.1.212; AVIS PG, 1954, NATURE, V173, P1230, DOI 10.1038/1731230a0; Beedham C, 2003, J CLIN PSYCHOPHARM, V23, P229, DOI 10.1097/00004714-200306000-00003; Beedham C, 1995, PROG BRAIN RES, V106, P345; Beedham C, 1997, PHARM WORLD SCI, V19, P255, DOI 10.1023/A:1008668913093; Buck LB, 2004, NUTR REV, V62, pS184, DOI 10.1111/j.1753-4887.2004.tb00097.x; Buzzell GR, 1996, MICROSC RES TECHNIQ, V34, P2, DOI 10.1002/(SICI)1097-0029(19960501)34:1<2::AID-JEMT2>3.0.CO;2-W; Calzi ML, 1995, J BIOL CHEM, V270, P31037, DOI 10.1074/jbc.270.52.31037; CAZZANIGA G, 1994, GENOMICS, V23, P390, DOI 10.1006/geno.1994.1515; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Clark MP, 1998, NUCLEIC ACIDS RES, V26, P1801, DOI 10.1093/nar/26.7.1801; Demontis S, 1999, BBA-GENE STRUCT EXPR, V1489, P207, DOI 10.1016/S0167-4781(99)00174-8; Dobbek H, 1999, P NATL ACAD SCI USA, V96, P8884, DOI 10.1073/pnas.96.16.8884; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; FABRE G, 1984, J BIOL CHEM, V259, P5066; FALCIANI F, 1992, BIOCHEM J, V285, P1001, DOI 10.1042/bj2851001; FALCIANI F, 1994, BIOCHEM J, V298, P69, DOI 10.1042/bj2980069; Frerichs-Deeken U, 2004, BIOCHEMISTRY-US, V43, P14485, DOI 10.1021/bi048735u; Garattini E, 2003, BIOCHEM J, V372, P15, DOI 10.1042/BJ20030121; GLATIGNY A, 1995, J BIOL CHEM, V270, P3534, DOI 10.1074/jbc.270.8.3534; Godber Ben, 1997, Biochemical Society Transactions, V25, p519S; Godber BLJ, 2005, BIOCHEM J, V388, P501, DOI 10.1042/BJ20041984; Gremer L, 2000, J BIOL CHEM, V275, P1864, DOI 10.1074/jbc.275.3.1864; GRIFFITH AB, 1988, BIOCHEM GENET, V26, P37, DOI 10.1007/BF00555487; Harrison R, 2004, DRUG METAB REV, V36, P363, DOI 10.1081/DMR-120037569; Hedges SB, 2002, NAT REV GENET, V3, P838, DOI 10.1038/nrg929; Huang DY, 1999, ARCH BIOCHEM BIOPHYS, V364, P264, DOI 10.1006/abbi.1999.1129; Jordan CGM, 1999, J PHARM PHARMACOL, V51, P411, DOI 10.1211/0022357991772619; Kurosaki M, 2004, J BIOL CHEM, V279, P50482, DOI 10.1074/jbc.M408734200; Kurosaki M, 1996, BIOCHEM J, V319, P801, DOI 10.1042/bj3190801; Kurosaki M, 1999, BIOCHEM J, V341, P71, DOI 10.1042/0264-6021:3410071; KUROSAKI M, 1995, BIOCHEM J, V306, P225, DOI 10.1042/bj3060225; Leimkuhler S, 2004, J BIOL CHEM, V279, P40437, DOI 10.1074/jbc.M405778200; Martin HM, 2004, INFECT IMMUN, V72, P4933, DOI 10.1128/IAI.72.9.4933-4939.2004; McManaman JL, 2002, J PHYSIOL-LONDON, V545, P567, DOI 10.1113/jphysiol.2002.027185; MISRA S, 2002, GENOME BIOL, V3, P83, DOI [DOI 10.1186/GB-2002-3-12-RESEARCH0083, 10.1186/gb-2002-3-12-research0083]; NISHINO T, 1989, J BIOL CHEM, V264, P5468; Nishino T, 2005, J BIOL CHEM, V280, P24888, DOI 10.1074/jbc.M501830200; NISHINO T, 1987, BIOCHEMISTRY-US, V26, P3068, DOI 10.1021/bi00385a018; Obach RS, 2004, DRUG METAB DISPOS, V32, P89, DOI 10.1124/dmd.32.1.89; Obach RS, 2004, J CLIN PHARMACOL, V44, P7, DOI 10.1177/0091270003260336; Ohtsubo T, 2004, CIRC RES, V95, P1118, DOI 10.1161/01.RES.0000149571.96304.36; Okamoto K, 2004, P NATL ACAD SCI USA, V101, P7931, DOI 10.1073/pnas.0400973101; Ori N, 1997, J BIOL CHEM, V272, P1019, DOI 10.1074/jbc.272.2.1019; Parschat K, 2003, J BIOL CHEM, V278, P27483, DOI 10.1074/jbc.M301330200; Renwick AB, 2002, XENOBIOTICA, V32, P849, DOI 10.1080/00498250210158221; Rivera SP, 2005, TOXICOLOGY, V207, P401, DOI 10.1016/j.tox.2004.10.009; Rodriguez-Trelles F, 2003, P NATL ACAD SCI USA, V100, P13413, DOI 10.1073/pnas.1835646100; Rooseboom M, 2004, PHARMACOL REV, V56, P53, DOI 10.1124/pr.56.1.3; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATO A, 1995, J BIOL CHEM, V270, P2818, DOI 10.1074/jbc.270.6.2818; Seo M, 2000, P NATL ACAD SCI USA, V97, P12908, DOI 10.1073/pnas.220426197; Terao M, 1997, BIOCHEM SOC T, V25, P791, DOI 10.1042/bst0250791; Terao M, 2000, J BIOL CHEM, V275, P30690, DOI 10.1074/jbc.M005355200; Terao M, 1998, BIOCHEM J, V332, P383, DOI 10.1042/bj3320383; Terao M, 2001, J BIOL CHEM, V276, P46347, DOI 10.1074/jbc.M105744200; Vasiliou V, 1999, PHARMACOGENETICS, V9, P421, DOI 10.1097/00008571-199910000-00004; Vasiliou V, 2004, DRUG METAB REV, V36, P279, DOI 10.1081/DMR-120034001; Vila R, 2004, J BIOL CHEM, V279, P8668, DOI 10.1074/jbc.M308137200; Vorbach C, 2002, GENE DEV, V16, P3223, DOI 10.1101/gad.1032702; WRIGHT RM, 1993, P NATL ACAD SCI USA, V90, P10690, DOI 10.1073/pnas.90.22.10690; WURZINGER KH, 1974, COMP BIOCHEM PHYSIOL, V49, P171, DOI 10.1016/0305-0491(74)90237-5; Xu P, 1996, GENOMICS, V34, P173, DOI 10.1006/geno.1996.0262; Yamamoto Y, 1997, DNA Res, V4, P91, DOI 10.1093/dnares/4.2.91; Yasuhara A, 2005, BIOSCI BIOTECH BIOCH, V69, P2435, DOI 10.1271/bbb.69.2435	67	54	57	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19748	19761		10.1074/jbc.M600850200	http://dx.doi.org/10.1074/jbc.M600850200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16672219	hybrid			2022-12-25	WOS:000238847000088
J	Enomoto, T; Lindstrom, MS; Jin, AW; Ke, HM; Zhang, YP				Enomoto, Takeharu; Lindstrom, Mikael S.; Jin, Aiwen; Ke, Hengming; Zhang, Yanping			Essential role of the B23/NPM core domain in regulating ARF binding and B23 stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOLAR PROTEIN B23; P19(ARF) TUMOR-SUPPRESSOR; NUCLEAR MATRIX PROTEIN; RIBOSOMAL-RNA; HELA-CELLS; P53-DEPENDENT APOPTOSIS; CENTROSOME DUPLICATION; CRYSTAL-STRUCTURE; 3T3 FIBROBLASTS; HISTONE BINDING	How cells coordinate inhibition of growth and division during genotoxic events is fundamental to our understanding of the origin of cancer. Despite increasing interest and extensive study, the mechanisms that link regulation of DNA synthesis and ribosomal biogenesis remain elusive. Recently, the tumor suppressor p14(ARF) (ARF) has been shown to interact functionally with the nucleolar proteinB23/NPM (B23) and inhibit rRNA biogenesis. However, the molecular basis of the ARF-B23 interaction is hitherto unclear. Here we show that a highly conserved motif in the B23 oligomerization domain is essential for mediating ARF binding in vivo. Mutagenesis of conserved B23 core residues (L102A, G105A, G107A) prevented B23 from interacting with ARF. Modeling of the B23 core indicated that substitutions in the GSGP loop motif could trigger conformational changes in B23 thereby obstructing ARF binding. Interestingly, the GSGP loop mutants were unstable, defective for oligomerization, and delocalized from the nucleolus to the nucleoplasm. B23 core mutants displayed increased ubiquitination and proteasomal degradation. We conclude that the functional integrity of the B23 core motif is required for stability, efficient nucleolar localization as well as ARF binding.	Univ N Carolina, Sch Med, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Zhang, YP (corresponding author), Univ N Carolina, Sch Med, Dept Radiat Oncol, Chapel Hill, NC 27599 USA.	ypzhang@med.unc.edu	Lindström, Mikael S/AAA-1451-2019	Lindström, Mikael S/0000-0003-1148-8497	NCI NIH HHS [R01 CA100302, K01 CA087580] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100302, K01CA087580] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1998, CURR OPIN CELL BIOL, V10, P791, DOI 10.1016/S0955-0674(98)80123-3; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Brady SN, 2004, MOL CELL BIOL, V24, P9327, DOI 10.1128/MCB.24.21.9327-9338.2004; Burns KH, 2003, SCIENCE, V300, P633, DOI 10.1126/science.1081813; Carson M, 1996, J COMPUT AID MOL DES, V10, P273, DOI 10.1007/BF00124497; CHAN PK, 1995, BBA-GENE STRUCT EXPR, V1262, P37, DOI 10.1016/0167-4781(95)00044-H; Chan PK, 1999, BIOCHEM BIOPH RES CO, V264, P305, DOI 10.1006/bbrc.1999.1255; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; Dingwall C, 1990, Semin Cell Biol, V1, P11; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; DURO D, 1995, ONCOGENE, V11, P21; Dutta S, 2001, MOL CELL, V8, P841, DOI 10.1016/S1097-2765(01)00354-9; Falini B, 2006, BLOOD, V107, P4514, DOI 10.1182/blood-2005-11-4745; FEUERSTEIN N, 1988, J CELL BIOL, V107, P1629, DOI 10.1083/jcb.107.5.1629; FEUERSTEIN N, 1987, J BIOL CHEM, V262, P11389; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; HADJIOLOVA KV, 1994, MOL CELL BIOL, V14, P4044, DOI 10.1128/MCB.14.6.4044; HERRERA JE, 1995, NUCLEIC ACIDS RES, V23, P3974, DOI 10.1093/nar/23.19.3974; Higuchi Y, 1998, BIOCHEM BIOPH RES CO, V248, P597, DOI 10.1006/bbrc.1998.8978; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huang N, 2005, J BIOL CHEM, V280, P5496, DOI 10.1074/jbc.M407856200; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MAO L, 1995, CANCER RES, V55, P2995; Namboodiri VMH, 2004, STRUCTURE, V12, P2149, DOI 10.1016/j.str.2004.09.017; Namboodiri VMH, 2003, STRUCTURE, V11, P175, DOI 10.1016/S0969-2126(03)00007-8; Nozawa Y, 1996, J PATHOL, V178, P48; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; OLSON MOJ, 1986, BIOCHEMISTRY-US, V25, P484, DOI 10.1021/bi00350a031; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; Shackleford G M, 2001, BMC Genomics, V2, P8, DOI 10.1186/1471-2164-2-8; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STONE S, 1995, CANCER RES, V55, P2988; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Szebeni A, 1999, PROTEIN SCI, V8, P905; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Wang W, 2005, NAT CELL BIOL, V7, P823, DOI 10.1038/ncb1282; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu MH, 2002, CARCINOGENESIS, V23, P93, DOI 10.1093/carcin/23.1.93; YUNG BY, 1990, CANCER RES, V50, P5987; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	60	57	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18463	18472		10.1074/jbc.M602788200	http://dx.doi.org/10.1074/jbc.M602788200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16679321	hybrid, Green Published			2022-12-25	WOS:000238687300025
J	Kosaka, N; Kodama, M; Sasaki, H; Yamamoto, Y; Takeshita, F; Takahama, Y; Sakamoto, H; Kato, T; Terada, M; Ochiya, T				Kosaka, Nobuyoshi; Kodama, Maho; Sasaki, Hideo; Yamamoto, Yusuke; Takeshita, Fumitaka; Takahama, Yasushi; Sakamoto, Hiromi; Kato, Takashi; Terada, Masaaki; Ochiya, Takahiro			FGF-4 regulates neural progenitor cell proliferation and neuronal differentiation	FASEB JOURNAL			English	Article						FGF-4; neural progenitor cell; neurogenesis; self-renewal	ADENOVIRUS-MEDIATED TRANSFER; GROWTH-FACTOR 2; STEM-CELLS; GENE-EXPRESSION; LIMB; PRECURSORS; EGF; REGIONALIZATION; DEMONSTRATE; GENERATION	The FGF-4 (fibroblast growth factor 4, known as HST-1) protein is an important mitogen for a variety of cell types. However, only limited information is available concerning tissue distribution and the biological role of FGF-4 in the brain. In situ hybridization analysis revealed localization of mouse Fgf-4 mRNA in the normal postnatal mouse hippocampus, subventricular zone (SVZ), and the rostral migratory stream where new neurons generate, migrate, and become incorporated into the functional circuitry of the brain. We also investigated whether FGF-4 could promote both proliferation and differentiation of the neural progenitor cells by using an in vitro neurosphere assay. The addition of recombinant FGF-4 generated large proliferative spheres that have a multipotent differentiation ability. Furthermore, recombinant FGF-4 significantly promotes neuronal differentiation in attached clonal neurosphere culture. These findings suggest that FGF-4 has an ability to promote neural stem cell proliferation and neuronal differentiation in the postnatal brain.	Natl Canc Ctr, Res Inst, Sect Studies Metastasis, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Div Genet, Tokyo 1040045, Japan; Waseda Univ, Sch Educ, Dept Biol, Tokyo, Japan; Waseda Univ, Grad Sch Sci & Engn, Tokyo, Japan; Nara Med Univ, Dept Surg 1, Nara, Japan	National Cancer Center - Japan; National Cancer Center - Japan; Waseda University; Waseda University; Nara Medical University	Ochiya, T (corresponding author), Natl Canc Ctr, Res Inst, Sect Studies Metastasis, Chuo Ku, 5-1-1, Tokyo 1040045, Japan.	tochiya@ncc.go.jp	Kato, Takashi/AFO-2557-2022; Ochiya, Takahiro/AAH-7585-2019	Kato, Takashi/0000-0003-0384-7971; 				Amoh Y, 2005, P NATL ACAD SCI USA, V102, P5530, DOI 10.1073/pnas.0501263102; Arsenijevic Y, 1998, J NEUROSCI, V18, P2118; Avecilla ST, 2004, NAT MED, V10, P64, DOI 10.1038/nm973; Basilico C, 1997, J CELL PHYSIOL, V173, P227, DOI 10.1002/(SICI)1097-4652(199711)173:2<227::AID-JCP26>3.0.CO;2-B; Chiasson BJ, 1999, J NEUROSCI, V19, P4462; Ciccolini F, 1998, J NEUROSCI, V18, P7869; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; Hirabayashi Y, 2004, DEVELOPMENT, V131, P2791, DOI 10.1242/dev.01165; KONISHI H, 1995, J CLIN INVEST, V96, P1125, DOI 10.1172/JCI118099; Kratochwil K, 2002, GENE DEV, V16, P3173, DOI 10.1101/gad.1035602; McGrew LL, 1997, MECH DEVELOP, V69, P105, DOI 10.1016/S0925-4773(97)00160-3; Moon AM, 2000, DEVELOPMENT, V127, P989; Nakayama EE, 2000, GENES IMMUN, V1, P293, DOI 10.1038/sj.gene.6363672; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NISWANDER L, 1994, MOL REPROD DEV, V39, P83, DOI 10.1002/mrd.1080390113; OCHIYA T, 1995, J CELL BIOL, V130, P997, DOI 10.1083/jcb.130.4.997; Qian XM, 1997, NEURON, V18, P81, DOI 10.1016/S0896-6273(01)80048-9; Ray J, 1997, P NATL ACAD SCI USA, V94, P7047, DOI 10.1073/pnas.94.13.7047; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P12368, DOI 10.1073/pnas.91.26.12368; Shamim H, 1999, DEVELOPMENT, V126, P945; Shimozaki K, 2003, DEVELOPMENT, V130, P2505, DOI 10.1242/dev.00476; Sun X, 2000, NAT GENET, V25, P83, DOI 10.1038/75644; Suzuki K, 2001, VIRCHOWS ARCH, V439, P616, DOI 10.1007/s004280100437; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Yamamoto H, 2002, ONCOGENE, V21, P899, DOI 10.1038/sj.onc.1205135; Yamamoto H, 2000, ONCOGENE, V19, P3805, DOI 10.1038/sj.onc.1203752; Ye WL, 1998, CELL, V93, P755, DOI 10.1016/S0092-8674(00)81437-3; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780; YOSHIDA T, 1991, ANN NY ACAD SCI, V638, P27, DOI 10.1111/j.1749-6632.1991.tb49015.x; YOSHIDA T, 1994, CANCER LETT, V83, P261, DOI 10.1016/0304-3835(94)90328-X; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V155, P1324, DOI 10.1016/S0006-291X(88)81286-5; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; Zappone MV, 2000, DEVELOPMENT, V127, P2367	39	48	53	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1484	+		10.1096/fj.05-5293fje	http://dx.doi.org/10.1096/fj.05-5293fje			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16723380				2022-12-25	WOS:000240266000025
J	Haase, H; Dobbernack, G; Tuennemann, G; Karczewski, P; Cardoso, C; Petzhold, D; Schlegel, WP; Lutter, S; Pierschalek, P; Behlke, J; Morano, I				Haase, Hannelore; Dobbernack, Gisela; Tuennemann, Gisela; Karczewski, Peter; Cardoso, Cristina; Petzhold, Daria; Schlegel, Wolfgang-Peter; Lutter, Steffen; Pierschalek, Petra; Behlke, Joachim; Morano, Ingo			Minigenes encoding N-terminal domains of human cardiac myosin light chain-1 improve heart function of transgenic rats	FASEB JOURNAL			English	Article						myosin light chain; actin; heart; contractility; rat	SKELETAL-MUSCLE MYOSIN; SUBFRAGMENT-1 ISOENZYMES; CHROMOSOMAL LOCATION; FAILURE MANAGEMENT; ACTIN; BINDING; CONTRACTION; SEQUENCE; REGION; GENE	In this study we investigated whether the expression of N-terminal myosin light chain-1 (MLC-1) peptides could improve the intrinsic contractility of the whole heart. We generated transgenic rats (TGR) that overexpressed minigenes encoding the N-terminal 15 amino acids of human atrial MLC-1 (TGR/hALC-1/1-15, lines 7475 and 3966) or human ventricular MLC-1 (TGR/hVLC-1/1-15, lines 6113 and 6114) isoforms in cardiomyocytes. Synthetic N-terminal peptides revealed specific actin binding, with a significantly (P < 0.01) lower dissociation constant (K(D)) for the hVLC-1/1-15-actin complex compared with the KD value of the hALC-1/1-15-actin complex. Using synthetic hVLC-1/1-15 as a TAT fusion peptide labeled with the fluorochrome TAMRA, we observed specific accumulation of the N-terminal MLC-1 peptide at the sarcomere predominantly within the actin-containing I-band, but also within the actin-myosin overlap zone (A-band) in intact adult cardiomyocytes. For the first time we show that the expression of N-terminal human MLC-1 peptides in TGR ( range: 3-6 mu M) correlated positively with significant (P < 0.001) improvements of the intrinsic contractile state of the isolated perfused heart (Langendorff mode): systolic force generation, as well as the rates of both force generation and relaxation, rose in TGR lines that expressed the transgenic human MLC-1 peptide, but not in a TGR line with undetectable transgene expression levels. The positive inotropic effect of MLC-1 peptides occurred in the absence of a hypertrophic response. Thus, expression of N-terminal domains of MLC-1 represent a valuable tool for the treatment of the failing heart.	Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Charite Univ Med, Johannes Muller Inst Physiol, Berlin, Germany; Franz Volhard Clin, Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Franz-Volhard Clinical Research Center	Morano, I (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.	imorano@mdc-berlin.de	Cardoso, M. Cristina/F-5215-2011	Lattig, Gisela/0000-0001-6485-1136				Abdelaziz AI, 2004, J MOL MED-JMM, V82, P265, DOI 10.1007/s00109-004-0525-4; ABILLON E, 1990, BIOCHIM BIOPHYS ACTA, V1037, P394, DOI 10.1016/0167-4838(90)90042-E; Abraham WT, 1997, CIRCULATION, V96, P2755, DOI 10.1161/01.CIR.96.9.2755; Behlke J, 1997, BIOCHEMISTRY-US, V36, P5149, DOI 10.1021/bi962755h; BHANDARI DG, 1986, EUR J BIOCHEM, V160, P349, DOI 10.1111/j.1432-1033.1986.tb09978.x; BOTTINELLI R, 1994, J PHYSIOL-LONDON, V478, P341, DOI 10.1113/jphysiol.1994.sp020254; BRENNER B, 1988, P NATL ACAD SCI USA, V85, P3265, DOI 10.1073/pnas.85.9.3265; CHALOVICH JM, 1984, BIOCHEMISTRY-US, V23, P4885, DOI 10.1021/bi00316a011; FODOR WL, 1989, J BIOL CHEM, V264, P2143; Fujita H, 1962, MATH THEORY SEDIMENT; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; HAYASHIBARA T, 1994, BIOCHEMISTRY-US, V33, P12821, DOI 10.1021/bi00209a013; HENRY GD, 1985, EUR J BIOCHEM, V148, P75, DOI 10.1111/j.1432-1033.1985.tb08809.x; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; Konstam MA, 2000, CIRCULATION, V102, P1076, DOI 10.1161/01.CIR.102.10.1076; LABBE JP, 1986, BIOCHEMISTRY-US, V25, P8325, DOI 10.1021/bi00373a029; LOWEY S, 1993, J BIOL CHEM, V268, P20414; Moore JR, 2000, BIOPHYS J, V78, P1431, DOI 10.1016/S0006-3495(00)76696-3; MORANO I, 1995, CIRC RES, V76, P720, DOI 10.1161/01.RES.76.5.720; MULLINS JJ, 1990, NATURE, V344, P541, DOI 10.1038/344541a0; Nieznanski K, 2003, ARCH BIOCHEM BIOPHYS, V417, P153, DOI 10.1016/S0003-9861(03)00382-5; Patchell VB, 2002, EUR J BIOCHEM, V269, P5088, DOI 10.1046/j.1432-1033.2002.03227.x; PRINCE HP, 1981, EUR J BIOCHEM, V121, P213, DOI 10.1111/j.1432-1033.1981.tb06451.x; Rarick HM, 1996, J BIOL CHEM, V271, P27039, DOI 10.1074/jbc.271.43.27039; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Ruegg J., 1986, CALCIUM MUSCLE ACTIV; SEHARASEYON J, 1990, GENOMICS, V7, P289, DOI 10.1016/0888-7543(90)90554-8; STEPKOWSKI D, 1995, FEBS LETT, V374, P6, DOI 10.1016/0014-5793(95)01049-K; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; Sweeney H. L., 1995, BIOPHYS J, V68, p112S; Timson DJ, 1999, J BIOL CHEM, V274, P18271, DOI 10.1074/jbc.274.26.18271; Timson DJ, 1998, EUR J BIOCHEM, V255, P654, DOI 10.1046/j.1432-1327.1998.2550654.x; TRAYER HR, 1985, FEBS LETT, V180, P170, DOI 10.1016/0014-5793(85)81065-6; TRAYER IP, 1987, EUR J BIOCHEM, V164, P259, DOI 10.1111/j.1432-1033.1987.tb11019.x; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WINSTANLEY MA, 1977, FEBS LETT, V77, P239, DOI 10.1016/0014-5793(77)80242-1	36	24	27	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					865	873		10.1096/fj.05-5414com	http://dx.doi.org/10.1096/fj.05-5414com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675844				2022-12-25	WOS:000240157700009
J	Jarvinen, AK; Autio, R; Haapa-Paananen, S; Wolf, M; Saarela, M; Grenman, R; Leivo, I; Kallioniemi, O; Makitie, AA; Monni, O				Jarvinen, A-K; Autio, R.; Haapa-Paananen, S.; Wolf, M.; Saarela, M.; Grenman, R.; Leivo, I.; Kallioniemi, O.; Makitie, A. A.; Monni, O.			Identification of target genes in laryngeal squamous cell carcinoma by high-resolution copy number and gene expression microarray analyses	ONCOGENE			English	Article						head and neck cancer; cDNA microarrays; oligonucleotide microarrays; comparative genomic hybridization	BREAST-CANCER; CDNA MICROARRAYS; MOLECULAR CLASSIFICATION; 17Q23 AMPLICON; HIGH-FREQUENCY; NECK-CANCER; PHASE-II; HEAD; RECURRENT; PATTERNS	Molecular mechanisms contributing to initiation and progression of head and neck squamous cell carcinoma are still poorly known. Numerous genetic alterations have been described, but molecular consequences of such alterations in most cases remain unclear. Here, we performed an integrated high-resolution microarray analysis of gene copy number and expression in 20 laryngeal cancer cell lines and primary tumors. Our aim was to identify genetic alterations that play a key role in disease pathogenesis and pinpoint genes whose expression is directly impacted by these events. Integration of DNA level data from array-based comparative genomic hybridization with RNA level information from oligonucleotide microarrays was achieved with custom-developed bioinformatic methods. High-level amplifications had a clear impact on gene expression. Across the genome, overexpression of 739 genes could be attributed to gene amplification events in cell lines, with 325 genes showing the same phenomenon in primary tumors including FADD and PPFIA1 at 11q13. The analysis of gene ontology and pathway distributions further pinpointed genes that may identify potential targets of therapeutic intervention. Our data highlight genes that may be critically important to laryngeal cancer progression and offer potential therapeutic targets.	Univ Helsinki, Biomedicum Biochip Ctr, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biomed, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Otorhinolaryngol Head & Neck Surg, Helsinki, Finland; Tampere Univ Technol, Inst Signal Proc, FIN-33101 Tampere, Finland; VTT Tech Res Ctr Finland, Turku, Finland; Turku Univ, FIN-20520 Turku, Finland; Turku Univ, Cent Hosp, Dept Otorhinolaryngol Head & Neck Surg, Turku, Finland; Turku Univ, Dept Biochem Med, Turku, Finland; Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Tampere University; VTT Technical Research Center Finland; University of Turku; University of Turku; University of Turku; University of Helsinki	Monni, O (corresponding author), Univ Helsinki, Biomedicum Biochip Ctr, POB 63,Rm A415B,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	outi.monni@helsinki.fi	Autio, Reija/D-2037-2014; Haapa-Paananen, Saija/D-3075-2012; Kallioniemi, Olli P/H-5111-2011	Kallioniemi, Olli P/0000-0002-3231-0332; Autio, Reija/0000-0002-6519-2715				Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Autio R, 2003, BIOINFORMATICS, V19, P1714, DOI 10.1093/bioinformatics/btg230; Baldwin C, 2005, CANCER RES, V65, P7561, DOI 10.1158/0008-5472.CAN-05-1513; Baselga J, 2005, J CLIN ONCOL, V23, P2445, DOI 10.1200/JCO.2005.11.890; Baudis M, 2001, BIOINFORMATICS, V17, P1228, DOI 10.1093/bioinformatics/17.12.1228; Belbin TJ, 2002, CANCER RES, V62, P1184; Choi P, 2005, CANCER-AM CANCER SOC, V104, P1113, DOI 10.1002/cncr.21293; Chung CH, 2004, CANCER CELL, V5, P489, DOI 10.1016/S1535-6108(04)00112-6; Cohen EEW, 2003, J CLIN ONCOL, V21, P1980, DOI 10.1200/JCO.2003.10.051; Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; Dong YY, 2005, CLIN CANCER RES, V11, P259; Garcia MJ, 2005, ONCOGENE, V24, P5235, DOI 10.1038/sj.onc.1208741; Ginos MA, 2004, CANCER RES, V64, P55, DOI 10.1158/0008-5472.CAN-03-2144; Gollin SM, 2001, HEAD NECK-J SCI SPEC, V23, P238, DOI 10.1002/1097-0347(200103)23:3<238::AID-HED1025>3.0.CO;2-H; GRENMAN R, 1992, ARCH OTOLARYNGOL, V118, P542; Hautaniemi S, 2004, J FRANKLIN I, V341, P77, DOI 10.1016/j.jfranklin.2003.12.005; Heidenblad M, 2005, ONCOGENE, V24, P1794, DOI 10.1038/sj.onc.1208383; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Hyman E, 2002, CANCER RES, V62, P6240; Imoto I, 2001, CANCER RES, V61, P6629; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Joslyn CA, 2004, BIOINFORMATICS, V20, P169, DOI 10.1093/bioinformatics/bth921; LANSFORD CD, 1999, HUMAN CELL CULTURE, V2, P185; Lin M, 2006, ONCOGENE, V25, P1424, DOI 10.1038/sj.onc.1209166; Mao EJ, 1998, J ORAL PATHOL MED, V27, P297; Mao L, 2004, CANCER CELL, V5, P311, DOI 10.1016/S1535-6108(04)00090-X; Miller CT, 2003, CANCER RES, V63, P4136; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; Nawata S, 2003, ELECTROPHORESIS, V24, P2277, DOI 10.1002/elps.200305501; Newton K, 2000, EMBO J, V19, P931, DOI 10.1093/emboj/19.5.931; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Redon R, 2002, CANCER RES, V62, P6211; Reed AL, 1996, CANCER RES, V56, P3630; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Sinclair CS, 2003, BREAST CANCER RES TR, V78, P313, DOI 10.1023/A:1023081624133; Soulieres D, 2004, J CLIN ONCOL, V22, P77, DOI 10.1200/JCO.2004.06.075; Strojan P, 2004, BRIT J CANCER, V90, P1961, DOI 10.1038/sj.bjc.6601830; Strome SE, 2003, CANCER RES, V63, P6501	40	81	82	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	52					6997	7008		10.1038/sj.onc.1209690	http://dx.doi.org/10.1038/sj.onc.1209690			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16715129				2022-12-25	WOS:000241732300010
J	Boulant, S; Montserret, R; Hope, RG; Ratinier, M; Targett-Adams, P; Lavergne, JP; Penin, F; McLauchlan, J				Boulant, Steeve; Montserret, Roland; Hope, R. Graham; Ratinier, Maxime; Targett-Adams, Paul; Lavergne, Jean-Pierre; Penin, Francois; McLauchlan, John			Structural determinants that target the hepatitis C virus core protein to lipid droplets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-RELATED PROTEIN; SIGNAL PEPTIDE PEPTIDASE; ANCHOR PERILIPIN-A; SUBCELLULAR-LOCALIZATION; INTRAMEMBRANE PROTEOLYSIS; HYDROPHOBIC DOMAIN; CELL-CULTURE; HLA-E; MEMBRANE; BINDING	Hepatitis C virus core protein is targeted to lipid droplets, which serve as intracellular storage organelles, by its C-terminal domain, termed D2. From circular dichroism and nuclear magnetic resonance analyses, we demonstrate that the major structural elements within D2 consist of two amphipathic alpha-helices (Helix I and Helix II) separated by a hydrophobic loop. Both helices require a hydrophobic environment for folding, indicating that lipid interactions contribute to their structural integrity. Mutational studies revealed that a combination of Helix I, the hydrophobic loop, and Helix II is essential for efficient lipid droplet association and pointed to an in-plane membrane interaction of the two helices at the phospholipid layer interface. Aside from lipid droplet association, membrane interaction of D2 is necessary for folding and stability of core following maturation at the endoplasmic reticulum membrane by signal peptide peptidase. These studies identify critical determinants within a targeting domain that enable trafficking and attachment of a viral protein to lipid droplets. They also serve as a unique model for elucidating the specificity of protein-lipid interactions between two membrane-bound organelles.	Univ Lyon 1, CNRS UMR 5086, IFR 128, Inst Biol & Chim Prot, F-69367 Lyon 07, France; Inst Virol, MRC, Virol Unit, Glasgow G11 5JR, Lanark, Scotland	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of Glasgow	Penin, F (corresponding author), Univ Lyon 1, CNRS UMR 5086, IFR 128, Inst Biol & Chim Prot, 7 Passage Verocrs, F-69367 Lyon 07, France.	f.penin@ibcp.fr; j.mclauchlan@vir.gla.ac.uk	Boulant, Steeve/W-3754-2019; PENIN, Francois/A-7315-2008	Boulant, Steeve/0000-0001-8614-4993; Targett-Adams, Paul/0000-0003-4967-1668; Ratinier, Maxime/0000-0003-2271-3549	MRC [MC_U130184143] Funding Source: UKRI; Medical Research Council [MC_U130184143, MC_UU_12014/1] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abell BM, 2004, PLANT J, V37, P461, DOI 10.1111/j.1365-313X.2003.01988.x; Alexander LG, 2002, PLANTA, V214, P546, DOI 10.1007/s004250100655; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Bland FA, 2003, J BIOL CHEM, V278, P33747, DOI 10.1074/jbc.M305593200; Boulant S, 2005, J VIROL, V79, P11353, DOI 10.1128/JVI.79.17.11353-11365.2005; Brasaemle DL, 2004, J BIOL CHEM, V279, P46835, DOI 10.1074/jbc.M409340200; Buck M, 1998, Q REV BIOPHYS, V31, P297, DOI 10.1017/S003358359800345X; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; Clayton RF, 2002, J VIROL, V76, P7672, DOI 10.1128/JVI.76.15.7672-7682.2002; Combet Christophe, 2004, Appl Bioinformatics, V3, P237, DOI 10.2165/00822942-200403040-00005; Crawshaw SG, 2004, BIOCHEM J, V384, P9, DOI 10.1042/BJ20041216; Favier A, 2002, J MOL BIOL, V317, P131, DOI 10.1006/jmbi.2002.5397; Fujimoto T, 2001, J CELL BIOL, V152, P1079, DOI 10.1083/jcb.152.5.1079; Fujimoto Y, 2004, BBA-MOL CELL RES, V1644, P47, DOI 10.1016/j.bbamcr.2003.10.018; Garcia A, 2003, J BIOL CHEM, V278, P625, DOI 10.1074/jbc.M206602200; Granseth E, 2005, J MOL BIOL, V346, P377, DOI 10.1016/j.jmb.2004.11.036; Hope RG, 2000, J GEN VIROL, V81, P1913, DOI 10.1099/0022-1317-81-8-1913; Hope RG, 2002, J BIOL CHEM, V277, P4261, DOI 10.1074/jbc.M108798200; Hussy P, 1996, VIROLOGY, V224, P93, DOI 10.1006/viro.1996.0510; JASANOFF A, 1994, BIOCHEMISTRY-US, V33, P2129, DOI 10.1021/bi00174a020; Lacey DJ, 1998, BIOCHEM J, V334, P469, DOI 10.1042/bj3340469; Lemberg MK, 2001, J IMMUNOL, V167, P6441, DOI 10.4049/jimmunol.167.11.6441; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; LO SY, 1995, VIROLOGY, V213, P455, DOI 10.1006/viro.1995.0018; Lu XY, 2001, MAMM GENOME, V12, P741, DOI 10.1007/s00335-01-2055-5; McLauchlan J, 2000, J VIRAL HEPATITIS, V7, P2; McLauchlan J, 2002, EMBO J, V21, P3980, DOI 10.1093/emboj/cdf414; MERUTKA G, 1995, J BIOMOL NMR, V5, P14, DOI 10.1007/BF00227466; Millichip M, 1996, BIOCHEM J, V314, P333, DOI 10.1042/bj3140333; Montserret R, 1999, BIOCHEMISTRY-US, V38, P6479, DOI 10.1021/bi9900222; Montserret R, 2000, BIOCHEMISTRY-US, V39, P8362, DOI 10.1021/bi000208x; Moradpour D, 1996, VIROLOGY, V222, P51, DOI 10.1006/viro.1996.0397; Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3; Nakamura N, 2003, BIOCHEM BIOPH RES CO, V306, P333, DOI 10.1016/S0006-291X(03)00979-3; Ostermeyer AG, 2004, J CELL BIOL, V164, P69, DOI 10.1083/jcb.200303037; Patel J, 1999, J GEN VIROL, V80, P1681, DOI 10.1099/0022-1317-80-7-1681; Penin F, 1997, J MOL BIOL, V270, P496, DOI 10.1006/jmbi.1997.1123; Penin F, 2004, J BIOL CHEM, V279, P40835, DOI 10.1074/jbc.M404761200; Penin F, 2004, HEPATOLOGY, V39, P5, DOI 10.1002/hep.20032; Rouille Y, 2006, J VIROL, V80, P2832, DOI 10.1128/JVI.80.6.2832-2841.2006; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; Schwer B, 2004, J VIROL, V78, P7958, DOI 10.1128/JVI.78.15.7958-7968.2004; Seabra MC, 2004, CURR OPIN CELL BIOL, V16, P451, DOI 10.1016/j.ceb.2004.06.014; Subramanian V, 2004, J LIPID RES, V45, P1983, DOI 10.1194/jlr.M400291-JLR200; Suzuki R, 2005, J VIROL, V79, P1271, DOI 10.1128/JVI.79.2.1271-1281.2005; Targett-Adams P, 2003, J BIOL CHEM, V278, P15998, DOI 10.1074/jbc.M211289200; Tauchi-Sato K, 2002, J BIOL CHEM, V277, P44507, DOI 10.1074/jbc.M207712200; Umlauf E, 2004, J BIOL CHEM, V279, P23699, DOI 10.1074/jbc.M310546200; WADA I, 1991, J BIOL CHEM, V266, P19599; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102	54	165	168	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22236	22247		10.1074/jbc.M601031200	http://dx.doi.org/10.1074/jbc.M601031200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16704979	hybrid			2022-12-25	WOS:000239387100070
J	Costa, ADT; Jakob, R; Costa, CL; Andrukhiv, K; West, IC; Garlid, KD				Costa, Alexandre D. T.; Jakob, Regina; Costa, Cinthia L.; Andrukhiv, Ksenia; West, Ian C.; Garlid, Keith D.			The mechanism by which the mitochondrial ATP-sensitive K+ channel opening and H2O2 inhibit the mitochondrial permeability transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; REACTIVE OXYGEN; HEART-MITOCHONDRIA; REPERFUSION INJURY; OXIDATIVE STRESS; EPSILON TRANSLOCATION; CARDIAC MITOCHONDRIA; SIGNALING COMPLEXES; LIGHT-SCATTERING; CA2+ OVERLOAD	Myocardial infarction is a manifestation of necrotic cell death as a result of opening of the mitochondrial permeability transition ( MPT). Receptor-mediated cardioprotection is triggered by an intracellular signaling pathway that includes phosphatidylinositol 3-kinase, endothelial nitric-oxide synthase, guanylyl cyclase, protein kinase G ( PKG), and the mitochondrial K-ATP channel ( mitoKATP). In this study, we explored the pathway that links mitoKATP with the MPT. We confirmed previous findings that diazoxide and activators of PKG or protein kinase C ( PKC) inhibited MPT opening. We extended these results and showed that other K+ channel openers as well as the K+ ionophore valinomycin also inhibited MPT opening and that this inhibition required reactive oxygen species. By using isoform-specific peptides, we found that the effects of K-ATP channel openers, PKG, or valinomycin were mediated by a PKC epsilon. Activation of PKC epsilon by phorbol 12-myristate 13-acetate or H2O2 resulted in mitoK(ATP)-independent inhibition of MPT opening, whereas activation of PKC epsilon by PKG or the specific PKC epsilon agonist psi epsilon receptor for activated C kinase caused mitoK(ATP)-dependent inhibition of MPT opening. Exogenous H2O2 inhibited MPT, because of its activation of PKC epsilon, with an IC50 of 0.4 ( +/- 0.1) mu M. On the basis of these results, we propose that two different PKC epsilon pools regulate this signaling pathway, one in association with mitoK(ATP) and the other in association with MPT.	Portland State Univ, Dept Biol, Portland, OR 97201 USA	Portland State University	Garlid, KD (corresponding author), Portland State Univ, Dept Biol, Portland, OR 97201 USA.	garlid@pdx.edu	Costa, Alexandre Dias Tavares/ABB-1896-2021; Costa, Alexandre Augusto da/HCJ-0140-2022	Costa, Alexandre Dias Tavares/0000-0001-8434-2152; Costa, Alexandre Augusto da/0000-0001-7558-5435; Garlid, Keith/0000-0002-6777-1235	NHLBI NIH HHS [HL36573, HL067842] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573, R01HL067842] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrukhiv A, 2005, J MOL CELL CARDIOL, V38, P813; Antunes F, 2002, FREE RADICAL BIO MED, V33, P1260, DOI 10.1016/S0891-5849(02)01016-X; Arnaud C, 2004, CLIN EXP PHARMACOL P, V31, P129, DOI 10.1111/j.1440-1681.2004.03966.x; Baines CP, 2002, CIRC RES, V90, P390, DOI 10.1161/01.RES.0000012702.90501.8D; Baines CP, 2003, CIRC RES, V92, P873, DOI 10.1161/01.RES.0000069215.36389.8D; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Bright R, 2005, STROKE, V36, P2781, DOI 10.1161/01.STR.0000189996.71237.f7; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Chen L, 2001, P NATL ACAD SCI USA, V98, P11114, DOI 10.1073/pnas.191369098; Costa ADT, 2005, CIRC RES, V97, P329, DOI 10.1161/01.RES.0000178451.08719.5b; Costa ADT, 2006, AM J PHYSIOL-HEART C, V290, pH406, DOI 10.1152/ajpheart.00794.2005; Crompton M, 2000, J PHYSIOL-LONDON, V529, P11, DOI 10.1111/j.1469-7793.2000.00011.x; CROMPTON M, 1988, BIOCHEM J, V255, P357; Das DK, 1999, MOL CELL BIOCHEM, V196, P59, DOI 10.1023/A:1006966128795; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; Facundo HTF, 2005, J BIOENERG BIOMEMBR, V37, P75, DOI 10.1007/s10863-005-4130-1; Garlid KD, 2000, BASIC RES CARDIOL, V95, P275, DOI 10.1007/s003950070046; GARLID KD, 1985, J BIOL CHEM, V260, P3434; Hausenloy DJ, 2005, TRENDS CARDIOVAS MED, V15, P69, DOI 10.1016/j.tcm.2005.03.001; Hausenloy DJ, 2004, AM J PHYSIOL-HEART C, V287, pH841, DOI 10.1152/ajpheart.00678.2003; Hausenloy DJ, 2002, CARDIOVASC RES, V55, P534, DOI 10.1016/S0008-6363(02)00455-8; Honda HM, 2005, ANN NY ACAD SCI, V1047, P248, DOI 10.1196/annals.1341.022; Inagaki K, 2005, CIRCULATION, V111, P44, DOI 10.1161/01.CIR.0000151614.22282.F1; Ishida H, 2004, N-S ARCH PHARMACOL, V369, P192, DOI 10.1007/s00210-003-0851-z; Jaburek M, 1998, J BIOL CHEM, V273, P13578; Kim JS, 2004, HEPATOLOGY, V39, P1533, DOI 10.1002/hep.20197; Knapp LT, 2000, J BIOL CHEM, V275, P24136, DOI 10.1074/jbc.M002043200; Korge P, 2002, P NATL ACAD SCI USA, V99, P3312, DOI 10.1073/pnas.052713199; Korichneva I, 2002, J BIOL CHEM, V277, P44327, DOI 10.1074/jbc.M205634200; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Kowaltowski AJ, 2001, AM J PHYSIOL-HEART C, V280, pH649, DOI 10.1152/ajpheart.2001.280.2.H649; MICKELSON JR, 1980, ANAL BIOCHEM, V109, P255, DOI 10.1016/0003-2697(80)90645-4; Mironova GD, 2004, J BIOL CHEM, V279, P32562, DOI 10.1074/jbc.M401115200; Murata M, 2001, CIRC RES, V89, P891, DOI 10.1161/hh2201.100205; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; Ping PP, 2003, CIRC RES, V93, P595, DOI 10.1161/01.RES.0000093221.98213.E0; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Schechtman D, 2004, J BIOL CHEM, V279, P15831, DOI 10.1074/jbc.M310696200; Schechtman D, 2002, METHOD ENZYMOL, V345, P470; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704; Toker A., 1998, FRONT BIOSCI-LANDMRK, V3, P1134, DOI 10.2741/A350; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; von Harsdorf R, 1999, CIRCULATION, V99, P2934, DOI 10.1161/01.CIR.99.22.2934; Vondriska TM, 2003, J MOL CELL CARDIOL, V35, P1027, DOI 10.1016/S0022-2828(03)00175-5; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Xie ZJ, 2003, ANN NY ACAD SCI, V986, P497, DOI 10.1111/j.1749-6632.2003.tb07234.x; Zhang HY, 2002, AM J PHYSIOL-HEART C, V282, pH1395, DOI 10.1152/ajpheart.00683.2001	51	155	163	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20801	20808		10.1074/jbc.M600959200	http://dx.doi.org/10.1074/jbc.M600959200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16720572	hybrid			2022-12-25	WOS:000239187300016
J	Gyohda, A; Zhu, SJ; Furuya, N; Komano, T				Gyohda, Atsuko; Zhu, Shujuan; Furuya, Nobuhisa; Komano, Teruya			Asymmetry of shufflon-specific recombination sites in plasmid R64 inhibits recombination between direct sfx sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA RECOMBINASE; INVERSION; REARRANGEMENTS	The shufflon of plasmid R64 consists of four DNA segments separated and flanked by seven sfx recombination sites. Rci-mediated recombination between any inverted sfx sequences causes inversion of the DNA segments independently or in groups. The R64 shufflon selects one of seven pilV genes encoding type IV pilus adhesins, in which the N-terminal region is constant, while the C-terminal regions are variable. The R64 sfx sequences are asymmetric. The sfx central region and right arm sequences are conserved, but left arm sequences are not. Here we constructed a symmetric sfx sequence, in which the sfx left arm sequence was changed to the inverted repeat of the right arm sequence and made artificial shufflon segments carrying symmetric sfx sequences in inverted or direct orientations. The symmetric sfx sequence exhibited the highest inversion frequency in a shufflon segment flanked by two inverted sfx sequences. Rci-dependent deletion of a shufflon segment flanked by two direct symmetric sfx sequences was observed, suggesting that asymmetry of R64 sfx sequences inhibits recombination between direct sfx sequences. In addition, intermolecular recombination between symmetric sfx sequences was also observed. The extra C-terminal domain of Rci was shown to be essential for inversion of the R64 shufflon using asymmetric sfx sequences but not essential for recombination using symmetric sfx sequences, suggesting that the Rci C-terminal segment helps the binding of Rci to asymmetric sfx sequences. Rci protein lacking the C-terminal domain bound to both arms of symmetric sfx sequence but only to the right arm of asymmetric sfx sequence.	Tokyo Metropolitan Univ, Dept Biol, Tokyo 1920397, Japan	Tokyo Metropolitan University	Komano, T (corresponding author), Tokyo Metropolitan Univ, Dept Biol, Tokyo 1920397, Japan.	komano-teruya@c.metro-u.ac.jp						ABREMSKI K, 1986, J BIOL CHEM, V261, P391; Azaro MA., 2002, MOBILE DNA-UK, P118, DOI DOI 10.1128/9781555817954.CH7; Crain Noreen, 2002, Pediatr Crit Care Med, V3, P11, DOI 10.1097/00130478-200201000-00003; Ennifar E, 2003, NUCLEIC ACIDS RES, V31, P5449, DOI 10.1093/nar/gkg732; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Guo F, 1999, P NATL ACAD SCI USA, V96, P7143, DOI 10.1073/pnas.96.13.7143; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Gyohda A, 2000, J BACTERIOL, V182, P2787, DOI 10.1128/JB.182.10.2787-2792.2000; Gyohda A, 2002, J MOL BIOL, V318, P975, DOI 10.1016/S0022-2836(02)00195-X; Ishiwa A, 2004, J MOL BIOL, V343, P615, DOI 10.1016/j.jmb.2004.08.059; Kim SR, 1997, J BACTERIOL, V179, P3594, DOI 10.1128/jb.179.11.3594-3603.1997; Komano T, 1999, ANNU REV GENET, V33, P171, DOI 10.1146/annurev.genet.33.1.171; KOMANO T, 1990, J BACTERIOL, V172, P2230, DOI 10.1128/jb.172.5.2230-2235.1990; KOMANO T, 1987, NUCLEIC ACIDS RES, V15, P1165, DOI 10.1093/nar/15.3.1165; KOMANO T, 1994, J MOL BIOL, V243, P6, DOI 10.1006/jmbi.1994.1625; KOMANO T, 1986, J BACTERIOL, V165, P94, DOI 10.1128/jb.165.1.94-100.1986; KUBO A, 1988, MOL GEN GENET, V213, P30, DOI 10.1007/BF00333394; Kuwahara T, 2004, P NATL ACAD SCI USA, V101, P14919, DOI 10.1073/pnas.0404172101; Lysnyansky I, 2001, J BACTERIOL, V183, P5698, DOI 10.1128/JB.183.19.5698-5708.2001; Martin SS, 2002, J MOL BIOL, V319, P107, DOI 10.1016/S0022-2836(02)00246-2; NASH HA, 1989, EMBO J, V8, P3523, DOI 10.1002/j.1460-2075.1989.tb08518.x; Sambrook J, 2001, MOL CLONING LAB MANU; Sauer B., 2002, MOBILE DNA, P38; Shen XJ, 2000, J BACTERIOL, V182, P2900, DOI 10.1128/JB.182.10.2900-2908.2000; Sitaraman R, 2002, MOL MICROBIOL, V46, P1033, DOI 10.1046/j.1365-2958.2002.03206.x; Sitaraman R, 1997, MOL MICROBIOL, V26, P109, DOI 10.1046/j.1365-2958.1997.5571938.x; Van Duyne G.D., 2002, MOBILE DNA, VII, P93; WADA M, 1989, GENE, V76, P345, DOI 10.1016/0378-1119(89)90174-1; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	29	10	10	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20772	20779		10.1074/jbc.M513654200	http://dx.doi.org/10.1074/jbc.M513654200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16723350	hybrid			2022-12-25	WOS:000239187300013
J	Paria, BC; Bair, AM; Xue, JP; Yu, YN; Malik, AB; Tiruppathi, C				Paria, Biman C.; Bair, Angela M.; Xue, Jiaping; Yu, Yanni; Malik, Asrar B.; Tiruppathi, Chinnaswamy			Ca2+ influx induced by protease-activated receptor-1 activates a feed-forward mechanism of TRPC1 expression via nuclear factor-kappa B activation in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE-1; THROMBIN STIMULATION; GENE-EXPRESSION; KINASE-C; CALCIUM; CHANNELS; INCREASE; ENTRY; PAR-1; TRANSCRIPTION	Thrombin activation of protease-activated receptor-1 induces Ca2+ influx through store-operated cation channel TRPC1 in endothelial cells. We examined the role of Ca2+ influx induced by the depletion of Ca2+ stores in signaling TRPC1 expression in endothelial cells. Both thrombin and a protease-activated receptor-1-specific agonist peptide induced TRPC1 expression in human umbilical vein endothelial cells, which was coupled to an augmented store-operated Ca2+ influx and increase in endothelial permeability. To delineate the mechanisms of thrombin-induced TRPC1 expression, we transfected in endothelial cells TRPC1-promoter-luciferase ( TRPC1-Pro-Luc) construct containing multiple nuclear factor-kappa B ( NF-kappa B) binding sites. Co-expression of dominant negative I kappa B alpha mutant prevented the thrombin-induced increase in TRPC1 expression, indicating the key role of NF-kappa B activation in mediating the response. Using TRPC1 promoter-deletion mutant constructs, we showed that NF-kappa B binding sites located between - 1623 and - 871 in the TRPC1 5'-regulatory region were required for thrombin-induced TRPC1 expression. Electrophoretic mobility shift assay utilizing TRPC1 promoter-specific oligonucleotides identified that the DNA binding activities of NF-kappa B to NF-kappa B consensus sites were located in this domain. Supershift assays using NF-kappa B protein-specific antibodies demonstrated the binding of p65 homodimer to the TRPC1 promoter. Inhibition of store Ca2+ depletion, buffering of intracellular Ca2+, or down-regulation of protein kinase C alpha downstream of Ca2+ influx all blocked thrombin-induced NF-kappa B activation and the resultant TRPC1 expression in endothelial cells. Thus, Ca2+ influx via TRPC1 is a critical feed-forward pathway responsible for TRPC1 expression. The NF-kappa B-regulated TRPC1 expression may be an essential mechanism of vascular inflammation and, hence, a novel therapeutic target.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Ctr Lung & Vasc Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Tiruppathi, C (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, M-C868,835 S Wolcott Ave, Chicago, IL 60612 USA.	tiruc@uic.edu		Malik, Asrar/0000-0002-8205-7128	NHLBI NIH HHS [P01HL077806, T32HL072742] Funding Source: Medline; NIGMS NIH HHS [GM-58531] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL077806, T32HL072742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058531] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; COUGLIN SR, 2002, NATURE, V407, P258; Damiano BP, 1999, J PHARMACOL EXP THER, V288, P671; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Ellis CA, 1999, J BIOL CHEM, V274, P13718, DOI 10.1074/jbc.274.19.13718; Ellis CA, 1999, AM J PHYSIOL-CELL PH, V276, pC38, DOI 10.1152/ajpcell.1999.276.1.C38; FREAY A, 1989, PFLUG ARCH EUR J PHY, V414, P377, DOI 10.1007/BF00585046; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Gewirtz AT, 2000, J CLIN INVEST, V105, P79, DOI 10.1172/JCI8066; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Lilienbaum A, 2003, MOL CELL BIOL, V23, P2680, DOI 10.1128/MCB.23.8.2680-2698.2003; Liu XB, 2001, J BIOL CHEM, V276, P29891, DOI 10.1074/jbc.M103283200; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; MANN KG, 1990, BLOOD, V76, P1; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005; Minami T, 2003, J BIOL CHEM, V278, P6976, DOI 10.1074/jbc.M208974200; Minami T, 2001, J BIOL CHEM, V276, P47632, DOI 10.1074/jbc.M108363200; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Moore TM, 1998, AM J PHYSIOL-LUNG C, V275, pL574, DOI 10.1152/ajplung.1998.275.3.L574; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; Paria BC, 2004, AM J PHYSIOL-LUNG C, V287, pL1303, DOI 10.1152/ajplung.00240.2004; Paria BC, 2003, J BIOL CHEM, V278, P37195, DOI 10.1074/jbc.M304287200; Patterson C, 2001, CIRC RES, V88, P987, DOI 10.1161/hh1001.091447; Pedersen SF, 2005, CELL CALCIUM, V38, P233, DOI 10.1016/j.ceca.2005.06.028; Putney JW, 1999, BIOESSAYS, V21, P38; Rahman A, 2000, AM J PHYSIOL-CELL PH, V279, pC906, DOI 10.1152/ajpcell.2000.279.4.C906; Rahman A, 1999, J IMMUNOL, V162, P5466; Rahman A, 2002, CIRC RES, V91, P398, DOI 10.1161/01.RES.0000033520.95242.A2; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; Sandoval R, 2001, AM J PHYSIOL-LUNG C, V280, pL239, DOI 10.1152/ajplung.2001.280.2.L239; Sandoval R, 2001, J PHYSIOL-LONDON, V533, P433, DOI 10.1111/j.1469-7793.2001.0433a.x; Strubing C, 2003, J BIOL CHEM, V278, P39014, DOI 10.1074/jbc.M306705200; SUGAMA Y, 1992, J CELL BIOL, V119, P935, DOI 10.1083/jcb.119.4.935; Tang Y, 2004, DIABETOLOGIA, V47, P2093, DOI 10.1007/s00125-004-1589-y; Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Tiruppathi C, 2002, VASC PHARMACOL, V39, P173, DOI 10.1016/S1537-1891(03)00007-7; Vogel SM, 2000, PHYSIOL GENOMICS, V4, P137, DOI 10.1152/physiolgenomics.2000.4.2.137; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Winter MC, 2004, AM J PHYSIOL-LUNG C, V287, pL816, DOI 10.1152/ajplung.00056.2004	47	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20715	20727		10.1074/jbc.M600722200	http://dx.doi.org/10.1074/jbc.M600722200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16709572	hybrid			2022-12-25	WOS:000239187300008
J	Gao, QX; Doneanu, CE; Shaffer, SA; Adman, ET; Goodlett, DR; Nelson, SD				Gao, Qiuxia; Doneanu, Catalin E.; Shaffer, Scott A.; Adman, Elinor T.; Goodlett, David R.; Nelson, Sidney D.			Identification of the interactions between cytochrome P450 2E1 and cytochrome b(5) by mass spectrometry and site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKED PEPTIDES; PERFORMANCE LIQUID-CHROMATOGRAPHY; ESCHERICHIA-COLI; CATALYTIC-ACTIVITIES; OPTICAL BIOSENSOR; ELECTRON-TRANSFER; COMPLEX-FORMATION; P450 REDUCTASE; PURIFICATION; LINKING	The reaction cycles of cytochrome P450s (P450) require input of two electrons. Electrostatic interactions are considered important driving forces in the association of P450s with their redox partners, which in turn facilitates the transfer of the two electrons. In this study, the cross-linking reagent, 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC), was used to covalently link cytochrome P450 2E1 (CYP2E1) with cytochrome b5 (b5) through the formation of specific amide bonds between complementary charged residue pairs. Cross-linked peptides in the resulting protein complex were distinguished from non-cross-linked peptides using an O-18-labeling method on the basis that cross-linked peptides incorporate twice as many O-18 atoms as non-cross-linked peptides during proteolysis conducted in O-18-water. Subsequent tandem mass spectrometric (MS/MS) analysis of the selected cross-linked peptide candidates led to the identification of two intermolecular cross-links, Lys(428)(CYP2E1)-Asp(53)(b(5)) and Lys(434)(CYP2E1)-Glu(56)(b(5)), which provides the first direct experimental evidence for the interacting orientations of a microsomal P450 and its redox partner. The biological importance of the two ion pairs for the CYP2E1-b(5) interaction, and the stimulatory effect of b(5), was confirmed by site-directed mutagenesis. Based on the characterized cross-links, a CYP2E1-b(5) complex model was constructed, leading to improved insights into the protein interaction. The described method is potentially useful for mapping the interactions of various P450 isoforms and their redox partners, because the method is relatively rapid and sensitive, and is capable of suggesting not only protein interacting regions, but also interacting orientations.	Univ Washington, Dept Med Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Nelson, SD (corresponding author), Univ Washington, Dept Med Chem, Box 357610, Seattle, WA 98195 USA.	sidnels@u.washington.edu	Shaffer, Scott A/F-8650-2010		NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR017262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057141] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032165] Funding Source: NIH RePORTER; NCRR NIH HHS [1S10RR17262-01] Funding Source: Medline; NIAID NIH HHS [1U54AI57141-01] Funding Source: Medline; NIEHS NIH HHS [P30ES07033] Funding Source: Medline; NIGMS NIH HHS [GM32165] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Back JW, 2002, ANAL CHEM, V74, P4417, DOI 10.1021/ac0257492; BAUER S, 1974, BIOTECHNOL BIOENG, V16, P933, DOI 10.1002/bit.260160707; Bridges A, 1998, J BIOL CHEM, V273, P17036, DOI 10.1074/jbc.273.27.17036; BUCK E, 2003, SCI STKE, V209, pRE14; Chang YT, 1997, PROTEIN ENG, V10, P119, DOI 10.1093/protein/10.2.119; Chen WQ, 1996, ARCH BIOCHEM BIOPHYS, V335, P123, DOI 10.1006/abbi.1996.0489; Chen WQ, 1998, CHEM RES TOXICOL, V11, P295, DOI 10.1021/tx9701687; Collins CJ, 2003, BIOORG MED CHEM LETT, V13, P4023, DOI 10.1016/j.bmcl.2003.08.053; Durley RCE, 1996, ACTA CRYSTALLOGR D, V52, P65, DOI 10.1107/S0907444995007827; Gao QX, 2006, ANAL CHEM, V78, P2145, DOI 10.1021/ac051339c; Gilep AA, 2001, J INORG BIOCHEM, V87, P237, DOI 10.1016/S0162-0134(01)00333-6; GILLAM EMJ, 1994, ARCH BIOCHEM BIOPHYS, V312, P59, DOI 10.1006/abbi.1994.1280; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; Guryev OL, 2001, BIOCHEMISTRY-US, V40, P5018, DOI 10.1021/bi002305w; Hlavica P, 2003, J INORG BIOCHEM, V96, P279, DOI 10.1016/S0162-0134(03)00152-1; HOLMANS PL, 1994, ARCH BIOCHEM BIOPHYS, V312, P554, DOI 10.1006/abbi.1994.1345; Ivanov YD, 1999, ARCH BIOCHEM BIOPHYS, V362, P87, DOI 10.1006/abbi.1998.0981; Ivanov YD, 2000, BIOCHEM BIOPH RES CO, V273, P750, DOI 10.1006/bbrc.2000.2973; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KENNEDY RT, 1989, ANAL CHEM, V61, P436, DOI 10.1021/ac00180a012; LARSON JR, 1991, P NATL ACAD SCI USA, V88, P9141, DOI 10.1073/pnas.88.20.9141; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; OMATA Y, 1994, BIOCHEM BIOPH RES CO, V201, P1090, DOI 10.1006/bbrc.1994.1817; Perret A, 1998, BIOCHEMISTRY-US, V37, P11412, DOI 10.1021/bi980908q; Porter TD, 2002, J BIOCHEM MOL TOXIC, V16, P311, DOI 10.1002/jbt.10052; RODGERS KK, 1991, J MOL BIOL, V221, P1453, DOI 10.1016/0022-2836(91)90945-3; Schenkman JB, 2003, PHARMACOL THERAPEUT, V97, P139, DOI 10.1016/S0163-7258(02)00327-3; Schenkman JB, 1999, DRUG METAB REV, V31, P351, DOI 10.1081/DMR-100101923; Schilling B, 2003, J AM SOC MASS SPECTR, V14, P834, DOI 10.1016/S1044-0305(03)00327-1; Schnolzer M, 1996, ELECTROPHORESIS, V17, P945, DOI 10.1002/elps.1150170517; SHEN AL, 1991, J BIOL CHEM, V266, P19976; Sinz A, 2003, J MASS SPECTROM, V38, P1225, DOI 10.1002/JMS.559; Sinz A, 2001, BIOCHEMISTRY-US, V40, P7903, DOI 10.1021/bi010259+; Spatzenegger M, 2003, J PHARMACOL EXP THER, V304, P477, DOI 10.1124/jpet.102.043323; STAYTON PS, 1989, BIOCHEMISTRY-US, V28, P8201, DOI 10.1021/bi00446a035; TAMBURINI PP, 1987, P NATL ACAD SCI USA, V84, P11, DOI 10.1073/pnas.84.1.11; Tang Y, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-S2-S9; Taverner T, 2002, J BIOL CHEM, V277, P46487, DOI 10.1074/jbc.M207370200; Wang YK, 2001, ANAL CHEM, V73, P3742, DOI 10.1021/ac010043d; Watt KC, 1997, ANAL BIOCHEM, V248, P26, DOI 10.1006/abio.1997.2109; Williams PA, 2000, J INORG BIOCHEM, V81, P183, DOI 10.1016/S0162-0134(00)00102-1; Wu SL, 2004, RAPID COMMUN MASS SP, V18, P2201, DOI 10.1002/rcm.1609; Wysocki VH, 2000, J MASS SPECTROM, V35, P1399, DOI 10.1002/1096-9888(200012)35:12<1399::AID-JMS86>3.0.CO;2-R; Yamazaki H, 1996, J BIOL CHEM, V271, P27438, DOI 10.1074/jbc.271.44.27438; Yamazaki H, 2002, PROTEIN EXPRES PURIF, V24, P329, DOI 10.1006/prep.2001.1578; Yamazaki H, 2001, J BIOL CHEM, V276, P30885, DOI 10.1074/jbc.M105011200; Yao XD, 2001, ANAL CHEM, V73, P2836, DOI 10.1021/ac001404c; Yi EC, 2003, RAPID COMMUN MASS SP, V17, P2093, DOI 10.1002/rcm.1150; Young MM, 2000, P NATL ACAD SCI USA, V97, P5802, DOI 10.1073/pnas.090099097; Yun CH, 2001, BIOCHEMISTRY-US, V40, P4521, DOI 10.1021/bi002906n	50	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20404	20417		10.1074/jbc.M601785200	http://dx.doi.org/10.1074/jbc.M601785200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16679316	hybrid			2022-12-25	WOS:000239038200064
J	Martinez-Hackert, E; Anikeeva, N; Kalams, SA; Walker, BD; Hendrickson, WA; Sykulev, Y				Martinez-Hackert, Erik; Anikeeva, Nadia; Kalams, Spyros A.; Walker, Bruce D.; Hendrickson, Wayne A.; Sykulev, Yuri			Structural basis for degenerate recognition of natural HIV peptide variants by cytotoxic lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; CRYSTAL-STRUCTURES; BINDING-SITE; POSITIVE SELECTION; CROSS-REACTIVITY; VIRAL PEPTIDES; MATRIX PROTEIN; MHC COMPLEXES; TCR BINDING; ANTIGEN	It is well established that even small changes in amino acid side chains of antigenic peptide bound to major histocompatibility complex (MHC) protein may completely abrogate recognition of the peptide-MHC (pMHC) complex by the T cell receptor (TCR). Often, however, several nonconservative substitutions in the peptide antigen are accommodated and do not impair its recognition by TCR. For example, a preponderance of natural sequence variants of the human immunodeficiency virus p17 Gag-derived peptide SLYNTVATL (SL9) are recognized by cytotoxic T lymphocytes, which implies that interactions with SL9 variants are degenerate both with respect to the class I MHCmolecule and with respect to TCR. Here we study the molecular basis for this degenerate recognition of SL9 variants. We show that several SL9 variants bind comparably well to soluble HLA-A2 and to a particular soluble TCR and that these variants are active in the cognate cytotoxicity assay. Natural SL9 variation is restricted by its context in the HIV p17 matrix protein. High resolution crystal structures of seven selected SL9 variants bound to HLA-A2 all have remarkably similar peptide conformations and side-chain dispositions outside sites of substitution. This preservation of the peptide conformation despite epitope variations suggests a mechanism for the observed degeneracy in pMHC recognition by TCR and may contribute to the persistence of SL9-mediated immune responses in chronically infected individuals.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Immunol & Microbiol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA; Vanderbilt Univ, Med Ctr, Div Infect Dis, Nashville, TN 37232 USA; Massachusetts Gen Hosp, AIDS Res Ctr, Boston, MA 02114 USA; Howard Hughes Med Inst, Boston, MA 02114 USA	Jefferson University; Jefferson University; Columbia University; Columbia University; Howard Hughes Medical Institute; Vanderbilt University; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute	Sykulev, Y (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Immunol & Microbiol, BLSB 650, Philadelphia, PA 19107 USA.	ysykulev@lac.jci.tju.edu		Martinez-Hackert, Erik/0000-0002-6182-7023	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI043254, R01AI043254, R01AI039966, R21AI058755] Funding Source: NIH RePORTER; NIAID NIH HHS [AI58755, AI39966, AI43254] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahlers JD, 1997, P NATL ACAD SCI USA, V94, P10856, DOI 10.1073/pnas.94.20.10856; Ahlers JD, 2001, J CLIN INVEST, V108, P1677, DOI 10.1172/JCI200113463; Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Anikeeva N, 2003, J IMMUNOL METHODS, V277, P75, DOI 10.1016/S0022-1759(03)00179-0; Anikeeva N, 2003, BIOCHEMISTRY-US, V42, P4709, DOI 10.1021/bi026864+; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; Berzofsky JA, 2001, NAT REV IMMUNOL, V1, P209, DOI 10.1038/35105075; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; Boniface JJ, 1999, P NATL ACAD SCI USA, V96, P11446, DOI 10.1073/pnas.96.20.11446; Bouvier M, 1998, PROTEINS, V33, P97, DOI 10.1002/(SICI)1097-0134(19981001)33:1<97::AID-PROT9>3.0.CO;2-I; Brander C, 1998, J CLIN INVEST, V101, P2559, DOI 10.1172/JCI2405; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buslepp J, 2003, J IMMUNOL, V170, P373, DOI 10.4049/jimmunol.170.1.373; CHEN ZW, 1992, J IMMUNOL, V149, P4060; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; Crawford F, 1998, IMMUNITY, V8, P675, DOI 10.1016/S1074-7613(00)80572-5; Ding YH, 1999, IMMUNITY, V11, P45, DOI 10.1016/S1074-7613(00)80080-1; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; Ferrari G, 2004, J IMMUNOL, V173, P2126, DOI 10.4049/jimmunol.173.3.2126; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; Gewurz BE, 2001, P NATL ACAD SCI USA, V98, P6794, DOI 10.1073/pnas.121172898; Goulder PJR, 1997, J EXP MED, V185, P1423, DOI 10.1084/jem.185.8.1423; Hill CP, 1996, P NATL ACAD SCI USA, V93, P3099, DOI 10.1073/pnas.93.7.3099; Hillig RC, 2001, J MOL BIOL, V310, P1167, DOI 10.1006/jmbi.2001.4816; HOGQUIST KA, 1993, J EXP MED, V177, P1469, DOI 10.1084/jem.177.5.1469; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, J MOL BIOL, V100, P283, DOI 10.1016/S0022-2836(76)80064-2; Khan AR, 2000, J IMMUNOL, V164, P6398, DOI 10.4049/jimmunol.164.12.6398; Kirksey TJ, 1999, J BIOL CHEM, V274, P37259, DOI 10.1074/jbc.274.52.37259; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Krogsgaard M, 2003, MOL CELL, V12, P1367, DOI 10.1016/S1097-2765(03)00474-X; Kuhns JJ, 1999, J BIOL CHEM, V274, P36422, DOI 10.1074/jbc.274.51.36422; Lee JK, 2004, J EXP MED, V200, P1455, DOI 10.1084/jem.20041251; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7; Minor W, 2002, ACTA PHYS POL A, V101, P613, DOI 10.12693/APhysPolA.101.613; Morikawa Y, 1998, J VIROL, V72, P7659, DOI 10.1128/JVI.72.9.7659-7663.1998; NAHILL SR, 1993, J EXP MED, V177, P317, DOI 10.1084/jem.177.2.317; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; Sliz P, 2001, J IMMUNOL, V167, P3276, DOI 10.4049/jimmunol.167.6.3276; Stewart-Jones GBE, 2003, NAT IMMUNOL, V4, P657, DOI 10.1038/ni942; Sykulev Y, 1998, IMMUNITY, V9, P475, DOI 10.1016/S1074-7613(00)80631-7; Tynan FE, 2005, J EXP MED, V202, P1249, DOI 10.1084/jem.20050864; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; Yang OO, 2003, J EXP MED, V197, P1365, DOI 10.1084/jem.20022138; Zhao R, 1999, J EXP MED, V189, P359, DOI 10.1084/jem.189.2.359	50	21	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20205	20212		10.1074/jbc.M601934200	http://dx.doi.org/10.1074/jbc.M601934200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16702212	hybrid			2022-12-25	WOS:000239038200045
J	Burgess, SC; Leone, TC; Wende, AR; Croce, MA; Chen, ZJ; Sherry, AD; Malloy, CR; Finck, BN				Burgess, Shawn C.; Leone, Teresa C.; Wende, Adam R.; Croce, Michelle A.; Chen, Zhouji; Sherry, A. Dean; Malloy, Craig R.; Finck, Brian N.			Diminished hepatic gluconeogenesis via defects in tricarboxylic acid cycle flux in peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha)-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; PPAR-ALPHA; NULL MICE; INSULIN-RESISTANCE; GLUCOSE-PRODUCTION; FASTING RESPONSE; INTEGRATED H-2; INBORN-ERRORS; REDOX STATE; RAT-LIVER	The peroxisome proliferator-activated receptor gamma(PPAR gamma) coactivator 1 alpha(PGC-1 alpha) is a highly inducible transcriptional coactivator implicated in the coordinate regulation of genes encoding enzymes involved in hepatic fatty acid oxidation, oxidative phosphorylation, and gluconeogenesis. The present study sought to assess the effects of chronic PGC-1 alpha deficiency on metabolic flux through the hepatic gluconeogenic, fatty acid oxidation, and tricarboxylic acid cycle pathways. To this end, hepatic metabolism was assessed in wild-type (WT) and PGC-1 alpha(-/-) mice using isotopomer-based NMR with complementary gene expression analyses. Hepatic glucose production was diminished in PGC-1 alpha(-/-) livers coincident with reduced gluconeogenic flux from phosphoenolpyruvate. Surprisingly, the expression of PGC-1 alpha target genes involved in gluconeogenesis was unaltered in PGC-1 alpha(-/-) compared withWTmice under fed and fasted conditions. Flux through tricarboxylic acid cycle and mitochondrial fatty acid beta-oxidation pathways was also diminished in PGC-1 alpha-/- livers. The expression of multiple genes encoding tricarboxylic acid cycle and oxidative phosphorylation enzymes was significantly depressed in PGC-1 alpha(-/-) mice and was activated by PGC-1 alpha overexpression in the livers of WT mice. Collectively, these findings suggest that chronic wholeanimal PGC-1 alpha deficiency results in defects in hepatic glucose production that are secondary to diminished fatty acid beta-oxidation and tricarboxylic acid cycle flux rather than abnormalities in gluconeogenic enzyme gene expression per se.	Washington Univ, Sch Med, Dept Med, Ctr Human Nutr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cardiovasc Res Ctr, St Louis, MO 63110 USA; Univ Texas, SW Med Ctr, Adv Imaging Res Ctr, Dallas, TX 75235 USA	Washington University (WUSTL); Washington University (WUSTL); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Finck, BN (corresponding author), Washington Univ, Sch Med, Dept Med, Ctr Human Nutr, 660 S Euclid Ave,Campus Box 8031, St Louis, MO 63110 USA.	bfinck@im.wustl.edu	Wende, Adam/AFG-8878-2022; Sherry, Dean/P-2348-2018	Wende, Adam/0000-0002-5536-4675; Finck, Brian/0000-0001-5411-3674; Malloy, Craig/0000-0001-5077-0642; Sherry, Dean/0000-0001-7150-8301	NCRR NIH HHS [RR02584, P41 RR002584, P41 RR002584-17] Funding Source: Medline; NHLBI NIH HHS [P01 HL057278-07, P01 HL057278, P01 HL57278, R01 HL101189, R01 HL058427, R01 HL58427] Funding Source: Medline; NIDDK NIH HHS [U24 DK059632, U24-DK59632, P30 DK56341, U24 DK059632-01, P30 DK056341-04, P30 DK056341-06, P30 DK056341, K01 DK062903, R01 DK45416, R01 DK045416, R01 DK045416-14, P30 DK056341-05S2] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002584] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL101189, R01HL058427, P01HL057278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U24DK059632, R01DK045416, P30DK056341, K01DK062903] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bandsma RHJ, 2004, J BIOL CHEM, V279, P8930, DOI 10.1074/jbc.M310067200; Bernal-Mizrachi C, 2003, NAT MED, V9, P1069, DOI 10.1038/nm898; Burgess SC, 2004, J BIOL CHEM, V279, P48941, DOI 10.1074/jbc.M407120200; Burgess SC, 2003, ANAL BIOCHEM, V318, P321, DOI 10.1016/S0003-2697(03)00158-1; Burton BK, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.6.e69; Chandramouli V, 1997, AM J PHYSIOL-ENDOC M, V273, pE1209, DOI 10.1152/ajpendo.1997.273.6.E1209; Chen ZJ, 2000, J BIOL CHEM, V275, P32807, DOI 10.1074/jbc.M004913200; Finck BN, 2005, CELL METAB, V1, P133, DOI 10.1016/j.cmet.2005.01.006; Guerre-Millo M, 2001, DIABETES, V50, P2809, DOI 10.2337/diabetes.50.12.2809; Hakimi Parvin, 2005, Nutr Metab (Lond), V2, P33, DOI 10.1186/1743-7075-2-33; Handschin C, 2005, CELL, V122, P505, DOI 10.1016/j.cell.2005.06.040; Hausler N, 2006, BIOCHEM J, V395, P663; Hausler N, 2006, BIOCHEM J, V394, P465, DOI 10.1042/BJ20051174; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Ibdah JA, 2001, J CLIN INVEST, V107, P1403, DOI 10.1172/JCI12590; Jin ES, 2004, ANAL BIOCHEM, V327, P149, DOI 10.1016/j.ab.2003.12.036; Jones JG, 2001, AM J PHYSIOL-ENDOC M, V281, pE848, DOI 10.1152/ajpendo.2001.281.4.E848; Jones JG, 1997, FEBS LETT, V412, P131, DOI 10.1016/S0014-5793(97)00764-3; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Koo SH, 2005, NATURE, V437, P1109, DOI 10.1038/nature03967; Koo SH, 2004, NAT MED, V10, P530, DOI 10.1038/nm1044; Koves TR, 2005, J BIOL CHEM, V280, P33588, DOI 10.1074/jbc.M507621200; Kunst A., 1984, METHOD ENZYMAT AN, VVI, P163; Kurtz DM, 1998, P NATL ACAD SCI USA, V95, P15592, DOI 10.1073/pnas.95.26.15592; LANDAU BR, 1995, J CLIN INVEST, V95, P172, DOI 10.1172/JCI117635; Leone TC, 2005, PLOS BIOL, V3, P672, DOI 10.1371/journal.pbio.0030101; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lin JD, 2005, CELL, V120, P261, DOI 10.1016/j.cell.2004.11.043; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; PASSONNEAU JV, 1974, ANAL BIOCHEM, V60, P405, DOI 10.1016/0003-2697(74)90248-6; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; She PX, 2003, DIABETES, V52, P1649, DOI 10.2337/diabetes.52.7.1649; SOVIK O, 1989, ACTA PAEDIATR SCAND, V78, P161, DOI 10.1111/j.1651-2227.1989.tb11052.x; Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037; Stanley C A, 1987, Adv Pediatr, V34, P59; STOCCHI V, 1987, ANAL BIOCHEM, V167, P181, DOI 10.1016/0003-2697(87)90150-3; Tordjman K, 2001, J CLIN INVEST, V107, P1025, DOI 10.1172/JCI11497; WILLIAMSON DH, 1962, BIOCHEM J, V82, P90, DOI 10.1042/bj0820090; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	44	91	93	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19000	19008		10.1074/jbc.M600050200	http://dx.doi.org/10.1074/jbc.M600050200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16670093	hybrid, Green Accepted			2022-12-25	WOS:000238847000013
J	Goswami, S; Adhya, S				Goswami, Srikanta; Adhya, Samit			The alpha-subunit of Leishmania F-1 ATP synthase hydrolyzes ATP in presence of tRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIA IN-VITRO; ENCODED TRANSFER-RNA; IMPORT; MEMBRANE; PROMASTIGOTES; RECEPTORS; DONOVANI; COMPLEX	Import of tRNAs into the mitochondria of the kinetoplastid protozoon Leishmania requires the tRNA-dependent hydrolysis of ATP leading to the generation of membrane potential through the pumping of protons. Subunit RIC1 of the inner membrane RNA import complex is a bi-functional protein that is identical to the alpha-subunit of F1F0 ATP synthase and specifically binds to a subset (Type I) of importable tRNAs. We show that recombinant, purified RIC1 is a Type I tRNA-dependent ATP hydrolase. The activity was insensitive to oligomycin, sensitive to mutations within the import signal of the tRNA, and required the cooperative interaction between the ATP-binding and C-terminal domains of RIC1. The ATPase activity of the intact complex was inhibited by anti-RIC1 antibody, while knockdown of RIC1 in Leishmania tropica resulted in deficiency of the tRNA-dependent ATPase activity of the mitochondrial inner membrane. Moreover, RIC1 knockdown extracts failed to generate a membrane potential across reconstituted proteoliposomes, as shown by a rhodamine 123 uptake assay, but activity was restored by adding back purified RIC1. These observations identify RIC1 as a novel form of the F-1 ATP synthase alpha-subunit that acts as the major energy transducer for tRNA import.	Indian Inst Chem Biol, Genet Engn Lab, Kolkata 700032, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Adhya, S (corresponding author), Indian Inst Chem Biol, Genet Engn Lab, 4 Raja SC Mullick Rd, Kolkata 700032, W Bengal, India.	sadhya@iicb.res.in						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Adhya S, 1997, J BIOL CHEM, V272, P21396, DOI 10.1074/jbc.272.34.21396; Bhattacharyya SN, 2004, J BIOL CHEM, V279, P11259, DOI 10.1074/jbc.C300540200; Bhattacharyya SN, 2003, MOL CELL BIOL, V23, P5217, DOI 10.1128/MCB.23.15.5217-5224.2003; Bhattacharyya SN, 2000, MOL CELL BIOL, V20, P7410, DOI 10.1128/MCB.20.19.7410-7417.2000; Bhattacharyya Suvendra Nath, 2004, RNA Biol, V1, P84, DOI 10.4161/rna.1.2.1180; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cellbio.4.1.155; DAS A, 1993, MOL BIOCHEM PARASIT, V60, P293, DOI 10.1016/0166-6851(93)90140-S; Delage L, 2003, MOL CELL BIOL, V23, P4000, DOI 10.1128/MCB.23.11.4000-4012.2003; Goswami S, 2006, P NATL ACAD SCI USA, V103, P8354, DOI 10.1073/pnas.0510869103; HANCOCK K, 1990, J BIOL CHEM, V265, P19203; MAHAPATRA S, 1994, NUCLEIC ACIDS RES, V22, P3381, DOI 10.1093/nar/22.16.3381; Mahapatra S, 1998, NUCLEIC ACIDS RES, V26, P2037, DOI 10.1093/nar/26.9.2037; Mukherjee S, 1999, J BIOL CHEM, V274, P31249, DOI 10.1074/jbc.274.44.31249; Rubio MAT, 2000, RNA, V6, P988, DOI 10.1017/S1355838200991519; SIMPSON AM, 1989, NUCLEIC ACIDS RES, V17, P5427, DOI 10.1093/nar/17.14.5427; Skordalakes E, 2003, CELL, V114, P135, DOI 10.1016/S0092-8674(03)00512-9; TARASSOV I, 1995, J MOL BIOL, V245, P15; TARRASOV I, 1992, NUCLEIC ACIDS RES, V20, P1277; Yermovsky-Kammerer AE, 1999, MOL CELL BIOL, V19, P6253; ZILBERSTEIN D, 1988, BIOCHEM J, V256, P13, DOI 10.1042/bj2560013	21	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					18914	18917		10.1074/jbc.C600089200	http://dx.doi.org/10.1074/jbc.C600089200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16735512	hybrid			2022-12-25	WOS:000238847000003
J	Liang, M; Cai, T; Tian, J; Qu, WK; Xie, ZJ				Liang, Man; Cai, Ting; Tian, Jiang; Qu, Weikai; Xie, Zi-Jian			Functional characterization of Src-interacting Na/K-ATPase using RNA interference assay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SIGNAL-TRANSDUCING FUNCTION; SITE-DIRECTED MUTAGENESIS; RAT NA,K-ATPASE ALPHA-1; GROWTH-FACTOR RECEPTOR; CARDIAC NA+/K+-ATPASE; CELL MOTILITY; SUBUNIT; BINDING; EXPRESSION	We have shown that the Na/K-ATPase and Src form a signaling receptor complex. Here we determined how alterations in the amount and properties of the Na/K-ATPase affect basal Src activity and ouabain-induced signal transduction. Several alpha 1 subunit knockdown cell lines were generated by transfecting LLC-PK1 cells with a vector expressing alpha 1-specific small interference RNA. Although the alpha 1 knockdown resulted in significant decreases in Na/K-ATPase activity, it increased the basal Src activity and tyrosine phosphorylation of focal adhesion kinase, a Src effector. Concomitantly it also abolished ouabain-induced activation of Src and ERK1/2. When the knockdown cells were rescued by a rat alpha 1, both Na/K-ATPase activity and the basal Src activity were restored. In addition, ouabain was able to stimulate Src and ERK1/2 in the rescued cells at a much higher concentration, consistent with the established differences in ouabain sensitivity between pig and rat alpha 1. Finally both fluorescence resonance energy transfer analysis and co-immunoprecipitation assay indicated that the pumping-null rat alpha 1 (D371E) mutant could also bind Src. Expression of this mutant restored the basal Src activity and focal adhesion kinase tyrosine phosphorylation. Taken together, the new findings suggest that LLC-PK1 cells contain a pool of Src-interacting Na/K-ATPase that not only regulates Src activity but also serves as a receptor for ouabain to activate protein kinases.	Med Univ Ohio, Dept Physiol Pharmacol Metab & Cardiovasc Sci, Toledo, OH 43614 USA		Xie, ZJ (corresponding author), Med Univ Ohio, Dept Physiol Pharmacol Metab & Cardiovasc Sci, 3035 Arlington Ave, Toledo, OH 43614 USA.	zxie@meduohio.edu			NHLBI NIH HHS [HL-67963, HL-36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573, R01HL067963] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aydemir-Koksoy A, 2001, J BIOL CHEM, V276, P46605, DOI 10.1074/jbc.M106178200; Barwe SP, 2005, MOL BIOL CELL, V16, P1082, DOI 10.1091/mbc.E04-05-0427; EMANUEL JR, 1988, J BIOL CHEM, V263, P7726; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Haas A, 2002, J BIOL CHEM, V277, P18694, DOI 10.1074/jbc.M111357200; Haas M, 2000, J BIOL CHEM, V275, P27832; Haskell MD, 2001, CHEM REV, V101, P2425, DOI 10.1021/cr0002341; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; KENT RB, 1987, SCIENCE, V237, P901, DOI 10.1126/science.3039660; KIM D, 1984, J PHARMACOL EXP THER, V231, P326; Kometiani P, 1998, J BIOL CHEM, V273, P15249, DOI 10.1074/jbc.273.24.15249; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Liu J, 2004, KIDNEY INT, V66, P227, DOI 10.1111/j.1523-1755.2004.00723.x; Liu J, 2000, J BIOL CHEM, V275, P27838; Liu LJ, 2004, AM J PHYSIOL-HEART C, V287, pH2173, DOI 10.1152/ajpheart.00352.2004; Liu LJ, 2003, AM J PHYSIOL-CELL PH, V284, pC1550, DOI 10.1152/ajpcell.00555.2002; Miyakawa-Naito A, 2003, J BIOL CHEM, V278, P50355, DOI 10.1074/jbc.M305378200; Mohammadi K, 2001, J BIOL CHEM, V276, P42050, DOI 10.1074/jbc.M107892200; OHTSUBO M, 1990, BIOCHIM BIOPHYS ACTA, V1021, P157, DOI 10.1016/0005-2736(90)90028-M; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Petrosian SA, 1998, ARCH BIOCHEM BIOPHYS, V357, P249, DOI 10.1006/abbi.1998.0816; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; Rajasekaran SA, 2001, MOL BIOL CELL, V12, P279, DOI 10.1091/mbc.12.2.279; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; SKOU JC, 1957, BIOCHIM BIOPHYS ACTA, V23, P394, DOI 10.1016/0006-3002(57)90343-8; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tian J, 2006, MOL BIOL CELL, V17, P317, DOI 10.1091/mbc.E05-08-0735; Tian J, 2001, AM J PHYSIOL-HEART C, V281, pH1899, DOI 10.1152/ajpheart.2001.281.5.H1899; Wang HJ, 2004, J BIOL CHEM, V279, P17250, DOI 10.1074/jbc.M313239200; XIE ZJ, 1989, ANAL BIOCHEM, V183, P215, DOI 10.1016/0003-2697(89)90470-3; Yuan ZK, 2005, MOL BIOL CELL, V16, P4034, DOI 10.1091/mbc.E05-04-0295	35	131	137	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19709	19719		10.1074/jbc.M512240200	http://dx.doi.org/10.1074/jbc.M512240200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16698801	hybrid			2022-12-25	WOS:000238847000084
J	Shiroishi, M; Kajikawa, M; Kuroki, K; Ose, T; Kohda, D; Maenaka, K				Shiroishi, Mitsunori; Kajikawa, Mizuho; Kuroki, Kimiko; Ose, Toyoyuki; Kohda, Daisuke; Maenaka, Katsumi			Crystal structure of the human monocyte-activating receptor, "Group 2" leukocyte Ig-like receptor A5 (LILRA5/LIR9/ILT11)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; INHIBITORY RECEPTOR; RHEUMATOID-ARTHRITIS; DENDRITIC CELLS; GROWTH-HORMONE; CUTTING EDGE; COMPLEX; BINDING; ILT2; MOLECULES	Human leukocyte Ig-like receptor B1 (LILRB1) and B2 (LILRB2) belong to "Group 1" receptors and recognize a broad range of major histocompatibility complex class I molecules (MHCIs). In contrast, "Group 2" receptors show low similarity with LILRB1/B2, and their ligands remain to be identified. To date, the structural and functional characteristics of Group 2 LILRs are poorly understood. Here we report the crystal structure of the extracellular domain of LILRA5, which is an activating Group2 LILR expressed on monocytes and neutrophils. Unexpectedly, the structure showed large changes in structural conformation and charge distribution in the region corresponding to the MHCI binding site of LILRB1/B2, which are also distinct from killer cell Ig-like receptors and F alpha receptors. These changes probably confer the structural hindrance for the MHCI binding, and their key amino acid substitutions are well conserved in Group 2 LILRs. Consistently, the surface plasmon resonance and flow cytometric analyses demonstrated that LILRA5 exhibited no affinities to all tested MHCIs. These results raised the possibility that LILRA5 as well as Group 2 LILRs do not play a role in any MHCI recognition but could possibly bind to non-MHCI ligand(s) on the target cells to provide a novel immune regulation mechanism.	Kyushu Univ, Div Struct Biol, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Maenaka, K (corresponding author), Kyushu Univ, Div Struct Biol, Med Inst Bioregulat, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	kmaenaka@bioreg.kyushu-u.ac.jp	Ose, Toyoyuki/AAW-7821-2020; Kuroki, Kimiko/F-6906-2012; Kohda, Daisuke/I-4990-2019	Ose, Toyoyuki/0000-0002-2001-9388; Kohda, Daisuke/0000-0001-8234-3776; Shiroishi, Mitsunori/0000-0002-3133-157X				Allen RL, 2001, J IMMUNOL, V167, P5543, DOI 10.4049/jimmunol.167.10.5543; Arase H, 2002, SCIENCE, V296, P1323, DOI 10.1126/science.1070884; Bleharski JR, 2003, SCIENCE, V301, P1527, DOI 10.1126/science.1087785; Borges L, 2003, BLOOD, V101, P1484, DOI 10.1182/blood-2002-05-1432; Borges L, 1997, J IMMUNOL, V159, P5192; Boyington JC, 2000, NATURE, V405, P537, DOI 10.1038/35014520; Bravo J, 1998, EMBO J, V17, P1665, DOI 10.1093/emboj/17.6.1665; Brown D, 2004, TISSUE ANTIGENS, V64, P215, DOI 10.1111/j.0001-2815.2004.00290.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cella M, 1997, J EXP MED, V185, P1743, DOI 10.1084/jem.185.10.1743; Chang CC, 2002, NAT IMMUNOL, V3, P237, DOI 10.1038/ni760; Chapman TL, 1999, IMMUNITY, V11, P603, DOI 10.1016/S1074-7613(00)80135-1; Chapman TL, 2000, IMMUNITY, V13, P727, DOI 10.1016/S1074-7613(00)00071-6; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Colonna M, 1998, J IMMUNOL, V160, P3096; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Fan QR, 1997, NATURE, V389, P96, DOI 10.1038/38028; Fan QR, 2001, NAT IMMUNOL, V2, P452, DOI 10.1038/87766; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Foster CE, 2003, J BIOL CHEM, V278, P46081, DOI 10.1074/jbc.M308491200; Herr AB, 2003, NATURE, V423, P614, DOI 10.1038/nature01685; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim-Schulze S, 2006, J IMMUNOL, V176, P2790, DOI 10.4049/jimmunol.176.5.2790; Kuroki K, 2005, HUM MOL GENET, V14, P2469, DOI 10.1093/hmg/ddi247; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lepin EJM, 2000, EUR J IMMUNOL, V30, P3552, DOI 10.1002/1521-4141(200012)30:12<3552::AID-IMMU3552>3.0.CO;2-L; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Maenaka K, 1999, STRUCTURE, V7, P391, DOI 10.1016/S0969-2126(99)80052-5; Martin AM, 2002, TRENDS IMMUNOL, V23, P81, DOI 10.1016/S1471-4906(01)02155-X; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Reid SW, 1996, FEBS LETT, V383, P119, DOI 10.1016/0014-5793(96)00226-8; Shiroishi M, 2003, P NATL ACAD SCI USA, V100, P8856, DOI 10.1073/pnas.1431057100; Sloane DE, 2004, BLOOD, V104, P2832, DOI 10.1182/blood-2004-01-0268; Snyder GA, 1999, P NATL ACAD SCI USA, V96, P3864, DOI 10.1073/pnas.96.7.3864; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Willcox BE, 2003, NAT IMMUNOL, V4, P913, DOI 10.1038/ni961; Willcox Benjamin E, 2002, BMC Struct Biol, V2, P6, DOI 10.1186/1472-6807-2-6	41	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19536	19544		10.1074/jbc.M603076200	http://dx.doi.org/10.1074/jbc.M603076200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16675463	hybrid			2022-12-25	WOS:000238847000068
J	Zhao, YT; He, DH; Saatian, B; Watkins, T; Spannhake, EW; Pyne, NJ; Natarajan, V				Zhao, Yutong; He, Donghong; Saatian, Bahman; Watkins, Tonya; Spannhake, Ernst Wm.; Pyne, Nigel J.; Natarajan, Viswanathan			Regulation of lysophosphatidic acid-induced epidermal growth factor receptor transactivation and interleukin-8 secretion in human bronchial epithelial cells by protein kinase C delta, Lyn kinase, and matrix metalloproteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC-DEPENDENT PHOSPHORYLATION; TYROSINE KINASE; SIGNAL-TRANSDUCTION; ACTIVATION; MITOGEN; LPA; PROLIFERATION; MECHANISMS; PATHWAYS; RELEASE	We have demonstrated earlier that lysophosphatidic acid (LPA)-induced interleukin-8 (IL-8) secretion is regulated by protein kinase C delta (PKC delta)-dependent NF-kappa B activation in human bronchial epithelial cells (HBEpCs). Here we provide evidence for signaling pathways that regulate LPA-mediated transactivation of epidermal growth factor receptor (EGFR) and the role of cross-talk between G-protein-coupled receptors and receptor-tyrosine kinases in IL-8 secretion in HBEpCs. Treatment of HBEpCs with LPA stimulated tyrosine phosphorylation of EGFR, which was attenuated by matrix metalloproteinase (MMP) inhibitor (GM6001), heparin binding (HB)-EGF inhibitor(CRM197), and HB-EGF neutralizing antibody. Overexpression of dominant negative PKC delta or pretreatment with a PKC delta inhibitor (rottlerin) or Src kinase family inhibitor (PP2) partially blocked LPA-induced MMP activation, proHB-EGF shedding, and EGFR tyrosine phosphorylation. Down-regulation of Lyn kinase, but not Src kinase, by specific small interfering RNA mitigated LPA-induced MMP activation, proHB-EGF shedding, and EGFR phosphorylation. In addition, overexpression of dominant negative PKC delta blocked LPA-induced phosphorylation and translocation of Lyn kinase to the plasma membrane. Furthermore, down-regulation of EGFR by EGFR small interfering RNA or pretreatment of cells with EGFR inhibitors AG1478 and PD158780 almost completely blocked LPA-dependent EGFR phosphorylation and partially attenuated IL-8 secretion, respectively. These results demonstrate that LPA-induced IL-8 secretion is partly dependent on EGFR transactivation regulated by PKC delta-dependent activation of Lyn kinase and MMPs and proHB-EGF shedding, suggesting a novel mechanism of crosstalk and interaction between G-protein-coupled receptors and receptor- tyrosine kinases in HBEpCs.	Univ Chicago, Dept Med, Sect Pulm & Crit Care, Chicago, IL 60637 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21224 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Sci, Baltimore, MD 21205 USA; Univ Strathclyde, Dept Physiol & Pharmacol, Strathclyde Inst Biomed Sci, Glasgow GN 0NR, Lanark, Scotland	University of Chicago; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Strathclyde	Natarajan, V (corresponding author), Univ Chicago, Dept Med, Sect Pulm & Crit Care, Ctr Integrat Sci Bldg,Rm 408B,929 E 57th, Chicago, IL 60637 USA.	vnataraj@medicine.bsd.uchicago.edu		Pyne, Nigel/0000-0002-5657-4578	NHLBI NIH HHS [HL71152, R01 HL071152-03, R01 HL071152] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071152] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abul H, 2001, MOL CELL BIOCHEM, V217, P107, DOI 10.1023/A:1007264411006; Amos S, 2005, J BIOL CHEM, V280, P7729, DOI 10.1074/jbc.M409056200; Bektas M, 2005, J CELL BIOL, V169, P801, DOI 10.1083/jcb.200407123; Bernacki SH, 1999, AM J RESP CELL MOL, V20, P595, DOI 10.1165/ajrcmb.20.4.3442; Brandt DT, 2003, J BIOL CHEM, V278, P34073, DOI 10.1074/jbc.M211650200; Brat DJ, 2005, NEURO-ONCOLOGY, V7, P122, DOI 10.1215/S1152851704001061; CARPENTER G, 2000, SCI STKE 2000; Cummings R, 2004, J BIOL CHEM, V279, P41085, DOI 10.1074/jbc.M404045200; Cummings R, 2002, MOL CELL BIOCHEM, V234, P99, DOI 10.1023/A:1015944828973; Ediger TL, 2002, AM J PHYSIOL-LUNG C, V282, pL91, DOI 10.1152/ajplung.2002.282.1.L91; Eguchi S, 2003, BIOCHEM SOC T, V31, P1198; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; English D, 2002, BBA-MOL CELL BIOL L, V1582, P228, DOI 10.1016/S1388-1981(02)00176-2; Facchini A, 2005, FEBS LETT, V579, P2919, DOI 10.1016/j.febslet.2005.04.044; Frank GD, 2003, MOL CELL BIOL, V23, P1581, DOI 10.1128/MCB.23.5.1581-1589.2003; Fukushima N, 2001, PROSTAG OTH LIPID M, V64, P21, DOI 10.1016/S0090-6980(01)00105-8; Goppelt-Struebe M, 2000, BIOCHEM J, V345, P217, DOI 10.1042/0264-6021:3450217; Hamilton LM, 2003, CLIN EXP ALLERGY, V33, P233, DOI 10.1046/j.1365-2222.2003.01593.x; Hashimoto T, 2003, J PHARMACOL SCI, V91, P8, DOI 10.1254/jphs.91.8; Hellermann GR, 2002, RESP RES, V3, DOI 10.1186/rr172; Joseloff E, 2002, J BIOL CHEM, V277, P12318, DOI 10.1074/jbc.M111618200; Julkunen I, 2000, VACCINE, V19, pS32, DOI 10.1016/S0264-410X(00)00275-9; Kim CK, 2005, CLIN EXP ALLERGY, V35, P591, DOI 10.1111/j.1365-2222.2005.02224.x; Kim J, 2003, BIOCHEMISTRY-US, V42, P2887, DOI 10.1021/bi026942t; Kim SN, 2000, J CELL BIOCHEM, V76, P386, DOI 10.1002/(SICI)1097-4644(20000301)76:3<386::AID-JCB6>3.0.CO;2-9; Kue PF, 2002, INT J CANCER, V102, P572, DOI 10.1002/ijc.10734; Lannutti BJ, 2004, BLOOD, V103, P3736, DOI 10.1182/blood-2003-10-3566; LANZREIN M, 1995, BIOCHEM J, V310, P285, DOI 10.1042/bj3100285; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 2002, CAN J PHYSIOL PHARM, V80, P375, DOI 10.1139/Y02-045; Miyamoto S, 2004, CANCER RES, V64, P5720, DOI 10.1158/0008-5472.CAN-04-0811; Mukaida N, 2003, AM J PHYSIOL-LUNG C, V284, pL566, DOI 10.1152/ajplung.00233.2002; Ozol D, 2005, RESP MED, V99, P1494, DOI 10.1016/j.rmed.2005.04.025; Pease James E, 2002, Am J Respir Med, V1, P19; Pyne NJ, 2003, BIOCHEM SOC T, V31, P1220; Richter A, 2002, AM J RESP CELL MOL, V27, P85, DOI 10.1165/ajrcmb.27.1.4789; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; Saatian B, 2006, BIOCHEM J, V393, P657, DOI 10.1042/BJ20050791; Saatian B, 2004, AM J PHYSIOL-LUNG C, V287, pL217, DOI 10.1152/ajplung.00132.2003; Saba JD, 2004, J CELL BIOCHEM, V92, P967, DOI 10.1002/jcb.20128; Sato K, 2003, GENES CELLS, V8, P995, DOI 10.1046/j.1356-9597.2003.00691.x; Schierhorn K, 1999, AM J RESP CELL MOL, V20, P1013, DOI 10.1165/ajrcmb.20.5.3268; Schmitz U, 2002, BIOCHEM BIOPH RES CO, V291, P687, DOI 10.1006/bbrc.2002.6493; Sengupta S, 2004, SEMIN CELL DEV BIOL, V15, P503, DOI 10.1016/j.semcdb.2004.05.003; Shah BH, 2005, MOL PHARMACOL, V67, P184, DOI 10.1124/mol.104.003533; Shah BH, 2004, TRENDS ENDOCRIN MET, V15, P241, DOI 10.1016/j.tem.2004.06.011; Shah BH, 2005, MOL ENDOCRINOL, V19, P2535, DOI 10.1210/me.2005-0082; Strieter RM, 2002, AM J PHYSIOL-LUNG C, V283, pL688, DOI 10.1152/ajplung.00146.2002; Svetlov SI, 2002, BBA-MOL CELL BIOL L, V1582, P251, DOI 10.1016/S1388-1981(02)00178-6; Toews ML, 2002, BBA-MOL CELL BIOL L, V1582, P240, DOI 10.1016/S1388-1981(02)00177-4; Toman RE, 2002, NEUROCHEM RES, V27, P619, DOI 10.1023/A:1020219915922; Uribe JM, 2002, AM J PHYSIOL-GASTR L, V283, pG923, DOI 10.1152/ajpgi.00237.2002; van Leeuwen FN, 2003, BIOCHEM SOC T, V31, P1209; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wang LX, 2003, J BIOL CHEM, V278, P39931, DOI 10.1074/jbc.M302896200; Waters CM, 2005, CELL SIGNAL, V17, P263, DOI 10.1016/j.cellsig.2004.07.011; Wu SS, 2002, AM J PHYSIOL-CELL PH, V282, pC1432, DOI 10.1152/ajpcell.00323.2001; Xu YK, 2005, IMMUNITY, V22, P9, DOI 10.1016/j.immuni.2004.12.004; Zhang Q, 2004, CANCER RES, V64, P6166, DOI 10.1158/0008-5472.CAN-04-0504; Zhao YT, 2005, BIOCHEM J, V385, P493, DOI 10.1042/BJ20041160	60	89	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19501	19511		10.1074/jbc.M511224200	http://dx.doi.org/10.1074/jbc.M511224200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16687414	Green Accepted, hybrid			2022-12-25	WOS:000238847000065
J	Cella, N; Contreras, A; Latha, K; Rosen, JM; Zhang, M				Cella, Nathalie; Contreras, Alejandro; Latha, Khatri; Rosen, Jeffrey M.; Zhang, Ming			Maspin is physically associated with beta 1 integrin regulating cell adhesion in mammary epithelial cells	FASEB JOURNAL			English	Article						maspin; cell adhesion; beta 1 integrin; RSL; ECM	TUMOR-SUPPRESSOR MASPIN; EXTRACELLULAR-MATRIX; PLASMINOGEN-ACTIVATOR; CRYSTAL-STRUCTURE; CYTOSKELETON; MEMBRANE; INHIBITION; EXPRESSION; APOPTOSIS; GROWTH	Maspin is a tumor-suppressor serpin (serine protease inhibitor), which inhibits cell invasion and migration. Here, we analyzed maspin function in cell adhesion in nontransformed mammary epithelial cells and investigated the underlying mechanism involved in this process. We report that maspin acts in the early steps in the cell adhesion process. Addition of recombinant maspin rapidly increased MCF-10A cell adhesion to the endogenously deposited matrix, and conversely both an antimaspin antibody (Ab) and maspin knockdown by RNA interference resulted in decreased cell adhesion. Mutation analyses revealed that a region of 86 amino acids located between aa 139 and aa 225 was responsible for maspin effect on adhesion. In addition, we show that maspin is associated with detergent-insoluble cortical cytoskeleton elements. Collectively, these results suggest that maspin is part of the supramolecular structure of the adhesion plaque and it modulates cell adhesion via a beta 1 integrin-dependent mechanism.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Zhang, M (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, ALKEK Bldg,Rm N630,1 Baylor Plaza, Houston, TX 77030 USA.	mzhang@bcm.tmc.edu	Cella, Nathalie/A-3542-2012; Cella, Nathalie/AAX-5494-2021	Cella, Nathalie/0000-0001-6060-1076; Cella, Nathalie/0000-0001-6060-1076	NATIONAL CANCER INSTITUTE [R01CA079736] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM056929] Funding Source: NIH RePORTER; NCI NIH HHS [CA79736] Funding Source: Medline; NIGMS NIH HHS [R25 GM056929] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham S, 2003, J UROLOGY, V169, P1157, DOI 10.1097/01.ju.0000040245.70349.37; Al-Ayyoubi M, 2004, J BIOL CHEM, V279, P55540, DOI 10.1074/jbc.M409957200; Bass R, 2002, J BIOL CHEM, V277, P46845, DOI 10.1074/jbc.C200532200; BENZEEV A, 1979, CELL, V17, P859, DOI 10.1016/0092-8674(79)90326-X; Biliran H, 2001, CANCER RES, V61, P8676; Bissell MJ, 2003, BREAST CANCER RES, V5, P117, DOI 10.1186/bcr579; BLACQUE OE, 2002, J BIOL CHEM; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; Cher ML, 2003, P NATL ACAD SCI USA, V100, P7847, DOI 10.1073/pnas.1331360100; Costes SV, 2004, BIOPHYS J, V86, P3993, DOI [10.1529/biophysj.103.038422, 10.1529/biophysi.103.038422]; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; DELCOMMENNE M, 1995, J BIOL CHEM, V270, P26794, DOI 10.1074/jbc.270.45.26794; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; Gao F, 2004, DEVELOPMENT, V131, P1479, DOI 10.1242/dev.01048; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Goldfinger LE, 1999, J CELL SCI, V112, P2615; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; GONEN A, 1979, BIOCHIM BIOPHYS ACTA, V552, P307, DOI 10.1016/0005-2736(79)90285-2; Hikita C, 2000, J CELL BIOL, V151, P1235, DOI 10.1083/jcb.151.6.1235; LANGHOFER M, 1993, J CELL SCI, V105, P753; Latha K, 2005, MOL CELL BIOL, V25, P1737, DOI 10.1128/MCB.25.5.1737-1748.2005; Law RHP, 2005, J BIOL CHEM, V280, P22356, DOI 10.1074/jbc.M412043200; Li N, 2005, EMBO J, V24, P1942, DOI 10.1038/sj.emboj.7600674; Liu T, 1999, J BIOL CHEM, V274, P29628, DOI 10.1074/jbc.274.42.29628; MANDERS EMM, 1992, J CELL SCI, V103, P857; MAUTNER V, 1977, J CELL BIOL, V75, P743, DOI 10.1083/jcb.75.3.743; McGowen R, 2000, CANCER RES, V60, P4771; NGAMKITIDECHAKU.C, 2003, J BIOL CHEM; Ngamkitidechakul C, 2001, INVEST OPHTH VIS SCI, V42, P3135; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; Pemberton PA, 1997, J HISTOCHEM CYTOCHEM, V45, P1697, DOI 10.1177/002215549704501213; Plopper GE, 1998, BREAST CANCER RES TR, V51, P57, DOI 10.1023/A:1006086218174; Seftor REB, 1998, CANCER RES, V58, P5681; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Shi HY, 2001, CANCER RES, V61, P6945; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; STEPHENS LE, 1995, GENE DEV, V9, P1883, DOI 10.1101/gad.9.15.1883; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zhang M, 1999, DEV BIOL, V215, P278, DOI 10.1006/dbio.1999.9442; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	47	52	57	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1510	+		10.1096/fj.05-5500fje	http://dx.doi.org/10.1096/fj.05-5500fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16720730				2022-12-25	WOS:000240266000034
J	Schwarz, J; Schwarz, SC; Dorigo, O; Stutzer, A; Wegner, F; Labarca, C; Deshpande, P; Gil, JS; Berk, AJ; Lester, HA				Schwarz, Johannes; Schwarz, Sigrid C.; Dorigo, Oliver; Stuetzer, Alexandra; Wegner, Florian; Labarca, Cesar; Deshpande, Purnima; Gil, Jose S.; Berk, Arnold J.; Lester, Henry A.			Enhanced expression of hypersensitive alpha 4*nAChR in adult mice increases the loss of midbrain dopaminergic neurons	FASEB JOURNAL			English	Article						nicotinic receptor; substantia nigra; cholinergic excitotoxicity; knock-in mouse; helper-dependent adenovirus; Parkinson's disease	CAPACITY ADENOVIRAL VECTORS; ALPHA-4 NICOTINIC RECEPTORS; VIRAL CODING SEQUENCES; RAT SUBSTANTIA-NIGRA; GENE-TRANSFER; PARKINSONS-DISEASE; INFLAMMATORY RESPONSE; EXTENDED EXPRESSION; BETA-GALACTOSIDASE; IMMUNE-RESPONSES	We describe an inducible genetic model for degeneration of midbrain dopaminergic neurons in adults. In previous studies, knock-in mice expressing hypersensitive M2 domain Leu9'Ser (L9'S) alpha 4 nicotinic receptors ( nAChR) at near-normal levels displayed dominant neonatal lethality and dopaminergic deficits in embryonic midbrain, because the hypersensitive nAChR is excitotoxic. However, heterozygous L9'S mice that retain the neomycin resistance cassette (neo) in a neighboring intron express low levels of the mutant allele (similar to 25% of normal levels), and these neo-intact mice are therefore viable and fertile. The neo cassette is flanked by loxP sites. In adult animals, we locally injected helper-dependent adenovirus (HDA) expressing cre recombinase. Local excision of the neo cassette, via cre-mediated recombination, was verified by genomic analysis. In L9'S HDA-cre injected animals, locomotion was reduced both under baseline conditions and after amphetamine application. There was no effect in L9'S HDA-control treated animals or in wild-type ( WT) littermates injected with either virus. Immunocytochemical analyses revealed marked losses (> 70%) of dopaminergic neurons in L9'S HDA-cre injected mice compared to controls. At 20-33 days postinjection in control animals, the coexpressed marker gene, yellow fluorescent protein (YFP), was expressed in many neurons and few glial cells near the injection, emphasizing the neurotropic utility of the HDA. Thus, HDA-mediated gene transfer into adult midbrain induced sufficient functional expression of cre in dopaminergic neurons to allow for postnatal deletion of neo. This produced increased L9'S mutant nAChR expression, which in turn led to nicotinic cholinergic excitotoxicity in dopaminergic neurons.	CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ Leipzig, Dept Neurol, D-7010 Leipzig, Germany; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90024 USA	California Institute of Technology; Leipzig University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Lester, HA (corresponding author), CALTECH, Div Biol, 156-26, Pasadena, CA 91125 USA.	lester@caltech.edu	BERK, ARNOLD/AAF-7052-2020		NIGMS NIH HHS [GM07185] Funding Source: Medline; NIMH NIH HHS [MH-49176] Funding Source: Medline; NINDS NIH HHS [NS-11756] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH049176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011756] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSEN JK, 1992, HUM GENE THER, V3, P487, DOI 10.1089/hum.1992.3.5-487; Arroyo-Jimenez MD, 1999, J NEUROSCI, V19, P6475; Breit S, 2001, EUR J NEUROSCI, V14, P1833, DOI 10.1046/j.0953-816x.2001.01800.x; Breyer Benjamin, 2001, Current Gene Therapy, V1, P149, DOI 10.2174/1566523013348689; Cartmell T, 1999, J NEUROSCI, V19, P1517; DOBSON AT, 1990, NEURON, V5, P353, DOI 10.1016/0896-6273(90)90171-B; Dorigo O, 2004, J VIROL, V78, P6556, DOI 10.1128/JVI.78.12.6556-6566.2004; Ehrengruber MU, 2002, MOL NEUROBIOL, V26, P183, DOI 10.1385/MN:26:2-3:183; Fonck C, 2003, J NEUROSCI, V23, P2582; FUNG YK, 1989, PHARMACOL BIOCHEM BE, V32, P221, DOI 10.1016/0091-3057(89)90237-2; FUTAMI T, 1995, NEUROSCI RES, V21, P331, DOI 10.1016/0168-0102(94)00869-H; Hsich G, 2002, HUM GENE THER, V13, P579, DOI 10.1089/10430340252837198; Ideguchi M, 2000, NEUROSCIENCE, V95, P217; Iribe Y, 1999, J NEUROPHYSIOL, V82, P925, DOI 10.1152/jn.1999.82.2.925; Kirik D, 2003, P NATL ACAD SCI USA, V100, P2884, DOI 10.1073/pnas.0536383100; Kirik D, 2002, J NEUROSCI, V22, P2780, DOI 10.1523/JNEUROSCI.22-07-02780.2002; Klein RL, 2002, HUM GENE THER, V13, P605, DOI 10.1089/10430340252837206; Kochanek S, 1999, HUM GENE THER, V10, P2451, DOI 10.1089/10430349950016807; Kochanek S, 1996, P NATL ACAD SCI USA, V93, P5731, DOI 10.1073/pnas.93.12.5731; Kochanek S, 2001, CURR OPIN MOL THER, V3, P454; KOVOOR A, 2005, IN PRESS J NEUROSCI; Labarca C, 2001, P NATL ACAD SCI USA, V98, P2786, DOI 10.1073/pnas.041582598; Lo Bianco C, 2002, P NATL ACAD SCI USA, V99, P10813, DOI 10.1073/pnas.152339799; Lowenstein PR, 2003, GENE THER, V10, P946, DOI 10.1038/sj.gt.3302048; Lowenstein PR, 2002, METHOD ENZYMOL, V346, P292; Luo SQ, 1998, J NEUROSCI, V18, P8571; Marazziti D, 2004, P NATL ACAD SCI USA, V101, P10189, DOI 10.1073/pnas.0403661101; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Millecamps S, 1999, NAT BIOTECHNOL, V17, P865, DOI 10.1038/12849; Morsy MA, 1998, P NATL ACAD SCI USA, V95, P7866, DOI 10.1073/pnas.95.14.7866; Morsy MA, 1999, MOL MED TODAY, V5, P18, DOI 10.1016/S1357-4310(98)01376-8; Nabel GJ, 1999, P NATL ACAD SCI USA, V96, P324, DOI 10.1073/pnas.96.2.324; Navarro V, 1999, GENE THER, V6, P1884, DOI 10.1038/sj.gt.3301008; Nisell M, 1996, SYNAPSE, V22, P369, DOI 10.1002/(SICI)1098-2396(199604)22:4<369::AID-SYN8>3.0.CO;2-9; Orb S, 2004, PHYSIOL GENOMICS, V18, P299, DOI 10.1152/physiolgenomics.00012.2004; Parks RJ, 1996, P NATL ACAD SCI USA, V93, P13565, DOI 10.1073/pnas.93.24.13565; Peltekian E, 2002, MOL THER, V5, P25, DOI 10.1006/mthe.2001.0517; Pidoplichko VI, 1997, NATURE, V390, P401, DOI 10.1038/37120; Post Leonard E, 2002, Curr Opin Investig Drugs, V3, P1768; Raper SE, 2003, MOL GENET METAB, V80, P148, DOI 10.1016/j.ymgme.2003.08.016; Sapolsky RM, 2003, NAT REV NEUROSCI, V4, P61, DOI 10.1038/nrn1006; SAUER H, 1994, NEUROSCIENCE, V59, P401, DOI 10.1016/0306-4522(94)90605-X; Schiedner G, 2002, J VIROL, V76, P1600, DOI 10.1128/JVI.76.4.1600-1609.2002; Soudais C, 2003, FASEB J, V17, P391, DOI 10.1096/fj.03-0438fje; STORCH A, 1995, EUR J PHARM-MOLEC PH, V290, P207, DOI 10.1016/0922-4106(95)00080-1; Takada M, 2000, EUR J NEUROSCI, V12, P1771, DOI 10.1046/j.1460-9568.2000.00062.x; Takaki T, 1995, Nihon Shinkei Seishin Yakurigaku Zasshi, V15, P335; Tapper AR, 2004, SCIENCE, V306, P1029, DOI 10.1126/science.1099420; TRIARHOU LC, 1988, EXP BRAIN RES, V70, P256; van der Putten H, 2000, J NEUROSCI, V20, P6021, DOI 10.1523/JNEUROSCI.20-16-06021.2000; Warren Robert S, 2002, Surg Oncol Clin N Am, V11, P571, DOI 10.1016/S1055-3207(02)00043-1; Worgall S, 1997, HUM GENE THER, V8, P1675, DOI 10.1089/hum.1997.8.14-1675	52	11	11	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					935	946		10.1096/fj.05-5497com	http://dx.doi.org/10.1096/fj.05-5497com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675851				2022-12-25	WOS:000240157700016
J	Thakrar, RR; Patel, VP; Hamilton, G; Fuller, BJ; Seifalian, AM				Thakrar, Raj R.; Patel, Vishal P.; Hamilton, George; Fuller, Barry J.; Seifalian, Alexander M.			Vitreous cryopreservation maintains the viscoelastic property of human vascular grafts	FASEB JOURNAL			English	Article						vessel wall; vitrification; vascular grafting; allograft	FRESH	Assess the effects of cryopreservation ( cryo) and vitrification ( vitro) on the viscoelastic properties of blood vessels. Human external Iliac artery vessels were harvested from liver organ donors (n = 8). In each case the vessel was segmented into 3 equal parts, which were randomly placed in one of 3 categories: Fresh ( stored in 4 degrees C UW for 6 h), Cryo ( Placed in 10% Dulbecco's modified Eagle medium ( DMEM) and slowly frozen to -196 degrees C), or Vitro ( Placed in 40% DMEM and rapidly cooled to -196 degrees C). A pulsatile flow circuit was used to perfuse arterial segments at physiological pulse pressure and flow. Intraluminal pressure was measured using a Millar Mikro-tip catheter transducer, and vessel wall motion was determined with duplex ultrasonography coupled with a novel echo-locked vessel wall tracking system. Diametrical compliance ( DC), Petersons elastic modulus (Ep), and stiffness index (beta) were then calculated for each of the three groups over 3 mean pressure ranging from 40 to 80 mmHg. The change in the viscous component of arterial wall (lag phase angle, theta) was calculated from hysteresis plots. No significant changes were observed in the elastic properties of fresh and vitrified vessels (P > 0.05 for each of DC, Ep, and beta). Similarly, variation in the wall viscosity between fresh and vitrified vessels appeared to be nonsignificant (theta = 12.60 +/- 4.04 vs. 17.60 +/- 1.14, respectively). In contrast, statistical analysis of results obtained for cryopreserved vessels to the fresh vessels showed significant reduction in elastic parameter values. There was also a significant increase in the phase angle theta of the cryopreserved vessels (theta = 24.30 +/- 6.32; P < 0.001) compared with fresh vessel. Results suggest that vitrification maintains both elastic and viscous components of the mechanical properties of vascular grafts, which is positively correlated with their functional patency. In contrast, damage caused during cryopreservation significantly affects the overall tensile strength and elasticity of the vessel (i.e., Ep and beta), the dynamic properties (DC), and appears to significantly affect the viscous component of the vessel wall (theta), which is likely reduce the patency of the graft for transplantation purposes.	UCL, Biomat & Tissue Engn Ctr, Acad Div Surg & Intervent Sci, London SW3 2PF, England; Royal Free Hampstead NHS Trust, Vasc Biol Unit, London, England	University of London; University College London; University of London; University College London	Seifalian, AM (corresponding author), UCL, Biomat & Tissue Engn Ctr, Acad Div Surg & Intervent Sci, Rowland Hill St, London SW3 2PF, England.	a.seifalian@medsch.ucl.ac.uk	Seifalian, Alexander M/I-6028-2013; hamilton, george/K-4764-2013	Seifalian, Alexander M/0000-0002-1180-3322; seifalian, Alexander/0000-0002-8334-9376				Baguneid M, 2004, BIOTECHNOL APPL BIOC, V39, P151, DOI 10.1042/BA20030148; BOUTRON P, 1986, CRYOBIOLOGY, V23, P453, DOI 10.1016/0011-2240(86)90031-3; Bujan J, 2000, EUR J VASC ENDOVASC, V20, P13, DOI 10.1053/ejvs.2000.1090; CHENG K, 2002, EUR J VASC ENDOVASC, V24, P7; Cheng KS, 2003, J VASC SURG, V37, P403, DOI 10.1067/mva.2003.52; FAHY GM, 1984, CRYOBIOLOGY, V21, P407, DOI 10.1016/0011-2240(84)90079-8; Fuller B.J., 1991, CLIN APPL CRYOBIOLOG; Gamero LG, 2001, EXP PHYSIOL, V86, P519, DOI 10.1113/eph8602172; Giudiceandrea A, 2000, J ARTIF ORGANS, V3, P16; GLUCK T, 1898, BERL KLIN, V70, P1; Harris L, 2001, J VASC SURG, V33, P528, DOI 10.1067/mva.2001.111729; JAMIESON NV, 1988, TRANSPLANTATION, V46, P512, DOI 10.1097/00007890-198810000-00009; Jiang ZH, 2004, AM J PHYSIOL-HEART C, V286, pH240, DOI 10.1152/ajpheart.00760.2003; Kannan RY, 2005, J BIOMED MATER RES B, V74B, P570, DOI 10.1002/jbm.b.30247; Kannan RY, 2005, BIOMATERIALS, V26, P1857, DOI 10.1016/j.biomaterials.2004.07.006; Lakhani K, 2002, CIRCULATION, V106, P81, DOI 10.1161/01.CIR.0000020681.19400.8A; LIN TT, 1989, CRYOBIOLOGY, V26, P453, DOI 10.1016/0011-2240(89)90070-9; McVeigh GE, 2002, CLIN SCI, V102, P51, DOI 10.1042/CS20010191; Mingoli A, 1996, J SURG RES, V62, P95, DOI 10.1006/jsre.1996.0180; Nichols WW, 1990, MCDONALDS BLOOD FLOW; Pascual G, 2002, EUR J VASC ENDOVASC, V24, P23, DOI 10.1053/ejvs.2002.1663; Pegg D.E., 1987, BIOPHYSICS ORGAN CRY, P117; Pegg DE, 1997, CRYOBIOLOGY, V34, P183, DOI 10.1006/cryo.1996.1997; Pukacki F, 2000, EUR J VASC ENDOVASC, V20, P21, DOI 10.1053/ejvs.2000.1120; RALL WF, 1980, NATURE, V286, P511, DOI 10.1038/286511a0; Rashid ST, 2004, CELL PROLIFERAT, V37, P351, DOI 10.1111/j.1365-2184.2004.00318.x; Sales KM, 2005, TRENDS BIOTECHNOL, V23, P461, DOI 10.1016/j.tibtech.2005.06.006; Shadwick RE, 1999, J EXP BIOL, V202, P3305; SHWOODSMITH MJ, 1988, HUM REPROD, V3, P795; Song YC, 2000, J INVEST SURG, V13, P279; Song YC, 2000, NAT BIOTECHNOL, V18, P296, DOI 10.1038/73737; Spurr EE, 2002, CRYOBIOLOGY, V44, P210, DOI 10.1016/S0011-2240(02)00027-5; Tai NR, 2000, BRIT J SURG, V87, P1516, DOI 10.1046/j.1365-2168.2000.01566.x; Taylor MJ, 2004, LIFE IN THE FROZEN STATE, P603, DOI 10.1201/9780203647073.ch22; Tiwari A, 2002, FASEB J, V16, DOI 10.1096/fj.01-0826com; Wusteman M, 2004, LIFE IN THE FROZEN STATE, P541, DOI 10.1201/9780203647073.ch19; Wusteman M. C., 2000, Cell and Tissue Banking, V1, P295, DOI 10.1023/A:1010167604609	37	32	36	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					874	881		10.1096/fj.05-5304com	http://dx.doi.org/10.1096/fj.05-5304com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675845				2022-12-25	WOS:000240157700010
J	Kjaer, S; Kurokawa, K; Perrinjaquet, M; Abrescia, C; Ibanez, CF				Kjaer, S.; Kurokawa, K.; Perrinjaquet, M.; Abrescia, C.; Ibanez, C. F.			Self-association of the transmembrane domain of RET underlies oncogenic activation by MEN2A mutations	ONCOGENE			English	Article						GDNF; ret; Hirschsprung; ToxCAT	NEOPLASIA TYPE 2B; ERYTHROPOIETIN RECEPTOR; GXXXG MOTIF; HIRSCHSPRUNGS-DISEASE; DRIVE ASSOCIATION; TRANSFORMING GENE; MEMBRANE-PROTEINS; TYROSINE KINASE; ERBB RECEPTORS; PROTOONCOGENE	In patients with medullary thyroid carcinoma (MTC) and type 2A multiple endocrine neoplasia (MEN2A), mutations of cysteine residues in the extracellular juxta-membrane region of the RET receptor tyrosine kinase cause the formation of covalent receptor dimers linked by intermolecular disulfide bonds between unpaired cysteines, followed by oncogenic activation of the RET kinase. The close proximity to the plasma membrane of the affected cysteine residues prompted us to investigate the possible role of the transmembrane (TM) domain of RET (RET-TM) in receptor-receptor interactions underlying dimer formation. Strong self-association of the RET-TM was observed in a biological membrane. Mutagenesis studies indicated the involvement of the evolutionary conserved residues Ser-649 and Ser-653 in RET-TM oligomerization. Unexpectedly, RET-TM interactions were also abrogated in the A639G/A641R double mutant, first identified in a sporadic case of MTC. In agreement with this, no transforming activity could be detected in full-length RET carrying the A639G and A641R mutations, which remained fully responsive to glial cell-line-derived neurotrophic factor (GDNF) stimulation. When introduced in the context of C634R-a cysteine replacement that is prevalent in MEN2A cases-the A639G/A641R mutations significantly reduced dimer formation and transforming activity in this otherwise highly oncogenic RET variant. These data suggest that a strong propensity to self-association in the RET-TM underlies-and may be required for-dimer formation and oncogenic activation of juxtamembrane cysteine mutants of RET, and explains the close proximity to the plasma membrane of cysteine residues implicated in MEN2A and MTC syndromes.	Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, S-17177 Stockholm, Sweden	Karolinska Institutet	Kjaer, S (corresponding author), Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, Berzelius Vag 35, S-17177 Stockholm, Sweden.	sven.kjaer@cancer.org.uk; carlos.ibanez@neuro.ki.se		Kjaer, Susanne/0000-0002-8347-1398				Abrescia C, 2005, FEBS LETT, V579, P3789, DOI 10.1016/j.febslet.2005.05.075; Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Arighi E, 2004, MOL ENDOCRINOL, V18, P1004, DOI 10.1210/me.2003-0173; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Asai N, 1999, BIOCHEM BIOPH RES CO, V255, P587, DOI 10.1006/bbrc.1999.0237; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Bongarzone I, 1998, ONCOGENE, V16, P2295, DOI 10.1038/sj.onc.1201759; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; Cerchia L, 2003, BIOCHEM J, V372, P897, DOI 10.1042/BJ20021530; Chappuis-Flament S, 1998, ONCOGENE, V17, P2851, DOI 10.1038/sj.onc.1202202; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; Geneste O, 1999, HUM MOL GENET, V8, P1989, DOI 10.1093/hmg/8.11.1989; Gimm O, 1997, J CLIN ENDOCR METAB, V82, P3902, DOI 10.1210/jc.82.11.3902; Gratkowski H, 2001, P NATL ACAD SCI USA, V98, P880, DOI 10.1073/pnas.98.3.880; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; Hahn M, 2001, P NATL ACAD SCI USA, V98, P1053, DOI 10.1073/pnas.021558598; Hoppner W, 1997, HUM MOL GENET, V6, P587, DOI 10.1093/hmg/6.4.587; Hoppner W, 1998, HUM MUTAT, pS128; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; Iwashita T, 1999, ONCOGENE, V18, P3919, DOI 10.1038/sj.onc.1202742; Iwashita T, 2001, GASTROENTEROLOGY, V121, P24, DOI 10.1053/gast.2001.25515; Jhiang SM, 1996, THYROID, V6, P115, DOI 10.1089/thy.1996.6.115; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; Kalinin VN, 2001, J MOL MED-JMM, V79, P609, DOI 10.1007/s001090100250; Kashuk CS, 2005, P NATL ACAD SCI USA, V102, P8949, DOI 10.1073/pnas.0503259102; Kjaer S, 2003, HUM MOL GENET, V12, P2133, DOI 10.1093/hmg/ddg227; Kubatzky KF, 2005, J BIOL CHEM, V280, P14844, DOI 10.1074/jbc.M411251200; Kubatzky KF, 2001, CURR BIOL, V11, P110, DOI 10.1016/S0960-9822(01)00018-5; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; Li E, 2005, BIOCHEMISTRY-US, V44, P352, DOI 10.1021/bi048480k; Li RH, 2004, J BIOL CHEM, V279, P26666, DOI 10.1074/jbc.M314168200; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Marx SJ, 2005, NAT REV CANCER, V5, P367, DOI 10.1038/nrc1610; Mcclain MS, 2003, J BIOL CHEM, V278, P12101, DOI 10.1074/jbc.M212595200; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Miyauchi A, 1999, JPN J CANCER RES, V90, P1; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; Roy R, 2004, BIOCHEMISTRY-US, V43, P4964, DOI 10.1021/bi0362875; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schneider D, 2004, J MOL BIOL, V343, P799, DOI 10.1016/j.jmb.2004.08.083; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Senes A, 2004, CURR OPIN STRUC BIOL, V14, P465, DOI 10.1016/j.sbi.2004.07.007; Seubert N, 2003, MOL CELL, V12, P1239, DOI 10.1016/S1097-2765(03)00389-7; Stanley AM, 2005, J MOL BIOL, V347, P759, DOI 10.1016/j.jmb.2005.01.059; Sulistijo ES, 2003, J BIOL CHEM, V278, P51950, DOI 10.1074/jbc.M308429200; Takahashi M, 1999, HUM MUTAT, V13, P331, DOI 10.1002/(SICI)1098-1004(1999)13:4<331::AID-HUMU11>3.3.CO;2-R; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; Vidal M, 2005, CANCER RES, V65, P3538, DOI 10.1158/0008-5472.CAN-04-4561; Young MT, 2003, J BIOL CHEM, V278, P32954, DOI 10.1074/jbc.M302527200; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698	63	38	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7086	7095		10.1038/sj.onc.1209698	http://dx.doi.org/10.1038/sj.onc.1209698			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16732321				2022-12-25	WOS:000241910500008
J	Difeo, A; Narla, G; Camacho-Vanegas, O; Nishio, H; Rose, SL; Buller, RE; Friedman, SL; Walsh, MJ; Martignetti, JA				DiFeo, A.; Narla, G.; Camacho-Vanegas, O.; Nishio, H.; Rose, S. L.; Buller, R. E.; Friedman, S. L.; Walsh, M. J.; Martignetti, J. A.			E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor	ONCOGENE			English	Article						KLF6; KLF6-SV1; E-cadherin; alternative splicing; ovarian cancer	KRUPPEL-LIKE FACTOR-6; CELL LUNG-CANCER; PROSTATE-CANCER; GENE-EXPRESSION; OVARIAN-CANCER; GROWTH; ACTIVATION; PROTEIN; INHIBITION; CARCINOMA	The tumor suppressor KLF6 is a member of the Kruppel-like family of transcription factors, which has been implicated in the pathogenesis of several human carcinomas. Uncovering the transcriptional targets relevant for its tumorigenic properties, including cellular proliferation and invasion, will be essential to understanding possible mechanisms by which KLF6 and its antagonistic splice form, KLF6-SV1, regulate this development. To begin de. ning possible metastatic-related pathways, we analysed the effect of KLF6 dysregulation on a recognized suppressor of cellular invasion, E-cadherin. Targeted KLF6 reduction in an ovarian cancer cell line, SKOV-3, resulted in a 50% reduction of E-cadherin expression (P < 0.01) and conversely, KLF6-SV1 silencing upregulated E-cadherin approximately fivefold (P < 0.0001). These changes resulted from KLF6 directly transactivating the E-cadherin promoter as demonstrated by luciferase promoter assay and chromatin immunoprecipitation (ChIP). KLF6-mediated changes in E-cadherin levels were accompanied by downstream changes in both the subcellular localization of beta-catenin and c-myc expression levels. Moreover, and consistent with these experimental findings, patient-derived epithelial ovarian tumors with low KLF6 and high KLF6-SV1 expression ratios had significantly decreased E-cadherin expression (P < 0.0001). These combined findings highlight the E-cadherin pathway as a novel and functionally important mediator by which changes in KLF6 and KLF6-SV1 can directly alter ovarian tumor invasion and metastasis.	Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Univ Iowa Hosp & Clin, Div Gynecol Oncol, Iowa City, IA 52242 USA; Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Iowa; Icahn School of Medicine at Mount Sinai	Martignetti, JA (corresponding author), Mt Sinai Sch Med, Dept Human Genet, 1425 Madison Ave,Box 1498, New York, NY 10029 USA.	john.martignetti@mssm.edu	Narla, Goutham/AAZ-5710-2020	Narla, Goutham/0000-0003-4098-4203; DiFeo, Analisa/0000-0001-8319-6763				Ananthanarayanan M, 2004, J BIOL CHEM, V279, P54348, DOI 10.1074/jbc.M410021200; Benzeno S, 2004, CANCER RES, V64, P3885, DOI 10.1158/0008-5472.CAN-03-2818; Berchuck A, 1997, BIOCHEM PHARMACOL, V54, P541, DOI 10.1016/S0006-2952(97)00061-0; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Chen CS, 2003, AM J PATHOL, V162, P1349, DOI 10.1016/S0002-9440(10)63930-2; Chen Han-kui, 2002, Ai Zheng, V21, P1047; Cho YG, 2005, ONCOGENE, V24, P4588, DOI 10.1038/sj.onc.1208670; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; DIFEO A, 2006, IN PRESS CLIN CANC R; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Gabbert HE, 1996, INT J CANCER, V69, P184, DOI 10.1002/(SICI)1097-0215(19960621)69:3<184::AID-IJC6>3.0.CO;2-W; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; Jeng YM, 2003, INT J CANCER, V105, P625, DOI 10.1002/ijc.11123; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kettunen E, 2004, CANCER GENET CYTOGEN, V149, P98, DOI 10.1016/s0165-4608(03)00300-5; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Kremer-Tal S, 2004, HEPATOLOGY, V40, P1047, DOI 10.1002/hep.20460; Macleod K, 2005, CANCER RES, V65, P6789, DOI 10.1158/0008-5472.CAN-04-2684; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Narla G, 2005, CANCER RES, V65, P5761, DOI 10.1158/0008-5472.CAN-05-0217; Narla G, 2005, CANCER RES, V65, P1213, DOI 10.1158/0008-5472.CAN-04-4249; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; Rubinstein M, 2004, ENDOCRINOLOGY, V145, P3769, DOI 10.1210/en.2004-0173; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Slavin DA, 2004, ONCOGENE, V23, P8196, DOI 10.1038/sj.onc.1208020; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; TALKREMER S, 2004, HEPATOLOGY, V40, P1047; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M	33	65	68	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2006	25	44					6026	6031		10.1038/sj.onc.1209611	http://dx.doi.org/10.1038/sj.onc.1209611			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16702959				2022-12-25	WOS:000240826300011
J	Benoit, V; de Moraes, E; Dar, NA; Taranchon, E; Bours, V; Hautefeuille, A; Taniere, P; Chariot, A; Scoazec, JY; Gallo, CVD; Merville, MP; Hainaut, P				Benoit, V.; de Moraes, E.; Dar, N. A.; Taranchon, E.; Bours, V.; Hautefeuille, A.; Taniere, P.; Chariot, A.; Scoazec, J-Y; Gallo, C. V. de Moura; Merville, M-P; Hainaut, P.			Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB	ONCOGENE			English	Article						p53; NF-kappaB; cyclooxygenase-2 esophageal cancer; Barrett's metaplasia	SQUAMOUS-CELL CARCINOMA; BARRETTS-ESOPHAGUS; GENE-EXPRESSION; UP-REGULATION; COLON-CANCER; B ACTIVATION; COX-2; INHIBITION; PROTEIN; INDUCTION	Overexpression of cyclooxygenase-2 (Cox-2) is thought to exert antiapoptotic effects in cancer. Here we show that the tumor suppressor p53 upregulated Cox-2 in esophageal and colon cancer cell lines by inducing the binding of nuclear factor-kappaB (NF-kappaB) to its response element in the COX-2 promoter. Inhibition of NF-kappaB prevented p53 induction of Cox-2 expression. Cooperation between p53 and NF-kappaB was required for activation of COX-2 promoter in response to daunomycin, a DNA-damaging agent. Pharmacological inhibition of Cox-2 enhanced apoptosis in response to daunomycin, in particular in cells containing active p53. In esophageal cancer, there was a correlation between Cox-2 expression and wild-type TP53 in Barrett's esophagus (BE) and in adenocarcinoma, but not in squamous cell carcinoma (P < 0.01). These results suggest that p53 and NF-kappaB cooperate in upregulating Cox-2 expression, promoting cell survival in inflammatory precursor lesions such as BE.	Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon, France; Univ Liege, Lab Med Chem & Human Genet, Ctr Biomed Integrated Genoproteom, Liege, Belgium; Hop Edouard Herriot, Dept Pathol, Lyon, France; State Uni Rio de Janeiro, Dept Cellular Biol & Genet, Rio De Janeiro, Brazil	World Health Organization; International Agency for Research on Cancer (IARC); University of Liege; CHU Lyon; Universidade do Estado do Rio de Janeiro	Hainaut, P (corresponding author), Int Agcy Res Canc, Grp Mol Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon, France.	hainaut@iarc.fr	Dar, NAZIR AHMAD/AAX-2763-2020; Hainaut, Pierre/B-6018-2012	Dar, NAZIR AHMAD/0000-0002-9517-9458; Hainaut, Pierre/0000-0002-1303-1610; Chariot, Alain/0000-0002-1691-4347; BENOIT, Valerie/0000-0002-1098-9452				Barnas C, 1997, INT J CANCER, V71, P79, DOI 10.1002/(SICI)1097-0215(19970328)71:1<79::AID-IJC14>3.0.CO;2-4; Beltrami E, 2004, J BIOL CHEM, V279, P2077, DOI 10.1074/jbc.M309479200; Benoit V, 2000, ONCOGENE, V19, P4787, DOI 10.1038/sj.onc.1203831; Bentires-Alj M, 1999, CANCER RES, V59, P811; Bentires-Alj M, 2001, ONCOGENE, V20, P2805, DOI 10.1038/sj.onc.1204343; Bentires-Alj M, 1999, DRUG RESIST UPDATE, V2, P274, DOI 10.1054/drup.1999.0093; Birkenkamp-Demtroder K, 2005, GUT, V54, P374, DOI 10.1136/gut.2003.036848; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Buskens CJ, 2003, GUT, V52, P1678, DOI 10.1136/gut.52.12.1678; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Corcoran CA, 2005, ONCOGENE, V24, P1634, DOI 10.1038/sj.onc.1208353; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Gilroy DW, 2001, FASEB J, V15, P288; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Han JH, 2004, MECH AGEING DEV, V125, P359, DOI 10.1016/j.mad.2004.02.002; Harris RE, 2000, CANCER RES, V60, P2101; Hla T, 1999, INT J BIOCHEM CELL B, V31, P551, DOI 10.1016/S1357-2725(98)00152-6; Jeong SJ, 2005, J BIOL CHEM, V280, P10326, DOI 10.1074/jbc.M412643200; Jiang XH, 2002, ONCOGENE, V21, P6113, DOI 10.1038/sj.onc.1205778; Jobin C, 1998, IMMUNOLOGY, V95, P537; Kaur BS, 2002, AM J PHYSIOL-GASTR L, V283, pG327, DOI 10.1152/ajpgi.00543.2001; Kaur BS, 2002, GASTROENTEROLOGY, V123, P60, DOI 10.1053/gast.2002.34244; Konturek PC, 2004, DIGEST DIS SCI, V49, P1075, DOI 10.1023/B:DDAS.0000037790.11724.70; Krysan K, 2004, FASEB J, V18, P205, DOI 10.1096/fj.03-0369fje; Krysan K, 2004, CANCER RES, V64, P6359, DOI 10.1158/0008-5472.CAN-04-1681; Kuo KT, 2003, ANN THORAC SURG, V76, P909, DOI 10.1016/S0003-4975(03)00717-3; Lagorce C, 2003, HISTOPATHOLOGY, V42, P457, DOI 10.1046/j.1365-2559.2003.01627.x; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; North S, 2002, MOL CARCINOGEN, V33, P181, DOI 10.1002/mc.10038; Oshima M, 2001, CANCER RES, V61, P1733; Rockwell P, 2004, CELL SIGNAL, V16, P343, DOI 10.1016/j.cellsig.2003.08.006; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sawaoka H, 1998, AM J PHYSIOL-GASTR L, V274, pG1061, DOI 10.1152/ajpgi.1998.274.6.G1061; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Sepehr A, 2001, ONCOGENE, V20, P7368, DOI 10.1038/sj.onc.1204912; Shamma A, 2000, CLIN CANCER RES, V6, P1229; Shirvani VN, 2000, GASTROENTEROLOGY, V118, P487, DOI 10.1016/S0016-5085(00)70254-X; Siewert JR, 1998, BRIT J SURG, V85, P1457; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Smith GV, 2005, AM J CLIN PATHOL, V123, P415, DOI 10.1309/263A4PQ83R9OCRUF; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3; Swamy MV, 2003, CANCER RES, V63, P5239; Tanabe T, 2002, PROSTAG OTH LIPID M, V68-9, P95, DOI 10.1016/S0090-6980(02)00024-2; Tsuji S, 2001, J EXP CLIN CANC RES, V20, P117; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Wu KK, 2005, ARTERIOSCL THROM VAS, V25, P679, DOI 10.1161/01.ATV.0000157899.35660.61; Yang D, 2004, P NATL ACAD SCI USA, V101, P15100, DOI 10.1073/pnas.0406665101; Yu HP, 2003, CANCER LETT, V198, P193, DOI 10.1016/S0304-3835(03)00340-9; Zhu Y, 2002, J BIOL CHEM, V277, P6923, DOI 10.1074/jbc.M108075200; Zimmermann KC, 1999, CANCER RES, V59, P198	56	45	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5708	5718		10.1038/sj.onc.1209579	http://dx.doi.org/10.1038/sj.onc.1209579			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16682957	Green Published			2022-12-25	WOS:000240765800002
J	Prevot, PP; Adam, B; Boudjeltia, KZ; Brossard, M; Lins, L; Cauchie, P; Brasseur, R; Vanhaeverbeek, M; Vanhamme, L; Godfroid, E				Prevot, Pierre-Paul; Adam, Benoit; Boudjeltia, Karim Zouaoui; Brossard, Michel; Lins, Laurence; Cauchie, Philippe; Brasseur, Robert; Vanhaeverbeek, Michel; Vanhamme, Luc; Godfroid, Edmond			Anti-hemostatic effects of a serpin from the saliva of the tick Ixodes ricinus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEINASE-INHIBITORS; ALPHA-1-PROTEINASE INHIBITOR; HAEMAPHYSALIS-LONGICORNIS; THROMBIN INHIBITOR; BLOOD-COAGULATION; FACTOR-XA; GLAND; IDENTIFICATION; SCAPULARIS; CLONING	Serpins (serine protease inhibitors) are a large family of structurally related proteins found in a wide variety of organisms, including hematophagous arthropods. Protein analyses revealed that Iris, previously described as an immunomodulator secreted in the tick saliva, is related to the leukocyte elastase inhibitor and possesses serpin motifs, including the reactive center loop (RCL), which is involved in the interaction between serpins and serine proteases. Only serine proteases were inhibited by purified recombinant Iris (rIris), whereas mutants L339A and A332P were found devoid of any protease inhibitory activity. The highest K-a was observed with human leukocyte-elastase, suggesting that elastase-like proteases are the natural targets of Iris. In addition, mutation M340R completely changed both Iris substrate specificity and affinity. This likely identified Met-340 as amino acid P1 in the RCL. The effects of rIris and its mutants were also tested on primary hemostasis, blood clotting, and fibrinolysis. rIris increased platelet adhesion, the contact phase-activated pathway of coagulation, and fibrinolysis times in a dose-dependent manner, whereas rIris mutant L339A affected only platelet adhesion. Taken together, these results indicate that Iris disrupts coagulation and fibrinolysis via the anti-proteolytic RCL domain. One or more other domains could be responsible for primary hemostasis inhibition. To our knowledge, this is the first ectoparasite serpin that interferes with both hemostasis and the immune response.	Univ Libre Bruxelles, Dept Genet Appl, Inst Biol & Med Mol, B-6041 Gosselies, Belgium; Univ Libre Bruxelles, Dept Parasitol Mol, Inst Biol & Med Mol, B-6041 Gosselies, Belgium; Fac Univ Sci Agron Gembloux, Ctr Biophys Mol Numer, B-6110 Gembloux, Belgium; Univ Libre Bruxelles, Expt Med Lab, Ctr Hosp Univ Andre Vesale, B-5030 Montignies le Tilleul, Belgium; Univ Neuchatel, Inst Zool, CH-2000 Neuchatel, Switzerland	Universite Libre de Bruxelles; Universite Libre de Bruxelles; University of Liege; Universite Libre de Bruxelles; University of Neuchatel	Godfroid, E (corresponding author), Univ Libre Bruxelles, Dept Genet Appl, Inst Biol & Med Mol, Rue Prof Jeener & Brachet 12, B-6041 Gosselies, Belgium.	Edmond.Godfroid@ulb.ac.be	LINS, LAURENCE/Y-1661-2019; Cauchie, Philippe/ABG-9290-2021	LINS, LAURENCE/0000-0001-7772-6748; CAUCHIE, Philippe/0000-0001-7390-7197				BEATTY K, 1980, J BIOL CHEM, V255, P3931; Boudjeltia K Zouaoui, 2002, BMC Biotechnol, V2, P8, DOI 10.1186/1472-6750-2-8; Brossard M, 2004, PARASITOLOGY, V129, pS161, DOI 10.1017/S0031182004004834; CAEN JP, 1973, NATURE-NEW BIOL, V244, P159, DOI 10.1038/newbio244159a0; Champagne Donald E., 2004, Current Drug Targets - Cardiovascular & Haematological Disorders, V4, P375, DOI 10.2174/1568006043335862; Das S, 2001, J INFECT DIS, V184, P1056, DOI 10.1086/323351; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DOOLITTLE RF, 1987, COLD SPRING HARB SYM, V52, P869, DOI 10.1101/SQB.1987.052.01.095; ELLIS V, 1982, BIOCHIM BIOPHYS ACTA, V701, P24; Francischetti IMB, 2002, BLOOD, V99, P3602, DOI 10.1182/blood-2001-12-0237; FROMMHERZ KJ, 1991, J BIOL CHEM, V266, P15356; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; Gallet X, 2000, J MOL BIOL, V302, P917, DOI 10.1006/jmbi.2000.4092; HEKMAN CM, 1987, SEMIN THROMB HEMOST, V13, P514, DOI 10.1055/s-2007-1003527; HOFFMANN A, 1991, PHARMAZIE, V46, P209; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; Horn F, 2000, ARCH BIOCHEM BIOPHYS, V384, P68, DOI 10.1006/abbi.2000.2076; Imamura S, 2005, VACCINE, V23, P1301, DOI 10.1016/j.vaccine.2004.08.041; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Iwanaga S, 2003, EUR J BIOCHEM, V270, P1926, DOI 10.1046/j.1432-1033.2003.03560.x; Kanost MR, 1999, DEV COMP IMMUNOL, V23, P291, DOI 10.1016/S0145-305X(99)00012-9; Kazimirova M, 2002, EXP APPL ACAROL, V28, P97, DOI 10.1023/A:1025398100044; Kopecky J, 1998, PARASITE IMMUNOL, V20, P169; KUNDU SK, 1995, SEMIN THROMB HEMOST, V21, P106; Lai R, 2004, GENE, V342, P243, DOI 10.1016/j.gene.2004.07.012; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAW JH, 1992, ANNU REV BIOCHEM, V61, P87, DOI 10.1146/annurev.bi.61.070192.000511; Leboulle G, 2002, AM J TROP MED HYG, V66, P225, DOI 10.4269/ajtmh.2002.66.225; Leboulle G, 2002, J BIOL CHEM, V277, P10083, DOI 10.1074/jbc.M111391200; Maizels RM, 2001, INT J PARASITOL, V31, P889, DOI 10.1016/S0020-7519(01)00213-2; Mulenga A, 2000, MICROBES INFECT, V2, P1353, DOI 10.1016/S1286-4579(00)01289-2; Mulenga A, 2003, INSECT BIOCHEM MOLEC, V33, P267, DOI 10.1016/S0965-1748(02)00240-0; Mulenga A, 2001, J VET MED SCI, V63, P1063, DOI 10.1292/jvms.63.1063; Narasimhan S, 2004, P NATL ACAD SCI USA, V101, P1141, DOI 10.1073/pnas.0307669100; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; RAHMAN M, 1994, J MOL GRAPHICS, V12, P212, DOI 10.1016/0263-7855(94)80090-1; Ribeiro JMC, 2006, INSECT BIOCHEM MOLEC, V36, P111, DOI 10.1016/j.ibmb.2005.11.005; RIBEIRO JMC, 1987, EXP PARASITOL, V64, P347, DOI 10.1016/0014-4894(87)90046-4; RIBEIRO JMC, 1995, INFECT AGENT DIS, V4, P143; Rubin H, 1996, NAT MED, V2, P632, DOI 10.1038/nm0696-632; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sangamnatdej S, 2002, INSECT MOL BIOL, V11, P79, DOI 10.1046/j.0962-1075.2001.00311.x; SAUER JR, 1995, ANNU REV ENTOMOL, V40, P245, DOI 10.1146/annurev.en.40.010195.001333; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SHEPHERD JC, 1991, MOL BIOCHEM PARASIT, V44, P81, DOI 10.1016/0166-6851(91)90223-S; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; SONENSHINE DE, 1991, BIOL TICKS, V1, P95; Sugino M, 2003, VACCINE, V21, P2844, DOI 10.1016/S0264-410X(03)00167-1; Thomas A, 2001, PROTEINS, V43, P28, DOI 10.1002/1097-0134(20010401)43:1<28::AID-PROT1014>3.3.CO;2-D; TRAVIS J, 1986, BIOL CHEM H-S, V367, P853, DOI 10.1515/bchm3.1986.367.2.853; Valenzuela JG, 2000, J BIOL CHEM, V275, P18717, DOI 10.1074/jbc.M001486200; Valenzuela JG, 2002, J EXP BIOL, V205, P2843; van Gent D, 2003, INT J BIOCHEM CELL B, V35, P1536, DOI 10.1016/S1357-2725(03)00134-1; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510; Wikel SK, 1996, EXP PARASITOL, V84, P304, DOI 10.1006/expr.1996.0118	56	95	97	2	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26361	26369		10.1074/jbc.M604197200	http://dx.doi.org/10.1074/jbc.M604197200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16672226	hybrid, Green Submitted			2022-12-25	WOS:000240249500053
J	Irieda, H; Homma, M; Homma, M; Kawagishi, I				Irieda, Hiroki; Homma, Motohiro; Homma, Michio; Kawagishi, Ikuro			Control of chemotactic signal gain via modulation of a pre-formed receptor array	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL ASPARTATE RECEPTOR; LIGAND-BINDING DOMAIN; ESCHERICHIA-COLI; DIFFERENT CHEMORECEPTOR; COVALENT MODIFICATION; SENSORY RECEPTOR; 2-STATE MODEL; CROSS-LINKING; COMPLEX; SENSITIVITY	The remarkably wide dynamic range of the chemotactic pathway of Escherichia coli, a model signal transduction system, is achieved by methylation/amidation of the transmembrane chemoreceptors that regulate the histidine kinase CheA in response to extracellular stimuli. The chemoreceptors cluster at a cell pole together with CheA and the adaptor CheW. Several lines of evidence have led to models that assume high cooperativity and sensitivity via collaboration of receptor dimers within a cluster. Here, using in vivo disulfide cross-linking assays, we have demonstrated a well defined arrangement of the aspartate chemoreceptor ( Tar). The differential effects of amidation on cross-linking at different positions indicate that amidation alters the relative orientation of Tar dimers to each other ( presumably inducing rotational displacements) without much affecting the conformation of the periplasmic domains. Interestingly, the effect of aspartate on cross-linking at any position tested was roughly opposite to that of receptor amidation. Furthermore, amidation attenuated the effects of aspartate by several orders of magnitude. These results suggest that receptor covalent modification controls signal gain by altering the arrangement or packing of receptor dimers in a pre-formed cluster.	Nagoya Univ, Div Biol Sci, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Nagoya Univ, Inst Adv Res, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University; Nagoya University	Kawagishi, I (corresponding author), Nagoya Univ, Div Biol Sci, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan.	i45406a@cc.nagoya-u.ac.jp	Irieda, Hiroki/N-8455-2015	Irieda, Hiroki/0000-0002-4545-9187				Ames P, 2002, P NATL ACAD SCI USA, V99, P7060, DOI 10.1073/pnas.092071899; ASAKURA S, 1984, J MOL BIOL, V176, P349, DOI 10.1016/0022-2836(84)90494-7; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; BLAIR DF, 1995, ANNU REV MICROBIOL, V49, P489, DOI 10.1146/annurev.mi.49.100195.002421; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; Bornhorst JA, 2003, J MOL BIOL, V326, P1597, DOI 10.1016/S0022-2836(03)00026-3; Bourret RB, 2002, J BIOL CHEM, V277, P9625, DOI 10.1074/jbc.R100066200; Bray D, 1998, NATURE, V393, P85, DOI 10.1038/30018; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; CHERVITZ SA, 1995, BIOCHEMISTRY-US, V34, P9722, DOI 10.1021/bi00030a010; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; Duke TAJ, 1999, P NATL ACAD SCI USA, V96, P10104, DOI 10.1073/pnas.96.18.10104; DUNTEN P, 1991, J BIOL CHEM, V266, P1491; Falke JJ, 2001, TRENDS BIOCHEM SCI, V26, P257, DOI 10.1016/S0968-0004(00)01770-9; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; Gestwicki JE, 2002, NATURE, V415, P81, DOI 10.1038/415081a; Homma M, 2004, P NATL ACAD SCI USA, V101, P3462, DOI 10.1073/pnas.0306660101; INOUE I, 2004, NANOBIOTECHNOLOGY, V2, P4; Iwama T, 1997, J BIOL CHEM, V272, P13810, DOI 10.1074/jbc.272.21.13810; Kim KK, 1999, NATURE, V400, P787, DOI 10.1038/23512; Kim SH, 2002, P NATL ACAD SCI USA, V99, P11611, DOI 10.1073/pnas.132376499; Levit MN, 2002, J BIOL CHEM, V277, P36760, DOI 10.1074/jbc.M204325200; Liberman L, 2004, J BACTERIOL, V186, P6643, DOI 10.1128/JB.186.19.6643-6646.2004; Lybarger SR, 2005, MOL MICROBIOL, V56, P1078, DOI 10.1111/j.1365-2958.2005.04593.x; MADDOCK JR, 1993, SCIENCE, V259, P1717; Mello BA, 2003, P NATL ACAD SCI USA, V100, P8223, DOI 10.1073/pnas.1330839100; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; Morton-Firth CJ, 1999, J MOL BIOL, V286, P1059, DOI 10.1006/jmbi.1999.2535; Ottemann KM, 1999, SCIENCE, V285, P1751, DOI 10.1126/science.285.5434.1751; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; Shimizu TS, 2000, NAT CELL BIOL, V2, P792, DOI 10.1038/35041030; Shiomi D, 2005, J BACTERIOL, V187, P7647, DOI 10.1128/JB.187.22.7647-7654.2005; Skidmore JM, 2000, J BACTERIOL, V182, P967, DOI 10.1128/JB.182.4.967-973.2000; Sourjik V, 2004, TRENDS MICROBIOL, V12, P569, DOI 10.1016/j.tim.2004.10.003; Sourjik V, 2004, NATURE, V428, P437, DOI 10.1038/nature02406; Sourjik V, 2002, P NATL ACAD SCI USA, V99, P123, DOI 10.1073/pnas.011589998; Sourjik V, 2000, MOL MICROBIOL, V37, P740, DOI 10.1046/j.1365-2958.2000.02044.x; Stock J, 2000, CURR BIOL, V10, pR11, DOI 10.1016/S0960-9822(99)00248-1; Studdert CA, 2004, P NATL ACAD SCI USA, V101, P2117, DOI 10.1073/pnas.0308622100; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987; WOLFE AJ, 1989, P NATL ACAD SCI USA, V86, P6973, DOI 10.1073/pnas.86.18.6973; Yeh JI, 1996, J MOL BIOL, V262, P186, DOI 10.1006/jmbi.1996.0507	45	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23880	23886		10.1074/jbc.M600018200	http://dx.doi.org/10.1074/jbc.M600018200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16679313	hybrid			2022-12-25	WOS:000239702900063
J	Grinstein, E; Shan, Y; Karawajew, L; Snijders, PJF; Meijer, CJLM; Royer, HD; Wernet, P				Grinstein, Edgar; Shan, Ying; Karawajew, Leonid; Snijders, Peter J. F.; Meijer, Chris J. L. M.; Royer, Hans-Dieter; Wernet, Peter			Cell cycle-controlled interaction of nucleolin with the retinoblastoma protein and cancerous cell transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-I TRANSCRIPTION; CERVICAL-CARCINOMA CELLS; TUMOR-SUPPRESSOR; BINDING-PROTEIN; HUMAN PAPILLOMAVIRUS-E7; RB/E2F PATHWAY; GENE; RB; IDENTIFICATION; REGION	Retinoblastoma protein (Rb) is a multifunctional tumor suppressor, frequently inactivated in certain types of human cancer. Nucleolin is an abundant multifunctional phosphoprotein of proliferating and cancerous cells, recently identified as cell cycle-regulated transcription activator, controlling expression of human papillomavirus type 18 (HPV18) oncogenes in cervical cancer. Here we find that nucleolin is associated with Rb in intact cells in the G(1) phase of the cell cycle, and the complex formation is mediated by the growth-inhibitory domain of Rb. Association with Rb inhibits the DNA binding function of nucleolin and in consequence the interaction of nucleolin with the HPV18 enhancer, resulting in Rb-mediated repression of the HPV18 oncogenes. The intracellular distribution of nucleolin in epithelial cells is Rb-dependent, and an altered nucleolin localization in human cancerous tissues results from a loss of Rb. Our findings suggest that deregulated nucleolin activity due to a loss of Rb contributes to tumor development in malignant diseases, thus providing further insights into the molecular network for the Rb-mediated tumor suppression.	Univ Dusseldorf, Inst Transplantat Diagnost & Cellular Therapeut, Med Ctr, D-40225 Dusseldorf, Germany; Inst Mol Pharmacol, D-13125 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; HELIOS Klinikum Berlin Buch, Charite, Sch Med, Robert Rossle Klin, D-13125 Berlin, Germany; Vrije Univ Amsterdam, Med Ctr, Dept Pathol, NL-1007 MB Amsterdam, Netherlands; Ctr Adv European Studies, D-53175 Bonn, Germany	Heinrich Heine University Dusseldorf; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helios Kliniken; Vrije Universiteit Amsterdam; Center of Advanced European Studies & Research (CAESAR)	Grinstein, E (corresponding author), Univ Dusseldorf, Inst Transplantat Diagnost & Cellular Therapeut, Med Ctr, Moorenstr 5,Bldg 14-80, D-40225 Dusseldorf, Germany.	Edgar.Grinstein@itz.uni-duesseldorf.de	Royer, Hans-dieter/AAH-6293-2019	Karawajew, Leonid/0000-0001-6876-6027				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Angus SP, 2003, MOL CELL BIOL, V23, P8172, DOI 10.1128/MCB.23.22.8172-8188.2003; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BRYS A, 1994, P NATL ACAD SCI USA, V91, P4915, DOI 10.1073/pnas.91.11.4915; BULFONEPAUS S, 1995, P NATL ACAD SCI USA, V92, P8293, DOI 10.1073/pnas.92.18.8293; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; Daniely Y, 2002, MOL CELL BIOL, V22, P6014, DOI 10.1128/MCB.22.16.6014-6022.2002; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DERENZINI M, 1995, LAB INVEST, V73, P497; Derenzini M, 2000, MICRON, V31, P117, DOI 10.1016/S0968-4328(99)00067-0; DICKINSON LA, 1995, MOL CELL BIOL, V15, P456, DOI 10.1128/MCB.15.1.456; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Fujita M, 2002, J BIOL CHEM, V277, P10354, DOI 10.1074/jbc.M111398200; GAFFNEY EV, 1982, CELL TISSUE RES, V227, P563, DOI 10.1007/BF00204786; GJETTING T, 1995, BIOL CHEM H-S, V376, P441; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Grinstein E, 1996, J BIOL CHEM, V271, P9215, DOI 10.1074/jbc.271.16.9215; Grinstein E, 2002, J EXP MED, V196, P1067, DOI 10.1084/jem.20011053; Hanakahi LA, 1997, P NATL ACAD SCI USA, V94, P3605, DOI 10.1073/pnas.94.8.3605; Hanakahi LA, 2000, NUCLEIC ACIDS RES, V28, P2651, DOI 10.1093/nar/28.14.2651; Hannan KM, 2000, ONCOGENE, V19, P3487, DOI 10.1038/sj.onc.1203690; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; Hovanessian AG, 2000, EXP CELL RES, V261, P312, DOI 10.1006/excr.2000.5071; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Khleif SN, 1996, P NATL ACAD SCI USA, V93, P4350, DOI 10.1073/pnas.93.9.4350; Klaes R, 2001, INT J CANCER, V92, P276, DOI 10.1002/ijc.1174; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MURAMATSU M, 1974, EXP CELL RES, V88, P345, DOI 10.1016/0014-4827(74)90250-X; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Parada CA, 1999, EMBO J, V18, P3688, DOI 10.1093/emboj/18.13.3688; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROGALSKY V, 1993, BIOCHEM BIOPH RES CO, V192, P1139, DOI 10.1006/bbrc.1993.1535; Roger B, 2002, J BIOL CHEM, V277, P10209, DOI 10.1074/jbc.M106412200; ROSL F, 1991, EMBO J, V10, P1337, DOI 10.1002/j.1460-2075.1991.tb07653.x; Sarcevic B, 1997, J BIOL CHEM, V272, P33327, DOI 10.1074/jbc.272.52.33327; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, EMBO J, V11, P2425, DOI 10.1002/j.1460-2075.1992.tb05307.x; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; Sengupta TK, 2004, J BIOL CHEM, V279, P10855, DOI 10.1074/jbc.M309111200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; SZEKELY L, 1991, CELL GROWTH DIFFER, V2, P287; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; van den Brule AJC, 2002, J CLIN MICROBIOL, V40, P779, DOI 10.1128/JCM.40.3.779-787.2002; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; YANG TH, 1994, MOL CELL BIOL, V14, P6068, DOI 10.1128/MCB.14.9.6068; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	71	37	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22223	22235		10.1074/jbc.M513335200	http://dx.doi.org/10.1074/jbc.M513335200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16698799	hybrid			2022-12-25	WOS:000239387100069
J	Mengel-Jorgensen, J; Jensen, SS; Rasmussen, A; Poehlsgaard, J; Iversen, JJL; Kirpekar, F				Mengel-Jorgensen, Jonas; Jensen, Soren Skov; Rasmussen, Anette; Poehlsgaard, Jacob; Iversen, Jens Jorgen Lonsmann; Kirpekar, Finn			Modifications in Thermus thermophilus 23 S ribosomal RNA are centered in regions of RNA-RNA contact	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEOLAR RNAS; PEPTIDYL TRANSFERASE CENTER; METHYLATION GUIDE SNORNAS; MALDI MASS-SPECTROMETRY; 5.5 ANGSTROM RESOLUTION; ESCHERICHIA-COLI; POSTTRANSCRIPTIONAL MODIFICATIONS; PSEUDOURIDINE RESIDUES; MODIFIED NUCLEOTIDES; FORM PSEUDOURIDINES	Ribosomal RNA from all organisms contains post-transcriptionally modified nucleotides whose function is far from clear. To gain insight into the molecular interactions of modified nucleotides, we investigated the modification status of Thermus thermophilus 5 S and 23 S ribosomal RNA by mass spectrometry and chemical derivatization/primer extension. A total of eleven modified nucleotides was found in 23 S rRNA, of which eight were singly methylated nucleotides and three were pseudouridines. These modified nucleotides were mapped into the published three-dimensional ribosome structure. Seven of the modified nucleotides located to domain IV, and four modified nucleotides located to domain V of the 23 S rRNA. All post-transcriptionally modified nucleotides map in the center of the ribosome, and none of them are in contact with ribosomal proteins. All except one of the modified nucleotides were found in secondary structure elements of the 23 S ribosomal RNA that contact either 16 S ribosomal RNA or transfer RNA, with five of these nucleotides physically involved in intermolecular RNARNA bridges. These findings strongly suggest that the post-transcriptional modifications play a role in modulating intermolecular RNA-RNA contacts, which is the first suggestion on a specific function of endogenous ribosomal RNA modifications.	Odense Univ, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark	University of Southern Denmark	Kirpekar, F (corresponding author), Odense Univ, Dept Biochem & Mol Biol, Campusvej 55, DK-5230 Odense M, Denmark.	f.kir@bmb.sdu.dk		Mengel-From, Jonas/0000-0003-1573-8908; Kirpekar, Finn/0000-0003-1901-2266				AGRIS PF, 1973, ARCH BIOCHEM BIOPHYS, V154, P277, DOI 10.1016/0003-9861(73)90058-1; Andersen TE, 2004, RNA, V10, P907, DOI 10.1261/rna.5259404; Ashraf SS, 1999, RNA, V5, P188, DOI 10.1017/S1355838299981529; Ashraf SS, 2000, CELL BIOCHEM BIOPHYS, V33, P241, DOI 10.1385/CBB:33:3:241; Aspegren A, 2004, NUCLEIC ACIDS RES, V32, P4646, DOI 10.1093/nar/gkh804; BAER RJ, 1981, NUCLEIC ACIDS RES, V9, P323, DOI 10.1093/nar/9.2.323; BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Barneche F, 2001, J MOL BIOL, V311, P57, DOI 10.1006/jmbi.2001.4851; Brown JWS, 2001, RNA, V7, P1817; Caldas T, 2000, BIOCHEM BIOPH RES CO, V271, P714, DOI 10.1006/bbrc.2000.2702; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; Clemons WM, 1999, NATURE, V400, P833, DOI 10.1038/23631; CUMMINS LL, 1995, NUCLEIC ACIDS RES, V23, P2019, DOI 10.1093/nar/23.11.2019; CUNNINGHAM PR, 1991, BIOCHIMIE, V73, P789, DOI 10.1016/0300-9084(91)90058-9; Del Lampo M, 2005, RNA, V11, P210, DOI 10.1261/rna.7209905; Gaspin C, 2000, J MOL BIOL, V297, P895, DOI 10.1006/jmbi.2000.3593; GOGIYA ZV, 1986, MOL BIOL+, V20, P415; Green R, 1999, BIOCHEMISTRY-US, V38, P1772, DOI 10.1021/bi982246a; Green R, 1996, RNA, V2, P1011; Gustafsson C, 1998, J BACTERIOL, V180, P359, DOI 10.1128/JB.180.2.359-365.1998; Gutgsell NS, 2001, RNA, V7, P990, DOI 10.1017/S1355838201000243; Hansen MA, 2002, RNA, V8, P202, DOI 10.1017/S1355838202013365; Higa S, 2002, BIOCHEM BIOPH RES CO, V297, P1344, DOI 10.1016/S0006-291X(02)02377-X; HOPFL P, 1988, NUCLEIC ACIDS RES, V16, P9043, DOI 10.1093/nar/16.18.9043; Huang ZP, 2005, RNA, V11, P1303, DOI 10.1261/rna.2380905; Kehrenberg C, 2005, MOL MICROBIOL, V57, P1064, DOI 10.1111/j.1365-2958.2005.04754.x; King TH, 2003, MOL CELL, V11, P425, DOI 10.1016/S1097-2765(03)00040-6; Kirpekar F, 2005, J MOL BIOL, V348, P563, DOI 10.1016/j.jmb.2005.03.009; Kirpekar F, 2000, RNA, V6, P296, DOI 10.1017/S1355838200992148; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lestrade L, 2006, NUCLEIC ACIDS RES, V34, pD158, DOI 10.1093/nar/gkj002; Liang XH, 2005, RNA, V11, P619, DOI 10.1261/rna.7174805; Liu MF, 2004, RNA, V10, P1713, DOI 10.1261/rna.7820104; Liu MF, 2002, MOL MICROBIOL, V44, P195, DOI 10.1046/j.1365-2958.2002.02866.x; Lowe TM, 1999, SCIENCE, V283, P1168, DOI 10.1126/science.283.5405.1168; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; Massenet S, 1999, FEBS LETT, V462, P94, DOI 10.1016/S0014-5793(99)01524-0; McCloskey JA, 2001, NUCLEIC ACIDS RES, V29, P4699, DOI 10.1093/nar/29.22.4699; MCLUCKEY SA, 1992, J AM SOC MASS SPECTR, V3, P60, DOI 10.1016/1044-0305(92)85019-G; Mengel-Jorgensen J, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf135; Meroueh M, 2000, NUCLEIC ACIDS RES, V28, P2075, DOI 10.1093/nar/28.10.2075; Noon KR, 1998, J BACTERIOL, V180, P2883, DOI 10.1128/JB.180.11.2883-2888.1998; Ofengand J, 1997, J MOL BIOL, V266, P246, DOI 10.1006/jmbi.1996.0737; Omer AD, 2000, SCIENCE, V288, P517, DOI 10.1126/science.288.5465.517; POMERANTZ SC, 1993, J AM SOC MASS SPECTR, V4, P204, DOI 10.1016/1044-0305(93)85082-9; Raychaudhuri S, 1998, RNA, V4, P1407, DOI 10.1017/S1355838298981146; Rozenski J, 1999, NUCLEIC ACIDS RES, V27, P196, DOI 10.1093/nar/27.1.196; Samarsky DA, 1999, NUCLEIC ACIDS RES, V27, P161, DOI 10.1093/nar/27.1.161; Schlunzen F, 2001, NATURE, V413, P814, DOI 10.1038/35101544; Schuwirth BS, 2005, SCIENCE, V310, P827, DOI 10.1126/science.1117230; Sengupta R, 2000, NUCLEIC ACIDS RES, V28, P1374, DOI 10.1093/nar/28.6.1374; SIRUMCONNOLLY K, 1995, BIOCHIMIE, V77, P30, DOI 10.1016/0300-9084(96)88101-6; SKINNER RH, 1982, J GEN MICROBIOL, V128, P2411; Treede I, 2003, MOL MICROBIOL, V49, P309, DOI 10.1046/j.1365-2958.2003.03558.x; VOGEL DW, 1987, BIOCHEM INT, V14, P167; Yang CY, 2005, BIOCHEM BIOPH RES CO, V328, P1224, DOI 10.1016/j.bbrc.2005.01.077; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	58	42	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22108	22117		10.1074/jbc.M600377200	http://dx.doi.org/10.1074/jbc.M600377200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16731530	hybrid			2022-12-25	WOS:000239387100058
J	Arnold, M; Nath, A; Hauber, J; Kehlenbach, RH				Arnold, Marc; Nath, Annegret; Hauber, Joachim; Kehlenbach, Ralph H.			Multiple importins function as nuclear transport receptors for the Rev protein of human immunodeficiency virus type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCALIZATION SIGNAL; KARYOPHERIN-BETA; NUCLEOCYTOPLASMIC TRANSPORT; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; MESSENGER-RNA; CORE HISTONES; PORE COMPLEX; FACTOR P97; IN-VIVO	The Rev protein of human immunodeficiency virus type 1 is an RNA-binding protein that is required for nuclear export of unspliced and partially spliced viral mRNAs. Nuclear import of human immunodeficiency virus type 1 Rev has been suggested to depend on the classic nuclear transport receptor importin beta, but not on the adapter protein importin alpha. We now show that, similar to importin alpha, Rev is able to dissociate RanGTP from recycling importin beta, a reaction that leads to the formation of a novel import complex. Besides importin beta, the transport receptors transportin, importin 5, and importin 7 specifically interact with Rev and promote its nuclear import in digitonin-permeabilized cells. A single arginine-rich nuclear localization sequence of Rev is required for interaction with all importins tested so far. In contrast to the importin beta-binding domain of importin alpha, Rev interacts with an N-terminal fragment of importin beta. Transportin contains two independent binding sites for Rev. Hence, the mode of interaction of importin beta and transportin with Rev is clearly distinct from that with their classic import cargoes. Taken together, the viral protein takes advantage of multiple cellular transport pathways for its nuclear accumulation.	Univ Heidelberg, Abt Virol, D-69120 Heidelberg, Germany; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Univ Gottingen, Zentrum Biochem & Mol Zellbiol, D-37073 Gottingen, Germany	Ruprecht Karls University Heidelberg; Heinrich Pette Institute; University of Hamburg; University of Gottingen	Kehlenbach, RH (corresponding author), Univ Heidelberg, Abt Virol, Neuenheimer Feld 324, D-69120 Heidelberg, Germany.	rkehlen@gwdg.de		Kehlenbach, Ralph/0000-0003-4920-9916				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Arnold M, 2006, J BIOL CHEM, V281, P5492, DOI 10.1074/jbc.M513281200; Askjaer P, 1999, MOL CELL BIOL, V19, P6276; Baake M, 2001, EUR J CELL BIOL, V80, P669, DOI 10.1078/0171-9335-00208; Bauerle M, 2002, J BIOL CHEM, V277, P32480, DOI 10.1074/jbc.M202765200; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; BOGERD H, 1993, J VIROL, V67, P2496, DOI 10.1128/JVI.67.5.2496-2502.1993; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Cingolani G, 2002, MOL CELL, V10, P1345, DOI 10.1016/S1097-2765(02)00727-X; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; Fahrenkrog B, 2003, NAT REV MOL CELL BIO, V4, P757, DOI 10.1038/nrm1230; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; Floer M, 1997, J BIOL CHEM, V272, P19538, DOI 10.1074/jbc.272.31.19538; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Forwood JK, 2001, BIOCHEMISTRY-US, V40, P5208, DOI 10.1021/bi002732+; Fridell RA, 1997, J CELL SCI, V110, P1325; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; Huber J, 1998, EMBO J, V17, P4114, DOI 10.1093/emboj/17.14.4114; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jakel S, 1999, EMBO J, V18, P2411, DOI 10.1093/emboj/18.9.2411; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; Kehlenbach RH, 2001, J BIOL CHEM, V276, P14524, DOI 10.1074/jbc.M011087200; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Lam MHC, 1999, J BIOL CHEM, V274, P7391, DOI 10.1074/jbc.274.11.7391; Lee SJ, 2003, SCIENCE, V302, P1571, DOI 10.1126/science.1088372; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; MADORE SJ, 1994, VIROLOGY, V202, P186, DOI 10.1006/viro.1994.1334; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MELCHIOR F, 1995, METHOD ENZYMOL, V257, P279; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; Muhlhausser P, 2001, EMBO REP, V2, P690, DOI 10.1093/embo-reports/kve168; Nagoshi E, 1999, MOL BIOL CELL, V10, P2221, DOI 10.1091/mbc.10.7.2221; OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Rigg RJ, 1995, J IMMUNOL METHODS, V188, P187, DOI 10.1016/0022-1759(95)00237-5; Strasser A, 2004, ACTA CRYSTALLOGR D, V60, P1628, DOI 10.1107/S0907444904015380; Thomas SL, 1998, J VIROL, V72, P2935, DOI 10.1128/JVI.72.4.2935-2944.1998; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; Truant R, 1999, MOL CELL BIOL, V19, P1210; Yamasaki H, 2005, GENES CELLS, V10, P455, DOI 10.1111/j.1365-2443.2005.00850.x; Yaseen NR, 1999, J BIOL CHEM, V274, P26493, DOI 10.1074/jbc.274.37.26493	56	69	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20883	20890		10.1074/jbc.M602189200	http://dx.doi.org/10.1074/jbc.M602189200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16704975	hybrid			2022-12-25	WOS:000239187300025
J	Bao, SZ; Song, HW; Wohltmann, M; Ramanadham, S; Jin, W; Bohrer, A; Turk, J				Bao, Shunzhong; Song, Haowei; Wohltmann, Mary; Ramanadham, Sasanka; Jin, Wu; Bohrer, Alan; Turk, John			Insulin secretory responses and phospholipid composition of pancreatic islets from mice that do not express Group VIA phospholipase A(2) and effects of metabolic stress on glucose homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ARACHIDONIC-ACID RELEASE; MECHANISM-BASED DISCRIMINATION; TANDEM MASS-SPECTROMETRY; ALTERED GENE-EXPRESSION; VASCULAR SMOOTH-MUSCLE; BETA-CELLS; P388D(1) MACROPHAGES; PROTEIN-KINASE; ELECTROSPRAY-IONIZATION; A(2) ENZYMES	Studies involving pharmacologic or molecular biologic manipulation of Group VIA phospholipase A(2) (iPLA(2)beta) activity in pancreatic islets and insulinoma cells suggest that iPLA(2)beta participates in insulin secretion. It has also been suggested that iPLA(2)beta is a housekeeping enzyme that regulates cell 2-lysophosphatidylcholine (LPC) levels and arachidonate incorporation into phosphatidylcholine (PC). We have generated iPLA(2)beta-null mice by homologous recombination and have reported that they exhibit reduced male fertility and defective motility of spermatozoa. Here we report that pancreatic islets from iPLA(2)beta-null mice have impaired insulin secretory responses to D-glucose and forskolin. Electrospray ionization mass spectrometric analyses indicate that the abundance of arachidonate-containing PC species of islets, brain, and other tissues from iPLA(2)beta-null mice is virtually identical to that of wild-type mice, and no iPLA(2)beta mRNA was observed in any tissue from iPLA(2)beta-null mice at any age. Despite the insulin secretory abnormalities of isolated islets, fasting and fed blood glucose concentrations of iPLA(2)beta-null and wild-type mice are essentially identical under normal circumstances, but iPLA(2)beta-null mice develop more severe hyperglycemia than wild-type mice after administration of multiple low doses of the beta-cell toxin streptozotocin, suggesting an impaired islet secretory reserve. A high fat diet also induces more severe glucose intolerance in iPLA(2)beta-null mice than in wild-type mice, but PLA(2)beta-null mice have greater responsiveness to exogenous insulin than do wild-type mice fed a high fat diet. These and previous findings thus indicate that iPLA(2)beta-null mice exhibit phenotypic abnormalities in pancreatic islets in addition to testes and macrophages.	Washington Univ, Sch Med, Mass Spectrometry Facil, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Endocrinol Metab & Lipid Res, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Turk, J (corresponding author), Washington Univ, Sch Med, Mass Spectrometry Facil, Campus Box 8127,660 S Euclid Ave, St Louis, MO 63110 USA.	jturk@wustl.edu		Bao, Shunzhong/0000-0002-3427-3678	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341, P60DK020579, R37DK034388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM103422] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR00954, P41 RR000954-30, P41 RR000954] Funding Source: Medline; NHLBI NIH HHS [P01 HL057278, P01-HL57278] Funding Source: Medline; NIDDK NIH HHS [P30 DK056341-05S2, P60 DK020579-269005, P30 DK056341-069003, P60 DK020579, P30-DK56341, R37 DK034388-23, R37 DK034388, P30 DK056341, R37-DK34388, P30 DK056341-06, P60-DK20579] Funding Source: Medline; NIGMS NIH HHS [P41 GM103422] Funding Source: Medline; PHS HHS [R01-69455] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Akiba S, 2004, BIOL PHARM BULL, V27, P1174, DOI 10.1248/bpb.27.1174; Akiba S, 1999, J BIOL CHEM, V274, P19906, DOI 10.1074/jbc.274.28.19906; ARKHAMMAR P, 1987, J BIOL CHEM, V262, P5448; Atsumi G, 2000, J BIOL CHEM, V275, P18248, DOI 10.1074/jbc.M000271200; Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Balboa MA, 2003, J IMMUNOL, V170, P5276, DOI 10.4049/jimmunol.170.10.5276; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 2005, CELL SIGNAL, V17, P1052, DOI 10.1016/j.cellsig.2005.03.002; Balsinde J, 2002, BIOCHEM J, V364, P695, DOI 10.1042/BJ20020142; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Bao SZ, 2006, J BIOL CHEM, V281, P187, DOI 10.1074/jbc.M509105200; Bao SZ, 2004, DIABETES, V53, pS186, DOI 10.2337/diabetes.53.2007.S186; Bao SZ, 2004, J BIOL CHEM, V279, P38194, DOI 10.1074/jbc.M406489200; Barbour SE, 1999, BBA-MOL CELL BIOL L, V1439, P77, DOI 10.1016/S1388-1981(99)00078-5; Bleich D, 1999, J CLIN INVEST, V103, P1431, DOI 10.1172/JCI5241; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Brash AR, 2001, J CLIN INVEST, V107, P1339, DOI 10.1172/JCI13210; Cheverud JM, 2004, DIABETES, V53, P3328, DOI 10.2337/diabetes.53.12.3328; Chilton FH, 1996, BBA-LIPID LIPID MET, V1299, P1, DOI 10.1016/0005-2760(95)00169-7; Collins S, 2004, PHYSIOL BEHAV, V81, P243, DOI 10.1016/j.physbeh.2004.02.006; COOK DL, 1988, DIABETES, V37, P495, DOI 10.2337/diabetes.37.5.495; DANIELS SB, 1983, J BIOL CHEM, V258, P5046; Easom RA, 1999, DIABETES, V48, P675, DOI 10.2337/diabetes.48.4.675; ECCLESTONE GT, 1995, AM J PHYSIOL, V268, pC181; EIZRIK DL, 1998, DIABETES, V37, P916; Forsell PKAL, 1998, FEBS LETT, V434, P295, DOI 10.1016/S0014-5793(98)00999-5; Forsell PKAL, 1999, EUR J BIOCHEM, V262, P575, DOI 10.1046/j.1432-1327.1999.00418.x; Fuentes L, 2003, J BIOL CHEM, V278, P44683, DOI 10.1074/jbc.M307209200; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Gunton JE, 2005, CELL, V122, P337, DOI 10.1016/j.cell.2005.05.027; Guo ZH, 2003, J BIOL CHEM, V278, P1856, DOI 10.1074/jbc.M211075200; HALLBERG A, 1984, BIOCHIM BIOPHYS ACTA, V796, P328, DOI 10.1016/0005-2760(84)90134-6; Han XL, 1998, BBA-BIOMEMBRANES, V1414, P95, DOI 10.1016/S0005-2736(98)00154-0; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; Hsu FF, 1998, BBA-LIPID LIPID MET, V1392, P202, DOI 10.1016/S0005-2760(98)00034-4; Hsu FF, 1998, J AM SOC MASS SPECTR, V9, P516, DOI 10.1016/S1044-0305(98)00012-9; Hsu FF, 2001, J AM SOC MASS SPECTR, V12, P1036, DOI 10.1016/S1044-0305(01)00285-9; Hsu FF, 2003, J AM SOC MASS SPECTR, V14, P352, DOI 10.1016/S1044-0305(03)00064-3; Jenkins CM, 2004, J BIOL CHEM, V279, P48968, DOI 10.1074/jbc.M407841200; Jenkins CM, 2002, J BIOL CHEM, V277, P32807, DOI 10.1074/jbc.M202568200; Kubota N, 2006, J BIOL CHEM, V281, P8748, DOI 10.1074/jbc.M505649200; LANDS WEM, 1997, ENZYMES BIOL MEMBRAN; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; Ma ZM, 1998, BBA-LIPID LIPID MET, V1391, P384, DOI 10.1016/S0005-2760(98)00027-7; Ma ZM, 2001, J BIOL CHEM, V276, P13198, DOI 10.1074/jbc.M010423200; Ma ZM, 2001, PROG NUCLEIC ACID RE, V67, P1, DOI 10.1016/S0079-6603(01)67023-5; Ma ZM, 1999, J BIOL CHEM, V274, P9607, DOI 10.1074/jbc.274.14.9607; Ma ZM, 1997, J BIOL CHEM, V272, P11118; Mancuso DJ, 2003, J BIOL CHEM, V278, P22231, DOI 10.1074/jbc.C300033200; Mancuso DJ, 2000, J BIOL CHEM, V275, P9937, DOI 10.1074/jbc.275.14.9937; Martinson BD, 2003, J LIPID RES, V44, P1686, DOI 10.1194/jlr.M300018-JLR200; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; Moran JM, 2005, J BIOL CHEM, V280, P28162, DOI 10.1074/jbc.M500013200; Moynihan KA, 2005, CELL METAB, V2, P105, DOI 10.1016/j.cmet.2005.07.001; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; MURPHY RC, 1990, METHOD ENZYMOL, V187, P90; Nowatzke W, 1998, ENDOCRINOLOGY, V139, P4073, DOI 10.1210/en.139.10.4073; Ohto T, 2005, J BIOL CHEM, V280, P24576, DOI 10.1074/jbc.M413711200; Owada S, 1999, J BIOL CHEM, V274, P2000, DOI 10.1074/jbc.274.4.2000; Pappan KL, 2005, J BIOL CHEM, V280, P9023, DOI 10.1074/jbc.M409706200; Perez R, 2004, J BIOL CHEM, V279, P40385, DOI 10.1074/jbc.M402562200; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; Radu CG, 2004, P NATL ACAD SCI USA, V101, P245, DOI 10.1073/pnas.2536801100; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P13499, DOI 10.1021/bi00212a015; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; Ramanadham S, 2003, BIOCHEMISTRY-US, V42, P13929, DOI 10.1021/bi034843p; Ramanadham S, 1998, BIOCHEMISTRY-US, V37, P4553, DOI 10.1021/bi9722507; Ramanadham S, 1998, BBA-LIPID LIPID MET, V1390, P301, DOI 10.1016/S0005-2760(97)00189-6; Ramanadham S, 1999, J BIOL CHEM, V274, P13915, DOI 10.1074/jbc.274.20.13915; RAMANADHAM S, 1992, BIOCHEM BIOPH RES CO, V184, P647, DOI 10.1016/0006-291X(92)90638-2; Ramanadham S, 1997, BBA-LIPID LIPID MET, V1344, P153, DOI 10.1016/S0005-2760(96)00139-7; RAMANADHAM S, 1994, BIOCHEMISTRY-US, V33, P7442, DOI 10.1021/bi00189a052; Remedi MS, 2004, DIABETES, V53, P3159, DOI 10.2337/diabetes.53.12.3159; Roe MW, 1998, J BIOL CHEM, V273, P10402, DOI 10.1074/jbc.273.17.10402; Seegers HC, 2002, J PHARMACOL EXP THER, V302, P918, DOI 10.1124/jpet.302.3.918; Seino S, 2000, DIABETES, V49, P311, DOI 10.2337/diabetes.49.3.311; Shirai Y, 2005, BBA-MOL CELL BIOL L, V1735, P119, DOI 10.1016/j.bbalip.2005.05.005; Simonsson E, 2000, INT J PANCREATOL, V27, P1, DOI 10.1385/IJGC:27:1:01; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Song CZ, 1999, J BIOL CHEM, V274, P17063, DOI 10.1074/jbc.274.24.17063; Song HW, 2006, BIOCHEMISTRY-US, V45, P1061, DOI 10.1021/bi052065q; Song HW, 2004, J AM SOC MASS SPECTR, V15, P1780, DOI 10.1016/j.jasms.2004.08.012; Song K, 2005, MOL ENDOCRINOL, V19, P504, DOI 10.1210/me.2004-0169; Su X, 2004, J BIOL CHEM, V279, P21740, DOI 10.1074/jbc.M314166200; SURWIT RS, 1988, DIABETES, V37, P1163, DOI 10.2337/diabetes.37.9.1163; Tanaka H, 2000, BIOCHEM BIOPH RES CO, V272, P320, DOI 10.1006/bbrc.2000.2776; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; TURK J, 1992, BIOCHIM BIOPHYS ACTA, V1125, P280, DOI 10.1016/0005-2760(92)90057-3; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; VACHER P, 1989, AM J PHYSIOL, V257, pE203, DOI 10.1152/ajpendo.1989.257.2.E203; van Tienhoven M, 2002, J BIOL CHEM, V277, P20942, DOI 10.1074/jbc.M200330200; Wang L, 2004, ENDOCRINOLOGY, V145, P3941, DOI 10.1210/en.2004-0281; Wang ZP, 2005, J BIOL CHEM, V280, P6840, DOI 10.1074/jbc.M405287200; WENCEL HE, 1995, PHYSIOL BEHAV, V57, P1215, DOI 10.1016/0031-9384(95)00022-B; WOLF BA, 1986, J BIOL CHEM, V261, P6284; WOLF BA, 1991, BIOCHEMISTRY-US, V30, P6372, DOI 10.1021/bi00240a004; Yang HC, 1999, J NEUROCHEM, V73, P1278, DOI 10.1046/j.1471-4159.1999.0731278.x; Yellaturu CR, 2003, J BIOL CHEM, V278, P43831, DOI 10.1074/jbc.M301472200	105	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20958	20973		10.1074/jbc.M600075200	http://dx.doi.org/10.1074/jbc.M600075200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16732058	Green Accepted, hybrid			2022-12-25	WOS:000239187300033
J	Marino, M; Deuss, M; Svergun, DI; Konarev, PV; Sterner, R; Mayans, O				Marino, Marco; Deuss, Miriam; Svergun, Dmitri I.; Konarev, Petr V.; Sterner, Reinhard; Mayans, Olga			Structural and mutational analysis of substrate complexation by anthranilate phosphoribosyltransferase from Sulfolobus solfataricus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE; QUINOLINIC ACID PHOSPHORIBOSYLTRANSFERASE; CRYSTAL-STRUCTURE; THYMIDINE PHOSPHORYLASE; MYCOBACTERIUM-TUBERCULOSIS; 3-DIMENSIONAL STRUCTURE; CATALYTIC MECHANISM; SCATTERING; PROTEINS; ENZYME	The metabolic synthesis and degradation of essential nucleotide compounds are primarily carried out by phosphoribosyltransferases (PRT) and nucleoside phosphorylases (NP), respectively. Despite the resemblance of their reactions, five classes of PRTs and NPs exist, where anthranilate PRT (AnPRT) constitutes the only evolutionary link between synthesis and degradation processes. We have characterized the active site of dimeric AnPRT from Sulfolobus solfataricus by elucidating crystal structures of the wild-type enzyme complexed to its two natural substrates anthranilate and 5-phosphoribosyl-1-pyrophosphate/Mg2+. These bind into two different domains within each protomer and are brought together during catalysis by rotational domain motions as shown by small angle x-ray scattering data. Steady-state kinetics of mutated AnPRT variants address the role of active site residues in binding and catalysis. Results allow the comparative analysis of PRT and pyrimidine NP families and expose related structural motifs involved in nucleotide/nucleoside recognition by these enzyme families.	Univ Basel, Div Struct Biol, Biozentrum, CH-4056 Basel, Switzerland; Univ Regensburg, Inst Biophys & Phys Biochem, D-93053 Regensburg, Germany; Univ Cologne, Inst Biochem, D-50674 Cologne, Germany; DESY, European Mol Biol Lab, Hamburg Outstn, D-22603 Hamburg, Germany; Russian Acad Sci, Inst Crystallog, Moscow 117333, Russia	University of Basel; University of Regensburg; University of Cologne; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS	Mayans, O (corresponding author), Univ Basel, Div Struct Biol, Biozentrum, Klingelbergstr 70, CH-4056 Basel, Switzerland.	Olga.Mayans@unibas.ch	Konarev, Petr V/W-1380-2017; Sterner, Reinhard/ABI-6781-2020; Mayans, Olga/A-3954-2008	Svergun, Dmitri/0000-0003-0830-5696; Konarev, Petr/0000-0002-5606-1596; Mayans, Olga/0000-0001-6876-8532; Sterner, Reinhard/0000-0001-8177-8460				Brandl M, 2001, J MOL BIOL, V307, P357, DOI 10.1006/jmbi.2000.4473; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Degano M, 1996, BIOCHEMISTRY-US, V35, P5971, DOI 10.1021/bi952999m; Eads JC, 1997, STRUCTURE, V5, P47, DOI 10.1016/S0969-2126(97)00165-2; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Heroux A, 2000, STRUCTURE, V8, P1309, DOI 10.1016/S0969-2126(00)00546-3; HOMMEL U, 1989, EUR J BIOCHEM, V180, P33, DOI 10.1111/j.1432-1033.1989.tb14611.x; Ivens A, 2001, EUR J BIOCHEM, V268, P2246, DOI 10.1046/j.1432-1327.2001.02102.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jurgens C, 2000, P NATL ACAD SCI USA, V97, P9925, DOI 10.1073/pnas.160255397; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kim C, 2002, FEBS LETT, V523, P239, DOI 10.1016/S0014-5793(02)02905-8; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; Kroemer M, 2004, ACTA CRYSTALLOGR D, V60, P1679, DOI 10.1107/S0907444904015215; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee CE, 2006, J MOL BIOL, V355, P784, DOI 10.1016/j.jmb.2005.11.016; Mayans O, 2002, EMBO J, V21, P3245, DOI 10.1093/emboj/cdf298; Mendieta J, 2004, BIOCHEMISTRY-US, V43, P405, DOI 10.1021/bi034793o; Meola M, 2003, J INORG BIOCHEM, V93, P235, DOI 10.1016/S0162-0134(02)00578-0; MOGHADDAM A, 1995, P NATL ACAD SCI USA, V92, P998, DOI 10.1073/pnas.92.4.998; MUSHEGIAN AR, 1994, PROTEIN SCI, V3, P1081, DOI 10.1002/pro.5560030711; Norman RA, 2004, STRUCTURE, V12, P75, DOI 10.1016/j.str.2003.11.018; Parish T, 2003, J BACTERIOL, V185, P6702, DOI 10.1128/JB.185.22.6702-6706.2003; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Prasad GS, 2001, CURR PROTEIN PEPT SC, V2, P301, DOI 10.2174/1389203013381017; Pugmire MJ, 2002, BIOCHEM J, V361, P1, DOI 10.1042/0264-6021:3610001; Pugmire MJ, 1998, STRUCTURE, V6, P1467, DOI 10.1016/S0969-2126(98)00145-2; Rick SW, 1999, PROTEINS, V37, P242, DOI 10.1002/(SICI)1097-0134(19991101)37:2<242::AID-PROT9>3.0.CO;2-5; SALERNO C, 1981, J BIOL CHEM, V256, P3671; Sharma V, 1998, STRUCTURE, V6, P1587, DOI 10.1016/S0969-2126(98)00156-7; Shin DH, 2005, J BIOL CHEM, V280, P18326, DOI 10.1074/jbc.M501622200; Sinha SC, 2001, CURR OPIN STRUC BIOL, V11, P733, DOI 10.1016/S0959-440X(01)00274-3; Smith DA, 2001, INFECT IMMUN, V69, P1142, DOI 10.1128/IAI.69.2.1442-1150.2001; Steiner T, 2001, J MOL BIOL, V305, P535, DOI 10.1006/jmbi.2000.4301; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; THOMPSON RE, 1978, BIOINORG CHEM, V9, P35, DOI 10.1016/S0006-3061(00)82004-9; WALTER MR, 1990, J BIOL CHEM, V265, P14016	39	21	22	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21410	21421		10.1074/jbc.M601403200	http://dx.doi.org/10.1074/jbc.M601403200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16714288	hybrid, Green Published			2022-12-25	WOS:000239187300077
J	Armoni, M; Harel, C; Karni, S; Chen, H; Bar-Yoseph, F; Ver, MR; Quon, MJ; Karnieli, E				Armoni, Michal; Harel, Chava; Karni, Shiri; Chen, Hui; Bar-Yoseph, Fabiana; Ver, Marel R.; Quon, Michael J.; Karnieli, Eddy			FOXO1 represses peroxisome proliferator-activated receptor-gamma 1 and -gamma 2 gene promoters in primary adipocytes - A novel paradigm to increase insulin sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; TRANSCRIPTION FACTOR FOXO1; SIGNALING PATHWAYS; EXPRESSION; FKHR; PHOSPHORYLATION; PROTEIN; TRANSACTIVATION; DIFFERENTIATION; INHIBITION	FOXO1 and peroxisome proliferator-activated receptor-gamma (PPAR gamma) are crucial transcription factors that regulate glucose metabolism and insulin responsiveness in insulin target tissues. We have shown that, in primary rat adipocytes, both factors regulate transcription of the insulin-responsive GLUT4 gene and that PPAR gamma 2 detachment from the GLUT4 promoter upon thiazolidinedione binding up-regulates GLUT4 gene expression, thus increasing insulin sensitivity (Armoni, M., Kritz, N., Harel, C., Bar-Yoseph, F., Chen, H., Quon, M. J., and Karnieli, E. (2003) J. Biol. Chem. 278, 30614-30623). However, the mechanisms regulating PPAR gamma gene transcription are largely unknown. We studied the effects of FOXO1 on human PPAR gamma gene expression in primary rat adipocytes and found that both genes are endogenously expressed. FOXO1 coexpression dose-dependently repressed transcription from either the PPAR gamma 1 or PPAR gamma 2 promoter reporter by 65%, whereas insulin (100 nM, 20-24 h) either partially or completely reversed this effect. Phosphorylation-defective FOXO1 mutants T24A, S256A, S319A, and T24A/S256A/S319A still repressed the PPAR gamma 1 promoter and partially lost their effects on the PPAR gamma 2 promoter in either basal or insulin-stimulated cells. Use of DNA binding-defective FOXO1(H215R) indicated that this domain is crucial for FOXO1 repression of the PPAR gamma 2 (but not PPAR gamma 1) promoter. Progressive 5'-deletion and gel retardation analyses revealed that this repression involves direct and specific binding of FOXO1 to the PPAR gamma 2 promoter; chromatin immunoprecipitation analysis confirmed that this binding occurs in cellulo. We suggest a novel paradigm to increase insulin sensitivity in adipocytes in which FOXO1 repression of PPAR gamma, the latter being a repressor of the GLUT4 promoter, consequently leads to GLUT4 derepression/up-regulation, thus enhancing cellular insulin sensitivity. The newly identified FOXO1-binding site on the PPAR gamma 2 promoter may serve as a therapeutic target for type 2 diabetes.	Rambam Med Ctr, Inst Endocrinol Diabet & Metab, Unite Endocrinol Mol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Rappaport Fac Med, IL-31096 Haifa, Israel; NCCAM, NIH, Bethesda, MD 20892 USA	Rambam Health Care Campus; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine	Armoni, M (corresponding author), Rambam Med Ctr, Inst Endocrinol Diabet & Metab, Unite Endocrinol Mol, POB 9602, IL-31096 Haifa, Israel.	amichal@tx.technion.ac.il	Quon, Michael/B-1970-2008	Quon, Michael/0000-0002-9601-9915; QUON, MICHAEL/0000-0002-5289-3707	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [ZIAAT000002, Z01AT000002] Funding Source: NIH RePORTER	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Arden KC, 2004, MOL CELL, V14, P416, DOI 10.1016/S1097-2765(04)00213-8; Armoni M, 2005, J BIOL CHEM, V280, P34786, DOI 10.1074/jbc.M502740200; Armoni M, 2003, J BIOL CHEM, V278, P30614, DOI 10.1074/jbc.M304654200; Armoni M, 2002, J CLIN ENDOCR METAB, V87, P5312, DOI 10.1210/jc.2002-020318; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Corton JC, 2005, J GERONTOL A-BIOL, V60, P1494, DOI 10.1093/gerona/60.12.1494; Dowell P, 2003, J BIOL CHEM, V278, P45485, DOI 10.1074/jbc.M309069200; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534-5807(02)00190-9; Gilde AJ, 2003, ACTA PHYSIOL SCAND, V178, P425, DOI 10.1046/j.1365-201X.2003.01161.x; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Kaestner KH, 2000, GENE DEV, V14, P142; Kloting N, 2006, DIABETES-METAB RES, V22, P146, DOI 10.1002/dmrr.582; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nowak DE, 2005, BIOTECHNIQUES, V39, P715, DOI 10.2144/000112014; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scheimann AO, 2001, HORM METAB RES, V33, P631, DOI 10.1055/s-2001-18687; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; TRAN H, 2003, SCI STKE, pRE5, DOI DOI 10.1126/STKE.2003.172.RE5; Tsai WC, 2003, ENDOCRINOLOGY, V144, P5615, DOI 10.1210/en.2003-0481; Zhang XH, 2002, J BIOL CHEM, V277, P45276, DOI 10.1074/jbc.M208063200; Zhao HH, 2001, J BIOL CHEM, V276, P27907, DOI 10.1074/jbc.M104278200	25	169	183	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					19881	19891		10.1074/jbc.M600320200	http://dx.doi.org/10.1074/jbc.M600320200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16670091	hybrid			2022-12-25	WOS:000239038200011
J	Kahler, CM; Lyons-Schindler, S; Choudhury, B; Glushka, J; Carlson, RW; Stephens, DS				Kahler, Charlene M.; Lyons-Schindler, Shauna; Choudhury, Biswa; Glushka, John; Carlson, Russell W.; Stephens, David S.			O-acetylation of the terminal N-acetylglucosamine of the lipooligosaccharide inner core in Neisseria meningitidis - Influence on inner core structure and assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPO-OLIGOSACCHARIDE; PHASE-VARIATION; GENETIC-BASIS; STRAIN NMB; LIPOPOLYSACCHARIDE; IMMUNOTYPE; IDENTIFICATION; BIOSYNTHESIS; PROTEIN; CELLS	O-Acetylation is a common decoration on endotoxins derived from many Gram-negative bacterial species, and it has been shown to be instrumental ( e. g. in Salmonella typhimurium) in determining the final tertiary structure of the endotoxin and the immunogenicity of the molecule. Structural heterogeneity of endotoxins produced by mucosal pathogens such as Neisseria meningitidis is determined by decorations on the heptose inner core, including O-acetylation of the terminal N-acetylglucosamine ( GlcNAc) attached to HepII. In this report, we show that O-acetylation of the meningococcal lipooligosaccharide (LOS) inner core has an important role in determining inner core assembly and immunotype expression. The gene encoding the LOS O-acetyltransferase, lot3, was identified by homology to NodX from Rhizobium leguminosarum. Inactivation of lot3 in strain NMB resulted in the loss of the O-acetyl group located at the C-3 position of the terminal GlcNAc of the LOS inner core. Inactivation of either lot3 or lgtG, which encodes the HepII glucosyltransferase, did not result in the appearance of the O-3-linked phosphoethanolamine ( PEA) groups on the LOS inner core. Construction of a double mutant in which both lot3 and lgtG were inactivated resulted in the appearance of O-3-linked PEA groups on the LOS inner core. In conclusion, O-acetylation status of the terminal GlcNAc of the alpha-chain of the meningococcal LOS inner core is an important determinant for the appearance or exclusion of the O-3-linked PEA group on the LOS inner core and contributes to LOS structural diversity. O-Acetylation also likely influences resistance to complement-mediated lysis and may be important in LOS conjugate vaccine design.	Monash Univ, Dept Microbiol, Clayton, Vic 3800, Australia; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Labs Microbial Pathogenesis, Atlanta, GA 30322 USA; Vet Affairs Med Ctr, Atlanta, GA 30322 USA	Monash University; University System of Georgia; University of Georgia; Emory University; Emory University; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System	Kahler, CM (corresponding author), Sch Biomed Biochem & Chem Sci, Discipline Microbiol & Immunol, L Block QE 2 Med Ctr, Perth, WA 6009, Australia.	ckahler@cyllene.uwa.edu.au	Stephens, David S/A-8788-2012; Kahler, Charlene M/H-5159-2014	Kahler, Charlene M/0000-0003-4322-3055; Pauldurai, Jona/0000-0002-7217-0872	NIAID NIH HHS [R01 AI033517] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033517] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Banerjee A, 1998, P NATL ACAD SCI USA, V95, P10872, DOI 10.1073/pnas.95.18.10872; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Cox AD, 2005, VACCINE, V23, P5045, DOI 10.1016/j.vaccine.2005.06.011; D'Haeze W, 2002, GLYCOBIOLOGY, V12, p79R, DOI 10.1093/glycob/12.6.79R; DAVIS EO, 1988, MOL GEN GENET, V212, P531, DOI 10.1007/BF00330860; DIFABIO JL, 1990, CAN J CHEM, V68, P1029, DOI 10.1139/v90-160; FIRMIN JL, 1993, MOL MICROBIOL, V10, P351, DOI 10.1111/j.1365-2958.1993.tb01961.x; GAMIAN A, 1992, J BIOL CHEM, V267, P922; Harvey HA, 2001, MOL MICROBIOL, V42, P659, DOI 10.1046/j.1365-2958.2001.02666.x; JANIK A, 1976, J CLIN MICROBIOL, V4, P71; Jarva H, 2005, J IMMUNOL, V174, P6299, DOI 10.4049/jimmunol.174.10.6299; JENNINGS HJ, 1984, INFECT IMMUN, V43, P407, DOI 10.1128/IAI.43.1.407-412.1984; Jennings MP, 1999, MICROBIOL-UK, V145, P3013, DOI 10.1099/00221287-145-11-3013; JONES DM, 1992, MICROB PATHOGENESIS, V13, P219, DOI 10.1016/0882-4010(92)90022-G; Kahler CM, 1998, CRIT REV MICROBIOL, V24, P281, DOI 10.1080/10408419891294216; Kahler CM, 1996, J BACTERIOL, V178, P6677, DOI 10.1128/jb.178.23.6677-6684.1996; Kahler CM, 2005, GLYCOBIOLOGY, V15, P409, DOI 10.1093/glycob/cwi018; Kahler CM, 1996, J BACTERIOL, V178, P1265, DOI 10.1128/jb.178.5.1265-1273.1996; Kim ML, 1999, FEMS IMMUNOL MED MIC, V26, P83, DOI 10.1111/j.1574-695X.1999.tb01375.x; Kogan G, 1997, CARBOHYD RES, V298, P191, DOI 10.1016/S0008-6215(96)00305-9; LEE FKN, 1995, INFECT IMMUN, V63, P2508, DOI 10.1128/IAI.63.7.2508-2515.1995; Mackinnon FG, 2002, MOL MICROBIOL, V43, P931, DOI 10.1046/j.1365-2958.2002.02754.x; MANDRELL RE, 1977, INFECT IMMUN, V16, P471, DOI 10.1128/IAI.16.2.471-475.1977; MICHON F, 1990, J BIOL CHEM, V265, P7243; Moller ASW, 2005, J INFECT DIS, V191, P768, DOI 10.1086/427514; Monteiro MA, 2003, CARBOHYD RES, V338, P2905, DOI 10.1016/j.carres.2003.08.014; MORSE SA, 1974, P SOC EXP BIOL MED, V145, P1418; Neal KR, 1999, EPIDEMIOL INFECT, V123, P507, DOI 10.1017/S0950268899003192; PAVLIAK V, 1993, J BIOL CHEM, V268, P14146; Plant L, 2006, INFECT IMMUN, V74, P1360, DOI 10.1128/IAI.74.2.1360-1367.2006; Rahman MM, 1998, CARBOHYD RES, V307, P311; Ram S, 2003, J BIOL CHEM, V278, P50853, DOI 10.1074/jbc.M308364200; SCHOLTEN RJPM, 1994, J MED MICROBIOL, V41, P236, DOI 10.1099/00222615-41-4-236; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; TSAI CM, 1987, INFECT IMMUN, V55, P1652, DOI 10.1128/IAI.55.7.1652-1656.1987; Tzeng YL, 2004, J BIOL CHEM, V279, P35053, DOI 10.1074/jbc.M401433200; VERHEUL AFM, 1991, INFECT IMMUN, V59, P3566, DOI 10.1128/IAI.59.10.3566-3573.1991; Virji M, 1995, MOL MICROBIOL, V18, P741, DOI 10.1111/j.1365-2958.1995.mmi_18040741.x; Warren MJ, 2004, FEMS IMMUNOL MED MIC, V41, P43, DOI 10.1016/j.femsim.2004.01.002; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yazdankhah SP, 2004, J MED MICROBIOL, V53, P821, DOI 10.1099/jmm.0.45529-0; YORK WS, 1986, METHOD ENZYMOL, V118, P3; ZOLLINGER WD, 1977, INFECT IMMUN, V18, P424, DOI 10.1128/IAI.18.2.424-433.1977	46	31	35	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					19939	19948		10.1074/jbc.M601308200	http://dx.doi.org/10.1074/jbc.M601308200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16687398	hybrid			2022-12-25	WOS:000239038200017
J	Trompier, D; Alibert, M; Davanture, S; Hamon, Y; Pierres, M; Chimini, G				Trompier, Doriane; Alibert, Melanie; Davanture, Suzel; Hamon, Yannick; Pierres, Michel; Chimini, Giovanna			Transition from dimers to higher oligomeric forms occurs during the ATPase cycle of the ABCA1 transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; RESONANCE ENERGY-TRANSFER; CHOLESTEROL EFFLUX; P-GLYCOPROTEIN; PLASMA-MEMBRANE; TANGIER-DISEASE; PROTEIN MRP1; APOA-I; BINDING; CELLS	Fluorescence resonance energy transfer and native PAGE analytical techniques were employed to assess the quaternary structure of ABCA1, an ATP binding cassette transporter playing a crucial role in cellular lipid handling. These experimental approaches support the conclusion that ABCA1 is associated in dimeric structures that undergo transition into higher order structures, i.e. tetramers, during the ATP catalytic cycle. Our data hence underline molecular assembly as a crucial parameter in ABCA1 function and the advantage of native PAGE as analytical tool for intractable membrane proteins.	Univ Mediterranee, INSERM, CNRS, Ctr Immunol, F-13288 Marseille 09, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Chimini, G (corresponding author), Univ Mediterranee, INSERM, CNRS, Ctr Immunol, Parc Sci Luminy,Case 906, F-13288 Marseille 09, France.	chimini@ciml.univ-mrs.fr	TROMPIER, Doriane/D-5862-2017; HAMON, Yannick/S-3118-2019; HAMON, Yannick YH/N-5372-2016	HAMON, Yannick/0000-0002-7636-2310; HAMON, Yannick YH/0000-0002-7636-2310; Trompier, Doriane/0000-0002-0746-1753				Attie AD, 2002, J LIPID RES, V43, P1610, DOI 10.1194/jlr.M200223-JLR200; Bezprozvanny I, 2001, P NATL ACAD SCI USA, V98, P787, DOI 10.1073/pnas.98.3.787; BOSCOBOINIK D, 1990, BIOCHIM BIOPHYS ACTA, V1027, P225, DOI 10.1016/0005-2736(90)90311-B; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Buechler C, 2002, BIOCHEM BIOPH RES CO, V293, P759, DOI 10.1016/S0006-291X(02)00303-0; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Chen JH, 2002, J MEMBRANE BIOL, V188, P55, DOI 10.1007/s00232-001-0174-2; Denis M, 2004, J BIOL CHEM, V279, P41529, DOI 10.1074/jbc.M406881200; Duong PT, 2006, J LIPID RES, V47, P832, DOI 10.1194/jlr.M500531-JLR200; Fitzgerald ML, 2004, J BIOL CHEM, V279, P48477, DOI 10.1074/jbc.M409848200; Fitzgerald ML, 2004, J LIPID RES, V45, P287, DOI 10.1194/jlr.M300355-JLR200; Fitzgerald ML, 2001, J BIOL CHEM, V276, P15137, DOI 10.1074/jbc.M100474200; Gaus K, 2004, FASEB J, V18, P574, DOI 10.1096/fj.03-0486fje; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hou YX, 2003, J BIOL CHEM, V278, P3599, DOI 10.1074/jbc.M210480200; Karpova TS, 2003, J MICROSC-OXFORD, V209, P56, DOI 10.1046/j.1365-2818.2003.01100.x; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; Kenworthy AK, 1998, J CELL BIOL, V142, P69, DOI 10.1083/jcb.142.1.69; Li CY, 2004, J BIOL CHEM, V279, P24673, DOI 10.1074/jbc.M400688200; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; MARSHALL J, 1994, J BIOL CHEM, V269, P2987; Maxfield FR, 2005, NATURE, V438, P612, DOI 10.1038/nature04399; Munehira Y, 2004, J BIOL CHEM, V279, P15091, DOI 10.1074/jbc.M313436200; NAITO M, 1992, BIOCHEM BIOPH RES CO, V185, P284, DOI 10.1016/S0006-291X(05)80988-X; Nofer JR, 2005, CELL MOL LIFE SCI, V62, P2150, DOI 10.1007/s00018-005-5125-0; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; PETER GF, 1991, J BIOL CHEM, V266, P16745; PORUCHYNSKY MS, 1994, BIOCHEMISTRY-US, V33, P4163, DOI 10.1021/bi00180a009; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Ramjeesingh M, 2003, BIOCHEM J, V374, P793, DOI 10.1042/BJ20030683; Ramjeesingh M, 2001, BIOCHEMISTRY-US, V40, P10700, DOI 10.1021/bi0108195; Rigot W, 2002, J LIPID RES, V43, P2077, DOI 10.1194/jlr.M200279-JLR200; Rosenberg MF, 2001, J BIOL CHEM, V276, P16076, DOI 10.1074/jbc.M100176200; Singaraja RR, 2003, ARTERIOSCL THROM VAS, V23, P1322, DOI 10.1161/01.ATV.0000078520.89539.77; Sitte HH, 2003, EUR J PHARMACOL, V479, P229, DOI 10.1016/j.ejphar.2003.08.072; Takahashi K, 2006, J BIOL CHEM, V281, P10760, DOI 10.1074/jbc.M513783200; TAM SP, 2006, IN PRESS AM J PHYSL; Trompier D, 2003, CELL MOL LIFE SCI, V60, P2164, DOI 10.1007/s00018-003-3177-6; Valentin G, 2005, NAT METHODS, V2, P801, DOI 10.1038/nmeth1105-801; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Zerhusen B, 1999, J BIOL CHEM, V274, P7627, DOI 10.1074/jbc.274.12.7627	42	36	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20283	20290		10.1074/jbc.M601072200	http://dx.doi.org/10.1074/jbc.M601072200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16709568	hybrid			2022-12-25	WOS:000239038200053
J	Carattino, MD; Sheng, SH; Bruns, JB; Pilewski, JM; Hughey, RP; Kleyman, TR				Carattino, Marcelo D.; Sheng, Shaohu; Bruns, James B.; Pilewski, Joseph M.; Hughey, Rebecca P.; Kleyman, Thomas R.			The epithelial Na+ channel is inhibited by a peptide derived from proteolytic processing of its alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; LIDDLES-SYNDROME; BETA-SUBUNIT; PORE REGION; SELECTIVITY FILTER; MISSENSE MUTATION; SERINE PROTEASES; GAMMA-SUBUNIT; AMILORIDE; ENAC	Epithelial sodium channels (ENaCs) mediate Na+ entry across the apical membrane of high resistance epithelia that line the distal nephron, airway and alveoli, and distal colon. These channels are composed of three homologous subunits, termed alpha, beta, and gamma, which have intracellular amino and carboxyl termini and two membrane spanning domains connected by large extracellular loops. Maturation of ENaC subunits involves furin-dependent cleavage of the extracellular loops at two sites within the alpha subunit and at a single site within the gamma subunit. The alpha subunits must be cleaved twice, immediately following Arg-205 and Arg-231, in order for channels to be fully active. Channels lacking alpha subunit cleavage are inactive with a very low open probability. In contrast, channels lacking both alpha subunit cleavage and the tract alpha Asp-206-Arg-231 are active when expressed in oocytes, suggesting that alpha Asp-206-Arg-231 functions as an inhibitor that stabilizes the channel in the closed conformation. A synthetic 26-mer peptide (alpha-26), corresponding to alpha Asp206- Arg-231, reversibly inhibits wild-type mouse ENaCs expressed in Xenopus oocytes, as well as endogenous Na+ channels expressed in either a mouse collecting duct cell line or primary cultures of human airway epithelial cells. The IC50 for amiloride block of ENaC was not affected by the presence of alpha-26, indicating that alpha-26 does not bind to or interact with the amiloride binding site. Substitution of Arg residues within alpha-26 with Glu, or substitution of Pro residues with Ala, significantly reduced the efficacy of alpha-26. The peptide inhibits ENaC by reducing channel open probability. Our results suggest that proteolysis of the alpha subunit activates ENaC by disassociating an inhibitory domain (alpha Asp-206-Arg-231) from its effector site within the channel complex.	Univ Pittsburgh, Renal Electrolyte Div, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Dept Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hughey, RP (corresponding author), Univ Pittsburgh, Renal Electrolyte Div, S933 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	hughey@dom.pitt.edu	Sheng, Shaohu/G-7052-2016; Pilewski, Joseph/AAF-5149-2021	Sheng, Shaohu/0000-0002-7198-1702; 	NIDDK NIH HHS [DK065161, P30 DK072506, P50 DK54690] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065161, R56DK065161, P30DK072506] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi M, 2001, J AM SOC NEPHROL, V12, P1114, DOI 10.1681/ASN.V1261114; Bens M, 1999, J AM SOC NEPHROL, V10, P923; Boucher RC, 2004, EUR RESPIR J, V23, P146, DOI 10.1183/09031936.03.00057003; Bridges RJ, 2001, AM J PHYSIOL-LUNG C, V281, pL16, DOI 10.1152/ajplung.2001.281.1.L16; Caldwell RA, 2005, AM J PHYSIOL-LUNG C, V288, pL813, DOI 10.1152/ajplung.00435.2004; Caldwell RA, 2004, AM J PHYSIOL-CELL PH, V286, pC190, DOI 10.1152/ajpcell.00342.2003; Carattino MD, 2005, J BIOL CHEM, V280, P17608, DOI 10.1074/jbc.M501770200; Carattino MD, 2005, J BIOL CHEM, V280, P4393, DOI 10.1074/jbc.M413123200; Carattino MD, 2003, J BIOL CHEM, V278, P36202, DOI 10.1074/jbc.M300312200; Chraibi A, 1998, J GEN PHYSIOL, V111, P127, DOI 10.1085/jgp.111.1.127; Condliffe SB, 2004, J BIOL CHEM, V279, P10085, DOI 10.1074/jbc.M313592200; Devor DC, 1999, AM J PHYSIOL-CELL PH, V276, pC827, DOI 10.1152/ajpcell.1999.276.4.C827; Donaldson SH, 2002, J BIOL CHEM, V277, P8338, DOI 10.1074/jbc.M105044200; Eaton DC, 2001, J MEMBRANE BIOL, V184, P313, DOI 10.1007/s00232-001-0098-x; Guipponi M, 2002, HUM MOL GENET, V11, P2829, DOI 10.1093/hmg/11.23.2829; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Hiltunen TP, 2002, J HYPERTENS, V20, P2383, DOI 10.1097/00004872-200212000-00017; Hirsh AJ, 2004, J PHARMACOL EXP THER, V311, P929, DOI 10.1124/jpet.104.071886; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; Hummler E, 1999, AM J PHYSIOL-GASTR L, V276, pG567, DOI 10.1152/ajpgi.1999.276.3.G567; Hummler E, 1998, KIDNEY BLOOD PRESS R, V21, P253, DOI 10.1159/000025868; Inoue J, 1998, J CLIN ENDOCR METAB, V83, P2210, DOI 10.1210/jc.83.6.2210; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; Li JQ, 2003, J BIOL CHEM, V278, P13867, DOI 10.1074/jbc.M300149200; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; Sheng S, 2006, AM J PHYSIOL-RENAL, V290, pF1488, DOI 10.1152/ajprenal.00439.2005; Sheng SH, 2005, J BIOL CHEM, V280, P8513, DOI 10.1074/jbc.M413880200; Sheng SH, 2000, J BIOL CHEM, V275, P8572, DOI 10.1074/jbc.275.12.8572; Sheng SH, 2001, J BIOL CHEM, V276, P44091, DOI 10.1074/jbc.M108522200; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Snyder PM, 1999, J BIOL CHEM, V274, P28484, DOI 10.1074/jbc.274.40.28484; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Snyder PM, 2000, J GEN PHYSIOL, V116, P781, DOI 10.1085/jgp.116.6.781; Stockand JD, 2002, AM J PHYSIOL-RENAL, V282, pF559, DOI 10.1152/ajprenal.00320.2001; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; Verrey F, 1999, AM J PHYSIOL-RENAL, V277, pF319, DOI 10.1152/ajprenal.1999.277.3.F319; Vuagniaux G, 2000, J AM SOC NEPHROL, V11, P828, DOI 10.1681/ASN.V115828; Vuagniaux G, 2002, J GEN PHYSIOL, V120, P191, DOI 10.1085/jgp.20028598; Yamashita Y, 2001, AM J KIDNEY DIS, V37, P499	43	113	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18901	18907		10.1074/jbc.M604109200	http://dx.doi.org/10.1074/jbc.M604109200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16690613	hybrid			2022-12-25	WOS:000238687300070
J	Pezza, RJ; Petukhova, GV; Ghirlando, R; Camerini-Otero, RD				Pezza, Roberto J.; Petukhova, Galina V.; Ghirlando, Rodolfo; Camerini-Otero, R. Daniel			Molecular activities of meiosis-specific proteins Hop2, Mnd1, and the Hop2-Mnd1 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; PREDICTING COILED COILS; MEIOTIC RECOMBINATION; SACCHAROMYCES-CEREVISIAE; GENETIC-RECOMBINATION; CHROMOSOME SYNAPSIS; DMC1; DNA; RAD51; SPO11	The mouse Hop2 and Mnd1 proteins, which can form a stable heterodimeric complex, ensure the proper synapsis of homologous chromosomes in meiosis by acting in concert with Rad51 and Dmc1 to promote the strand invasion (D-loop formation) step of homologous recombination. Hop2 alone promotes D-loop formation, but Mnd1 and the Hop2-Mnd1 complex do not. Here we show that only the heterodimer complex, but not the individual proteins, can stimulate strand invasion by Dmc1. Furthermore, we demonstrate that the interaction with Mnd1 provokes changes in Hop2 that are responsible not only for abrogating the recombinase activity of Hop2 but also for generating a new molecular interface able to physically interact with and stimulate Dmc1. We also show that coiled-coil motifs in Hop2 and Mnd1 are essential for their interaction with each other and that a clearly delineated region near the COOH terminus of both proteins is necessary for both the DNA binding and single-strand annealing by the Hop-Mnd1 heterodimer. Finally, we describe a point mutation in Hop2 that dissociates its strand invasion activity from its ability to bind and anneal DNA.	NIDDK, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Camerini-Otero, RD (corresponding author), Bldg 5,Rm 205A,5 Mem Dr,MSC0538, Bethesda, MD 20892 USA.	camerini@ncifcrf.gov	Ghirlando, Rodolfo/A-8880-2009		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK033007, Z01DK052032, Z01DK033007, Z01DK052008, ZIADK052032] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baudat F, 2000, MOL CELL, V6, P989, DOI 10.1016/S1097-2765(00)00098-8; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Chen YK, 2004, P NATL ACAD SCI USA, V101, P10572, DOI 10.1073/pnas.0404195101; Enomoto R, 2004, J BIOL CHEM, V279, P35263, DOI 10.1074/jbc.M402481200; Gerton JL, 2002, P NATL ACAD SCI USA, V99, P6895, DOI 10.1073/pnas.102167899; Gupta RC, 2001, P NATL ACAD SCI USA, V98, P8433, DOI 10.1073/pnas.121005298; Hong ERL, 2001, J BIOL CHEM, V276, P41906, DOI 10.1074/jbc.M105563200; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Leu JY, 1998, CELL, V94, P375, DOI 10.1016/S0092-8674(00)81480-4; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Masson JY, 1999, EMBO J, V18, P6552, DOI 10.1093/emboj/18.22.6552; Neale MJ, 2005, NATURE, V436, P1053, DOI 10.1038/nature03872; Passy SI, 1999, P NATL ACAD SCI USA, V96, P10684, DOI 10.1073/pnas.96.19.10684; Petukhova GV, 2005, NAT STRUCT MOL BIOL, V12, P449, DOI 10.1038/nsmb923; Petukhova GV, 2003, DEV CELL, V5, P927, DOI 10.1016/S1534-5807(03)00369-1; Rabitsch KP, 2001, CURR BIOL, V11, P1001, DOI 10.1016/S0960-9822(01)00274-3; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Romanienko PJ, 2000, MOL CELL, V6, P975, DOI 10.1016/S1097-2765(00)00097-6; Saito TT, 2004, NUCLEIC ACIDS RES, V32, P3325, DOI 10.1093/nar/gkh654; Sauvageau S, 2004, BIOESSAYS, V26, P1151, DOI 10.1002/bies.20150; Shinohara A, 2004, CYTOGENET GENOME RES, V107, P201, DOI 10.1159/000080598; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; Sung P, 2003, J BIOL CHEM, V278, P42729, DOI 10.1074/jbc.R300027200; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Tsubouchi H, 2003, DEV CELL, V5, P915, DOI 10.1016/S1534-5807(03)00357-5; Tsubouchi H, 2002, MOL CELL BIOL, V22, P3078, DOI 10.1128/MCB.22.9.3078-3088.2002; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Zickler D, 1999, ANNU REV GENET, V33, P603, DOI 10.1146/annurev.genet.33.1.603	32	52	56	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18426	18434		10.1074/jbc.M601073200	http://dx.doi.org/10.1074/jbc.M601073200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16675459	hybrid			2022-12-25	WOS:000238687300021
J	Muhlhausler, BS; Adam, CL; Findlay, PA; Duffield, JA; McMillen, IC				Muhlhausler, B. S.; Adam, C. L.; Findlay, P. A.; Duffield, J. A.; McMillen, I. C.			Increased maternal nutrition alters development of the appetite-regulating network in the brain	FASEB JOURNAL			English	Article						nutrition; programming; energy balance; obesity	HYPOTHALAMIC GENE-EXPRESSION; BROWN ADIPOSE-TISSUE; NEUROPEPTIDE-Y; LEPTIN RECEPTOR; MESSENGER-RNA; NEURONS; SHEEP; RESPONSES; INSULIN; OVINE	Individuals exposed to an increased nutrient supply before birth have a high risk of becoming obese children and adults. It has been proposed that exposure of the fetus to high maternal nutrient intake results in permanent changes within the central appetite regulatory network. No studies, however, have investigated the impact of increased maternal nutrition on the appetite regulatory network in species in which this network develops before birth, as in the human. In the present study, pregnant ewes were fed a diet which provided 100% (control, n = 8) or similar to 160% (well-fed, n=8) of metabolizable energy requirements. Ewes were allowed to lamb spontaneously, and lambs were sacrificed at 30 days of postnatal age. All fat depots were dissected and weighed, and expression of the appetite-regulating neuropeptides and the leptin receptor ( OBRb) were determined by in situ hybridization. Lambs of well-fed ewes had higher glucose (Glc) concentrations during early postnatal life (F=5.93, P < 0.01) and a higher relative subcutaneous (s.c.) fat mass at 30 days of age (34.9 +/- 4.7 g/ kg vs. 22.8 +/- 3.3 g/ kg; P < 0.05). The hypothalamic expression of proopiomelanocortin was higher in lambs of well-fed ewes (0.48 +/- 0.09 vs. 0.28 +/- 0.04, P < 0.05). In lambs of over-nourished mothers, but not in controls, the expression of OBRb was inversely related to total relative fat mass (r(2)=0.50, P=0.05, n=8), and the direct relationship between the expression of the central appetite inhibitor CART and fat mass was lost. The expression of neuropeptide Y and AGRP was inversely related to total relative fat mass (NPY, r(2)=0.28, P < 0.05; agouti-related peptide, r(2)=0.39, P < 0.01). These findings suggest that exposure to increased nutrition before birth alters the responses of the central appetite regulatory system to signals of increased adiposity after birth.-Muhlhausler, B. S., Adam, C. L., Findlay, P. A., Duffield, J. A., and McMillen, I. C. Increased maternal nutrition alters development of the appetite-regulating network in the brain.	Univ Adelaide, Res Ctr Early Origins Adult Hlth, Sch Mol & Biomed Sci, Adelaide, SA, Australia; Rowett Res Inst, Obes & Metab Div, Aberdeen, Scotland	University of Adelaide; University of Aberdeen	McMillen, IC (corresponding author), Univ S Adelaide, Sansom Res Inst, Adelaide, SA 5005, Australia.	caroline.mcmillen@unisa.edu.au	McMillen, Isabella Caroline/N-5540-2019	Muhlhausler, Beverly/0000-0002-9021-6790				Adam CL, 1997, J ENDOCRINOL, V152, P329, DOI 10.1677/joe.0.1520329; Adam CL, 2002, NEUROENDOCRINOLOGY, V75, P250, DOI 10.1159/000054716; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; ALDERMANN GA, 1975, MINISTRY AGR FISHERI, V33; Barrett P, 2001, J NEUROENDOCRINOL, V13, P347, DOI 10.1046/j.1365-2826.2001.00634.x; Bouret SG, 2004, SCIENCE, V304, P108, DOI 10.1126/science.1095004; Budge H, 2000, PEDIATR RES, V47, P781, DOI 10.1203/00006450-200006000-00017; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Catalano PM, 2003, AM J OBSTET GYNECOL, V189, P1698, DOI 10.1016/S0002-9378(03)00828-7; Cone RD, 2001, INT J OBESITY, V25, pS63, DOI 10.1038/sj.ijo.0801913; Davidowa H, 2003, EUR J NEUROSCI, V18, P613, DOI 10.1046/j.1460-9568.2003.02789.x; Davidowa H, 2000, NEUROSCI LETT, V293, P21, DOI 10.1016/S0304-3940(00)01475-0; Davidowa H, 2000, NEUROREPORT, V11, P2795, DOI 10.1097/00001756-200008210-00037; Davidowa H, 2001, NEUROREPORT, V12, P3201, DOI 10.1097/00001756-200110290-00012; Dunn-Meynell AA, 2002, DIABETES, V51, P2056, DOI 10.2337/diabetes.51.7.2056; FOWDEN AL, 1995, FETUS NEONATE PHYSL, V3, P31; Grove KL, 2003, PHYSIOL BEHAV, V79, P47, DOI 10.1016/S0031-9384(03)00104-5; HIGUCHI H, 1988, J BIOL CHEM, V263, P6288; HINCH GN, 1989, APPL ANIM BEHAV SCI, V22, P39, DOI 10.1016/0168-1591(89)90078-6; Ibrahim N, 2003, ENDOCRINOLOGY, V144, P1331, DOI 10.1210/en.2002-221033; Kalra SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/er.20.1.68; Kauter K, 2000, J ENDOCRINOL, V166, P127, DOI 10.1677/joe.0.1660127; Koutcherov Y, 2003, J CHEM NEUROANAT, V26, P253, DOI 10.1016/j.jchemneu.2003.07.002; Martin RJ, 1998, P SOC EXP BIOL MED, V219, P200; Mercer JG, 1998, REGUL PEPTIDES, V75-6, P271, DOI 10.1016/S0167-0115(98)00078-0; MERCER JG, 1995, AM J PHYSIOL-REG I, V269, pR1099, DOI 10.1152/ajpregu.1995.269.5.R1099; Mercer JG, 2000, AM J PHYSIOL-REG I, V278, pR271, DOI 10.1152/ajpregu.2000.278.1.R271; Muhlhausler BS, 2004, J NEUROENDOCRINOL, V16, P502, DOI 10.1111/j.1365-2826.2004.01197.x; Muhlhausler BS, 2005, J PHYSIOL-LONDON, V565, P185, DOI 10.1113/jphysiol.2004.079079; Muhlhausler BS, 2002, BIOL REPROD, V67, P493, DOI 10.1095/biolreprod67.2.493; PETTITT DJ, 1987, DIABETES CARE, V10, P76, DOI 10.2337/diacare.10.1.76; Picciano MF, 2003, J NUTR, V133, p1997S, DOI 10.1093/jn/133.6.1997S; Plagemann A, 1997, INT J OBESITY, V21, P451, DOI 10.1038/sj.ijo.0800429; Plagemann A, 1999, J NEUROENDOCRINOL, V11, P541; RUSSEL AJF, 1981, J AGR SCI, V97, P723, DOI 10.1017/S0021859600037096; Silverman BL, 1998, DIABETES CARE, V21, pB142; SILVERMAN BL, 1991, DIABETES, V40, P121, DOI 10.2337/diab.40.2.S121; Warnes KE, 1998, J NEUROENDOCRINOL, V10, P51, DOI 10.1046/j.1365-2826.1998.00172.x; Williams G, 2001, PHYSIOL BEHAV, V74, P683, DOI 10.1016/S0031-9384(01)00612-6; Williams LM, 1999, J NEUROENDOCRINOL, V11, P165	40	175	177	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1257	+		10.1096/fj.05-5241fje	http://dx.doi.org/10.1096/fj.05-5241fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16684802				2022-12-25	WOS:000240210300044
J	Robert, JS				Robert, Jason Scott			The science and ethics of making part-human animals in stem cell biology	FASEB JOURNAL			English	Article						chimeras; ethics; history; policy; stem cells	CHIMERAS; ISSUES; MODEL; SHEEP; DIFFERENTIATION; TRANSPLANTATION; ORGANISM; DEFENSE; DIGNITY; PATENTS	The National Academy of Sciences recently issued voluntary guidelines to govern human embryonic stem cell research. Among other restrictions, these guidelines prohibit certain kinds of combinations of human and nonhuman animal cells, and call for ethics review and oversight of any protocol involving the transfer of human embryonic stem cells into nonhuman animals. In this essay, I discuss the history of and scientific rationales for combining human cells with cells of nonhuman animals, and critically assess the most recent attempts to limit such research on moral grounds-and find them lacking. Nonetheless, as I show, this research remains scientifically and morally contested. I then explore whether and how the NAS's recommended Embryonic Stem Cell Research and Oversight committees will allow for scientifically well-informed moral assessment of this controversial, but possibly important, research.	Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	Robert, JS (corresponding author), Arizona State Univ, Sch Life Sci, POB 874501, Tempe, AZ 85287 USA.	jason.robert@asu.edu		Robert, Jason/0000-0002-5346-0575				Almeida-Porada G, 2005, BRIT J HAEMATOL, V130, P276, DOI 10.1111/j.1365-2141.2005.05588.x; Almeida-Porada G, 2004, YONSEI MED J, V45, P7; Almeida-Porada G, 2004, BLOOD, V104, P2582, DOI 10.1182/blood-2004-01-0259; Bostrom N, 2005, BIOETHICS, V19, P202, DOI 10.1111/j.1467-8519.2005.00437.x; Brivanlou AH, 2003, SCIENCE, V300, P913, DOI 10.1126/science.1082940; Brustle O, 1998, NAT BIOTECHNOL, V16, P1040, DOI 10.1038/3481; Caulfield T, 2005, PLOS MED, V2, P736, DOI 10.1371/journal.pmed.0020244; Check E, 2004, NATURE, V431, P885, DOI 10.1038/431885a; Chen Y, 2003, CELL RES, V13, P251, DOI 10.1038/sj.cr.7290170; Dawson L, 2003, FERTIL STERIL, V80, P1077, DOI 10.1016/S0015-0282(03)02218-0; DeWitt N, 2002, NATURE, V420, P255, DOI 10.1038/420255a; Dick JE, 2001, ANN NY ACAD SCI, V938, P184; DICK JE, 1991, CANCER CELL-MON REV, V3, P39; DOWIE M, 2004, MOTHER JONES     JAN, P48; DOWIE M, 2004, MOTHER JONES     JAN, P84; Erdo F, 2003, J CEREBR BLOOD F MET, V23, P780, DOI 10.1097/01.WCB.0000071886.63724.FB; FEHILLY CB, 1984, NATURE, V307, P634, DOI 10.1038/307634a0; Fukuyama Francis, 2002, OUR POSTHUMAN FUTURE; Goldstein RS, 2002, DEV DYNAM, V225, P80, DOI 10.1002/dvdy.10108; Greene M, 2005, SCIENCE, V309, P385, DOI 10.1126/science.1112207; HARRISON RG, 1969, ORG DEV EMBRYO, P215; Institute of Medicine and National Research Council, 2007, GUID HUM EMBR STEM C, DOI [10.17226/11870, DOI 10.17226/11153]; Karpowicz P, 2005, KENNEDY INST ETHIC J, V15, P107, DOI 10.1353/ken.2005.0015; Karpowicz P, 2003, AM J BIOETHICS, V3, pW17; Karpowicz P, 2004, NAT MED, V10, P331, DOI 10.1038/nm0404-331; KRIEGER LM, 2002, MERCURY NEWS    1209; Laubichler MD, 2000, PHILOS SCI, V67, pS256, DOI 10.1086/392823; Laubichler MD, 2000, PHILOS SCI, V67, pS289, DOI 10.1086/392826; Le Douarin N., 1969, Bulletin Biologique de la France et de la Belgique, V103, P435; Le Douarin NM, 2004, MECH DEVELOP, V121, P1089, DOI 10.1016/j.mod.2004.06.003; Macklin R, 2003, BRIT MED J, V327, P1419, DOI 10.1136/bmj.327.7429.1419; Maienschein Jane., 2003, WHOSE VIEW LIFE EMBR, DOI [10.4159/9780674040434, DOI 10.4159/9780674040434]; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; McLaren A., 1976, MAMMALIAN CHIMAERAS; MEINECKETILLMANN S, 1984, NATURE, V307, P637, DOI 10.1038/307637a0; MORENO JD, 2005, NTA BIOTECHNOL, V23, P723; MOSIER DE, 1996, SEMIN IMMUNOL, V8, P185; MOTT M, 2005, NATL GEOGRAPHIC 0125; NEWMAN SA, 2002, LAHEY CLIN MED ETHIC, V9, P4; NEWMAN SA, 2002, LAHEY CLIN MED ETHIC, V9, P7; Ourednik V, 2001, SCIENCE, V293, P1820, DOI 10.1126/science.1060580; Resnik DB, 2003, AM J BIOETHICS, V3, P35, DOI 10.1162/15265160360706534; Resnik DB, 2001, J LAW MED ETHICS, V29, P152, DOI 10.1111/j.1748-720X.2001.tb00335.x; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Robert JS, 2004, BIOESSAYS, V26, P1005, DOI 10.1002/bies.20100; ROSSANT J, 1980, SCIENCE, V208, P419, DOI 10.1126/science.7367871; Solter D, 2003, NAT BIOTECHNOL, V21, P1154, DOI 10.1038/nbt1003-1154; Tam PPL, 2003, DEVELOPMENT, V130, P6155, DOI 10.1242/dev.00893; TARKOWSKI AK, 1961, NATURE, V190, P857, DOI 10.1038/190857a0; WEISS R, 2005, WASHINGTON POST 0213	50	33	33	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					838	845		10.1096/fj.05-4286lsf	http://dx.doi.org/10.1096/fj.05-4286lsf			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675841				2022-12-25	WOS:000240157700006
J	Kiser, KF; Colombi, M; Moroni, C				Kiser, K. F.; Colombi, M.; Moroni, C.			Isolation and characterization of dominant and recessive IL-3-independent hematopoietic transformants	ONCOGENE			English	Article						mutagenesis; Raf-1; ICR191; mast cells; stat	COLONY-STIMULATING FACTOR; ABROGATE CYTOKINE DEPENDENCY; MESSENGER-RNA TURNOVER; BCR-ABL; AUTOCRINE TRANSFORMATION; DIFFERENTIAL ABILITIES; SIGNAL-TRANSDUCTION; FACTOR-INDEPENDENCE; PREVENT APOPTOSIS; BETA-SUBUNIT	Retroviral integration mutagenesis and treatment with the frameshift mutagen ICR191 were used to transform v-H-ras expressing PB-3c cells to interleukin-3 (IL-3) independence. Six clones displayed viral integrations into the 30 region of the IL-3 gene thus acting posttranscriptionally by disrupting the AU-rich instability element. Two clones contained reverse orientation integration into the raf-1 gene revealing an enhancer insertion mechanism. Growth by this mechanism was sensitive to the Raf-1 inhibitor BAY 43-9006 and the Mek inhibitor U0126. Following treatment with ICR191, IL-3-independent clones were recovered and studied by cell fusion. With 21/22 clones, IL-3 independence resulted from a recessive mechanism as cellular hybrids with parental cells reverted to IL-3 dependence. Recessive clone D2c displayed increased phospho-Erk1/2 levels and was growth sensitive to U0126, but not to BAY43-9006. The single dominant clone, D5a, showed no signs of mitogen-activated protein kinases pathway activation but displayed constitutive phosphorylation of Stat5. We conclude that PB-3c has several options to acquire IL-3 growth autonomy involving transcriptional or posttranscriptional mechanisms affecting the distal regulators Erk or Stat5. The reported panel of independent dominant and recessive transformants should provide a useful tool for inhibitor profiling.	Univ Basel, Dept Clin Biol Sci, Inst Med Microbiol, CH-4051 Basel, Switzerland	University of Basel	Moroni, C (corresponding author), Univ Basel, Dept Clin Biol Sci, Inst Med Microbiol, Peterspl 10, CH-4051 Basel, Switzerland.	christoph.moroni@unibas.ch						ALGATE PA, 1993, ONCOGENE, V8, P1221; ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; Benjamin D, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh086; Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Blalock WL, 2000, ONCOGENE, V19, P526, DOI 10.1038/sj.onc.1203337; DANDREA R, 1994, BLOOD, V83, P2802, DOI 10.1182/blood.V83.10.2802.2802; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HANNEMANN J, 1995, MOL CELL BIOL, V15, P2402; Hayakawa F, 2000, ONCOGENE, V19, P624, DOI 10.1038/sj.onc.1203354; HIRSCH HH, 1993, J EXP MED, V178, P403, DOI 10.1084/jem.178.2.403; Hoyle PE, 2000, LEUKEMIA, V14, P642, DOI 10.1038/sj.leu.2401720; IHLE JN, 1981, J IMMUNOL, V127, P2565; Jiang XY, 2002, BLOOD, V100, P3731, DOI 10.1182/blood-2002-05-1324; Joung YH, 2003, EXP MOL MED, V35, P350, DOI 10.1038/emm.2003.46; Liu CB, 1999, J BIOL CHEM, V274, P6342, DOI 10.1074/jbc.274.10.6342; McCormack MP, 1997, BLOOD, V90, P1471, DOI 10.1182/blood.V90.4.1471.1471_1471_1481; McCubrey JA, 2004, ONCOGENE, V23, P7810, DOI 10.1038/sj.onc.1208055; McCubrey JA, 1998, LEUKEMIA, V12, P1903, DOI 10.1038/sj.leu.2401215; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nagata Y, 1996, BIOCHEM BIOPH RES CO, V221, P785, DOI 10.1006/bbrc.1996.0674; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; Nosaka T, 2002, EXP HEMATOL, V30, P697, DOI 10.1016/S0301-472X(02)00808-1; Onishi M, 1996, BLOOD, V88, P1399, DOI 10.1182/blood.V88.4.1399.bloodjournal8841399; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Onishi M, 1996, EXP HEMATOL, V24, P324; OVERELL RW, 1987, MOL CELL BIOL, V7, P3394, DOI 10.1128/MCB.7.10.3394; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; Shelton JG, 2003, ONCOGENE, V22, P2478, DOI 10.1038/sj.onc.1206321; SHOUNAN Y, 1995, EXP HEMATOL, V23, P492; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; Stoecklin G, 2003, ONCOGENE, V22, P3554, DOI 10.1038/sj.onc.1206418; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; Stoecklin G, 2002, EMBO J, V21, P4709, DOI 10.1093/emboj/cdf444; Testa U, 2004, LEUKEMIA, V18, P219, DOI 10.1038/sj.leu.2403224; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0	38	4	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2006	25	50					6595	6603		10.1038/sj.onc.1209673	http://dx.doi.org/10.1038/sj.onc.1209673			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16702946				2022-12-25	WOS:000241569700004
J	Vijayakumar, S; Merkx-Jacques, A; Ratnayake, DB; Gryski, I; Obhi, RK; Houle, S; Dozois, CM; Creuzenet, C				Vijayakumar, Somalinga; Merkx-Jacques, Alexandra; Ratnayake, Dinath B.; Gryski, Irene; Obhi, Ravinder Kaur; Houle, Sebastien; Dozois, Charles M.; Creuzenet, Carole			Cj1121c, a novel UDP-4-keto-6-deoxy-GlcNAc C-4 aminotransferase essential for protein glycosylation and virulence in Campylobacter jejuni	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMIDINE DIPHOSPHATE 4-ACETAMIDO-4,6-DIDEOXYHEXOSES; GUILLAIN-BARRE-SYNDROME; PSEUDAMINIC ACID; EPITHELIAL-CELLS; FUNCTIONAL-CHARACTERIZATION; HELICOBACTER-PYLORI; ESCHERICHIA-COLI; 4-KETO-6-DEOXY-D-GLUCOSE TRANSAMINASE; BIOCHEMICAL-CHARACTERIZATION; SUBSTRATE-SPECIFICITY	Campylobacter jejuni produces glycoproteins that are essential for virulence. These glycoproteins carry diacetamidobacillosamine (DAB), a sugar that is not found in humans. Hence, the enzymes responsible for DAB synthesis represent potential therapeutic targets. We describe the biochemical characterization of Cj1121c, a putative aminotransferase encoded by the general protein glycosylation locus, to assess its role in DAB biosynthesis. By using overexpressed and affinity-purified enzyme, we demonstrate that Cj1121c has pyridoxal phosphate- and glutamate-dependent UDP-4-keto-6-deoxy-GlcNAc C-4 transaminase activity and produces UDP-4-amino-4,6-dideoxy-GlcNAc. This is consistent with a role in DAB biosynthesis and distinguishes Cj1121c from Cj1294, a homologous UDP-2-acetamido-2,6-dideoxy-beta-L-arabino-4-hexulose C-4 aminotransferase that we characterized previously. We show that Cj1121c can also use this 4-keto-arabino sugar indirectly as a substrate, that Cj1121c and Cj1294 are active simultaneously in C. jejuni, and that the activity of Cj1121c is preponderant under standard growth conditions. Kinetic data indicate that Cj1121c has a slightly higher catalytic efficiency than Cj1294 with regard to the 4-keto-arabino substrate. By site-directed mutagenesis, we show that residues Glu-158 and Leu-131 are not essential for catalysis or for substrate specificity contrary to expectations. We further demonstrate that a Cj1121c knock-out mutant is impaired for flagella-mediated motility, for invasion of intestinal epithelial cells, and for persistence in the chicken intestine, clearly demonstrating that Cj1121c is essential for host colonization and virulence. Finally, we show that Cj1121c is necessary for protein glycosylation by lectin Western blotting. Collectively, these results validate Cj1121c as a promising drug target and provide the means to assay for inhibitors.	Univ Western Ontario, Infect Dis Res Grp, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada; INRS Energie, Inst Armand Frappier, Laval, PQ H7V 1B7, Canada	Western University (University of Western Ontario); University of Quebec; Institut national de la recherche scientifique (INRS)	Creuzenet, C (corresponding author), Univ Western Ontario, Infect Dis Res Grp, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada.	ccreuzen@uwo.ca						AGRAWAL PK, 1992, PHYTOCHEMISTRY, V31, P3307, DOI 10.1016/0031-9422(92)83678-R; Albermann C, 2001, GLYCOBIOLOGY, V11, P655, DOI 10.1093/glycob/11.8.655; ASPINALL GO, 1992, J BACTERIOL, V174, P1324, DOI 10.1128/jb.174.4.1324-1332.1992; ASPINALL GO, 1994, INFECT IMMUN, V62, P2122, DOI 10.1128/IAI.62.5.2122-2125.1994; ASPINALL GO, 1994, BIOCHEMISTRY-US, V33, P241, DOI 10.1021/bi00167a032; Bacon DJ, 2001, MOL MICROBIOL, V40, P769, DOI 10.1046/j.1365-2958.2001.02431.x; Blaser M. J., 1997, J INFECT DIS S2, V176, P103; BLASER MJ, 1983, INFECT IMMUN, V42, P276, DOI 10.1128/IAI.42.1.276-284.1983; Breazeale SD, 2003, J BIOL CHEM, V278, P24731, DOI 10.1074/jbc.M304043200; Carrillo CD, 2004, J BIOL CHEM, V279, P20327, DOI 10.1074/jbc.M401134200; Chou WK, 2005, J BIOL CHEM, V280, P35922, DOI 10.1074/jbc.M507483200; Creuzenet C, 2000, J BIOL CHEM, V275, P34873, DOI 10.1074/jbc.M006369200; Creuzenet C, 2000, J BIOL CHEM, V275, P19060, DOI 10.1074/jbc.M001171200; Creuzenet C, 2004, FEBS LETT, V559, P136, DOI 10.1016/S0014-5793(04)00057-2; Creuzenet C, 2001, MOL MICROBIOL, V41, P1295, DOI 10.1046/j.1365-2958.2001.02589.x; Demendi M, 2005, BIOCHEM J, V389, P173, DOI 10.1042/BJ20050263; Eads JC, 1999, BIOCHEMISTRY-US, V38, P9840, DOI 10.1021/bi990018q; Engberg J, 2001, EMERG INFECT DIS, V7, P24, DOI 10.3201/eid0701.010104; Gibreel A, 1998, ANTIMICROB AGENTS CH, V42, P3276, DOI 10.1128/AAC.42.12.3276; Goon S, 2003, MOL MICROBIOL, V50, P659, DOI 10.1046/j.1365-2958.2003.03725.x; Hickey TE, 2000, INFECT IMMUN, V68, P6535, DOI 10.1128/IAI.68.12.6535-6541.2000; Hwang BY, 2004, CHEM BIOL, V11, P915, DOI 10.1016/j.chembiol.2004.04.015; ISHIYAMA N, 2006, IN PRESS J BIOL CHEM; Jin SM, 2001, MOL MICROBIOL, V39, P1225, DOI 10.1046/j.1365-2958.2001.02294.x; Karlyshev AV, 2004, MICROBIOL-SGM, V150, P1957, DOI 10.1099/mic.0.26721-0; Kucerova D, 2002, INT J MOL MED, V10, P779; Larsen JC, 2004, J BACTERIOL, V186, P6508, DOI 10.1128/JB.186.19.6508-6514.2004; Linton D, 2005, MOL MICROBIOL, V55, P1695, DOI 10.1111/j.1365-2958.2005.04519.x; MATSUHASHI M, 1966, J BIOL CHEM, V241, P4738; Merkx-Jacques A, 2004, J BACTERIOL, V186, P2253, DOI 10.1128/JB.186.8.2253-2265.2004; Newton DT, 1999, BIOCHEM J, V339, P63, DOI 10.1042/0264-6021:3390063; NUIJTEN PJM, 1989, INFECT IMMUN, V57, P1084, DOI 10.1128/IAI.57.4.1084-1088.1989; Obhi RK, 2005, J BIOL CHEM, V280, P20902, DOI 10.1074/jbc.M413832200; OHASHI H, 1971, J BIOL CHEM, V246, P2325; Palyada K, 2004, J BACTERIOL, V186, P4714, DOI 10.1128/JB.186.14.4714-4729.2004; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; PEI ZH, 1993, J BIOL CHEM, V268, P18717; PEREZ GIP, 1985, INFECT IMMUN, V47, P353, DOI 10.1128/IAI.47.2.353-359.1985; Pfoestl A, 2003, J BIOL CHEM, V278, P26410, DOI 10.1074/jbc.M300858200; Schoenhofen IC, 2006, J BIOL CHEM, V281, P8907, DOI 10.1074/jbc.M512987200; Schoenhofen IC, 2006, J BIOL CHEM, V281, P723, DOI 10.1074/jbc.M511021200; SOMALINGA V, 2005, P 105 GEN M AM SOC M, P53; Song YC, 2004, MOL MICROBIOL, V53, P541, DOI 10.1111/j.1365-2958.2004.04175.x; Soo EC, 2004, ANAL CHEM, V76, P619, DOI 10.1021/ac034875i; Szymanski CM, 1999, MOL MICROBIOL, V32, P1022, DOI 10.1046/j.1365-2958.1999.01415.x; Szymanski CM, 2002, INFECT IMMUN, V70, P2242, DOI 10.1128/IAI.70.4.2242-2244.2002; Thibault P, 2001, J BIOL CHEM, V276, P34862, DOI 10.1074/jbc.M104529200; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Van Vliet AHM, 1998, METHOD MICROBIOL, V27, P407; Wacker M, 2002, SCIENCE, V298, P1790, DOI 10.1126/science.298.5599.1790; YAO RJ, 1993, GENE, V130, P127, DOI 10.1016/0378-1119(93)90355-7; Young NM, 2002, J BIOL CHEM, V277, P42530, DOI 10.1074/jbc.M206114200	52	30	32	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27733	27743		10.1074/jbc.M511714200	http://dx.doi.org/10.1074/jbc.M511714200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16690622	hybrid			2022-12-25	WOS:000240534400009
J	Mori, K; Asakawa, M; Hayashi, M; Imura, M; Ohki, T; Hirao, E; Kim-Kaneyama, JR; Nose, K; Shibanuma, M				Mori, Kazunori; Asakawa, Masayuki; Hayashi, Miki; Imura, Miwako; Ohki, Takahiro; Hirao, Etsuko; Kim-Kaneyama, Joo-ri; Nose, Kiyoshi; Shibanuma, Motoko			Oligomerizing potential of a focal adhesion LIM protein Hic-5 organizing a nuclear-cytoplasmic shuttling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-LINKED KINASE; CELL-SHAPE MODULATION; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID-RECEPTOR; MOLECULAR DISSECTION; PTP-PEST; PAXILLIN; BINDING; MATRIX; PINCH	Hic-5 is a focal adhesion LIM protein serving as a scaffold in integrin signaling. The protein comprises four LD domains in its N-terminal half and four LIM domains in its C-terminal half with a nuclear export signal in LD3 and is shuttled between the cytoplasmic and nuclear compartments. In this study, immunoprecipitation and in vitro cross-linking experiments showed that Hic-5 homo-oligomerized through its most C-terminal LIM domain, LIM4. Strikingly, paxillin, the protein most homologous to Hic-5, did not show this capability. Gel filtration analysis also revealed that Hic-5 differs from paxillin in that it has multiple forms in the cellular environment, and Hic-5 but not paxillin was capable of hetero-oligomerization with a LIM- only protein, PINCH, another molecular scaffold at focal adhesions. The fourth LIM domain of Hic-5 and the fifth LIM domain region of PINCH constituted the interface for the interaction. The complex included integrin-linked kinase, a binding partner of PINCH, which also interacted with Hic-5 through the region encompassing the pleckstrin homology-like domain and LIM domains of Hic-5. Of note, Hic-5 marginally affected the subcellular distribution of PINCH but directed its shuttling between the cytoplasmic and nuclear compartments in the presence of integrin-linked kinase. Uncoupling of the two signaling platforms of Hic-5 and PINCH through interference with the hetero-oligomerization resulted in impairment of cellular growth. Hic-5 is, thus, a molecular scaffold with the potential to dock with another scaffold through the LIM domain, organizing a mobile supramolecular unit and coordinating the adhesion signal with cellular activities in the two compartments.	Showa Univ, Sch Pharmaceut Sci, Dept Microbiol, Shinagawa Ku, Tokyo 1428555, Japan	Showa University	Shibanuma, M (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Microbiol, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	smotoko@pharm.showa-u.ac.jp		Mori, Kazunori/0000-0001-7121-9956				Campana WM, 2003, GLIA, V41, P213, DOI 10.1002/glia.10138; Chang DF, 2003, DEV CELL, V4, P107, DOI 10.1016/S1534-5807(02)00396-9; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Drori S, 2005, GENE DEV, V19, P362, DOI 10.1101/gad.1240705; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200; Guerrero-Santoro J, 2004, J CELL BIOCHEM, V92, P810, DOI 10.1002/jcb.20109; Ishino K, 2000, J CELL BIOCHEM, V76, P411, DOI 10.1002/(SICI)1097-4644(20000301)76:3<411::AID-JCB9>3.0.CO;2-J; Jia YF, 2001, J BIOL CHEM, V276, P39911, DOI 10.1074/jbc.M103510200; Kadrmas JL, 2004, NAT REV MOL CELL BIO, V5, P920, DOI 10.1038/nrm1499; Kim-Kaneyama J, 2005, J CELL SCI, V118, P937, DOI 10.1242/jcs.01683; Kim-Kaneyama J, 2002, BIOCHEM BIOPH RES CO, V299, P360, DOI 10.1016/S0006-291X(02)02644-X; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Li FG, 1999, J CELL SCI, V112, P4589; Li SH, 2005, J CELL SCI, V118, P2913, DOI 10.1242/jcs.02422; Matsuya M, 1998, J BIOL CHEM, V273, P1003, DOI 10.1074/jbc.273.2.1003; Nikolopoulos SN, 2002, J BIOL CHEM, V277, P1568, DOI 10.1074/jbc.M108612200; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Nishiya N, 1999, J BIOL CHEM, V274, P9847, DOI 10.1074/jbc.274.14.9847; Nishiya N, 2002, J BIOCHEM, V132, P279, DOI 10.1093/oxfordjournals.jbchem.a003222; Nishiya N, 1998, NUCLEIC ACIDS RES, V26, P4267, DOI 10.1093/nar/26.18.4267; Nishiya N, 2001, MOL CELL BIOL, V21, P5332, DOI 10.1128/MCB.21.16.5332-5345.2001; Sakai T, 2003, GENE DEV, V17, P926, DOI 10.1101/gad.255603; Shibanuma M, 2005, ANTIOXID REDOX SIGN, V7, P335, DOI 10.1089/ars.2005.7.335; Shibanuma M, 2004, J CELL BIOCHEM, V91, P633, DOI 10.1002/jcb.10754; Shibanuma M, 2003, MOL BIOL CELL, V14, P1158, DOI 10.1091/mbc.02-06-0099; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Takahashi RH, 2004, J NEUROSCI, V24, P3592, DOI 10.1523/JNEUROSCI.5167-03.2004; Thomas SM, 1999, J CELL SCI, V112, P181; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Wang H, 2005, J BIOL CHEM, V280, P5154, DOI 10.1074/jbc.M411575200; Woods AJ, 2002, J BIOL CHEM, V277, P6428, DOI 10.1074/jbc.M109446200; Wu CY, 2005, TRENDS CELL BIOL, V15, P460, DOI 10.1016/j.tcb.2005.07.002; Wu RF, 2005, J CELL BIOL, V171, P893, DOI 10.1083/jcb.200507004; Xu Z, 2005, J BIOL CHEM, V280, P27631, DOI 10.1074/jbc.M504189200; Yang L, 2000, MOL BIOL CELL, V11, P2007, DOI 10.1091/mbc.11.6.2007; Zhang YJ, 2002, J BIOL CHEM, V277, P318, DOI 10.1074/jbc.M108257200	38	19	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22048	22061		10.1074/jbc.M513111200	http://dx.doi.org/10.1074/jbc.M513111200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16737959	hybrid			2022-12-25	WOS:000239387100052
J	Gehret, AU; Bajaj, A; Naider, F; Dumont, ME				Gehret, Austin U.; Bajaj, Anshika; Naider, Fred; Dumont, Mark E.			Oligomerization of the yeast alpha-factor receptor - Implications for dominant negative effects of mutant receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; RESONANCE ENERGY-TRANSFER; LIVING CELLS; SACCHAROMYCES-CEREVISIAE; TRANSMEMBRANE SEGMENTS; TRANSFER BRET; PHEROMONE RECEPTOR; EXTRACELLULAR ENDS; OPIOID RECEPTORS; C-TERMINUS	Oligomerization of G protein-coupled receptors is commonly observed, but the functional significance of oligomerization for this diverse family of receptors remains poorly understood. We used bioluminescence resonance energy transfer ( BRET) to examine oligomerization of Ste2p, a G protein-coupled receptor that serves as the receptor for the alpha-mating pheromone in the yeast Saccharomyces cerevisiae, under conditions where the functional effects of oligomerization could be examined. Consistent with previous results from fluorescence resonance energy transfer ( Overton, M. C., and Blumer, K. J. ( 2000) Curr. Biol. 10, 341 - 344), we detected efficient energy transfer between Renilla luciferase and a modified green fluorescent protein individually fused to truncated alpha-factor receptors lacking the cytoplasmic C- terminal tail. In addition, the low background of the BRET system allowed detection of significant, but less efficient, energy transfer between full-length receptors. The reduced efficiency of energy transfer between full-length receptors does not appear to result from different levels of receptor expression. Instead, attachment of fluorescent reporter proteins to the full-length receptors appears to significantly increase the distance between reporters. Mutations that were previously reported to block dimerization of truncated alpha-factor receptors reduce but do not completely eliminate BRET transfer between receptors. Dominant negative effects of mutant alleles of alpha-factor receptors appear to be mediated by receptor oligomerization since these effects are abrogated by introduction of additional mutations that reduce oligomerization. We find that heterodimers of normal and dominant negative receptors are defective in their ability to signal. Thus, signal transduction by oligomeric receptors appears to be a cooperative process requiring an interaction between functional monomers.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; CUNY Coll Staten Isl, Dept Chem, Staten Isl, NY 10314 USA	University of Rochester; City University of New York (CUNY) System; College of Staten Island (CUNY)	Dumont, ME (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, POB 712, Rochester, NY 14642 USA.	mark_dumont@urmc.rochester.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059357, R01GM022086, R56GM022086] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59357, GM22086] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Arai R, 2001, ANAL BIOCHEM, V289, P77, DOI 10.1006/abio.2000.4924; Bajaj A, 2004, BIOCHEMISTRY-US, V43, P13564, DOI 10.1021/bi0494018; Bernier V, 2004, MOL ENDOCRINOL, V18, P2074, DOI 10.1210/me.2004-0080; Bertrand L, 2002, J RECEPT SIGNAL TR R, V22, P533, DOI 10.1081/RRS-120014619; Boute N, 2001, MOL PHARMACOL, V60, P640; Bulenger S, 2005, TRENDS PHARMACOL SCI, V26, P131, DOI 10.1016/j.tips.2005.01.004; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; Chinault SL, 2004, J BIOL CHEM, V279, P16091, DOI 10.1074/jbc.M311099200; Devi LA, 2001, TRENDS PHARMACOL SCI, V22, P532, DOI 10.1016/S0165-6147(00)01799-5; Dosil M, 2000, MOL CELL BIOL, V20, P5321, DOI 10.1128/MCB.20.14.5321-5329.2000; Dosil M, 1998, MOL CELL BIOL, V18, P5981, DOI 10.1128/MCB.18.10.5981; Gelperin DM, 2005, GENE DEV, V19, P2816, DOI 10.1101/gad.1362105; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Herrick-Davis K, 2005, J BIOL CHEM, V280, P40144, DOI 10.1074/jbc.M507396200; Jansen LET, 1998, J BIOL CHEM, V273, P33111, DOI 10.1074/jbc.273.50.33111; Jendeberg L, 1996, BIOCHEMISTRY-US, V35, P22, DOI 10.1021/bi9512814; Jensen AA, 2002, EUR J BIOCHEM, V269, P5076, DOI 10.1046/j.1432-1033.2002.03218.x; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; Law PY, 2005, J BIOL CHEM, V280, P11152, DOI 10.1074/jbc.M500171200; Leavitt LM, 1999, MOL GEN GENET, V261, P917, DOI 10.1007/s004380051039; Lin JC, 2003, BIOCHEMISTRY-US, V42, P293, DOI 10.1021/bi026766o; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14649, DOI 10.1073/pnas.251554498; Martin NP, 1999, BIOCHEMISTRY-US, V38, P682, DOI 10.1021/bi982062w; Mellado M, 1999, NATURE, V400, P723, DOI 10.1038/23382; Melnyk RA, 2004, J BIOL CHEM, V279, P16591, DOI 10.1074/jbc.M313936200; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Mulholland J, 1999, MOL BIOL CELL, V10, P799, DOI 10.1091/mbc.10.3.799; Nelson G, 2002, NATURE, V416, P199, DOI 10.1038/nature726; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Overton MC, 2003, J BIOL CHEM, V278, P49369, DOI 10.1074/jbc.M308654200; Overton MC, 2002, J BIOL CHEM, V277, P41463, DOI 10.1074/jbc.M205368200; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Pfleger KDG, 2005, BIOCHEM J, V385, P625, DOI 10.1042/BJ20041361; Ramsay D, 2002, BIOCHEM J, V365, P429, DOI 10.1042/BJ20020251; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; Rios CD, 2001, PHARMACOL THERAPEUT, V92, P71, DOI 10.1016/S0163-7258(01)00160-7; Rose MD., 1990, METHODS YEAST GENETI; Salahpour A, 2004, J BIOL CHEM, V279, P33390, DOI 10.1074/jbc.M403363200; SERRANO R, 1978, MOL CELL BIOCHEM, V22, P51; Shah A, 1996, BIOCHEM BIOPH RES CO, V226, P242, DOI 10.1006/bbrc.1996.1340; Sommers CM, 2000, BIOCHEMISTRY-US, V39, P6898, DOI 10.1021/bi992616a; Sommers CM, 1997, J MOL BIOL, V266, P559, DOI 10.1006/jmbi.1996.0816; Springael JY, 2005, CYTOKINE GROWTH F R, V16, P611, DOI 10.1016/j.cytogfr.2005.05.005; Stefan CJ, 1999, J BIOL CHEM, V274, P1835, DOI 10.1074/jbc.274.3.1835; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719; Svartz J, 2003, BBA-MOL CELL BIOL L, V1633, P90, DOI 10.1016/S1388-1981(03)00091-X; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Wang DX, 2005, MOL PHARMACOL, V67, P2173, DOI 10.1124/mol.104.010272; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; Yesilaltay A, 2000, MOL BIOL CELL, V11, P2873, DOI 10.1091/mbc.11.9.2873; Zhou FG, 2006, CELL SIGNAL, V18, P318, DOI 10.1016/j.cellsig.2005.05.014; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	60	48	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20698	20714		10.1074/jbc.M513642200	http://dx.doi.org/10.1074/jbc.M513642200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16709573	hybrid			2022-12-25	WOS:000239187300007
J	Luo, YD; Ye, S; Kan, MK; McKeehan, WL				Luo, Yongde; Ye, Sheng; Kan, Mikio; McKeehan, Wallace L.			Control of fibroblast growth factor (FGF) 7-and FGF1-induced mitogenesis and downstream signaling by distinct heparin octasaccharide motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN/HEPARAN SULFATE; CRYSTAL-STRUCTURE; BINDING-SITES; RECEPTOR; COMPLEX; SPECIFICITY; BIOACTIVITY; ECTODOMAIN; DIVERSITY; INTERACT	Variation in length, disaccharide composition, and sulfation of heparan sulfate (HS) affects fibroblast growth factor (FGF) signaling. However, it is unclear whether the specific distribution of groups within oligosaccharides or random variations in charge density underlies the effects. Recently we showed that a mixture of undersulfated octasaccharides exhibiting 7 and 8 sulfates (7,8-S-OctaF7) generated from heparin had the highest affinity for FGF7 monitored by salt resistance (> 0.60 M salt) of octasaccharide-FGF7 complexes. 7,8-S-OctaF7 also had the highest specific activity for formation of a complex with dimeric FGFR2IIIb competent to bind FGF7. Here we show that when endogenous HS was inhibited by chlorate treatment, 7,8-S-OctaF7 specifically supported FGF7-stimulated DNA synthesis and downstream signaling in FGFR2IIIb-expressing mouse keratinocytes. It failed to support FGF1 signaling in both HS-deficient mouse keratinocytes and 3T3 fibroblasts. In contrast, abundant, more highly sulfated and heterogenous mixtures of octasaccharides with lower affinity (0.30-0.60 M salt) for FGF7 supported FGF1-induced signaling in both cell types. In contrast to the two-component 7,8-S-OctaF7 mixture from FGF7, the high affinity octasaccharide fraction from FGF1 was a heterogeneous mixture with components ranging from 8 to 12 sulfates with 11-S-octasaccharides the most abundant. The high affinity fraction exhibited similar properties to the lower affinity fractions from both FGF1 and FGF7. Octasaccharide mixtures eluting from FGF1 between 0.30 and 0.60 M and above 0.60 M salt were nearly equal in support of FGF1 signaling in fibroblasts and keratinocytes. Both were deficient in support of FGF7-induced signaling in keratinocytes. The results show that both variations in overall charge density and specific distribution of charged groups within HS motifs exhibit FGF-specific control over formation of FGF-HS-FGFR complexes and downstream signaling.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Syst Hlth Sci Ctr, Ctr Canc Biol & Nutr, Inst Biosci & Technol, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Zeria Pharmaceut Co Ltd, GS PlatZ, Osato, Saitama 3600111, Japan	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Zeria Pharmaceutical Co Ltd	McKeehan, WL (corresponding author), 2121 W Holcombe Blvd, Houston, TX 77030 USA.	wmckeehan@ibt.tamhsc.edu			NATIONAL CANCER INSTITUTE [R01CA059971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035310] Funding Source: NIH RePORTER; NCI NIH HHS [CA59971] Funding Source: Medline; NIDDK NIH HHS [DK35310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashikari-Hada S, 2004, J BIOL CHEM, V279, P12346, DOI 10.1074/jbc.M313523200; Berman B, 1999, J BIOL CHEM, V274, P36132, DOI 10.1074/jbc.274.51.36132; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Chu CL, 2005, BIOCHEMISTRY-US, V44, P12203, DOI 10.1021/bi050241p; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Ford-Perriss M, 2002, GLYCOBIOLOGY, V12, P721, DOI 10.1093/glycob/cwf072; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; Itoh N, 2004, TRENDS GENET, V20, P563, DOI 10.1016/j.tig.2004.08.007; Jang JH, 1997, IN VITRO CELL DEV-AN, V33, P819; Jeffers Michael, 2002, Expert Opin Ther Targets, V6, P469, DOI 10.1517/14728222.6.4.469; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; Kan M, 1999, J BIOL CHEM, V274, P15947, DOI 10.1074/jbc.274.22.15947; Kan M, 1996, J BIOL CHEM, V271, P26143, DOI 10.1074/jbc.271.42.26143; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Kreuger J, 2005, BIOCHEM J, V389, P145, DOI 10.1042/BJ20042129; LaRochelle WJ, 1999, BIOCHEMISTRY-US, V38, P1765, DOI 10.1021/bi982092z; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Linhardt RJ, 2003, J MED CHEM, V46, P2551, DOI 10.1021/jm030176m; Loo BM, 2001, J BIOL CHEM, V276, P16868, DOI 10.1074/jbc.M011226200; Lu WQ, 1999, J BIOL CHEM, V274, P12827, DOI 10.1074/jbc.274.18.12827; Luo YD, 1996, J BIOL CHEM, V271, P26876, DOI 10.1074/jbc.271.43.26876; Luo YD, 2006, J CELL BIOCHEM, V97, P1241, DOI 10.1002/jcb.20724; Luo YD, 1998, BIOCHEMISTRY-US, V37, P16506, DOI 10.1021/bi9816599; Luo YD, 2004, PROTEIN EXPRES PURIF, V33, P326, DOI 10.1016/j.pep.2003.10.013; Luo YD, 2003, J PHARM SCI-US, V92, P2117, DOI 10.1002/jps.10472; McKeehan WL, 1999, J BIOL CHEM, V274, P21511, DOI 10.1074/jbc.274.31.21511; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Mulloy B, 2001, CURR OPIN STRUC BIOL, V11, P623, DOI 10.1016/S0959-440X(00)00257-8; Ornitz DM, 2001, GENOME BIOL, V2; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Powell AK, 2002, J BIOL CHEM, V277, P28554, DOI 10.1074/jbc.M111754200; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; REICHSLOTKY R, 1994, J BIOL CHEM, V269, P32279; RON D, 1993, J BIOL CHEM, V268, P2984; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUSNATI M, 1994, BIOCHEM BIOPH RES CO, V203, P450, DOI 10.1006/bbrc.1994.2203; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Wu ZLL, 2003, J BIOL CHEM, V278, P17121, DOI 10.1074/jbc.M212590200; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; Yates EA, 2004, J MED CHEM, V47, P277, DOI 10.1021/jm0309755; Ye S, 2001, BIOCHEMISTRY-US, V40, P14429, DOI 10.1021/bi011000u	46	31	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21052	21061		10.1074/jbc.M601559200	http://dx.doi.org/10.1074/jbc.M601559200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16728399	hybrid			2022-12-25	WOS:000239187300042
J	Oh, RS; Bai, XL; Rommens, JM				Oh, Ray S.; Bai, Xinli; Rommens, Johanna M.			Human homologs of Ubc6p ubiquitin-conjugating enzyme and phosphorylation of HsUbc6e in response to endoplasmic reticulum stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; CELL-RECEPTOR SUBUNITS; PROTEASOME PATHWAY; MEMBRANE-PROTEIN; TRANSLATIONAL CONTROL; ER DEGRADATION; (ER)-ASSOCIATED DEGRADATION; SACCHAROMYCES-CEREVISIAE; SECRETORY PROTEIN; MAMMALIAN UBC7	Ubiquitin-conjugating enzyme Ubc6p is a tail-anchored protein that is localized to the cytoplasmic face of the endoplasmic reticulum ( ER) membrane and has been implicated in the degradation of many misfolded membrane proteins in yeast. We have undertaken characterization studies of two human homologs, hsUbc6 and hsUbc6e. Both possess tail-anchored protein motifs, display high conservation in their catalytic domains, and are functional ubiquitin-conjugating enzymes as determined by in vitro thiol-ester assay. Both also display induction by the unfolded protein response, a feature of many ER-associated degradation (ERAD) components. Post-translational modification involving phosphorylation of hsUbc6e was observed to be ER-stress-related and dependent on signaling of the PRK-like ER kinase ( PERK). The phosphorylation site was mapped to Ser-184, which resides within the uncharacterized region linking the highly conserved catalytic core and the C-terminal transmembrane domain. Phosphorylation of hsUbc6e also did not alter stability, subcellular localization, or interaction with a partner ubiquitin-protein isopeptide ligase. Assays of hsUbc6e(S184D) and hsUbc6e(S184E), which mimic the phosphorylated state, suggest that phosphorylation may reduce capacity for forming ubiquitin-enzyme thiol-esters. The occurrence of two distinct Ubc6p homologs in vertebrates, including one with phosphorylation modification in response to ER stress, emphasizes diversity in function between these Ub-conjugating enzymes during ERAD processes.	Hosp Sick Children, Program Genet & Genom Biol, Toronto, ON M5G 1L7, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Rommens, JM (corresponding author), Hosp Sick Children, Program Genet & Genom Biol, 101 Coll St,East Tower, Toronto, ON M5G 1L7, Canada.	jrommens@sickkids.ca	Rommens, Johanna/AAT-7465-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049096] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49096] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Galan JM, 1998, FASEB J, V12, P315, DOI 10.1096/fasebj.12.3.315; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hodgins R, 1996, J BIOL CHEM, V271, P28766, DOI 10.1074/jbc.271.46.28766; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Khan MM, 2004, J BIOL CHEM, V279, P11814, DOI 10.1074/jbc.M312121200; Kim BW, 2003, MOL ENDOCRINOL, V17, P2603, DOI 10.1210/me.2003-0082; Lenk U, 2002, J CELL SCI, V115, P3007; Lester D, 2000, BIOCHEM BIOPH RES CO, V269, P474, DOI 10.1006/bbrc.2000.2302; Loayza D, 1998, MOL BIOL CELL, V9, P2767, DOI 10.1091/mbc.9.10.2767; Mathias N, 1998, J BIOL CHEM, V273, P4040, DOI 10.1074/jbc.273.7.4040; Merkley N, 2003, J BIOMOL NMR, V26, P147, DOI 10.1023/A:1023571703783; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; PROSTKO CR, 1992, J BIOL CHEM, V267, P16751; Proud CG, 2005, SEMIN CELL DEV BIOL, V16, P3, DOI 10.1016/j.semcdb.2004.11.004; Ravid T, 2000, J BIOL CHEM, V275, P35840, DOI 10.1074/jbc.M004793200; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Sambrook J, 2001, MOL CLONING LAB MANU; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Semplici F, 2002, ONCOGENE, V21, P3978, DOI 10.1038/sj.onc.1205574; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; Tiwari S, 2001, J BIOL CHEM, V276, P16193, DOI 10.1074/jbc.M007640200; Walter J, 2001, EMBO J, V20, P3124, DOI 10.1093/emboj/20.12.3124; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Webster JM, 2003, J BIOL CHEM, V278, P38238, DOI 10.1074/jbc.M305600200; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wu CJ, 2005, EMBO J, V24, P1886, DOI 10.1038/sj.emboj.7600649; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Younger JM, 2004, J CELL BIOL, V167, P1075, DOI 10.1083/jcb.200410065; Zhang PC, 2002, MOL CELL BIOL, V22, P3864, DOI 10.1128/MCB.22.11.3864-3874.2002; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	55	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21480	21490		10.1074/jbc.M601843200	http://dx.doi.org/10.1074/jbc.M601843200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16720581	hybrid			2022-12-25	WOS:000239187300083
J	Witola, WH; Pessi, G; El Bissati, K; Reynolds, JM; Ben Mamoun, C				Witola, William H.; Pessi, Gabriella; El Bissati, Kamal; Reynolds, Jennifer M.; Ben Mamoun, Choukri			Localization of the phosphoethanolamine methyltransferase of the human malaria parasite Plasmodium falciparum to the Golgi apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-METABOLISM; ANTIMALARIAL ACTIVITY; ENDOPLASMIC-RETICULUM; N-METHYLTRANSFERASE; BIOSYNTHESIS; IDENTIFICATION; APICOPLAST; YEAST	Phosphatidylcholine is the most abundant phospholipid in the membranes of Plasmodium falciparum, the agent of severe human malaria. The synthesis of this phospholipid occurs via two routes, the CDP-choline pathway, which uses host choline as a precursor, and the plant-like serine decarboxylase-phosphoethanolamine methyltransferase (SDPM) pathway, which uses host serine as a precursor. Although various components of these pathways have been identified, their cellular locations remain unknown. We have previously reported the identification and characterization of the phosphoethanolamine methyltransferase, Pfpmt, of P. falciparum and shown that it plays a critical role in the synthesis of phosphatidylcholine via the SDPM pathway. Here we provide the first evidence that the transmethylation step of the SDPM pathway occurs in the parasite Golgi apparatus. We show that the level of Pfpmt protein in the infected erythrocyte is regulated in a stage-specific fashion, with high levels detected during the trophozoite stage at the peak of parasite membrane biogenesis. Confocal microscopy revealed that Pfpmt is not cytoplasmic. Immunoelectron microscopy revealed that Pfpmt localizes to membrane structures that extend from the nuclear membrane but that it only partially co-localizes with the endoplasmic reticulum marker BiP. Using transgenic parasites expressing green fluorescent protein targeted to different cellular compartments, a complete co-localization was detected with Rab6, a marker of the Golgi apparatus. Together these studies provide the first evidence that the transmethylation step of the SDPM pathway of P. falciparum occurs in the Golgi apparatus and indicate an important role for this organelle in parasite membrane biogenesis.	Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA	University of Connecticut	Ben Mamoun, C (corresponding author), Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, 263 Farmington Ave, Farmington, CT 06030 USA.	Choukri@up.uchc.edu	Witola, WIlliam Harold/AAD-6647-2020; Pessi, Gabriella/AGW-2342-2022	Pessi, Gabriella/0000-0002-8138-5541; EL BISSATI, KAMAL/0000-0001-9341-4162	NCRR NIH HHS [M01RR06192] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR006192] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ancelin ML, 2003, ANTIMICROB AGENTS CH, V47, P2590, DOI 10.1128/AAC.47.8.2590-2597.2003; Ancelin ML, 1998, BLOOD, V91, P1426, DOI 10.1182/blood.V91.4.1426; Ben Mamoun C, 1998, J BIOL CHEM, V273, P11241, DOI 10.1074/jbc.273.18.11241; Bolognese CP, 2000, PLANT PHYSIOL, V124, P1800, DOI 10.1104/pp.124.4.1800; Calas M, 2000, J MED CHEM, V43, P505, DOI 10.1021/jm9911027; Calas M, 1997, J MED CHEM, V40, P3557, DOI 10.1021/jm9701886; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; Charron JBF, 2002, PLANT PHYSIOL, V129, P363, DOI 10.1104/pp.001776; deCastro FA, 1996, MOL BIOCHEM PARASIT, V80, P77, DOI 10.1016/0166-6851(96)02670-9; Fidock DA, 1998, MOL PHARMACOL, V54, P1140, DOI 10.1124/mol.54.6.1140; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; Foth BJ, 2003, SCIENCE, V299, P705, DOI 10.1126/science.1078599; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Krishna S, 1997, BMJ-BRIT MED J, V315, P730, DOI 10.1136/bmj.315.7110.730; MAGO N, 1990, J MED VET MYCOL, V28, P355; Mamoun CB, 2001, MOL MICROBIOL, V39, P26, DOI 10.1046/j.1365-2958.2001.02222.x; Nuccio ML, 2000, J BIOL CHEM, V275, P14095, DOI 10.1074/jbc.275.19.14095; Pessi G, 2005, J BIOL CHEM, V280, P12461, DOI 10.1074/jbc.M414626200; Pessi G, 2004, P NATL ACAD SCI USA, V101, P6206, DOI 10.1073/pnas.0307742101; Rager N, 2001, J BIOL CHEM, V276, P41095, DOI 10.1074/jbc.M107037200; Roggero R, 2004, ANTIMICROB AGENTS CH, V48, P2816, DOI 10.1128/AAC.48.8.2816-2824.2004; Santiago TC, 2004, J BIOL CHEM, V279, P9222, DOI 10.1074/jbc.M310502200; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; van Dooren GG, 2005, MOL MICROBIOL, V57, P405, DOI 10.1111/j.1365-2958.2005.04699.x; Vance JE, 2004, BIOCHEM CELL BIOL, V82, P113, DOI 10.1139/o03-073; VanWye J, 1996, MOL BIOCHEM PARASIT, V83, P107, DOI 10.1016/S0166-6851(96)02759-4; Vial HJ, 2005, MOLECULAR APPROACHES TO MALARIA, P327; Wengelnik K, 2002, SCIENCE, V295, P1311, DOI 10.1126/science.1067236; WHO Expert Committee on Malaria, 2000, WHO TECH REP SER, V892, P1	29	33	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21305	21311		10.1074/jbc.M603260200	http://dx.doi.org/10.1074/jbc.M603260200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16704982	hybrid			2022-12-25	WOS:000239187300066
J	Dinadayala, P; Kaur, D; Berg, S; Amin, AG; Vissa, VD; Chatterjee, D; Brennan, PJ; Crick, DC				Dinadayala, Premkumar; Kaur, Devinder; Berg, Stefan; Amin, Anita G.; Vissa, Varalakshmi D.; Chatterjee, Delphi; Brennan, Patrick J.; Crick, Dean C.			Genetic basis for the synthesis of the immunomodulatory mannose caps of lipoarabinomannan in Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRUNCATED STRUCTURAL VARIANTS; NONREDUCING TERMINI; CELL-WALLS; BOVIS BCG; BIOSYNTHESIS; LIPOMANNAN; RECOGNITION; ETHAMBUTOL; STRAINS; ARABINOGALACTAN	Lipoarabinomannan ( LAM) is a high molecular weight, heterogenous lipoglycan present in abundant quantities in Mycobacterium tuberculosis and many other actinomycetes. In M. tuberculosis, the non-reducing arabinan termini of the LAM are capped with alpha 1 -> 2 mannose residues; in some other species, the arabinan of LAM is not capped or is capped with inositol phosphate. The nature and extent of this capping plays an important role in disease pathogenesis. MT1671 in M. tuberculosis CDC1551 was identified as a glycosyltransferase that could be involved in LAM capping. To determine the function of this protein a mutant strain of M. tuberculosis CDC1551 was studied, in which MT1671 was disrupted by transposition. SDS-PAGE analysis showed that the LAM of the mutant strain migrated more rapidly than that of the wild type and did not react with concanavalin A as did wild-type LAM. Structural analysis using NMR, gas chromatography/mass spectrometry, endoarabinanase digestion, Dionex high pH anion exchange chromatography, and matrix-assisted laser desorption ionization-time-of-flight mass spectrometry demonstrated that the LAM of the mutant strain was devoid of mannose capping. Since an ortholog of MT1671 is not present in Mycobacterium smegmatis mc(2)155, a recombinant strain was constructed that expressed this protein. Analysis revealed that the LAM of the recombinant strain was larger than that of the wild type, had gained concanavalin A reactivity, and that the arabinan termini were capped with a single mannose residue. Thus, MT1671 is the mannosyltransferase involved in deposition of the first of the mannose residues on the non-reducing arabinan termini and the basis of much of the interaction between the tubercle bacillus and the host cell.	Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA	Colorado State University	Crick, DC (corresponding author), Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.	dean.crick@colostate.edu	Berg, Stefan/AAU-6463-2020; Crick, Dean/H-8251-2017; Berg, Stefan O/D-3847-2011	Berg, Stefan/0000-0002-3470-7579; Crick, Dean/0000-0001-9281-7058; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018357, R22AI018357, R56AI049151, R37AI018357, R01AI037139, R01AI049151, R01AI064798, R21AI037139] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37139, AI64798, AI49151, AI18357] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berg S, 2005, J BIOL CHEM, V280, P5651, DOI 10.1074/jbc.M411418200; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; Briken V, 2004, MOL MICROBIOL, V53, P391, DOI 10.1111/j.1365-2958.2004.04183.x; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; CHATTERJEE D, 1993, GLYCOBIOLOGY, V3, P497, DOI 10.1093/glycob/3.5.497; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; Chen P, 2000, INFECT IMMUN, V68, P5575, DOI 10.1128/IAI.68.10.5575-5580.2000; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Dao DN, 2004, INFECT IMMUN, V72, P2067, DOI 10.1128/IAI.72.4.2067-2074.2004; DELL A, 1994, METHOD ENZYMOL, V230, P108; Delmas C, 1997, GLYCOBIOLOGY, V7, P811, DOI 10.1093/glycob/7.6.811; Gibson KJC, 2003, J BIOL CHEM, V278, P40842, DOI 10.1074/jbc.M307988200; Gilleron M, 1997, J BIOL CHEM, V272, P117; Guerardel Y, 2003, J BIOL CHEM, V278, P36637, DOI 10.1074/jbc.M305427200; Guerardel Y, 2002, J BIOL CHEM, V277, P30635, DOI 10.1074/jbc.M204398200; Kaur D, 2002, MICROBIOL-SGM, V148, P3049, DOI 10.1099/00221287-148-10-3049; Khoo HH, 2001, J BIOL CHEM, V276, P3863, DOI 10.1074/jbc.M004010200; KHOO KH, 1995, J BIOL CHEM, V270, P12380, DOI 10.1074/jbc.270.21.12380; Khoo KH, 1996, J BIOL CHEM, V271, P28682, DOI 10.1074/jbc.271.45.28682; KHOO KH, 1995, GLYCOBIOLOGY, V5, P117, DOI 10.1093/glycob/5.1.117; Lamichhane G, 2003, P NATL ACAD SCI USA, V100, P7213, DOI 10.1073/pnas.1231432100; Liu J, 2003, PROTEIN SCI, V12, P1418, DOI 10.1110/ps.0302103; Maeda N, 2003, J BIOL CHEM, V278, P5513, DOI 10.1074/jbc.C200586200; MCNEIL MR, 1994, GLYCOBIOLOGY, V4, P165, DOI 10.1093/glycob/4.2.165; Morita YS, 2004, BIOCHEM J, V378, P589, DOI 10.1042/BJ20031372; Nigou J, 2000, J MOL BIOL, V299, P1353, DOI 10.1006/jmbi.2000.3821; Nigou J, 1997, J BIOL CHEM, V272, P23094, DOI 10.1074/jbc.272.37.23094; Nigou J, 2003, BIOCHIMIE, V85, P153, DOI 10.1016/S0300-9084(03)00048-8; Oriol R, 2002, MOL BIOL EVOL, V19, P1451, DOI 10.1093/oxfordjournals.molbev.a004208; PRINZIS S, 1993, J GEN MICROBIOL, V139, P2649, DOI 10.1099/00221287-139-11-2649; Quesniaux VJ, 2004, J IMMUNOL, V172, P4425, DOI 10.4049/jimmunol.172.7.4425; Sambrook J, 2001, MOL CLONING LAB MANU; SCHLESINGER LS, 1994, J IMMUNOL, V152, P4070; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; Torrelles JB, 2004, J BIOL CHEM, V279, P41227, DOI 10.1074/jbc.M405180200; Treumann A, 2002, J MOL BIOL, V316, P89, DOI 10.1006/jmbi.2001.5317; VanderVen BC, 2005, SCIENCE, V309, P941, DOI 10.1126/science.1114347; VENISSE A, 1993, J BIOL CHEM, V268, P12401; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328; YORK WS, 1986, METHOD ENZYMOL, V118, P3; Zhang N, 2003, MOL MICROBIOL, V50, P69, DOI 10.1046/j.1365-2958.2003.03681.x	41	65	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20027	20035		10.1074/jbc.M603395200	http://dx.doi.org/10.1074/jbc.M603395200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16704981	hybrid			2022-12-25	WOS:000239038200027
J	Dumin, E; Bendikov, I; Foltyn, VN; Misumi, Y; Ikehara, Y; Kartvelishvily, E; Wolosker, H				Dumin, Elena; Bendikov, Inna; Foltyn, Veronika N.; Misumi, Yoshio; Ikehara, Yukio; Kartvelishvily, Elena; Wolosker, Herman			Modulation of D-serine levels via ubiquitin-dependent proteasomal degradation of serine racemase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; D-ASPARTATE RECEPTORS; MOLECULAR CHARACTERIZATION; HIPPOCAMPAL SLICES; NMDA-RECEPTORS; GOLGI-COMPLEX; PROTEIN; ACTIVATION; GLYCINE; TURNOVER	Mammalian serine racemase is a brain-enriched enzyme that converts L-into D-serine in the nervous system. D-Serine is an endogenous co-agonist at the "glycine site" of N-methyl D-as-partate (NMDA) receptors that is required for the receptor/ channel opening. Factors regulating the synthesis of D-serine have implications for the NMDA receptor transmission, but little is known on the signals and events affecting serine racemase levels. We found that serine racemase interacts with the Golgin subfamily A member 3 (Golga3) protein in yeast two-hybrid screening. The interaction was confirmed in vitro with the recombinant proteins in co-transfected HEK293 cells and in vivo by co-immunoprecipitation studies from brain homogenates. Golga3 and serine racemase co- localized at the cytosol, perinuclear Golgi region, and neuronal and glial cell processes in primary cultures. Golga3 significantly increased serine racemase steady-state levels in co-transfected HEK293 cells and primary astrocyte cultures. This observation led us to investigate mechanisms regulating serine racemase levels. We found that serine racemase is degraded through the ubiquitin-proteasomal system in a Golga3-modulated manner. Golga3 decreased the ubiquitylation of serine racemase both in vitro and in vivo and significantly increased the protein half-life in pulse-chase experiments. Our results suggest that the ubiquitin system is a main regulator of serine racemase and D-serine levels. Modulation of serine racemase degradation, such as that promoted by Golga3, provides a new mechanism for regulating brain D-serine levels and NMDA receptor activity.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Biochem, IL-31096 Haifa, Israel; Fukuoka Univ, Sch Med, Dept Cell Biol, Fukuoka 8140180, Japan; Daiichi Univ, Inst Pharmaceut Sci, Fukuoka 8158511, Japan	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Fukuoka University	Wolosker, H (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Biochem, IL-31096 Haifa, Israel.	hwolosker@tx.technion.ac.il		Wolosker, Herman/0000-0001-5508-9194				Alroy I, 2005, P NATL ACAD SCI USA, V102, P1478, DOI 10.1073/pnas.0408717102; Bartke T, 2004, MOL CELL, V14, P801, DOI 10.1016/j.molcel.2004.05.018; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Bundis F, 2006, CELL PHYSIOL BIOCHEM, V17, P1, DOI 10.1159/000091454; Cha H, 2004, J CELL SCI, V117, P751, DOI 10.1242/jcs.00897; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; Danysz W, 1998, PHARMACOL REV, V50, P597; De Miranda J, 2000, GENE, V256, P183, DOI 10.1016/S0378-1119(00)00356-5; de Miranda J, 2002, P NATL ACAD SCI USA, V99, P14542, DOI 10.1073/pnas.222421299; Dunlop DS, 1997, BIOCHEM BIOPH RES CO, V235, P26, DOI 10.1006/bbrc.1997.6724; Ehlers MD, 2003, NAT NEUROSCI, V6, P231, DOI 10.1038/nn1013; EISENTHAL R, 1993, ENZYME ASSAYS PRACTI, P75; Foltyn VN, 2005, J BIOL CHEM, V280, P1754, DOI 10.1074/jbc.M405726200; FRITZLER MJ, 1993, J EXP MED, V178, P49, DOI 10.1084/jem.178.1.49; Harlow E., 1988, ANTIBODIES LAB MANUA, P343; HERSHKO A, 1982, J BIOL CHEM, V257, P3964; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicks SW, 2005, J BIOL CHEM, V280, P28944, DOI 10.1074/jbc.M504937200; Hicks SW, 2002, J BIOL CHEM, V277, P35833, DOI 10.1074/jbc.M206280200; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; Kartvelishvily E, 2006, J BIOL CHEM, V281, P14151, DOI 10.1074/jbc.M512927200; Kato A, 2005, P NATL ACAD SCI USA, V102, P5600, DOI 10.1073/pnas.0501769102; Kim PM, 2005, P NATL ACAD SCI USA, V102, P2105, DOI 10.1073/pnas.0409723102; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; Liani E, 2004, P NATL ACAD SCI USA, V101, P5500, DOI 10.1073/pnas.0401081101; Maag RS, 2005, MOL BIOL CELL, V16, P3019, DOI 10.1091/mbc.E04-11-0971; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Misumi Y, 1997, J BIOL CHEM, V272, P23851, DOI 10.1074/jbc.272.38.23851; Mothet JP, 2005, P NATL ACAD SCI USA, V102, P5606, DOI 10.1073/pnas.0408483102; Mothet JP, 2000, P NATL ACAD SCI USA, V97, P4926, DOI 10.1073/pnas.97.9.4926; Nakamura N, 2005, MOL BIOL CELL, V16, P1696, DOI 10.1091/mbc.E04-03-0216; Ohta E, 2003, J BIOL CHEM, V278, P51957, DOI 10.1074/jbc.M310014200; Panizzutti R, 2001, P NATL ACAD SCI USA, V98, P5294, DOI 10.1073/pnas.091002298; SCHELL MJ, 1995, P NATL ACAD SCI USA, V92, P3948, DOI 10.1073/pnas.92.9.3948; Shleper M, 2005, J NEUROSCI, V25, P9413, DOI 10.1523/JNEUROSCI.3190-05.2005; Stevens ER, 2003, P NATL ACAD SCI USA, V100, P6789, DOI 10.1073/pnas.1237052100; Williams SM, 2006, GLIA, V53, P401, DOI 10.1002/glia.20300; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P13409, DOI 10.1073/pnas.96.23.13409; Wolosker H, 2002, NEUROCHEM INT, V41, P327, DOI 10.1016/S0197-0186(02)00055-4; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P721, DOI 10.1073/pnas.96.2.721; Wolosker H, 1998, FASEB J, V12, P91, DOI 10.1096/fasebj.12.1.91; Yang S, 2005, NEUROSCI LETT, V379, P7, DOI 10.1016/j.neulet.2004.12.033; Yang YL, 2003, P NATL ACAD SCI USA, V100, P15194, DOI 10.1073/pnas.2431073100; Yi JJ, 2005, NEURON, V47, P629, DOI 10.1016/j.neuron.2005.07.008; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	48	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20291	20302		10.1074/jbc.M601971200	http://dx.doi.org/10.1074/jbc.M601971200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16714286	hybrid			2022-12-25	WOS:000239038200054
J	Fang, HY; Patanavanich, S; Rajagopal, S; Yi, XB; Gill, MS; Sando, JJ; Kamatchi, GL				Fang, Hongyu; Patanavanich, Saharat; Rajagopal, Senthilkumar; Yi, Xiaobin; Gill, Monica S.; Sando, Julianne J.; Kamatchi, Ganesan L.			Inhibitory role of Ser-425 of the alpha(1) 2.2 subunit in the enhancement of Ca-v 2.2 currents by phorbol-12-myristate, 13-acetate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CALCIUM-CHANNELS; ACETYL-BETA-METHYLCHOLINE; PROTEIN-KINASE-C; IDENTIFICATION; MODULATION; SITES	Voltage-gated calcium channels (Ca-v) 2.2 currents are potentiated by phorbol-12-myristate, 13-acetate (PMA), whereas Cav 2.3 currents are increased by both PMA and acetyl-beta-methylcholine (MCh). MCh-selective sites were identified in the alpha(1) 2.3 subunit, whereas the identified PMA sites responded to both PMA and MCh (Kamatchi, G. L., Franke, R., Lynch, C., III, and Sando, J. J. ( 2004) J. Biol. Chem. 279, 4102-4109; Fang, H., Franke, R., Patanavanich, S., Lalvani, A., Powell, N. K., Sando, J. J., and Kamatchi, G. L. ( 2005) J. Biol. Chem. 280,23559 - 23565). The hypothesis that PMA sites in the alpha(1) 2.2 subunit are homologous to the PMA-responsive sites in alpha(1) 2.3 subunit was tested with Ser/Thr -> Ala mutations in the alpha(1) 2.2 subunit. WT alpha(1) 2.2 or mutants were expressed in Xenopus oocytes in combination with beta 1b and alpha 2/delta subunits. Inward current (I-Ba) was recorded using Ba2+ as the charge carrier. T422A, S1757A, S2108A, or S2132A decreased the PMA response. In contrast, S425A increased the response to PMA, and thus, it was considered an inhibitory site. Replacement of each of the identified stimulatory Ser/Thr sites with Asp increased the basal current and decreased the PMA-induced enhancement, consistent with regulation by phosphorylation at these sites. Multiple mutant combinations showed (i) greater inhibition than that caused by the single Ala mutations; (ii) that enhancement observed when Thr-422 and Ser-2108 are available may be inhibited by the presence of Ser-425; and (iii) that the combination of Thr-422, Ser-2108, and either Ser-1757 or Ser-2132 can provide a greater response to PMA when Ser-425 is replaced with Ala. The homologous sites in alpha(1) 2.2 and alpha(1) 2.3 subunits seem to be functionally different. The existence of an inhibitory phosphorylation site in the I-II linker seems to be unique to the alpha(1) 2.2 subunit.	Univ Virginia, Hlth Sci Syst, Dept Anesthesiol, Charlottesville, VA 22908 USA; Washington Univ, Dept Anesthesiol, St Louis, MO 63110 USA	University of Virginia; Washington University (WUSTL)	Kamatchi, GL (corresponding author), Univ Virginia, Hlth Sci Syst, Dept Anesthesiol, POB 800710, Charlottesville, VA 22908 USA.	gk3p@virginia.edu	Rajagopal, Senthilkumar/B-5404-2012	Rajagopal, Senthilkumar/0000-0002-8404-8209	NIGMS NIH HHS [GM65214] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065214] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bell TJ, 2004, NEURON, V41, P127, DOI 10.1016/S0896-6273(03)00801-8; Elmslie KS, 2003, J BIOENERG BIOMEMBR, V35, P477, DOI 10.1023/B:JOBB.0000008021.55853.18; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Fang HY, 2005, J BIOL CHEM, V280, P23559, DOI 10.1074/jbc.M501540200; Hamid J, 1999, J BIOL CHEM, V274, P6195, DOI 10.1074/jbc.274.10.6195; Kamatchi GL, 2004, J BIOL CHEM, V279, P4102, DOI 10.1074/jbc.M308606200; Kamatchi GL, 2003, BRAIN RES, V968, P227, DOI 10.1016/S0006-8993(03)02245-5; Lin ZX, 1997, NEURON, V18, P153, DOI 10.1016/S0896-6273(01)80054-4; Melliti K, 2000, J NEUROSCI, V20, P7167; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287	12	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20011	20017		10.1074/jbc.M601776200	http://dx.doi.org/10.1074/jbc.M601776200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16704976	hybrid			2022-12-25	WOS:000239038200025
J	Jancura, D; Antalik, M; Berka, V; Palmer, G; Fabian, M				Jancura, Daniel; Antalik, Marian; Berka, Vladimir; Palmer, Graham; Fabian, Marian			Filling the catalytic site of cytochrome c oxidase with electrons - Reduced Cu-b facilitates internal electron transfer to heme a(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARACOCCUS-DENITRIFICANS; RHODOBACTER-SPHAEROIDES; COPPER OXIDASES; PROTON-TRANSFER; 2.8 ANGSTROM; REDUCTION; EQUILIBRIUM; RESOLUTION; SPECTROSCOPY; OXIDATION	In the reductive phase of its catalytic cycle, cytochrome c oxidase receives electrons from external electron donors. Two electrons have to be transferred into the catalytic center, composed of heme a(3) and Cu-B, before reaction with oxygen takes place. In addition, this phase of catalysis appears to be involved in proton translocation. Here, we report for the first time the kinetics of electron transfer to both heme a(3) and CuB during the transition from the oxidized to the fully reduced state. The state of reduction of both heme a(3) and CuB was monitored by a combination of EPR spectroscopy, the rapid freeze procedure, and the stopped-flow method. The kinetics of cytochrome c oxidase reduction by hexaamineruthenium under anaerobic conditions revealed that the rate-limiting step is the initial electron transfer to the catalytic site that proceeds with apparently identical rates to both heme a(3) and CuB. After CuB is reduced, electron transfer to oxidized heme a(3) is enhanced relative to the rate of entry of the first electron.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, Houston, TX 77030 USA	Rice University; University of Texas System; University of Texas Health Science Center Houston	Fabian, M (corresponding author), Rice Univ, Dept Biochem & Cell Biol, MS 140,6100 Main, Houston, TX 77005 USA.	fabian@rice.edu			NIGMS NIH HHS [GM 55807] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1976, BIOCHIM BIOPHYS ACTA, V422, P260, DOI 10.1016/0005-2744(76)90137-6; Adelroth P, 1996, P NATL ACAD SCI USA, V93, P12292, DOI 10.1073/pnas.93.22.12292; AHMAD I, 1982, BIOCHEMISTRY-US, V21, P3122, DOI 10.1021/bi00256a014; Antalik M, 2005, BIOCHEMISTRY-US, V44, P14881, DOI 10.1021/bi050824z; Branden M, 2003, BIOCHEMISTRY-US, V42, P13178, DOI 10.1021/bi0347407; Brunori M, 1997, J BIOL CHEM, V272, P19870, DOI 10.1074/jbc.272.32.19870; Farver O, 2000, EUR J BIOCHEM, V267, P950, DOI 10.1046/j.1432-1327.2000.01072.x; FETTER JR, 1995, P NATL ACAD SCI USA, V92, P1604, DOI 10.1073/pnas.92.5.1604; GEREN LM, 1995, J BIOL CHEM, V270, P2466, DOI 10.1074/jbc.270.6.2466; Harrenga A, 1999, J BIOL CHEM, V274, P33296, DOI 10.1074/jbc.274.47.33296; HARTZELL CR, 1973, P NATL ACAD SCI USA, V70, P2477, DOI 10.1073/pnas.70.9.2477; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; JACOBS EE, 1960, J BIOL CHEM, V235, P531; JONES GD, 1983, BIOCHEM J, V209, P175, DOI 10.1042/bj2090175; KOBAYASHI K, 1989, J BIOL CHEM, V264, P7976; LENAZ G, 1967, METHOD ENZYMOL, V10, P499; Liao GL, 1996, BBA-BIOENERGETICS, V1274, P109, DOI 10.1016/0005-2728(96)00014-X; MALATESTA F, 1990, P NATL ACAD SCI USA, V87, P7410, DOI 10.1073/pnas.87.19.7410; MARGALIT R, 1973, EUR J BIOCHEM, V32, P492, DOI 10.1111/j.1432-1033.1973.tb02633.x; MERKEL JR, 1954, BIOCHIM BIOPHYS ACTA, V14, P303, DOI 10.1016/0006-3002(54)90188-2; MITCHELL R, 1994, BBA-BIOENERGETICS, V1186, P19, DOI 10.1016/0005-2728(94)90130-9; Moody AJ, 1996, BBA-BIOENERGETICS, V1276, P6; MORGAN JE, 1989, BIOCHEMISTRY-US, V28, P6975, DOI 10.1021/bi00443a030; NILSSON T, 1992, P NATL ACAD SCI USA, V89, P6497, DOI 10.1073/pnas.89.14.6497; OLIVEBERG M, 1991, BIOCHEMISTRY-US, V30, P7053, DOI 10.1021/bi00243a003; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; PAN LP, 1993, BIOCHEMISTRY-US, V32, P8492, DOI 10.1021/bi00084a014; Parul D, 2005, BIOCHEMISTRY-US, V44, P4562, DOI 10.1021/bi048435c; REICHARDT JKV, 1982, J BIOL CHEM, V257, P9268; Ruitenberg M, 2002, NATURE, V417, P99, DOI 10.1038/417099a; SCOTT RA, 1980, J AM CHEM SOC, V102, P3219, DOI 10.1021/ja00529a054; Soulimane T, 2000, EMBO J, V19, P1766, DOI 10.1093/emboj/19.8.1766; SOULIMANE T, 1995, EUR J BIOCHEM, V227, P588, DOI 10.1111/j.1432-1033.1995.tb20429.x; Svensson-Ek M, 2002, J MOL BIOL, V321, P329, DOI 10.1016/S0022-2836(02)00619-8; Szundi I, 2001, BIOCHEMISTRY-US, V40, P2186, DOI 10.1021/bi002341v; Tomson FL, 2003, BIOCHEMISTRY-US, V42, P1711, DOI 10.1021/bi026750y; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VANGELDE.BF, 1969, BIOCHIM BIOPHYS ACTA, V189, P1, DOI 10.1016/0005-2728(69)90219-9; VERKHOVSKY MI, 1992, BIOCHEMISTRY-US, V31, P11860, DOI 10.1021/bi00162a026; VERKHOVSKY MI, 1995, BIOCHEMISTRY-US, V34, P7483, DOI 10.1021/bi00022a023; Wang KF, 2002, BIOCHEMISTRY-US, V41, P2298, DOI 10.1021/bi0114630; WIKSTROM M, 1992, J BIOL CHEM, V267, P10266; Wikstrom M, 2000, BBA-BIOENERGETICS, V1459, P514, DOI 10.1016/S0005-2728(00)00191-2; WINKLER JR, 1995, BIOPHYS CHEM, V54, P199, DOI 10.1016/0301-4622(94)00156-E; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723; Zaslavsky D, 2004, P NATL ACAD SCI USA, V101, P10544, DOI 10.1073/pnas.0401521101; Zaslavsky D, 1998, BIOCHEMISTRY-US, V37, P14910, DOI 10.1021/bi981490z	48	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20003	20010		10.1074/jbc.M602066200	http://dx.doi.org/10.1074/jbc.M602066200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16704969	hybrid			2022-12-25	WOS:000239038200024
J	Mahmoudi, T; Parra, M; Vries, RGJ; Kauder, SE; Verrijzer, CP; Ott, M; Verdin, E				Mahmoudi, Tokameh; Parra, Maribel; Vries, Robert G. J.; Kauder, Steven E.; Verrijzer, C. Peter; Ott, Melanie; Verdin, Eric			The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CREB-BINDING-PROTEIN; SWI-SNF COMPLEX; TRANSCRIPTIONAL ACTIVITY; HISTONE ACETYLTRANSFERASE; ORDERED RECRUITMENT; PCAF BROMODOMAIN; GENE-EXPRESSION; ACETYLATION; P300	Tat is a critical viral transactivator essential for human immunodeficiency virus (HIV) gene expression. Activation involves binding to an RNA stem-loop structure and recruitment of the positive transcription elongation factor b. Tat also induces the remodeling of a single nucleosome in the HIV promoter. However, the mechanism of this remodeling has remained unclear. Knockdown of INI-1 and BRG-1, two components of the SWI/SNF chromatin-remodeling complex, suppressed Tat-mediated transactivation. Cells lacking INI-1 (G401 and MON) or BRG-1 (C33A) exhibited defective transactivation by Tat that was restored upon INI-1 and BRG-1 expression, respectively. Tat was co-immunoprecipitated with several SWI/SNF subunits, including INI-1, BRG-1, and beta-actin. The SWI/SNF complex interacted with the integrated HIV promoter in a Tat-dependent manner. We also found that INI-1 and BRG-1 synergized with the p300 acetyltransferase to activate the HIV promoter. This synergism depended on the acetyltransferase activity of p300 and on Tat Lys50 and Lys51. In conclusion, Tat-mediated activation of the HIV promoter requires the SWI/SNF complex in synergy with the coactivator p300.	Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA; Erasmus Univ, Med Ctr, Ctr Biomed Genet, Dept Biochem, NL-3000 DR Rotterdam, Netherlands	University of California System; University of California San Francisco; The J David Gladstone Institutes; Erasmus University Rotterdam; Erasmus MC	Verdin, E (corresponding author), Univ Calif San Francisco, Gladstone Inst Virol & Immunol, 1650 Owens St, San Francisco, CA 94158 USA.	everdin@gladstone.ucsf.edu	Verdin, Eric/AAB-7999-2019; Parra, Maribel/AAO-6345-2021	Ott, Melanie/0000-0002-5697-1274; Verdin, Eric/0000-0003-3703-3183; Parra, Maribel/0000-0002-9072-5763	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051671] Funding Source: NIH RePORTER; NIAID NIH HHS [P01 AI158708] Funding Source: Medline; NIGMS NIH HHS [R01 GM051671] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; Biggar SR, 1999, EMBO J, V18, P2254, DOI 10.1093/emboj/18.8.2254; Bres V, 2002, EMBO J, V21, P6811, DOI 10.1093/emboj/cdf669; Col E, 2001, J BIOL CHEM, V276, P28179, DOI 10.1074/jbc.M101385200; Cosma MP, 2002, MOL CELL, V10, P227, DOI 10.1016/S1097-2765(02)00604-4; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Coull JJ, 2000, J VIROL, V74, P6790, DOI 10.1128/JVI.74.15.6790-6799.2000; Deng LW, 2001, VIROLOGY, V289, P312, DOI 10.1006/viro.2001.1129; Deng LW, 2000, VIROLOGY, V277, P278, DOI 10.1006/viro.2000.0593; Dorr A, 2002, EMBO J, V21, P2715, DOI 10.1093/emboj/21.11.2715; ElKharroubi A, 1996, MOL CELL BIOL, V16, P2958; Gregory PD, 1999, EMBO J, V18, P6407, DOI 10.1093/emboj/18.22.6407; Gregory PD, 1998, CURR OPIN CELL BIOL, V10, P339, DOI 10.1016/S0955-0674(98)80009-4; He GC, 2002, MOL CELL BIOL, V22, P2965, DOI 10.1128/MCB.22.9.2965-2973.2002; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Jordan A, 2003, EMBO J, V22, P1868, DOI 10.1093/emboj/cdg188; Jordan A, 2001, EMBO J, V20, P1726, DOI 10.1093/emboj/20.7.1726; Kaehlcke K, 2003, MOL CELL, V12, P167, DOI 10.1016/S1097-2765(03)00245-4; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; Keen NJ, 1996, P NATL ACAD SCI USA, V93, P2505, DOI 10.1073/pnas.93.6.2505; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Klochendler-Yeivin A, 2002, CURR OPIN GENET DEV, V12, P73, DOI 10.1016/S0959-437X(01)00267-2; Lusic M, 2003, EMBO J, V22, P6550, DOI 10.1093/emboj/cdg631; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; Mujtaba S, 2002, MOL CELL, V9, P575, DOI 10.1016/S1097-2765(02)00483-5; Olave IA, 2002, ANNU REV BIOCHEM, V71, P755, DOI 10.1146/annurev.biochem.71.110601.135507; Ott M, 1999, CURR BIOL, V9, P1489, DOI 10.1016/S0960-9822(00)80120-7; Ott Melanie, 2004, Novartis Found Symp, V259, P182; Pagans S, 2005, PLOS BIOL, V3, P210, DOI 10.1371/journal.pbio.0030041; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Rando OJ, 2002, P NATL ACAD SCI USA, V99, P2824, DOI 10.1073/pnas.032662899; Roberts SM, 1997, GENETICS, V147, P451; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sudarsanam P, 1999, EMBO J, V18, P3101, DOI 10.1093/emboj/18.11.3101; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Turelli P, 2001, MOL CELL, V7, P1245, DOI 10.1016/S1097-2765(01)00255-6; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; Vries RGJ, 2005, GENE DEV, V19, P665, DOI 10.1101/gad.335805; Wang W, 2003, CURR TOP MICROBIOL, V274, P143; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Yung E, 2004, J VIROL, V78, P2222, DOI 10.1128/JVI.78.5.2222-2231.2004; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	46	128	136	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					19960	19968		10.1074/jbc.M603336200	http://dx.doi.org/10.1074/jbc.M603336200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16687403	hybrid			2022-12-25	WOS:000239038200019
J	Marchand, A; Tomkiewicz, C; Magne, L; Barouki, R; Garlatti, M				Marchand, Alexandre; Tomkiewicz, Celine; Magne, Laurent; Barouki, Robert; Garlatti, Michele			Endoplasmic reticulum stress induction of insulin-like growth factor-binding protein-1 involves ATF4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID DEPRIVATION; ZIPPER TRANSCRIPTION FACTORS; ASPARAGINE SYNTHETASE GENE; ER-ASSOCIATED DEGRADATION; TRANSGENIC MICE; TRANSLATIONAL CONTROL; MESSENGER-RNA; IGFBP-1 EXPRESSION; CELL-SURVIVAL; IGF-I	Endoplasmic reticulum ( ER) stress is sensed by cells in different physiopathological conditions in which there is an accumulation of unfolded proteins in the ER. A coordinated adaptive program called the unfolded protein response is triggered and includes translation inhibition, transcriptional activation of a set of genes encoding mostly intracellular proteins, and ultimately apoptosis. Here we show that insulin-like growth factor (IGF)-binding protein-1 (IGFBP-1), a secreted protein that modulates IGF bioavailability and has other IGF-independent effects, is potently induced during ER stress in human hepatocytes. Various ER stress-inducing agents were able to increase IGFBP-1 mRNA levels, as well as cellular and secreted IGFBP-1 protein up to 20-fold. A distal regulatory region of the human IGFBP-1 gene (-6682/-6384) containing an activating transcription factor 4 (ATF4) composite site was required for promoter activation upon ER stress. Mutation of the ATF4 composite site led to the loss of IGFBP-1 regulation. Electrophoretic mobility shift assay revealed an ER stress-inducible complex that was displaced by an ATF4 antibody. Knockdown of ATF4 expression using two specific small interfering RNAs impaired up-regulation of IGFBP-1 mRNA, which highlights the relevance of ATF4 in endogenous IGFBP-1 gene induction. In addition to intracellular proteins involved in secretory and metabolic pathways, we conclude that ER stress induces the synthesis of secreted proteins. Increased secretion of IGFBP-1 during hepatic ER stress may thus constitute a signal to modulate cell growth and metabolism and induce a systemic adaptive response.	Univ Paris Descartes, INSERM, UMR S 747, F-75270 Paris 06, France; Assistance Publ Hop Paris Europeen Georges Pompid, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP	Garlatti, M (corresponding author), Univ Paris Descartes, INSERM, UMR S 747, 45 Rue St Peres, F-75270 Paris 06, France.	Michele.Garlatti@univ-paris5.fr						Abcouwer SF, 2002, INVEST OPHTH VIS SCI, V43, P2791; Averous J, 2005, FEBS LETT, V579, P2609, DOI 10.1016/j.febslet.2005.03.077; Averous J, 2004, J BIOL CHEM, V279, P15706; Averous J, 2004, J BIOL CHEM, V279, P5288, DOI 10.1074/jbc.M311862200; Baxter RC, 2001, BEST PRACT RES CL EN, V15, P421, DOI 10.1053/beem.2001.0161; Bruhat A, 2002, J BIOL CHEM, V277, P48107, DOI 10.1074/jbc.M206149200; CARLSON JA, 1989, J CLIN INVEST, V83, P1183, DOI 10.1172/JCI113999; Chen C, 2004, J BIOL CHEM, V279, P27948, DOI 10.1074/jbc.M313920200; Chen H, 2004, J BIOL CHEM, V279, P50829, DOI 10.1074/jbc.M409173200; Crossey PA, 2002, J CLIN INVEST, V110, P411, DOI 10.1172/JCI200210077; Crossey PA, 2000, DIABETES, V49, P457, DOI 10.2337/diabetes.49.3.457; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; ERIKSSON S, 1986, NEW ENGL J MED, V314, P736, DOI 10.1056/NEJM198603203141202; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Froment P, 2004, ENDOCRINOLOGY, V145, P2080, DOI 10.1210/en.2003-0956; Gay E, 1997, ENDOCRINOLOGY, V138, P2937, DOI 10.1210/en.138.7.2937; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; Hwang DL, 2003, GROWTH HORM IGF RES, V13, P316, DOI 10.1016/S1096-6374(03)00042-X; ISOM HC, 1985, P NATL ACAD SCI USA, V82, P3252, DOI 10.1073/pnas.82.10.3252; Jousse C, 1998, BIOCHEM J, V334, P147, DOI 10.1042/bj3340147; Kajimura S, 2005, P NATL ACAD SCI USA, V102, P1240, DOI 10.1073/pnas.0407443102; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Kaufman RJ, 2004, TRENDS BIOCHEM SCI, V29, P152, DOI 10.1016/j.tibs.2004.01.004; Kurisu J, 2003, GENES CELLS, V8, P189, DOI 10.1046/j.1365-2443.2003.00625.x; Lang CH, 2001, GROWTH HORM IGF RES, V11, P250, DOI 10.1054/ghir.2001.0233; Lang CH, 2003, ENDOCRINOLOGY, V144, P3922, DOI 10.1210/en.2002-0192; Lang CH, 2002, CURR OPIN CLIN NUTR, V5, P271, DOI 10.1097/00075197-200205000-00006; Lang CH, 1999, AM J PHYSIOL-GASTR L, V276, pG719, DOI 10.1152/ajpgi.1999.276.3.G719; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; LEE PDK, 1993, P SOC EXP BIOL MED, V204, P4; Lee PDK, 1997, P SOC EXP BIOL MED, V216, P319; Leu JI, 2003, MOL CELL BIOL, V23, P1251, DOI 10.1128/MCB.23.4.1251-1259.2003; Leu JI, 2003, J CLIN INVEST, V111, P129, DOI 10.1172/JCI200316712; LEWITT MS, 1990, ENDOCRINOLOGY, V126, P1527, DOI 10.1210/endo-126-3-1527; Li YH, 1997, AM J PHYSIOL-REG I, V272, pR1990, DOI 10.1152/ajpregu.1997.272.6.R1990; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Luo SZ, 2003, J BIOL CHEM, V278, P37375, DOI 10.1074/jbc.M303619200; Ma YJ, 2004, J BIOL CHEM, V279, P13792, DOI 10.1074/jbc.M313724200; Ma YJ, 2003, J BIOL CHEM, V278, P34864, DOI 10.1074/jbc.M301107200; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Marchand A, 2005, MOL PHARMACOL, V67, P444, DOI 10.1124/mol.104.004010; Murphy Liam J, 2003, Exp Diabesity Res, V4, P213, DOI 10.1155/EDR.2003.213; Murray JI, 2004, MOL BIOL CELL, V15, P2361, DOI 10.1091/mbc.E03-11-0799; Nayak NR, 2003, PLACENTA, V24, P281, DOI 10.1053/plac.2002.0906; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Rajkumar K, 1999, BBA-GEN SUBJECTS, V1426, P491, DOI 10.1016/S0304-4165(98)00162-7; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shen XH, 2004, J CHEM NEUROANAT, V28, P79, DOI 10.1016/j.jchemneu.2004.02.006; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; SUWANICHKUL A, 1990, J BIOL CHEM, V265, P21185; Tazuke SI, 1998, P NATL ACAD SCI USA, V95, P10188, DOI 10.1073/pnas.95.17.10188; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200	65	32	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19124	19133		10.1074/jbc.M602157200	http://dx.doi.org/10.1074/jbc.M602157200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16687408	hybrid			2022-12-25	WOS:000238847000027
J	Wang, QY; Yang, GY; Liu, YL; Feng, Y				Wang, Qiuyan; Yang, Guangyu; Liu, Yanli; Feng, Yan			Discrimination of esterase and peptidase activities of acylaminoacyl peptidase from hyperthermophilic Aeropyrum pernix K1 by a single mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL OLIGOPEPTIDASE FAMILY; HORMONE-SENSITIVE LIPASE; INDIVIDUAL RATE CONSTANTS; CRYSTAL-STRUCTURE; SERINE PROTEASES; ACTIVE-SITE; BACILLUS-ACIDOCALDARIUS; SATURATION MUTAGENESIS; SEQUENCE SIMILARITY; SUBSTRATE-BINDING	It has been shown that highly conserved residues that form crucial structural elements of the catalytic apparatus may be used to account for the evolutionary history of enzymes. Using saturation mutagenesis, we investigated the role of a conserved residue (Arg(526)) at the active site of acylaminoacyl peptidase from hyperthermophilic Aeropyrum pernix K1 in substrate discrimination and catalytic mechanism. This enzyme has both peptidase and esterase activities. The esterase activity of the wild-type enzyme with p-nitrophenyl caprylate as substrate is similar to 7 times higher than the peptidase activity with Ac-Leu-p-nitroanilide as substrate. However, with the same substrates, this difference was increased to similar to 150-fold for mutant R526V. A more dramatic effect occurred with mutant R526E, which essentially completely abolished the peptidase activity but decreased the esterase activity only by a factor of 2, leading to a 785-fold difference in the enzyme activities. These results provide rare examples that illustrate how enzymes can be evolved to discriminate their substrates by a single mutation. The possible structural and energetic effects of the mutations on k(cat) and K-m of the enzyme were discussed based on molecular dynamics simulation studies.	Jilin Univ, Minist Educ, Key Lab Mol Enzymol & Engn, Changchun 130023, Peoples R China	Jilin University	Feng, Y (corresponding author), Jilin Univ, Minist Educ, Key Lab Mol Enzymol & Engn, Changchun 130023, Peoples R China.	yfeng@mail.jlu.edu.cn						Ayala YM, 2000, PROTEIN SCI, V9, P1589, DOI 10.1110/ps.9.8.1589; BARRETT AJ, 1992, BIOL CHEM H-S, V373, P353, DOI 10.1515/bchm3.1992.373.2.353; Bartlam M, 2004, STRUCTURE, V12, P1481, DOI 10.1016/j.str.2004.05.019; Bobofchak KM, 2005, J BIOL CHEM, V280, P25644, DOI 10.1074/jbc.M503499200; De Simone G, 2004, J BIOL CHEM, V279, P6815, DOI 10.1074/jbc.M307738200; De Simone G, 2001, J MOL BIOL, V314, P507, DOI 10.1006/jmbi.2001.5152; Fulop V, 2001, J BIOL CHEM, V276, P1262, DOI 10.1074/jbc.M007003200; Gao RJ, 2003, J MOL CATAL B-ENZYM, V24-5, P1, DOI 10.1016/S1381-1177(03)00064-X; HEMILA H, 1994, BBA-LIPID LIPID MET, V1210, P249, DOI 10.1016/0005-2760(94)90129-5; Judice WAS, 2001, EUR J BIOCHEM, V268, P6578, DOI 10.1046/j.0014-2956.2001.02612.x; Krem MM, 2002, J BIOL CHEM, V277, P40260, DOI 10.1074/jbc.M206173200; Manco G, 1997, PROTEIN PEPTIDE LETT, V4, P375; Manco G, 1998, BIOCHEM J, V332, P203, DOI 10.1042/bj3320203; Manco G, 2001, J BIOL CHEM, V276, P37482, DOI 10.1074/jbc.M103017200; Nardini M, 2000, J BIOL CHEM, V275, P31219, DOI 10.1074/jbc.M003903200; POLGAR L, 1992, FEBS LETT, V311, P281, DOI 10.1016/0014-5793(92)81120-B; Polgar L, 2002, CELL MOL LIFE SCI, V59, P349, DOI 10.1007/s00018-002-8427-5; POLGAR L, 1994, PROLYL OLIGOPEPTIDAS, P188; Polgar Laszlo, 2002, Current Medicinal Chemistry - Central Nervous System Agents, V2, P251, DOI 10.2174/1568015023357860; RAWLINGS ND, 1991, BIOCHEM J, V279, P907, DOI 10.1042/bj2790907; RENNEX D, 1991, BIOCHEMISTRY-US, V30, P2195, DOI 10.1021/bi00222a025; Rui LY, 2004, APPL ENVIRON MICROB, V70, P3246, DOI 10.1128/AEM.70.6.3246-3252.2004; Shan L, 2005, P NATL ACAD SCI USA, V102, P3599, DOI 10.1073/pnas.0408286102; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; Szeltner Z, 2003, J BIOL CHEM, V278, P48786, DOI 10.1074/jbc.M309555200; Venalainen JI, 2004, EUR J BIOCHEM, V271, P2705, DOI 10.1111/j.1432-1033.2004.04199.x; Zheng L, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh110	27	33	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18618	18625		10.1074/jbc.M601015200	http://dx.doi.org/10.1074/jbc.M601015200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16670095	hybrid			2022-12-25	WOS:000238687300041
J	Broome, CS; Kayani, AC; Palomero, J; Dillmann, WH; Mestril, R; Jackson, MJ; McArdle, A				Broome, Caroline S.; Kayani, Anna C.; Palomero, Jesus; Dillmann, Wolfgang H.; Mestril, Ruben; Jackson, Malcolm J.; McArdle, Anne			Effect of lifelong overexpression of HSP70 in skeletal muscle on age-related oxidative stress and adaptation after nondamaging contractile activity	FASEB JOURNAL			English	Article						aging; exercise	REACTIVE OXYGEN; CALORIC RESTRICTION; SUPEROXIDE-DISMUTASE; DIETARY RESTRICTION; KAPPA-B; RAT; INCREASES; PROTEIN; ANTIOXIDANTS; GENERATION	Skeletal muscle aging is characterized by atrophy, a deficit in specific force generation, increased susceptibility to injury, and incomplete recovery after severe injury. The ability of muscles of old mice to produce heat shock proteins (HSPs) in response to stress is severely diminished. Studies in our laboratory using HSP70 overexpressor mice demonstrated that lifelong overexpression of HSP70 in skeletal muscle provided protection against damage and facilitated successful recovery after damage in muscles of old mice. The mechanisms by which HSP70 provides this protection are unclear. Aging is associated with the accumulation of oxidation products, and it has been proposed that this may play a major role in age-related muscle dysfunction. Muscles of old wild-type (WT) mice demonstrated increased lipid peroxidation, decreased glutathione content, increased catalase and superoxide dismutase (SOD) activities, and an inability to activate nuclear factor (NF)-kappa B after contractions in comparison with adult WT mice. In contrast, levels of lipid peroxidation, glutathione content, and the activities of catalase and SOD in muscles of old HSP70 overexpressor mice were similar to adult mice and these muscles also maintained the ability to activate NF-kappa B after contractions. These data provide an explanation for the preservation of muscle function in old HSP70 overexpressor mice.	Univ Liverpool, Sch Clin Sci, Div Metab & Cellular Med, Liverpool L69 3GA, Merseyside, England; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Loyola Univ, Dept Physiol, Chicago, IL 60611 USA	University of Liverpool; University of California System; University of California San Diego; Loyola University Chicago	McArdle, A (corresponding author), Univ Liverpool, Sch Clin Sci, Div Metab & Cellular Med, Liverpool L69 3GA, Merseyside, England.	mdcr02@liv.ac.uk	Palomero, Jesus/L-4783-2014	Palomero, Jesus/0000-0002-1013-9992; Mestril, Ruben/0000-0003-3631-2236; Jackson, Malcolm/0000-0003-3683-8297	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061339, R37HL049434, R01HL067971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG020591] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37HL-049434, HL-61339, HL-67971] Funding Source: Medline; NIA NIH HHS [AG20591] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Aspnes LE, 1997, FASEB J, V11, P573, DOI 10.1096/fasebj.11.7.9212081; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BROOKS SV, 1990, AM J PHYSIOL, V258, pC436, DOI 10.1152/ajpcell.1990.258.3.C436; BROOKS SV, 1988, J PHYSIOL-LONDON, V404, P71, DOI 10.1113/jphysiol.1988.sp017279; CHIRICO S, 1994, METHOD ENZYMOL, V233, P314; Claiborne A, 1985, CRC HDB METHODS OXYG, P283; Cotto JJ, 1999, BIOCHEM SOC SYMP, P105; Crapo J D, 1978, Methods Enzymol, V53, P382; DIMONTE D, 1984, ARCH BIOCHEM BIOPHYS, V235, P334, DOI 10.1016/0003-9861(84)90206-6; Drew B, 2003, AM J PHYSIOL-REG I, V284, pR474, DOI 10.1152/ajpregu.00455.2002; Grune T, 2001, J GERONTOL A-BIOL, V56, pB459, DOI 10.1093/gerona/56.11.B459; HADLEY EC, 1993, J GERONTOL, V48, pR7, DOI 10.1093/geronj/48.Special_Issue.vii; Hollander JM, 2003, FREE RADICAL BIO MED, V35, P742, DOI 10.1016/S0891-5849(03)00400-3; Jackson MJ, 2002, MOL ASPECTS MED, V23, P209, DOI 10.1016/S0098-2997(02)00018-3; JACKSON MJ, 1985, BIOCHIM BIOPHYS ACTA, V847, P185, DOI 10.1016/0167-4889(85)90019-9; JI LL, 1990, AM J PHYSIOL, V258, pR918, DOI 10.1152/ajpregu.1990.258.4.R918; Kumar A, 2003, FASEB J, V17, P386, DOI 10.1096/fj.02-0542com; Lass A, 1998, FREE RADICAL BIO MED, V25, P1089, DOI 10.1016/S0891-5849(98)00144-0; LEEUWENBURGH C, 1994, AM J PHYSIOL, V267, pR439, DOI 10.1152/ajpregu.1994.267.2.R439; LUHTALA TA, 1994, J GERONTOL, V49, pB231, DOI 10.1093/geronj/49.5.B231; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; McArdle A, 2001, AM J PHYSIOL-CELL PH, V280, pC621, DOI 10.1152/ajpcell.2001.280.3.C621; McArdle A, 2003, FASEB J, V17, P355, DOI 10.1096/fj.03-0395fje; McArdle A, 2004, AM J PHYSIOL-CELL PH, V286, pC1152, DOI 10.1152/ajpcell.00322.2003; Merry BJ, 2002, INT J BIOCHEM CELL B, V34, P1340, DOI 10.1016/S1357-2725(02)00038-9; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Porter M. M., 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P129; Radak Z, 2002, EXP GERONTOL, V37, P1423, DOI 10.1016/S0531-5565(02)00116-X; Reid MB, 2002, ANN NY ACAD SCI, V959, P108, DOI 10.1111/j.1749-6632.2002.tb02087.x; Reid MB, 1996, NEWS PHYSIOL SCI, V11, P114, DOI 10.1152/physiologyonline.1996.11.3.114; Sastre J, 2003, FREE RADICAL BIO MED, V35, P1, DOI 10.1016/S0891-5849(03)00184-9; Selsby JT, 2005, EXP GERONTOL, V40, P37, DOI 10.1016/j.exger.2004.08.012; SOHAL RS, 1992, ANN NY ACAD SCI, V663, P74, DOI 10.1111/j.1749-6632.1992.tb38651.x; Vasilaki A, 2003, BIOCHEM SOC T, V31, P455, DOI 10.1042/BST0310455; Vasilaki A, 2002, MUSCLE NERVE, V25, P902, DOI 10.1002/mus.10094; WARNER HR, 1994, FREE RADICAL BIO MED, V17, P249, DOI 10.1016/0891-5849(94)90080-9; ZERBA E, 1990, AM J PHYSIOL, V258, pC429, DOI 10.1152/ajpcell.1990.258.3.C429; Zhou LZH, 2001, FREE RADICAL BIO MED, V31, P1405, DOI 10.1016/S0891-5849(01)00719-5	39	131	136	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1549	+		10.1096/fj.05-4935fje	http://dx.doi.org/10.1096/fj.05-4935fje			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16723383				2022-12-25	WOS:000240266000047
J	Simon, DM; Arikan, MC; Srisuma, S; Bhattacharya, S; Tsai, LW; Ingenito, EP; Gonzalez, F; Shapiro, SD; Mariani, TJ				Simon, Dawn M.; Arikan, Meltem C.; Srisuma, Sorachai; Bhattacharya, Soumyaroop; Tsai, Larry W.; Ingenito, Edward P.; Gonzalez, Frank; Shapiro, Steven D.; Mariani, Thomas J.			Epithelial cell PPAR gamma contributes to normal lung maturation	FASEB JOURNAL			English	Article						Cre recombinase; Clara cell; lung development; airspace enlargement	ACTIVATED-RECEPTOR-GAMMA; NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; TERMINAL DIFFERENTIATION; ADIPOSE-TISSUE; MOUSE MODEL; INFLAMMATION; APOPTOSIS; INDUCTION; LIGANDS	Peroxisome proliferator-activated receptor (PPAR)-gamma is a member of the nuclear hormone receptor superfamily that can promote cellular differentiation and organ development. PPAR gamma expression has been reported in a number of pulmonary cell types, including inflammatory, mesenchymal, and epithelial cells. We find that PPAR gamma is prominently expressed in the airway epithelium in the mouse lung. In an effort to define the physiological role of PPAR gamma within the lung, we have ablated PPAR gamma using a novel line of mice capable of specifically targeting the airway epithelium. Airway epithelial cell PPAR gamma-targeted mice display enlarged airspaces resulting from insufficient postnatal lung maturation. The increase in airspace size is accompanied by alterations in lung physiology, including increased lung volumes and decreased tissue resistance. Genome-wide expression profiling reveals a reduction in structural extracellular matrix (ECM) gene expression in conditionally targeted mice, suggesting a disruption in epithelial-mesenchymal interactions necessary for the establishment of normal lung structure. Expression profiling of airway epithelial cells isolated from conditionally targeted mice indicates PPAR gamma regulates genes encoding known PPAR gamma targets, additional lipid metabolism enzymes, and markers of cellular differentiation. These data reveal airway epithelial cell PPAR gamma is necessary for normal lung structure and function.	Harvard Univ, Div Pulm & Crit Care Med, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Div Resp Dis, Boston, MA 02115 USA; Mahidol Univ, Siriraj Hosp, Fac Med, Dept Physiol, Bangkok 10700, Thailand; Natl Canc Inst, Lab Metab, Bethesda, MD USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Mahidol University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Mariani, TJ (corresponding author), Harvard Univ, Div Pulm & Crit Care Med, Brigham & Womens Hosp, Sch Med, 75 Francis St,Thorn 908, Boston, MA 02115 USA.	tmariani@rics.bwh.harvard.edu	Bhattacharya, Soumyaroop/E-7669-2010	Bhattacharya, Soumyaroop/0000-0003-1140-7845	NHLBI NIH HHS [HL70321, HL071885] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070321, R01HL071885] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akiyama TE, 2002, MOL CELL BIOL, V22, P2607, DOI 10.1128/MCB.22.8.2607-2619.2002; Arikan MC, 2005, J CELL PHYSIOL, V204, P139, DOI 10.1002/jcp.20271; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Benayoun L, 2001, AM J RESP CRIT CARE, V164, P1487, DOI 10.1164/ajrccm.164.8.2101070; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Birrell MA, 2004, EUR RESPIR J, V24, P18, DOI 10.1183/09031936.04.00098303; Bren-Mattison Y, 2005, ONCOGENE, V24, P1412, DOI 10.1038/sj.onc.1208333; Buhling F, 2002, DEV DYNAM, V225, P14, DOI 10.1002/dvdy.10134; Cabrero A, 2003, METABOLISM, V52, P652, DOI 10.1053/meta.2003.50100; Chang TH, 2000, CANCER RES, V60, P1129; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; Clark RB, 2000, J IMMUNOL, V164, P1364, DOI 10.4049/jimmunol.164.3.1364; Daynes RA, 2002, NAT REV IMMUNOL, V2, P748, DOI 10.1038/nri912; Drori S, 2005, GENE DEV, V19, P362, DOI 10.1101/gad.1240705; Genovese T, 2005, EUR RESPIR J, V25, P225, DOI 10.1183/09031936.05.00049704; Gosset P, 2001, EUR J IMMUNOL, V31, P2857, DOI 10.1002/1521-4141(2001010)31:10<2857::AID-IMMU2857>3.0.CO;2-X; Hammad H, 2004, AM J PATHOL, V164, P263, DOI 10.1016/S0002-9440(10)63116-1; Honda K, 2004, J ALLERGY CLIN IMMUN, V113, P882, DOI 10.1016/j.jaci.2004.02.036; Hoyle GW, 1998, AM J RESP CELL MOL, V18, P149, DOI 10.1165/ajrcmb.18.2.2803m; Ito S, 2005, J APPL PHYSIOL, V98, P503, DOI 10.1152/japplphysiol.00590.2004; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Lian XM, 2005, AM J PATHOL, V167, P813, DOI 10.1016/S0002-9440(10)62053-6; Lian XM, 2004, AM J PHYSIOL-LUNG C, V286, pL801, DOI 10.1152/ajplung.00335.2003; Mariani TJ, 2002, AM J RESP CELL MOL, V26, P541, DOI 10.1165/ajrcmb.26.5.2001-00080c; Mariani TJ, 1998, MOL BIOL CELL, V9, P1411, DOI 10.1091/mbc.9.6.1411; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Padilla J, 2000, ANN NY ACAD SCI, V905, P97; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Roth-Kleiner M, 2003, BIOL NEONATE, V84, P83, DOI 10.1159/000071009; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Shankaranarayanan P, 2003, J IMMUNOL, V170, P887, DOI 10.4049/jimmunol.170.2.887; Shannon JM, 2004, ANNU REV PHYSIOL, V66, P625, DOI 10.1146/annurev.physiol.66.032102.135749; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Tokunou M, 2000, LAB INVEST, V80, P1643, DOI 10.1038/labinvest.3780174; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; Wang ACC, 2001, AM J RESP CELL MOL, V24, P688, DOI 10.1165/ajrcmb.24.6.4376; Woerly G, 2003, J EXP MED, V198, P411, DOI 10.1084/jem.20021384; Yang L, 2003, J BIOL CHEM, V278, P36841, DOI 10.1074/jbc.M304156200; You YJ, 2002, AM J PHYSIOL-LUNG C, V283, pL1315, DOI 10.1152/ajplung.00169.2002; Yue LL, 2004, J BIOL CHEM, V279, P47626, DOI 10.1074/jbc.M408461200; Zhang JF, 2004, P NATL ACAD SCI USA, V101, P10703, DOI 10.1073/pnas.0403652101	41	81	82	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1507	+		10.1096/fj.05-5410fje	http://dx.doi.org/10.1096/fj.05-5410fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16720732				2022-12-25	WOS:000240266000033
J	Wang, X; Hockerman, GH; Green, HW; Babbs, CF; Mohammad, SI; Gerrard, D; Latour, MA; London, B; Hannon, KM; Pond, AL				Wang, Xun; Hockerman, Gregory H.; Green, Henry W., III; Babbs, Charles F.; Mohammad, Sulma I.; Gerrard, David; Latour, Mickey A.; London, Barry; Hannon, Kevin M.; Pond, Amber L.			Merg1a K+ channel induces skeletal muscle atrophy by activating the ubiquitin proteasome pathway	FASEB JOURNAL			English	Article						ectopic gene expression; hindlimb suspension; astemizole	SIGNALING PATHWAYS; I-KR; MOUSE; EXPRESSION; HYPERTROPHY; HEART; RAT; PROTEOLYSIS; COMPONENT; PROTEINS	Skeletal muscle atrophy results from an imbalance in protein degradation and protein synthesis and occurs in response to injury, various disease states, disuse, and normal aging. Current treatments for this debilitating condition are inadequate. More information about mechanisms involved in the onset and progression of muscle atrophy is necessary for development of more effective therapies. Here we show that expression of the mouse ether-a-go-go related gene (Merg1a) K+ channel is up-regulated in skeletal muscle of mice experiencing atrophy as a result of both malignant tumor expression and disuse. Further, ectopic expression of Merg1a in vivo induces atrophy in healthy wt-bearing mice, while expression of a dysfunctional Merg1a mutant suppresses atrophy in hindlimb-suspended mice. Treatment of hindlimb-suspended mice with astemizole, a known Merg1a channel blocker, inhibits atrophy in these animals. Importantly, in vivo expression of Merg1a in mouse skeletal muscle activates the ubiquitin proteasome pathway that is responsible for the majority of protein degradation that causes muscle atrophy, yet expression of a dysfunctional Merg1a mutant decreases levels of ubiquitin-proteasome proteolysis. Thus, expression of Merg1a likely initiates atrophy by activating ubiquitin-proteasome proteolysis. This gene and its product are potential targets for prevention and treatment of muscle atrophy.	Purdue Univ, Sch Vet Med, Dept Basic Med Sci, W Lafayette, IN 47907 USA; Purdue Univ, Coll Pharm, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA; Purdue Univ, Sch Vet Med, Dept Vet Clin Sci, W Lafayette, IN 47907 USA; Purdue Univ, Dept Vet Pathobiol, W Lafayette, IN 47907 USA; Purdue Univ, Ctr Canc, W Lafayette, IN 47907 USA; Purdue Univ, Coll Agr, Dept Anim Sci, W Lafayette, IN 47907 USA; Univ Pittsburgh, Cardiovasc Inst, Pittsburgh, PA USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Pond, AL (corresponding author), Purdue Univ, Sch Vet Med, Dept Basic Med Sci, 625 Harrison St, W Lafayette, IN 47907 USA.	pond@purdue.edu	gerrard, david/AAG-7507-2019	gerrard, david/0000-0002-3482-1400; Pond, Amber/0000-0002-2836-889X; London, Barry/0000-0003-1506-3947				Alzghoul MB, 2004, FASEB J, V18, P221, DOI 10.1096/fj.03-0293fje; BIAN JS, 2004, AJP HEART, V287, P2154; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Chiesa N, 1997, J PHYSIOL-LONDON, V501, P313, DOI 10.1111/j.1469-7793.1997.313bn.x; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Franch HA, 2005, CURR OPIN CLIN NUTR, V8, P271, DOI 10.1097/01.mco.0000165005.01331.45; Fraysse B, 2003, FASEB J, V17, P1916, DOI 10.1096/fj.02-1012fje; Glass DJ, 2003, NAT CELL BIOL, V5, P87, DOI 10.1038/ncb0203-87; Haddad F, 2003, J APPL PHYSIOL, V95, P791, DOI 10.1152/japplphysiol.01113.2002; Jackman RW, 2004, AM J PHYSIOL-CELL PH, V287, pC834, DOI 10.1152/ajpcell.00579.2003; Jones EMC, 2004, J BIOL CHEM, V279, P44690, DOI 10.1074/jbc.M408344200; Kirchhoff S, 1998, CURR BIOL, V8, P299, DOI 10.1016/S0960-9822(98)70114-9; LeesMiller JP, 1997, CIRC RES, V81, P719; London B, 1997, CIRC RES, V81, P870; Luker GD, 2003, NAT MED, V9, P969, DOI 10.1038/nm894; Matsushita S, 1999, CANCER RES, V59, P1911; McArdle A, 2003, FASEB J, V17, P355, DOI 10.1096/fj.03-0395fje; Miranda P, 2005, J PHYSIOL-LONDON, V566, P717, DOI 10.1113/jphysiol.2005.085803; Mitchell GF, 1998, AM J PHYSIOL-HEART C, V274, pH747, DOI 10.1152/ajpheart.1998.274.3.H747; Pette D, 2001, HISTOCHEM CELL BIOL, V115, P359, DOI 10.1007/s004180100268; Polvani S, 2003, GENE EXPR PATTERNS, V3, P767, DOI 10.1016/S1567-133X(03)00124-8; Pond AL, 2000, J BIOL CHEM, V275, P5997, DOI 10.1074/jbc.275.8.5997; Razeghi P, 2003, CIRCULATION, V108, P2536, DOI 10.1161/01.CIR.0000096481.45105.13; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Rosati B, 2000, FASEB J, V14, P2601, DOI 10.1096/fj.00-0077com; SCULPTOREANU A, 1993, NATURE, V364, P240, DOI 10.1038/364240a0; Selyanko AA, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-05-j0001.2002; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; Tawa NE, 1997, J CLIN INVEST, V100, P197, DOI 10.1172/JCI119513; Taylor J, 2004, BMC BIOTECHNOL, V4, DOI 10.1186/1472-6750-4-11; Thomas D, 2004, BASIC RES CARDIOL, V99, P279, DOI 10.1007/s00395-004-0474-7; Zhou ZF, 1999, J CARDIOVASC ELECTR, V10, P836, DOI 10.1111/j.1540-8167.1999.tb00264.x	32	21	23	2	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1531	+		10.1096/fj.05-5350fje	http://dx.doi.org/10.1096/fj.05-5350fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16723379				2022-12-25	WOS:000240266000041
J	Balkhi, MY; Trivedi, AK; Geletu, M; Christopeit, M; Bohlander, SK; Behre, HM; Behre, G				Balkhi, M. Y.; Trivedi, A. K.; Geletu, M.; Christopeit, M.; Bohlander, S. K.; Behre, H. M.; Behre, G.			Proteomics of acute myeloid leukaemia: cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications	ONCOGENE			English	Article						acute myeloid leukaemia; proteomics; post-translational modification; mass spectrometry	N-ARGININE METHYLATION; C/EBP-ALPHA; O-GLCNAC; EXPRESSION; CANCER; IDENTIFICATION; GLYCOSYLATION; SUPPRESSES; DISEASE; CEBPA	Acute myeloid leukaemia (AML) is characterized by specific cytogenetic aberrations that are strong determinants of prognostic outcome and therapeutic response. Because the pathological outcome of AML patients with cytogenetic abnormalities differs considerably, we hypothesized that their proteome may also differ specifically in their expression pattern, protein interaction pathways and post-translational modifications (PTM). We performed this study using 42 AML patients diagnosed for various cytogenetic abnormalities based on two-dimensional gel electrophoresis and matrix-assisted laser desorption/ ionization time of flight mass spectrometry (MS) and MSMS tandem MS. We could identify signi. cant differences in the proteome and PTM of peptides, later confirmed by other methods, between cytogenetic groups. The interactome analysis based on computational bioinformatics reveals major regulating networks: MAPK8 and MYC for complex aberrant karyotype, TP53 for t(8; 21), TP53-MYC-PRKAC for 11q23 and JUN and MYC for Inv(16). Further, we analysed 42 MS spectra representative of hnRNPH1, calreticulin and hnRNPA2/ B1 in a peak explorer, which reveals a cytogenetic-specific PTM of beta-O-linked N-acetyl glucosamine (O-GlcNAc) of hnRNPH1 in AML patients with 11q23 translocation, an acetylation of calreticulin in t(8; 21) translocation and methylation of hnRNPA2/ B1 in patients with translocations of t(8; 21) and inv(16). This report may lead to a new thinking about AML pathogenesis, as differences at PTM level could be used to distinguish different subtypes of AML.	Univ Halle Wittenberg, Bone Marrow Transplantat Sect, Dept Internal Med Hematol & Oncol 4, State Ctr Cell & Gene Therapy, D-06097 Halle, Germany; Univ Munich, Dept Med 3, Munich, Germany; Univ Halle Wittenberg, Dept Urol, Androl Sect, D-06097 Halle, Germany	Martin Luther University Halle Wittenberg; University of Munich; Martin Luther University Halle Wittenberg	Behre, G (corresponding author), Univ Halle Wittenberg, Bone Marrow Transplantat Sect, Dept Internal Med Hematol & Oncol 4, State Ctr Cell & Gene Therapy, Ernst Grube Str 40, D-06097 Halle, Germany.	gerhard.behre@medizin.uni-halle.de	Trivedi, Arun Kumar/W-1883-2019	Trivedi, Arun Kumar/0000-0002-6316-0947; Bohlander, Stefan/0000-0002-2202-9088; Christopeit, Maximilian/0000-0003-4627-0412				Bienz M, 2005, CLIN CANCER RES, V11, P1416, DOI 10.1158/1078-0432.CCR-04-1552; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Cristea IM, 2004, BLOOD, V103, P3624, DOI 10.1182/blood-2003-09-3295; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Gurbuxani S, 2005, P NATL ACAD SCI USA, V102, P11480, DOI 10.1073/pnas.0500303102; Haferlach T., 2004, Annals of Hematology, V83, pS97; Helbling D, 2005, BLOOD, V106, P1369, DOI 10.1182/blood-2004-11-4392; Helbling D, 2004, P NATL ACAD SCI USA, V101, P13312, DOI 10.1073/pnas.0404731101; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; IGARASHI K, 1995, P NATL ACAD SCI USA, V92, P7445, DOI 10.1073/pnas.92.16.7445; Khidekel N, 2004, P NATL ACAD SCI USA, V101, P13132, DOI 10.1073/pnas.0403471101; Li C, 1998, ARCH BIOCHEM BIOPHYS, V351, P53, DOI 10.1006/abbi.1997.0526; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lin CH, 2000, J BIOCHEM, V128, P493, DOI 10.1093/oxfordjournals.jbchem.a022779; Lominadze G, 2005, J IMMUNOL, V174, P7257, DOI 10.4049/jimmunol.174.11.7257; Mann M, 2003, NAT BIOTECHNOL, V21, P255, DOI 10.1038/nbt0303-255; Marcucci G, 2004, J CLIN ONCOL, V22, P2410, DOI 10.1200/JCO.2004.03.023; Nedelkov D, 2005, P NATL ACAD SCI USA, V102, P10852, DOI 10.1073/pnas.0500426102; Petricoin EF, 2005, J CLIN ONCOL, V23, P3614, DOI 10.1200/JCO.2005.02.509; Sagil D, 2005, PROTEOMICS, V5, P2689, DOI 10.1002/pmic.200401312; Satterwhite E, 2001, BLOOD, V98, P3413, DOI 10.1182/blood.V98.12.3413; Schoch C, 2005, GENE CHROMOSOME CANC, V43, P227, DOI 10.1002/gcc.20193; Timchenko LT, 2002, MOL CELL BIOL, V22, P7242, DOI 10.1128/MCB.22.20.7242-7257.2002; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Vosseller K, 2001, BIOCHIMIE, V83, P575, DOI 10.1016/S0300-9084(01)01295-0; Wang ZF, 2004, CELL, V119, P831, DOI 10.1016/j.cell.2004.11.010; Wells L, 2003, BIOCHEM BIOPH RES CO, V302, P435, DOI 10.1016/S0006-291X(03)00175-X; Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481; Zhou J, 2001, LUNG CANCER, V34, P341, DOI 10.1016/S0169-5002(01)00254-9	29	40	43	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7041	7058		10.1038/sj.onc.1209689	http://dx.doi.org/10.1038/sj.onc.1209689			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16732326				2022-12-25	WOS:000241910500004
J	Paruchuri, S; Mezhybovska, M; Juhas, M; Sjolander, A				Paruchuri, S.; Mezhybovska, M.; Juhas, M.; Sjolander, A.			Endogenous production of leukotriene D-4 mediates autocrine survival and proliferation via CysLT(1) receptor signalling in intestinal epithelial cells	ONCOGENE			English	Article						CysLT(1) receptor; apoptosis; caspase-3; epithelial cells	CANCER; DISRUPTION; INHIBITORS; APOPTOSIS; PROTEIN	The cysteinyl leukotriene(1) (CysLT(1)) receptor (CysLT(1)R) enhances survival and proliferation of intestinal cells via distinct pathways. Here, we have demonstrated that there is significant endogenous production of CysLTs from both non-tumour-and tumour-derived intestinal epithelial cells. Treatment of two non-tumour cell lines, Int 407 and IEC-6, with CysLT1R antagonists led to shrinkage and detachment of cells, confirmed as apoptotic cell death, and a dose-dependent reduction in proliferation. However, in the tumour intestinal cell lines Caco-2, SW480, HCT-116 and HT-29, treatment with CysLT1R antagonists significantly reduced proliferation, but had no effect on apoptosis. A unique characteristic of intestinal cancer cells is the presence of nuclear CysLT(1)Rs, which are inaccessible to receptor antagonists. In these cells, inhibition of the endogenous production of CysLTs indirectly, by 5-lipoxygenase inhibition, impaired CysLT1R signalling throughout the cell, and resulted in apoptosis of the tumour cells. These data reveal the existence of constitutive CysLT1R signalling that mediates both survival and proliferation in intestinal cells. Importantly, we propose that tumour-derived intestinal cells are resistant to CysLT(1)R antagonist-induced apoptosis, a phenomena that could be explained by nuclear CysLT1R signalling.	Lund Univ, Malmo Univ Hosp, Dept Lab Med, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Sjolander, A (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Lab Med, SE-20502 Malmo, Sweden.	anita.sjolander@exppat.mas.lu.se						Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Claesson HE, 1999, J INTERN MED, V245, P205, DOI 10.1046/j.1365-2796.1999.00418.x; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Ghosh J, 1998, P NATL ACAD SCI USA, V95, P13182, DOI 10.1073/pnas.95.22.13182; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Hennig R, 2004, CANCER LETT, V210, P41, DOI 10.1016/j.canlet.2004.02.023; Lee E, 2000, AM J RESP CRIT CARE, V161, P1881, DOI 10.1164/ajrccm.161.6.9907054; Lynch KR, 1999, NATURE, V399, P789; Maekawa A, 2002, J BIOL CHEM, V277, P20820, DOI 10.1074/jbc.M203163200; Mann JR, 2004, CANCER J, V10, P145, DOI 10.1097/00130404-200405000-00001; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Nielsen CK, 2005, CANCER RES, V65, P732; Ohd JF, 2000, GASTROENTEROLOGY, V119, P1007, DOI 10.1053/gast.2000.18141; Ohd JF, 2003, GASTROENTEROLOGY, V124, P57, DOI 10.1053/gast.2003.50011; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; Pachernik J, 2002, ARCH DERMATOL RES, V293, P626, DOI 10.1007/s00403-001-0288-5; Paruchuri S, 2003, J BIOL CHEM, V278, P45577, DOI 10.1074/jbc.M302881200; Paruchuri S, 2002, J CELL SCI, V115, P1883; Shi ZZ, 2001, MOL CELL BIOL, V21, P5389, DOI 10.1128/MCB.21.16.5389-5395.2001; Wkstrom K, 2003, BIOCHEM J, V371, P115; Wu X, 2003, CELL BIOL TOXICOL, V19, P135, DOI 10.1023/A:1024789810277	21	44	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6660	6665		10.1038/sj.onc.1209666	http://dx.doi.org/10.1038/sj.onc.1209666			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16715140				2022-12-25	WOS:000241569700010
J	Kavanagh, KL; Dunford, JE; Bunkoczi, G; Russell, RGG; Oppermann, U				Kavanagh, Kathryn L.; Dunford, James E.; Bunkoczi, Gabor; Russell, R. Graham G.; Oppermann, Udo			The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL DIPHOSPHATE SYNTHASE; CHAIN-LENGTH; IN-VITRO; BISPHOSPHONATES; MECHANISM; TRANSFERASE; PRENYLATION; PROTEINS; OSTEOCLASTS; MODEL	Modification of GTPases with isoprenoid molecules derived from geranylgeranyl pyrophosphate or farnesyl pyrophosphate is an essential requisite for cellular signaling pathways. The synthesis of these isoprenoids proceeds in mammals through the mevalonate pathway, and the final steps in the synthesis are catalyzed by the related enzymes farnesyl pyrophosphate synthase and geranylgeranyl pyrophosphate synthase. Both enzymes play crucial roles in cell survival, and inhibition of farnesyl pyrophosphate synthase by nitrogen-containing bisphosphonates is an established concept in the treatment of bone disorders such as osteoporosis or certain forms of cancer in bone. Here we report the crystal structure of human geranylgeranyl pyrophosphate synthase, the first mammalian ortholog to have its x-ray structure determined. It reveals that three dimers join together to form a propeller-bladed hexameric molecule with a mass of similar to 200 kDa. Structure-based sequence alignments predict this quaternary structure to be restricted to mammalian and insect orthologs, whereas fungal, bacterial, archaeal, and plant forms exhibit the dimeric organization also observed in farnesyl pyrophosphate synthase. Geranylgeranyl pyrophosphate derived from heterologous bacterial expression is tightly bound in a cavity distinct from the chain elongation site described for farnesyl pyrophosphate synthase. The structure most likely represents an inhibitory complex, which is further corroborated by steady-state kinetics, suggesting a possible feedback mechanism for regulating enzyme activity. Structural comparisons between members of this enzyme class give deeper insights into conserved features important for catalysis.	Univ Oxford, Botnar Res Ctr, Struct Genom Conortium, Oxford OX3 7LD, England; Univ Oxford, Nuffield Dept Orthopaed Surg, Botnar Res Ctr, Inst Musculoskeletal Sci, Oxford OX3 7LD, England	University of Oxford; University of Oxford	Kavanagh, KL (corresponding author), Univ Oxford, Botnar Res Ctr, Struct Genom Conortium, Oxford OX3 7LD, England.	kate.kavanagh@sgc.ox.ac.uk; udo.oppermann@sgc.ox.ac.uk		Dunford, James/0000-0002-9932-4042; Russell, Robert Graham G/0000-0002-4136-1828	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARNARD GF, 1981, BIOCHIM BIOPHYS ACTA, V661, P87, DOI 10.1016/0005-2744(81)90086-3; Basso AD, 2006, J LIPID RES, V47, P15, DOI 10.1194/jlr.R500012-JLR200; Chang TH, 2006, J BIOL CHEM, V281, P14991, DOI 10.1074/jbc.M512886200; CHEN AJ, 1994, PROTEIN SCI, V3, P600; Cheng F, 2004, J MED CHEM, V47, P5149, DOI 10.1021/jm040036s; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Coxon FP, 2001, J BIOL CHEM, V276, P48213, DOI 10.1074/jbc.M106473200; Coxon FP, 2005, BONE, V37, P349, DOI 10.1016/j.bone.2005.04.021; Coxon FP, 2003, CALCIFIED TISSUE INT, V72, P80, DOI 10.1007/s00223-002-2017-2; Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gabelli SB, 2006, PROTEINS, V62, P80, DOI 10.1002/prot.20754; Garzoni LR, 2004, INT J ANTIMICROB AG, V23, P286, DOI 10.1016/j.ijantimicag.2003.07.019; Hosfield DJ, 2004, J BIOL CHEM, V279, P8526, DOI 10.1074/jbc.C300511200; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KABSCH W, 2001, INT TABLES CRYSTALLO, VF, P218; Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103; Kuzuguchi T, 1999, J BIOL CHEM, V274, P5888, DOI 10.1074/jbc.274.9.5888; LUTZ RJ, 1992, J BIOL CHEM, V267, P7983; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Molnar G, 2001, BIOCHEMISTRY-US, V40, P10542, DOI 10.1021/bi011158e; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Murthy S, 2005, J BIOL CHEM, V280, P41793, DOI 10.1074/jbc.M504101200; Niesor EJ, 2001, CURR PHARM DESIGN, V7, P231, DOI 10.2174/1381612013398185; POULTER CD, 1977, BIOCHEMISTRY-US, V16, P5470, DOI 10.1021/bi00644a012; POULTER CD, 1978, J BIOL CHEM, V253, P7227; REED BC, 1976, BIOCHEMISTRY-US, V15, P3739, DOI 10.1021/bi00662a015; Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059; Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756-3282(99)00116-7; SAGAMI H, 1994, J BIOL CHEM, V269, P20561; Sheldrick G.M, 2001, International Tables for Macromolecular Crystallography, P333; Sheldrick GM, 2002, Z KRISTALLOGR, V217, P644, DOI 10.1524/zkri.217.12.644.20662; Sinensky M, 2000, BBA-MOL CELL BIOL L, V1529, P203, DOI 10.1016/S1388-1981(00)00149-9; Sinensky M, 2000, BBA-MOL CELL BIOL L, V1484, P93, DOI 10.1016/S1388-1981(00)00009-3; Szabo CM, 2002, J MED CHEM, V45, P2185, DOI 10.1021/jm010412y; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018	38	122	127	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22004	22012		10.1074/jbc.M602603200	http://dx.doi.org/10.1074/jbc.M602603200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16698791	Green Published, hybrid			2022-12-25	WOS:000239387100047
J	Wei, Q; Xia, Y				Wei, Qin; Xia, Yong			Proteasome inhibition down-regulates endothelial nitric-oxide synthase phosphorylation and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; ACTIVATION; UBIQUITIN; AKT; ROLES; ENOS	Endothelial nitric-oxide synthase ( eNOS) function is fundamentally modulated by protein phosphorylation. In particular, phosphorylation of serine 1179 ( bovine)/1177 ( human) by Akt has been shown to be the central mechanism of eNOS regulation. Here we revealed a novel role of proteasome in controlling eNOS serine 1179 phosphorylation and function. Rather than affecting eNOS turnover, proteasomal inhibition specifically dephosphorylated eNOS serine 1179, leading to decreased enzymatic activity. Blocking protein phosphatase 2A ( PP2A) by okadaic acid or PP2A knockdown restored eNOS serine 1179 phosphorylation and activity in proteasome-inhibited cells. Although total PP2A expression and activity in cells were not affected by proteasome inhibitors, proteasomal inhibition induced PP2A ubiquitination and ubiquitinated PP2A translocated from cytosol to membrane. Further biochemical analyses demonstrated that eNOS associated with PP2A on cell membranes. Proteasomal inhibition markedly enhanced PP2A association to eNOS, and this increase of PP2A dephosphorylated eNOS and its upstream kinase Akt. Taken together, these studies identified a novel pathway in which proteasome modulates eNOS phosphorylation by inducing intracellular PP2A translocation.	Ohio State Univ, Davis Heart & Lung Res Inst 605, Div Cardiovasc Med, Dept Mol & Cellular Biochem,Med Ctr, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Xia, Y (corresponding author), Ohio State Univ, Davis Heart & Lung Res Inst 605, Div Cardiovasc Med, Dept Mol & Cellular Biochem,Med Ctr, 473 W 12th Ave, Columbus, OH 43210 USA.	yong.xia@osumc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077575] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL77575] Funding Source: Medline; NIA NIH HHS [AG00835] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bauman AL, 2002, NAT CELL BIOL, V4, pE203, DOI 10.1038/ncb0802-e203; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Fleming I, 2003, AM J PHYSIOL-REG I, V284, pR1, DOI 10.1152/ajpregu.00323.2002; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Fulton D, 2001, J PHARMACOL EXP THER, V299, P818; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Govers R, 2003, LIFE SCI, V73, P2225, DOI 10.1016/S0024-3205(03)00644-1; Greif DM, 2002, BIOCHEMISTRY-US, V41, P15845, DOI 10.1021/bi026732g; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Osawa Y, 2003, J PHARMACOL EXP THER, V304, P493, DOI 10.1124/jpet.102.035055; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Stangl V, 2004, FASEB J, V18, P272, DOI 10.1096/fj.03-0054com; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Wei Q, 2005, J BIOL CHEM, V280, P18081, DOI 10.1074/jbc.M413607200; Witowsky JA, 2003, J BIOL CHEM, V278, P1403, DOI 10.1074/jbc.C200616200; Xia Y, 1997, P NATL ACAD SCI USA, V94, P12705, DOI 10.1073/pnas.94.23.12705	32	63	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21652	21659		10.1074/jbc.M602105200	http://dx.doi.org/10.1074/jbc.M602105200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16737962	hybrid			2022-12-25	WOS:000239387100010
J	Zhang, YN; Yeh, S; Appleton, BA; Held, HA; Kausalya, PJ; Phua, DCY; Wong, WL; Lasky, LA; Wiesmann, C; Hunziker, W; Sidhu, SS				Zhang, Yingnan; Yeh, Sherry; Appleton, Brent A.; Held, Heike A.; Kausalya, P. Jaya; Phua, Dominic C. Y.; Wong, Wai Lee; Lasky, Laurence A.; Wiesmann, Christian; Hunziker, Walter; Sidhu, Sachdev S.			Convergent and divergent ligand specificity among PDZ domains of the LAP and zonula occludens (ZO) families	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; ARMADILLO-REPEAT PROTEIN; HUMAN PHOSPHATASE HPTP1E; NMDA RECEPTOR SUBUNITS; GAP-JUNCTION PROTEIN; TIGHT JUNCTION; BETA-CATENIN; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; E-CADHERIN	We present a detailed comparative analysis of the PDZ domains of the human LAP proteins Erbin, Densin-180, and Scribble and the MAGUK ZO-1. Phage-displayed peptide libraries and in vitro affinity assays were used to define ligand binding profiles for each domain. The analysis reveals the importance of interactions with all four C-terminal residues of the ligand, which constitute a core recognition motif, and also the role of interactions with more upstream ligand residues that support and modulate the core binding interaction. In particular, the results highlight the importance of site(-1), which interacts with the penultimate residue of ligand C termini. Site(-1) was found to be monospecific in the Erbin PDZ domain (accepts tryptophan only), bispecific in the first PDZ domain of ZO-1 (accepts tryptophan or tyrosine), and promiscuous in the Scribble PDZ domains. Furthermore, it appears that the level of promiscuity within site(-1) greatly influences the range of potential biological partners and functions that can be associated with each protein. These findings show that subtle changes in binding specificity can significantly alter the range of biological partners for PDZ domains, and the insights enhance our understanding of this diverse family of peptide-binding modules.	Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Assay Automat, San Francisco, CA 94080 USA; Inst Mol & Cell Biol, Epithelial Cell Biol Lab, Singapore 138673, Singapore	Roche Holding; Genentech; Roche Holding; Genentech; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Sidhu, SS (corresponding author), Genentech Inc, Dept Prot Engn, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA.	sidhu@gene.com	Hunziker, Walter/GSM-8190-2022; Hunziker, Walter/B-3140-2010	Hunziker, Walter/0000-0002-5265-4933; Appleton, Brent/0000-0003-1136-5649; Wiesmann, Christian/0000-0002-4092-9880				Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; Apperson ML, 1996, J NEUROSCI, V16, P6839; Appleton BA, 2006, J BIOL CHEM, V281, P22312, DOI 10.1074/jbc.M602901200; Audebert S, 2004, CURR BIOL, V14, P987, DOI 10.1016/j.cub.2004.05.051; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Bryant PJ, 2000, NAT CELL BIOL, V2, pE141, DOI 10.1038/35019616; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Deshayes K, 2002, CHEM BIOL, V9, P495, DOI 10.1016/S1074-5521(02)00129-1; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Fuh G, 2000, J BIOL CHEM, V275, P21486, DOI 10.1074/jbc.275.28.21486; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; Gaudet S, 2000, P NATL ACAD SCI USA, V97, P5167, DOI 10.1073/pnas.090102397; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; Greaves S, 2000, NAT CELL BIOL, V2, pE140, DOI 10.1038/35019613; Harris BZ, 2001, J CELL SCI, V114, P3219; Harris BZ, 2001, BIOCHEMISTRY-US, V40, P5921, DOI 10.1021/bi010142l; Held HA, 2004, J MOL BIOL, V340, P587, DOI 10.1016/j.jmb.2004.04.060; Hoover KB, 1998, AM J PATHOL, V153, P1767, DOI 10.1016/S0002-9440(10)65691-X; Huang YZ, 2001, J BIOL CHEM, V276, P19318, DOI 10.1074/jbc.M100494200; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Ikari A, 2004, J BIOL CHEM, V279, P54826, DOI 10.1074/jbc.M406331200; Im YJ, 2003, J BIOL CHEM, V278, P48099, DOI 10.1074/jbc.M306919200; Im YJ, 2003, J BIOL CHEM, V278, P8501, DOI 10.1074/jbc.M212263200; Imamura F, 2002, J BIOL CHEM, V277, P3640, DOI 10.1074/jbc.M106940200; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; Izawa I, 2002, J BIOL CHEM, V277, P5345, DOI 10.1074/jbc.M110052200; Jaulin-Bastard F, 2002, J BIOL CHEM, V277, P2869, DOI 10.1074/jbc.M109652200; Jaulin-Bastard F, 2001, J BIOL CHEM, V276, P15256, DOI 10.1074/jbc.M010032200; Kang BS, 2003, STRUCTURE, V11, P845, DOI 10.1016/S0969-2126(03)00125-4; Karthikeyan S, 2002, J BIOL CHEM, V277, P18973, DOI 10.1074/jbc.M201507200; Karthikeyan S, 2001, J BIOL CHEM, V276, P19683, DOI 10.1074/jbc.C100154200; Kausalya PJ, 2004, MOL BIOL CELL, V15, P5503, DOI 10.1091/mbc.E04-04-0350; Kausalya PJ, 2001, FEBS LETT, V505, P92, DOI 10.1016/S0014-5793(01)02786-7; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kozlov G, 2000, BIOCHEMISTRY-US, V39, P2572, DOI 10.1021/bi991913c; Kozlov G, 2002, J MOL BIOL, V320, P813, DOI 10.1016/S0022-2836(02)00544-2; Laing JG, 2001, J BIOL CHEM, V276, P23051, DOI 10.1074/jbc.M100303200; Laura RP, 2002, J BIOL CHEM, V277, P12906, DOI 10.1074/jbc.M200818200; Legouis R, 2000, NAT CELL BIOL, V2, P415, DOI 10.1038/35017046; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Mathew D, 2002, CURR BIOL, V12, P531, DOI 10.1016/S0960-9822(02)00758-3; Matsumoto S, 2004, BIOCHEM BIOPH RES CO, V325, P997, DOI 10.1016/j.bbrc.2004.10.133; Metais JY, 2005, FEBS LETT, V579, P3725, DOI 10.1016/j.febslet.2005.05.062; Mitic LL, 1999, J CELL BIOL, V146, P683, DOI 10.1083/jcb.146.3.683; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; NAVARRO C, 2005, ONCOGENE; Niethammer M, 1996, J NEUROSCI, V16, P2157; Nishimura W, 2002, J NEUROSCI, V22, P757, DOI 10.1523/JNEUROSCI.22-03-00757.2002; Ohno H, 2002, ONCOGENE, V21, P7042, DOI 10.1038/sj.onc.1205852; Ohtakara K, 2002, GENES CELLS, V7, P1149, DOI 10.1046/j.1365-2443.2002.00589.x; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Patrie KM, 2002, J BIOL CHEM, V277, P30183, DOI 10.1074/jbc.M203072200; Peifer M, 2000, NATURE, V403, P611, DOI 10.1038/35001187; Perego C, 2000, EMBO J, V19, P3978, DOI 10.1093/emboj/19.15.3978; Rajasekaran AK, 1996, J CELL BIOL, V132, P451, DOI 10.1083/jcb.132.3.451; Roche JP, 2002, J NEUROSCI, V22, P6471, DOI 10.1523/jneurosci.22-15-06471.2002; Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397; Santoni MJ, 2002, TRENDS GENET, V18, P494, DOI 10.1016/S0168-9525(02)02738-5; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Sheng M, 2001, P NATL ACAD SCI USA, V98, P7058, DOI 10.1073/pnas.111146298; Shibata T, 2003, HEPATOLOGY, V38, P178, DOI 10.1053/jhep.2003.50270; Sidhu SS, 2000, METHOD ENZYMOL, V328, P333, DOI 10.1016/S0076-6879(00)28406-1; Skelton NJ, 2003, J BIOL CHEM, V278, P7645, DOI 10.1074/jbc.M209751200; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stricker NL, 1999, METHOD ENZYMOL, V303, P451; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; Wakabayashi M, 2003, J BIOL CHEM, V278, P21709, DOI 10.1074/jbc.M211004200; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Wodarz A, 2000, CURR BIOL, V10, pR624, DOI 10.1016/S0960-9822(00)00658-8; Yon C, 2005, J BIOL CHEM, V280, P27412, DOI 10.1074/jbc.M501393200; YONEMURA S, 1995, J CELL SCI, V108, P127; Zito K, 1997, NEURON, V19, P1007, DOI 10.1016/S0896-6273(00)80393-1	92	86	90	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22299	22311		10.1074/jbc.M602902200	http://dx.doi.org/10.1074/jbc.M602902200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16737968	hybrid			2022-12-25	WOS:000239387100075
J	Borza, CM; Pozzi, A; Borza, DB; Pedchenko, V; Hellmark, T; Hudson, BG; Zent, R				Borza, Corina M.; Pozzi, Ambra; Borza, Dorin-Bogdan; Pedchenko, Vadim; Hellmark, Thomas; Hudson, Billy G.; Zent, Roy			Integrin alpha 3 beta 1, a Novel Receptor for alpha 3(IV) noncollagenous domain and a trans-dominant inhibitor for integrin alpha v beta 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTINCT ANTITUMOR PROPERTIES; GROWTH IN-VIVO; IV COLLAGEN; INTEGRIN ALPHA(V)BETA(3); TUMOR-CELLS; BASEMENT-MEMBRANE; GOODPASTURE AUTOANTIGEN; NC1 DOMAIN; CHAIN; TUMSTATIN	Exogenous soluble human alpha 3 noncollagenous (NC1) domain of collagen IV inhibits angiogenesis and tumor growth. These biological functions are attributed to the binding of alpha 3NC1 to integrin alpha v beta 3. However, in some tumor cells that express integrin alpha v beta 3, the alpha 3NC1 domain does not inhibit proliferation, suggesting that integrin alpha v beta 3 expression is not sufficient to mediate the anti-tumorigenic activity of this domain. Therefore, in the present study, we searched for novel binding receptors for the soluble alpha 3NC1 domain in cells lacking alpha v beta 3 integrin. In these cells, soluble alpha 3NC1 bound integrin alpha 3 beta 1; however, unlike alpha v beta 3, alpha 3 beta 1 integrin did not mediate cell adhesion to immobilized alpha 3NC1 domain. Interestingly, in cells lacking integrin alpha 3 beta 1, adhesion to the alpha 3NC1 domain was enhanced due to activation of integrin alpha v beta 3. These findings indicate that integrin alpha 3 beta 1 is a receptor for the alpha 3NC1 domain and transdominantly inhibits integrin alpha v beta 3 activation. Thus integrin alpha 3 beta 1, in conjunction with integrin alpha v beta 3, modulates cellular responses to the alpha 3NC1 domain, which may be pivotal in the mechanism underpinning its anti-angiogenic and anti-tumorigenic activities.	Vanderbilt Univ, Ctr Med, Dept Med, Sch Med,Div Nephrol, Nashville, TN 37232 USA; Vet Affairs Hosp, Dept Med Res, Nashville, TN 37232 USA; Lund Univ, Kidney Res Lab, S-22185 Lund, Sweden	Vanderbilt University; Lund University	Hudson, BG (corresponding author), Vanderbilt Univ, Ctr Med, Dept Med, Sch Med,Div Nephrol, Rm C3210, Nashville, TN 37232 USA.	Billy.Hudson@vanderbilt.edu	Borza, Corina/AAF-5292-2020; Hellmark, Thomas/U-6289-2017; Pedchenko, Vadim/A-6873-2009; Borza, Dorin-Bogdan/AAF-2156-2020; Borza, Corina/A-1603-2013	Hellmark, Thomas/0000-0002-2952-1155; Borza, Dorin-Bogdan/0000-0003-4568-279X; Hudson, Billy/0000-0002-5420-4100; Borza, Corina/0000-0001-9113-110X	NATIONAL CANCER INSTITUTE [R01CA094849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK065375, R37DK018381, R01DK074359, R01DK069921, P01DK065123] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA94849] Funding Source: Medline; NIDDK NIH HHS [P01 DK65123, 4R37 DK18381, R01-DK074359, 5F32 DK065375, R01-DK 69921] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; Borza DB, 2002, J BIOL CHEM, V277, P40075, DOI 10.1074/jbc.M207769200; Chen D, 2004, AM J PHYSIOL-RENAL, V287, pF602, DOI 10.1152/ajprenal.00015.2004; Chen LL, 2003, KIDNEY INT, V64, P2108, DOI 10.1046/j.1523-1755.2003.00332.x; Colorado PC, 2000, CANCER RES, V60, P2520; Frank DB, 2005, CIRC RES, V97, P496, DOI 10.1161/01.RES.0000181152.65534.07; Gonzalez AM, 2002, P NATL ACAD SCI USA, V99, P16075, DOI 10.1073/pnas.252649399; Han J, 1997, J BIOL CHEM, V272, P20395, DOI 10.1074/jbc.272.33.20395; Hodivala-Dilke KM, 1998, J CELL BIOL, V142, P1357, DOI 10.1083/jcb.142.5.1357; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Konstandin MH, 2006, J IMMUNOL METHODS, V310, P67, DOI 10.1016/j.jim.2005.12.005; Ly DP, 2003, J BIOL CHEM, V278, P21878, DOI 10.1074/jbc.M212538200; Maeshima Y, 2000, J BIOL CHEM, V275, P23745, DOI 10.1074/jbc.C000186200; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; Maeshima Y, 2001, J BIOL CHEM, V276, P31959, DOI 10.1074/jbc.M103024200; Maeshima Y, 2001, J BIOL CHEM, V276, P15240, DOI 10.1074/jbc.M007764200; Magnon C, 2005, CANCER RES, V65, P4353, DOI 10.1158/0008-5472.CAN-04-3536; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; Netzer KO, 1999, J BIOL CHEM, V274, P11267, DOI 10.1074/jbc.274.16.11267; Pampori N, 1999, J BIOL CHEM, V274, P21609, DOI 10.1074/jbc.274.31.21609; Pasco S, 2000, CANCER RES, V60, P467; Pasco S, 2000, J BIOL CHEM, V275, P32999, DOI 10.1074/jbc.M005235200; Pasco S, 2005, CANCER DETECT PREV, V29, P260, DOI 10.1016/j.cdp.2004.09.003; Pasco S, 2004, EXP CELL RES, V301, P251, DOI 10.1016/j.yexcr.2004.07.036; Pedchenko V, 2004, J BIOL CHEM, V279, P2772, DOI 10.1074/jbc.M311901200; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; Pozzi A, 2002, ONCOGENE, V21, P272, DOI 10.1038/sj.onc.1205045; Roth JM, 2005, AM J PATHOL, V166, P901, DOI 10.1016/S0002-9440(10)62310-3; Shahan T, 2004, CONNECT TISSUE RES, V45, P151, DOI 10.1080/03008200490505923; Shahan TA, 1999, CANCER RES, V59, P4584; Shahan TA, 2000, J BIOL CHEM, V275, P4796, DOI 10.1074/jbc.275.7.4796; Wang ZM, 1999, J CELL SCI, V112, P2925; Yao B, 2005, HUM GENE THER, V16, P1075, DOI 10.1089/hum.2005.16.1075; ZHANG XM, 1994, DEV BIOL, V164, P10, DOI 10.1006/dbio.1994.1176	35	49	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20932	20939		10.1074/jbc.M601147200	http://dx.doi.org/10.1074/jbc.M601147200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16731529	hybrid			2022-12-25	WOS:000239187300030
J	Gonzalez, L; Agullo-Ortuno, MT; Garcia-Martinez, JM; Calcabrini, A; Gamallo, C; Palacios, J; Aranda, A; Martin-Perez, J				Gonzalez, Lorena; Agullo-Ortuno, Maria Teresa; Garcia-Martinez, Jose Manuel; Calcabrini, Annarica; Gamallo, Carlos; Palacios, Jose; Aranda, Ana; Martin-Perez, Jorge			Role of c-Src in human MCF7 breast cancer cell tumorigenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PP60C-SRC PROTEIN-KINASE; EPIDERMAL-GROWTH-FACTOR; FAMILY KINASES; PHOSPHATIDYLINOSITOL 3-KINASE; GENE-EXPRESSION; MEDIATED PHOSPHORYLATION; TUMOR PROGRESSION; INDUCED APOPTOSIS; REGULATED KINASE	To study the role of c-Src in breast cancer tumorigenesis, we generated a cell line derived from MCF7 carrying an inducible dominant negative c-Src ( c-SrcDN: K295M/Y527F) under tetracycline control ( Tet-On system). c-SrcDN expression caused phenotypic changes, relocation of c-Src, Fak, and paxillin, and loss of correct actin fiber assembly. These alterations were coupled to increased Fak-Tyr(397) autophosphorylation and to inhibition of Fak-Tyr(925), p130(CAS),and paxillin phosphorylation. An increased association of total Src with Fak and a decreased interaction of p130CAS and p85-PI3K with Fak were also observed. SrcDN inhibited cell attachment, spreading, and migration. Serum and EGF-induced stimulation of cell proliferation and Akt phosphorylation were also significantly reduced by SrcDN, whereas p27(Kip1) expression was increased. Consistently, silencing c-Src expression by siRNA in MCF7 cells significantly reduced cell migration, attachment, spreading and proliferation. Inoculation of MCF7 cells carrying inducible SrcDN to nude mice generated tumors. However, doxycycline administration to mice significantly reduced tumorigenesis, and when doxycycline treatment was installed after tumor development, a significant tumor regression was observed. In both situations, inhibition of tumorigenesis was associated with decreased Ki67 staining and increased apoptosis in tumors. These data undoubtedly demonstrate the relevance of the Src/Fak complex in breast cancer tumorigenesis.	UAM, CSIC, Inst Invest Biomed Alberto Sols, Madrid, Spain; Ist Super Sanita, I-00161 Rome, Italy; Ctr Nacl Invest Oncol, Madrid 28029, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Istituto Superiore di Sanita (ISS)	Martin-Perez, J (corresponding author), UAM, CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid, Spain.	jmartin@iib.uam.es	Martínez, José Manuel García/AAB-5909-2019; Agulló-Ortuño, M. Teresa/ABA-3155-2021; Aranda, Ana/ABG-8820-2020; Martin-Perez, Jorge/A-3522-2008; Agulló Ortuño, M. Teresa/T-1494-2017; Palacios, Jose/AAV-3765-2020; Calcabrini, Annarica/C-9897-2015	Martínez, José Manuel García/0000-0002-6498-5174; Agulló-Ortuño, M. Teresa/0000-0002-7617-6681; Aranda, Ana/0000-0002-8338-9589; Martin-Perez, Jorge/0000-0002-2292-0057; Agulló Ortuño, M. Teresa/0000-0002-7617-6681; Calcabrini, Annarica/0000-0002-9600-1117; Gonzalez, Lorena/0000-0002-0575-7833				Acosta JJ, 2003, MOL ENDOCRINOL, V17, P2268, DOI 10.1210/me.2002-0422; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; Brunton VG, 2005, CANCER RES, V65, P1335, DOI 10.1158/0008-5472.CAN-04-1949; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Chan PC, 1999, J BIOL CHEM, V274, P26901, DOI 10.1074/jbc.274.38.26901; Chang LC, 2005, J BIOMED SCI, V12, P571, DOI 10.1007/s11373-005-7212-5; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Dominguez-Caceres MA, 2004, ONCOGENE, V23, P7378, DOI 10.1038/sj.onc.1208002; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Gaben AM, 2004, MOL ENDOCRINOL, V18, P2700, DOI 10.1210/me.2003-0133; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; Haynes MP, 2003, J BIOL CHEM, V278, P2118, DOI 10.1074/jbc.M210828200; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; HYNES R, 1982, CELL, V28, P437, DOI 10.1016/0092-8674(82)90196-9; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; JACOBS C, 1983, CANCER RES, V43, P1696; Jones RJ, 2002, BRIT J CANCER, V87, P1128, DOI 10.1038/sj.bjc.6600594; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kim HP, 2005, BBA-MOL CELL RES, V1743, P151, DOI 10.1016/j.bbamcr.2004.09.014; Kook S, 2000, CELL BIOCHEM FUNCT, V18, P1; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Maly DJ, 2000, P NATL ACAD SCI USA, V97, P2419, DOI 10.1073/pnas.97.6.2419; Migliaccio A, 2002, J STEROID BIOCHEM, V83, P31, DOI 10.1016/S0960-0760(02)00264-9; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Moissoglu K, 2005, BIOCHEM BIOPH RES CO, V330, P673, DOI 10.1016/j.bbrc.2005.03.025; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Munoz-Guerra MF, 2005, CANCER-AM CANCER SOC, V103, P960, DOI 10.1002/cncr.20858; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Olayioye MA, 2001, EXP CELL RES, V267, P81, DOI 10.1006/excr.2001.5242; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Pal S, 2001, CANCER RES, V61, P6952; Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Vara JAF, 2001, MOL BIOL CELL, V12, P2171, DOI 10.1091/mbc.12.7.2171; Venditti M, 2002, INT J CANCER, V99, P35, DOI 10.1002/ijc.10269; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wei L, 2004, J CELL BIOCHEM, V91, P325, DOI 10.1002/jcb.10760; Weng LP, 1999, GENES CELLS, V4, P185, DOI 10.1046/j.1365-2443.1999.00251.x; Westhoff MA, 2004, MOL CELL BIOL, V24, P8113, DOI 10.1128/MCB.24.18.8113-8133.2004; Xia H, 2004, J BIOL CHEM, V279, P33024, DOI 10.1074/jbc.M313265200; Yakes FM, 2002, CANCER RES, V62, P4132	61	73	77	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20851	20864		10.1074/jbc.M601570200	http://dx.doi.org/10.1074/jbc.M601570200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16728403	hybrid			2022-12-25	WOS:000239187300022
J	Keppler, BR; Grady, AT; Jarstfer, MB				Keppler, Brian R.; Grady, Allen T.; Jarstfer, Michael B.			The biochemical role of the heat shock protein 90 chaperone complex in establishing human telomerase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; CATALYTIC SUBUNIT GENE; REVERSE-TRANSCRIPTASE; GLUCOCORTICOID-RECEPTOR; TUMOR-CELLS; MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; BINDING DOMAIN; HSP90; RNA	Telomerase is a ribonucleoprotein complex that synthesizes the G-rich DNA found at the 3'-ends of linear chromosomes. Human telomerase consists minimally of a catalytic protein ( hTERT) and a template-containing RNA(hTR), although other proteins are involved in regulating telomerase activity in vivo. Several chaperone proteins, including hsp90 and p23, have demonstrable roles in establishing telomerase activity both in vitro and in vivo, and previous reports indicate that hsp90 and p23 are required for the reconstitution of telomerase activity from recombinant hTERT and hTR. Here we report that hTERT and hTR associate in the absence of a functional hsp90-p23 heterocomplex. We also report that hsp90 inhibitors geldanamycin and novobiocin inhibit recombinant telomerase even after telomerase is assembled. Inhibition by geldanamycin could be overcome by allowing telomerase to first bind its primer, suggesting a role for hsp90 in loading telomerase onto the telomere. Inhibition by novobiocin could not similarly be overcome but instead resulted in destabilization of the hTERT polypeptide. We propose that the hsp90-p23 complex fine tunes and stabilizes a functional telomerase structure, allowing primer loading and extension.	Univ N Carolina, Sch Pharm, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Jarstfer, MB (corresponding author), Univ N Carolina, Sch Pharm, Div Med Chem & Nat Prod, Campus Box 7360, Chapel Hill, NC 27599 USA.	jarstfer@unc.edu		Keppler, Bernhard/0000-0003-0877-1822				Akalin A, 2001, CANCER RES, V61, P4791; Barent RL, 1998, MOL ENDOCRINOL, V12, P342, DOI 10.1210/me.12.3.342; Bledsoe RK, 2002, CELL, V110, P93, DOI 10.1016/S0092-8674(02)00817-6; Bohen SP, 1998, MOL CELL BIOL, V18, P3330, DOI 10.1128/MCB.18.6.3330; Bryan TM, 2000, MOL CELL, V6, P493, DOI 10.1016/S1097-2765(00)00048-4; Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; Chang JTC, 2002, EUR J BIOCHEM, V269, P3442, DOI 10.1046/j.1432-1033.2002.03025.x; Chen JL, 2003, EMBO J, V22, P304, DOI 10.1093/emboj/cdg024; Chen JL, 2002, NUCLEIC ACIDS RES, V30, P592, DOI 10.1093/nar/30.2.592; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; Fang YF, 1998, MOL CELL BIOL, V18, P3727, DOI 10.1128/MCB.18.7.3727; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Forsythe HL, 2001, J BIOL CHEM, V276, P15571, DOI 10.1074/jbc.C100055200; Freitag DG, 1997, BIOCHEMISTRY-US, V36, P10221, DOI 10.1021/bi963030g; Fu D, 2003, MOL CELL, V11, P1361, DOI 10.1016/S1097-2765(03)00196-5; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Haendeler J, 2003, FEBS LETT, V536, P180, DOI 10.1016/S0014-5793(03)00058-9; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; Keppler BR, 2004, BIOCHEMISTRY-US, V43, P334, DOI 10.1021/bi035583e; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; Kim JH, 2005, GENE DEV, V19, P776, DOI 10.1101/gad.1289405; Koide A, 2002, P NATL ACAD SCI USA, V99, P1253, DOI 10.1073/pnas.032665299; Konigsberg WH, 1995, METHOD ENZYMOL, V262, P331; LAI BT, 1984, MOL CELL BIOL, V4, P2802, DOI 10.1128/MCB.4.12.2802; Machida H, 2003, INT J RADIAT BIOL, V79, P973, DOI 10.1080/09553000310001626135; Marcu MG, 2000, J BIOL CHEM, V275, P37181, DOI 10.1074/jbc.M003701200; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mitchell JR, 2000, MOL CELL, V6, P361, DOI 10.1016/S1097-2765(00)00036-8; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Murphy PJM, 2001, J BIOL CHEM, V276, P30092, DOI 10.1074/jbc.M103773200; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; PRATT WB, 1993, J BIOL CHEM, V268, P21455; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Rhodes D, 2002, EMBO REP, V3, P1139, DOI 10.1093/embo-reports/kvf246; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schnapp G, 1998, NUCLEIC ACIDS RES, V26, P3311, DOI 10.1093/nar/26.13.3311; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; Tesmer VM, 1999, MOL CELL BIOL, V19, P6207; Wang XT, 2003, J VIROL, V77, P4471, DOI 10.1128/JVI.77.8.4471-4480.2003; Wegele H, 2004, REV PHYSIOL BIOCH P, V151, P1, DOI 10.1007/s10254-003-0021-1; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; YAMAKI H, 1982, J ANTIBIOT, V35, P886, DOI 10.7164/antibiotics.35.886; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007; Yun BG, 2004, BIOCHEMISTRY-US, V43, P8217, DOI 10.1021/bi0497998	56	62	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					19840	19848		10.1074/jbc.M511067200	http://dx.doi.org/10.1074/jbc.M511067200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16714764	hybrid, Green Published			2022-12-25	WOS:000239038200007
J	Kiyatkin, A; Aksamitiene, E; Markevich, NI; Borisov, NM; Hoek, JB; Kholodenko, BN				Kiyatkin, Anatoly; Aksamitiene, Edita; Markevich, Nick I.; Borisov, Nikolay M.; Hoek, Jan B.; Kholodenko, Boris N.			Scaffolding protein Grb2-associated binder 1 sustains epidermal growth factor-induced mitogenic and survival signaling by multiple positive feedback loops	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOCKING PROTEIN; MAP KINASE; PHOSPHOINOSITIDE 3-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; LYSOPHOSPHATIDIC ACID; PHOSPHORYLATION SITE; DUAL PHOSPHORYLATION; NEGATIVE FEEDBACK; TYROSINE KINASE; EGF RECEPTOR	Grb2-associated binder 1 (GAB1) is a scaffold protein involved in numerous interactions that propagate signaling by growth factor and cytokine receptors. Here we explore in silico and validate in vivo the role of GAB1 in the control of mitogenic (Ras/MAPK) and survival ( phosphatidylinositol 3-kinase (PI3K)/Akt) signaling stimulated by epidermal growth factor (EGF). We built a comprehensive mechanistic model that allows for reliable predictions of temporal patterns of cellular responses to EGF under diverse perturbations, including different EGF doses, GAB1 suppression, expression of mutant proteins, and pharmacological inhibitors. We show that the temporal dynamics of GAB1 tyrosine phosphorylation is significantly controlled by positive GAB1-PI3K feedback and negative MAPK-GAB1 feedback. Our experimental and computational results demonstrate that the essential function of GAB1 is to enhance PI3K/Akt activation and extend the duration of Ras/MAPK signaling. By amplifying positive interactions between survival and mitogenic pathways, GAB1 plays the critical role in cell proliferation and tumorigenesis.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University	Kholodenko, BN (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, 1020 Locust St, Philadelphia, PA 19107 USA.	Boris.Kholodenko@jefferson.edu	Borissoff, Nicolas/CAA-9993-2022; Nikolay, Borisov/O-9641-2017; Kiyatkin, Anatoly/A-8707-2009; markevich, nikolai i/J-9564-2014; Admin, SBI/HGB-2738-2022; Aksamitiene, Edita/AAV-3060-2020	Borissoff, Nicolas/0000-0002-1671-5524; Nikolay, Borisov/0000-0002-1671-5524; Kiyatkin, Anatoly/0000-0002-5060-6081; Hoek, Jan/0000-0001-7127-4218; Aksamitiene, Edita/0000-0002-5089-0596; Kholodenko, Boris/0000-0002-9483-4975	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA015311] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA015311] Funding Source: Medline; NIGMS NIH HHS [R01 GM059570-07, GM59570, R01 GM059570] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Arnaud M, 2004, J IMMUNOL, V173, P3962, DOI 10.4049/jimmunol.173.6.3962; Blinov ML, 2006, BIOSYSTEMS, V83, P136, DOI 10.1016/j.biosystems.2005.06.014; Blinov ML, 2004, BIOINFORMATICS, V20, P3289, DOI 10.1093/bioinformatics/bth378; Borisov NM, 2006, BIOSYSTEMS, V83, P152, DOI 10.1016/j.biosystems.2005.03.006; Borisov NM, 2005, BIOPHYS J, V89, P951, DOI 10.1529/biophysj.105.060533; Burack WR, 1997, BIOCHEMISTRY-US, V36, P5929, DOI 10.1021/bi970535d; Cai T, 2002, J CELL BIOL, V159, P103, DOI 10.1083/jcb.200205017; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; Cullen PJ, 2001, CURR BIOL, V11, pR342, DOI 10.1016/S0960-9822(01)00189-0; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Dixon RJ, 1999, KIDNEY INT, V56, P2064, DOI 10.1046/j.1523-1755.1999.00797.x; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Faeder JR, 2005, COMPLEXITY, V10, P22, DOI 10.1002/cplx.20074; Ferrell JE, 1997, J BIOL CHEM, V272, P19008, DOI 10.1074/jbc.272.30.19008; Goldstein B, 2002, MOL IMMUNOL, V38, P1213, DOI 10.1016/S0161-5890(02)00066-4; Grimm V, 2005, SCIENCE, V310, P987, DOI 10.1126/science.1116681; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Hatakeyama M, 2003, BIOCHEM J, V373, P451, DOI 10.1042/BJ20021824; Haugh JM, 1997, BIOPHYS J, V72, P2014, DOI 10.1016/S0006-3495(97)78846-5; Hlavacek WS, 2003, BIOTECHNOL BIOENG, V84, P783, DOI 10.1002/bit.10842; Hoffmann KM, 2006, CELL SIGNAL, V18, P942, DOI 10.1016/j.cellsig.2005.08.013; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Hu YL, 1996, ONCOGENE, V12, P1865; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Ingham RJ, 2001, J BIOL CHEM, V276, P12257, DOI 10.1074/jbc.M010590200; Ingham RJ, 1998, J BIOL CHEM, V273, P30630, DOI 10.1074/jbc.273.46.30630; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Kholodenko BN, 2000, TRENDS CELL BIOL, V10, P173, DOI 10.1016/S0962-8924(00)01741-4; Kholodenko BN, 1999, J BIOL CHEM, V274, P30169, DOI 10.1074/jbc.274.42.30169; Kholodenko BN, 2000, EUR J BIOCHEM, V267, P1583, DOI 10.1046/j.1432-1327.2000.01197.x; Kim SO, 2002, ENDOCRINOLOGY, V143, P4856, DOI 10.1210/en.2002-220565; King AJ, 2001, FEBS LETT, V497, P6, DOI 10.1016/S0014-5793(01)02425-5; Lamothe B, 2004, MOL CELL BIOL, V24, P5657, DOI 10.1128/MCB.24.13.5657-5666.2004; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; Lehr S, 2004, BIOCHEMISTRY-US, V43, P12133, DOI 10.1021/bi049753e; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Lok L, 2005, NAT BIOTECHNOL, V23, P131, DOI 10.1038/nbt1054; Markevich N. I., 2004, Systems Biology, V1, P104, DOI 10.1049/sb:20045003; Markevich NI, 2004, J CELL BIOL, V164, P353, DOI 10.1083/jcb.200308060; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Mattoon DR, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-24; Meng SS, 2005, BIOCHEM J, V391, P143, DOI 10.1042/BJ20050229; Moehren G, 2002, BIOCHEMISTRY-US, V41, P306, DOI 10.1021/bi011506c; Montagner A, 2005, J BIOL CHEM, V280, P5350, DOI 10.1074/jbc.M410012200; Morton-Firth CJ, 1998, J THEOR BIOL, V192, P117, DOI 10.1006/jtbi.1997.0651; O'Neill E, 2004, BRIT J CANCER, V90, P283, DOI 10.1038/sj.bjc.6601488; Osawa M, 2004, J BIOL CHEM, V279, P29691, DOI 10.1074/jbc.M309371200; Page K, 2000, AM J RESP CELL MOL, V23, P436, DOI 10.1165/ajrcmb.23.4.3953; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; RAABE T, 1995, EMBO J, V14, P2509, DOI 10.1002/j.1460-2075.1995.tb07248.x; Ren Y, 2004, J BIOL CHEM, V279, P8497, DOI 10.1074/jbc.M312575200; Resat H, 2003, BIOPHYS J, V85, P730, DOI 10.1016/S0006-3495(03)74516-0; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Roshan B, 1999, J BIOL CHEM, V274, P36362, DOI 10.1074/jbc.274.51.36362; Sasagawa S, 2005, NAT CELL BIOL, V7, P365, DOI 10.1038/ncb1233; Saxton TM, 2001, CURR BIOL, V11, P662, DOI 10.1016/S0960-9822(01)00198-1; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Schlessinger J, 2004, SCIENCE, V306, P1506, DOI 10.1126/science.1105396; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schoeberl B, 2002, NAT BIOTECHNOL, V20, P370, DOI 10.1038/nbt0402-370; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Suenaga A, 2004, J BIOL CHEM, V279, P4657, DOI 10.1074/jbc.M310598200; Tran NH, 2003, J BIOL CHEM, V278, P11221, DOI 10.1074/jbc.M210318200; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Wolf I, 2002, MOL CELL BIOL, V22, P231, DOI 10.1128/MCB.22.1.231-244.2002; Yamasaki S, 2003, ONCOGENE, V22, P1546, DOI 10.1038/sj.onc.1206284; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200; Yu CF, 2002, J BIOL CHEM, V277, P19382, DOI 10.1074/jbc.M200732200; Zhao Y, 2001, J BIOL CHEM, V276, P32382, DOI 10.1074/jbc.M103369200; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	85	127	131	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					19925	19938		10.1074/jbc.M600482200	http://dx.doi.org/10.1074/jbc.M600482200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16687399	hybrid, Green Accepted			2022-12-25	WOS:000239038200016
J	Huang, Y; Keen, JC; Pledgie, A; Marton, LJ; Zhu, T; Sukumar, S; Park, BH; Blair, B; Brenner, K; Casero, RA; Davidson, NE				Huang, Yi; Keen, Judith C.; Pledgie, Allison; Marton, Laurence J.; Zhu, Tao; Sukumar, Saraswati; Park, Ben Ho; Blair, Brian; Brenner, Keith; Casero, Robert A., Jr.; Davidson, Nancy E.			Polyamine analogues down-regulate estrogen receptor alpha expression in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED GROWTH-INHIBITION; NUCLEIC-ACID INTERACTIONS; INVOLVEMENT; APOPTOSIS; PROMOTER; BINDING; DNA	The critical role of polyamines in cell growth has led to the development of a number of agents that interfere with polyamine metabolism including a novel class of polyamine analogues, oligoamines. Here we demonstrate that oligoamines specifically suppress the mRNA and protein expression of estrogen receptor alpha (ER alpha) and ER alpha target genes in ER-positive human breast cancer cell lines, whereas neither ER beta nor other steroid hormonal receptors are affected by oligoamines. The constitutive expression of a cytomegalovirus promoter-driven exogenous ER alpha in ER-negative MDA-MB-231 human breast cancer cells was not altered by oligoamines, suggesting that oligoamines specifically suppress ER alpha transcription rather than affect mRNA or protein stability. Further analysis demonstrated that oligoamines disrupted the DNA binding activity of Sp1 transcription factor family members to an ER alpha minimal promoter element containing GC/CA-rich boxes. Treatment of MDA-MB-231 cells with the JNK-specific inhibitor SP600125 or expression of the c-Jun dominant negative inhibitor TAM67 blocked the oligoamine-activated JNK/c-Jun pathway and enhanced oligoamine-inhibited ER alpha expression, suggesting that AP-1 is a positive regulator of ER alpha expression and that oligoamine-activated JNK/AP-1 activity may antagonize the down-regulation of ER alpha induced by oligoamines. Taken together, these results suggest a novel antiestrogenic mechanism for specific polyamine analogues in human breast cancer cells.	Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Breast Canc Program, Baltimore, MD 21231 USA; Cellgate Inc, Redwood City, CA 94065 USA	Johns Hopkins University; Johns Hopkins Medicine	Davidson, NE (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Breast Canc Program, 1650 Orleans St,Rm 409, Baltimore, MD 21231 USA.	davidna@jhmi.edu	Huang, Yi/AAW-7892-2021	Huang, Yi/0000-0002-9982-117X; Casero, Robert/0000-0001-5653-3306	NATIONAL CANCER INSTITUTE [P50CA088843, R01CA051085, R01CA098454] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA088843, CA51085, P50CA88843, CA98454, R01 CA051085, R01 CA098454] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bacchi CJ, 2002, ANTIMICROB AGENTS CH, V46, P55, DOI 10.1128/AAC.46.1.55-61.2002; COHEN FJ, 1988, CANCER RES, V48, P6819; DECONINCK EC, 1995, MOL CELL BIOL, V15, P2191; deGraffenried LA, 2002, J STEROID BIOCHEM, V82, P7, DOI 10.1016/S0960-0760(02)00151-6; FEUERSTEIN BG, 1991, J CELL BIOCHEM, V46, P37, DOI 10.1002/jcb.240460107; HAWORTH IS, 1991, P ROY SOC B-BIOL SCI, V244, P107, DOI 10.1098/rspb.1991.0058; Huang Y, 2005, ANTI-CANCER DRUG, V16, P229, DOI 10.1097/00001813-200503000-00002; Huang Y, 2005, CANCER BIOL THER, V4, P1006, DOI 10.4161/cbt.4.9.1970; Huang Y, 2004, MOL CANCER RES, V2, P81; Huang Y, 2003, CLIN CANCER RES, V9, P2769; Keen JC, 2005, J BIOL CHEM, V280, P29519, DOI 10.1074/jbc.M505317200; LAMURAGLIA GM, 1986, ANN SURG, V204, P89, DOI 10.1097/00000658-198607000-00013; Leveque J, 2000, BREAST CANCER RES TR, V60, P99, DOI 10.1023/A:1006319818530; Manni A, 2002, IN VIVO, V16, P493; Manni A, 1994, Cancer Treat Res, V71, P209; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; PANAGIOTIDIS CA, 1995, NUCLEIC ACIDS RES, V23, P1800, DOI 10.1093/nar/23.10.1800; PORTER CW, 1987, CANCER, V60, P1275, DOI 10.1002/1097-0142(19870915)60:6<1275::AID-CNCR2820600619>3.0.CO;2-I; RUSSELL DH, 1983, CRC CR REV CL LAB SC, V18, P261; Shah N, 2001, ONCOGENE, V20, P1715, DOI 10.1038/sj.onc.1204247; Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011; Tang ZQ, 1997, MOL CELL BIOL, V17, P1274, DOI 10.1128/MCB.17.3.1274; THOMAS T, 1993, BREAST CANCER RES TR, V29, P189; Tomitori H, 2002, BBA-GENE STRUCT EXPR, V1579, P180, DOI 10.1016/S0167-4781(02)00545-6; Valasinas A, 2003, BIOORGAN MED CHEM, V11, P4121, DOI 10.1016/S0968-0896(03)00453-X; ZAKRZEWSKA K, 1986, BIOPOLYMERS, V25, P375, DOI 10.1002/bip.360250302	26	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19055	19063		10.1074/jbc.M600910200	http://dx.doi.org/10.1074/jbc.M600910200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16679312	hybrid, Green Accepted			2022-12-25	WOS:000238847000019
J	Omori, E; Matsumoto, K; Sanjo, H; Sato, S; Akira, S; Smart, RC; Ninomiya-Tsuji, J				Omori, Emily; Matsumoto, Kunihiro; Sanjo, Hideki; Sato, Shintaro; Akira, Shizuo; Smart, Robert C.; Ninomiya-Tsuji, Jun			TAK1 is a master regulator of epidermal homeostasis involving skin inflammation and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SEVERE LIVER DEGENERATION; KAPPA-B ACTIVATION; SIGNALING PATHWAYS; MICE DEFICIENT; RECEPTOR; SUPERFAMILY; RESISTANT; DISEASE; ALPHA	Transforming growth factor beta-activated kinase 1 (TAK1) functions downstream of inflammatory cytokines to activate c-Jun N-terminal kinase (JNK) as well as NF-kappa B in several cell types. However, the functional role of TAK1 in an in vivo setting has not been determined. Here we have demonstrated that TAK1 is the major regulator of skin inflammation as well as keratinocyte death in vivo. Epidermal-specific deletion of TAK1 causes a severe inflammatory skin condition by postnatal day 6-8. The mutant skin also exhibits massive keratinocyte death. Analysis of keratinocytes isolated from the mutant skin revealed that TAK1 deficiency results in a striking increase in apoptosis in response to tumor necrosis factor (TNF). TAK1-deficient keratinocytes cannot activate NF-kappa B or JNK upon TNF treatment. These results suggest that TNF induces TAK1-deficient keratinocyte death because of the lack of NF-kappa B (and possibly JNK)-mediated cell survival signaling. Finally, we have shown that deletion of the TNF receptor can largely rescue keratinocyte death as well as inflammatory skin condition in epidermal-specific TAK1-deficient mice. Our results demonstrate that TAK1 is a master regulator of TNF signaling in skin and regulates skin inflammation and keratinocyte death.	N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA; Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Nagoya, Aichi 4648602, Japan; RIKEN Res Ctr Allergy & Immunol, Yokohama, Kanagawa 2300045, Japan; Osaka Univ, Res Inst Microbial Dis, Dept Host Def, Osaka 5650871, Japan	University of North Carolina; North Carolina State University; Nagoya University; RIKEN; Osaka University	Ninomiya-Tsuji, J (corresponding author), N Carolina State Univ, Dept Environm & Mol Toxicol, Campus Bosx 7633, Raleigh, NC 27695 USA.	Jun_Tsuji@ncsu.edu	Akira, Shizuo/C-3134-2009	Sato, Shintaro/0000-0001-5156-3354; Smart, Robert/0000-0002-6767-6756; Ninomiya-Tsuji, Jun/0000-0002-5584-0176	NIAMS NIH HHS [AR050972, R21 AR050972] Funding Source: Medline; NIGMS NIH HHS [GM068812, R01 GM068812] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR050972] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068812] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Arnott CH, 2004, ONCOGENE, V23, P1902, DOI 10.1038/sj.onc.1207317; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630; Lind MH, 2004, P NATL ACAD SCI USA, V101, P4972, DOI 10.1073/pnas.0307106101; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Nenci A, 2006, HUM MOL GENET, V15, P531, DOI 10.1093/hmg/ddi470; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Ramirez A, 2004, GENESIS, V39, P52, DOI 10.1002/gene.20025; Rudolph D, 2000, GENE DEV, V14, P854; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; van Hogerlinden M, 2004, J INVEST DERMATOL, V123, P101, DOI 10.1111/j.0022-202X.2004.22706.x; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Wright K, 1999, J BIOL CHEM, V274, P17193, DOI 10.1074/jbc.274.24.17193; Zhang JY, 2005, J CELL BIOL, V168, P561, DOI 10.1083/jcb.200411060; Zhang JY, 2004, GENE DEV, V18, P17, DOI 10.1101/gad.1160904	28	123	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19610	19617		10.1074/jbc.M603384200	http://dx.doi.org/10.1074/jbc.M603384200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16675448	Green Accepted, hybrid			2022-12-25	WOS:000238847000075
J	Gao, Y; Wang, HY				Gao, Yuan; Wang, Hsien-yu			Casein kinase 2 is activated and essential for Wnt/beta-catenin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE CK2; F9 TERATOCARCINOMA CELLS; BETA-CATENIN; XENOPUS EMBRYOS; RAT FRIZZLED-1; AXIS FORMATION; PATHWAY; PHOSPHORYLATION; DIFFERENTIATION; DROSOPHILA	Wnt/beta-catenin signaling is essential to early development. Activation of Frizzled-1 by Wnts induces nuclear accumulation of beta-catenin and activation of Lef/Tcf-dependent gene expression. Casein kinase 2 has been shown to affect Wnt/beta-catenin signaling. How casein kinase 2 exerts an influence in Wnt signaling is not clear; casein kinase 2 has been reported to be constitutively active (i.e. not regulated). Herein we show to the contrary that casein kinase 2 activity is rapidly and transiently increased in response to Wnt3a stimulation and is essential for Wnt/beta-catenin signaling. Chemical inhibition of casein kinase 2 or suppression of its expression blocks Frizzled-1 activation of Lef/Tcf-sensitive gene expression. Treatment with pertussis toxin or knock down of G alpha(q) or G alpha(o) blocks Wnt stimulation of casein kinase 2 activation, as does suppression of the phosphoprotein Dishevelled, demonstrating that casein kinase 2 is downstream of heterotrimeric G proteins and Dishevelled. Expression of a constitutively active mutant of either G alpha(q) or G alpha(o) stimulates casein kinase 2 activation and Lef/Tcf-sensitive gene expression. Thus, casein kinase 2 is shown to be regulated by Wnt3a and essential to stimulation of the Frizzled-1/beta-catenin/Lef-Tcf pathway.	SUNY Stony Brook, Dept Physiol & Biophys, Diabet & Metab Dis Res Ctr, Sch Med,Hlth Sci Ctr, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Wang, HY (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Diabet & Metab Dis Res Ctr, Sch Med,Hlth Sci Ctr, Stony Brook, NY 11794 USA.	wangh@pharm.stonybrook.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069375] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 069375] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; Ahumada A, 2002, SCIENCE, V298, P2006, DOI 10.1126/science.1073776; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Dominguez I, 2005, MOL CELL BIOCHEM, V274, P125, DOI 10.1007/s11010-005-3073-5; Dominguez I, 2004, DEV BIOL, V274, P110, DOI 10.1016/j.ydbio.2004.06.021; Donella-Deana A, 2003, BIOCHEM J, V372, P841, DOI 10.1042/BJ20021905; Escalier D, 2003, MOL REPROD DEV, V66, P190, DOI 10.1002/mrd.10346; Hammerlein A, 2005, CELL MOL LIFE SCI, V62, P606, DOI 10.1007/s00018-005-4507-7; Homma MK, 2002, P NATL ACAD SCI USA, V99, P5959, DOI 10.1073/pnas.092143199; ITOH K, 1906, J BIOL, V4, P3; Katanaev VL, 2005, CELL, V120, P111, DOI 10.1016/j.cell.2004.11.014; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Liu T, 1999, J BIOL CHEM, V274, P33539, DOI 10.1074/jbc.274.47.33539; Liu T, 2001, SCIENCE, V292, P1718, DOI 10.1126/science.1060100; Liu XX, 1999, P NATL ACAD SCI USA, V96, P14383, DOI 10.1073/pnas.96.25.14383; Maizel A, 2002, DEVELOPMENT, V129, P3545; Malbon CC, 2001, BIOCHEM BIOPH RES CO, V287, P589, DOI 10.1006/bbrc.2001.5630; Malbon CC, 2005, NAT REV MOL CELL BIO, V6, P689, DOI 10.1038/nrm1716; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Miravet S, 2002, J BIOL CHEM, V277, P1884, DOI 10.1074/jbc.M110248200; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Pagano MA, 2004, BIOCHEM BIOPH RES CO, V321, P1040, DOI 10.1016/j.bbrc.2004.07.067; Pinna LA, 2003, ACCOUNTS CHEM RES, V36, P378, DOI 10.1021/ar020164f; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; Sarno S, 2003, BIOCHEM J, V374, P639, DOI 10.1042/BJ20030674; SOKOL SY, 1995, DEVELOPMENT, V121, P1637; Solyakov L, 2004, J BIOL CHEM, V279, P43403, DOI 10.1074/jbc.M403239200; Song DH, 2003, J BIOL CHEM, V278, P24018, DOI 10.1074/jbc.M212260200; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; Wang JB, 2004, CURR OPIN GENET DEV, V14, P533, DOI 10.1016/j.gde.2004.07.013; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1	37	85	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18394	18400		10.1074/jbc.M601112200	http://dx.doi.org/10.1074/jbc.M601112200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16672224	hybrid			2022-12-25	WOS:000238687300017
J	Hines, JK; Fromm, HJ; Honzatko, RB				Hines, Justin K.; Fromm, Herbert J.; Honzatko, Richard B.			Novel allosteric activation site in Escherichia coli fructose-1,6-bisphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRUCTOSE 1,6-BISPHOSPHATASE; CRYSTAL-STRUCTURE; RECOMBINANT PORCINE; CATION ACTIVATION; INHIBITION; PURIFICATION; MECHANISM; AMP; GLUCONEOGENESIS; BISPHOSPHATASE	Fructose-1,6-bisphosphatase (FBPase) governs a key step in gluconeogenesis, the conversion of fructose 1,6-bisphosphate into fructose 6-phosphate. In mammals, the enzyme is subject to metabolic regulation, but regulatory mechanisms of bacterial FBPases are not well understood. Presented here is the crystal structure ( resolution, u1.45 angstrom) of recombinant FBPase from Escherichia coli, the first structure of a prokaryotic Type I FBPase. The E. coli enzyme is a homotetramer, but in a quaternary state between the canonical R- and T-states of porcine FBPase. Phe(15) and residues at the C-terminal side of the first alpha-helix (helix H1) occupy the AMP binding pocket. Residues at the N-terminal side of helix H1 hydrogen bond with sulfate ions buried at a subunit interface, which in porcine FBPase undergoes significant conformational change in response to allosteric effectors. Phosphoenolpyruvate and sulfate activate E. coli FBPase by at least 300%. Key residues that bind sulfate anions are conserved among many heterotrophic bacteria, but are absent in FBPases of organisms that employ fructose 2,6-bisphosphate as a regulator. These observations suggest a new mechanism of regulation in the FBPase enzyme family: anionic ligands, most likely phosphoenolpyruvate, bind to allosteric activator sites, which in turn stabilize a tetramer and a polypeptide fold that obstructs AMP binding.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Honzatko, RB (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, 4206 Mol Biol Bldg, Ames, IA 50011 USA.	honzatko@iastate.edu			NINDS NIH HHS [NS10456] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BABUL J, 1983, ARCH BIOCHEM BIOPHYS, V225, P944, DOI 10.1016/0003-9861(83)90109-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BLANGY D, 1968, J MOL BIOL, V31, P13, DOI 10.1016/0022-2836(68)90051-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAMBOST JP, 1980, J BIOL CHEM, V255, P2867; Choe JY, 2000, BIOCHEMISTRY-US, V39, P8565, DOI 10.1021/bi000574g; Choe JY, 1998, BIOCHEMISTRY-US, V37, P11441, DOI 10.1021/bi981112u; Choe JY, 2003, J BIOL CHEM, V278, P51176, DOI 10.1074/jbc.M308396200; DALDAL F, 1983, J BACTERIOL, V153, P390, DOI 10.1128/JB.153.1.390-394.1983; Donahue JL, 2000, J BACTERIOL, V182, P5624, DOI 10.1128/JB.182.19.5624-5627.2000; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Erion MD, 2005, P NATL ACAD SCI USA, V102, P7970, DOI 10.1073/pnas.0502983102; EVANS P, 1992, MRC LMB; FRAENKEL DG, 1966, ARCH BIOCHEM BIOPHYS, V114, P4, DOI 10.1016/0003-9861(66)90298-0; FRAENKEL DG, 1965, J BACTERIOL, V90, P837, DOI 10.1128/JB.90.4.837-842.1965; FRANZEN JS, 1961, J BIOL CHEM, V236, P515; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; FUJITA Y, 1979, J BIOL CHEM, V254, P5340; HAMILTON WDO, 1988, NUCLEIC ACIDS RES, V16, P8707, DOI 10.1093/nar/16.17.8707; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HUBERT E, 1970, ARCH BIOCHEM BIOPHYS, V138, P590, DOI 10.1016/0003-9861(70)90385-1; Iancu CV, 2005, J BIOL CHEM, V280, P19737, DOI 10.1074/jbc.M501011200; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243; Kelley-Loughnane N, 2002, BBA-PROTEIN STRUCT M, V1594, P6, DOI 10.1016/S0167-4838(01)00261-8; Kelley-Loughnane N, 2001, PROTEINS, V44, P255, DOI 10.1002/prot.1090; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1971, J BIOL CHEM, V246, P6511; MARCUS F, 1984, BIOCHEM BIOPH RES CO, V119, P1103, DOI 10.1016/0006-291X(84)90888-X; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; NAKASHIMA K, 1976, J BIOL CHEM, V251, P4315; Nelson SW, 2002, J BIOL CHEM, V277, P15539, DOI 10.1074/jbc.M112304200; Nelson SW, 2001, J BIOL CHEM, V276, P6119, DOI 10.1074/jbc.M009485200; Nelson SW, 2001, FEBS LETT, V492, P254, DOI 10.1016/S0014-5793(01)02262-1; Nishimasu H, 2004, STRUCTURE, V12, P949, DOI 10.1016/j.str.2004.03.026; Okar DA, 1999, BIOFACTORS, V10, P1, DOI 10.1002/biof.5520100101; OPHEIM DJ, 1975, J BIOL CHEM, V250, P3024; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; Shyur LF, 1996, J BIOL CHEM, V271, P33301, DOI 10.1074/jbc.271.52.33301; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Van Schaftingen E., 1987, ADV ENZYMOL RELAT AR, V59, P45; VILLERET V, 1995, BIOCHEMISTRY-US, V34, P4299, DOI 10.1021/bi00013a019; Weeks CM, 1999, ACTA CRYSTALLOGR D, V55, P93, DOI 10.1107/S0907444998008750; Wright SW, 2002, J MED CHEM, V45, P3865, DOI 10.1021/jm010496a; YOSHIDA M, 1973, J BIOCHEM-TOKYO, V74, P1183, DOI 10.1093/oxfordjournals.jbchem.a130346; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755	53	31	33	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18386	18393		10.1074/jbc.M602553200	http://dx.doi.org/10.1074/jbc.M602553200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16670087	hybrid			2022-12-25	WOS:000238687300016
J	Daviaud, D; Boucher, J; Gesta, S; Dray, C; Guigne, C; Quilliot, D; Ayav, A; Ziegler, O; Carpene, C; Saulnier-Blache, JS; Valet, P; Castan-Laurell, I				Daviaud, Daniele; Boucher, Jeremie; Gesta, Stephane; Dray, Cedric; Guigne, Charlotte; Quilliot, Didier; Ayav, Ahmet; Ziegler, Olivier; Carpene, Christian; Saulnier-Blache, Jean-Sebastien; Valet, Philippe; Castan-Laurell, Isabelle			TNF alpha up-regulates apelin expression in human and mouse adipose tissue	FASEB JOURNAL			English	Article						obesity; adipocyte; adipokine	NECROSIS-FACTOR-ALPHA; PLASMINOGEN-ACTIVATOR INHIBITOR-1; INSULIN-RESISTANCE; PEPTIDE APELIN; RECEPTOR; APJ; LIGAND; OBESITY; ADIPOCYTES; CLONING	We have recently identified apelin as a novel adipokine up-regulated by insulin and obesity. Since obesity and insulin resistance are associated with chronically elevated levels of both insulin and TNF alpha, the present study was performed to investigate a putative regulation of apelin expression in adipocytes by TNF alpha. Herein, we report a tight correlation between apelin and TNF alpha expression in adipose tissue of lean and obese humans. Apelin regulation by TNF alpha was further studied in cultured explants of human adipose tissue. The endogenous expression of TNF alpha in adipocytes isolated from the explants was accompanied by a 6-9 h subsequent increase of apelin expression in adipocytes. This increase was reversed by inhibiting TNF alpha expression with 100 mu M isobutylmethylxanthine. In different mouse models of obesity, expression of both TNF alpha and apelin was also significantly increased in adipocytes of obese mice. Furthermore, short-term exposure to an i.p. injection of TNF alpha in C57B16/J mice induced an increase of apelin expression in adipose tissue as well as apelin plasma levels. Finally, a direct positive effect of TNF alpha has been shown in differentiated 3T3F442A adipocytes on apelin expression and secretion. The signaling pathways of TNF alpha for the induction of apelin were dependent of PI3-kinase, c-Jun NH2-terminal kinase (JNK), and MAPK but not PKC activation. All together, these findings suggest that apelin might be a candidate to better understand potential links between obesity and associated disorders such as inflammation and insulin resistance.	Univ Toulouse 3, Inst Louis Bugnard, FIR 31, U586,INSERM,IFR31,Unite Rech Obesites, F-31432 Toulouse 4, France; CHU Nancy, Hop J DArc, Serv Diabetol Malad Metab & Nutr, Nancy, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Nancy	Castan-Laurell, I (corresponding author), Univ Toulouse 3, Inst Louis Bugnard, FIR 31, U586,INSERM,IFR31,Unite Rech Obesites, BP 84 225, F-31432 Toulouse 4, France.	isabelle.castan@toulouse.inserm.fr	Carpéné, Christian/S-3279-2019; Valet, Philippe/N-7472-2017; Quillot, Didier/ABB-5326-2021; Saulnier-Blache, Jean Sebastien/X-7729-2018; Boucher, Jeremie/G-6602-2015; dray, cedric/N-7440-2017	Valet, Philippe/0000-0001-6520-7393; Saulnier-Blache, Jean Sebastien/0000-0002-8971-7723; Castan-Laurell, Isabelle/0000-0002-0488-9789; DRAY, Cedric/0000-0002-4712-791X				Ashley EA, 2005, CARDIOVASC RES, V65, P73, DOI 10.1016/j.cardiores.2004.08.018; Boucher J, 2005, ENDOCRINOLOGY, V146, P1764, DOI 10.1210/en.2004-1427; Boucher J, 2005, HORM METAB RES, V37, P761, DOI 10.1055/s-2005-921098; Brailoiu GC, 2002, NEUROSCI LETT, V327, P193, DOI 10.1016/S0304-3940(02)00411-1; Coppack SW, 2001, P NUTR SOC, V60, P349, DOI 10.1079/PNS2001110; De Mota N, 2000, NEUROENDOCRINOLOGY, V72, P400, DOI 10.1159/000054609; De Mota N, 2004, P NATL ACAD SCI USA, V101, P10464, DOI 10.1073/pnas.0403518101; Engelman JA, 2000, MOL ENDOCRINOL, V14, P1557, DOI 10.1210/me.14.10.1557; Foldes G, 2003, BIOCHEM BIOPH RES CO, V308, P480, DOI 10.1016/S0006-291X(03)01424-4; Gesta S, 2003, HORM METAB RES, V35, P158, DOI 10.1055/s-2003-39070; Gronning LM, 2002, MOL ENDOCRINOL, V16, P873, DOI 10.1210/me.16.4.873; Heinonen MV, 2005, REGUL PEPTIDES, V130, P7, DOI 10.1016/j.regpep.2005.05.003; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Ishida J, 2004, J BIOL CHEM, V279, P26274, DOI 10.1074/jbc.M404149200; Jain RG, 1999, J CELL PHYSIOL, V179, P58, DOI 10.1002/(SICI)1097-4652(199904)179:1<58::AID-JCP8>3.0.CO;2-1; Kasai A, 2004, BIOCHEM BIOPH RES CO, V325, P395, DOI 10.1016/j.bbrc.2004.10.042; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Kleinz MJ, 2004, REGUL PEPTIDES, V118, P119, DOI 10.1016/j.regpep.2003.11.002; Kleinz MJ, 2005, PHARMACOL THERAPEUT, V107, P198, DOI 10.1016/j.pharmthera.2005.04.001; Lee DK, 2000, J NEUROCHEM, V74, P34, DOI 10.1046/j.1471-4159.2000.0740034.x; Masri B, 2005, CELL SIGNAL, V17, P415, DOI 10.1016/j.cellsig.2004.09.018; Pandey M, 2005, FASEB J, V19, P1317, DOI 10.1096/fj.04-3459fje; Ruan H, 2003, CYTOKINE GROWTH F R, V14, P447, DOI 10.1016/S1359-6101(03)00052-2; Samad F, 1996, J CLIN INVEST, V97, P37, DOI 10.1172/JCI118404; Taheri S, 2002, BIOCHEM BIOPH RES CO, V291, P1208, DOI 10.1006/bbrc.2002.6575; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Valet P, 2000, J BIOL CHEM, V275, P34797, DOI 10.1074/jbc.M005210200; Winzell MS, 2005, REGUL PEPTIDES, V131, P12, DOI 10.1016/j.regpep.2005.05.004; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451	29	166	182	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1528	+		10.1096/fj.05-5243fje	http://dx.doi.org/10.1096/fj.05-5243fje			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16723381				2022-12-25	WOS:000240266000040
J	Hasenbrink, G; Sievernich, A; Wildt, L; Ludwig, J; Lichtenberg-Frate, H				Hasenbrink, Guido; Sievernich, Andre; Wildt, Ludwig; Ludwig, Jost; Lichtenberg-Frate, Hella			Estrogenic effects of natural and synthetic compounds including tibolone assessed in Saccharomyces cerevisiae expressing the human estrogen alpha and beta receptors	FASEB JOURNAL			English	Article						S. cerevisiae in vitro assay; hER alpha; hER beta	GREEN FLUORESCENT PROTEIN; POTASSIUM-TRANSPORT; YEAST; ACTIVATION; SCREEN; ASSAY; PHYTOESTROGENS; METABOLISM; MECHANISM; MUTANTS	The human estrogen receptors (hER)alpha and hER beta, differentially expressed and localized in various tissues and cell types, mediate transcriptional activation of target genes. These encode a variety of physiological reproductive and nonreproductive functions involved in energy metabolism, salt balance, immune system, development, and differentiation. As a step toward developing a screening assay for the use in applications where significant numbers of compounds or complex matrices need to be tested for (anti) estrogenic bioactivity, hER alpha and hER beta were expressed in a genetically modified Saccharomyces cerevisiae strain, devoid of three endogenous xenobiotic transporters (PDR5, SNQ2, and YOR1). By using receptor-mediated transcriptional activation of the green fluorescent protein optimized for expression in yeast (yEGFP) as reporter 17 natural, comprising estrogens and phytoestrogens or synthetic compounds among which tibolone with its metabolites, gestagens, and antiestrogens were investigated. The reporter assay deployed a simple and robust protocol for the rapid detection of estrogenic effects within a 96-well microplate format. Results were expressed as effective concentrations (EC50) and correlated to other yeast based and cell line assays. Tibolone and its metabolites exerted clear estrogenic effects, though considerably less potent than all other natural and synthetic compounds. For the blood serum of two volunteers, considerable higher total estrogenic bioactivity than single estradiol concentrations as determined by immunoassay was found. Visualization of a hER alpha/GFP fusion protein in yeast revealed a sub cellular cytosolic localization. This study demonstrates the versatility of (anti) estrogenic bioactivity determination using sensitized S. cerevisiae cells to assess estrogenic exposure and effects.	Univ Bonn, IZMB, AG Mol Bioenerget, D-53115 Bonn, Germany; Univ Innsbruck, Klin Gynakol Endokrinol & Sterilitat, A-6020 Innsbruck, Austria	University of Bonn; University of Innsbruck	Lichtenberg-Frate, H (corresponding author), Univ Bonn, IZMB, AG Mol Bioenerget, Kirschallee 1, D-53115 Bonn, Germany.	h.lichtenberg@uni-bonn.de	Ludwig, Jost/K-3446-2017					Agradi E, 2001, PLANTA MED, V67, P553, DOI 10.1055/s-2001-16485; Almlof T, 1997, MOL CELL BIOL, V17, P934, DOI 10.1128/MCB.17.2.934; Arnold SF, 1996, ENVIRON HEALTH PERSP, V104, P544, DOI 10.2307/3432996; Bertl A, 2003, MOL MICROBIOL, V47, P767, DOI 10.1046/j.1365-2958.2003.03335.x; Bovee TFH, 2004, J STEROID BIOCHEM, V91, P99, DOI 10.1016/j.jsbmb.2004.03.118; Bovee TFH, 2004, GENE, V325, P187, DOI 10.1016/j.gene.2003.10.015; Caplan AJ, 1997, TRENDS ENDOCRIN MET, V8, P271, DOI 10.1016/S1043-2760(97)00079-9; Chen CW, 1997, BIOCHEM PHARMACOL, V53, P1161; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; De Boever P, 2001, ENVIRON HEALTH PERSP, V109, P691, DOI 10.2307/3454785; de Gooyer ME, 2003, STEROIDS, V68, P21, DOI 10.1016/S0039-128X(02)00112-5; DeFranco Donald B., 1999, Cell Biochemistry and Biophysics, V30, P1, DOI 10.1007/BF02737882; Graumann K, 1996, J STEROID BIOCHEM, V57, P293, DOI 10.1016/0960-0760(95)00274-X; Graumann K, 1999, SCI TOTAL ENVIRON, V225, P69; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Gustafsson JA, 1999, J ENDOCRINOL, V163, P379, DOI 10.1677/joe.0.1630379; Gutendorf B, 2001, TOXICOLOGY, V166, P79, DOI 10.1016/S0300-483X(01)00437-1; Hobe G, 2002, STEROIDS, V67, P883, DOI 10.1016/S0039-128X(02)00058-2; Jungbauer A, 2002, J CHROMATOGR B, V777, P167, DOI 10.1016/S1570-0232(02)00083-1; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; Kloosterboer HJ, 2004, MATURITAS, V49, pS5, DOI 10.1016/j.maturitas.2004.06.022; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; McEwan IJ, 1999, FEMS MICROBIOL LETT, V176, P1; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Payne J, 2000, ENVIRON HEALTH PERSP, V108, P983, DOI 10.1289/ehp.00108983; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; RODRIGUEZNAVARRO A, 1984, J BACTERIOL, V159, P940; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J, 1989, MOL CLONING; Schultis T, 2004, CHEMOSPHERE, V57, P1649, DOI 10.1016/j.chemosphere.2004.06.027; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; Shiau SP, 1996, GENE, V179, P205, DOI 10.1016/S0378-1119(96)00345-9; Sievernich A, 2004, J STEROID BIOCHEM, V92, P455, DOI 10.1016/j.jsbmb.2004.09.004; Vico P, 2002, YEAST, V19, P873, DOI 10.1002/yea.882; vom Baur E, 1998, GENE DEV, V12, P1278, DOI 10.1101/gad.12.9.1278; Witters HE, 2001, WATER SCI TECHNOL, V43, P117, DOI 10.2166/wst.2001.0080; WRENN CK, 1993, J BIOL CHEM, V268, P24089	39	24	24	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1552	+		10.1096/fj.05-5413fje	http://dx.doi.org/10.1096/fj.05-5413fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16720731				2022-12-25	WOS:000240266000048
J	Kauser, S; Slominski, A; Wei, ET; Tobin, DJ				Kauser, Sobia; Slominski, Andrzej; Wei, Edward T.; Tobin, Desmond J.			Modulation of the human hair follicle pigmentary unit by corticotropin-releasing hormone and urocortin peptides	FASEB JOURNAL			English	Article						hair follicle melanocytes; melanogenesis; corticotropin-releasing hormone; CRH receptors; hair growth	NORMAL HUMAN MELANOCYTES; HUMAN SKIN; CUTANEOUS EXPRESSION; CYTOKINETIC DYNAMICS; BETA-ENDORPHIN; MELANOMA-CELLS; MAMMALIAN SKIN; GROWTH-CONTROL; CRH-RECEPTOR; DNA-DAMAGE	Human skin is a local source of cortico-tropin-releasing hormone (CRH) and expresses CRH and CRH receptors (CRH-R) at mRNA and protein levels. Epidermal melanocytes respond to CRH by induction of cAMP with up-regulation of pro-opiomelanocortin gene expression and subsequent production of adrenocorticotropin hormone. However, the role of CRH/CRH-R in melanocyte biology is complicated by the significant heterogeneity of cutaneous melanocyte subpopulations, from continuously active and UV-responsive melanocytes in epidermis to UV nonresponsive, hair growth cycle-coupled melanogenesis in hair follicles. In the present study we report that normal human scalp hair follicle melanocytes express CRH at the mRNA level. Furthermore, CRH, urocortin and CRH-R 1 and 2 were differentially expressed in follicular melanocytes, fibroblasts, and keratinocytes depending on anatomic location and differentiation status in situ and in vitro. Stimulation of follicular melanocytes with CRH and CRH peptides, modified for selectivity for CRH-R1 and/or CRH-R2, variably induced cell melanogenesis, dendricity, and proliferation. CRH-peptides also stimulated the expression and activity of Tyrosinase, and expression of Tyrosinase-related protein-1 and-2. However, a modified urocortin peptide highly selective for CRH-R2 down-regulated melanocyte differentiation phenotype. This study indicates that CRH peptides can differentially influence hair follicle melanocyte behavior not only via CRH-R1 signaling but also by complex cross-talk between CRH-R1 and CRH-R2.	Univ Bradford, Dept Biomed Sci, Bradford BD7 1DP, W Yorkshire, England; Univ Tennessee, Dept Pathol & Lab Med, HSC, Memphis, TN 38163 USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	University of Bradford; University of Tennessee System; University of Tennessee Health Science Center; University of California System; University of California Berkeley	Tobin, DJ (corresponding author), Univ Bradford, Dept Biomed Sci, Bradford BD7 1DP, W Yorkshire, England.	dtobin@bradford.ac.uk	; Tobin, Desmond/A-5228-2009	Slominski, Andrzej/0000-0001-8963-3995; Tobin, Desmond/0000-0003-4566-9392	NIAMS NIH HHS [R01 AR047079-01A2, 1R01-AR047079, R01 AR047079, R01 AR047079-02] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047079] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aguilera G, 2001, PEPTIDES, V22, P769, DOI 10.1016/S0196-9781(01)00390-4; Bittencourt JC, 1999, J COMP NEUROL, V415, P285; Bohm M, 2005, J BIOL CHEM, V280, P5795, DOI 10.1074/jbc.M406334200; Botchkarev VA, 2003, AM J PATHOL, V162, P709, DOI 10.1016/S0002-9440(10)63866-7; Carlson KW, 2001, ANTICANCER RES, V21, P1173; CASTROL MG, 1995, MOL CELL ENDOCRINOL, V107, P17, DOI 10.1016/0303-7207(94)03416-Q; EKMAN R, 1993, J NEUROIMMUNOL, V44, P7, DOI 10.1016/0165-5728(93)90262-W; Fazal N, 1998, FEBS LETT, V435, P187, DOI 10.1016/S0014-5793(98)01067-9; Funasaka Y, 1999, J INVEST DERM SYMP P, V4, P105, DOI 10.1038/sj.jidsp.5640192; Gillbro JM, 2004, J INVEST DERMATOL, V123, P346, DOI 10.1111/j.0022-202X.2004.23210.x; Grammatopoulos DK, 2002, TRENDS ENDOCRIN MET, V13, P436, DOI 10.1016/S1043-2760(02)00670-7; HALABAN R, 1984, IN VITRO CELL DEV B, V20, P447; Hearing VJ, 1999, J INVEST DERM SYMP P, V4, P24, DOI 10.1038/sj.jidsp.5640176; Ito N, 2005, FASEB J, V19, P1332, DOI 10.1096/fj.04-1968fje; Ito N, 2004, J INVEST DERMATOL, V122, P235, DOI 10.1046/j.1523-1747.2003.22145.x; Kadekaro AL, 2005, CANCER RES, V65, P4292, DOI 10.1158/0008-5472.CAN-04-4535; Kauser S, 2005, ENDOCRINOLOGY, V146, P532, DOI 10.1210/en.2004-1145; Kauser S, 2004, J INVEST DERMATOL, V123, P184, DOI 10.1111/j.0022-202X.2004.22724.x; Kauser S, 2003, J INVEST DERMATOL, V120, P1073, DOI 10.1046/j.1523-1747.2003.12242.x; Kishimoto T, 2000, NAT GENET, V24, P415, DOI 10.1038/74271; Magerl M, 2002, EXP DERMATOL, V11, P381, DOI 10.1034/j.1600-0625.2002.110414.x; Miki F, 2004, J PHARMACOL SCI, V96, P170, DOI 10.1254/jphs.FP0040364; Morrison Ewan, 1993, Biochemical Society Transactions, V21, p318S; Nordlund JJ, 1998, PIGMENTARY SYSTEM PH, P475; ORTH DN, 1992, ENDOCR REV, V13, P164, DOI 10.1210/er.13.2.164; Pedersen WA, 2002, J NEUROSCI, V22, P404, DOI 10.1523/JNEUROSCI.22-02-00404.2002; Peters EMJ, 2000, J INVEST DERMATOL, V114, P430, DOI 10.1046/j.1523-1747.2000.00913.x; Quevedo ME, 2001, IN VITRO CELL DEV-AN, V37, P50; Rees JL, 2003, ANNU REV GENET, V37, P67, DOI 10.1146/annurev.genet.37.110801.143233; RomeroGraillet C, 1996, J BIOL CHEM, V271, P28052, DOI 10.1074/jbc.271.45.28052; SAPHIER PW, 1992, J ENDOCRINOL, V133, P487, DOI 10.1677/joe.0.1330487; Slominski A, 2000, J CLIN ENDOCR METAB, V85, P815, DOI 10.1210/jc.85.2.815; Slominski A, 2000, ENDOCR REV, V21, P457, DOI 10.1210/er.21.5.457; Slominski A, 2005, FASEB J, V19, P176, DOI 10.1096/fj.04-2079rev; Slominski A, 2005, AM J PHYSIOL-ENDOC M, V288, pE701, DOI 10.1152/ajpendo.00519.2004; Slominski A, 2005, ENDOCRINOLOGY, V146, P1245, DOI 10.1210/en.2004-0733; Slominski A, 2004, EUR J BIOCHEM, V271, P4178, DOI 10.1111/j.1432-1033.2004.04356.x; Slominski A, 1998, J CLIN ENDOCR METAB, V83, P1020, DOI 10.1210/jc.83.3.1020; Slominski A, 1996, INT J DERMATOL, V35, P849, DOI 10.1111/j.1365-4362.1996.tb05049.x; Slominski A, 2004, PHYSIOL REV, V84, P1155, DOI 10.1152/physrev.00044.2003; Slominski A, 2005, J INVEST DERMATOL, V124, P13, DOI 10.1111/j.0022-202X.2004.23528.x; SLOMINSKI A, 1995, FEBS LETT, V374, P113, DOI 10.1016/0014-5793(95)01090-2; Slominski A, 2002, J INVEST DERMATOL, V119, P1449, DOI 10.1046/j.1523-1747.2002.19617.x; SLOMINSKI A, 1993, J INVEST DERMATOL, V101, pS90, DOI 10.1111/1523-1747.ep12362991; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Slominski A, 2004, ENDOCRINOLOGY, V145, P941, DOI 10.1210/en.2003-0851; Slominski A, 2005, J NEUROIMMUNOL, V162, P97, DOI 10.1016/j.jneuroim.2005.01.014; Slominski A, 2001, FASEB J, V15, P1678, DOI 10.1096/fj.00-0850rev; Slominski A, 2006, J CELL PHYSIOL, V206, P780, DOI 10.1002/jcp.20530; SLOMINSKI A, 2005, IN PRESS DERMATOLOGY; Slominski AT, 2000, IN VITRO CELL DEV-AN, V36, P211; Slominski AT, 1999, ANN NY ACAD SCI, V885, P287; Tobin DJ, 2001, EXP GERONTOL, V36, P29, DOI 10.1016/S0531-5565(00)00210-2; TOBIN DJ, 1995, J INVEST DERMATOL, V104, P86, DOI 10.1111/1523-1747.ep12613573; Tobin DJ, 1996, PIGM CELL RES, V9, P304, DOI 10.1111/j.1600-0749.1996.tb00122.x; Tobin DJ, 2003, J INVEST DERMATOL, V120, P895, DOI 10.1046/j.1523-1747.2003.12237.x; Tobin DJ, 2003, J INVEST DERM SYMP P, V8, P80, DOI 10.1046/j.1523-1747.2003.12177.x; TOBIN DJ, 2004, HAIR NAIL SKIN, P319; VENNEGOOR C, 1988, AM J PATHOL, V130, P179; Wei ET, 1998, PEPTIDES, V19, P1183, DOI 10.1016/S0196-9781(98)00085-0; Wiesner B, 2003, J CELL SCI, V116, P1261, DOI 10.1242/jcs.00301; Wille S, 1999, J NEUROCHEM, V72, P388, DOI 10.1046/j.1471-4159.1999.0720388.x; Zbytek B, 2005, BRIT J DERMATOL, V152, P474, DOI 10.1111/J.1365-2133.2005.06217.X; Zbytek B, 2005, J CELL PHYSIOL, V203, P118, DOI 10.1002/jcp.20209; Zouboulis CC, 2002, P NATL ACAD SCI USA, V99, P7148, DOI 10.1073/pnas.102180999	65	39	44	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					882	895		10.1096/fj.05-5257com	http://dx.doi.org/10.1096/fj.05-5257com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675846	Green Accepted			2022-12-25	WOS:000240157700011
J	Heidenblad, M; Hallor, KH; Staaf, J; Jonsson, G; Borg, A; Hoglund, M; Mertens, F; Mandahl, N				Heidenblad, M.; Hallor, K. H.; Staaf, J.; Jonsson, G.; Borg, A.; Hoglund, M.; Mertens, F.; Mandahl, N.			Genomic profiling of bone and soft tissue tumors with supernumerary ring chromosomes using tiling resolution bacterial artificial chromosome microarrays	ONCOGENE			English	Article						sarcoma; array-based CGH; genome-wide; gene amplification; ring chromosome	MALIGNANT FIBROUS HISTIOCYTOMAS; HUMAN SARCOMAS; LIPOMATOUS TUMORS; HYBRIDIZATION ANALYSIS; DEDIFFERENTIATED LIPOSARCOMAS; PAROSTEAL OSTEOSARCOMA; MARKER CHROMOSOMES; SEQUENCES; IDENTIFICATION; AMPLICON	Ring chromosomes and/or giant marker chromosomes have been observed in a variety of human tumor types, but they are particularly common in a subgroup of mesenchymal tumors of low-grade or borderline malignancy. These rings and markers have been shown to contain amplified material predominantly from 12q13-15, but also sequences from other chromosomes. Such amplified sequences were mapped in detail by genome-wide array comparative genomic hybridization in ring-containing tumor samples from soft tissue (n = 15) and bone (n = 6), using tiling resolution microarrays, encompassing 32 433 bacterial artificial chromosome clones. The DNA copy number profiles revealed multiple amplification targets, in many cases highly discontinuous, leading to delineation of large numbers of very small amplicons. A total number of 356 (median size: 0.64 Mb) amplicons were seen in the soft tissue tumors and 90 (median size: 1.19 Mb) in the bone tumors. Notably, more than 40% of all amplicons in both soft tissue and bone tumors were mapped to chromosome 12, and at least one of the previously reported recurrent amplifications in 12q13.3-14.1 and 12q15.1, including SAS and CDK4, and MDM2, respectively, were present in 85% of the soft tissue tumors and in all of the bone tumors. Although chromosome 12 was the only chromosome displaying recurrent amplification in the bone tumors, the soft tissue tumors frequently showed recurrent amplicons mapping to other chromosomes, that is, 1p32, 1q23-24, 3p11-12, 6q24-25 and 20q11-12. Of particular interest, amplicons containing genes involved in the c-jun NH2-terminal kinase/mitogen-activated protein kinase pathway, that is, JUN in 1p32 and MAP3K7IP2 (TAB2) in 6q24-25, were found to be independently amplified in eight of 11 cases with 12q amplification, providing strong support for the notion that aberrant expression of this pathway is an important step in the dedifferentiation of liposarcomas.	Univ Lund Hosp, Dept Clin Genet, SE-22185 Lund, Sweden; Univ Lund Hosp, Dept Oncol, SE-22185 Lund, Sweden	Lund University; Skane University Hospital; Lund University; Skane University Hospital	Heidenblad, M (corresponding author), Univ Lund Hosp, Dept Clin Genet, SE-22185 Lund, Sweden.	markus.heidenblad@med.lu.se	Jönsson, Göran/D-1212-2014	Hansen Nord, Karolin/0000-0002-2397-2254; Hoglund, Mattias/0000-0001-9283-4421; Mertens, Fredrik/0000-0002-6278-5232				Autio R, 2003, BIOINFORMATICS, V19, P1714, DOI 10.1093/bioinformatics/btg230; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; Chibon F, 2004, GENE CHROMOSOME CANC, V40, P32, DOI 10.1002/gcc.20012; Chibon F, 2002, CANCER GENET CYTOGEN, V139, P24, DOI 10.1016/S0165-4608(02)00614-3; Coindre JM, 2004, J PATHOL, V203, P822, DOI 10.1002/path.1579; Coindre JM, 2003, MODERN PATHOL, V16, P256, DOI 10.1097/01.MP.0000056983.78547.77; Dahlen A, 2003, INT J CANCER, V103, P616, DOI 10.1002/ijc.10864; DALCIN P, 1993, CANCER GENET CYTOGEN, V68, P85, DOI 10.1016/0165-4608(93)90001-3; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P15, DOI 10.1002/gcc.2870140104; Forus A, 1998, BRIT J CANCER, V78, P495, DOI 10.1038/bjc.1998.521; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P8, DOI 10.1002/gcc.2870140103; GAMBERI G, 2000, CLIN ORTHOP RELAT R, V377, P195; Gisselsson D, 2002, GENE CHROMOSOME CANC, V33, P133, DOI 10.1002/gcc.1219; Heidenblad M, 2005, ONCOGENE, V24, P1794, DOI 10.1038/sj.onc.1208383; Jonsson G, 2005, JNCI-J NATL CANCER I, V97, P1377, DOI 10.1093/jnci/dji280; Kanoe H, 1999, ONCOGENE, V18, P721, DOI 10.1038/sj.onc.1202364; Kresse SH, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-39; Mairal A, 1999, CANCER GENET CYTOGEN, V111, P134, DOI 10.1016/S0165-4608(98)00227-1; Mansoor A, 2004, CANCER GENET CYTOGEN, V152, P61, DOI 10.1016/j.cancergencyto.2003.10.004; MELTZER PS, 1991, CELL GROWTH DIFFER, V2, P495; Mertens F, 2004, CYTOGENET GENOME RES, V106, P33, DOI 10.1159/000078557; Mertens F, 1998, GENE CHROMOSOME CANC, V22, P16, DOI 10.1002/(SICI)1098-2264(199805)22:1<16::AID-GCC3>3.0.CO;2-A; Meza-Zepeda LA, 2002, ONCOGENE, V21, P2261, DOI 10.1038/sj.onc.1205339; Meza-Zepeda LA, 2001, GENE CHROMOSOME CANC, V31, P264, DOI 10.1002/gcc.1143; Micci F, 2002, CYTOGENET GENOME RES, V97, P13, DOI 10.1159/000064038; Mitelman F, 2005, MITELMAN DATABASE CH; NILBERT M, 1994, GENE CHROMOSOME CANC, V9, P261, DOI 10.1002/gcc.2870090406; Nilsson M, 2004, INT J CANCER, V109, P363, DOI 10.1002/ijc.11716; ORNDAL C, 1992, CANCER GENET CYTOGEN, V60, P170, DOI 10.1016/0165-4608(92)90011-V; PEDEUTOUR F, 1994, GENE CHROMOSOME CANC, V10, P85, DOI 10.1002/gcc.2870100203; Pedeutour F, 1999, GENE CHROMOSOME CANC, V24, P30, DOI 10.1002/(SICI)1098-2264(199901)24:1<30::AID-GCC5>3.0.CO;2-P; Platzer P, 2002, CANCER RES, V62, P1134; Saal LH, 2002, GENOME BIOL, V3; Sabah M, 2005, VIRCHOWS ARCH, V447, P842, DOI 10.1007/s00428-005-0024-1; Simons A, 2000, CANCER GENET CYTOGEN, V118, P89, DOI 10.1016/S0165-4608(99)00178-8; Sirvent N, 2003, GENE CHROMOSOME CANC, V37, P1, DOI 10.1002/gcc.10202; Smith DI, 2006, CANCER LETT, V232, P48, DOI 10.1016/j.canlet.2005.06.049; Szymanska J, 1996, GENE CHROMOSOME CANC, V16, P31; Szymanska J, 1997, CANCER GENET CYTOGEN, V99, P14, DOI 10.1016/S0165-4608(96)00436-0; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	40	35	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7106	7116		10.1038/sj.onc.1209693	http://dx.doi.org/10.1038/sj.onc.1209693			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16732325				2022-12-25	WOS:000241910500010
J	Bellovin, DI; Simpson, KJ; Danilov, T; Maynard, E; Rimm, DL; Oettgen, P; Mercurio, AM				Bellovin, D. I.; Simpson, K. J.; Danilov, T.; Maynard, E.; Rimm, D. L.; Oettgen, P.; Mercurio, A. M.			Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma	ONCOGENE			English	Article						RhoC; epithelial mesenchymal transition; colorectal carcinoma	EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTIONAL REPRESSOR SNAIL; INFLAMMATORY BREAST-CANCER; ETS-1 PROTOONCOGENE; GENOMIC ANALYSIS; METASTASIS; EXPRESSION; PHENOTYPE; ORGANOIDS; SURVIVAL	Understanding how RhoC expression and activation are regulated is essential for deciphering its contribution to tumorigenesis. Here, we report that RhoC expression and activation are induced by the epithelial to mesenchymal transition (EMT) of colon carcinoma. Using LIM 1863 colon cancer cells, RhoC protein expression and subsequent activation were detected coincident with the loss of E-cadherin and acquisition of mesenchymal characteristics. Several Ets-1 binding sites were identified in the RhoC promoter, and evidence was obtained using chromatin immunoprecipitation that Ets-1 can regulate RhoC expression during the EMT. Interestingly, a marked decrease in RhoA activation associated with the EMT was observed that corresponds to the increase in RhoC expression. Use of shRNA established that RhoA inhibits and RhoC promotes post-EMT cell migration, demonstrating functional significance for their coordinate regulation. To assess the importance of RhoC expression in colon cancer, immunohistochemistry was performed on 566 colorectal tumors with known clinical outcome. The level of RhoC ranged from no expression to high expression, and statistical analysis revealed that elevated RhoC expression correlates with poor outcome as well as aberrant expression and localization of E-cadherin. These data provide one mechanism for how RhoC expression is regulated in colon carcinoma and substantiate its utility as a prognostic marker.	Beth Israel Deaconess Med Ctr, Dept Pathol, Div Canc Biol & Angiogenesis, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA; Beth Israel Deaconess Med Ctr, Div Prevent Cardiol, Boston, MA 02215 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Yale University	Mercurio, AM (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, LRB-408,364 Plantat St, Worcester, MA 01605 USA.	arthur.mercurio@umassmed.edu	Oettgen, Peter/AAF-5026-2021	Rimm, David/0000-0001-5820-4397; Simpson, Kaylene/0000-0001-9136-1781	NCI NIH HHS [CA107548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA107548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alipov G, 2005, HISTOPATHOLOGY, V46, P202, DOI 10.1111/j.1365-2559.2005.02059.x; Bates RC, 2005, J CLIN INVEST, V115, P339, DOI 10.1172/JCI200523183; Bates RC, 2003, CURR BIOL, V13, P1721, DOI 10.1016/j.cub.2003.09.002; Bates RC, 2003, MOL BIOL CELL, V14, P1790, DOI 10.1091/mbc.E02-09-0583; Bellovin DI, 2005, CANCER RES, V65, P10938, DOI 10.1158/0008-5472.CAN-05-1947; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177; Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805; Hu M, 2005, CANCER RES, V65, P8715, DOI 10.1158/0008-5472.CAN-05-0700; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Roy HK, 2005, DIGEST DIS SCI, V50, P42, DOI 10.1007/s10620-005-1275-z; Sato Y, 1998, Hum Cell, V11, P207; Schwiebert LM, 1997, AM J RESP CELL MOL, V17, P106, DOI 10.1165/ajrcmb.17.1.2775; Shikada Y, 2003, CLIN CANCER RES, V9, P5282; Simpson KJ, 2004, CANCER RES, V64, P8694, DOI 10.1158/0008-5472.CAN-04-2247; Span PN, 2002, ONCOGENE, V21, P8506, DOI 10.1038/sj.onc.1206040; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; Tootle TL, 2005, BIOESSAYS, V27, P285, DOI 10.1002/bies.20198; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; van Golen KL, 2000, CANCER RES, V60, P5832; Wang H, 2004, CLIN CANCER RES, V10, P1633, DOI 10.1158/1078-0432.CCR-0829-3; Wang W, 2004, BRIT J CANCER, V90, P2349, DOI 10.1038/sj.bjc.6601749; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	28	102	114	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	52					6959	6967		10.1038/sj.onc.1209682	http://dx.doi.org/10.1038/sj.onc.1209682			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16715134				2022-12-25	WOS:000241732300006
J	Yan, H; Thomas, J; Liu, T; Raj, D; London, N; Tandeski, T; Leachman, SA; Lee, RM; Grossman, D				Yan, H.; Thomas, J.; Liu, T.; Raj, D.; London, N.; Tandeski, T.; Leachman, S. A.; Lee, R. M.; Grossman, D.			Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable survivin antagonist	ONCOGENE			English	Article						survivin; apoptosis; melanoma; TAT; xenograft	PROTEIN TRANSDUCTION; MAMMALIAN-CELLS; IN-VIVO; CANCER; EXPRESSION; GENE; DIVISION; INTERFERENCE; CHECKPOINT; THERAPY	The inhibitor of apoptosis gene family member Survivin is highly expressed in most tumors, and appears to be a promising target for cancer therapy. Although a variety of Survivin antagonists have been shown to induce apoptosis in malignant cells, the potential utility of these agents is limited by inefficient delivery and cell impermeability. We generated recombinant fusion proteins containing the TAT protein transduction domain and either wild-type Survivin (TAT-Surv-WT) or a dominant-negative mutant (TAT-Surv-T34A). The TAT-Surv proteins were purified by sequential affinity and ion-exchange chromatography, and at 30 nM concentration demonstrated rapid entry into cells at 30 min. Whereas TAT-Surv-WT had minimal effect on YUSAC2 or WM793 melanoma cells, TAT-Surv-T34A induced cell detachment, DNA fragmentation, caspase-3 activation and mitochondrial release of apoptosis-inducing factor at low mu M concentrations. Intraperitoneal (i.p.)injection of mice bearing subcutaneous YUSAC2 xenografts with TAT-Surv-T34A (10 mg/ kg) was associated with rapid tumor accumulation at 1 h, and increased tumor cell apoptosis and aberrant nuclei formation in situ. Repeated i.p. injection of TAT- Surv-T34A resulted in a 40-50% reduction in growth and mass of established tumors, compared to those similarly injected with saline buffer or TAT-Surv-WT. These studies demonstrate the feasibility of systemic tumor treatment using a cell-permeable Survivin antagonist.	Univ Utah, Huntsman Canc Inst, Dept Dermatol & Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Dermatol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Grossman, D (corresponding author), Univ Utah, Huntsman Canc Inst, Dept Dermatol & Oncol Sci, 2000 Circle Hope,Suite 5243, Salt Lake City, UT 84112 USA.	doug.grossman@hci.utah.edu			NIAMS NIH HHS [AR050102, R01 AR050102-03, R01 AR050102] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050102] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Azuhata T, 2001, J PEDIATR SURG, V36, P1785, DOI 10.1053/jpsu.2001.28839; Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; Beltrami E, 2004, J BIOL CHEM, V279, P2077, DOI 10.1074/jbc.M309479200; Caldas H, 2005, ONCOGENE, V24, P1994, DOI 10.1038/sj.onc.1208350; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Fortugno P, 2003, P NATL ACAD SCI USA, V100, P13791, DOI 10.1073/pnas.2434345100; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; Kanwar JR, 2001, J NATL CANCER I, V93, P1541, DOI 10.1093/jnci/93.20.1541; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li FZ, 1999, CANCER RES, V59, P3143; Ling X, 2004, BIOTECHNIQUES, V36, P450, DOI 10.2144/04363RR01; Liu T, 2004, ONCOGENE, V23, P39, DOI 10.1038/sj.onc.1206978; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Muchmore SW, 2000, MOL CELL, V6, P173, DOI 10.1016/S1097-2765(00)00018-6; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Pennati M, 2002, J CLIN INVEST, V109, P285; Plescia J, 2005, CANCER CELL, V7, P457, DOI 10.1016/j.ccr.2005.03.035; Satyamoorthy K, 2003, CANCER RES, V63, P756; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Shankar SL, 2001, J NEUROCHEM, V79, P426, DOI 10.1046/j.1471-4159.2001.00596.x; Takeuchi H, 2005, INT J CANCER, V117, P1032, DOI 10.1002/ijc.21267; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Vong QP, 2005, SCIENCE, V310, P1499, DOI 10.1126/science.1120160	30	44	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	52					6968	6974		10.1038/sj.onc.1209676	http://dx.doi.org/10.1038/sj.onc.1209676			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16702945	Green Accepted			2022-12-25	WOS:000241732300007
J	Keating, AK; Salzberg, DB; Sather, S; Liang, X; Nickoloff, S; Anwar, A; DeRyckere, D; Hill, K; Joung, D; Sawczyn, KK; Park, J; Curran-Everett, D; McGavran, L; Meltesen, L; Gore, L; Johnson, GL; Graham, DK				Keating, A. K.; Salzberg, D. B.; Sather, S.; Liang, X.; Nickoloff, S.; Anwar, A.; DeRyckere, D.; Hill, K.; Joung, D.; Sawczyn, K. K.; Park, J.; Curran-Everett, D.; McGavran, L.; Meltesen, L.; Gore, L.; Johnson, G. L.; Graham, D. K.			Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase	ONCOGENE			English	Article						receptor tyrosine kinase; MerTK; leukemia; lymphoma; transgenic mouse	GENE-EXPRESSION; V-RYK; LEUKEMIA; GROWTH; MYC; CELLS; MOUSE; PROTOONCOGENE; MICROARRAYS; ACTIVATION	Mer (MerTK) is a receptor tyrosine kinase important in platelet aggregation, as well as macrophage cytokine secretion and clearance of apoptotic cells. Mer is not normally expressed in thymocytes or lymphocytes; however, ectopic Mer RNA transcript and protein expression is found in a subset of acute lymphoblastic leukemia cell lines and patient samples, suggesting a role in leukemogenesis. To investigate the oncogenic potential of Mer in vivo, we created a transgenic mouse line (Mer(Tg)) that expresses Mer in the hematopoietic lineage under control of the Vav promoter. Ectopic expression and activation of the transgenic Mer protein was demonstrated in lymphocytes and thymocytes of the Mer(Tg) mice. At 12 - 24 months of age, greater than 55% of the Mer(Tg) mice, compared to 12% of the wild type, developed adenopathy, hepatosplenomegaly, and circulating lymphoblasts. Histopathological analysis and flow cytometry were consistent with T-cell lymphoblastic leukemia/lymphoma. Mer may contribute to leukemogenesis by activation of Akt and ERK1/2 anti-apoptotic signals, which were upregulated in MerTg mice. Additionally, a significant survival advantage was noted in MerTg lymphocytes compared to wild-type lymphocytes after dexamethasone treatment. These data suggest that Mer plays a cooperative role in leukemogenesis and may be an effective target for biologically based leukemia/lymphoma therapy.	Univ Colorado Denver & Hlth Sci Ctr, Dept Pathol, Denver, CO USA; Natl Jewish Med & Res Ctr, Div Biostat, Denver, CO USA; Univ Colorado Denver & Hlth Sci Ctr, Dept Pediat, Denver, CO USA; Univ Colorado Denver & Hlth Sci Ctr, Dept Prevent Med, Denver, CO USA; Univ Colorado Denver & Hlth Sci Ctr, Dept Biometr, Denver, CO USA; Univ Colorado Denver & Hlth Sci Ctr, Dept Physiol & Biophys, Denver, CO USA; Univ Colorado Denver & Hlth Sci Ctr, Colorado Cytogenet, Denver, CO USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC USA	University of Colorado System; University of Colorado Anschutz Medical Campus; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of North Carolina; University of North Carolina Chapel Hill	Graham, DK (corresponding author), Univ Colorado Denver & Hlth Sci Ctr, Dept Pediat, Mail Stop 8302,Bldg RC-1 N,POB 6511,12800 E 19th, Aurora, CO 80045 USA.	doug.graham@uchsc.edu			NATIONAL CANCER INSTITUTE [T32CA082086] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA86068604, T32 CA082086] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1999, ONCOGENE, V18, P5268, DOI 10.1038/sj.onc.1202997; Anderson KE, 2003, INT J BIOCHEM CELL B, V35, P1028, DOI 10.1016/S1357-2725(02)00270-4; Behrens EM, 2003, EUR J IMMUNOL, V33, P2160, DOI 10.1002/eji.200324076; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Borgel D, 2006, CRIT CARE MED, V34, P219, DOI 10.1097/01.CCM.0000195014.56254.8A; Chen J, 1997, ONCOGENE, V14, P2033, DOI 10.1038/sj.onc.1201039; Curran-Everett D, 2000, AM J PHYSIOL-REG I, V279, pR1, DOI 10.1152/ajpregu.2000.279.1.R1; Dirks W, 1999, LEUKEMIA RES, V23, P643, DOI 10.1016/S0145-2126(99)00075-2; Dormady SP, 2000, P NATL ACAD SCI USA, V97, P12260, DOI 10.1073/pnas.97.22.12260; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Ek S, 2002, CANCER RES, V62, P4398; Evans CO, 2001, J CLIN ENDOCR METAB, V86, P3097, DOI 10.1210/jc.86.7.3097; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Georgescu MM, 1999, MOL CELL BIOL, V19, P1171; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; GRAHAM DK, 1995, ONCOGENE, V10, P2349; GRAHAM DK, 2006, IN PRESS CLIN CANC R, V12; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Grandage VL, 2005, LEUKEMIA, V19, P586, DOI 10.1038/sj.leu.2403653; Graux C, 2004, NAT GENET, V36, P1084, DOI 10.1038/ng1425; Guttridge KL, 2002, J BIOL CHEM, V277, P24057, DOI 10.1074/jbc.M112086200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HENZE G, 1991, BLOOD, V78, P1166; JIA R, 1992, J VIROL, V66, P5975, DOI 10.1128/JVI.66.10.5975-5987.1992; JIA R, 1994, J BIOL CHEM, V269, P1839; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389; LING L, 1995, MOL CELL BIOL, V15, P6582; Naf D, 2002, CANCER RES, V62, P1235; Ogilvy S, 1999, BLOOD, V94, P1855; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Sattler M, 2004, LEUKEMIA RES, V28, pS11, DOI 10.1016/j.leukres.2003.10.004; Savage DG, 2002, NEW ENGL J MED, V346, P683, DOI 10.1056/NEJMra013339; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schrappe M, 2000, LEUKEMIA, V14, P2193, DOI 10.1038/sj.leu.2401977; Silverman LB, 2001, BLOOD, V97, P1211, DOI 10.1182/blood.V97.5.1211; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Tibes R, 2005, ANNU REV PHARMACOL, V45, P357, DOI 10.1146/annurev.pharmtox.45.120403.100124; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wolfraim LA, 2004, NEW ENGL J MED, V351, P552, DOI 10.1056/NEJMoa031197; Wu CW, 2002, ANTICANCER RES, V22, P1071; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6	49	68	81	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6092	6100		10.1038/sj.onc.1209633	http://dx.doi.org/10.1038/sj.onc.1209633			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16652142				2022-12-25	WOS:000241101200006
J	Manuvakhova, M; Thottassery, JV; Hays, S; Qu, Z; Rentz, SS; Westbrook, L; Kern, FG				Manuvakhova, M.; Thottassery, J. V.; Hays, S.; Qu, Z.; Rentz, S. S.; Westbrook, L.; Kern, F. G.			Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells	ONCOGENE			English	Article						breast cancer; antiestrogen resistance; FGF; SNT-1 PTB domain; signal transduction	P70 S6 KINASE; SIGNAL-TRANSDUCTION PATHWAYS; DOCKING-PROTEIN FRS2-ALPHA; PC12 CELLS; FACTOR RECEPTORS; TYROSINE KINASE; RAPAMYCIN TOR; MCF-7 CELLS; NUDE-MICE; FACTOR-IV	Fibroblast growth factor (FGF) signaling can bypass the requirement for estrogen receptor (ER) activation in the growth of ER-positive (ER+) breast cancer cells. Fibroblast growth factor-1 stimulation leads to phosphorylation of the adaptor protein Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated target (SNT-1) on C-terminal tyrosine residues, whereas it is constitutively bound through its N-terminal phosphotyrosine-binding domain (PTB) to FGF receptors (FGFRs). By expressing the PTB domain of SNT-1 (SNT-1 PTB) in an inducible manner in an ER+ breast carcinoma line, ML20, we asked whether we could uncouple FGFR activation from its downstream signaling components and abrogate FGF-1-induced antiestrogen-resistant growth. Induction of SNT-1 PTB resulted in a significant decrease of FGF-1-dependent tyrosine phosphorylation of endogenous SNT-1, strong inhibition of complex formation between SNT-1, Gab-1 and Sos-1, and reduced activation of Ras, mitogen-activated protein kinase (MAP kinase), and Akt. SNT-1 PTB also inhibited the phosphorylation of p70S6K on Thr421/Ser424 and Ser411, which may result from the abrogation of MAP kinase activity. Moreover, we also observed a decreased phosphorylation of the MAP kinase-independent site Thr389. This may reflect both inhibition of PI-3 kinase pathways and mammalian target of rapamycin (mTOR)-dependent signaling, as the phosphorylation of Thr389 site was sensitive to treatment with the PI3-K and mTOR inhibitors, LY294002 and rapamycin, respectively. Collectively these results suggest that SNT-1 plays a pivotal role in FGF-dependent activation of the Ras-MAP kinase, PI-3 kinase, and mTOR pathways in these cells. Fibroblast growth factor-1 dependent colony formation of ML20 cells in media containing the pure antiestrogen ICI 182,780 was also markedly inhibited upon induction of SNT-1 PTB, suggesting that blockade of FGFR-SNT-1 interactions might abrogate FGF-mediated antiestrogen resistance in breast cancers.	Lexicon Genet Inc, Div Pharmaceut Biol, The Woodlands, TX 77381 USA; So Res Inst, Drug Discovery Div, Dept Biochem & Mol Biol, Birmingham, AL 35255 USA; UAB Comprehens Canc Ctr, Birmingham, AL USA	Lexicon Pharmaceuticals; University of Alabama System; University of Alabama Birmingham	Kern, FG (corresponding author), Lexicon Genet Inc, Div Pharmaceut Biol, 8800 Technol Forest Pl, The Woodlands, TX 77381 USA.	fkern@lexgen.com			NCI NIH HHS [CA50376, P30CA13148] Funding Source: Medline; NIAID NIH HHS [P30AI27767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148, R01CA050376] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027767] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; Califano D, 2000, J BIOL CHEM, V275, P19297, DOI 10.1074/jbc.M905866199; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; Dennis PB, 1998, J BIOL CHEM, V273, P14845, DOI 10.1074/jbc.273.24.14845; Dhalluin C, 2000, MOL CELL, V6, P921, DOI 10.1016/S1097-2765(00)00089-7; Dunican DJ, 2001, CELL GROWTH DIFFER, V12, P255; Ehrhard KN, 2000, NAT BIOTECHNOL, V18, P1075, DOI 10.1038/80274; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gonzalez-Garcia A, 2002, J BIOL CHEM, V277, P1500, DOI 10.1074/jbc.M103808200; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Iijima Y, 2002, J BIOL CHEM, V277, P23065, DOI 10.1074/jbc.M200328200; JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kimpinski K, 2001, J NEUROSCI RES, V63, P486, DOI 10.1002/jnr.1043; Klint P, 1999, ONCOGENE, V18, P3354, DOI 10.1038/sj.onc.1202680; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Koziczak M, 2004, ONCOGENE, V23, P3501, DOI 10.1038/sj.onc.1207331; KUREBAYASHI J, 1993, CANCER RES, V53, P2178; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; Lamothe B, 2004, MOL CELL BIOL, V24, P5657, DOI 10.1128/MCB.24.13.5657-5666.2004; Lax I, 2002, MOL CELL, V10, P709, DOI 10.1016/S1097-2765(02)00689-5; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; McLeskey SW, 1998, CLIN CANCER RES, V4, P697; MCLESKEY SW, 1993, CANCER RES, V53, P2168; McLeskey SW, 1996, BREAST CANCER RES TR, V39, P103, DOI 10.1007/BF01806082; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Moffa AB, 2004, MOL CANCER RES, V2, P643; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Ong SH, 1996, BIOCHEM BIOPH RES CO, V225, P1021, DOI 10.1006/bbrc.1996.1288; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; PRICE DJ, 1991, J BIOL CHEM, V266, P16281; Qu ZC, 2004, GENE, V327, P61, DOI 10.1016/j.gene.2003.10.029; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Romanelli A, 2002, J BIOL CHEM, V277, P40281, DOI 10.1074/jbc.M205168200; Stoletov KV, 2002, FASEB J, V16, P1283, DOI 10.1096/fj.01-0835fje; Tsoulfas P, 1996, J BIOL CHEM, V271, P5691, DOI 10.1074/jbc.271.10.5691; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197; Wang F, 2002, IN VITRO CELL DEV-AN, V38, P178; Wang JK, 1996, ONCOGENE, V13, P721; Wu YJ, 2003, BIOL CHEM, V384, P1215, DOI 10.1515/BC.2003.134; XIE WQ, 1991, BIOTECHNIQUES, V11, P324; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; Xu H, 2001, J BIOL CHEM, V276, P13049, DOI 10.1074/jbc.M009925200; Yonezawa K, 2004, BIOCHEM BIOPH RES CO, V313, P437, DOI 10.1016/j.bbrc.2003.07.018; Yoshimura N, 1998, CLIN IMMUNOL IMMUNOP, V89, P28, DOI 10.1006/clin.1998.4551; Yuen EC, 1999, EXP NEUROL, V159, P297, DOI 10.1006/exnr.1999.7148; Zhang LR, 1997, ONCOGENE, V15, P2093, DOI 10.1038/sj.onc.1201386; Zhang YG, 2001, J BIOL CHEM, V276, P20913, DOI 10.1074/jbc.M009047200; Zhang YY, 2004, J BIOL CHEM, V279, P55348, DOI 10.1074/jbc.M409230200	59	15	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2006	25	44					6003	6014		10.1038/sj.onc.1209592	http://dx.doi.org/10.1038/sj.onc.1209592			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16682955				2022-12-25	WOS:000240826300009
J	Bonn, S; Herrero, S; Breitenlechner, CB; Erlbruch, A; Lehmann, W; Engh, RA; Gassel, M; Bossemeyer, D				Bonn, Stefan; Herrero, Saturnino; Breitenlechner, Christine B.; Erlbruch, Andrea; Lehmann, Wolf; Engh, Richard A.; Gassel, Michael; Bossemeyer, Dirk			Structural analysis of protein kinase A mutants with Rho-kinase inhibitor specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURES; PHOSPHORYLATION; MECHANISM; COMPLEX; CELLS; SELECTIVITY; DESIGN; SENSITIZATION	Controlling aberrant kinase-mediated cellular signaling is a major strategy in cancer therapy; successful protein kinase inhibitors such as Tarceva and Gleevec verify this approach. Specificity of inhibitors for the targeted kinase(s), however, is a crucial factor for therapeutic success. Based on homology modeling, we previously identified four amino acids in the active site of Rho-kinase that likely determine inhibitor specificities observed for Rho-kinase relative to protein kinase A (PKA) (in PKA numbering: T183A, L49I, V123M, and E127D), and a fifth (Q181K) that played a surprising role in PKA-PKB hybrid proteins. We have systematically mutated these residues in PKA to their counterparts in Rho-kinase, individually and in combination. Using four Rho-kinase-specific, one PKA- specific, and one pan-kinase-specific inhibitor, we measured the inhibitor-binding properties of the mutated proteins and identify the roles of individual residues as specificity determinants. Two combined mutant proteins, containing the combination of mutations T183A and L49I, closely mimic Rho- kinase. Kinetic results corroborate the hypothesis that side-chain identities form the major determinants of selectivity. An unexpected result of the analysis is the consistent contribution of the individual mutations by simple factors. Crystal structures of the surrogate kinase inhibitor complexes provide a detailed basis for an understanding of these selectivity determinant residues. The ability to obtain kinetic and structural data from these PKA mutants, combined with their Rho-kinase-like selectivity profiles, make them valuable for use as surrogate kinases for structure-based inhibitor design.	German Canc Res Ctr, Grp Struct Biochem, D-69120 Heidelberg, Germany; German Canc Res Ctr, Dept Cent Spect, D-69120 Heidelberg, Germany; Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Roche Diagnost GmbH, Dept Med Chem, D-82372 Penzberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Max Planck Society; Roche Holding	Bonn, S (corresponding author), German Canc Res Ctr, Grp Struct Biochem, D-69120 Heidelberg, Germany.	d.bossemeyer@dkfz-heidelberg.de		Engh, Richard/0000-0002-6207-0560; Bonn, Stefan/0000-0003-4366-5662				Amano M, 2000, METHOD ENZYMOL, V325, P149; Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; Breitenlechner C, 2003, STRUCTURE, V11, P1595, DOI 10.1016/j.str.2003.11.002; Breitenlechner C, 2004, ONCOL RES, V14, P267; Breitenlechner CB, 2005, J MED CHEM, V48, P163, DOI 10.1021/jm049701n; Breitenlechner CB, 2004, J MED CHEM, V47, P1375, DOI 10.1021/jm0310479; Brown ER, 2005, EXPERT REV ANTICANC, V5, P767, DOI 10.1586/14737140.5.5.767; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cohen MS, 2005, SCIENCE, V308, P1318, DOI 10.1126/science1108367; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; Corbin AS, 2000, BLOOD, V96, p470A; Engh RA, 1996, J BIOL CHEM, V271, P26157, DOI 10.1074/jbc.271.42.26157; Fukata Y, 2001, TRENDS PHARMACOL SCI, V22, P32, DOI 10.1016/S0165-6147(00)01596-0; Gassel M, 2004, J BIOL CHEM, V279, P23679, DOI 10.1074/jbc.M314082200; Gassel M, 2003, J MOL BIOL, V329, P1021, DOI 10.1016/S0022-2836(03)00518-7; GIBBS CS, 1991, BIOCHEMISTRY-US, V30, P5329, DOI 10.1021/bi00236a001; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIDAKA H, 1991, METHOD ENZYMOL, V201, P328; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Ikenoya M, 2002, J NEUROCHEM, V81, P9, DOI 10.1046/j.1471-4159.2002.00801.x; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Ito K, 2003, J PHYSIOL-LONDON, V546, P823, DOI 10.1113/jphysiol.2002.030775; Jabs A, 1999, J MOL BIOL, V286, P291, DOI 10.1006/jmbi.1998.2459; Jacobs M, 2006, J BIOL CHEM, V281, P260, DOI 10.1074/jbc.M508847200; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KREBS EG, 1989, JAMA-J AM MED ASSOC, V262, P1815, DOI 10.1001/jama.262.13.1815; KREBS EG, 1985, BIOCHEM SOC T, V13, P813, DOI 10.1042/bst0130813; Lessel U, 1997, PROTEIN ENG, V10, P659, DOI 10.1093/protein/10.6.659; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; Ono-Saito N, 1999, PHARMACOL THERAPEUT, V82, P123, DOI 10.1016/S0163-7258(98)00070-9; PAWSON T, 1994, CURR OPIN GENET DEV, V4, P1, DOI 10.1016/0959-437X(94)90084-1; Prade L, 1997, STRUCTURE, V5, P1627, DOI 10.1016/S0969-2126(97)00310-9; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Sasaki Y, 2002, PHARMACOL THERAPEUT, V93, P225, DOI 10.1016/S0163-7258(02)00191-2; Shimokawa H, 2002, J CARDIOVASC PHARM, V40, P749; Turner MS, 2002, ARCH BIOCHEM BIOPHYS, V405, P13, DOI 10.1016/S0003-9861(02)00249-7; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Wettschureck N, 2002, J MOL MED, V80, P629, DOI 10.1007/s00109-002-0370-2	43	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24818	24830		10.1074/jbc.M512374200	http://dx.doi.org/10.1074/jbc.M512374200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16699172	hybrid			2022-12-25	WOS:000239847800077
J	Williams, JC; Armesilla, AL; Mohamed, TMA; Hagarty, CL; McIntyre, FH; Schomburg, S; Zaki, AO; Oceandy, D; Cartwright, EJ; Buch, MH; Emerson, M; Neyses, L				Williams, Judith C.; Armesilla, Angel L.; Mohamed, Tamer M. A.; Hagarty, Cassandra L.; McIntyre, Fiona H.; Schomburg, Sybille; Zaki, Aly O.; Oceandy, Delvac; Cartwright, Elizabeth J.; Buch, Mamta H.; Emerson, Michael; Neyses, Ludwig			The sarcolemmal calcium pump, alpha-1 syntrophin, and neuronal nitric-oxide synthase are parts of a macromolecular protein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; NEUROMUSCULAR-JUNCTION; SKELETAL-MUSCLE; HEART-DISEASE; MEMBRANE; KINASE; LOCALIZATION; ISOFORMS; DOMAIN; BINDS	The main role of the plasma membrane Ca2+/calmodulin-dependent ATPase (PMCA) is in the removal of Ca2+ from the cytosol. Recently, we and others have suggested a new function for PMCA as a modulator of signal transduction pathways. This paper shows the physical interaction between PMCA (isoforms 1 and 4) and alpha-1 syntrophin and proposes a ternary complex of interaction between endogenous PMCA, alpha-1 syntrophin, and NOS-1 in cardiac cells. We have identified that the linker region between the pleckstrin homology 2 (PH2) and the syntrophin unique (SU) domains, corresponding to amino acids 399 -447 of alpha-1 syntrophin, is crucial for interaction with PMCA1 and -4. The PH2 and the SU domains alone failed to interact with PMCA. The functionality of the interaction was demonstrated by investigating the inhibition of neuronal nitric-oxide synthase-1 (NOS-1); PMCA is a negative regulator of NOS-1-dependent NO production, and overexpression of alpha-1 syntrophin and PMCA4 resulted in strongly increased inhibition of NO production. Analysis of the expression levels of alpha-1 syntrophin protein in the heart, skeletal muscle, brain, uterus, kidney, or liver of PMCA4(-/)-mice, did not reveal any differences when compared with those found in the same tissues of wild-type mice. These results suggest that PMCA4 is tethered to the syntrophin complex as a regulator of NOS-1, but its absence does not cause collapse of the complex, contrary to what has been reported for other proteins within the complex, such as dystrophin. In conclusion, the present data demonstrate for the first time the localization of PMCA1b and -4b to the syntrophin(.)dystrophin complex in the heart and provide a specific molecular mechanism of interaction as well as functionality.	Univ Manchester, Div Cardiol, Manchester M13 9PT, Lancs, England; Wolverhampton Univ, Mol Pharmacol Grp, Res Inst Healthcare Sci, Sch Appl Sci, Wolverhampton WV1 1SB, England	University of Manchester; University of Wolverhampton	Neyses, L (corresponding author), Univ Manchester, Div Cardiol, Rm 1-302,Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	Ludwig.Neyses@manchester.ac.uk	Oceandy, Delvac/G-9911-2015; Neyses, Ludwig/AGY-7446-2022	Oceandy, Delvac/0000-0002-6242-6491; Armesilla, Angel/0000-0003-3546-5580; Cartwright, Elizabeth/0000-0002-6836-7795	MRC [G0500025] Funding Source: UKRI; Medical Research Council [G0500025] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ADAMS ME, 1995, J BIOL CHEM, V270, P25859, DOI 10.1074/jbc.270.43.25859; AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; Armesilla AL, 2004, J BIOL CHEM, V279, P31318, DOI 10.1074/jbc.M307557200; Barouch LA, 2002, NATURE, V416, P337, DOI 10.1038/416337a; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Blake DJ, 2000, TRENDS NEUROSCI, V23, P92, DOI 10.1016/S0166-2236(99)01510-6; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Buch MH, 2005, J BIOL CHEM, V280, P29479, DOI 10.1074/jbc.M501326200; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Cox GF, 1997, CURR OPIN CARDIOL, V12, P329; Damy T, 2004, LANCET, V363, P1365, DOI 10.1016/S0140-6736(04)16048-0; DeMarco SJ, 2001, J BIOL CHEM, V276, P21594, DOI 10.1074/jbc.M101448200; Gee SH, 1998, J NEUROSCI, V18, P128; Goellner GM, 2003, ANN NY ACAD SCI, V986, P461, DOI 10.1111/j.1749-6632.2003.tb07230.x; Hammes A, 1998, CIRC RES, V83, P877; Hein S, 2000, CARDIOVASC RES, V45, P273, DOI 10.1016/S0008-6363(99)00268-0; Kachinsky AM, 1999, J CELL BIOL, V145, P391, DOI 10.1083/jcb.145.2.391; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Kramarcy NR, 2000, MOL CELL NEUROSCI, V15, P262, DOI 10.1006/mcne.1999.0823; Newey SE, 2000, CURR BIOL, V10, P1295, DOI 10.1016/S0960-9822(00)00760-0; PETERS MF, 1994, NEUROREPORT, V5, P1577, DOI 10.1097/00001756-199408150-00009; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; Prasad V, 2004, BIOCHEM BIOPH RES CO, V322, P1192, DOI 10.1016/j.bbrc.2004.07.156; Sadeghi A, 2002, AM J PHYSIOL-CELL PH, V282, pC1502, DOI 10.1152/ajpcell.00435.2001; Schuh K, 2004, J BIOL CHEM, V279, P28220, DOI 10.1074/jbc.M312599200; Schuh K, 2003, J BIOL CHEM, V278, P41246, DOI 10.1074/jbc.M307606200; Schuh K, 2003, J BIOL CHEM, V278, P9778, DOI 10.1074/jbc.M212507200; Schuh K, 2001, J CELL BIOL, V155, P201, DOI 10.1083/jcb.200104131; Sears CE, 2003, CIRC RES, V92, pE52, DOI 10.1161/01.RES.0000064585.95749.6D; SUZUKI A, 1995, J CELL BIOL, V128, P373, DOI 10.1083/jcb.128.3.373; Wang Y, 2004, CIRC RES, V95, P84, DOI 10.1161/01.RES.0000133679.38825.a6; Xiong DD, 2002, NAT MED, V8, P872, DOI 10.1038/nm737; Xu KY, 1999, P NATL ACAD SCI USA, V96, P657, DOI 10.1073/pnas.96.2.657; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	35	112	119	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23341	23348		10.1074/jbc.M513341200	http://dx.doi.org/10.1074/jbc.M513341200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16735509	hybrid, Green Published			2022-12-25	WOS:000239702900008
J	Cliff, MJ; Limpkin, C; Cameron, A; Burston, SG; Clarke, AR				Cliff, Matthew J.; Limpkin, Claire; Cameron, Angus; Burston, Steven G.; Clarke, Anthony R.			Elucidation of steps in the capture of a protein substrate for efficient encapsulation by GroE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED ALLOSTERIC TRANSITIONS; CHAPERONIN ATPASE CYCLE; CRYSTAL-STRUCTURE; KINETIC-ANALYSIS; ALPHA-LACTALBUMIN; ESCHERICHIA-COLI; BINDING; POLYPEPTIDE; COMPLEX; RELEASE	We have identified five structural rearrangements in GroEL induced by the ordered binding of ATP and GroES. The first discernable rearrangement (designated T -> R-1) is a rapid, cooperative transition that appears not to be functionally communicated to the apical domain. In the second (R-1 -> R-2) step, a state is formed that binds GroES weakly in a rapid, diffusion-limited process. However, a second optical signal, carried by a protein substrate bound to GroEL, responds neither to formation of the R-2 state nor to the binding of GroES. This result strongly implies that the substrate protein remains bound to the inner walls of the initially formed GroEL (.) GroES cavity, and is not yet displaced from its sites of interaction with GroEL. In the next rearrangement (R-2 (.) GroES -> R-3 (.) GroES) the strength of interaction between GroEL and GroES is greatly enhanced, and there is a large and coincident loss of fluorescence-signal intensity in the labeled protein substrate, indicating that there is either a displacement from its binding sites on GroEL or at least a significant change of environment. These results are consistent with a mechanism in which the shift in orientation of GroEL apical domains between that seen in the apo-protein and stable GroEL (.) GroES complexes is highly ordered, and transient conformational intermediates permit the association of GroES before the displacement of bound polypeptide. This ensures efficient encapsulation of the polypeptide within the GroEL central cavity underneath GroES.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Burston, SG (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England.	s.g.burston@bristol.ac.uk		Burston, Steven/0000-0003-1848-1853; Cliff, Matthew/0000-0002-7482-0234	Biotechnology and Biological Sciences Research Council [BB/C507702/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Amir A, 2004, J MOL BIOL, V338, P979, DOI 10.1016/j.jmb.2004.02.076; BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; BURSTON SG, 2004, PROTEIN FOLDING HD 2, P683; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; Chen LL, 1999, CELL, V99, P757, DOI 10.1016/S0092-8674(00)81673-6; Cliff MJ, 1999, J MOL BIOL, V293, P667, DOI 10.1006/jmbi.1999.3138; Farr GW, 2000, CELL, V100, P561, DOI 10.1016/S0092-8674(00)80692-3; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; Inobe T, 2003, J MOL BIOL, V327, P183, DOI 10.1016/S0022-2836(03)00087-1; Kad NM, 1998, J MOL BIOL, V278, P267, DOI 10.1006/jmbi.1998.1704; KOSHLAND DE, 1964, J AM CHEM SOC, V86, P1448, DOI 10.1021/ja01061a045; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P441; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Motojima F, 2004, P NATL ACAD SCI USA, V101, P15005, DOI 10.1073/pnas.0406132101; OKAZAKI A, 1994, NAT STRUCT BIOL, V1, P439, DOI 10.1038/nsb0794-439; Poso D, 2004, J MOL BIOL, V338, P969, DOI 10.1016/j.jmb.2004.03.010; Ranson NA, 2001, CELL, V107, P869, DOI 10.1016/S0092-8674(01)00617-1; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; Saibil HR, 2002, TRENDS BIOCHEM SCI, V27, P627, DOI 10.1016/S0968-0004(02)02211-9; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Sparrer H, 1996, J MOL BIOL, V258, P74, DOI 10.1006/jmbi.1996.0235; STANIFORTH RA, 1994, BIOCHEM J, V300, P651, DOI 10.1042/bj3000651; Thirumalai D, 2001, ANNU REV BIOPH BIOM, V30, P245, DOI 10.1146/annurev.biophys.30.1.245; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Yifrach O, 1998, BIOCHEMISTRY-US, V37, P7083, DOI 10.1021/bi980370o; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001; Yifrach O, 1996, J MOL BIOL, V255, P356, DOI 10.1006/jmbi.1996.0028	44	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21266	21275		10.1074/jbc.M601605200	http://dx.doi.org/10.1074/jbc.M601605200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16684774	hybrid			2022-12-25	WOS:000239187300062
J	Honda, H; Pazin, MJ; Ji, H; Wernyj, RP; Morin, PJ				Honda, Hiroshi; Pazin, Michael J.; Ji, Hongxiu; Wernyj, Roman P.; Morin, Patrice J.			Crucial roles of Sp1 and epigenetic modifications in the regulation of the CLDN4 promoter in ovarian cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIUM-PERFRINGENS ENTEROTOXIN; TIGHT JUNCTION PROTEINS; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; POTENTIAL MARKERS; EPITHELIAL-CELLS; BARRIER FUNCTION; CLAUDIN-4; METHYLATION; CHROMATIN	Claudins form a large family of tight junction proteins that have essential roles in the control of paracellular ion flux and the maintenance of cell polarity. Many studies have shown that several claudin family members are abnormally expressed in various cancers. In particular, CLDN4 ( encoding claudin-4) is overexpressed in ovarian cancer. However, although CLDN4 overexpression is well established, the mechanisms responsible for this abnormal regulation remain unknown. In the present study, we delineate a small region of the CLDN4 promoter critical for its expression. This region contains two Sp1 sites, both of which are required for promoter activity. However, because of the ubiquitous expression of Sp1, these sites, although necessary, are not sufficient to explain the patterns of gene expression of CLDN4 in various ovarian tissues. We show that the CLDN4 promoter is further controlled by epigenetic modifications of the Sp1-containing critical promoter region. Cells that overexpress CLDN4 exhibit low DNA methylation and high histone H3 acetylation of the critical CLDN4 promoter region, and the reverse is observed in cells that do not express CLDN4. Moreover, the CLDN4-negative cells can be induced to express CLDN4 through treatment with demethylating and/or acetylating agents. Because CLDN4 is elevated in a large fraction of ovarian cancer, the mechanism leading to deregulation may represent a general pathway in ovarian tumorigenesis and may lead to novel strategies for therapy and an overall better understanding of the biology of this disease.	NIA, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21287 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University; Johns Hopkins Medicine	Morin, PJ (corresponding author), NIA, Cellular & Mol Biol Lab, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	morinp@grc.nia.nih.gov		Pazin, Michael/0000-0002-7561-3640	Intramural NIH HHS [ZIA AG000377-02] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [Z01AG000524, Z01AG000512] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agarwal R, 2005, CANCER RES, V65, P7378, DOI 10.1158/0008-5472.CAN-05-1036; Alikhani-Koopaei R, 2004, J CLIN INVEST, V114, P1146, DOI 10.1172/JCI200421647; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; D'Souza T, 2005, J BIOL CHEM, V280, P26233, DOI 10.1074/jbc.M502003200; Deng GR, 2004, CANCER RES, V64, P2692, DOI 10.1158/0008-5472.CAN-03-3000; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; Fujibe M, 2004, EXP CELL RES, V295, P36, DOI 10.1016/j.yexcr.2003.12.014; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gartel AL, 2000, ONCOGENE, V19, P5182, DOI 10.1038/sj.onc.1203900; Gerber AN, 1997, GENE DEV, V11, P436, DOI 10.1101/gad.11.4.436; Gregoire L, 1998, IN VITRO CELL DEV-AN, V34, P636; Hibbs K, 2004, AM J PATHOL, V165, P397, DOI 10.1016/S0002-9440(10)63306-8; Hough CD, 2000, CANCER RES, V60, P6281; Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389; Katahira J, 1997, J BIOL CHEM, V272, P26652, DOI 10.1074/jbc.272.42.26652; Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199; Lu KH, 2004, CLIN CANCER RES, V10, P3291, DOI 10.1158/1078-0432.CCR-03-0409; Luo MP, 1997, GYNECOL ONCOL, V67, P277, DOI 10.1006/gyno.1997.4880; Mima S, 2005, CANCER RES, V65, P1868, DOI 10.1158/0008-5472.CAN-04-2770; Morin PJ, 2005, CANCER RES, V65, P9603, DOI 10.1158/0008-5472.CAN-05-2782; Rangel LBA, 2003, CLIN CANCER RES, V9, P2567; Rosen DG, 2005, GYNECOL ONCOL, V99, P267, DOI 10.1016/j.ygyno.2005.06.040; Salvatori L, 2003, ONCOGENE, V22, P4875, DOI 10.1038/sj.onc.1206784; Santin AD, 2005, CANCER RES, V65, P4334, DOI 10.1158/0008-5472.CAN-04-3472; Santin AD, 2004, INT J CANCER, V112, P14, DOI 10.1002/ijc.20408; Sowa Y, 1999, CANCER RES, V59, P4266; Stewart JJ, 2006, MOL CELL PROTEOMICS, V5, P433, DOI 10.1074/mcp.M500140-MCP200; Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690; Stoner M, 2004, ONCOGENE, V23, P1052, DOI 10.1038/sj.onc.1207201; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Yu B, 2003, NUCLEIC ACIDS RES, V31, P5368, DOI 10.1093/nar/gkg706; Zhang Y, 2005, MOL CELL BIOL, V25, P7929, DOI 10.1128/MCB.25.18.7929-7939.2005; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003; Zhu YH, 2006, INT J CANCER, V118, P1884, DOI 10.1002/ijc.21506; Zou MX, 2004, ONCOGENE, V23, P330, DOI 10.1038/sj.onc.1207053	36	118	121	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21433	21444		10.1074/jbc.M603767200	http://dx.doi.org/10.1074/jbc.M603767200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16714763	hybrid			2022-12-25	WOS:000239187300079
J	Nygaard, TK; Blouin, GC; Liu, MY; Fukumura, M; Olson, JS; Fabian, M; Dooley, DM; Lei, BF				Nygaard, Tyler K.; Blouin, George C.; Liu, Mengyao; Fukumura, Maki; Olson, John S.; Fabian, Marian; Dooley, David M.; Lei, Benfang			The mechanism of direct heme transfer from the streptococcal cell surface protein shp to HtsA of the HtsABC transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; ARABIDOPSIS-THALIANA; PATHOGENIC BACTERIA; IRON; HEMOGLOBIN; BINDING; IDENTIFICATION; ACQUISITION; PYOGENES; DISSOCIATION	The heme-binding proteins Shp and HtsA are part of the heme acquisition machinery found in Streptococcus pyogenes. The hexacoordinate heme ( Fe( II)-protoporphyrin IX) or hemochrome form of holoShp ( hemoShp) is stable in air in Tris-HCl buffer, pH 8.0, binds to apoHtsA with a K-d of 120 +/- 18 mu M, and transfers its heme to apoHtsA with a rate constant of 28 +/- 6 s(-1) at 25 degrees C, pH 8.0. The hemoHtsA product then autoxidizes to the hexacoordinate hemin ( Fe( III)-protoporphyrin IX) or hemichrome form ( hemiHtsA) with an apparent rate constant of 0.017 +/- 0.002 s(-1). HemiShp also rapidly transfers hemin to apoHtsA through a hemiShp (.) apoHtsA complex ( K-d = 48 +/- 7 mu M) at a rate 40,000 times greater than the rate of simple hemin dissociation from hemiShp into solvent ( k(transfer) = 43 +/- 3 s(-1) versus k (-) (hemin) = 0.0003 +/- 0.00006 s(-1)). The rate constants for hemin binding to and dissociation from HtsA ( k'(hemin) approximate to 80 mu M-1 s(-1), k (-hemin) = 0.0026 +/- 0.0002 s(-1)) are 50- and 10-fold greater than the corresponding rate constants for Shp ( k (-hemin) approximate to 1.6 mu M-1 s(-1), k (-hemin) = 0.0003 s(-1)), which implies that HtsA has a more accessible active site. However, the affinity of apoHtsA for hemin ( K-hemin approximate to 31,000 mu M-1) is roughly 5-fold greater than that of apoShp ( K-hemin approximate to 5,300 mu M-1), accounting for the net transfer from Shp to HstA. These results support a direct, rapid, and affinity-driven mechanism of heme and hemin transfer from the cell surface receptor Shp to the ATP-binding cassette transporter system.	Montana State Univ, Dept Vet Mol Biol, Bozeman, MT 59717 USA; Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59717 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Rice Univ, WM Keck Ctr Computat Biol, Houston, TX 77005 USA	Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; Rice University; Rice University	Lei, BF (corresponding author), Montana State Univ, Dept Vet Mol Biol, POB 173610, Bozeman, MT 59717 USA.	blei@montana.edu		Olson, John/0000-0002-0760-5403; Nygaard, Tyler/0000-0002-4736-0156; Lei, Benfang Lei/0000-0001-8133-6021	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020185] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K22AI057347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055807, R01GM035649] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR020185-010002, P20 RR020185, P20 RR-020185, P20 RR020185-020002] Funding Source: Medline; NHLBI NIH HHS [R01 HL047020, R01 HL47020] Funding Source: Medline; NIAID NIH HHS [K22 AI057347, K22 AI057347-02, K22 AI057347-01] Funding Source: Medline; NIGMS NIH HHS [R01 GM35649, R01 GM055807, R01 GM035649, R01 GM55804] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ascoli F, 1981, Methods Enzymol, V76, P72; Bates CS, 2003, INFECT IMMUN, V71, P1042, DOI 10.1128/IAI.71.3.1042-1055.2003; BLUMBERG WE, 1971, ADV CHEM, V100, P271; Caillet-Saguy C, 2006, J AM CHEM SOC, V128, P150, DOI 10.1021/ja054902h; Chen CJ, 1996, INFECT IMMUN, V64, P5008, DOI 10.1128/IAI.64.12.5008-5014.1996; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Deniau C, 2003, BIOCHEMISTRY-US, V42, P10627, DOI 10.1021/bi030015k; Drazek ES, 2000, MOL MICROBIOL, V36, P68, DOI 10.1046/j.1365-2958.2000.01818.x; Eichenbaum Z, 1996, INFECT IMMUN, V64, P5428, DOI 10.1128/IAI.64.12.5428-5429.1996; FRANCIS RT, 1985, INT J BIOCHEM, V17, P767, DOI 10.1016/0020-711X(85)90262-9; Fuhrhop J. H., 1975, PORPHYRINS METALLOPO, P804; GRIFFITHS E, 1999, IRON INFECT MOL PHYS, P87; HARGROVE MS, 1994, J BIOL CHEM, V269, P4207; Hargrove MS, 1996, BIOCHEMISTRY-US, V35, P11293, DOI 10.1021/bi960371l; Hargrove MS, 1997, J BIOL CHEM, V272, P17385, DOI 10.1074/jbc.272.28.17385; Hargrove MS, 2000, STRUCTURE, V8, P1005, DOI 10.1016/S0969-2126(00)00194-5; KLEBBA PE, 1993, J BIOENERG BIOMEMBR, V25, P603; Lei BF, 2003, INFECT IMMUN, V71, P5962, DOI 10.1128/IAI.71.10.5962-5969.2003; Lei BF, 2002, INFECT IMMUN, V70, P4494, DOI 10.1128/IAI.70.8.4494-4500.2002; LETOFFE S, 1994, P NATL ACAD SCI USA, V91, P9876, DOI 10.1073/pnas.91.21.9876; Letoffe S, 2003, MOL MICROBIOL, V50, P77, DOI 10.1046/j.1365-2958.2003.03686.x; Liu MY, 2005, INFECT IMMUN, V73, P5086, DOI 10.1128/IAI.73.8.5086-5092.2005; Liu W, 2004, J BIOL CHEM, V279, P29805, DOI 10.1074/jbc.M401779200; Mazmanian SK, 2003, SCIENCE, V299, P906, DOI 10.1126/science.1081147; OTTO BR, 1992, CRIT REV MICROBIOL, V18, P217, DOI 10.3109/10408419209114559; PALMER G, 2000, PHYS METHODS BIOINOR, P121; ROSE MY, 1983, J BIOL CHEM, V258, P4298; Rouault TA, 2004, SCIENCE, V305, P1577, DOI 10.1126/science.1102975; Shaw AL, 1999, J BIOL CHEM, V274, P9911, DOI 10.1074/jbc.274.15.9911; Skaar EP, 2004, SCIENCE, V305, P1626, DOI 10.1126/science.1099930; Trevaskis B, 1997, P NATL ACAD SCI USA, V94, P12230, DOI 10.1073/pnas.94.22.12230	31	76	76	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20761	20771		10.1074/jbc.M601832200	http://dx.doi.org/10.1074/jbc.M601832200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16717094	hybrid, Green Accepted			2022-12-25	WOS:000239187300012
J	Pecqueur, L; D'Autreaux, B; Dupuy, J; Nicolet, Y; Jacquamet, L; Brutscher, B; Michaud-Soret, I; Bersch, B				Pecqueur, Ludovic; D'Autreaux, Benoit; Dupuy, Jerome; Nicolet, Yvain; Jacquamet, Lilian; Brutscher, Bernhard; Michaud-Soret, Isabelle; Bersch, Beate			Structural changes of Escherichia coli ferric uptake regulator during metal-dependent dimerization and activation explored by NMR and x-ray crystallography	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UPTAKE REGULATION PROTEIN; PSEUDOMONAS-AERUGINOSA; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; FUR PROTEIN; DNA-BINDING; IRON; ZINC; REPRESSOR; SITE	Ferric uptake regulator (Fur) is a global bacterial regulator that uses iron as a cofactor to bind to specific DNA sequences. Escherichia coli Fur is usually isolated as a homodimer with two metal sites per subunit. Metal binding to the iron site induces protein activation; however the exact role of the structural zinc site is still unknown. Structural studies of three different forms of the Escherichia coli Fur protein (nonactivated dimer, monomer, and truncated Fur-(1-82)) were performed. Dimerization of the oxidized monomer was followed by NMR in the presence of a reductant (dithiothreitol) and Zn(II). Reduction of the disulfide bridges causes only local structure variations, whereas zinc addition to reduced Fur induces protein dimerization. This demonstrates for the first time the essential role of zinc in the stabilization of the quaternary structure. The secondary structures of the mono- and dimeric forms are almost conserved in the N-terminal DNA-binding domain, except for the first helix, which is not present in the nonactivated dimer. In contrast, the C-terminal dimerization domain is well structured in the dimer but appears flexible in the monomer. This is also confirmed by heteronuclear Overhauser effect data. The crystal structure at 1.8A resolution of a truncated protein (Fur-(1-82)) is described and found to be identical to the N-terminal domain in the monomeric and in the metal-activated state. Altogether, these data allow us to propose an activation mechanism for E. coli Fur involving the folding/unfolding of the N-terminal helix.	CEA Grenoble, Lab Physicochim Metaux Biol, Dept Reponse & Dynam Cellulaires, CNRS,UMR 5155, F-38054 Grenoble 9, France; Univ Grenoble 1, CEA, CNRS, UMR 5075,Lab Resonance Magnet Nucl Prot, F-38027 Grenoble 1, France; Univ Grenoble 1, CEA, CNRS,Inst Biol Struct Jean Pierre Ebel, UMR 5075,Lab Cristallog & Cristallogenes Prot, F-38027 Grenoble 1, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA	Michaud-Soret, I (corresponding author), CEA Grenoble, Lab Physicochim Metaux Biol, Dept Reponse & Dynam Cellulaires, CNRS,UMR 5155, 17 Ave Martyrs, F-38054 Grenoble 9, France.	imichaud@cea.fr; beate.bersch@ibs.fr	Yvain, Nicolet/AAP-9763-2020; Bersch, Beate/A-7011-2013; Dupuy, Jerome/AAD-3438-2020; Michaud-Soret, Isabelle/P-7048-2019; D'Autreaux, Benoit/M-8520-2018	Yvain, Nicolet/0000-0002-4189-7067; Bersch, Beate/0000-0003-1138-4911; Dupuy, Jerome/0000-0002-2721-5365; Michaud-Soret, Isabelle/0000-0002-8936-4964; D'Autreaux, Benoit/0000-0002-1276-3019; Pecqueur, Ludovic/0000-0002-0396-699X				Adrait A, 1999, BIOCHEMISTRY-US, V38, P6248, DOI 10.1021/bi9823232; Alekshun MN, 2001, NAT STRUCT BIOL, V8, P710, DOI 10.1038/90429; Althaus EW, 1999, BIOCHEMISTRY-US, V38, P6559, DOI 10.1021/bi982788s; BAGG A, 1987, BIOCHEMISTRY-US, V26, P5471, DOI 10.1021/bi00391a039; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barton HA, 1996, MOL MICROBIOL, V21, P1001, DOI 10.1046/j.1365-2958.1996.381426.x; BRUTSCHER B, 1995, J BIOMOL NMR, V5, P202, DOI 10.1007/BF00208811; COY M, 1994, BIOMETALS, V7, P292; COY M, 1991, BIOCHEMISTRY-US, V30, P8201, DOI 10.1021/bi00247a016; D'Autreaux B, 2002, P NATL ACAD SCI USA, V99, P16619, DOI 10.1073/pnas.252591299; DAUTREAUX B, 2002, THESIS U J FOURIER G; de Peredo AG, 1999, BIOCHEMISTRY-US, V38, P8582, DOI 10.1021/bi9902283; de Peredo AG, 2001, J MOL BIOL, V310, P83, DOI 10.1006/jmbi.2001.4769; DELORENZO V, 1987, J BACTERIOL, V169, P2624, DOI 10.1128/jb.169.6.2624-2630.1987; DEPEREDO AG, 2000, THESIS U J FOURIER G; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FARROW NA, 1994, J BIOMOL NMR, V4, P727, DOI 10.1007/BF00404280; Friedman YE, 2004, J BIOL CHEM, V279, P32100, DOI 10.1074/jbc.M404924200; Garcia-Castellanos R, 2004, J BIOL CHEM, V279, P17888, DOI 10.1074/jbc.M313123200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hantke K, 2001, CURR OPIN MICROBIOL, V4, P172, DOI 10.1016/S1369-5274(00)00184-3; Jacquamet L, 1998, BIOCHEMISTRY-US, V37, P2564, DOI 10.1021/bi9721344; Jacquamet L, 2000, J AM CHEM SOC, V122, P394, DOI 10.1021/ja991932+; Jansson M, 1996, J BIOMOL NMR, V7, P131; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JW, 2006, NATURE, V440, P363, DOI 10.1038/nature04537; Lewin AC, 2002, MICROBIOL-SGM, V148, P2449, DOI 10.1099/00221287-148-8-2449; Maret W, 2004, BIOCHEMISTRY-US, V43, P3301, DOI 10.1021/bi036340p; MichaudSoret I, 1997, FEBS LETT, V413, P473, DOI 10.1016/S0014-5793(97)00963-0; MORELLE N, 1995, FEBS LETT, V365, P172, DOI 10.1016/0014-5793(95)00450-N; OCHSNER UA, 1995, J BACTERIOL, V177, P7194, DOI 10.1128/jb.177.24.7194-7201.1995; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; Pohl E, 2003, MOL MICROBIOL, V47, P903, DOI 10.1046/j.1365-2958.2003.03337.x; Roth M, 2002, ACTA CRYSTALLOGR D, V58, P805, DOI 10.1107/S0907444902003943; SAITO T, 1991, EUR J BIOCHEM, V197, P43, DOI 10.1111/j.1432-1033.1991.tb15880.x; SAITO T, 1991, EUR J BIOCHEM, V197, P29, DOI 10.1111/j.1432-1033.1991.tb15878.x; SAITO T, 1991, EUR J BIOCHEM, V197, P39, DOI 10.1111/j.1432-1033.1991.tb15879.x; Servant Florence, 2002, Brief Bioinform, V3, P246, DOI 10.1093/bib/3.3.246; SZYPERSKI T, 1995, J MAGN RESON SER B, V108, P197, DOI 10.1006/jmrb.1995.1124; Tiss A, 2005, FEBS LETT, V579, P5454, DOI 10.1016/j.febslet.2005.08.067; Wee S, 1988, Biol Met, V1, P62, DOI 10.1007/BF01128019; WISHART DS, 1994, J BIOMOL NMR, V4, P171	43	81	82	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21286	21295		10.1074/jbc.M601278200	http://dx.doi.org/10.1074/jbc.M601278200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16690618	Green Published, hybrid			2022-12-25	WOS:000239187300064
J	Udell, CM; Samayawardhena, LA; Kawakami, Y; Kawakami, T; Craig, AWB				Udell, Christian M.; Samayawardhena, Lionel A.; Kawakami, Yuko; Kawakami, Toshiaki; Craig, Andrew W. B.			Fer and Fps/Fes participate in a Lyn-dependent pathway from Fc epsilon RI to platelet-endothelial cell adhesion molecule 1 to limit mast cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; AFFINITY IGE RECEPTOR; CD31-DEFICIENT MICE; CYTOKINE PRODUCTION; ENDOTOXIC-SHOCK; GROWTH-FACTOR; T-CELLS; PECAM-1; PHOSPHORYLATION; DEGRANULATION	Mast cells express the high affinity IgE receptor Fc epsilon RI, which upon aggregation by multivalent antigens elicits signals that cause rapid changes within the mast cell and in the surrounding tissue. We previously showed that Fc epsilon RI aggregation caused a rapid increase in phosphorylation of both Fer and Fps/Fes kinases in bone marrow-derived mast cells. In this study, we report that Fc epsilon RI aggregation leads to increased Fer/Fps kinase activities and that Fer phosphorylation downstream of Fc epsilon RI is independent of Syk, Fyn, and Gab2 but requires Lyn. Activated Fer/Fps readily phosphorylate the C terminus of platelet-endothelial cell adhesion molecule 1 (Pecam-1) on immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and a non-ITIM residue (Tyr(700)) in vitro and in transfected cells. Mast cells devoid of Fer/Fps kinase activities display a reduction in Fc epsilon RI aggregation-induced tyrosine phosphorylation of Pecam-1, with no defects in recruitment of Shp1/Shp2 phosphatases observed. Lyn-deficient mast cells display a dramatic reduction in Pecam-1 phosphorylation at Tyr(685) and a complete loss of Shp2 recruitment, suggesting a role as an initiator kinase for Pecam-1. Consistent with previous studies of Pecam-1-deficient mast cells, we observe an exaggerated degranulation response in mast cells lacking Fer/Fps kinases at low antigen dosages. Thus, Lyn and Fer/Fps kinases cooperate to phosphorylate Pecam-1 and activate Shp1/Shp2 phosphatases that function in part to limit mast cell activation.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA	Queens University - Canada; La Jolla Institute for Immunology	Craig, AWB (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.	ac15@post.queensu.ca	Craig, Andrew/G-2312-2017; Craig, Andrew/AAC-6923-2019; Kawakami, Toshiaki/O-1616-2015	Craig, Andrew/0000-0002-2039-2393; Craig, Andrew/0000-0002-2039-2393; 				Asai K, 2001, IMMUNITY, V14, P791, DOI 10.1016/S1074-7613(01)00157-1; Boesiger J, 1998, J EXP MED, V188, P1135, DOI 10.1084/jem.188.6.1135; Cao MY, 1998, J BIOL CHEM, V273, P15765, DOI 10.1074/jbc.273.25.15765; Carrithers M, 2005, AM J PATHOL, V166, P185, DOI 10.1016/S0002-9440(10)62243-2; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; Costello PS, 1996, ONCOGENE, V13, P2595; Craig AWB, 1999, J BIOL CHEM, V274, P19934, DOI 10.1074/jbc.274.28.19934; Craig AWB, 2002, MOL CELL BIOL, V22, P6363, DOI 10.1128/MCB.22.18.6363-6374.2002; Craig AWB, 2001, MOL CELL BIOL, V21, P603, DOI 10.1128/MCB.21.2.603-613.2001; Demo SD, 1999, CYTOMETRY, V36, P340, DOI 10.1002/(SICI)1097-0320(19990801)36:4<340::AID-CYTO9>3.0.CO;2-C; Duncan GS, 1999, J IMMUNOL, V162, P3022; Furumoto Y, 2004, J BIOL CHEM, V279, P49177, DOI 10.1074/jbc.M404730200; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Gerwien J, 1999, J IMMUNOL, V163, P1742; Greer P, 2002, NAT REV MOL CELL BIO, V3, P278, DOI 10.1038/nrm783; GRUBER BL, 1995, BLOOD, V86, P2488; Grutzkau A, 1998, MOL BIOL CELL, V9, P875, DOI 10.1091/mbc.9.4.875; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Hernandez-Hansen V, 2004, J IMMUNOL, V173, P100, DOI 10.4049/jimmunol.173.1.100; Ilan N, 2001, DEV BIOL, V232, P219, DOI 10.1006/dbio.2001.0186; Ilan N, 2003, CURR OPIN CELL BIOL, V15, P515, DOI 10.1016/S0955-0674(03)00100-5; Imada A, 2000, EUR RESPIR J, V15, P1087, DOI 10.1034/j.1399-3003.2000.01517.x; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; Kamata T, 2003, J CLIN INVEST, V111, P109, DOI 10.1172/JCI200315719; Kapus A, 2000, J BIOL CHEM, V275, P32289, DOI 10.1074/jbc.M003172200; Kawakami T, 2005, J IMMUNOL, V175, P4167, DOI 10.4049/jimmunol.175.7.4167; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kogata N, 2003, MOL BIOL CELL, V14, P3553, DOI 10.1091/mbc.E03-02-0080; Maas M, 2005, AM J PHYSIOL-HEART C, V288, pH159, DOI 10.1152/ajpheart.00500.2004; Marsden VS, 2006, BLOOD, V107, P1872, DOI 10.1182/blood-2005-05-2160; McCafferty DM, 2002, J IMMUNOL, V168, P4930, DOI 10.4049/jimmunol.168.10.4930; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Nishida K, 2005, J CELL BIOL, V170, P115, DOI 10.1083/jcb.200501111; Odom S, 2004, J EXP MED, V199, P1491, DOI 10.1084/jem.20040382; Parravicini V, 2002, NAT IMMUNOL, V3, P741, DOI 10.1038/ni817; Sagawa K, 1997, J BIOL CHEM, V272, P31086, DOI 10.1074/jbc.272.49.31086; Salem Y, 2005, CELL SIGNAL, V17, P341, DOI 10.1016/j.cellsig.2004.08.001; Senis Y, 1999, MOL CELL BIOL, V19, P7436; Senis YA, 2003, EXP HEMATOL, V31, P673, DOI 10.1016/S0301-472X(03)00107-3; Siraganian RP, 2002, MOL IMMUNOL, V38, P1229, DOI 10.1016/S0161-5890(02)00068-8; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; Vonakis BM, 2001, J BIOL CHEM, V276, P1041, DOI 10.1074/jbc.M003397200; Wong MX, 2002, J IMMUNOL, V168, P6455, DOI 10.4049/jimmunol.168.12.6455; Xie ZH, 2002, J IMMUNOL, V168, P4682, DOI 10.4049/jimmunol.168.9.4682; Zirngibl RA, 2002, MOL CELL BIOL, V22, P2472, DOI 10.1128/MCB.22.8.2472-2486.2002	45	33	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20949	20957		10.1074/jbc.M604252200	http://dx.doi.org/10.1074/jbc.M604252200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16731527	hybrid			2022-12-25	WOS:000239187300032
J	Duret, G; Delcour, AH				Duret, Guillaume; Delcour, Anne H.			Deoxycholic acid blocks Vibrio cholerae OmpT but not OmpU porin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRULENCE FACTOR EXPRESSION; BILE RESISTANCE; ENVIRONMENTAL SIGNALS; CHANNEL; PROTEIN; EFFLUX; ACTIVATION; TRANSPORT; MOTILITY; INDUCE	OmpT and OmpU are general diffusion porins of the human intestinal pathogen Vibrio cholerae. The sole presence of OmpT in the outer membrane sensitizes cells to the bile component deoxycholic acid, and the repression of OmpT in the intestine may play an important role in the adaptation of cells to the host environment. Here we report a novel important functional difference between the two porins, namely the sensitivity to deoxycholic acid. Single channel recordings show that submicellar concentrations of sodium deoxycholate induce time-resolved blocking events of OmpT but are devoid of any effect on OmpU. The effects are dose-, voltage-, and pH-dependent. They are elicited by deoxycholate applied to either side of the membrane, with some asymmetry in the sensitivity. The voltage dependence remains even when deoxycholate is applied symmetrically, indicating that it is intrinsic to the binding site. The pH dependence suggests that the active form is the neutral deoxycholic acid and not the negatively charged species. The results are interpreted as deoxycholic acid acting as an open-channel blocker, which may relate to deoxycholic acid permeation.	Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA	University of Houston System; University of Houston	Delcour, AH (corresponding author), Univ Houston, Dept Biol & Biochem, 369 Sci & Res Bldg 2, Houston, TX 77204 USA.	adelcour@uh.edu						Akare S, 2005, BBA-MOL CELL BIOL L, V1735, P59, DOI 10.1016/j.bbalip.2005.04.006; Alcaraz A, 2004, BIOPHYS J, V87, P943, DOI 10.1529/biophysj.104/043414; Begley M, 2005, FEMS MICROBIOL REV, V29, P625, DOI 10.1016/j.femsre.2004.09.003; Bina JE, 2001, INFECT IMMUN, V69, P4681, DOI 10.1128/IAI.69.7.4681-4685.2001; Chakrabarti Sr, 1996, J BACTERIOL, V178, P524, DOI 10.1128/jb.178.2.524-530.1996; Chatterjee A, 2004, J BACTERIOL, V186, P6809, DOI 10.1128/JB.186.20.6809-6814.2004; Crawford JA, 1998, MOL MICROBIOL, V29, P235, DOI 10.1046/j.1365-2958.1998.00925.x; Danelon C, 2006, BIOPHYS J, V90, P1617, DOI 10.1529/biophysj.105.075192; DELCOUR AH, 1989, BIOPHYS J, V56, P631, DOI 10.1016/S0006-3495(89)82710-9; Gupta S, 1997, INFECT IMMUN, V65, P1131, DOI 10.1128/IAI.65.3.1131-1134.1997; Hung DT, 2006, MOL MICROBIOL, V59, P193, DOI 10.1111/j.1365-2958.2005.04846.x; Hung DT, 2005, P NATL ACAD SCI USA, V102, P3028, DOI 10.1073/pnas.0409559102; Im E, 2004, J NUTR, V134, P483, DOI 10.1093/jn/134.2.483; Iyer R, 1997, J BIOL CHEM, V272, P18595, DOI 10.1074/jbc.272.30.18595; Klose KE, 2001, INT J MED MICROBIOL, V291, P81, DOI 10.1078/1438-4221-00104; Krukonis ES, 2003, CURR OPIN MICROBIOL, V6, P186, DOI 10.1016/S1369-5274(03)00032-8; Kullman L, 2002, BIOPHYS J, V82, P803, DOI 10.1016/S0006-3495(02)75442-8; Lee SH, 1999, CELL, V99, P625, DOI 10.1016/S0092-8674(00)81551-2; Li CYC, 2000, MOL MICROBIOL, V35, P189, DOI 10.1046/j.1365-2958.2000.01699.x; Matsuoka K, 2002, BBA-MOL CELL BIOL L, V1580, P189, DOI 10.1016/S1388-1981(01)00203-7; Mauricio AC, 1999, EXP PHYSIOL, V84, P489; Nestorovich EM, 2003, BIOPHYS J, V85, P3718, DOI 10.1016/S0006-3495(03)74788-2; Nestorovich EM, 2002, P NATL ACAD SCI USA, V99, P9789, DOI 10.1073/pnas.152206799; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; Provenzano D, 2000, P NATL ACAD SCI USA, V97, P10220, DOI 10.1073/pnas.170219997; Provenzano D, 2000, INFECT IMMUN, V68, P1491, DOI 10.1128/IAI.68.3.1491-1497.2000; Provenzano D, 2001, J BACTERIOL, V183, P3652, DOI 10.1128/JB.183.12.3652-3662.2001; Rosenberg EY, 2003, MOL MICROBIOL, V48, P1609, DOI 10.1046/j.1365-2958.2003.03531.x; SCHINDLER H, 1978, P NATL ACAD SCI USA, V75, P3751, DOI 10.1073/pnas.75.8.3751; Schuhmacher DA, 1999, J BACTERIOL, V181, P1508, DOI 10.1128/JB.181.5.1508-1514.1999; Schwarz G, 2003, BIOPHYS J, V84, P2990, DOI 10.1016/S0006-3495(03)70025-3; Simonet VC, 2003, J BIOL CHEM, V278, P17539, DOI 10.1074/jbc.M301202200; Skorupski K, 1997, MOL MICROBIOL, V25, P1003, DOI 10.1046/j.1365-2958.1997.5481909.x; STADLER J, 1988, GUT, V29, P1326, DOI 10.1136/gut.29.10.1326; Thanassi DG, 1997, J BACTERIOL, V179, P2512, DOI 10.1128/jb.179.8.2512-2518.1997; Wibbenmeyer JA, 2002, INFECT IMMUN, V70, P121, DOI 10.1128/IAI.70.1.121-126.2002	36	27	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					19899	19905		10.1074/jbc.M602426200	http://dx.doi.org/10.1074/jbc.M602426200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16670088	hybrid			2022-12-25	WOS:000239038200013
J	Schmidtke, G; Kalveram, B; Weber, E; Bochtler, P; Lukasiak, S; Hipp, MS; Groettrup, M				Schmidtke, Gunter; Kalveram, Birte; Weber, Elvira; Bochtler, Petra; Lukasiak, Sebastian; Hipp, Mark Steffen; Groettrup, Marcus			The UBA domains of NUB1L are required for binding but not for accelerated degradation of the ubiquitin-like modifier FAT10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN FAT10; DNA-REPAIR; PROTEASOME; RAD23; NEDD8; INTERFERON; IDENTIFICATION; PROTEOLYSIS; CHAINS; GENES	Proteins selected for degradation are labeled with multiple molecules of ubiquitin and are subsequently cleaved by the 26 S proteasome. A family of proteins containing at least one ubiquitin-associated (UBA) domain and one ubiquitin-like (UBL) domain have been shown to act as soluble ubiquitin receptors of the 26 S proteasome and introduce a new level of specificity into the degradation system. They bind ubiquitylated proteins via their UBA domains and the 26 S proteasome via their UBL domain and facilitate the contact between substrate and protease. NEDD8 ultimate buster-1 long (NUB1L) belongs to this class of proteins and contains one UBL and three UBA domains. We recently reported that NUB1L interacts with the ubiquitin-like modifier FAT10 and accelerates its degradation and that of its conjugates. Here we show that a deletion mutant of NUB1L lacking the UBL domain is still able to bind FAT10 but not the proteasome and no longer accelerates FAT10 degradation. version of NUB1L lacking all three UBA domains, on the other hand, looses the ability to bind FAT10 but is still able to interact with the proteasome and accelerates the degradation of FAT10. The degradation of a FAT10 mutant containing only the C-terminal UBL domain is also still accelerated by NUB1L, even though the two proteins do not interact. In addition, we show that FAT10 and either one of its UBL domains alone can interact directly with the 26 S proteasome. We propose that NUB1L not only acts as a linker between the 26 S proteasome and ubiquitin-like proteins, but also as a facilitator of proteasomal degradation.	Univ Konstanz, Dept Biol, Div Immunol, D-78457 Constance, Germany	University of Konstanz	Groettrup, M (corresponding author), Univ Konstanz, Dept Biol, Div Immunol, Univ Str 10, D-78457 Constance, Germany.	marcus.groettrup@uni-konstanz.de	Weber, Elvira/AAY-1329-2021; Groettrup, Marcus/AAT-2623-2020; Hipp, Mark/AAA-4238-2022	Weber, Elvira/0000-0002-0100-923X; Hipp, Mark/0000-0002-0497-3016				Bates EFM, 1997, EUR J IMMUNOL, V27, P2471, DOI 10.1002/eji.1830271002; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Biggins S, 1996, J CELL BIOL, V133, P1331, DOI 10.1083/jcb.133.6.1331; Chen L, 2002, MOL CELL BIOL, V22, P4902, DOI 10.1128/MCB.22.13.4902-4913.2002; Fan WF, 1996, IMMUNOGENETICS, V44, P97, DOI 10.1007/s002510050095; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; HENDIL KB, 1995, BIOCHEM J, V305, P245, DOI 10.1042/bj3050245; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hipp MS, 2005, MOL CELL BIOL, V25, P3483, DOI 10.1128/MCB.25.9.3483-3491.2005; Hipp MS, 2004, J BIOL CHEM, V279, P16503, DOI 10.1074/jbc.M310114200; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Janse DM, 2004, J BIOL CHEM, V279, P21415, DOI 10.1074/jbc.M402954200; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; Kamitani T, 2001, J BIOL CHEM, V276, P46655, DOI 10.1074/jbc.M108636200; Khan S, 2004, J VIROL, V78, P1831, DOI 10.1128/JVI.78.4.1831-1842.2004; Kim KI, 2005, J IMMUNOL, V175, P847, DOI 10.4049/jimmunol.175.2.847; Kito K, 2001, J BIOL CHEM, V276, P20603, DOI 10.1074/jbc.M100920200; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Lai EC, 2002, CURR BIOL, V12, pR74, DOI 10.1016/S0960-9822(01)00679-0; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lambertson D, 1999, GENETICS, V153, P69; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Miller J, 2005, FEBS LETT, V579, P3224, DOI 10.1016/j.febslet.2005.03.042; MILLER RD, 1982, MOL GEN GENET, V188, P235, DOI 10.1007/BF00332681; Moradpour D, 2001, HEPATOLOGY, V33, P1282, DOI 10.1053/jhep.2001.23793; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Ortolan TG, 2000, NAT CELL BIOL, V2, P601, DOI 10.1038/35023547; Osaka F, 2000, EMBO J, V19, P3475, DOI 10.1093/emboj/19.13.3475; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Raasi S, 2004, J MOL BIOL, V341, P1367, DOI 10.1016/j.jmb.2004.06.057; Raasi S, 2005, NAT STRUCT MOL BIOL, V12, P708, DOI 10.1038/nsmb962; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Raasi S, 2001, J BIOL CHEM, V276, P35334, DOI 10.1074/jbc.M105139200; Raasi S, 1999, EUR J IMMUNOL, V29, P4030, DOI 10.1002/(SICI)1521-4141(199912)29:12<4030::AID-IMMU4030>3.0.CO;2-Y; Rao H, 2002, J BIOL CHEM, V277, P11691, DOI 10.1074/jbc.M200245200; Ritchie KJ, 2004, NAT MED, V10, P1374, DOI 10.1038/nm1133; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V293, P986, DOI 10.1016/S0006-291X(02)00340-6; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; Tanaka T, 2003, J BIOL CHEM, V278, P32905, DOI 10.1074/jbc.M212057200; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Verma R, 2004, CELL, V118, P99, DOI 10.1016/j.cell.2004.06.014; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	50	48	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20045	20054		10.1074/jbc.M603063200	http://dx.doi.org/10.1074/jbc.M603063200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16707496	hybrid, Green Published			2022-12-25	WOS:000239038200029
J	Zhuo, LS; Kanamori, A; Kannagi, R; Itano, N; Wu, JW; Hamaguchi, M; Ishiguro, N; Kimata, K				Zhuo, Lisheng; Kanamori, Akiko; Kannagi, Reiji; Itano, Naoki; Wu, Jiwen; Hamaguchi, Michinari; Ishiguro, Naoki; Kimata, Koji			SHAP potentiates the CD44-mediated leukocyte adhesion to the hyaluronan substratum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; COLLAGEN-INDUCED ARTHRITIS; ALPHA-TRYPSIN INHIBITOR; LINK PROTEIN; CD44 VARIANT; HEAVY-CHAINS; BINDING; ACID; GLYCOSYLATION; SURFACE	CD44-hyaluronan (HA) interaction is involved in diverse physiological and pathological processes. Regulation of interacting avidity is well studied on CD44 but rarely on HA. We discovered a unique covalent modification of HA with a protein, SHAP, that corresponds to the heavy chains of inter-alpha-trypsin inhibitor family molecules circulating in blood. Formation of the SHAP(.)HA complex is often associated with inflammation, a well known process involving the CD44-HA interaction. We therefore examined the effect of SHAP on the CD44-HA interaction-mediated lymphocyte adhesion. Under both static and flowing conditions, Hut78 cells (CD44-positive) and CD44-transfected Jurkat cells (originally CD44-negative) adhered preferentially to the immobilized SHAP(.)HA complex than to HA. The enhanced adhesion is exclusively mediated by the CD44-HA interaction, because it was inhibited by HA, but not I alpha I, and was completely abolished by pretreating the cells with anti-CD44 antibodies. SHAP appears to potentiate the interaction by increasing the avidity of HA to CD44 and altering their distribution on cell surfaces. Large amounts of the SHAP(.)HA complex accumulate in the hyperplastic synovium of rheumatoid arthritis patients. Leukocytes infiltrated to the synovium were strongly positive for HA, SHAP, and CD44 on their surfaces, suggesting a role for the adhesion-enhancing effect of SHAP in pathogenesis.	Aichi Med Univ, Inst Mol Sci Med, Nagakute, Aichi 4801195, Japan; Aichi Canc Ctr, Res Inst, Program Mol Pathol, Nagoya, Aichi 4648681, Japan; CREST, Japan Sci & Technol Agcy, Kawaguchi, Saitama 5600082, Japan; Nagoya Univ, Grad Sch Med, Dept Mol Pathogenesis, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Orthoped, Nagoya, Aichi 4668550, Japan	Aichi Medical University; Aichi Cancer Center; Japan Science & Technology Agency (JST); Nagoya University; Nagoya University	Kimata, K (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Nagakute, Aichi 4801195, Japan.	kimata@amugw.aichi-med-u.ac.jp	Kannagi, Reiji/Q-6459-2018; Ishiguro, Naoki/I-1563-2012	Kannagi, Reiji/0000-0003-4202-2921; 				Bartolazzi A, 1996, J CELL BIOL, V132, P1199, DOI 10.1083/jcb.132.6.1199; Brennan FR, 1999, IMMUNOLOGY, V98, P427, DOI 10.1046/j.1365-2567.1999.00894.x; Brown KL, 2001, J IMMUNOL, V167, P5367, DOI 10.4049/jimmunol.167.9.5367; CAMP RL, 1993, J EXP MED, V178, P497, DOI 10.1084/jem.178.2.497; Catterall JB, 1999, CLIN EXP METASTAS, V17, P583, DOI 10.1023/A:1006756518500; Chen DW, 2001, J IMMUNOL, V166, P5889, DOI 10.4049/jimmunol.166.10.5889; Cowman MK, 2005, BIOPHYS J, V88, P590, DOI 10.1529/biophysj.104.049361; Cuff CA, 2001, J CLIN INVEST, V108, P1031, DOI 10.1172/JCI12455; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; de la Motte CA, 2003, AM J PATHOL, V163, P121, DOI 10.1016/S0002-9440(10)63636-X; de la Motte CA, 1999, J BIOL CHEM, V274, P30747, DOI 10.1074/jbc.274.43.30747; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; English NM, 1998, CANCER RES, V58, P3736; Fulop C, 2003, DEVELOPMENT, V130, P2253, DOI 10.1242/dev.00422; Gunthert U, 1993, Curr Top Microbiol Immunol, V184, P47; GUO YJ, 1994, INT IMMUNOL, V6, P213, DOI 10.1093/intimm/6.2.213; Hu BC, 2001, J BIOL CHEM, V276, P17693, DOI 10.1074/jbc.M009340200; HUANG L, 1993, J BIOL CHEM, V268, P26725; Jun Z, 1997, CLIN EXP IMMUNOL, V108, P69, DOI 10.1046/j.1365-2249.1997.d01-977.x; Kanamori A, 2002, J BIOL CHEM, V277, P32578, DOI 10.1074/jbc.M204400200; Katoh S, 1999, J IMMUNOL, V162, P5058; KATOH S, 1995, J EXP MED, V182, P419, DOI 10.1084/jem.182.2.419; Kida D, 1999, J RHEUMATOL, V26, P1230; LAWRENCE MB, 1987, BLOOD, V70, P1284; LAZAAR AL, 1994, J EXP MED, V180, P807, DOI 10.1084/jem.180.3.807; Lesley J, 2000, J BIOL CHEM, V275, P26967; Lesley J, 2004, J BIOL CHEM, V279, P25745, DOI 10.1074/jbc.M313319200; LESLEY J, 1995, J EXP MED, V182, P431, DOI 10.1084/jem.182.2.431; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; Liu DC, 1997, J IMMUNOL, V159, P2702; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; MIKECZ K, 1995, NAT MED, V1, P558, DOI 10.1038/nm0695-558; Milinkovic M, 2004, BLOOD, V103, P740, DOI 10.1182/blood-2003-05-1500; MORGELIN M, 1988, BIOCHEM J, V253, P175; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; Nedvetzki S, 1999, J AUTOIMMUN, V13, P39, DOI 10.1006/jaut.1999.0294; Peck D, 1998, J CELL SCI, V111, P1595; Rugg MS, 2005, J BIOL CHEM, V280, P25674, DOI 10.1074/jbc.M501332200; Sackstein R, 2003, BLOOD, V101, P771, DOI 10.1182/blood-2002-05-1452; Sanggaard KW, 2005, J BIOL CHEM, V280, P11936, DOI 10.1074/jbc.M409016200; SCOTT JE, 1991, BIOCHEM J, V274, P699, DOI 10.1042/bj2740699; Skelton TP, 1998, J CELL BIOL, V140, P431, DOI 10.1083/jcb.140.2.431; Sleeman J, 1996, J CELL BIOL, V135, P1139, DOI 10.1083/jcb.135.4.1139; Sohara Y, 2001, MOL BIOL CELL, V12, P1859, DOI 10.1091/mbc.12.6.1859; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; Stoop R, 2001, ARTHRITIS RHEUM, V44, P2922, DOI 10.1002/1529-0131(200112)44:12<2922::AID-ART480>3.0.CO;2-7; Takahashi K, 1996, J BIOL CHEM, V271, P9490, DOI 10.1074/jbc.271.16.9490; Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659; Termeer C, 2003, TRENDS IMMUNOL, V24, P112, DOI 10.1016/S1471-4906(03)00029-2; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Wallach-Dayan SB, 2001, J CELL SCI, V114, P3463; Weiss JM, 1998, J INVEST DERMATOL, V111, P227, DOI 10.1046/j.1523-1747.1998.00286.x; Wight TN, 2004, CIRC RES, V94, P1158, DOI 10.1161/01.RES.0000126921.29919.51; Wik HB, 1998, WENN GR INT, V72, P25; WISNIEWSKI HG, 1993, J IMMUNOL, V151, P6593; Wittig BM, 2000, J EXP MED, V191, P2053, DOI 10.1084/jem.191.12.2053; Wolf D, 2001, HEPATOLOGY, V34, P535, DOI 10.1053/jhep.2001.27218; Xu HP, 2002, J LEUKOCYTE BIOL, V72, P1133; Yingsung W, 2003, J BIOL CHEM, V278, P32710, DOI 10.1074/jbc.M303658200; YONEDA M, 1990, J BIOL CHEM, V265, P5247; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657; ZHAO M, 2002, HYALURONAN, V1, P497; Zhuo LS, 2004, CHEMISTRY AND BIOLOGY OF HYALURONAN, P205	65	109	118	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20303	20314		10.1074/jbc.M506703200	http://dx.doi.org/10.1074/jbc.M506703200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16702221	hybrid			2022-12-25	WOS:000239038200055
J	Ding, HP; Matthews, TA; Johnson, GVW				Ding, Huiping; Matthews, Tori A.; Johnson, Gail V. W.			Site-specific phosphorylation and caspase cleavage differentially impact tau-microtubule interactions and tau aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMERS-DISEASE; PROTEIN-TAU; IN-VITRO; BINDING; INHIBITION; PATHOLOGY; TANGLES; HYPERPHOSPHORYLATION; POLYMERIZATION	The microtubule-associated protein tau is hyperphosphorylated and forms neurofibrillary tangles in Alzheimer disease. Additionally caspase-cleaved tau is present in Alzheimer disease brains co-localized with fibrillar tau pathologies. To further understand the role of site-specific phosphorylation and caspase cleavage of tau in regulating its function, constructs of full-length tau (T4) or tau truncated at Asp(421) (T4C3) to mimic caspase-3 cleavage with and without site-directed mutations that mimic phosphorylation at Thr(231)/Ser(235), Ser(396)/Ser(404), or at all four sites (Thr(231)/Ser(235)/Ser(396)/Ser(404)) were made and expressed in cells. Pseudophosphorylation of T4, but not T4C3, at either Thr(231)/Ser(235) or Ser(396)/Ser(404) increased its phosphorylation at Ser(262) and Ser(199). Pseudophosphorylation at Thr(231)/Ser(235) impaired the microtubule binding of both T4 and T4C3. In contrast, pseudophosphorylation at Ser(396)/Ser(404) only affected microtubule binding of T4C3 but did make T4 less soluble and more aggregated, which is consistent with the previous finding (Abraha, A., Ghoshal, N., Gamblin, T. C., Cryns, V., Berry, R. W., Kuret, J., and Binder, L. I. (2000) J. Cell Sci. 113, 3737-3745) that pseudophosphorylation at Ser(396)/Ser(404) enhances tau polymerization in vitro. In situ T4C3 was more prevalent in the cytoskeletal and microtubule-associated fractions compared with T4, whereas purified recombinant T4 bound microtubules with higher affinity than did T4C3 in an in vitro assay. These data indicate the importance of cellular factors in regulating tau-microtubule interactions and that, in the cells, phosphorylation of T4 might impair its microtubule binding ability more than caspase cleavage. Treatment of cells with nocodazole revealed that pseudophosphorylation of T4 at both Thr(231)/Ser(235) and Ser(396)/Ser(404) diminished the ability of tau to protect against microtubule depolymerization, whereas with T4C3 only pseudophosphorylation at Ser(396)/Ser(404) attenuated the ability of tau to stabilize the microtubules. These results show that site-specific phosphorylation and caspase cleavage of tau differentially affect the ability of tau to bind and stabilize microtubules and facilitate tau self-association.	Univ Alabama, Dept Psychiat, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Johnson, GVW (corresponding author), Univ Alabama, Dept Psychiat, 1720 7th Ave S,SC1061, Birmingham, AL 35294 USA.	gvwj@uab.edu	Johnson, Gail V.W./K-4723-2012	Johnson, Gail V.W./0000-0003-3464-0404; Ding, Huiping/0000-0001-5783-0759	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS051279] Funding Source: NIH RePORTER; NINDS NIH HHS [NS051279] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abraha A, 2000, J CELL SCI, V113, P3737; Ackmann M, 2000, J BIOL CHEM, V275, P30335, DOI 10.1074/jbc.M002590200; Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Berry RW, 2003, BIOCHEMISTRY-US, V42, P8325, DOI 10.1021/bi027348m; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; Cho JH, 2004, J BIOL CHEM, V279, P54716, DOI 10.1074/jbc.M403364200; Cho JH, 2004, J NEUROCHEM, V88, P349, DOI 10.1046/j.1471-4159.2003.02155.x; Cho JH, 2003, J BIOL CHEM, V278, P187, DOI 10.1074/jbc.M206236200; Chung CW, 2001, NEUROBIOL DIS, V8, P162, DOI 10.1006/nbdi.2000.0335; DeTure M, 2002, AM J PATHOL, V161, P1711, DOI 10.1016/S0002-9440(10)64448-3; Eidenmuller J, 2000, BIOCHEMISTRY-US, V39, P13166, DOI 10.1021/bi001290z; Eidenmuller J, 2001, BIOCHEM J, V357, P759, DOI 10.1042/0264-6021:3570759; Fasulo L, 2000, J NEUROCHEM, V75, P624, DOI 10.1046/j.1471-4159.2000.0750624.x; Fath T, 2002, J NEUROSCI, V22, P9733; Ferrari A, 2003, J BIOL CHEM, V278, P40162, DOI 10.1074/jbc.M308243200; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; Gamblin TC, 2003, BIOCHEMISTRY-US, V42, P15009, DOI 10.1021/bi035722s; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; Grober E, 1999, NEUROBIOL AGING, V20, P573, DOI 10.1016/S0197-4580(99)00063-9; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; Haase C, 2004, J NEUROCHEM, V88, P1509, DOI 10.1046/j.1471-4159.2003.02287.x; Hoffmann R, 1997, BIOCHEMISTRY-US, V36, P8114, DOI 10.1021/bi970380+; Johnson GVW, 2002, J ALZHEIMERS DIS, V4, P375, DOI 10.3233/JAD-2002-4505; Johnson GVW, 1997, J NEUROCHEM, V68, P430; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; Leger J, 1997, J BIOL CHEM, V272, P8441, DOI 10.1074/jbc.272.13.8441; Li GB, 2004, J BIOL CHEM, V279, P15938, DOI 10.1074/jbc.M314116200; Makrides V, 2003, J BIOL CHEM, V278, P33298, DOI 10.1074/jbc.M305207200; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Rapoport M, 2002, P NATL ACAD SCI USA, V99, P6364, DOI 10.1073/pnas.092136199; Rissman RA, 2004, J CLIN INVEST, V114, P121, DOI 10.1172/JCI200420640; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; Sengupta A, 1998, ARCH BIOCHEM BIOPHYS, V357, P299, DOI 10.1006/abbi.1998.0813; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; Zhang B, 2004, J NEUROSCI, V24, P4657, DOI 10.1523/JNEUROSCI.0797-04.2004	41	85	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19107	19114		10.1074/jbc.M511697200	http://dx.doi.org/10.1074/jbc.M511697200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16687396	hybrid			2022-12-25	WOS:000238847000025
J	Higgins, MK; Oprian, DD; Schertler, GFX				Higgins, Matthew K.; Oprian, Daniel D.; Schertler, Gebhard F. X.			Recoverin binds exclusively to an amphipathic peptide at the N terminus of rhodopsin kinase, inhibiting rhodopsin phosphorylation without affecting catalytic activity of the kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTOR KINASES; ROD OUTER SEGMENTS; PHOSPHATIDYLINOSITOL 4-KINASE ISOFORM; CA2+-DEPENDENT INTERACTION; CA2+-BINDING PROTEINS; MYRISTOYL GROUP; AMINO-TERMINUS; CALCIUM SENSOR; RETINAL RODS; S-MODULIN	Recoverin is a calcium-dependent inhibitor of rhodopsin kinase. It prevents premature phosphorylation of rhodopsin until the opening of cGMP-gated ion channels causes a decrease in intracellular calcium levels, signaling completion of the light response. This calcium depletion causes release of recoverin from rhodopsin kinase, freeing the kinase to phosphorylate rhodopsin and to terminate the light response. Previous studies have shown that recoverin is able to bind to a region at the N terminus of rhodopsin kinase. In this study we map this interaction interface, showing that residues 1-15 of the kinase form the interaction site for recoverin binding. Mutation of hydrophobic residues in this region have the greatest effect on the interaction. The periodic nature of these residues suggests that they lie along one face of an amphipathic helix. We show that this region is essential for recoverin binding, as a catalytically active kinase lacking these residues is unable to bind recoverin. In addition, we show that neither the N-terminal deletion nor the presence of recoverin inhibits the overall catalytic activity of the kinase, as measured by light-independent autophosphorylation. Finally, we observe that a kinase mutant lacking the N-terminal recoverin binding site is unable to phosphorylate light-activated rhodopsin. Taken together, these data support a model in which recoverin prevents rhodopsin phosphorylation by sterically blocking a region of kinase essential for its interaction with rhodopsin, thereby preventing recognition of rhodopsin as a kinase substrate.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA; Brandeis Univ, Volen Ctr Complex Syst, Waltham, MA 02454 USA	MRC Laboratory Molecular Biology; Brandeis University; Brandeis University	Schertler, GFX (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	gfx@mrc-lmb.cam.ac.uk	Schertler, Gebhard/M-9512-2014	Higgins, Matthew/0000-0002-2870-1955; Schertler, Gebhard F.X./0000-0002-5846-6810	Medical Research Council [MC_U105178937] Funding Source: Medline; NEI NIH HHS [EY09514] Funding Source: Medline; MRC [MC_U105178937] Funding Source: UKRI; NATIONAL EYE INSTITUTE [R01EY009514] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ames JB, 1995, J BIOL CHEM, V270, P30909, DOI 10.1074/jbc.270.52.30909; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Bahring R, 2001, J BIOL CHEM, V276, P23888, DOI 10.1074/jbc.M101320200; BUCZYLKO J, 1991, P NATL ACAD SCI USA, V88, P2568, DOI 10.1073/pnas.88.6.2568; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Cha KW, 1997, P NATL ACAD SCI USA, V94, P10577, DOI 10.1073/pnas.94.20.10577; Chen CK, 2000, METHOD ENZYMOL, V315, P404; Chen CK, 1999, P NATL ACAD SCI USA, V96, P3718, DOI 10.1073/pnas.96.7.3718; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16003; Edwards PC, 2004, J MOL BIOL, V343, P1439, DOI 10.1016/j.jmb.2004.08.089; Erickson MA, 1998, P NATL ACAD SCI USA, V95, P6474, DOI 10.1073/pnas.95.11.6474; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GAN X, 1999, J BIOL CHEM, V279, P49741; GRAYKELLER MP, 1993, NEURON, V10, P523, DOI 10.1016/0896-6273(93)90339-S; Huttner IG, 2003, J BIOL CHEM, V278, P4862, DOI 10.1074/jbc.M207920200; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KELLEHER DJ, 1990, J BIOL CHEM, V265, P2632; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; LEE RH, 1982, BIOCHEMISTRY-US, V21, P3303, DOI 10.1021/bi00257a009; Levay K, 1998, BIOCHEMISTRY-US, V37, P13650, DOI 10.1021/bi980998z; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; Makino CL, 2004, J GEN PHYSIOL, V123, P729, DOI 10.1085/jgp.200308994; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P8764, DOI 10.1021/bi00448a013; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; PALCZEWSKI K, 1992, J BIOL CHEM, V267, P18991; Penn RB, 2000, TRENDS CARDIOVAS MED, V10, P81, DOI 10.1016/S1050-1738(00)00053-0; Possee RD., 1992, BACULOVIRUS EXPRESSI; Sampath AP, 2005, NEURON, V46, P413, DOI 10.1016/j.neuron.2005.04.006; Satpaev DK, 1998, BIOCHEMISTRY-US, V37, P10256, DOI 10.1021/bi9804986; SHI W, 1995, J BIOL CHEM, V270, P2112, DOI 10.1074/jbc.270.5.2112; Strahl T, 2003, J BIOL CHEM, V278, P49589, DOI 10.1074/jbc.M309017200; Tachibanaki S, 2000, J BIOL CHEM, V275, P3313, DOI 10.1074/jbc.275.5.3313; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; Thurmond RL, 1997, P NATL ACAD SCI USA, V94, P1715, DOI 10.1073/pnas.94.5.1715; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; Yu QM, 1999, J NEUROCHEM, V73, P1222, DOI 10.1046/j.1471-4159.1999.0731222.x; Zhou W, 2004, NEURON, V41, P573, DOI 10.1016/S0896-6273(04)00045-5; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	46	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19426	19432		10.1074/jbc.M602203200	http://dx.doi.org/10.1074/jbc.M602203200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16675451	hybrid			2022-12-25	WOS:000238847000058
J	Miura, S; Fujino, M; Hanzawa, H; Kiya, Y; Imaizumi, S; Matsuo, Y; Tomita, S; Uehara, Y; Karnik, SS; Yanagisawa, H; Koike, H; Komuro, I; Saku, K				Miura, Shin-ichiro; Fujino, Masahiro; Hanzawa, Hiroyuki; Kiya, Yoshihiro; Imaizumi, Satoshi; Matsuo, Yoshino; Tomita, Sayo; Uehara, Yoshinari; Karnik, Sadashiva S.; Yanagisawa, Hiroaki; Koike, Hiroyuki; Komuro, Issei; Saku, Keijiro			Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; AT(1) RECEPTOR; TRANSMEMBRANE HELICES; CONSTITUTIVE ACTIVATION; NONPEPTIDE ANTAGONISTS; RHODOPSIN; DISCOVERY; ASN(111); MUTATION; DOMAIN	To delineate the molecular mechanism underlying the inverse agonist activity of olmesartan, a potent angiotensin II type 1 (AT(1)) receptor antagonist, we performed binding affinity studies and an inositol phosphate production assay. Binding affinity of olmesartan and its related compounds to wild-type and mutant AT(1) receptors demonstrated that interactions between olmesartan and Tyr(113), Lys(199), His(256), and Gln(257) in the AT(1) receptor were important. The inositol phosphate production assay of olmesartan and related compounds using mutant receptors indicated that the inverse agonist activity required two interactions, that between the hydroxyl group of olmesartan and Tyr(113) in the receptor and that between the carboxyl group of olmesartan and Lys(199) and His(256) in the receptor. Gln(257) was found to be important for the interaction with olmesartan but not for the inverse agonist activity. Based on these results, we constructed a model for the interaction between olmesartan and the AT(1) receptor. Although the activation of G protein-coupled receptors is initiated by anti-clockwise rotation of transmembrane (TM) III and TM VI followed by changes in the conformation of the receptor, in this model, cooperative interactions between the hydroxyl group and Tyr(113) in TM III and between the carboxyl group and His(256) in TM VI were essential for the potent inverse agonist activity of olmesartan. We speculate that the specific interaction of olmesartan with these two TMs is essential for stabilizing the AT(1) receptor in an inactive conformation. A better understanding of the molecular mechanisms of the inverse agonism could be useful for the development of new G protein-coupled receptor antagonists with inverse agonist activity.	Fukuoka Univ, Sch Med, Dept Cardiol, Jonan Ku, Fukuoka 8140180, Japan; Sankyo Co Ltd, Res & Dev Headquarters, Tokyo 1400005, Japan; Cleveland Clin Fdn, Dept Mol Cardiol, Cleveland, OH 44195 USA; Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chiba 2608670, Japan	Fukuoka University; Daiichi Sankyo Company Limited; Cleveland Clinic Foundation; Chiba University	Miura, S (corresponding author), Fukuoka Univ, Sch Med, Dept Cardiol, Jonan Ku, 7-45-1Nanakuma, Fukuoka 8140180, Japan.	miuras@cis.fukuoka-u.ac.jp	Imaizumi, Satoshi/AHB-5318-2022; Saku, Keijiro/HGB-6168-2022; Karnik, Sadashiva/Y-2477-2019	Karnik, Sadashiva/0000-0003-0746-2753	NHLBI NIH HHS [R01 HL083243, R01 HL057470, R01 HL064845] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Baleanu-Gogonea C, 2006, J MOL MODEL, V12, P325, DOI 10.1007/s00894-005-0049-z; Balmforth AJ, 1997, J BIOL CHEM, V272, P4245, DOI 10.1074/jbc.272.7.4245; Bondensgaard K, 2004, J MED CHEM, V47, P888, DOI 10.1021/jm0309452; CARINI DJ, 1991, J MED CHEM, V34, P2525, DOI 10.1021/jm00112a031; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; de Gasparo M, 2000, PHARMACOL REV, V52, P415; de Ligt RAF, 2000, BRIT J PHARMACOL, V130, P1, DOI 10.1038/sj.bjp.0703311; Engelhardt S, 2001, MOL PHARMACOL, V60, P712; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Feng YH, 1998, BIOCHEMISTRY-US, V37, P15791, DOI 10.1021/bi980863t; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; Gruden G, 1999, J AM SOC NEPHROL, V10, P730; Herrick-Davis K, 2000, J PHARMACOL EXP THER, V295, P226; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MARIE J, 1994, J BIOL CHEM, V269, P20815; Miura S, 1999, J BIOL CHEM, V274, P7103, DOI 10.1074/jbc.274.11.7103; Miura S, 2003, J BIOL CHEM, V278, P3720, DOI 10.1074/jbc.M211338200; Miura S, 2003, HYPERTENS RES, V26, P937, DOI 10.1291/hypres.26.937; Miura S, 2005, CURR HYPERTENS REV, V1, P115, DOI 10.2174/1573402054022285; NODA K, 1995, J BIOL CHEM, V270, P2284, DOI 10.1074/jbc.270.5.2284; Noda K, 1996, BIOCHEMISTRY-US, V35, P16435, DOI 10.1021/bi961593m; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; SCHAMBYE HT, 1994, P NATL ACAD SCI USA, V91, P7046, DOI 10.1073/pnas.91.15.7046; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; Takezako T, 2004, J BIOL CHEM, V279, P15248, DOI 10.1074/jbc.M312728200; Zou YZ, 2004, NAT CELL BIOL, V6, P499, DOI 10.1038/ncb1137	30	102	107	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19288	19295		10.1074/jbc.M602144200	http://dx.doi.org/10.1074/jbc.M602144200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16690611	hybrid			2022-12-25	WOS:000238847000043
J	Rafiq, K; Kolpakov, MA; Abdelfettah, M; Streblow, DN; Hassid, A; Dell'Italia, LJ; Sabri, A				Rafiq, Khadija; Kolpakov, Mikhail A.; Abdelfettah, Malika; Streblow, Daniel N.; Hassid, Aviv; Dell'Italia, Louis J.; Sabri, Abdelkarim			Role of protein-tyrosine phosphatase SHP2 in focal adhesion kinase down-regulation during neutrophil cathepsin G-induced cardiomyocytes anoikis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; RAT CARDIAC MYOCYTES; MYOCARDIAL-ISCHEMIA; CELL-MIGRATION; ANGIOTENSIN-II; SUBSTRATE P130(CAS); LEUKOCYTE ELASTASE; REPERFUSION INJURY; SRC KINASE; C-SRC	Inflammatory cells and their proteases contribute to tissue reparation at site of inflammation. Although beneficial at early stages, excessive inflammatory reaction leads to cell death and tissue damage. CathepsinG(Cat. G), a neutrophil-derived serine protease, has been shown to induce neonatal rat cardiomyocyte detachment and apoptosis by anoikis through caspase-3 dependent pathway. However the early mechanisms that trigger Cat. G-induced caspase-3 activation are not known. This study identifies focal adhesion kinase (FAK) tyrosine dephosphorylation as an early mechanism that regulates Cat. G-induced anoikis in cardiomyocytes. Both FAK tyrosine phosphorylation at Tyr-397 and kinase activity decrease rapidly upon Cat. G treatment and was associated with a decrease of FAK association with adapter and cytoskeletal proteins, p130(Cas) and paxillin, respectively. FAK-decreased tyrosine phosphorylation is required for Cat. G-induced myocyte anoikis as concurrent expression of phosphorylation-deficient FAK mutated at Tyr-397 or pretreatment with a protein-tyrosine phosphatase (PTP) inhibitor, pervanadate, blocks Cat. G-induced FAK tyrosine dephosphorylation, caspase-3 activation and DNA fragmentation. Analysis of PTPs activation shows that Cat. G treatment induces an increase of SHP2 and PTEN phosphorylation; however, only SHP2 forms a complex with FAK in response to Cat. G. Expression of dominant negative SHP2 mutant markedly attenuates FAK tyrosine dephosphorylation induced by Cat. G and protects myocytes to undergo apoptosis. In contrast, increased SHP2 expression exacerbates Cat. G-induced FAK tyrosine dephosphorylation and myocyte apoptosis. Taken together, these results show that Cat. G induces SHP2 activation that leads to FAK tyrosine dephosphorylation and promotes cardiomyocyte anoikis.	Temple Univ, Cardiovasc Res Ctr, Dept Anat & Cell Biol, Philadelphia, PA 19140 USA; Oregon Hlth Sci Univ, Portland, OR 97201 USA; Univ Tennessee, Memphis, TN 38163 USA; Univ Alabama, Birmingham, AL 35294 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Oregon Health & Science University; University of Tennessee System; University of Tennessee Health Science Center; University of Alabama System; University of Alabama Birmingham	Sabri, A (corresponding author), Temple Univ, Cardiovasc Res Ctr, Dept Anat & Cell Biol, MRB 801,3420 N Broad St, Philadelphia, PA 19140 USA.	sabri@temple.edu			NHLBI NIH HHS [HL76799, HL63886, HL72902] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076799, R01HL063886, R01HL072902] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; Ali MS, 1997, J BIOL CHEM, V272, P12373, DOI 10.1074/jbc.272.19.12373; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Angers-Loustau A, 1999, BIOCHEM CELL BIOL, V77, P493, DOI 10.1139/bcb-77-6-493; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Chang YZ, 2002, CIRC RES, V91, P390, DOI 10.1161/01.RES.0000033524.92083.64; Cheng A, 2001, J BIOL CHEM, V276, P25848, DOI 10.1074/jbc.M009734200; COBB B, 2001, MOL CELL BIOL, V276, P36183; Ding B, 2000, CIRCULATION, V101, P2854, DOI 10.1161/01.CIR.101.24.2854; Erlich JH, 2000, AM J PATHOL, V157, P1849, DOI 10.1016/S0002-9440(10)64824-9; FENG GS, 1993, SCIENCE, V259, P1611; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gibson TLB, 1999, GROWTH HORM IGF RES, V9, P241, DOI 10.1054/ghir.1999.0115; Goldsmith EC, 2003, AM J PHYSIOL-HEART C, V284, pH2227, DOI 10.1152/ajpheart.00920.2002; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; HANSEN PR, 1995, CIRCULATION, V91, P1872, DOI 10.1161/01.CIR.91.6.1872; Heidkamp MC, 2002, CIRC RES, V90, P1282, DOI 10.1161/01.RES.0000023201.41774.EA; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Kovacic-Milivojevic B, 2001, MOL BIOL CELL, V12, P2290, DOI 10.1091/mbc.12.8.2290; Kuppuswamy D, 1997, J BIOL CHEM, V272, P4500, DOI 10.1074/jbc.272.7.4500; LEMA C, 1998, J CELL BIOL, V140, P1125; Ma A, 2001, MOL BIOL CELL, V12, P1; MAINARDI CL, 1980, J BIOL CHEM, V255, P2006; Manes S, 1999, MOL CELL BIOL, V19, P3125; Melendez J, 2004, J BIOL CHEM, V279, P53516, DOI 10.1074/jbc.M408475200; MOLINO M, 1995, J BIOL CHEM, V270, P11168, DOI 10.1074/jbc.270.19.11168; MUROHARA T, 1995, METHOD FIND EXP CLIN, V17, P499; Nakaoka Y, 2003, CIRC RES, V93, P221, DOI 10.1161/01.RES.0000085562.48906.4A; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; REILLY CF, 1982, J BIOL CHEM, V257, P8619; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Sabri A, 2003, J BIOL CHEM, V278, P23944, DOI 10.1074/jbc.M302718200; Sabri A, 1998, CIRC RES, V82, P1053, DOI 10.1161/01.RES.82.10.1053; Sabri A, 1998, CIRC RES, V83, P841, DOI 10.1161/01.RES.83.8.841; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; SCUDERI P, 1991, CELL IMMUNOL, V135, P299, DOI 10.1016/0008-8749(91)90275-G; Streblow DN, 1999, CELL, V99, P511, DOI 10.1016/S0092-8674(00)81539-1; Takahashi N, 1999, CIRC RES, V84, P1194, DOI 10.1161/01.RES.84.10.1194; Tobe K, 1996, MOL CELL BIOL, V16, P4765; Torsoni AS, 2003, CIRC RES, V93, P140, DOI 10.1161/01.RES.0000081595.25297.1B; Uehara A, 2003, J IMMUNOL, V170, P5690, DOI 10.4049/jimmunol.170.11.5690; van de Water B, 1999, J BIOL CHEM, V274, P13328, DOI 10.1074/jbc.274.19.13328; van de Water B, 2001, J BIOL CHEM, V276, P36183, DOI 10.1074/jbc.M102091200; VARTIO T, 1981, J BIOL CHEM, V256, P471; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Yamazaki T, 1998, IMMUNOLOGY, V93, P115; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	50	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19781	19792		10.1074/jbc.M513040200	http://dx.doi.org/10.1074/jbc.M513040200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16690621	hybrid			2022-12-25	WOS:000238847000091
J	Guo, FK; Debidda, M; Yang, L; Williams, DA; Zheng, Y				Guo, Fukun; Debidda, Marcella; Yang, Linda; Williams, David A.; Zheng, Yi			Genetic deletion of Rac1 GTPase reveals its critical role in actin stress fiber formation and focal adhesion complex assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY GTPASES; REGULATES CELL MOTILITY; PHOSPHATIDYLINOSITOL 3-KINASE; P21-ACTIVATED KINASE; NEURITE OUTGROWTH; LIM-KINASE; CDC42; GROWTH; ACTIVATION; CYTOSKELETAL	Rac1 is an intracellular signal transducer regulating a variety of cell functions. Previous studies by overexpression of dominant-negative or constitutively active mutants of Rac1 in clonal cell lines have established that Rac1 plays a key role in actin lamellipodia induction, cell-matrix adhesion, and cell anoikis. In the present studies, we have examined the cellular behaviors of Rac1 gene-targeted primary mouse embryonic fibroblasts (MEFs) after Cre recombinase-mediated deletion of Rac1 gene. Rac1-null MEFs became contracted and elongated in morphology and were defective in lamellipodia formation, cell spreading, cell-fibronectin adhesion, and focal contact formation in response to platelet-derived growth factor or serum. Unexpectedly, deletion of Rac1 also abolished actin stress fibers in the cells without detectable alteration of endogenous RhoA activity. Although the expression and/or activation status of focal adhesion complex components such as Src, FAK, and vinculin were not affected by Rac1 deletion, the number and size of adhesion plaques were significantly reduced, and the molecular complex between Src, FAK, and vinculin was dissembled in Rac1-null cells. Overexpression of an active RhoA mutant or ROK failed to rescue the stress fiber and adhesion plaque defects of the Rac1-null cells. Although Rac1 deletion caused a significant reduction in phospho-PAK1, -AKT, and -ERK under serum stimulation, reconstitution of active PAK1, but not AKT orMEK1, was able to rescue the actin cytoskeleton and adhesion phenotypes of the Rac1-deficient cells. Furthermore, Rac1 deletion led to a marked increase in spontaneous apoptosis that could be rescued by active PAK1, AKT, or MEK1 expression. Our results obtained from gene-targeted primary MEFs indicate that Rac1 is essential not only for lamellipodia induction but also for the RhoA-regulated actin stress fiber and focal adhesion complex formation and that Rac1 is involved in cell survival regulation through anoikis-dependent as well as-independent mechanisms.	Univ Cincinnati, Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Zheng, Y (corresponding author), Univ Cincinnati, Childrens Hosp Res Fdn, Div Expt Hematol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	yi.zheng@chmcc.org	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060523] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK062757, R01 DK062757] Funding Source: Medline; NIGMS NIH HHS [GM53943, GM60523] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen WE, 1997, J CELL SCI, V110, P707; Aoki K, 2004, J BIOL CHEM, V279, P713, DOI 10.1074/jbc.M306382200; Arthur WT, 2002, BIOL RES, V35, P239, DOI 10.4067/S0716-97602002000200016; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Beeser A, 2005, J BIOL CHEM, V280, P36609, DOI 10.1074/jbc.M502306200; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Cerione RA, 2004, TRENDS CELL BIOL, V14, P127, DOI 10.1016/j.tcb.2004.01.008; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Coniglio SJ, 2001, J BIOL CHEM, V276, P28113, DOI 10.1074/jbc.M102299200; Crean JKG, 2002, J BIOL CHEM, V277, P44187, DOI 10.1074/jbc.M203715200; Debreceni B, 2004, J BIOL CHEM, V279, P3777, DOI 10.1074/jbc.M308282200; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fan SJ, 2005, ONCOGENE, V24, P1749, DOI 10.1038/sj.onc.1208327; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Gorlach A, 2005, THROMB HAEMOSTASIS, V93, P1168, DOI 10.1160/TH05-01-0006; Gu Y, 2003, SCIENCE, V302, P445, DOI 10.1126/science.1088485; Guan KL, 2000, J BIOL CHEM, V275, P27354; Guo FK, 2004, ONCOGENE, V23, P5577, DOI 10.1038/sj.onc.1207752; Guo FK, 2004, MOL CELL BIOL, V24, P1426, DOI 10.1128/MCB.24.3.1426-1438.2004; Guo FK, 2003, J BIOL CHEM, V278, P14414, DOI 10.1074/jbc.M300341200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Kaverina I, 2002, INT J BIOCHEM CELL B, V34, P746, DOI 10.1016/S1357-2725(01)00171-6; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Pawlak G, 2002, J BIOL CHEM, V277, P26927, DOI 10.1074/jbc.M202261200; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Qian Y, 2005, ONCOGENE, V24, P3154, DOI 10.1038/sj.onc.1208525; Qian Y, 2004, AM J PHYSIOL-CELL PH, V286, pC153, DOI 10.1152/ajpcell.00142.2003; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sarner S, 2000, MOL CELL BIOL, V20, P158, DOI 10.1128/MCB.20.1.158-172.2000; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Suetsugu S, 2003, DEV CELL, V5, P595, DOI 10.1016/S1534-5807(03)00297-1; VAN AL, 1997, GENE DEV, V11, P2295; Wilkinson S, 2005, NAT CELL BIOL, V7, P255, DOI 10.1038/ncb1230; Woo CH, 2002, MOL CELLS, V13, P470; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zugasti O, 2001, MOL CELL BIOL, V21, P6706, DOI 10.1128/MCB.21.19.6706-6717.2001	52	128	131	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18652	18659		10.1074/jbc.M603508200	http://dx.doi.org/10.1074/jbc.M603508200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16698790	hybrid			2022-12-25	WOS:000238687300045
J	Deng, R; Li, W; Guan, Z; Zhou, JM; Wang, Y; Mei, YP; Li, MT; Feng, GK; Huang, W; Liu, ZC; Han, Y; Zeng, YX; Zhu, XF				Deng, R.; Li, W.; Guan, Z.; Zhou, J-M; Wang, Y.; Mei, Y-P; Li, M-T; Feng, G-K; Huang, W.; Liu, Z-C; Han, Y.; Zeng, Y-X; Zhu, X-F			Acetylcholinesterase expression mediated by c-Jun-NH2-terminal kinase pathway during anticancer drug-induced apoptosis	ONCOGENE			English	Article						acetylcholinesterase (AChE); c-Jun NH2-terminal kinase (JNK); apoptosis; mitogen-activated protein kinase ( MAPK); extracellular signal regulated kinase ( ERK)	CYTOCHROME-C RELEASE; JUN; ACTIVATION; JNK; CELLS; DEATH; BAX; PHOSPHORYLATION; INDUCTION; RAT	It has been shown that acetylcholinesterase (AChE) expression was induced during apoptosis and the antisense oligonucleotides and siRNA of AChE may prevent apoptosis in various cell types. However, the mechanisms underlying AChE upregulation remain elusive. We demonstrated here that c-Jun NH2-terminal kinase (JNK) could mediate AChE expression. In this study, both etoposide and excisanin A, two anticancer agents, induced apoptosis in colon cancer cell line SW620 as determined by Annexin V staining, the cleavage of caspase-3 and the proteolytic degradation of poly (ADPribose) polymerase (PARP). The results showed that both the agents upregulated AChE in SW620 cells. In the meantime, JNK was also activated and the expression and phosphorylation of c-Jun increased in SW620 cells exposed to the two agents. The induced AChE mRNA and protein expression could be blocked by SP600125, a specific inhibitor of SAPK/JNK, and small interfering RNA directed against JNK1/2. Transfection with adenovirus-mediated dominant negative c-Jun also blocked the upregulation of AChE expression. Together, these results suggest that AChE expression may be mediated by the activation of JNK pathway during apoptosis through a c-Jun-dependent mechanism.	Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol So China, Guangzhou 510060, Peoples R China; Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Sun Yat Sen Univ, Dept Pharmacol, Proteom Lab, Guangzhou, Peoples R China	Sun Yat Sen University; Hong Kong University of Science & Technology; Sun Yat Sen University	Zhu, XF (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol So China, 651 DongFeng Rd E, Guangzhou 510060, Peoples R China.	bcyfhan@ust.hk; xfzhu70@public.guangzhou.gd.cn		Han, Yifan/0000-0002-5833-069X				Chen YR, 2000, INT J ONCOL, V16, P651; Cohen TV, 2004, J NEUROCHEM, V90, P1059, DOI 10.1111/j.1471-4159.2004.02564.x; Collett GP, 2004, CARCINOGENESIS, V25, P2183, DOI 10.1093/carcin/bgh233; Cuadrado A, 2004, ONCOGENE, V23, P4673, DOI 10.1038/sj.onc.1207636; Eminel S, 2004, J BIOL CHEM, V279, P55385, DOI 10.1074/jbc.M405858200; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; GAO YH, 2000, CHIN TRADIT HERB DRU, V31, P645; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; Grisaru D, 1999, EUR J BIOCHEM, V264, P672, DOI 10.1046/j.1432-1327.1999.00693.x; Gururajan M, 2005, BLOOD, V106, P1382, DOI 10.1182/blood-2004-10-3819; Hamdi M, 2005, ONCOGENE, V24, P7135, DOI 10.1038/sj.onc.1208875; KARPEL R, 1994, EXP CELL RES, V210, P268, DOI 10.1006/excr.1994.1039; Khelifi AF, 2005, CELL DEATH DIFFER, V12, P724, DOI 10.1038/sj.cdd.4401559; Kirkland RA, 2003, ANTIOXID REDOX SIGN, V5, P589, DOI 10.1089/152308603770310257; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kuntzen C, 2005, CANCER RES, V65, P6780, DOI 10.1158/0008-5472.CAN-04-2618; Kurinna SM, 2004, CANCER RES, V64, P7852, DOI 10.1158/0008-5472.CAN-04-1552; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Meshorer E, 2005, MOL PSYCHIATR, V10, P985, DOI 10.1038/sj.mp.4001735; Meshorer E, 2004, J BIOL CHEM, V279, P29740, DOI 10.1074/jbc.M402752200; Park SE, 2004, CANCER RES, V64, P2652, DOI 10.1158/0008-5472.CAN-04-0649; Perry C, 2002, ONCOGENE, V21, P8428, DOI 10.1038/sj.onc.1205945; Small DH, 1996, NEUROCHEM INT, V28, P453, DOI 10.1016/0197-0186(95)00099-2; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Teraishi F, 2005, CANCER RES, V65, P6380, DOI 10.1158/0008-5472.CAN-05-0575; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; TRANUMJENSEN J, 1981, EUR J CELL BIOL, V24, P281; Yin D, 2005, ONCOGENE, V24, P344, DOI 10.1038/sj.onc.1208225; Zhang XJ, 2002, CELL DEATH DIFFER, V9, P790, DOI 10.1038/sj.cdd.4401034; Zhou JM, 2006, ONCOGENE, V25, P503, DOI 10.1038/sj.onc.1209067; Zhu XF, 2005, MOL PHARMACOL, V67, P1444, DOI 10.1124/mol.104.009894; Zhu XF, 2002, LIFE SCI, V70, P1259, DOI 10.1016/S0024-3205(01)01501-6; Zou W, 2004, CANCER RES, V64, P7570, DOI 10.1158/0008-5472.CAN-04-1238	34	58	60	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7070	7077		10.1038/sj.onc.1209686	http://dx.doi.org/10.1038/sj.onc.1209686			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16715131				2022-12-25	WOS:000241910500006
J	Gort, EH; Groot, AJ; van de Ven, TLPD; van der Groep, P; Verlaan, I; van Laar, T; van Diest, PJ; van der Wall, E; Shvarts, A				Gort, E. H.; Groot, A. J.; van de Ven, T. L. P. Derks; van der Groep, P.; Verlaan, I.; van Laar, T.; van Diest, P. J.; van der Wall, E.; Shvarts, A.			Hypoxia-inducible factor-1 alpha expression requires PI 3-kinase activity and correlates with Akt1 phosphorylation in invasive breast carcinomas	ONCOGENE			English	Article						HIF-1 alpha; PI 3-kinase; Akt; hypoxia; breast cancer	ENDOTHELIAL GROWTH-FACTOR; PROTEIN-KINASE-B; FACTOR 1-ALPHA; PROLYL HYDROXYLATION; GENE-TRANSCRIPTION; PROSTATE-CANCER; HIF-ALPHA; ACTIVATION; PATHWAY; CELLS	Hypoxia-inducible factor-1 alpha (HIF-1 alpha) is the regulatory subunit of the heterodimeric transcription factor HIF-1 and the key factor in cellular response to low oxygen tension. Expression of HIF-1 alpha protein is associated with poor patient survival and therapy resistance in many types of solid tumors. Insight into HIF-1 alpha regulation in solid tumors is important for therapeutic strategies. In this study, we determined the pathophysiological relevance of HIF-1 alpha regulation by the oncogenic phosphatidylinositol 3'-kinase (PI 3-kinase)/Akt signaling pathway. We modeled the physiology of hypoxic tumor regions by culturing carcinoma cells under low oxygen tension in the absence of serum. We observed that hypoxic induction of HIF-1 alpha protein was decreased by serum deprivation. Overexpression of dominant-active Akt1 restored HIF-1 alpha expression, whereas inhibition of PI 3-kinase activity reduced hypoxic HIF-1 alpha protein levels to a similar extent as serum deprivation. Immunohistochemical analysis of 95 human breast cancers revealed that lack of Akt1 phosphorylation correlates with low HIF-1 alpha levels. To our knowledge, this is the first reported comparison between HIF-1 alpha expression and Akt phosphorylation in human carcinomas. We conclude that Akt activity is physiologically relevant for HIF-1 alpha expression in breast cancer. This implies that HIF-1 alpha function might be therapeutically targeted by inhibition of the PI 3-kinase/Akt pathway.	Univ Med Ctr Utrecht, Dept Pathol, NL-3508 GA Utrecht, Netherlands; Univ Med Ctr Utrecht, Div Internal Med & Dermatol, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	van Diest, PJ (corresponding author), Univ Med Ctr Utrecht, Dept Pathol, POB 85500, NL-3508 GA Utrecht, Netherlands.	p.j.vandiest@azu.nl						Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alvarez-Tejado M, 2002, J BIOL CHEM, V277, P13508, DOI 10.1074/jbc.M200017200; Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200; Bardos JI, 2004, MOL CELL BIOL, V24, P2905, DOI 10.1128/MCB.24.7.2905-2914.2004; Birner P, 2000, CANCER RES, V60, P4693; Bos R, 2003, CANCER, V97, P1573, DOI 10.1002/cncr.11246; Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Dales JP, 2005, INT J CANCER, V116, P734, DOI 10.1002/ijc.20984; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kirkegaard T, 2005, J PATHOL, V207, P139, DOI 10.1002/path.1829; Kreisberg JI, 2004, CANCER RES, V64, P5232, DOI 10.1158/0008-5472.CAN-04-0272; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mottet D, 2003, J BIOL CHEM, V278, P31277, DOI 10.1074/jbc.M300763200; Schmitz KJ, 2004, MODERN PATHOL, V17, P15, DOI 10.1038/modpathol.3800002; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shibata T, 1998, INT J RADIAT ONCOL, V42, P913, DOI 10.1016/S0360-3016(98)00298-3; Skinner HD, 2004, J BIOL CHEM, V279, P45643, DOI 10.1074/jbc.M404097200; Tang TTL, 2003, J BIOL CHEM, V278, P30125, DOI 10.1074/jbc.M302042200; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; van Diest PJ, 2002, BMJ-BRIT MED J, V325, P648, DOI 10.1136/bmj.325.7365.648; Vaupel P, 2005, TRANSFUS CLIN BIOL, V12, P5, DOI 10.1016/j.tracli.2004.11.005; Vleugel MM, 2005, J CLIN PATHOL, V58, P172, DOI 10.1136/jcp.2004.019885; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zhong H, 2000, CANCER RES, V60, P1541; Zhou J, 2004, J BIOL CHEM, V279, P13506, DOI 10.1074/jbc.M310164200	39	49	53	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6123	6127		10.1038/sj.onc.1209643	http://dx.doi.org/10.1038/sj.onc.1209643			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16682946				2022-12-25	WOS:000241101200009
J	Hirohashi, Y; Wang, Q; Liu, Q; Li, B; Du, X; Zhang, H; Furuuchi, K; Masuda, K; Sato, N; Greene, MI				Hirohashi, Y.; Wang, Q.; Liu, Q.; Li, B.; Du, X.; Zhang, H.; Furuuchi, K.; Masuda, K.; Sato, N.; Greene, M. I.			Centrosomal proteins Nde1 and Su48 form a complex regulated by phosphorylation	ONCOGENE			English	Article						centrosome; mitosis; cancer; phosphorylation	CYTOPLASMIC DYNEIN; MALIGNANT-TUMORS; MITOTIC SPINDLE; LIVING CELLS; DEFECTS; LIS1; KINETOCHORES; INSTABILITY; PROGRESSION; CARCINOMA	The centrosome modulates spindle formation and plays a critical role in guiding proper segregation of chromosomes during cell division. Centrosome aberrations, frequently seen in human tumors, may cause abnormal chromosome segregation and contribute to malignant transformation. To explore the components of the centrosomes, we previously identified a novel centrosomal protein called Su48. To further characterize the Su48-containing protein ensemble in the centrosome, we performed yeast two-hybrid screens and isolated a number of Su48- interacting molecules, including the centrosomal protein Nde1. Here, we demonstrate that Su48 can associate with Nde1. Moreover, we found that Nde1 is subjected to phosphorylation in vivo. In particular, we identified six putative Cdc2 phosphorylation sites in Nde1 and found that alteration of these sites diminishes phosphorylation by Cdc2 in vitro and affects the stability of Su48- Nde1 interactions and the centrosomal localization of Nde1. Ablation of Nde1 by gene specific small interfering RNA causes mitotic delay and cell death, coupled with a modest decrease in the incidence of the cells that harbor excessive centrosomes. Collectively, our findings indicate that Nde1 can form a protein complex with Su48 in the centrosome and plays an important role for successful mitosis.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Sapporo Med Univ, Sch Med, Dept Pathol, Chuo Ku, Sapporo, Hokkaido, Japan	University of Pennsylvania; Sapporo Medical University	Greene, MI (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 36th Hamilton Walk,252 John Morgan Bldg, Philadelphia, PA 19104 USA.	greene@reo.med.upenn.edu	Hirohashi, Yoshihiko/AFQ-4227-2022; Wang, Qiang/N-7310-2015	Wang, Qiang/0000-0001-9409-0251; Zhang, Hongtao/0000-0001-9173-0049				Doxsey S, 2002, MOL CELL, V10, P439, DOI 10.1016/S1097-2765(02)00654-8; Efimov VP, 2000, J CELL BIOL, V150, P681, DOI 10.1083/jcb.150.3.681; Faulkner NE, 2000, NAT CELL BIOL, V2, P784, DOI 10.1038/35041020; Feng YY, 2004, NEURON, V44, P279, DOI 10.1016/j.neuron.2004.09.023; Feng YY, 2000, NEURON, V28, P665, DOI 10.1016/S0896-6273(00)00145-8; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Howell BJ, 2004, CURR BIOL, V14, P953, DOI 10.1016/j.cub.2004.05.053; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lingle WL, 2000, CURR TOP DEV BIOL, V49, P313; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; Pihan GA, 2001, CANCER RES, V61, P2212; Pihan GA, 1998, CANCER RES, V58, P3974; Quintyne NJ, 2005, SCIENCE, V307, P127, DOI 10.1126/science.1104905; Sasaki S, 2000, NEURON, V28, P681, DOI 10.1016/S0896-6273(00)00146-X; Sato N, 1999, CLIN CANCER RES, V5, P963; Shono M, 2001, LAB INVEST, V81, P945, DOI 10.1038/labinvest.3780306; Wang Q, 2004, DNA CELL BIOL, V23, P475, DOI 10.1089/1044549041562276; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang Q, 2001, ONCOGENE, V20, P4640, DOI 10.1038/sj.onc.1204625; Yan XM, 2003, MOL CELL BIOL, V23, P1239, DOI 10.1128/MCB.23.4.1239-1250.2003; Young A, 2000, MOL BIOL CELL, V11, P2047, DOI 10.1091/mbc.11.6.2047	22	33	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2006	25	45					6048	6055		10.1038/sj.onc.1209637	http://dx.doi.org/10.1038/sj.onc.1209637			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16682949				2022-12-25	WOS:000241101200002
J	Tremblay, PL; Auger, FA; Huot, J				Tremblay, P-L; Auger, F. A.; Huot, J.			Regulation of transendothelial migration of colon cancer cells by E-selectin-mediated activation of p38 and ERK MAP kinases	ONCOGENE			English	Article						E-selectin; MAP kinases; transendothelial migration; colon cancer	VASCULAR ENDOTHELIAL-CELLS; ACTIN REORGANIZATION; LEUKOCYTE ADHESION; BARRIER DYSFUNCTION; OXIDATIVE STRESS; LIVER METASTASIS; CARCINOMA CELLS; TUMOR-CELLS; PERMEABILITY; PHOSPHORYLATION	The invasive properties of cancer cells depend on their intrinsic motile potential and on their ability to breach the endothelial barrier. In the present work, we investigated the mechanisms by which adhesion of colon cancer cells to E-selectin expressed by endothelial cells regulates the barrier function of these cells and modulates transmigration of cancer cells. We found that the stimulation of E-selectin by activating antibodies or the adhesion of HT-29 cells results in an increase in the activity of extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinases. In turn, the activation of p38 and ERK enhances transendothelial permeability and migration of HT-29 cells. We also obtained evidence suggesting that p38-mediated increase in transendothelial migration of cancer cells depends on a myosin light chain phosphorylation-mediated formation of stress fibres. On the other hand, the activation of ERK by E-selectin modulates the opening of interendothelial spaces by initiating the activation of Src kinase activities and the dissociation of the VE-cadherin/beta-catenin complex. We conclude that activation of E-selectin by adhering cancer cells is an important process that regulates the extravasation of colon cancer cells by initiating p38- and ERK-dependent mechanisms that both contribute to regulate the integrity of the endothelial layer.	Univ Laval, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada; Univ Quebec, Ctr Hosp, Lab Organogenese Expt, Ste Foy, PQ G1S 4L8, Canada	Laval University; Laval University; University of Quebec	Huot, J (corresponding author), Univ Laval, Ctr Rech Cancerol, 9,Rue McMahon, Quebec City, PQ G1R 2J6, Canada.	Jacques.Huot@phc.ulaval.ca						Baldwin AL, 2001, CRIT REV BIOMED ENG, V29, P247, DOI 10.1615/CritRevBiomedEng.v29.i2.20; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; Bogatcheva NV, 2002, VASC PHARMACOL, V39, P201, DOI 10.1016/S1537-1891(03)00009-0; Borbiev T, 2004, AM J PHYSIOL-LUNG C, V287, pL911, DOI 10.1152/ajplung.00372.2003; Brembeck FH, 2004, GENE DEV, V18, P2225, DOI 10.1101/gad.317604; Brodt P, 1997, INT J CANCER, V71, P612, DOI 10.1002/(SICI)1097-0215(19970516)71:4<612::AID-IJC17>3.0.CO;2-D; Burdick MM, 2003, AM J PHYSIOL-CELL PH, V284, pC977, DOI 10.1152/ajpcell.00423.2002; Criscuoli ML, 2005, BLOOD, V105, P1508, DOI 10.1182/blood-2004-06-2246; DEJANA E, 1992, LAB INVEST, V66, P324; Dejana E, 2001, THROMB HAEMOSTASIS, V86, P308; Dejana E, 1999, EXP CELL RES, V252, P13, DOI 10.1006/excr.1999.4601; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Haier J, 2001, DIS COLON RECTUM, V44, P876, DOI 10.1007/BF02234713; Hale KK, 1999, J IMMUNOL, V162, P4246; Houle FO, 2003, MOL BIOL CELL, V14, P1418, DOI 10.1091/mbc.E02-04-0235; Hu YY, 2001, J BIOL CHEM, V276, P48549, DOI 10.1074/jbc.M105513200; Hu YY, 2000, J IMMUNOL, V165, P2142, DOI 10.4049/jimmunol.165.4.2142; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; Ionescu CV, 2003, MICROCIRCULATION, V10, P205, DOI 10.1038/sj.mn.7800185; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kevil CG, 1998, J BIOL CHEM, V273, P15099, DOI 10.1074/jbc.273.24.15099; Kevil CG, 2001, ENDOTHELIUM-J ENDOTH, V8, P107, DOI 10.3109/10623320109165320; Khatib AM, 2002, CANCER RES, V62, P5393; Khatib AM, 1999, CANCER RES, V59, P1356; Kobayashi K, 2000, CANCER RES, V60, P3978; Krause T, 1999, CLIN EXP METASTAS, V17, P183, DOI 10.1023/A:1006626500852; Laferriere J, 2001, J BIOL CHEM, V276, P33762, DOI 10.1074/jbc.M008564200; Laferriere J, 2002, ANN NY ACAD SCI, V973, P562, DOI 10.1111/j.1749-6632.2002.tb04702.x; Lafferriere J, 2004, CLIN EXP METASTAS, V21, P257, DOI 10.1023/B:CLIN.0000037708.09420.9a; Lamalice L, 2004, ONCOGENE, V23, P434, DOI 10.1038/sj.onc.1207034; Le Boeuf F, 2004, J BIOL CHEM, V279, P39175, DOI 10.1074/jbc.M405493200; Mehta D, 1999, J PHYSIOL-LONDON, V519, P829, DOI 10.1111/j.1469-7793.1999.0829n.x; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; Peng HH, 2005, FRONT BIOSCI-LANDMRK, V10, P1597, DOI 10.2741/1643; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Rousseau S, 2000, TRENDS CARDIOVAS MED, V10, P321, DOI 10.1016/S1050-1738(01)00072-X; Saito H, 1998, J IMMUNOL, V161, P1533; SAWADA R, 1994, J BIOL CHEM, V269, P1425; SCHNITTLER HJ, 1990, J PHYSIOL-LONDON, V431, P379, DOI 10.1113/jphysiol.1990.sp018335; Shaw L, 2003, J VASC RES, V40, P1, DOI 10.1159/000068940; Tinsley JH, 1999, J BIOL CHEM, V274, P24930, DOI 10.1074/jbc.274.35.24930; Verin AD, 2000, AM J PHYSIOL-LUNG C, V279, pL360, DOI 10.1152/ajplung.2000.279.2.L360; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Wang Q, 2001, J IMMUNOL, V166, P6877, DOI 10.4049/jimmunol.166.11.6877; Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130; Wojciak-Stothard B, 2002, VASC PHARMACOL, V39, P187, DOI 10.1016/S1537-1891(03)00008-9; YAMADA N, 1995, DIGEST DIS SCI, V40, P1005, DOI 10.1007/BF02064189; Yao J, 2001, ONCOGENE, V20, P8066, DOI 10.1038/sj.onc.1204944; Yoshida M, 2003, ARTERIOSCL THROM VAS, V23, P783, DOI 10.1161/01.ATV.0000067427.40133.59; Yoshida M, 1996, J CELL BIOL, V133, P445, DOI 10.1083/jcb.133.2.445; Yuan SY, 2002, VASC PHARMACOL, V39, P213, DOI 10.1016/S1537-1891(03)00010-7; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539	54	115	116	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6563	6573		10.1038/sj.onc.1209664	http://dx.doi.org/10.1038/sj.onc.1209664			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16715142				2022-12-25	WOS:000241569700001
J	Fien, K; Hurwitz, J				Fien, Karen; Hurwitz, Jerard			Fission yeast Mcm10p contains primase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-ALPHA; RNA PRIMER SYNTHESIS; SACCHAROMYCES-CEREVISIAE; CHROMOSOMAL DNA; SCHIZOSACCHAROMYCES-POMBE; CHROMATIN ASSOCIATION; REPLICATION FACTORS; HELICASE ACTIVITY; BUDDING YEAST; CDC23 MCM10	Although Mcm10p is a conserved essential component in eukaryotes required for both the initiation and elongation of DNA chains, its biochemical properties are unknown. Here, we report that the Schizosaccharomyces pombe fission yeast Mcm10protein contains primase activity. Primases are enzymes that synthesize RNA primers on single-stranded DNA templates that are extended by DNA polymerases. In keeping with this property, Mcm10p supported oligoribonucleotide synthesis of short RNA primers (preferentially initiating synthesis on a dT template) that were extended with dATP by Escherichia coli DNA polymerase I. The C terminus of Mcm10p synthesized RNA, but less efficiently than the full-length protein at low rNTP levels. Mcm10p homologs contain a C-terminal motif found in proteins that polymerize nucleotides. A point mutant within this motif of S. pombe Mcm10p was defective in primer synthesis in vitro, and this mutant failed to support growth in vivo, suggesting that the primase activity of Mcm10p may be essential for cell viability.	Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Fien, K (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.	fienk@mskcc.org; j-hurwitz@ski.mskcc.org						Araki Y, 2003, GENES CELLS, V8, P465, DOI 10.1046/j.1365-2443.2003.00648.x; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1609, DOI 10.1093/nar/27.7.1609; Arezi B, 2000, TRENDS BIOCHEM SCI, V25, P572, DOI 10.1016/S0968-0004(00)01680-7; Aves SJ, 1998, CURR GENET, V34, P164, DOI 10.1007/s002940050382; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; Corn JE, 2005, MOL CELL, V20, P391, DOI 10.1016/j.molcel.2005.09.004; Fien K, 2004, J BIOL CHEM, V279, P16144, DOI 10.1074/jbc.M400142200; Frick DN, 2001, ANNU REV BIOCHEM, V70, P39, DOI 10.1146/annurev.biochem.70.1.39; Gregan J, 2003, MOL BIOL CELL, V14, P3876, DOI 10.1091/mbc.E03-02-0090; Hart EA, 2002, CURR GENET, V41, P342, DOI 10.1007/s00294-002-0316-9; Homesley L, 2000, GENE DEV, V14, P913; Huang Y, 1997, BIOCHEMISTRY-US, V36, P13718, DOI 10.1021/bi971609o; ILYANA TV, 1992, J MOL EVOL, V34, P351; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; KAGUNI LS, 1988, BIOCHIM BIOPHYS ACTA, V950, P87, DOI 10.1016/0167-4781(88)90001-2; Kanemaki M, 2003, NATURE, V423, P720, DOI 10.1038/nature01692; Kaplan DL, 2003, J BIOL CHEM, V278, P49171, DOI 10.1074/jbc.M308074200; Kato M, 2003, MOL CELL, V11, P1349, DOI 10.1016/S1097-2765(03)00195-3; Kawasaki Y, 2000, GENES CELLS, V5, P975, DOI 10.1046/j.1365-2443.2000.00387.x; Keck JL, 2000, SCIENCE, V287, P2482, DOI 10.1126/science.287.5462.2482; Kusakabe T, 1997, J BIOL CHEM, V272, P12446, DOI 10.1074/jbc.272.19.12446; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Lee JK, 2003, P NATL ACAD SCI USA, V100, P2334, DOI 10.1073/pnas.0237384100; Lee SJ, 2004, J BIOL CHEM, V279, P23384, DOI 10.1074/jbc.M400857200; Lee SJ, 2001, J BIOL CHEM, V276, P49419, DOI 10.1074/jbc.M108443200; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Liang DT, 2001, GENETICS, V159, P471; Liu QQ, 2000, J BIOL CHEM, V275, P1615, DOI 10.1074/jbc.275.3.1615; Merchant AM, 1997, MOL CELL BIOL, V17, P3261, DOI 10.1128/MCB.17.6.3261; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Ricke RM, 2004, MOL CELL, V16, P173, DOI 10.1016/j.molcel.2004.09.017; Sawyer SL, 2004, J MOL BIOL, V340, P195, DOI 10.1016/j.jmb.2004.04.066; SCHERZINGER E, 1977, EUR J BIOCHEM, V72, P543, DOI 10.1111/j.1432-1033.1977.tb11278.x; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SOLOMON NA, 1992, YEAST, V8, P273, DOI 10.1002/yea.320080405; Takayama Y, 2003, GENE DEV, V17, P1153, DOI 10.1101/gad.1065903; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; Yang XW, 2005, BMC MOL BIOL, V6, DOI 10.1186/1471-2199-6-13; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	43	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22248	22260		10.1074/jbc.M512997200	http://dx.doi.org/10.1074/jbc.M512997200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16720577	hybrid			2022-12-25	WOS:000239387100071
J	Popescu, CI; Mares, A; Zdrentu, L; Zitzmann, N; Dwek, RA; Petrescu, SM				Popescu, Costin I.; Mares, Alina; Zdrentu, Livia; Zitzmann, Nicole; Dwek, Raymond A.; Petrescu, Stefana M.			Productive folding of tyrosinase ectodomain is controlled by the transmembrane anchor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; INFLUENZA HEMAGGLUTININ; VIRUS GLYCOPROTEIN; IN-VIVO; CALNEXIN; CALRETICULIN; MATURATION; PROTEIN; DOMAIN	Transmembrane domains ( TMDs) are known as structural elements required for the insertion into the membrane of integral membrane proteins. We have provided here an example showing that the presence of the TMD is compulsory for the productive folding pathway of a membrane-anchored glycoprotein. Tyrosinase, a type I transmembrane protein whose insertion into the melanosomal membrane initiates melanin synthesis, is misfolded and degraded when expressed as a truncated polypeptide. We used constructs of tyrosinase ectodomain fused with chimeric TMDs or glycosylphosphatidylinositol anchor to gain insights into how the TMD enables the productive folding pathway of the ectodomain. We found that in contrast to the soluble constructs, the membrane-anchored chimeras fold into the native conformation, which allows their endoplasmic reticulum exit. They recruit calnexin to monitor their productive folding pathway characterized by the post-translational formation of buried disulfides. Lacking calnexin assistance, the truncated mutant is arrested in an unstable conformation bearing exposed disulfides. We showed that the transmembrane anchor of a protein may crucially, albeit indirectly, control the folding pathway of the ectodomain.	Inst Biochem, Bucharest 060031 17, Romania; Oxford Glycobiol Inst, Dept Biochem, Oxford OX1 3QU, England	Romanian Academy of Sciences; Institute of Biochemistry, Bucharest; University of Oxford	Petrescu, SM (corresponding author), Romanian Acad, Inst Biochem, Splaiul Independentei 296, Bucharest 77700 17, Romania.	stefana.petrescu@biochim.ro	Popescu, Costin-Ioan/C-3033-2012; Petrescu, Stefana M/I-9240-2012; Petrescu, Stefana/AAJ-9505-2021; Sima, Livia E/C-2882-2011; Sima, Livia/M-4389-2019	Petrescu, Stefana M/0000-0002-4047-0811; Petrescu, Stefana/0000-0002-4047-0811; Sima, Livia E/0000-0002-3404-4162; Sima, Livia/0000-0002-3404-4162	Wellcome Trust [CRIG 064227] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Berson JF, 2000, J BIOL CHEM, V275, P12281, DOI 10.1074/jbc.275.16.12281; Branza-Nichita N, 2000, J BIOL CHEM, V275, P8169, DOI 10.1074/jbc.275.11.8169; Branza-Nichita N, 1999, BIOCHEM BIOPH RES CO, V261, P720, DOI 10.1006/bbrc.1999.1030; Cannon KS, 2001, EMBO J, V20, P2443, DOI 10.1093/emboj/20.10.2443; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; Cocquerel L, 1998, J VIROL, V72, P2183, DOI 10.1128/JVI.72.3.2183-2191.1998; Dalley JA, 2003, BIOCHEM SOC T, V31, P1257; Danilczyk UG, 2001, J BIOL CHEM, V276, P25532, DOI 10.1074/jbc.M100270200; Del Vecchio RL, 2005, J BIOL CHEM, V280, P1603, DOI 10.1074/jbc.M410181200; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; HEARING VJ, 1985, INT J CANCER, V35, P403, DOI 10.1002/ijc.2910350317; Hebert DN, 1997, J CELL BIOL, V139, P613, DOI 10.1083/jcb.139.3.613; Maggioni MC, 2005, NAT STRUCT MOL BIOL, V12, P258, DOI 10.1038/nsmb897; Maillard AP, 2002, J GEN VIROL, V83, P1465, DOI 10.1099/0022-1317-83-6-1465; Molinari M, 2004, MOL CELL, V13, P125, DOI 10.1016/S1097-2765(03)00494-5; Negroiu G, 2000, J BIOL CHEM, V275, P32200, DOI 10.1074/jbc.M005186200; Oberdorf J, 2005, J BIOL CHEM, V280, P38193, DOI 10.1074/jbc.M504200200; Petrescu SM, 2000, BIOCHEMISTRY-US, V39, P5229, DOI 10.1021/bi000107z; Popescu CI, 2005, J BIOL CHEM, V280, P13833, DOI 10.1074/jbc.M413087200; Sprong H, 2001, J CELL BIOL, V155, P369, DOI 10.1083/jcb.200106104; Swanton E, 2003, EMBO J, V22, P2948, DOI 10.1093/emboj/cdg300; TATU U, 1995, EMBO J, V14, P1340, DOI 10.1002/j.1460-2075.1995.tb07120.x; Toyofuku K, 1999, J BIOCHEM, V125, P82, DOI 10.1093/oxfordjournals.jbchem.a022272; Wang N, 2005, MOL BIOL CELL, V16, P3740, DOI 10.1091/mbc.E05-05-0381; Yin HS, 2005, P NATL ACAD SCI USA, V102, P9288, DOI 10.1073/pnas.0503989102	26	8	12	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21682	21689		10.1074/jbc.M603841200	http://dx.doi.org/10.1074/jbc.M603841200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16737954	hybrid			2022-12-25	WOS:000239387100013
J	Bigg, HF; Wait, R; Rowan, AD; Cawston, TE				Bigg, Heather F.; Wait, Robin; Rowan, Andrew D.; Cawston, Tim E.			The mammalian chitinase-like lectin, YKL-40, binds specifically to type I collagen and modulates the rate of type I collagen fibril formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CARTILAGE GLYCOPROTEIN-39; SMOOTH-MUSCLE-CELLS; SUBSTRATE-ASSISTED CATALYSIS; HUMAN ARTICULAR CHONDROCYTES; BOVINE NASAL CARTILAGE; X-RAY-STRUCTURE; RHEUMATOID-ARTHRITIS; SERUM YKL-40; CRYSTAL-STRUCTURE; SYNTHESIZE HYALURONAN	YKL-40 is expressed in arthritic cartilage and produced in large amounts by cultured chondrocytes, but its exact role is unclear, and the identities of its physiological ligands remain unknown. Purification of YKL-40 from resorbing bovine nasal cartilage and chondrocyte monolayers demonstrated the existence of three isoforms, a major and minor form from resorbing cartilage and a third species from chondrocytes. Affinity chromatography experiments with purified YKL-40 demonstrated specific binding of all three forms to collagen types I, II, and III, thus identifying collagens as potential YKL-40 ligands. Binding to immobilized type I collagen was inhibited by soluble native ligand, but not heat-denatured ligand, confirming a specific interaction. Binding of the chondrocyte-derived species to type I collagen was also demonstrated by surface plasmon resonance analysis, and the dissociation rate constant was calculated (3.42 x 10(-3) to 4.50 x 10(-3) s(-1)). The chondrocyte-derived species was found to prevent collagenolytic cleavage of type I collagen and to stimulate the rate of type I collagen fibril formation in a concentration-dependent manner. By contrast, the cartilage major form had an inhibitory effect on type I collagen fibrillogenesis. Digestion with N-glycosidase F, endoglycosidase H and lectin blotting did not reveal any difference in the carbohydrate component of these two YKL-40 species, indicating that this does not account for the opposing effects on fibril formation rate.	Newcastle Univ, Sch Med, Musculoskeletal Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Imperial Coll London, Fac Med, Kennedy Inst Rheumatol Div, London W6 8LH, England	Newcastle University - UK; Imperial College London; University of Oxford	Bigg, HF (corresponding author), Newcastle Univ, Sch Med, Musculoskeletal Res Grp, 4th Floor,Catherine Cookson Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	Heather.Bigg@ncl.ac.uk						BERGMAN I, 1963, ANAL CHEM, V35, P1961, DOI 10.1021/ac60205a053; BIGG HF, 1994, BBA-PROTEIN STRUCT M, V1208, P157, DOI 10.1016/0167-4838(94)90173-2; Bokma E, 2002, EUR J BIOCHEM, V269, P893, DOI 10.1046/j.0014-2956.2001.02721.x; Boot RG, 2001, J BIOL CHEM, V276, P6770, DOI 10.1074/jbc.M009886200; Buhi WC, 2002, REPRODUCTION, V123, P355, DOI 10.1530/rep.0.1230355; Canty EG, 2002, COMP BIOCHEM PHYS A, V133, P979, DOI 10.1016/S1095-6433(02)00212-X; CAWSTON TE, 1995, BIOCHEM BIOPH RES CO, V215, P377, DOI 10.1006/bbrc.1995.2476; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; Chang NCA, 2001, J BIOL CHEM, V276, P17497, DOI 10.1074/jbc.M010417200; Cintin C, 1999, BRIT J CANCER, V79, P1494, DOI 10.1038/sj.bjc.6690238; Cintin C, 2002, CANCER-AM CANCER SOC, V95, P267, DOI 10.1002/cncr.10644; Connor JR, 2000, OSTEOARTHR CARTILAGE, V8, P87, DOI 10.1053/joca.1999.0276; De Ceuninck F, 2001, BIOCHEM BIOPH RES CO, V285, P926, DOI 10.1006/bbrc.2001.5253; De Ceuninck F, 1998, J CELL BIOCHEM, V69, P414, DOI 10.1002/(SICI)1097-4644(19980615)69:4<414::AID-JCB3>3.0.CO;2-Q; ELLIS AJ, 1994, BIOCHEM BIOPH RES CO, V201, P94, DOI 10.1006/bbrc.1994.1673; Fusetti F, 2003, J BIOL CHEM, V278, P37753, DOI 10.1074/jbc.M303137200; Fusetti F, 2002, J BIOL CHEM, V277, P25537, DOI 10.1074/jbc.M201636200; Gruber J, 2004, ARTHRITIS RHEUM-US, V50, P2539, DOI 10.1002/art.20369; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; Harvey S, 2000, SCAND J RHEUMATOL, V29, P391; Harvey S, 1998, CLIN CHEM, V44, P509; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Hollis T, 2000, PROTEIN SCI, V9, P544, DOI 10.1110/ps.9.3.544; Houston DR, 2003, J BIOL CHEM, V278, P30206, DOI 10.1074/jbc.M303371200; Hu B, 1996, J BIOL CHEM, V271, P19415, DOI 10.1074/jbc.271.32.19415; Johansen JS, 1999, RHEUMATOLOGY, V38, P618, DOI 10.1093/rheumatology/38.7.618; JOHANSEN JS, 1995, EUR J CANCER, V31A, P1437, DOI 10.1016/0959-8049(95)00196-P; Johansen JS, 1996, BRIT J RHEUMATOL, V35, P553; Johansen JS, 1997, SCAND J GASTROENTERO, V32, P582, DOI 10.3109/00365529709025104; JOHANSEN JS, 1993, BRIT J RHEUMATOL, V32, P949; Johansen JS, 2001, ARTHRITIS RHEUM-US, V44, P826; JOHANSEN JS, 1992, J BONE MINER RES, V7, P501; Kadler KE, 1996, BIOCHEM J, V316, P1; Kirkpatrick RB, 1997, EXP CELL RES, V237, P46, DOI 10.1006/excr.1997.3764; Koshy PJT, 1999, ANAL BIOCHEM, V275, P202, DOI 10.1006/abio.1999.4310; Krause SW, 1996, J LEUKOCYTE BIOL, V60, P540, DOI 10.1002/jlb.60.4.540; Kzhyshkowska J, 2006, BLOOD, V107, P3221, DOI 10.1182/blood-2005-07-2843; Ling H, 2004, BIOCHEM J, V380, P651, DOI 10.1042/BJ20040099; Malinda KM, 1999, EXP CELL RES, V250, P168, DOI 10.1006/excr.1999.4511; Meyer MF, 1996, P NATL ACAD SCI USA, V93, P4543, DOI 10.1073/pnas.93.10.4543; MILLIS AJT, 1986, J CELL PHYSIOL, V127, P366, DOI 10.1002/jcp.1041270304; MILLIS AJT, 1985, J BIOL CHEM, V260, P3754; MIYAHARA M, 1982, J BIOL CHEM, V257, P8442; Mohanty AK, 2003, J BIOL CHEM, V278, P14451, DOI 10.1074/jbc.M208967200; Nishikawa KC, 2003, EXP CELL RES, V287, P79, DOI 10.1016/S0014-4827(03)00069-7; NYIRKOS P, 1990, BIOCHEM J, V269, P265, DOI 10.1042/bj2690265; OHARE MC, 1995, BIOCHEM BIOPH RES CO, V216, P329, DOI 10.1006/bbrc.1995.2628; Papanikolau Y, 2001, BIOCHEMISTRY-US, V40, P11338, DOI 10.1021/bi010505h; PERRAKIS A, 1994, STRUCTURE, V2, P1169, DOI 10.1016/S0969-2126(94)00119-7; Recklies AD, 2005, J BIOL CHEM, V280, P41213, DOI 10.1074/jbc.M510146200; Recklies AD, 2002, BIOCHEM J, V365, P119, DOI 10.1042/BJ20020075; REJMAN JJ, 1988, BIOCHEM BIOPH RES CO, V150, P329, DOI 10.1016/0006-291X(88)90524-4; RENKEMA GH, 1995, J BIOL CHEM, V270, P2198, DOI 10.1074/jbc.270.5.2198; Renkema GH, 1998, EUR J BIOCHEM, V251, P504, DOI 10.1046/j.1432-1327.1998.2510504.x; Semino CE, 1996, P NATL ACAD SCI USA, V93, P4548, DOI 10.1073/pnas.93.10.4548; SHACKELTON LM, 1995, J BIOL CHEM, V270, P13076, DOI 10.1074/jbc.270.22.13076; Steiglitz BM, 2002, J BIOL CHEM, V277, P49820, DOI 10.1074/jbc.M209891200; Sun YJ, 2001, J BIOL CHEM, V276, P17507, DOI 10.1074/jbc.M010416200; Tanwar MK, 2002, CANCER RES, V62, P4364; Tews I, 1997, J AM CHEM SOC, V119, P7954, DOI 10.1021/ja970674i; Tsark EC, 2002, J IMMUNOL, V169, P6625, DOI 10.4049/jimmunol.169.11.6625; van Aalten DMF, 2001, P NATL ACAD SCI USA, V98, P8979, DOI 10.1073/pnas.151103798; van Aalten DMF, 2000, P NATL ACAD SCI USA, V97, P5842, DOI 10.1073/pnas.97.11.5842; VANSCHELTINGA ACT, 1994, STRUCTURE, V2, P1181, DOI 10.1016/S0969-2126(94)00120-0; VANSCHELTINGA ACT, 1995, BIOCHEMISTRY-US, V34, P15619, DOI 10.1021/bi00048a003; Varki A, 1996, P NATL ACAD SCI USA, V93, P4523, DOI 10.1073/pnas.93.10.4523; Verheijden GFM, 1997, ARTHRITIS RHEUM, V40, P1115, DOI 10.1002/art.1780400616; Volck B, 1999, SCAND J RHEUMATOL, V28, P171; Volck B, 1998, P ASSOC AM PHYSICIAN, V110, P351; Volck B, 2001, OSTEOARTHR CARTILAGE, V9, P203, DOI 10.1053/joca.2000.0377; Wait R, 2002, ELECTROPHORESIS, V23, P3418, DOI 10.1002/1522-2683(200210)23:19&lt;3418::AID-ELPS3418&gt;3.0.CO;2-7; Wait R, 2001, ELECTROPHORESIS, V22, P3043, DOI 10.1002/1522-2683(200108)22:14<3043::AID-ELPS3043>3.0.CO;2-M; Zhang YN, 1996, J BIOL CHEM, V271, P8015, DOI 10.1074/jbc.271.14.8015	73	105	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21082	21095		10.1074/jbc.M601153200	http://dx.doi.org/10.1074/jbc.M601153200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16704970	hybrid			2022-12-25	WOS:000239187300045
J	Song, XF; Raman, D; Gurevich, EV; Vishnivetskiy, SA; Gurevich, VV				Song, Xiufeng; Raman, Dayanidhi; Gurevich, Eugenia V.; Vishnivetskiy, Sergey A.; Gurevich, Vsevolod V.			Visual and both non-visual arrestins in their "inactive" conformation bind JNK3 and Mdm2 and relocalize them from the nucleus to the cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ARRESTIN; EXPORT SIGNAL; CRYSTAL-STRUCTURE; BETA(2)-ADRENERGIC RECEPTOR; CLATHRIN ADAPTER; S-ANTIGEN; PHOSPHORHODOPSIN; ACTIVATION; MECHANISM	Arrestins bind active phosphorylated G protein-coupled receptors, terminating G protein activation. Receptor-bound non-visual arrestins interact with numerous partners, redirecting signaling to alternative pathways. Arrestins also have nuclear localization and nuclear exclusion signals and shuttle between the nucleus and the cytoplasm. Constitutively shuttling proteins often redistribute their interaction partners between the two compartments. Here we took advantage of the nucleoplasmic shuttling of free arrestins and used a "nuclear exclusion assay" to study their interactions with two proteins involved in "life-and-death" decisions in the cell, the kinase JNK3 and the ubiquitin ligase Mdm2. In human embryonic kidney 293 cells green fluorescent protein (GFP)-JNK3 and GFP-Mdm2 predominantly localize in the nucleus, whereas visual arrestin, arrestin2(Q394L) mutant equipped with the nuclear exclusion signal, and arrestin3 localize exclusively to the cytoplasm. Co-expression of arrestins moves both GFP-JNK3 and GFP-Mdm2 to the cytoplasm. Arrestin mutants "frozen" in the basal conformation are the most efficacious. Thus, arrestins in their basal state interact with JNK3 and Mdm2, suggesting that arrestins are likely "preloaded" with their interaction partners when they bind the receptor. Robust interaction of free arrestins with JNK3 and Mdm2 and their ability to regulate subcellular localization of these proteins may play an important role in the survival of photoreceptors and other neurons, as well as in retinal and neuronal degeneration.	Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University	Gurevich, VV (corresponding author), Vanderbilt Univ, Dept Pharmacol, 2200 Pierce Ave,PRB,Rm 418, Nashville, TN 37232 USA.	vsevolod.gurevich@vanderbilt.edu	Gurevich, Vsevolod/A-3236-2008; Vishnivetskiy, Sergey/AAJ-8661-2020	Gurevich, Vsevolod/0000-0002-3950-5351; 	NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045117] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY011500-10, R01 EY011500, EY11500] Funding Source: Medline; NINDS NIH HHS [NS45117, R01 NS045117, R01 NS045117-03] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Askjaer P, 1998, J BIOL CHEM, V273, P33414, DOI 10.1074/jbc.273.50.33414; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Carter JM, 2005, J MOL BIOL, V351, P865, DOI 10.1016/j.jmb.2005.06.048; Celver J, 2002, J BIOL CHEM, V277, P9043, DOI 10.1074/jbc.M107400200; DONOSO LA, 1990, CURR EYE RES, V9, P343, DOI 10.3109/02713689008999622; Evans SC, 2001, ONCOGENE, V20, P4041, DOI 10.1038/sj.onc.1204533; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Gurevich EV, 2004, J NEUROCHEM, V91, P1404, DOI 10.1111/j.1471-4159.2004.02830.x; Gurevich EV, 2002, NEUROSCIENCE, V109, P421, DOI 10.1016/S0306-4522(01)00511-5; Gurevich VV, 2006, PHARMACOL THERAPEUT, V110, P465, DOI 10.1016/j.pharmthera.2005.09.008; Gurevich VV, 2003, STRUCTURE, V11, P1037, DOI 10.1016/S0969-2126(03)00184-9; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; GUREVICH VV, 2004, TIPS, V25, P59; HAMM HE, 1986, BIOCHEMISTRY-US, V25, P4512, DOI 10.1021/bi00364a010; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hanson SM, 2006, J BIOL CHEM, V281, P9765, DOI 10.1074/jbc.M510738200; Hanson SM, 2006, P NATL ACAD SCI USA, V103, P4900, DOI 10.1073/pnas.0600733103; Hao WS, 2002, NAT GENET, V32, P254, DOI 10.1038/ng984; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Kang JH, 2005, CELL, V123, P833, DOI 10.1016/j.cell.2005.09.011; Kawamura Satoru, 1995, P105; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Miller WE, 2001, J BIOL CHEM, V276, P27770, DOI 10.1074/jbc.M102264200; Nair KS, 2005, NEURON, V46, P555, DOI 10.1016/j.neuron.2005.03.023; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pan L, 2003, J BIOL CHEM, V278, P11623, DOI 10.1074/jbc.M209532200; Scott MGH, 2002, J BIOL CHEM, V277, P37693, DOI 10.1074/jbc.M207552200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; Strissel KJ, 2006, J NEUROSCI, V26, P1146, DOI 10.1523/JNEUROSCI.4289-05.2006; Sutton RB, 2005, J MOL BIOL, V354, P1069, DOI 10.1016/j.jmb.2005.10.023; Vishnivetskiy SA, 2002, J BIOL CHEM, V277, P43961, DOI 10.1074/jbc.M206951200; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Wang P, 2003, J BIOL CHEM, V278, P11648, DOI 10.1074/jbc.M208109200; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2	45	95	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21491	21499		10.1074/jbc.M603659200	http://dx.doi.org/10.1074/jbc.M603659200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16737965	Green Accepted, hybrid			2022-12-25	WOS:000239187300084
J	Cui, GF; Nan, BY; Hu, JC; Wang, YP; Jin, CW; Xia, B				Cui, Gaofeng; Nan, Beiyan; Hu, Jicheng; Wang, Yiping; Jin, Changwen; Xia, Bin			Identification and solution structures of a single domain biotin/lipoyl attachment protein from Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE MULTIENZYME COMPLEX; ACETYL-COA CARBOXYLASE; ESCHERICHIA-COLI; POSTTRANSLATIONAL MODIFICATION; LIPOYL DOMAIN; MULTIFUNCTIONAL ENZYMES; EXCEPTIONAL SPECIFICITY; 3-DIMENSIONAL STRUCTURE; CARRIER PROTEIN; SWINGING ARMS	Protein biotinylation and lipoylation are post-translational modifications, in which biotin or lipoic acid is covalently attached to specific proteins containing biotin/lipoyl attachment domains. All the currently reported natural proteins containing biotin/lipoyl attachment domains are multidomain proteins and can only be modified by either biotin or lipoic acid in vivo. We have identified a single domain protein with 73 amino acid residues from Bacillus subtilis strain 168, and it can be both biotinylated and lipoylated in Escherichia coli. The protein is therefore named as biotin/lipoyl attachment protein (BLAP). This is the first report that a natural single domain protein exists as both a biotin and lipoic acid receptor. The solution structure of apo-BLAP showed that it adopts a typical fold of biotin/lipoyl attachment domain. The structure of biotinylated BLAP revealed that the biotin moiety is covalently attached to the side chain of Lys35, and the bicyclic ring of biotin is folded back and immobilized on the protein surface. The biotin moiety immobilization is mainly due to an interaction between the biotin ureido ring and the indole ring of Trp12. NMR study also indicated that the lipoyl group of the lipoylated BLAP is also immobilized on the protein surface in a similar fashion as the biotin moiety in the biotinylated protein.	Peking Univ, Beijing Nucl Magnet Resonance Ctr, Beijing 100871, Peoples R China; Peking Univ, Coll Chem & Mol Engn, Beijing 100871, Peoples R China; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China	Peking University; Peking University; Peking University	Xia, B (corresponding author), Peking Univ, Beijing Nucl Magnet Resonance Ctr, Beijing 100871, Peoples R China.	binxia@pku.edu.cn	Cui, Gaofeng/A-1107-2013	Cui, Gaofeng/0000-0001-5267-9033; Wang, Yiping/0000-0002-1995-8521				Alban C, 2000, ANNU REV PLANT PHYS, V51, P17, DOI 10.1146/annurev.arplant.51.1.17; Athappilly FK, 1995, STRUCTURE, V3, P1407, DOI 10.1016/S0969-2126(01)00277-5; Berg A, 1996, J MOL BIOL, V261, P432, DOI 10.1006/jmbi.1996.0474; Breeze AL, 2000, PROG NUCL MAG RES SP, V36, P323, DOI 10.1016/S0079-6565(00)00020-0; Chang CF, 2002, J BIOL CHEM, V277, P15865, DOI 10.1074/jbc.M110952200; Chapman-Smith A, 1999, TRENDS BIOCHEM SCI, V24, P359, DOI 10.1016/S0968-0004(99)01438-3; Chapman-Smith A, 1999, J BIOL CHEM, V274, P1449, DOI 10.1074/jbc.274.3.1449; Choi-Rhee E, 2003, J BIOL CHEM, V278, P30806, DOI 10.1074/jbc.M302507200; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cronan JE, 2002, PROG LIPID RES, V41, P407, DOI 10.1016/S0163-7827(02)00007-3; DARDEL F, 1993, J MOL BIOL, V229, P1037, DOI 10.1006/jmbi.1993.1103; de Kok A, 1998, BBA-PROTEIN STRUCT M, V1385, P353, DOI 10.1016/S0167-4838(98)00079-X; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Duggan BM, 2001, J BIOMOL NMR, V19, P321, DOI 10.1023/A:1011227824104; Fujiwara K, 1996, J BIOL CHEM, V271, P12932, DOI 10.1074/jbc.271.22.12932; GREEN JDF, 1995, J MOL BIOL, V248, P328, DOI 10.1006/jmbi.1995.0225; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Iwahara J, 2001, J BIOMOL NMR, V19, P231, DOI 10.1023/A:1011296112710; Jin CW, 1999, J MOL BIOL, V292, P641, DOI 10.1006/jmbi.1999.3106; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Jones DD, 2000, BIOCHEMISTRY-US, V39, P8448, DOI 10.1021/bi992978i; Jones DD, 2000, J MOL BIOL, V295, P289, DOI 10.1006/jmbi.1999.3335; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Macherel D, 1996, EUR J BIOCHEM, V236, P27, DOI 10.1111/j.1432-1033.1996.00027.x; Maiti R, 2004, NUCLEIC ACIDS RES, V32, pW590, DOI 10.1093/nar/gkh477; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MARKLEY JL, 1971, J CHEM PHYS, V55, P3604, DOI 10.1063/1.1676626; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; Polyak SW, 2001, J BIOL CHEM, V276, P3037, DOI 10.1074/jbc.M003968200; Reche P, 1998, BIOCHEM J, V329, P589, DOI 10.1042/bj3290589; Reche P, 1999, EMBO J, V18, P2673, DOI 10.1093/emboj/18.10.2673; Reddy DV, 1997, BIOCHEMISTRY-US, V36, P14676, DOI 10.1021/bi971674y; Reddy DV, 2000, BIOCHEMISTRY-US, V39, P2509, DOI 10.1021/bi9925367; Roberts EL, 1999, BIOCHEMISTRY-US, V38, P5045, DOI 10.1021/bi982466o; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; WALLIS NG, 1994, J MOL BIOL, V236, P209, DOI 10.1006/jmbi.1994.1130; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Yao X, 1997, BIOCHEMISTRY-US, V36, P15089, DOI 10.1021/bi971485f	42	10	12	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20598	20607		10.1074/jbc.M602660200	http://dx.doi.org/10.1074/jbc.M602660200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16699181	hybrid			2022-12-25	WOS:000239038200081
J	Flajollet, S; Lefebvre, B; Rachez, C; Lefebvre, P				Flajollet, Sebastien; Lefebvre, Bruno; Rachez, Christophe; Lefebvre, Philippe			Distinct roles of the steroid receptor coactivator 1 and of MED1 in retinoid-induced transcription and cellular differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; ACID RECEPTOR; THYROID-HORMONE; HISTONE ACETYLTRANSFERASE; MAMMALIAN MEDIATOR; NEURONAL DIFFERENTIATION; TRAP220 COMPONENT; NUCLEAR RECEPTORS; X-RECEPTOR; ALL-TRANS	Retinoic acid receptors (RARs) are the molecular relays of retinoid action on transcription, cellular differentiation and apoptosis. Transcriptional activation of retinoid-regulated promoters requires the dismissal of corepressors and the recruitment of coactivators to promoter-bound RAR. RARs recruit in vitro a plethora of coactivators whose actual contribution to retinoid-induced transcription is poorly characterized in vivo. Embryonal carcinoma P19 cells, which are highly sensitive to retinoids, were depleted from archetypical coactivators by RNAi. SRC1-deficient P19 cells showed severely compromised retinoid-induced responses, in agreement with the supposed role of SRC1 as a RAR coactivator. Unexpectedly, Med1/TRAP220/DRIP205-depleted cells exhibited an exacerbated response to retinoids, both in terms transcriptional responses and of cellular differentiation. Med1 depletion affected TFIIH and cdk9 detection at the prototypical retinoid-regulated RAR beta 2 promoter, and favored a higher RNA polymerase II detection in transcribed regions of the RAR beta 2 gene. Furthermore, the nature of the ligand impacted strongly on the ability of RARs to interact with a given coactivator and to activate transcription in intact cells. Thus RAR accomplishes transcriptional activation as a function of the ligand structure, by recruiting regulatory complexes which control distinct molecular events at retinoid-regulated promoters.	Fac Med Henri Warembourg, INSERM, U459, F-59045 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Lefebvre, P (corresponding author), Fac Med Lille, 1 Pl Verdun, F-59045 Lille, France.	p.lefebvre@lille.inserm.fr	, lefebvre/T-3005-2018; Rachez, Christophe/GLR-0102-2022; Lefebvre, Philippe/F-2685-2010	, lefebvre/0000-0003-4953-3185; Lefebvre, Philippe/0000-0002-9366-5129; Rachez, Christophe/0000-0001-8502-4738				Akoulitchev S, 2000, NATURE, V407, P102, DOI 10.1038/35024111; BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; Balciunas D, 1999, P NATL ACAD SCI USA, V96, P376, DOI 10.1073/pnas.96.2.376; Benkoussa M, 2002, MOL CELL BIOL, V22, P4522, DOI 10.1128/MCB.22.13.4522-4534.2002; Bourbon HM, 2004, MOL CELL, V14, P553, DOI 10.1016/j.molcel.2004.05.011; Brand Celine, 2002, BMC Pharmacol, V2, P13, DOI 10.1186/1471-2210-2-13; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Delva L, 1999, MOL CELL BIOL, V19, P7158; Depoix C, 2001, J BIOL CHEM, V276, P9452, DOI 10.1074/jbc.M008004200; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783; FUKASAWA H, 1993, BIOL PHARM BULL, V16, P343; Germain P, 2002, NATURE, V415, P187, DOI 10.1038/415187a; Hong SH, 1999, J BIOL CHEM, V274, P2885, DOI 10.1074/jbc.274.5.2885; Horn V, 1996, FASEB J, V10, P1071, DOI 10.1096/fasebj.10.9.8801169; Huang ZQ, 2003, EMBO J, V22, P2146, DOI 10.1093/emboj/cdg219; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Ito M, 2002, EMBO J, V21, P3464, DOI 10.1093/emboj/cdf348; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; KAGECHIKA H, 1989, J MED CHEM, V32, P1098, DOI 10.1021/jm00125a027; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KRUYT FAE, 1992, DIFFERENTIATION, V49, P27, DOI 10.1111/j.1432-0436.1992.tb00766.x; Landles C, 2003, MOL ENDOCRINOL, V17, P2418, DOI 10.1210/me.2003-0097; Lefebvre B, 2002, EMBO REP, V3, P335, DOI 10.1093/embo-reports/kvf066; Lefebvre B, 2002, MOL CELL BIOL, V22, P1446, DOI 10.1128/MCB.22.5.1446-1459.2002; Lefebvre B, 1998, BIOCHEMISTRY-US, V37, P9240, DOI 10.1021/bi9804840; Lefebvre P, 2005, VITAM HORM, V70, P199, DOI 10.1016/S0083-6729(05)70007-8; Li XT, 2003, MOL CELL BIOL, V23, P3763, DOI 10.1128/MCB.23.11.3763-3773.2003; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Malik S, 2005, TRENDS BIOCHEM SCI, V30, P256, DOI 10.1016/j.tibs.2005.03.009; Mark M, 2004, P NATL ACAD SCI USA, V101, P4453, DOI 10.1073/pnas.0400234101; Martin PJ, 2005, NUCLEIC ACIDS RES, V33, P4311, DOI 10.1093/nar/gki745; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Mouchon A, 1999, MOL CELL BIOL, V19, P3073; MUMMERY CL, 1987, DEV BIOL, V121, P10, DOI 10.1016/0012-1606(87)90133-3; Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697; Pavri R, 2005, MOL CELL, V18, P83, DOI 10.1016/j.molcel.2005.02.034; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; REYNOLDS JN, 1994, NEUROSCI LETT, V165, P129, DOI 10.1016/0304-3940(94)90726-9; Sato S, 2004, MOL CELL, V14, P685, DOI 10.1016/j.molcel.2004.05.006; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; SLACK RS, 1995, J CELL BIOL, V129, P779, DOI 10.1083/jcb.129.3.779; Soutoglou E, 2001, EMBO J, V20, P1984, DOI 10.1093/emboj/20.8.1984; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STAINES WA, 1994, NEUROSCIENCE, V58, P735, DOI 10.1016/0306-4522(94)90451-0; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; Trievel RC, 2000, ANAL BIOCHEM, V287, P319, DOI 10.1006/abio.2000.4855; Weiss RE, 1999, EMBO J, V18, P1900, DOI 10.1093/emboj/18.7.1900; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P14584; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhang JC, 1999, MOL ENDOCRINOL, V13, P1130, DOI 10.1210/me.13.7.1130	59	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20338	20348		10.1074/jbc.M603023200	http://dx.doi.org/10.1074/jbc.M603023200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16723356	hybrid			2022-12-25	WOS:000239038200058
J	Ito, K; Nakanishi, M; Lee, WC; Sasaki, H; Zenno, S; Saigo, K; Kitade, Y; Tanokura, M				Ito, Kosuke; Nakanishi, Masayuki; Lee, Woo-Cheol; Sasaki, Hiroshi; Zenno, Shuhei; Saigo, Kaoru; Kitade, Yukio; Tanokura, Masaru			Three-dimensional structure of AzoR from Escherichia coli - An oxidereductase conserved in microorganisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAD(P)H-QUINONE REDUCTASE; CRYSTAL-STRUCTURE; SUBSTRATE-BINDING; GENOME SEQUENCE; AZOREDUCTASE; NITROREDUCTASE; DEGRADATION; PROGRAM; ENZYME; NAD(P)H-FMN	The crystal structure of AzoR (azoreductase) has been determined in complex with FMN for two different crystal forms at 1.8 and 2.2 angstrom resolution. AzoR is an oxidoreductase isolated from Escherichia coli as a protein responsible for the degradation of azo compounds. This enzyme is an FMN-dependent NADH-azoreductase and catalyzes the reductive cleavage of azo groups by a ping-pong mechanism. The structure suggests that AzoR acts in a homodimeric state forming the two identical catalytic sites to which both monomers contribute. The structure revealed that each monomer of AzoR has a flavodoxin-like structure, without the explicit overall amino acid sequence homology. Superposition of the structures from the two different crystal forms revealed the conformational change and suggested a mechanism for accommodating substrates of different size. Furthermore, comparison of the active site structure with that of NQO1 complexed with substrates provides clues to the possible substrate-binding mechanism of AzoR.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan; Gifu Univ, Fac Engn, Dept Biomol Sci, Gifu 5011193, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; Gifu University; University of Tokyo	Tanokura, M (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	amtanok@mail.ecc.u-tokyo.ac.jp		Tanokura, Masaru/0000-0001-5072-2480				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAYNEY RM, 1987, J BIOL CHEM, V262, P572; BENSON AM, 1980, P NATL ACAD SCI-BIOL, V77, P5216, DOI 10.1073/pnas.77.9.5216; Cavelier G, 2001, PROTEINS, V43, P420, DOI 10.1002/prot.1055.abs; Chain PSG, 2004, P NATL ACAD SCI USA, V101, P13826, DOI 10.1073/pnas.0404012101; Chen CY, 2003, GENOME RES, V13, P2577, DOI 10.1101/gr.1295503; CHESIS PL, 1984, P NATL ACAD SCI-BIOL, V81, P1696, DOI 10.1073/pnas.81.6.1696; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; Duchaud E, 2003, NAT BIOTECHNOL, V21, P1307, DOI 10.1038/nbt886; Faig M, 2000, P NATL ACAD SCI USA, V97, P3177, DOI 10.1073/pnas.050585797; Foster CE, 1999, BIOCHEMISTRY-US, V38, P9881, DOI 10.1021/bi990799v; Fraaije MW, 2000, TRENDS BIOCHEM SCI, V25, P126, DOI 10.1016/S0968-0004(99)01533-9; Frazao C, 2000, NAT STRUCT BIOL, V7, P1041; Ghosh Dilip K., 1993, Indian Journal of Experimental Biology, V31, P951; GHOSH DK, 1992, FEMS MICROBIOL LETT, V98, P229, DOI 10.1016/0378-1097(92)90161-G; Harrison A, 2005, J BACTERIOL, V187, P4627, DOI 10.1128/JB.187.13.4627-4636.2005; Haynes CA, 2002, J BIOL CHEM, V277, P11513, DOI 10.1074/jbc.M111334200; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Holme I., 1984, ECOLOGICAL ASPECTS C, P111; Ito K, 2005, ACTA CRYSTALLOGR F, V61, P399, DOI 10.1107/S1744309105007918; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; Koike H, 1998, J MOL BIOL, V280, P259, DOI 10.1006/jmbi.1998.1871; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEVINE WG, 1991, DRUG METAB REV, V23, P253, DOI 10.3109/03602539109029761; LI RB, 1995, P NATL ACAD SCI USA, V92, P8846, DOI 10.1073/pnas.92.19.8846; Liger D, 2004, J BIOL CHEM, V279, P34890, DOI 10.1074/jbc.M405404200; Lovering AL, 2001, J MOL BIOL, V309, P203, DOI 10.1006/jmbi.2001.4653; Maier J, 2004, APPL ENVIRON MICROB, V70, P837, DOI 10.1128/AEM.70.2.837-844.2004; McClelland M, 2004, NAT GENET, V36, P1268, DOI 10.1038/ng1470; McGaughey GB, 1998, J BIOL CHEM, V273, P15458, DOI 10.1074/jbc.273.25.15458; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Meyer U., 1981, MICROBIAL DEGRADATIO, P371; Moutaouakkil A, 2003, ARCH BIOCHEM BIOPHYS, V413, P139, DOI 10.1016/S0003-9861(03)00096-1; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakanishi M, 2001, J BIOL CHEM, V276, P46394, DOI 10.1074/jbc.M104483200; Nelson KE, 2002, ENVIRON MICROBIOL, V4, P799, DOI 10.1046/j.1462-2920.2002.00366.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RAFII F, 1993, APPL ENVIRON MICROB, V59, P1731, DOI 10.1128/AEM.59.6.1731-1734.1993; Ramalho PA, 2005, APPL ENVIRON MICROB, V71, P3882, DOI 10.1128/AEM.71.7.3882-3888.2005; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Robinson T, 2001, BIORESOURCE TECHNOL, V77, P247, DOI 10.1016/S0960-8524(00)00080-8; Smith MT, 1999, P NATL ACAD SCI USA, V96, P7624, DOI 10.1073/pnas.96.14.7624; Stolz A, 2001, APPL MICROBIOL BIOT, V56, P69, DOI 10.1007/s002530100686; Suzuki Y, 2001, J BIOL CHEM, V276, P9059, DOI 10.1074/jbc.M008083200; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; UNDEN G, 1997, BIOCHIM BIOPHYS ACTA, V1320, P127; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Zhao QJ, 1997, P NATL ACAD SCI USA, V94, P1669, DOI 10.1073/pnas.94.5.1669; Ziegler GA, 1999, J MOL BIOL, V289, P981, DOI 10.1006/jmbi.1999.2807; ZIMMERMANN T, 1984, ARCH MICROBIOL, V138, P37, DOI 10.1007/BF00425404; ZIMMERMANN T, 1982, EUR J BIOCHEM, V129, P197, DOI 10.1111/j.1432-1033.1982.tb07040.x	57	63	68	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20567	20576		10.1074/jbc.M513345200	http://dx.doi.org/10.1074/jbc.M513345200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16684776	hybrid			2022-12-25	WOS:000239038200078
J	Akasaka-Manya, K; Manya, H; Nakajima, A; Kawakita, M; Endo, T				Akasaka-Manya, Keiko; Manya, Hiroshi; Nakajima, Ai; Kawakita, Masao; Endo, Tamao			Physical and functional association of human protein O-mannosyltransferases 1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WALKER-WARBURG-SYNDROME; CONGENITAL MUSCULAR-DYSTROPHIES; O-MANNOSYLTRANSFERASE ACTIVITY; SACCHAROMYCES-CEREVISIAE; ALPHA-DYSTROGLYCAN; MENTAL-RETARDATION; MANNOSYL GLYCANS; HEPARAN-SULFATE; POMT1 GENE; GLYCOSYLATION	A defect of protein O-mannosylation causes congenital muscular dystrophy with brain malformation and structural eye abnormalities, so-called Walker-Warburg syndrome. Protein O-mannosylation is catalyzed by protein O-mannosyltransferase 1 (POMT1) and its homologue, POMT2. Coexpression of POMT1 and POMT2 is required to show O-mannosylation activity. Here we have shown that POMT1 forms a complex with POMT2 and the complex possesses protein O-mannosyltransferase activity. Results indicate that POMT1 and POMT2 associate physically and functionally in vivo. Recently, three mutations were reported in the POMT1 gene of patients who showed milder phenotypes than typical Walker-Warburg syndrome. We coexpressed these mutant POMT1s with POMT2 and found that none of them had any activity. However, all POMT1 mutants, including previously identified POMT1 mutants, coprecipitated with POMT2. These results indicate that the mutant POMT1s could form heterocomplexes with POMT2 but that such complexes are insufficient for enzymatic activity.	Tokyo Metropolitan Inst Gerontol, Glycobiol Res Grp, Fdn Res Aging & Promot Human Welf, Itabashi Ku, Tokyo 1730015, Japan; Kogakuin Univ, Dept Appl Chem, Tokyo 1638677, Japan	Tokyo Metropolitan Institute of Gerontology; Kogakuin University	Endo, T (corresponding author), Tokyo Metropolitan Inst Gerontol, Glycobiol Res Grp, Fdn Res Aging & Promot Human Welf, Itabashi Ku, 35-2 Sakaecho, Tokyo 1730015, Japan.	endo@tmig.or.jp		Manya, Hiroshi/0000-0003-1573-9177				Akasaka-Manya K, 2004, BIOCHEM BIOPH RES CO, V325, P75, DOI 10.1016/j.bbrc.2004.10.001; Balci B, 2005, NEUROMUSCULAR DISORD, V15, P271, DOI 10.1016/j.nmd.2005.01.013; Barresi R, 2004, NAT MED, V10, P696, DOI 10.1038/nm1059; Beltran-Valero de Bernabe D, 2002, AM J HUM GENET, V71, P1033, DOI 10.1086/342975; Chiba A, 1997, J BIOL CHEM, V272, P2156; Currier SC, 2005, AM J MED GENET A, V133A, P53, DOI 10.1002/ajmg.a.30487; Dincer P, 2003, NEUROMUSCULAR DISORD, V13, P771, DOI 10.1016/S0960-8966(03)00161-5; Endo T, 2004, GLYCOCONJUGATE J, V21, P3, DOI 10.1023/B:GLYC.0000043740.26062.2c; GENTZSCH M, 1995, GLYCOBIOLOGY, V5, P77, DOI 10.1093/glycob/5.1.77; Gentzsch M, 1995, FEBS LETT, V377, P128, DOI 10.1016/0014-5793(95)01324-5; Girrbach V, 2003, J BIOL CHEM, V278, P12554, DOI 10.1074/jbc.M212582200; Girrbach V, 2000, J BIOL CHEM, V275, P19288, DOI 10.1074/jbc.M001771200; Haltiwanger RS, 2004, ANNU REV BIOCHEM, V73, P491, DOI 10.1146/annurev.biochem.73.011303.074043; Ichimiya T, 2004, J BIOL CHEM, V279, P42638, DOI 10.1074/jbc.M404900200; IMMERVOLL T, 1995, YEAST, V11, P1345, DOI 10.1002/yea.320111403; Ju TZ, 2005, NATURE, V437, P1252, DOI 10.1038/4371252a; Ju TZ, 2002, P NATL ACAD SCI USA, V99, P16613, DOI 10.1073/pnas.262438199; Jurado LAP, 1999, GENOMICS, V58, P171, DOI 10.1006/geno.1999.5819; Kim BT, 2003, J BIOL CHEM, V278, P41618, DOI 10.1074/jbc.M304831200; Kim DS, 2004, NEUROLOGY, V62, P1009, DOI 10.1212/01.WNL.0000115386.28769.65; Kitagawa H, 2003, J BIOL CHEM, V278, P23666, DOI 10.1074/jbc.M302493200; LUSSIER M, 1995, J BIOL CHEM, V270, P2770, DOI 10.1074/jbc.270.6.2770; Manya H, 2004, P NATL ACAD SCI USA, V101, P500, DOI 10.1073/pnas.0307228101; Manya H, 2003, BIOCHEM BIOPH RES CO, V306, P93, DOI 10.1016/S0006-291X(03)00924-0; MartinBlanco E, 1996, P NATL ACAD SCI USA, V93, P6048, DOI 10.1073/pnas.93.12.6048; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; Michele DE, 2003, J BIOL CHEM, V278, P15457, DOI 10.1074/jbc.R200031200; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; Strahl-Bolsinger S, 1999, J BIOL CHEM, V274, P9068, DOI 10.1074/jbc.274.13.9068; Strahl-Bolsinger S, 1999, BBA-GEN SUBJECTS, V1426, P297, DOI 10.1016/S0304-4165(98)00131-7; STRAHLBOLSINGER S, 1993, P NATL ACAD SCI USA, V90, P8164, DOI 10.1073/pnas.90.17.8164; STRAHLBOLSINGER S, 1991, EUR J BIOCHEM, V196, P185, DOI 10.1111/j.1432-1033.1991.tb15802.x; Van Reeuwijk J, 2006, HUM MUTAT, V27, P453, DOI 10.1002/humu.20313; van Reeuwijk J, 2005, J MED GENET, V42, P907, DOI 10.1136/jmg.2005.031963; VanderVen BC, 2005, SCIENCE, V309, P941, DOI 10.1126/science.1114347; Villanova M, 2000, NEUROMUSCULAR DISORD, V10, P541, DOI 10.1016/S0960-8966(00)00139-5; Willer T, 2003, CURR OPIN STRUC BIOL, V13, P621, DOI 10.1016/j.sbi.2003.09.003; Willer T, 2002, GLYCOBIOLOGY, V12, P771, DOI 10.1093/glycob/cwf086; Willer T, 2004, P NATL ACAD SCI USA, V101, P14126, DOI 10.1073/pnas.0405899101; Yoshida A, 2001, DEV CELL, V1, P717, DOI 10.1016/S1534-5807(01)00070-3	40	75	75	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19339	19345		10.1074/jbc.M601091200	http://dx.doi.org/10.1074/jbc.M601091200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16698797	hybrid			2022-12-25	WOS:000238847000049
J	Couture, JF; Hauk, G; Thompson, MJ; Blackburn, GM; Trievel, RC				Couture, Jean-Francois; Hauk, Glenn; Thompson, Mark J.; Blackburn, G. Michael; Trievel, Raymond C.			Catalytic roles for carbon-oxygen hydrogen bonding in SET domain lysine methyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTER-DOT-O; PROTEIN-LIGAND COMPLEXES; STRUCTURAL BASIS; PRODUCT SPECIFICITY; HISTONE METHYLATION; FUNCTIONAL-ANALYSIS; WEAK-INTERACTIONS; CRYSTAL-STRUCTURE; ALPHA-HELICES; MECHANISM	SET domain enzymes represent a distinct family of protein lysine methyltransferases in eukaryotes. Recent studies have yielded significant insights into the structural basis of substrate recognition and the product specificities of these enzymes. However, the mechanism by which SET domain methyltransferases catalyze the transfer of the methyl group from S-adeno-syl-L-methionine to the lysine epsilon-amine has remained unresolved. To elucidate this mechanism, we have determined the structures of the plant SET domain enzyme, pea ribulose-1,5 bisphosphate carboxylase/oxygenase large subunit methyltransferase, bound to S-adenosyl-L-methionine, and its non-reactive analogs Aza-adenosyl-L-methionine and Sinefungin, and characterized the binding of these ligands to a homolog of the enzyme. The structural and biochemical data collectively reveal that S-adenosyl-L-methionine is selectively recognized through carbon-oxygen hydrogen bonds between the cofactor's methyl group and an array of structurally conserved oxygens that comprise the methyl transfer pore in the active site. Furthermore, the structure of the enzyme co-crystallized with the product epsilon-N-trimethyllysine reveals a trigonal array of carbon-oxygen interactions between the epsilon-ammonium methyl groups and the oxygens in the pore. Taken together, these results establish a central role for carbon-oxygen hydrogen bonding in aligning the cofactor's methyl group for transfer to the lysine epsilon-amine and in coordinating the methyl groups after transfer to facilitate multiple rounds of lysine methylation.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Sheffield, Dept Chem, Sheffield S3 7HF, S Yorkshire, England	University of Michigan System; University of Michigan; University of Sheffield	Trievel, RC (corresponding author), Univ Michigan, Dept Biol Chem, 1301 Catherine Rd,4412 Med Sci Bldg 1, Ann Arbor, MI 48109 USA.	rtrievel@umich.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073839] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM073839] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babu MM, 2002, J MOL BIOL, V322, P871, DOI 10.1016/S0022-2836(02)00715-5; Bach RD, 2002, J PHYS CHEM B, V106, P4325, DOI 10.1021/jp020029k; Bella J, 1996, J MOL BIOL, V264, P734, DOI 10.1006/jmbi.1996.0673; Bond CS, 1999, STRUCTURE, V7, P81, DOI 10.1016/S0969-2126(99)80011-2; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chakrabarti P, 1998, J MOL BIOL, V284, P867, DOI 10.1006/jmbi.1998.2199; Chamberlain AK, 2002, J MOL BIOL, V322, P497, DOI 10.1016/S0022-2836(02)00785-4; CHIRPICH TP, 1970, J BIOL CHEM, V245, P1778; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Couture JF, 2006, NAT STRUCT MOL BIOL, V13, P140, DOI 10.1038/nsmb1045; Couture JF, 2005, GENE DEV, V19, P1455, DOI 10.1101/gad.1318405; DEREWENDA ZS, 1995, J MOL BIOL, V252, P248, DOI 10.1006/jmbi.1995.0492; DEREWENDA ZS, 1994, J MOL BIOL, V241, P83, DOI 10.1006/jmbi.1994.1475; Dillon SC, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-227; Engh RA, 1996, STRUCTURE, V4, P1353, DOI 10.1016/S0969-2126(96)00142-6; Fabiola GF, 1997, ACTA CRYSTALLOGR D, V53, P316, DOI 10.1107/S0907444997000383; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HOUTZ RL, 1991, PLANT PHYSIOL, V97, P913, DOI 10.1104/pp.97.3.913; Hu P, 2006, J AM CHEM SOC, V128, P1272, DOI 10.1021/ja056153+; Jacobs SA, 2002, NAT STRUCT BIOL, V9, P833, DOI 10.1038/nsb861; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jiang L, 2002, J BIOL CHEM, V277, P37732, DOI 10.1074/jbc.M204514200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Klaholz BP, 2002, STRUCTURE, V10, P1197, DOI 10.1016/S0969-2126(02)00828-6; Kwon T, 2003, EMBO J, V22, P292, DOI 10.1093/emboj/cdg025; Mandel-Gutfreund Y, 1998, J MOL BIOL, V277, P1129, DOI 10.1006/jmbi.1998.1660; Manikandan K, 2004, PROTEINS, V56, P768, DOI 10.1002/prot.20152; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; Meyer P, 2000, EMBO J, V19, P3520, DOI 10.1093/emboj/19.14.3520; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; PARSONS ID, 1995, NUCLEIC ACIDS RES, V23, P211, DOI 10.1093/nar/23.2.211; Pierce AC, 2005, J MED CHEM, V48, P1278, DOI 10.1021/jm0492249; Pierce AC, 2002, PROTEINS, V49, P567, DOI 10.1002/prot.10259; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Sarkhel S, 2004, PROTEINS, V54, P247, DOI 10.1002/prot.10567; Scheiner S, 2001, J BIOL CHEM, V276, P9832, DOI 10.1074/jbc.M010770200; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Senes A, 2001, P NATL ACAD SCI USA, V98, P9056, DOI 10.1073/pnas.161280798; Thompson MJ, 1999, J ORG CHEM, V64, P7467, DOI 10.1021/jo9907742; Treger M, 2001, J MOL RECOGNIT, V14, P199, DOI 10.1002/jmr.534; Trievel RC, 2003, NAT STRUCT BIOL, V10, P545, DOI 10.1038/nsb946; Trievel RC, 2002, CELL, V111, P91, DOI 10.1016/S0092-8674(02)01000-0; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Vargas R, 2000, J AM CHEM SOC, V122, P4750, DOI 10.1021/ja993600a; Wilson JR, 2002, CELL, V111, P105, DOI 10.1016/S0092-8674(02)00964-9; Xiao B, 2003, NATURE, V421, P652, DOI 10.1038/nature01378; Xiao B, 2005, GENE DEV, V19, P1444, DOI 10.1101/gad.1315905; Xiao B, 2003, CURR OPIN STRUC BIOL, V13, P699, DOI 10.1016/j.sbi.2003.10.003; Yeates TO, 2002, CELL, V111, P5, DOI 10.1016/S0092-8674(02)01010-3; Zhang X, 2002, CELL, V111, P117, DOI 10.1016/S0092-8674(02)00999-6; Zhang X, 2003, MOL CELL, V12, P177, DOI 10.1016/S1097-2765(03)00224-7	52	67	68	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19280	19287		10.1074/jbc.M602257200	http://dx.doi.org/10.1074/jbc.M602257200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16682405	hybrid			2022-12-25	WOS:000238847000042
J	Fosbrink, M; Niculescu, F; Rus, V; Shin, ML; Rus, H				Fosbrink, Matthew; Niculescu, Florin; Rus, Violeta; Shin, Moon L.; Rus, Horea			C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL COMPLEMENT COMPLEX; SMOOTH-MUSCLE-CELLS; PROTEIN-KINASE-B; MEMBRANE ATTACK COMPLEX; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEASOMAL DEGRADATION; NUCLEAR TRANSLOCATION; PHOSPHORYLATION SITES; ATHEROSCLEROTIC WALL	Migration and proliferation of aortic endothelial cells (AEC) are critical processes involved in angiogenesis, atherosclerosis, and postangioplasty restenosis. Activation of complement and assembly of the C5b-9 complement complex have been implicated in the pre-lesional stage of atherogenesis and progression of the atherosclerotic lesion. We have shown that C5b-9 induces proliferation and activates phosphatidylinositol 3-kinase (PI3K), but it is unknown whether this can lead to activation of Akt in AEC, a major downstream target of PI3K, or if C5b-9 can induce the migration of AEC, a critical step in angiogenesis. In this study, we show that C5b-9 induces AEC proliferation and migration and also activates the PI3K/Akt pathway. C5b-9 activates Akt as shown by in vitro kinase assay and phosphorylation of Ser-473. C5b-9-induced cell cycle activation was inhibited by pretreatment with LY294002 (PI3K inhibitor), SH-5 (Akt inhibitor), or transfection with Akt siRNA. These data suggests that the PI3K/Akt pathway is required for C5b-9-induced cell cycle activation. FOXO1, a member of forkhead transcription factor family, was phosphorylated at Ser-256 and inactivated after C5b-9 stimulation as shown by a decrease in DNA binding and cytoplasmic relocalization. Cytoplasmic relocalization was significantly reduced after pretreatment with LY294002, SH-5, or transfection with Akt siRNA. Silencing FOXO1 expression using siRNA stimulated AEC proliferation and regulated angiogenic factor release. Our data indicate that C5b-9 regulation of the cell cycle activation in AEC through Akt pathway is dependent on inactivation of FOXO1.	Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Div Rheumatol & Clin Immunol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Div Pathol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Rus, H (corresponding author), Univ Maryland, Sch Med, Dept Neurol, 655 W Baltimore St,BRB 12-014, Baltimore, MD 21201 USA.	hrus@umaryland.edu	Rus, Horea/AAF-2583-2020		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007263] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042011] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 07263] Funding Source: Medline; NINDS NIH HHS [R0-1 NS42011] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abid R, 2004, ARTERIOSCL THROM VAS, V24, P294, DOI 10.1161/01.ATV.0000110502.10593.06; ALPERNELRAN H, 1989, J NEUROSURG, V70, P942, DOI 10.3171/jns.1989.70.6.0942; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Aoki M, 2004, P NATL ACAD SCI USA, V101, P13613, DOI 10.1073/pnas.0405454101; Badea T, 2002, J BIOL CHEM, V277, P502, DOI 10.1074/jbc.M109354200; Badea TC, 1998, J BIOL CHEM, V273, P26977, DOI 10.1074/jbc.273.41.26977; BENZAQUEN LR, 1994, J EXP MED, V179, P985, DOI 10.1084/jem.179.3.985; BHAKDI S, 1995, J EXP MED, V182, P1959, DOI 10.1084/jem.182.6.1959; Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292; Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491; Brasen JH, 2001, ARTERIOSCL THROM VAS, V21, P1720, DOI 10.1161/hq1101.098230; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; CARNEY DF, 1990, J IMMUNOL, V145, P623; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Fosbrink M, 2005, IMMUNOL RES, V31, P37, DOI 10.1385/IR:31:1:37; Furuyama T, 2004, J BIOL CHEM, V279, P34741, DOI 10.1074/jbc.M314214200; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Hila S, 2001, GLIA, V36, P58, DOI 10.1002/glia.1095; Hunt BJ, 2000, LUPUS, V9, P189, DOI 10.1191/096120300678828244; Kaestner KH, 2000, GENE DEV, V14, P142; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Khurana R, 2005, CIRCULATION, V112, P1813, DOI 10.1161/CIRCULATIONAHA.105.535294; Kilgore KS, 1997, AM J PATHOL, V150, P2019; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Kops GJPL, 2000, J ANAT, V197, P571, DOI 10.1046/j.1469-7580.2000.19740571.x; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Machida S, 2003, J CELL PHYSIOL, V196, P523, DOI 10.1002/jcp.10339; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Moulton KS, 2003, P NATL ACAD SCI USA, V100, P4736, DOI 10.1073/pnas.0730843100; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; NICULESCU F, 1987, ATHEROSCLEROSIS, V65, P1, DOI 10.1016/0021-9150(87)90002-5; Niculescu F, 2004, IMMUNOL RES, V30, P73, DOI 10.1385/IR:30:1:073; Niculescu F, 1997, J IMMUNOL, V158, P4405; Niculescu F, 2001, IMMUNOL RES, V24, P191, DOI 10.1385/IR:24:2:191; Niculescu F, 1999, ATHEROSCLEROSIS, V142, P47, DOI 10.1016/S0021-9150(98)00185-3; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Potente M, 2005, J CLIN INVEST, V115, P2382, DOI 10.1172/JCI23126; Potente M, 2003, J BIOL CHEM, V278, P29619, DOI 10.1074/jbc.M305385200; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rus HG, 1996, J IMMUNOL, V156, P4892; Rus HG, 1996, ATHEROSCLEROSIS, V127, P263, DOI 10.1016/S0021-9150(96)05968-0; RUS HG, 1989, IMMUNOL LETT, V20, P305, DOI 10.1016/0165-2478(89)90039-4; SEIFERT PS, 1990, J EXP MED, V172, P547, DOI 10.1084/jem.172.2.547; SEIFERT PS, 1989, LAB INVEST, V60, P747; Shankland SJ, 1999, KIDNEY INT, V56, P538, DOI 10.1046/j.1523-1755.1999.00560.x; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Soane L, 2001, J IMMUNOL, V167, P2305, DOI 10.4049/jimmunol.167.4.2305; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Torzewski J, 1996, ARTERIOSCL THROM VAS, V16, P673, DOI 10.1161/01.ATV.16.5.673; Viedt C, 2000, FASEB J, V14, P2370; Vogt PK, 2005, CELL CYCLE, V4, P908, DOI 10.4161/cc.4.7.1796; Zhang XH, 2002, J BIOL CHEM, V277, P45276, DOI 10.1074/jbc.M208063200; Zhao XS, 2004, BIOCHEM J, V378, P839, DOI 10.1042/BJ20031450; Ziche M, 1997, LAB INVEST, V76, P517	64	72	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19009	19018		10.1074/jbc.M602055200	http://dx.doi.org/10.1074/jbc.M602055200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16670089	hybrid			2022-12-25	WOS:000238847000014
J	Li, HW; Rauch, T; Chen, ZX; Szabo, PE; Riggs, AD; Pfeifer, GP				Li, Hongwei; Rauch, Tibor; Chen, Zhao-Xia; Szabo, Piroska E.; Riggs, Arthur D.; Pfeifer, Gerd P.			The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H3 LYSINE-9 METHYLATION; TUMOR-SUPPRESSOR GENE; CPG BINDING-PROTEINS; DE-NOVO METHYLATION; PERICENTRIC HETEROCHROMATIN; TRANSCRIPTIONAL REPRESSION; EPIGENETIC INACTIVATION; MAMMALIAN DEVELOPMENT; NEUROSPORA-CRASSA; IN-VIVO	DNA CpG methylation can cooperate with histone H3 lysine 9 (H3-K9) methylation in heterochromatin formation and gene silencing. Trimethylation of H3-K9 by the recently identified euchromatic histone methyltransferase SETDB1/ESET may be responsible for transcriptional repression of certain promoters. Here, we show that SETDB1 associates with endogenous DNA methyltransferase activity. SETDB1 interacts with the de novo DNA methyltransferases DNMT3A and DNMT3B but not with the maintenance methyltransferase DNMT1. The interaction of SETDB1 with DNMT3A was further characterized and confirmed by in vivo and in vitro interaction studies. A direct interaction of the two proteins occurs through the N terminus of SETDB1 and the plant homeodomain of DNMT3A. Co-expression of SETDB1 and DNMT3A was essential for repression of reporter gene expression in a Gal4-based tethering assay and resulted in their recruitment to the artificial promoter. We further demonstrate that the CpG-methylated promoters of the endogenous p53BP2 gene in HeLa cells and the RASSF1A gene in MDA-MB-231 cells are simultaneously occupied by both SETDB1 and DNMT3A proteins, which provides evidence for SETDB1 being at least partly responsible for H3-K9 trimethylation at the promoter of RASSF1A, a gene frequently silenced in human cancers. In summary, our data demonstrate the direct physical interaction and functional connection between the H3-K9 trimethylase SETDB1 and the DNA methyltransferase DNMT3A and thus contribute to a better understanding of the complexity of the self-reinforcing heterochromatin machinery operating at silenced promoters.	Beckman Res Inst, Div Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Pfeifer, GP (corresponding author), Beckman Res Inst, Div Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.	gpfeifer@coh.org		Riggs, Arthur/0000-0002-8184-5288; Szabo, Piroska/0000-0001-9314-7009	NCI NIH HHS [CA104967] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104967] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; Ayyanathan K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803; Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509; Chen TP, 2003, MOL CELL BIOL, V23, P5594, DOI 10.1128/MCB.23.16.5594-5605.2003; Chen TP, 2002, J BIOL CHEM, V277, P38746, DOI 10.1074/jbc.M205312200; Chen ZX, 2005, J CELL BIOCHEM, V95, P902, DOI 10.1002/jcb.20447; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2005, HISTOL HISTOPATHOL, V20, P645, DOI 10.14670/HH-20.645; Dodge JE, 2004, MOL CELL BIOL, V24, P2478, DOI 10.1128/MCB.24.6.2478-2486.2004; Fahrner JA, 2002, CANCER RES, V62, P7213; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Ichimura T, 2005, J BIOL CHEM, V280, P13928, DOI 10.1074/jbc.M413654200; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Jin SG, 2005, J BIOL CHEM, V280, P12700, DOI 10.1074/jbc.M413492200; Kim JH, 2003, MOL CELL, V12, P1537, DOI 10.1016/S1097-2765(03)00450-7; Kourmouli N, 2005, BIOCHEM BIOPH RES CO, V337, P901, DOI 10.1016/j.bbrc.2005.09.132; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lee DH, 2003, J BIOL CHEM, V278, P10314, DOI 10.1074/jbc.M212696200; Lee DY, 2005, ENDOCR REV, V26, P147, DOI 10.1210/er.2004-0008; Lees-Murdock DJ, 2005, DEV DYNAM, V232, P992, DOI 10.1002/dvdy.20288; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Li HW, 2004, J BIOL CHEM, V279, P4212, DOI 10.1074/jbc.M311374200; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Sarraf SA, 2004, MOL CELL, V15, P595, DOI 10.1016/j.molcel.2004.06.043; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Smothers JF, 2000, CURR BIOL, V10, P27, DOI 10.1016/S0960-9822(99)00260-2; Soppe WJJ, 2002, EMBO J, V21, P6549, DOI 10.1093/emboj/cdf657; Strunnikova M, 2005, MOL CELL BIOL, V25, P3923, DOI 10.1128/MCB.25.10.3923-3933.2005; Szabo PE, 2002, MECH DEVELOP, V115, P157, DOI 10.1016/S0925-4773(02)00087-4; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Tamaru H, 2003, NAT GENET, V34, P75, DOI 10.1038/ng1143; Verschure PJ, 2005, MOL CELL BIOL, V25, P4552, DOI 10.1128/MCB.25.11.4552-4564.2005; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Wang HB, 2003, MOL CELL, V12, P475, DOI 10.1016/j.molcel.2003.08.007; Yang L, 2002, ONCOGENE, V21, P148, DOI 10.1038/sj.onc.1204998; Yang L, 2003, BIOCHEM J, V369, P651, DOI 10.1042/BJ20020854; Yokochi T, 2002, J BIOL CHEM, V277, P11735, DOI 10.1074/jbc.M106590200	51	225	240	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19489	19500		10.1074/jbc.M513249200	http://dx.doi.org/10.1074/jbc.M513249200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16682412	hybrid			2022-12-25	WOS:000238847000064
J	de Wolf, CJF; Cupers, RMJ; Bertina, RM; Vos, HL				de Wolf, Cornelia J. F.; Cupers, Rosemiek M. J.; Bertina, Rogier M.; Vos, Hans L.			The constitutive expression of anticoagulant protein S is regulated through multiple binding sites for Sp1 and Sp3 transcription factors in the protein S gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-DEPENDENT PROTEIN; C4B-BINDING PROTEIN; ENDOTHELIAL-CELLS; VENOUS THROMBOSIS; APOPTOTIC CELLS; FACTOR-VIII; RB PROTEIN; SP-FAMILY; DEFICIENCY; COMPLEX	Protein S (PS) is a vitamin K-dependent plasma protein that inhibits blood coagulation by serving as a nonenzymatic cofactor for activated protein C in the protein C anticoagulant pathway. Low PS levels are a risk factor for the development of deep venous thrombosis. The regulation of PS levels through transcriptional regulation of the PS gene was investigated in this report. A minimal PS gene promoter 370 bp upstream from the translational initiation codon was sufficient for maximal promoter activity in transient transfections regardless of the cell type. A pivotal role for Sp1 in the constitutive expression of the PS gene was demonstrated through electrophoretic mobility shift assay experiments, transient expression of mutant PS promoter-reporter gene constructs, and chromatin immunoprecipitations in HepG2 cells. At least four Sp-binding sites were identified. The two sites most proximal to the translational start codon were found to be indispensable for PS promoter activity, whereas mutation of the two most distal Sp-binding sites had a negligible influence on basal promoter activity. In addition, all other major promoter-binding proteins that were found by electrophoretic mobility shift assay could be positively identified in supershift assays. We identified binding sites for the hepatocyte-specific forkhead transcription factor FOXA2, nuclear factor Y, and the cAMP-response element-binding protein/activating transcription factor family of transcription factors. Their relevance was investigated using site-directed mutagenesis.	Leiden Univ, Ctr Med, Hemostasis & Thrombosis Res Ctr, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Vos, HL (corresponding author), Leiden Univ, Ctr Med, Hemostasis & Thrombosis Res Ctr, C2-R139,POB 9600, NL-2300 RC Leiden, Netherlands.	h.l.vos@lumc.nl	Bertina, Rogier/AGQ-5246-2022					Beauchamp NJ, 2004, BRIT J HAEMATOL, V125, P647, DOI 10.1111/j.1365-2141.2004.04961.x; Benzakour O, 2000, BLOOD, V95, P2008, DOI 10.1182/blood.V95.6.2008; Boekhoudt GH, 2003, J IMMUNOL, V170, P4139, DOI 10.4049/jimmunol.170.8.4139; COMP PC, 1986, BLOOD, V68, P881; DAHLBACK B, 1986, J BIOL CHEM, V261, P2022; DAHLBACK B, 1981, P NATL ACAD SCI-BIOL, V78, P2512, DOI 10.1073/pnas.78.4.2512; DANGELO A, 1988, J CLIN INVEST, V81, P1445, DOI 10.1172/JCI113475; De Wolf CJF, 2005, J THROMB HAEMOST, V3, P410, DOI 10.1111/j.1538-7836.2005.01138.x; DEUTZTERLOUW PP, 1990, CLIN CHIM ACTA, V186, P321, DOI 10.1016/0009-8981(90)90318-M; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dykes AC, 2001, BRIT J HAEMATOL, V113, P636; EDENBRANDT CM, 1990, BIOCHEMISTRY-US, V29, P7861, DOI 10.1021/bi00486a012; ENGESSER L, 1987, ANN INTERN MED, V106, P677, DOI 10.7326/0003-4819-106-5-677; FAIR DS, 1986, BLOOD, V67, P64; FAIR DS, 1986, BLOOD, V67, P1168; FULCHER CA, 1984, BLOOD, V63, P486; Gandrille S, 2000, THROMB HAEMOSTASIS, V84, P918; Gandrille S, 1997, THROMB HAEMOSTASIS, V77, P1201; GRIFFIN JH, 1992, BLOOD, V79, P3203; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HACKENG TM, 1994, J BIOL CHEM, V269, P21051; Heeb MJ, 2004, J THROMB HAEMOST, V2, P1766, DOI 10.1111/j.1538-7836.2004.00901.x; Kask L, 2004, J BIOL CHEM, V279, P23869, DOI 10.1074/jbc.C400159200; KEMKESMATTHES B, 1992, CLIN INVESTIGATOR, V70, P529; KOPPELMAN SJ, 1995, BLOOD, V86, P1062; KOSTER T, 1995, BLOOD, V85, P2756, DOI 10.1182/blood.V85.10.2756.bloodjournal85102756; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LALLI E, 1994, J BIOL CHEM, V269, P17359; Loots GG, 2002, GENOME RES, V12, P832, DOI 10.1101/gr.225502; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MAILLARD C, 1992, ENDOCRINOLOGY, V130, P1599, DOI 10.1210/en.130.3.1599; Makris M, 2000, BLOOD, V95, P1935, DOI 10.1182/blood.V95.6.1935; MALM J, 1994, BIOCHEM J, V302, P845, DOI 10.1042/bj3020845; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; Mummaneni P, 1998, NUCLEIC ACIDS RES, V26, P5163, DOI 10.1093/nar/26.22.5163; OGURA M, 1987, BLOOD, V70, P301; Peng YW, 2002, BLOOD, V99, P2408, DOI 10.1182/blood.V99.7.2408; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; Sapetschnig A, 2004, J BIOL CHEM, V279, P42095, DOI 10.1074/jbc.M404989200; Schenone M, 2004, CURR OPIN HEMATOL, V11, P272, DOI 10.1097/01.moh.0000130308.37353.d4; SCHMIDEL DK, 1990, BIOCHEMISTRY-US, V29, P7845, DOI 10.1021/bi00486a010; SCHWARZ HP, 1984, BLOOD, V64, P1297; SCHWARZ HP, 1985, BLOOD, V66, P1452; STERN D, 1986, J CELL BIOL, V102, P1971, DOI 10.1083/jcb.102.5.1971; Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Tans G, 2000, THROMB HAEMOSTASIS, V84, P15, DOI 10.1055/s-0037-1613960; Tatewaki H, 2003, THROMB HAEMOSTASIS, V90, P1029, DOI 10.1160/TH03-07-0443; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VANAMSTEL HKP, 1990, BIOCHEMISTRY-US, V29, P7853, DOI 10.1021/bi00486a011; VIGANODANGELO S, 1987, ANN INTERN MED, V107, P42, DOI 10.7326/0003-4819-107-1-42; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; Webb JH, 2002, J IMMUNOL, V169, P2580, DOI 10.4049/jimmunol.169.5.2580; Yegneswaran S, 1997, J BIOL CHEM, V272, P25013, DOI 10.1074/jbc.272.40.25013	58	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17635	17643		10.1074/jbc.M603094200	http://dx.doi.org/10.1074/jbc.M603094200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16672217	hybrid			2022-12-25	WOS:000238490300012
J	Ko, HS; Kim, SW; Sriram, SR; Dawson, VL; Dawson, TM				Ko, Han Seok; Kim, Seong Who; Sriram, Sathya R.; Dawson, Valina L.; Dawson, Ted M.			Identification of far upstream element-binding protein-1 as an authentic parkin substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE; NEURODEGENERATION	Aminoacyl-tRNA synthetase-interacting multifunctional protein type 2 was recently identified as an authentic substrate of the ubiquitin E3 ligase, parkin, a gene associated with autosomal recessive juvenile parkinsonism. Far upstream element-binding protein 1 is known to be degraded in an aminoacyl-tRNA synthetase interacting multifunctional protein type 2 dependent manner, which is crucial for lung cell maturation in early development. Therefore, we wondered whether far upstream element-binding protein 1 levels are altered in the absence of Parkin and in Parkinson disease. We herein report that far upstream element-binding protein 1 accumulates in Parkin knock-out mice, patients with autosomal recessive juvenile parkinsonism, sporadic Parkinson disease, and diffuse Lewy Body disease as well as the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. Moreover, Parkin interacts with and ubiquitinates far upstream element-binding protein 1 facilitating its degradation through the ubiquitin proteasome system. Taken together, these results suggest that far upstream element-binding protein 1 is an authentic substrate of Parkin and that far upstream element-binding protein 1 might play an important role in development of Parkinson disease pathology along with aminoacyl-tRNA synthetase interacting multifunctional protein type 2.	Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Univ Ulsan, Coll Med, Dept Biochem & Mol Biol, Seoul 138736, South Korea	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Ulsan	Dawson, TM (corresponding author), Johns Hopkins Univ, Sch Med, Inst Cell Engn, 733 N Broadway,Suite 731, Baltimore, MD 21205 USA.	tdawson@jhmi.edu	Dawson, Valina/Y-9757-2019	Dawson, Valina/0000-0002-2915-3970	NINDS NIH HHS [P50 NS038377, NS 38377] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038377] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Chung KKK, 2004, SCIENCE, V304, P1328, DOI 10.1126/science.1093891; Corti O, 2003, HUM MOL GENET, V12, P1427, DOI 10.1093/hmg/ddg159; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Kim MJ, 2003, NAT GENET, V34, P330, DOI 10.1038/ng1182; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Ko HS, 2005, J NEUROSCI, V25, P7968, DOI 10.1523/JNEUROSCI.2172-05.2005; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718; von Coelln R, 2004, P NATL ACAD SCI USA, V101, P10744, DOI 10.1073/pnas.0401297101; von Coelln R, 2004, CELL TISSUE RES, V318, P175, DOI 10.1007/s00441-004-0924-4	10	79	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16193	16196		10.1074/jbc.C600041200	http://dx.doi.org/10.1074/jbc.C600041200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16672220	hybrid			2022-12-25	WOS:000238165700003
J	Parsons, MJ; Vertino, PM				Parsons, M. J.; Vertino, P. M.			Dual role of TMS1/ASC in death receptor signaling	ONCOGENE			English	Article						TNF alpha; TRAIL; apoptosis; NF-kappa B; epigenetic silencing; caspase-8	NF-KAPPA-B; CASPASE RECRUITMENT DOMAIN; CONTAINING APAF1-LIKE PROTEIN; FACTOR-INDUCED APOPTOSIS; INDUCED-PROXIMITY MODEL; SPECK-LIKE PROTEIN; ABERRANT METHYLATION; HUMAN BREAST; REGULATES ACTIVATION; TERMINAL KINASE	Aberrant DNA methylation of promoter region CpG islands is associated with gene silencing and serves as an alternative to mutations in the inactivation of tumor suppressor genes in human cancers. We identified a gene TMS1 ( for Target of Methylation-mediated Silencing) that is subject to such epigenetic silencing in a significant proportion of human breast and other cancers. Also known as ASC and PYCARD, TMS1 encodes a bipartite intracellular signaling molecule with proposed roles in apoptosis and inflammation. However, the precise role of this protein in the pathogenesis of breast and other cancers has not been clearly defined. In this study, we examined the role of TMS1/ASC in death receptor signaling. We found that TMS1/ASC is upregulated in response to treatment with TNF-related apoptosis-inducing ligand ( TRAIL) and tumor necrosis factor-alpha (TNF alpha) in breast epithelial cells, but not in human fibroblasts. This upregulation was not dependent on the synthesis of a TNF alpha-regulated intermediate or alterations in mRNA stability, suggesting a direct effect on TMS1/ASC transcription. Induction of TMS1/ASC by TNFa was blocked by co-expression of a dominant negative I kappa B alpha, small interfering RNA-mediated knockdown of RelA/p65, or concurrent treatment with SP600125, indicating a requirement for the nuclear factor-kappa B (NF-kappa B) and jun kinase signaling pathways. Although previous work has suggested that TMS1/ASC may be directly regulated by p53, we found that whereas treatment of breast epithelial cells or normal diploid. broblasts with DNA damaging agents resulted in the stabilization of endogenous p53 and a concomitant increase in p21, it had little impact on the expression of TMS1/ASC mRNA or protein. We further show that whereas TMS1/ASC is not required for TNF alpha or TRAIL-induced activation of NF-kappa B or caspase-8, it can promote caspase-8 activation independently of death receptor-ligand interactions. Taken together, these data suggest that upregulation of TMS1/ASC by TNF alpha and subsequent activation of caspase-8 could function to amplify the apoptotic signal induced by death receptors in some cell types, including breast epithelial cells.	Emory Univ, Dept Radiat Oncol, Atlanta, GA 30322 USA; Emory Univ, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA; Emory Univ, Winship Canc Ctr, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Vertino, PM (corresponding author), Emory Univ, Dept Radiat Oncol, 1365-C Clifton Rd,NE, Atlanta, GA 30322 USA.	pvertin@emory.edu						Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Conway KE, 2000, CANCER RES, V60, P6236; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Furukawa Y, 2005, MOL CANCER RES, V3, P325, DOI 10.1158/1541-7786.MCR-04-0105; Grenier JM, 2002, FEBS LETT, V530, P73, DOI 10.1016/S0014-5793(02)03416-6; Guan X, 2003, INT J CANCER, V107, P202, DOI 10.1002/ijc.11376; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; Hasegawa M, 2005, J BIOL CHEM, V280, P15122, DOI 10.1074/jbc.M412284200; Horak P, 2005, MOL CANCER RES, V3, P335, DOI 10.1158/1541-7786.MCR-04-0136; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, MOL CELL BIOL, V19, P2021; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Levine JJ, 2003, ONCOGENE, V22, P3475, DOI 10.1038/sj.onc.1206430; Li GQ, 2004, J BIOL CHEM, V279, P1123, DOI 10.1074/jbc.M305893200; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Manji GA, 2002, J BIOL CHEM, V277, P11570, DOI 10.1074/jbc.M112208200; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; Masumoto J, 2003, BIOCHEM BIOPH RES CO, V303, P69, DOI 10.1016/S0006-291X(03)00309-7; Masumoto J, 2001, J HISTOCHEM CYTOCHEM, V49, P1269, DOI 10.1177/002215540104901009; Mayo MW, 2003, J BIOL CHEM, V278, P18980, DOI 10.1074/jbc.M211695200; McConnell BB, 2000, CANCER RES, V60, P6243; McConnell BB, 2004, APOPTOSIS, V9, P5, DOI 10.1023/B:APPT.0000012117.32430.0c; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Moriai R, 2002, ANTICANCER RES, V22, P4163; Muppidi JR, 2004, IMMUNITY, V21, P461, DOI 10.1016/j.immuni.2004.10.001; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087; Richards N, 2001, J BIOL CHEM, V276, P39320, DOI 10.1074/jbc.M104730200; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Sharp DA, 2005, J BIOL CHEM, V280, P19401, DOI 10.1074/jbc.M413962200; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shetty S, 2005, MOL CELL BIOL, V25, P5404, DOI 10.1128/MCB.25.13.5404-5416.2005; Shi YG, 2004, CELL, V117, P855, DOI 10.1016/j.cell.2004.06.007; Shiohara M, 2002, BIOCHEM BIOPH RES CO, V293, P1314, DOI 10.1016/S0006-291X(02)00384-4; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stehlik C, 2003, J IMMUNOL, V171, P6154, DOI 10.4049/jimmunol.171.11.6154; Stehlik C, 2002, J EXP MED, V196, P1605, DOI 10.1084/jem.20021552; Stone AR, 2004, AM J PATHOL, V165, P1151, DOI 10.1016/S0002-9440(10)63376-7; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Tian B, 2005, J BIOL CHEM, V280, P17435, DOI 10.1074/jbc.M500437200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; van Noesel MM, 2002, CANCER RES, V62, P2157; Virmani A, 2003, INT J CANCER, V106, P198, DOI 10.1002/ijc.11206; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Yamamoto M, 2004, GENES CELLS, V9, P1055, DOI 10.1111/j.1365-2443.2004.00789.x; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yokoyama T, 2003, CANCER LETT, V202, P101, DOI 10.1016/j.canlet.2003.08.027; Yu JW, 2006, CELL DEATH DIFFER, V13, P236, DOI 10.1038/sj.cdd.4401734; Zhou A, 2003, ONCOGENE, V22, P2054, DOI 10.1038/sj.onc.1206262	66	22	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	52					6948	6958		10.1038/sj.onc.1209684	http://dx.doi.org/10.1038/sj.onc.1209684			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16715133				2022-12-25	WOS:000241732300005
J	Huang, CL; Ueno, M; Liu, D; Masuya, D; Nakano, J; Yokomise, H; Nakagawa, T; Miyake, M				Huang, C-L; Ueno, M.; Liu, D.; Masuya, D.; Nakano, J.; Yokomise, H.; Nakagawa, T.; Miyake, M.			MRP-1/CD9 gene transduction regulates the actin cytoskeleton through the downregulation of WAVE2	ONCOGENE			English	Article						MRP-1/CD9; WAVE2; actin; motility	ARP2/3 COMPLEX; PHOSPHATIDYLINOSITOL 3-KINASE; CELL-MIGRATION; MAJOR CD9; N-WASP; PROTEIN; MOTILITY; KINASE; ACTIVATION; EXPRESSION	Motility-related protein-1 (MRP-1/CD9) is involved in cell motility. We studied the change in the actin cytoskeleton, and the expression of actin-related protein (Arp) 2 and Arp3 and the Wiskott-Aldrich syndrome protein ( WASP) family according to MRP-1/CD9 gene transduction into HT1080 cells. The frequency of cells with lamellipodia was significantly lower in MRP-1/CD9-transfected HT1080 cells than in control HT1080 cells (P < 0.0001). MRP-1/CD9 gene transduction affected the subcellular localization of Arp2 and Arp3 proteins. Furthermore, MRP-1/CD9 gene transduction induced a downregulation of WAVE2 expression (P < 0.0001). However, no difference was observed in the expression of Arp2, Arp3 or other WASPs. A neutralizing anti-MRP-1/CD9 monoclonal antibody inhibited downregulation of WAVE2 in MRP-1/CD9-transfected HT1080 cells (P < 0.0001 ), and reversed the morphological effects of MRP-1/CD9 gene transduction. Furthermore, downregulation of WAVE2 by transfection of WAVE2-specific small interfering RNA ( siRNA) mimicked the morphological effects of MRP-1/CD9 gene transduction and suppressed cell motility. However, transfection of each siRNA for Wnt1, Wnt2b1 or Wnt5a did not affect WAVE2 expression. Transfection of WAVE2-specific siRNA also did not affect expressions of these Wnts. These results indicate that MRP-1/CD9 regulates the actin cytoskeleton by downregulating of the WAVE2, through the Wnt-independent signal pathway.	Kagawa Univ, Dept Surg 2, Fac Med, Kagawa 7610793, Japan; Kagawa Univ, Fac Med, Dept Pathol & Host Def, Kagawa, Japan; Kagawa Univ, Life Sci Res Ctr, Kagawa, Japan; Kitano Hosp, Dept Oncol 5, Tazuke Kofukai Med Res Inst, Dept Thorac Surg, Osaka, Japan	Kagawa University; Kagawa University; Kagawa University; Kitano Hospital	Huang, CL (corresponding author), Kagawa Univ, Dept Surg 2, Fac Med, 1750-1,Miki Cho, Kagawa 7610793, Japan.	chuang@kms.ac.jp						Bailly M, 1999, J CELL BIOL, V145, P331, DOI 10.1083/jcb.145.2.331; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Charrin S, 2001, J BIOL CHEM, V276, P14329, DOI 10.1074/jbc.M011297200; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Condeelis JS, 2001, SEMIN CANCER BIOL, V11, P119, DOI 10.1006/scbi.2000.0363; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Gutierrez-Lopez MD, 2003, J BIOL CHEM, V278, P208, DOI 10.1074/jbc.M207805200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8; Huang CL, 2004, ONCOGENE, V23, P7475, DOI 10.1038/sj.onc.1208063; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kurisu S, 2005, ONCOGENE, V24, P1309, DOI 10.1038/sj.onc.1208177; Le Naour F, 2004, CANCER IMMUNOL IMMUN, V53, P148, DOI 10.1007/s00262-003-0477-5; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miyake M, 2000, ONCOGENE, V19, P5221, DOI 10.1038/sj.onc.1203919; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; Park KR, 2000, MOL HUM REPROD, V6, P719, DOI 10.1093/molehr/6.8.719; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Soderling SH, 2003, P NATL ACAD SCI USA, V100, P1723, DOI 10.1073/pnas.0438033100; Stipp CS, 2001, J BIOL CHEM, V276, P40545, DOI 10.1074/jbc.M107338200; Suetsugu S, 2003, DEV CELL, V5, P595, DOI 10.1016/S1534-5807(03)00297-1; Takenawa T, 2001, J CELL SCI, V114, P1801; Vartiainen MK, 2004, CURR OPIN CELL BIOL, V16, P174, DOI 10.1016/j.ceb.2004.02.004; Yamaguchi H, 2000, P NATL ACAD SCI USA, V97, P12631, DOI 10.1073/pnas.190351397; Yamazaki D, 2003, NATURE, V424, P452, DOI 10.1038/nature01770; Yan C, 2003, EMBO J, V22, P3602, DOI 10.1093/emboj/cdg350; Yauch RL, 2000, BIOCHEM J, V351, P629, DOI 10.1042/0264-6021:3510629; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200; Zhu BM, 2005, GENOMICS, V85, P657, DOI 10.1016/j.ygeno.2005.02.012; Zilber MT, 2005, BLOOD, V106, P3074, DOI 10.1182/blood-2004-10-4094	34	19	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2006	25	49					6480	6488		10.1038/sj.onc.1209654	http://dx.doi.org/10.1038/sj.onc.1209654			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16682943				2022-12-25	WOS:000241395100004
J	Komiya, T; Park, Y; Modi, S; Coxon, AB; Oh, H; Kaye, FJ				Komiya, T.; Park, Y.; Modi, S.; Coxon, A. B.; Oh, H.; Kaye, F. J.			Sustained expression of Mect1-Mam12 is essential for tumor cell growth in salivary gland cancers carrying the t(11 ; 19) translocation	ONCOGENE			English	Article						mucoepidermoid cancer; salivary gland cancer; chromosomal translocation; RNAi	MUCOEPIDERMOID CARCINOMA; GENE FUSION; IDENTIFICATION; FAMILY; COACTIVATORS; ACTIVATION; BENIGN	Mucoepidermoid (MEC) salivary gland tumors arise from a t(11; 19) rearrangement which generates a fusion oncogene, Mect1-Maml2, that functions to activate CREB-responsive target genes. To determine if sustained expression of Mect1-Maml2 is required for tumor cell growth, we first showed that ectopic expression of Mect1-Maml2 in rat epithelial RK3E cells is tumorigenic in vivo in nude mice and that excised xenografts continue to express the fusion oncogene. We then generated a hairpin RNAi vector that selectively suppressed the fusion peptide and showed that ectopic expression in either parotid or pulmonary MEC tumor cell lines containing the t(11; 19) rearrangement resulted in at least 90% colony growth inhibition. In contrast, single nucleotide changes within this RNAi sequence abolished the ability to suppress Mect1-Maml2 protein and abolished all growth inhibition of these MEC tumor lines. In addition, the RNAi-specific vector had no effect on colony growth of non-MEC tumors including a lung tumor or two other salivary gland cell lines that do not express Mect1-Maml2. We also generated a mutant Mect1-Maml2 expression plasmid that carried silent nucleotide changes within the RNAi target sequence and observed that co-transfection of this mutant, but not wild-type Mect1-Maml2, could partially rescue RNAi growth inhibition in the MEC tumor line. The recent detection of acquired fusion oncogenes in epithelial solid tumors has suggested new possibilities for the diagnosis and therapy of these cancers. Our data show that the 'gain-of-function' activity from aberrant Mect1-Maml2 expression is a candidate therapeutic target for this group of malignant salivary gland tumors.	NCI, Canc Res Ctr, Genat Branch, Bethesda, MD 20892 USA; Natl Naval Med Ctr, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center	Kaye, FJ (corresponding author), Bldg 8,Rm 5101, Bethesda, MD 20889 USA.	fkaye@helix.nih.gov	kaye, frederic/E-2437-2011		Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIASC007256, Z01SC007256] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behboudi A, 2005, GENE CHROMOSOME CANC, V43, P202, DOI 10.1002/gcc.20168; Cho-Chung YS, 2003, ANN NY ACAD SCI, V1002, P124, DOI 10.1196/annals.1281.011; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Coxon A, 2005, CANCER RES, V65, P7137, DOI 10.1158/0008-5472.CAN-05-1125; ElNaggar AK, 1996, CANCER GENET CYTOGEN, V87, P29, DOI 10.1016/0165-4608(95)00266-9; Enlund F, 2004, EUR J ORAL SCI, V112, P545, DOI 10.1111/j.1600-0722.2004.00174.x; Enlund F, 2004, EXP CELL RES, V292, P21, DOI 10.1016/j.yexcr.2003.09.007; GRENMAN R, 1992, ARCH OTOLARYNGOL, V118, P542; Iourgenko V, 2003, P NATL ACAD SCI USA, V100, P12147, DOI 10.1073/pnas.1932773100; Lin SE, 2002, J BIOL CHEM, V277, P50612, DOI 10.1074/jbc.M209529200; Martins C, 2004, J MOL DIAGN, V6, P205, DOI 10.1016/S1525-1578(10)60511-9; Mitelman F, 2004, NAT GENET, V36, P331, DOI 10.1038/ng1335; Roberts Thomas G Jr, 2003, Clin Adv Hematol Oncol, V1, P486; Speight PM, 2002, ORAL DIS, V8, P229, DOI 10.1034/j.1601-0825.2002.02870.x; Stenman G, 1998, VIRCHOWS ARCH, V433, P579, DOI 10.1007/s004280050293; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tonon G, 2003, NAT GENET, V33, P208, DOI 10.1038/ng1083; Wu L, 2002, MOL CELL BIOL, V22, P7688, DOI 10.1128/MCB.22.21.7688-7700.2002; Wu LZ, 2005, EMBO J, V24, P2391, DOI 10.1038/sj.emboj.7600719	20	61	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2006	25	45					6128	6132		10.1038/sj.onc.1209627	http://dx.doi.org/10.1038/sj.onc.1209627			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16652146				2022-12-25	WOS:000241101200010
J	Reynolds, CM; Ribeiro, AA; McGrath, SC; Cotter, RJ; Raetz, CRH; Trent, MS				Reynolds, C. Michael; Ribeiro, Anthony A.; McGrath, Sara C.; Cotter, Robert J.; Raetz, Christian R. H.; Trent, M. Stephen			An outer membrane enzyme encoded by Salmonella typhimurium IpxR that removes the 3 '-acyloxyacyl moiety of lipid A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDE RESISTANCE; ENTERICA SEROVAR TYPHIMURIUM; ESCHERICHIA-COLI LIPOPOLYSACCHARIDE; HUMAN ACYLOXYACYL HYDROLASE; TOLL-LIKE RECEPTOR-4; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; POLYMYXIN RESISTANCE; PHOSPHOLIPASE-A; PHOP-PHOQ; TRANSCRIPTIONAL REGULATOR	The Salmonella and related bacteria modify the structure of the lipid A portion of their lipopolysaccharide in response to environmental stimuli. Some lipid A modifications are required for virulence and resistance to cationic antimicrobial peptides. We now demonstrate that membranes of Salmonella typhimurium contain a novel hydrolase that removes the 3'-acyloxyacyl residue of lipid A in the presence of 5 mM Ca2+. We have identified the gene encoding the S. typhimurium lipid A 3'-O-deacylase, designated lpxR, by screening an ordered S. typhimurium genomic DNA library, harbored in Escherichia coli K-12, for expression of Ca2+-dependent 3'-O-deacylase activity in membranes. LpxR is synthesized with an N-terminal type I signal peptide and is localized to the outer membrane. Mass spectrometry was used to confirm the position of lipid A deacylation in vitro and the release of the intact 3'-acyloxyacyl group. Heterologous expression of lpxR in the E. coli K-12 W3110, which lacks lpxR, resulted in production of significant amounts of 3'-O-deacylated lipid A in growing cultures. Orthologues of LpxR are present in the genomes of E. coli O157: H7, Yersinia enterocolitica, Helicobacter pylori, and Vibrio cholerae. The function of LpxR is unknown, but it could play a role in pathogenesis because it might modulate the cytokine response of an infected animal.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, NMR Spect Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Middle Atlantic Mass Spectrometry Lab, Baltimore, MD 21205 USA; E Tennessee State Univ, James H Quillen Coll Med, Dept Microbiol, Johnson City, TN 37614 USA	Duke University; Duke University; Duke University; Johns Hopkins University; East Tennessee State University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu; trentms@mail.etsu.edu			NATIONAL CANCER INSTITUTE [P30CA014236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064184] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064402, R01GM051310] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-14236, P30 CA014236] Funding Source: Medline; NIAID NIH HHS [R01 AI064184, AI-064184] Funding Source: Medline; NIGMS NIH HHS [R01 GM051310-12, GM-64402, R01 GM051310, GM-51310, R01 GM064402] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Ahn VE, 2004, EMBO J, V23, P2931, DOI 10.1038/sj.emboj.7600320; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Baker SJ, 1999, MICROBIOL-SGM, V145, P367, DOI 10.1099/13500872-145-2-367; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brabetz W, 1997, EUR J BIOCHEM, V247, P716, DOI 10.1111/j.1432-1033.1997.00716.x; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; Buchmeier N, 1997, INFECT IMMUN, V65, P3725, DOI 10.1128/IAI.65.9.3725-3730.1997; Carlson SA, 2005, MICROB PATHOGENESIS, V38, P181, DOI 10.1016/j.micpath.2005.01.004; COSTELLO CE, 1990, METHOD ENZYMOL, V193, P738, DOI 10.1016/0076-6879(90)93448-T; Darveau RP, 2004, INFECT IMMUN, V72, P5041, DOI 10.1128/IAI.72.9.5041-5051.2004; Dekker N, 1997, J BIOL CHEM, V272, P3179, DOI 10.1074/jbc.272.6.3179; Dekker N, 2000, MOL MICROBIOL, V35, P711, DOI 10.1046/j.1365-2958.2000.01775.x; DINARELLO CA, 1991, BLOOD, V77, P1627; Doerrler WT, 2002, J BIOL CHEM, V277, P36697, DOI 10.1074/jbc.M205857200; ERWIN AL, 1990, J BIOL CHEM, V265, P16444; Garcia-del Portillo F, 1999, TRENDS MICROBIOL, V7, P467, DOI 10.1016/S0966-842X(99)01618-2; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; Gibbons HS, 2000, J BIOL CHEM, V275, P32940, DOI 10.1074/jbc.M005779200; Gibbons HS, 2005, MOL MICROBIOL, V55, P425, DOI 10.1111/j.1365-2958.2004.04409.x; GROISMAN EA, 1989, P NATL ACAD SCI USA, V86, P7077, DOI 10.1073/pnas.86.18.7077; Groisman EA, 1997, J BACTERIOL, V179, P7040, DOI 10.1128/jb.179.22.7040-7045.1997; Gunn JS, 2000, INFECT IMMUN, V68, P6139, DOI 10.1128/IAI.68.11.6139-6146.2000; Gunn JS, 2001, J ENDOTOXIN RES, V7, P57, DOI 10.1177/09680519010070011001; Gunn JS, 1996, J BACTERIOL, V178, P6857, DOI 10.1128/jb.178.23.6857-6864.1996; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; GUYCAFFEY JK, 1992, J BACTERIOL, V174, P2460, DOI 10.1128/jb.174.8.2460-2465.1992; HAGEN FS, 1991, BIOCHEMISTRY-US, V30, P8415, DOI 10.1021/bi00098a020; Helander IM, 1996, EUR J BIOCHEM, V237, P272, DOI 10.1111/j.1432-1033.1996.0272n.x; Hoshino K, 1999, J IMMUNOL, V162, P3749; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; Jones BD, 1996, ANNU REV IMMUNOL, V14, P533, DOI 10.1146/annurev.immunol.14.1.533; Kaneko A, 2002, MICROBIOL IMMUNOL, V46, P109, DOI 10.1111/j.1348-0421.2002.tb02666.x; Kanipes MI, 2001, J BIOL CHEM, V276, P1156, DOI 10.1074/jbc.M009019200; Kawasaki K, 2005, J ENDOTOXIN RES, V11, P57, DOI 10.1179/096805105225006696; Kawasaki K, 2005, J BACTERIOL, V187, P2448, DOI 10.1128/JB.187.7.2448-2457.2005; Kawasaki K, 2004, J ENDOTOXIN RES, V10, P439, DOI 10.1179/096805104225006264; Kawasaki K, 2004, J BIOL CHEM, V279, P20044, DOI 10.1074/jbc.M401275200; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee H, 2004, J BACTERIOL, V186, P4124, DOI 10.1128/JB.186.13.4124-4133.2004; Lindgren SW, 1996, P NATL ACAD SCI USA, V93, P4197, DOI 10.1073/pnas.93.9.4197; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; Ludwig A, 1995, MOL GEN GENET, V249, P474, DOI 10.1007/BF00290573; McClelland M, 2001, NATURE, V413, P852, DOI 10.1038/35101614; MILLER SI, 1990, J BACTERIOL, V172, P2485, DOI 10.1128/jb.172.5.2485-2490.1990; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; Monack DM, 1996, P NATL ACAD SCI USA, V93, P9833, DOI 10.1073/pnas.93.18.9833; Moran AP, 1997, J BACTERIOL, V179, P6453, DOI 10.1128/jb.179.20.6453-6463.1997; Navarre WW, 2005, MOL MICROBIOL, V56, P492, DOI 10.1111/j.1365-2958.2005.04553.x; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; Osborn M J, 1974, Methods Enzymol, V31, P642; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, V2, P1035; Rebeil R, 2004, MOL MICROBIOL, V52, P1363, DOI 10.1111/j.1365-2958.2004.04059.x; Reynolds CM, 2005, J BIOL CHEM, V280, P21202, DOI 10.1074/jbc.M500964200; Ribeiro AA, 1999, MAGN RESON CHEM, V37, P620, DOI 10.1002/(SICI)1097-458X(199909)37:9<620::AID-MRC517>3.0.CO;2-Q; RichterDahlfors A, 1997, J EXP MED, V186, P569, DOI 10.1084/jem.186.4.569; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Sambrook J, 2001, MOL CLONING LAB MANU; SHERER CA, 2001, PRINCIPLES BACTERIAL, P229; Shi YX, 2004, J BIOL CHEM, V279, P38618, DOI 10.1074/jbc.M406149200; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Snijder HJ, 2001, J MOL BIOL, V309, P477, DOI 10.1006/jmbi.2001.4675; Stapleton MR, 2002, J BIOL CHEM, V277, P17630, DOI 10.1074/jbc.M110178200; Steeghs L, 2002, CELL MICROBIOL, V4, P599, DOI 10.1046/j.1462-5822.2002.00214.x; Suda Y, 2001, J ENDOTOXIN RES, V7, P95, DOI 10.1179/096805101101532594; Trent M. Stephen, 2002, Journal of Endotoxin Research, V8, P158; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; Trent MS, 2001, J BIOL CHEM, V276, P9083, DOI 10.1074/jbc.M010730200; VAARA M, 1981, FEBS LETT, V129, P145, DOI 10.1016/0014-5793(81)80777-6; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; Vinogradov E, 2002, EUR J BIOCHEM, V269, P6112, DOI 10.1046/j.1432-1033.2002.03321.x; Vorachek-Warren MK, 2002, J BIOL CHEM, V277, P14194, DOI 10.1074/jbc.M200409200; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; Watson PR, 1999, INFECT IMMUN, V67, P4950, DOI 10.1128/IAI.67.9.4950-4954.1999; Wosten MMSM, 2000, CELL, V103, P113, DOI 10.1016/S0092-8674(00)00092-1; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466; Zhou ZM, 2000, J BIOL CHEM, V275, P13542, DOI 10.1074/jbc.275.18.13542	89	76	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21974	21987		10.1074/jbc.M603527200	http://dx.doi.org/10.1074/jbc.M603527200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16704973	hybrid, Green Accepted, Green Submitted			2022-12-25	WOS:000239387100044
J	Li, TF; Chen, D; Wu, QQ; Chen, M; Sheu, TJ; Schwarz, EM; Drissi, H; Zuscik, M; O'Keefe, RJ				Li, Tian-Fang; Chen, Di; Wu, Qiuqian; Chen, Mo; Sheu, Tzong-Jen; Schwarz, Edward M.; Drissi, Hicham; Zuscik, Michael; O'Keefe, Regis J.			Transforming growth factor-beta stimulates cyclin D-1 expression through activation of beta-catenin signaling in chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-BOX PROTEIN; TGF-BETA; UBIQUITIN LIGASE; CELL-CYCLE; S-PHASE; DIFFERENTIATION; MATURATION; COMPLEX; PLATE; PROLIFERATION	Transforming growth factor-beta(TGF-beta) plays an essential role in chondrocyte maturation. It stimulates chondrocyte proliferation but inhibits chondrocyte differentiation. In this study, we found that TGF-beta rapidly induced beta-catenin protein levels and signaling in murine neonatal sternal primary chondrocytes. TGF-beta-increased beta-catenin induction was reproduced by overexpression of SMAD3 and was absent in Smad3(-/-) chondrocytes treated with TGF-beta. SMAD3 inhibited beta-transducin repeat-containing protein-mediated degradation of beta-catenin and immunoprecipitated with beta-catenin following TGF-beta treatment. Both SMAD3 and beta-catenin co-localized to the nucleus after TGF-beta treatment. Although both TGF-beta and beta-catenin stimulated cyclin D-1 expression in chondrocytes, the effect of TGF-beta was inhibited with beta-catenin gene deletion or SMAD3 loss of function. These results demonstrate that TGF-beta stimulates cyclin D-1 expression at least in part through activation of beta-catenin signaling.	Univ Rochester, Ctr Musculoskeletal Res, Dept Orthopaed, Rochester, NY 14642 USA	University of Rochester	O'Keefe, RJ (corresponding author), Univ Rochester, Med Ctr, Dept Orthopaed, POB 665, Rochester, NY 14642 USA.	regis_okeefe@urmc.rochester.edu	Chen, Mo/E-8234-2010	Zuscik, Michael/0000-0003-0461-8708; drissi, hicham/0000-0002-3322-281X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038945, R01AR051189, R01AR054465, K02AR052411, R29AR038945] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR054465-01, R01 AR054465, R01 AR051189-03, AR051189, R01 AR051189, AR38945, R01 AR051189-02, K02 AR052411, R01 AR038945, K02 AR052411-01A2, K02 AR052411-02] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104; Alvarez J, 2001, DEV DYNAM, V221, P311, DOI 10.1002/dvdy.1141; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; Beier F, 2001, MOL BIOL CELL, V12, P3852, DOI 10.1091/mbc.12.12.3852; Brault V, 2001, DEVELOPMENT, V128, P1253; Chen M, 2005, J BONE MINER RES, V20, pS29; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016; Dong YF, 2005, J CELL BIOCHEM, V95, P1057, DOI 10.1002/jcb.20466; Enomoto-Iwamoto M, 2002, DEV BIOL, V251, P142, DOI 10.1006/dbio.2002.0802; Ferguson CM, 2000, ENDOCRINOLOGY, V141, P4728, DOI 10.1210/en.141.12.4728; Graham TA, 2002, MOL CELL, V10, P563, DOI 10.1016/S1097-2765(02)00637-8; Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013; Ionescu AM, 2003, EXP CELL RES, V288, P198, DOI 10.1016/S0014-4827(03)00181-2; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kotsinas A, 2002, AM J PATHOL, V161, P1619, DOI 10.1016/S0002-9440(10)64440-9; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Li TF, 2006, J BONE MINER RES, V21, P4, DOI 10.1359/JBMR.050911; Masckauchan T. Nestor H., 2005, Angiogenesis, V8, P43, DOI 10.1007/s10456-005-5612-9; Matsunaga S, 1999, INT J ONCOL, V14, P1063; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Pateder DB, 2000, EXP CELL RES, V256, P555, DOI 10.1006/excr.2000.4860; Serra Rosa, 2003, Birth Defects Research, V69, P333, DOI 10.1002/bdrc.10023; Shang XZ, 2004, LAB INVEST, V84, P332, DOI 10.1038/labinvest.3700043; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Tago K, 2000, GENE DEV, V14, P1741; TAYLOR LM, 1993, ENDOCRINOLOGY, V133, P2292, DOI 10.1210/en.133.5.2292; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Wang W, 2004, ONCOGENE, V23, P1064, DOI 10.1038/sj.onc.1207204; Warner DR, 2005, FEBS LETT, V579, P3539, DOI 10.1016/j.febslet.2005.05.024; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wing-Hoi C, 2001, J CELL BIOCHEM, P79; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Yang X, 2001, J CELL BIOL, V153, P35, DOI 10.1083/jcb.153.1.35	39	65	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21296	21304		10.1074/jbc.M600514200	http://dx.doi.org/10.1074/jbc.M600514200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16690606	hybrid, Green Accepted			2022-12-25	WOS:000239187300065
J	Soundar, S; O'Hagan, M; Fomulu, KS; Colman, RF				Soundar, Sambanthamurthy; O'Hagan, Molly; Fomulu, Kenneth S.; Colman, Roberta F.			Identification of Mn2+-binding aspartates from alpha, beta, and gamma subunits of human NAD-dependent isocitrate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALLOSTERIC ADP SITE; METAL-ION BINDING; PIG-HEART; AFFINITY LABEL; 2-(4-BROMO-2,3-DIOXOBUTYLTHIO)ADENOSINE 5'-DIPHOSPHATE; CARBOXYPEPTIDASE-A; CRYSTAL-STRUCTURE; TARGET PEPTIDES; MANGANOUS ION; MUTAGENESIS	The human NAD-dependent isocitrate dehydrogenase (IDH), with three types of subunits present in the ratio of 2 alpha:1 beta:1 gamma, requires a divalent metal ion to catalyze the oxidative decarboxylation of isocitrate. With the aim of identifying ligands of the enzyme-bound Mn2+, we mutated aspartates on the alpha, beta, or gamma subunits. Mutagenesis target sites were based on crystal structures of metal-isocitrate complexes of Escherichia coli and pig mitochondrial NADP-IDH and sequence alignments. Aspartates replaced by asparagine or cysteine were 206, 230, and 234 of the alpha subunit and those corresponding to alpha-Asp-206: 217 of the alpha subunit and 215 of the gamma subunit. Each expressed, purified mutant enzyme has two wild-type subunits and one subunit with a single mutation. Specific activities of WT, alpha-D206N, alpha-D230C, alpha-D234C, alpha-D217N, and alpha-D215N enzymes are 22, 29, 1.4, 0.2, 7.3 and 3.7 mu mol of NADH/min/mg, respectively, whereas alpha-D230N and beta-D234N enzymes showed no activity. The K-m,Mn(2+) for alpha-D230C and gamma-D215N are increased 32- and 100-fold, respectively, along with elevations in Km, isocitrate. The K-m,K-NAD of alpha-D230C is increased 16-fold, whereas that of beta-D217N is elevated 10-fold. For all the mutants Km, isocitrate is decreased by ADP, indicating that these aspartates are not needed for normal ADP activation. This study demonstrates that alpha-Asp-230 and alpha-Asp-234 are critical for catalytic activity, but alpha-Asp-206 is not needed; alpha-Asp-230 and gamma-Asp-215 may interact directly with the Mn2+; and alpha-Asp-230 and beta-Asp-217 contribute to the affinity of the enzyme for NAD. These results suggest that the active sites of the human NAD-IDH are shared between alpha and gamma subunits and between alpha and beta subunits.	Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA	University of Delaware	Colman, RF (corresponding author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.	rfcolman@udel.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067774] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL67774] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AULD DS, 1970, BIOCHEMISTRY-US, V9, P4352, DOI 10.1021/bi00824a016; BLACKSHEAR PJ, 1984, METHOD ENZYMOL, V104, P237; Ceccarelli C, 2002, J BIOL CHEM, V277, P43454, DOI 10.1074/jbc.M207306200; Chen HY, 1998, BIOCHEMISTRY-US, V37, P6541, DOI 10.1021/bi973032g; COHEN PF, 1974, EUR J BIOCHEM, V47, P35, DOI 10.1111/j.1432-1033.1974.tb03665.x; COHEN PF, 1972, BIOCHEMISTRY-US, V11, P1501, DOI 10.1021/bi00758a027; COLMAN RF, 1983, PEPTIDE PROTEIN REV, V1, P41; DiTusa CA, 2001, BIOCHEMISTRY-US, V40, P5345, DOI 10.1021/bi0017327; EHRLICH RS, 1990, BIOCHEMISTRY-US, V29, P5179, DOI 10.1021/bi00473a026; EHRLICH RS, 1983, J BIOL CHEM, V258, P7079; EHRLICH RS, 1981, J BIOL CHEM, V256, P1276; EHRLICH RS, 1982, J BIOL CHEM, V257, P4769; EHRLICH RS, 1981, J BIOL CHEM, V256, P560; EHRLICH RS, 1995, BBA-PROTEIN STRUCT M, V1246, P135, DOI 10.1016/0167-4838(94)00192-J; Grodsky NB, 2000, BIOCHEMISTRY-US, V39, P2193, DOI 10.1021/bi9919753; Hu G, 2005, ACTA CRYSTALLOGR F, V61, P486, DOI 10.1107/S1744309105010651; HUANG Y, 1986, J BIOL CHEM, V261, P14100; Huang YC, 2004, BIOCHEMISTRY-US, V43, P2821, DOI 10.1021/bi030253f; HUANG YC, 1989, J BIOL CHEM, V264, P12208; Huang YC, 1997, ARCH BIOCHEM BIOPHYS, V348, P207, DOI 10.1006/abbi.1997.0392; HUHEEY JE, 1993, INORGANIC CHEM PRINC, P328; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; Kim TK, 2003, J BIOL CHEM, V278, P49323, DOI 10.1074/jbc.M303781200; KIM YO, 1995, BIOCHEM J, V308, P63, DOI 10.1042/bj3080063; Kim YO, 1999, J BIOL CHEM, V274, P36866, DOI 10.1074/jbc.274.52.36866; KUMAR A, 1994, ARCH BIOCHEM BIOPHYS, V308, P357, DOI 10.1006/abbi.1994.1051; Lesburg CA, 1997, BIOCHEMISTRY-US, V36, P15780, DOI 10.1021/bi971296x; Lin AP, 2003, J BIOL CHEM, V278, P12864, DOI 10.1074/jbc.M300154200; Lin AP, 2002, J BIOL CHEM, V277, P22475, DOI 10.1074/jbc.M202534200; LIPPARD SJ, 1994, PRINCIPLES BIOINORGA, P25; MAKINEN MW, 1979, J BIOL CHEM, V254, P356; Panisko EA, 2001, J BIOL CHEM, V276, P1204, DOI 10.1074/jbc.M005056200; RAMACHANDRAN N, 1974, FEBS LETT, V49, P129, DOI 10.1016/0014-5793(74)80648-4; RAMACHANDRAN N, 1977, BIOCHEMISTRY-US, V16, P1564, DOI 10.1021/bi00627a006; RAMACHANDRAN N, 1980, J BIOL CHEM, V255, P8859; RAMACHANDRAN N, 1978, P NATL ACAD SCI USA, V75, P252, DOI 10.1073/pnas.75.1.252; Singh SK, 2001, J BIOL CHEM, V276, P26154, DOI 10.1074/jbc.M101191200; Soundar S, 2005, FASEB J, V19, pA1400; SOUNDAR S, 1993, J BIOL CHEM, V268, P5264; Soundar S, 2003, J BIOL CHEM, V278, P52146, DOI 10.1074/jbc.M306178200; STODDARD BL, 1993, BIOCHEMISTRY-US, V32, P9310, DOI 10.1021/bi00087a008; Warburg O., 1942, BIOCHEM Z, V310, P384	42	20	21	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21073	21081		10.1074/jbc.M602956200	http://dx.doi.org/10.1074/jbc.M602956200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16737955	hybrid			2022-12-25	WOS:000239187300044
J	Zhong, N; Kim, CY; Rizzu, P; Geula, C; Porter, DR; Pothos, EN; Squitieri, F; Heutink, P; Xu, J				Zhong, Nan; Kim, Christina Y.; Rizzu, Patrizia; Geula, Changiz; Porter, Douglas R.; Pothos, Emmanuel N.; Squitieri, Ferdinando; Heutink, Peter; Xu, Jin			DJ-1 transcriptionally up-regulates the human tyrosine hydroxylase by inhibiting the sumoylation of pyrimidine tract-binding protein-associated splicing factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONSET PARKINSONS-DISEASE; OXIDATIVE STRESS; DROSOPHILA DJ-1; CELL-DEATH; ANTIOXIDATIVE STRESS; ANDROGEN RECEPTOR; SUMO; GENE; MICE; MUTATIONS	Loss-of-function mutations in DJ-1 cause a subset of familial Parkinson disease (PD). However, the mechanism underlying the selective vulnerability in dopaminergic pathway due to the inactivation of DJ-1 is unclear. Previously, we have reported that DJ-1 is a neuroprotective transcriptional coactivator interacting with the transcriptional co-repressor pyrimidine tract-binding protein-associated splicing factor (PSF). Here we show that DJ-1 and PSF bind and regulate the human tyrosine hydroxylase (TH) promoter. Inactivation of DJ-1 by small interference RNA ( siRNA) results in decreased TH expression and L-DOPA production in human dopaminergic cell lines. Consistent with its role as a transcriptional regulator, DJ-1 specifically suppresses the global SUMO-1 modification. High molecular weight sumoylated protein species, including PSF, accumulate in the lymphoblast cells from the patients carrying pathogenic DJ-1 mutations. DJ-1 elevates the TH expression by inhibiting the sumoylation of PSF and preventing its sumoylation-dependent recruitment of histone deacetylase 1. Furthermore, siRNA silencing of DJ-1 decreases the acetylation of TH promoter-bound histones, and histone deacetylase inhibitors restore the DJ-1 siRNA-induced repression of TH. Therefore, our results suggest DJ-1 as a regulator of protein sumoylation and directly link the loss of DJ-1 expression and transcriptional dysfunction to impaired dopamine synthesis.	Tufts Univ, Dept Neurol, Sch Med, Caritas St Elizabeths Med Ctr, Brighton, MA 02135 USA; Vrise Univ, Univ Med Ctr, Dept Human Genet, Amsterdam, Netherlands; Vrije Univ Amsterdam, Amsterdam, Netherlands; Harvard Univ, Sch Med, Lab Neurodegenerat & Aging Res, Dept Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Gerontol, Boston, MA 02115 USA; Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02111 USA; IRCCS Neuromed, Neurogenet Unit, I-86077 Pozzilli, Italy	St. Elizabeth's Medical Center; Tufts University; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Tufts University; IRCCS Neuromed	Xu, J (corresponding author), Tufts Univ, Dept Neurol, Sch Med, Caritas St Elizabeths Med Ctr, 736 Cambridge St,CBR4, Brighton, MA 02135 USA.	Jin.Xu@tufts.edu	Squitieri, Ferdinando/N-1852-2019	Squitieri, Ferdinando/0000-0002-7397-1727; Heutink, Peter/0000-0001-5218-1737; Xu, Jin/0000-0001-6617-5311; Pothos, Emmanuel/0000-0001-8825-7852				Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Canet-Aviles RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101; Chen LN, 2005, J BIOL CHEM, V280, P21418, DOI 10.1074/jbc.M413955200; Dekker MCJ, 2004, J NEURAL TRANSM, V111, P1575, DOI 10.1007/s00702-004-0165-4; Ferrante RJ, 2003, J NEUROSCI, V23, P9418; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Girdwood DWH, 2004, SEMIN CELL DEV BIOL, V15, P201, DOI 10.1016/j.semcdb.2003.12.001; Goldberg MS, 2005, NEURON, V45, P489, DOI 10.1016/j.neuron.2005.01.041; HAYASHI M, 1990, AM J PHYSIOL, V258, pF28, DOI 10.1152/ajprenal.1990.258.1.F28; Hedrich K, 2004, NEUROLOGY, V62, P389, DOI 10.1212/01.WNL.0000113022.51739.88; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Junn E, 2005, P NATL ACAD SCI USA, V102, P9691, DOI 10.1073/pnas.0409635102; Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010; Kim RH, 2005, P NATL ACAD SCI USA, V102, P5215, DOI 10.1073/pnas.0501282102; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; Macedo MG, 2003, HUM MOL GENET, V12, P2807, DOI 10.1093/hmg/ddg304; Martinat C, 2004, PLOS BIOL, V2, P1754, DOI 10.1371/journal.pbio.0020327; Mathur M, 2001, MOL CELL BIOL, V21, P2298, DOI 10.1128/MCB.21.7.2298-2311.2001; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Menzies FM, 2005, CURR BIOL, V15, P1578, DOI 10.1016/j.cub.2005.07.036; Meulener M, 2005, CURR BIOL, V15, P1572, DOI 10.1016/j.cub.2005.07.064; MOORE DJ, 2006, SCI AGING KNOWLEDGE, pPE2; Niki T, 2003, MOL CANCER RES, V1, P247; Olzmann JA, 2004, J BIOL CHEM, V279, P8506, DOI 10.1074/jbc.M311017200; Park J, 2005, GENE, V361, P133, DOI 10.1016/j.gene.2005.06.040; Perez FA, 2005, P NATL ACAD SCI USA, V102, P2174, DOI 10.1073/pnas.0409598102; Rosas-Acosta G, 2005, MOL CELL PROTEOMICS, V4, P56, DOI 10.1074/mcp.M400149-MCP200; Shendelman S, 2004, PLOS BIOL, V2, P1764, DOI 10.1371/journal.pbio.0020362; Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100; Shinbo Y, 2006, CELL DEATH DIFFER, V13, P96, DOI 10.1038/sj.cdd.4401704; Shinbo YM, 2005, INT J ONCOL, V26, P641; Taira T, 2004, EMBO REP, V5, P213, DOI 10.1038/sj.embor.7400074; Takahashi K, 2001, J BIOL CHEM, V276, P37556, DOI 10.1074/jbc.M101730200; Takahashi-Niki K, 2004, BIOCHEM BIOPH RES CO, V320, P389, DOI 10.1016/j.bbrc.2004.05.187; Watts FZ, 2004, SEMIN CELL DEV BIOL, V15, P211, DOI 10.1016/j.semcdb.2003.12.002; Wilson MA, 2003, P NATL ACAD SCI USA, V100, P9256, DOI 10.1073/pnas.1133288100; Xu J, 2005, HUM MOL GENET, V14, P1231, DOI 10.1093/hmg/ddi134; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yang YF, 2005, P NATL ACAD SCI USA, V102, P13670, DOI 10.1073/pnas.0504610102; Yokota T, 2003, BIOCHEM BIOPH RES CO, V312, P1342, DOI 10.1016/j.bbrc.2003.11.056; Zhou WB, 2005, J BIOL CHEM, V280, P43150, DOI 10.1074/jbc.M507124200	43	150	157	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20940	20948		10.1074/jbc.M601935200	http://dx.doi.org/10.1074/jbc.M601935200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16731528	hybrid			2022-12-25	WOS:000239187300031
J	Bryan, KE; Wen, KK; Zhu, M; Rendtorff, ND; Feldkamp, M; Tranebjaerg, L; Friderici, KH; Rubenstein, PA				Bryan, Keith E.; Wen, Kuo-Kuang; Zhu, Mei; Rendtorff, Nanna Dahl; Feldkamp, Michael; Tranebjaerg, Lisbeth; Friderici, Karen H.; Rubenstein, Peter A.			Effects of human deafness gamma-actin mutations (DFNA20/26) on actin function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERELY DECREASED HYDROPHOBICITY; NONSYNDROMIC HEARING-LOSS; SNELLS-WALTZER MICE; SUBDOMAIN 3/4 LOOP; MYOSIN VIIA GENE; YEAST ACTIN; SACCHAROMYCES-CEREVISIAE; ARP2/3 COMPLEX; MITOCHONDRIAL MOVEMENT; SKELETAL-MUSCLE	Six point mutations in non-muscle gamma-actin at the DFNA20/26 locus cause autosomal dominant nonsyndromic hearing loss. The molecular basis for the hearing loss is unknown. We have engineered each gamma-actin mutation into yeast actin to investigate the effects of these mutations on actin function in vivo and in vitro. Cells expressing each of the mutant actins as the sole actin in the cell were viable. Four of the six mutant strains exhibited significant growth deficiencies in complete medium and an inability to grow on glycerol as the sole carbon source, implying a mitochondrial defect(s). These four strains exhibited abnormal mitochondrial morphology, although the mtDNA was retained. All of the mutant cells exhibited an abnormally high percentage of fragmented/non-polarized actin cables or randomly distributed actin patches. Five of the six mutants displayed strain-specific vacuole morphological abnormalities. Two of the purified mutant actins exhibited decreased thermal stability and increased rates of nucleotide exchange, indicative of increased protein flexibility. V370A actin alone polymerized abnormally. It aggregated in low ionic strength buffer and polymerized faster than wild-type actin, probably in part because of enhanced nucleation. Mixtures of wild-type and V370A actins displayed kinetic properties in proportion to the mole fraction of each actin in the mixture. No dominant effect of the mutant actin was observed. Our results suggest that a major factor in the deafness caused by these mutations is an altered ability of the actin filaments to be properly regulated by actin-binding proteins rather than an inability to polymerize.	Univ Iowa, Carver Coll Med, Dept Biochem, Iowa City, IA 52242 USA; Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA; Michigan State Univ, Dept Pediat & Human Dev, E Lansing, MI 48824 USA; Univ Copenhagen, Wilhelm Johannsen Ctr Funct Genom, Dept Biochem Med, DK-2400 Copenhagen K, Denmark; Bispebjerg Hosp, Dept Audiol, DK-2400 Copenhagen NV, Denmark	University of Iowa; Michigan State University; Michigan State University; University of Copenhagen; University of Copenhagen; Bispebjerg Hospital	Rubenstein, PA (corresponding author), Univ Iowa, Carver Coll Med, Dept Biochem, Bowen Sci Bldg 51,Newton Rd, Iowa City, IA 52242 USA.	peter-rubenstein@uiowa.edu		Rubenstein, Peter/0000-0003-1225-4414	NIDCD NIH HHS [DC004568] Funding Source: Medline; NIGMS NIH HHS [GM33689] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004568] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Amann KJ, 2001, P NATL ACAD SCI USA, V98, P15009, DOI 10.1073/pnas.211556398; Amberg DC, 1998, MOL BIOL CELL, V9, P3259, DOI 10.1091/mbc.9.12.3259; Avraham KB, 1997, HUM MOL GENET, V6, P1225, DOI 10.1093/hmg/6.8.1225; Blondin L, 2001, EUR J BIOCHEM, V268, P6426, DOI 10.1046/j.0014-2956.2001.02592.x; Boldogh IR, 2005, GENE, V354, P28, DOI 10.1016/j.gene.2005.03.049; Boldogh IR, 2004, MOL BIOL CELL, V15, P3994, DOI 10.1091/mbc.E04-01-0053; Boldogh IR, 2001, P NATL ACAD SCI USA, V98, P3162, DOI 10.1073/pnas.051494698; BRETSCHER A, 1994, J CELL BIOL, V126, P821, DOI 10.1083/jcb.126.4.821; Chen WZ, 2006, BIOPHYS J, V90, P1308, DOI 10.1529/biophysj.105.064634; Cheng DM, 1999, J BIOL CHEM, V274, P35873, DOI 10.1074/jbc.274.50.35873; COOK RK, 1992, J BIOL CHEM, V267, P9430; COOK RK, 1991, J BIOL CHEM, V266, P16825; DEROSIER DJ, 1989, J CELL BIOL, V109, P2853, DOI 10.1083/jcb.109.6.2853; Donaudy F, 2004, AM J HUM GENET, V74, P770, DOI 10.1086/383285; Donaudy F, 2003, AM J HUM GENET, V72, P1571, DOI 10.1086/375654; DRUBIN DG, 1990, CELL MOTIL CYTOSKEL, V15, P7, DOI 10.1002/cm.970150103; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Evangelista Marie, 2002, Nature Cell Biology, V4, P260; Fehrenbacher KL, 2004, CURR BIOL, V14, P1996, DOI 10.1016/j.cub.2004.11.004; Furness DN, 2005, HEARING RES, V207, P22, DOI 10.1016/j.heares.2005.05.006; Hill KL, 1996, J CELL BIOL, V135, P1535, DOI 10.1083/jcb.135.6.1535; HIROKAWA N, 1982, J CELL BIOL, V95, P249, DOI 10.1083/jcb.95.1.249; Hofer D, 1997, J CELL SCI, V110, P765; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; Ichetovkin I, 2002, CURR BIOL, V12, P79, DOI 10.1016/S0960-9822(01)00629-7; Kovar DR, 2003, J CELL BIOL, V161, P875, DOI 10.1083/jcb.200211078; Kuang B, 1997, J BIOL CHEM, V272, P1237, DOI 10.1074/jbc.272.2.1237; Kuang B, 1997, J BIOL CHEM, V272, P4412, DOI 10.1074/jbc.272.7.4412; Laing NG, 2004, ANN NEUROL, V56, P689, DOI 10.1002/ana.20260; Lalwani AK, 2000, AM J HUM GENET, V67, P1121, DOI 10.1016/S0002-9297(07)62942-5; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Liu XZ, 1997, NAT GENET, V17, P268, DOI 10.1038/ng1197-268; Lu XY, 2005, J PHYSIOL-LONDON, V564, P65, DOI 10.1113/jphysiol.2004.078055; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; McKane M, 2005, J BIOL CHEM, V280, P36494, DOI 10.1074/jbc.M506970200; Melchionda S, 2001, AM J HUM GENET, V69, P635, DOI 10.1086/323156; Miller CJ, 1996, BIOCHEMISTRY-US, V35, P16557, DOI 10.1021/bi962388+; Minin AA, 2006, J CELL SCI, V119, P659, DOI 10.1242/jcs.02762; Moseley JB, 2004, MOL BIOL CELL, V15, P896, DOI 10.1091/mbc.E03-08-0621; Muller U, 2001, TRENDS CELL BIOL, V11, P334, DOI 10.1016/S0962-8924(01)02046-3; Musib R, 2002, J BIOL CHEM, V277, P22699, DOI 10.1074/jbc.M203096200; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; Nowak KJ, 1999, NAT GENET, V23, P208, DOI 10.1038/13837; Otomo T, 2005, NATURE, V433, P488, DOI 10.1038/nature03251; Page R, 1998, J MOL BIOL, V280, P463, DOI 10.1006/jmbi.1998.1879; Probst FJ, 1998, SCIENCE, V280, P1444, DOI 10.1126/science.280.5368.1444; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; RENDTORFF ND, 2006, IN PRESS EUR J HUM G; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; Sagot I, 2002, NAT CELL BIOL, V4, P42, DOI 10.1038/ncb719; SHORTLE D, 1984, P NATL ACAD SCI-BIOL, V81, P4889, DOI 10.1073/pnas.81.15.4889; Shvetsov A, 2002, BIOCHEMISTRY-US, V41, P10787, DOI 10.1021/bi020205f; SIKORSKI RS, 1989, GENETICS, V122, P19; Simon VR, 1997, CELL MOTIL CYTOSKEL, V37, P199, DOI 10.1002/(SICI)1097-0169(1997)37:3<199::AID-CM2>3.0.CO;2-2; SIMON VR, 1995, J CELL BIOL, V130, P345, DOI 10.1083/jcb.130.2.345; SUTOH K, 1989, BIOCHEMISTRY-US, V28, P102, DOI 10.1021/bi00427a015; TILNEY LG, 1983, J CELL BIOL, V96, P822, DOI 10.1083/jcb.96.3.822; van Wijk E, 2003, J MED GENET, V40, P879, DOI 10.1136/jmg.40.12.879; VANDEKERCKHOVE J, 1978, ARCH INT PHYSIOL BIO, V86, P891; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Vorobiev S, 2003, P NATL ACAD SCI USA, V100, P5760, DOI 10.1073/pnas.0832273100; Walsh T, 2002, P NATL ACAD SCI USA, V99, P7518, DOI 10.1073/pnas.102091699; Wang AH, 1998, SCIENCE, V280, P1447, DOI 10.1126/science.280.5368.1447; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; Wen KK, 2005, J BIOL CHEM, V280, P24168, DOI 10.1074/jbc.M502024200; Wen KK, 2003, J BIOL CHEM, V278, P48386, DOI 10.1074/jbc.M308980200; Wen KK, 2000, J BIOL CHEM, V275, P40594, DOI 10.1074/jbc.M007201200; Yang HC, 2001, METHOD CELL BIOL, V65, P333, DOI 10.1016/S0091-679X(01)65020-9; Yao XY, 2002, J BIOL CHEM, V277, P22875, DOI 10.1074/jbc.M201685200; Zhu M, 2003, AM J HUM GENET, V73, P1082, DOI 10.1086/379286	72	33	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20129	20139		10.1074/jbc.M601514200	http://dx.doi.org/10.1074/jbc.M601514200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16690605	hybrid			2022-12-25	WOS:000239038200037
J	Robertson, AB; Pattishall, SR; Gibbons, EA; Matson, SW				Robertson, Adam B.; Pattishall, Steven R.; Gibbons, Erin A.; Matson, Steven W.			MutL-catalyzed ATP hydrolysis is required at a post-UvrD loading step in methyl-directed mismatch repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA HELICASE-II; ESCHERICHIA-COLI MUTS; C-TERMINAL DOMAIN; GENE-PRODUCT; REPLICATION FIDELITY; GENOME INSTABILITY; IN-VIVO; BINDING; PROTEIN; CANCER	Methyl-directed mismatch repair is a coordinated process that ensures replication fidelity and genome integrity by resolving base pair mismatches and insertion/deletion loops. This post-replicative event involves the activities of several proteins, many of which appear to be regulated by MutL. MutL interacts with and modulates the activities of MutS, MutH, UvrD, and perhaps other proteins. The purified protein catalyzes a slow ATP hydrolysis reaction that is essential for its role in mismatch repair. However, the role of the ATP hydrolysis reaction is not understood. We have begun to address this issue using two point mutants: MutL-E29A, which binds nucleotide but does not catalyze ATP hydrolysis, and MutL-D58A, which does not bind nucleotide. As expected, both mutants failed to complement the loss of MutL in genetic assays. Purified MutL-E29A protein interacted with MutS and stimulated the MutH-catalyzed nicking reaction in a mismatch-dependent manner. Importantly, MutL-E29A stimulated the loading of UvrD on model substrates. In fact, stimulation of UvrD-catalyzed unwinding was more robust with MutL-E29A than the wild-type protein. MutL-D58A, on the other hand, did not interact with MutS, stimulate MutH- catalyzed nicking, or stimulate the loading of UvrD. We conclude that ATP-bound MutL is required for the incision steps associated with mismatch repair and that ATP hydrolysis by MutL is required for a step in the mismatch repair pathway subsequent to the loading of UvrD and may serve to regulate helicase loading.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol & Cellular Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Matson, SW (corresponding author), Univ N Carolina, Dept Biol, CB 3280,Coker Hall, Chapel Hill, NC 27599 USA.	smatson@bio.unc.edu						Acharya S, 2003, MOL CELL, V12, P233, DOI 10.1016/S1097-2765(03)00219-3; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Aronshtam A, 1996, NUCLEIC ACIDS RES, V24, P2498, DOI 10.1093/nar/24.13.2498; AU KG, 1992, J BIOL CHEM, V267, P12142; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; BENDE SM, 1991, NUCLEIC ACIDS RES, V19, P1549, DOI 10.1093/nar/19.7.1549; BROSH RM, 1995, J BACTERIOL, V177, P5612, DOI 10.1128/jb.177.19.5612-5621.1995; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Burdett V, 2001, P NATL ACAD SCI USA, V98, P6765, DOI 10.1073/pnas.121183298; COOPER DL, 1993, J BIOL CHEM, V268, P11823; Dao V, 1998, J BIOL CHEM, V273, P9202, DOI 10.1074/jbc.273.15.9202; Drotschmann K, 1998, NUCLEIC ACIDS RES, V26, P948, DOI 10.1093/nar/26.4.948; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; Fischer CJ, 2004, J MOL BIOL, V344, P1287, DOI 10.1016/j.jmb.2004.10.005; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GEORGE JW, 1994, J MOL BIOL, V235, P424, DOI 10.1006/jmbi.1994.1003; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; GRILLEY M, 1990, MUTAT RES, V236, P253, DOI 10.1016/0921-8777(90)90009-T; Guarne A, 2004, EMBO J, V23, P4134, DOI 10.1038/sj.emboj.7600412; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Hall MC, 1998, EMBO J, V17, P1535, DOI 10.1093/emboj/17.5.1535; Hall MC, 2002, J BIOL CHEM, V277, P3673, DOI 10.1074/jbc.M106120200; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jiricny J, 1996, CANCER SURV, V28, P47; Junop MS, 2003, DNA REPAIR, V2, P387, DOI 10.1016/S1568-7864(02)00245-8; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; Kosinski J, 2005, J MOL BIOL, V351, P895, DOI 10.1016/j.jmb.2005.06.044; Kunkel TA, 2005, ANNU REV BIOCHEM, V74, P681, DOI 10.1146/annurev.biochem.74.082803.133243; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Luria SE, 1943, GENETICS, V28, P491; MATSON SW, 1986, J BIOL CHEM, V261, P169; Mechanic LE, 2000, J BIOL CHEM, V275, P38337, DOI 10.1074/jbc.M006268200; Mechanic LE, 1999, J BIOL CHEM, V274, P12488, DOI 10.1074/jbc.274.18.12488; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; Robertson A, 2006, J BIOL CHEM, V281, P8399, DOI 10.1074/jbc.M509184200; RUNYON GT, 1989, J BIOL CHEM, V264, P17502; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; Schofield MJ, 2003, ANNU REV MICROBIOL, V57, P579, DOI 10.1146/annurev.micro.57.030502.090847; Schofield MJ, 2001, J BIOL CHEM, V276, P28291, DOI 10.1074/jbc.M103148200; Selmane T, 2003, J MOL BIOL, V334, P949, DOI 10.1016/j.jmb.2003.10.010; SHERMAN JA, 1994, J BIOL CHEM, V269, P26220; Spampinato C, 2000, J BIOL CHEM, V275, P9863, DOI 10.1074/jbc.275.13.9863; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; WELSH KM, 1987, J BIOL CHEM, V262, P15624; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197	60	24	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					19949	19959		10.1074/jbc.M601604200	http://dx.doi.org/10.1074/jbc.M601604200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16690604	Green Published, hybrid			2022-12-25	WOS:000239038200018
J	Trujillo, M; Mauri, P; Benazzi, L; Comini, M; De Palma, A; Flohe, L; Radi, R; Stehr, M; Singh, M; Ursini, F; Jaeger, T				Trujillo, Madia; Mauri, PierLuigi; Benazzi, Louise; Comini, Marcelo; De Palma, Antonella; Flohe, Leopold; Radi, Rafael; Stehr, Matthias; Singh, Mahavir; Ursini, Fulvio; Jaeger, Timo			The mycobacterial thioredoxin peroxidase can act as a one-cysteine peroxiredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPAREDOXIN PEROXIDASE; TRYPANOSOMA-BRUCEI; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; THIOL PEROXIDASE; SULFENIC ACID; PEROXYNITRITE; OXIDATION; TUBERCULOSIS; MUTAGENESIS	Thioredoxin peroxidase (TPx) has been reported to dominate the defense against H2O2, other hydroperoxides, and peroxynitrite at the expense of thioredoxin (Trx) B and C in Mycobacterium tuberculosis (Mt). By homology, the enzyme has been classified as an atypical 2-C-peroxiredoxin (Prx), with Cys(60) as the "peroxidatic" cysteine (C-P) forming a complex catalytic center with Cys(93) as the "resolving" cysteine (CR). Site-directed mutagenesis confirms Cys(60) to be CP and Cys(80) to be catalytically irrelevant. Replacing Cys(93) with serine leads to fast inactivation as seen by conventional activity determination, which is associated with oxidation of Cys(60) to a sulfinic acid derivative. However, in comparative stopped-flow analysis, WT-MtTPx and MtTPx C93S reduce peroxynitrite and react with TrxB and -C similarly fast. Reduction of pre-oxidized WT-MtTPx and MtTPx C93S by MtTrxB is demonstrated by monitoring the redox-dependent tryptophan fluorescence of MtTrxB. Furthermore, MtTPx C93S remains stable for 10 min at a morpholinosydnonimine hydrochloride-generated low flux of peroxynitrite and excess MtTrxB in a dihydrorhodamine oxidation model. Liquid chromatography-tandem mass spectrometry analysis revealed disulfide bridges between Cys(60) and Cys(93) and between Cys(60) and Cys(80) in oxidized WT-MtTPx. Reaction of pre-oxidized WT-MtTPx and MtTPx (CS)-S-93 with MtTrxB C34S or MtTrxC C40S yielded dead-end intermediates in which the Trx mutants are preferentially linked via disulfide bonds to Cys(60) and never to Cys(93) of the TPx. It is concluded that neither Cys(80) nor Cys(93) is required for the catalytic cycle of the peroxidase. Instead, MtTPx can react as a 1-C-Prx with Cys(60) being the site of attack for both the oxidizing and the reducing substrate. The role of Cys(93) is likely to conserve the oxidation equivalents of the sulfenic acid state of CP as a disulfide bond to prevent overoxidation of Cys(60) under a restricted supply of reducing substrate.	MOLISA GmbH, D-39106 Magdeburg, Germany; Univ Republica, Fac Med, Dept Bioquim, UY-11800 Montevideo, Uruguay; CNR, Inst Biomed Technol, I-20090 Milan, Italy; Heidelberg Univ, Ctr Biochem, D-69120 Heidelberg, Germany; German Res Ctr Biotechnol, Dept Gen Anal, D-38124 Braunschweig, Germany; Univ Padua, Dept Biol Chem, I-35121 Padua, Italy	Universidad de la Republica, Uruguay; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); Ruprecht Karls University Heidelberg; Helmholtz Association; Helmholtz-Center for Infection Research; University of Padua	Jaeger, T (corresponding author), MOLISA GmbH, Univ Pl 2, D-39106 Magdeburg, Germany.	t.jaeger@molisa.biz	benazzi, louise/AAW-2684-2020; Mauri, Pietro Luigi/AAC-3095-2019; De Palma, Antonella/K-8451-2016	Mauri, Pietro Luigi/0000-0003-4364-0393; De Palma, Antonella/0000-0001-5937-8604; Trujillo, Madia/0000-0003-2087-017X; Comini, Marcelo/0000-0001-5000-1333				Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Baker LMS, 2003, J BIOL CHEM, V278, P9203, DOI 10.1074/jbc.M209888200; Bryk R, 2002, SCIENCE, V295, P1073, DOI 10.1126/science.1067798; Budde H, 2003, BIOL CHEM, V384, P619, DOI 10.1515/BC.2003.069; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Choi JK, 2003, J BIOL CHEM, V278, P49478, DOI 10.1074/jbc.M309015200; Flohe L, 2002, ARCH BIOCHEM BIOPHYS, V397, P324, DOI 10.1006/abbi.2001.2688; Flohe L, 2001, SELENIUM: ITS MOLECULAR BIOLOGY AND ROLE IN HUMAN HEALTH, P157; Flohe L., 1989, GLUTATHIONE CHEM BIO, P643; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Jacob C, 2003, ANGEW CHEM INT EDIT, V42, P4742, DOI 10.1002/anie.200300573; Jaeger T, 2004, ARCH BIOCHEM BIOPHYS, V423, P182, DOI 10.1016/j.abb.2003.11.021; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; Li S, 2005, J MOL BIOL, V346, P1035, DOI 10.1016/j.jmb.2004.12.046; Mauri P, 2003, BIOL CHEM, V384, P575, DOI 10.1515/BC.2003.065; Mendes P, 1997, TRENDS BIOCHEM SCI, V22, P361, DOI 10.1016/S0968-0004(97)01103-1; Poole LB, 2005, ARCH BIOCHEM BIOPHYS, V433, P240, DOI 10.1016/j.abb.2004.09.006; Poole LB, 2002, METHOD ENZYMOL, V348, P122, DOI 10.1016/S0076-6879(02)48632-6; RADI R, 1991, J BIOL CHEM, V266, P4244; Rhee SG, 2005, ANTIOXID REDOX SIGN, V7, P619, DOI 10.1089/ars.2005.7.619; SHERMAN DR, 1995, P NATL ACAD SCI USA, V92, P6625, DOI 10.1073/pnas.92.14.6625; Sherman DR, 1996, SCIENCE, V272, P1641, DOI 10.1126/science.272.5268.1641; Stehr M, 2006, ACTA CRYSTALLOGR D, V62, P563, DOI 10.1107/S0907444906008249; STORZ G, 1987, P NATL ACAD SCI USA, V84, P8917, DOI 10.1073/pnas.84.24.8917; Trujillo M, 2004, J BIOL CHEM, V279, P34175, DOI 10.1074/jbc.M404317200; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	29	32	34	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20555	20566		10.1074/jbc.M601008200	http://dx.doi.org/10.1074/jbc.M601008200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16682410	Green Submitted, hybrid			2022-12-25	WOS:000239038200077
J	Kang, YH; Ng, B; Leung, YM; He, Y; Xie, HL; Lodwick, D; Norman, RI; Tinker, A; Tsushima, RG; Gaisano, HY				Kang, Youhou; Ng, Betty; Leung, Yuk-Man; He, Yan; Xie, Huanli; Lodwick, David; Norman, Robert I.; Tinker, Andrew; Tsushima, Robert G.; Gaisano, Herbert Y.			Syntaxin-1A actions on sulfonylurea receptor 2A can block acidic pH-induced cardiac K-ATP channel activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE POTASSIUM CHANNELS; NUCLEAR MAGNETIC-RESONANCE; ISCHEMIC RAT-HEART; SKELETAL-MUSCLE; VENTRICULAR MYOCARDIUM; INTRACELLULAR H+; REPERFUSION; INHIBITION; MODULATION; MAGNESIUM	During cardiac ischemia, ATP stores are depleted, and cardiomyocyte intracellular pH lowers to < 7.0. The acidic pH acts on the Kir6.2 subunit of K-ATP channels to reduce its sensitivity to ATP, causing channel opening. We recently reported that syntaxin-1A (Syn-1A) binds nucleotide binding folds (NBF)-1 and NBF2 of sulfonylurea receptor 2A (SUR2A) to inhibit channel activity (Kang, Y., Leung, Y. M., Manning-Fox, J. E., Xia, F., Xie, H., Sheu, L., Tsushima, R. G., Light, P. E., and Gaisano, H. Y. (2004) J. Biol. Chem. 279, 47125-47131). Here, we examined Syn-1A actions on SUR2A to influence the pH regulation of cardiac K-ATP channels. K-ATP channel currents from inside-out patches excised from Kir6.2/SUR2A expressing HEK293 cells and freshly isolated cardiac myocytes were increased by reducing intracellular pH from 7.4 to 6.8, which could be blocked by increasing concentrations of Syn-1A added to the cytoplasmic surface. Syn-1A had no effect on C-terminal truncated Kir6.2 (Kir6.2-Delta C26) channels expressed in TSA cells without the SUR subunit. In vitro binding and co-immunoprecipitation studies show that Syn-1A binding to SUR2A or its NBF-1 and NBF-2 domain proteins increased progressively as pH was reduced from 7.4 to 6.0. The enhancement of Syn-1A binding to SUR2A by acidic pH was further regulated by Mg2+ and ATP. Therefore, pH regulates Kir.6.2/SUR2A channels not only by its direct actions on the Kir6.2 subunit but also by modulation of Syn-1A binding to SUR2A. The increased Syn-1A binding to the SUR2A at acidic pH would assert some inhibition of the K-ATP channels, which may serve as a "brake" to temper the fluctuation of low pH-induced K-ATP channel opening that could induce fatal re-entrant arrhythmias.	Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; China Med Univ, Dept Physiol, Taichung, Taiwan; Univ Leicester, Dept Cardiovasc Sci, Leicester LE2 7LX, Leics, England; UCL, London WC1E 6JJ, England	University of Toronto; University of Toronto; China Medical University Taiwan; University of Leicester; University of London; University College London	Gaisano, HY (corresponding author), Univ Toronto, Dept Med, Med Sci Bldg,Rm 7226, Toronto, ON M5S 1A8, Canada.	herbert.gaisano@utoronto.ca						ALLARD B, 1995, J PHYSIOL-LONDON, V485, P283, DOI 10.1113/jphysiol.1995.sp020730; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; BOND JM, 1991, BIOCHEM BIOPH RES CO, V179, P798, DOI 10.1016/0006-291X(91)91887-I; BORCHGREVINK PC, 1989, AM J PHYSIOL, V256, pH195, DOI 10.1152/ajpheart.1989.256.1.H195; BROOKS WM, 1983, J MOL CELL CARDIOL, V15, P495, DOI 10.1016/0022-2828(83)90325-5; Buja LM, 2005, CARDIOVASC PATHOL, V14, P170, DOI 10.1016/j.carpath.2005.03.006; CASCIO WE, 1995, J CARDIOVASC ELECTR, V6, P1039, DOI 10.1111/j.1540-8167.1995.tb00381.x; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Conti LR, 2001, J BIOL CHEM, V276, P41270, DOI 10.1074/jbc.M106555200; Cui N, 2003, J MEMBRANE BIOL, V192, P111, DOI 10.1007/s00232-002-1069-6; DAVIES NW, 1990, NATURE, V343, P375, DOI 10.1038/343375a0; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; GARLICK PB, 1979, BIOCHEM J, V184, P547, DOI 10.1042/bj1840547; Giblin JP, 2002, J BIOL CHEM, V277, P13717, DOI 10.1074/jbc.M112209200; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Kang Y, 2002, DIABETOLOGIA, V45, P231, DOI 10.1007/s00125-001-0718-0; Kang YH, 2004, J BIOL CHEM, V279, P47125, DOI 10.1074/jbc.M404954200; KIRKELS JH, 1989, J MOL CELL CARDIOL, V21, P1209, DOI 10.1016/0022-2828(89)90697-4; KLEBER AG, 1990, EXPERIENTIA, V46, P1162; KOYANO T, 1993, J PHYSIOL-LONDON, V463, P747, DOI 10.1113/jphysiol.1993.sp019620; LEDERER WJ, 1989, J PHYSIOL-LONDON, V419, P193, DOI 10.1113/jphysiol.1989.sp017869; Leung YM, 2003, J BIOL CHEM, V278, P17532, DOI 10.1074/jbc.M213088200; MURPHY E, 1989, J BIOL CHEM, V264, P5622; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; Pasyk EA, 2004, J BIOL CHEM, V279, P4234, DOI 10.1074/jbc.M309667200; Piao HL, 2001, J BIOL CHEM, V276, P36673, DOI 10.1074/jbc.M106123200; Saffitz JE, 2005, CARDIOVASC PATHOL, V14, P195, DOI 10.1016/j.carpath.2005.04.005; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; STEENBERGEN C, 1993, CIRC RES, V72, P112, DOI 10.1161/01.RES.72.1.112; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; VIVAUDOU M, 1995, J PHYSIOL-LONDON, V486, P629, DOI 10.1113/jphysiol.1995.sp020840; Wang R, 2005, J MEMBRANE BIOL, V204, P1, DOI 10.1007/s00232-005-0741-z; Wang XR, 2003, CIRC RES, V92, P1225, DOI 10.1161/01.RES.0000075601.95738.6D; Wu J, 2002, J MEMBRANE BIOL, V190, P105, DOI 10.1007/s00232-002-1029-1; Wu JP, 2002, J PHYSIOL-LONDON, V543, P495, DOI 10.1113/jphysiol.2002.025247; Xu HX, 2001, J BIOL CHEM, V276, P38690, DOI 10.1074/jbc.M106595200; Xu HX, 2001, J BIOL CHEM, V276, P12898, DOI 10.1074/jbc.M009631200	40	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19019	19028		10.1074/jbc.M513160200	http://dx.doi.org/10.1074/jbc.M513160200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16672225	hybrid			2022-12-25	WOS:000238847000015
J	Shrivastava, A; Tiwari, M; Sinha, RA; Kumar, A; Balapure, AK; Bajpai, VK; Sharma, R; Mitra, K; Tandon, A; Godbole, MM				Shrivastava, Ashutosh; Tiwari, Meenakshi; Sinha, Rohit A.; Kumar, Ashok; Balapure, Anil K.; Bajpai, Virendra K.; Sharma, Ramesh; Mitra, Kalyan; Tandon, Ashwani; Godbole, Madan M.			Molecular iodine induces caspase-independent apoptosis in human breast carcinoma cells involving the mitochondria-mediated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; RAT MAMMARY-GLAND; CANCER CELLS; THYROID-CELLS; BAX; PROTEIN; DEATH; ACTIVATION; INHIBITION; AIF	Molecular iodine (I-2) is known to inhibit the induction and promotion of N-methyl-n-nitrosourea-induced mammary carcinogenesis, to regress 7,12-dimethylbenz(a) anthracene-induced breast tumors in rat, and has also been shown to have beneficial effects in fibrocystic human breast disease. Cytotoxicity of iodine on cultured human breast cancer cell lines, namely MCF-7, MDA-MB-231, MDA-MB-453, ZR-75-1, and T-47D, is reported in this communication. Iodine induced apoptosis in all of the cell lines tested, except MDA-MB-231, shown by sub-G1 peak analysis using flow cytometry. Iodine inhibited proliferation of normal human peripheral blood mononuclear cells; however, it did not induce apoptosis in these cells. The iodine-induced apoptotic mechanism was studied in MCF-7 cells. DNA fragmentation analysis confirmed internucleosomal DNA degradation. Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling established that iodine induced apoptosis in a time- and dose-dependent manner in MCF-7 cells. Iodine-induced apoptosis was independent of caspases. Iodine dissipated mitochondrial membrane potential, exhibited antioxidant activity, and caused depletion in total cellular thiol content. Western blot results showed a decrease in Bcl-2 and up-regulation of Bax. Immunofluorescence studies confirmed the activation and mitochondrial membrane localization of Bax. Ectopic Bcl-2 overexpression did not rescue iodine-induced cell death. Iodine treatment induces the translocation of apoptosis-inducing factor from mitochondria to the nucleus, and treatment of N-acetyl-L-cysteine prior to iodine exposure restored basal thiol content, ROS levels, and completely inhibited nuclear translocation of apoptosis-inducing factor and subsequently cell death, indicating that thiol depletion may play an important role in iodine-induced cell death. These results demonstrate that iodine treatment activates a caspase-independent and mitochondria-mediated apoptotic pathway.	Sanjay Gandhi Postgrad Inst Med Sci, Dept Endocrinol, Lucknow 226014, Uttar Pradesh, India; Cent Drug Res Inst, Natl Lab Anim Cell Culture, Lucknow 226014, Uttar Pradesh, India; Cent Drug Res Inst, Electron Microscopy Unit, Lucknow 226014, Uttar Pradesh, India	Sanjay Gandhi Postgraduate Institute of Medical Sciences; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI)	Godbole, MM (corresponding author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Endocrinol, Raebareli Rd, Lucknow 226014, Uttar Pradesh, India.	madangodbole@yahoo.co.in	Sinha, Rohit/GXV-2427-2022; SHRIVASTAVA, ASHUTOSH/ABH-5605-2020	BALAPURE, ANIL/0000-0003-1213-4586				Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Cann SA, 1999, J CLIN ENDOCR METAB, V84, P821, DOI 10.1210/jc.84.2.821; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Cowan KJ, 2003, J EXP BIOL, V206, P1107, DOI 10.1242/jeb.00220; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dohan O, 2003, ENDOCR REV, V24, P48, DOI 10.1210/er.2001-0029; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; DUGRILLON A, 1990, ENDOCRINOLOGY, V127, P337, DOI 10.1210/endo-127-1-337; Dugrillon A, 1996, EXP CLIN ENDOCR DIAB, V104, P41, DOI 10.1055/s-0029-1211700; ESKIN BA, 1995, BIOL TRACE ELEM RES, V49, P9, DOI 10.1007/BF02788999; ESKIN BA, 1975, CANCER RES, V35, P2332; Funahashi H, 1999, JPN J CANCER RES, V90, P922, DOI 10.1111/j.1349-7006.1999.tb00836.x; Funahashi H, 1996, J SURG ONCOL, V61, P209, DOI 10.1002/(SICI)1096-9098(199603)61:3<209::AID-JSO9>3.0.CO;2-F; Garcia-Solis P, 2005, MOL CELL ENDOCRINOL, V236, P49, DOI 10.1016/j.mce.2005.03.001; GHENT WR, 1993, CAN J SURG, V36, P453; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Houde C, 2004, J NEUROSCI, V24, P9977, DOI 10.1523/JNEUROSCI.3356-04.2004; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kallio A, 2005, APOPTOSIS, V10, P1395, DOI 10.1007/s10495-005-2137-z; Kenkel J, 1994, ANAL CHEM TECHNICIAN, P164; Kessler Jack H, 2004, Breast J, V10, P328, DOI 10.1111/j.1075-122X.2004.21341.x; KURITA T, 1994, J CELL PHYSIOL, V161, P63, DOI 10.1002/jcp.1041610109; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Langer R, 2003, EXP CLIN ENDOCR DIAB, V111, P325, DOI 10.1055/s-2003-42721; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lipton SA, 2002, CELL, V111, P147, DOI 10.1016/S0092-8674(02)01046-2; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; MIYASHITA T, 1995, CELL, V80, P293; OLTVAI ZN, 1993, CELL, V74, P619; Otera H, 2005, EMBO J, V24, P1375, DOI 10.1038/sj.emboj.7600614; Panneels V, 1996, J BIOL CHEM, V271, P23006, DOI 10.1074/jbc.271.38.23006; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Pozo-Guisado E, 2005, INT J CANCER, V115, P74, DOI 10.1002/ijc.20856; Qi XM, 2002, J BIOL CHEM, V277, P25884, DOI 10.1074/jbc.M203039200; Seth R, 2005, J BIOL CHEM, V280, P31230, DOI 10.1074/jbc.M503305200; STRUM JM, 1978, ANAT REC, V192, P235, DOI 10.1002/ar.1091920204; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Upadhyay G, 2002, MITOCHONDRION, V2, P199, DOI 10.1016/S1567-7249(02)00068-5; Upadhyay G, 2003, BREAST CANCER RES TR, V77, P157, DOI 10.1023/A:1021321409159; van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944; Venturi S, 2001, BREAST, V10, P379, DOI 10.1054/brst.2000.0267; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vitale M, 2000, ENDOCRINOLOGY, V141, P598, DOI 10.1210/en.141.2.598; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yuste VJ, 2005, CELL DEATH DIFFER, V12, P1445, DOI 10.1038/sj.cdd.4401687; Zhang L, 2003, CANCER RES, V63, P5065	56	106	115	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19762	19771		10.1074/jbc.M600746200	http://dx.doi.org/10.1074/jbc.M600746200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16679319	hybrid			2022-12-25	WOS:000238847000089
J	Lind, MI; Missirlis, F; Melefors, O; Uhrigshardt, H; Kirby, K; Phillips, JP; Soderhall, K; Rouault, TA				Lind, Maria I.; Missirlis, Fanis; Melefors, Ojar; Uhrigshardt, Helge; Kirby, Kim; Phillips, John P.; Soderhall, Kenneth; Rouault, Tracey A.			Of two cytosolic aconitases expressed in drosophila, only one functions as an iron-regulatory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE-ELEMENT-BINDING; TRANSFERRIN RECEPTOR EXPRESSION; SULFUR CLUSTER BIOGENESIS; RNA-BINDING; MESSENGER-RNA; TRANSLATIONAL REGULATION; CAENORHABDITIS-ELEGANS; 5-UNTRANSLATED REGION; TRYPANOSOMA-BRUCEI; IN-VITRO	In mammalian cells, iron homeostasis is largely regulated by post-transcriptional control of gene expression through the binding of iron-regulatory proteins (IRP1 and IRP2) to iron-responsive elements (IREs) contained in the untranslated regions of target mRNAs. IRP2 is the dominant iron sensor in mammalian cells under normoxia, but IRP1 is the more ancient protein in evolutionary terms and has an additional function as a cytosolic aconitase. The Caenorhabditis elegans genome does not contain an IRP2 homolog or identifiable IREs; its IRP1 homolog has aconitase activity but does not bind to mammalian IREs. The Drosophila genome offers an evolutionary intermediate containing two IRP1-like proteins (IRP-1A and IRP-1B) and target genes with IREs. Here, we used purified recombinant IRP-1A and IRP-1B from Drosophila melanogaster and showed that only IRP-1A can bind to IREs, although both proteins possess aconitase activity. These results were also corroborated in whole-fly homogenates from transgenic flies that overexpress IRP-1A and IRP-1B in their fat bodies. Ubiquitous and muscle-specific overexpression of IRP-1A, but not of IRP-1B, resulted in pre-adult lethality, underscoring the importance of the biochemical difference between the two proteins. Domain-swap experiments showed that multiple amino acid substitutions scattered throughout the IRP1 domains are synergistically required for conferring IRE binding activity. Our data suggest that as a first step during the evolution of the IRP/IRE system, the ancient cytosolic aconitase was duplicated in insects with one variant acquiring IRE-specific binding.	Uppsala Univ, Dept Comparat Physiol, Evolutionary Biol Ctr, S-75236 Uppsala, Sweden; NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Univ Guelph, Dept Cellular & Mol Biol, Guelph, ON N1G 2W1, Canada	Uppsala University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Karolinska Institutet; University of Guelph	Lind, MI (corresponding author), Uppsala Univ, Dept Comparat Physiol, Evolutionary Biol Ctr, Norbyvagen 18A, S-75236 Uppsala, Sweden.	maria.Lind@ebc.uu.se	Melefors, Öjar/N-6164-2015; Missirlis, Fanis/C-1137-2011	Melefors, Öjar/0000-0003-4115-1190; Missirlis, Fanis/0000-0003-0467-8444	Intramural NIH HHS Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001602] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001602] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BASILION JP, 1994, P NATL ACAD SCI USA, V91, P574, DOI 10.1073/pnas.91.2.574; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brazzolotto X, 1999, J BIOL CHEM, V274, P21625, DOI 10.1074/jbc.274.31.21625; Charlesworth A, 1997, EUR J BIOCHEM, V247, P470, DOI 10.1111/j.1432-1033.1997.00470.x; Chen XJ, 2005, SCIENCE, V307, P714, DOI 10.1126/science.1106391; CONSTABLE A, 1992, P NATL ACAD SCI USA, V89, P4554, DOI 10.1073/pnas.89.10.4554; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; Drapier JC, 1996, METHOD ENZYMOL, V269, P26; Dupuy J, 2006, STRUCTURE, V14, P129, DOI 10.1016/j.str.2005.09.009; Fast B, 1999, BIOCHEM J, V342, P691, DOI 10.1042/0264-6021:3420691; Gegout V, 1999, J BIOL CHEM, V274, P15052, DOI 10.1074/jbc.274.21.15052; Georgieva T, 1999, P NATL ACAD SCI USA, V96, P2716, DOI 10.1073/pnas.96.6.2716; Gourley BL, 2003, J BIOL CHEM, V278, P3227, DOI 10.1074/jbc.M210333200; Gray NK, 1996, P NATL ACAD SCI USA, V93, P4925, DOI 10.1073/pnas.93.10.4925; GRAY NK, 1993, EUR J BIOCHEM, V218, P657, DOI 10.1111/j.1432-1033.1993.tb18420.x; Gruer MJ, 1997, TRENDS BIOCHEM SCI, V22, P3, DOI 10.1016/S0968-0004(96)10069-4; Gu HF, 1997, CHROMOSOME RES, V5, P463, DOI 10.1023/A:1018417013699; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Hodges M, 2005, MOL BIOCHEM PARASIT, V143, P29, DOI 10.1016/j.molbiopara.2005.05.004; Hughes AL, 2005, P NATL ACAD SCI USA, V102, P8791, DOI 10.1073/pnas.0503922102; Ishikawa H, 2005, MOL CELL, V19, P171, DOI 10.1016/j.molcel.2005.05.027; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; Kaldy P, 1999, EMBO J, V18, P6073, DOI 10.1093/emboj/18.21.6073; Kim HY, 1996, J BIOL CHEM, V271, P24226, DOI 10.1074/jbc.271.39.24226; Kohler SA, 1995, J BIOL CHEM, V270, P30781, DOI 10.1074/jbc.270.51.30781; Kondrashov FA, 2004, TRENDS GENET, V20, P287, DOI 10.1016/j.tig.2004.05.001; Lind MI, 1998, FEBS LETT, V436, P476, DOI 10.1016/S0014-5793(98)01186-7; LIND ML, 2000, THESIS UPPSALA U UPP; Loyevsky M, 2001, BLOOD, V98, P2555, DOI 10.1182/blood.V98.8.2555; Melefors O, 1996, BIOCHEM BIOPH RES CO, V221, P437, DOI 10.1006/bbrc.1996.0613; Meyron-Holtz EG, 2004, SCIENCE, V306, P2087, DOI 10.1126/science.1103786; Meyron-Holtz EG, 2004, EMBO J, V23, P386, DOI 10.1038/sj.emboj.7600041; Missirlis F, 2006, P NATL ACAD SCI USA, V103, P5893, DOI 10.1073/pnas.0601471103; Missirlis F, 2003, J BIOL CHEM, V278, P47365, DOI 10.1074/jbc.M307700200; Missirlis F, 2002, J BIOL CHEM, V277, P11521, DOI 10.1074/jbc.M111692200; Muckenthaler M, 1998, EUR J BIOCHEM, V254, P230, DOI 10.1046/j.1432-1327.1998.2540230.x; Mueller S, 2005, BIOFACTORS, V24, P171, DOI 10.1002/biof.5520240121; Nichol H, 2002, INSECT BIOCHEM MOLEC, V32, P1699, DOI 10.1016/S0965-1748(02)00110-8; Pantopoulos K, 2004, ANN NY ACAD SCI, V1012, P1, DOI 10.1196/annals.1306.001; PHILPOTT CC, 1994, P NATL ACAD SCI USA, V91, P7321, DOI 10.1073/pnas.91.15.7321; PHILPOTT CC, 1993, J BIOL CHEM, V268, P17655; Regev-Rudzki N, 2005, MOL BIOL CELL, V16, P4163, DOI 10.1091/mbc.e04-11-1028; Richards S, 2005, GENOME RES, V15, P1, DOI 10.1101/gr.3059305; ROTHENBERGER S, 1990, NUCLEIC ACIDS RES, V18, P1175, DOI 10.1093/nar/18.5.1175; Rouault TA, 2005, NAT REV MOL CELL BIO, V6, P345, DOI 10.1038/nrm1620; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Saas J, 2000, J BIOL CHEM, V275, P2745, DOI 10.1074/jbc.275.4.2745; Schaible ME, 2004, NAT REV MICROBIOL, V2, P946, DOI 10.1038/nrmicro1046; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Smith SR, 2006, BLOOD CELL MOL DIS, V36, P283, DOI 10.1016/j.bcmd.2005.12.006; Soum E, 2003, BIOCHEMISTRY-US, V42, P7648, DOI 10.1021/bi030041i; Tong WH, 2006, CELL METAB, V3, P199, DOI 10.1016/j.cmet.2006.02.003; Wingert RA, 2005, NATURE, V436, P1035, DOI 10.1038/nature03887; Zhang D, 2002, INSECT BIOCHEM MOLEC, V32, P579, DOI 10.1016/S0965-1748(01)00138-2; Zhang D, 2001, INSECT MOL BIOL, V10, P531, DOI 10.1046/j.0962-1075.2001.00293.x	57	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18707	18714		10.1074/jbc.M603354200	http://dx.doi.org/10.1074/jbc.M603354200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16679315	hybrid			2022-12-25	WOS:000238687300051
J	Kong, KC; Billington, CK; Gandhi, U; Panettieri, RA; Penn, RB				Kong, Kok Choi; Billington, Charlotte K.; Gandhi, Uma; Panettieri, Reynold A., Jr.; Penn, Raymond B.			Cooperative mitogenic signaling by G protein-coupled receptors and growth factors is dependent on G(q/11)	FASEB JOURNAL			English	Article						airway remodeling; airway smooth muscle; asthma; p70S6 kinase; phosphoinositide 3 '-kinase	AIRWAY SMOOTH-MUSCLE; G-BETA-GAMMA; BRONCHOALVEOLAR LAVAGE FLUID; TYROSINE KINASES; ACTIVATION; SRC; STIMULATION; ASTHMA; PHOSPHORYLATION; PROLIFERATION	Previously we reported that the G protein-coupled receptor (GPCR) agonist thrombin potentiated the mitogenic effect of epidermal growth factor (EGF) on human airway smooth muscle (ASM) by promoting sustained late-phase activation of PI3K and p70S6K via a pathway dependent on G beta gamma subunits of heterotrimeric G proteins. Here, we provide additional mechanistic insight and reveal the robustness of this phenomenon by demonstrating that H1 histamine and thromboxane receptors utilize the same mechanism to augment ASM growth via specific activation of the heterotrimeric G protein G(q/11). Thrombin, histamine, and U46619 all enhanced EGF-stimulated [H-3]-thymidine incorporation as well as late-phase Akt and p70S6K phosphorylation in ASM cultures. Heterologous expression of G beta gamma sequestrants (GRK2CT-GFP or G alpha(i)G203A), as well as GRK2NT-GFP (an RGS protein for G(q/11)) but neither p115RhoGEFRGS-GFP (an RGS for G(12/13)) nor pertussis toxin pretreatment (inactivating G(i/o)), attenuated the effects on both signaling and growth. Inhibition of Rho, Rho kinase, or Src, or modulation of arrestin expression did not significantly affect the cooperative signaling by EGF and any of the GPCR agonists. Thus, G(q/11)-coupled receptors are the principal GPCR subfamily mediating cooperative mitogenic signaling in ASM, acting through G beta gamma-dependent, and Src/arrestin-independent activation of PI3K and p70S6K.	Wake Forest Univ, Hlth Sci Ctr, Ctr Human Genom, Winston Salem, NC 27157 USA; Wake Forest Univ, Hlth Sci Ctr, Dept Internal Med, Winston Salem, NC 27157 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	Wake Forest University; Wake Forest University; University of Pennsylvania	Penn, RB (corresponding author), Wake Forest Univ, Hlth Sci Ctr, Ctr Human Genom, Med Ctr Blvd, Winston Salem, NC 27157 USA.	rpenn@wfubmc.edu	Billington, Charlotte/A-2304-2011; Gandhi, Uma/ABB-3802-2021; panettieri, reynold/AAG-9485-2019		NHLBI NIH HHS [R01 HL065338, HL58506, P01 HL067663, P50 HL067663, HL67663, R29 HL058506, HL65338] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058506, R29HL058506, P01HL067663, P50HL067663, R01HL065338] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMAN V, 1995, J ALLERGY CLIN IMMUN, V96, P618, DOI 10.1016/S0091-6749(95)70260-1; Bhattacharyya R, 2003, BIOCHEM J, V371, P709, DOI 10.1042/BJ20021897; Billington CK, 2005, BIOCHEMISTRY-US, V44, P14595, DOI 10.1021/bi0510734; Billington CK, 2003, RESP RES, V4; Carman CV, 2000, J BIOL CHEM, V275, P10443, DOI 10.1074/jbc.275.14.10443; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; CASALE TB, 1987, J CLIN INVEST, V79, P1197, DOI 10.1172/JCI112937; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Ediger TL, 2000, J PHARMACOL EXP THER, V294, P1076; Ediger TL, 2003, EUR RESPIR J, V21, P759, DOI 10.1183/09031936.03.00075702; Goel R, 2004, J BIOL CHEM, V279, P6701, DOI 10.1074/jbc.M308753200; Goel R, 2002, J BIOL CHEM, V277, P18640, DOI 10.1074/jbc.M108995200; Gosens R, 2003, AM J RESP CELL MOL, V28, P257, DOI 10.1165/rcmb.2002-0128OC; Hauck RW, 1999, AM J PHYSIOL-LUNG C, V277, pL22, DOI 10.1152/ajplung.1999.277.1.L22; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Hirshman CA, 1999, AM J PHYSIOL-LUNG C, V277, pL653, DOI 10.1152/ajplung.1999.277.3.L653; Krymskaya VP, 2004, FASEB J, V18, P428, DOI 10.1096/fj.04-2869fje; Krymskaya VP, 2000, AM J RESP CELL MOL, V23, P546, DOI 10.1165/ajrcmb.23.4.4115; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Lutz S, 2005, J BIOL CHEM, V280, P11134, DOI 10.1074/jbc.M411322200; MURRAY RK, 1993, AM J PHYSIOL, V264, pC485, DOI 10.1152/ajpcell.1993.264.2.C485; Panettieri Jr RA, 1994, AIRWAYS SMOOTH MUSCL, P41; PANETTIERI RA, 1995, AM J RESP CELL MOL, V13, P205, DOI 10.1165/ajrcmb.13.2.7626288; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; Penn RB, 2001, J BIOL CHEM, V276, P32648, DOI 10.1074/jbc.M104143200; PENN RB, 1998, HDB PHYSL, P125; Rakhit S, 1999, BIOCHEM J, V338, P643, DOI 10.1042/0264-6021:3380643; Seasholtz TM, 1999, CIRC RES, V84, P1186, DOI 10.1161/01.RES.84.10.1186; SOFIA M, 1993, RESPIRATION, V60, P89; UEDA N, 1994, J BIOL CHEM, V269, P4388; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3; ZEHR BB, 1989, CHEST, V95, P1059, DOI 10.1378/chest.95.5.1059	40	36	36	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1558	+		10.1096/fj.05-5622fje	http://dx.doi.org/10.1096/fj.05-5622fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16723377				2022-12-25	WOS:000240266000050
J	Prosperi, E				Prosperi, Ennio			The fellowship of the rings: distinct pools of proliferating cell nuclear antigen trimer at work	FASEB JOURNAL			English	Article						proliferating cell nuclear antigen; DNA replication; DNA repair; CDK2; chromatin-modifying enzymes	DNA-POLYMERASE-DELTA; REPLICATION SITES; STRUCTURAL BASIS; PCNA-BINDING; TERMINAL DEOXYNUCLEOTIDYLTRANSFERASE; POLY(ADP-RIBOSE) POLYMERASE-1; FLAP ENDONUCLEASE-1; SUBUNIT; PROTEIN; REPAIR	The proliferating cell nuclear antigen ( PCNA) is a homotrimeric ring-shaped protein that, by encircling DNA, may function as a sliding platform for proteins participating in various DNA transactions. PCNA plays a fundamental role in DNA replication and repair, but also in postreplicative events, like DNA methylation, chromatin assembly and remodeling, sister chromatid cohesion, and coordinates these activities with cell cycle control. However, relevant aspects of PCNA function are still not well understood, like the role of PCNA in the association with partner proteins, and how multiple protein interactions are orchestrated. Based on emerging evidence, I suggest that 1) PCNA interacting proteins may be reclassified in three major categories, namely, a) cell cycle control; b) DNA replication/repair; c) chromatin regulation/transcription. 2) PCNA is a negative regulator, rather than a processivity/recruitment factor, of chromatin-modifying enzymes. 3) At DNA replication sites, PCNA function may be envisaged with a model of "dynamic hand-off" of interacting partners that rapidly and transiently exchange in a mutually exclusive manner, while cyclin-dependent kinase ( Cdk) 2 ( CDK2) is stably bound to PCNA. The partner exchange might occur through a conformational change of the PCNA/protein/DNA complex allowing CDK2 to phosphorylate the partner protein, thereby enabling its hand-off from PCNA.	Univ Pavia, CNR, Ist Genet Mol, Sez Istochim & Citometria,Dept Biol Anim, I-27100 Pavia, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of Pavia	Prosperi, E (corresponding author), Univ Pavia, CNR, Ist Genet Mol, Sez Istochim & Citometria,Dept Biol Anim, Piazza Botta 10, I-27100 Pavia, Italy.	prosperi@igm.cnr.it		Prosperi, Ennio/0000-0001-5391-5157				Bruning JB, 2004, STRUCTURE, V12, P2209, DOI 10.1016/j.str.2004.09.018; Bunting KA, 2003, EMBO J, V22, P5883, DOI 10.1093/emboj/cdg568; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Cazzalini O, 2003, CELL CYCLE, V2, P596, DOI 10.4161/cc.2.6.502; Chapados BR, 2004, CELL, V116, P39, DOI 10.1016/S0092-8674(03)01036-5; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; DARLYMPLE BP, 2001, P NATL ACAD SCI USA, V98, P11627; Dionne I, 2003, MOL CELL, V11, P275, DOI 10.1016/S1097-2765(02)00824-9; Ducoux M, 2001, J BIOL CHEM, V276, P49258, DOI 10.1074/jbc.M106990200; Feng XL, 2002, TRENDS CELL BIOL, V12, P532, DOI 10.1016/S0962-8924(02)02391-7; Frouin I, 2003, J BIOL CHEM, V278, P39265, DOI 10.1074/jbc.C300098200; Fujita K, 2003, GENES CELLS, V8, P559, DOI 10.1046/j.1365-2443.2003.00656.x; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hasan S, 2002, J MOL MED, V80, P463, DOI 10.1007/s00109-002-0341-7; HENDERSON DS, 1994, EMBO J, V13, P1450, DOI 10.1002/j.1460-2075.1994.tb06399.x; Henderson DS, 2000, GENETICS, V154, P1721; HENNECKE G, 2003, EMBO REP, V4, P1; Hingorani MM, 2000, CURR BIOL, V10, pR25, DOI 10.1016/S0960-9822(99)00252-3; Hong R, 2003, J BIOL CHEM, V278, P44505, DOI 10.1074/jbc.M303138200; Ibe S, 2001, GENES CELLS, V6, P815, DOI 10.1046/j.1365-2443.2001.00460.x; Ise T, 1999, CANCER RES, V59, P342; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Martin PJ, 2005, NUCLEIC ACIDS RES, V33, P4311, DOI 10.1093/nar/gki745; Milutinovic S, 2002, J BIOL CHEM, V277, P20974, DOI 10.1074/jbc.M202504200; Naryzhny SN, 2005, J BIOL CHEM, V280, P13888, DOI 10.1074/jbc.M500304200; Oyama M, 2004, BIOCHEM BIOPH RES CO, V321, P183, DOI 10.1016/j.bbrc.2004.06.136; Pascal JM, 2004, NATURE, V432, P473, DOI 10.1038/nature03082; Paunesku T, 2001, INT J RADIAT BIOL, V77, P1007, DOI 10.1080/09553000110069335; Pohler JRG, 2005, BMC MOL BIOL, V6, DOI 10.1186/1471-2199-6-17; Poot RA, 2004, NAT CELL BIOL, V6, P1236, DOI 10.1038/ncb1196; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; Riva F, 2004, EXP CELL RES, V293, P357, DOI 10.1016/j.yexcr.2003.10.025; Rouleau M, 2004, J CELL SCI, V117, P815, DOI 10.1242/jcs.01080; Sakurai S, 2005, EMBO J, V24, P683, DOI 10.1038/sj.emboj.7600519; Solovjeva L, 2005, MOL BIOL CELL, V16, P2518, DOI 10.1091/mbc.e04-12-1066; Sporbert A, 2005, NUCLEIC ACIDS RES, V33, P3521, DOI 10.1093/nar/gki665; Sporbert A, 2002, MOL CELL, V10, P1355, DOI 10.1016/S1097-2765(02)00729-3; Stauffer ME, 2004, J BIOL CHEM, V279, P30915, DOI 10.1074/jbc.R400015200; Sukhanova MV, 2005, NUCLEIC ACIDS RES, V33, P1222, DOI 10.1093/nar/gki266; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; Vivona JB, 2003, FEBS LETT, V546, P167, DOI 10.1016/S0014-5793(03)00622-7; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; Xia LQ, 2005, J MOL BIOL, V346, P1259, DOI 10.1016/j.jmb.2005.01.014; Xin HW, 2004, J BIOL CHEM, V279, P9539, DOI 10.1074/jbc.M311587200; Xu H, 2001, BIOCHEMISTRY-US, V40, P4512, DOI 10.1021/bi010103+; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189	49	38	40	2	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					833	837		10.1096/fj.05-5469hyp	http://dx.doi.org/10.1096/fj.05-5469hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675840				2022-12-25	WOS:000240157700005
J	Cruz-Munoz, W; Sanchez, OH; Di Grappa, M; English, JL; Hill, RP; Khokha, R				Cruz-Munoz, W.; Sanchez, O. H.; Di Grappa, M.; English, J. L.; Hill, R. P.; Khokha, R.			Enhanced metastatic dissemination to multiple organs by melanoma and lymphoma cells in timp-3(-/-) mice	ONCOGENE			English	Article						TIMP-3; metastasis; melanoma; lymphoma; deficient mice	TISSUE INHIBITOR; MATRIX METALLOPROTEINASE-2; LIVER METASTASIS; TUMOR INVASION; A MMP-2; EXPRESSION; PROGRESSION; CANCER; TIMP; LUNG	Identifying versatile inhibitors of metastasis that operate in multiple sites against distinct cancer cell types is important for designing novel therapeutics for metastasis. We show that multiple tissues of timp-3(-/-) mice are more susceptible to metastatic colonization. Overall, a 5-14-fold increase in liver and kidney colonization occurred by EL-4 lymphoma cells, and a twofold increase upon targeting B16F10 melanoma cells to the bone or lung of timp-3(-/-) mice. There was a general lack of macrophage or neutrophil localization to metastases in the liver, kidney and lung, and of osteoclasts to bone in both genotypes. Analysis of lung showed that proliferation or angiogenesis were unaltered within the metastatic colonies. Lung-trap assays revealed that initial tumor cell trapping was similar in the lung vasculature of timp-3(-/-) and wild-type mice. However, more tumor cells were found in timp-3(-/-) lungs at 48 and 96 h after tumor cell injection indicating more efficient extravasation and initial proliferation. Activation of pro-MMP-2 was greater in timp-3(-/-) lungs at these time points. These data demonstrate TIMP-3 functions to inhibit metastatic dissemination of diverse cancer cells to multiple organs. TIMP-3 regulates MMP-2 activation to limit tumor cell extravasation and subsequent colonization of the lung, without augmenting inflammatory cell response.	Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Ontario, Inst Technol, Oshawa, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Ontario Tech University	Khokha, R (corresponding author), Univ Toronto, Ontario Canc Inst, 610 Univ Ave,Room 10 328, Toronto, ON M5G 2M9, Canada.	rkhokha@uhnres.utoronto.ca		Hill, Richard Peter/0000-0001-5331-8045				Ahonen M, 1998, CANCER RES, V58, P2310; Airola K, 1999, BRIT J CANCER, V80, P733, DOI 10.1038/sj.bjc.6690417; Banerji A, 2004, CANCER LETT, V211, P235, DOI 10.1016/j.canlet.2004.02.007; Cameron MD, 2000, CANCER RES, V60, P2541; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Cruz-Munoz W, 2006, ONCOGENE, V25, P650, DOI 10.1038/sj.onc.1209104; De Larco JE, 2004, CLIN CANCER RES, V10, P4895, DOI 10.1158/1078-0432.CCR-03-0760; Ding L, 2001, BRIT J CANCER, V85, P431, DOI 10.1054/bjoc.2001.1911; English JL, 2006, J BIOL CHEM, V281, P10337, DOI 10.1074/jbc.M512009200; Gill SE, 2003, DEV BIOL, V261, P313, DOI 10.1016/S0012-1606(03)00318-X; Hofmann UB, 2000, J PATHOL, V191, P245; Hofmann UB, 2005, ARCH DERMATOL RES, V297, P154, DOI 10.1007/s00403-005-0588-2; Itoh T, 1998, CANCER RES, V58, P1048; Kassiri Z, 2005, CIRC RES, V97, P380, DOI 10.1161/01.RES.0000178789.16929.cf; Khatib AM, 1999, CANCER RES, V59, P1356; Kitakata H, 2002, CANCER RES, V62, P6682; Leco KJ, 2001, J CLIN INVEST, V108, P817, DOI 10.1172/JCI12067; LECO KJ, 1994, J BIOL CHEM, V269, P9352; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; Miyazaki T, 2004, BRIT J CANCER, V91, P1556, DOI 10.1038/sj.bjc.6602185; Mohammed FF, 2004, NAT GENET, V36, P969, DOI 10.1038/ng1413; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Nuttall RK, 2004, FEBS LETT, V563, P129, DOI 10.1016/S0014-5793(04)00281-9; ORR FW, 1993, BREAST CANCER RES TR, V25, P151, DOI 10.1007/BF00662140; Pastorino U, 1997, J CLIN ONCOL, V15, P2858, DOI 10.1200/JCO.1997.15.8.2858; Perez M, 2001, EUR J CANCER, V37, P629, DOI 10.1016/S0959-8049(00)00436-6; Powe DG, 1997, BRIT J CANCER, V75, P1678, DOI 10.1038/bjc.1997.285; Rustgi A. K., 2003, GASTROINTESTINAL CAN, P69; Salmela MT, 2003, MODERN PATHOL, V16, P108, DOI 10.1097/01.MP.0000051681.43441.82; SanchezSweatman OH, 1997, EUR J CANCER, V33, P918, DOI 10.1016/S0959-8049(97)00513-3; Shamamian P, 2001, J CELL PHYSIOL, V189, P197, DOI 10.1002/jcp.10014; Soloway PD, 1996, ONCOGENE, V13, P2307; Spurbeck WW, 2002, BLOOD, V100, P3361, DOI 10.1182/blood.V100.9.3361; Urban BA, 2000, RADIOGRAPHICS, V20, P197, DOI 10.1148/radiographics.20.1.g00ja09197; Woessner JF, 2001, J CLIN INVEST, V108, P799, DOI 10.1172/JCI13709; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200; Zhang L, 2004, CANCER RES, V64, P4180, DOI 10.1158/0008-5472.CAN-03-3038	39	34	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2006	25	49					6489	6496		10.1038/sj.onc.1209663	http://dx.doi.org/10.1038/sj.onc.1209663			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16702949				2022-12-25	WOS:000241395100005
J	Zhang, H; OzakiZ, I; Mizuta, T; Hamajima, H; Yasutake, T; Eguchi, Y; Ideguchi, H; Yamamoto, K; Matsuhashi, S				Zhang, H.; Ozaki, I.; Mizuta, T.; Hamajima, H.; Yasutake, T.; Eguchi, Y.; Ideguchi, H.; Yamamoto, K.; Matsuhashi, S.			Involvement of programmed cell death 4 in transforming growth factor-beta 1-induced apoptosis in human hepatocellular carcinoma	ONCOGENE			English	Article						PDCD4 gene; TGF-beta 1; HCC; Smad; tumor suppressor	GROWTH-FACTOR-BETA; PROGRAMMED CELL-DEATH; INITIATION-FACTOR 4A; HUMAN HEPATOMA-CELLS; CHICKEN PDCD4 GENE; NF-KAPPA-B; TGF-BETA; TRANSFORMATION SUPPRESSOR; AP-1 TRANSACTIVATION; BINDING-PROTEIN	The programmed cell death 4 (PDCD4) gene was originally identified as a tumor-related gene in humans and acts as a tumor-suppressor in mouse epidermal carcinoma cells. However, its function and regulatory mechanisms of expression in human cancer remain to be elucidated. We therefore investigated the expression of PDCD4 in human hepatocellular carcinoma (HCC) and the role of PDCD4 in human HCC cells. Downregulation of PDCD4 protein was observed in all HCC tissues tested compared with corresponding noncancerous liver, as revealed by Western blotting or immunohistochemical staining. Human HCC cell line, Huh7, transfected with PDCD4 cDNA showed nuclear fragmentation and DNA laddering characteristic of apoptotic cells associated with mitochondrial changes and caspase activation. Transforming growth factor-beta 1 (TGF-beta 1) treatment of Huh7 cells resulted in increased PDCD4 expression and occurrence of apoptosis, also concomitant with mitochondrial events and caspase activation. Transfection of Smad7, a known antagonist to TGF-beta 1 signaling, protected cells from TGF-beta 1-mediated apoptosis and suppressed TGF-beta 1-induced PDCD4 expression. Moreover, antisense PDCD4 transfectants were resistant to apoptosis induced by TGF-beta 1. In conclusion, these data suggest that PDCD4 is a proapoptotic molecule involved in TGF-beta 1-induced apoptosis in human HCC cells, and a possible tumor suppressor in hepatocarcinogenesis.	Saga Univ, Saga Med Sch, Hlth Adm Ctr, Saga 8498501, Japan; Saga Univ, Saga Med Sch, Dept Internal Med, Div Hepatol & Metab, Saga 840, Japan; China Med Univ, Affiliated Hosp 1, Dept Surg 2, Shenyang, Peoples R China; Saga Univ, Saga Med Sch, Dept Pathol, Saga 840, Japan; Towha Univ, Fac Engn, Fukuoka, Japan	Saga University; Saga University; China Medical University; Saga University	OzakiZ, I (corresponding author), Saga Univ, Saga Med Sch, Hlth Adm Ctr, 5-1-1 Nabeshima, Saga 8498501, Japan.	ozaki@cc.saga-u.ac.jp		Zhang, Hao/0000-0002-9938-8433				Afonja O, 2004, ONCOGENE, V23, P8135, DOI 10.1038/sj.onc.1207983; AKAO Y, 1994, CANCER RES, V54, P2468; Aravind L, 2000, GENOME RES, V10, P1172, DOI 10.1101/gr.10.8.1172; Azzoni L, 1998, J IMMUNOL, V161, P3493; Bissell DM, 2001, HEPATOLOGY, V34, P859, DOI 10.1053/jhep.2001.28457; Bohm M, 2003, ONCOGENE, V22, P4905, DOI 10.1038/sj.onc.1206710; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Horowitz J, 1999, CURR OPIN MOL THER, V1, P500; Huang JZ, 2003, WORLD J GASTROENTERO, V9, P84, DOI 10.3748/wjg.v9.i1.84; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Jansen AP, 2004, MOL CANCER THER, V3, P103; Jurisicova A, 1998, MOL REPROD DEV, V51, P243, DOI 10.1002/(SICI)1098-2795(199811)51:3&lt;243::AID-MRD3&gt;3.0.CO;2-P; Kang MJ, 2002, BIOCHEM BIOPH RES CO, V293, P617, DOI 10.1016/S0006-291X(02)00264-4; KITAJIMA Y, 1991, J BIOCHEM-TOKYO, V109, P544, DOI 10.1093/oxfordjournals.jbchem.a123417; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Lankat-Buttgereit B, 2003, BIOL CELL, V95, P515, DOI 10.1016/j.biolcel.2003.09.003; Matsuhashi Sachiko, 1997, Research Communications in Biochemistry and Cell and Molecular Biology, V1, P109; Matsuzaki K, 2000, CANCER RES, V60, P1394; Musch A, 2005, DIGESTION, V71, P78, DOI 10.1159/000084523; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Onishi Y, 1998, GENE, V215, P453, DOI 10.1016/S0378-1119(98)00313-8; Ozaki I, 2000, CANCER RES, V60, P6519; Ozturk M, 1999, SEMIN LIVER DIS, V19, P235, DOI 10.1055/s-2007-1007113; Paik SY, 2003, MODERN PATHOL, V16, P86, DOI 10.1097/01.MP.0000047308.03300.9C; Rider MA, 2002, INT J ONCOL, V20, P235; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; Schlichter U, 2001, BBA-GENE STRUCT EXPR, V1520, P99, DOI 10.1016/S0167-4781(01)00252-4; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Shima Y, 1999, HEPATOLOGY, V30, P1215, DOI 10.1002/hep.510300503; Simmons HM, 2005, GENE, V347, P137, DOI 10.1016/j.gene.2004.12.027; Soejima H, 1999, CYTOGENET CELL GENET, V87, P113, DOI 10.1159/000015408; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wong SF, 2001, PATHOLOGY, V33, P85; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yoshinaga H, 1999, PATHOL INT, V49, P1067, DOI 10.1046/j.1440-1827.1999.00995.x; Yoshinaga Hidetoshi, 1997, Research Communications in Biochemistry and Cell and Molecular Biology, V1, P121; Young MR, 2003, TRENDS MOL MED, V9, P36, DOI 10.1016/S1471-4914(02)00009-6; Zhang H, 2004, CANCER SCI, V95, P878, DOI 10.1111/j.1349-7006.2004.tb02197.x	49	212	237	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2006	25	45					6101	6112		10.1038/sj.onc.1209634	http://dx.doi.org/10.1038/sj.onc.1209634			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16682950				2022-12-25	WOS:000241101200007
J	Carre-Mlouka, A; Mejean, A; Quillardet, P; Ashida, H; Saito, Y; Yokota, A; Callebaut, I; Sekowska, A; Dittmann, E; Bouchier, C; de Marsac, NT				Carre-Mlouka, Alyssa; Mejean, Annick; Quillardet, Philippe; Ashida, Hiroki; Saito, Yohtaro; Yokota, Akiho; Callebaut, Isabelle; Sekowska, Agnieszka; Dittmann, Elke; Bouchier, Christiane; de Marsac, Nicole Tandeau			A new Rubisco-like protein coexists with a photosynthetic Rubisco in the planktonic cyanobacteria Microcystis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE 1,5-BISPHOSPHATE CARBOXYLASE/OXYGENASE; HYDROPHOBIC CLUSTER-ANALYSIS; CRYSTAL-STRUCTURE; SULFUR METABOLISM; BACILLUS-SUBTILIS; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE/OXYGENASE; CHLOROBIUM-TEPIDUM; ARCHAEAL RUBISCO; SMALL-SUBUNIT; METHIONINE	Two genes encoding proteins related to large subunits of Rubisco were identified in the genome of the planktonic cyanobacterium Microcystis aeruginosa PCC 7806 that forms water blooms worldwide. The rbcL(I) gene belongs to the form I subfamily typically encountered in cyanobacteria, green algae, and land plants. The second and newly discovered gene is of the form IV subfamily and widespread in the Microcystis genus. In M. aeruginosa PCC 7806 cells, the expression of both rbcL(I) and rbcL(IV) is sulfur-dependent. The purified recombinant RbcL(IV) overexpressed in Escherichia coli cells did not display CO2 fixation activity but catalyzed enolization of 2,3-diketo-5-methylthiopentyl-1-phosphate, and the rbcL(IV) gene rescued a Bacillus subtilis MtnW-deficient mutant. Therefore, the Microcystis RbcL(IV) protein functions both in vitro and in vivo and might be involved in a methionine salvage pathway. Despite variations in the amino acid sequences, RbcL(IV) shares structural similarities with all members of the Rubisco superfamily. Invariant amino acids within the catalytic site may thus represent the minimal set for enolization, whereas variations, especially located in loop 6, may account for the limitation of the catalytic reaction to enolization. Even at low protein concentrations in vitro, the recombinant RbcL(IV) assembles spontaneously into dimers, the minimal unit required for Rubisco forms I-III activity. The discovery of the coexistence of RbcL(I) and RbcL(IV) in cyanobacteria, the ancestors of chloroplasts, enlightens episodes of the chaotic evolutionary history of the Rubiscos, a protein family of major importance for life on Earth.	Inst Pasteur, Dept Microbiol, Unite Cyanobacteries, CNRS,URA 2172, F-75724 Paris 15, France; Nara Inst Sci & Technol, Grad Sch Biol Sci, Ikoma, Nara 6300101, Japan; Univ Paris 06, Dept Biol Structurale, Inst Mineral & Phys Milieux Condense, CNRS,UMR 7590, F-75252 Paris 05, France; Univ Paris 07, Dept Biol Structurale, Inst Mineral & Phys Milieux Condense, CNRS,UMR 7590, F-75252 Paris 05, France; HKU Pasteur Res Ctr, Hong Kong, Hong Kong, Peoples R China; Humboldt Univ, Inst Biol, D-10115 Berlin, Germany	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Nara Institute of Science & Technology; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Institut de Recherche pour le Developpement (IRD); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Institut de Recherche pour le Developpement (IRD); Universite Paris Cite; University of Hong Kong; Humboldt University of Berlin	de Marsac, NT (corresponding author), Inst Pasteur, Dept Microbiol, Unite Cyanobacteries, CNRS,URA 2172, 28 Rue Dr Roux, F-75724 Paris 15, France.	ntmarsac@pasteur.fr	Dittmann, Elke/B-4742-2018; Quillardet, Philippe/D-6747-2010; Saito, Yohtaro/C-9838-2017	Dittmann, Elke/0000-0002-7549-7918; Saito, Yohtaro/0000-0002-1024-5154; Carre-Mlouka, Alyssa/0000-0002-6141-8115				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; Ashida H, 2005, RES MICROBIOL, V156, P611, DOI 10.1016/j.resmic.2005.01.014; Ashida H, 2003, SCIENCE, V302, P286, DOI 10.1126/science.1086997; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; Castenholz RW, 2001, BERGEYS MANUAL SYSTE, P473, DOI DOI 10.1007/978-0-387-21609-6_27; Delwiche CF, 1996, MOL BIOL EVOL, V13, P873, DOI 10.1093/oxfordjournals.molbev.a025647; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; Ezaki S, 1999, J BIOL CHEM, V274, P5078, DOI 10.1074/jbc.274.8.5078; Finn MW, 2003, J BACTERIOL, V185, P3049, DOI 10.1128/JB.185.10.3049-3059.2003; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; Grundy FJ, 1998, MOL MICROBIOL, V30, P737, DOI 10.1046/j.1365-2958.1998.01105.x; Hanson TE, 2003, PHOTOSYNTH RES, V78, P231, DOI 10.1023/B:PRES.0000006829.41444.3d; Hanson TE, 2001, P NATL ACAD SCI USA, V98, P4397, DOI 10.1073/pnas.081610398; HARTMAN FC, 1994, ANNU REV BIOCHEM, V63, P197, DOI 10.1146/annurev.biochem.63.1.197; Heilbronn J, 1999, J BACTERIOL, V181, P1739, DOI 10.1128/JB.181.6.1739-1747.1999; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kim L, 1996, GENE, V181, P71, DOI 10.1016/S0378-1119(96)00466-0; Kitano K, 2001, STRUCTURE, V9, P473, DOI 10.1016/S0969-2126(01)00608-6; KUNST F, 1995, J BACTERIOL, V177, P2403, DOI 10.1128/jb.177.9.2403-2407.1995; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li HY, 2005, STRUCTURE, V13, P779, DOI 10.1016/j.str.2005.02.017; LUNDQVIST T, 1991, J BIOL CHEM, V266, P12604; Luo S, 2001, J BIOL CHEM, V276, P7023, DOI 10.1074/jbc.M006838200; Maeda N, 2002, J BIOL CHEM, V277, P31656, DOI 10.1074/jbc.M203117200; MARCHITTO KS, 1985, J GEN MICROBIOL, V131, P2153; Mlouka A, 2004, J BACTERIOL, V186, P2355, DOI 10.1128/JB.186.8.2355-2365.2004; Mur L., 1999, TOXIC CYANOBACTERIA, P15; MURPHY E, 1985, MOL GEN GENET, V200, P33, DOI 10.1007/BF00383309; NEWMAN J, 1994, STRUCTURE, V2, P495, DOI 10.1016/S0969-2126(00)00050-2; Roy Harry, 2000, VVolume 9, P53; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J., 1989, MOL CLONING LAB MANU, pL25; SCHNEIDER G, 1990, EMBO J, V9, P2045, DOI 10.1002/j.1460-2075.1990.tb07371.x; Sekowska A, 2004, BMC MICROBIOL, V4, DOI 10.1186/1471-2180-4-9; Sekowska A, 2002, BMC MICROBIOL, V2, DOI 10.1186/1471-2180-2-8; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Spreitzer RJ, 2003, ARCH BIOCHEM BIOPHYS, V414, P141, DOI 10.1016/S0003-9861(03)00171-1; Spreitzer RJ, 2002, ANNU REV PLANT BIOL, V53, P449, DOI 10.1146/annurev.arplant.53.100301.135233; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; SUFRIN JR, 1995, ANTIMICROB AGENTS CH, V39, P2511, DOI 10.1128/AAC.39.11.2511; Tabita FR, 1999, PHOTOSYNTH RES, V60, P1, DOI 10.1023/A:1006211417981; TABITA FR, 1988, MICROBIOL REV, V52, P155, DOI 10.1128/MMBR.52.2.155-189.1988; WANG SY, 1982, PLANT PHYSIOL, V70, P117, DOI 10.1104/pp.70.1.117; Watson GMF, 1997, FEMS MICROBIOL LETT, V146, P13, DOI 10.1016/S0378-1097(96)00417-X; Watson GMF, 1999, J BACTERIOL, V181, P1569, DOI 10.1128/JB.181.5.1569-1575.1999	48	21	24	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24462	24471		10.1074/jbc.M602973200	http://dx.doi.org/10.1074/jbc.M602973200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16737967	hybrid			2022-12-25	WOS:000239847800041
J	Kristof, AS; Fielhaber, J; Triantafillopoulos, A; Nemoto, S; Moss, J				Kristof, Arnold S.; Fielhaber, Jill; Triantafillopoulos, Alexandra; Nemoto, Shino; Moss, Joel			Phosphatidylinositol 3-kinase-dependent suppression of the human inducible nitric-oxide synthase promoter is mediated by FKHRL1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; NF-KAPPA-B; PROTEIN-KINASE B; RAW 264.7 CELLS; GENE-EXPRESSION; SIGNALING PATHWAYS; 3-KINASE ACTIVITY; INTERFERON-GAMMA; FACTOR FKHR-L1; ACTIVATION	The synthesis of nitric oxide by inducible nitric-oxide synthase (iNOS) plays an important role in the innate immune response by promoting microbial killing and cell damage. In response to inflammatory cytokines and bacterial products, the human iNOS (hiNOS) gene undergoes rapid transcriptional activation via binding of stimulatory transcription factors (e. g. AP-1 and NF-kappa B) to its 5 '-flanking region. However, maximal hiNOS promoter induction was suppressed via an unknown phosphatidylinositol 3-kinase (PI3K)-dependent mechanism. We hypothesized that inhibition of the transcription factor FKHRL1 by the PI3K/protein kinase B pathway attenuates hiNOS promoter induction by bacterial lipopolysaccharide and interferon-gamma (LPS/IFN-gamma). Human lung epithelial adenocarcinoma (A549) cells were transiently transfected with an 8.3-kb hiNOS promoter luciferase reporter construct. Co-expression of dominant-negative protein kinase B potentiated LPS/IFN-gamma-stimulated hiNOS promoter activity. In response to LPS/IFN-gamma FKHRL1 was phosphorylated in a PI3K- and time-dependent fashion. Co-expression of constitutively active FKHRL1 increased hiNOS promoter activity and mRNA levels. Dominant-negative siRNA expression showed that FKHRL1 was necessary for the inhibitory effects of PI3K on hiNOS induction. The same effect was observed upon mutation of a consensus FKHRL1-binding site in the hiNOS promoter. By gel-shift analysis, the corresponding oligonucleotide probe bound endogenous FKHRL1 in an LPS/IFN-gamma- and PI3K-sensitive fashion. Regulation of the hiNOS promoter by FKHRL1 represents a potentially important molecular mechanism by which the PI3K pathway might suppress pro-inflammatory and proapoptotic responses to cytokines and bacterial products.	McGill Univ, Royal Victoria Hosp, Crit Care Div, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Resp Div, Montreal, PQ H3A 1A1, Canada; NHLBI, Cardiovasc Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Pulm Crit Care Med Branch, Bethesda, MD 20892 USA; McGill Univ, Meakins Christie Labs, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); McGill University	Kristof, AS (corresponding author), McGill Univ, Royal Victoria Hosp, Crit Care Div, 687 Pine Ave W,Rm L3-05, Montreal, PQ H3A 1A1, Canada.	arnold.kristof@muhc.mcgill.ca			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002541, Z01HL002541] Funding Source: NIH RePORTER; CIHR [69007] Funding Source: Medline; Intramural NIH HHS Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); CIHR(Canadian Institutes of Health Research (CIHR)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Ackermann K, 2001, MOL CELL BIOCHEM, V227, P59, DOI 10.1023/A:1013104705100; Beutler B, 2003, J LEUKOCYTE BIOL, V74, P479, DOI 10.1189/jlb.0203082; Brune B, 1999, CELL DEATH DIFFER, V6, P969, DOI 10.1038/sj.cdd.4400582; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen CW, 2003, J IMMUNOL, V171, P979, DOI 10.4049/jimmunol.171.2.979; Chu SC, 1998, BIOCHEM BIOPH RES CO, V248, P871, DOI 10.1006/bbrc.1998.9062; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; Diaz-Guerra MJM, 1999, J IMMUNOL, V162, P6184; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P32028, DOI 10.1074/jbc.271.50.32028; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Feng XS, 2002, P NATL ACAD SCI USA, V99, P14212, DOI 10.1073/pnas.212306199; Foley E, 2004, PLOS BIOL, V2, P1091, DOI 10.1371/journal.pbio.0020203; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Ganster RW, 2001, P NATL ACAD SCI USA, V98, P8638, DOI 10.1073/pnas.151239498; Ghaffari S, 2003, P NATL ACAD SCI USA, V100, P6523, DOI 10.1073/pnas.0731871100; Guha M, 2002, J BIOL CHEM, V277, P32124, DOI 10.1074/jbc.M203298200; Hofseth LJ, 2003, P NATL ACAD SCI USA, V100, P143, DOI 10.1073/pnas.0237083100; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Kleinert H, 1998, BRIT J PHARMACOL, V123, P1716, DOI 10.1038/sj.bjp.0701782; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kristof AS, 2003, J BIOL CHEM, V278, P33637, DOI 10.1074/jbc.M301053200; Kristof AS, 2001, J BIOL CHEM, V276, P8445, DOI 10.1074/jbc.M009563200; Li JX, 2004, J CELL BIOL, V165, P77, DOI 10.1083/jcb.200401004; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LOWENSTEIN CJ, 1994, ANN INTERN MED, V120, P227, DOI 10.7326/0003-4819-120-3-199402010-00009; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Monick MM, 2002, J BIOL CHEM, V277, P32992, DOI 10.1074/jbc.M203218200; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Murphy MP, 1999, BBA-BIOENERGETICS, V1411, P401, DOI 10.1016/S0005-2728(99)00029-8; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; Pahan K, 1999, J BIOL CHEM, V274, P7528, DOI 10.1074/jbc.274.11.7528; Park YC, 1997, BIOCHEM BIOPH RES CO, V240, P692, DOI 10.1006/bbrc.1997.7722; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Salh B, 1998, J IMMUNOL, V161, P6947; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Xu WL, 2003, AM J PHYSIOL-LUNG C, V285, pL137, DOI 10.1152/ajplung.00441.2002	55	26	26	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23958	23968		10.1074/jbc.M513918200	http://dx.doi.org/10.1074/jbc.M513918200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16687394	hybrid			2022-12-25	WOS:000239702900070
J	Megha, M; Bakht, O; London, E				Megha, Megha; Bakht, Omar; London, Erwin			Cholesterol precursors stabilize ordinary and ceramide-rich ordered lipid domains (lipid rafts) to different degrees - Implications for the bloch hypothesis and sterol biosynthesis disorders	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODEL MEMBRANES; BILAYER-MEMBRANES; MALFORMATION SYNDROMES; STRUCTURE DETERMINES; REPLACE CHOLESTEROL; CELLS; PHASE; LANOSTEROL; PROTEINS; PHOSPHATIDYLCHOLINE	Genetic disorders of cholesterol biosynthesis result in accumulation of cholesterol precursors and cause severe disease. We examined whether cholesterol precursors alter the stability and properties of ordered lipid domains (rafts). Tempo quenching of a raft-binding fluorophore was used to measure raft stability in vesicles containing sterol, dioleoylphosphatidylcholine, and one of the following ordered domain-forming lipids/lipid mixtures: dipalmitoylphosphatidylcholine (DPPC), sphingomyelin (SM), a SM/cerebroside mixture or a SM/ceramide (cer) mixture. Relative to cholesterol, early cholesterol precursors containing an 8-9 double bond (lanosterol, dihydrolanosterol, zymosterol, and zymostenol) only weakly stabilized raft formation by SM or DPPC. Desmosterol, a late precursor containing the same 5-6 double bond as cholesterol, but with an additional 24-25 double bond, also stabilized domain formation weakly. In contrast, two late precursors containing 7-8 double bonds (lathosterol and 7-dehydrocholesterol) were better raft stabilizers than cholesterol. For vesicles containing SM/cerebroside and SM/cer mixtures the effect of precursor upon raft stability was small, although the relative effects of different precursors were the same. Using both detergent resistance and a novel assay involving fluorescence quenching induced by certain sterols we found cholesterol precursors were displaced from cer-rich rafts, and could displace cer from rafts. Precursor displacement by cer was inversely correlated to precursor raft-stabilizing abilities, whereas precursor displacement of cer was greatest for the most highly raft-stabilizing precursors. These observations support the hypothesis that sterols and cer compete for raft-association (Megha, and London, E. (2004) J. Biol. Chem. 279, 9997-10004). The results of this study have important implications for how precursors might alter raft structure and function in cells, and for the Bloch hypothesis, which postulates that sterol properties are gradually optimized for function along the biosynthetic pathway.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	London, E (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	Erwin.London@stonybrook.edu						Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Alanko SMK, 2005, BBA-BIOMEMBRANES, V1715, P111, DOI 10.1016/j.bbamem.2005.08.002; Bacia K, 2005, P NATL ACAD SCI USA, V102, P3272, DOI 10.1073/pnas.0408215102; Beattie ME, 2005, BIOPHYS J, V89, P1760, DOI 10.1529/biophysj.104.049635; BLOCH KE, 1983, CRC CR REV BIOCH MOL, V14, P47, DOI 10.3109/10409238309102790; Bollinger CR, 2005, BBA-MOL CELL RES, V1746, P284, DOI 10.1016/j.bbamcr.2005.09.001; Braverman N, 1999, NAT GENET, V22, P291, DOI 10.1038/10357; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Brunetti-Pierri N, 2002, AM J HUM GENET, V71, P952, DOI 10.1086/342668; BUTTKE TM, 1992, J BIOL CHEM, V267, P8819; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; Cooper MK, 2003, NAT GENET, V33, P508, DOI 10.1038/ng1134; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; Fastenberg ME, 2003, BIOCHEMISTRY-US, V42, P12376, DOI 10.1021/bi034718d; FLORINECASTEEL K, 1988, BIOCHIM BIOPHYS ACTA, V941, P102, DOI 10.1016/0005-2736(88)90218-0; Grassme H, 2005, J BIOL CHEM, V280, P26256, DOI 10.1074/jbc.M500835200; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Grassme H, 2001, BIOCHEM BIOPH RES CO, V284, P1016, DOI 10.1006/bbrc.2001.5045; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Herman GE, 2003, HUM MOL GENET, V12, pR75, DOI 10.1093/hmg/ddg072; Holowka D, 2005, BBA-MOL CELL RES, V1746, P252, DOI 10.1016/j.bbamcr.2005.06.007; Huang JY, 1999, BIOPHYS J, V76, P2142, DOI 10.1016/S0006-3495(99)77369-8; Huster D, 2005, BIOPHYS J, V88, P1838, DOI 10.1529/biophysj.104.048926; IRONS M, 1993, LANCET, V341, P1414, DOI 10.1016/0140-6736(93)90983-N; Keller RK, 2004, J LIPID RES, V45, P347, DOI 10.1194/jlr.M300232-JLR200; KLEEMANN W, 1976, BIOCHIM BIOPHYS ACTA, V419, P206, DOI 10.1016/0005-2736(76)90347-3; LENTZ BR, 1976, BIOCHEMISTRY-US, V15, P4529, DOI 10.1021/bi00665a030; London E, 2004, BIOPHYS J, V86, p202A; London E, 2000, METHOD ENZYMOL, V312, P272; London M, 2004, J BIOL CHEM, V279, P9997, DOI 10.1074/jbc.M309992200; Lusa S, 2003, J BIOL CHEM, V278, P19844, DOI 10.1074/jbc.M212503200; Martinez GV, 2004, LANGMUIR, V20, P1043, DOI 10.1021/la036063n; Miao L, 2002, BIOPHYS J, V82, P1429, DOI 10.1016/S0006-3495(02)75497-0; Miyaji M, 2005, J EXP MED, V202, P249, DOI 10.1084/jem.20041685; Nyholm TKM, 2003, BIOPHYS J, V84, P3138, DOI 10.1016/S0006-3495(03)70038-1; Ostermeyer AG, 1999, J BIOL CHEM, V274, P34459, DOI 10.1074/jbc.274.48.34459; Patterson G.W., 1991, PHYSL BIOCH STEROLS; Porter FD, 2003, CURR OPIN PEDIATR, V15, P607, DOI 10.1097/00008480-200312000-00011; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Rotolo JA, 2005, J BIOL CHEM, V280, P26425, DOI 10.1074/jbc.M414569200; Rozman D, 2005, MOL CELL ENDOCRINOL, V234, P47, DOI 10.1016/j.mce.2004.11.009; RUOCCO MJ, 1983, BIOPHYS J, V43, P91, DOI 10.1016/S0006-3495(83)84327-6; Scheidt HA, 2005, BIOPHYS J, V89, P2504, DOI 10.1529/biophysj.105.062018; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Vainio S, 2005, BIOCHEM J, V391, P465, DOI 10.1042/BJ20050460; Vainio S, 2006, J BIOL CHEM, V281, P348, DOI 10.1074/jbc.M509530200; Wang JW, 2004, BIOCHEMISTRY-US, V43, P1010, DOI 10.1021/bi035696y; Wang TY, 2003, BIOPHYS J, V84, P367, DOI 10.1016/S0006-3495(03)74857-7; Waterham HR, 2001, AM J HUM GENET, V69, P685, DOI 10.1086/323473; Wechsler A, 2003, SCIENCE, V302, P2087, DOI 10.1126/science.1090776; Xu F, 2005, P NATL ACAD SCI USA, V102, P14551, DOI 10.1073/pnas.0503590102; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; Xu XL, 2000, BIOCHEMISTRY-US, V39, P843, DOI 10.1021/bi992543v; Yu CJ, 2005, J LIPID RES, V46, P1678, DOI 10.1194/jlr.M500060-JLR200; Zaas DW, 2005, BBA-MOL CELL RES, V1746, P305, DOI 10.1016/j.bbamcr.2005.10.003	56	116	119	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21903	21913		10.1074/jbc.M600395200	http://dx.doi.org/10.1074/jbc.M600395200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16735517	hybrid			2022-12-25	WOS:000239387100037
J	De, M; Bell, J; Blackburn, NJ; Mains, RE; Eipper, BA				De, Mithu; Bell, Joseph; Blackburn, Ninian J.; Mains, Richard E.; Eipper, Betty A.			Role for an essential tyrosine in peptide amidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURPLE ACID-PHOSPHATASE; ALPHA-HYDROXYLATING MONOOXYGENASE; DOPAMINE-BETA-HYDROXYLASE; RESONANCE RAMAN; PEPTIDYLAMIDOGLYCOLATE LYASE; UREIDOGLYCOLLATE LYASE; URATE DEGRADATION; HUMAN LACTOFERRIN; CRYSTAL-STRUCTURE; CATALYTIC CORE	The catalytic core of the peptidyl-alpha-hydroxyglycine alpha-amidating lyase ( PAL) domain of peptidylglycine alpha-amidating monooxygenase was investigated with respect to its ability to function as a ureidoglycolate lyase and the identity and role of its bound metal ions. The purified PAL catalytic core ( PALcc) contains molar equivalents of calcium and zinc along with substoichiometric amounts of iron and functions as a ureidoglycolate lyase. Limiting iron availability in the cells synthesizing PALcc reduces the specific activity of the enzyme produced. Concentrated samples of native PALcc have an absorption maximum at 560 nm, suggestive of a phenolate-Fe( III) charge transfer complex. An essential role for a Tyr residue was confirmed by elimination of PAL activity following site-directed mutagenesis. Purified PALcc in which the only conserved Tyr residue ( Tyr(654)) was mutated to Phe was secreted normally, but was catalytically inactive and lacked bound iron and bound zinc. Our data demonstrate an essential role for Tyr654 and suggest that it serves as an Fe( III) ligand in an essential iron-zinc bimetallic site.	Univ Connecticut, Ctr Hlth, Dept Neurosci, Farmington, CT 06030 USA	University of Connecticut	Eipper, BA (corresponding author), Univ Connecticut, Ctr Hlth, Dept Neurosci, 263 Farmington Ave, Farmington, CT 06030 USA.	eipper@uchc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK032949, R01DK032949, R37DK032949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027583] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32949] Funding Source: Medline; NINDS NIH HHS [NS27583] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AINSCOUGH EW, 1980, BIOCHEMISTRY-US, V19, P4072, DOI 10.1021/bi00558a026; Aisen P, 2001, INT J BIOCHEM CELL B, V33, P940, DOI 10.1016/S1357-2725(01)00063-2; ARAMINI JM, 1994, BIOCHEMISTRY-US, V33, P3304, DOI 10.1021/bi00177a022; Asada A, 2005, FEBS J, V272, P942, DOI 10.1111/j.1742-4658.2004.04528.x; Bateman RL, 2001, J BIOL CHEM, V276, P15284, DOI 10.1074/jbc.M007621200; BATTISTUZZI G, 1995, BIOCHEM BIOPH RES CO, V206, P161, DOI 10.1006/bbrc.1995.1023; Bell J, 1997, BIOCHEMISTRY-US, V36, P16239, DOI 10.1021/bi970903d; CHOI KS, 1966, ANAL BIOCHEM, V17, P413, DOI 10.1016/0003-2697(66)90177-1; Czyzyk TA, 2005, DEV BIOL, V287, P301, DOI 10.1016/j.ydbio.2005.09.001; Davies PS, 2004, J BIOL CHEM, V279, P25085, DOI 10.1074/jbc.M400537200; DAVIS JC, 1981, BIOCHEMISTRY-US, V20, P4062, DOI 10.1021/bi00517a018; Durmus A, 1999, EUR J BIOCHEM, V260, P709, DOI 10.1046/j.1432-1327.1999.00230.x; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1991, J BIOL CHEM, V266, P7827; FUJIWARA S, 1995, BIOCHEM J, V15, P315; Halleen JM, 1998, ARCH BIOCHEM BIOPHYS, V352, P97, DOI 10.1006/abbi.1998.0600; Han M, 2004, J NEUROCHEM, V90, P129, DOI 10.1111/j.1471-4159.2004.02464.x; HARRIS WR, 1983, BIOCHEMISTRY-US, V22, P292, DOI 10.1021/bi00271a010; HARRIS WR, 1986, BIOCHEMISTRY-US, V25, P803, DOI 10.1021/bi00352a011; HUSTEN EJ, 1993, J BIOL CHEM, V268, P9709; KATOPODIS AG, 1990, BIOCHEMISTRY-US, V29, P6115, DOI 10.1021/bi00478a001; KATOPODIS AG, 1990, BIOCHEMISTRY-US, V29, P4541, DOI 10.1021/bi00471a006; Klabunde T, 1996, J MOL BIOL, V259, P737, DOI 10.1006/jmbi.1996.0354; Knecht AK, 2001, DEV BIOL, V234, P365, DOI 10.1006/dbio.2001.0275; Kolhekar AS, 1997, BIOCHEMISTRY-US, V36, P10901, DOI 10.1021/bi9708747; Kolhekar AS, 1997, J NEUROSCI, V17, P1363, DOI 10.1523/jneurosci.17-04-01363.1997; Kolhekar AS, 2002, BIOCHEMISTRY-US, V41, P12384, DOI 10.1021/bi0260280; KUBAL G, 1993, BIOCHEMISTRY-US, V32, P3387, DOI 10.1021/bi00064a024; LINDBLAD B, 1977, P NATL ACAD SCI USA, V74, P4641, DOI 10.1073/pnas.74.10.4641; Lok CN, 1998, BIOL SIGNAL RECEPT, V7, P157; MARTIN RB, 1988, MET IONS BIOL SYST, V24, P1; MAY SW, 1978, BIOCHEMISTRY-US, V17, P1853, DOI 10.1021/bi00603a008; McIninch JK, 2003, J BIOL CHEM, V278, P50091, DOI 10.1074/jbc.M303828200; Merkx M, 1998, BIOCHEMISTRY-US, V37, P8490, DOI 10.1021/bi972929a; MICHAUDSORET I, 1995, BIOCHEMISTRY-US, V34, P5504, DOI 10.1021/bi00016a022; Moriwaki Y, 1999, HISTOL HISTOPATHOL, V14, P1321, DOI 10.14670/HH-14.1321; Mounier CE, 1997, J BIOL CHEM, V272, P5016, DOI 10.1074/jbc.272.8.5016; Munoz A, 2001, PLANT PHYSIOL, V125, P828, DOI 10.1104/pp.125.2.828; Napier I, 2005, BLOOD, V105, P1867, DOI 10.1182/blood-2004-10-3856; PERKINS SN, 1990, BIOCHEM BIOPH RES CO, V171, P926, DOI 10.1016/0006-291X(90)90772-F; PINEDA M, 1994, ANAL BIOCHEM, V222, P450, DOI 10.1006/abio.1994.1515; PING DS, 1992, J AM CHEM SOC, V114, P3998, DOI 10.1021/ja00036a071; PING DS, 1995, J BIOL CHEM, V270, P29250, DOI 10.1074/jbc.270.49.29250; Prigge ST, 2000, CELL MOL LIFE SCI, V57, P1236, DOI 10.1007/PL00000763; RICHARD HH, 1996, CHEM REV, V96, P2239; Riordan J F, 1972, Methods Enzymol, V25, P494, DOI 10.1016/S0076-6879(72)25045-5; Schenk G, 1999, ARCH BIOCHEM BIOPHYS, V370, P183, DOI 10.1006/abbi.1999.1407; Schenk G, 2001, J BIOL CHEM, V276, P19084, DOI 10.1074/jbc.M009778200; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SIU DCT, 1992, BIOCHEMISTRY-US, V31, P10443, DOI 10.1021/bi00158a005; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; STEWART LC, 1988, ANNU REV BIOCHEM, V57, P551; SUZUKI K, 1990, EMBO J, V9, P4259, DOI 10.1002/j.1460-2075.1990.tb07874.x; TAKADA Y, 1986, BIOCHEM J, V235, P391, DOI 10.1042/bj2350391; TAKADA Y, 1987, J BACTERIOL, V169, P2284, DOI 10.1128/jb.169.5.2284-2286.1987; Timm DE, 1999, STRUCTURE, V7, P1023, DOI 10.1016/S0969-2126(99)80170-1; TRIJBELS F, 1966, BIOCHIM BIOPHYS ACTA, V113, P292, DOI 10.1016/S0926-6593(66)80068-1; VALENTINE R, 1961, BIOCHEM BIOPH RES CO, V5, P305, DOI 10.1016/0006-291X(61)90168-1; VALENTINE RC, 1962, J BIOL CHEM, V237, P2271; VOGELS GD, 1970, ANAL BIOCHEM, V33, P143, DOI 10.1016/0003-2697(70)90448-3; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; Wang XD, 1996, BIOCHEMISTRY-US, V35, P13946, DOI 10.1021/bi961436n; WELLS XE, 1991, ARCH BIOCHEM BIOPHYS, V287, P151, DOI 10.1016/0003-9861(91)90400-D; Wenzel NF, 2004, J BIOL INORG CHEM, V9, P429, DOI 10.1007/s00775-004-0535-2; Williamson M, 2000, BIOCHEM BIOPH RES CO, V277, P7, DOI 10.1006/bbrc.2000.3629; WOODWORTH RC, 1987, BIOCHEMISTRY-US, V26, P3115, DOI 10.1021/bi00385a025; Xin XN, 2004, J BIOL CHEM, V279, P48159, DOI 10.1074/jbc.M407486200; Zambonelli C, 2003, J BIOL CHEM, V278, P13706, DOI 10.1074/jbc.M210363200	68	18	19	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20873	20882		10.1074/jbc.M513886200	http://dx.doi.org/10.1074/jbc.M513886200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16704972	hybrid			2022-12-25	WOS:000239187300024
J	Sastry, KSR; Smith, AJ; Karpova, Y; Datta, SR; Kulik, G				Sastry, Konduru S. R.; Smith, Adrienne Joy; Karpova, Yelena; Datta, Sandeep Robert; Kulik, George			Diverse antiapoptotic signaling pathways activated by vasoactive intestinal polypeptide, epidermal growth factor, and phosphatidylinositol 3-kinase in prostate cancer cells converge on BAD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DEATH AGONIST BAD; FACTOR-RECEPTOR; NEUROENDOCRINE DIFFERENTIATION; TUMOR-SUPPRESSOR; FACTOR-ALPHA; INHIBITS APOPTOSIS; SURVIVAL PATHWAY; EXPRESSION; AKT	It has been demonstrated that vasoactive intestinal polypeptide, epidermal growth factor, and chronic activation of phosphatidylinositol 3-kinase can protect prostate cancer cells from apoptosis; however, the signaling pathways that they use and molecules that they target are unknown. We report that vasoactive intestinal polypeptide, epidermal growth factor, and phosphatidylinositol 3-kinase activate independent signaling pathways that phosphorylate the proapoptotic protein BAD. Vasoactive intestinal polypeptide operated via protein kinase A, epidermal growth factor required Ras activity, and effects of phosphatidylinositol 3-kinase were predominantly mediated by Akt. BAD phosphorylation was critical for the antiapoptotic effects of each signaling pathway. None of these survival signals was able to rescue cells that express BAD with mutations in phosphorylation sites, whereas knockdown of BAD expression with small hairpin RNA rendered cells insensitive to apoptosis. Taken together, these results identify BAD as a convergence point of several antiapoptotic signaling pathways in prostate cells.	Wake Forest Univ, Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA	Wake Forest University; Columbia University	Kulik, G (corresponding author), Wake Forest Univ, Sch Med, Dept Canc Biol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.	gkulik@wfubmc.edu	Sastry, Konduru Seetharama/GQY-6005-2022	Datta, Sandeep/0000-0002-8068-3862				Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Bakin RE, 2003, CANCER RES, V63, P1981; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Carson JP, 1999, CANCER RES, V59, P1449; Chen X, 2005, J BIOL CHEM, V280, P2700, DOI 10.1074/jbc.M412558200; Collado B, 2005, INT J ONCOL, V26, P1629; Cotteret S, 2003, MOL CELL BIOL, V23, P5526, DOI 10.1128/MCB.23.16.5526-5539.2003; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Delgado M, 1996, BLOOD, V87, P5152, DOI 10.1182/blood.V87.12.5152.bloodjournal87125152; DENIS L, 1993, CANCER, V72, P3888, DOI 10.1002/1097-0142(19931215)72:12+<3888::AID-CNCR2820721726>3.0.CO;2-B; Denmeade SR, 1996, PROSTATE, V28, P251; Djakiew D, 2000, PROSTATE, V42, P150, DOI 10.1002/(SICI)1097-0045(20000201)42:2<150::AID-PROS10>3.0.CO;2-H; Dolloff NG, 2005, ONCOGENE, V24, P6848, DOI 10.1038/sj.onc.1208815; Downward Julian, 2003, Biochem J, V376, pe9, DOI 10.1042/BJ20031745; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; FLAWS JA, 1995, ENDOCRINOLOGY, V136, P4351, DOI 10.1210/en.136.10.4351; Garcia-Fernandez MO, 2003, PEPTIDES, V24, P893, DOI 10.1016/S0196-9781(03)00162-1; Gilmore AP, 2002, J BIOL CHEM, V277, P27643, DOI 10.1074/jbc.M108863200; Goswami A, 2005, MOL CELL, V20, P33, DOI 10.1016/j.molcel.2005.08.016; Guo MH, 2005, BIOCHEMISTRY-US, V44, P13771, DOI 10.1021/bi051255y; Gutierrez-Canas I, 2005, PROSTATE, V63, P44, DOI 10.1002/pros.20173; Gutierrez-Canas I, 2003, BRIT J PHARMACOL, V139, P1050, DOI 10.1038/sj.bjp.0705317; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hernes E, 2004, BRIT J CANCER, V90, P449, DOI 10.1038/sj.bjc.6601536; HIGGINS JRA, 1989, PROSTATE, P5; Juarranz MG, 2001, CELL SIGNAL, V13, P887, DOI 10.1016/S0898-6568(01)00199-1; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kulik G, 2001, CANCER RES, V61, P2713; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KYPRIANOU N, 1988, ENDOCRINOLOGY, V122, P552, DOI 10.1210/endo-122-2-552; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lin JQ, 1999, CANCER RES, V59, P2891; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Mack D, 1997, EUR J CANCER, V33, P317, DOI 10.1016/S0959-8049(96)00402-9; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Mimeault M, 2003, GROWTH FACTORS, V21, P1, DOI 10.1080/0897719031000094921; MYERS RB, 1993, MODERN PATHOL, V6, P733; Nelson JB, 2005, NEOPLASIA, V7, P631, DOI 10.1593/neo.04787; Plonowski A, 2002, INT J CANCER, V98, P624, DOI 10.1002/ijc.10221; Scher HI, 1995, CLIN CANCER RES, V1, P545; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; She QB, 2005, CANCER CELL, V8, P287, DOI 10.1016/j.ccr.2005.09.006; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Shulby SA, 2004, CANCER RES, V64, P4693, DOI 10.1158/0008-5472.CAN-03-3437; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Sumitomo M, 2001, CANCER RES, V61, P3294; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Tang DG, 1997, PROSTATE, V32, P284; Thompson JE, 2004, J CLIN ONCOL, V22, P4217, DOI 10.1200/jco.2004.01.103; Tombal B, 2000, PROSTATE, V43, P303; Tortora G, 2003, CLIN CANCER RES, V9, P1566; Uzgare AR, 2005, INT J BIOCHEM CELL B, V37, P707, DOI 10.1016/j.biocel.2004.11.018; Vashchenko N, 2005, EUR UROL, V47, P147, DOI 10.1016/j.eururo.2004.09.007; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wen Y, 2000, CANCER RES, V60, P6841; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Wertz IE, 2000, J BIOL CHEM, V275, P11470, DOI 10.1074/jbc.275.15.11470; Yang CC, 2003, J BIOL CHEM, V278, P25872, DOI 10.1074/jbc.M301744200; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	69	42	44	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20891	20901		10.1074/jbc.M602928200	http://dx.doi.org/10.1074/jbc.M602928200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16728406	hybrid			2022-12-25	WOS:000239187300026
J	Wang, WS; Lindsey-Boltz, LA; Sancar, A; Bambara, RA				Wang, Wensheng; Lindsey-Boltz, Laura A.; Sancar, Aziz; Bambara, Robert A.			Mechanism of stimulation of human DNA ligase I by the Rad9-Rad1-Hus1 checkpoint complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; NUCLEOTIDE EXCISION-REPAIR; FLAP ENDONUCLEASE-1; REPLICATION FORK; FACTOR-C; DAMAGE; PCNA; PHOSPHORYLATION; RECRUITMENT; PROTEINS	Accumulating evidence suggests that the Rad9-Rad1-Hus1 ( 9-1-1) checkpoint complex, known to be a sensor of DNA damage, is also a component of DNA repair systems. Recent results show that 9-1-1 interacts with several base excision repair proteins. It binds the DNA glycosylase MutY homolog, and stimulates DNA polymerase beta, flap endonuclease 1, and DNA ligase I. 9-1-1 resembles proliferating cell nuclear antigen ( PCNA), which stimulates some of these same repair enzymes, and is loaded onto DNA in a similar manner. The complex of 9-1-1 with DNA ligase I can be immunoprecipitated from human cells. Moreover, UV irradiation stimulates 9-1-1 (.) ligase I complex formation, suggesting a role for 9-1-1 in DNA repair. Examining the nature of 9-1-1 interaction with DNA ligase I, we show that there is a similar degree of stimulation on ligation substrates with different structures, and that there is specificity for DNA ligase I. 9-1-1 improves the binding of DNA ligase I to nicked double strand DNA. Furthermore, although high concentrations of casein kinase II strongly inhibits DNA ligase I activity, it does not affect the ability of 9-1-1 to stimulate. This suggests that 9-1-1 is also an activator of DNA ligase I during DNA damage. Unlike PCNA, 9-1-1 stimulates DNA ligase I activity to the same extent on both linear and circular substrates, indicating that encirclement is not a requirement for stimulation. These data are consistent with a direct role for 9-1-1 in DNA repair, but possibly employing a different mechanism than PCNA.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of Rochester; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Bambara, RA (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Box 712,601 Elmwood Ave, Rochester, NY 14642 USA.	robert_bambara@urmc.rochester.edu	Lindsey-Boltz, Laura/A-3121-2010	Lindsey-Boltz, Laura/0000-0001-6493-8194	NIGMS NIH HHS [GM024441, GM322833] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Araujo SJ, 2000, GENE DEV, V14, P349; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; CHAN JYH, 1985, CARCINOGENESIS, V6, P1275, DOI 10.1093/carcin/6.9.1275; Chang DY, 2005, J BIOL CHEM, V280, P408, DOI 10.1074/jbc.M406800200; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; Dianov GL, 2003, MUTAT RES-FUND MOL M, V531, P157, DOI 10.1016/j.mrfmmm.2003.09.003; Ellison V, 2003, PLOS BIOL, V1, P231, DOI 10.1371/journal.pbio.0000033; Friedrich-Heineken F, 2005, J MOL BIOL, V353, P980, DOI 10.1016/j.jmb.2005.09.018; Griffith JD, 2002, J BIOL CHEM, V277, P15233, DOI 10.1074/jbc.C200129200; Helt CE, 2005, CELL CYCLE, V4, P529, DOI 10.4161/cc.4.4.1598; Helt CE, 2004, AM J PHYSIOL-LUNG C, V286, pL506, DOI 10.1152/ajplung.00243.2003; Henricksen LA, 2002, J BIOL CHEM, V277, P22361, DOI 10.1074/jbc.M201765200; Honma M, 2003, ENVIRON MOL MUTAGEN, V42, P288, DOI 10.1002/em.10201; Jiang GC, 2006, MOL CELL BIOL, V26, P39, DOI 10.1128/MCB.26.1.39-49.2006; Kupiec M, 2000, MUTAT RES-FUND MOL M, V451, P91, DOI 10.1016/S0027-5107(00)00042-7; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Liu Y, 2004, MOL CELL BIOL, V24, P4049, DOI 10.1128/MCB.24.9.4049-4064.2004; Loizou JI, 2004, CELL, V117, P17, DOI 10.1016/S0092-8674(04)00206-5; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Martin IV, 2002, GENOME BIOL, V3; MONTECUCCO A, 1992, NUCLEIC ACIDS RES, V20, P6209, DOI 10.1093/nar/20.23.6209; Pascal JM, 2004, NATURE, V432, P473, DOI 10.1038/nature03082; PRIGENT C, 1994, MOL CELL BIOL, V14, P310, DOI 10.1128/MCB.14.1.310; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; Ranalli TA, 2002, J BIOL CHEM, V277, P41715, DOI 10.1074/jbc.M207207200; Rossi R, 1999, EMBO J, V18, P5745, DOI 10.1093/emboj/18.20.5745; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; Smirnova E, 2005, BIOCHEM J, V389, P13, DOI 10.1042/BJ20050211; SODERHALL S, 1976, FEBS LETT, V67, P1, DOI 10.1016/0014-5793(76)80858-7; TERAOKA H, 1982, J BIOL CHEM, V257, P4758; TERAOKA H, 1993, J BIOL CHEM, V268, P24156; Timson DJ, 2000, MUTAT RES-DNA REPAIR, V460, P301, DOI 10.1016/S0921-8777(00)00033-1; Tom S, 2001, J BIOL CHEM, V276, P48781, DOI 10.1074/jbc.M109626200; Tom S, 2001, J BIOL CHEM, V276, P24817, DOI 10.1074/jbc.M101673200; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; Toueille M, 2004, NUCLEIC ACIDS RES, V32, P3316, DOI 10.1093/nar/gkh652; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; Veeraraghavan J, 2003, J BIOL CHEM, V278, P42854, DOI 10.1074/jbc.M305137200; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WAGA S, 1994, J BIOL CHEM, V269, P10923; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Wang WS, 2004, P NATL ACAD SCI USA, V101, P16762, DOI 10.1073/pnas.0407686101; Wang WS, 2005, J BIOL CHEM, V280, P5391, DOI 10.1074/jbc.M412359200; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, P NATL ACAD SCI USA, V100, P13827, DOI 10.1073/pnas.2336100100	55	44	44	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20865	20872		10.1074/jbc.M602289200	http://dx.doi.org/10.1074/jbc.M602289200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16731526	Green Published, hybrid			2022-12-25	WOS:000239187300023
J	Chen, Q; Coffey, A; Bourgoin, SG; Gadina, M				Chen, Qian; Coffey, Alan; Bourgoin, Sylvain G.; Gadina, Massimo			Cytohesin binder and regulator augments T cell receptor-induced nuclear factor of activated T cells center dot AP-1 activation through regulation of the JNK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VAV-FAMILY PROTEINS; COMPLEX; NFAT; KINASES; DOMAIN; RECRUITMENT; EXPRESSION; INTERACTS; POLARITY; TAMALIN	Cytohesin binder and regulator (Cybr; also known as CYTIP, CASP, and PSCDBP) is a cytokine-induced gene preferentially expressed in hematopoietic tissues and in T helper 1 cells. Cybr protein associates with members of the cytohesin family, which are known ADP-ribosylation factors-GDP/GTP exchange factors, and its functions appear to regulate lymphocyte adhesion and cell-cell contact. Here we show that Cybr mRNA and protein levels are increased upon T cell receptor engagement. Cybr expression then influences T cell receptor-dependent signaling events, such as nuclear factor of activated T cells and AP-1 transcriptional activity. In addition, expression of Cybr results in increased T cell receptor-mediated activation of the Rho/Rac exchange factor Vav and of the JNK-p38 MAPK signaling pathway. The effects of Cybr on nuclear factor of activated T cells and AP-1 are dependent on MAPK activation, and enhanced activation of this cascade results in cooperation between the two transcription factors in the regulation of gene expression. These findings provide the first evidence that the adaptor protein Cybr not only regulates lymphocyte adhesion and cell-cell interaction but also contributes to the regulation of the signaling cascade and of the genetic program downstream of the T cell receptor.	Queens Univ Belfast, Ctr Canc Res & Cell Biol, Div Infect & Immun, Belfast BT9 7BL, Antrim, North Ireland; Univ Laval, Ctr Rech Rhumatol & Immunol, Ste Foy, PQ G1V 4G2, Canada	Queens University Belfast; Laval University	Gadina, M (corresponding author), Whitla Med Bldg,Rm 222,97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	m.g.gadina@qub.ac.uk	Gadina, Massimo/R-4195-2019	Bourgoin, Sylvain/0000-0001-9779-0368				Boehm T, 2003, EMBO J, V22, P1014, DOI 10.1093/emboj/cdg101; de Nadal E, 2002, EMBO REP, V3, P735, DOI 10.1093/embo-reports/kvf158; DIXON B, 1993, BIOCHIM BIOPHYS ACTA, V1216, P321, DOI 10.1016/0167-4781(93)90165-A; Dombroski D, 2005, J IMMUNOL, V174, P1385, DOI 10.4049/jimmunol.174.3.1385; Genot EM, 2000, MOL CELL BIOL, V20, P5469, DOI 10.1128/MCB.20.15.5469-5478.2000; Hirose M, 2004, J BIOL CHEM, V279, P32308, DOI 10.1074/jbc.M400547200; Hofer S, 2006, BLOOD, V107, P1003, DOI 10.1182/blood-2005-01-0425; Hornstein I, 2004, CELL SIGNAL, V16, P1, DOI 10.1016/S0898-6568(03)00110-4; Houlard M, 2002, J EXP MED, V195, P1115, DOI 10.1084/jem.20011701; Huang YP, 2004, J BIOL CHEM, V279, P28827, DOI 10.1074/jbc.R400012200; Kaminska B, 2000, ACTA NEUROBIOL EXP, V60, P395; Kaminuma O, 2001, MOL CELL BIOL, V21, P3126, DOI 10.1128/MCB.21.9.3126-3136.2001; Katzav S, 2004, BLOOD, V103, P2443, DOI 10.1182/blood-2003-08-2834; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim LJ, 2001, MOL CELL BIOL, V21, P3503, DOI 10.1128/MCB.21.10.3503-3513.2001; Kim Loree J., 2000, BMC Immunology, V1, P1, DOI 10.1186/1471-2172-1-1; Kitano J, 2003, J BIOL CHEM, V278, P14762, DOI 10.1074/jbc.M300184200; Kitano J, 2002, J NEUROSCI, V22, P1280, DOI 10.1523/JNEUROSCI.22-04-01280.2002; Koretzky GA, 2001, NAT REV IMMUNOL, V1, P95, DOI 10.1038/35100523; Ludford-Menting MJ, 2005, IMMUNITY, V22, P737, DOI 10.1016/j.immuni.2005.04.009; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; Mansour M, 2002, J BIOL CHEM, V277, P32302, DOI 10.1074/jbc.M202898200; Matsuda S, 2000, EMBO REP, V1, P428, DOI 10.1093/embo-reports/kvd090; Moores SL, 2000, MOL CELL BIOL, V20, P6364, DOI 10.1128/MCB.20.17.6364-6373.2000; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Parkin J, 2001, LANCET, V357, P1777, DOI 10.1016/S0140-6736(00)04904-7; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; RACIOPPI L, 1990, J IMMUNOL, V145, P3635; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Romero F, 1996, CELL SIGNAL, V8, P545, DOI 10.1016/S0898-6568(96)00118-0; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; Round JL, 2005, J EXP MED, V201, P419, DOI 10.1084/jem.20041428; Sun LJ, 1997, P NATL ACAD SCI USA, V94, P4919, DOI 10.1073/pnas.94.10.4919; Tang PT, 2002, P NATL ACAD SCI USA, V99, P2625, DOI 10.1073/pnas.052712999; Tartare-Deckert S, 2001, J BIOL CHEM, V276, P20849, DOI 10.1074/jbc.M010588200; Teixeiro E, 2002, J BIOL CHEM, V277, P3993, DOI 10.1074/jbc.M107797200; Tybulewicz VL, 2005, CURR OPIN IMMUNOL, V17, P267, DOI 10.1016/j.coi.2005.04.003; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Winslow MM, 2003, CURR OPIN IMMUNOL, V15, P299, DOI 10.1016/S0952-7915(03)00050-5; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; WU J, 1995, MOL CELL BIOL, V15, P4337; Xavier R, 2005, IMMUNITY, V22, P655, DOI 10.1016/j.immuni.2005.06.003; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	45	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					19985	19994		10.1074/jbc.M601629200	http://dx.doi.org/10.1074/jbc.M601629200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16702224	hybrid			2022-12-25	WOS:000239038200022
J	Horiuchi, M; Itoh, A; Pleasure, D; Itoh, T				Horiuchi, Makoto; Itoh, Aki; Pleasure, David; Itoh, Takayuki			MEK-ERK signaling is involved in interferon-gamma-induced death of oligodendroglial progenitor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; ACTIVATED PROTEIN-KINASES; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HISTONE H1 PHOSPHORYLATION; CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; IFN-GAMMA; MULTIPLE-SCLEROSIS; GENE-EXPRESSION; NITRIC-OXIDE	Oligodendrocytes are exposed to various cytokines in inflammatory lesions in the central nervous system. In this study, we focused on the direct effects of interferon-gamma ( IFNG) on highly purified rat oligodendroglial cultures at different developmental stages. Among the three stages tested, IFNG had direct cytotoxic effects on actively proliferating oligodendrocyte progenitors but much less on immature oligodendrocytes and none on mature oligodendrocytes. This stage-specific susceptibility of progenitors to IFNG-induced cytotoxicity consisted of two components, delay in the G(1)/S transition of the cell cycle and increased cell death at least partly mediated by apoptosis, suggesting that progression of the cell cycle was tightly linked to this toxic mechanism. There was no functional difference in the signal transducers and activators of transcription (STAT) pathways between progenitors and mature oligodendrocytes as determined by induction of IRF1 mRNA in response to IFNG. We found that partial inhibition of the MEK-ERK pathway, one of the mitogen-activated protein kinase phosphorelay modules, by U0126 partially reversed the IFNG-induced cytotoxicity in progenitors. In addition, ERK activity was quickly down-regulated after in vitro differentiation of progenitors to immature oligodendrocytes. Therefore, we concluded that simultaneous activation of the STAT pathway by IFNG and of the ERK pathway by exogenous trophic factors played a role in the stage-specific IFNG-induced cytotoxicity in oligodendroglial progenitors. Our study has implications with respect to the mechanisms of periventricular leukomalacia in infants and of persistent demyelination in multiple sclerosis lesions in adults.	Univ Calif Davis, Sch Med, Dept Neurol, Sacramento, CA 95817 USA; Shriners Hosp Children, Inst Pediat Regenerat Med, Sacramento, CA 95817 USA	University of California System; University of California Davis	Itoh, T (corresponding author), Univ Calif Davis, Sch Med, Dept Neurol, 601A Shriners Hosp Children No Calif,2425 Stockto, Sacramento, CA 95817 USA.	takito@ucdavis.edu	Horiuchi, Makoto/M-5344-2014; Horiuchi, Makoto/AAD-7281-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025044] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS025044, R01 NS025044-21, R01 NS025044-22, NS25044] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agresti C, 1998, EUR J NEUROSCI, V10, P2975, DOI 10.1046/j.1460-9568.1998.00313.x; Agresti C, 1996, EUR J NEUROSCI, V8, P1106, DOI 10.1111/j.1460-9568.1996.tb01278.x; Andrews T, 1998, J NEUROSCI RES, V54, P574, DOI 10.1002/(SICI)1097-4547(19981201)54:5<574::AID-JNR2>3.3.CO;2-S; Back SA, 2004, SEMIN PERINATOL, V28, P405, DOI 10.1053/j.semperi.2004.10.010; Baerwald KD, 1998, J NEUROSCI RES, V52, P230, DOI 10.1002/(SICI)1097-4547(19980415)52:2<230::AID-JNR11>3.3.CO;2-P; Bhat NR, 1996, J NEUROCHEM, V66, P1986; Bhat NR, 1999, J NEUROCHEM, V72, P112, DOI 10.1046/j.1471-4159.1999.0720112.x; Bhat NR, 1999, J NEUROCHEM, V72, P472, DOI 10.1046/j.1471-4159.1999.0720472.x; Bhattacharjee RN, 2001, MOL CELL BIOL, V21, P5417, DOI 10.1128/MCB.21.16.5417-5425.2001; BILLIAU A, 1988, J IMMUNOL, V140, P1506; Brosnan CF, 1996, BRAIN PATHOL, V6, P243, DOI 10.1111/j.1750-3639.1996.tb00853.x; Buntinx M, 2004, J NEUROSCI RES, V76, P846, DOI 10.1002/jnr.20117; Buntinx M, 2004, J NEUROSCI RES, V76, P834, DOI 10.1002/jnr.20118; Cannella B, 2004, ANN NEUROL, V55, P46, DOI 10.1002/ana.10764; CHANDEE DN, 2002, ONCOGENE, V21, P8397; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chew LJ, 2005, GLIA, V52, P127, DOI 10.1002/glia.20232; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Corbin JG, 1996, MOL CELL NEUROSCI, V7, P354, DOI 10.1006/mcne.1996.0026; Ferber IA, 1996, J IMMUNOL, V156, P5; Folkerth RD, 2004, BRAIN PATHOL, V14, P265; Fragoso G, 2004, J NEUROCHEM, V90, P392, DOI 10.1111/j.1471-4159.2004.02488.x; Furlan R, 2001, J IMMUNOL, V167, P1821, DOI 10.4049/jimmunol.167.3.1821; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Harvat BL, 2001, J INVEST DERMATOL, V117, P1274, DOI 10.1046/j.0022-202x.2001.01495.x; Harvat BL, 1997, ONCOGENE, V14, P2111, DOI 10.1038/sj.onc.1201055; Herrera RE, 1996, P NATL ACAD SCI USA, V93, P11510, DOI 10.1073/pnas.93.21.11510; Horwitz MS, 1997, NAT MED, V3, P1037, DOI 10.1038/nm0997-1037; Hoshino R, 2001, J BIOL CHEM, V276, P2686, DOI 10.1074/jbc.M006132200; Huynh H, 2004, INT J ONCOL, V25, P1839; Itoh T, 2003, J NEUROCHEM, V85, P1500, DOI 10.1046/j.1471-4159.2003.01795.x; Itoh T, 2002, J NEUROCHEM, V81, P390, DOI 10.1046/j.1471-4159.2002.00866.x; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kadhim H, 2001, NEUROLOGY, V56, P1278, DOI 10.1212/WNL.56.10.1278; Kavanaugh B, 2000, J NEUROSCI RES, V60, P725; Kominsky S, 1998, ONCOGENE, V17, P2973, DOI 10.1038/sj.onc.1202217; Krakowski M, 1996, EUR J IMMUNOL, V26, P1641, DOI 10.1002/eji.1830260735; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; LUBLIN FD, 1993, AUTOIMMUNITY, V16, P267, DOI 10.3109/08916939309014645; Maier J, 2002, AM J PATHOL, V160, P271, DOI 10.1016/S0002-9440(10)64371-4; Mann-Chandler MN, 2005, J IMMUNOL, V175, P3000, DOI 10.4049/jimmunol.175.5.3000; MERRILL JE, 1993, J IMMUNOL, V151, P2132; Molina-Holgado E, 2001, EUR J NEUROSCI, V13, P493, DOI 10.1046/j.0953-816x.2000.01412.x; Moran J, 1999, J NEUROCHEM, V73, P568, DOI 10.1046/j.1471-4159.1999.0730568.x; MUCKE L, 1993, FASEB J, V7, P1226, DOI 10.1096/fasebj.7.13.8405808; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; PANITCH HS, 1987, LANCET, V1, P893; Pouly S, 2000, J NEUROPATH EXP NEUR, V59, P280, DOI 10.1093/jnen/59.4.280; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; RENNO T, 1995, J EXP MED, V181, P2283, DOI 10.1084/jem.181.6.2283; Rosenberg PA, 2003, J NEUROSCI RES, V71, P237, DOI 10.1002/jnr.10472; Rubinfeld H, 2005, MOL BIOTECHNOL, V31, P151, DOI 10.1385/MB:31:2:151; SAKAI N, 1995, J NEUROCHEM, V65, P895; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tang XM, 2000, J CELL BIOCHEM, V76, P270, DOI 10.1002/(SICI)1097-4644(20000201)76:2<270::AID-JCB10>3.0.CO;2-6; THORNBERRY NA, 1994, METHOD ENZYMOL, V244, P615; VARTANIAN T, 1995, MOL MED, V1, P732, DOI 10.1007/BF03401888; Willenborg DO, 1996, J IMMUNOL, V157, P3223; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899	62	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20095	20106		10.1074/jbc.M603179200	http://dx.doi.org/10.1074/jbc.M603179200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16728393	hybrid			2022-12-25	WOS:000239038200034
J	Kotova, O; Al-Khalili, L; Talia, S; Hooke, C; Fedorova, OV; Bagrov, AY; Chibalin, AV				Kotova, Olga; Al-Khalili, Lubna; Talia, Sara; Hooke, Catherine; Fedorova, Olga V.; Bagrov, Alexei Y.; Chibalin, Alexander V.			Cardiotonic steroids stimulate glycogen synthesis in human skeletal muscle cells via a Src- and ERK1/2-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+,K+-ATPASE ALPHA-SUBUNIT; OUABAIN-LIKE COMPOUND; PROTEIN-KINASE-C; NA+/K+-ATPASE; NA/K-ATPASE; ENDOGENOUS OUABAIN; ESSENTIAL-HYPERTENSION; CALCIUM OSCILLATIONS; SIGNAL-TRANSDUCTION; CARDIAC MYOCYTES	The cardiotonic steroid, ouabain, a specific inhibitor of Na+, K+-ATPase, initiates protein-protein interactions that lead to an increase in growth and proliferation in different cell types. We explored the effects of ouabain on glucose metabolism in human skeletal muscle cells (HSMC) and clarified the mechanisms of ouabain signal transduction. In HSMC, ouabain increased glycogen synthesis in a concentration-dependent manner reaching the maximum at 100 nM. The effect of ouabain was additive to the effect of insulin and was independent of phosphatidylinositol 3-kinase inhibitor LY294002 but was abolished in the presence of a MEK1/2 inhibitor (PD98059) or a Src inhibitor (PP2). Ouabain increased Src-dependent tyrosine phosphorylation of alpha(1)- and alpha(2)-subunits of Na+, K+-ATPase and promoted interaction of alpha(1)- and alpha(2)-subunits with Src, as assessed by co-immunoprecipitation with Src. Phosphorylation of ERK1/2 and GSK3 alpha/beta, as well as p90rsk activity, was increased in response to ouabain in HSMC, and these responses were prevented in the presence of PD98059 and PP2. Incubation of HSMC with 100 nM ouabain increased phosphorylation of the alpha-subunits of the Na-pump at a MAPK-specific Thr-Pro motif. Ouabain treatment decreased the surface abundance of alpha(2)-subunit, whereas abundance of the alpha(1)-subunit was unchanged. Marinobufagenin, an endogenous vertebrate bufadienolide cardiotonic steroid, increased glycogen synthesis in HSMC at 10 nM concentration, similarly to 100 nM ouabain. In conclusion, ouabain and marinobufagenin stimulate glycogen synthesis in skeletal muscle. This effect is mediated by activation of a Src-, ERK1/2-, p90rsk-, and GSK3-dependent signaling pathway.	Karolinska Inst, Dept Mol Med & Surg, Sect Integrat Physiol, SE-17177 Stockholm, Sweden; NIA, Cardiovasc Sci Lab, NIH, Baltimore, MD 21224 USA	Karolinska Institutet; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Chibalin, AV (corresponding author), Karolinska Inst, Dept Mol Med & Surg, Sect Integrat Physiol, von Eulers Vag 4,4 Tr, SE-17177 Stockholm, Sweden.	Alexander.Chibalin@ki.se	Bagrov, Alexei/AAM-6509-2020	Chibalin, Alexander/0000-0002-6339-6271; Bagrov, Alexei/0000-0002-2903-8673	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE ON AGING [ZIAAG000609, Z01AG000609] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aizman O, 2001, P NATL ACAD SCI USA, V98, P13420, DOI 10.1073/pnas.221315298; Al-Khalili L, 2003, ANN NY ACAD SCI, V986, P449, DOI 10.1111/j.1749-6632.2003.tb07228.x; Al-Khalili L, 2003, CELL MOL LIFE SCI, V60, P991, DOI 10.1007/s00018-003-3001-3; Al-Khalili L, 2003, FEBS LETT, V536, P198, DOI 10.1016/S0014-5793(03)00047-4; Al-Khalili L, 2004, J BIOL CHEM, V279, P25211, DOI 10.1074/jbc.M402152200; Arnon A, 2000, AM J PHYSIOL-HEART C, V279, pH679, DOI 10.1152/ajpheart.2000.279.2.H679; BAGROV AY, 1993, EUR J PHARMACOL, V234, P165, DOI 10.1016/0014-2999(93)90950-M; Bagrov AY, 1998, HYPERTENSION, V31, P1097, DOI 10.1161/01.HYP.31.5.1097; Bagrov YY, 2005, FRONT BIOSCI-LANDMRK, V10, P2257, DOI 10.2741/1695; Bauer N, 2005, HYPERTENSION, V45, P1024, DOI 10.1161/01.HYP.0000165024.47728.f7; Chibalin AV, 2001, ENDOCRINOLOGY, V142, P3474, DOI 10.1210/en.142.8.3474; Chibalin AV, 1998, MOL BIOL CELL, V9, P1209, DOI 10.1091/mbc.9.5.1209; Clausen T, 1996, ACTA PHYSIOL SCAND, V156, P227, DOI 10.1046/j.1365-201X.1996.209000.x; CLAUSEN T, 1966, BIOCHIM BIOPHYS ACTA, V120, P361, DOI 10.1016/0926-6585(66)90303-7; Crambert G, 2004, MOL PHARMACOL, V65, P335, DOI 10.1124/mol.65.2.335; CUTILLETTA AF, 1977, AM J PHYSIOL, V233, pH600, DOI 10.1152/ajpheart.1977.233.5.H600; Dmitrieva RI, 2003, J BIOL CHEM, V278, P28160, DOI 10.1074/jbc.M303768200; Dostanic-Larson I, 2005, P NATL ACAD SCI USA, V102, P15845, DOI 10.1073/pnas.0507358102; EWART HS, 1995, AM J PHYSIOL-CELL PH, V269, pC295, DOI 10.1152/ajpcell.1995.269.2.C295; Fedorova OV, 2002, HYPERTENSION, V39, P298, DOI 10.1161/hy0202.104344; Fedorova OV, 2001, AM J PHYSIOL-REG I, V281, pR352, DOI 10.1152/ajpregu.2001.281.1.R352; Fedorova OV, 1997, AM J HYPERTENS, V10, P929, DOI 10.1016/S0895-7061(97)00096-4; Feraille E, 2000, MOL BIOL CELL, V11, P39, DOI 10.1091/mbc.11.1.39; Ferrandi M, 2004, J BIOL CHEM, V279, P33306, DOI 10.1074/jbc.M402187200; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Fridman AI, 2002, J HYPERTENS, V20, P1189, DOI 10.1097/00004872-200206000-00032; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gonick HC, 1998, CLIN EXP HYPERTENS, V20, P617, DOI 10.3109/10641969809053240; GOTO A, 1995, HYPERTENSION, V26, P1173, DOI 10.1161/01.HYP.26.6.1173; Haas A, 2002, J BIOL CHEM, V277, P18694, DOI 10.1074/jbc.M111357200; HAMLYN JM, 1982, NATURE, V300, P650, DOI 10.1038/300650a0; Huang LY, 1997, J MOL CELL CARDIOL, V29, P429, DOI 10.1006/jmcc.1996.0320; Isenovic ER, 2004, ENDOCRINOLOGY, V145, P1151, DOI 10.1210/en.2003-0100; Kawamura A, 1999, P NATL ACAD SCI USA, V96, P6654, DOI 10.1073/pnas.96.12.6654; Kometiani P, 2005, MOL PHARMACOL, V67, P929, DOI 10.1124/mol.104.007302; Komiyama Y, 2005, CLIN BIOCHEM, V38, P36, DOI 10.1016/j.clinbiochem.2004.08.005; Laredo J, 1997, HYPERTENSION, V29, P401, DOI 10.1161/01.HYP.29.1.401; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Liu JA, 2005, KIDNEY INT, V67, P1844, DOI 10.1111/j.1523-1755.2005.00283.x; MARBAN E, 1982, J PHYSIOL-LONDON, V329, P589, DOI 10.1113/jphysiol.1982.sp014321; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Miyakawa-Naito A, 2003, J BIOL CHEM, V278, P50355, DOI 10.1074/jbc.M305378200; Mohammadi K, 2001, J BIOL CHEM, V276, P42050, DOI 10.1074/jbc.M107892200; Nielsen JN, 2004, P NUTR SOC, V63, P233, DOI 10.1079/PNS2004348; Peng M, 1996, J BIOL CHEM, V271, P10372, DOI 10.1074/jbc.271.17.10372; Pierdomenico SD, 2001, AM J HYPERTENS, V14, P44, DOI 10.1016/S0895-7061(00)01225-5; Schoner W, 2003, ANN NY ACAD SCI, V986, P678, DOI 10.1111/j.1749-6632.2003.tb07282.x; Schoner W, 2002, EUR J BIOCHEM, V269, P2440, DOI 10.1046/j.1432-1033.2002.02911.x; Shaw M, 1999, FEBS LETT, V461, P120, DOI 10.1016/S0014-5793(99)01434-9; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; Tian J, 2006, MOL BIOL CELL, V17, P317, DOI 10.1091/mbc.E05-08-0735; Wang HJ, 2004, J BIOL CHEM, V279, P17250, DOI 10.1074/jbc.M313239200; Xie Zijian, 2003, Mol Interv, V3, P157, DOI 10.1124/mi.3.3.157; Xie ZJ, 2002, EUR J BIOCHEM, V269, P2434, DOI 10.1046/j.1432-1033.2002.02910.x; Xie ZJ, 2003, ANN NY ACAD SCI, V986, P497, DOI 10.1111/j.1749-6632.2003.tb07234.x; Yudowski GA, 2000, P NATL ACAD SCI USA, V97, P6556, DOI 10.1073/pnas.100128297; Zhong Z, 2004, CELL MOL LIFE SCI, V61, P2782, DOI 10.1007/s00018-004-4258-x	59	57	60	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20085	20094		10.1074/jbc.M601577200	http://dx.doi.org/10.1074/jbc.M601577200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16714287	hybrid			2022-12-25	WOS:000239038200033
J	Rodriguez-Contreras, D; Landfear, SM				Rodriguez-Contreras, Dayana; Landfear, Scott M.			Metabolic changes in glucose transporter-deficient Leishmania mexicana and parasite virulence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETED ACID-PHOSPHATASE; CARBOHYDRATE-METABOLISM; MONOCLONAL-ANTIBODIES; FREE GPIS; AMASTIGOTES; ENZYME; LIPOPHOSPHOGLYCAN; PROMASTIGOTES; BIOSYNTHESIS; PROTEINS	Leishmania mexicana are parasitic protozoa that express a variety of glycoconjugates that play important roles in their biology as well as the storage carbohydrate beta-mannan, which is an essential virulence factor for survival of intracellular amastigote forms in the mammalian host. Glucose transporter null mutants, which are viable as insect form promastigotes but not as amastigotes, do not take up glucose and other hexoses but are still able to synthesize these glycoconjugates and beta-mannan, although at reduced levels. Synthesis of these carbohydrate-containing macromolecules could be accounted for by incorporation of non-carbohydrate precursors into carbohydrates by gluconeogenesis. However, the significantly reduced level of the virulence factor beta-mannan in the glucose transporter null mutants compared with wild-type parasites may contribute to the non-viability of these null mutants in the disease-causing amastigote stage of the life cycle.	Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA	Oregon Health & Science University	Landfear, SM (corresponding author), Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, 3181 SW Sam Sackson Pk Rd, Portland, OR 97239 USA.	landfear@ohsu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025920] Funding Source: NIH RePORTER; NIAID NIH HHS [AI25920, R01 AI025920] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATES PA, 1994, PARASITOLOGY, V108, P1, DOI 10.1017/S0031182000078458; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; Beverley SM, 1998, TRENDS MICROBIOL, V6, P35, DOI 10.1016/S0966-842X(97)01180-3; Bringaud F, 1998, P NATL ACAD SCI USA, V95, P7963, DOI 10.1073/pnas.95.14.7963; Burchmore RJS, 1998, J BIOL CHEM, V273, P29118, DOI 10.1074/jbc.273.44.29118; Burchmore RJS, 2003, P NATL ACAD SCI USA, V100, P3901, DOI 10.1073/pnas.0630165100; Burchmore RJS, 2001, INT J PARASITOL, V31, P1311, DOI 10.1016/S0020-7519(01)00259-4; Burchmore RJS, 1995, MOL BIOCHEM PARASIT, V74, P77, DOI 10.1016/0166-6851(95)02485-9; CAZZULO JJ, 1992, FASEB J, V6, P3153, DOI 10.1096/fasebj.6.13.1397837; CAZZULO JJ, 1985, MOL BIOCHEM PARASIT, V16, P329, DOI 10.1016/0166-6851(85)90074-X; Christiansen AC, 2003, CLIM POLICY, V3, P343, DOI 10.1016/j.clipol.2003.09.003; COOMBS GH, 1982, MOL BIOCHEM PARASIT, V5, P199, DOI 10.1016/0166-6851(82)90021-4; FUNK VA, 1994, MOL BIOCHEM PARASIT, V63, P23, DOI 10.1016/0166-6851(94)90005-1; Garami A, 2001, EMBO J, V20, P3657, DOI 10.1093/emboj/20.14.3657; Garami A, 2001, MOL CELL BIOL, V21, P8168, DOI 10.1128/MCB.21.23.8168-8183.2001; GLEW RH, 1988, MICROBIOL REV, V52, P412, DOI 10.1128/MMBR.52.4.412-432.1988; Gourbal B, 2004, J BIOL CHEM, V279, P31010, DOI 10.1074/jbc.M403959200; HART DT, 1982, EXP PARASITOL, V54, P397, DOI 10.1016/0014-4894(82)90049-2; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; ILG T, 1993, EUR J BIOCHEM, V217, P603, DOI 10.1111/j.1432-1033.1993.tb18283.x; ILG T, 1991, J CELL SCI, V99, P175; ILG T, 1991, P NATL ACAD SCI USA, V88, P8774, DOI 10.1073/pnas.88.19.8774; ILG T, 1992, J BIOL CHEM, V267, P6834; Ilg T, 1996, J BIOL CHEM, V271, P21583, DOI 10.1074/jbc.271.35.21583; ILG T, 1994, PARASITOLOGY, V108, pS63, DOI 10.1017/S0031182000075739; Ilg T, 2000, EMBO J, V19, P1953, DOI 10.1093/emboj/19.9.1953; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; Ivens AC, 2005, SCIENCE, V309, P436, DOI 10.1126/science.1112680; KEEGAN FP, 1992, MOL BIOCHEM PARASIT, V53, P193, DOI 10.1016/0166-6851(92)90021-B; Kohl L, 1996, MOL BIOCHEM PARASIT, V76, P159, DOI 10.1016/0166-6851(95)02556-1; Krauth-Siegel RL, 2005, ANGEW CHEM INT EDIT, V44, P690, DOI 10.1002/anie.200300639; MAHLER HR, 1971, BIOL CHEM, P488; MARTIN E, 1976, J PROTOZOOL, V23, P600, DOI 10.1111/j.1550-7408.1976.tb03850.x; Maugeri DA, 2003, MOL BIOCHEM PARASIT, V130, P117, DOI 10.1016/S0166-6851(03)00173-7; MCCONVILLE MJ, 1987, P NATL ACAD SCI USA, V84, P8941, DOI 10.1073/pnas.84.24.8941; MEADE JC, 1984, J PROTOZOOL, V31, P156, DOI 10.1111/j.1550-7408.1984.tb04307.x; Mensa-Wilmot K, 1999, MOL BIOCHEM PARASIT, V99, P103, DOI 10.1016/S0166-6851(99)00003-1; MOTTRAM JC, 1985, BIOCHIM BIOPHYS ACTA, V827, P310, DOI 10.1016/0167-4838(85)90216-X; MOTTRAM JC, 1985, EXP PARASITOL, V59, P265, DOI 10.1016/0014-4894(85)90081-5; Naderer T, 2006, P NATL ACAD SCI USA, V103, P5502, DOI 10.1073/pnas.0509196103; Nasser MIA, 2004, MOL BIOCHEM PARASIT, V135, P89, DOI 10.1016/j.molbiopara.2004.01.009; Ralton JE, 1998, J BIOL CHEM, V273, P4245, DOI 10.1074/jbc.273.7.4245; Ralton JE, 2003, J BIOL CHEM, V278, P40757, DOI 10.1074/jbc.M307660200; Ralton JE, 2002, BIOCHEM J, V363, P365, DOI 10.1042/0264-6021:3630365; RYAN KA, 1993, P NATL ACAD SCI USA, V90, P8609, DOI 10.1073/pnas.90.18.8609; Sacks D, 2001, ANNU REV MICROBIOL, V55, P453, DOI 10.1146/annurev.micro.55.1.453; SCHLEIN Y, 1986, Parasitology Today, V2, P175, DOI 10.1016/0169-4758(86)90150-X; Stafford JL, 2002, CRIT REV MICROBIOL, V28, P187, DOI 10.1080/1040-840291046731; STRYER L, 1988, BIOCHEMISTRY-US, P427; TURCO SJ, 1987, BIOCHEMISTRY-US, V26, P6233, DOI 10.1021/bi00393a042; WILSON ME, 1988, J IMMUNOL, V141, P265; Yao CQ, 2003, MOL BIOCHEM PARASIT, V132, P1, DOI 10.1016/S0166-6851(03)00211-1; Yao CQ, 2002, MOL BIOCHEM PARASIT, V121, P119, DOI 10.1016/S0166-6851(02)00030-0	53	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20068	20076		10.1074/jbc.M603265200	http://dx.doi.org/10.1074/jbc.M603265200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16707495	hybrid			2022-12-25	WOS:000239038200031
J	Johs, A; Hammel, M; Waldner, I; May, RP; Laggner, P; Prassl, R				Johs, Alexander; Hammel, Michal; Waldner, Ines; May, Roland P.; Laggner, Peter; Prassl, Ruth			Modular structure of solubilized human apolipoprotein B-100 - Low resolution model revealed by small angle neutron scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; PROTEIN SECONDARY STRUCTURE; RECEPTOR-BINDING DOMAINS; X-RAY; SODIUM DEOXYCHOLATE; ANALYTICAL ULTRACENTRIFUGATION; APOPROTEIN-B; IDENTIFICATION; CONFORMATION; SEQUENCE	Being intimately involved in cholesterol transport and lipid metabolism human low density lipoprotein (LDL) plays a prominent role in atherogenesis and cardiovascular diseases. The receptor-mediated cellular uptake of LDL is triggered by apolipoprotein B-100 (apoB-100), which represents the single protein moiety of LDL. Due to the size and hydrophobic nature of apoB-100, its structure is not well characterized. Here we present a low resolution structure of solubilized apoB-100. We have used small angle neutron scattering in combination with advanced shape reconstruction algorithms to generate a three-dimensional model of lipid-free apoB-100. Our model clearly reveals that apoB-100 is composed of distinct domains connected by flexible regions. The apoB-100 molecule adopts a curved shape with a central cavity. In comparison to LDL-associated apoB-100, the lipid-free protein is expanded, whereas according to spectroscopic data the secondary structure is widely preserved. Finally, the low resolution model was used as a template to reconstruct a hypothetical domain organization of apoB-100 on LDL, including information derived from a secondary structure prediction.	Austrian Acad Sci, Inst Biophys & Xray Struct Res, A-8042 Graz, Austria; Univ Missouri, Sch Biol Sci, Div Cell Biol & Biophys, Kansas City, MO 64110 USA; Inst Max Von Laue Paul Langevin, F-38042 Grenoble 9, France	Austrian Academy of Sciences; University of Missouri System; University of Missouri Kansas City; Institut Laue-Langevin (ILL)	Prassl, R (corresponding author), Austrian Acad Sci, Inst Biophys & Xray Struct Res, A-8042 Graz, Austria.	ruth.prassl@oeaw.ac.at	Prassl, Ruth/AAE-1523-2021; Johs, Alexander/F-1229-2011	Johs, Alexander/0000-0003-0098-2254; Hammel, Michal/0000-0002-5610-9289; Prassl, Ruth/0000-0002-1010-9494				Aslam M, 2001, J MOL BIOL, V309, P1117, DOI 10.1006/jmbi.2001.4720; Boehm MK, 1999, J MOL BIOL, V286, P1421, DOI 10.1006/jmbi.1998.2556; Boren J, 1998, J CLIN INVEST, V101, P1084, DOI 10.1172/JCI1847; CHATTERTON JE, 1995, J LIPID RES, V36, P2027; CHATTERTON JE, 1991, J BIOL CHEM, V266, P5955; Dashti N, 2002, BIOCHEMISTRY-US, V41, P6978, DOI 10.1021/bi011757l; FEIGIN LA, 1987, STRUTURAL ANAL SMALL; Furtado PB, 2004, J MOL BIOL, V338, P921, DOI 10.1016/j.jmb.2004.03.007; Gantz DL, 2000, J LIPID RES, V41, P1464; GHOSH RE, 1989, COMPUTING GUIDE SMAL; GLATTER O, 1977, J APPL CRYSTALLOGR, V10, P415, DOI 10.1107/S0021889877013879; Glatter O., 1982, SMALL ANGLE XRAY SCA, P119; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Guinier A., 1955, SMALL ANGLE SCATTERI; Hammel M, 2005, J BIOL CHEM, V280, P38562, DOI 10.1074/jbc.M503168200; HOSPATTANKAR AV, 1986, BIOCHEM BIOPH RES CO, V139, P1078, DOI 10.1016/S0006-291X(86)80287-X; IKAI A, 1980, J BIOCHEM-TOKYO, V88, P1349, DOI 10.1093/oxfordjournals.jbchem.a133103; JACROT B, 1981, BIOPOLYMERS, V20, P2413, DOI 10.1002/bip.1981.360201110; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; LAGGNER P, 1978, EUR J BIOCHEM, V84, P227, DOI 10.1111/j.1432-1033.1978.tb12160.x; LAGGNER P, 1984, P NATL ACAD SCI-BIOL, V81, P4389, DOI 10.1073/pnas.81.14.4389; LAGGNER P, 1978, Q REV BIOPHYS, V11, P371, DOI 10.1017/S0033583500002304; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; Lund-Katz S, 1998, BIOCHEMISTRY-US, V37, P12867, DOI 10.1021/bi980828m; Lunin VY, 2001, ACTA CRYSTALLOGR D, V57, P108, DOI 10.1107/S0907444900014608; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; MELNIK BC, 1988, ANAL BIOCHEM, V171, P320, DOI 10.1016/0003-2697(88)90493-9; MULLER K, 1978, EUR J BIOCHEM, V82, P73, DOI 10.1111/j.1432-1033.1978.tb11998.x; Orlova EV, 1999, P NATL ACAD SCI USA, V96, P8420, DOI 10.1073/pnas.96.15.8420; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PHILLIPS ML, 1989, J LIPID RES, V30, P415; PILZ I, 1973, BIOCHEMISTRY-US, V12, P4998, DOI 10.1021/bi00748a028; PILZ I, 1982, SMALL ANGLE XRAY SCA, P239; Pollastri G, 2002, PROTEINS, V47, P228, DOI 10.1002/prot.10082; Porollo AA, 2004, BIOINFORMATICS, V20, P2460, DOI 10.1093/bioinformatics/bth248; Prassl R, 1996, J BIOL CHEM, V271, P28731, DOI 10.1074/jbc.271.46.28731; Richardson PE, 2005, BIOPHYS J, V88, P2789, DOI 10.1529/biophysj.104.046235; Ritter S, 1997, PROTEINS, V28, P293; Segrest JP, 1998, J LIPID RES, V39, P85; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; Shelness GS, 2003, J BIOL CHEM, V278, P44702, DOI 10.1074/jbc.M307562200; SPIN JM, 1995, BIOPHYS J, V68, P2115, DOI 10.1016/S0006-3495(95)80392-9; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268; WALSH MT, 1986, J LIPID RES, V27, P316; WALSH MT, 1983, BIOCHEMISTRY-US, V22, P3170, DOI 10.1021/bi00282a021; WALSH MT, 1990, J LIPID RES, V31, P1051; WATT RM, 1980, BIOCHEMISTRY-US, V19, P1593, DOI 10.1021/bi00549a010; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YANG CY, 1990, P NATL ACAD SCI USA, V87, P5523, DOI 10.1073/pnas.87.14.5523; YANG CY, 1989, J PROTEIN CHEM, V8, P689, DOI 10.1007/BF01024895; ZACCAI G, 1983, ANNU REV BIOPHYS BIO, V12, P139, DOI 10.1146/annurev.bb.12.060183.001035; ZAMPIGHI G, 1980, J CELL BIOL, V87, P555, DOI 10.1083/jcb.87.3.555	57	60	61	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19732	19739		10.1074/jbc.M601688200	http://dx.doi.org/10.1074/jbc.M601688200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16704977	hybrid			2022-12-25	WOS:000238847000086
J	Lemmens, K; Segers, VFM; Demolder, M; De Keulenaer, GW				Lemmens, Katrien; Segers, Vincent F. M.; Demolder, Marc; De Keulenaer, Gilles W.			Role of neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METASTATIC BREAST-CANCER; NITRIC-OXIDE SYNTHASE; VENTRICULAR MYOCYTES; CARDIAC DEVELOPMENT; ENDOCARDIAL ENDOTHELIUM; MONOCLONAL-ANTIBODIES; IN-VITRO; CELLS; GROWTH; ERBB2	Neuregulin-1 (NRG-1), a cardioactive growth factor released from endothelial cells, has been shown to be indispensable for the normal function of the adult heart by binding to ErbB4 receptors on cardiomyocytes. In the present study, we have investigated to what extent ErbB2, the favored co-factor of ErbB4 for heterodimerization, participates in the cardiac effects of endothelium-derived NRG-1. Inaddition, in view of our previously described anti-adrenergic effects of NRG-1, we have studied which neurohormonal stimuli affect endothelial NRG-1 expression and release and how this may fit into a broader frame of cardiovascular physiology. Immunohistochemical staining of rat heart and aorta showed that NRG-1 expression was restricted to the endocardial endothelium and the cardiac microvascular endothelium (CMVE); by contrast, NRG-1 expression was absent in larger coronary arteries and veins and in aortic endothelium. In rat CMVE in culture, NRG-1 mRNA and protein expression was down-regulated by angiotensin II and phenylephrine and up-regulated by endothelin-1 and mechanical strain. CMVE-derived NRG-1 was shown to phosphorylate cardiomyocyte ErbB2, an event prevented by a 24-h preincubation of myocytes with monoclonal ErbB2 antibodies. Pretreating cardiomyocytes with these inhibitory anti-ErbB2 antibodies significantly attenuated CMVE-induced cardiomyocyte hypertrophy and abolished the protective actions of CMVE against cardiomyocyte apoptosis. Accordingly, ErbB2 signaling participated in the paracrine survival and growth controlling effects of NRG1 on cardiomyocytes in vitro, explaining the cardiotoxicity of ErbB2 antibodies in patients. Cardiac NRG-1 synthesis occurs in endothelial cells adjacent to cardiac myocytes and is sensitive to factors related to the regulation of blood pressure.	Univ Antwerp, Dept Physiol, B-2020 Antwerp, Belgium	University of Antwerp	De Keulenaer, GW (corresponding author), Univ Antwerp, Physiol Lab, Groenenborgerlaan 171,Bldg 5,6th Fl, B-2020 Antwerp, Belgium.	gilles.dekeulenaer@ua.ac.be	Segers, Vincent F/J-1191-2019; De Keulenaer, Gilles/D-9321-2017	Segers, Vincent F/0000-0001-7796-2222; De Keulenaer, Gilles/0000-0002-4238-4183				Brutsaert DL, 2003, PHYSIOL REV, V83, P59, DOI 10.1152/physrev.00017.2002; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Cheng GC, 1997, CIRC RES, V80, P28, DOI 10.1161/01.RES.80.1.28; CLARK AL, 2000, HEART FAIL REV, V5, P104; Condorelli G, 1999, CIRCULATION, V99, P3071, DOI 10.1161/01.CIR.99.23.3071; Cote GM, 2005, EXP CELL RES, V311, P135, DOI 10.1016/j.yexcr.2005.08.017; Coucelo J, 2000, J EXP ZOOL, V286, P585, DOI 10.1002/(SICI)1097-010X(20000501)286:6<585::AID-JEZ5>3.0.CO;2-Z; Erickson SL, 1997, DEVELOPMENT, V124, P4999; Feldman AM, 2000, CIRCULATION, V102, P272; Fransen P, 2004, CARDIOVASC RES, V63, P700, DOI 10.1016/j.cardiores.2004.05.017; Fransen P, 2001, CARDIOVASC RES, V52, P487, DOI 10.1016/S0008-6363(01)00412-6; Frenzel KE, 2001, J NEUROCHEM, V77, P1; Fukazawa R, 2003, J MOL CELL CARDIOL, V35, P1473, DOI 10.1016/j.yjmcc.2003.09.012; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Grazette LP, 2004, J AM COLL CARDIOL, V44, P2231, DOI 10.1016/j.jacc.2004.08.066; Hendrickx J, 2004, PHYSIOL GENOMICS, V19, P198, DOI 10.1152/physiolgenomics.00143.2004; Herrlich A, 2004, P NATL ACAD SCI USA, V101, P15799, DOI 10.1073/pnas.0406853101; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Klapper LN, 1997, ONCOGENE, V14, P2099, DOI 10.1038/sj.onc.1201029; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; Kuramochi Y, 2004, J BIOL CHEM, V279, P51141, DOI 10.1074/jbc.M408662200; Kuramochi Y, 2004, AM J PHYSIOL-CELL PH, V286, pC222, DOI 10.1152/ajpcell.00312.2003; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lemmens K, 2005, CIRCULATION, V111, pE175, DOI 10.1161/01.CIR.0000160374.89416.90; Lemmens K, 2004, CIRCULATION, V109, P324, DOI 10.1161/01.CIR.0000114521.88547.5E; Martinet W, 2004, J PATHOL, V202, P382, DOI 10.1002/path.1525; McMurray JJV, 2004, J RENIN-ANGIO-ALDO S, V5, pS17, DOI 10.3317/jraas.2004.019; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Montero JC, 2000, MOL CELL NEUROSCI, V16, P631, DOI 10.1006/mcne.2000.0896; NISHIDA M, 1993, AM J PHYSIOL, V264, P639; Ozcelik C, 2002, P NATL ACAD SCI USA, V99, P8880, DOI 10.1073/pnas.122249299; Rohrbach S, 2005, J MOL CELL CARDIOL, V38, P485, DOI 10.1016/j.yjmcc.2004.12.013; Shirakabe K, 2001, J BIOL CHEM, V276, P9352, DOI 10.1074/jbc.M007913200; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; TEICHHOLZ LE, 1976, AM J CARDIOL, V37, P7, DOI 10.1016/0002-9149(76)90491-4; UNGUREANULONGROIS D, 1995, CIRC RES, V77, P494, DOI 10.1161/01.RES.77.3.494; Yamamoto K, 1999, J BIOL CHEM, V274, P21840, DOI 10.1074/jbc.274.31.21840; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569; Yip YL, 2002, CANCER IMMUNOL IMMUN, V50, P569, DOI 10.1007/s002620100226; Zhao YY, 1998, J BIOL CHEM, V273, P10261, DOI 10.1074/jbc.273.17.10261	40	133	152	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19469	19477		10.1074/jbc.M600399200	http://dx.doi.org/10.1074/jbc.M600399200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16698793	hybrid			2022-12-25	WOS:000238847000062
J	Pittman, YR; Valente, L; Jeppesen, MG; Andersen, GR; Patel, S; Kinzy, TG				Pittman, Yvette R.; Valente, Louis; Jeppesen, Mads Gravers; Andersen, Gregers Rom; Patel, Smita; Kinzy, Terri Goss			Mg2+ and a key lysine modulate exchange activity of eukaryotic translation elongation factor 1B alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR 1-ALPHA; NUCLEOTIDE EXCHANGE; TRANSFER-RNA; SACCHAROMYCES-CEREVISIAE; FACTOR TS; FACTOR-I; COMPLEX; YEAST; PURIFICATION; ARTEMIA	To sustain efficient translation, eukaryotic elongation factor B alpha(eEF1B alpha) functions as the guanine nucleotide exchange factor for eEF1A. Stopped- flow kinetics using 2'-(or 3 ')-O-N-methylanthraniloyl (mant)-GDP showed spontaneous release of nucleotide from eEF1A is extremely slow and accelerated 700-fold by eEF1B alpha. The eEF1B alpha-stimulated reaction was inhibited by Mg2+ with a K-1/2 of 3.8 mM. Previous structural studies predicted the Lys-205 residue of eEF1B alpha plays an important role in promoting nucleotide exchange by disrupting the Mg2+ binding site. Co-crystal structures of the lethal K205A mutant in the catalytic C terminus of eEF1B alpha with eEF1A and eEF1A(.)GDP established that the lethality was not due to a structural defect. Instead, the K205A mutant drastically reduced the nucleotide exchange activity even at very low concentrations of Mg2+. A K205R eEF1B alpha mutant on the other hand was functional in vivo and showed nearly wild-type nucleotide dissociation rates but almost no sensitivity to Mg2+. These results indicate the significant role of Mg2+ in the nucleotide exchange reaction by eEF1B alpha and establish the catalytic function of Lys-205 in displacing Mg2+ from its binding site.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Microbiol & Immunol, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Univ Aarhus, Dept Mol Biol, Ctr Struct Biol, DK-8000 Aarhus, Denmark; Inst Canc Res, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Aarhus University	Kinzy, TG (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet, 675 Hoes Lane, Piscataway, NJ 08854 USA.	kinzytg@umdnj.edu		Andersen, Gregers Rom/0000-0001-6292-3319; Kinzy, Terri/0000-0003-1394-9226	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062789, R37GM051966, R01GM051966] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51966, GM62789, R01 GM062789] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen GR, 2000, MOL CELL, V6, P1261, DOI 10.1016/S1097-2765(00)00122-2; Andersen GR, 2001, NAT STRUCT BIOL, V8, P531, DOI 10.1038/88598; BEC G, 1994, J BIOL CHEM, V269, P2086; BELFIELD GP, 1993, MOL MICROBIOL, V9, P411, DOI 10.1111/j.1365-2958.1993.tb01702.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burke D., 2000, METHODS YEAST GENETI; Carr-Schmid A, 1999, MOL CELL BIOL, V19, P5257; CARVALHO MDD, 1984, ARCH BIOCHEM BIOPHYS, V234, P603, DOI 10.1016/0003-9861(84)90310-2; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; Gromadski KB, 2002, BIOCHEMISTRY-US, V41, P162, DOI 10.1021/bi015712w; Guo Z, 2005, BIOCHEMISTRY-US, V44, P15423, DOI 10.1021/bi0518601; HALL A, 1986, J BIOL CHEM, V261, P963; HIRAGA K, 1993, FEBS LETT, V316, P165, DOI 10.1016/0014-5793(93)81208-H; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANSSEN GMC, 1988, J BIOL CHEM, V263, P1773; JANSSEN GMC, 1988, EUR J BIOCHEM, V171, P119, DOI 10.1111/j.1432-1033.1988.tb13766.x; JONES E W, 1991, P428; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KINZY TG, 1994, NUCLEIC ACIDS RES, V22, P2703, DOI 10.1093/nar/22.13.2703; KINZY TG, 1995, GENETICS, V141, P481; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Levin MK, 2002, J BIOL CHEM, V277, P29377, DOI 10.1074/jbc.M112315200; Liu G, 1996, J CELL BIOL, V135, P953, DOI 10.1083/jcb.135.4.953; Merrick WC, 2000, COLD SPRING HARBOR M, V39, P89; Munshi R, 2001, GENETICS, V157, P1425; OLAREWAJU O, 2004, RNA BIOL, V1, P12; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan JY, 1996, J BIOL CHEM, V271, P1322, DOI 10.1074/jbc.271.3.1322; Pan JY, 1998, BIOESSAYS, V20, P516, DOI 10.1002/(SICI)1521-1878(199806)20:6<516::AID-BIES11>3.0.CO;2-3; Pedersen L, 2001, ACTA CRYSTALLOGR D, V57, P159, DOI 10.1107/S0907444900015559; SAHA SK, 1986, J BIOL CHEM, V261, P2599; SLOBIN LI, 1978, EUR J BIOCHEM, V84, P69, DOI 10.1111/j.1432-1033.1978.tb12142.x; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P20473, DOI 10.1074/jbc.270.35.20473; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Vitagliano L, 2001, EMBO J, V20, P5305, DOI 10.1093/emboj/20.19.5305	35	25	25	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19457	19468		10.1074/jbc.M601076200	http://dx.doi.org/10.1074/jbc.M601076200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16675455	hybrid			2022-12-25	WOS:000238847000061
J	Pulina, MV; Rizzuto, R; Brini, M; Carafoli, E				Pulina, Maria V.; Rizzuto, Rosario; Brini, Marisa; Carafoli, Ernesto			Inhibitory interaction of the plasma membrane Na+/Ca2+ exchangers with the 14-3-3 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC NA+-CA2+ EXCHANGER; PROTEIN; EXPRESSION; ISOFORMS; CLONING; BINDS; NCX3; CA2+	The three Na+/Ca2+ exchanger isoforms, NCX1, NCX2, and NCX3, contain a large cytoplasmic loop that is responsible for the regulation of activity. We have used 347 residues of the loop of NCX2 as the bait in a yeast two-hybrid approach to identify proteins that could interact with the exchanger and regulate its activity. Screening of a human brain cDNA library identified the epsilon and zeta isoforms of the 14-3-3 protein family as interacting partners of the exchanger. The interaction was confirmed by immunoprecipitation and in vitro binding experiments. The effect of the interaction on the homeostasis of Ca2+ was investigated by co-expressing NCX2 and 14-3-3 epsilon in HeLa cells together with the recombinant Ca2+ probe aequorin; the ability of cells expressing both NCX2 and 14-3-3 epsilon to dispose of a Ca2+ transient induced by an InsP3-producing agonist was substantially decreased, indicating a reduction of NCX2 activity. The 14-3-3 epsilon protein also inhibited the NCX1 and NCX3 isoforms. In vitro binding experiments revealed that all three NCX isoforms interacted with multiple 14-3-3 isoforms. 14-3-3 was bound by both phosphorylated and nonphosphorylated NCX, but the phosphorylated form had much higher binding affinity.	Univ Padua, Venetian Inst Mol Med, I-35100 Padua, Italy; Univ Padua, Dept Biochem, I-35100 Padua, Italy; Univ Ferrara, Dept Expt & Diagnost Med, Interdisciplinary Ctr Study Inflammat, I-44100 Ferrara, Italy	University of Padua; Veneto Institute Molecular Medicine; University of Padua; University of Ferrara	Carafoli, E (corresponding author), Univ Padua, Venetian Inst Mol Med, Via Orus 2, I-35100 Padua, Italy.	ernesto.carafoli@unipd.it	Carafoli, Ernesto/K-5192-2016; Rizzuto, Rosario/B-6312-2008; Brini, Marisa/K-5189-2016	Carafoli, Ernesto/0000-0002-7826-0094; Rizzuto, Rosario/0000-0001-7044-5097; Brini, Marisa/0000-0001-5141-0243	Telethon [GP0193Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Annunziato L, 2004, PHARMACOL REV, V56, P633, DOI 10.1124/pr.56.4.5; Bridges D, 2004, SCI STKE, V2004, pre10; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Carafoli E, 2001, CRIT REV BIOCHEM MOL, V36, P107, DOI 10.1080/20014091074183; DOERING AE, 1993, J PHYSIOL-LONDON, V466, P481; Fraysse B, 2001, AM J PHYSIOL-CELL PH, V280, pC146, DOI 10.1152/ajpcell.2001.280.1.C146; He ZP, 2000, AM J PHYSIOL-CELL PH, V278, pC661, DOI 10.1152/ajpcell.2000.278.4.C661; Hinata M, 2004, J PHARMACOL SCI, V96, P15, DOI 10.1254/jphs.FMJ04002X3; Iwamoto T, 1998, BIOCHEMISTRY-US, V37, P17230, DOI 10.1021/bi981521q; Katanosaka Y, 2005, J BIOL CHEM, V280, P5764, DOI 10.1074/jbc.M410240200; Li L, 2000, J BIOL CHEM, V275, P20903, DOI 10.1074/jbc.M000995200; LI Z, 1994, J BIOL CHEM, V269, P6640; LI ZP, 1993, J BIOL CHEM, V268, P11489; Lytton J, 2002, ANN NY ACAD SCI, V976, P382; Mackintosh C, 2004, BIOCHEM J, V381, P329, DOI 10.1042/BJ20031332; Masters SC, 1999, BIOCHEMISTRY-US, V38, P5216, DOI 10.1021/bi982492m; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; Matsuoka S, 1997, J GEN PHYSIOL, V109, P273, DOI 10.1085/jgp.109.2.273; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Quednau BD, 2004, PFLUG ARCH EUR J PHY, V447, P543, DOI 10.1007/s00424-003-1065-4; Rimessi A, 2005, J BIOL CHEM, V280, P37195, DOI 10.1074/jbc.M504921200; Santacruz-Toloza L, 2000, J BIOL CHEM, V275, P182, DOI 10.1074/jbc.275.1.182; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Thurneysen T, 2002, MOL BRAIN RES, V107, P145, DOI 10.1016/S0169-328X(02)00461-8; Wilker E, 2004, J MOL CELL CARDIOL, V37, P633, DOI 10.1016/j.yjmcc.2004.04.015	28	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19645	19654		10.1074/jbc.M602033200	http://dx.doi.org/10.1074/jbc.M602033200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16679322	hybrid			2022-12-25	WOS:000238847000078
J	Shi, LB; Berg, S; Lee, A; Spencer, JS; Zhang, J; Vissa, V; McNeil, MR; Khoo, KH; Chatterjee, D				Shi, Libin; Berg, Stefan; Lee, Arwen; Spencer, John S.; Zhang, Jian; Vissa, Varalakshmi; McNeil, Michael R.; Khoo, Kay-Hooi; Chatterjee, Delphi			The carboxy terminus of EmbC from Mycobacterium smegmatis mediates chain length extension of the arabinan in lipoarabinomannan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRUNCATED STRUCTURAL VARIANTS; HEXAARABINOFURANOSYL MOTIF; NONREDUCING TERMINI; MASS-SPECTROMETRY; CELL-WALLS; TUBERCULOSIS; BIOSYNTHESIS; ARABINOGALACTAN; ETHAMBUTOL; STRAINS	D-Arabinofurans, attached to either a galactofuran or a lipomannan, are the primary constituents of mycobacterial cell wall, forming the unique arabinogalactan (AG) and lipoarabinomannan (LAM), respectively. Emerging data indicate that the arabinans of AG and LAM are distinguished by virtue of the additional presence of linear termini in LAM, which entails some unknown feature of the EmbC protein for proper synthesis. In common with the two paralogous EmbA and EmbB proteins functionally implicated for the arabinosylation of AG, EmbC is predicted to carry 13 transmembrane spanning helices in an integral N-terminal domain followed by a hydrophilic extracytoplasmic C-terminal domain. To delineate the function of this C-terminal domain, the embC knock-out mutant of Mycobacterium smegmatis was complemented with plasmids expressing truncated embC genes. The expression level of serially truncated EmbC protein thus induced was examined by EmbC-specific peptide antibody, and their functional implications were inferred from ensuing detailed structural analysis of the truncated LAM variants synthesized. Apart from critically showing that the smaller arabinans are mostly devoid of the linear terminal motif, beta-D-Araf(1 -> 2)-alpha-D-Araf(1 -> 5)-alpha-D-Araf(1 -> 5)-alpha-D-Araf, our studies clearly implicate the C- terminal domain of EmbC in the chain extension of LAM. For the first time a full range of arabinan chains as large as 18-22 Araf residues and beyond could be released intact by the use of an endogenous endo-D-arabinanase from M. smegmatis, profiled, and sequenced directly by tandem mass spectrometry. In conjunction with NMR studies, our results unequivocally show that the LAM-specific linear termini are an extension on a well defined inner branched Ara-(18-22) core. This hitherto unrecognized feature not only allows a significant revision of the structural model of LAM-arabinan since its first description a decade ago but also furnishes a probable molecular basis of selectivity in biosynthesis, as conferred by the EmbC protein.	Natl Taiwan Univ, Inst Biol Sci, Taipei 106, Taiwan; Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA; Dalian Med Univ, Dept Biochem & Mol Biol, Liaoning 116027, Peoples R China; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan	National Taiwan University; Colorado State University; Dalian Medical University; Academia Sinica - Taiwan	Khoo, KH (corresponding author), Natl Taiwan Univ, Inst Biol Sci, Taipei 106, Taiwan.	kkhoo@gate.sinica.edu.tw; delphi@lamar.colostate.edu	Spencer, John S/G-6968-2017; Berg, Stefan/AAU-6463-2020; McNeil, Michael/G-3325-2019; Khoo, Kay-Hooi/E-1989-2019; Berg, Stefan O/D-3847-2011	Spencer, John S/0000-0002-8051-3038; Berg, Stefan/0000-0002-3470-7579; Khoo, Kay-Hooi/0000-0003-2906-406X; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047197, N01AI025469, R21AI037139, R01AI037139, R01AI033706] Funding Source: NIH RePORTER; NIAID NIH HHS [N01 AI-25469, AI-33706, AI-47197, AI-37139] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alderwick LJ, 2005, J BIOL CHEM, V280, P32362, DOI 10.1074/jbc.M506339200; Becker A, 1998, J BACTERIOL, V180, P395, DOI 10.1128/JB.180.2.395-399.1998; Belanger AE, 1996, P NATL ACAD SCI USA, V93, P11919, DOI 10.1073/pnas.93.21.11919; Berg S, 2005, J BIOL CHEM, V280, P5651, DOI 10.1074/jbc.M411418200; BESRA GS, 1995, BIOCHEMISTRY-US, V34, P4257, DOI 10.1021/bi00013a015; BESRA GS, 1994, CARBOHYD RES, V251, P99, DOI 10.1016/0008-6215(94)84279-5; Brennan PJ, 1997, BIOCHEM SOC T, V25, P188, DOI 10.1042/bst0250188; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Briken V, 2004, MOL MICROBIOL, V53, P391, DOI 10.1111/j.1365-2958.2004.04183.x; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; CHATTERJEE D, 1991, J BIOL CHEM, V266, P9652; CHATTERJEE D, 1993, GLYCOBIOLOGY, V3, P497, DOI 10.1093/glycob/3.5.497; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; Clarke BR, 2004, J BIOL CHEM, V279, P35709, DOI 10.1074/jbc.M404738200; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Crick DC, 2001, GLYCOBIOLOGY, V11, p107R, DOI 10.1093/glycob/11.9.107R; Daniels C, 1999, MOL MICROBIOL, V34, P181, DOI 10.1046/j.1365-2958.1999.01591.x; DELL A, 1994, METHOD ENZYMOL, V230, P108; Delmas C, 1997, GLYCOBIOLOGY, V7, P811, DOI 10.1093/glycob/7.6.811; Dong X, 2006, APPL ENVIRON MICROB, V72, P2601, DOI 10.1128/AEM.72.4.2601-2605.2006; Dover LG, 2004, FEMS MICROBIOL REV, V28, P225, DOI 10.1016/j.femsre.2003.10.001; Escuyer VE, 2001, J BIOL CHEM, V276, P48854, DOI 10.1074/jbc.M102272200; Gibson KJC, 2003, MICROBIOL-SGM, V149, P1437, DOI 10.1099/mic.0.26161-0; Gilleron M, 1997, J BIOL CHEM, V272, P117; Kall L, 2004, J MOL BIOL, V338, P1027, DOI 10.1016/j.jmb.2004.03.016; Kaur D, 2002, MICROBIOL-SGM, V148, P3049, DOI 10.1099/00221287-148-10-3049; KHOO K-H, 1990, Glycobiology, V1, P83, DOI 10.1093/glycob/1.1.83; KHOO KH, 1995, J BIOL CHEM, V270, P12380, DOI 10.1074/jbc.270.21.12380; Khoo KH, 1996, J BIOL CHEM, V271, P28682, DOI 10.1074/jbc.271.45.28682; Lee REB, 2005, GLYCOBIOLOGY, V15, P139, DOI 10.1093/glycob/cwh150; Lety MA, 1997, ANTIMICROB AGENTS CH, V41, P2629, DOI 10.1128/AAC.41.12.2629; Liu J, 2003, PROTEIN SCI, V12, P1418, DOI 10.1110/ps.0302103; MCNEIL M, 1989, METHOD ENZYMOL, V179, P215; MCNEIL M, 1990, J BIOL CHEM, V265, P18200; MCNEIL M, 1991, J BIOL CHEM, V266, P13217; MCNEIL MR, 1994, GLYCOBIOLOGY, V4, P165, DOI 10.1093/glycob/4.2.165; Nigou J, 2000, J MOL BIOL, V299, P1353, DOI 10.1006/jmbi.2000.3821; Nigou J, 1997, J BIOL CHEM, V272, P23094, DOI 10.1074/jbc.272.37.23094; PRINZIS S, 1993, J GEN MICROBIOL, V139, P2649, DOI 10.1099/00221287-139-11-2649; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; Spencer JS, 2004, INFECT IMMUN, V72, P3161, DOI 10.1128/IAI.72.6.3161-3170.2004; Strohmeier GR, 1999, MICROBES INFECT, V1, P709, DOI 10.1016/S1286-4579(99)80072-0; Telenti A, 1997, NAT MED, V3, P567, DOI 10.1038/nm0597-567; Torrelles JB, 2004, J BIOL CHEM, V279, P41227, DOI 10.1074/jbc.M405180200; Treumann A, 2002, J MOL BIOL, V316, P89, DOI 10.1006/jmbi.2001.5317; Turnbull WB, 2004, ANGEW CHEM INT EDIT, V43, P3918, DOI 10.1002/anie.200454119; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328; Xin Y, 1999, BBA-GEN SUBJECTS, V1473, P267, DOI 10.1016/S0304-4165(99)00204-4; Zhang N, 2003, MOL MICROBIOL, V50, P69, DOI 10.1046/j.1365-2958.2003.03681.x	51	63	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19512	19526		10.1074/jbc.M513846200	http://dx.doi.org/10.1074/jbc.M513846200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16687411	Green Published, hybrid			2022-12-25	WOS:000238847000066
J	Shukla, A; Stanojevic, N; Duan, Z; Shadle, T; Bhaumik, SR				Shukla, Abhijit; Stanojevic, Nadia; Duan, Zhen; Shadle, Thomas; Bhaumik, Sukesh R.			Functional analysis of H2B-Lys-123 ubiquitination in regulation of H3-Lys-4 methylation and recruitment of RNA polymerase II at the coding sequences of several active genes in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H2B UBIQUITYLATION; H3 LYSINE-4 METHYLATION; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; NUCLEOSOME CORE; X-CHROMOSOMES; YEAST; SET1; COMPLEX; SAGA	Previous biochemical studies have demonstrated that Lys-123 ubiquitination of histone H2B is globally required for up-regulation of mono-, di, and trimethylation of Lys-4 of histone H3. However, recent studies have implicated H2B-Lys-123 ubiquitination in the regulation of di- and trimethylation, but not monomethylation, of H3- Lys-4 in vivo. Using a formaldehyde-based cross-linking and chromatin immunoprecipitation assay, we show that H3-Lys-4 trimethylation, but not dimethylation, is up-regulated by H2B-Lys-123 ubiquitination in vivo at the coding sequences of a set of transcriptionally active genes such as ADH1, PHO84, and PYK1. Both the ubiquitination of H2B-Lys-123 and the methylation of H3-Lys-4 are dispensable for recruitment of RNA polymerase II to the coding sequences of these genes, and hence, their transcription is not altered in the absence of these covalent modifications. However, recruitment of RNA polymerase II to the coding sequence of a galactose-inducible gene, GAL1, is significantly reduced in the absence of H2B-Lys-123 ubiquitination but not H3-Lys-4 methylation. Consistently, transcription of GAL1 is altered in the H2B-K123R point mutant strain. Finally, we show that H3-Lys-4 methylation does not regulate H3-Lys-9/14 acetylation. Collectively, our data reveal a "trans-tail" regulation of H3-Lys-4 tribut not dimethylation by H2B-Lys-123 ubiquitination, and these modifications are dispensable for transcription of a certain set of genes in vivo.	So Illinois Univ, Sch Med, Dept Biochem & Mol Biol, Carbondale, IL 62901 USA	Southern Illinois University System; Southern Illinois University	Bhaumik, SR (corresponding author), So Illinois Univ, Sch Med, Dept Biochem & Mol Biol, Carbondale, IL 62901 USA.	sbhaumik@siumed.edu						Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Bhaumik SR, 2004, GENE DEV, V18, P333, DOI 10.1101/gad.1148404; Bhaumik SR, 2003, METHOD ENZYMOL, V370, P445; Bhaumik SR, 2002, MOL CELL BIOL, V22, P7365, DOI 10.1128/MCB.22.21.7365-7371.2002; Bhaumik SR, 2001, GENE DEV, V15, P1935, DOI 10.1101/gad.911401; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; Brachmann CB, 1998, YEAST, V14, P115; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Bryk M, 2002, CURR BIOL, V12, P165, DOI 10.1016/S0960-9822(01)00652-2; Carvin CD, 2004, J BIOL CHEM, V279, P33057, DOI 10.1074/jbc.M405033200; Daniel JA, 2004, J BIOL CHEM, V279, P1867, DOI 10.1074/jbc.C300494200; Dehe PM, 2005, J MOL BIOL, V353, P477, DOI 10.1016/j.jmb.2005.08.059; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Ezhkova E, 2004, MOL CELL, V13, P435, DOI 10.1016/S1097-2765(04)00026-7; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Gendrel AV, 2002, SCIENCE, V297, P1871, DOI 10.1126/science.1074950; Gerber M, 2003, J BIOL CHEM, V278, P26303, DOI 10.1074/jbc.R300014200; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Hayes JJ, 2001, CURR OPIN GENET DEV, V11, P124, DOI 10.1016/S0959-437X(00)00168-4; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0; Kao CF, 2004, GENE DEV, V18, P184, DOI 10.1101/gad.1149604; Kao CF, 2003, METHODS, V31, P59, DOI 10.1016/S1046-2023(03)00088-4; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lacoste N, 2002, J BIOL CHEM, V277, P30421, DOI 10.1074/jbc.C200366200; Laribee RN, 2005, CURR BIOL, V15, P1487, DOI 10.1016/j.cub.2005.07.028; Lee KK, 2005, MOL CELL BIOL, V25, P1173, DOI 10.1128/MCB.25.3.1173-1182.2005; Li XY, 2000, SCIENCE, V288, P1242, DOI 10.1126/science.288.5469.1242; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Liu CL, 2005, PLOS BIOL, V3, P1753, DOI 10.1371/journal.pbio.0030328; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Ng HH, 2002, J BIOL CHEM, V277, P34655, DOI 10.1074/jbc.C200433200; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; Noma K, 2002, P NATL ACAD SCI USA, V99, P16438, DOI 10.1073/pnas.182436399; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; Reuben M, 2002, DEV BIOL, V245, P71, DOI 10.1006/dbio.2002.0634; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schneider J, 2005, MOL CELL, V19, P849, DOI 10.1016/j.molcel.2005.07.024; Shahbazian MD, 2005, MOL CELL, V19, P271, DOI 10.1016/j.molcel.2005.06.010; Shukla A, 2006, MOL CELL BIOL, V26, P3339, DOI 10.1128/MCB.26.9.3339-3352.2006; SIKORSKI RS, 1989, GENETICS, V122, P19; Singer MS, 1998, GENETICS, V150, P613; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; VANHOLDE KE, 1989, HISTONE MODIFICATION, P111; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Xiao TJ, 2005, MOL CELL BIOL, V25, P637, DOI 10.1128/MCB.25.2.637-651.2005; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	63	32	34	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19045	19054		10.1074/jbc.M513533200	http://dx.doi.org/10.1074/jbc.M513533200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16675445	hybrid			2022-12-25	WOS:000238847000018
J	Siculella, L; Sabetta, S; Giudetti, AM; Gnoni, GV				Siculella, Luisa; Sabetta, Simona; Giudetti, Anna M.; Gnoni, Gabriele V.			Hypothyroidism reduces tricarboxylate carrier activity and expression in rat liver mitochondria by reducing nuclear transcription rate and splicing efficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK-EMBRYO HEPATOCYTES; ACETYL-COA CARBOXYLASE; FATTY-ACID SYNTHESIS; THYROID-HORMONES; MESSENGER-RNA; TRANSPORT PROTEIN; LIPID-COMPOSITION; MALIC ENZYME; TRIIODOTHYRONINE; GENE	The tricarboxylate carrier (TCC), also known as citrate carrier, is an integral protein of the mitochondrial inner membrane. It is an essential component of the shuttle system by which mitochondrial acetyl-CoA, primer for both fatty acid and cholesterol synthesis, is transported into the cytosol, where lipogenesis occurs. The effect of hypothyroidism on the activity and expression of the hepatic mitochondrial TCC was investigated in this study. TCC activity was significantly decreased in hypothyroid rats as compared with euthyroid animals. This hormone deficiency effect was due to a reduction in the amount of carrier protein, which resulted from a proportionate decrease of the specific mRNA. Hypothyroidism did not influence TCC mRNA stability. On the other hand, nuclear run-on assay revealed that the transcriptional rate of TCC mRNA decreased by similar to 40% in the nuclei from hypothyroid versus euthyroid rats. In addition, the ribonuclease protection assay showed that, in the nuclei of hypothyroid rats, the ratio of mature to precursor RNA decreased, indicating that the splicing of TCC RNA is affected. Furthermore, we found that the ratio of polyadenylated/unpolyadenylated TCC RNA as well as the length of the TCC RNA poly(A) tail were similar in both euthyroid and hypothyroid rats. Thus, the rate of formation of the TCC 3'-end is not altered in hypothyroidism. These results suggest that hypothyroidism affects TCC expression at both the transcriptional and post-transcriptional levels.	Univ Lecce, Lab Biochim & Biol Mol, Dipartimento Sci & Tecnol Biol & Ambientali, I-73100 Lecce, Italy	University of Salento	Gnoni, GV (corresponding author), Univ Lecce, Lab Biochim & Biol Mol, Dipartimento Sci & Tecnol Biol & Ambientali, Via Prov Lecce Monteroni, I-73100 Lecce, Italy.	gabriele.gnoni@unile.it	Giudetti, Anna Maria/ABF-4049-2021	GIUDETTI, ANNA MARIA/0000-0002-9204-040X; Siculella, Luisa/0000-0002-6890-3674				Amir-Ahmady B, 2001, J BIOL CHEM, V276, P10514, DOI 10.1074/jbc.M010535200; BLENNEMANN B, 1995, MOL CELL ENDOCRINOL, V110, P1, DOI 10.1016/0303-7207(95)03509-6; Brown SB, 1997, J BIOL CHEM, V272, P2163, DOI 10.1074/jbc.272.4.2163; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COMTE B, 1990, METABOLISM, V39, P259, DOI 10.1016/0026-0495(90)90044-D; Dummler K, 1996, BIOCHEM J, V317, P913; FREAKE HC, 1989, ENDOCRINOLOGY, V125, P2868, DOI 10.1210/endo-125-6-2868; Giudetti AM, 2003, J LIPID RES, V44, P2135, DOI 10.1194/jlr.M300237-JLR200; GNONI GV, 1985, BIOCHEM BIOPH RES CO, V128, P525, DOI 10.1016/0006-291X(85)90078-6; Goglia F, 1999, FEBS LETT, V452, P115, DOI 10.1016/S0014-5793(99)00642-0; GOODRIDGE AG, 1986, ANN NY ACAD SCI, V478, P46, DOI 10.1111/j.1749-6632.1986.tb15520.x; GOODRIDGE AG, 1973, J BIOL CHEM, V248, P4318; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; HOCH FL, 1988, PROG LIPID RES, V27, P199, DOI 10.1016/0163-7827(88)90013-6; Huang CL, 1998, BIOCHEM BIOPH RES CO, V249, P704, DOI 10.1006/bbrc.1998.9217; JUMP DB, 1989, J BIOL CHEM, V264, P4698; KAPLAN RS, 1990, ARCH BIOCHEM BIOPHYS, V280, P181, DOI 10.1016/0003-9861(90)90534-6; KAPLAN RS, 1991, ARCH BIOCHEM BIOPHYS, V287, P305, DOI 10.1016/0003-9861(91)90483-Y; KAPLAN RS, 1993, J BIOL CHEM, V268, P13682; KAPLAN RS, 1993, J BIOENERG BIOMEMBR, V25, P503, DOI 10.1007/BF01108407; KATSURADA A, 1990, EUR J BIOCHEM, V190, P435, DOI 10.1111/j.1432-1033.1990.tb15593.x; LANDRISCINA C, 1976, EUR J BIOCHEM, V71, P135, DOI 10.1111/j.1432-1033.1976.tb11099.x; Liu YL, 1996, NUCLEIC ACIDS RES, V24, P2718, DOI 10.1093/nar/24.14.2718; LLOBERA M, 1980, ENDOCRINOLOGY, V106, P1628, DOI 10.1210/endo-106-5-1628; MARIASH CN, 1984, BIOCHEM BIOPH RES CO, V123, P1122; Moreno M, 1997, J PHYSIOL-LONDON, V505, P529, DOI 10.1111/j.1469-7793.1997.529bb.x; MULLER MJ, 1987, BIOCHEM PHARMACOL, V36, P1623, DOI 10.1016/0006-2952(87)90046-3; Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7; PALMIERI F, 1972, EUR J BIOCHEM, V26, P587, DOI 10.1111/j.1432-1033.1972.tb01801.x; Paradies G, 1997, BBA-MOL BASIS DIS, V1362, P193, DOI 10.1016/S0925-4439(97)00075-6; PARADIES G, 1991, BIOCHIM BIOPHYS ACTA, V1070, P180, DOI 10.1016/0005-2736(91)90161-Z; PARADIES G, 1990, ARCH BIOCHEM BIOPHYS, V278, P425, DOI 10.1016/0003-9861(90)90280-C; RONCARI DAK, 1975, J BIOL CHEM, V250, P4134; RUGGIERO FM, 1987, LIPIDS, V22, P148, DOI 10.1007/BF02537293; SALATI LM, 1991, J BIOL CHEM, V266, P4010; Siculella L, 2004, J LIPID RES, V45, P1333, DOI 10.1194/jlr.M400061-JLR200; Siculella L, 2002, BIOCHEM BIOPH RES CO, V299, P418, DOI 10.1016/S0006-291X(02)02666-9; SONG MKH, 1988, J BIOL CHEM, V263, P17970; STAPLETON SR, 1990, J BIOL CHEM, V265, P18442; Tao HM, 2002, J BIOL CHEM, V277, P31270, DOI 10.1074/jbc.M203196200; TATA JR, 1963, BIOCHEM J, V86, P408, DOI 10.1042/bj0860408; Walker JD, 1996, ENDOCRINOLOGY, V137, P2293, DOI 10.1210/en.137.6.2293; WATSON JA, 1970, J BIOL CHEM, V245, P5993; Weitzel JM, 2003, J MOL ENDOCRINOL, V31, P291, DOI 10.1677/jme.0.0310291; Weitzel JM, 2003, EXP PHYSIOL, V88, P121, DOI 10.1113/eph8802506; Yehuda-Shnaidman E, 2005, ENDOCRINOLOGY, V146, P2462, DOI 10.1210/en.2004-1161; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Zara V, 2001, EUR J BIOCHEM, V268, P5734, DOI 10.1046/j.0014-2956.2001.02508.x	48	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19072	19080		10.1074/jbc.M507237200	http://dx.doi.org/10.1074/jbc.M507237200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16682415	hybrid			2022-12-25	WOS:000238847000021
J	Hahlen, K; Ebbing, B; Reinders, J; Mergler, J; Sickmann, A; Woehlke, G				Hahlen, Katrin; Ebbing, Bettina; Reinders, Joerg; Mergler, Judith; Sickmann, Albert; Woehlke, Guenther			Feedback of the kinesin-1 neck-linker position on the catalytic site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR PROTEIN KINESIN; KINETIC CHARACTERIZATION; ESCHERICHIA-COLI; DIMERIC KINESIN; MECHANISM; DOMAINS; ATPASE; MOTILITY; CONFORMATIONS; PROCESSIVITY	Kinesin-1 motor proteins step along microtubules by a mechanism in which the heads cycle through microtubule-bound and unbound states in an interlaced fashion. An important contribution to head-head coordination arises from the action of the neck-linker that docks onto the core motor domain upon ATP binding. We show here that the docked neck-linker not only guides the microtubule-unbound head to the next microtubule binding site but also signals its position to the head to which it is attached. Cross-linking studies on mutated kinesin constructs reveal that residues at the interface motor core/docked neck-linker, among them most importantly a conserved tyrosine, are involved in this feedback. The primary effect of the docked neck-linker is a reduced microtubule binding affinity in the ADP state.	Univ Munich, Inst Cell Biol, D-80336 Munich, Germany; Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, D-97078 Wurzburg, Germany	University of Munich; University of Wurzburg	Woehlke, G (corresponding author), Univ Munich, Inst Cell Biol, Schillerstr 42, D-80336 Munich, Germany.	guenther.woehlke@lrz.uni-muenchen.de	Lechner, Bettina/A-2448-2013; Sickmann, Albert/A-1010-2011	Sickmann, Albert/0000-0002-2388-5265; Reinders, Joerg/0000-0003-1025-7849; Woehlke, Gunther/0000-0001-8462-9962				Alonso MC, 1998, EMBO J, V17, P945, DOI 10.1093/emboj/17.4.945; Bathe F, 2005, MOL BIOL CELL, V16, P3529, DOI 10.1091/mbc.E04-11-0957; Carter NJ, 2005, NATURE, V435, P308, DOI 10.1038/nature03528; Crevel I, 1999, EMBO J, V18, P5863, DOI 10.1093/emboj/18.21.5863; Crevel IMTC, 2004, EMBO J, V23, P23, DOI 10.1038/sj.emboj.7600042; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; Frazier AE, 2004, NAT STRUCT MOL BIOL, V11, P226, DOI 10.1038/nsmb735; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; Hackney DD, 2002, BIOCHEMISTRY-US, V41, P4437, DOI 10.1021/bi0159229; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; HUANG TG, 1994, J BIOL CHEM, V269, P16493; HUANG TG, 1994, J BIOL CHEM, V269, P16502; Kallipolitou A, 2001, EMBO J, V20, P6226, DOI 10.1093/emboj/20.22.6226; Kaseda K, 2003, NAT CELL BIOL, V5, P1079, DOI 10.1038/ncb1067; Kozielski F, 1997, J STRUCT BIOL, V119, P28, DOI 10.1006/jsbi.1997.3872; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MANDELKOW EM, 1985, J MOL BIOL, V185, P311, DOI 10.1016/0022-2836(85)90406-1; Motulsky H., 1995, INTUITIVE BIOSTATIST; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Rice S, 2003, BIOPHYS J, V84, P1844, DOI 10.1016/S0006-3495(03)74992-3; Rosenfeld SS, 2003, J BIOL CHEM, V278, P18550, DOI 10.1074/jbc.M300849200; Rosenfeld SS, 2002, J BIOL CHEM, V277, P36731, DOI 10.1074/jbc.M205261200; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; Schafer F, 2003, EMBO J, V22, P450, DOI 10.1093/emboj/cdg036; Shimizu T, 2000, BIOCHEMISTRY-US, V39, P5265, DOI 10.1021/bi9928344; Sindelar CV, 2002, NAT STRUCT BIOL, V9, P844, DOI 10.1038/nsb852; Skiniotis G, 2003, EMBO J, V22, P1518, DOI 10.1093/emboj/cdg164; Song YH, 2001, EMBO J, V20, P6213, DOI 10.1093/emboj/20.22.6213; Tomishige M, 2000, J CELL BIOL, V151, P1081, DOI 10.1083/jcb.151.5.1081; Tomishige M, 2002, SCIENCE, V297, P2263, DOI 10.1126/science.1073386; Visscher K, 1999, NATURE, V400, P184, DOI 10.1038/22146; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3; Yildiz A, 2004, SCIENCE, V303, P676, DOI 10.1126/science.1093753	34	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18868	18877		10.1074/jbc.M508019200	http://dx.doi.org/10.1074/jbc.M508019200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16682419	hybrid			2022-12-25	WOS:000238687300067
J	Ugarte, G; Brandan, E				Ugarte, Gonzalo; Brandan, Enrique			Transforming growth factor beta (TGF-beta) signaling is regulated by electrical activity in skeletal muscle cells - TGF-beta type I receptor is transcriptionally regulated by myotube excitability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE SODIUM-CHANNELS; DELTA-SUBUNIT GENE; ACETYLCHOLINE-RECEPTOR; MYOGENIC DIFFERENTIATION; RAT MYOTUBES; BONE-CELLS; EXPRESSION; PROMOTER; MYOD; CLONING	Transforming growth factor (TGF-beta) is involved in several cellular processes such as cell proliferation, differentiation, and apoptosis. At the cell surface, TGF-beta binds to serine-threonine kinase transmembrane receptors (type II and type I) to initiate Smad-dependent intracellular signaling cascades. During the early stages of skeletal muscle differentiation, myotubes start to evoke spontaneous electrical activity in association with contractions that arise following the maturation of the excitation-contraction apparatus. In this work, we report that TGF-beta-dependent signaling is regulated by electrical activity in developing rat primary myotubes, as determined by Smad2 phosphorylation, Smad4 nuclear translocation, and p3TPLux reporter activity. This electrical activity-dependent regulation is associated with changes in TGF-beta type I receptor (T beta RI) levels, correlated with changes in transducing receptors at the cell membrane (measured through radiolabeling binding assays). The inhibition of electrical activity with tetrodotoxin, a voltage-dependent sodium channel blocker, increases T beta RI levels via a transcription-dependent mechanism. In contrast, the promotion of electrical activity in myotube cultures, induced by the up-regulation of voltage-dependent sodium channels or by direct stimulation with extracellular electrodes, causes T beta RI levels to decrease. Similar results were obtained in denervated adult muscles, suggesting that electrical activity-dependent regulation of T beta RI also occurs in vivo. Additional results suggest that this activity dependent regulation is mediated by myogenin. Altogether, these findings support the possibility for a novel regulatory mechanism acting on TGF-beta signaling cascade in skeletal muscle cells.	Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Biol Celular & Mol,Millennium Inst Fundament, MIFAB,Ctr Regulac Celular & Patol Joaquin V Luco, Santiago 114D, Chile	Pontificia Universidad Catolica de Chile	Brandan, E (corresponding author), Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Biol Celular & Mol,Millennium Inst Fundament, MIFAB,Ctr Regulac Celular & Patol Joaquin V Luco, Santiago 114D, Chile.	ebrandan@bio.puc.cl	Brandan, Enrique/A-7063-2017	Brandan, Enrique/0000-0002-6820-5059				BESSEREAU JL, 1993, EMBO J, V12, P443, DOI 10.1002/j.1460-2075.1993.tb05676.x; Biesiada E, 1999, MOL CELL BIOL, V19, P2577; BRODIE C, 1989, BRAIN RES, V488, P186, DOI 10.1016/0006-8993(89)90708-7; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; Centrella M, 1996, J BIOL CHEM, V271, P18616, DOI 10.1074/jbc.271.31.18616; CHAHINE KG, 1993, J BIOL CHEM, V268, P2893; CHAHINE KG, 1992, DEVELOPMENT, V115, P213; Chang WZ, 2002, GENE, V299, P65, DOI 10.1016/S0378-1119(02)01013-2; COGNARD C, 1993, DEVELOPMENT, V117, P1153; COOK DR, 1993, J CELL PHYSIOL, V157, P307, DOI 10.1002/jcp.1041570213; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; DUTTON EK, 1993, P NATL ACAD SCI USA, V90, P2040, DOI 10.1073/pnas.90.5.2040; EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349; FADIC R, 1990, J NEUROSCI, V10, P3516; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROUSELLE M, 1991, PFLUG ARCH EUR J PHY, V418, P40, DOI 10.1007/BF00370450; Ji CH, 1996, J CELL BIOCHEM, V63, P478; Ji CH, 1999, J BIOL CHEM, V274, P30487, DOI 10.1074/jbc.274.43.30487; JOHNSTON LA, 1992, MOL CELL BIOL, V12, P5123, DOI 10.1128/MCB.12.11.5123; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; KLOCKE R, 1994, J BIOL CHEM, V269, P27635; Koli KM, 1997, J BIOL CHEM, V272, P6423, DOI 10.1074/jbc.272.10.6423; Liu D, 2004, EMBO J, V23, P1557, DOI 10.1038/sj.emboj.7600179; Lopez-Casillas F, 2003, J BIOL CHEM, V278, P382, DOI 10.1074/jbc.M208520200; Macpherson P, 2002, J BIOL CHEM, V277, P15638, DOI 10.1074/jbc.M109864200; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; McLennan IS, 2002, INT J DEV BIOL, V46, P559; Mejat A, 2005, NAT NEUROSCI, V8, P313, DOI 10.1038/nn1408; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; PIETTE J, 1989, EMBO J, V8, P687, DOI 10.1002/j.1460-2075.1989.tb03427.x; Pribnow D, 1999, MUSCLE NERVE, V22, P742, DOI 10.1002/(SICI)1097-4598(199906)22:6<742::AID-MUS11>3.0.CO;2-1; Riquelme C, 2001, J BIOL CHEM, V276, P3589, DOI 10.1074/jbc.M004602200; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; SHERMAN SJ, 1982, J GEN PHYSIOL, V80, P753, DOI 10.1085/jgp.80.5.753; SHERMAN SJ, 1984, P NATL ACAD SCI-BIOL, V81, P262, DOI 10.1073/pnas.81.1.262; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Tang HB, 2004, CELL SIGNAL, V16, P551, DOI 10.1016/j.cellsig.2003.09.006; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Walke W, 1996, J NEUROSCI, V16, P3641; WILLIAMS PE, 1988, J ANAT, V158, P109; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Zhao Y, 2000, AM J PHYSIOL-LUNG C, V278, pL1231, DOI 10.1152/ajplung.2000.278.6.L1231	44	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18473	18481		10.1074/jbc.M600918200	http://dx.doi.org/10.1074/jbc.M600918200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16682418	hybrid			2022-12-25	WOS:000238687300026
J	Boulter, E; Grall, D; Cagnol, S; Van Obberghen-Schilling, E				Boulter, Etienne; Grall, Dominique; Cagnol, Sebastien; Van Obberghen-Schilling, Ellen			Regulation of cell-matrix adhesion dynamics and Rac-1 by integrin linked kinase	FASEB JOURNAL			English	Article						Rho family GTPase; integrin signaling; cell spreading; RNA interference	BINDING PROTEIN; FOCAL ADHESIONS; ALPHA-PIX; ILK; PAXILLIN; ACTIN; COMPLEX; GROWTH; PAK; SITES	Extracellular matrix (ECM) receptors of the integrin family initiate changes in cell shape and motility by recruiting signaling components that coordinate these events. Integrin-linked kinase (ILK) is one such partner of beta 1 integrins that participates in dynamic rearrangement of cell-matrix adhesions and cell spreading by mechanisms that are not well understood. To further elucidate the role of ILK in these events, we engineered a chimeric molecule comprising ILK fused to a membrane-targeted green fluorescent protein (ILK-GFP-F). ILK-GFP-F is highly enriched in cell-matrix adhesions, and its expression in fibroblasts leads to an accumulation of focal adhesions (2-5 mu m) and elongated adhesions (> 5 mu m). ILK-GFP-F enhances cell spreading on fibronectin and induces a constitutive increase in the levels of GTP-bound Rac-1. Conversely, ILK knock-down by siRNA transfection decreases active Rac-1. Endogenous ILK was found to associate with PKL (paxillin kinase linker) and the Rac/Cdc42 guanine nucleotide exchange factor beta PIX. Further, expression of a dominant negative beta PIX mutant reversed the increase in active Rac-1 levels of ILK-GFP-F-expressing cells, thus placing beta PIX in the pathway leading from ILK to Rac-1 activation. However, expression of constitutively active Rac only partially restores the spreading defects of ILK-depleted cells, suggesting that an additional ILK-dependent signal is required for cell spreading.	CNRS, Inst Signaling Dev Biol & Canc Res, UMR6543, Ctr Antoine Lacassagne, F-06189 Nice, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Centre Antoine Lacassagne	Van Obberghen-Schilling, E (corresponding author), CNRS, Inst Signaling Dev Biol & Canc Res, UMR6543, Ctr Antoine Lacassagne, 33 Ave Valombrose, F-06189 Nice, France.	vanobber@unice.fr	Van Obberghen-Schilling, Ellen/Q-4372-2019; Van Obberghen-Schilling, Ellen/O-1581-2016; Boulter, Etienne/R-1737-2016	Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; Boulter, Etienne/0000-0001-6597-9086				Adams JC, 2001, CELL MOL LIFE SCI, V58, P371, DOI 10.1007/PL00000864; Arthur WT, 2004, J CELL BIOL, V167, P111, DOI 10.1083/jcb.200404068; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; Deroanne C, 2003, J CELL SCI, V116, P1367, DOI 10.1242/jcs.00308; Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200; Gadea G, 2002, EMBO J, V21, P2373, DOI 10.1093/emboj/21.10.2373; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Grashoff C, 2004, CURR OPIN CELL BIOL, V16, P565, DOI 10.1016/j.ceb.2004.07.004; Guo LD, 2001, AM J PATHOL, V159, P1735, DOI 10.1016/S0002-9440(10)63020-9; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ishibe S, 2004, MOL CELL, V16, P257, DOI 10.1016/j.molcel.2004.10.006; Katz BZ, 2003, J BIOL CHEM, V278, P29115, DOI 10.1074/jbc.M212396200; KHYRUL WA, 2004, J BIOL CHEM; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Lamorte L, 2003, MOL BIOL CELL, V14, P2818, DOI 10.1091/mbc.E02-08-0497; Leung-Hagesteijn C, 2001, EMBO J, V20, P2160, DOI 10.1093/emboj/20.9.2160; Liu SC, 2000, J CELL SCI, V113, P3563; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Mishima W, 2004, GENES CELLS, V9, P193, DOI 10.1111/j.1356-9597.2004.00717.x; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Nishiya N, 2005, NAT CELL BIOL, V7, P343, DOI 10.1038/ncb1234; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175; Rosenberger G, 2003, HUM MOL GENET, V12, P155, DOI 10.1093/hmg/ddg019; Sakai T, 2003, GENE DEV, V17, P926, DOI 10.1101/gad.255603; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Torgler CN, 2004, DEV CELL, V6, P357, DOI 10.1016/S1534-5807(04)00055-3; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Vouret-Craviari V, 2004, J CELL SCI, V117, P4559, DOI 10.1242/jcs.01331; Vouret-Craviari V, 2002, J CELL SCI, V115, P2475; Wu CY, 2004, BBA-MOL CELL RES, V1692, P55, DOI 10.1016/j.bbamcr.2004.01.006; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Zamir E, 2001, J CELL SCI, V114, P3577; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhang YJ, 2004, J BIOL CHEM, V279, P41695, DOI 10.1074/jbc.M401563200; Zhang YJ, 2002, J CELL SCI, V115, P4777, DOI 10.1242/jcs.00166; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000	50	43	44	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1489	+		10.1096/fj.05-4579fje	http://dx.doi.org/10.1096/fj.05-4579fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16723384				2022-12-25	WOS:000240266000027
J	Eckert, M; Meek, SEM; Ball, KL				Eckert, Mirjam; Meek, Sarah E. M.; Ball, Kathryn L.			A novel repressor domain is required for maximal growth inhibition by the IRF-1 tumor suppressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR IRF-1; REGULATORY FACTOR-I; NUCLEAR RECEPTOR; SIGNATURE MOTIF; DNA-DAMAGE; LONG ARM; ACTIVATION; GENES; FACTOR-1; IFN	Interferon regulatory factor-1 (IRF-1) is a transcription factor and tumor suppressor that can regulate gene expression in a manner requiring either its sequence specific DNA binding activity or its ability to bind the p300 coactivator. We show that IRF-1-mediated growth inhibition is dependent on the integrity of a C-terminal transcriptional enhancer domain. An enhancer subdomain (amino acids 301-325) that differentially regulates IRF-1 activity has been identified and this region mediates the repression of Cdk2. The repressor domain encompasses an LXXLL coregulator signature motif and mutations or deletions within this region completely uncouple transcriptional activation from repression. The loss of growth suppressor activity when the Cdk2-repressor domain of IRF-1 is mutated implicates repression as a determinant of its maximal growth inhibitory potential. The data link IRF-1 regulatory domains to its growth inhibitory activity and provide information about how differential gene regulation may contribute to IRF-1 tumor suppressor activity.	Univ Edinburgh, Canc Res Ctr, CRUK Interferon & Cell Signalling Grp, Cell Signalling Unit, Edinburgh EH4 2XR, Midlothian, Scotland	University of Edinburgh	Ball, KL (corresponding author), Univ Edinburgh, Canc Res Ctr, CRUK Interferon & Cell Signalling Grp, Cell Signalling Unit, Edinburgh EH4 2XR, Midlothian, Scotland.	kathryn.ball@ed.ac.uk		Eckert, Mirjam/0000-0001-8641-8763				CHANG CH, 1992, IMMUNOGENETICS, V35, P378; Clarke N, 2004, EMBO J, V23, P3051, DOI 10.1038/sj.emboj.7600302; Coccia EM, 1999, ONCOGENE, V18, P2129, DOI 10.1038/sj.onc.1202536; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Dornan D, 2001, EMBO REP, V2, P139, DOI 10.1093/embo-reports/kve025; Dornan D, 2004, MOL CELL BIOL, V24, P10083, DOI 10.1128/MCB.24.22.10083-10098.2004; Escalante CR, 1998, NATURE, V391, P103, DOI 10.1038/34224; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; Gongora C, 2000, NUCLEIC ACIDS RES, V28, P2333, DOI 10.1093/nar/28.12.2333; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Kim EJ, 2003, BIOCHEM BIOPH RES CO, V304, P253, DOI 10.1016/S0006-291X(03)00575-8; Kirchhoff S, 1998, BIOCHIMIE, V80, P659, DOI 10.1016/S0300-9084(99)80019-4; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; Kirchhoff S, 2000, EUR J BIOCHEM, V267, P6753, DOI 10.1046/j.1432-1327.2000.01750.x; Kroger A, 2003, ONCOGENE, V22, P1045, DOI 10.1038/sj.onc.1206260; LIN RT, 1994, J BIOL CHEM, V269, P17542; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Nakagawa K, 2000, EUR J BIOCHEM, V267, P1680, DOI 10.1046/j.1432-1327.2000.01163.x; Nguyen H, 1999, ONCOGENE, V18, P5455, DOI 10.1038/sj.onc.1202924; Nguyen H, 1997, ONCOGENE, V15, P1425, DOI 10.1038/sj.onc.1201318; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; Ogasawara S, 1996, GASTROENTEROLOGY, V110, P52, DOI 10.1053/gast.1996.v110.pm8536888; Pamment J, 2002, ONCOGENE, V21, P7776, DOI 10.1038/sj.onc.1205981; Rogers RS, 2003, J BIOL CHEM, V278, P30091, DOI 10.1074/jbc.M301344200; Romeo G, 2002, J INTERF CYTOK RES, V22, P39, DOI 10.1089/107999002753452647; Savkur RS, 2004, J PEPT RES, V63, P207, DOI 10.1111/j.1399-3011.2004.00126.x; Schaper F, 1998, BIOCHEM J, V335, P147, DOI 10.1042/bj3350147; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tamura G, 1996, CANCER RES, V56, P612; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; WALDMAN T, 1995, CANCER RES, V55, P5187; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Xie RL, 2003, J BIOL CHEM, V278, P26589, DOI 10.1074/jbc.M301491200	39	15	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23092	23102		10.1074/jbc.M512589200	http://dx.doi.org/10.1074/jbc.M512589200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16679314	hybrid			2022-12-25	WOS:000239542600073
J	Rand, KD; Jorgensen, TJD; Olsen, OH; Persson, E; Jensen, ON; Stennicke, HR; Andersen, MD				Rand, Kasper D.; Jorgensen, Thomas J. D.; Olsen, Ole H.; Persson, Egon; Jensen, Ole N.; Stennicke, Henning R.; Andersen, Mette D.			Allosteric activation of coagulation factor VIIa visualized by hydrogen exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE DOMAIN; CRYSTAL-STRUCTURE; BINDING; DESIGN; IDENTIFICATION; CONFORMATION; COFACTOR; REGION; CA2+	Coagulation factor VIIa (FVIIa) is a serine protease that, after binding to tissue factor (TF), plays a pivotal role in the initiation of blood coagulation. We used hydrogen exchange monitored by mass spectrometry to visualize the details of FVIIa activation by comparing the exchange kinetics of distinct molecular states, namely zymogen FVII, endoproteolytically cleaved FVIIa, TF-bound zymogen FVII, TF-bound FVIIa, and FVIIa in complex with an active site inhibitor. The hydrogen exchange kinetics of zymogen FVII and FVIIa are identical indicating highly similar solution structures. However, upon tissue factor binding, FVIIa undergoes dramatic structural stabilization as indicated by decreased exchange rates localized throughout the protease domain and in distant parts of the light chain, spanning across 50 angstrom and revealing a concerted interplay between functional sites in FVIIa. The results provide novel insights into the cofactor-induced activation of this important protease and reveal the potential for allosteric regulation in the trypsin family of proteases.	Novo Nordisk AS, Dept Haemostasis Biochem, DK-2760 Malov, Denmark; Odense Univ, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark	Novo Nordisk; University of Southern Denmark	Rand, KD (corresponding author), Novo Nordisk AS, Dept Haemostasis Biochem, DK-2760 Malov, Denmark.	kprn@novonordisk.com	Jensen, Ole N/J-1763-2012; Rand, Kasper/ABG-7446-2021	Jensen, Ole N/0000-0003-1862-8528; Persson, Egon/0000-0003-3005-4926; Rand, Kasper/0000-0002-6337-5489; Jorgensen, Thomas J.D./0000-0002-7149-316X				Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; Eigenbrot C, 2001, STRUCTURE, V9, P627, DOI 10.1016/S0969-2126(01)00624-4; FEHLHAMMER H, 1977, J MOL BIOL, V111, P415, DOI 10.1016/S0022-2836(77)80062-4; Freskgard PO, 1996, PROTEIN SCI, V5, P1531, DOI 10.1002/pro.5560050809; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Hoofnagle AN, 2003, ANNU REV BIOPH BIOM, V32, P1, DOI 10.1146/annurev.biophys.32.110601.142417; Hopfner KP, 1999, STRUCTURE, V7, P989, DOI 10.1016/S0969-2126(99)80125-7; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; Jorgensen TJD, 2004, BIOCHEMISTRY-US, V43, P15044, DOI 10.1021/bi048706j; Kelley RF, 2004, BIOCHEMISTRY-US, V43, P1223, DOI 10.1021/bi035738i; Klingler O, 2004, BIOORG MED CHEM LETT, V14, P3715, DOI 10.1016/j.bmcl.2004.05.006; Klingler O, 2003, BIOORG MED CHEM LETT, V13, P1463, DOI 10.1016/S0960-894X(03)00168-9; Leonard BJN, 2000, J BIOL CHEM, V275, P34894, DOI 10.1074/jbc.M001166200; Liang ZX, 2004, P NATL ACAD SCI USA, V101, P9556, DOI 10.1073/pnas.0403337101; Lisal J, 2005, NAT STRUCT MOL BIOL, V12, P460, DOI 10.1038/nsmb927; LYER GH, 2005, J MOL BIOL, V351, P1110; Mandell JG, 1998, P NATL ACAD SCI USA, V95, P14705, DOI 10.1073/pnas.95.25.14705; Olsen OH, 2004, BIOCHEMISTRY-US, V43, P14096, DOI 10.1021/bi048721o; Perera L, 2005, J THROMB HAEMOST, V3, P1543, DOI 10.1111/j.1538-7836.2005.01433.x; Persson E, 1997, J BIOL CHEM, V272, P19919, DOI 10.1074/jbc.272.32.19919; Persson E, 2004, BIOCHEM J, V379, P497, DOI 10.1042/BJ20031596; Persson E, 2001, P NATL ACAD SCI USA, V98, P13583, DOI 10.1073/pnas.241339498; Pike ACW, 1999, P NATL ACAD SCI USA, V96, P8925, DOI 10.1073/pnas.96.16.8925; Pineda AO, 2004, J BIOL CHEM, V279, P31842, DOI 10.1074/jbc.M401756200; Ruf W, 1998, TRENDS CARDIOVAS MED, V8, P350, DOI 10.1016/S1050-1738(98)00031-0; Sichler K, 2002, J MOL BIOL, V322, P591, DOI 10.1016/S0022-2836(02)00747-7; Sorensen BB, 1997, J BIOL CHEM, V272, P11863, DOI 10.1074/jbc.272.18.11863; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; Wales TE, 2006, MASS SPECTROM REV, V25, P158, DOI 10.1002/mas.20064; WILDGOOSE P, 1990, BIOCHEMISTRY-US, V29, P3413, DOI 10.1021/bi00465a039; Wong L, 2005, J MOL BIOL, V351, P131, DOI 10.1016/j.jmb.2005.05.042	34	48	48	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23018	23024		10.1074/jbc.M602968200	http://dx.doi.org/10.1074/jbc.M602968200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16687401	hybrid			2022-12-25	WOS:000239542600064
J	Guo, SL; Zhang, YB; Yuan, FH; Gao, Y; Gu, LY; Wong, I; Li, GM				Guo, Shuangli; Zhang, Yanbin; Yuan, Fenghua; Gao, Yin; Gu, Liya; Wong, Isaac; Li, Guo-Min			Regulation of replication protein a functions in DNA mismatch repair by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; CELL NUCLEAR ANTIGEN; BINDING PROTEIN; HELA-CELLS; IN-VITRO; ATAXIA-TELANGIECTASIA; MOLECULAR-MECHANISMS; KINETIC-ANALYSIS; P34 SUBUNIT; DAMAGE	Replication protein A ( RPA) is involved in multiple stages of DNA mismatch repair ( MMR); however, the modulation of its functions between different stages is unknown. We show here that phosphorylation likely modulates RPA functions during MMR. Unphosphorylated RPA initially binds to nicked heteroduplex DNA to facilitate assembly of the MMR initiation complex. The unphosphorylated protein preferentially stimulates mismatch-provoked excision, possibly by cooperatively binding to the resultant single-stranded DNA gap. The DNA-bound RPA begins to be phosphorylated after extensive excision, resulting in severalfold reduction in the DNA binding affinity of RPA. Thus, during the phase of repair DNA synthesis, the phosphorylated RPA readily disassociates from DNA, making the DNA template available for DNA polymerase delta-catalyzed resynthesis. These observations support a model of how phosphorylation alters the DNA binding affinity of RPA to fulfill its differential requirement at the various stages of MMR.	Univ Kentucky, Med Ctr, Grad Ctr Toxicol, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Pathol, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky	Li, GM (corresponding author), Univ Kentucky, Med Ctr, Grad Ctr Toxicol, 800 Rose St, Lexington, KY 40536 USA.	gmli@uky.edu	Li, Guo-Min/I-5016-2014; Yuan, Fenghua/F-8736-2011; Zhang, Yanbin/F-2998-2011	Zhang, Yanbin/0000-0002-7263-5510; Li, Guo-Min/0000-0002-9842-4578	NATIONAL CANCER INSTITUTE [R01CA104333] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058771, R01GM072756] Funding Source: NIH RePORTER; NCI NIH HHS [CA104333] Funding Source: Medline; NIGMS NIH HHS [GM58771, GM072756] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 2003, MOL CELL, V12, P233, DOI 10.1016/S1097-2765(03)00219-3; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Ariza RR, 1996, NUCLEIC ACIDS RES, V24, P433, DOI 10.1093/nar/24.3.433; Balajee AS, 2004, EXP CELL RES, V300, P320, DOI 10.1016/j.yexcr.2004.07.022; Bao KK, 2002, J BIOL CHEM, V277, P12099, DOI 10.1074/jbc.M111314200; Binz SK, 2003, J BIOL CHEM, V278, P35584, DOI 10.1074/jbc.M305388200; Binz SK, 2004, DNA REPAIR, V3, P1015, DOI 10.1016/j.dnarep.2004.03.028; Blackwell LJ, 1996, MOL CELL BIOL, V16, P4798; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; CANTOR CR, 1970, BIOPOLYMERS, V9, P1059, DOI 10.1002/bip.1970.360090909; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; Chan DW, 1996, BIOCHEM CELL BIOL, V74, P67, DOI 10.1139/o96-007; Constantin N, 2005, J BIOL CHEM, V280, P39752, DOI 10.1074/jbc.M509701200; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; Dianov GL, 1999, BIOCHEMISTRY-US, V38, P11021, DOI 10.1021/bi9908890; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; Dzantiev L, 2004, MOL CELL, V15, P31, DOI 10.1016/j.molcel.2004.06.016; Fishel R, 2001, CANCER RES, V61, P7369; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; GABRIELSEN OS, 1993, METHOD ENZYMOL, V218, P508; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Genschel J, 2003, MOL CELL, V12, P1077, DOI 10.1016/S1097-2765(03)00428-3; Genschel J, 2002, J BIOL CHEM, V277, P13302, DOI 10.1074/jbc.M111854200; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; Guarne A, 2004, EMBO J, V23, P4134, DOI 10.1038/sj.emboj.7600412; Guo SL, 2004, J BIOL CHEM, V279, P16912, DOI 10.1074/jbc.M313213200; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P24203; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Henricksen LA, 1996, NUCLEIC ACIDS RES, V24, P3107, DOI 10.1093/nar/24.15.3107; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; Junop MS, 2001, MOL CELL, V7, P1, DOI 10.1016/S1097-2765(01)00149-6; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Kunkel TA, 2005, ANNU REV BIOCHEM, V74, P681, DOI 10.1146/annurev.biochem.74.082803.133243; LEE SH, 1995, J BIOL CHEM, V270, P12801, DOI 10.1074/jbc.270.21.12801; Li GM, 1999, ONCOL RES, V11, P393; Li GM, 2003, FRONT BIOSCI-LANDMRK, V8, pD997, DOI 10.2741/1121; Lin YL, 1998, J BIOL CHEM, V273, P1453, DOI 10.1074/jbc.273.3.1453; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Liu YY, 2005, J BIOL CHEM, V280, P32775, DOI 10.1074/jbc.M505705200; McCulloch SD, 2003, J BIOL CHEM, V278, P50803, DOI 10.1074/jbc.M309025200; Mendillo ML, 2005, J BIOL CHEM, V280, P22245, DOI 10.1074/jbc.M407545200; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14550, DOI 10.1021/bi00252a023; Myung K, 2001, NAT GENET, V27, P113, DOI 10.1038/83673; Niu HW, 1997, J BIOL CHEM, V272, P12634, DOI 10.1074/jbc.272.19.12634; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; PAN ZQ, 1995, P NATL ACAD SCI USA, V92, P4636, DOI 10.1073/pnas.92.10.4636; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Patrick SM, 2005, BIOCHEMISTRY-US, V44, P8438, DOI 10.1021/bi048057b; Patrick SM, 2001, J BIOL CHEM, V276, P22630, DOI 10.1074/jbc.M010314200; Ramilo C, 2002, MOL CELL BIOL, V22, P2037, DOI 10.1128/MCB.22.7.2037-2046.2002; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Schofield MJ, 2003, ANNU REV MICROBIOL, V57, P579, DOI 10.1146/annurev.micro.57.030502.090847; Stojic L, 2004, DNA REPAIR, V3, P1091, DOI 10.1016/j.dnarep.2004.06.006; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Umezu K, 1998, GENETICS, V148, P989; Vassin VM, 2004, MOL CELL BIOL, V24, P1930, DOI 10.1128/MCB.24.5.1930-1943.2004; Wang HY, 2001, CANCER RES, V61, P8554; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wu X, 2005, BIOCHEM J, V391, P473, DOI 10.1042/BJ20050379; ZernikKobak M, 1997, J BIOL CHEM, V272, P23896, DOI 10.1074/jbc.272.38.23896; Zhang YB, 2005, CELL, V122, P693, DOI 10.1016/j.cell.2005.06.027; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430; Zou Y, 2006, J CELL PHYSIOL, V208, P267, DOI 10.1002/jcp.20622	68	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21607	21616		10.1074/jbc.M603504200	http://dx.doi.org/10.1074/jbc.M603504200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16731533	hybrid			2022-12-25	WOS:000239387100006
J	Muckenfuss, H; Hamdorf, M; Held, U; Perkovic, M; Lower, J; Cichutek, K; Flory, E; Schumann, GG; Munk, C				Muckenfuss, Heide; Hamdorf, Matthias; Held, Ulrike; Perkovic, Mario; Loewer, Johannes; Cichutek, Klaus; Flory, Egbert; Schumann, Gerald G.; Muenk, Carsten			APOBEC3 proteins inhibit human LINE-1 retrotransposition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEOPROTEIN PARTICLE FORMATION; HIGH-FREQUENCY RETROTRANSPOSITION; HUMAN L1 RETROTRANSPOSITION; LEUKEMIA-VIRUS TYPE-1; ANTIRETROVIRAL DEFENSE; REVERSE TRANSCRIPTION; LTR-RETROTRANSPOSON; POTENT INHIBITORS; HIV-1 INFECTION; ORF1 PROTEIN	The human cytidine deaminase family APOBEC3 represents a novel group of proteins in the field of innate defense mechanisms that has been shown to be active against a variety of retroviruses. Here we examined whether members of the APOBEC3 family have an impact on retrotransposition of human long interspersed nuclear elements (LINE-1s or L1s). Using a retrotransposition reporter assay in HeLa cells, we demonstrate that in the presence of transiently transfected APOBEC3A, L1 retrotransposition frequency was reduced by up to 85%. Although APOBEC3G and -3H did not influence L1 retrotransposition notably, expression of APOBEC3B, -3C, and -3F inhibited transposition by similar to 75%. Although reverse transcription of L1s occurs in the nucleus and APOBEC3 proteins are believed to act via DNA deamination during reverse transcription, activity against L1 retrotransposition was not correlated with nuclear localization of APOBEC3s. We demonstrate that APOBEC3C and APOBEC3B were endogenously expressed in HeLa cells. Accordingly, down-regulation of APOBEC3C by RNA interference enhanced L1 retrotransposition by similar to 78%. Sequence analyses of de novo L1 retrotransposition events that occurred in the presence of overexpressed APOBEC3 proteins as well as the analyses of pre-existing endogenous L1 elements did not reveal an enhanced rate of G-to-A transitions, pointing to a mechanism independent of DNA deamination. This study presents evidence for a role of host-encoded APOBEC3 proteins in the regulation of L1 retrotransposition.	Paul Ehrlich Inst, Sect Retroelements Pr2, D-63225 Langen, Germany; Paul Ehrlich Inst, Div Med Biotechnol, D-63225 Langen, Germany	Paul Ehrlich Institute; Paul Ehrlich Institute	Schumann, GG (corresponding author), Paul Ehrlich Inst, Sect Retroelements Pr2, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.	schgr@pei.de; mueca@pei.de	Perkovic, Mario/AAZ-2653-2021	Perkovic, Mario/0000-0002-8969-5157				BECKER KG, 1993, HUM MOL GENET, V2, P1697, DOI 10.1093/hmg/2.10.1697; Bieniasz PD, 2004, NAT IMMUNOL, V5, P1109, DOI 10.1038/ni1125; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; Bishop KN, 2004, CURR BIOL, V14, P1392, DOI 10.1016/j.cub.2004.06.057; Bogerd HP, 2006, NUCLEIC ACIDS RES, V34, P89, DOI 10.1093/nar/gkj416; Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100; Chen H, 2006, CURR BIOL, V16, P480, DOI 10.1016/j.cub.2006.01.031; Chiu YL, 2005, NATURE, V435, P108, DOI 10.1038/nature03493; Conticello SG, 2005, MOL BIOL EVOL, V22, P367, DOI 10.1093/molbev/msi026; Cost GJ, 2002, EMBO J, V21, P5899, DOI 10.1093/emboj/cdf592; Delebecque F, 2006, J VIROL, V80, P605, DOI 10.1128/JVI.80.2.605-614.2006; Dewannieux M, 2003, NAT GENET, V35, P41, DOI 10.1038/ng1223; Doehle BP, 2005, J VIROL, V79, P8201, DOI 10.1128/JVI.79.13.8201-8207.2005; DOMBROSKI BA, 1994, MOL CELL BIOL, V14, P4485, DOI 10.1128/MCB.14.7.4485; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; Dutko JA, 2005, CURR BIOL, V15, P661, DOI 10.1016/j.cub.2005.02.051; Esnault C, 2005, NATURE, V433, P430, DOI 10.1038/nature03238; FANNING T, 1987, NUCLEIC ACIDS RES, V15, P2251, DOI 10.1093/nar/15.5.2251; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; Gaddis NC, 2004, J VIROL, V78, P12041, DOI 10.1128/JVI.78.21.12041-12046.2004; Gilbert N, 2005, MOL CELL BIOL, V25, P7780, DOI 10.1128/MCB.25.17.7780-7795.2005; Gilbert N, 2002, CELL, V110, P315, DOI 10.1016/S0092-8674(02)00828-0; Han JS, 2004, NATURE, V429, P268, DOI 10.1038/nature02536; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Hohjoh H, 1996, EMBO J, V15, P630, DOI 10.1002/j.1460-2075.1996.tb00395.x; Kimberland ML, 1999, HUM MOL GENET, V8, P1557, DOI 10.1093/hmg/8.8.1557; Kolosha VO, 2003, J BIOL CHEM, V278, P8112, DOI 10.1074/jbc.M210487200; Kolosha VO, 1997, P NATL ACAD SCI USA, V94, P10155, DOI 10.1073/pnas.94.19.10155; Kulpa DA, 2005, HUM MOL GENET, V14, P3237, DOI 10.1093/hmg/ddi354; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Liddament MT, 2004, CURR BIOL, V14, P1385, DOI 10.1016/j.cub.2004.06.050; Lochelt M, 2005, P NATL ACAD SCI USA, V102, P7982, DOI 10.1073/pnas.0501445102; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; Mahieux R, 2005, J GEN VIROL, V86, P2489, DOI 10.1099/vir.0.80973-0; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; Martin SL, 2001, MOL CELL BIOL, V21, P467, DOI 10.1128/MCB.21.2.467-475.2001; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; MATHIAS SL, 1993, BIOCHEM BIOPH RES CO, V191, P625, DOI 10.1006/bbrc.1993.1263; MINAKAMI R, 1992, NUCLEIC ACIDS RES, V20, P3139, DOI 10.1093/nar/20.12.3139; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; Navarro F, 2005, VIROLOGY, V333, P374, DOI 10.1016/j.virol.2005.01.011; Newman ENC, 2005, CURR BIOL, V15, P166, DOI 10.1016/j.cub.2004.12.068; Noguchi C, 2005, HEPATOLOGY, V41, P626, DOI 10.1002/hep.20580; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; RASMUSSEN HH, 1993, J INVEST DERMATOL, V101, P560, DOI 10.1111/1523-1747.ep12365986; Rosler C, 2005, HEPATOLOGY, V42, P301, DOI 10.1002/hep.20801; Rosler C, 2004, SCIENCE, V305, p1403A, DOI 10.1126/science.1100464; Russell RA, 2005, J VIROL, V79, P8724, DOI 10.1128/JVI.79.14.8724-8731.2005; Sasada A, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-32; Schumacher AJ, 2005, P NATL ACAD SCI USA, V102, P9854, DOI 10.1073/pnas.0501694102; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Shindo K, 2003, J BIOL CHEM, V278, P44412, DOI 10.1074/jbc.C300376200; Soifer HS, 2005, NUCLEIC ACIDS RES, V33, P846, DOI 10.1093/nar/gki223; Speek M, 2001, MOL CELL BIOL, V21, P1973, DOI 10.1128/MCB.21.6.1973-1985.2001; Stenglein MD, 2006, J BIOL CHEM, V281, P16837, DOI 10.1074/jbc.M602367200; Suspene R, 2005, P NATL ACAD SCI USA, V102, P8321, DOI 10.1073/pnas.0408223102; Symer DE, 2002, CELL, V110, P327, DOI 10.1016/S0092-8674(02)00839-5; Takeuchi H, 2005, J BIOL CHEM, V280, P375, DOI 10.1074/jbc.M408987200; Tchenio T, 2000, NUCLEIC ACIDS RES, V28, P411, DOI 10.1093/nar/28.2.411; Turelli P, 2004, J BIOL CHEM, V279, P43371, DOI 10.1074/jbc.C400334200; Turelli P, 2004, SCIENCE, V303, P1829, DOI 10.1126/science.1092066; Wedekind JE, 2003, TRENDS GENET, V19, P207, DOI 10.1016/S0168-9525(03)00054-4; Wei W, 2000, ANAL BIOCHEM, V284, P435, DOI 10.1006/abio.2000.4675; Wei W, 2001, MOL CELL BIOL, V21, P1429, DOI 10.1128/MCB.21.4.1429-1439.2001; Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246; Yang N, 2003, NUCLEIC ACIDS RES, V31, P4929, DOI 10.1093/nar/gkg663; Yu F, 2001, NUCLEIC ACIDS RES, V29, P4493, DOI 10.1093/nar/29.21.4493; Yu Q, 2004, J BIOL CHEM, V279, P53379, DOI 10.1074/jbc.M408802200; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Zheng YH, 2004, J VIROL, V78, P6073, DOI 10.1128/JVI.78.11.6073-6076.2004; Zingler N, 2005, GENOME RES, V15, P780, DOI 10.1101/gr.3421505	74	276	279	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22161	22172		10.1074/jbc.M601716200	http://dx.doi.org/10.1074/jbc.M601716200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16735504	hybrid			2022-12-25	WOS:000239387100063
J	Wilkinson, B; Koenigsknecht-Talboo, J; Grommes, C; Lee, CYD; Landreth, G				Wilkinson, Brandy; Koenigsknecht-Talboo, Jessica; Grommes, Christian; Lee, C. Y. Daniel; Landreth, Gary			Fibrillar beta-amyloid-stimulated intracellular signaling cascades require Vav for induction of respiratory burst and phagocytosis in monocytes and microglia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAC2-DEFICIENT MURINE NEUTROPHILS; NADPH OXIDASE ACTIVITY; ALZHEIMERS-DISEASE; LIPID-PEROXIDATION; PROINFLAMMATORY RESPONSES; SUPEROXIDE-PRODUCTION; OXIDATIVE STRESS; RAC ACTIVATION; PROTEIN RAC; MECHANISMS	Microglial interaction with extracellular beta-amyloid fibrils ( fA beta) is mediated through an ensemble of cell surface receptors, including the B-class scavenger receptor CD36, the alpha(6)beta(1)-integrin, and the integrin-associated protein/CD47. The binding of fA beta to this receptor complex has been shown to drive a tyrosine kinase-based signaling cascade leading to production of reactive oxygen species and stimulation of phagocytic activity; however, little is known about the intracellular signaling cascades governing the microglial response to fA beta. This study reports a direct mechanistic link between the fA beta cell surface receptor complex and downstream signaling events responsible for NADPH oxidase activation and phagosome formation. The Vav guanine nucleotide exchange factor is tyrosine-phosphorylated in response to fA beta peptides as a result of the engagement of the microglia fA beta cell surface receptor complex. Co-immunoprecipitation studies demonstrate an A beta-dependent association between Vav and both Lyn and Syk kinases. The downstream target of Vav, the small GTPase Rac1, is GTP-loaded in an A beta-dependent manner. Rac1 is both an essential component of the NADPH oxidase and a critical regulator of microglial phagocytosis. The direct role of Vav in fA beta-stimulated intracellular signaling cascades was established using primary microglia obtained from Vav(-/-) mice. Stimulation of Vav(-/-) microglia with fA beta failed to generate NADPH oxidase-derived reactive oxygen species and displayed a dramatically attenuated phagocytic response. These findings directly link Vav phosphorylation to the A beta-receptor complex and demonstrate that Vav activity is required for fA beta-stimulated intracellular signaling events upstream of reactive oxygen species production and phagosome formation.	Case Western Reserve Univ, Sch Med, Dept Neurosci, Alzheimers Res Lab, Cleveland, OH 44106 USA	Case Western Reserve University	Wilkinson, B (corresponding author), Case Western Reserve Univ, Sch Med, Dept Neurosci, Alzheimers Res Lab, Cleveland, OH 44106 USA.	blw9@po.cwru.edu			NATIONAL INSTITUTE ON AGING [R01AG016740, F32AG024031] Funding Source: NIH RePORTER; NIA NIH HHS [AG16740, F32 AG24031] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abramov AY, 2005, J NEUROSCI, V25, P9176, DOI 10.1523/JNEUROSCI.1632-05.2005; Abramov AY, 2005, PHILOS T R SOC B, V360, P2309, DOI 10.1098/rstb.2005.1766; Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Ard MD, 1996, J NEUROSCI RES, V43, P190, DOI 10.1002/(SICI)1097-4547(19960115)43:2<190::AID-JNR7>3.0.CO;2-B; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bamberger ME, 2003, J NEUROSCI, V23, P2665; Bamberger ME, 2001, MICROSC RES TECHNIQ, V54, P59, DOI 10.1002/jemt.1121; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Barger SW, 2004, FRONT BIOSCI-LANDMRK, V9, P3286, DOI 10.2741/1481; Behl C, 2005, SUB CELL BIOCHEM, V38, P65; Bergendi L, 1999, LIFE SCI, V65, P1865, DOI 10.1016/S0024-3205(99)00439-7; BIANCA VD, 1999, J BIOL CHEM, V274, P15493; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; BURDICK D, 1992, J BIOL CHEM, V267, P546; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; Combs CK, 2000, J NEUROSCI, V20, P558, DOI 10.1523/JNEUROSCI.20-02-00558.2000; Combs CK, 2001, NEUROCHEM INT, V39, P449, DOI 10.1016/S0197-0186(01)00052-3; Combs CK, 2001, J NEUROSCI, V21, P1179; Combs CK, 1999, J NEUROSCI, V19, P928; Cordle A, 2005, J BIOL CHEM, V280, P34202, DOI 10.1074/jbc.M505268200; Cougoule C, 2006, J BIOL CHEM, V281, P8756, DOI 10.1074/jbc.M513731200; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Crowley MT, 1996, J BIOL CHEM, V271, P1145, DOI 10.1074/jbc.271.2.1145; Crowley MT, 1997, J EXP MED, V186, P1027, DOI 10.1084/jem.186.7.1027; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; DeCoursey TE, 2005, CELL MOL LIFE SCI, V62, P2173, DOI 10.1007/s00018-005-5177-1; DeWitt DA, 1998, EXP NEUROL, V149, P329, DOI 10.1006/exnr.1997.6738; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; Fujimoto M, 1999, J IMMUNOL, V162, P7088; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; GHISO J, 1992, BIOCHEM J, V288, P1053, DOI 10.1042/bj2881053; Husemann J, 2002, GLIA, V40, P195, DOI 10.1002/glia.10148; Innocenti M, 2002, J CELL BIOL, V156, P125, DOI 10.1083/jcb.200108035; Isberg RR, 2000, MICROBES INFECT, V2, P793, DOI 10.1016/S1286-4579(00)90364-2; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; Kim C, 2006, J LEUKOCYTE BIOL, V79, P223, DOI 10.1189/jlb.0705371; Koenigsknecht J, 2004, J NEUROSCI, V24, P9838, DOI 10.1523/JNEUROSCI.2557-04.2004; Koenigsknecht-Talboo J, 2005, J NEUROSCI, V25, P8240, DOI 10.1523/JNEUROSCI.1808-05.2005; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Li SJ, 2002, J IMMUNOL, V169, P5043, DOI 10.4049/jimmunol.169.9.5043; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Mark RJ, 1997, J NEUROCHEM, V68, P255; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; McDonald DR, 1997, J NEUROSCI, V17, P2284; McDonald DR, 1998, J NEUROSCI, V18, P4451; McGee K, 2003, FEBS LETT, V533, P35, DOI 10.1016/S0014-5793(02)03745-6; Meda L, 1996, NEUROSCI LETT, V219, P91, DOI 10.1016/S0304-3940(96)13177-3; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Nunomura A, 1999, J NEUROSCI, V19, P1959; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; Patel JC, 2002, MOL BIOL CELL, V13, P1215, DOI 10.1091/mbc.02-01-0002; PEARCE SFA, 1995, J BIOL CHEM, V270, P2981, DOI 10.1074/jbc.270.7.2981; PERLMUTTER LS, 1990, NEUROSCI LETT, V119, P32, DOI 10.1016/0304-3940(90)90748-X; Pick E, 1986, Methods Enzymol, V132, P407; Pratico D, 2004, J ALZHEIMERS DIS, V6, P171; Pratico D, 2001, J NEUROSCI, V21, P4183, DOI 10.1523/JNEUROSCI.21-12-04183.2001; Price MO, 2002, J BIOL CHEM, V277, P19220, DOI 10.1074/jbc.M200061200; Price MO, 2002, BLOOD, V99, P2653, DOI 10.1182/blood.V99.8.2653; QIN B, 2006, IN PRESS NEUROBIOL A; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Sayre LM, 1997, J NEUROCHEM, V68, P2092; Shimohama S, 2000, BIOCHEM BIOPH RES CO, V273, P5, DOI 10.1006/bbrc.2000.2897; Smith MA, 1997, J NEUROSCI, V17, P2653; Stalder M, 2001, NEUROBIOL AGING, V22, P427, DOI 10.1016/S0197-4580(01)00209-3; TERZI E, 1994, BIOCHEMISTRY-US, V33, P7434, DOI 10.1021/bi00189a051; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; Van Muiswinkel FL, 1999, J NEUROIMMUNOL, V96, P121, DOI 10.1016/S0165-5728(99)00019-3; Zhao XX, 2003, J BIOL CHEM, V278, P40788, DOI 10.1074/jbc.M302208200	77	110	114	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20842	20850		10.1074/jbc.M600627200	http://dx.doi.org/10.1074/jbc.M600627200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16728400	hybrid			2022-12-25	WOS:000239187300021
J	Batthyany, C; Schopfer, FJ; Baker, PRS; Duran, R; Baker, LMS; Huang, Y; Cervenansky, C; Branchaud, BP; Freeman, BA				Batthyany, Carlos; Schopfer, Francisco J.; Baker, Paul R. S.; Duran, Rosario; Baker, Laura M. S.; Huang, Yingying; Cervenansky, Carlos; Branchaud, Bruce P.; Freeman, Bruce A.			Reversible post-translational modification of proteins by nitrated fatty acids in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL MEMBRANE; LOW-DENSITY-LIPOPROTEIN; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; NITRIC-OXIDE; NITROLINOLEIC ACID; HYDROGEN-PEROXIDE; MASS-SPECTROMETRY; S-NITROSYLATION; PEROXYNITRITE; INACTIVATION	Nitric oxide ((NO)-N-center dot)-derived reactive species nitrate unsaturated fatty acids, yielding nitroalkene derivatives, including the clinically abundant nitrated oleic and linoleic acids. The olefinic nitro group renders these derivatives electrophilic at the carbon beta to the nitro group, thus competent for Michael addition reactions with cysteine and histidine. By using chromatographic and mass spectrometric approaches, we characterized this reactivity by using in vitro reaction systems, and we demonstrated that nitroalkene-protein and GSH adducts are present in vivo under basal conditions in healthy human red cells. Nitro-linoleic acid (9-, 10-, 12-, and 13-nitro-9,12-octadecadienoic acids) (m/z 324.2) and nitro-oleic acid (9- and 10-nitro-9-octadecaenoic acids) (m/z 326.2) reacted with GSH (m/z 306.1), yielding adducts with m/z of 631.3 and 633.3, respectively. At physiological concentrations, nitroalkenes inhibited glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which contains a critical catalytic Cys (Cys-149). GAPDH inhibition displayed an IC50 of similar to 3 mu M for both nitroalkenes, an IC50 equivalent to the potent thiol oxidant peroxynitrite (ONOO-) and an IC50 30-fold less than H2O2, indicating that nitroalkenes are potent thiol-reactive species. Liquid chromatography-mass spectrometry analysis revealed covalent adducts between fatty acid nitroalkene derivatives and GAPDH, including at the catalytic Cys-149. Liquid chromatography-mass spectrometry-based proteomic analysis of human red cells confirmed that nitroalkenes readily undergo covalent, thiol-reversible post-translational modification of nucleophilic amino acids in GSH and GAPDH in vivo. The adduction of GAPDH and GSH by nitroalkenes significantly increased the hydrophobicity of these molecules, both inducing translocation to membranes and suggesting why these abundant derivatives had not been detected previously via traditional high pressure liquid chromatography analysis. The occurrence of these electrophilic nitroalkylation reactions in vivo indicates that this reversible post-translational protein modification represents a new pathway for redox regulation of enzyme function, cell signaling, and protein trafficking.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Republica, Fac Med, Dept Bioquim, Montevideo 11600, Uruguay; Minist Educ & Cultura, Inst Invest Biol Clemente Estable, Unidad Bioquim Analit, Montevideo 11600, Uruguay; Thermo Electron Corp, San Jose, CA 95134 USA; Univ Oregon, Dept Chem, Eugene, OR 97403 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Universidad de la Republica, Uruguay; Instituto de Investigaciones Biologicas Clemente Estable Uruguay; University of Oregon	Freeman, BA (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA.	freerad@pitt.edu	Durán, Rosario/GQH-8502-2022; Schopfer, Francisco Jose/AAE-8125-2020; Freeman, Bruce A/H-9342-2012; Schopfer, Francisco/AAW-6505-2021; Batthyany, Carlos I./A-6478-2009	Schopfer, Francisco Jose/0000-0001-9526-695X; Duran, Rosario/0000-0002-8575-9651; Batthyany, Carlos/0000-0002-0627-1982	NHLBI NIH HHS [R01 HL058115, R37 HL058115, HL58115, R01 HL064937, HL64937, R01 HL058115-09, T32HL07457, R01 HL064937-05A1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064937, T32HL007457, R01HL058115, R37HL058115] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baker PRS, 2005, J BIOL CHEM, V280, P42464, DOI 10.1074/jbc.M504212200; Baker PRS, 2004, P NATL ACAD SCI USA, V101, P11577, DOI 10.1073/pnas.0402587101; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; Botti H, 2004, FREE RADICAL BIO MED, V36, P152, DOI 10.1016/j.freeradbiomed.2003.10.006; BRODIE AE, 1990, ARCH BIOCHEM BIOPHYS, V276, P212, DOI 10.1016/0003-9861(90)90028-W; BRODIE AE, 1987, BIOCHEM BIOPH RES CO, V148, P120, DOI 10.1016/0006-291X(87)91084-9; Burford N, 2005, J INORG BIOCHEM, V99, P1992, DOI 10.1016/j.jinorgbio.2005.06.019; Ceaser EK, 2004, BIOCHEM SOC T, V32, P151, DOI 10.1042/BST0320151; Chuang DM, 2005, ANNU REV PHARMACOL, V45, P269, DOI 10.1146/annurev.pharmtox.45.120403.095902; Coles B, 2002, CIRC RES, V91, P375, DOI 10.1161/01.RES.0000032114.68919.EF; Coles B, 2002, J BIOL CHEM, V277, P5832, DOI 10.1074/jbc.M105209200; Cowan-Jacob SW, 2003, ACTA CRYSTALLOGR D, V59, P2218, DOI 10.1107/S0907444903020493; Crabb JW, 2002, PROTEIN SCI, V11, P831, DOI 10.1110/ps.4400102; ESTERBAUER H, 1975, Z NATURFORSCH C, V30, P466; Fukuda A, 1996, ARCH BIOCHEM BIOPHYS, V333, P419, DOI 10.1006/abbi.1996.0410; Gladwin MT, 2005, NAT CHEM BIOL, V1, P308, DOI 10.1038/nchembio1105-308; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; HARRIS I, 1963, NATURE, V198, P154, DOI 10.1038/198154a0; Harris J. I., 1976, ENZYMES; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; Ishii T, 2003, BIOCHEMISTRY-US, V42, P3474, DOI 10.1021/bi027172o; Kim JW, 2005, TRENDS BIOCHEM SCI, V30, P142, DOI 10.1016/j.tibs.2005.01.005; KLIMAN HJ, 1980, J BIOL CHEM, V255, P6314; Levonen AL, 2004, BIOCHEM J, V378, P373, DOI 10.1042/BJ20031049; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; Lim DG, 2002, P NATL ACAD SCI USA, V99, P15941, DOI 10.1073/pnas.232409599; LITTLE C, 1969, EUR J BIOCHEM, V10, P533, DOI 10.1111/j.1432-1033.1969.tb00721.x; Lynch KR, 1999, NATURE, V399, P789; Mazzola JL, 2003, BBA-GEN SUBJECTS, V1622, P50, DOI 10.1016/S0304-4165(03)00117-X; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; Mohr S, 1996, J BIOL CHEM, V271, P4209; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; Napolitano A, 2000, J ORG CHEM, V65, P4853, DOI 10.1021/jo000090q; O'Donnell VB, 2003, ANTIOXID REDOX SIGN, V5, P195, DOI 10.1089/152308603764816550; O'Donnell VB, 1999, CHEM RES TOXICOL, V12, P83, DOI 10.1021/tx980207u; ONO N, 2002, NITRO GROUP ORGANIC, P70; Piraud M, 2003, RAPID COMMUN MASS SP, V17, P1297, DOI 10.1002/rcm.1054; RACKER E, 1952, NATURE, V169, P1043, DOI 10.1038/1691043a0; RADI R, 1991, J BIOL CHEM, V266, P4244; RAVICHANDRAN V, 1994, J BIOL CHEM, V269, P25010; Rubbo H, 1996, CHEM RES TOXICOL, V9, P809, DOI 10.1021/tx960037q; Schopfer FJ, 2005, J BIOL CHEM, V280, P19289, DOI 10.1074/jbc.M414689200; Schopfer FJ, 2005, P NATL ACAD SCI USA, V102, P2340, DOI 10.1073/pnas.0408384102; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; Smotrys JE, 2004, ANNU REV BIOCHEM, V73, P559, DOI 10.1146/annurev.biochem.73.011303.073954; Souza JM, 1998, ARCH BIOCHEM BIOPHYS, V360, P187, DOI 10.1006/abbi.1998.0932; Spengler B, 1997, J MASS SPECTROM, V32, P1019, DOI 10.1002/(SICI)1096-9888(199711)32:10<1019::AID-JMS595>3.0.CO;2-G; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SZWEDA LI, 1993, J BIOL CHEM, V268, P3342; TSAI IH, 1982, J BIOL CHEM, V257, P1438; UCHIDA K, 1992, P NATL ACAD SCI USA, V89, P4544, DOI 10.1073/pnas.89.10.4544; UCHIDA K, 1993, J BIOL CHEM, V268, P6388; VEDIA LM, 1992, J BIOL CHEM, V267, P24929	56	222	240	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20450	20463		10.1074/jbc.M602814200	http://dx.doi.org/10.1074/jbc.M602814200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16682416	Green Accepted, hybrid			2022-12-25	WOS:000239038200068
J	Park, HJ; Ward, SM; Desgrosellier, JS; Georgescu, SP; Papageorge, AG; Zhuang, XL; Barnett, JV; Galper, JB				Park, Ho-Jin; Ward, Simone M.; Desgrosellier, Jay S.; Georgescu, Serban P.; Papageorge, Alexander G.; Zhuang, Xiaoli; Barnett, Joey V.; Galper, Jonas B.			Transforming growth factor beta regulates the expression of the M-2 muscarinic receptor in atrial myocytes via an effect on RhoA and p190RhoGAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEALED MYOCARDIAL-INFARCTION; LOW-DENSITY LIPOPROTEINS; CHICK HEART-CELLS; TGF-BETA; PARASYMPATHETIC RESPONSIVENESS; AUTONOMIC NEUROPATHY; DEPENDENT MECHANISM; SIGNALING PATHWAYS; SUDDEN-DEATH; K+ CHANNEL	Transforming growth factor beta(TGF beta) signaling is involved in the development and regulation of multiple organ systems and cellular signaling pathways. We recently demonstrated that TGF beta regulates the response of atrial myocytes to parasympathetic stimulation. Here, TGF beta(1) is shown to inhibit expression of the M-2 muscarinic receptor (M2), which plays a critical role in the parasympathetic response of the heart. This effect is mimicked by overexpression of a dominant negative mutant of RhoA and by the RhoA kinase inhibitor Y27632, whereas adenoviral expression of a dominant activating-RhoA reverses TGF beta inhibition of M2 expression. TGF beta(1) also mediates a decrease in GTP-bound RhoA and a reciprocal increase in the expression of the RhoA GTPase-activating protein, p190RhoGAP, whereas total RhoA is unchanged. Inhibition of M2 promoter activity by TGF beta 1 is mimicked by overexpression of p190RhoGAP, whereas a dominant negative mutant of p190RhoGAP reverses this effect of TGF beta 1. In contrast to atrial myocytes, in mink lung epithelial cells, in which TGF beta signaling through activation of RhoA has been previously identified, TGF beta 1 stimulated an increase in GTP-bound RhoA in association with a reciprocal decrease in the expression of p190RhoGAP. Both effects demonstrated a similar dose dependence on TGF beta 1. Thus TGF beta regulation of M2 muscarinic receptor expression is dependent on RhoA, and TGF beta regulation of p190RhoGAP expression may be a cell type-specific mechanism for TGF beta signaling through RhoA.	Tufts Univ, New England Med Ctr, Mol Cardiol Res Inst, Dept Med, Boston, MA 02111 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; NCI, NIH, Bethesda, MD 20892 USA	Tufts Medical Center; Tufts University; Tufts University; Harvard University; Brigham & Women's Hospital; Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Galper, JB (corresponding author), Tufts Univ, New England Med Ctr, Mol Cardiol Res Inst, Dept Med, Boston, MA 02111 USA.	hpark@tufts-nemc.org; jgalper@tufts-nemc.org	Desgrosellier, Jay S/A-8756-2008		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054225, R01HL066467, R01HL052922] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL052922, HL54225, R01 HL052922-10, HL52922, HL66467] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Barnes PJ, 1997, LIFE SCI, V60, P1015, DOI 10.1016/S0024-3205(97)00042-8; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Contreras RG, 1999, J CELL SCI, V112, P4223; CURB JD, 1995, CIRCULATION, V91, P2591, DOI 10.1161/01.CIR.91.10.2591; DEHAAN RL, 1967, CIRCULATION, V35, P821, DOI 10.1161/01.CIR.35.5.821; Donahue JK, 2000, NAT MED, V6, P1395; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; GADBUT AP, 1994, J BIOL CHEM, V269, P30707; Gadbut AP, 1997, EMBO J, V16, P7250, DOI 10.1093/emboj/16.24.7250; HAIGH LS, 1988, J BIOL CHEM, V263, P15608; Haskell MD, 2001, J CELL SCI, V114, P1699; HOLTZMAN EJ, 1991, J BIOL CHEM, V266, P1763; Jackson DA, 1997, BIOCHEM PHARMACOL, V54, P525, DOI 10.1016/S0006-2952(97)00219-0; Kalman D, 1999, MOL BIOL CELL, V10, P1665, DOI 10.1091/mbc.10.5.1665; KILBOURNE EJ, 1994, GENE, V150, P341, DOI 10.1016/0378-1119(94)90449-9; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Li R, 1997, J BIOL CHEM, V272, P32830, DOI 10.1074/jbc.272.52.32830; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MacKenna D, 2000, CARDIOVASC RES, V46, P257, DOI 10.1016/S0008-6363(00)00030-4; Martin J, 2005, CARDIOVASC RES, V65, P694, DOI 10.1016/j.cardiores.2004.10.041; McGowan Tracy A, 2004, Curr Diab Rep, V4, P447, DOI 10.1007/s11892-004-0055-z; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Noren NK, 2003, J BIOL CHEM, V278, P13615, DOI 10.1074/jbc.C200657200; OBRIEN JA, 1991, Q J MED, V79, P495; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OPIE L, 2004, MECHANISMS CARDIAC C; Orchard TJ, 1996, DIABETES RES CLIN PR, V34, pS165, DOI 10.1016/S0168-8227(96)01321-6; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; QIU MS, 1991, J CELL BIOL, V115, P795, DOI 10.1083/jcb.115.3.795; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Rosenkranz S, 2004, CARDIOVASC RES, V63, P423, DOI 10.1016/j.cardiores.2004.04.030; Rosoff ML, 1996, P NATL ACAD SCI USA, V93, P14889, DOI 10.1073/pnas.93.25.14889; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; SAMBROOK J, 1990, MOL CLONING LAB MANU, P719; SCHWARTZ P J, 1992, Circulation, V85, pI77; SCHWARTZ PJ, 1984, CIRCULATION, V69, P790, DOI 10.1161/01.CIR.69.4.790; SERRA R, 1992, CELL GROWTH DIFFER, V3, P693; Tatsis N, 1998, J BIOL CHEM, V273, P34631, DOI 10.1074/jbc.273.51.34631; VANOLI E, 1991, CIRC RES, V68, P1471, DOI 10.1161/01.RES.68.5.1471; Ward SM, 2002, J BIOL CHEM, V277, P50183, DOI 10.1074/jbc.M209668200; Ward SM, 2002, J MOL CELL CARDIOL, V34, P1217, DOI 10.1006/jmcc.2002.7023; Weber KT, 2000, CURR OPIN CARDIOL, V15, P264, DOI 10.1097/00001573-200007000-00010; Wolf RM, 2003, GENE DEV, V17, P476, DOI 10.1101/gad.1040003; Yue JB, 1999, ONCOGENE, V18, P2033, DOI 10.1038/sj.onc.1202521; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380; ZIPES DP, 2004, CARDIAC ELECTROPHYSI, P103	51	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					19995	20002		10.1074/jbc.M513095200	http://dx.doi.org/10.1074/jbc.M513095200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16707504	hybrid			2022-12-25	WOS:000239038200023
J	Borchert, A; Wang, CC; Ufer, C; Schiebel, H; Savaskan, NE; Kuhn, H				Borchert, Astrid; Wang, Chi Chiu; Ufer, Christoph; Schiebel, Heike; Savaskan, Nicolai E.; Kuhn, Hartmut			The role of phospholipid hydroperoxide glutathione peroxidase isoforms in murine embryogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; TRANSREGULATORY ELEMENTS; CHROMOSOMAL LOCALIZATION; EXPRESSION PATTERN; SPERM MATURATION; OXIDATIVE DAMAGE; PHGPX; GENE; IDENTIFICATION; GPX4	Phospholipid hydroperoxide glutathione peroxidase (GPx4) is a selenocysteine-containing enzyme, and three different isoforms (cytosolic, mitochondrial, and nuclear) originate from the GPx4 gene. Homozygous GPx4-deficient mice die in utero at midgestation, since they fail to initiate gastrulation and do not develop embryonic cavities. To investigate the biological basis for embryonic lethality, we first explored expression of the GPx4 in adult murine brain and found expression of the protein in cerebral neurons. Next, we profiled mRNA expression during the time course of embryogenesis (embryonic days 6.5-17.5 (E6.5-17.5)) and detected mitochondrial and cytosolic mRNA species at high concentrations. In contrast, the nuclear isoform was only expressed in small amounts. Cytosolic GPx4 mRNA was present at constant levels (about 100 copies per 1000 copies of glyceraldehyde-3-phosphate dehydrogenase mRNA), whereas nuclear and mitochondrial isoforms were down-regulated between E14.5 and E17.5. In situ hybridization indicated expression of GPx4 isoforms in all developing germ layers during gastrulation and in the somite stage in the developing central nervous system and in the heart. When we silenced expression of GPx4 isoforms during in vitro embryogenesis using short interfering RNA technology, we observed that knockdown of mitochondrial GPx4 strongly impaired segmentation of rhombomeres 5 and 6 during hindbrain development and induced cerebral apoptosis. In contrast, silencing expression of the nuclear isoform led to retardations in atrium formation. Taken together, our data indicate specific expression of GPx4 isoforms in embryonic brain and heart and strongly suggest a role of this enzyme in organogenesis. These findings may explain in part intrauterine lethality of GPx4 knock-out mice.	Univ Med Berlin, Charite, Inst Biochem, D-10117 Berlin, Germany; Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Obstet & Gynaecol, Shatin, Hong Kong, Peoples R China; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Chinese University of Hong Kong; Chinese University of Hong Kong; Netherlands Cancer Institute	Kuhn, H (corresponding author), Univ Med Berlin, Charite, Inst Biochem, Monbijoustr 2, D-10117 Berlin, Germany.	hartmut.kuehn@charite.de	Wang, Ronald/C-6541-2014; Savaskan, Nicolai/D-2923-2018	Wang, Ronald/0000-0002-3928-7278; Borchert, Astrid/0000-0003-3551-5592; Savaskan, Nicolai/0000-0003-1348-094X				Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; Blaschke AJ, 1996, DEVELOPMENT, V122, P1165; Blaschke AJ, 1998, J COMP NEUROL, V396, P39, DOI 10.1002/(SICI)1096-9861(19980622)396:1<39::AID-CNE4>3.0.CO;2-J; Borchert A, 2003, J BIOL CHEM, V278, P2571, DOI 10.1074/jbc.M209064200; Boschan C, 2002, GENOMICS, V79, P387, DOI 10.1006/geno.2001.6715; Brigelius-Flohe R, 1999, FREE RADICAL BIO MED, V27, P951, DOI 10.1016/S0891-5849(99)00173-2; Chan LYS, 2002, REPROD TOXICOL, V16, P841, DOI 10.1016/S0890-6238(02)00047-3; Conrad M, 2005, MOL CELL BIOL, V25, P7637, DOI 10.1128/MCB.25.17.7637-7644.2005; Imai H, 2000, SEIKAGAKU, V72, P1344; Imai H, 1998, J BIOL CHEM, V273, P1990, DOI 10.1074/jbc.273.4.1990; Imai H, 2003, BIOCHEM BIOPH RES CO, V305, P278, DOI 10.1016/S0006-291X(03)00734-4; Imai H, 2003, FREE RADICAL BIO MED, V34, P145, DOI 10.1016/S0891-5849(02)01197-8; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jiang YY, 2005, J NEUROSCI, V25, P6962, DOI 10.1523/JNEUROSCI.1446-05.2005; Kelner MJ, 1998, BIOCHEM BIOPH RES CO, V249, P53, DOI 10.1006/bbrc.1998.9086; Knopp EA, 1999, MAMM GENOME, V10, P601, DOI 10.1007/s003359901053; Maiorino M, 2003, J BIOL CHEM, V278, P34286, DOI 10.1074/jbc.M305327200; Maiorino M, 2003, BIOL REPROD, V68, P1134, DOI 10.1095/biolreprod.102.007500; Nomura K, 1999, J BIOL CHEM, V274, P29294, DOI 10.1074/jbc.274.41.29294; NOVACK DV, 1994, AM J PATHOL, V145, P61; Pfeifer H, 2001, FASEB J, V15, P1236, DOI 10.1096/fj.00-0655fje; Puglisi R, 2005, CONTRACEPTION, V72, P291, DOI 10.1016/j.contraception.2005.03.002; PUSHPAREKHA TR, 1995, J BIOL CHEM, V270, P26993, DOI 10.1074/jbc.270.45.26993; Ranger AM, 2001, NAT GENET, V28, P113, DOI 10.1038/88815; Roveri A, 2002, METHOD ENZYMOL, V347, P208; Roveri A, 2001, BIOFACTORS, V14, P213, DOI 10.1002/biof.5520140127; SATTLER W, 1994, ARCH BIOCHEM BIOPHYS, V309, P214, DOI 10.1006/abbi.1994.1105; Schittny JC, 1998, AM J RESP CELL MOL, V18, P786, DOI 10.1165/ajrcmb.18.6.3031; Sorenson CM, 2004, BBA-MOL CELL RES, V1644, P169, DOI 10.1016/j.bbamcr.2003.08.010; TAKAHASHI T, 1995, J NEUROSCI, V15, P6046; THOMAS JP, 1990, J BIOL CHEM, V265, P454; Tramer F, 2004, BIOCHEM J, V383, P179, DOI 10.1042/BJ20040974; Ufer C, 2003, NUCLEIC ACIDS RES, V31, P4293, DOI 10.1093/nar/gkg650; Ursini F, 1999, SCIENCE, V285, P1393, DOI 10.1126/science.285.5432.1393; URSINI F, 1987, CHEM PHYS LIPIDS, V44, P255, DOI 10.1016/0009-3084(87)90053-3; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Yant LJ, 2003, FREE RADICAL BIO MED, V34, P496, DOI 10.1016/S0891-5849(02)01360-6	37	66	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19655	19664		10.1074/jbc.M601195200	http://dx.doi.org/10.1074/jbc.M601195200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16684775	hybrid			2022-12-25	WOS:000238847000079
J	Lakhe-Reddy, S; Khan, S; Konieczkowski, M; Jarad, G; Wu, KL; Reichardt, LF; Takai, Y; Bruggeman, LA; Wang, BC; Sedor, JR; Schelling, JR				Lakhe-Reddy, Sujata; Khan, Shenaz; Konieczkowski, Martha; Jarad, George; Wu, Karen L.; Reichardt, Louis F.; Takai, Yoshimi; Bruggeman, Leslie A.; Wang, Bingcheng; Sedor, John R.; Schelling, Jeffrey R.			beta 8 integrin binds Rho GDP dissociation inhibitor-1 and activates Rac1 to inhibit mesangial cell myofibroblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN ALPHA-V-BETA-8; CEREBRAL-HEMORRHAGE; NEGATIVE REGULATION; PROTEIN; EXPRESSION; ACTIN; RECEPTOR; DOMAIN; GROWTH; PHOSPHORYLATION	alpha v beta 8 integrin expression is restricted primarily to kidney, brain, and placenta. Targeted alpha v or beta 8 deletion is embryonic lethal due to defective placenta and brain angiogenesis, precluding investigation of kidney alpha v beta 8 function. We find that kidney beta 8 is localized to glomerular mesangial cells, and expression is decreased in mouse models of glomerulosclerosis, suggesting that beta 8 regulates normal mesangial cell differentiation. To interrogate beta 8 signaling pathways, yeast two-hybrid and co-precipitation studies demonstrated beta 8 interaction with Rho guanine nucleotide dissociation inhibitor-1 (GDI). Selective beta 8 stimulation enhanced beta 8-GDI interaction as well as Rac1 (but not RhoA) activation and lamellipodia formation. Mesangial cells from itgb8-/- mice backcrossed to a genetic background that permitted survival, or gdi-/- mice, which develop glomerulosclerosis, demonstrated RhoA (but not Rac1) activity and alpha-smooth muscle actin assembly, which characterizes mesangial cell myofibroblast transformation in renal disease. To determine whether Rac1 directly modulates RhoA-associated myofibroblast differentiation, mesangial cells were transduced with inhibitory Rac peptide fused to human immunodeficiency virusTat, resulting in enhanced alpha-smooth muscle actin organization. We conclude that the beta 8 cytosolic tail in mesangial cells organizes a signaling complex that culminates in Rac1 activation to mediate wild- type differentiation, whereas decreased beta 8 activation shifts mesangial cells toward a RhoA- dependent myofibroblast phenotype.	Case Western Reserve Univ, Sch Med, Metrohlth Med Ctr, Rammelkamp Ctr Educ & Res,Dept Med, Cleveland, OH 44109 USA; Case Western Reserve Univ, Sch Med, Metrohlth Med Ctr, Rammelkamp Ctr Educ & Res,Dept Pharmacol, Cleveland, OH 44109 USA; Case Western Reserve Univ, Sch Med, Metrohlth Med Ctr, Rammelkamp Ctr Educ & Res,Dept Physiol & Biophys, Cleveland, OH 44109 USA; Univ Calif San Francisco, Dept Physiol & Biochem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biophys, San Francisco, CA 94143 USA; Howard Hughes Med Inst, San Francisco, CA 94143 USA; Osaka Univ, Grad Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Case Western Reserve University; MetroHealth System; Case Western Reserve University; MetroHealth System; Case Western Reserve University; MetroHealth System; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Osaka University	Schelling, JR (corresponding author), Case Western Reserve Univ, Sch Med, Metrohlth Med Ctr, Rammelkamp Ctr Educ & Res,Dept Med, 2500 MetroHlth Dr,R415, Cleveland, OH 44109 USA.	jeffrey.schelling@case.edu			NCI NIH HHS [R01 CA096533, R01 CA092259] Funding Source: Medline; NIDDK NIH HHS [R01 DK061395, P50 DK054178, R01 DK064719] Funding Source: Medline; NINDS NIH HHS [R01 NS019090, R01 NS019090-23] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096533, R01CA092259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064719, R01DK061395, P50DK054178] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019090] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Akakura S, 2004, EXP CELL RES, V292, P403, DOI 10.1016/j.yexcr.2003.09.011; Allenspach EJ, 2001, IMMUNITY, V15, P739, DOI 10.1016/S1074-7613(01)00224-2; *APPL BIOSY, 2001, APPL BIOSY US B, V2; Berrier AL, 2002, J CELL SCI, V115, P4285, DOI 10.1242/jcs.00109; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Cambier S, 2000, CANCER RES, V60, P7084; Carol RJ, 2005, NATURE, V438, P1013, DOI 10.1038/nature04198; CHEN YP, 1994, J BIOL CHEM, V269, P18307; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; CHUANG TH, 1993, J BIOL CHEM, V268, P775; Danen EHJ, 2005, J CELL BIOL, V169, P515, DOI 10.1083/jcb.200412081; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; DerMardirossian C, 2005, TRENDS CELL BIOL, V15, P356, DOI 10.1016/j.tcb.2005.05.001; DerMardirossian C, 2004, MOL CELL, V15, P117, DOI 10.1016/j.molcel.2004.05.019; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Dovas A, 2005, BIOCHEM J, V390, P1, DOI 10.1042/BJ20050104; Dransart E, 2005, J BIOL CHEM, V280, P4674, DOI 10.1074/jbc.M409741200; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Gandhi PN, 2004, BIOCHEM J, V378, P409, DOI 10.1042/BJ20030979; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Gibson RM, 2001, BIOCHEM J, V359, P285, DOI 10.1042/0264-6021:3590285; Grande-Garcia A, 2005, BIOCHEM SOC T, V33, P609, DOI 10.1042/BST0330609; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANCOCK JF, 1993, EMBO J, V12, P1915, DOI 10.1002/j.1460-2075.1993.tb05840.x; Hansen K, 2003, KIDNEY INT, V64, P110, DOI 10.1046/j.1523-1755.2003.00039.x; Hansen KM, 1998, MATRIX BIOL, V17, P117, DOI 10.1016/S0945-053X(98)90025-7; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Hugo C, 1998, KIDNEY INT, V53, P302, DOI 10.1046/j.1523-1755.1998.00774.x; Humphries MJ, 2003, TRENDS BIOCHEM SCI, V28, P313, DOI 10.1016/S0968-0004(03)00112-9; Jarad G, 2002, J BIOL CHEM, V277, P47826, DOI 10.1074/jbc.M204901200; KANAME S, 1992, KIDNEY INT, V42, P1319, DOI 10.1038/ki.1992.423; Khan S, 2001, KIDNEY INT, V60, P65, DOI 10.1046/j.1523-1755.2001.00771.x; Khan S, 1999, LAB INVEST, V79, P1089; Kikkawa Y, 2003, J CELL BIOL, V161, P187, DOI 10.1083/jcb.200211121; Kiosses WB, 2002, CIRC RES, V90, P697, DOI 10.1161/01.RES.0000014227.76102.5D; KOPP JB, 1992, P NATL ACAD SCI USA, V89, P1577, DOI 10.1073/pnas.89.5.1577; Kreidberg JA, 2000, AM J PHYSIOL-RENAL, V279, pF233, DOI 10.1152/ajprenal.2000.279.2.F233; Kreisberg JI, 1997, AM J PHYSIOL-RENAL, V273, pF283, DOI 10.1152/ajprenal.1997.273.2.F283; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; Lin Q, 2003, CURR BIOL, V13, P1469, DOI 10.1016/S0960-9822(03)00613-4; Loo DT, 1998, J BIOL CHEM, V273, P23304, DOI 10.1074/jbc.273.36.23304; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Mattila E, 2005, NAT CELL BIOL, V7, P78, DOI 10.1038/ncb1209; McCarty JH, 2005, P NATL ACAD SCI USA, V102, P13479, DOI 10.1073/pnas.0506068102; McCarty JH, 2005, DEVELOPMENT, V132, P165, DOI 10.1242/dev.01551; McCarty JH, 2002, MOL CELL BIOL, V22, P7667, DOI 10.1128/MCB.22.21.7667-7677.2002; Meng WX, 2004, EMBO J, V23, P760, DOI 10.1038/sj.emboj.7600095; Miao H, 2003, J CELL BIOL, V162, P1281, DOI 10.1083/jcb.200304018; MIURA Y, 1993, J BIOL CHEM, V268, P510; Moissoglu K, 2006, MOL BIOL CELL, V17, P2770, DOI 10.1091/mbc.E06-01-0005; MOYLE M, 1991, J BIOL CHEM, V266, P19650; Mu DZ, 2002, J CELL BIOL, V157, P493, DOI 10.1083/jcb.200109100; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; NISHIMURA SL, 1994, J BIOL CHEM, V269, P28708; Nishiya N, 2005, NAT CELL BIOL, V7, P343, DOI 10.1038/ncb1234; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Patel K, 2003, J CELL PHYSIOL, V195, P435, DOI 10.1002/jcp.10267; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; Racusen LC, 1997, J LAB CLIN MED, V129, P318, DOI 10.1016/S0022-2143(97)90180-3; Sakisaka T, 2002, EMBO J, V21, P6125, DOI 10.1093/emboj/cdf603; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; SCHELLING JR, 1992, J CLIN INVEST, V90, P2472, DOI 10.1172/JCI116139; Schelling JR, 1998, LAB INVEST, V78, P813; Schvartz I, 1999, INT J BIOCHEM CELL B, V31, P539, DOI 10.1016/S1357-2725(99)00005-9; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Sivars U, 2003, NATURE, V425, P856, DOI 10.1038/nature02057; Srichai MB, 2004, J BIOL CHEM, V279, P14398, DOI 10.1074/jbc.M314155200; Stefansson A, 2004, J BIOL CHEM, V279, P21200, DOI 10.1074/jbc.M400771200; Stepp MA, 1999, DEV DYNAM, V214, P216, DOI 10.1002/(SICI)1097-0177(199903)214:3<216::AID-AJA5>3.3.CO;2-W; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TAMAKI K, 1995, LAB INVEST, V73, P81; Togawa A, 1999, ONCOGENE, V18, P5373, DOI 10.1038/sj.onc.1202921; Turck J, 1996, J BIOL CHEM, V271, P15074, DOI 10.1074/jbc.271.25.15074; van Leeuwen FN, 1999, NAT CELL BIOL, V1, P242, DOI 10.1038/12068; Vastrik I, 1999, CURR BIOL, V9, P991, DOI 10.1016/S0960-9822(99)80447-3; VENSTROM K, 1995, MOL BIOL CELL, V6, P419, DOI 10.1091/mbc.6.4.419; WERBER HI, 1987, J IMMUNOL, V138, P3207; Wu KL, 2003, AM J PHYSIOL-RENAL, V284, pF829, DOI 10.1152/ajprenal.00314.2002; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045; ZALUPS RK, 1993, AM J PHYSIOL, V264, pF53, DOI 10.1152/ajprenal.1993.264.1.F53; Zhang BL, 2005, CANCER RES, V65, P6054, DOI 10.1158/0008-5472.CAN-05-0175; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235; Zhou H, 2005, J BIOL CHEM, V280, P10624, DOI 10.1074/jbc.M411900200; Zhu JW, 2002, DEVELOPMENT, V129, P2891; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	92	31	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19688	19699		10.1074/jbc.M601110200	http://dx.doi.org/10.1074/jbc.M601110200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16690620	Green Accepted, hybrid			2022-12-25	WOS:000238847000082
J	Mitsunaga, C; Mikami, T; Mizumoto, S; Fukuda, J; Sugahara, K				Mitsunaga, Chie; Mikami, Tadahisa; Mizumoto, Shuji; Fukuda, Junko; Sugahara, Kazuyuki			Chondroitin sulfate/dermatan sulfate hybrid chains in the development of cerebellum - Spatiotemporal regulation of the expression of critical disulfated disaccharides by specific sulfotransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-ASSOCIATED MOLECULE; OUTGROWTH-PROMOTING ACTIVITY; HIGH-AFFINITY BINDING; EMBRYONIC PIG BRAIN; ADULT-RAT BRAIN; L-IDURONIC ACID; NEURITE OUTGROWTH; DERMATAN SULFATE; ZETA/RPTP-BETA; NEURITOGENIC ACTIVITY	Chondroitin sulfate/dermatan sulfate (CS/DS) chains regulate the development of the central nervous system in vertebrates. Previously, we demonstrated that CS/DS hybrid chains from embryonic pig brain exhibit neuritogenic and growth factor binding activities, which depended on their IdoUA content defining the DS-like structure. To elucidate the distribution of such functional sugar chains during the development of the brain, in situ hybridization was performed to examine expression of three CS/DS GalNAc 4-O-sulfotransferases, D4ST-1, C4ST-1, and C4ST-2, and a single uronyl 2-O-sulfotransferase (UST) involved in the biosynthesis of DS in addition to CS intermediates. C4ST-1 and C4ST-2 were ubiquitously expressed in the postnatal mouse brain, whereas the expression of D4ST-1 and UST was restricted in the developing cerebellum and culminated at postnatal day 14 as shown by reverse transcriptase-PCR analysis. In situ analysis of the disaccharides of CS/DS in brain sections revealed that the concentration of CS/DS increases 2-fold during development (postnatal day 7 to 7 weeks). The proportions of DS-specific, principal disaccharides, IdoUA-GalNAc(4-O-sulfate) (iA) and IdoUA(2-O-sulfate)-GalNAc(4-O-sulfate) (iB), produced by the sequential actions of D4ST-1 and UST, were higher in the CS/DS chains from cerebellum than those from whole brain sections. A dramatic increase (10-fold) in the proportion of iB during development was noteworthy. In contrast, GlcUA/IdoUA(2-O-sulfate)-GalNAc(6-O-sulfate) (D/iD) and GlcUA/IdoUA-GalNAc(4, 6-O-disulfate) (E/iE) decreased to 50 and 30%, respectively, in the developing cerebellum. These results suggest that the IdoUA-containing iA and iB units along with D/iD and E/iE units in the CS/DS hybrid play important roles in the formation of the cerebellar neural network during postnatal brain development.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan	Kobe Pharmaceutical University	Sugahara, K (corresponding author), Hokkaido Univ, Frontier Res Ctr Post Genom Sci & Technol, Fac Adv Life Sci, Kita Ku, Nishi 11 Chome,Kita 21-Jo, Sapporo, Hokkaido 0010021, Japan.	k-sugar@sci.hokudai.ac.jp	Mizumoto, Shuji/F-8313-2018	Mizumoto, Shuji/0000-0002-4641-1505				Ba-Charvet KTN, 1998, DEVELOPMENT, V125, P4273; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; Bao XF, 2005, J BIOL CHEM, V280, P9180, DOI 10.1074/jbc.M413423200; Bao XF, 2004, J BIOL CHEM, V279, P9765, DOI 10.1074/jbc.M310877200; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; CHENG F, 1994, GLYCOBIOLOGY, V4, P685, DOI 10.1093/glycob/4.5.685; Clement AM, 1999, NEUROSCI LETT, V269, P125, DOI 10.1016/S0304-3940(99)00432-2; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; Evers MR, 2001, J BIOL CHEM, V276, P36344, DOI 10.1074/jbc.M105848200; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; Fansson LA, 2000, MATRIX BIOL, V19, P367, DOI 10.1016/S0945-053X(00)00083-4; Ford-Perriss M, 2001, CLIN EXP PHARMACOL P, V28, P493, DOI 10.1046/j.1440-1681.2001.03477.x; Fukuta M, 1998, BBA-GENE STRUCT EXPR, V1399, P57, DOI 10.1016/S0167-4781(98)00089-X; Garwood J, 1999, J NEUROSCI, V19, P3888; Gilbert RJ, 2005, MOL CELL NEUROSCI, V29, P545, DOI 10.1016/j.mcn.2005.04.006; GOMEZPINILLA F, 1992, J NEUROSCI, V12, P345; Habuchi O, 2000, BBA-GEN SUBJECTS, V1474, P115, DOI 10.1016/S0304-4165(00)00016-7; Hikino M, 2003, J BIOL CHEM, V278, P43744, DOI 10.1074/jbc.M308169200; Ito Y, 2005, GLYCOBIOLOGY, V15, P593, DOI 10.1093/glycob/cwi036; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; Kobayashi M, 1999, J BIOL CHEM, V274, P10474, DOI 10.1074/jbc.274.15.10474; Koshiishi I, 1999, ANAL BIOCHEM, V267, P222, DOI 10.1006/abio.1998.3010; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maeda N, 2003, J BIOL CHEM, V278, P35805, DOI 10.1074/jbc.M305530200; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; MALMSTROM A, 1975, J BIOL CHEM, V250, P3419; MARK M P, 1990, International Journal of Developmental Biology, V34, P191; MICHELACCI YM, 1975, BIOCHEM J, V151, P121, DOI 10.1042/bj1510121; Mikami T, 2003, J BIOL CHEM, V278, P36115, DOI 10.1074/jbc.M306044200; Milev P, 1998, J BIOL CHEM, V273, P6998, DOI 10.1074/jbc.273.12.6998; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; Nandini CD, 2005, J BIOL CHEM, V280, P4058, DOI 10.1074/jbc.M412074200; Nandini CD, 2004, J BIOL CHEM, V279, P50799, DOI 10.1074/jbc.M404746200; Ohtake S, 2001, J BIOL CHEM, V276, P43894, DOI 10.1074/jbc.M104922200; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Rhodes KE, 2004, J ANAT, V204, P33, DOI 10.1111/j.1469-7580.2004.00261.x; SAITO H, 1968, J BIOL CHEM, V243, P1536; Shimazaki Y, 2005, J NEUROSCI RES, V82, P172, DOI 10.1002/jnr.20639; Silbert JE, 2002, GLYCOCONJUGATE J, V19, P227, DOI 10.1023/A:1025379812535; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; Tanaka M, 2003, J NEUROSCI, V23, P2804, DOI 10.1523/jneurosci.23-07-02804.2003; Taylor KR, 2005, J BIOL CHEM, V280, P5300, DOI 10.1074/jbc.m410412200; Trowbridge JM, 2002, GLYCOBIOLOGY, V12, p117R, DOI 10.1093/glycob/cwf066; Tsuchida K, 2001, J BIOL CHEM, V276, P37155, DOI 10.1074/jbc.M105818200; Tully SE, 2004, J AM CHEM SOC, V126, P7736, DOI 10.1021/ja0484045; Uchimura K, 2002, J BIOL CHEM, V277, P1443, DOI 10.1074/jbc.M104719200; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; WILLIAMS EJ, 1994, DEVELOPMENT, V120, P1685; Yamada Shuhei, 2003, Methods Mol Biol, V213, P71; Yoshida K., 1993, DERMATAN SULFATE PRO, P55	57	45	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					18942	18952		10.1074/jbc.M510870200	http://dx.doi.org/10.1074/jbc.M510870200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16702220	hybrid			2022-12-25	WOS:000238847000007
J	Xu, Y; Kim, SO; Li, YL; Han, JH				Xu, Yue; Kim, Sung Ouk; Li, Yilei; Han, Jiahuai			Autophagy contributes to caspase-independent macrophage cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; RECEPTOR-INTERACTING PROTEIN; ANTHRAX LETHAL FACTOR; KAPPA-B; POLY(ADP-RIBOSE) POLYMERASE; SACCHAROMYCES-CEREVISIAE; MEDIATED APOPTOSIS; DNA-DAMAGE; LIPOPOLYSACCHARIDE; KINASE	Macrophage cell death plays a role in many physiological and pathophysiological conditions. Previous work has shown that macrophages can undergo caspase-independent cell death, and this process is associated with Nur77 induction, which is involved in inducing chromatin condensation and DNA fragmentation. Here we show that autophagy is a cytosolic event that controls caspase-independent macrophage cell death. Autophagy was induced in macrophages treated with lipopolysaccharides (LPSs) and the pan- caspase inhibitor benzyloxycarbonyl-Val- Ala-Asp (Z-VAD), and the inhibition of autophagy by either chemical inhibitors or by the RNA interference knockdown of beclin (a protein required for autophagic body formation) inhibited caspase-independent macrophage cell death. We also found an increase in poly(ADP-ribose) (PAR) polymerase (PARP) activation and reactive oxygen species (ROS) production in LPS + Z-VAD-treated macrophages, and both are involved in caspase-independent macrophage cell death. We further determined that the formation of autophagic bodies in macrophages occurs downstream of PARP activation, and PARP activation occurs downstream of ROS production. Using macrophages in which receptor-interacting protein 1 (RIP1) was knocked down by small interfering RNA, and macrophages isolated from Toll/ interleukin-1 receptor-domain-containing adaptor inducing IFN-beta (TRIF)-deficient mice, we found that TRIF and RIP1 function upstream of ROS production in LPS + Z-VAD-treated macrophages. We also found that Z-VAD inhibits LPS-induced RIP1 cleavage, which may contribute to ROS over-production in macrophages. This paper reveals that TRIF, RIP1, and ROS production, as well as PARP activation, are involved in inducing autophagy, which contributes to caspase-independent macrophage cell death.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6G 2B4, Canada	Scripps Research Institute; Western University (University of Western Ontario)	Han, JH (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines, La Jolla, CA 92037 USA.	jhan@scripps.edu	Kim, Sung Ouk/AAO-1795-2020; Han, J/G-4671-2010; KIM, Sung Ouk/A-1309-2008	Kim, Sung Ouk/0000-0002-0282-6661; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067101] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM67101] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham MC, 2004, TRENDS CELL BIOL, V14, P184, DOI 10.1016/j.tcb.2004.03.002; Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200; Bajenova O, 2004, APOPTOSIS, V9, P561, DOI 10.1023/B:APPT.0000038030.47068.49; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Brune B, 1997, J BIOL CHEM, V272, P7253, DOI 10.1074/jbc.272.11.7253; Chan FKM, 2003, J BIOL CHEM, V278, P51613, DOI 10.1074/jbc.M305633200; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Cusson-Hermance N, 2005, J BIOL CHEM, V280, P36560, DOI 10.1074/jbc.M506831200; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; FARRINGTON JA, 1973, BIOCHIM BIOPHYS ACTA, V314, P372, DOI 10.1016/0005-2728(73)90121-7; Franchi L, 2003, BLOOD, V102, P2910, DOI 10.1182/blood-2003-03-0967; Garrido C, 2004, CURR OPIN CELL BIOL, V16, P639, DOI 10.1016/j.ceb.2004.09.008; Gotoh T, 1999, J CELL BIOL, V144, P427, DOI 10.1083/jcb.144.3.427; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kaiser WJ, 2005, J IMMUNOL, V174, P4942, DOI 10.4049/jimmunol.174.8.4942; Karahashi H, 1998, EXP CELL RES, V241, P373, DOI 10.1006/excr.1998.4062; Kim HS, 2005, MOL CELL BIOL, V25, P6821, DOI 10.1128/MCB.25.15.6821-6833.2005; Kim SO, 2003, J EXP MED, V197, P1441, DOI 10.1084/jem.20021842; Kim SO, 2001, J ENDOTOXIN RES, V7, P292, DOI 10.1179/096805101101532873; Kim SO, 2001, AM J PHYSIOL-LUNG C, V281, pL1095, DOI 10.1152/ajplung.2001.281.5.L1095; Leulier F, 2000, EMBO REP, V1, P353, DOI 10.1093/embo-reports/kvd073; Liaudet L, 2000, P NATL ACAD SCI USA, V97, P10203, DOI 10.1073/pnas.170226797; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272; Ma YY, 2005, J BIOL CHEM, V280, P41827, DOI 10.1074/jbc.M510849200; Maianski NA, 2003, BLOOD, V101, P1987, DOI 10.1182/blood-2002-02-0522; Orth K, 2000, SCIENCE, V290, P1594, DOI 10.1126/science.290.5496.1594; Park JM, 2002, SCIENCE, V297, P2048, DOI 10.1126/science.1073163; PETERS T, 1990, EUR J BIOCHEM, V191, P583, DOI 10.1111/j.1432-1033.1990.tb19161.x; Petrilli V, 2004, J CLIN INVEST, V114, P1072, DOI 10.1172/JCI200421854; Ricevuti G, 1997, ANN NY ACAD SCI, V832, P426, DOI 10.1111/j.1749-6632.1997.tb46269.x; Sade H, 2004, CELL DEATH DIFFER, V11, P416, DOI 10.1038/sj.cdd.4401347; SCHWEICHEL JU, 1973, TERATOLOGY, V7, P253, DOI 10.1002/tera.1420070306; Shen HM, 2004, MOL CELL BIOL, V24, P5914, DOI 10.1128/MCB.24.13.5914-5922.2004; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shrivastava P, 2004, MOL CELL BIOL, V24, P6763, DOI 10.1128/MCB.24.15.6763-6772.2004; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Sullivan GW, 2000, J LEUKOCYTE BIOL, V67, P591, DOI 10.1002/jlb.67.5.591; Suzuki T, 2004, INFECT IMMUN, V72, P1856, DOI 10.1128/IAI.72.4.1856-1865.2004; Takada Y, 2003, J BIOL CHEM, V278, P23390, DOI 10.1074/jbc.M213237200; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; VAN RN, 1997, J LEUKOCYTE BIOL, V62, P702; Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Yang JY, 2004, MOL CELL BIOL, V24, P10425, DOI 10.1128/MCB.24.23.10425-10436.2004; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	57	182	186	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19179	19187		10.1074/jbc.M513377200	http://dx.doi.org/10.1074/jbc.M513377200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16702227	hybrid			2022-12-25	WOS:000238847000032
J	Dang, PMC; Elbim, C; Marie, JC; Chiandotto, M; Gougerot-Pocidalo, MA; El-Benna, J				Dang, Pham My-Chan; Elbim, Carole; Marie, Jean-Claude; Chiandotto, Melanie; Gougerot-Pocidalo, Marie-Anne; El-Benna, Jamel			Anti-inflammatory effect of interleukin-10 on human neutrophil respiratory burst involves inhibition of GM-CSF-induced p47(PHOX) phosphorylation through a decrease in ERK1/2 activity	FASEB JOURNAL			English	Article						IL-10; NADPH oxidase; inflammation; ROS	COLONY-STIMULATING FACTOR; TUMOR-NECROSIS-FACTOR; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; IL-1 RECEPTOR ANTAGONIST; PROTEIN-KINASE-C; NADPH OXIDASE; TNF-ALPHA; ACTIVATION; EXPRESSION; CYTOKINE	Interleukin-10 (IL-10) exerts its anti-inflammatory properties by down-regulating polymorphonuclear neutrophil (PMN) functions such as reactive oxygen species (ROS) production via NADPH oxidase. The molecular mechanisms underlying this process are unclear. Partial phosphorylation of the NADPH oxidase cytosolic component p47(PHOX) induced by proinflammatory cytokines, such as granulocyte-macrophage colony stimulating factor (GM-CSF) and tumor necrosis factor (TNF)-alpha, is essential for priming ROS production by PMN. The aim of this study was to determine whether IL-10 inhibits GM-CSF- and TNF alpha-induced p47PHOX phosphorylation and to investigate the molecular mechanisms involved in this effect. We found that IL-10 selectively inhibited GM-CSF- but not TNF alpha-induced p47PHOX phosphorylation in a concentration-dependent manner. As GM-CSF-induced p47(PHOX) phosphorylation is mediated by extracellular signal-regulated kinase 1/2 (ERK1/2), we tested the effect of IL-10 on this pathway. We found that IL-10 inhibited GM-CSF-induced ERK1/2 activity in an immunocomplex kinase assay. This inhibitory effect was confirmed by analyzing the phosphorylation status of the endogenous substrate of ERK1/2, p90RSK, in intact PMN. Furthermore, IL-10 decreased ROS production by adherent GM-CSF-treated PMN in keeping with the higher ROS production observed in whole blood from IL-10 knockout mice compared to their wild-type counterparts. Together, these results suggest that IL-10 inhibits GM-CSF-induced priming of ROS production by inhibiting p47PHOX phosphorylation through a decrease in ERK1/2 activity. This IL-10 effect could contribute to the tight regulation of NADPH oxidase activity at the inflammatory site.	CHU Xavier Bichat, INSERM, U773, Fac Med, F-75018 Paris, France; Univ Paris Denis Diderot 7, Paris, France; AP HP, CIB, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP)	Dang, PMC (corresponding author), CHU Xavier Bichat, INSERM, U773, Fac Med, 16 Rue Henri Huchard, F-75018 Paris, France.	dang@bichat.inserm.fr						Al-Shami A, 1998, J BIOL CHEM, V273, P1058, DOI 10.1074/jbc.273.2.1058; BABIOR BM, 1984, BLOOD, V64, P959; BENGISGARBER C, 1995, CELL SIGNAL, V7, P721, DOI 10.1016/0898-6568(95)00040-V; BERKOW RL, 1987, J IMMUNOL, V139, P3783; Bovolenta C, 1998, J IMMUNOL, V160, P911; Brizzi MF, 1996, J BIOL CHEM, V271, P3562; Bussolati B, 1997, IMMUNOLOGY, V90, P440, DOI 10.1111/j.1365-2567.1997.00440.x; Capsoni F, 1997, SCAND J IMMUNOL, V45, P269, DOI 10.1046/j.1365-3083.1997.d01-393.x; CASSATELLA MA, 1993, J EXP MED, V178, P2207, DOI 10.1084/jem.178.6.2207; CASSATELLA MA, 1994, J EXP MED, V179, P1695, DOI 10.1084/jem.179.5.1695; Cassatella MA, 1998, INT J CLIN LAB RES, V28, P148, DOI 10.1007/s005990050036; Chaves MM, 1996, INFLAMM RES, V45, P313, DOI 10.1007/BF02252942; Crepaldi L, 2002, INT IMMUNOL, V14, P1145, DOI 10.1093/intimm/dxf079; Crepaldi L, 2001, J IMMUNOL, V167, P2312, DOI 10.4049/jimmunol.167.4.2312; DANG PM, 2006, IN PRESS J CLIN INVE; Dang PMC, 1999, J BIOL CHEM, V274, P20704, DOI 10.1074/jbc.274.29.20704; Dang PMC, 2002, P NATL ACAD SCI USA, V99, P4262, DOI 10.1073/pnas.072345299; DeLeo FR, 1999, J IMMUNOL, V163, P6732; Dewas C, 2003, J IMMUNOL, V171, P4392, DOI 10.4049/jimmunol.171.8.4392; DOWNEY GP, 1995, SEMIN CELL BIOL, V6, P345, DOI 10.1016/S1043-4682(05)80005-4; El Benna J, 2002, INFLAMMATION, V26, P273; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; ELBIM C, 1993, BLOOD, V82, P633; Elbim C, 2001, J IMMUNOL, V166, P5201, DOI 10.4049/jimmunol.166.8.5201; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; Gallova L, 2004, PHYSIOL RES, V53, P199; Gasperini S, 1999, J IMMUNOL, V162, P4928; Geijsen N, 1999, BLOOD, V94, P1121, DOI 10.1182/blood.V94.3.1121.415k04_1121_1130; GENG Y, 1994, P NATL ACAD SCI USA, V91, P8602, DOI 10.1073/pnas.91.18.8602; Groemping Y, 2005, BIOCHEM J, V386, P401, DOI 10.1042/BJ20041835; Grutz G, 2005, J LEUKOCYTE BIOL, V77, P3, DOI 10.1189/jlb.0904484; HALLETT MB, 1995, IMMUNOL TODAY, V16, P264, DOI 10.1016/0167-5699(95)80178-2; Heyworth PG, 2003, CURR OPIN IMMUNOL, V15, P578, DOI 10.1016/S0952-7915(03)00109-2; HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267; Inoue Y, 2004, J IMMUNOL, V172, P2147, DOI 10.4049/jimmunol.172.4.2147; Joseph DE, 1996, J BIOL CHEM, V271, P13088, DOI 10.1074/jbc.271.22.13088; KASAMA T, 1994, J IMMUNOL, V152, P3559; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laichalk LL, 1996, FEMS IMMUNOL MED MIC, V15, P181, DOI 10.1016/0928-8244(96)00048-X; LIU Y, 1994, J IMMUNOL, V152, P1821; McLeish KR, 1998, J LEUKOCYTE BIOL, V64, P537, DOI 10.1002/jlb.64.4.537; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; MULLER T, 1989, J BIOLUM CHEMILUM, V3, P105, DOI 10.1002/bio.1170030304; Niiro H, 1997, BLOOD, V89, P1621, DOI 10.1182/blood.V89.5.1621.1621_1621_1628; Nijhuis E, 2002, J LEUKOCYTE BIOL, V71, P115; OKUDA K, 1992, BLOOD, V79, P2880; Opal SM, 2000, CHEST, V117, P1162, DOI 10.1378/chest.117.4.1162; Ricevuti G, 1997, ANN NY ACAD SCI, V832, P426, DOI 10.1111/j.1749-6632.1997.tb46269.x; Roos D, 1996, BLOOD, V87, P1663; Spencer SD, 1998, J EXP MED, V187, P571, DOI 10.1084/jem.187.4.571; SULLIVAN GW, 1993, BLOOD, V81, P1863; Sur R, 2005, BIOCHEM J, V387, P315, DOI 10.1042/BJ20041713; Suzuki K, 1999, BLOOD, V93, P341, DOI 10.1182/blood.V93.1.341.401k09_341_349; Thivierge M, 1999, J IMMUNOL, V162, P3590; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Williams LM, 2004, IMMUNOLOGY, V113, P281, DOI 10.1111/j.1365-2567.2004.01988.x; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138; Zacharowski P, 2005, EUR J PHARMACOL, V508, P7, DOI 10.1016/j.ejphar.2004.11.064	62	53	55	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1504	+		10.1096/fj.05-5395fje	http://dx.doi.org/10.1096/fj.05-5395fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16720733				2022-12-25	WOS:000240266000032
J	James, SR; Link, PA; Karpf, AR				James, S. R.; Link, P. A.; Karpf, A. R.			Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b	ONCOGENE			English	Article						cancer/germline antigens; cancer-testis antigens; DNMT1; DNMT3b; gene expression; DNA methylation; histone modifications	CYTOLYTIC T-LYMPHOCYTES; DE-NOVO METHYLATION; DNA METHYLATION; CANCER-CELLS; CANCER/TESTIS ANTIGENS; CPG METHYLATION; GERM-LINE; METHYLTRANSFERASES; EXPRESSION; TUMOR	We examined the function of two key DNA methyltransferase (DNMT) enzymes in epigenetic regulation of X-linked cancer/germline (CG-X) antigen genes in human cancer cells, using MAGE-A1, NY-ESO-1, and XAGE-1 as models. In HCT116 cells, genetic knockout of DNMT1 caused moderate activation of CG-X genes, DNMT3b knockout had a negligible effect, and double knockout of both enzymes caused robust gene induction. Similarly, dual DNMT knockout caused dramatic hypomethylation of the MAGE-A1 and NY-ESO-1 promoters, DNMT1 knockout showed moderate hypomethylation, and DNMT3b knockout elicited only slight methylation changes. In contrast, both single and double knockout cells showed significant hypomethylation of the XAGE-1 promoter. RNA interference (RNAi) targeting of DNMT1 in HCT116 cells validated the results seen using genetic knockout cells; however, RNAi targeting of DNMT1 in a different colorectal cancer cell line revealed a greater independent role for DNMT1 in mediating CG-X gene repression and promoter methylation in other cell types. Notably, the histone H3 modi. cation pattern at CG-X promoters was altered following DNMT knockout. DNMT1 or DNMT3b knockout reduced dimethylated lysine-9 (diMe-H3K9) levels, but did not significantly affect dimethylated lysine-4 (diMe-H3K4) or acetylated lysine-9 (Ac-H3-K9) levels. In contrast, dual DNMT1/3b knockout reduced the level of diMe-H3K9 and dramatically increased the levels of diMe-H3K4 and Ac-H3K9 at CG-X gene loci. In summary, DNMT1 and DNMT3b were found to perform both redundant and independent functions in epigenetic regulation of CG-X antigen genes in human cancer cells.	New York State Dept Hlth, Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Canc Drug Ctr, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Karpf, AR (corresponding author), New York State Dept Hlth, Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Canc Drug Ctr, Elm & Carlton St, Buffalo, NY 14263 USA.	adam.karpf@roswellpark.org		Karpf, Adam/0000-0002-0866-0666	NATIONAL CANCER INSTITUTE [P30CA016056, R01CA116674] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA116674, R01 CA116674-01A1, CA16056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cheng JC, 2004, CANCER CELL, V6, P151, DOI 10.1016/j.ccr.2004.06.023; Chomez P, 2001, CANCER RES, V61, P5544; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; DE SC, 1996, P NATL ACAD SCI USA, V93, P7149, DOI DOI 10.1073/PNAS.93.14.7149; De Smet C, 2004, MOL CELL BIOL, V24, P4781, DOI 10.1128/MCB.24.11.4781-4790.2004; De Smet C, 1999, MOL CELL BIOL, V19, P7327; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gillespie AM, 1999, CANCER TREAT REV, V25, P219, DOI 10.1053/ctrv.1999.0126; Guo ZS, 2006, CANCER RES, V66, P1105, DOI 10.1158/0008-5472.CAN-05-3020; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jiang GC, 2004, J CELL BIOCHEM, V93, P286, DOI 10.1002/jcb.20146; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; Karpf AR, 2004, MOL PHARMACOL, V65, P18, DOI 10.1124/mol.65.1.18; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; Koslowski M, 2004, CANCER RES, V64, P5988, DOI 10.1158/0008-5472.CAN-04-1187; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311; Maio M, 2003, ONCOGENE, V22, P6484, DOI 10.1038/sj.onc.1206956; Odunsi K, 2003, CANCER RES, V63, P6076; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Qian Feng, 2004, Cancer Immun, V4, P12; Reynolds SR, 2003, CLIN CANCER RES, V9, P657; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Rozen S, 2000, Methods Mol Biol, V132, P365; Shi HD, 2003, CANCER RES, V63, P2164; Sigalotti L, 2004, CANCER RES, V64, P9167, DOI 10.1158/0008-5472.CAN-04-1442; Sigalotti L, 2002, J IMMUNOTHER, V25, P16, DOI 10.1097/00002371-200201000-00002; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Song LG, 2005, ANAL CHEM, V77, P504, DOI 10.1021/ac0489420; Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046; Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Ting AH, 2006, CANCER RES, V66, P729, DOI 10.1158/0008-5472.CAN-05-1537; Ting AH, 2004, NAT GENET, V36, P582, DOI 10.1038/ng1365; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; WEBER J, 1994, CANCER RES, V54, P1766; Weiser TS, 2001, J IMMUNOTHER, V24, P151, DOI 10.1097/00002371-200103000-00010	53	87	92	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	52					6975	6985		10.1038/sj.onc.1209678	http://dx.doi.org/10.1038/sj.onc.1209678			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16715135				2022-12-25	WOS:000241732300008
J	Telang, S; Yalcin, A; Clem, AL; Bucala, R; Lane, AN; Eaton, JW; Chesney, J				Telang, S.; Yalcin, A.; Clem, A. L.; Bucala, R.; Lane, A. N.; Eaton, J. W.; Chesney, J.			Ras transformation requires metabolic control by 6-phosphofructo-2-kinase	ONCOGENE			English	Article						ras; metabolism; phosphofructokinase	6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE GENE PFKFB3; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; FRUCTOSE 2,6-BISPHOSPHATE; ACTIVATED RAS; HUMAN CANCERS; NUCLEIC-ACID; GLYCOLYSIS; EXPRESSION; GLUCOSE; CELLS	Neoplastic cells transport large amounts of glucose in order to produce anabolic precursors and energy within the inhospitable environment of a tumor. The ras signaling pathway is activated in several cancers and has been found to stimulate glycolytic flux to lactate. Glycolysis is regulated by ras via the activity of 6-phosphofructo-2-kinase/fructose- 2,6-bisphosphatases (PFK2/FBPase), which modulate the intracellular concentration of the allosteric glycolytic activator, fructose-2,6-bisphosphate (F2,6BP). We report herein that sequential immortalization and ras-transformation of mouse fibroblasts or human bronchial epithelial cells paradoxically decreases the intracellular concentration of F2,6BP. This marked reduction in the intracellular concentration of F2,6BP sensitizes transformed cells to the antimetabolic effects of PFK2/FBPase inhibition. Moreover, despite co-expression of all four mRNA species (PFKFB1-4), heterozygotic genomic deletion of the inducible PFKFB3 gene in ras-transformed mouse lung fibroblasts suppresses F2,6BP production, glycolytic flux to lactate, and growth as soft agar colonies or tumors in athymic mice. These data indicate that the PFKFB3 protein product may serve as an essential downstream metabolic mediator of oncogenic ras, and we propose that pharmacologic inhibition of this enzyme should selectively suppress the high rate of glycolysis and growth by cancer cells.	Univ Louisville, James Graham Brown Canc Ctr, Mol Targets Program, Louisville, KY 40202 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA	University of Louisville; Yale University	Chesney, J (corresponding author), Univ Louisville, James Graham Brown Canc Ctr, Mol Targets Program, 580 S Preston St, Louisville, KY 40202 USA.	jason.chesney@louisville.edu	Yalcin, Abdullah/ABI-4164-2020; Yalcin, Abdullah/AAA-6938-2022	Yalcin, Abdullah/0000-0001-8519-8375; 	NCI NIH HHS [1 R01 CA11642801] Funding Source: Medline; NCRR NIH HHS [1P20 RR18733] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018733] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Atsumi T, 2002, CANCER RES, V62, P5881; Blum R, 2005, CANCER RES, V65, P999; Boren J, 2001, J BIOL CHEM, V276, P37747; Boros LG, 2001, PANCREAS, V22, P1, DOI 10.1097/00006676-200101000-00001; Boros LG, 2000, CANCER RES, V60, P1183; Chesney J, 2005, BIOCHEM BIOPH RES CO, V331, P139, DOI 10.1016/j.bbrc.2005.02.193; Chesney J, 1999, P NATL ACAD SCI USA, V96, P3047, DOI 10.1073/pnas.96.6.3047; CHESNEY J, 2001, BIOTECHNOL INT, V3, P213; Hamilton JA, 1997, MOL ENDOCRINOL, V11, P490, DOI 10.1210/me.11.4.490; HUE L, 1993, ADV ENZYME REGUL, V33, P97; Kessler R, 2001, MOL BRAIN RES, V87, P190, DOI 10.1016/S0169-328X(01)00014-6; KOLE HK, 1991, ARCH BIOCHEM BIOPHYS, V286, P586, DOI 10.1016/0003-9861(91)90084-V; Mahlknecht U, 2003, INT J ONCOL, V23, P883; Manzano A, 1998, CYTOGENET CELL GENET, V83, P214, DOI 10.1159/000015181; Mazurek S, 2001, ONCOGENE, V20, P6891, DOI 10.1038/sj.onc.1204792; Minchenko A, 2002, J BIOL CHEM, V277, P6183, DOI 10.1074/jbc.M110978200; Minchenko O, 2004, FEBS LETT, V576, P14, DOI 10.1016/j.febslet.2004.08.053; Minchenko O, 2003, FEBS LETT, V554, P264, DOI 10.1016/S0014-5793(03)01179-7; MUELLERKLIESER W, 1986, BRIT J CANCER, V53, P345, DOI 10.1038/bjc.1986.58; Navarro-Sabate A, 2001, GENE, V264, P131, DOI 10.1016/S0378-1119(00)00591-6; Okar DA, 1999, BIOFACTORS, V10, P1, DOI 10.1002/biof.5520100101; RACKER E, 1985, P NATL ACAD SCI USA, V82, P3535, DOI 10.1073/pnas.82.11.3535; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Sakai A, 1996, J BIOCHEM-TOKYO, V119, P506; Sakakibara R, 1997, J BIOCHEM-TOKYO, V122, P122; Sakakibara R, 1999, BIOCHEM BIOPH RES CO, V257, P177, DOI 10.1006/bbrc.1999.0429; Soejima K, 2003, ONCOGENE, V22, P4723, DOI 10.1038/sj.onc.1206510; TAETLE R, 1987, CANCER TREAT REP, V71, P297; VALENZUELA DM, 1986, NUCLEIC ACIDS RES, V14, P843, DOI 10.1093/nar/14.2.843; VANDENBERGHE N, 1994, MOL CELL BIOL, V14, P2372, DOI 10.1128/MCB.14.4.2372; VANSCHAFTINGEN E, 1981, P NATL ACAD SCI-BIOL, V78, P3483; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; Vizan P, 2005, CANCER RES, V65, P5512, DOI 10.1158/0008-5472.CAN-05-0074; Walenta S, 2004, CURR MED CHEM, V11, P2195, DOI 10.2174/0929867043364711; WANG T, 1976, NATURE, V261, P702, DOI 10.1038/261702a0; Warburg O, 1924, BIOCHEM Z, V152, P319; Wechatekar K, 2005, CLIN RADIOL, V60, P1143, DOI 10.1016/j.crad.2005.05.018; Zhong H, 1999, CANCER RES, V59, P5830	38	130	140	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	55					7225	7234		10.1038/sj.onc.1209709	http://dx.doi.org/10.1038/sj.onc.1209709			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16715124				2022-12-25	WOS:000242244700001
J	Cerveira, N; Correia, C; Bizarro, S; Pinto, C; Lisboa, S; Mariz, JM; Marques, M; Teixeira, MR				Cerveira, N.; Correia, C.; Bizarro, S.; Pinto, C.; Lisboa, S.; Mariz, J. M.; Marques, M.; Teixeira, M. R.			SEPT2 is a new fusion partner of MLL in acute myeloid leukemia with t(2 ; 11)(q37 ; q23)	ONCOGENE			English	Article						MLL-SEPT2; fusion oncogenes; t(2;11) (q37; q23); therapy-related AML	ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN INHERITED DISEASE; FUSES MLL; DROSOPHILA-TRITHORAX; FAMILY GENE; 11Q23; TRANSLOCATION; PROTEINS; DELETION; REARRANGEMENTS	We have identified a new mixed lineage leukemia (MLL) gene fusion partner in a patient with treatment-related acute myeloid leukemia (AML) presenting a t(2; 11)(q37; q23) as the only cytogenetic abnormality. Fluorescence in situ hybridization demonstrated a rearrangement of the MLL gene and molecular genetic analyses identified a septin family gene, SEPT2, located on chromosome 2q37, as the fusion partner of MLL. RNA and DNA analyses showed the existence of an in-frame fusion of MLL exon 7 with SEPT2 exon 3, with the genomic breakpoints located in intron 7 and 2 of MLL and SEPT2, respectively. Search for DNA sequence motifs revealed the existence of two sequences with 94.4% homology with the topoisomerase II consensus cleavage site in MLL intron 7 and SEPT2 intron 2. SEPT2 is the fifth septin family gene fused with MLL, making this gene family the most frequently involved in MLL-related AML (about 10% of all known fusion partners). The protein encoded by SEPT2 is highly homologous to septins 1, 4 and 5 and is involved in the coordination of several key steps of mitosis. Further studies are warranted to understand why the septin protein family is particularly involved in the pathogenesis of MLL-associated leukemia.	Portuguese Oncol Inst, Dept Genet, P-4200072 Oporto, Portugal; Portuguese Oncol Inst, Dept Oncohematol, Oporto, Portugal	Portuguese Institute of Oncology; Portuguese Institute of Oncology	Teixeira, MR (corresponding author), Portuguese Oncol Inst, Dept Genet, Rua Dr Antonio Bernardino Almeida, P-4200072 Oporto, Portugal.	mteixeir@ipoporto.min-saude.pt	Teixeira, Manuel AC/AAZ-7251-2020; Teixeira, Manuel António Rodrigues/E-4885-2011	Teixeira, Manuel AC/0000-0002-1959-0624; Teixeira, Manuel António Rodrigues/0000-0002-4896-5982; Correia, Cecilia/0000-0002-4838-7756; Pinto, Carla/0000-0001-8689-3388; Cerveira, Nuno/0000-0001-5098-3840; Lisboa, Susana/0000-0002-9773-331X; de Campos Bizarro, Susana/0000-0002-3495-2080				Abeysinghe SS, 2003, HUM MUTAT, V22, P229, DOI 10.1002/humu.10254; BERGER R, 1987, CANCER GENET CYTOGEN, V29, P9, DOI 10.1016/0165-4608(87)90026-4; Borkhardt A, 2000, P NATL ACAD SCI USA, V97, P9168, DOI 10.1073/pnas.150079597; Chinwalla V, 2003, ONCOGENE, V22, P1400, DOI 10.1038/sj.onc.1206273; Chuzhanova N, 2003, HUM MUTAT, V22, P245, DOI 10.1002/humu.10253; Daser A, 2005, SEMIN CANCER BIOL, V15, P175, DOI 10.1016/j.semcancer.2005.01.007; DELOZIERBLANCHET CD, 1985, CANCER GENET CYTOGEN, V16, P95, DOI 10.1016/0165-4608(85)90001-9; Fischer K, 1997, BLOOD, V89, P2036, DOI 10.1182/blood.V89.6.2036; Fuchs U, 2001, P NATL ACAD SCI USA, V98, P8756, DOI 10.1073/pnas.121433898; Grier DG, 2005, J PATHOL, V205, P154, DOI 10.1002/path.1710; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hall PA, 2004, J PATHOL, V204, P489, DOI 10.1002/path.1654; Harrison CJ, 1998, LEUKEMIA, V12, P811, DOI 10.1038/sj.leu.2401017; Hayette S, 2000, ONCOGENE, V19, P4446, DOI 10.1038/sj.onc.1203789; HURET JL, 2005, ATLAS GENETICS CYTOG; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Kojima K, 2004, LEUKEMIA, V18, P998, DOI 10.1038/sj.leu.2403334; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Li ZY, 2005, LEUKEMIA, V19, P183, DOI 10.1038/sj.leu.2403602; MAROSI C, 1992, CANCER GENET CYTOGEN, V61, P14, DOI 10.1016/0165-4608(92)90364-E; Megonigal MD, 1998, P NATL ACAD SCI USA, V95, P6413, DOI 10.1073/pnas.95.11.6413; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Mitelman F., 1995, INT SYSTEM HUMAN CYT; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Ono R, 2005, J CLIN INVEST, V115, P919, DOI 10.1172/JCI200522725; Ono R, 2002, CANCER RES, V62, P333; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; Poirel H, 1996, BLOOD, V87, P2496, DOI 10.1182/blood.V87.6.2496.bloodjournal8762496; Popovic R, 2005, J CELL BIOCHEM, V95, P234, DOI 10.1002/jcb.20430; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; Pui CH, 2000, BRIT J HAEMATOL, V109, P13, DOI 10.1046/j.1365-2141.2000.01843.x; RASMUSSEN SW, 2004, SEQ TOOLS VERSION 8; RUDIGER NS, 1995, NUCLEIC ACIDS RES, V23, P256, DOI 10.1093/nar/23.2.256; Russell SEH, 2005, BRIT J CANCER, V93, P499, DOI 10.1038/sj.bjc.6602753; Satake N, 1999, LEUKEMIA, V13, P1013, DOI 10.1038/sj.leu.2401439; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; Slany RK, 2005, HEMATOL ONCOL, V23, P1, DOI 10.1002/hon.739; SMIT AFA, 2004, REPEATMASKER OPE 3 0; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Spiliotis ET, 2005, SCIENCE, V307, P1781, DOI 10.1126/science.1106823; Strehl S, 2003, ONCOGENE, V22, P157, DOI 10.1038/sj.onc.1206042; Surka MC, 2002, MOL BIOL CELL, V13, P3532, DOI 10.1091/mbc.E02-01-0042; Taki T, 1999, P NATL ACAD SCI USA, V96, P14535, DOI 10.1073/pnas.96.25.14535; Taki T, 1999, CANCER RES, V59, P4261; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; von Bergh ARM, 2004, GENE CHROMOSOME CANC, V39, P324, DOI 10.1002/gcc.20004; WINICK NJ, 1993, J CLIN ONCOL, V11, P209, DOI 10.1200/JCO.1993.11.2.209; YAMAMOTO K, 1994, BLOOD, V83, P2912, DOI 10.1182/blood.V83.10.2912.2912	51	34	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6147	6152		10.1038/sj.onc.1209626	http://dx.doi.org/10.1038/sj.onc.1209626			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16682951				2022-12-25	WOS:000241101200013
J	Mise, N; Drosten, M; Racek, T; Tannapfel, A; Putzer, BM				Mise, N.; Drosten, M.; Racek, T.; Tannapfel, A.; Puetzer, B. M.			Evaluation of potential mechanisms underlying genotype-phenotype correlations in multiple endocrine neoplasia type 2	ONCOGENE			English	Article						RET receptor tyrosine kinase; RET protooncogene mutations; multiple endocrine neoplasia type 2 (MEN 2); genotype-phenotype correlation	MEDULLARY-THYROID CARCINOMA; RET TYROSINE KINASE; SIGNALING COMPLEXES; HUMAN CANCER; CYCLIN-E; IN-VIVO; MEN 2A; C-CELL; PROTOONCOGENE; MUTATIONS	Distinct dominant activating mutations in the RET protooncogene are responsible for the development of multiple endocrine neoplasia type 2 (MEN 2). Concise examination of the mutated codons led to the detection of a striking genotype-phenotype correlation between the mutated codon and the MEN 2 phenotype in terms of onset and aggressiveness of the disease, suggesting that manifestation and clinical progression is conditioned by the type of mutation. To gain insight into the molecular basis for this genotype-phenotype correlation, we analysed the impact of common and rare mutations identified in MEN 2A (C609Y, C634R), MEN 2B (A883F, M918T) and familial medullary thyroid carcinoma (Y791F) patients on several aspects of cell transformation, including proliferation, apoptosis, anchorage-independent growth and signaling. We found that tumor cells arising from distinct extracellular or intracellular MEN 2 mutations clearly differ in their proliferation properties owing to the activation of different molecular pathways, but importantly, also in resistance to apoptosis. Whereas MEN 2A mutants resulted in accelerated cell proliferation, MEN 2B-RET mutants significantly enhanced suppression of apoptosis, which may account, at least partially, for some of the clinical differences in MEN 2 patients.	Univ Rostock, Dept Vectorol & Expt Gene Therapy, Biomed Res Ctr, D-18055 Rostock, Germany; Univ Leipzig, Sch Med, Dept Pathol, D-7010 Leipzig, Germany	University of Rostock; Leipzig University	Putzer, BM (corresponding author), Univ Rostock, Dept Vectorol & Expt Gene Therapy, Biomed Res Ctr, Schillingallee 69, D-18055 Rostock, Germany.	brigitte.puetzer@med.uni-rostock.de		Drosten, Matthias/0000-0002-3205-456X				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Arighi E, 2005, CYTOKINE GROWTH F R, V16, P441, DOI 10.1016/j.cytogfr.2005.05.010; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Bocciardi R, 1997, ONCOGENE, V15, P2257, DOI 10.1038/sj.onc.1201413; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Drosten M, 2004, JNCI-J NATL CANCER I, V96, P1231, DOI 10.1093/jnci/djh226; Durbec PL, 1996, DEVELOPMENT, V122, P349; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; Freche B, 2005, J BIOL CHEM, V280, P36584, DOI 10.1074/jbc.M505707200; Gimm O, 2002, SURGERY, V132, P952, DOI 10.1067/msy.2002.128559; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hansford JR, 2000, J MED GENET, V37, P817, DOI 10.1136/jmg.37.11.817; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Ichihara M, 2004, CANCER LETT, V204, P197, DOI 10.1016/S0304-3835(03)00456-7; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Jijiwa M, 2004, MOL CELL BIOL, V24, P8026, DOI 10.1128/MCB.24.18.8026-8036.2004; Kurokawa K, 2003, J INTERN MED, V253, P627, DOI 10.1046/j.1365-2796.2003.01167.x; Le Hir H, 2000, ONCOLOGY-BASEL, V58, P311, DOI 10.1159/000012118; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Marshall GM, 1997, CANCER RES, V57, P5399; Marx SJ, 2005, NAT REV CANCER, V5, P367, DOI 10.1038/nrc1610; Menacho IP, 2005, CANCER RES, V65, P1729, DOI 10.1158/0008-5472.CAN-04-2363; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Moroy T, 2004, INT J BIOCHEM CELL B, V36, P1424, DOI 10.1016/S1357-2725(03)00432-1; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Murakami H, 2002, J BIOL CHEM, V277, P32781, DOI 10.1074/jbc.M202336200; Reynolds L, 2001, ONCOGENE, V20, P3986, DOI 10.1038/sj.onc.1204434; Salvatore D, 2001, CANCER RES, V61, P1426; Santoro M, 2004, CELL MOL LIFE SCI, V61, P2954, DOI 10.1007/s00018-004-4276-8; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Smith-Hicks CL, 2000, EMBO J, V19, P612, DOI 10.1093/emboj/19.4.612; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; Takahashi M, 1998, J INTERN MED, V243, P509; Thimmaiah KN, 2005, J BIOL CHEM, V280, P31924, DOI 10.1074/jbc.M507057200; Tsui-Pierchala BA, 2002, J BIOL CHEM, V277, P34618, DOI 10.1074/jbc.M203580200; Vitale G, 2001, CANCER-AM CANCER SOC, V91, P1797, DOI 10.1002/1097-0142(20010501)91:9<1797::AID-CNCR1199>3.0.CO;2-P; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Watanabe T, 2002, AM J PATHOL, V161, P249, DOI 10.1016/S0002-9440(10)64176-4; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Yip L, 2003, ARCH SURG-CHICAGO, V138, P409, DOI 10.1001/archsurg.138.4.409	47	31	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2006	25	50					6637	6647		10.1038/sj.onc.1209669	http://dx.doi.org/10.1038/sj.onc.1209669			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16715139				2022-12-25	WOS:000241569700008
J	Shafiei, MS; Rockey, DC				Shafiei, Mahnoush S.; Rockey, Don C.			The role of integrin-linked kinase in liver wound healing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC STELLATE CELLS; GROWTH-FACTOR-BETA; EXTRACELLULAR-MATRIX; MOLECULAR REGULATION; I COLLAGEN; RAT; ILK; ACTIVATION; FIBROSIS; ADHESION	Liver wound healing is an integrated process in which hepatic stellate cells play a major role. We hypothesized that the cell-extracellular signaling protein integrin-linked kinase (ILK) is important in transducing signals from the extracellular matrix to stellate cells and thus plays a critical role in stellate cell activation and fibrogenesis during liver injury. Liver injury and subsequent stellate cell activation led to a 3-fold increase in ILK expression and increased kinase activity. Overexpression of ILK in isolated stellate cells led to enhanced motility and adhesion as well as increases in smooth muscle alpha-actin and type I collagen mRNAexpression. The effects of ILK on stellate cell phenotypes were phosphatidylinositol 3-kinase-dependent. Forced expression of ILK in vivo led to increases in type I collagen, smooth muscle alpha-actin, transforming growth factor-beta, and extra domain A (EDA) fibronectin mRNAs (by 3.2-, 3.5-, 2.5-, and 2.2-fold, respectively; n = 8, p < 0.05 for each versus the control), whereas inhibition of ILK in vivo led to significant reductions in these mRNAs. Morphometric analysis revealed that ILK overexpression led to a 31.4% increase in liver collagen content (n = 8, p < 0.05 versus the control); in contrast ILK knockdown in vivo led to a significant reduction in fibrogenesis. We conclude that ILK plays an important pathophysiological role in vivo in liver wound healing.	Univ Texas, SW Med Ctr, Div Digest & Liver Dis, Dept Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Rockey, DC (corresponding author), Univ Texas, SW Med Ctr, Div Digest & Liver Dis, Dept Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	don.rockey@utsouthwestern.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050574] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 50574, R01 DK 60338] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Barker TH, 2005, J BIOL CHEM, V280, P36483, DOI 10.1074/jbc.M504663200; Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; BISSELL DM, 1995, J CLIN INVEST, V96, P447, DOI 10.1172/JCI118055; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Chen XW, 2004, AM J PATHOL, V165, P617, DOI 10.1016/S0002-9440(10)63326-3; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; FRIEDMAN SL, 1989, J BIOL CHEM, V264, P10756; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; Gao RP, 2004, J BIOL CHEM, V279, P8848, DOI 10.1074/jbc.M313204200; George J, 1999, P NATL ACAD SCI USA, V96, P12719, DOI 10.1073/pnas.96.22.12719; Graness A, 2006, CELL SIGNAL, V18, P433, DOI 10.1016/j.cellsig.2005.05.011; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Ikeda K, 2002, J BIOL CHEM, V277, P19206, DOI 10.1074/jbc.M201078200; Ikeda K, 1999, HEPATOLOGY, V29, P1760, DOI 10.1002/hep.510290640; JARNAGIN WR, 1994, J CELL BIOL, V127, P2037, DOI 10.1083/jcb.127.6.2037; Khyrul WAKM, 2004, J BIOL CHEM, V279, P54131, DOI 10.1074/jbc.M410051200; KOUNTOURAS J, 1984, BRIT J EXP PATHOL, V65, P305; Levinson H, 2004, ANN PLAS SURG, V52, P204, DOI 10.1097/01.sap.0000100893.35542.f6; Li YJ, 2003, J CLIN INVEST, V112, P503, DOI 10.1172/JCI200317913; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Nikolopoulos SN, 2002, J BIOL CHEM, V277, P1568, DOI 10.1074/jbc.M108612200; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; PROCTOR E, 1982, GASTROENTEROLOGY, V83, P1183; Qian Y, 2005, ONCOGENE, V24, P3154, DOI 10.1038/sj.onc.1208525; Reif S, 2003, J BIOL CHEM, V278, P8083, DOI 10.1074/jbc.M212927200; Rockey DC, 1996, J CLIN INVEST, V98, P1381, DOI 10.1172/JCI118925; ROCKEY DC, 1993, J CLIN INVEST, V92, P1795, DOI 10.1172/JCI116769; Sakai T, 2003, GENE DEV, V17, P926, DOI 10.1101/gad.255603; SCHUPPAN D, 1990, SEMIN LIVER DIS, V10, P1, DOI 10.1055/s-2008-1040452; Sepulveda JL, 2005, CURR TOP DEV BIOL, V68, P183, DOI 10.1016/S0070-2153(05)68007-6; Shao R, 2003, MOL BIOL CELL, V14, P2327, DOI 10.1091/mbc.02-06-0093; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Wu CY, 2005, TRENDS CELL BIOL, V15, P460, DOI 10.1016/j.tcb.2005.07.002; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Yu Q, 2002, AM J PHYSIOL-GASTR L, V282, pG565, DOI 10.1152/ajpgi.00512.2000; Zhou XY, 2004, J BIOL CHEM, V279, P23996, DOI 10.1074/jbc.M311668200	39	35	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24863	24872		10.1074/jbc.M513544200	http://dx.doi.org/10.1074/jbc.M513544200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16728409	hybrid			2022-12-25	WOS:000239847800080
J	Yamada, M; Ohnishi, J; Ohkawara, B; Iemura, S; Satoh, K; Hyodo-Miura, J; Kawachi, K; Natsume, T; Shibuya, H				Yamada, Misato; Ohnishi, Junji; Ohkawara, Bisei; Iemura, Shunichiro; Satoh, Kiyotoshi; Hyodo-Miura, Junko; Kawachi, Kaoru; Natsume, Tohru; Shibuya, Hiroshi			NARF, an nemo-like kinase (NLK)-associated ring finger protein regulates the ubiquitylation and degradation of T cell factor/lymphoid enhancer factor (TCF/LEF)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN LIGASE; BETA-CATENIN; C-CBL; NEGATIVE REGULATOR; E3 LIGASE; WNT; PATHWAY; COMPLEX; APC11; NLK	beta-Catenin is a key player in the Wnt signaling pathway, and interacts with cofactor T cell factor/lymphoid enhancer factor ( TCF/LEF) to generate a transcription activator complex that activates Wnt-induced genes. We previously reported that Nemo-like kinase ( NLK) negatively regulates Wnt signaling via phosphorylation of TCF/LEF. To further evaluate the physiological roles of NLK, we performed yeast two-hybrid screening to identify NLK-interacting proteins. From this screen, we isolated a novel RING finger protein that we term NARF ( NLK associated RING finger protein). Here, we show that NARF induces the ubiquitylation of TCF/LEF in vitro and in vivo, and functions as an E3 ubiquitin-ligase that specifically cooperates with the E2 conjugating enzyme E2-25K. We found that NLK augmented NARF binding and ubiquitylation of TCF/LEF, and this required NLK kinase activity. The ubiquitylated TCF/LEF was subsequently degraded by the proteasome. Furthermore, NARF inhibited formation of the secondary axis induced by the ectopic expression of beta-catenin in Xenopus embryos. Collectively, our findings raise the possibility that NARF functions as a novel ubiquitin-ligase to suppress the Wnt-beta-catenin signaling.	Tokyo Med & Dent Univ, Inst Med Res, Dept Mol Cell Biol, Chiyoda Ku, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, Sch Biomed Sci, Chiyoda Ku, Tokyo 1010062, Japan; JST, SORST, Chiyoda Ku, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, Ctr Excellence Program Res Mol Destruct & Reconst, Tokyo 1010062, Japan; Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr JBIRC, Kohtoh Ku, Tokyo 1350064, Japan; Natl Inst Basic Biol, Dept Dev Biol, Div Morphogenesis, Okazaki, Aichi 4448585, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); Tokyo Medical & Dental University (TMDU); National Institute of Advanced Industrial Science & Technology (AIST); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Shibuya, H (corresponding author), Tokyo Med & Dent Univ, Inst Med Res, Dept Mol Cell Biol, Chiyoda Ku, Tokyo 1010062, Japan.	shibuya.mcb@mri.tmd.ac.jp	Satoh, Kiyotoshi/M-3653-2017; Natsume, Tohru/M-7627-2018	Satoh, Kiyotoshi/0000-0001-6029-6534; Natsume, Tohru/0000-0002-1510-2582; Ohkawara, Bisei/0000-0002-1987-458X				Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Brott BK, 1998, P NATL ACAD SCI USA, V95, P963, DOI 10.1073/pnas.95.3.963; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; Fang S, 2004, CELL MOL LIFE SCI, V61, P1546, DOI 10.1007/s00018-004-4129-5; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Gay F, 2003, GENE DEV, V17, P717, DOI 10.1101/gad.1042403; Gmachl M, 2000, P NATL ACAD SCI USA, V97, P8973, DOI 10.1073/pnas.97.16.8973; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Huang HK, 2000, J BIOL CHEM, V275, P26661; Hyodo-Miura J, 2002, GENES CELLS, V7, P487, DOI 10.1046/j.1365-2443.2002.00536.x; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kanei-Ishii C, 2004, GENE DEV, V18, P816, DOI 10.1101/gad.1170604; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lee SJ, 2001, FEBS LETT, V503, P61, DOI 10.1016/S0014-5793(01)02689-8; Leverson JD, 2000, MOL BIOL CELL, V11, P2315, DOI 10.1091/mbc.11.7.2315; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Natsume T, 2002, ANAL CHEM, V74, P4725, DOI 10.1021/ac020018n; Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Ohkawara B, 2004, GENE DEV, V18, P381, DOI 10.1101/gad.1166904; Ohnishi J, 2001, MOL ENDOCRINOL, V15, P747, DOI 10.1210/me.15.5.747; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Song S, 2003, MOL CELL, V12, P553, DOI 10.1016/j.molcel.2003.08.005; Suzuki A, 1997, BIOCHEM BIOPH RES CO, V232, P153, DOI 10.1006/bbrc.1997.6219; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yamada M, 2003, GENES CELLS, V8, P677, DOI 10.1046/j.1365-2443.2003.00666.x; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamamoto H, 2003, EMBO J, V22, P2047, DOI 10.1093/emboj/cdg204; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216	50	99	110	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20749	20760		10.1074/jbc.M602089200	http://dx.doi.org/10.1074/jbc.M602089200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16714285	hybrid			2022-12-25	WOS:000239187300011
J	Li, ZZ; Cao, R; Wang, M; Myers, MP; Zhang, Y; Xu, RM				Li, Zhizhong; Cao, Ru; Wang, Ming; Myers, Michael P.; Zhang, Yi; Xu, Rui-Ming			Structure of a Bmi-1-Ring1B polycomb group ubiquitin ligase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE METHYLTRANSFERASE ACTIVITY; H2A UBIQUITINATION; DIFFRACTION DATA; GROUP PROTEINS; CHROMATIN; UBIQUITYLATION; METHYLATION; BRCA1-BARD1; MECHANISMS; LYSINE-27	Polycomb group proteins Bmi-1 and Ring1B are core subunits of the PRC1 complex, which plays important roles in the regulation of Hox gene expression, X-chromosome inactivation, tumorigenesis, and stem cell self-renewal. The RING finger protein Ring1B is an E3 ligase that participates in the ubiquitination of lysine 119 of histone H2A, and the binding of Bmi-1 stimulates the E3 ligase activity. We have mapped the regions of Bmi-1 and Ring1B required for efficient ubiquitin transfer and determined a 2.5-A structure of the Bmi-1-Ring1B core domain complex. The structure reveals that Ring1B "hugs" Bmi-1 through extensive RING domain contacts and its N-terminal tail wraps around Bmi-1. The two regions of interaction have a synergistic effect on the E3 ligase activity. Our analyses suggest a model where the Bmi-1-Ring1B complex stabilizes the interaction between the E2 enzyme and the nucleosomal substrate to allow efficient ubiquitin transfer.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Howard Hughes Med Inst, Chapel Hill, NC 27599 USA	Cold Spring Harbor Laboratory; University of North Carolina; University of North Carolina Chapel Hill; Howard Hughes Medical Institute; University of North Carolina; University of North Carolina Chapel Hill	Xu, RM (corresponding author), NYU, Sch Med, Struct Biol Program, Skirball Inst Biomol Med, 540 1St Ave, New York, NY 10016 USA.	rmxu@saturn.med.nyu.edu	xu, rui/GRX-5734-2022	Zhang, Yi/0000-0002-2789-0811	NIGMS NIH HHS [GM63718, GM68804] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068804] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; de Napoles M, 2004, DEV CELL, V7, P663, DOI 10.1016/j.devcel.2004.10.005; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Fang J, 2004, J BIOL CHEM, V279, P52812, DOI 10.1074/jbc.C400493200; Francis NJ, 2004, SCIENCE, V306, P1574, DOI 10.1126/science.1100576; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Francis NJ, 2001, MOL CELL, V8, P545, DOI 10.1016/S1097-2765(01)00316-1; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Gil J, 2005, DNA CELL BIOL, V24, P117, DOI 10.1089/dna.2005.24.117; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Hernadez-Munoz I, 2005, P NATL ACAD SCI USA, V102, P7635, DOI 10.1073/pnas.0408918102; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V24, P946; Levine SS, 2002, MOL CELL BIOL, V22, P6070, DOI 10.1128/MCB.22.17.6070-6078.2002; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Reverter D, 2005, NATURE, V435, P687, DOI 10.1038/nature03588; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	37	181	189	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20643	20649		10.1074/jbc.M602461200	http://dx.doi.org/10.1074/jbc.M602461200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16714294	hybrid, Green Published			2022-12-25	WOS:000239038200085
J	Ugolev, Y; Molshanski-Mor, S; Weinbaum, C; Pick, E				Ugolev, Yelena; Molshanski-Mor, Shahar; Weinbaum, Carolyn; Pick, Edgar			Liposomes comprising anionic but not neutral phospholipids cause dissociation of rac(1 or 2)center dot RhoGDI complexes and support amphiphile-independent NADPH oxidase activation by such complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CELL-FREE SYSTEM; GTP-BINDING PROTEIN; RESPIRATORY BURST OXIDASE; DEPENDENT SUPEROXIDE PRODUCTION; ADENINE-DINUCLEOTIDE PHOSPHATE; SODIUM DODECYL-SULFATE; RHO PROTEINS; POLYMORPHONUCLEAR LEUKOCYTES; MEMBRANE TRANSLOCATION; CYTOSOLIC COMPONENT	Activation of the phagocyte NADPH oxidase involves the assembly of a membrane-localized cytochrome b(559) with the cytosolic components p47(phox), p67(phox), p40(phox), and the GTPase Rac (1 or 2). In resting phagocytes, Rac is found in the cytosol as a prenylated protein in the GDP-bound form, associated with the Rho GDP dissociation inhibitor (RhoGDI). In the process of NADPH oxidase activation, Rac is dissociated from RhoGDI and translocates to the membrane, in concert with the other cytosolic components. The mechanism responsible for dissociation of Rac from RhoGDI is poorly understood. We generated Rac(1 or 2)center dot RhoGDI complexes in vitro from recombinant Rac(1 or 2), prenylated enzymatically, and recombinant RhoGDI, and purified these by anion exchange chromatography. Exposing Rac(1 or 2)center dot(GDP)center dot RhoGDI complexes to liposomes containing four different anionic phospholipids caused the dissociation of Rac(1 or 2)( GDP) from RhoGDI and its binding to the anionic liposomes. Rac2(GDP)center dot RhoGDI complexes were more resistant to dissociation, reflecting the lesser positive charge of Rac2. Liposomes consisting of neutral phospholipid did not cause dissociation of Rac(1 or 2)center dot RhoGDI complexes. Rac1 exchanged to the hydrolysis-resistant GTP analogue, GMPPNP, associated with RhoGDI with lower affinity than Rac1( GDP) and Rac1(GMPPNP)center dot RhoGDI complexes were more readily dissociated by anionic liposomes. Rac1(GMPPNP)center dot RhoGDI complexes elicited NADPH oxidase activation in native phagocyte membrane liposomes in the presence of p67(phox), without the need for an anionic amphiphile, as activator. Both Rac1(GDP)center dot RhoGDI and Rac1(GMPPNP)center dot RhoGDI complexes elicited amphiphile-independent, p67(phox)-dependent NADPH oxidase activation in phagocyte membrane liposomes enriched in anionic phospholipids but not in membrane liposomes enriched in neutral phospholipids.	Tel Aviv Univ, Dept Human Microbiol, Sackler Sch Med, Julius Friedrich Cohnheim Minerva Ctr Phagocyte R, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Ela Kodesz Inst Host Def Infect Dis, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Duke University	Pick, E (corresponding author), Tel Aviv Univ, Dept Human Microbiol, Sackler Sch Med, Julius Friedrich Cohnheim Minerva Ctr Phagocyte R, IL-69978 Tel Aviv, Israel.	epick@post.tau.ac.il	Pick, Edgar/B-1795-2008	Pick, Edgar/0000-0003-4625-3233	NIGMS NIH HHS [GM46372] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO A, 1991, J BIOL CHEM, V266, P23577; ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; Adra CN, 1997, P NATL ACAD SCI USA, V94, P4279, DOI 10.1073/pnas.94.9.4279; Alloul N, 2001, BIOCHEMISTRY-US, V40, P14557, DOI 10.1021/bi0117347; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bokoch GM, 2005, TRENDS CELL BIOL, V15, P163, DOI 10.1016/j.tcb.2005.01.002; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; BROMBERG Y, 1994, J BIOL CHEM, V269, P7055; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; CHUANG TH, 1993, J BIOL CHEM, V268, P775; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; Dang PMC, 2002, P NATL ACAD SCI USA, V99, P4262, DOI 10.1073/pnas.072345299; Dang PMC, 2001, P NATL ACAD SCI USA, V98, P3001, DOI 10.1073/pnas.061029698; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; DerMardirossian C, 2005, TRENDS CELL BIOL, V15, P356, DOI 10.1016/j.tcb.2005.05.001; DerMardirossian C, 2004, MOL CELL, V15, P117, DOI 10.1016/j.molcel.2004.05.019; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; Di-Poi N, 2001, BIOCHEMISTRY-US, V40, P10014, DOI 10.1021/bi010289c; DINITTO JP, 2003, SCI STKE, pRE16, DOI DOI 10.1126/STKE.2132003RE16; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; Dovas A, 2005, BIOCHEM J, V390, P1, DOI 10.1042/BJ20050104; Dransart E, 2005, TRAFFIC, V6, P957, DOI 10.1111/j.1600-0854.2005.00335.x; Dransart E, 2005, J BIOL CHEM, V280, P4674, DOI 10.1074/jbc.M409741200; Ebisu K, 2001, J BIOL CHEM, V276, P24498, DOI 10.1074/jbc.M101122200; Faure J, 1999, EUR J BIOCHEM, V262, P879, DOI 10.1046/j.1432-1327.1999.00458.x; Forget MA, 2002, BIOCHEM J, V361, P243, DOI 10.1042/0264-6021:3610243; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; Gillooly DJ, 2001, J CELL BIOL, V155, P15, DOI 10.1083/jcb.200109001; Gorzalczany Y, 2002, J BIOL CHEM, V277, P18605, DOI 10.1074/jbc.M202114200; Gorzalczany Y, 2000, J BIOL CHEM, V275, P40073, DOI 10.1074/jbc.M006013200; Gosser YQ, 1997, NATURE, V387, P814, DOI 10.1038/42961; Grizot S, 2001, BIOCHEMISTRY-US, V40, P10007, DOI 10.1021/bi010288k; Groemping Y, 2005, BIOCHEM J, V386, P401, DOI 10.1042/BJ20041835; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; HANCOCK JF, 1993, EMBO J, V12, P1915, DOI 10.1002/j.1460-2075.1993.tb05840.x; Henriques C, 2003, PARASITOL RES, V89, P123, DOI 10.1007/s00436-002-0728-y; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; JOSEPH G, 1994, J BIOL CHEM, V269, P29024; Keep NH, 1997, STRUCTURE, V5, P623, DOI 10.1016/S0969-2126(97)00218-9; Kim C, 2001, J IMMUNOL, V166, P1223, DOI 10.4049/jimmunol.166.2.1223; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; Koshkin V, 1997, BBA-BIOENERGETICS, V1319, P139, DOI 10.1016/S0005-2728(96)00154-5; KRECK ML, 1994, J BIOL CHEM, V269, P4161; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Longenecker KL, 2001, ACTA CRYSTALLOGR D, V57, P679, DOI 10.1107/S0907444901003122; MASON RJ, 1972, J CLIN INVEST, V51, P2399, DOI 10.1172/JCI107052; MCPHAIL LC, 1993, EUR J HAEMATOL, V51, P294; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; Mesmin B, 2004, J BIOL CHEM, V279, P49876, DOI 10.1074/jbc.M406903200; Michaelson D, 2005, MOL BIOL CELL, V16, P1606, DOI 10.1091/mbc.e04-11-0960; Mizrahi A, 2005, J BIOL CHEM, V280, P3802, DOI 10.1074/jbc.M410257200; Mizrahi A, 2006, J LEUKOCYTE BIOL, V79, P881, DOI 10.1189/jlb.1005553; Murray D, 1997, STRUCTURE, V5, P985, DOI 10.1016/S0969-2126(97)00251-7; Nauseef WM, 2004, HISTOCHEM CELL BIOL, V122, P277, DOI 10.1007/s00418-004-0679-8; Nomanbhoy TK, 1996, J BIOL CHEM, V271, P10004, DOI 10.1074/jbc.271.17.10004; Papaharalambus C, 2005, J BIOL CHEM, V280, P18790, DOI 10.1074/jbc.M410081200; Peng GH, 2003, BIOCHEM J, V373, P221, DOI 10.1042/BJ20021629; Perisic O, 2004, ADV ENZYME REGUL, V44, P279, DOI 10.1016/j.advenzreg.2003.11.003; PICK E, 1993, EUR J BIOCHEM, V217, P441, DOI 10.1111/j.1432-1033.1993.tb18264.x; PICK E, 1987, J BIOL CHEM, V262, P16476; Price LS, 2003, J BIOL CHEM, V278, P39413, DOI 10.1074/jbc.M302083200; Price MO, 2002, J BIOL CHEM, V277, P19220, DOI 10.1074/jbc.M200061200; Quinn MT, 2004, J LEUKOCYTE BIOL, V76, P760, DOI 10.1189/jlb.0404216; Read PW, 2000, PROTEIN SCI, V9, P376; Robbe K, 2003, J BIOL CHEM, V278, P4756, DOI 10.1074/jbc.M210412200; Sarfstein R, 2004, J BIOL CHEM, V279, P16007, DOI 10.1074/jbc.M312394200; SASAKI T, 1993, J BIOL CHEM, V268, P23959; Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; Sigal N, 2003, INFLAMMATION, V27, P147, DOI 10.1023/A:1023869828688; Sigal N, 2003, J BIOL CHEM, V278, P4854, DOI 10.1074/jbc.M211011200; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; Szabo A.G., 2000, SPECTROPHOTOMETRY SP, P33; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TAMURA M, 1988, J BIOL CHEM, V263, P17621; Taylor RM, 2004, BBA-BIOMEMBRANES, V1663, P201, DOI 10.1016/j.bbamem.2004.03.009; Toporik A, 1998, BIOCHEMISTRY-US, V37, P7147, DOI 10.1021/bi9800404; UEDA T, 1990, J BIOL CHEM, V265, P9373; Ueyama T, 2005, J IMMUNOL, V175, P2381, DOI 10.4049/jimmunol.175.4.2381; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; Williams DA, 2000, BLOOD, V96, P1646; Xu XM, 1997, BIOCHEMISTRY-US, V36, P626, DOI 10.1021/bi962059h; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045; Yamauchi A, 2004, J IMMUNOL, V173, P5971, DOI 10.4049/jimmunol.173.10.5971; Zalcman G, 1996, J BIOL CHEM, V271, P30366, DOI 10.1074/jbc.271.48.30366; Zalcman G, 1999, Prog Mol Subcell Biol, V22, P85; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhao XX, 2003, J BIOL CHEM, V278, P40788, DOI 10.1074/jbc.M302208200	102	27	28	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19204	19219		10.1074/jbc.M600042200	http://dx.doi.org/10.1074/jbc.M600042200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16702219	hybrid			2022-12-25	WOS:000238847000035
J	McNally, DJ; Hui, JPM; Aubry, AJ; Mui, KKK; Guerry, P; Brisson, JR; Logan, SM; Soo, EC				McNally, David J.; Hui, Joseph P. M.; Aubry, Annie J.; Mui, Kenneth K. K.; Guerry, Patricia; Brisson, Jean-Robert; Logan, Susan M.; Soo, Evelyn C.			Functional characterization of the flagellar glycosylation locus in Campylobacter jejuni 81-176 using a focused metabolomics approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-SPECIFIC POLYSACCHARIDE; HYDROPHILIC INTERACTION CHROMATOGRAPHY; PERFORMANCE LIQUID-CHROMATOGRAPHY; PSEUDOMONAS-AERUGINOSA; PROTEIN GLYCOSYLATION; PSEUDAMINIC ACID; SOMATIC ANTIGENS; LIPOPOLYSACCHARIDE; IDENTIFICATION; VIRULENCE	Bacterial genome sequencing has provided a wealth of genetic data. However, the definitive functional characterization of hypothetical open reading frames and novel biosynthetic genes remains challenging. This is particularly true for genes involved in protein glycosylation because the isolation of their glycan moieties is often problematic. We have developed a focused metabolomics approach to define the function of flagellin glycosylation genes in Campylobacter jejuni 81-176. A capillary electrophoresis-electrospray mass spectrometry and precursor ion scanning method was used to examine cell lysates of C. jejuni 81-176 for sugar nucleotides. Novel nucleotide-activated intermediates of the pseudaminic acid (Pse5NAc7NAc) pathway and its acetamidino derivative (PseAm) were found to accumulate within select isogenic mutants, and use of a hydrophilic interaction liquid chromatography-mass spectrometry method permitted large scale purifications of the intermediates. NMR with cryo probe ( cold probe) technology was utilized to complete the structural characterization of microgram quantities of CMP-5-acetamido-7-acetamidino3,5,7,9-tetradeoxy-L-glycero-alpha-L-manno-nonulosonic acid (CMP-P-se5NAc7Am), which is the first report of Pse modified at C7 with an acetamidino group in Campylobacter, and UDP-2,4-diacetamido-2,4,6-trideoxy-alpha-D-glucopyranose, which is a bacillosamine derivative found in the N-linked protein glycan. Using this focused metabolomics approach, pseB, pseC, pseF, pseI, and for the first time pseA, pseG, and pseH were found to be directly involved in either the biosynthesis of CMP-Pse5NAc7NAc or CMP-Pse5NAc7Am. In contrast, it was shown that pseD, pseE, Cj1314c, Cj1315c, Cjb1301, Cj1334, Cj1341c, and Cj1342c have no role in the CMP-Pse5NAc7NAc or CMP-Pse5NAc7Am pathways. These results demonstrate the usefulness of this approach for targeting compounds within the bacterial metabolome to assign function to genes, identify metabolic intermediates, and elucidate novel biosynthetic pathways.	Natl Res Council Canada, Inst Marine Biosci, Halifax, NS B3H 3Z1, Canada; Natl Res Council Canada, Inst Marine Biosci, Halifax, NS B3H 3Z1, Canada; Univ Waterloo, Dept Chem, Waterloo, ON N2L 3G1, Canada; USN, Med Res Ctr, Silver Spring, MD 20910 USA	International Business Machines (IBM); National Research Council Canada; International Business Machines (IBM); National Research Council Canada; University of Waterloo; United States Department of Defense; United States Navy	Soo, EC (corresponding author), Natl Res Council Canada, Inst Marine Biosci, 1411 Oxford St, Halifax, NS B3H 3Z1, Canada.	evelyn.soo@nrc-cnrc.gc.ca	Guerry, Patricia/A-8024-2011		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043559] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI43559] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alksne LE, 2002, EXPERT OPIN INV DRUG, V11, P1149, DOI 10.1517/13543784.11.8.1149; Arora SK, 2005, INFECT IMMUN, V73, P4395, DOI 10.1128/IAI.73.7.4395-4398.2005; Benz I, 2002, MOL MICROBIOL, V45, P267, DOI 10.1046/j.1365-2958.2002.03030.x; BRISSON JR, 2002, NMR SPECTROSCOPY GLY, P59; Burton IW, 2005, ANAL CHEM, V77, P3123, DOI 10.1021/ac048385h; Champion OL, 2005, P NATL ACAD SCI USA, V102, P16043, DOI 10.1073/pnas.0503252102; Chou WK, 2005, J BIOL CHEM, V280, P35922, DOI 10.1074/jbc.M507483200; Edebrink P, 1996, CARBOHYD RES, V287, P225, DOI 10.1016/0008-6215(96)00076-6; Glover KJ, 2005, CHEM BIOL, V12, P1311, DOI 10.1016/j.chembiol.2005.10.004; Goon S, 2003, MOL MICROBIOL, V50, P659, DOI 10.1046/j.1365-2958.2003.03725.x; Guerry P, 2006, MOL MICROBIOL, V60, P299, DOI 10.1111/j.1365-2958.2006.05100.x; Guo Y, 2005, J CHROMATOGR A, V1074, P71, DOI 10.1016/j.chroma.2005.03.058; Hanniffy OM, 1998, CARBOHYD RES, V307, P291, DOI 10.1016/S0008-6215(97)10108-2; HERMANSSON K, 1993, EUR J BIOCHEM, V212, P801, DOI 10.1111/j.1432-1033.1993.tb17721.x; Karlyshev AV, 2002, MICROBIOL-SGM, V148, P473, DOI 10.1099/00221287-148-2-473; Kauppi AM, 2003, CHEM BIOL, V10, P241, DOI 10.1016/S1074-5521(03)00046-2; KENNE L, 1988, CARBOHYD RES, V184, P288, DOI 10.1016/0008-6215(88)80033-8; KNIREL YA, 1986, EUR J BIOCHEM, V157, P129, DOI 10.1111/j.1432-1033.1986.tb09648.x; KNIREL YA, 1987, EUR J BIOCHEM, V163, P639, DOI 10.1111/j.1432-1033.1987.tb10913.x; Kocharova NA, 2001, CARBOHYD RES, V330, P83, DOI 10.1016/S0008-6215(00)00271-8; Kondakova AN, 2001, CARBOHYD RES, V333, P241, DOI 10.1016/S0008-6215(01)00145-8; Linton D, 2005, MOL MICROBIOL, V55, P1695, DOI 10.1111/j.1365-2958.2005.04519.x; Logan SM, 2002, MOL MICROBIOL, V46, P587, DOI 10.1046/j.1365-2958.2002.03185.x; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; Rabina J, 2001, GLYCOCONJUGATE J, V18, P799, DOI 10.1023/A:1021107602535; Sadovskaya I, 1998, EUR J BIOCHEM, V253, P319, DOI 10.1046/j.1432-1327.1998.2530319.x; Schirm M, 2003, MOL MICROBIOL, V48, P1579, DOI 10.1046/j.1365-2958.2003.03527.x; Schoenhofen IC, 2006, J BIOL CHEM, V281, P723, DOI 10.1074/jbc.M511021200; Soo EC, 2004, ANAL CHEM, V76, P619, DOI 10.1021/ac034875i; Szymanski CM, 2005, NAT REV MICROBIOL, V3, P225, DOI 10.1038/nrmicro1100; Thibault P, 2001, J BIOL CHEM, V276, P34862, DOI 10.1074/jbc.M104529200; Uhrin D, 2000, NMR IN MICROBIOLOGY: THEORY AND APPLICATIONS, P165; Upreti RK, 2003, PROTEOMICS, V3, P363, DOI 10.1002/pmic.200390052; Wang XD, 2005, J CHROMATOGR A, V1083, P58, DOI 10.1016/j.chroma.2005.05.082; Weckwerth W, 2005, DRUG DISCOV TODAY, V10, P1551, DOI 10.1016/S1359-6446(05)03609-3; Weckwerth W, 2003, ANNU REV PLANT BIOL, V54, P669, DOI 10.1146/annurev.arplant.54.031902.135014; Young NM, 2002, J BIOL CHEM, V277, P42530, DOI 10.1074/jbc.M206114200	37	106	114	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18489	18498		10.1074/jbc.M603777200	http://dx.doi.org/10.1074/jbc.M603777200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16684771	hybrid			2022-12-25	WOS:000238687300028
J	Kues, WA; Schwinzer, R; Wirth, D; Verhoeyen, E; Lemme, E; Herrmann, D; Barg-Kues, B; Hauser, H; Wonigeit, K; Niemann, H				Kues, Wilfried A.; Schwinzer, Reinhard; Wirth, Dagmar; Verhoeyen, Els; Lemme, Erika; Herrmann, Doris; Barg-Kues, Brigitte; Hauser, Hansjorg; Wonigeit, Kurt; Niemann, Heiner			Epigenetic silencing and tissue independent expression of a novel tetracycline inducible system in double-transgenic pigs	FASEB JOURNAL			English	Article						autoregulative cassette; bicistronic; transgenic livestock; tissue independent expression; DNA methylation	GENE-EXPRESSION; AUTOREGULATORY LOOP; PROMOTER; CELLS; VECTORS; BRAIN; INTEGRATION; REPRESSION; DELIVERY; MURINE	The applicability of tightly regulated transgenesis in domesticated animals is severely hampered by the present lack of knowledge of regulatory mechanisms and the long generation intervals. To capitalize on the tightly controlled expression of mammalian genes made possible by using prokaryotic control elements, we have used a single-step transduction to introduce an autoregulative tetracycline-responsive bicistronic expression cassette (NTA) into transgenic pigs. Transgenic pigs carrying one NTA cassette showed a mosaic transgene expression restricted to single muscle fibers. In contrast, crossbred animals carrying two NTA cassettes with different transgenes, revealed a broad tissue-independent and tightly regulated expression of one cassette, but not of the other one. The expression pattern correlated inversely with the methylation status of the NTA transcription start sites indicating epigenetic silencing of one NTA cassette. This first approach on tetracycline regulated transgene expression in farm animals will be valuable for developing precisely controlled expression systems for transgenes in large animals relevant for biomedical and agricultural biotechnology.	Hannover Med Sch, Klin Viszeral & Transplantat Clin, D-30623 Hannover, Germany; Hannover Med Sch, Viszeral & Transplantat Chirurg Klin, D-30623 Hannover, Germany; Inst Anim Breeding, Dept Biotechnol, Mariensee, Germany; Gesell Biotechnol Forsch mbH, D-3300 Braunschweig, Germany	Hannover Medical School; Hannover Medical School; Gesellschaft fur Biotechnologische Forschung mbH	Niemann, H (corresponding author), Hannover Med Sch, Klin Viszeral & Transplantat Clin, Carl Neuberg Str 1, D-30623 Hannover, Germany.	niemann@tzv.fal.de	Kues, Wilfried/AAX-2466-2020; Kues, Wilfried/D-9232-2011; Verhoeyen, Els/AAW-4853-2021; Verhoeyen, Els/H-6360-2016	Kues, Wilfried/0000-0002-0850-8103; Verhoeyen, Els/0000-0001-9224-5491; 				Antequera F, 2003, CELL MOL LIFE SCI, V60, P1647, DOI 10.1007/s00018-003-3088-6; BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; Boger H, 1999, MECH DEVELOP, V83, P141, DOI 10.1016/S0925-4773(99)00042-8; Corbel SY, 2002, CURR OPIN BIOTECH, V13, P448, DOI 10.1016/S0958-1669(02)00361-0; DIRKS W, 1994, GENE, V149, P387, DOI 10.1016/0378-1119(94)90186-4; Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gunther EJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0551com; Hajkova Petra, 2002, Methods Mol Biol, V200, P143; Hofmann A, 1996, P NATL ACAD SCI USA, V93, P5185, DOI 10.1073/pnas.93.11.5185; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Kringstein AM, 1998, P NATL ACAD SCI USA, V95, P13670, DOI 10.1073/pnas.95.23.13670; Kues WA, 2004, TRENDS BIOTECHNOL, V22, P286, DOI 10.1016/j.tibtech.2004.04.003; Kues WA, 2005, BIOL REPROD, V72, P1020, DOI 10.1095/biolreprod.104.031229; KUES WA, 1995, J CELL BIOL, V130, P949, DOI 10.1083/jcb.130.4.949; Kuhnel F, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh034; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; Lewandoski M, 2001, NAT REV GENET, V2, P743, DOI 10.1038/35093537; Lindeberg J, 2002, J NEUROSCI RES, V68, P248, DOI 10.1002/jnr.10213; Markusic D, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni062; May T, 2004, NUCLEIC ACIDS RES, V32, P5529, DOI 10.1093/nar/gkh887; MAYO KE, 1982, CELL, V29, P99, DOI 10.1016/0092-8674(82)90094-0; MILLER KF, 1989, J ENDOCRINOL, V120, P481, DOI 10.1677/joe.0.1200481; Niemann H, 2003, ANIM REPROD SCI, V79, P291, DOI 10.1016/S0378-4320(03)00169-6; Niemann H, 2001, TRANSPLANTATION, V72, P1898, DOI 10.1097/00007890-200112270-00006; PURSEL VG, 1989, SCIENCE, V244, P1281, DOI 10.1126/science.2499927; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Robertson A, 2002, GENE, V282, P65, DOI 10.1016/S0378-1119(01)00793-4; ROBERTSON KD, 1995, MOL CELL BIOL, V15, P6150; Sakai N, 2002, MOL PHARMACOL, V61, P1453, DOI 10.1124/mol.61.6.1453; Schoberlein L., 1976, Monatshefte fur Veterinarmedizin, V31, P457; Schultze N, 1996, NAT BIOTECHNOL, V14, P499, DOI 10.1038/nbt0496-499; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Smith-Arica JR, 2000, MOL THER, V2, P579, DOI 10.1006/mthe.2000.0215; Spitzer D, 1999, HUM GENE THER, V10, P1893, DOI 10.1089/10430349950017572; Stepensky D, 2003, CLIN PHARMACOKINET, V42, P863, DOI 10.2165/00003088-200342100-00001; Unsinger J, 2004, BIOCHEM BIOPH RES CO, V319, P879, DOI 10.1016/j.bbrc.2004.05.067; Unsinger J, 2001, MOL THER, V4, P484, DOI 10.1006/mthe.2001.0480; White D, 1996, TRENDS BIOTECHNOL, V14, P3, DOI 10.1016/0167-7799(96)80906-1; Yew NS, 2002, MOL THER, V5, P731, DOI 10.1006/mthe.2002.0598; Zhu Z, 2001, J BIOL CHEM, V276, P25222, DOI 10.1074/jbc.M101512200	45	62	62	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1200	+		10.1096/fj.05-5415fje	http://dx.doi.org/10.1096/fj.05-5415fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16684801				2022-12-25	WOS:000240210300025
J	Sotiropoulos, KB; Clermont, A; Yasuda, Y; Rask-Madsen, C; Mastumoto, M; Takahashi, J; Della Vecchia, K; Kondo, T; Aiello, LP; King, GL				Sotiropoulos, Konstantinos B.; Clermont, Allen; Yasuda, Yutaka; Rask-Madsen, Christian; Mastumoto, Motonobu; Takahashi, Junichi; Della Vecchia, Kim; Kondo, Tatsuya; Aiello, Lloyd P.; King, George L.			Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPAR gamma agonist's effects on edema and weight gain	FASEB JOURNAL			English	Article						Zucker diabetic fatty rat; ruboxistaurin; vascular endothelial growth factor; insulin receptor knockout mice; thiazolidinedione	ENDOTHELIAL GROWTH-FACTOR; TIGHT JUNCTION PERMEABILITY; INSULIN-RESISTANCE; GENE-EXPRESSION; SKELETAL-MUSCLE; DIABETIC-RATS; THIAZOLIDINEDIONE; BETA; ISOFORM; OVEREXPRESSION	PPAR gamma agonists, thiazolidinediones, cause fluid retention and edema due to unknown mechanisms. We characterized the effect of rosiglitazone (RSG), a thiazolidinedione, to induce vascular permeability, vascular endothelial growth factor (VEGF) expression, and protein kinase C (PKC) activation with edema and wt gain. In lean, fatty and diabetic Zucker rats, and endothelial insulin receptor knockout mice, RSG increased wt and vascular permeability, selectively in fat and retina, but not in heart or skeletal muscle. H2O content and wt of epididymal fat were increased by RSG and correlated to increases in capillary permeability in fat and body wt. RSG induced VEGF mRNA expression and PKC activation in fat and retina up to 2.5-fold. Ruboxistaurin, a PKC beta isoform inhibitor, in the latter 2 wk of a 4-wk study, normalized vascular permeability in fat and decreased total wt gain, H2O content, and wt of fat vs. RSG alone but did not decrease VEGF expression, basal permeability, or food intake. Finally, RSG did not increase wt or vascular permeability in PKC beta knockout vs. control mice. Thus, thiazolidinedione's effects on edema and wt are partially due to an adipose tissue-selective activation of PKC and vascular permeability that may be prevented by PKC beta inhibition.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	King, GL (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.	george.king@joslin.harvard.edu		Kondo, Tatsuya/0000-0003-4830-8955; Rask-Madsen, Christian/0000-0002-8548-466X	NEI NIH HHS [EY05110] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abiko T, 2003, DIABETES, V52, P829, DOI 10.2337/diabetes.52.3.829; Acarregui MJ, 2003, AM J PHYSIOL-LUNG C, V284, pL395, DOI 10.1152/ajplung.00202.2002; Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473; Chou E, 2002, CIRCULATION, V105, P373, DOI 10.1161/hc0302.102143; Claesson-Welsh L, 2003, BIOCHEM SOC T, V31, P20, DOI 10.1042/bst0310020; Clarke H, 2000, J CELL SCI, V113, P3187; Etgen GJ, 2002, DIABETES, V51, P1083, DOI 10.2337/diabetes.51.4.1083; Hollenberg NK, 2003, AM J MED, V115, P111, DOI 10.1016/j.amjmed.2003.09.018; Idris I, 2003, DIABETOLOGIA, V46, P288, DOI 10.1007/s00125-002-1008-1; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; Isshiki K, 2000, DIABETES, V49, P1022, DOI 10.2337/diabetes.49.6.1022; Jiang GQ, 2002, DIABETES, V51, P2412, DOI 10.2337/diabetes.51.8.2412; Jiang ZY, 1999, J CLIN INVEST, V104, P447, DOI 10.1172/JCI5971; Knudsen ST, 2002, DIABETES CARE, V25, P2328, DOI 10.2337/diacare.25.12.2328; Kondo T, 2003, J CLIN INVEST, V111, P1835, DOI 10.1172/JCI200317455; Koya D, 1997, J CLIN INVEST, V100, P115, DOI 10.1172/JCI119503; Kruszynska YT, 1998, J CLIN INVEST, V101, P543, DOI 10.1172/JCI1076; Lebovitz HE, 2002, DIABETES-METAB RES, V18, pS23, DOI 10.1002/dmrr.252; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; Mullin JM, 1998, AM J PHYSIOL-CELL PH, V275, pC544, DOI 10.1152/ajpcell.1998.275.2.C544; Murata T, 2001, ARCH OPHTHALMOL-CHIC, V119, P709, DOI 10.1001/archopht.119.5.709; Nagpala PG, 1996, J CELL PHYSIOL, V166, P249, DOI 10.1002/(SICI)1097-4652(199602)166:2<249::AID-JCP2>3.0.CO;2-P; Nesto RW, 2003, CIRCULATION, V108, P2941, DOI 10.1161/01.CIR.0000103683.99399.7E; Newton Alexandra C, 2003, Methods Mol Biol, V233, P3; Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; Panigrahy D, 2002, J CLIN INVEST, V110, P923, DOI 10.1172/JCI200215634; Raskin P, 2001, DIABETES CARE, V24, P1226, DOI 10.2337/diacare.24.7.1226; Rosson D, 1997, J BIOL CHEM, V272, P14950, DOI 10.1074/jbc.272.23.14950; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SPENCE CA, 1978, BRIT J NUTR, V39, P647, DOI 10.1079/BJN19780080; STASEK JE, 1992, J CELL PHYSIOL, V153, P62, DOI 10.1002/jcp.1041530110; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Wakasaki H, 1997, P NATL ACAD SCI USA, V94, P9320, DOI 10.1073/pnas.94.17.9320; Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269; Way KJ, 2001, DIABETIC MED, V18, P945, DOI 10.1046/j.0742-3071.2001.00638.x; Werner AL, 2001, PHARMACOTHERAPY, V21, P1082, DOI 10.1592/phco.21.13.1082.34615; Xu QW, 2001, INVEST OPHTH VIS SCI, V42, P789; Yamakawa K, 2000, BIOCHEM BIOPH RES CO, V271, P571, DOI 10.1006/bbrc.2000.2665; Yang BC, 2003, J CARDIOVASC PHARM, V42, P436, DOI 10.1097/00005344-200309000-00016; Zanchi A, 2004, J CLIN ENDOCR METAB, V89, P1140, DOI 10.1210/jc.2003-031526; Zhang H, 2005, P NATL ACAD SCI USA, V102, P9406, DOI 10.1073/pnas.0501744102; Zierath JR, 1998, ENDOCRINOLOGY, V139, P5034, DOI 10.1210/en.139.12.5034	46	73	78	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1203	+		10.1096/fj.05-4617fje	http://dx.doi.org/10.1096/fj.05-4617fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16672634				2022-12-25	WOS:000240210300026
J	Mahmoodzadeh, S; Eder, S; Nordmeyer, J; Ehler, E; Huber, O; Martus, P; Weiske, J; Pregla, R; Hetzer, R; Regitz-Zagrosek, V				Mahmoodzadeh, Shokoufeh; Eder, Sarah; Nordmeyer, Johannes; Ehler, Elisabeth; Huber, Otmar; Martus, Peter; Weiske, Joerg; Pregla, Reinhard; Hetzer, Roland; Regitz-Zagrosek, Vera			Estrogen receptor alpha up-regulation and redistribution in human heart failure	FASEB JOURNAL			English	Article						estrogen receptors; dilated cardiomyopathy; intercalated disc	RAT CARDIOMYOCYTES; IN-VITRO; MEMBRANE; ACTIVATION; EXPRESSION; CONNEXIN43; JUNCTIONS; CATENIN; SEX	Clinical and animal studies suggest that estrogen receptors are involved in the development of myocardial hypertrophy and heart failure. In this study, we investigated whether human myocardial estrogen receptor alpha (ER alpha) expression, localization, and association with structural proteins was altered in end stage-failing hearts. We found a 1.8-fold increase in ER alpha mRNA and protein in end-stage human dilated cardiomyopathy ( DCM, n = 41), as compared with controls (n = 25). ER alpha was visualized by confocal immunofluorescence microscopy and localized to the cytoplasm, sarcolemma, intercalated discs and nuclei of cardiomyocytes. Immunofluorescence studies demonstrated colocalization of ER alpha with beta-catenin at the intercalated disc in control hearts and immunoprecipitation studies confirmed complex formation of both proteins. Interestingly, the ER alpha/beta-catenin colocalization was lost at the intercalated disc in DCM hearts. Thus, the ER alpha/beta-catenin colocalization in the intercalated disc may be of functional relevance and a loss of this association may play a role in the progression of heart failure. The increase of total ER alpha expression may represent a compensatory process to contribute to the stability of cardiac intercalated discs.	Deutsch Herzzentrum Berlin, D-13353 Berlin, Germany; Charite, Cardiovasc Res Ctr, Berlin, Germany; DHZB, Klin Herz Gefass & Thoraxchirurg, Berlin, Germany; DHZB Berlin, Klin Herz Gefass & Thoraxchirurg, Berlin, Germany; Kings Coll London, Randall Div Cell & Mol Biophys, London WC2R 2LS, England; Kings Coll London, Div Cardiovasc, London WC2R 2LS, England; Inst Clin Chem & Pathobiochem, Berlin, Germany; Inst Med Stat & Clin Epidemiol, Berlin, Germany	German Heart Center Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; German Heart Center Berlin; German Heart Center Berlin; University of London; King's College London; University of London; King's College London	Regitz-Zagrosek, V (corresponding author), Deutsch Herzzentrum Berlin, Augustenburger Pl 1, D-13353 Berlin, Germany.	vrz@dhzb.de	Huber, Otmar/AAA-4548-2021	Huber, Otmar/0000-0003-4359-1747; Regitz-Zagrosek, Vera/0000-0002-3566-3467; Ehler, Elisabeth/0000-0001-5646-5964; Mahmoodzadeh, Shokoufeh/0000-0002-3094-7874				Arnold SF, 1997, MOL ENDOCRINOL, V11, P48, DOI 10.1210/me.11.1.48; Babiker FA, 2004, CIRCULATION, V109, P269, DOI 10.1161/01.CIR.0000105682.85732.BD; Beardslee MA, 2000, CIRC RES, V87, P656, DOI 10.1161/01.RES.87.8.656; Beardslee MA, 1998, CIRC RES, V83, P629, DOI 10.1161/01.RES.83.6.629; Cardona-Gomez P, 2004, MOL CELL NEUROSCI, V25, P363, DOI 10.1016/j.mcn.2003.10.008; CARROLL JD, 1992, CIRCULATION, V86, P1099, DOI 10.1161/01.CIR.86.4.1099; Chambliss KL, 2000, CIRC RES, V87, pE44, DOI 10.1161/01.RES.87.11.e44; Chung TH, 2004, J MOL CELL CARDIOL, V37, P1013, DOI 10.1016/j.yjmcc.2004.08.003; Du XJ, 2004, CARDIOVASC RES, V63, P510, DOI 10.1016/j.cardiores.2004.03.027; Ehler E, 2001, J CELL BIOL, V153, P763, DOI 10.1083/jcb.153.4.763; Fielitz J, 2001, J AM COLL CARDIOL, V37, P1443, DOI 10.1016/S0735-1097(01)01170-6; Grohe C, 1997, FEBS LETT, V416, P107, DOI 10.1016/S0014-5793(97)01179-4; Grohe C, 1998, J ENDOCRINOL, V156, pR1, DOI 10.1677/joe.0.156R001; Groten T, 2005, FASEB J, V19, P1368, DOI 10.1096/fj.04-2558fje; Guerra S, 1999, CIRC RES, V85, P856, DOI 10.1161/01.RES.85.9.856; Hertig CM, 1996, J CELL SCI, V109, P1; Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200; Lechat P, 1999, LANCET, V353, P9; Leinwand LA, 2003, J CLIN INVEST, V112, P302, DOI 10.1172/JCI200319429; Levy D, 2002, NEW ENGL J MED, V347, P1397, DOI 10.1056/NEJMoa020265; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Nadal A, 2001, NEWS PHYSIOL SCI, V16, P251; Nordmeyer J, 2004, CIRCULATION, V110, P3270, DOI 10.1161/01.CIR.0000147610.41984.E8; Nuedling S, 1999, CARDIOVASC RES, V43, P666, DOI 10.1016/S0008-6363(99)00093-0; Patten RD, 2004, CIRC RES, V95, P692, DOI 10.1161/01.RES.0000144126.57786.89; Perissi V, 2005, NAT REV MOL CELL BIO, V6, P542, DOI 10.1038/nrm1680; Perriard JC, 2003, TRENDS CARDIOVAS MED, V13, P30, DOI 10.1016/S1050-1738(02)00209-8; Qing L, 2004, P NATL ACAD SCI USA, V101, P17126, DOI 10.1073/pnas.0407492101; Razandi M, 2004, MOL ENDOCRINOL, V18, P2854, DOI 10.1210/me.2004-0115; Weiske J, 2001, J BIOL CHEM, V276, P41175, DOI 10.1074/jbc.M105769200; Wu JC, 2003, J CELL BIOCHEM, V88, P823, DOI 10.1002/jcb.10390; Zhang ZG, 2002, BIOCHEM BIOPH RES CO, V294, P926, DOI 10.1016/S0006-291X(02)00348-0	32	104	109	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					926	934		10.1096/fj.05-5148com	http://dx.doi.org/10.1096/fj.05-5148com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675850				2022-12-25	WOS:000240157700015
J	Deniaud, E; Baguet, J; Mathieu, AL; Pages, G; Marvel, J; Leverrier, Y				Deniaud, E.; Baguet, J.; Mathieu, A-L; Pages, G.; Marvel, J.; Leverrier, Y.			Overexpression of Sp1 transcription factor induces apoptosis	ONCOGENE			English	Article						apoptosis; Sp1; transcription factor	ENDOTHELIAL GROWTH-FACTOR; DNA-BINDING ACTIVITY; CELL-GROWTH; BCL-X; HEMATOPOIETIC-CELLS; GASTRIC-CANCER; S-PHASE; EXPRESSION; INDUCTION; GENE	Transcription factor Sp1 has recently been shown to be overexpressed in a number of human cancers and its overexpression contributes to malignant transformation. Sp1 regulates the expression of a number of genes participating in multiple aspects of tumorigenesis such as angiogenesis, cell growth and apoptosis resistance. To better understand the role of increased Sp1 levels on apoptosis regulation we have used retroviruses to overexpress this protein in haematopoietic Baf-3 cells and in 3T3 fibroblasts. We have also used inducible expression systems to control ectopic Sp1 levels in different cell types. Surprisingly, Sp1 overexpression on its own induces apoptosis in all the cellular models tested. The apoptotic pathways induced by Sp1 overexpression are cell type specific. Finally, using a truncated form of Sp1, we show that Sp1-induced apoptosis requires its DNA-binding domain. Our results highlight that Sp1 levels in untransformed cells must be tightly regulated as Sp1 overexpression leads to the induction of apoptosis. Our results also suggest that cancer cells overexpressing Sp1 can avoid Sp1-induced apoptosis.	Inserm U503, F-69007 Lyon, France; BioSci Lyon Gerland, IFR 128, Lyon, France; Univ Lyon 1, F-69365 Lyon, France; Univ Nice Sophia Antipolis, CNRS, UMR 6543, Ctr Antoine Lacassagne, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Marvel, J (corresponding author), Inserm U503, 21 Ave Tony Garnier, F-69007 Lyon, France.	marvel@cervi-lyon.inserm.fr; leverrier@cervi-lyon.inserm.fr	LEVERRIER, Yann/M-3767-2014; marvel, jacqueline/H-8638-2014; Deniaud, Emmanuelle/B-9518-2008; Pages, Gilles/N-7135-2017	LEVERRIER, Yann/0000-0002-4227-5446; marvel, jacqueline/0000-0001-6241-459X; Mathieu, Anne-Laure/0000-0002-2893-7001				Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Chae YM, 2004, BIOCHEM BIOPH RES CO, V319, P550, DOI 10.1016/j.bbrc.2004.05.025; Chen F, 2000, ANTICANCER RES, V20, P661; Chiefari E, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-35; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Demeret C, 2003, ONCOGENE, V22, P168, DOI 10.1038/sj.onc.1206108; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; French SW, 2003, J BIOL CHEM, V278, P948, DOI 10.1074/jbc.M207166200; Gala S, 2001, BLOOD, V97, P227, DOI 10.1182/blood.V97.1.227; Gonin-Giraud S, 2002, CELL DEATH DIFFER, V9, P1147, DOI 10.1038/sj.cdd.4401079; Grillot DAM, 1997, J IMMUNOL, V158, P4750; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Heinrich J, 2000, J MOL MED-JMM, V78, P380, DOI 10.1007/s001090000116; Hofmann A, 1996, P NATL ACAD SCI USA, V93, P5185, DOI 10.1073/pnas.93.11.5185; Im HJ, 2002, J BIOL CHEM, V277, P14612, DOI 10.1074/jbc.M109414200; Ishibashi H, 2000, CANCER RES, V60, P6531; Kavurma MM, 2001, J BIOL CHEM, V276, P4964, DOI 10.1074/jbc.M009251200; Kavurma MM, 2003, J BIOL CHEM, V278, P32537, DOI 10.1074/jbc.M305650200; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Kumar A, 2003, MOL CELL BIOL, V23, P6631, DOI 10.1128/MCB.23.18.6631-6645.2003; Kumar AP, 1999, CANCER LETT, V137, P159, DOI 10.1016/S0304-3835(98)00351-6; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Leverrier Y, 1999, CELL DEATH DIFFER, V6, P290, DOI 10.1038/sj.cdd.4400492; Lietard J, 1997, AM J PATHOL, V151, P1663; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Lomberk G, 2005, BIOCHEM J, V392, P1, DOI 10.1042/BJ20051234; Lou Z, 2005, CANCER RES, V65, P1007; Low W, 2001, ONCOGENE, V20, P4476, DOI 10.1038/sj.onc.1204580; Mangeney M, 1996, ONCOGENE, V13, P1441; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Mathieu AL, 2001, J BIOL CHEM, V276, P10935, DOI 10.1074/jbc.M007147200; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Munoz-Pinedo C, 2001, BIOCHEM J, V353, P101, DOI 10.1042/bj3530101; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Persengiev SP, 2002, GENE DEV, V16, P1806, DOI 10.1101/gad.992202; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Pore N, 2004, MOL BIOL CELL, V15, P4841, DOI 10.1091/mbc.E04-05-0374; Preston GA, 1996, MOL CELL BIOL, V16, P211; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; Ryu H, 2003, J NEUROSCI, V23, P3597; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Santos SCR, 2000, ONCOGENE, V19, P1164, DOI 10.1038/sj.onc.1203418; Shi Q, 2001, CANCER RES, V61, P4143; SHORT ML, 1994, BIOCHEM J, V304, P391, DOI 10.1042/bj3040391; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Takahara T, 2000, J BIOL CHEM, V275, P38067, DOI 10.1074/jbc.M002010200; Thomas J, 1998, ONCOGENE, V16, P1399, DOI 10.1038/sj.onc.1201672; Wang LW, 2003, CLIN CANCER RES, V9, P6371; Yao JC, 2004, CLIN CANCER RES, V10, P4109, DOI 10.1158/1078-0432.CCR-03-0628; Zannetti A, 2000, CANCER RES, V60, P1546	54	73	77	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 9	2006	25	53					7096	7105		10.1038/sj.onc.1209696	http://dx.doi.org/10.1038/sj.onc.1209696			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16715126				2022-12-25	WOS:000241910500009
J	Kiyono, M; Shibuya, M				Kiyono, M.; Shibuya, M.			Inhibitory Smad transcription factors protect arterial endothelial cells from apoptosis induced by BMP4	ONCOGENE			English	Article						apoptosis; BMP4; endothelial cell; I-Smads	BONE MORPHOGENETIC PROTEIN; VENOUS DIFFERENTIATION; MEDIATES APOPTOSIS; ANGIOGENESIS; EXPRESSION; VASCULOGENESIS; RECEPTORS; GENES; FLOW	Arterial endothelial cells (EC) at the adult stage differ from capillary and venous EC in terms of resistance to stress; however, the molecular basis of this resistance is not clear. Here, we found that arterial EC are highly resistant to bone morphogenetic protein (BMP) 4-dependent apoptosis, whereas capillary and venous EC are not. The expression of inhibitory Smads (I-Smads) in arterial EC was well correlated with the resistance to this apoptosis. After the knockdown of I-Smad expression by short interfering RNA, the resistant arterial EC became sensitive to BMP4. In contrast, the ectopic expression of I-Smads in BMP4-sensitive cells suppressed BMP4-induced apoptosis. Furthermore, intravenous administration of BMP4 into mice caused hemorrhage of capillary EC in brain and lung. These results strongly suggest that BMP4/ I-Smads are a novel regulator for the stability of vascular EC.	Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Shibuya, M (corresponding author), Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	shibuya@ims.u-tokyo.ac.jp						Bourdeau A, 2000, TRENDS CARDIOVAS MED, V10, P279, DOI 10.1016/S1050-1738(01)00062-7; Duff SE, 2003, FASEB J, V17, P984, DOI 10.1096/fj.02-0634rev; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; Gu K, 1996, ARCH ORAL BIOL, V41, P919, DOI 10.1016/S0003-9969(96)00052-0; Hanyu A, 2001, J CELL BIOL, V155, P1017, DOI 10.1083/jcb.200106023; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Herzog Y, 2001, MECH DEVELOP, V109, P115, DOI 10.1016/S0925-4773(01)00518-4; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; Kiyono M, 2003, MOL CELL BIOL, V23, P4627, DOI 10.1128/MCB.23.13.4627-4636.2003; le Noble F, 2004, DEVELOPMENT, V131, P361, DOI 10.1242/dev.00929; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Moyon D, 2001, DEVELOPMENT, V128, P3359; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Patan S, 2004, CANC TREAT, V117, P3; Shawber CJ, 2003, ANN NY ACAD SCI, V995, P162, DOI 10.1111/j.1749-6632.2003.tb03219.x; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; Shibuya M, 1999, CURR TOP MICROBIOL, V237, P59; Shin D, 2001, DEV BIOL, V230, P139, DOI 10.1006/dbio.2000.9957; Souchelnytskyi S, 1998, J BIOL CHEM, V273, P25364, DOI 10.1074/jbc.273.39.25364; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	25	22	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	54					7131	7137		10.1038/sj.onc.1209700	http://dx.doi.org/10.1038/sj.onc.1209700			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16732319				2022-12-25	WOS:000242046900002
J	Mulherkar, N; Ramaswamy, M; Mordi, DC; Prabhakar, BS				Mulherkar, N.; Ramaswamy, M.; Mordi, D. C.; Prabhakar, B. S.			MADD/DENN splice variant of the IG20 gene is necessary and sufficient for cancer cell survival	ONCOGENE			English	Article						IG20pa; MADD; DENN-SV; shRNA; alternative-splicing; apoptosis	GDP/GTP EXCHANGE PROTEIN; SMALL INTERFERING RNAS; DEATH DOMAIN PROTEIN; INDUCED APOPTOSIS; NEOPLASTIC-CELLS; MAMMALIAN-CELLS; DENN-SV; MADD; EXPRESSION; RECEPTOR	The IG20 gene is overexpressed in human tumors and cancer cell lines, and encodes at least four splice variants (SVs) namely, IG20pa, MADD, IG20-SV2 and DENNSV. Earlier, gain-of-function studies showed that IG20SVs can exhibit diverse functions and play a critical role in cell proliferation and apoptosis. Expression of exogenous IG20pa or DENN-SV rendered cells either susceptible or resistant to induced apoptosis, respectively, whereas MADD and IG20-SV2 had no apparent effect. In order to understand the contrasting effects of the IG20-SVs in a physiologically more relevant system, we expressed exon-specific small hairpin RNAs (shRNAs) to selectively knockdown specific IG20-SVs. Consistent with an earlier study, knockdown of all IG20-SVs resulted in spontaneous apoptosis of HeLa and PA-1 cells. In addition, we unambiguously demonstrated that knockdown of MADD can render cells susceptible to spontaneous apoptosis but had no discernible effect on cell proliferation, colony size or cell cycle progression. Moreover, expression of MADD alone, and not DENN-SV, in the absence of endogenous IG20-SVs was sufficient to prevent spontaneous apoptosis. Our results show the utility of shRNAs for selective knockdown of particular IG20-SVs and their potential therapeutic value in cancer. Further, they demonstrate that MADD alone is sufficient and necessary for cancer cell survival.	Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA; NIAMSD, NIH, Bethesda, MD 20892 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Prabhakar, BS (corresponding author), Univ Illinois, Coll Med, Dept Microbiol & Immunol, M-C 790,Room E-705,835 S Wolcott Ave, Chicago, IL 60612 USA.	bprabhak@uic.edu		Ramaswamy, Madhu/0000-0001-8870-5328	NATIONAL CANCER INSTITUTE [R01CA107506] Funding Source: NIH RePORTER; NCI NIH HHS [5R01CA107506] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Zoubi AM, 2001, J BIOL CHEM, V276, P47202, DOI 10.1074/jbc.M104835200; ANDREADIS A, 1987, ANNU REV CELL BIOL, V3, P207, DOI 10.1146/annurev.cellbio.3.1.207; Brinkman BMN, 1999, J BIOL CHEM, V274, P30882, DOI 10.1074/jbc.274.43.30882; Brown TL, 1998, CURR BIOL, V8, pR191; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chow VTK, 1998, GENOME, V41, P543, DOI 10.1139/gen-41-4-543; Chow VTK, 1996, DNA SEQUENCE, V6, P263, DOI 10.3109/10425179609020873; Cullen BR, 2004, VIRUS RES, V102, P3, DOI 10.1016/j.virusres.2004.01.009; CULLEN BR, 2005, GENE THER, V6, P503; Cunningham SJ, 1996, THESIS U TEXAS MED B; Del Villar K, 2004, P NATL ACAD SCI USA, V101, P4210, DOI 10.1073/pnas.0307349101; Efimova E, 2003, CANCER RES, V63, P8768; Efimova EV, 2004, ONCOGENE, V23, P1076, DOI 10.1038/sj.onc.1207210; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; GOTO Y, 1992, J BIOL CHEM, V267, P15252; Hall J, 2004, NAT REV GENET, V5, P552, DOI 10.1038/nrg1382; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Iwasaki K, 2000, EMBO J, V19, P4806, DOI 10.1093/emboj/19.17.4806; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Lee MTM, 2003, J VIROL, V77, P11964, DOI 10.1128/JVI.77.22.11964-11972.2003; Levivier E, 2001, BIOCHEM BIOPH RES CO, V287, P688, DOI 10.1006/bbrc.2001.5652; Lim KM, 2004, INT J CANCER, V109, P24, DOI 10.1002/ijc.11660; Lim KM, 2002, MOL CARCINOGEN, V35, P110, DOI 10.1002/mc.10082; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Murakami-Mori K, 1999, J IMMUNOL, V162, P3672; Ramaswamy M, 2004, ONCOGENE, V23, P6083, DOI 10.1038/sj.onc.1207804; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; Tanaka M, 2001, MOL BIOL CELL, V12, P1421, DOI 10.1091/mbc.12.5.1421; Telliez JB, 2000, BBA-PROTEIN STRUCT M, V1478, P280, DOI 10.1016/S0167-4838(00)00029-7; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; Yamaguchi K, 2002, P NATL ACAD SCI USA, V99, P14536, DOI 10.1073/pnas.212511399; Zhang Y, 1998, P NATL ACAD SCI USA, V95, P2586, DOI 10.1073/pnas.95.5.2586	35	27	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2006	25	47					6252	6261		10.1038/sj.onc.1209650	http://dx.doi.org/10.1038/sj.onc.1209650			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16682944				2022-12-25	WOS:000241218200003
J	Hossain, A; Nixon, M; Kuo, MT; Saunders, GF				Hossain, Anwar; Nixon, Molly; Kuo, Macus T.; Saunders, Grady F.			N-terminally truncated WT1 protein with oncogenic properties overexpressed in leukemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILMS-TUMOR GENE; MINIMAL RESIDUAL DISEASE; ACUTE MYELOID-LEUKEMIA; SUPPRESSOR WT1; EXPRESSION; ISOFORMS; QUANTIFICATION; CONTRIBUTES; TRANSCRIPTS; INHIBITION	WT1 was originally identified as an inactivated gene in Wilms tumor, a childhood kidney cancer. Alternative splicing of the WT1 transcript generates four major protein iso-forms, each having different functional properties. Here we characterized a short transcript originating from a second promoter located within intron 1 of WT1. This 2.3-kb sWT1 transcript encodes a protein of similar to 35-37 kDa that retains intact DNA-binding and transactivation domains but lacks the 147 amino acids at the N terminus required for transcriptional repression. We found sWT1 to be a more potent transcriptional activator than WT1 for cyclin E and insulin-like growth factor 1 receptor promoters, which are normally repressed by WT1. The expression patterns of the sWT1 and WT1 transcripts differed slightly in various organs; we found sWT1 protein in tissue samples from adult testis and fetal kidney, with low-level expression in adult kidney as well. The sWT1 transcript, but not the full-length transcript, was over-expressed in the leukemia samples tested. sWT1-specific small interfering RNA retarded the proliferation of leukemia cell line K562 in vitro. Finally, sWT1 cooperated with Ras in transforming primary fibroblasts in vitro. Further studies are needed to clarify the oncogenic behavior of this isoform and to determine the mechanism underlying its up-regulation in leukemia and other forms of cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Unit 951, Houston, TX 77054 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77054 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Hossain, A (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Unit 951, 7435 Fannin St, Houston, TX 77054 USA.	ahossain@mdanderson.org			NCI NIH HHS [CA34936, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA034936, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; Cilloni D, 2004, ACTA HAEMATOL-BASEL, V112, P79, DOI 10.1159/000077562; Dallosso AR, 2004, HUM MOL GENET, V13, P405, DOI 10.1093/hmg/ddh038; Dechsukhum C, 2000, MOL DIAGN, V5, P117, DOI 10.1016/S1084-8592(00)80029-6; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; Henderson RA, 2005, VACCINE, V23, P2359, DOI 10.1016/j.vaccine.2005.01.082; Hossain A, 2004, MOL ENDOCRINOL, V18, P1428, DOI 10.1210/me.2003-0176; Hossain A, 2003, BIOL REPROD, V69, P1808, DOI 10.1095/biolreprod.103.015826; Hossain A, 2001, J BIOL CHEM, V276, P16817, DOI 10.1074/jbc.M009056200; Hubinger G, 2001, EXP HEMATOL, V29, P1226, DOI 10.1016/S0301-472X(01)00719-6; INOUE K, 1994, BLOOD, V84, P3071, DOI 10.1182/blood.V84.9.3071.3071; Kennedy D, 1996, NAT GENET, V12, P329, DOI 10.1038/ng0396-329; Loeb DM, 2002, INT J HEMATOL, V76, P117, DOI 10.1007/BF02982573; Maheswaran S, 1998, GENE DEV, V12, P1108, DOI 10.1101/gad.12.8.1108; MENSSEN HD, 1995, LEUKEMIA, V9, P1060; MIWA H, 1992, LEUKEMIA, V6, P405; Miyamura T, 2004, INT J HEMATOL, V79, P243, DOI 10.1532/IJH97.03113; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Patmasiriwat P, 1996, LEUKEMIA, V10, P1127; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Rivera MN, 2005, NAT REV CANCER, V5, P699, DOI 10.1038/nrc1696; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; Wang WH, 2001, J BIOL CHEM, V276, P16810, DOI 10.1074/jbc.M009687200; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; Weisser M, 2005, LEUKEMIA, V19, P1416, DOI 10.1038/sj.leu.2403809; Wilhelm D, 2002, GENE DEV, V16, P1839, DOI 10.1101/gad.220102; Yamagami T, 1996, BLOOD, V87, P2878, DOI 10.1182/blood.V87.7.2878.bloodjournal8772878	34	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28122	28130		10.1074/jbc.M512391200	http://dx.doi.org/10.1074/jbc.M512391200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16698800	hybrid			2022-12-25	WOS:000240534400050
J	Sugii, S; Lin, S; Ohgami, N; Ohashi, M; Chang, CCY; Chang, TY				Sugii, Shigeki; Lin, Song; Ohgami, Nobutaka; Ohashi, Masato; Chang, Catherine C. Y.; Chang, Ta-Yuan			Roles of endogenously synthesized sterols in the endocytic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; COENZYME-A REDUCTASE; HAMSTER OVARY CELLS; PLASMA-MEMBRANE; CHOLESTEROL TRAFFICKING; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; GOLGI TRANSPORT; LATE ENDOSOMES; RAB GTPASES	The effect(s) of endogenously synthesized cholesterol (endo-CHOL) on the endosomal system in mammalian cells has not been examined. Here we treated Chinese hamster ovary cell lines with lovastatin (a hydroxymethylglutaryl-CoA reductase inhibitor) and mevalonate (a precursor for isoprenoids) to block endo-CHOL synthesis and then examined its effects on the fate of cholesterol liberated from low density lipoprotein (LDL-CHOL). The results showed that blocking endo-CHOL synthesis for 2 h or longer does not impair the hydrolysis of cholesteryl esters but partially impairs the transport of LDL-CHOL to the plasma membrane. Blocking endo-CHOL synthesis for 2 h or longer also alters the localization patterns of the late endosomes/lysosomes and retards their motility, as monitored by time-lapse microscopy. LDL-CHOL overcomes the effect of blocking endo-CHOL synthesis on endosomal localization patterns and on endosomal motility. Overexpressing Rab9, a key late endosomal small GTPase, relieves the endosomal cholesterol accumulation in Niemann-Pick type C1 cells but does not revert the reduced endosomal motility caused by blocking endo-CHOL synthesis. Our results suggested that endo-CHOL contributes to the cholesterol content of late endosomes and controls its motility, in a manner independent of NPC1. These results also supported the concept that endosomal motility plays an important role in controlling cholesterol trafficking activities.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Okazaki Inst Integrat Biosci, Natl Inst Nat Sci, Okazaki, Aichi 4448787, Japan	Dartmouth College; National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB)	Chang, TY (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA.	Ta.Yuan.Chang@dartmouth.edu	Ohgami, Nobutaka/I-4572-2014	Sugii, Shigeki/0000-0002-2537-9534; Chang, Ta-Yuan/0000-0002-3249-0468	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036709, R37HL036709] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36709] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; BLOCH K, 1992, STEROIDS, V57, P378, DOI 10.1016/0039-128X(92)90081-J; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; CADIGAN KM, 1988, J BIOL CHEM, V263, P274; Chang CCY, 2000, J BIOL CHEM, V275, P28083; Chang TY, 2005, J BIOL CHEM, V280, P20917, DOI 10.1074/jbc.R400040200; CHANG TY, 1980, J BIOL CHEM, V255, P7787; CHIN J, 1981, J BIOL CHEM, V256, P6304; Choudhury A, 2004, MOL BIOL CELL, V15, P4500, DOI 10.1091/mbc.E04-05-0432; Choudhury A, 2002, J CLIN INVEST, V109, P1541, DOI 10.1172/JCI200215420; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; Cruz JC, 2000, J BIOL CHEM, V275, P41309, DOI 10.1074/jbc.M008272200; Dietschy JM, 2004, J LIPID RES, V45, P1375, DOI 10.1194/jlr.R400004-JLR200; DIETSCHY JM, 1993, J LIPID RES, V34, P1637; Eskelinen EL, 2004, MOL BIOL CELL, V15, P3132, DOI 10.1091/mbc.E04-02-0103; FAUST JR, 1977, J BIOL CHEM, V252, P4861; Frolov A, 2001, J BIOL CHEM, V276, P46414, DOI 10.1074/jbc.M108099200; GIBBONS GF, 1982, BIOCH CHOLESTEROL; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Grimmer S, 2000, MOL BIOL CELL, V11, P4205, DOI 10.1091/mbc.11.12.4205; Hao MM, 2004, J BIOL CHEM, V279, P14171, DOI 10.1074/jbc.M309793200; Hao MM, 2002, J BIOL CHEM, V277, P609, DOI 10.1074/jbc.M108861200; HASAN MT, 1994, SOMAT CELL MOLEC GEN, V20, P183, DOI 10.1007/BF02254759; Heese-Peck A, 2002, MOL BIOL CELL, V13, P2664, DOI 10.1091/mbc.E02-04-0186; Heino S, 2000, P NATL ACAD SCI USA, V97, P8375, DOI 10.1073/pnas.140218797; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Klansek JJ, 1996, J BIOL CHEM, V271, P4923; Ko DC, 2003, P NATL ACAD SCI USA, V100, P2518, DOI 10.1073/pnas.0530027100; Kobayashi T, 2002, J BIOL CHEM, V277, P32157, DOI 10.1074/jbc.M202838200; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; Lebrand C, 2002, EMBO J, V21, P1289, DOI 10.1093/emboj/21.6.1289; Liscum L, 2000, TRAFFIC, V1, P218, DOI 10.1034/j.1600-0854.2000.010304.x; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1989, J BIOL CHEM, V264, P11796; Lougheed M, 1999, ARTERIOSCL THROM VAS, V19, P1881, DOI 10.1161/01.ATV.19.8.1881; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; Mayran N, 2003, EMBO J, V22, P3242, DOI 10.1093/emboj/cdg321; Miwako I, 2001, J CELL SCI, V114, P1765; Ohashi M, 2003, J BIOL CHEM, V278, P36819, DOI 10.1074/jbc.M301408200; Ohashi M, 1999, J CELL SCI, V112, P1125; Ohashi M, 2000, J CELL SCI, V113, P2187; Ohgami N, 2004, P NATL ACAD SCI USA, V101, P12473, DOI 10.1073/pnas.0405255101; Patterson M. C., 2001, METABOLIC MOL BASES, VIII, P3611; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Reid PC, 2003, J LIPID RES, V44, P1010, DOI 10.1194/jlr.M300009-JLR200; Seabra MC, 2004, TRAFFIC, V5, P393, DOI 10.1111/j.1398-9219.2004.00190.x; Shogomori H, 2001, J NEUROCHEM, V78, P991, DOI 10.1046/j.1471-4159.2001.00489.x; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; SPILLANE DM, 1995, BBA-LIPID LIPID MET, V1254, P283, DOI 10.1016/0005-2760(94)00190-A; Sugii S, 2003, J BIOL CHEM, V278, P27180, DOI 10.1074/jbc.M300542200; Sugii S, 2003, J LIPID RES, V44, P1033, DOI 10.1194/jlr.D200036-JLR200; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; URBANI L, 1990, J BIOL CHEM, V265, P1919; Walter M, 2003, J LIPID RES, V44, P243, DOI 10.1194/jlr.M200230-JLR200; Wojtanik KM, 2003, J BIOL CHEM, V278, P14850, DOI 10.1074/jbc.M300488200	58	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23191	23206		10.1074/jbc.M603215200	http://dx.doi.org/10.1074/jbc.M603215200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16737966	hybrid			2022-12-25	WOS:000239542600082
J	Bobay, BG; Mueller, GA; Thompson, RJ; Murzin, AG; Venters, RA; Strauch, MA; Cavanagh, J				Bobay, Benjamin G.; Mueller, Geoffrey A.; Thompson, Richele J.; Murzin, Alexey G.; Venters, Ronald A.; Strauch, Mark A.; Cavanagh, John			NMR structure of AbhN and comparison with AbrBN - First insights into the DNA binding promiscuity and specificity of AbrB-like transition state regulator proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE RESONANCE EXPERIMENTS; BACILLUS-SUBTILIS; GENE-EXPRESSION; CLOSTRIDIUM-ACETOBUTYLICUM; TRANSCRIPTIONAL ANALYSIS; SEQUENTIAL ASSIGNMENT; SPORULATION; RECOGNITION; ANTHRACIS; DOMAIN	Understanding the molecular mechanisms of transition state regulator proteins is critical, since they play a pivotal role in the ability of bacteria to cope with changing environments. Although much effort has focused on their genetic characterization, little is known about their structural and functional conservation. Here we present the high resolution NMR solution structure of the N-terminal domain of the Bacillus subtilis transition state regulator Abh (AbhN), only the second such structure to date. We then compare AbhN to the N-terminal DNA-binding domain of B. subtilis AbrB (AbrBN). This is the first such comparison between two AbrB-like transition state regulators. AbhN and AbrBN are very similar, suggesting a common structural basis for their DNA binding. However, we also note subtle variances between the AbhN and AbrBN structures, which may play important roles in DNA target specificity. The results of accompanying in vitro DNA-binding studies serve to highlight binding differences between the two proteins.	N Carolina State Univ, Dept Mol & Struct Biochem, Raleigh, NC 27695 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; MRC, Ctr Prot Engn, Cambridge CB2 2QH, England; Duke Univ, NMR Ctr, Durham, NC 27710 USA; Univ Maryland, Sch Dent, Dept Biomed Sci, Baltimore, MD 21201 USA	University of North Carolina; North Carolina State University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Cambridge; Duke University; University System of Maryland; University of Maryland Baltimore	Cavanagh, J (corresponding author), N Carolina State Univ, Dept Mol & Struct Biochem, Raleigh, NC 27695 USA.	john_cavanagh@ncsu.edu	Mueller, Geoffrey A/I-2909-2017; Bobay, Benjamin G/ABF-8860-2021	Mueller, Geoffrey A/0000-0001-8361-5323; Bobay, Benjamin/0000-0003-4775-3686; Venters, Ronald/0000-0001-6457-823X	Intramural NIH HHS [Z99 ES999999] Funding Source: Medline; Medical Research Council [MC_U105192716] Funding Source: Medline; NIGMS NIH HHS [R01 GM046700, GM46700, GM55769, R01 GM055769] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055769, R01GM046700] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alsaker KV, 2004, J BACTERIOL, V186, P1959, DOI 10.1128/JB.186.7.1959-1971.2004; Bagyan I, 1996, J BACTERIOL, V178, P4500, DOI 10.1128/jb.178.15.4500-4507.1996; Baillie L, 1998, J APPL MICROBIOL, V84, P741; Benson LM, 2002, ANAL BIOCHEM, V306, P222, DOI 10.1006/abio.2002.5704; Bobay BG, 2005, FEBS LETT, V579, P5669, DOI 10.1016/j.febslet.2005.09.045; Bobay BG, 2004, BIOCHEMISTRY-US, V43, P16106, DOI 10.1021/bi048399h; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Coles M, 2005, STRUCTURE, V13, P919, DOI 10.1016/j.str.2005.03.017; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Davis IW, 2004, NUCLEIC ACIDS RES, V32, pW615, DOI 10.1093/nar/gkh398; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DeLano W, 2002, PYMOL 0 99; Dong TC, 2004, FEMS MICROBIOL LETT, V233, P247, DOI 10.1016/j.femsle.2004.02.013; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; Driks A, 2002, CELL MOL LIFE SCI, V59, P389, DOI 10.1007/s00018-002-8430-x; DUBNAU D, 1994, RES MICROBIOL, V145, P403, DOI 10.1016/0923-2508(94)90088-4; DUBNAU EJ, 1987, J BACTERIOL, V169, P1182, DOI 10.1128/jb.169.3.1182-1191.1987; Fischer S.H., 2002, BACILLUS SUBTILIS IT, P181; Fujita M, 2005, J BACTERIOL, V187, P1357, DOI 10.1128/JB.187.4.1357-1368.2005; Furukawa S, 2005, INT J FOOD MICROBIOL, V102, P107, DOI 10.1016/j.ijfoodmicro.2004.12.004; Grandvalet C, 2001, MICROBIOL-SGM, V147, P1805, DOI 10.1099/00221287-147-7-1805; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Huang XJ, 1998, J MOL BIOL, V279, P165, DOI 10.1006/jmbi.1998.1765; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; Johnson Bruce A, 2004, Methods Mol Biol, V278, P313; Junius FK, 1996, J BIOL CHEM, V271, P13663, DOI 10.1074/jbc.271.23.13663; Koehler TM, 2002, CURR TOP MICROBIOL, V271, P143; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Lilley D. M. J., 1995, DNA PROTEIN STRUCTUR; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; LOGAN TM, 1993, J BIOMOL NMR, V3, P225; LOGAN TM, 1992, FEBS LETT, V314, P413, DOI 10.1016/0014-5793(92)81517-P; MAGILL NG, 1994, J BACTERIOL, V176, P2252, DOI 10.1128/JB.176.8.2252-2258.1994; MONTELIONE GT, 1992, BIOPOLYMERS, V32, P327, DOI 10.1002/bip.360320406; Nicholson WL, 2000, MICROBIOL MOL BIOL R, V64, P548, DOI 10.1128/MMBR.64.3.548-572.2000; Persuh M, 2002, J BACTERIOL, V184, P2310, DOI 10.1128/JB.184.8.2310-2313.2002; Phillips ZEV, 2002, CELL MOL LIFE SCI, V59, P392, DOI 10.1007/s00018-002-8431-9; Phillips ZEV, 2001, FEMS MICROBIOL LETT, V203, P207, DOI 10.1016/S0378-1097(01)00347-0; Rowbury Robin J., 2004, Science Progress, V87, P193, DOI 10.3184/003685004783238508; Saile E, 2002, J BACTERIOL, V184, P370, DOI 10.1128/JB.184.2.370-380.2002; SETLOW P, 1995, ANNU REV MICROBIOL, V49, P29, DOI 10.1146/annurev.mi.49.100195.000333; Shafikhani SH, 2003, CURR MICROBIOL, V47, P300, DOI 10.1007/s00284-002-4012-2; Shchepetov M, 1997, GENE, V184, P133, DOI 10.1016/S0378-1119(96)00603-8; Soriano M, 2005, CURR MICROBIOL, V50, P114, DOI 10.1007/s00284-004-4382-8; STRAUCH M, 1990, P NATL ACAD SCI USA, V87, P1801, DOI 10.1073/pnas.87.5.1801; STRAUCH MA, 1989, EMBO J, V8, P1615, DOI 10.1002/j.1460-2075.1989.tb03546.x; Strauch MA, 2005, MICROBIOL-SGM, V151, P1751, DOI 10.1099/mic.0.27803-0; STRAUCH MA, 1993, MOL MICROBIOL, V7, P337, DOI 10.1111/j.1365-2958.1993.tb01125.x; STRAUCH MA, 1995, J BACTERIOL, V177, P6999, DOI 10.1128/jb.177.23.6999-7002.1995; Strauch MA, 1996, MOL GEN GENET, V250, P742, DOI 10.1007/s004380050128; STRAUCH MA, 1995, J BACTERIOL, V177, P4532, DOI 10.1128/jb.177.15.4532-4536.1995; Suck Dietrich, 1994, Journal of Molecular Recognition, V7, P65, DOI 10.1002/jmr.300070203; Tomas CA, 2003, J BACTERIOL, V185, P4539, DOI 10.1128/JB.185.15.4539-4547.2003; Travers A., 1993, DNA PROTEIN INTERACT; Vary P, 1992, Biotechnology, V22, P251; Vaughn JL, 2000, NAT STRUCT BIOL, V7, P1139; Vaughn JL, 2005, NAT STRUCT MOL BIOL, V12, P380, DOI 10.1038/nsmb0405-380; Xu K, 1996, J BIOL CHEM, V271, P2621, DOI 10.1074/jbc.271.5.2621; Xu K, 1996, MOL MICROBIOL, V19, P145, DOI 10.1046/j.1365-2958.1996.358882.x; Xu K, 2001, J BACTERIOL, V183, P4094, DOI 10.1128/JB.183.13.4094-4098.2001; Yao F, 2005, J BACTERIOL, V187, P6354, DOI 10.1128/JB.187.18.6354-6362.2005	62	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21399	21409		10.1074/jbc.M601963200	http://dx.doi.org/10.1074/jbc.M601963200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16702211	hybrid, Green Accepted			2022-12-25	WOS:000239187300076
J	De Chiara, G; Marcocci, ME; Torcia, M; Lucibello, M; Rosini, P; Bonini, P; Higashimoto, Y; Damonte, G; Armirotti, A; Amodei, S; Palamara, AT; Russo, T; Garaci, E; Cozzolino, F				De Chiara, Giovanna; Marcocci, Maria Elena; Torcia, Maria; Lucibello, Maria; Rosini, Paolo; Bonini, Paolo; Higashimoto, Yukiro; Damonte, Gianluca; Armirotti, Andrea; Amodei, Sarah; Palamara, Anna Teresa; Russo, Tommaso; Garaci, Enrico; Cozzolino, Federico			Bcl-2 phosphorylation by p38 MAPK - Identification of target sites and biologic consequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; B-CELL LINE; INDUCED APOPTOSIS; CARDIAC MYOCYTES; C-JUN; POLYACRYLAMIDE-GELS; FAMILY PROTEINS; DNA-DAMAGE; DEATH; BCL-X(L)	The antiapoptotic role of Bcl-2 can be regulated by its phosphorylation in serine and threonine residues located in a nonstructured loop that links BH3 and BH4 domains. p38 MAPK has been identified as one of the kinases able to mediate such phosphorylation, through direct interaction with Bcl-2 protein in the mitochondrial compartment. In this study, we identify, by using mass spectrometry techniques and specific anti-phosphopeptide antibodies, Ser(87) and Thr(56) as the Bcl-2 residues phosphorylated by p38 MAPK and show that phosphorylation of these residues is always associated with a decrease in the antiapoptotic potential of Bcl-2 protein. Furthermore, we obtained evidence that p38 MAPK-induced Bcl-2 phosphorylation plays a key role in the early events following serum deprivation in embryonic fibroblasts. Both cytochrome c release and caspase activation triggered by p38 MAPK activation and Bcl-2 phosphorylation are absent in embryonic fibroblasts from p38 alpha knock-out mice (p38 alpha(-/-) MEF), whereas they occur within 12 h of serum withdrawal in p38 alpha(-/-) MEF; moreover, they can be prevented by p38 MAPK inhibitors and are not associated with the synthesis of the proapoptotic proteins Bax and Fas. Thus, Bcl-2 phosphorylation by activated p38 MAPK is a key event in the early induction of apoptosis under conditions of cellular stress.	Ist Super Sanita, Dept Cell Biol & Neurosci, I-00161 Rome, Italy; Univ Roma Tor Vergata, Dipartimento Matemat, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; Univ Florence, Dept Clin Physiopathol, I-50139 Florence, Italy; CNR, Inst Neurobiol & Mol Med, I-00133 Rome, Italy; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Genoa, Ctr Excellence Biomed Res, Mass Spectrometry Facil, DIMES Biochem Sect, I-16132 Genoa, Italy; Univ Roma La Sapienza, Dept Publ Hlth Sci G Sanarelli, I-00185 Rome, Italy; Univ Naples Federico II, CEINGE Biotecnol Avanzate, Dept Biochem & Med Biotechnol, I-80131 Naples, Italy	Istituto Superiore di Sanita (ISS); University of Rome Tor Vergata; University of Florence; Consiglio Nazionale delle Ricerche (CNR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Genoa; Sapienza University Rome; CEINGE Biotecnologie Avanzate; University of Naples Federico II	De Chiara, G (corresponding author), Ist Super Sanita, Dept Cell Biol & Neurosci, Viale Regina Elena 299, I-00161 Rome, Italy.	dechiara@uniroma2.it; f.cozzolino@dfc.unifi.it	Elena, Marcocci Maria/I-9550-2014; GARACI, ENRICO/AAB-3349-2021; De Chiara, Giovanna/AAJ-7843-2021; lucibello, maria/AAI-1417-2020; Torcia, Maria Gabriella G/K-1840-2018; Armirotti, Andrea/AAB-3284-2019; Russo, Tommaso/K-1331-2016	Elena, Marcocci Maria/0000-0003-4751-4263; De Chiara, Giovanna/0000-0002-2219-6097; Torcia, Maria Gabriella G/0000-0003-4740-4646; Russo, Tommaso/0000-0003-4426-0106; PALAMARA, ANNA TERESA/0000-0001-8330-4381; Armirotti, Andrea/0000-0002-3766-8755; Cozzolino, Federico/0000-0002-2800-640X				Basu A, 2002, INT J ONCOL, V21, P597; Blagosklonny MV, 2001, LEUKEMIA, V15, P869, DOI 10.1038/sj.leu.2402134; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Breckenridge DG, 2004, CURR OPIN CELL BIOL, V16, P647, DOI 10.1016/j.ceb.2004.09.009; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Furukawa Y, 2000, J BIOL CHEM, V275, P21661, DOI 10.1074/jbc.M906893199; Grethe S, 2004, EXP CELL RES, V298, P632, DOI 10.1016/j.yexcr.2004.05.007; Haldar S, 1996, CANCER RES, V56, P1253; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Ishikawa Y, 2003, MOL CELL NEUROSCI, V24, P451, DOI 10.1016/S1044-7431(03)00203-3; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Kaiser RA, 2004, J BIOL CHEM, V279, P15524, DOI 10.1074/jbc.M313717200; Kang YJ, 2000, J BIOL CHEM, V275, P13690, DOI 10.1074/jbc.275.18.13690; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lee JC, 1999, PHARMACOL THERAPEUT, V82, P389, DOI 10.1016/S0163-7258(99)00008-X; Mackay K, 2000, J MOL CELL CARDIOL, V32, P1585, DOI 10.1006/jmcc.2000.1194; Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272; Marzo I, 1998, BIOMED PHARMACOTHER, V52, P248, DOI 10.1016/S0753-3322(98)80009-7; Mathura VS, 2003, J MOL MODEL, V9, P298, DOI 10.1007/s00894-003-0152-y; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; PANDEY S, 1995, J CELL BIOCHEM, V58, P135, DOI 10.1002/jcb.240580203; Porras A, 2004, MOL BIOL CELL, V15, P922, DOI 10.1091/mbc.E03-08-0592; Reed JC, 1996, LEUKEMIA RES, V20, P109, DOI 10.1016/0145-2126(95)00135-2; Rosini P, 2000, BIOCHEM BIOPH RES CO, V278, P753, DOI 10.1006/bbrc.2000.3871; Rosini P, 2004, J BIOL CHEM, V279, P14016, DOI 10.1074/jbc.M305356200; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Sharov VG, 2003, EUR J HEART FAIL, V5, P121, DOI 10.1016/S1388-9842(02)00254-4; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1; Torcia M, 2001, J BIOL CHEM, V276, P39027, DOI 10.1074/jbc.M102970200; Ueno H, 2000, MOL BIOL CELL, V11, P735, DOI 10.1091/mbc.11.2.735; Vantieghem A, 2002, J BIOL CHEM, V277, P37718, DOI 10.1074/jbc.M204348200; Wakabayashi T, 2002, J CELL MOL MED, V6, P497, DOI 10.1111/j.1582-4934.2002.tb00452.x; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zhu WD, 1999, CIRCULATION, V100, P2100, DOI 10.1161/01.CIR.100.20.2100; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	44	161	163	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21353	21361		10.1074/jbc.M511052200	http://dx.doi.org/10.1074/jbc.M511052200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16714293	hybrid			2022-12-25	WOS:000239187300071
J	Ma, KW; Zheng, SQ; Zuo, ZY				Ma, Kaiwen; Zheng, Shuqiu; Zuo, Zhiyi			The transcription factor regulatory factor X1 increases the expression of neuronal glutamate transporter type 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; RFX PROTEINS; ACTIVATION; PROMOTER; SUBTYPE; FAMILY; DOMAIN	Glutamate transporters (excitatory amino acid transporters, EAAT) play an important role in maintaining extracellular glutamate homeostasis and regulating glutamate neurotransmission. However, very few studies have investigated the regulation of EAAT expression. A binding sequence for the regulatory factor X1 (RFX1) exists in the promoter region of the gene encoding for EAAT3, a neuronal EAAT, but not in the promoter regions of the genes encoding for EAAT1 and EAAT2, two glial EAATs. RFX proteins are transcription factors binding to X-boxes of DNA sequences. Although RFX proteins are necessary for the normal function of sensory neurons in Caenorhabditis elegans, their roles in the mammalian brain are not known. We showed that RFX1 increased EAAT3 expression and activity in C6 glioma cells. RFX1 binding complexes were found in the nuclear extracts of C6 cells. The activity of EAAT3 promoter as measured by luciferase reporter activity was increased by RFX1 in C6 cells and the neuron-like SH-SY5Y cells. However, RFX1 did not change the expression of EAAT2 proteins in the NRK52E cells. RFX1 proteins were expressed in the neurons of rat brain. A high expression level of RFX1 proteins was found in the neurons of cerebral cortex and Purkinje cells. Knockdown of the RFX1 expression by RFX1 antisense oligonucleotides decreased EAAT3 expression in rat cortical neurons in culture. These results suggest that RFX1 enhances the activity of EAAT3 promoter to increase the expression of EAAT3 proteins. This study provides initial evidence for the regulation of gene expression in the nervous cells by RFX1.	Univ Virginia, Dept Anesthesiol & Neurosci, Charlottesville, VA 22908 USA	University of Virginia	Zuo, ZY (corresponding author), Univ Virginia Hlth Syst, Dept Anesthesiol, POB 800710, Charlottesville, VA 22908 USA.	zz3c@virginia.edu	Zuo, Zhiyi/F-3950-2010	Zuo, Zhiyi/0000-0002-3542-5047	NIGMS NIH HHS [R01 GM065211] Funding Source: Medline; NINDS NIH HHS [R01 NS045983] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065211] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045983] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARBOUR B, 1994, NEURON, V12, P1331, DOI 10.1016/0896-6273(94)90448-0; Billups B, 1998, PROG BRAIN RES, V116, P45, DOI 10.1016/S0079-6123(08)60429-X; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Davis KE, 1998, J NEUROSCI, V18, P2475; Diamond JS, 1997, J NEUROSCI, V17, P4672; Emery P, 1996, MOL CELL BIOL, V16, P4486; Emery P, 1996, NUCLEIC ACIDS RES, V24, P803, DOI 10.1093/nar/24.5.803; Huang YM, 2005, MOL PHARMACOL, V67, P1522, DOI 10.1124/mol.104.007443; Huang YM, 2003, ANESTHESIOLOGY, V99, P1346, DOI 10.1097/00000542-200312000-00016; Iwama A, 1999, MOL CELL BIOL, V19, P3940; Liu MS, 1999, J BIOL CHEM, V274, P15433, DOI 10.1074/jbc.274.22.15433; Ma KW, 2003, MOL CANCER RES, V1, P438; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; Nakayama A, 2003, J BIOL CHEM, V278, P233, DOI 10.1074/jbc.M209574200; Paillart C, 2003, J NEUROSCI, V23, P4092; REITH W, 1989, P NATL ACAD SCI USA, V86, P4200, DOI 10.1073/pnas.86.11.4200; Sepkuty JP, 2002, J NEUROSCI, V22, P6372; SIEGRIST CA, 1993, EUR J IMMUNOL, V23, P2903, DOI 10.1002/eji.1830231126; SIEGRIST CA, 1993, MOL CELL BIOL, V13, P6375, DOI 10.1128/MCB.13.10.6375; Sims KD, 2000, J BIOL CHEM, V275, P5228, DOI 10.1074/jbc.275.7.5228; Zheng SQ, 2004, MOL PHARMACOL, V65, P1172, DOI 10.1124/mol.65.5.1172; Zuo Z, 1999, NEUROSCIENCE, V93, P1167, DOI 10.1016/S0306-4522(99)00194-3	22	48	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21250	21255		10.1074/jbc.M600521200	http://dx.doi.org/10.1074/jbc.M600521200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16723357	hybrid			2022-12-25	WOS:000239187300060
J	Wang, ZY; Aris, VM; Ogburn, KD; Soteropoulos, P; Figueiredo-Pereira, ME				Wang, Zhiyou; Aris, Virginie M.; Ogburn, Kenyon D.; Soteropoulos, Patricia; Figueiredo-Pereira, Maria E.			Prostaglandin J2 alters pro-survival and pro-death gene expression patterns and 26 S proteasome assembly in human neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECAY-ACCELERATING FACTOR; NF-KAPPA-B; CYCLOPENTENONE PROSTAGLANDINS; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); CYCLOOXYGENASE-2 EXPRESSION; INDUCIBLE CYCLOOXYGENASE; ENDOGENOUS ELECTROPHILE; MULTIPLE STEPS; INFLAMMATION; SYSTEM	Many neurodegenerative disorders are characterized by two pathological hallmarks: progressive loss of neurons and occurrence of inclusion bodies containing ubiquitinated proteins. Inflammation may be critical to neurodegeneration associated with ubiquitin-protein aggregates. We previously showed that prostaglandin J2 ( PGJ2), one of the endogenous products of inflammation, induces neuronal death and the accumulation of ubiquitinated proteins into distinct aggregates. We now report that temporal microarray analysis of human neuroblastoma SK-N-SH revealed that PGJ2 triggered a "repair" response including increased expression of heat shock, protein folding, stress response, detoxification and cysteine metabolism genes. PGJ2 also decreased expression of cell growth/maintenance genes and increased expression of apoptotic genes. Over time pro-death responses prevailed over pro-survival responses, leading to cellular demise. Furthermore, PGJ2 increased the expression of proteasome and other ubiquitin-proteasome pathway genes. This increase failed to overcome PGJ2 inhibition of 26 S proteasome activity. Ubiquitinated proteins are degraded by the 26 S proteasome, shown here to be the most active proteasomal form in SK-N-SH cells. We demonstrate that PGJ2 impairs 26 S proteasome assembly, which is an ATP-dependent process. PGJ2 perturbs mitochondrial function, which could be critical to the observed 26 S proteasome disassembly, suggesting a cross-talk between mitochondrial and proteasomal impairment. In conclusion neurotoxic products of inflammation, such as PGJ2, may play a role in neurodegenerative disorders associated with the aggregation of ubiquitinated proteins by impairing 26 S proteasome activity and inducing a chain of events that culminates in neuronal cell death. Temporal characterization of these events is relevant to understanding the underlying mechanisms and to identifying potential early biomarkers.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA; Publ Hlth Res Inst, Ctr Appl Genom, Newark, NJ 07103 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Figueiredo-Pereira, ME (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Park Ave, New York, NY 10021 USA.	pereira@genectr.hunter.cuny.edu			NCRR NIH HHS [RR03037] Funding Source: Medline; NIGMS NIH HHS [GM060665] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM060665] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Babbitt SE, 2005, CELL, V121, P553, DOI 10.1016/j.cell.2005.03.028; Bajorek M, 2003, CURR BIOL, V13, P1140, DOI 10.1016/S0960-9822(03)00417-2; BERGER M, 1987, J CLIN INVEST, V79, P214, DOI 10.1172/JCI112786; BIEDLER JL, 1978, CANCER RES, V38, P3751; Djordjevic VB, 2004, INT REV CYTOL, V237, P57, DOI 10.1016/S0074-7696(04)37002-6; Eucker J, 2004, ANTI-CANCER DRUG, V15, P955, DOI 10.1097/00001813-200411000-00004; Exner M, 2004, FREE RADICAL BIO MED, V37, P1097, DOI 10.1016/j.freeradbiomed.2004.07.008; Figueiredo-Pereira ME, 1998, J BIOL CHEM, V273, P12703, DOI 10.1074/jbc.273.21.12703; FUKUSHIMA M, 1990, EICOSANOIDS, V3, P189; Gao HM, 2003, TRENDS PHARMACOL SCI, V24, P395, DOI 10.1016/S0165-6147(03)00176-7; Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Giri S, 2004, J IMMUNOL, V173, P5196, DOI 10.4049/jimmunol.173.8.5196; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Herschman HR, 1997, ADV EXP MED BIOL, V407, P61; Ho L, 1999, J NEUROSCI RES, V57, P295; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Ishii T, 2005, BIOCHEMISTRY-US, V44, P13893, DOI 10.1021/bi051336u; Kondo M, 2002, P NATL ACAD SCI USA, V99, P7367, DOI 10.1073/pnas.112212599; Kondo M, 2001, J BIOL CHEM, V276, P12076, DOI 10.1074/jbc.M009630200; Kulkarni SK, 2000, METHOD FIND EXP CLIN, V22, P291, DOI 10.1358/mf.2000.22.5.796648; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; Li ZM, 2004, J NEUROSCI RES, V78, P824, DOI 10.1002/jnr.20346; Li ZM, 2004, BIOCHEM BIOPH RES CO, V319, P1171, DOI 10.1016/j.bbrc.2004.05.098; Liang XB, 2005, J NEUROCHEM, V92, P477, DOI 10.1111/j.1471-4159.2004.02870.x; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; Martinez B, 2005, J LIPID RES, V46, P736, DOI 10.1194/jlr.M400392-JLR200; MATTAMMAL MB, 1995, J NEUROCHEM, V64, P1645; McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007; Minghetti L, 2004, J NEUROPATH EXP NEUR, V63, P901, DOI 10.1093/jnen/63.9.901; Monneret G, 2002, J IMMUNOL, V168, P3563, DOI 10.4049/jimmunol.168.7.3563; Mrak RE, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-5; Mullally JE, 2001, J BIOL CHEM, V276, P30366, DOI 10.1074/jbc.M102198200; Musiek ES, 2005, BRAIN PATHOL, V15, P149; Nosjean O, 2002, CELL SIGNAL, V14, P573, DOI 10.1016/S0898-6568(01)00281-9; OFFENBACHER S, 1986, J PERIODONTAL RES, V21, P101, DOI 10.1111/j.1600-0765.1986.tb01443.x; Pasinetti GM, 1998, NEUROSCIENCE, V87, P319, DOI 10.1016/S0306-4522(98)00218-8; Pignatelli M, 2005, CARCINOGENESIS, V26, P81, DOI 10.1093/carcin/bgh308; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Scher JU, 2005, CLIN IMMUNOL, V114, P100, DOI 10.1016/j.clim.2004.09.008; Shibata T, 2003, BIOCHEMISTRY-US, V42, P13960, DOI 10.1021/bi035215a; Shibata T, 2002, J BIOL CHEM, V277, P10459, DOI 10.1074/jbc.M110314200; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Soberman RJ, 2003, J CLIN INVEST, V111, P1107, DOI 10.1172/JCI200318338; Stamatakis K, 2006, J AM SOC NEPHROL, V17, P89, DOI 10.1681/ASN.2005030329; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006.abs; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Teismann P, 2003, P NATL ACAD SCI USA, V100, P5473, DOI 10.1073/pnas.0837397100; Urade Y, 2000, VITAM HORM, V58, P89, DOI 10.1016/S0083-6729(00)58022-4; van Beek J, 2005, J IMMUNOL, V174, P2353, DOI 10.4049/jimmunol.174.4.2353; Viviani B, 2004, TOXICOL LETT, V149, P85, DOI 10.1016/j.toxlet.2003.12.022; Wang ZY, 2005, MOL CELL NEUROSCI, V29, P222, DOI 10.1016/j.mcn.2005.02.011; WIBORG O, 1985, EMBO J, V4, P755, DOI 10.1002/j.1460-2075.1985.tb03693.x; Wilmer WA, 2001, BIOCHEM BIOPH RES CO, V281, P57, DOI 10.1006/bbrc.2001.4301; Wu KK, 2005, PROSTAG LEUKOTR ESS, V72, P89, DOI 10.1016/j.plefa.2004.11.001; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Yasojima K, 2001, NEUROLOGY, V57, P952, DOI 10.1212/WNL.57.6.952	60	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21377	21386		10.1074/jbc.M601201200	http://dx.doi.org/10.1074/jbc.M601201200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16737963	hybrid			2022-12-25	WOS:000239187300074
J	Faour, WH; He, QW; Mancini, A; Jovanovic, D; Antoniou, J; Di Battista, JA				Faour, Wissam H.; He, QingWen; Mancini, Arturo; Jovanovic, Dragan; Antoniou, John; Di Battista, John A.			Prostaglandin E-2 stimulates p53 transactivational activity through specific serine 15 phosphorylation in human synovial fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CYCLOOXYGENASE-2 GENE-EXPRESSION; NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATION; MESSENGER-RNA; ARTHRITIS; RECRUITMENT; APOPTOSIS; ENHANCEMENT; STABILITY	Cyclooxygenase-2 (COX-2) overexpression has been linked to cell survival, transformation, and hyperproliferation. We examined the regulation of the tumor suppressor gene p53 and p53 target genes by prostaglandin E-2 (PGE(2)) in human synovial fibroblasts (HSF). PGE(2) induced a time-dependent increase in p53 Ser(15) phosphorylation, with no discernible change in overall p53 levels. PGE2 dependent Ser(15) phosphorylation was apparently mediated by activated p38 MAP kinase as SB202190, a p38 kinase inhibitor, blocked the response. Overexpression of a MKK3 construct, but not MKK1, stimulated SB202190-sensitive p53 Ser15 phosphorylation. PGE2-stimulated [phospho-Ser(15)] p53 transactivated a p53 response element(GADD45)-luciferase reporter in transiently transfected HSF (SN7); the effect was compromised by overexpression of a dominant-negative mutant (dnm) of p53 or excess p53S15A expression plasmid but mimicked by a constitutively active p53S15E expression construct. PGE2, wtp53 expression in the presence of PGE2, and p53S15E suppressed steady-state levels of MEKK1-induced MMP-1 mRNA, effects nullified with co-transfection of p53 dnm or p53S15A. MEKK1-induced MMP-1 promoter-driven luciferase activity was largely dependent on a c/EBP beta-NF-kappa B-like enhancer site at - 2008 to - 1972 bp, as judged by deletion and point mutation analyses. PGE2, overexpression of p53wt with PGE2, or p53S15E abolished the MEKK1-induced MMP-1 promoter luciferase activity. Gel-shift/super gel-shift analyses identified c/EBP beta dimers and c/EBP beta/NF-kappa B p65 heterodimers as binding species at the apparent site of MEKK1-dependent transactivation. PGE2-stimulated [phospho-Ser15] p53 abrogated the DNA binding of c/EBP beta dimers and c/EBP beta/NF-kappa B p65 heterodimers. Our data suggest that COX-2 prostaglandins may be implicated in p53 function and p53 target gene expression.	McGill Univ, Royal Victoria Hosp, Ctr Hlth, Div Rheumatol, Montreal, PQ H3A 1A1, Canada; Univ Ottawa, Ottawa Hlth Res Inst, Ottawa, ON K1H 8M5, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 1A1, Canada; Jewish Gen Hosp, Dept Orthopaed Surg, Montreal, PQ H3T 1E2, Canada	McGill University; Royal Victoria Hospital; University of Ottawa; Ottawa Hospital Research Institute; McGill University; McGill University; McGill University	Di Battista, JA (corresponding author), McGill Univ, Royal Victoria Hosp, Ctr Hlth, Div Rheumatol & Clin Immunol, 687 Pine Ave W,Rm M11-22, Montreal, PQ H3A 1A1, Canada.	john.dibattista@mcgill.ca	faour, wissam/J-3419-2019	faour, wissam/0000-0002-0746-3687				AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Di Battista JA, 1999, ARTHRITIS RHEUM, V42, P157, DOI 10.1002/1529-0131(199901)42:1<157::AID-ANR19>3.0.CO;2-P; DIBATTISTA JA, 1995, J RHEUMATOL, V22, P123; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Faour WH, 2005, J BIOL CHEM, V280, P9536, DOI 10.1074/jbc.M414067200; Faour WH, 2003, J BIOL CHEM, V278, P26897, DOI 10.1074/jbc.M212790200; Faour WH, 2001, J BIOL CHEM, V276, P31720, DOI 10.1074/jbc.M104036200; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661; Firestein GS, 1996, AM J PATHOL, V149, P2143; Firestein GS, 1997, P NATL ACAD SCI USA, V94, P10895, DOI 10.1073/pnas.94.20.10895; Fosslien E, 2000, ANN CLIN LAB SCI, V30, P3; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Hakem R, 2001, ANNU REV GENET, V35, P209, DOI 10.1146/annurev.genet.35.102401.090432; HE QW, 2001, OSTEOARTHRITIS CAR B, V9, pS9; HE QW, 2004, INFLAMM RES, V53, pS228; He W, 2002, J RHEUMATOL, V29, P546; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; Mancini A, 2006, FRONT BIOSCI-LANDMRK, V11, P423, DOI 10.2741/1809; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MORIN N, 1999, OSTEOARTHR CARTILAGE, V7, pS21; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Parant JM, 2003, HUM MUTAT, V21, P321, DOI 10.1002/humu.10186; Rutter JL, 1997, J CELL BIOCHEM, V66, P322, DOI 10.1002/(SICI)1097-4644(19970901)66:3<322::AID-JCB5>3.3.CO;2-D; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Sun Y, 2002, SEMIN ARTHRITIS RHEU, V31, P299, DOI 10.1053/sarh.2002.31550; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Vincenti MP, 2001, J CLIN INVEST, V108, P181; Vincenti MP, 2002, ARTHRITIS RES, V4, P157, DOI 10.1186/ar401; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zagariya A, 1998, MOL CELL BIOL, V18, P2815, DOI 10.1128/MCB.18.5.2815; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	46	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					19849	19860		10.1074/jbc.M601293200	http://dx.doi.org/10.1074/jbc.M601293200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16714289	hybrid			2022-12-25	WOS:000239038200008
J	Nakanishi, H; Shindou, H; Hishikawa, D; Harayama, T; Ogasawara, R; Suwabe, A; Taguchi, R; Shimizu, T				Nakanishi, Hiroki; Shindou, Hideo; Hishikawa, Daisuke; Harayama, Takeshi; Ogasawara, Rie; Suwabe, Akira; Taguchi, Ryo; Shimizu, Takao			Cloning and characterization of mouse lung-type acyl-CoA: Lysophosphatidylcholine acyltransferase 1 (LPCAT1) - Expression in alveolar type II cells and possible involvement in surfactant production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID ACYLTRANSFERASE; COENZYME-A; CDNA CLONING; GENE; IDENTIFICATION; METABOLISM; PHOSPHATIDYLCHOLINE; GLYCEROLIPIDS; SEQUENCE; LIPIDS	Phosphatidylcholine (1,2-diacyl-sn-glycero-3-phosphocholine, PC), is an important constituent of biological membranes. It is also the major component of serum lipoproteins and pulmonary surfactant. In the remodeling pathway of PC biosynthesis, 1-acyl-sn-glycero-3- phosphocholine (LPC) is converted to PC by acyl-CoA:lyso-phosphatidylcholine acyltransferase (LPCAT, EC 2.3.1.23). Whereas LPCAT activity has been detected in several tissues, the structure and detailed biochemical information on the enzyme have not yet been reported. Here, we present the cloning and characterization of a cDNA for mouse lung-type LPCAT (LPCAT1). The cDNA encodes an enzyme of 60kDa, with three putative transmembrane domains. When expressed in Chinese hamster ovary cells, mouse LPCAT1 exhibited Ca2(+)-independent activity with a pH optimum between 7.4 and 10. LPCAT1 demonstrated a clear preference for saturated fatty acyl-CoAs, and 1-myristoyl- or 1-palmitoyl-LPC as acyl donors and acceptors, respectively. Furthermore, the enzyme was predominantly expressed in the lung, in particular in alveolar type II cells. Thus, the enzyme might synthesize phosphatidylcholine in pulmonary surfactant and play a pivotal role in respiratory physiology.	Univ Tokyo, Fac Med, Dept Metabolome, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan; Iwate Med Univ, Sch Med, Dept Lab Med, Morioka, Iwate 0208505, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3328613, Japan	University of Tokyo; University of Tokyo; Iwate Medical University; Japan Science & Technology Agency (JST)	Shimizu, T (corresponding author), Univ Tokyo, Fac Med, Dept Metabolome, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	tshimizu@m.u-tokyo.ac.jp	Harayama, Takeshi/AAD-8852-2022; Shimizu, Takao/AAV-7052-2021	Harayama, Takeshi/0000-0003-2255-4197; Nakanishi, Hiroki/0000-0002-5108-1598				Aguado B, 1997, BIOCHEM SOC T, V25, pS597, DOI 10.1042/bst025s597; Aguado B, 1998, J BIOL CHEM, V273, P4096, DOI 10.1074/jbc.273.7.4096; Balakireva L, 2003, J VIROL, V77, P4858, DOI 10.1128/JVI.77.8.4858-4866.2003; Barth PG, 1999, J INHERIT METAB DIS, V22, P555, DOI 10.1023/A:1005568609936; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cao JS, 2004, J BIOL CHEM, V279, P31727, DOI 10.1074/jbc.M402930200; COLEMAN J, 1992, MOL GEN GENET, V232, P295, DOI 10.1007/BF00280009; DENBREEJEN JN, 1989, BIOCHIM BIOPHYS ACTA, V1002, P277, DOI 10.1016/0005-2760(89)90341-X; DEVRIES ACJ, 1985, BIOCHIM BIOPHYS ACTA, V833, P93, DOI 10.1016/0005-2760(85)90256-5; Dircks L, 1999, PROG LIPID RES, V38, P461, DOI 10.1016/S0163-7827(99)00012-0; DOBBS LG, 1979, J CLIN INVEST, V63, P378, DOI 10.1172/JCI109313; Eberhardt C, 1997, J BIOL CHEM, V272, P20299, DOI 10.1074/jbc.272.32.20299; Floros J, 1998, ANNU REV PHYSIOL, V60, P365, DOI 10.1146/annurev.physiol.60.1.365; FUNKHOUSER JD, 1981, BIOCHIM BIOPHYS ACTA, V666, P1, DOI 10.1016/0005-2760(81)90084-9; GREEN PR, 1983, J BIOL CHEM, V258, P862; Halliday HL, 2005, BIOL NEONATE, V87, P26, DOI 10.1159/000080949; KENNEDY EP, 1961, FED PROC, V20, P934; Kume K, 1997, BIOCHEM BIOPH RES CO, V237, P663, DOI 10.1006/bbrc.1997.7214; LANDS WEM, 1960, J BIOL CHEM, V235, P2233; LANDS WEM, 1963, J BIOL CHEM, V238, P898; Lewin TM, 2004, J BIOL CHEM, V279, P13488, DOI 10.1074/jbc.M314032200; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; LEWIS JF, 1993, AM REV RESPIR DIS, V147, P218, DOI 10.1164/ajrccm/147.1.218; Li D, 2003, J HUM GENET, V48, P438, DOI 10.1007/s10038-003-0045-z; LIGHTNER VA, 1983, J BIOL CHEM, V258, P856; Lu B, 2005, BIOCHEM J, V385, P469, DOI 10.1042/BJ20041348; Maki M, 2002, BBA-PROTEINS PROTEOM, V1600, P51, DOI 10.1016/S1570-9639(02)00444-2; MASON RJ, 1980, J BIOL CHEM, V255, P5101; MERKL I, 1963, J BIOL CHEM, V238, P905; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OKUYAMA H, 1983, ARCH BIOCHEM BIOPHYS, V221, P99, DOI 10.1016/0003-9861(83)90125-X; Shikano S, 2003, P NATL ACAD SCI USA, V100, P5783, DOI 10.1073/pnas.1031748100; SHIN DH, 1991, J BIOL CHEM, V266, P23834; Stamps AC, 1997, BIOCHEM J, V326, P455, DOI 10.1042/bj3260455; SUWABE A, 1992, J BIOL CHEM, V267, P19884; Testet E, 2005, BIOCHEM J, V387, P617, DOI 10.1042/BJ20041491; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; VANHEUSDEN GPH, 1981, BIOCHIM BIOPHYS ACTA, V666, P508, DOI 10.1016/0005-2760(81)90313-1; VANHEUSDEN GPH, 1980, J BIOL CHEM, V255, P9312; Veldhuizen R, 1998, BBA-MOL BASIS DIS, V1408, P90, DOI 10.1016/S0925-4439(98)00061-1; West J, 1997, DNA CELL BIOL, V16, P691, DOI 10.1089/dna.1997.16.691; YAMADA K, 1979, ARCH BIOCHEM BIOPHYS, V196, P209, DOI 10.1016/0003-9861(79)90568-X; Yamashita A, 2001, J BIOL CHEM, V276, P26745, DOI 10.1074/jbc.M101795200; Yamashita A, 1997, J BIOCHEM-TOKYO, V122, P1; Yang YZ, 2004, J BIOL CHEM, V279, P55866, DOI 10.1074/jbc.M406710200; Ye GM, 2005, DNA SEQUENCE, V16, P386, DOI 10.1080/10425170500213712; YET SF, 1993, BIOCHEMISTRY-US, V32, P9486, DOI 10.1021/bi00087a029; Yu SH, 2003, J LIPID RES, V44, P621, DOI 10.1194/jlr.M200380-JLR200	50	174	184	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20140	20147		10.1074/jbc.M600225200	http://dx.doi.org/10.1074/jbc.M600225200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16704971	hybrid			2022-12-25	WOS:000239038200038
J	Ohmae, S; Takemoto-Kimura, S; Okamura, M; Adachi-Morishima, A; Nonaka, M; Fuse, T; Kida, S; Tanji, M; Furuyashiki, T; Arakawa, Y; Narumiya, S; Okuno, H; Bito, H				Ohmae, Shogo; Takemoto-Kimura, Sayaka; Okamura, Michiko; Adachi-Morishima, Aki; Nonaka, Mio; Fuse, Toshimitsu; Kida, Satoshi; Tanji, Masahiro; Furuyashiki, Tomoyuki; Arakawa, Yoshiki; Narumiya, Shuh; Okuno, Hiroyuki; Bito, Haruhiko			Molecular identification and characterization of a family of kinases with homology to Ca2+/calmodulin-dependent protein kinases I/IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; DOUBLECORTIN-LIKE KINASE; CEREBELLAR GRANULE NEURONS; LONG-TERM POTENTIATION; CREB COACTIVATOR TORC2; MUTANT MICE; TRANSCRIPTIONAL ACTIVATION; SYNAPTIC PLASTICITY; SPLICE VARIANTS; GENE-EXPRESSION	Despite the critical importance of Ca2+/calmodulin (CaM)-dependent protein kinase (CaMK) II signaling in neuroplasticity, only a limited amount of work has so far been available regarding the presence and significance of another predominant CaMK subfamily, the CaMKI/CaMKIV family, in the central nervous system. We here searched for kinases with a core catalytic structure similar to CaMKI and CaMKIV. We isolated full-length cDNAs encoding three mouse CaMKI/CaMKIV-related kinases, CLICK-I (CL1)/doublecortin and CaM kinase-Like (DCAMKL)1, CLICK-II (CL2)/DCAMKL2, and CLICK-I, II-related (CLr)/DCAMKL3, the kinase domains of which had an intermediate homology not only to CaMKI/CaMKIV but also to CaMKII. Furthermore, CL1, CL2, and CLr were highly ;expressed in the central nervous system, in a neuron-specific fashion. CL1 alpha and CL1 beta were shorter isoforms of DCAMKL1, which lacked the doublecortin-like domain (Dx). In contrast, CL2 alpha and CL2 beta contained a full N-terminal Dx, whereas CLr only possessed a partial and dysfunctional Dx. Interestingly, despite a large similarity in the kinase domain, CL1/CL2/CLr had an impact on CRE-dependent gene expression distinct from that of the related CaMKI/CaMKIV and CaMKII. Although these were previously shown to activate Ca2+/cAMP-response element-binding protein (CREB)-dependent transcription, we here show that CL1 and CL2 were unable to significantly phosphorylate CREB Ser-133 and rather inhibited CRE-dependent gene expression by a dominant mechanism that bypassed CREB and was mediated by phosphorylated TORC2.	Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068315, Japan; Univ Tokyo, Grad Sch Med, Dept Neurochem, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Ctr Integrated Brain Med Sci, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Univ Agr, Dept Biosci, Setagaya Ku, Tokyo 1568502, Japan; JST, SORST, Kawaguchi 3320012, Japan	Kyoto University; University of Tokyo; University of Tokyo; Tokyo University of Agriculture; Japan Science & Technology Agency (JST)	Bito, H (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068315, Japan.	hbito@m.u-tokyo.ac.jp	Arakawa, Yoshiki/H-6067-2017; Furuyashiki, Tomoyuki/AAG-5283-2019; Bito, Haruhiko/A-8635-2008; Furuyashiki, Tomoyuki/B-8760-2014	Arakawa, Yoshiki/0000-0003-4626-4645; Furuyashiki, Tomoyuki/0000-0001-8089-8399; Furuyashiki, Tomoyuki/0000-0001-8089-8399; Bito, Haruhiko/0000-0001-6315-9594; Ohmae, Shogo/0000-0003-1726-4961; OKUNO, HIROYUKI/0000-0001-6237-6503				Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; Arakawa Y, 2003, J CELL BIOL, V161, P381, DOI 10.1083/jcb.200210149; Bai JL, 2003, NAT NEUROSCI, V6, P1277, DOI 10.1038/nn1153; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bito H, 2003, CELL CALCIUM, V34, P425, DOI 10.1016/S0143-4160(03)00140-4; Bito H, 2000, NEURON, V26, P431, DOI 10.1016/S0896-6273(00)81175-7; Burgess HA, 2002, J BIOL CHEM, V277, P17696, DOI 10.1074/jbc.M111981200; Burgess HA, 1999, J NEUROSCI RES, V58, P567, DOI 10.1002/(SICI)1097-4547(19991115)58:4<567::AID-JNR9>3.3.CO;2-K; Burgess HA, 2000, MOL CELL NEUROSCI, V16, P529, DOI 10.1006/mcne.2000.0891; Caenepeel S, 2004, P NATL ACAD SCI USA, V101, P11707, DOI 10.1073/pnas.0306880101; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Corbo JC, 2002, J NEUROSCI, V22, P7548; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; Edelman AM, 2005, J BIOL CHEM, V280, P8531, DOI 10.1074/jbc.M411027200; Elgersma Y, 2002, NEURON, V36, P493, DOI 10.1016/S0896-6273(02)01007-3; Engels BM, 2004, MOL BRAIN RES, V120, P103, DOI 10.1016/j.molbrainres.2003.10.006; Feng YY, 2001, NAT REV NEUROSCI, V2, P408, DOI 10.1038/35077559; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; Frankland PW, 2001, NATURE, V411, P309, DOI 10.1038/35077089; Fujisawa H, 2001, J BIOCHEM-TOKYO, V129, P193, DOI 10.1093/oxfordjournals.jbchem.a002843; Furuyashiki T, 2002, P NATL ACAD SCI USA, V99, P14458, DOI 10.1073/pnas.212148999; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; Glazewski S, 1996, SCIENCE, V272, P421, DOI 10.1126/science.272.5260.421; Gordon JA, 1996, NEURON, V17, P491, DOI 10.1016/S0896-6273(00)80181-6; Hevroni D, 1998, J MOL NEUROSCI, V10, P75, DOI 10.1007/BF02737120; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Ho N, 2000, J NEUROSCI, V20, P6459, DOI 10.1523/JNEUROSCI.20-17-06459.2000; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Hoshinoso M, 1999, J BIOL CHEM, V274, P17837, DOI 10.1074/jbc.274.25.17837; Hu SC, 1999, NEURON, V22, P799, DOI 10.1016/S0896-6273(00)80738-2; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Iourgenko V, 2003, P NATL ACAD SCI USA, V100, P12147, DOI 10.1073/pnas.1932773100; Ishikawa Y, 2003, FEBS LETT, V550, P57, DOI 10.1016/S0014-5793(03)00817-2; Kang HJ, 2001, CELL, V106, P771, DOI 10.1016/S0092-8674(01)00497-4; Katoh Y, 2004, EUR J BIOCHEM, V271, P4307, DOI 10.1111/j.1432-1033.2004.04372.x; Koo SH, 2005, NATURE, V437, P1109, DOI 10.1038/nature03967; Lin PT, 2000, J NEUROSCI, V20, P9152; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Mizuguchi M, 1999, AM J PATHOL, V155, P1713, DOI 10.1016/S0002-9440(10)65486-7; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Naito Y, 1997, J BIOL CHEM, V272, P32704, DOI 10.1074/jbc.272.51.32704; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Nishimura H, 2003, J NEUROCHEM, V85, P1216, DOI 10.1046/j.1471-4159.2003.01760.x; Omori Y, 1998, J HUM GENET, V43, P169, DOI 10.1007/s100380050063; Schmitt JM, 2005, J NEUROSCI, V25, P1281, DOI 10.1523/JNEUROSCI.4086-04.2005; Schmitt JM, 2004, J BIOL CHEM, V279, P24064, DOI 10.1074/jbc.M401501200; Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015; See V, 2001, FASEB J, V15, P134, DOI 10.1096/fj.00-0106com; Shang LM, 2003, BIOCHEMISTRY-US, V42, P2185, DOI 10.1021/bi026913i; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Silverman MA, 1999, J BIOL CHEM, V274, P2631, DOI 10.1074/jbc.274.5.2631; Soderling TR, 2001, CHEM REV, V101, P2341, DOI 10.1021/cr0002386; Sossey-Alaoui K, 1999, GENOMICS, V56, P121, DOI 10.1006/geno.1998.5718; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; Tabuchi A, 2002, J BIOL CHEM, V277, P35920, DOI 10.1074/jbc.M204784200; Takemoto-Kimura S, 2003, J BIOL CHEM, V278, P18597, DOI 10.1074/jbc.M300578200; Vreugdenhil E, 2001, MOL BRAIN RES, V94, P67, DOI 10.1016/S0169-328X(01)00213-3; Vreugdenhil E, 1999, J NEUROBIOL, V39, P41, DOI 10.1002/(SICI)1097-4695(199904)39:1<41::AID-NEU4>3.0.CO;2-X; Wayman GA, 2004, J NEUROSCI, V24, P3786, DOI 10.1523/JNEUROSCI.3294-03.2004; Wei F, 2002, NAT NEUROSCI, V5, P573, DOI 10.1038/nn0602-855	67	26	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20427	20439		10.1074/jbc.M513212200	http://dx.doi.org/10.1074/jbc.M513212200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16684769	hybrid			2022-12-25	WOS:000239038200066
J	Sanchez, JF; Lescar, J; Chazalet, V; Audfray, A; Gagnon, J; Alvarez, R; Breton, C; Imberty, A; Mitchell, EP				Sanchez, Jean-Frederic; Lescar, Julien; Chazalet, Valerie; Audfray, Aymeric; Gagnon, Jean; Alvarez, Richard; Breton, Christelle; Imberty, Anne; Mitchell, Edward P.			Biochemical and structural analysis of Helix pomatia agglutinin - A hexameric lectin with a novel fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-D-GALACTOSAMINE; CARBOHYDRATE CHAINS; INNATE IMMUNITY; PROTEIN; BINDING; SNAIL; PURIFICATION; PROGRAM; SPECIFICITIES; REFINEMENT	Helix pomatia agglutinin (HPA) is a N-acetylgalactosamine (GalNAc) binding lectin found in the albumen gland of the roman snail. As a constituent of perivitelline fluid, HPA protects fertilized eggs from bacteria and is part of the innate immunity system of the snail. The peptide sequence deduced from gene cloning demonstrates that HPA belongs to a family of carbohydratebinding proteins recently identified in several invertebrates. This domain is also present in discoidin from the slime mold Dictyostelium discoideum. Investigation of the lectin specificity was performed with the use of glycan arrays, demonstrating that several GalNAc-containing oligosaccharides are bound and rationalizing the use of this lectin as a cancer marker. Titration microcalorimetry performed on the interaction between HPA and GalNAc indicates an affinity in the 10(-4) M range with an enthalpy-driven binding mechanism. The crystal structure of HPA demonstrates the occurrence of a new beta-sandwich lectin fold. The hexameric quaternary state was never observed previously for a lectin. The high resolution structure complex of HPA with GalNAc characterizes a new carbohydrate binding site and rationalizes the observed preference for alpha GalNAc-containing oligosaccharides.	Univ Grenoble 1, CNRS, CERMAV, Ctr Rech Macromol Vegetales, F-38041 Grenoble 09, France; Nanyang Technol Univ, Sch Biol Sci, Singapore 637616, Singapore; Univ Grenoble 1, CNRS, FRE2685, F-38706 La Tronche, France; Univ Oklahoma, Dept Biochem Mol Biol, Oklahoma City, OK 73104 USA; European Synchrotron Radiat Facil, Expt Div, F-38043 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Oklahoma System; University of Oklahoma Health Sciences Center; European Synchrotron Radiation Facility (ESRF)	Mitchell, EP (corresponding author), Univ Grenoble 1, CNRS, CERMAV, Ctr Rech Macromol Vegetales, BP 53, F-38041 Grenoble 09, France.	mitchell@esrf.fr	Gagnon, Jean/C-3136-2008; Imberty, Anne/P-6451-2018	Gagnon, Jean/0000-0002-0177-824X; Imberty, Anne/0000-0001-6825-9527	NIGMS NIH HHS [GM62116] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARONDES SH, 1984, SCIENCE, V223, P1259, DOI 10.1126/science.6367039; Bianchet MA, 2002, NAT STRUCT BIOL, V9, P628, DOI 10.1038/nsb817; Blixt O, 2004, P NATL ACAD SCI USA, V101, P17033, DOI 10.1073/pnas.0407902101; Brooks SA, 2003, ACTA HISTOCHEM, V105, P205, DOI 10.1078/0065-1281-00705; CAMUS ML, 1899, CR HEBD ACAD SCI, V129, P233; DALLINGER R, 1984, COMP BIOCHEM PHYS C, V79, P117, DOI 10.1016/0742-8413(84)90173-7; Dam TK, 2002, CHEM REV, V102, P387, DOI 10.1021/cr000401x; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; FRAZIER WA, 1975, J BIOL CHEM, V250, P7714; Gerlach D, 2005, FEMS IMMUNOL MED MIC, V43, P223, DOI 10.1016/j.femsim.2004.08.006; Grosse-Kunstleve RW, 2003, ACTA CRYSTALLOGR D, V59, P1966, DOI 10.1107/S0907444903018043; Gutternigg M, 2004, EUR J BIOCHEM, V271, P1348, DOI 10.1111/j.1432-1033.2004.04045.x; Hakomori S, 2001, ADV EXP MED BIOL, V491, P369; HAMMARST.S, 1969, BIOCHEMISTRY-US, V8, P2696, DOI 10.1021/bi00835a002; HAMMARST.S, 1971, BIOCHEMISTRY-US, V10, P1681; HAMMARSTROM S, 1972, Scandinavian Journal of Immunology, V1, P295, DOI 10.1111/j.1365-3083.1972.tb03295.x; Iwanaga S, 2005, J BIOCHEM MOL BIOL, V38, P128; Iwanaga S, 2002, CURR OPIN IMMUNOL, V14, P87, DOI 10.1016/S0952-7915(01)00302-8; Jimbo M, 2005, BIOCHEM BIOPH RES CO, V330, P157, DOI 10.1016/j.bbrc.2005.02.137; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOHLER W, 1973, J MED MICROBIOL, V6, P127, DOI 10.1099/00222615-6-1-127; Koike K, 2004, BIOL BULL-US, V207, P80, DOI 10.2307/1543582; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Lisgarten JN, 1999, ACTA CRYSTALLOGR D, V55, P1903; Lommerse JPM, 1997, EUR J BIOCHEM, V249, P195, DOI 10.1111/j.1432-1033.1997.00195.x; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MULLER WEG, 1985, ACTA HISTOCHEM, P37; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; PATCHETT RA, 1991, J APPL BACTERIOL, V71, P277, DOI 10.1111/j.1365-2672.1991.tb04459.x; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PILLER V, 1990, EUR J BIOCHEM, V191, P461, DOI 10.1111/j.1432-1033.1990.tb19144.x; PROKOP O, 1968, VOX SANG, V14, P321, DOI 10.1111/j.1423-0410.1968.tb01722.x; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SLIFKIN M, 1989, J CLIN MICROBIOL, V27, P1036, DOI 10.1128/JCM.27.5.1036-1039.1989; UHLENBRU.G, 1966, VOX SANG, V11, P519, DOI 10.1111/j.1423-0410.1966.tb04250.x; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VANKUIK JA, 1985, J BIOL CHEM, V260, P3984; Vasta GR, 2004, CURR OPIN STRUC BIOL, V14, P617, DOI 10.1016/j.sbi.2004.09.008; VASTA GR, 1994, ANN NY ACAD SCI, V712, P55, DOI 10.1111/j.1749-6632.1994.tb33562.x; VRETBLAD P, 1979, BIOCHIM BIOPHYS ACTA, V579, P52, DOI 10.1016/0005-2795(79)90086-2; Weaver AJ, 2000, J BIOL CHEM, V275, P23045, DOI 10.1074/jbc.M003410200; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WU AM, 1991, CARBOHYD RES, V213, P127, DOI 10.1016/S0008-6215(00)90604-9	46	105	107	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20171	20180		10.1074/jbc.M603452200	http://dx.doi.org/10.1074/jbc.M603452200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16704980	hybrid			2022-12-25	WOS:000239038200041
J	Funes, M; Miller, JK; Lai, C; Carraway, KL; Sweeney, C				Funes, Melanie; Miller, Jamie K.; Lai, Cary; Carraway, Kermit L., III; Sweeney, Colleen			The mucin muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SIALOMUCIN COMPLEX; MUC4/SIALOMUCIN COMPLEX; TYROSINE KINASE; PROTEIN-KINASE; INTRAMEMBRANE MODULATOR; MALIGNANT-MELANOMA; MAMMARY-GLAND; BREAST-CANCER; TUMOR	Mucins provide a protective barrier for epithelial surfaces, and their overexpression in tumors has been implicated in malignancy. We have previously demonstrated that Muc4, a transmembrane mucin that promotes tumor growth and metastasis, physically interacts with the ErbB2 receptor tyrosine kinase and augments receptor tyrosine phosphorylation in response to the neuregulin-1 beta (NRG1 beta) growth factor. In the present study we demonstrate that Muc4 expression in A375 human melanoma cells, as well as MCF7 and T47D human breast cancer cells, enhances NRG1 beta signaling through the phosphatidylinositol 3-kinase pathway. In examining the mechanism underlying Muc4-potetiated ErbB2 signaling, we found that Muc4 expression markedly augments NRG1 beta binding to A375 cells without altering the total quantity of receptors expressed by the cells. Cell-surface protein biotinylation experiments and immunofluorescence studies suggest that Muc4 induces the relocalization of the ErbB2 and ErbB3 receptors from intracellular compartments to the plasma membrane. Moreover, Muc4 interferes with the accumulation of surface receptors within internal compartments following NRG1 beta treatment by suppressing the efficiency of receptor internalization. These observations suggest that transmembrane mucins can modulate receptor tyrosine kinase signaling by influencing receptor localization and trafficking and contribute to our understanding of the mechanisms by which mucins contribute to tumor growth and progression.	Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA; Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA	University of California System; University of California Davis; Scripps Research Institute	Carraway, KL (corresponding author), Univ Calif Davis, Ctr Canc, Res Bldg 3,Rm 1400,4645 2nd Ave, Sacramento, CA 95817 USA.	klcarraway@ucdavis.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068994] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM068994] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; Arango ME, 2001, INVEST OPHTH VIS SCI, V42, P2749; Bottcher RT, 2004, NAT CELL BIOL, V6, P38, DOI 10.1038/ncb1082; Bourguignon LYW, 1997, J BIOL CHEM, V272, P27913, DOI 10.1074/jbc.272.44.27913; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; Carraway KL, 2002, PROG NUCLEIC ACID RE, V71, P149, DOI 10.1016/S0079-6603(02)71043-X; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; Cicenas J, 2006, EUR J CANCER, V42, P636, DOI 10.1016/j.ejca.2005.11.012; Diamonti AJ, 2002, P NATL ACAD SCI USA, V99, P2866, DOI 10.1073/pnas.052709799; Filippa N, 1999, MOL CELL BIOL, V19, P4989; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Haugh JM, 2002, J CELL SCI, V115, P303; Hellyer NJ, 2001, J BIOL CHEM, V276, P42153, DOI 10.1074/jbc.M102079200; Herrera-Gayol A, 1999, EXP MOL PATHOL, V66, P149, DOI 10.1006/exmp.1999.2251; Higuchi T, 2004, MOL CELL BIOL, V24, P7456, DOI 10.1128/MCB.24.17.7456-7468.2004; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Idris N, 2001, J CELL PHYSIOL, V189, P162, DOI 10.1002/jcp.10012; Jepson S, 2002, ONCOGENE, V21, P7524, DOI 10.1038/sj.onc.1205970; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; Komatsu M, 2001, ONCOGENE, V20, P461, DOI 10.1038/sj.onc.1204106; Komatsu M, 1999, CANCER RES, V59, P2229; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Llinares K, 2004, MODERN PATHOL, V17, P150, DOI 10.1038/modpathol.3800027; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; RICCI A, 1995, ONCOGENE, V11, P1519; Rossi EA, 1996, J BIOL CHEM, V271, P33476, DOI 10.1074/jbc.271.52.33476; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; SHENG Z, 1990, J BIOL CHEM, V265, P8505; Sherman LS, 2000, J CELL BIOL, V150, P1071, DOI 10.1083/jcb.150.5.1071; Shibahara H, 2004, HEPATOLOGY, V39, P220, DOI 10.1002/hep.20031; Shimizu A, 2001, J BIOL CHEM, V276, P27749, DOI 10.1074/jbc.C100286200; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Stahl JM, 2003, CANCER RES, V63, P2881; Swan JS, 2002, CURR EYE RES, V24, P397, DOI 10.1076/ceyr.24.5.397.8521; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Sweeney C, 2001, J BIOL CHEM, V276, P22685, DOI 10.1074/jbc.M100602200; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu CJ, 1997, AM J RESP CRIT CARE, V155, P1419, DOI 10.1164/ajrccm.155.4.9105088; Zhang J, 2005, J CELL PHYSIOL, V204, P166, DOI 10.1002/jcp.20277; Zhang YZ, 2000, J NEUROSCI, V20, P5671, DOI 10.1523/JNEUROSCI.20-15-05671.2000	45	66	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19310	19319		10.1074/jbc.M603225200	http://dx.doi.org/10.1074/jbc.M603225200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16690615	Green Submitted, hybrid			2022-12-25	WOS:000238847000046
J	Guillouf, C; Gallais, I; Moreau-Gachelin, F				Guillouf, Christel; Gallais, Isabelle; Moreau-Gachelin, Francois			Spi-1/PU.1 oncoprotein affects splicing decisions in a promoter binding-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; MULTIPLE FUNCTIONAL DOMAINS; TRANSCRIPTION FACTOR PU.1; ACUTE MYELOID-LEUKEMIA; POL-II ELONGATION; ERYTHROID-DIFFERENTIATION; IN-VIVO; SITE SELECTION; ETS-DOMAIN; FACTOR TLS	The expression of the Spi-1/PU.1 transcription factor is tightly regulated as a function of the hematopoeitic lineage. It is required for myeloid and B lymphoid differentiation. When overexpressed in mice, Spi-1 is associated with the emergence of transformed proerythroblasts unable to differentiate. In the course of a project undertaken to characterize the oncogenic function of Spi-1, we found that Spi-1 interacts with proteins of the spliceosome in Spi-1-transformed proerythroblasts and participates in alternative splice site selection. Because Spi-1 is a transcription factor, it could be hypothesized that these two functions are coordinated. Here, we have developed a system allowing the characterization of transcription and splicing from a single target. It is shown that Spi-1 is able to regulate alternative splicing of a pre-mRNA for a gene whose transcription it regulates. Using a combination of Spi-1 mutants and Spi-1-dependent promoters, we demonstrate that Spi-1 must bind and transactivate a given promoter to favor the use of the proximal 5' alternative site. This establishes that Spi-1 affects splicing decisions in a promoter binding-dependent manner. These results provide new insight into how Spi-1 may act in the blockage of differentiation by demonstrating that it can deregulate gene expression and also modify the nature of the products generated from target genes.	Inst Curie, INSERM, U528, F-75248 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Guillouf, C (corresponding author), 26 Rue Ulm, F-75248 Paris 05, France.	guillouf.christel@curie.fr; framoreau@curie.fr						Auboeuf D, 2004, P NATL ACAD SCI USA, V101, P2270, DOI 10.1073/pnas.0308133100; Auboeuf D, 2004, MOL CELL BIOL, V24, P442, DOI 10.1128/MCB.24.1.442-453.2004; Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; Back J, 2005, EXP HEMATOL, V33, P395, DOI 10.1016/j.exphem.2004.12.010; Baklouti F, 1996, BLOOD, V87, P3934, DOI 10.1182/blood.V87.9.3934.bloodjournal8793934; Bakri Y, 2005, BLOOD, V105, P2707, DOI 10.1182/blood-2004-04-1448; Batsche E, 2006, NAT STRUCT MOL BIOL, V13, P22, DOI 10.1038/nsmb1030; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Brass AL, 1999, EMBO J, V18, P977, DOI 10.1093/emboj/18.4.977; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Chansky HA, 2001, CANCER RES, V61, P3586; CHASIS JA, 1993, J CLIN INVEST, V91, P329, DOI 10.1172/JCI116189; Cook WD, 2004, BLOOD, V104, P3437, DOI 10.1182/blood-2004-06-2234; Cowper AE, 2001, J BIOL CHEM, V276, P48908, DOI 10.1074/jbc.M103967200; Cramer P, 1999, MOL CELL, V4, P251, DOI 10.1016/S1097-2765(00)80372-X; Cramer P, 1997, P NATL ACAD SCI USA, V94, P11456, DOI 10.1073/pnas.94.21.11456; de la Mata M, 2003, MOL CELL, V12, P525, DOI 10.1016/j.molcel.2003.08.001; Delva L, 2004, ONCOGENE, V23, P4389, DOI 10.1038/sj.onc.1207578; GATTONI R, 1991, GENE DEV, V5, P1847, DOI 10.1101/gad.5.10.1847; Ge H, 1998, MOL CELL, V2, P751, DOI 10.1016/S1097-2765(00)80290-7; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; Hou VC, 2001, CURR OPIN HEMATOL, V8, P74, DOI 10.1097/00062752-200103000-00003; Kadener S, 2002, P NATL ACAD SCI USA, V99, P8185, DOI 10.1073/pnas.122246099; Kadener S, 2001, EMBO J, V20, P5759, DOI 10.1093/emboj/20.20.5759; Kameoka S, 2004, EMBO J, V23, P1782, DOI 10.1038/sj.emboj.7600187; Kang HC, 2005, MOL CELL BIOL, V25, P6005, DOI 10.1128/MCB.25.14.6005-6020.2005; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Knoop LL, 2001, J BIOL CHEM, V276, P22317, DOI 10.1074/jbc.M008950200; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; Kornblihtt AR, 2004, RNA, V10, P1489, DOI 10.1261/rna.7100104; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; Lerga A, 2001, J BIOL CHEM, V276, P6807, DOI 10.1074/jbc.M008304200; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Nogues G, 2003, J BIOL CHEM, V278, P52166, DOI 10.1074/jbc.M309156200; Nutt SL, 2005, J EXP MED, V201, P221, DOI 10.1084/jem.20041535; Perkel JM, 1998, J IMMUNOL, V160, P241; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RAYGALLET D, 1995, ONCOGENE, V11, P303; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; Starck J, 1999, MOL CELL BIOL, V19, P121; Suraweera N, 2005, ONCOGENE, V24, P3678, DOI 10.1038/sj.onc.1208422; Theoleyre O, 2004, ONCOGENE, V23, P920, DOI 10.1038/sj.onc.1207206; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; Yang G, 2005, BLOOD, V105, P2146, DOI 10.1182/blood-2004-05-1757; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zhang WJ, 1996, MOL CELL BIOL, V16, P5400	55	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19145	19155		10.1074/jbc.M512049200	http://dx.doi.org/10.1074/jbc.M512049200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16698794	hybrid			2022-12-25	WOS:000238847000029
J	Kobrinsky, E; Stevens, L; Kazmi, Y; Wray, D; Soldatov, NM				Kobrinsky, Evgeny; Stevens, Louisa; Kazmi, Yasir; Wray, Dennis; Soldatov, Nikolai M.			Molecular rearrangements of the K(v)2.1 potassium channel termini associated with voltage gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; DEPENDENT K+ CHANNEL; ACTIVATION; DOMAIN; T1; MODULATION; SUBUNITS; TAILS; CELLS	The voltage-gated K(v)2.1 channel is composed of four identical subunits folded around the central pore and does not inactivate appreciably during short depolarizing pulses. To study voltage-induced relative molecular rearrangements of the channel, K(v)2.1 subunits were genetically fused with enhanced cyan fluorescent protein and/or enhanced yellow fluorescent protein, expressed in COS1 cells, and investigated using fluorescence resonance energy transfer ( FRET) microscopy combined with patch clamp. Fusion of fluorophores to either or both termini of the K(v)2.1 monomer did not significantly affect the gating properties of the channel. FRET between the N- and C-terminal tags fused to the same or different K(v)2.1 monomers decreased upon activation of the channel by depolarization from - 80 to + 60 mV, suggesting voltage-gated relative rearrangement between the termini. Because FRET between the K(v)2.1 N- or C-terminal tags and the membrane-trapped EYFPN-PH pleckstrin homology domains did not change on depolarization, voltage-gated relative movements between the K(v)2.1 termini occurred in a plane parallel to the plasma membrane, within a distance of 1-10 nm. FRET between the N-terminal tags did not change upon depolarization, indicating that the N termini do not rearrange relative to each other, but they could either move cooperatively with the K(v)2.1 tetramer or not move at all. No FRET was detected between the C-terminal tags. Assuming their randomized orientation in the symmetrically arranged K(v)2.1 subunits, C termini may move outwards in order to produce relative rearrangements between N and C termini upon depolarization.	NIA, NIH, Baltimore, MD 21224 USA; Univ Leeds, Fac Biol Sci, Leeds LS2 9JT, W Yorkshire, England	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Leeds	Soldatov, NM (corresponding author), NIA, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	soldatovN@grc.nia.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE ON AGING [Z01AG000294, ZIAAG000294] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bezanilla F, 2002, J GEN PHYSIOL, V120, P465, DOI 10.1085/jgp.20028660; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; Cuello LG, 2004, SCIENCE, V306, P491, DOI 10.1126/science.1101373; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Ju M, 2003, J BIOL CHEM, V278, P12769, DOI 10.1074/jbc.M212973200; Kerschensteiner D, 2005, P NATL ACAD SCI USA, V102, P6160, DOI 10.1073/pnas.0500468102; Kobertz WR, 2000, BIOCHEMISTRY-US, V39, P10347, DOI 10.1021/bi001292j; Kobrinsky E, 2005, J BIOL CHEM, V280, P12474, DOI 10.1074/jbc.M412140200; Kobrinsky E, 2004, BIOPHYS J, V87, P844, DOI 10.1529/biophysj.104.041152; Kobrinsky E, 2003, J BIOL CHEM, V278, P5021, DOI 10.1074/jbc.M211254200; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Minor DL, 2000, CELL, V102, P657, DOI 10.1016/S0092-8674(00)00088-X; Murakoshi H, 1997, MOL PHARMACOL, V52, P821, DOI 10.1124/mol.52.5.821; Riven I, 2003, NEURON, V38, P225, DOI 10.1016/S0896-6273(03)00193-4; Scholle A, 2004, BIOPHYS J, V87, P873, DOI 10.1529/biophysj.104.040550; Schulteis CT, 1996, BIOCHEMISTRY-US, V35, P12133, DOI 10.1021/bi961083s; SHEN NV, 1993, NEURON, V11, P67; SHI GY, 1994, J BIOL CHEM, V269, P23204; Sokolova O, 2001, STRUCTURE, V9, P215, DOI 10.1016/S0969-2126(01)00578-0; van der Wal J, 2001, J BIOL CHEM, V276, P15337, DOI 10.1074/jbc.M007194200; WILSON GG, 1994, PFLUG ARCH EUR J PHY, V428, P186, DOI 10.1007/BF00374857; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Zerangue N, 2000, P NATL ACAD SCI USA, V97, P3591, DOI 10.1073/pnas.060016797	28	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19233	19240		10.1074/jbc.M601231200	http://dx.doi.org/10.1074/jbc.M601231200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16690619	hybrid			2022-12-25	WOS:000238847000037
J	Xin, MG; Deng, XM				Xin, Meiguo; Deng, Xingming			Protein phosphatase 2A enhances the proapoptotic function of Bax through dephosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBERS; CELL-DEATH; REGULATORY SUBUNITS; INDUCED APOPTOSIS; CERAMIDE; MITOCHONDRIA; PHOSPHORYLATION; TRANSLOCATION; MEMBRANE; SURVIVAL	Bax is a major proapoptotic member of the Bcl2 family that is required for apoptotic cell death. We have recently discovered that Bax phosphorylation at serine 184 induced by nicotine through activation of protein kinase AKT abolishes its proapoptotic function in human lung cancer cells. Here we found that either treatment of cells with the protein phosphatase 2A (PP2A) inhibitor okadaic acid or specific disruption of PP2A activity by expression of SV40 small tumor antigen enhanced Bax phosphorylation, whereas C-2-ceramide, a potent PP2A activator, reduced nicotine-induced Bax phosphorylation, suggesting that PP2A may function as a physiological Bax phosphatase. PP2A co-localized and interacted with Bax. Purified, active PP2A directly dephosphorylated Bax in vitro. Overexpression of the PP2A catalytic subunit (PP2A/C) suppressed nicotine-stimulated Bax phosphorylation in association with increased apoptotic cell death. By contrast, depletion of PP2A/C by RNA interference enhanced Bax phosphorylation and prolonged cell survival. Mechanistically C-2-ceramide-induced Bax dephosphorylation caused a conformational change by exposure of the 6A7 epitope (amino acids 13-19) that is normally hidden at its N terminus that promoted the insertion of Bax into mitochondrial membranes and formation of Bax oligomers leading to cytochrome c release and apoptosis. In addition, PP2A directly disrupted the Bcl2/Bax association to liberate Bax from the heterodimer complex. Thus, PP2A may function as a physiological Bax regulatory phosphatase that not only dephosphorylates Bax but also activates its proapoptotic function.	Univ Florida, Shands Canc Ctr, Gainesville, FL 32610 USA; Univ Florida, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Deng, XM (corresponding author), Univ Florida, Shands Canc Ctr, 1600 SW Archer Rd,Acad Res Bldg,R4-216,POB 100232, Gainesville, FL 32610 USA.	xdeng@ufscc.ufl.edu			NCI NIH HHS [R01 CA112183] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA112183] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Cao XF, 2003, BLOOD, V102, P2605, DOI 10.1182/blood-2003-01-0211; Deng XM, 1998, J BIOL CHEM, V273, P34157, DOI 10.1074/jbc.273.51.34157; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Eldering E, 2004, EUR J IMMUNOL, V34, P1950, DOI 10.1002/eji.200324817; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Groeger AM, 2001, ANTICANCER RES, V21, P3627; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gulbins E, 2003, PHARMACOL RES, V47, P393, DOI 10.1016/S1043-6618(03)00052-5; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; IKONEN E, 1995, FEBS LETT, V358, P273, DOI 10.1016/0014-5793(94)01444-6; Jarvis WD, 1996, J BIOL CHEM, V271, P8275, DOI 10.1074/jbc.271.14.8275; Jarvis WD, 1996, CLIN CANCER RES, V2, P1; Jin ZJ, 2005, J BIOL CHEM, V280, P16045, DOI 10.1074/jbc.M413488200; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LAW B, 1995, J BIOL CHEM, V270, P12808, DOI 10.1074/jbc.270.21.12808; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Linseman DA, 2004, J NEUROSCI, V24, P9993, DOI 10.1523/JNEUROSCI.2057-04.2004; MAYERJAEKEL RE, 1992, MOL BIOL CELL, V3, P287, DOI 10.1091/mbc.3.3.287; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLTVAI ZN, 1993, CELL, V74, P619; QUINTANS J, 1994, BIOCHEM BIOPH RES CO, V202, P710, DOI 10.1006/bbrc.1994.1988; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Ruvolo PP, 2002, J BIOL CHEM, V277, P22847, DOI 10.1074/jbc.M201830200; Ruvolo PP, 2003, PHARMACOL RES, V47, P383, DOI 10.1016/S1043-6618(03)00050-1; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Smaili SS, 2003, BRAZ J MED BIOL RES, V36, P183, DOI 10.1590/S0100-879X2003000200004; Smyth M J, 1997, Adv Pharmacol, V41, P133, DOI 10.1016/S1054-3589(08)61057-1; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xin MG, 2005, J BIOL CHEM, V280, P10781, DOI 10.1074/jbc.M500084200; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	54	116	120	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18859	18867		10.1074/jbc.M512543200	http://dx.doi.org/10.1074/jbc.M512543200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16679323	hybrid			2022-12-25	WOS:000238687300066
J	Belloni, L; Moretti, F; Merlo, P; Damalas, A; Costanzo, A; Blandino, G; Levrero, M				Belloni, L.; Moretti, F.; Merlo, P.; Damalas, A.; Costanzo, A.; Blandino, G.; Levrero, M.			DNp73 alpha protects myogenic cells from apoptosis	ONCOGENE			English	Article						p73; DNp73; myogenic differentiation; apoptosis	P73 EXPRESSION; DNA-DAMAGE; DIFFERENTIATION; P53; ACETYLATION; FAMILY; ROLES; GENE	The P73 gene is transcribed from two promoters, P1 and P2, that direct the expression of multiple transactivation competent (TA) and dominant negative (DN) isoforms. TAp73 transcription factors mediate cell cycle arrest and/or apoptosis in response to DNA damage and are involved in developmental processes. P73 mRNA levels increase and the P1p73 promoter is upregulated during myogenic differentiation of C2C12 skeletal muscle satellite cells. The DNp73 proteins act as trans-repressors of p53- and p73-dependent transcription, and possess both antiapoptotic and pro-proliferative potential. Here, we show that DNp73 alpha is expressed in proliferating C2C12 myoblasts, rapidly accumulates in differentiating myocytes and remains elevated in C2C12 myotubes. By combining transactivation assays and chromatin immunoprecipitation analysis, we could show that the upregulation of the P2p73 promoter during myogenic differentiation is mediated by the coordinated recruitment and activity of MyoD and p53/p73. Abrogation of DNp73 expression by specific siRNA led to a strong potentiation of the spontaneous apoptosis of C2C12 myoblasts induced to differentiate. Finally, unlike TAp73 that contributes to DNA damage-induced apoptosis of myotubes, endogenous DNp73 mediates the relative resistance of differentiated myotubes to DNA damage. Altogether, our findings identify DNp73 alpha as an important target in designing strategies aimed at the potentiation of the regenerative potential of skeletal satellite cells.	Univ Roma La Sapienza, Lab Gene Express, Fdn Andrea Cesalpino, Ist Tumori Regina Elena,CRS, I-00158 Rome, Italy; Univ Roma La Sapienza, Dept Internal Med, I-00158 Rome, Italy; Regina Elena Inst Canc Res, Rome Oncogenom Ctr, Rome, Italy; Regina Elena Inst Canc Res, Dept Expt Oncol, Rome, Italy; Univ Roma Tor Vergata, Dept Dermatol, Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Sapienza University Rome; Sapienza University Rome; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Rome Tor Vergata	Levrero, M (corresponding author), Univ Roma La Sapienza, Lab Gene Express, Fdn Andrea Cesalpino, Ist Tumori Regina Elena,CRS, Via Messi Oro 156, I-00158 Rome, Italy.	levmax@tin.it	Costanzo, Antonio/GZG-2433-2022; Blandino, Giovanni/B-1137-2013; Belloni, Laura/S-1432-2019; Merlo, Paola/K-5330-2014; Costanzo, Antonio/D-3896-2012; Levrero, Massimo/G-5680-2016	Costanzo, Antonio/0000-0001-9697-2557; Blandino, Giovanni/0000-0002-6970-2241; Merlo, Paola/0000-0003-0105-7044; Levrero, Massimo/0000-0002-4978-0875	Telethon [E.1325, GGP030358] Funding Source: Medline	Telethon(Fondazione Telethon)		Billon N, 2004, DEVELOPMENT, V131, P1211, DOI 10.1242/dev.01035; Cerone MA, 2000, CELL DEATH DIFFER, V7, P506, DOI 10.1038/sj.cdd.4400676; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; HALEVY O, 1993, BIOCHEM BIOPH RES CO, V192, P714, DOI 10.1006/bbrc.1993.1473; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Latella L, 2004, MOL CELL BIOL, V24, P6350, DOI 10.1128/MCB.24.14.6350-6361.2004; Levrero M, 2000, J CELL SCI, V113, P1661; Li CY, 2005, J BIOL CHEM, V280, P2159, DOI 10.1074/jbc.M411194200; Liu G, 2004, MOL CELL BIOL, V24, P487, DOI 10.1128/MCB.24.2.487-501.2004; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Porrello A, 2000, J CELL BIOL, V151, P1295, DOI 10.1083/jcb.151.6.1295; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Pozniak CD, 2002, J NEUROSCI, V22, P9800; Puri PL, 2002, NAT GENET, V32, P585, DOI 10.1038/ng1023; Rentzsch F, 2003, GENE, V323, P19, DOI 10.1016/j.gene.2003.10.002; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Tschan MP, 2000, BIOCHEM BIOPH RES CO, V277, P62, DOI 10.1006/bbrc.2000.3627; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607	28	25	25	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3606	3612		10.1038/sj.onc.1209321	http://dx.doi.org/10.1038/sj.onc.1209321			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16652159				2022-12-25	WOS:000238448200013
J	Ribas, J; Bettayeb, K; Ferandin, Y; Knockaert, M; Garrofe-Ochoa, X; Totzke, F; Schachtele, C; Mester, J; Polychronopoulos, P; Magiatis, P; Skaltsounis, AL; Boix, J; Meijer, L				Ribas, J.; Bettayeb, K.; Ferandin, Y.; Knockaert, M.; Garrofe-Ochoa, X.; Totzke, F.; Schachtele, C.; Mester, J.; Polychronopoulos, P.; Magiatis, P.; Skaltsounis, A. -L.; Boix, J.; Meijer, L.			7-bromoindirubin-3 '-oxime induces caspase-independent cell death	ONCOGENE			English	Article						indirubin; protein kinase; cell death; autophagy; caspase; cancer	ARYL-HYDROCARBON RECEPTOR; PROTEIN-KINASE INHIBITORS; CYCLIN-DEPENDENT KINASES; INDIRUBIN DERIVATIVES; SELECTIVE INHIBITORS; CRYSTAL-STRUCTURE; TYRIAN PURPLE; AH RECEPTOR; APOPTOSIS; INDUCTION	Indirubin, an isomer of indigo, is a reported inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase-3 (GSK-3) as well as an agonist of the aryl hydrocarbon receptor (AhR). Indirubin is the active ingredient of a traditional Chinese medicinal recipe used against chronic myelocytic leukemia. Numerous indirubin analogs have been synthesized to optimize this promising kinase inhibitor scaffold. We report here on the cellular effects of 7-bromoindirubin-3'-oxime (7BIO). In contrast to its 5-bromo- and 6-bromo-isomers, and to indirubin-3'-oxime, 7BIO has only a marginal inhibitory activity towards CDKs and GSK-3. Unexpectedly, 7BIO triggers a rapid cell death process distinct from apoptosis. 7-Bromoindirubin-3'-oxime induces the appearance of large pycnotic nuclei, without classical features of apoptosis such as chromatin condensation and nuclear fragmentation. 7-Bromoindirubin-3'-oxime-induced cell death is not accompanied by cytochrome c release neither by any measurable effector caspase activation. Furthermore, the death process is not altered either by the presence of Q-VD-OPh, a broad-spectrum caspase inhibitor, or the overexpression of Bcl-2 and Bcl-XL proteins. Neither AhR nor p53 is required during 7BIO-induced cell death. Thus, in contrast to previously described indirubins, 7BIO triggers the activation of non-apoptotic cell death, possibly through necroptosis or autophagy. Although their molecular targets remain to be identified, 7-substituted indirubins may constitute a new class of potential antitumor compounds that would retain their activity in cells refractory to apoptosis.	CNRS, Cell Cycle Grp, F-29682 Roscoff, France; CNRS, Biol Stn, F-29682 Roscoff, France; Univ Lleida, Sch Med, DCMB, Mol Pharmacol Lab, Catalunya, Spain; ProQinase GmbH, Freiburg, Germany; INSERM, U482, Paris, France; Univ Athens, Dept Pharm, Div Pharmacognosy & Nat Prod Chem, Athens, Greece	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universitat de Lleida; ProQinase; Institut National de la Sante et de la Recherche Medicale (Inserm); National & Kapodistrian University of Athens	Meijer, L (corresponding author), CNRS, Cell Cycle Grp, UPS2682,BP 74, F-29682 Roscoff, France.	meijer@sb-roscoff.fr	Magiatis, Prokopios/A-2008-2008; Ribas, Judit/B-3362-2011; skaltsounis, alexios leandros/AAE-9617-2019	Ribas, Judit/0000-0003-0834-2577; Totzke, Frank/0000-0002-7261-8155; , laurent/0000-0003-3511-4916; Magiatis, Prokopios/0000-0002-0399-5344				Adachi J, 2001, J BIOL CHEM, V276, P31475, DOI 10.1074/jbc.C100238200; BACH S, 2006, IN PRESS MONOGRAPHS, V2; Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666; Balfour-Paul Jenny, 1998, INDIGO; Benson C, 2005, BRIT J CANCER, V92, P7, DOI 10.1038/sj.bjc.6602229; Bertrand JA, 2003, J MOL BIOL, V333, P393, DOI 10.1016/j.jmb.2003.08.031; Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223; Caserta TM, 2003, APOPTOSIS, V8, P345, DOI 10.1023/A:1024116916932; Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Cooksey CJ, 2001, MOLECULES, V6, P736, DOI 10.3390/60900736; Damiens E, 2001, ONCOGENE, V20, P3786, DOI 10.1038/sj.onc.1204503; Davies TG, 2001, STRUCTURE, V9, P389, DOI 10.1016/S0969-2126(01)00598-6; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; Elferink Cornelis J, 2003, Prog Cell Cycle Res, V5, P261; Fischer Peter M, 2003, Prog Cell Cycle Res, V5, P235; Fischer PM, 2004, CURR MED CHEM, V11, P1563, DOI 10.2174/0929867043365062; Fischer PM, 2005, EXPERT OPIN INV DRUG, V14, P457, DOI 10.1517/13543784.14.4.457; Guengerich FP, 2004, J MED CHEM, V47, P3236, DOI 10.1021/jm030561b; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; Holton S, 2003, STRUCTURE, V11, P1329, DOI 10.1016/j.str.2003.09.020; Jaattela M, 2004, ONCOGENE, V23, P2746, DOI 10.1038/sj.onc.1207513; Jautelat R, 2005, CHEMBIOCHEM, V6, P531, DOI 10.1002/cbic.200400108; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; Kawanishi M, 2003, MUTAT RES-GEN TOX EN, V540, P99, DOI 10.1016/S1383-5718(03)00174-8; Knockaert M, 2004, ONCOGENE, V23, P4400, DOI 10.1038/sj.onc.1207535; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Kosmopoulou MN, 2004, EUR J BIOCHEM, V271, P2280, DOI 10.1111/j.1432-1033.2004.04173.x; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Lee JW, 2005, BIOORG MED CHEM LETT, V15, P3948, DOI 10.1016/j.bmcl.2005.05.105; Lu HS, 2005, J MED CHEM, V48, P737, DOI 10.1021/jm049353p; Mapelli M, 2005, J MED CHEM, V48, P671, DOI 10.1021/jm049323m; Marko D, 2001, BRIT J CANCER, V84, P283, DOI 10.1054/bjoc.2000.1546; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010; Merz K H, 2004, Int J Clin Pharmacol Ther, V42, P656; Nam S, 2005, P NATL ACAD SCI USA, V102, P5998, DOI 10.1073/pnas.0409467102; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; Polychronopoulos P, 2004, J MED CHEM, V47, P935, DOI 10.1021/jm031016d; Ribas J, 2005, EUR J PHARMACOL, V524, P49, DOI 10.1016/j.ejphar.2005.09.021; Ribas J, 2004, EXP CELL RES, V295, P9, DOI 10.1016/j.yexcr.2003.12.019; Spink BC, 2003, BIOCHEM PHARMACOL, V66, P2313, DOI 10.1016/j.bcp.2003.08.019; Sugihara K, 2004, BIOCHEM BIOPH RES CO, V318, P571, DOI 10.1016/j.bbrc.2004.04.066; Teng X, 2005, BIOORG MED CHEM LETT, V15, P5039, DOI 10.1016/j.bmcl.2005.07.077; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Weinmann H, 2005, CHEMBIOCHEM, V6, P455, DOI 10.1002/cbic.200500034; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; Wu ZLL, 2005, CHEM BIODIVERS, V2, P51, DOI 10.1002/cbdv.200490166; Xiao ZJ, 2002, LEUKEMIA LYMPHOMA, V43, P1763, DOI 10.1080/1042819021000006295; Yuste VJ, 2002, J NEUROCHEM, V80, P126, DOI 10.1046/j.0022-3042.2001.00695.x	52	87	97	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2006	25	47					6304	6318		10.1038/sj.onc.1209648	http://dx.doi.org/10.1038/sj.onc.1209648			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16702956	Green Accepted			2022-12-25	WOS:000241218200007
J	Carragher, NO; Walker, SM; Carragher, LSA; Harris, F; Sawyer, TK; Brunton, VG; Ozanne, BW; Frame, MC				Carragher, N. O.; Walker, S. M.; Carragher, L. A. Scott; Harris, F.; Sawyer, T. K.; Brunton, V. G.; Ozanne, B. W.; Frame, M. C.			Calpain 2 and Src dependence distinguishes mesenchymal and amoeboid modes of tumour cell invasion: a link to integrin function	ONCOGENE			English	Article						calpain; Src; invasion; ROCK; mesenchymal; amoeboid	FOCAL ADHESION KINASE; MATRIX METALLOPROTEINASES; EXTRACELLULAR-MATRIX; COLORECTAL-CANCER; CLINICAL-TRIALS; LUNG-CANCER; MIGRATION; DYNAMICS; PROTEOLYSIS; INHIBITOR	Cancer cells can invade three-dimensional matrices by distinct mechanisms, recently defined by their dependence on extracellular proteases, including matrix metalloproteinases. Upon treatment with protease inhibitors, some tumour cells undergo a 'mesenchymal to amoeboid' transition that allows invasion in the absence of pericellular proteolysis and matrix degradation. We show here that in HT1080 cells, this transition is associated with weakened integrin-dependent adhesion, consistently reduced cell surface expression of the alpha 2 beta 1 integrin collagen receptor and impaired signalling downstream, as judged by reduced autophosphorylation of focal adhesion kinase (FAK). On examining cancer cells that use defined invasion strategies, we show that distinct from mesenchymal invasion, amoeboid invasion is independent of intracellular calpain 2 proteolytic activity that is usually needed for turnover of integrin-linked adhesions during two-dimensional planar migration. Moreover, an inhibitor of Rho/ROCK signalling, which specifically impairs amoeboid-like invasion, restores cell surface expression of alpha 2 beta 1 integrin, downstream FAK autophosphorylation and calpain 2 sensitivity - features of mesenchymal invasion. These findings link weakened integrin function to a lack of requirement for calpain 2-mediated integrin adhesion turnover during amoeboid invasion. In keeping with the need for integrin adhesion turnover, mesenchymal invasion is uniquely sensitive to Src inhibitors. Thus, the need for a major pathway that controls integrin adhesion turnover defines and distinguishes cancer cell invasion strategies.	Canc Res UK Beatson Labs, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA	Beatson Institute; Takeda Pharmaceutical Company Ltd; Takeda Oncology	Frame, MC (corresponding author), Canc Res UK Beatson Labs, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland.	m.frame@beatson.gla.ac.uk		Frame, Margaret/0000-0001-5882-1942; Carragher, Neil/0000-0001-5541-9747				Adachi Y, 2001, TUMOR BIOL, V22, P247, DOI 10.1159/000050623; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Brand K, 2000, CANCER RES, V60, P5723; Brunton VG, 2005, CANCER RES, V65, P1335, DOI 10.1158/0008-5472.CAN-04-1949; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; Carragher NO, 2003, CURR BIOL, V13, P1442, DOI 10.1016/S0960-9822(03)00544-X; Carragher NO, 2001, J BIOL CHEM, V276, P4270, DOI 10.1074/jbc.M008972200; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Cooke DW, 2005, MOL CELL ENDOCRINOL, V232, P37, DOI 10.1016/j.mce.2004.12.008; Cuevas BD, 2003, EMBO J, V22, P3346, DOI 10.1093/emboj/cdg322; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; Dourdin N, 2001, J BIOL CHEM, V276, P48382, DOI 10.1074/jbc.M108893200; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FALCIONI R, 1994, EXP CELL RES, V210, P113, DOI 10.1006/excr.1994.1017; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Franco SJ, 2004, NAT CELL BIOL, V6, P977, DOI 10.1038/ncb1175; Friedl P, 2004, CURR OPIN CELL BIOL, V16, P14, DOI 10.1016/j.ceb.2003.11.001; Friedl P, 2001, J LEUKOCYTE BIOL, V70, P491; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Goss KJH, 1998, INT J CANCER, V78, P629; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jaspars LH, 1996, J PATHOL, V178, P36, DOI 10.1002/(SICI)1096-9896(199601)178:1<36::AID-PATH426>3.0.CO;2-S; Krylyshkina O, 2002, J CELL BIOL, V156, P349, DOI 10.1083/jcb.200105051; Lokuta MA, 2003, P NATL ACAD SCI USA, V100, P4006, DOI 10.1073/pnas.0636533100; Lozonschi L, 1999, CANCER RES, V59, P1252; Malliri A, 2003, CURR OPIN CELL BIOL, V15, P583, DOI 10.1016/S0955-0674(03)00098-X; Mamoune A, 2003, CANCER RES, V63, P4632; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Palecek SP, 1998, J CELL SCI, V111, P929; Pavlaki M, 2003, CANCER METAST REV, V22, P177, DOI 10.1023/A:1023047431869; Petroll WM, 2003, CELL MOTIL CYTOSKEL, V55, P254, DOI 10.1002/cm.10126; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Rintoul RC, 2002, CLIN SCI, V102, P417, DOI 10.1042/CS20010216; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Scott LA, 2004, MOL CELL BIOL, V24, P1540, DOI 10.1128/MCB.24.4.1540-1559.2004; Shepherd FA, 2002, J CLIN ONCOL, V20, P4434, DOI 10.1200/JCO.2002.02.108; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Wagenaar-Miller RA, 2004, CANCER METAST REV, V23, P119, DOI 10.1023/A:1025819214508; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Yamada KM, 2003, BRAZ J MED BIOL RES, V36, P959, DOI 10.1590/S0100-879X2003000800001; Zamir E, 2001, J CELL SCI, V114, P3583; Zhai JB, 2003, J BIOL CHEM, V278, P24865, DOI 10.1074/jbc.M302381200; Zucker S, 2004, CANCER METAST REV, V23, P101, DOI 10.1023/A:1025867130437	54	121	126	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 21	2006	25	42					5726	5740		10.1038/sj.onc.1209582	http://dx.doi.org/10.1038/sj.onc.1209582			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16652152				2022-12-25	WOS:000240765800004
J	Gupta, SK; Gupta, M; Hoffman, B; Liebermann, DA				Gupta, S. K.; Gupta, M.; Hoffman, B.; Liebermann, D. A.			Hematopoietic cells from gadd45a-deficient and gadd45b-deficient mice exhibit impaired stress responses to acute stimulation with cytokines, myeloablation and inflammation	ONCOGENE			English	Article						hematopoiesis; differentiation; stress; apoptosis	KINASE INHIBITORS; UV-IRRADIATION; GENE MYD118; MAP KINASE; STEM-CELLS; GADD45; EXPRESSION; DIFFERENTIATION; GROWTH; APOPTOSIS	The gadd45 family of gene(s) is rapidly induced by genotoxic stress or by differentiation-inducing cytokines. Using bone marrow ( BM) from gadd45a-/-, gadd45b-/- and wild-type (wt) mice, we investigated their role in stress responses of myeloid cells to acute stimulation with differentiating cytokines, myelotoxic agents and inflammatory substances. Bone marrow cells from gadd45a -/- and gadd45b -/- mice displayed compromised myeloid differentiation and higher apoptosis in vitro, following acute stimulation with a variety of differentiating cytokines. Intriguingly, gadd45a -/- and gadd45b -/- colony forming units granulocyte/macrophage progenitors displayed prolonged proliferation capacity compared to wt controls upon re-plating in methylcellulose supplemented with interleukin-3. The recovery of the BM myeloid compartment following 5-Fluorouracil-induced myeloablation was much slower in gadd45a -/- and gadd45b -/- mice compared to wt controls. Furthermore, the response of myeloid cells to inflammatory stress, inflicted via intraperitoneal administration of sodium caseinate was impaired in gadd45a -/- and gadd45b -/- mice compared to age-matched wt mice, as indicated by lower percentage of Gr-1-positive cells in the BM and lower number of myeloid cells in peritoneal exudates. Overall, these data indicate that both gadd45a and gadd45b play a role in modulating physiological stress responses of myeloid cells to acute stimulation with differentiating cytokines, myelo-ablation and inflammation. These findings should aid in understanding the response of normal and malignant hematopoietic cells to physiological and chemical stressors including anticancer agents.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Dept Biochem, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Liebermann, DA (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Dept Biochem, 3307 N Broad St,Room 331, Philadelphia, PA 19140 USA.	lieberma@temple.edu			NHLBI NIH HHS [R01 HL70530-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070530] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; Amanullah A, 2003, NATURE, V424, P741, DOI 10.1038/424741b; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Azam N, 2001, J BIOL CHEM, V276, P2766, DOI 10.1074/jbc.M005626200; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; DAEMS WT, 1978, CELL TISSUE RES, V190, P47; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Gupta M, 2005, ONCOGENE, V24, P7170, DOI 10.1038/sj.onc.1208847; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HESTDAL K, 1991, J IMMUNOL, V147, P22; Hildesheim J, 2002, CANCER RES, V62, P7305; Hoffmeyer A, 2001, MOL CELL BIOL, V21, P3137, DOI 10.1128/MCB.21.9.3137-3143.2001; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Lang R, 2002, J IMMUNOL, V169, P2253, DOI 10.4049/jimmunol.169.5.2253; Liebermann D A, 1994, Curr Opin Hematol, V1, P24; Liebermann DA, 2003, BLOOD CELL MOL DIS, V31, P213, DOI 10.1016/S1079-9796(03)00160-8; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; Lu BF, 2004, NAT IMMUNOL, V5, P38, DOI 10.1038/ni1020; Lu BF, 2001, IMMUNITY, V14, P583, DOI 10.1016/S1074-7613(01)00141-8; Marone M, 2002, LEUKEMIA LYMPHOMA, V43, P51, DOI 10.1080/10428190210195; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; NAKAHATA T, 1982, P NATL ACAD SCI-BIOL, V79, P3843, DOI 10.1073/pnas.79.12.3843; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Randall TD, 1997, BLOOD, V89, P3596, DOI 10.1182/blood.V89.10.3596.3596_3596_3606; RICHMAN CM, 1976, BLOOD, V47, P1031; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1996, ONCOGENE, V13, P2255; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Taylor PR, 2003, EUR J IMMUNOL, V33, P2090, DOI 10.1002/eji.200324003; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Vairapandi M, 2002, J CELL PHYSIOL, V192, P327, DOI 10.1002/jcp.10140; Vairapandi M, 1996, ONCOGENE, V12, P2579; Vairapandi M, 2000, J BIOL CHEM, V275, P16810, DOI 10.1074/jbc.275.22.16810; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Yang JF, 2001, NAT IMMUNOL, V2, P157, DOI 10.1038/84264; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Zazzeroni F, 2003, BLOOD, V102, P3270, DOI 10.1182/blood-2003-03-0689; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885	47	36	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2006	25	40					5537	5546		10.1038/sj.onc.1209555	http://dx.doi.org/10.1038/sj.onc.1209555			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16732331				2022-12-25	WOS:000240370400007
J	Cheng, KY; Noble, MEM; Skamnaki, V; Brown, NR; Lowe, ED; Kontogiannis, L; Shen, K; Cole, PA; Siligardi, G; Johnson, LN				Cheng, Kin-Yip; Noble, Martin E. M.; Skamnaki, Vicky; Brown, Nick R.; Lowe, Ed D.; Kontogiannis, Luke; Shen, Kui; Cole, Philip A.; Siligardi, Giuliano; Johnson, Louise N.			The role of the phospho-CDK2/cyclin A recruitment site in substrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE 2; CRYSTAL-STRUCTURE; PROTEIN-KINASE; CYCLIN-A; DOCKING-SITE; EFFICIENT PHOSPHORYLATION; STRUCTURAL BASIS; BINDING DOMAIN; SPECIFICITY; MOTIF	Phospho-CDK2/cyclin A, a kinase that is active in cell cycle S phase, contains an RXL substrate recognition site that is over 40 angstrom from the catalytic site. The role of this recruitment site, which enhances substrate affinity and catalytic efficiency, has been investigated using peptides derived from the natural substrates, namely CDC6 and p107, and a bispeptide inhibitor in which the gamma-phosphate of ATP is covalently attached by a linker to the CDC6 substrate peptide. X-ray studies with a 30-residue CDC6 peptide in complex with pCDK2/cyclin A showed binding of a dodecamer peptide at the recruitment site and a heptapeptide at the catalytic site, but no density for the linking 11 residues. Kinetic studies established that the CDC6 peptide had an 18-fold lower K-m compared with heptapeptide substrate and that this effect required the recruitment peptide to be covalently linked to the substrate peptide. X-ray studies with the CDC6 bispeptide showed binding of the dodecamer at the recruitment site and the modified ATP in two alternative conformations at the catalytic site. The CDC6 bispeptide was a potent inhibitor competitive with both ATP and peptide substrate of pCDK2/cyclin A activity against a heptapeptide substrate (K-i = 0.83 nM) but less effective against RXL-containing substrates. We discuss how localization at the recruitment site (K-D 0.4 mu M) leads to increased catalytic efficiency and the design of a potent inhibitor. The notion of a flexible linker between the sites, which must have more than a minimal number of residues, provides an explanation for recognition and discrimination against different substrates.	Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Diamond Light Source, Didcot OX11 0QX, Oxon, England	University of Oxford; Johns Hopkins University; Diamond Light Source	Johnson, LN (corresponding author), Univ Oxford, Dept Biochem, Lab Mol Biophys, S Parks Rd, Oxford OX1 3QU, England.	louise.johnson@biop.ox.ac.uk	Siligardi, Giuliano/AAO-7024-2020	Noble, Martin/0000-0002-3595-9807	Medical Research Council [G0400957] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G0400957] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ablooglu AJ, 2000, J BIOL CHEM, V275, P30394, DOI 10.1074/jbc.M003524200; ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; Adams PD, 1999, MOL CELL BIOL, V19, P1068; Adams PD, 1996, MOL CELL BIOL, V16, P6623; Andrews MJI, 2004, ORG BIOMOL CHEM, V2, P2735, DOI 10.1039/b409157d; Aubol BE, 2004, J BIOL CHEM, V279, P30182, DOI 10.1074/jbc.M402797200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Biondi RM, 2003, BIOCHEM J, V372, P1, DOI 10.1042/BJ20021641; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Brown NR, 1999, J BIOL CHEM, V274, P8746, DOI 10.1074/jbc.274.13.8746; BRUNGER AT, 1996, XPLOR VERSION 3 8 SY; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; Cook A, 2002, BIOCHEMISTRY-US, V41, P7301, DOI 10.1021/bi0201724; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; Driscoll B, 1999, J BIOL CHEM, V274, P9463, DOI 10.1074/jbc.274.14.9463; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; Fenton J W 2nd, 1981, Ann N Y Acad Sci, V370, P468, DOI 10.1111/j.1749-6632.1981.tb29757.x; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; Gasteiger E., 2005, PROTEIN IDENTIFICATI, DOI 10.1385/1592598900; Guida P, 1999, BIOCHEM BIOPH RES CO, V258, P596, DOI 10.1006/bbrc.1999.0656; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Harper JW, 2001, CHEM REV, V101, P2511, DOI 10.1021/cr0001030; Hines AC, 2004, BIOORG MED CHEM LETT, V14, P2951, DOI 10.1016/j.bmcl.2004.03.039; Honda R, 2005, EMBO J, V24, P452, DOI 10.1038/sj.emboj.7600554; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; JENKS WP, 1981, BIOCHEMISTRY-US, V18, P4046; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEMP BE, 1975, P NATL ACAD SCI USA, V72, P3448, DOI 10.1073/pnas.72.9.3448; Kim C, 2005, SCIENCE, V307, P690, DOI 10.1126/science.1104607; Leatherbarrow RJ, 1992, GRAFFIT VERSION 3 0; Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; Leng XH, 2002, MOL CELL BIOL, V22, P2242, DOI 10.1128/MCB.22.7.2242-2254.2002; LESLIE AG, 1992, MOSFLM JOINT CCP4 ES; Lieser SA, 2005, J BIOL CHEM, V280, P7769, DOI 10.1074/jbc.M411736200; Lolli G, 2004, STRUCTURE, V12, P2067, DOI 10.1016/j.str.2004.08.013; Lowe ED, 2002, BIOCHEMISTRY-US, V41, P15625, DOI 10.1021/bi0268910; Luciani MG, 2000, J MOL BIOL, V300, P503, DOI 10.1006/jmbi.2000.3830; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Mendoza N, 2003, CANCER RES, V63, P1020; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Parang K, 2001, NAT STRUCT BIOL, V8, P37; Pechik I, 2004, P NATL ACAD SCI USA, V101, P2718, DOI 10.1073/pnas.0303440101; Qiao F, 2006, EMBO J, V25, P70, DOI 10.1038/sj.emboj.7600924; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Siligardi G, 2002, J BIOL CHEM, V277, P20151, DOI 10.1074/jbc.M201287200; Siligardi G, 1998, ENANTIOMER, V3, P77; Song HW, 2001, MOL CELL, V7, P615, DOI 10.1016/S1097-2765(01)00208-8; Sorensen CS, 2001, MOL CELL BIOL, V21, P3692, DOI 10.1128/MCB.21.11.3692-3703.2001; Stevenson-Lindert LM, 2003, J BIOL CHEM, V278, P50956, DOI 10.1074/jbc.M306546200; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; Takeda DY, 2001, J BIOL CHEM, V276, P1993, DOI 10.1074/jbc.M005719200; Wohlschlegel JA, 2001, MOL CELL BIOL, V21, P4868, DOI 10.1128/MCB.21.15.4868-4874.2001; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; Zhu GZ, 2005, J BIOL CHEM, V280, P10743, DOI 10.1074/jbc.M413159200; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	63	79	79	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23167	23179		10.1074/jbc.M600480200	http://dx.doi.org/10.1074/jbc.M600480200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16707497	hybrid			2022-12-25	WOS:000239542600080
J	Muller, A; Severi, E; Mulligan, C; Watts, AG; Kelly, DJ; Wilson, KS; Wilkinson, AJ; Thomas, GH				Muller, Axel; Severi, Emmanuele; Mulligan, Christopher; Watts, Andrew G.; Kelly, David J.; Wilson, Keith S.; Wilkinson, Anthony J.; Thomas, Gavin H.			Conservation of structure and mechanism in primary and secondary transporters exemplified by SiaP, a sialic acid binding virulence factor from Haemophilus influenzae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; RHODOBACTER-CAPSULATUS; TRAP TRANSPORTERS; LIGAND-BINDING; HEMAGGLUTININ-NEURAMINIDASE; HALOMONAS-ELONGATA; MOLECULAR-GRAPHICS; SERUM RESISTANCE; SUGAR-BINDING; PROTEIN DCTP	Extracytoplasmic solute receptors (ESRs) are important components of solute uptake systems in bacteria, having been studied extensively as parts of ATP binding cassette transporters. Herein we report the first crystal structure of an ESR protein from a functionally characterized electrochemical ion gradient-dependent secondary transporter. This protein, SiaP, forms part of a tripartite ATP-independent periplasmic transporter specific for sialic acid in Haemophilus influenzae. Surprisingly, the structure reveals an overall topology similar to ATP binding cassette ESR proteins, which is not apparent from the sequence, demonstrating that primary and secondary transporters can share a common structural component. The structure of SiaP in the presence of the sialic acid analogue 2,3-didehydro-2-deoxyN-acetylneuraminic acid reveals the ligand bound in a deep cavity with its carboxylate group forming a salt bridge with a highly conserved Arg residue. Sialic acid binding, which obeys simple bimolecular association kinetics as determined by stopped-flow fluorescence spectroscopy, is accompanied by domain closure about a hinge region and the kinking of an alpha-helix hinge component. The structure provides insight into the evolution, mechanism, and substrate specificity of ESR-dependent secondary transporters that are widespread in prokaryotes.	Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England; Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	University of York - UK; University of York - UK; University of Sheffield	Wilkinson, AJ (corresponding author), Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England.	ajw@ysbl.york.ac.uk; ght2@york.ac.uk	Thomas, Gavin H/E-5753-2011	Thomas, Gavin H/0000-0002-9763-1313; Wilkinson, Anthony/0000-0003-4577-9479; Watts, Andrew/0000-0003-4299-2717; Wilson, Keith/0000-0002-3581-2194; Mulligan, Christopher/0000-0001-5157-4651	Biotechnology and Biological Sciences Research Council [BB/C509807/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Allen S, 2005, INFECT IMMUN, V73, P5291, DOI 10.1128/IAI.73.9.5291-5300.2005; Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; BROSSMER R, 1971, H-S Z PHYSIOL CHEM, V352, P1715, DOI 10.1515/bchm2.1971.352.2.1715; BURMEISTER WP, 1992, EMBO J, V11, P49, DOI 10.1002/j.1460-2075.1992.tb05026.x; Clarke TE, 2000, NAT STRUCT BIOL, V7, P287; Crennell S, 2000, NAT STRUCT BIOL, V7, P1068; CRENNELL SJ, 1993, P NATL ACAD SCI USA, V90, P9852, DOI 10.1073/pnas.90.21.9852; Crocker PR, 2002, CURR OPIN STRUC BIOL, V12, P609, DOI 10.1016/S0959-440X(02)00375-5; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; Ducros VMA, 2001, J MOL BIOL, V306, P759, DOI 10.1006/jmbi.2001.4443; Dwyer MA, 2004, CURR OPIN STRUC BIOL, V14, P495, DOI 10.1016/j.sbi.2004.07.004; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Forward JA, 1997, J BACTERIOL, V179, P5482, DOI 10.1128/jb.179.17.5482-5493.1997; Fukami-Kobayashi K, 1999, J MOL BIOL, V286, P279, DOI 10.1006/jmbi.1998.2454; Fukami-Kobayashi K, 2003, MOL BIOL EVOL, V20, P267, DOI 10.1093/molbev/msg038; Grammann K, 2002, J BACTERIOL, V184, P3078, DOI 10.1128/JB.184.11.3078-3085.2002; HAMBLIN MJ, 1993, MOL GEN GENET, V237, P215, DOI 10.1007/BF00282803; Hayward S, 2002, J MOL GRAPH MODEL, V21, P181, DOI 10.1016/S1093-3263(02)00140-7; Hood DW, 1999, MOL MICROBIOL, V33, P679, DOI 10.1046/j.1365-2958.1999.01509.x; Huvent I, 2006, J MOL BIOL, V356, P1014, DOI 10.1016/j.jmb.2005.11.096; Jacobs MHJ, 1996, P NATL ACAD SCI USA, V93, P12786, DOI 10.1073/pnas.93.23.12786; Kelly DJ, 2001, FEMS MICROBIOL REV, V25, P405, DOI 10.1111/j.1574-6976.2001.tb00584.x; Lawrence MC, 2004, J MOL BIOL, V335, P1343, DOI 10.1016/j.jmb.2003.11.032; Lawrence MC, 1998, STRUCTURE, V6, P1553, DOI 10.1016/S0969-2126(98)00153-1; Ledvina PS, 1998, PROTEIN SCI, V7, P2550, DOI 10.1002/pro.5560071208; Lee YH, 1999, NAT STRUCT BIOL, V6, P628; May AP, 1998, MOL CELL, V1, P719, DOI 10.1016/S1097-2765(00)80071-4; MILLER DM, 1980, J BIOL CHEM, V255, P2465; MILLER DM, 1983, J BIOL CHEM, V258, P3665; Moustafa I, 2004, J BIOL CHEM, V279, P40819, DOI 10.1074/jbc.M404965200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; Potterton L, 2004, ACTA CRYSTALLOGR D, V60, P2288, DOI 10.1107/S0907444904023716; Prakash S, 2003, BBA-BIOMEMBRANES, V1618, P79, DOI 10.1016/j.bbamem.2003.10.010; Rabus R, 1999, MICROBIOL-SGM, V145, P3431, DOI 10.1099/00221287-145-12-3431; SCHMID W, 1988, TETRAHEDRON LETT, V29, P3643, DOI 10.1016/S0040-4039(00)82143-7; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Severi E, 2005, MOL MICROBIOL, V58, P1173, DOI 10.1111/j.1365-2958.2005.04901.x; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SHAW JG, 1991, MOL MICROBIOL, V5, P3055, DOI 10.1111/j.1365-2958.1991.tb01865.x; Steenbergen SM, 2005, INFECT IMMUN, V73, P1284, DOI 10.1128/IAI.73.3.1284-1294.2005; Takahashi H, 2004, ACTA CRYSTALLOGR D, V60, P1846, DOI 10.1107/S0907444904019420; Taylor G, 1996, CURR OPIN STRUC BIOL, V6, P830, DOI 10.1016/S0959-440X(96)80014-5; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Tetsch L, 2002, FEMS MICROBIOL LETT, V211, P213, DOI 10.1111/j.1574-6968.2002.tb11227.x; Thomas GH, 2006, MICROBIOL-SGM, V152, P187, DOI 10.1099/MIC.0.28334-0; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Vimr ER, 2004, MICROBIOL MOL BIOL R, V68, P132, DOI 10.1128/MMBR.68.1.132-153.2004; WALLIS R, 1995, BIOCHEMISTRY-US, V34, P13743, DOI 10.1021/bi00042a004; WALMSLEY AR, 1992, BIOCHEMISTRY-US, V31, P11175, DOI 10.1021/bi00160a031; WALMSLEY AR, 1992, J BIOL CHEM, V267, P8064; Wilkinson T., 2003, ABC PROTEINS BACTERI, P187; Wyborn NR, 2001, FEMS MICROBIOL LETT, V194, P13, DOI 10.1111/j.1574-6968.2001.tb09439.x	55	62	63	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22212	22222		10.1074/jbc.M603463200	http://dx.doi.org/10.1074/jbc.M603463200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16702222	Green Accepted, hybrid			2022-12-25	WOS:000239387100068
J	Ou, XM; Chen, K; Shih, JC				Ou, Xiao-Ming; Chen, Kevin; Shih, Jean C.			Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5-HT1A RECEPTOR GENE; SIGNAL-TRANSDUCTION PATHWAY; B-GENES; DNA-BINDING; PROMOTER ORGANIZATION; TRANSCRIPTION FACTORS; MOLECULAR-BASIS; POINT MUTATION; MAO-A; PROTEIN	Monoamine oxidase (MAO) A is a key enzyme for the degradation of neurotransmitters serotonin, norepinephrine, and dopamine. There are three consensus glucocorticoid/androgen response elements and four Sp1-binding sites in the human monoamine oxidase A 2-kb promoter. A novel transcription factor R1 (RAM2/CDCA7L) interacts with Sp1-binding sites and represses MAO A gene expression. Luciferase assays show that glucocorticoid ( dexamethasone) and androgen ( R1881) increase MAO A promoter and catalytic activities in human neuroblastoma and glioblastoma cells. Gel-shift analysis demonstrates that glucocorticoid/androgen receptors interact directly with the third glucocorticoid/androgen response element. Glucocorticoid/androgen receptors also interact with Sp1-binding sites indirectly via transcription factor Sp1. In addition, dexamethasone induces R1 translocation from the cytosol to the nucleus in a time-dependent manner in both the neuroblastoma and wild-type UW228 cell lines but not in R1 knock-down UW228 cells. In summary, this study shows that glucocorticoid enhances monoamine oxidase A gene expression by 1) regulation of R1 translocation; 2) direct interaction of the glucocorticoid receptor with the third glucocorticoid/androgen response element; and 3) indirect interaction of glucocorticoid receptor with the Sp1 or R1 transcription factor on Sp1-binding sites of the MAO A promoter. Androgen also up-regulatesMAOA gene expression by direct interaction of androgen receptor with the third glucocorticoid/androgen response element. Androgen receptor indirectly interacts with the Sp1, but not R1 transcription factor, on Sp1-binding sites. This study provides new insights on the differential regulation of MAO A by glucocorticoid and androgen.	Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Shih, JC (corresponding author), Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, 1985 Zonal Ave,PSC 528, Los Angeles, CA 90033 USA.	jcshih@usc.edu	Chen, Kevin/GYU-8963-2022		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH067968, R37MH039085] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH67968, R37 MH39085] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; BEATO M, 1989, J STEROID BIOCHEM, V32, P737, DOI 10.1016/0022-4731(89)90521-9; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; Chen K, 2004, J BIOL CHEM, V279, P39645, DOI 10.1074/jbc.M405550200; Chen K, 2005, J BIOL CHEM, V280, P11552, DOI 10.1074/jbc.M410033200; Curtin D, 2001, MOL ENDOCRINOL, V15, P1906, DOI 10.1210/me.15.11.1906; De Zutter GS, 2001, P NATL ACAD SCI USA, V98, P6168, DOI 10.1073/pnas.111027698; DEKLOET ER, 1990, J STEROID BIOCHEM, V37, P387, DOI 10.1016/0960-0760(90)90489-8; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EDELSTEIN SB, 1986, CELL MOL NEUROBIOL, V6, P121, DOI 10.1007/BF00711066; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Geha RM, 2001, J BIOL CHEM, V276, P9877, DOI 10.1074/jbc.M006972200; GRIMSBY J, 1991, P NATL ACAD SCI USA, V88, P3637, DOI 10.1073/pnas.88.9.3637; Grimsby J, 1997, NAT GENET, V17, P206, DOI 10.1038/ng1097-206; Huang A, 2005, CANCER RES, V65, P5607, DOI 10.1158/0008-5472.CAN-05-0500; Joels M, 2004, STRESS, V7, P221, DOI 10.1080/10253890500070005; JOHNSTON JP, 1968, BIOCHEM PHARMACOL, V17, P1285, DOI 10.1016/0006-2952(68)90066-X; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; Kato M, 1998, J PHARMACOL EXP THER, V284, P983; Knoll J, 1972, Adv Biochem Psychopharmacol, V5, P393; LAN NC, 1989, GENOMICS, V4, P552, DOI 10.1016/0888-7543(89)90279-6; Lee AL, 2002, BIPOLAR DISORD, V4, P117, DOI 10.1034/j.1399-5618.2002.01144.x; LUINE VN, 1975, BRAIN RES, V86, P293, DOI 10.1016/0006-8993(75)90704-0; Lyng FM, 2000, BIOL REPROD, V63, P736, DOI 10.1095/biolreprod63.3.736; Nelson CC, 1999, MOL ENDOCRINOL, V13, P2090, DOI 10.1210/me.13.12.2090; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Ou XM, 2000, J BIOL CHEM, V275, P8161, DOI 10.1074/jbc.275.11.8161; Ou XM, 2004, J BIOL CHEM, V279, P21021, DOI 10.1074/jbc.M312638200; Ou XM, 2003, J NEUROSCI, V23, P7415; Ou XM, 2001, J BIOL CHEM, V276, P14299, DOI 10.1074/jbc.M005363200; Rao MA, 2002, J BIOL CHEM, V277, P48020, DOI 10.1074/jbc.M209741200; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Sabol SZ, 1998, HUM GENET, V103, P273, DOI 10.1007/s004390050816; SHIH JC, 1991, NEUROPSYCHOPHARMACOL, V4, P1; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; SHIH JC, 1993, J PSYCHIATR NEUROSCI, V18, P25; Slagsvold T, 2001, J BIOL CHEM, V276, P31030, DOI 10.1074/jbc.M104310200; Slotkin TA, 1998, BRAIN RES BULL, V47, P345, DOI 10.1016/S0361-9230(98)00111-7; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; TRAISH AM, 1984, ENDOCRINOLOGY, V114, P1761, DOI 10.1210/endo-114-5-1761; Volz HP, 1998, DRUG AGING, V13, P341, DOI 10.2165/00002512-199813050-00002; Wolkowitz OM, 1999, PSYCHOSOM MED, V61, P698, DOI 10.1097/00006842-199909000-00011; Wong WK, 2002, J BIOL CHEM, V277, P22222, DOI 10.1074/jbc.M202844200; Wong WK, 2001, MOL PHARMACOL, V59, P852, DOI 10.1124/mol.59.4.852; ZHU QS, 1994, J NEUROSCI, V14, P7393; ZHU QS, 1992, J NEUROSCI, V12, P4437	47	121	125	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21512	21525		10.1074/jbc.M600250200	http://dx.doi.org/10.1074/jbc.M600250200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16728402	hybrid			2022-12-25	WOS:000239187300086
J	Nelson, RF; Glenn, KA; Miller, VM; Wen, H; Paulson, HL				Nelson, Rick F.; Glenn, Kevin A.; Miller, Victor M.; Wen, Hsiang; Paulson, Henry L.			A novel route for F-box protein-mediated ubiquitination links CHIP to glycoprotein quality control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOGNIZES SUGAR CHAINS; HEAT-SHOCK PROTEINS; LIGASE COMPLEX; FAMILY; DEGRADATION; IDENTIFICATION; UBIQUITYLATION; PROTEOLYSIS; EXPRESSION; INTERACTS	In SCF (Skp1/Cullin/F-box protein) ubiquitin ligases, substrate specificity is conferred by a diverse array of F-box proteins. Only in fully assembled SCF complexes, it is believed, can substrates bound to F-box proteins become ubiquitinated. Here we show that Fbx2, a brain-enriched F-box protein implicated in the ubiquitination of glycoproteins discarded from the endoplasmic reticulum, binds the co-chaperone/ubiquitin ligase CHIP (C terminus of Hsc-70-interacting protein) through a unique N-terminal PEST domain in Fbx2. CHIP facilitates the ubiquitination and degradation of Fbx2-bound glycoproteins, including unassembled NMDA receptor subunits. These findings indicate that CHIP acts with Fbx2 in a novel ubiquitination pathway that links CHIP to glycoprotein quality control in neurons. In addition, they expand the repertoire of pathways by which F-box proteins can regulate ubiquitination and suggest a new role for PEST domains as a protein interaction motif.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Neurol, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille A Carver Coll Med, Grad Program Genet, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille A Carver Coll Med, Med Sci Training Program, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille A Carver Coll Med, Grad Program Neurosci, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Internal Med, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa; University of Iowa	Paulson, HL (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Neurol, 2007 RCP, Iowa City, IA 52242 USA.	henry-paulson@uiowa.edu		Glenn, Kevin/0000-0002-6941-9649; Nelson, Rick/0000-0001-5749-6383	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047535, F30NS047872] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM08629] Funding Source: Medline; NINDS NIH HHS [F30 NS047872, R01 NS47535] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Dai Q, 2003, EMBO J, V22, P5446, DOI 10.1093/emboj/cdg529; Erhardt JA, 1998, J BIOL CHEM, V273, P35222, DOI 10.1074/jbc.273.52.35222; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Henzl MT, 2004, HEARING RES, V191, P101, DOI 10.1016/j.heares.2004.01.005; Henzl MT, 2001, HEARING RES, V157, P100, DOI 10.1016/S0378-5955(01)00285-4; Ilyin GP, 2000, GENOMICS, V67, P40, DOI 10.1006/geno.2000.6211; Ilyin GP, 2002, GENE, V296, P11, DOI 10.1016/S0378-1119(02)00867-3; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kato A, 2005, P NATL ACAD SCI USA, V102, P5600, DOI 10.1073/pnas.0501769102; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Li KW, 2004, J BIOL CHEM, V279, P987, DOI 10.1074/jbc.M303116200; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Mizushima T, 2004, NAT STRUCT MOL BIOL, V11, P365, DOI 10.1038/nsmb732; Murai-Takebe R, 2004, J BIOL CHEM, V279, P11616, DOI 10.1074/jbc.M311463200; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Yoshida Y, 2002, NATURE, V418, P438, DOI 10.1038/nature00890; Yoshida Y, 2003, J BIOL CHEM, V278, P43877, DOI 10.1074/jbc.M304157200; Yoshida Y, 2005, METHOD ENZYMOL, V398, P159, DOI 10.1016/S0076-6879(05)98014-2; Zhang MH, 2005, MOL CELL, V20, P525, DOI 10.1016/j.molcel.2005.09.023; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	35	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20242	20251		10.1074/jbc.M602423200	http://dx.doi.org/10.1074/jbc.M602423200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16682404	hybrid			2022-12-25	WOS:000239038200049
J	Yamagishi, S; Nakamura, K; Matsui, T; Inagaki, Y; Takenaka, K; Jinnouchi, Y; Yoshida, Y; Matsuura, T; Narama, I; Motomiya, Y; Takeuchi, M; Inoue, H; Yoshimura, A; Bucala, R; Imaizumi, T				Yamagishi, Sho-ichi; Nakamura, Kazuo; Matsui, Takanori; Inagaki, Yosuke; Takenaka, Katsuhiko; Jinnouchi, Yuko; Yoshida, Yumiko; Matsuura, Tetsuro; Narama, Isao; Motomiya, Yoshihiro; Takeuchi, Masayoshi; Inoue, Hiroyoshi; Yoshimura, Akihiko; Bucala, Richard; Imaizumi, Tsutomu			Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIABETIC-RETINOPATHY; INDUCED APOPTOSIS; INDUCED INJURY; UP-REGULATION; SERUM-LEVELS; FACTOR PEDF; ANGIOGENESIS; STRESS; RECEPTOR; AGE	Pigment epithelium-derived factor (PEDF) is the most potent inhibitor of angiogenesis, suggesting that loss of PEDF contributes to proliferative diabetic retinopathy. However, the role of PEDF against retinal vascular hyperpermeability remains to be elucidated. We investigated here whether and how PEDF could inhibit the advanced glycation end product (AGE) signaling to vascular hyperpermeability. Intravenous administration of AGEs to normal rats not only increased retinal vascular permeability by stimulating vascular endothelial growth factor (VEGF) expression but also decreased retinal PEDF levels. Simultaneous treatments with PEDF inhibited the AGE-elicited VEGF-mediated permeability by down-regulating mRNA levels of p22(phox) and gp91(phox), membrane components of NADPH oxidase, and subsequently decreasing retinal levels of an oxidative stress marker, 8-hydroxydeoxy-guanosine. PEDF also inhibited the AGE-induced vascular hyperpermeability evaluated by transendothelial electrical resistance by suppressing VEGF expression. Furthermore, PEDF decreased reactive oxygen species (ROS) generation in AGE-exposed endothelial cells by suppressing NADPH oxidase activity via down-regulation of mRNA levels of p22(PHOX) and gp91(PHOX). This led to blockade of the AGE-elicited Ras activation and NF-kappa B-dependent VEGF gene induction in endothelial cells. These results indicate that the central mechanism for PEDF inhibition of the AGE signaling to vascular permeability is by suppression of NADPH oxidase-mediated ROS generation and subsequent VEGF expression. Substitution of PEDF may offer a promising strategy for halting the development of diabetic retinopathy.	Kurume Univ, Sch Med, Dept Internal Med 3, Kurume, Fukuoka 8300011, Japan; Kurume Univ, Sch Med, Radioisotope Inst Basic & Clin Med, Kurume, Fukuoka 8300011, Japan; Setsunan Univ, Fac Pharmaceut Sci, Dept Pathol, Hirakata, Osaka 573000, Japan; Suiyukai Clin, Kashihara, Nara 634000, Japan; Hokuriku Univ, Fac Pharmaceut Sci, Dept Pathophysiol Sci, Kanazawa, Ishikawa 9201181, Japan; Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunool, Fukuoka 8120054, Japan; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA	Kurume University; Kurume University; Setsunan University; Hokuriku University; Kyushu University; Yale University	Yamagishi, S (corresponding author), Kurume Univ, Sch Med, Dept Internal Med 3, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.	shoichi@med.kurume-u.ac.jp	Yoshimura, Akihiko/K-5515-2013	Matsui, Takanori/0000-0001-9506-7571				Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Amano S, 2005, MICROVASC RES, V69, P45, DOI 10.1016/j.mvr.2004.11.001; Becker PM, 2005, CIRC RES, V96, P1257, DOI 10.1161/01.RES.0000171756.13554.49; Boehm BO, 2004, DIABETOLOGIA, V47, P1376, DOI 10.1007/s00125-004-1455-y; Boehm BO, 2003, DIABETOLOGIA, V46, P394, DOI 10.1007/s00125-003-1040-9; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; Cai J, 2006, J BIOL CHEM, V281, P3604, DOI 10.1074/jbc.M507401200; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Duh E, 1999, DIABETES, V48, P1899, DOI 10.2337/diabetes.48.10.1899; Duh EJ, 2002, INVEST OPHTH VIS SCI, V43, P821; DVORAK HF, 1995, AM J PATHOL, V146, P1029; DYER DG, 1991, J BIOL CHEM, V266, P11654; FRANK RN, 1991, OPHTHALMOLOGY, V98, P586; Gerdemann A, 2002, NEPHROL DIAL TRANSPL, V17, P1045, DOI 10.1093/ndt/17.6.1045; GRANDHEE SK, 1991, J BIOL CHEM, V266, P11649; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Liu H, 2004, P NATL ACAD SCI USA, V101, P6605, DOI 10.1073/pnas.0308342101; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; Miura J, 2003, J DIABETES COMPLICAT, V17, P16, DOI 10.1016/S1056-8727(02)00183-6; Moore TCB, 2003, INVEST OPHTH VIS SCI, V44, P4457, DOI 10.1167/iovs.02-1063; Mucha DR, 2003, AM J PHYSIOL-HEART C, V284, pH994, DOI 10.1152/ajpheart.00862.2002; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Ogata N, 2001, AM J OPHTHALMOL, V132, P378, DOI 10.1016/S0002-9394(01)01008-X; Okamoto T, 2002, FASEB J, V16, P1928, DOI 10.1096/fj.02-0030fje; Okamoto T, 2002, BIOCHEM BIOPH RES CO, V297, P419, DOI 10.1016/S0006-291X(02)02218-0; Pachydaki SI, 2006, EXP EYE RES, V82, P807, DOI 10.1016/j.exer.2005.09.022; Pal S, 2001, CANCER RES, V61, P6952; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Rak J, 2000, CANCER RES, V60, P490; Sasaki N, 2002, NEUROSCI LETT, V326, P117, DOI 10.1016/S0304-3940(02)00310-5; Schafer G, 2003, J BIOL CHEM, V278, P8190, DOI 10.1074/jbc.M211999200; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Spranger J, 2001, DIABETES, V50, P2641, DOI 10.2337/diabetes.50.12.2641; Stitt Alan W., 2000, Molecular Cell Biology Research Communications, V3, P380, DOI 10.1006/mcbr.2000.0243; Stitt AW, 2003, EXP MOL PATHOL, V75, P95, DOI 10.1016/S0014-4800(03)00035-2; Stitt AW, 1997, AM J PATHOL, V150, P523; Takeuchi M, 1999, MOL MED, V5, P393, DOI 10.1007/BF03402128; Takeuchi M, 2003, J NEUROPATH EXP NEUR, V62, P486, DOI 10.1093/jnen/62.5.486; Takeuchi M, 2000, MOL MED, V6, P114, DOI 10.1007/BF03401779; TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Vlassara H, 1996, DIABETES, V45, pS65, DOI 10.2337/diab.45.3.S65; Wautier MP, 2001, AM J PHYSIOL-ENDOC M, V280, pE685, DOI 10.1152/ajpendo.2001.280.5.E685; Wendt Thoralf, 2002, Curr Atheroscler Rep, V4, P228, DOI 10.1007/s11883-002-0024-4; Yamagishi S, 1997, J BIOL CHEM, V272, P8723, DOI 10.1074/jbc.272.13.8723; Yamagishi S, 1998, DIABETOLOGIA, V41, P1435, DOI 10.1007/s001250051089; Yamagishi S, 2005, DRUG EXP CLIN RES, V31, P227; Yamagishi S, 2003, KIDNEY INT, V63, P464, DOI 10.1046/j.1523-1755.2003.00752.x; Yamagishi S, 2002, BIOCHEM BIOPH RES CO, V296, P877, DOI 10.1016/S0006-291X(02)00940-3; Yamagishi S, 2002, MOL MED, V8, P546, DOI 10.1007/BF03402164; Yamagishi S, 2002, J BIOL CHEM, V277, P20309, DOI 10.1074/jbc.M202634200; YAN SD, 1994, J BIOL CHEM, V269, P9889	56	206	218	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20213	20220		10.1074/jbc.M602110200	http://dx.doi.org/10.1074/jbc.M602110200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16707486	hybrid			2022-12-25	WOS:000239038200046
J	Zhu, YH; Vionnet, C; Conzelmann, A				Zhu, Yonghua; Vionnet, Christine; Conzelmann, Andreas			Ethanolaminephosphate side chain added to glycosylphosphatidylinositol (GPI) anchor by Mcd4p is required for ceramide remodeling and forward transport of GPI proteins from endoplasmic reticulum to golgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL INTEGRITY; BUD-SITE SELECTION; SACCHAROMYCES-CEREVISIAE; MEMBRANE ANCHORS; ALPHA-1,4-LINKED MANNOSE; TRYPANOSOMA-BRUCEI; CORE STRUCTURE; BUDDING YEAST; 1ST STEP; BIOSYNTHESIS	Glycosylphosphatidylinositol (GPI) anchors of mammals as well as yeast contain ethanolaminephosphate side chains on the alpha 1-4- and the alpha 1-6-linked mannoses of the anchor core structure (protein-CO-NH-(CH2)(2)-PO4-6Man alpha 1-2Man alpha 1-6Man alpha 1-4GlcNH(2)-inositol-PO4- lipid). In yeast, the ethanolaminephosphate on the alpha 1-4-linked mannose is added during the biosynthesis of the GPI lipid by Mcd4p. MCD4 is essential because Gpi10p, the mannosyltransferase adding the subsequent alpha 1-2-linked mannose, requires substrates with an ethanolaminephosphate on the alpha 1-4-linked mannose. The Gpi10p ortholog of Trypanosoma brucei has no such requirement. Here we show that the overexpression of this ortholog rescues mcd4 Delta cells. Phenotypic analysis of the rescued mcd4 Delta cells leads to the conclusion that the ethanolaminephosphate on the alpha 1-4-linked mannose, beyond being an essential determinant for Gpi10p, is necessary for an efficient recognition of GPI lipids and GPI proteins by the GPI transamidase for the efficient transport of GPI-anchored proteins from the endoplasmic reticulum to Golgi and for the physiological incorporation of ceramides into GPI anchors by lipid remodeling. Furthermore, mcd4 Delta cells have a marked defect in axial bud site selection, whereas this process is normal in gpi7 Delta and gpi1. This also suggests that axial bud site selection specifically depends on the presence of the ethanolaminephosphate on the alpha 1-4-linked mannose.	Univ Fribourg, Dept Med Biochem, CH-1700 Fribourg, Switzerland	University of Fribourg	Conzelmann, A (corresponding author), Div Biochem, Chemin Musee 5, CH-1700 Fribourg, Switzerland.	andreas.conzelmann@unifr.ch						ASH J, 1995, J BIOL CHEM, V270, P20847, DOI 10.1074/jbc.270.35.20847; Barz WP, 1999, MOL BIOL CELL, V10, P1043, DOI 10.1091/mbc.10.4.1043; Benachour A, 1999, J BIOL CHEM, V274, P15251, DOI 10.1074/jbc.274.21.15251; BENGHEZAL M, 1995, J CELL BIOL, V130, P1333, DOI 10.1083/jcb.130.6.1333; Canivenc-Gansel E, 1998, GLYCOBIOLOGY, V8, P761, DOI 10.1093/glycob/8.8.761; Casamayor A, 2002, CURR OPIN MICROBIOL, V5, P179, DOI 10.1016/S1369-5274(02)00300-4; CONZELMANN A, 2005, CELL BIOL DYNAMICS Y, P133; Doering TL, 1996, EMBO J, V15, P182, DOI 10.1002/j.1460-2075.1996.tb00346.x; FANKHAUSER C, 1993, J BIOL CHEM, V268, P26365; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 2006, ESSENTIAL GLYCOBIOLO; Flury I, 2000, J BIOL CHEM, V275, P24458, DOI 10.1074/jbc.M003844200; Fujita M, 2004, J BIOL CHEM, V279, P51869, DOI 10.1074/jbc.M405232200; Gaynor EC, 1999, MOL BIOL CELL, V10, P627, DOI 10.1091/mbc.10.3.627; Guillas I, 2000, METHOD ENZYMOL, V312, P506; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; Hong YJ, 1999, J BIOL CHEM, V274, P35099, DOI 10.1074/jbc.274.49.35099; Imhof I, 2004, J BIOL CHEM, V279, P19614, DOI 10.1074/jbc.M401873200; Imhof I, 2000, GLYCOBIOLOGY, V10, P1271, DOI 10.1093/glycob/10.12.1271; Kapteyn JC, 1997, J BACTERIOL, V179, P6279, DOI 10.1128/JB.179.20.6279-6284.1997; Kinoshita T, 2000, CURR OPIN CHEM BIOL, V4, P632, DOI 10.1016/S1367-5931(00)00151-4; Kushnirov VV, 2000, YEAST, V16, P857, DOI 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B; Leidich SD, 1996, J BIOL CHEM, V271, P27829, DOI 10.1074/jbc.271.44.27829; Maneesri J, 2005, J BIOSCI BIOENG, V99, P354, DOI 10.1263/jbb.99.354; MCCONVILLE MJ, 1993, J BIOL CHEM, V268, P15595; Mondesert G, 1997, GENETICS, V147, P421; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Muniz M, 2000, J CELL BIOL, V148, P925, DOI 10.1083/jcb.148.5.925; Nagamune K, 2000, P NATL ACAD SCI USA, V97, P10336, DOI 10.1073/pnas.180230697; Ni L, 2001, MOL BIOL CELL, V12, P2147, DOI 10.1091/mbc.12.7.2147; NUOFFER C, 1993, J BIOL CHEM, V268, P10558; Packeiser AN, 1999, YEAST, V15, P1485, DOI 10.1002/(SICI)1097-0061(199910)15:14<1485::AID-YEA477>3.0.CO;2-4; Reggiori F, 1997, EMBO J, V16, P3506, DOI 10.1093/emboj/16.12.3506; Sherman F, 2002, METHOD ENZYMOL, V350, P3, DOI 10.1016/S0076-6879(02)50954-X; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; Sipos G, 1997, EMBO J, V16, P3494, DOI 10.1093/emboj/16.12.3494; Sobering AK, 2004, CELL, V117, P637, DOI 10.1016/j.cell.2004.05.003; Storey MK, 2001, BBA-MOL CELL BIOL L, V1532, P234, DOI 10.1016/S1388-1981(01)00129-9; Sutterlin C, 1998, BIOCHEM J, V332, P153; Sutterlin C, 1997, EMBO J, V16, P6374, DOI 10.1093/emboj/16.21.6374; TOH EA, 2002, GENES GENET SYST, V77, P309; TOH EA, 2001, GENES GENET SYST, V76, P393; Tomishige N, 2005, YEAST, V22, P141, DOI 10.1002/yea.1206; Vossen JH, 1997, J BACTERIOL, V179, P2202, DOI 10.1128/jb.179.7.2202-2209.1997; Watanabe R, 2002, J BIOL CHEM, V277, P49538, DOI 10.1074/jbc.M206209200	45	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					19830	19839		10.1074/jbc.M601425200	http://dx.doi.org/10.1074/jbc.M601425200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16704983	hybrid, Green Submitted			2022-12-25	WOS:000239038200006
J	Schachter, KA; Du, Y; Lin, AN; Gallo, KA				Schachter, Karen A.; Du, Yan; Lin, Anning; Gallo, Kathleen A.			Dynamic positive feedback phosphorylation of mixed lineage kinase 3 by JNK reversibly regulates its distribution to triton-soluble domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIXED-LINEAGE KINASE; PROTEIN-KINASE; MAP KINASE; SIGNALING PATHWAY; OOCYTE MATURATION; TYROSINE KINASE; BINDING MOTIF; IN-VIVO; B-RAF; ACTIVATION	MLK3 (mixed lineage kinase 3) is a widely expressed, mammalian serine/threonine protein kinase that activates multiple MAPK pathways. Previously our laboratory used in vivo labeling/mass spectrometry to identify phosphorylation sites of activated MLK3. Seven of 11 identified sites correspond to the consensus motif for phosphorylation by proline-directed kinases. Based on these results, we hypothesized that JNK, or another proline-directed kinase, phosphorylates MLK3 as part of a feedback loop. Herein we provide evidence that MLK3 can be phosphorylated by JNK in vitro and in vivo. Blockade of JNK results in dephosphorylation of MLK3. The hypophosphorylated form of MLK3 is inactive and redistributes to a Triton-insoluble fraction. Recovery from JNK inhibition restores MLK3 solubility and activity, indicating that the redistribution process is reversible. This work describes a novel mode of regulation of MLK3, by which JNK-mediated feedback phosphorylation of MLK3 regulates its activation and deactivation states by cycling between Triton-soluble and Triton-insoluble forms.	Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Michigan State Univ, Cell & Mol Biol Program, E Lansing, MI 48824 USA; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA	Michigan State University; Michigan State University; Michigan State University; University of Chicago	Gallo, KA (corresponding author), Michigan State Univ, Dept Physiol, 4180 Biomed & Phys Sci Bldg, E Lansing, MI 48824 USA.	gallok@msu.edu						Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bock BC, 2000, J BIOL CHEM, V275, P14231, DOI 10.1074/jbc.275.19.14231; Brancho D, 2005, MOL CELL BIOL, V25, P3670, DOI 10.1128/MCB.25.9.3670-3681.2005; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Brummer T, 2003, ONCOGENE, V22, P8823, DOI 10.1038/sj.onc.1207185; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Chadee DN, 2006, P NATL ACAD SCI USA, V103, P4463, DOI 10.1073/pnas.0510651103; Chadee DN, 2004, NAT CELL BIOL, V6, P770, DOI 10.1038/ncb1152; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dawson John F., 1999, Frontiers in Bioscience, V4, pd646, DOI 10.2741/Dawson; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Du Y, 2005, J BIOL CHEM, V280, P42984, DOI 10.1074/jbc.M502671200; Esch RK, 2002, P NATL ACAD SCI USA, V99, P9160, DOI 10.1073/pnas.142034399; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Ganguly A, 2004, J NEUROCHEM, V88, P469, DOI 10.1046/j.1471-4159.2003.02176.x; Ghosh S, 2001, MOL BIOL CELL, V12, P3864, DOI 10.1091/mbc.12.12.3864; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; Hall JP, 2002, J CELL BIOCHEM, V86, P1, DOI 10.1002/jcb.10187; Harris CA, 2002, J NEUROSCI, V22, P103, DOI 10.1523/JNEUROSCI.22-01-00103.2002; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Kim KY, 2004, J BIOL CHEM, V279, P29478, DOI 10.1074/jbc.M313947200; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Liu YF, 2000, J BIOL CHEM, V275, P19035, DOI 10.1074/jbc.C000180200; Matten WT, 1996, DEV BIOL, V179, P485, DOI 10.1006/dbio.1996.0277; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Mota M, 2001, J NEUROSCI, V21, P4949, DOI 10.1523/JNEUROSCI.21-14-04949.2001; Nihalani D, 2001, EMBO J, V20, P3447, DOI 10.1093/emboj/20.13.3447; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; Phelan DR, 2001, J BIOL CHEM, V276, P10801, DOI 10.1074/jbc.M008237200; Pittet JF, 2005, J IMMUNOL, V174, P384, DOI 10.4049/jimmunol.174.1.384; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; Roy LM, 1996, ONCOGENE, V12, P2203; Rushworth LK, 2006, MOL CELL BIOL, V26, P2262, DOI 10.1128/MCB.26.6.2262-2272.2006; Sathyanarayana P, 2002, MOL CELL, V10, P1527, DOI 10.1016/S1097-2765(02)00734-7; Schoorlemmer J, 2002, J BIOL CHEM, V277, P49111, DOI 10.1074/jbc.M205520200; Schulenberg B, 2004, ELECTROPHORESIS, V25, P2526, DOI 10.1002/elps.200406007; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Steinberg TH, 2003, PROTEOMICS, V3, P1128, DOI 10.1002/pmic.200300434; Stickney JT, 2004, CANCER RES, V64, P2717, DOI 10.1158/0008-5472.CAN-03-3798; Stronach B, 2002, GENE DEV, V16, P377, DOI 10.1101/gad.953002; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Vacratsis PO, 2000, J BIOL CHEM, V275, P27893; Vacratsis PO, 2002, BIOCHEMISTRY-US, V41, P5613, DOI 10.1021/bi016075c; Wang LH, 2004, ANNU REV PHARMACOL, V44, P451, DOI 10.1146/annurev.pharmtox.44.101802.121840; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Witowsky JA, 2003, J BIOL CHEM, V278, P1403, DOI 10.1074/jbc.C200616200; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; Xu ZH, 2005, MOL CELL BIOL, V25, P9949, DOI 10.1128/MCB.25.22.9949-9959.2005; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Yan SR, 1996, FEBS LETT, V380, P198; Zhang H, 2001, J BIOL CHEM, V276, P45598, DOI 10.1074/jbc.M107176200; Zhang HF, 2004, J BIOL CHEM, V279, P44955, DOI 10.1074/jbc.M407617200; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	67	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19134	19144		10.1074/jbc.M603324200	http://dx.doi.org/10.1074/jbc.M603324200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16687404	hybrid			2022-12-25	WOS:000238847000028
J	Zhou, MY; Li, XM; Lavker, RM				Zhou, Mingyuan; Li, Xin-min; Lavker, Robert M.			Transcriptional profiling of enriched Populations of stem cells versus transient amplifying cells - A comparison of limbal and corneal epithelial basal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; LABEL-RETAINING CELLS; GENE-EXPRESSION; DIFFERENTIAL EXPRESSION; MICROARRAY ANALYSIS; CLONAL ANALYSIS; EPIREGULIN; TRANSPLANTATION; CONJUNCTIVAL; MOVEMENT	The basal layer of limbal and central corneal epithelium is enriched in stem cells and transient amplifying cells, respectively. This physical separation of stem and transient amplifying cells makes the limbal/corneal epithelium an exceptionally suitable system for isolating basal cells enriched in these two proliferative populations. Prior attempts to isolate epithelial stem cells used methods such as proteolytic tissue dissociation and cell sorting that could potentially alter their gene expression profile. Using laser capture microdissection, we were able to isolate resting limbal and corneal basal cells from frozen sections with minimal tissue processing, thereby improving the yield and quality of RNA. Analyses of RNA isolated from 300 limbal and corneal basal cells from eight mice revealed a set of similar to 100 genes that are differentially expressed in limbal cells versus corneal epithelial basal cells. Semiquantitative reverse transcription-PCR confirmed the up-regulation of three limbal and three corneal genes. LacZ identification of epiregulin from epiregulin-null mice and immunohistochemical staining of wild type mice confirmed that epiregulin, one of the limbal epithelium-enriched genes, was associated with the limbal epithelial basal cells. Within the limbal and corneal basal cells, we detected previously unknown genes that were differentially expressed in these two regions that contribute further to our understanding of the unique heterogeneity of these two closely related basal cell populations. Our findings indicate that we can obtain accurate gene expression profiles of the stem cell-enriched limbal basal cell population in their "natural" quiescent state.	Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA; Univ Chicago, Dept Genet Anal, Chicago, IL 60637 USA	Northwestern University; Feinberg School of Medicine; University of Chicago	Lavker, RM (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Dermatol, 303 E Chicago Ave,Ward-9-125, Chicago, IL 60611 USA.	r-lavker@northwestern.edu			NATIONAL EYE INSTITUTE [R03EY013711] Funding Source: NIH RePORTER; NEI NIH HHS [EY06769, EY13711] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AURAN JD, 1995, OPHTHALMOLOGY, V102, P33; Bickenbach JR, 1998, EXP CELL RES, V244, P184, DOI 10.1006/excr.1998.4163; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; BUCK RC, 1985, INVEST OPHTH VIS SCI, V26, P1296; Budak MT, 2005, J CELL SCI, V118, P1715, DOI 10.1242/jcs.02279; Cao TY, 2001, J CELL BIOL, V152, P651, DOI 10.1083/jcb.152.3.651; Collinson JM, 2004, INVEST OPHTH VIS SCI, V45, P1101, DOI 10.1167/iovs.03-1118; Collinson JM, 2002, DEV DYNAM, V224, P432, DOI 10.1002/dvdy.10124; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; COTSARELIS G, 1989, CELL, V57, P201, DOI 10.1016/0092-8674(89)90958-6; Daniels JT, 2001, WOUND REPAIR REGEN, V9, P483, DOI 10.1046/j.1524-475x.2001.00483.x; DAVANGER M, 1971, NATURE, V229, P560, DOI 10.1038/229560a0; Diehn JJ, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-9-r74; Draper BK, 2003, J CELL BIOCHEM, V89, P1126, DOI 10.1002/jcb.10584; Draper BK, 2003, WOUND REPAIR REGEN, V11, P188, DOI 10.1046/j.1524-475X.2003.11307.x; Dua HS, 2003, EYE, V17, P877, DOI 10.1038/sj.eye.6700573; EBATO B, 1988, INVEST OPHTH VIS SCI, V29, P1533; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; Holland EJ, 2000, CORNEA, V19, P688, DOI 10.1097/00003226-200009000-00014; Hooper LV, 2003, NAT IMMUNOL, V4, P269, DOI 10.1038/ni888; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; Jun AS, 2001, ARCH OPHTHALMOL-CHIC, V119, P1629; KENYON KR, 1989, OPHTHALMOLOGY, V96, P709; Kerman IA, 2006, J NEUROSCI METH, V153, P71, DOI 10.1016/j.jneumeth.2005.10.010; KRUSE FE, 1990, INVEST OPHTH VIS SCI, V31, P1903; Lavker RM, 2004, EXP EYE RES, V78, P433, DOI 10.1016/j.exer.2003.09.008; Lavker RM, 2000, P NATL ACAD SCI USA, V97, P13473, DOI 10.1073/pnas.250380097; Lavker RM, 1998, INVEST OPHTH VIS SCI, V39, P301; Lee D, 2004, MOL CELL BIOL, V24, P8907, DOI 10.1128/MCB.24.20.8907-8916.2004; Lee JS, 2001, CURR EYE RES, V23, P69, DOI 10.1076/ceyr.23.1.69.5421; Lehrer MS, 1998, J CELL SCI, V111, P2867; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li DQ, 2005, EXP EYE RES, V80, P581, DOI 10.1016/j.exer.2004.11.011; Li X, 2002, SCIENCE, V297, P1180; Lindvall C, 2003, CANCER RES, V63, P1743; LOVELLBADGE R, 1990, DEVELOPMENT, V109, P635; Morris RJ, 1999, J INVEST DERMATOL, V112, P470, DOI 10.1046/j.1523-1747.1999.00537.x; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; MUELLER O, 2004, 59891165EN; Nagasaki T, 2003, INVEST OPHTH VIS SCI, V44, P558, DOI 10.1167/iovs.02-0705; Narayanan S, 2005, EXP EYE RES, V80, P175, DOI 10.1016/j.exer.2004.08.027; Nielsen K, 2005, CORNEA, V24, P661, DOI 10.1097/01.ico.0000153556.59407.69; Nielsen K, 2003, INVEST OPHTH VIS SCI, V44, P2466, DOI 10.1167/iovs.02-0671; Nolan TM, 2003, AM J PATHOL, V162, P567, DOI 10.1016/S0002-9440(10)63850-3; Pajoohesh-Ganji A, 2005, BIOL CELL, V97, P265, DOI 10.1042/BC20040114; Parker GC, 2005, STEM CELLS DEV, V14, P463, DOI 10.1089/scd.2005.14.463; Pellegrini G, 1997, LANCET, V349, P990, DOI 10.1016/S0140-6736(96)11188-0; Pellegrini G, 1999, J CELL BIOL, V145, P769, DOI 10.1083/jcb.145.4.769; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Saghizadeh M, 2005, INVEST OPHTH VIS SCI, V46, P3604, DOI 10.1167/iovs.04-1507; SCHERMER A, 1986, J CELL BIOL, V103, P49, DOI 10.1083/jcb.103.1.49; Schmahl J, 2003, DEV BIOL, V258, P264, DOI 10.1016/S0012-1606(03)00122-2; Schmahl J, 2000, DEVELOPMENT, V127, P65; Stepp MA, 2005, OCUL SURF, V3, P15, DOI 10.1016/S1542-0124(12)70119-2; Sun L, 2006, J CELL PHYSIOL, V206, P103, DOI 10.1002/jcp.20433; Sun LJ, 1999, J BIOL CHEM, V274, P17334, DOI 10.1074/jbc.274.24.17334; Sun LJ, 2000, EXP CELL RES, V259, P96, DOI 10.1006/excr.2000.4922; Swain A, 1998, NATURE, V391, P761, DOI 10.1038/35799; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; Tsai RJ, 2000, NEW ENGL J MED, V343, P86, DOI 10.1056/NEJM200007133430202; TSAI RJF, 1994, CORNEA, V13, P389, DOI 10.1097/00003226-199409000-00003; TSENG SCG, 1989, EYE, V3, P141, DOI 10.1038/eye.1989.22; Tsubota K, 1999, NEW ENGL J MED, V340, P1697, DOI 10.1056/NEJM199906033402201; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Wang ZY, 2003, INT J BIOCHEM CELL B, V35, P339, DOI 10.1016/S1357-2725(02)00254-6; WEI ZG, 1993, INVEST OPHTH VIS SCI, V34, P1814; Wolosin JM, 2004, INT J DEV BIOL, V48, P981, DOI 10.1387/ijdb.041876jw; Wong MH, 2000, P NATL ACAD SCI USA, V97, P12601, DOI 10.1073/pnas.230237997; Xu XW, 2003, AM J PATHOL, V163, P969, DOI 10.1016/S0002-9440(10)63456-6; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	73	55	56	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19600	19609		10.1074/jbc.M600777200	http://dx.doi.org/10.1074/jbc.M600777200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16675456	hybrid			2022-12-25	WOS:000238847000074
J	Solito, E; Christian, HC; Festa, M; Mulla, A; Tierney, T; Flower, RJ; Buckingham, JC				Solito, E.; Christian, H. C.; Festa, M.; Mulla, A.; Tierney, T.; Flower, R. J.; Buckingham, J. C.			Post-translational modification plays an essential role in the translocation of annexin A1 from the cytoplasm to the cell surface	FASEB JOURNAL			English	Article						phosphorylation; green fluorescence protein; lipidation; signaling	ANTERIOR-PITUITARY GLAND; N-TERMINAL DOMAIN; 1 EXPRESSION; PROTEIN; GLUCOCORTICOIDS; LIPOCORTIN-1; RAT; PHOSPHORYLATION; DEXAMETHASONE; INHIBITION	Annexin A1 (ANXA1) has an important role in cell-cell communication in the host defense and neuroendocrine systems. In both systems, its actions are exerted extracellularly via membrane-bound receptors on adjacent sites after translocation of the protein from the cytoplasm to the cell surface of adjacent cells. This study used molecular, microscopic, and pharmacological approaches to explore the mechanisms underlying the cellular exportation of ANXA1 in TtT/GF (pituitary folliculo-stellate) cells. LPS caused serine-phosphorylation of ANXA1 (ANXA1-S-27-PO4) and translocation of the phosphorylated protein to the cell membrane. The fundamental requirement of phosphorylation for membrane translocation was confirmed by immunofluorescence microscopy on cells transfected with wild-type or mutated (S-27/A) ANXA1 constructs tagged with enhanced green fluorescence protein. The trafficking of ANXA1-S-27-PO4 to the cell surface was dependent on PI3-kinase and MAP-kinase. It also required HMG-coenzyme A and myristoylation. The effects of HMG-coenzyme A blockade were overcome by mevalonic acid (the product of HMG-coenzyme A) and farnesyl-pyrophosphate but not by geranyl-geranylpyrophosphate or cholesterol. Together, these results suggest that serine-27 phosphorylation is essential for the translocation of ANXA1 across the cell membrane and also identify a role for isoprenyl lipids. Such lipids could target consensus sequences in ANXA1. Alternatively, they may target other proteins in the signal transduction cascade (e.g., transporters).	Univ London Imperial Coll Sci Technol & Med, Dept Cellular & Mol Neurosci, Div Neurosci & Mental Hlth, London W12 0NN, England; Univ Oxford, Dept Human Anat & Genet, Oxford, England; William Harvey Res Inst, Dept Biochem Pharmacol, London, England	Imperial College London; University of Oxford; University of London; Queen Mary University London	Solito, E (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Cellular & Mol Neurosci, Div Neurosci & Mental Hlth, Hammersmith Campus,Cane Rd, London W12 0NN, England.			Solito, Egle/0000-0001-5279-0049; Mulla, Abeda/0000-0002-0364-7972	Wellcome Trust [040269, N:069234/B/02/Z] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; AMBROSE MP, 1990, AM J RESP CELL MOL, V3, P349, DOI 10.1165/ajrcmb/3.4.349; Beishuizen A, 2003, J ENDOTOXIN RES, V9, P3, DOI 10.1179/096805103125001298; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Chapman L, 2002, ENDOCRINOLOGY, V143, P4330, DOI 10.1210/en.2002-220529; Christian HC, 1997, ENDOCRINOLOGY, V138, P5341, DOI 10.1210/en.138.12.5341; CHRISTMAS P, 1991, J BIOL CHEM, V266, P2499; Croxtall JD, 2000, BRIT J PHARMACOL, V130, P289, DOI 10.1038/sj.bjp.0703272; de Coupade C, 2000, HEPATOLOGY, V31, P371, DOI 10.1002/hep.510310217; DECATERINA R, 1993, J APPL PHYSIOL, V75, P2368, DOI 10.1152/jappl.1993.75.6.2368; DelVillar K, 1996, BIOCHEM SOC T, V24, P709; Dorovkov MV, 2004, J BIOL CHEM, V279, P50643, DOI 10.1074/jbc.C400441200; Farazi TA, 2001, J BIOL CHEM, V276, P39501, DOI 10.1074/jbc.R100042200; Galbiati F, 1996, BIOCHEM J, V313, P717, DOI 10.1042/bj3130717; Gloddek J, 2001, EXP CLIN ENDOCR DIAB, V109, P410, DOI 10.1055/s-2001-18995; GOULDING NJ, 1992, ARTHRITIS RHEUM, V35, P1395, DOI 10.1002/art.1780351126; John C, 2002, ENDOCRINOLOGY, V143, P3060, DOI 10.1210/en.143.8.3060; John CD, 2004, TRENDS ENDOCRIN MET, V15, P103, DOI 10.1016/j.tem.2004.02.001; Kusumawati A, 2001, CELL BIOL INT, V25, P809, DOI 10.1006/cbir.2000.0704; Lohrer P, 2000, ENDOCRINOLOGY, V141, P4457, DOI 10.1210/en.141.12.4457; LOXLEY HD, 1993, NEUROENDOCRINOLOGY, V57, P801, DOI 10.1159/000126439; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Monick MM, 2003, J IMMUNOL, V171, P2625, DOI 10.4049/jimmunol.171.5.2625; Mulla A, 2004, CLIN ENDOCRINOL, V60, P107, DOI 10.1111/j.1365-2265.2004.01936.x; MUNCK A, 1994, ANN NY ACAD SCI, V746, P115, DOI 10.1111/j.1749-6632.1994.tb39221.x; PAYNE J, 2005, 24 JOINT M BRIT END, V9; PEPINSKY RB, 1986, J BIOL CHEM, V261, P4239; Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786; Philip JG, 1998, REGUL PEPTIDES, V73, P133, DOI 10.1016/S0167-0115(97)01077-X; Rescher U, 2000, J CELL SCI, V113, P3931; Smith T., 1993, Molecular Neuropharmacology, V3, P45; SOLITO E, 1991, FEBS LETT, V291, P238, DOI 10.1016/0014-5793(91)81293-H; Solito E, 2003, ENDOCRINOLOGY, V144, P1164, DOI 10.1210/en.2002-220592; Solito E, 1998, CYTOKINE, V10, P514, DOI 10.1006/cyto.1997.0325; Solito E, 1998, CELL GROWTH DIFFER, V9, P327; Solito E, 1998, BRIT J PHARMACOL, V124, P1675, DOI 10.1038/sj.bjp.0701991; TAYLOR AD, 1993, NEUROENDOCRINOLOGY, V58, P430, DOI 10.1159/000126572; Taylor AD, 1997, ENDOCRINOLOGY, V138, P2909, DOI 10.1210/en.138.7.2909; Tierney T, 2003, J NEUROENDOCRINOL, V15, P1134, DOI 10.1111/j.1365-2826.2003.01111.x; Traverso V, 1999, ENDOCRINOLOGY, V140, P4311, DOI 10.1210/en.140.9.4311; YASUMURA Y, 1968, AM ZOOL, V8, P285	43	83	86	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1498	+		10.1096/fj.05-5319fje	http://dx.doi.org/10.1096/fj.05-5319fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16720734	Green Accepted			2022-12-25	WOS:000240266000030
J	Converso, DP; Taille, C; Carreras, MC; Jaitovich, A; Poderoso, JJ; Boczkowski, J				Converso, Daniela P.; Taille, Camille; Carreras, Maria Cecilia; Jaitovich, Ariel; Poderoso, Juan Jose; Boczkowski, Jorge			HO-1 is located in liver mitochondria and modulates mitochondrial heme content and metabolism	FASEB JOURNAL			English	Article						cytochrome c oxidase; NOS; oxygen consumption	CYTOCHROME-C-OXIDASE; NITRIC-OXIDE; BILIVERDIN REDUCTASE; RAT-LIVER; SYNTHASE; OXYGENASE; PROTEIN; ACTIVATION; BILIRUBIN; LOCALIZATION	This study investigated whether inducible HO-1 is targeted to mitochondria and its putative effects on oxidative metabolism in rat liver. Western blot and immune-electron microscopy in whole purified and fractionated organelles showed basal expression of HO-1 protein in both microsomes and mitochondria (inner membrane), accompanied by a parallel HO activity. Inducers of HO-1 increased HO-1 targeting to the inner mitochondrial membrane, which also contained biliverdin reductase, supporting that both enzymes are in the same compartmentalization. Induction of mitochondrial HO-1 was associated with a decrease of mitochondrial heme content and selective reduction of protein expression of cytochrome oxidase ( COX) subunit I, which is coded by the mitochondrial genome and synthesized in the mitochondria depending on heme availability; these changes resulted in decreased COX spectrum and activity. Mitochondrial HO-1 induction was also associated with down-regulation of mitochondrial-targeted NO synthase expression and activity, resulting in a reduction of NO-dependent mitochondrial oxidant yield; inhibition of HO-1 activity reverted these effects. In conclusion, we demonstrated for the first time localization of HO-1 protein in mitochondria. It is surmised that mitochondrial HO-1 has important biological roles in regulating mitochondrial heme protein turnover and in protecting against conditions such as hypoxia, neurodegenerative diseases, or sepsis, in which substantially increased mitochondrial NO and oxidant production have been implicated. -Converso, D. P., Taille, C., Carreras, M. C., Jaitovich, A., Poderoso, J. J., Boczkowski, J. HO-1 is located in liver mitochondria and modulates mitochondrial heme content and metabolism.	Univ Paris 07, INSERM U700, Fac Xavier Bichat, F-75870 Paris 18, France; Univ Buenos Aires, Lab Oxygen Metab, Univ Hosp, Buenos Aires, DF, Argentina	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Buenos Aires	Boczkowski, J (corresponding author), Univ Paris 07, INSERM U700, Fac Xavier Bichat, BP416, F-75870 Paris 18, France.	jbb2@bichat.inserm.fr	Boczkowski, Jorge/S-7474-2018; Taille, Camille/J-3751-2017	Boczkowski, Jorge/0000-0001-6619-5785; 				Albakri QA, 1996, J BIOL CHEM, V271, P5414, DOI 10.1074/jbc.271.10.5414; Almeida A, 1999, FEBS LETT, V452, P290, DOI 10.1016/S0014-5793(99)00628-6; Alonso M, 2004, J NEUROCHEM, V89, P248, DOI 10.1111/j.1471-4159.2004.02323.x; Atamna H, 2001, J BIOL CHEM, V276, P48410, DOI 10.1074/jbc.M108362200; BALLA G, 1992, J BIOL CHEM, V267, P18148; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; Bender AT, 2000, J BIOL CHEM, V275, P26018, DOI 10.1074/jbc.275.34.26018; Boczkowski J, 1999, FASEB J, V13, P1637, DOI 10.1096/fasebj.13.12.1637; Boss V, 2005, BIOL NEONATE, V88, P313, DOI 10.1159/000087629; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Calabrese V, 2004, ANTIOXID REDOX SIGN, V6, P895, DOI 10.1089/1523086041798051; Carreras MC, 2004, HEPATOLOGY, V40, P157, DOI 10.1002/hep.20255; Clark JE, 2000, AM J PHYSIOL-HEART C, V278, pH643, DOI 10.1152/ajpheart.2000.278.2.H643; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; DRUMMOND GS, 1981, P NATL ACAD SCI-BIOL, V78, P6466, DOI 10.1073/pnas.78.10.6466; Drysdale J, 2002, BLOOD CELL MOL DIS, V29, P376, DOI 10.1006/bcmd.2002.0577; Duchen Michael R., 2004, Molecular Aspects of Medicine, V25, P365, DOI 10.1016/j.mam.2004.03.001; Dzikaite V, 2003, BBA-GENE STRUCT EXPR, V1630, P19, DOI 10.1016/j.bbaexp.2003.08.012; ENYEDI P, 1993, CELL CALCIUM, V14, P485, DOI 10.1016/0143-4160(93)90007-S; Foresti R, 1999, FREE RADICAL RES, V31, P459, DOI 10.1080/10715769900301031; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; HUANG TJ, 1989, J BIOL CHEM, V264, P7844; Iwata Y, 2004, EUR J CELL BIOL, V83, P555, DOI 10.1078/0171-9335-00415; Juckett M, 1998, J BIOL CHEM, V273, P23388, DOI 10.1074/jbc.273.36.23388; Kim HP, 2004, FASEB J, V18, P1080, DOI 10.1096/fj.03-1391com; Kim YS, 2005, FREE RADICAL BIO MED, V38, P85, DOI 10.1016/j.freeradbiomed.2004.09.031; Knowles RG, 1998, METH MOL B, V100, P67; Kone BC, 2003, AM J PHYSIOL-RENAL, V285, pF178, DOI 10.1152/ajprenal.00048.2003; KUTTY RK, 1987, BIOCHEM J, V246, P467, DOI 10.1042/bj2460467; LATHROP JT, 1993, SCIENCE, V259, P522, DOI 10.1126/science.8424176; LEMASTERS JJ, 2005, BIOCH BIOPHYS ACTA; Lisdero CL, 2004, METHOD ENZYMOL, V382, P67; Lithgow T, 2000, FEBS LETT, V476, P22, DOI 10.1016/S0014-5793(00)01663-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1975, J BIOL CHEM, V250, P2363; MAINES MD, 1974, P NATL ACAD SCI USA, V71, P4293, DOI 10.1073/pnas.71.11.4293; Maines MD, 2001, J PHARMACOL EXP THER, V296, P1091; MATUDA S, 1984, JPN J MED SCI BIOL, V37, P171, DOI 10.7883/yoken1952.37.171; MOTTERLINI R, 1995, AM J PHYSIOL-HEART C, V269, pH648, DOI 10.1152/ajpheart.1995.269.2.H648; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; NORSETH J, 1982, BIOCHIM BIOPHYS ACTA, V719, P569, DOI 10.1016/0304-4165(82)90247-1; Ockaili R, 2005, AM J PHYSIOL-HEART C, V289, pH542, DOI 10.1152/ajpheart.00089.2005; Piantadosi CA, 2002, ANTIOXID REDOX SIGN, V4, P259, DOI 10.1089/152308602753666316; Poderoso JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85, DOI 10.1006/abbi.1996.0146; Poderoso JJ, 1999, J BIOL CHEM, V274, P37709, DOI 10.1074/jbc.274.53.37709; Ren SY, 2000, ARCH BIOCHEM BIOPHYS, V377, P195, DOI 10.1006/abbi.2000.1755; Richter OMH, 2003, REV PHYSIOL BIOCH P, V147, P47, DOI 10.1007/s10254-003-0006-0; Riobo NA, 2002, J BIOL CHEM, V277, P42447, DOI 10.1074/jbc.M204580200; Schulte U, 2001, J BIOENERG BIOMEMBR, V33, P205, DOI 10.1023/A:1010730919074; SHARMA RV, 1986, AM J PHYSIOL, V250, pC65, DOI 10.1152/ajpcell.1986.250.1.C65; Srivastava P, 1996, INT J BIOCHEM CELL B, V28, P1071, DOI 10.1016/1357-2725(96)00030-1; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Susa S, 2002, BLOOD, V100, P4678, DOI 10.1182/blood-2002-08-2621; Taanman JW, 2001, BIOCHEM SOC T, V29, P446, DOI 10.1042/BST0290446; Taille C, 2004, J BIOL CHEM, V279, P28681, DOI 10.1074/jbc.M310661200; Taille C, 2001, AM J RESP CRIT CARE, V163, P753, DOI 10.1164/ajrccm.163.3.2004202; VANNESTE WH, 1966, BIOCHIM BIOPHYS ACTA, V113, P175, DOI 10.1016/S0926-6593(66)80132-7; Vijayasarathy C, 1999, EUR J BIOCHEM, V266, P191, DOI 10.1046/j.1432-1327.1999.00843.x	60	122	126	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1236	+		10.1096/fj.05-4204fje	http://dx.doi.org/10.1096/fj.05-4204fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16672635				2022-12-25	WOS:000240210300037
J	Balavenkatraman, KK; Jandt, E; Friedrich, K; Kautenburger, T; Pool-Zobel, B; Ostman, A; Bohmer, FD				Balavenkatraman, K. K.; Jandt, E.; Friedrich, K.; Kautenburger, T.; Pool-Zobel, B. L.; Ostman, A.; Boehmer, F. D.			DEP-1 protein tyrosine phosphatase inhibits proliferation and migration of colon carcinoma cells and is upregulated by protective nutrients	ONCOGENE			English	Article						protein-tyrosine phosphatase; colon cancer; DEP-1; cell migration; cell proliferation	GLUTATHIONE S-TRANSFERASES; GROWTH-FACTOR RECEPTOR; IN-VITRO; ETA SUPPRESSES; CANCER CELLS; EXPRESSION; DEPHOSPHORYLATION; CARCINOGENESIS; ACTIVATION; ADHESION	The transmembrane protein-tyrosine phosphatase (PTP) DEP-1 (density-enhanced phosphatase) is a candidate tumor suppressor in the colon epithelium. We have explored the function of DEP-1 in colon epithelial cells by inducible re-expression in a DEP-1- deficient human colon cancer cell line. Density-enhanced phosphatase-1 re-expression led to profound inhibition of cell proliferation and cell migration, and was associated with cytoskeletal rearrangements. These effects were dependent on the PTP activity of DEP-1 as they were not observed with cells expressing the catalytically inactive DEP-1 C1239S variant. shRNA-mediated suppression of DEP-1 in a colon epithelial cell line with high endogenous DEP-1 levels enhanced proliferation, further supporting the antiproliferative function of DEP-1. Nutrients, which are considered to be chemoprotective with respect to colon cancer development, including butyrate, green tea and apple polyphenols, had the capacity to elevate transcription of endogenous DEP-1 mRNA and expression of DEP-1 protein. Upregulation of DEP-1 expression, and in turn inhibition of cell growth and migration may present a previously unrecognized mechanism of chemoprevention by nutrients.	Univ Jena, Fac Med, Inst Mol Cell Biol, D-07747 Jena, Germany; Univ Jena, Fac Med, Inst Biochem 1, D-6900 Jena, Germany; Univ Jena, Inst Nutr, Dept Nutr Toxicol, D-6900 Jena, Germany; Karolinska Inst, Ctr Canc, Stockholm, Sweden	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Karolinska Institutet	Bohmer, FD (corresponding author), Univ Jena, Fac Med, Inst Mol Cell Biol, Drackendorfer Str 1, D-07747 Jena, Germany.	i5frbo@rz.uni-jena.de						Barth SW, 2005, CARCINOGENESIS, V26, P1414, DOI 10.1093/carcin/bgi082; Glei M, 2003, TOXICOL IN VITRO, V17, P723, DOI 10.1016/S0887-2333(03)00099-7; Gosse F, 2005, CARCINOGENESIS, V26, P1291, DOI 10.1093/carcin/bgi074; Iuliano R, 2003, CANCER RES, V63, P882; Jandt E, 2003, ONCOGENE, V22, P4175, DOI 10.1038/sj.onc.1206652; KAUTENBURGER T, 2006, IN PRESS INT J CANC; Keane MM, 1996, CANCER RES, V56, P4236; Kellie S, 2004, J CELL SCI, V117, P609, DOI 10.1242/jcs.00879; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Le Pera I, 2005, ONCOGENE, V24, P3187, DOI 10.1038/sj.onc.1208510; Massa A, 2004, J BIOL CHEM, V279, P29004, DOI 10.1074/jbc.M403573200; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Pool-Zobel B, 2005, MUTAT RES-FUND MOL M, V591, P74, DOI 10.1016/j.mrfmmm.2005.04.020; Pool-Zobel BL, 2005, CARCINOGENESIS, V26, P1064, DOI 10.1093/carcin/bgi059; Richter M, 2002, EUR J CANCER, V38, P1937, DOI 10.1016/S0959-8049(02)00158-2; Ruivenkamp C, 2003, ONCOGENE, V22, P3472, DOI 10.1038/sj.onc.1206246; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; Shimizu M, 2005, CLIN CANCER RES, V11, P2735, DOI 10.1158/1078-0432.CCR-04-2014; Takahashi T, 2003, MOL CELL BIOL, V23, P1817, DOI 10.1128/MCB.23.5.1817-1831.2003; Tenev T, 2000, EUR J CELL BIOL, V79, P261, DOI 10.1078/S0171-9335(04)70029-1; Trapasso F, 2004, CARCINOGENESIS, V25, P2107, DOI 10.1093/carcin/bgh224; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000	24	65	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2006	25	47					6319	6324		10.1038/sj.onc.1209647	http://dx.doi.org/10.1038/sj.onc.1209647			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16682945				2022-12-25	WOS:000241218200008
J	Hill, A; McFarlane, S; Mulligan, K; Gillespie, H; Draffin, JE; Trimble, A; Ouhtit, A; Johnston, PG; Harkin, DP; McCormick, D; Waugh, DJJ				Hill, A.; McFarlane, S.; Mulligan, K.; Gillespie, H.; Draffin, J. E.; Trimble, A.; Ouhtit, A.; Johnston, P. G.; Harkin, D. P.; McCormick, D.; Waugh, D. J. J.			Cortactin underpins CD44-promoted invasion and adhesion of breast cancer cells to bone marrowendothelial cells	ONCOGENE			English	Article						CD44; cortactin; breast cancer; metastasis; invasion	CYTOSKELETON FUNCTION; EXTRACELLULAR-MATRIX; CD44 INTERACTION; PROMOTES; HYALURONAN; KINASE; CARCINOMA; MIGRATION; EMS1; IDENTIFICATION	Using a validated tetracycline (tet)-regulated MCF7-founder (MCF7F) expression system to modulate expression of CD44 standard form (CD44s), we report the functional importance of CD44s and that of a novel transcriptional target of hyaluronan (HA)/CD44s signaling, EMS1/cortactin, in underpinning breast cancer metastasis. In functional experiments, tet-regulated induction of CD44s potentiated the migration and invasion of MCF7F cells through HA-supplemented Matrigel. EMS1/cortactin was identified by expression profiling as a novel transcriptional target of HA/CD44 signaling, an association validated by quantitative PCR and immunoblotting experiments in a range of breast cancer cell lines. The mechanistic basis underpinning CD44-promoted transcription of EMS1/cortactin was shown to be dependent upon a NF kappa B mechanism, since pharmacological inhibition of I kappa Kinase-2 or suppression of p65 Rel A expression attenuated CD44-induced increases in cortactin mRNA transcript levels. Overexpression of a c-myc tagged murine cortactin construct in the weakly invasive, CD44-deficient MCF7F and T47D cells potentiated their invasion. Furthermore, the functional importance of cortactin to CD44s-promoted metastasis was demonstrated by selective suppression of cortactin in CD44-expressing MCF7F-B5 and MDA-MB-231 breast cancer cells using RNAi, which was shown to result in attenuated CD44-promoted invasion and CD44-promoted adhesion to bone marrow endothelial cells (BMECs).	Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast City Hosp, Belfast BT9 7AB, Antrim, North Ireland	Belfast City Hospital; Queens University Belfast	Waugh, DJJ (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast City Hosp, Univ Floor,Lisburn Rd, Belfast BT9 7AB, Antrim, North Ireland.	d.waugh@qub.ac.uk		WAUGH, DAVID/0000-0002-4022-3765	MRC [G0200103] Funding Source: UKRI; Medical Research Council [G0200103] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Arderiu G, 2002, BIOCHEM J, V364, P65, DOI 10.1042/bj3640065; Auvinen P, 2000, AM J PATHOL, V156, P529, DOI 10.1016/S0002-9440(10)64757-8; Berner HS, 2001, BREAST CANCER RES TR, V65, P23, DOI 10.1023/A:1006417412046; Bourguignon LYW, 2004, J BIOL CHEM, V279, P29654, DOI 10.1074/jbc.M403608200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Bryce NS, 2005, CURR BIOL, V15, P1276, DOI 10.1016/j.cub.2005.06.043; Draffin JE, 2004, CANCER RES, V64, P5702, DOI 10.1158/0008-5472.CAN-04-0389; Fitzgerald KA, 2000, J IMMUNOL, V164, P2053, DOI 10.4049/jimmunol.164.4.2053; Herrera-Gayol A, 2001, INT J EXP PATHOL, V82, P193, DOI 10.1111/j.1365-2613.2001.iep196.x; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hui R, 1997, ONCOGENE, V15, P1617, DOI 10.1038/sj.onc.1201311; Isacke CM, 2002, INT J BIOCHEM CELL B, V34, P718, DOI 10.1016/S1357-2725(01)00166-2; Kinoshita J, 1999, BREAST CANCER RES TR, V53, P177, DOI 10.1023/A:1006130601575; Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911-005-5399-8; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; LESTER BR, 1992, CANCER METAST REV, V11, P31, DOI 10.1007/BF00047601; Li YS, 2001, CANCER RES, V61, P6906; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; Monaghan M, 2000, J PATHOL, V192, P519; Mullins RD, 2000, CURR OPIN CELL BIOL, V12, P91, DOI 10.1016/S0955-0674(99)00061-7; Oliferenko S, 2000, J CELL BIOL, V148, P1159, DOI 10.1083/jcb.148.6.1159; Rodrigo JP, 2000, CLIN CANCER RES, V6, P3177; SAYEGH TY, 2005, MOL BIOL CELL, V12, P5514; SCHUURING E, 1992, ONCOGENE, V7, P355; Tilghman RW, 2002, FASEB J, V16, P1257, DOI 10.1096/fj.01-0969fje; Timpson P, 2005, CANCER RES, V65, P3273, DOI 10.1158/0008-5472.CAN-04-2118; Toole BP, 2002, GLYCOBIOLOGY, V12, p37R, DOI 10.1093/glycob/12.3.37R; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; van Rossum AGSH, 2005, BREAST CANCER RES, V7, P235, DOI 10.1186/bcr1316; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Weber GF, 2002, CANCER RES, V62, P2281; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Zhu D, 1998, CELL MOTIL CYTOSKEL, V39, P209, DOI 10.1002/(SICI)1097-0169(1998)39:3<209::AID-CM4>3.0.CO;2-#	39	96	98	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6079	6091		10.1038/sj.onc.1209628	http://dx.doi.org/10.1038/sj.onc.1209628			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16652145				2022-12-25	WOS:000241101200005
J	Graziani, S; Bernauer, J; Skouloubris, S; Graille, M; Zhou, CZ; Marchand, C; Decottignies, P; van Tilbeurgh, H; Myllykallio, H; Liebl, U				Graziani, Sebastien; Bernauer, Julie; Skouloubris, Stephane; Graille, Marc; Zhou, Cong-Zhao; Marchand, Christophe; Decottignies, Paulette; van Tilbeurgh, Herman; Myllykallio, Hannu; Liebl, Ursula			Catalytic mechanism and structure of viral flavin-dependent thymidylate synthase ThyX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-ANALYSIS; ACTIVE-SITE; SYNTHETASE; REFINEMENT; RESOLUTION; SUBSTRATE; REDUCTASE; PROTEIN	By using biochemical and structural analyses, we have investigated the catalytic mechanism of the recently discovered flavin dependent thymidylate synthase ThyX from Paramecium bursaria chlorella virus-1 (PBCV-1). Site-directed mutagenesisexperiments have identified several residues implicated in either NADPH oxidation or deprotonation activity of PBCV-1 ThyX. Chemical modification by diethyl pyrocarbonate and mass spectroscopic analyses identified a histidine residue (His(53)) crucial for NADPH oxidation and located in the vicinity of the redox active N-5 atom of the FAD ring system. Moreover, we observed that the conformation of active site key residues of PBCV-1 ThyX differs from earlier reported ThyX structures, suggesting structural changes during catalysis. Steady-state kinetic analyses support a reaction mechanism where ThyX catalysis proceeds via formation of distinct ternary complexes without formation of a methyl enzyme intermediate.	Ecole Polytech, Lab Opt & Biosci, CNRS, UMR 7645, F-91128 Palaiseau, France; Univ Paris 06, INSERM, AVENIR Grp, Inst Genet & Microbiol,CNRS,UMR 8621, F-91405 Orsay, France; Univ Paris 11, CNRS, UMR 8619, Inst Biochim & Biophys Mol & Cellulaire, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); Institut Polytechnique de Paris; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Liebl, U (corresponding author), Ecole Polytech, Lab Opt & Biosci, CNRS, UMR 7645, F-91128 Palaiseau, France.	ursula.liebl@polytechnique.edu	MARCHAND, Christophe H/B-5854-2008; Zhou, Cong-Zhao/E-9174-2011; Bernauer, Julie/M-7518-2014; GRAILLE, Marc/D-3242-2014; Myllykallio, Hannu/Y-5462-2019	MARCHAND, Christophe H/0000-0002-0729-3841; Zhou, Cong-Zhao/0000-0002-6881-7151; Bernauer, Julie/0000-0003-2345-995X; GRAILLE, Marc/0000-0002-7853-5852; Skouloubris, Stephane/0000-0001-6660-0023; LIEBL, Ursula/0000-0003-0869-4388; Myllykallio, Hannu/0000-0002-0541-1197				Agrawal N, 2004, BIOCHEMISTRY-US, V43, P10295, DOI 10.1021/bi0490439; CARRERAS CW, 1995, ANNU REV BIOCHEM, V64, P721, DOI 10.1146/annurev.bi.64.070195.003445; DARON HH, 1978, J BIOL CHEM, V253, P940; Demarre G, 2005, RES MICROBIOL, V156, P245, DOI 10.1016/j.resmic.2004.09.007; Fraaije MW, 2000, TRENDS BIOCHEM SCI, V25, P126, DOI 10.1016/S0968-0004(99)01533-9; Gattis SG, 2005, J AM CHEM SOC, V127, P832, DOI 10.1021/ja0432214; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Graziani S, 2004, J BIOL CHEM, V279, P54340, DOI 10.1074/jbc.M409121200; Griffin J, 2005, J BIOL CHEM, V280, P5456, DOI 10.1074/jbc.M412415200; Hubbard PA, 2003, J BIOL CHEM, V278, P37553, DOI 10.1074/jbc.M304642200; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leduc D, 2004, P NATL ACAD SCI USA, V101, P7252, DOI 10.1073/pnas.0401365101; LEMAIRE M, 1994, J BIOL CHEM, V269, P27291; LORENSON MY, 1967, J BIOL CHEM, V242, P3332; Mathews II, 2003, STRUCTURE, V11, P677, DOI 10.1016/S0969-2126(03)00097-2; Miles E W, 1977, Methods Enzymol, V47, P431; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Myllykallio H, 2002, SCIENCE, V297, P105, DOI 10.1126/science.1072113; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; POGOLOTTI AL, 1976, BIOCHEM BIOPH RES CO, V70, P972, DOI 10.1016/0006-291X(76)90687-2; Roussel A., 1989, SILICON GRAPHICS GEO; Sampathkumar P, 2005, J MOL BIOL, V352, P1091, DOI 10.1016/j.jmb.2005.07.071; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766	25	48	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					24048	24057		10.1074/jbc.M600745200	http://dx.doi.org/10.1074/jbc.M600745200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16707489	hybrid			2022-12-25	WOS:000239702900078
J	Li, XWS; Sun, JNN; Okamoto-Shibayama, K; Edgerton, M				Li, Xuewei S.; Sun, Jianing N.; Okamoto-Shibayama, Kazuko; Edgerton, Mira			Candida albicans cell wall Ssa proteins bind and facilitate import of salivary histatin 5 required for toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; FUNCTIONAL INTERACTION; IDENTIFICATION; YEAST; HSP70; GENE; MORPHOGENESIS; TRANSLOCATION; RECEPTORS	Fungicidal activity of Hst 5 is initiated by binding to cell surface proteins on Candida albicans, followed by intracellular transport to cytoplasmic effectors leading to cell death. As we identified heat shock 70 proteins (Ssa1p and/or Ssa2p) from C. albicans lysates that bind Hst 5, direct interactions between purified recombinant Ssa proteins and Hst 5 were tested by pulldown and yeast two-hybrid assays. Pulldown of both native complexes and those stabilized by cross-linking demonstrated higher affinity of Hst 5 for Ssa2p than for Ssa1p, in agreement with higher levels of interactions between Ssa2p and Hst 5 measured by yeast two-hybrid analyses. C. albicans ssa1 Delta and ssa2 Delta mutants were constructed to examine Hst 5 binding, translocation, and candidacidal activities. Both ssa1 Delta and ssa2 Delta mutants were indistinguishable from wild-type cells in growth and hyphal formation. However, C. albicans ssa2 Delta mutants were highly resistant to the candidacidal activity of Hst 5, although the ssa1 Delta mutant did not have any significant reduction in killing by Hst 5. Total cellular binding of I-125-Hst 5 in the ssa2 Delta mutant was reduced to one-third that of wild-type cells, in contrast to the ssa1 Delta mutant whose total cellular binding of Hst 5 was similar to the wild-type strain. Intracellular transport of Hst 5 was significantly impaired in the ssa2 Delta mutant strain, but only mildly so in the ssa1 Delta mutant. Thus, C. albicans Ssa2p facilitates fungicidal activity of Hst 5 in binding and intracellular translocation, whereas Ssa1p appears to have a lesser functional role in Hst 5 toxicity.	SUNY Buffalo, Dept Oral Biol, Sch Dent Med, Buffalo, NY 14214 USA; SUNY Buffalo, Dept Restorat Dent, Sch Dent Med, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Edgerton, M (corresponding author), SUNY Buffalo, Dept Oral Biol, Sch Dent Med, 310 Foster Hall,Main St Campus,3435 Main St, Buffalo, NY 14214 USA.	edgerto@buffalo.edu			NIDCR NIH HHS [R01 DE010641-12, R01 DE010641, DE10641] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R29DE010641] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alloush HM, 1997, MICROBIOL-SGM, V143, P321, DOI 10.1099/00221287-143-2-321; Angiolella L, 1996, J INFECT DIS, V173, P684, DOI 10.1093/infdis/173.3.684; Baev D, 2004, J BIOL CHEM, V279, P55060, DOI 10.1074/jbc.M411031200; Baev D, 2003, INFECT IMMUN, V71, P3251, DOI 10.1128/IAI.71.6.3251-3260.2003; Becker J, 1996, MOL CELL BIOL, V16, P4378; Bihler H, 2002, BBA-BIOMEMBRANES, V1558, P109, DOI 10.1016/S0005-2736(01)00414-X; Bromuro C, 1998, INFECT IMMUN, V66, P2154, DOI 10.1128/IAI.66.5.2154-2162.1998; Cassone A, 1989, Curr Top Med Mycol, V3, P248; Chaffin WL, 1998, MICROBIOL MOL BIOL R, V62, P130, DOI 10.1128/MMBR.62.1.130-180.1998; Christlet THT, 2001, BIOPHYS J, V80, P952, DOI 10.1016/S0006-3495(01)76074-2; CRAIG EA, 1984, CELL, V38, P841, DOI 10.1016/0092-8674(84)90279-4; Davis JE, 1999, P NATL ACAD SCI USA, V96, P9269, DOI 10.1073/pnas.96.16.9269; Edgerton M, 1998, J BIOL CHEM, V273, P20438, DOI 10.1074/jbc.273.32.20438; Eroles P, 1997, MICROBIOL-SGM, V143, P313, DOI 10.1099/00221287-143-2-313; EROLES P, 1995, FEMS MICROBIOL LETT, V128, P95, DOI 10.1111/j.1574-6968.1995.tb07506.x; FONZI WA, 1993, GENETICS, V134, P717; Gale CA, 1998, SCIENCE, V279, P1355, DOI 10.1126/science.279.5355.1355; Gastpar R, 2004, J IMMUNOL, V172, P972, DOI 10.4049/jimmunol.172.2.972; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Gross C, 2003, J BIOL CHEM, V278, P41173, DOI 10.1074/jbc.M302644200; Hardt M, 2005, BIOCHEMISTRY-US, V44, P2885, DOI 10.1021/bi048176r; Herrero AB, 2004, EUKARYOT CELL, V3, P1423, DOI 10.1128/EC.3.6.1423-1432.2004; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Journet L, 2001, MOL MICROBIOL, V42, P331, DOI 10.1046/j.1365-2958.2001.02592.x; Koshlukova SE, 2000, INFECT IMMUN, V68, P6848, DOI 10.1128/IAI.68.12.6848-6856.2000; LAVALLE R, 1995, INFECT IMMUN, V63, P4039, DOI 10.1128/IAI.63.10.4039-4045.1995; Lazdunski CJ, 1998, J BACTERIOL, V180, P4993, DOI 10.1128/JB.180.19.4993-5002.1998; Lee CM, 2004, MOL MICROBIOL, V51, P691, DOI 10.1111/j.1365-2958.2003.03879.x; Li XWS, 2003, J BIOL CHEM, V278, P28553, DOI 10.1074/jbc.M300680200; Long KH, 2003, J IMMUNOL, V170, P487, DOI 10.4049/jimmunol.170.1.487; LopezRibot JL, 1996, INFECT IMMUN, V64, P3333; MATTHEWS R, 1989, FEMS MICROBIOL LETT, V60, P25, DOI 10.1016/0378-1097(89)90071-2; McClellan AJ, 2000, GENETICS, V156, P501; Millson SH, 2005, EUKARYOT CELL, V4, P849, DOI 10.1128/EC.4.5.849-860.2005; Morschhauser J, 1999, MOL MICROBIOL, V32, P547, DOI 10.1046/j.1365-2958.1999.01393.x; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; ODDS FC, 1987, CRC CR REV MICROBIOL, V15, P1; OPPENHEIM FG, 1988, J BIOL CHEM, V263, P7472; Pitarch A, 2002, MOL CELL PROTEOMICS, V1, P967, DOI 10.1074/mcp.M200062-MCP200; Singh-Jasuja H, 2001, BIOL CHEM, V382, P629, DOI 10.1515/BC.2001.074; Sudbery P, 2004, TRENDS MICROBIOL, V12, P317, DOI 10.1016/j.tim.2004.05.008; Tobian AAR, 2004, J IMMUNOL, V172, P5277, DOI 10.4049/jimmunol.172.9.5277; Urban C, 2003, FEBS LETT, V544, P228, DOI 10.1016/S0014-5793(03)00455-1; WERNERWASHBURNE M, 1989, J BACTERIOL, V171, P2680, DOI 10.1128/jb.171.5.2680-2688.1989; Whiteway M, 2004, CURR OPIN MICROBIOL, V7, P350, DOI 10.1016/j.mib.2004.06.005; XU T, 1991, INFECT IMMUN, V59, P2549, DOI 10.1128/IAI.59.8.2549-2554.1991; Zakharov SD, 2004, FRONT BIOSCI-LANDMRK, V9, P1311, DOI 10.2741/1334; Zugel U, 1999, IMMUNOBIOLOGY, V201, P22	48	60	63	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22453	22463		10.1074/jbc.M604064200	http://dx.doi.org/10.1074/jbc.M604064200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16720580	hybrid			2022-12-25	WOS:000239542600006
J	Chen, CC; Hu, ST				Chen, Chang-Chieh; Hu, Shiau-Ting			Two frameshift products involved in the transposition of bacterial insertion sequence IS629	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE VIRULENCE PLASMID; COMPLETE DNA-SEQUENCE; GENOME SEQUENCE; TN5 TRANSPOSASE; GENE; IDENTIFICATION; COMPLEX; MU; RECOMBINATION; EXPRESSION	IS629 is 1,310 bp in length with a pair of 25-bp imperfect inverted repeats at its termini. Two partially overlapping open reading frames, orfA and orfB, are present in IS629, and two putative translational frameshift signals, TTTTG ( T(4)G) and AAAAT ( A(4)T), are located near the 3'-end of orfA. With the lacZ gene as the reporter, both T(4)G and A(4)T motifs are determined to be a -1 frameshift signal. Two peptides representing the two transframe products designated OrfAB' and OrfAB, are identified by a liquid chromatography-tandem mass spectrometric approach. Results of transposition assays show that OrfAB' is the transposase and that OrfAB aids in the transposition of IS629. Pulse-chase experiments and Escherichia coli two-hybrid assays demonstrate that OrfAB binds to and stabilizes OrfAB', thus increasing the transposition activity of IS629. This is the first transposable element in the IS3 family shown to have two functional frameshifted products involved in transposition and to use a transframe product to regulate transposition.	Natl Yang Ming Univ, Inst Microbiol & Immunol, Sch Life Sci, Taipei 112, Taiwan; Natl Yang Ming Univ, Dept Microbiol, Sch Med, Taipei 112, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Hu, ST (corresponding author), Natl Yang Ming Univ, Inst Microbiol & Immunol, Sch Life Sci, 155,Li Nong St,Sec 2, Taipei 112, Taiwan.	tingnahu@ym.edu.tw						Andrake MD, 1996, J BIOL CHEM, V271, P19633, DOI 10.1074/jbc.271.33.19633; Braam LAM, 1998, J BIOL CHEM, V273, P10908, DOI 10.1074/jbc.273.18.10908; Buchrieser C, 2000, MOL MICROBIOL, V38, P760, DOI 10.1046/j.1365-2958.2000.02179.x; Burland V, 1998, NUCLEIC ACIDS RES, V26, P4196, DOI 10.1093/nar/26.18.4196; CHANDLER M, 1993, MOL MICROBIOL, V7, P497, DOI 10.1111/j.1365-2958.1993.tb01140.x; Craig NL, 1996, CURR TOP MICROBIOL, V204, P27; DERBYSHIRE KM, 1990, P NATL ACAD SCI USA, V87, P4048, DOI 10.1073/pnas.87.11.4048; Haren L, 1998, J MOL BIOL, V283, P29, DOI 10.1006/jmbi.1998.2053; Haren L, 2000, J MOL BIOL, V296, P757, DOI 10.1006/jmbi.1999.3485; HU ST, 1988, MOL GEN GENET, V214, P490, DOI 10.1007/BF00330485; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; Jiang Y, 2005, PLASMID, V54, P149, DOI 10.1016/j.plasmid.2005.03.002; Jin Q, 2002, NUCLEIC ACIDS RES, V30, P4432, DOI 10.1093/nar/gkf566; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LI CC, 1999, THESIS NATL YANG MIN; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Mahillon J, 1998, MICROBIOL MOL BIOL R, V62, P725, DOI 10.1128/MMBR.62.3.725-774.1998; Makino K, 1998, DNA Res, V5, P1, DOI 10.1093/dnares/5.1.1; MATSUTANI S, 1993, GENE, V127, P111; MATSUTANI S, 1990, NUCLEIC ACIDS RES, V18, P1899, DOI 10.1093/nar/18.7.1899; MATSUTANI S, 1987, J MOL BIOL, V196, P445, DOI 10.1016/0022-2836(87)90023-4; May EW, 1996, SCIENCE, V272, P401, DOI 10.1126/science.272.5260.401; Miller JH., 1972, EXPT MOL GENETICS; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; Nagy Z, 2004, RES MICROBIOL, V155, P387, DOI 10.1016/j.resmic.2004.01.008; Perna NT, 2001, NATURE, V409, P529, DOI 10.1038/35054089; POLARD P, 1991, J MOL BIOL, V222, P465, DOI 10.1016/0022-2836(91)90490-W; POLARD P, 1995, MOL MICROBIOL, V15, P13, DOI 10.1111/j.1365-2958.1995.tb02217.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sarnovsky RJ, 1996, EMBO J, V15, P6348, DOI 10.1002/j.1460-2075.1996.tb01024.x; SEKINE Y, 1994, J MOL BIOL, V235, P1406, DOI 10.1006/jmbi.1994.1097; Sekine Y, 1997, GENES CELLS, V2, P547, DOI 10.1046/j.1365-2443.1997.1440342.x; SHAPIRA SK, 1983, GENE, V25, P71, DOI 10.1016/0378-1119(83)90169-5; SPIELMANNRYSER J, 1991, MOL GEN GENET, V226, P441, DOI 10.1007/BF00260657; Tsay YG, 2000, ANAL BIOCHEM, V287, P55, DOI 10.1006/abio.2000.4837; Tsay YG, 2005, ANAL BIOCHEM, V339, P83, DOI 10.1016/j.ab.2004.12.031; Venkatesan MM, 2001, INFECT IMMUN, V69, P3271, DOI 10.1128/IAI.69.5.3271-3285.2001; VOGELE K, 1991, NUCLEIC ACIDS RES, V19, P4377, DOI 10.1093/nar/19.16.4377; Wei J, 2003, INFECT IMMUN, V71, P2775, DOI 10.1128/IAI.71.5.2775-2786.2003; WEINREICH MD, 1994, J MOL BIOL, V241, P166, DOI 10.1006/jmbi.1994.1486	42	9	9	1	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21617	21628		10.1074/jbc.M602437200	http://dx.doi.org/10.1074/jbc.M602437200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16731525	hybrid			2022-12-25	WOS:000239387100007
J	Rodriguez-Caso, C; Montanez, R; Cascante, M; Sanchez-Jimenez, F; Medina, MA				Rodriguez-Caso, Carlos; Montanez, Raul; Cascante, Marta; Sanchez-Jimenez, Francisca; Medina, Miguel A.			Mathematical modeling of polyamine metabolism in mammals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE DECARBOXYLASE; SPERMIDINE-SPERMINE N-1-ACETYLTRANSFERASE; HUMAN-MELANOMA CELLS; HAMSTER OVARY CELLS; BREAST-CANCER CELLS; ORNITHINE-DECARBOXYLASE; TRANSGENIC MICE; SYSTEMS BIOLOGY; MOLECULAR-MECHANISMS; ENHANCED SENSITIVITY	Polyamines are considered as essential compounds in living cells, since they are involved in cell proliferation, transcription, and translation processes. Furthermore, polyamine homeostasis is necessary to cell survival, and its deregulation is involved in relevant processes, such as cancer and neurodegenerative disorders. Great efforts have been made to elucidate the nature of polyamine homeostasis, giving rise to relevant information concerning the behavior of the different components of polyamine metabolism, and a great amount of information has been generated. However, a complex regulation at transcriptional, translational, and metabolic levels as well as the strong relationship between polyamines and essential cell processes make it difficult to discriminate the role of polyamine regulation itself from the whole cell response when an experimental approach is given in vivo. To overcome this limitation, a bottom-up approach to model mathematically metabolic pathways could allow us to elucidate the systemic behavior from individual kinetic and molecular properties. In this paper, we propose a mathematical model of polyamine metabolism from kinetic constants and both metabolite and enzyme levels extracted from bibliographic sources. This model captures the tendencies observed in transgenic mice for the so-called key enzymes of polyamine metabolism, ornithine decarboxylase, S- adenosylmethionine decarboxylase and spermine spermidine N- acetyl transferase. Furthermore, the model shows a relevant role of S- adenosylmethionine and acetyl-CoA availability in polyamine homeostasis, which are not usually considered in systemic experimental studies.	Univ Malaga, Dept Biol Mol & Buiquim, Fac Ciencias, E-29071 Malaga, Spain; Univ Barcelona, Dept Bioquim, Fac Quim, E-08028 Barcelona, Spain	Universidad de Malaga; University of Barcelona	Medina, MA (corresponding author), Univ Malaga, Dept Biol Mol & Buiquim, Fac Ciencias, E-29071 Malaga, Spain.	medina@uma.es	CASCANTE, MARTA/AAG-4355-2022; Medina, Miguel Ángel/K-1763-2014; Rodriguez-Caso, Carlos/K-7774-2014; Martínez, Raúl Montañez/K-9769-2014; Jiménez, Francisca María Sánchez/H-2513-2015; CASCANTE, MARTA/AFK-5991-2022	CASCANTE, MARTA/0000-0002-2062-4633; Medina, Miguel Ángel/0000-0001-7275-6462; Rodriguez-Caso, Carlos/0000-0002-0423-6681; Martínez, Raúl Montañez/0000-0003-1667-2218; Jiménez, Francisca María Sánchez/0000-0002-4958-6060; CASCANTE, MARTA/0000-0002-2062-4633				Alberghina L, 2004, CHEMBIOCHEM, V5, P1322, DOI 10.1002/cbic.200400170; Alhonen L, 1998, J BIOL CHEM, V273, P1964, DOI 10.1074/jbc.273.4.1964; Alhonen L, 1999, MOL PHARMACOL, V55, P693; Auvinen M, 1997, CANCER RES, V57, P3016; Bachrach U, 2001, NEWS PHYSIOL SCI, V16, P106, DOI 10.1152/physiologyonline.2001.16.3.106; Benner SA, 2005, NAT REV GENET, V6, P533, DOI 10.1038/nrg1637; Berntsson PSH, 1999, BIOCHEM BIOPH RES CO, V263, P13, DOI 10.1006/bbrc.1999.1293; Bettuzzi S, 1999, FEBS LETT, V446, P18, DOI 10.1016/S0014-5793(99)00182-9; BOGLE RG, 1994, AM J PHYSIOL, V284, pC776; Brandes LJ, 1998, J CELL BIOCHEM, V69, P233, DOI 10.1002/(SICI)1097-4644(19980601)69:3<233::AID-JCB1>3.0.CO;2-S; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; Childs AC, 2003, CELL MOL LIFE SCI, V60, P1394, DOI 10.1007/s00018-003-2332-4; Coffino P, 2000, P NATL ACAD SCI USA, V97, P4421, DOI 10.1073/pnas.97.9.4421; COFFINO P, 1991, J CELL BIOCHEM, V45, P54, DOI 10.1002/jcb.240450112; Cohen S.S., 1998, GUIDE POLYAMINES, V1st ed.; Coleman CS, 2002, CARCINOGENESIS, V23, P359, DOI 10.1093/carcin/23.2.359; DAVIS RH, 1990, J CELL BIOCHEM, V44, P199, DOI 10.1002/jcb.240440402; DELLARAGIONE F, 1982, BIOCHEMISTRY-US, V21, P6152, DOI 10.1021/bi00267a020; Edwards JS, 2001, NAT BIOTECHNOL, V19, P125, DOI 10.1038/84379; Esposito C, 2005, FEBS J, V272, P615, DOI 10.1111/j.1742-4658.2004.04476.x; Fell D., 1997, UNDERSTANDING CONTRO; Ferioli ME, 2004, CELL MOL LIFE SCI, V61, P2767, DOI 10.1007/s00018-004-4295-5; FogelPetrovic M, 1996, BIOCHEMISTRY-US, V35, P14436, DOI 10.1021/bi9612273; FogelPetrovic M, 1996, FEBS LETT, V391, P89, DOI 10.1016/0014-5793(96)00710-7; FOGELPETROVIC M, 1993, J BIOL CHEM, V268, P19118; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; HALMEKYTO M, 1991, BIOCHEM J, V278, P895, DOI 10.1042/bj2780895; HALMEKYTO M, 1993, BIOCHEM J, V291, P505, DOI 10.1042/bj2910505; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; Hector S, 2004, MOL CANCER THER, V3, P813; Heljasvaara R, 1997, BIOCHEM J, V323, P457, DOI 10.1042/bj3230457; Hu X, 2005, CANCER RES, V65, P11026, DOI 10.1158/0008-5472.CAN-05-1339; Huang Y, 2005, ANTI-CANCER DRUG, V16, P229, DOI 10.1097/00001813-200503000-00002; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; Ivanov IP, 2000, EMBO J, V19, P1907, DOI 10.1093/emboj/19.8.1907; Janne J, 2004, EUR J BIOCHEM, V271, P877, DOI 10.1111/j.1432-1033.2004.04009.x; Kee K, 2004, J BIOL CHEM, V279, P40076, DOI 10.1074/jbc.M406002200; Kitano H, 2002, SCIENCE, V295, P1662, DOI 10.1126/science.1069492; Kitano H, 2002, NATURE, V420, P206, DOI 10.1038/nature01254; Kitano H, 2001, FDN SYSTEMS BIOL; Korhonen VP, 2001, MOL PHARMACOL, V59, P231, DOI 10.1124/mol.59.2.231; KRAMER D, 1995, J BIOL CHEM, V270, P2124, DOI 10.1074/jbc.270.5.2124; Kramer DL, 1999, CANCER RES, V59, P1278; Kutuzov MA, 2005, J BIOL CHEM, V280, P25388, DOI 10.1074/jbc.M413202200; Lesort M, 2000, PROG NEUROBIOL, V61, P439, DOI 10.1016/S0301-0082(99)00052-0; MANNI A, 1995, CANCER LETT, V95, P23, DOI 10.1016/0304-3835(95)03860-Y; Martinov MV, 2000, J THEOR BIOL, V204, P521, DOI 10.1006/jtbi.2000.2035; Medina MA, 2005, J CELL MOL MED, V9, P854, DOI 10.1111/j.1582-4934.2005.tb00384.x; Medina MA, 2003, CRIT REV BIOCHEM MOL, V38, P23, DOI 10.1080/713609209; Mitchell JLA, 2004, BIOCHEM J, V384, P271, DOI 10.1042/BJ20040972; Morohashi M, 2002, J THEOR BIOL, V216, P19, DOI 10.1006/jtbi.2002.2537; MOSHIER JA, 1993, CANCER RES, V53, P2618; Murakami Y, 2000, BIOCHEM BIOPH RES CO, V267, P1, DOI 10.1006/bbrc.1999.1706; Nijhout HF, 2004, J BIOL CHEM, V279, P55008, DOI 10.1074/jbc.M410818200; Nilsson JA, 2005, CANCER CELL, V7, P433, DOI 10.1016/j.ccr.2005.03.036; Nisenberg O, 2006, BIOCHEM J, V393, P295, DOI 10.1042/BJ20051196; Nishimura K, 2002, GENES CELLS, V7, P41, DOI 10.1046/j.1356-9597.2001.00494.x; PAJULA RL, 1983, BIOCHEM J, V215, P669, DOI 10.1042/bj2150669; PARRY L, 1995, BIOCHEM J, V305, P451, DOI 10.1042/bj3050451; PEGG AE, 1988, CANCER RES, V48, P759; Pegg AE, 2003, BIOCHEM SOC T, V31, P356, DOI 10.1042/BST0310356; PEGG AE, 1987, BIOCHEM J, V241, P305, DOI 10.1042/bj2410305; PEGG AE, 1989, J BIOL CHEM, V264, P11744; PEGG AE, 1983, METHOD ENZYMOL, V94, P234; Pegg AE, 2006, J BIOL CHEM, V281, P14529, DOI 10.1074/jbc.R500031200; Pendeville H, 2001, MOL CELL BIOL, V21, P6549, DOI 10.1128/MCB.21.19.6549-6558.2001; Pietila M, 2005, J INVEST DERMATOL, V124, P596, DOI 10.1111/j.0022-202X.2005.23636.x; Pietila M, 1997, J BIOL CHEM, V272, P18746, DOI 10.1074/jbc.272.30.18746; RAINA A, 1984, BIOCHEM J, V219, P991, DOI 10.1042/bj2190991; Ravasz E, 2002, SCIENCE, V297, P1551, DOI 10.1126/science.1073374; Reed MC, 2004, J THEOR BIOL, V226, P33, DOI 10.1016/j.jtbi.2003.08.001; Ruiz-Chica J, 2001, BIOPHYS J, V80, P443, DOI 10.1016/S0006-3495(01)76027-4; SAVAGEAU MA, 1972, BIOCHEM BIOPH RES CO, V48, P41, DOI 10.1016/0006-291X(72)90341-5; SAVAGEAU MA, 1971, NATURE, V229, P542, DOI 10.1038/229542a0; Schipper RG, 2000, PROSTATE, V44, P313, DOI 10.1002/1097-0045(20000901)44:4<313::AID-PROS8>3.0.CO;2-D; Seiler N, 1996, INT J BIOCHEM CELL B, V28, P843, DOI 10.1016/1357-2725(96)00021-0; Seiler N, 2005, PHARMACOL THERAPEUT, V107, P99, DOI 10.1016/j.pharmthera.2005.02.001; Seiler N, 2004, AMINO ACIDS, V26, P217, DOI 10.1007/s00726-004-0070-z; SEPPANEN P, 1984, BIOCHEM J, V221, P483, DOI 10.1042/bj2210483; SHANTZ LM, 1992, BIOCHEM J, V288, P511, DOI 10.1042/bj2880511; SHAPPELL NW, 1993, FEBS LETT, V321, P179, DOI 10.1016/0014-5793(93)80103-2; Suppola S, 2001, BIOCHEM J, V358, P343, DOI 10.1042/0264-6021:3580343; SUZUKI T, 1993, EUR J BIOCHEM, V215, P247, DOI 10.1111/j.1432-1033.1993.tb18029.x; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852; Thomas T, 2003, J CELL MOL MED, V7, P113, DOI 10.1111/j.1582-4934.2003.tb00210.x; Tucker JM, 2005, CANCER RES, V65, P5390, DOI 10.1158/0008-5472.CAN-05-0229; Urdiales JL, 2001, EUR J GASTROEN HEPAT, V13, P1015, DOI 10.1097/00042737-200109000-00003; Vujcic S, 2003, BIOCHEM J, V370, P19, DOI 10.1042/BJ20021779; Wallace HM, 1998, BIOCHEM SOC T, V26, P571, DOI 10.1042/bst0260571; Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327; Wallace HM, 2004, AMINO ACIDS, V26, P353, DOI 10.1007/s00726-004-0092-6; Wang YL, 1998, J BIOL CHEM, V273, P34623, DOI 10.1074/jbc.273.51.34623; Wang YL, 2001, CANCER RES, V61, P5370; WATANABE S, 1991, J BIOL CHEM, V266, P20803; Weston AD, 2004, J PROTEOME RES, V3, P179, DOI 10.1021/pr0499693; Yang CR, 2005, J BIOL CHEM, V280, P11224, DOI 10.1074/jbc.M411471200	98	48	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21799	21812		10.1074/jbc.M602756200	http://dx.doi.org/10.1074/jbc.M602756200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16709566	hybrid			2022-12-25	WOS:000239387100026
J	Murata, T; Shimotohno, K				Murata, Takayuki; Shimotohno, Kunitada			Ubiquitination and proteasome-dependent degradation of human eukaryotic translation initiation factor 4E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; EIF4E; PROTEIN; TRANSFORMATION; EXPRESSION; PATHWAY; STRESS; GROWTH; AFFINITY; EIF-4E	Translation initiation factor 4E ( eIF4E) is a cytoplasmic cap-binding protein that is required for cap-dependent translation initiation. Here, we have shown that eIF4E is ubiquitinated primarily at Lys-159 and incubation of cells with a proteasome inhibitor leads to increased eIF4E levels, suggesting the proteasome-dependent proteolysis of ubiquitinated eIF4E. Ubiquitinated eIF4E retained its cap binding ability, whereas eIF4E phosphorylation and eIF4G binding were reduced by ubiquitination. The W73A mutant of eIF4E exhibited enhanced ubiquitination/degradation, and 4E-BP overexpression protected eIF4E from ubiquitination/degradation. Because heat shock or the expression of the carboxyl terminus of heat shock cognate protein 70-interacting protein ( Chip) dramatically increased eIF4E ubiquitination, Chip may be at least one ubiquitin E3 ligase responsible for eIF4E ubiquitination.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Shimotohno, K (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan.	kshimoto@virus.kyoto-u.ac.jp	Murata, Takayuki/I-2621-2013	Murata, Takayuki/0000-0001-7228-0839				Chang W, 2003, GENE DEV, V17, P1328, DOI 10.1101/gad.1077103; Ciechanover A, 2004, TRENDS CELL BIOL, V14, P103, DOI 10.1016/j.tcb.2004.01.004; Cohen N, 2001, EMBO J, V20, P4547, DOI 10.1093/emboj/20.16.4547; Fahrenkrug SC, 1999, DIFFERENTIATION, V65, P191, DOI 10.1046/j.1432-0436.1999.6540191.x; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Hong Y, 2006, J BIOL CHEM, V281, P11595, DOI 10.1074/jbc.M513061200; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; Lynch M, 2005, MOL CELL BIOL, V25, P6436, DOI 10.1128/MCB.25.15.6436-6453.2005; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; MAO XH, 1992, J BIOL CHEM, V267, P20444; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; McClellan AJ, 2005, NAT CELL BIOL, V7, P736, DOI 10.1038/ncb0805-736; McKendrick L, 1999, INT J BIOCHEM CELL B, V31, P31, DOI 10.1016/S1357-2725(98)00129-0; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; Morley SJ, 2005, CELL DEATH DIFFER, V12, P571, DOI 10.1038/sj.cdd.4401591; Murata T, 2005, VIROLOGY, V340, P105, DOI 10.1016/j.virol.2005.06.015; Murata T, 2005, VIROLOGY, V331, P407, DOI 10.1016/j.virol.2004.10.036; Ohshima T, 2003, J BIOL CHEM, V278, P50833, DOI 10.1074/jbc.M307533200; Othumpangat S, 2005, J BIOL CHEM, V280, P25162, DOI 10.1074/jbc.M414303200; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Schmidt EV, 2004, ONCOGENE, V23, P3217, DOI 10.1038/sj.onc.1207548; Shatkin AJ, 2000, NAT STRUCT BIOL, V7, P838, DOI 10.1038/79583; Shcherbik N, 2004, J CELL BIOCHEM, V93, P11, DOI 10.1002/jcb.20130; Teleman AA, 2005, GENE DEV, V19, P1844, DOI 10.1101/gad.341505; Tettweiler G, 2005, GENE DEV, V19, P1840, DOI 10.1101/gad.1311805; Tomoo K, 2003, J MOL BIOL, V328, P365, DOI 10.1016/S0022-2836(03)00314-0; Tomoo K, 2002, BIOCHEM J, V362, P539, DOI 10.1042/0264-6021:3620539; Vries RGJ, 1997, J BIOL CHEM, V272, P32779, DOI 10.1074/jbc.272.52.32779; Walsh D, 2003, DIFFERENTIATION, V71, P126, DOI 10.1046/j.1432-0436.2003.710203.x; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Zuberek J, 2004, BIOCHEMISTRY-US, V43, P5370, DOI 10.1021/bi030266t	36	65	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20788	20800		10.1074/jbc.M600563200	http://dx.doi.org/10.1074/jbc.M600563200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16720573	hybrid			2022-12-25	WOS:000239187300015
J	Zupnick, A; Prives, C				Zupnick, Andrew; Prives, Carol			Mutational analysis of the p53 core domain L1 loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; CHECKPOINT KINASES CHK1; DNA-BINDING; TRANSCRIPTIONAL REPRESSION; CRYSTAL-STRUCTURE; IN-VIVO; MAMMALIAN-CELLS; TARGET GENES; MUTANT P53; APOPTOSIS	The p53 tumor suppressor gene acquires missense mutations in over 50% of human cancers, and most of these mutations occur within the central core DNA binding domain. One structurally defined region of the core, the L1 loop (residues 112 124), is a mutational "cold spot" in which relatively few tumor-derived mutations have been identified. To further understand the L1 loop, we subjected this region to both alanine- and arginine-scanning mutagenesis and tested mutants for DNA binding in vitro. Select mutants were then analyzed for transactivation and cell cycle analysis in either transiently transfected cells or cells stably expressing wild-type and mutant proteins at regulatable physiological levels. We focused most extensively on two p53 L1 loop mutants, T123A and K120A. The T123A mutant p53 displayed significantly better DNA binding in vitro as well as stronger transactivation and apoptotic activity in vivo than wild-type p53, particularly toward its pro-apoptotic target AIP1. By contrast, K120A mutant p53, although capable of strong binding in vitro and wild- type levels of transactivation and apoptosis when transfected into cells, showed impaired activity when expressed at normal cellular levels. Our experiments indicate a weaker affinity for DNA in vivo by K120A p53 as the main reason for its defects in transactivation and apoptosis. Overall, our findings demonstrate an important, yet highly modular role for the L1 loop in the recognition of specific DNA sequences, target transactivation, and apoptotic signaling by p53.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	clp3@columbia.edu			NATIONAL CANCER INSTITUTE [R01CA077742] Funding Source: NIH RePORTER; NCI NIH HHS [CA77742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Attardi LD, 2005, MUTAT RES-FUND MOL M, V569, P145, DOI 10.1016/j.mrfmmm.2004.04.019; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Berger Michael, 2003, Methods Mol Biol, V234, P245; Beroud C, 2003, HUM MUTAT, V21, P176, DOI 10.1002/humu.10187; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chene P, 1998, J MOL BIOL, V281, P205, DOI 10.1006/jmbi.1998.1897; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; Friedler A, 2005, J BIOL CHEM, V280, P8051, DOI 10.1074/jbc.M411176200; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Haupt Y, 1996, Behring Inst Mitt, P32; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Hublitz P, 2005, GENE DEV, V19, P2912, DOI 10.1101/gad.351205; Huyen Y, 2004, STRUCTURE, V12, P1237, DOI 10.1016/j.str.2004.05.007; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Inga A, 2001, ONCOGENE, V20, P3409, DOI 10.1038/sj.onc.1204457; Inga A, 2001, ONCOGENE, V20, P501, DOI 10.1038/sj.onc.1204116; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Joerger AC, 2005, J BIOL CHEM, V280, P16030, DOI 10.1074/jbc.M500179200; Joerger AC, 2004, J BIOL CHEM, V279, P1291, DOI 10.1074/jbc.M309732200; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kim E, 2003, BIOCHEM CELL BIOL, V81, P141, DOI 10.1139/o03-046; Klein C, 2001, J BIOL CHEM, V276, P49020, DOI 10.1074/jbc.M107516200; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; Ma BY, 2005, P NATL ACAD SCI USA, V102, P3988, DOI 10.1073/pnas.0500215102; Mayo LD, 2005, J BIOL CHEM, V280, P25953, DOI 10.1074/jbc.M503026200; McKinney K, 2004, MOL CELL, V16, P413, DOI 10.1016/j.molcel.2004.09.032; Menendez D, 2006, MOL CELL BIOL, V26, P2297, DOI 10.1128/MCB.26.6.2297-2308.2006; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Pan YP, 2005, BIOCHEMISTRY-US, V44, P1423, DOI 10.1021/bi047845y; Pearson S, 2004, NAT BIOTECHNOL, V22, P3, DOI 10.1038/nbt0104-3; Prives C, 1999, J PATHOL, V187, P112; Qian H, 2002, ONCOGENE, V21, P7901, DOI 10.1038/sj.onc.1205974; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; Rippin TM, 2002, J MOL BIOL, V319, P351, DOI 10.1016/S0022-2836(02)00326-1; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Shieh SY, 2000, GENE DEV, V14, P289; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; Zhao KH, 2001, J BIOL CHEM, V276, P12120, DOI 10.1074/jbc.M011644200	57	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20464	20473		10.1074/jbc.M603387200	http://dx.doi.org/10.1074/jbc.M603387200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16687402	hybrid			2022-12-25	WOS:000239038200069
J	Crisona, NJ; Cozzarelli, NR				Crisona, Nancy J.; Cozzarelli, Nicholas R.			Alteration of Escherichia coli topoisomerase IV conformation upon enzyme binding to positively supercoiled DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II TOPOISOMERASES; SINGLE-MOLECULE; MECHANISM; GYRASE; REPLICATION; RECOMBINATION; PURIFICATION; UNLINKING; ROLES	Escherichia coli topoisomerase IV (topo IV) is an essential enzyme that unlinks the daughter chromosomes for proper segregation at cell division. In vitro, topo IV readily distinguishes between the two possible chiralities of crossing segments in a DNA substrate. The enzyme relaxes positive supercoils and left-handed braids 20 times faster, and with greater processivity, than negative supercoils and right-handed braids. Here, we used chemical cross-linking of topo IV to demonstrate that enzyme bound to positively supercoiled DNA is in a different conformation from that bound to other forms of DNA. Using three different reagents, we observed novel cross-linked species of topo IV when positively supercoiled DNA was in the reaction. We show that the ParE subunits are in close enough proximity to be crosslinked only when the enzyme is bound to positively supercoiled DNA. We suggest that the altered conformation reflects efficient binding by topo IV of the two DNA segments that participate in the strand passage reaction.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Crisona, NJ (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 16 Barker Hall, Berkeley, CA 94720 USA.	crisona@calmail.berkeley.edu						Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Charvin G, 2003, P NATL ACAD SCI USA, V100, P9820, DOI 10.1073/pnas.1631550100; Corbett KD, 2005, J MOL BIOL, V351, P545, DOI 10.1016/j.jmb.2005.06.029; Crisona NJ, 2000, GENE DEV, V14, P2881, DOI 10.1101/gad.838900; Crisona NJ, 1999, J MOL BIOL, V289, P747, DOI 10.1006/jmbi.1999.2771; Deibler RW, 2001, GENE DEV, V15, P748, DOI 10.1101/gad.872301; DYNAN WS, 1981, J BIOL CHEM, V256, P5860; Holmes VF, 2000, P NATL ACAD SCI USA, V97, P1322, DOI 10.1073/pnas.040576797; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO J, 1992, J BIOL CHEM, V267, P25676; Khodursky AB, 2000, P NATL ACAD SCI USA, V97, P9419, DOI 10.1073/pnas.97.17.9419; Levine C, 1998, BBA-GENE STRUCT EXPR, V1400, P29, DOI 10.1016/S0167-4781(98)00126-2; PENG H, 1995, J BIOL CHEM, V270, P25286, DOI 10.1074/jbc.270.42.25286; SANDMAN K, 1994, P NATL ACAD SCI USA, V91, P12624, DOI 10.1073/pnas.91.26.12624; SPENGLER SJ, 1985, CELL, V42, P325, DOI 10.1016/S0092-8674(85)80128-8; Stone MD, 2003, P NATL ACAD SCI USA, V100, P8654, DOI 10.1073/pnas.1133178100; Ullsperger C, 1996, J BIOL CHEM, V271, P31549, DOI 10.1074/jbc.271.49.31549; WEBER K, 1969, J BIOL CHEM, V244, P4406; Zechiedrich EL, 1997, GENE DEV, V11, P2580, DOI 10.1101/gad.11.19.2580; ZECHIEDRICH EL, 1995, GENE DEV, V9, P2859, DOI 10.1101/gad.9.22.2859	20	12	12	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					18927	18932		10.1074/jbc.M603068200	http://dx.doi.org/10.1074/jbc.M603068200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16684778	hybrid			2022-12-25	WOS:000238847000005
J	Jank, T; Pack, U; Giesemann, T; Schmidt, G; Aktories, K				Jank, Thomas; Pack, Ulrike; Giesemann, Torsten; Schmidt, Gudula; Aktories, Klaus			Exchange of a single amino acid switches the substrate properties of RhoA and RhoD toward glucosylating and transglutaminating toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOTOXIC NECROTIZING FACTOR-1; GUANINE-NUCLEOTIDE EXCHANGE; CLOSTRIDIAL CYTOTOXINS; STRUCTURAL BASIS; ENDOSOME DYNAMICS; CELL-MIGRATION; PROTEIN CDC42; BINDING; DOMAIN; COMPLEX	Rho GTPases are the preferred targets of various bacterial cytotoxins, including Clostridium difficile toxins A and B, Clostridium sordellii lethal toxin, the cytotoxic necrotizing factors (CNF1) from Escherichia coli, and the dermonecrotizing toxin (DNT) from Bordetella species. The toxins inactivate or activate specific sets of Rho GTPases by mono-O-glucosylation and deamidation/transglutamination, respectively. Here we studied the structural basis of the recognition of RhoA, which is modified by toxin B, CNF1, and DNT, in comparison with RhoD, which is solely a substrate for lethal toxin. We found that a single amino acid residue in RhoA and RhoD defines the substrate specificity for toxin B and lethal toxin. Change of serine 73 to phenylalanine in RhoA turned RhoA into a substrate for lethal toxin. Accordingly, change of the equivalently positioned phenylalanine 85 in RhoD with serine allowed glucosylation by toxin B. Comparable results were achieved with the Rho-activating and transglutaminating enzymes CNF1 and DNT. Here, amino acid glutamate 64 of RhoA and the equivalent aspartate 76 of RhoD define substrate specificity for CNF1 and DNT, respectively. These data indicate that single amino acid residues located in the switch II region of Rho proteins determine enzyme specificity for diverse bacterial toxins.	Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Freiburg	Aktories, K (corresponding author), Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, Otto Krayer Haus,Albert Str 25, D-79104 Freiburg, Germany.	Klaus.Aktories@pharmakol.uni-freiburg.de	Jank, Thomas/R-9627-2017; Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				Aktories K, 2005, CURR TOP MICROBIOL, V291, P113; AKTORIES K, 1995, TRENDS CELL BIOL, V5, P441, DOI 10.1016/S0962-8924(00)89107-2; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Buchwald G, 2002, EMBO J, V21, P3286, DOI 10.1093/emboj/cdf329; Dvorsky R, 2004, EMBO REP, V5, P1130, DOI 10.1038/sj.embor.7400293; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Flatau G, 2000, BIOCHEM BIOPH RES CO, V267, P588, DOI 10.1006/bbrc.1999.1904; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Gasman S, 2003, NAT CELL BIOL, V5, P195, DOI 10.1038/ncb935; Gizachew D, 2000, BIOCHEMISTRY-US, V39, P3963, DOI 10.1021/bi992646d; Heo WD, 2003, CELL, V113, P315; Herrmann C, 1998, J BIOL CHEM, V273, P16134, DOI 10.1074/jbc.273.26.16134; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Hofmann F, 1998, INFECT IMMUN, V66, P1076, DOI 10.1128/IAI.66.3.1076-1081.1998; Hofmann F, 1997, J BIOL CHEM, V272, P11074; Horiguchi Y, 2001, TOXICON, V39, P1619, DOI 10.1016/S0041-0101(01)00149-0; Jank T, 2005, J BIOL CHEM, V280, P37833, DOI 10.1074/jbc.M506836200; Just I, 2005, REV PHYSIOL BIOCH P, V152, P23, DOI 10.1007/s10254-004-0033-5; JUST I, 1994, J BIOL CHEM, V269, P10706; Just I, 1996, J BIOL CHEM, V271, P10149, DOI 10.1074/jbc.271.17.10149; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Lerm M, 1999, J BIOL CHEM, V274, P28999, DOI 10.1074/jbc.274.41.28999; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; Muller S, 1999, EUR J BIOCHEM, V266, P1073, DOI 10.1046/j.1432-1327.1999.00951.x; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; Pfeifer G, 2003, J BIOL CHEM, V278, P44535, DOI 10.1074/jbc.M307540200; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Rupnik M, 2005, MICROBIOL-SGM, V151, P199, DOI 10.1099/mic.0.27474-0; Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392; Schmidt G, 1998, J BIOL CHEM, V273, P13669, DOI 10.1074/jbc.273.22.13669; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Sehr P, 1998, BIOCHEMISTRY-US, V37, P5296, DOI 10.1021/bi972592c; Tarricone C, 2001, NATURE, V411, P215, DOI 10.1038/35075620; Tsubakimoto K, 1999, ONCOGENE, V18, P2431, DOI 10.1038/sj.onc.1202604; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Wurtele M, 2001, FEBS LETT, V491, P26, DOI 10.1016/S0014-5793(01)02105-6	43	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19527	19535		10.1074/jbc.M600863200	http://dx.doi.org/10.1074/jbc.M600863200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16702216	hybrid			2022-12-25	WOS:000238847000067
J	Wang, WP; Chan, JY				Wang, Weiping; Chan, Jefferson Y.			Nrf1 is targeted to the endoplasmic reticulum membrane by an N-terminal transmembrane domain - Inhibition of nuclear translocation and transacting function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BZIP TRANSCRIPTION FACTOR; ANTIOXIDANT RESPONSE ELEMENT; CUL3-BASED E3 LIGASE; OXIDATIVE STRESS; PROTEASOMAL DEGRADATION; EMBRYONIC LETHALITY; GENE-EXPRESSION; FACTOR TCF11; PROTEIN; KEAP1	Expression of antioxidant and phase 2 xenobiotic metabolizing enzyme genes is regulated through cis-acting sequences known as antioxidant response elements. Transcriptional activation through the antioxidant response elements involves members of the CNC (Cap 'n' Collar) family of basic leucine zipper proteins including Nrf1 and Nrf2. Nrf2 activity is regulated by Keap1-mediated compartmentalization in the cell. Given the structural similarities between Nrf1 and Nrf2, we sought to investigate whether Nrf1 activity is regulated similarly to Nrf2. Nrf1 also resides normally in the cytoplasm of cells. Cytoplasmic localization however, is independent of Keap1. Colocalization analysis using green fluorescent protein-tagged Nrf1 and subcellular fractionation of endogenous Nrf1 and fusion proteins indicate that Nrf1 is primarily a membrane-bound protein localized in the endoplasmic reticulum. Membrane targeting is mediated by the N terminus of the Nrf1 protein that contains a predicted transmembrane domain, and deletion of this domain resulted in a predominantly nuclear localization of Nrf1 that significantly increased the activation of reporter gene expression. Treatment with tunicamycin, an endoplasmic reticulum stress inducer, caused an accumulation of a smaller form of Nrf1 that correlated with detection of Nrf1 in the nucleus by biochemical fractionation and immunofluorescent analysis. These results suggest that Nrf1 is normally targeted to the endoplasmic reticulum membrane and that endoplasmic reticulum stress may play a role in modulating Nrf1 function as a transcriptional activator.	Univ Calif Irvine, Dept Lab Med & Pathol, Irvine, CA 92697 USA	University of California System; University of California Irvine	Chan, JY (corresponding author), Univ Calif Irvine, Dept Lab Med & Pathol, D440 Med Sci 1, Irvine, CA 92697 USA.	jchan@uci.edu			NCI NIH HHS [CA91907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA091907, R01CA091907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Chan JY, 1998, EMBO J, V17, P1779, DOI 10.1093/emboj/17.6.1779; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; Husberg C, 2003, BBA-MOL CELL RES, V1640, P143, DOI 10.1016/S0167-4889(03)00041-7; Husberg C, 2001, J BIOL CHEM, V276, P17641, DOI 10.1074/jbc.M007951200; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Katoh Y, 2005, ARCH BIOCHEM BIOPHYS, V433, P342, DOI 10.1016/j.abb.2004.10.012; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kobayashi M, 2005, ANTIOXID REDOX SIGN, V7, P385, DOI 10.1089/ars.2005.7.385; Kondo S, 2005, NAT CELL BIOL, V7, P186, DOI 10.1038/ncb1213; Kwong M, 1999, J BIOL CHEM, V274, P37491, DOI 10.1074/jbc.274.52.37491; Leung L, 2003, J BIOL CHEM, V278, P48021, DOI 10.1074/jbc.M308439200; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; Mathers J, 2004, BIOCHEM SOC SYMP, V71, P157, DOI 10.1042/bss0710157; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; McMahon M, 2004, J BIOL CHEM, V279, P31556, DOI 10.1074/jbc.M403061200; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; Myhrstad MCW, 2001, BBA-GENE STRUCT EXPR, V1517, P212, DOI 10.1016/S0167-4781(00)00276-1; Nguyen T, 2005, J BIOL CHEM, V280, P32485, DOI 10.1074/jbc.M503074200; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Shih AY, 2003, J NEUROSCI, V23, P3394, DOI 10.1523/jneurosci.23-08-03394.2003; Shimano H, 2001, PROG LIPID RES, V40, P439, DOI 10.1016/S0163-7827(01)00010-8; Sies H, 1997, EXP PHYSIOL, V82, P291, DOI 10.1113/expphysiol.1997.sp004024; Stirling J, 2006, MOL BIOL CELL, V17, P413, DOI 10.1091/mbc.E05-06-0500; Stitziel NO, 2004, CANCER RES, V64, P8682, DOI 10.1158/0008-5472.CAN-04-1729; Velichkova M, 2005, MOL CELL BIOL, V25, P4501, DOI 10.1128/MCB.25.11.4501-4513.2005; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; ZIEGLER EC, 2005, SCI STKE	43	124	129	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19676	19687		10.1074/jbc.M602802200	http://dx.doi.org/10.1074/jbc.M602802200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16687406	hybrid			2022-12-25	WOS:000238847000081
J	Bader, R; Seeliger, MA; Kelly, SE; Ilag, LL; Meersman, F; Limones, A; Luisi, BF; Dobson, CM; Itzhaki, LS				Bader, Reto; Seeliger, Markus A.; Kelly, Sadie E.; Ilag, Leopold L.; Meersman, Filip; Limones, Alejandra; Luisi, Ben F.; Dobson, Christopher M.; Itzhaki, Laura S.			Folding and fibril formation of the cell cycle protein Cks1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-LIKE FIBRILS; CRYSTAL-STRUCTURE; HUNTINGTONS-DISEASE; EXPANDED GLUTAMINE; CORE STRUCTURE; BETA-HELIX; IN-VITRO; POLYGLUTAMINE; AGGREGATION; RECRUITMENT	The Saccharomyces cerevisiae Cks protein Cks1 has a COOH-terminal glutamine-rich sequence not present in other homologues. Cks proteins domain swap to form dimers but unique to Cks1 is the anti-parallel arrangement of protomers within the dimer. Despite the differences in Cks1 compared with other Cks proteins, we find the domain swapping properties are very similar. However, aggregation of Cks1 occurs by a route distinct from the other Cks proteins studied to date. Cks1 formed fibrillar aggregates at room temperature and neutral pH. During this process, Cks1 underwent proteolytic cleavage at a trypsin-like site into two fragments, the globular Cks domain and the glutamine-rich COOH terminus. At high protein concentrations, the rate of fibril formation was the same as the rate of proteolysis. The dominant species present within the fibrils was the glutamine-rich sequence. Consistent with this result, fibril formation was enhanced by addition of trypsin. Moreover, a truncated variant lacking the glutamine-rich sequence did not form fibrils under the same conditions. A lag phase at low protein concentrations indicates that fibril formation occurs through a nucleation and growth mechanism. The aggregates appear to resemble amyloid fibrils, in that they show the typical cross-beta-ray diffraction pattern. Moreover, infrared spectroscopy data indicate that the glutamine side chains are hydrogen-bonded along the axis of the fibril. Our results indicate that the proteolytic reaction is the crucial step initiating aggregation and demonstrate that Cks1 is a simple, tunable model system for exploring aggregation mechanisms associated with polyglutamine deposition diseases.	Hutchinson MRC Res Ctr, MRC Canc Cell Unit, Cambridge CB2 2XZ, England; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; MRC, Ctr Prot Engn, Cambridge CB2 2QH, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	University of Cambridge; University of Cambridge; University of Cambridge	Itzhaki, LS (corresponding author), Hutchinson MRC Res Ctr, MRC Canc Cell Unit, Hills Rd, Cambridge CB2 2XZ, England.	lsi10@cam.ac.uk	Seeliger, Markus A/D-6409-2013	Ilag, Leopold/0000-0003-3678-7100; Seeliger, Markus/0000-0003-0990-1756	MRC [MC_U105370180] Funding Source: UKRI; Medical Research Council [MC_U105370180] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		ARVAI AS, 1995, J MOL BIOL, V249, P835, DOI 10.1006/jmbi.1995.0341; Bates G, 2003, LANCET, V361, P1642, DOI 10.1016/S0140-6736(03)13304-1; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bevivino AE, 2001, P NATL ACAD SCI USA, V98, P11955, DOI 10.1073/pnas.211305198; BIRCK C, 1995, FEBS LETT, V363, P145, DOI 10.1016/0014-5793(95)00300-X; Bouchard M, 2000, PROTEIN SCI, V9, P1960, DOI 10.1110/ps.9.10.1960; Bourne Y, 2000, STRUCT FOLD DES, V8, P841, DOI 10.1016/S0969-2126(00)00175-1; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Chen S, 2001, J MOL BIOL, V311, P173, DOI 10.1006/jmbi.2001.4850; Chen SM, 2002, BIOCHEMISTRY-US, V41, P7391, DOI 10.1021/bi011772q; Chen YW, 1999, P NATL ACAD SCI USA, V96, P1257, DOI 10.1073/pnas.96.4.1257; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Dobson CM, 2004, SEMIN CELL DEV BIOL, V15, P3, DOI 10.1016/j.semcdb.2003.12.008; ENDICOTT JA, 1995, EMBO J, V14, P1004, DOI 10.1002/j.1460-2075.1995.tb07081.x; Fandrich M, 2002, EMBO J, V21, P5682, DOI 10.1093/emboj/cdf573; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; Huang CC, 1998, SOMAT CELL MOLEC GEN, V24, P217, DOI 10.1023/B:SCAM.0000007124.19463.e5; Ilag LL, 2004, STRUCTURE, V12, P269, DOI 10.1016/j.str.2004.01.007; Jenkins J, 2001, PROG BIOPHYS MOL BIO, V77, P111, DOI 10.1016/S0079-6107(01)00013-X; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Khazanovich N, 1996, STRUCTURE, V4, P299, DOI 10.1016/S0969-2126(96)00034-2; Khurana R, 2000, BIOPHYS J, V78, P994, DOI 10.1016/S0006-3495(00)76657-4; Kishimoto A, 2004, BIOCHEM BIOPH RES CO, V315, P739, DOI 10.1016/j.bbrc.2004.01.117; KRULL LH, 1965, BIOCHEMISTRY-US, V4, P626, DOI 10.1021/bi00880a003; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Masino L, 2002, FEBS LETT, V513, P267, DOI 10.1016/S0014-5793(02)02335-9; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; Nelson R, 2005, NATURE, V435, P773, DOI 10.1038/nature03680; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; PARGE HE, 1993, SCIENCE, V262, P387, DOI 10.1126/science.8211159; Perez MK, 1998, J CELL BIOL, V143, P1457, DOI 10.1083/jcb.143.6.1457; Perutz MF, 2001, NATURE, V412, P143, DOI 10.1038/35084141; Perutz MF, 2002, P NATL ACAD SCI USA, V99, P5596, DOI 10.1073/pnas.042681599; Perutz MF, 2002, P NATL ACAD SCI USA, V99, P5591, DOI 10.1073/pnas.042681399; Pines J, 1996, CURR BIOL, V6, P1399, DOI 10.1016/S0960-9822(96)00741-5; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; Rahmelow K, 1998, ANAL BIOCHEM, V257, P1, DOI 10.1006/abio.1997.2502; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Rousseau F, 2001, P NATL ACAD SCI USA, V98, P5596, DOI 10.1073/pnas.101542098; Sambashivan S, 2005, NATURE, V437, P266, DOI 10.1038/nature03916; Schaffar G, 2004, MOL CELL, V15, P95, DOI 10.1016/j.molcel.2004.06.029; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Schymkowitz JWH, 2000, J MOL BIOL, V301, P199, DOI 10.1006/jmbi.2000.3958; Seeliger MA, 2002, BIOCHEMISTRY-US, V41, P1202, DOI 10.1021/bi0113465; Sikorski P, 2005, BIOMACROMOLECULES, V6, P425, DOI 10.1021/bm0494388; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; Sugars KL, 2003, TRENDS GENET, V19, P233, DOI 10.1016/S0168-9525(03)00074-X; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Tanaka M, 2003, J BIOL CHEM, V278, P34717, DOI 10.1074/jbc.M209852200; Tanaka M, 2002, BIOCHEMISTRY-US, V41, P10277, DOI 10.1021/bi0258905; Venkatraman P, 2004, MOL CELL, V14, P95, DOI 10.1016/S1097-2765(04)00151-0; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1243, DOI 10.1002/bip.360301309; Wellington CL, 2000, CLIN GENET, V57, P1, DOI 10.1034/j.1399-0004.2000.570101.x; Wetzel R, 2002, STRUCTURE, V10, P1031, DOI 10.1016/S0969-2126(02)00809-2; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	60	13	13	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18816	18824		10.1074/jbc.M603628200	http://dx.doi.org/10.1074/jbc.M603628200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16675442	hybrid			2022-12-25	WOS:000238687300062
J	Honda, M; Inoue, J; Yoshimasu, M; Ito, Y; Shibata, T; Mikawa, T				Honda, Masayoshi; Inoue, Jin; Yoshimasu, Masatoshi; Ito, Yutaka; Shibata, Takehiko; Mikawa, Tsutomu			Identification of the RecR toprim domain as the binding site for both RecF and RecO - A role of RecR in RecFOR assembly at double-stranded DNA-single-stranded DNA junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RECF; GENETIC-RECOMBINATION; PROTEIN FUNCTION; EXCISION-REPAIR; ATP; SSDNA; RENATURATION; ARCHITECTURE; REPLICATION; FILAMENTS	The RecR protein forms complexes with RecF or RecO that direct the specific loading of RecA onto gapped DNA. However, the binding sites of RecF and RecO on RecR have yet to be identified. In this study, a Thermus thermophilus RecR dimer model was constructed by NMR analysis and homology modeling. NMR titration analysis suggested that the hairpin region of the helix-hairpin-helix motif in the cavity of the RecR dimer is a binding site for double-stranded DNA (dsDNA) and that the acidic cluster region of the Toprim domain is a RecO binding site. Mutations of Glu-84, Asp-88, and Glu-144 residues comprising that acidic cluster were generated. The E144A and E84A mutations decreased the binding affinity for RecO, but the D88A did not. Interestingly, the binding ability to RecF was abolished by E144A, suggesting that the region surrounding the RecR Glu-144 residue could be a binding site not only for RecO but also for RecF. Furthermore, RecR and RecF formed a 4: 2 heterohexamer in solution that was unaffected by adding RecO, indicating a preference by RecR for RecF over RecO. The RecFR complex is considered to be involved in the recognition of the dsDNA-ssDNA junction, whereas RecO binds single-strandedDNA ( ssDNA) and ssDNA-binding protein. Thus, the RecR Toprim domain may contribute to the RecO interaction with RecFR complexes at the dsDNA-ssDNA junction site during recombinational DNA repair mediated by the RecFOR.	RIKEN, Discovery Res Inst, Wako, Saitama 3510198, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 5600082, Japan; Tokyo Metropolitan Univ, Dept Chem, Hachioji, Tokyo 1920397, Japan; RIKEN, Harima Inst, Mikazuki, Hyogo 6795148, Japan	RIKEN; Yokohama City University; Japan Science & Technology Agency (JST); Tokyo Metropolitan University; RIKEN	Mikawa, T (corresponding author), RIKEN, Discovery Res Inst, Bio Supramol Struct Funct Grp, Tsurumi Ku, 1-7-29 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	mikawa@riken.jp	Mikawa, Tsutomu/E-6510-2013; Ito, Yutaka/P-2604-2015	Mikawa, Tsutomu/0000-0003-2325-5084; Ito, Yutaka/0000-0002-1030-4660; Honda, Masayoshi/0000-0001-8920-6301				Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4205, DOI 10.1093/nar/26.18.4205; Bork JM, 2001, EMBO J, V20, P7313, DOI 10.1093/emboj/20.24.7313; Courcelle J, 1997, P NATL ACAD SCI USA, V94, P3714, DOI 10.1073/pnas.94.8.3714; Courcelle J, 1999, J BACTERIOL, V181, P916, DOI 10.1128/JB.181.3.916-922.1999; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; Englander SW, 1996, CURR OPIN STRUC BIOL, V6, P18, DOI 10.1016/S0959-440X(96)80090-X; FRIEDBERG EC, 2006, DNA REPAIR MUTAGENES, P576; Honda M, 2004, J BIOMOL NMR, V28, P199, DOI 10.1023/B:JNMR.0000013821.02982.01; Kagawa W, 2001, J BIOL CHEM, V276, P35201, DOI 10.1074/jbc.M104938200; Kantake N, 2002, P NATL ACAD SCI USA, V99, P15327, DOI 10.1073/pnas.252633399; Kato M, 2003, MOL CELL, V11, P1349, DOI 10.1016/S1097-2765(03)00195-3; Keck JL, 2000, SCIENCE, V287, P2482, DOI 10.1126/science.287.5462.2482; Kowalczykowski SC, 2005, NATURE, V433, P591, DOI 10.1038/433591a; KRAULIS PJ, 1989, J MAGN RESON, V84, P627, DOI 10.1016/0022-2364(89)90130-3; KUSHNER SR, 1971, P NATL ACAD SCI USA, V68, P824, DOI 10.1073/pnas.68.4.824; LAUE ED, 1986, J MAGN RESON, V68, P14, DOI 10.1016/0022-2364(86)90312-4; Lee BI, 2004, EMBO J, V23, P2029, DOI 10.1038/sj.emboj.7600222; LLOYD RG, 1985, J BACTERIOL, V164, P836, DOI 10.1128/JB.164.2.836-844.1985; LUISIDELUCA C, 1994, J MOL BIOL, V236, P124, DOI 10.1006/jmbi.1994.1123; LUISIDELUCA C, 1995, J BACTERIOL, V177, P566, DOI 10.1128/jb.177.3.566-572.1995; MADIRAJU MVVS, 1992, J BACTERIOL, V174, P7705, DOI 10.1128/JB.174.23.7705-7710.1992; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; Morimatsu K, 2003, MOL CELL, V11, P1337, DOI 10.1016/S1097-2765(03)00188-6; Nichols MD, 1999, EMBO J, V18, P6177, DOI 10.1093/emboj/18.21.6177; Olofsson A, 2004, J BIOL CHEM, V279, P5699, DOI 10.1074/jbc.M310605200; Rajesh S, 1999, BIOCHEMISTRY-US, V38, P9242, DOI 10.1021/bi9903953; Rocha EPC, 2005, PLOS GENET, V1, P247, DOI 10.1371/journal.pgen.0010015; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P5100, DOI 10.1073/pnas.76.10.5100; Shigemori Y, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni111; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; UMEZU K, 1994, J BIOL CHEM, V269, P30005; Webb BL, 1997, CELL, V91, P347, DOI 10.1016/S0092-8674(00)80418-3; Webb BL, 1999, J BIOL CHEM, V274, P15367, DOI 10.1074/jbc.274.22.15367; Webb BL, 1995, J BIOL CHEM, V270, P31397, DOI 10.1074/jbc.270.52.31397; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126; Wuthrich K, 1986, NMR PROTEINS NUCL AC, P117; Yang HJ, 2005, NATURE, V433, P653, DOI 10.1038/nature03234	40	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18549	18559		10.1074/jbc.M512658200	http://dx.doi.org/10.1074/jbc.M512658200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16675461	hybrid			2022-12-25	WOS:000238687300034
J	Freilinger, A; Rosner, M; Krupitza, G; Nishino, M; Lubec, G; Korsmeyer, SJ; Hengstschlager, M				Freilinger, A.; Rosner, M.; Krupitza, G.; Nishino, M.; Lubec, G.; Korsmeyer, S. J.; Hengstschlaeger, M.			Tuberin activates the proapoptotic molecule BAD	ONCOGENE			English	Article						TSC2; tuberin; BAD; apoptosis	TUMOR-SUPPRESSOR GENE; CELL-SURVIVAL; SCLEROSIS COMPLEX; PRODUCT; TSC2; PHOSPHORYLATION; GROWTH; DEATH; AKT; TARGET	TSC1, encoding hamartin, and TSC2, encoding tuberin, are tumor suppressor genes responsible for the autosomal dominantly inherited disease tuberous sclerosis (TSC). TSC affects similar to 1 in 6000 individuals and is characterized by the development of tumors, named hamartomas, in different organs. Hamartin and tuberin form a complex, of which tuberin is assumed to be the functional component. The TSC proteins have been implicated in the control of cell cycle and cell size. In addition to enhanced growth, reduced death rates can lead to tumor development. Therefore, defects in the apoptosis-inducing pathways contribute to neoplastic cell expansion. Here, we show that tuberin triggers apoptosis, accompanied by downregulation of p70S6K activity and of phosphorylation of BAD on residue Ser136, and by upregulation of the interaction of BAD/BCL-2 and BAD/BCL-X-L. AKT phosphorylation negatively regulates tuberin's potential to trigger apoptosis. Experiments with BAD-/- cells demonstrate BAD to be a mediator of tuberin's effects on the regulation of apoptosis. Tuberin interferes with insulin-like growth factor-1-induced BAD Ser136 phosphorylation and cell survival. Our work proposes a model in which tuberin-mediated inhibition of p70S6K activates BAD to heterodimerize with BCL-2 and BCL-XL to promote apoptosis. A mutation of TSC2 - as it occurs in TSC patients - attenuates this proapoptotic potential, underscoring the relevance of our findings for human pathophysiology.	Med Univ Vienna, Gen Hosp, A-1090 Vienna, Austria; Med Univ Vienna, Inst Clin Pathol, Vienna, Austria; Harvard Univ, Sch Med, Howard Hughes Med Inst, Dana Farber Canc Inst,Dept Pathol, Boston, MA USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Dana Farber Canc Inst,Dept Med, Boston, MA USA; Med Univ Vienna, Dept Pediat, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Medical University of Vienna	Hengstschlager, M (corresponding author), Med Univ Vienna, Gen Hosp, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	markus.hengstschlaeger@meduniwien.ac.at		Krupitza, Georg/0000-0003-2949-7906; Lubec, Gert/0000-0002-6333-9461				Arrebola F, 2005, APOPTOSIS, V10, P1317, DOI 10.1007/s10495-005-2718-x; Astrinidis A, 2005, ONCOGENE, V24, P7475, DOI 10.1038/sj.onc.1209090; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; Chong-Kopera H, 2006, J BIOL CHEM, V281, P8313, DOI 10.1074/jbc.C500451200; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Grusch M, 2002, CELL DEATH DIFFER, V9, P169, DOI 10.1038/sj.cdd.4400937; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Harrington LS, 2005, TRENDS BIOCHEM SCI, V30, P35, DOI 10.1016/j.tibs.2004.11.003; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; Kolb TM, 2005, TOXICOL SCI, V88, P331, DOI 10.1093/toxsci/kfi310; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Maheshwar MM, 1997, HUM MOL GENET, V6, P1991, DOI 10.1093/hmg/6.11.1991; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; NELLIST M, 1993, CELL, V75, P1305; Pan DJ, 2004, TRENDS CELL BIOL, V14, P78, DOI 10.1016/j.tcb.2003.12.006; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Rosner M, 2004, J BIOL CHEM, V279, P48707, DOI 10.1074/jbc.M405528200; Rosner M, 2003, ONCOGENE, V22, P4786, DOI 10.1038/sj.onc.1206776; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wohlfart S, 2004, AM J PATHOL, V164, P1081, DOI 10.1016/S0002-9440(10)63195-1; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	42	41	41	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2006	25	49					6467	6479		10.1038/sj.onc.1209660	http://dx.doi.org/10.1038/sj.onc.1209660			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16702951				2022-12-25	WOS:000241395100003
J	Rodrigues, S; Rodrigue, CM; Attoub, S; Flejou, JF; Bruyneel, E; Bracke, M; Emami, S; Gespach, C				Rodrigues, S.; Rodrigue, C. M.; Attoub, S.; Flejou, J. F.; Bruyneel, E.; Bracke, M.; Emami, S.; Gespach, C.			Induction of the adenoma-carcinoma progression and Cdc25A-B phosphatases by the trefoil factor TFF1 in human colon epithelial cells	ONCOGENE			English	Article						differential display; anchorage-independent growth; invasion; apoptosis; tumor growth; human colorectal tumors	HUMAN COLORECTAL-CARCINOMA; HUMAN BREAST-CANCER; IN-VIVO; SIGNALING PATHWAYS; CELLULAR INVASION; POOR-PROGNOSIS; EXPRESSION; PEPTIDES; MDM2; P53	TFF1 is overexpressed in inflammatory diseases and human cancers of the digestive and urogenital systems. To examine the transforming potential of TFF1 in human colon epithelial cells, premalignant PC/AA/C1 adenoma cells (PC) derived from a patient with familial adenomatous polyposis (FAP) were transformed by the TFF1 cDNA and used as a model of the adenoma-carcinoma transition. Constitutive expression of TFF1 increased anchorage-independent cell growth in soft agar, and induced or potentiated the growth of colon PC-TFF1 and kidney MDCKts.src-TFF1 tumor xenografts in athymic mice. This resulted in reduction of thapsigargin-induced apoptosis and promotion of collagen type I invasion through several oncogenic pathways. Using the differential display approach to identify TFF1 target genes, we found that the dual specific phosphatases Cdc25A and B implicated in cell cycle transitions are strongly upregulated under active forms in both PC-TFF1 and HCT8/S11-TFF1 colon cancer cells. Accordingly, TFF1 expression is absent in normal human colon crypts but is induced in correlation with Cdc25a and b transcript levels and tumor grade in familial and sporadic colon adenomas and carcinomas. We propose that TFF1 and Cdc25A-B cooperate with other dominant oncogenic pathways to induce the adenoma and adenocarcinoma transitions. Agents that target TFF1/Cdc25 signaling pathways may be useful for treating patients with TFF1-positive solid tumors.	Hop St Antoine, INSERM, U673, F-75571 Paris 12, France; Univ Paris 06, Paris 12, France; Hop St Antoine, Dept Pathol, F-75571 Paris 12, France; Ghent Univ Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital	Gespach, C (corresponding author), Hop St Antoine, INSERM, U673, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.	gespach@st-antoine.inserm.fr	Attoub, Samir/N-6852-2018					Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P489, DOI 10.1053/gast.1996.v110.pm8566596; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bossenmeyer-Pourie C, 2002, J CELL BIOL, V157, P761, DOI 10.1083/jcb200108056; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; BRACKE ME, 2001, METHODS MOL MED; Brezak MC, 2005, MOL CANCER THER, V4, P1378, DOI 10.1158/1535-7163.MCT-05-0168; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; Christine R, 2005, CANCER RES, V65, P195; Daga RR, 1999, J CELL SCI, V112, P3137; Dhar DK, 2005, CLIN CANCER RES, V11, P6472, DOI 10.1158/1078-0432.CCR-05-0671; Emami S, 2004, PEPTIDES, V25, P885, DOI 10.1016/j.peptides.2003.10.019; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; Empereur S, 1997, BRIT J CANCER, V75, P241, DOI 10.1038/bjc.1997.40; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Hernandez S, 2001, LAB INVEST, V81, P465, DOI 10.1038/labinvest.3780254; Hipfner DR, 2004, NAT REV MOL CELL BIO, V5, P805, DOI 10.1038/nrm1491; Jourdan F, 2003, VIRCHOWS ARCH, V443, P115, DOI 10.1007/s00428-003-0833-z; Kallstrom H, 2005, EXP CELL RES, V303, P89, DOI 10.1016/j.yexcr.2004.09.012; Kang CM, 2004, CARCINOGENESIS, V25, P123, DOI 10.1093/carcin/bgg187; KINDON H, 1995, GASTROENTEROLOGY, V109, P516, DOI 10.1016/0016-5085(95)90340-2; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Leisser C, 2004, CELL DEATH DIFFER, V11, P80, DOI 10.1038/sj.cdd.4401318; Loffler H, 2003, ONCOGENE, V22, P8063, DOI 10.1038/sj.onc.1206976; Mitra J, 2004, ONCOGENE, V23, P3361, DOI 10.1038/sj.onc.1207446; Moore L, 2003, ONCOGENE, V22, P7831, DOI 10.1038/sj.onc.1206985; Onel K, 2004, MOL CANCER RES, V2, P1; Ozen M, 2005, CLIN CANCER RES, V11, P4701, DOI 10.1158/1078-0432.CCR-04-2551; RIO MC, 1988, SCIENCE, V241, P705, DOI 10.1126/science.3041593; Rodrigue CM, 2005, ONCOGENE, V24, P3274, DOI 10.1038/sj.onc.1208485; Rodrigues S, 2003, FASEB J, V17, P7, DOI 10.1096/fj.02-0201com; Rodrigues S, 2003, ONCOGENE, V22, P4488, DOI 10.1038/sj.onc.1206685; Rodrigues S, 2001, FASEB J, V15, P1517, DOI 10.1096/fj.00-0802com; SHOUSHA S, 1993, MODERN PATHOL, V6, P446; Soufla G, 2005, INT J BIOL MARKER, V20, P18, DOI 10.1177/172460080502000104; Takemasa I, 2000, CANCER RES, V60, P3043; Taupin D, 2003, NAT REV MOL CELL BIO, V4, P721, DOI 10.1038/nrm1203; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; Tomasetto C, 2000, GASTROENTEROLOGY, V118, P70, DOI 10.1016/S0016-5085(00)70415-X; Torres LF, 2002, MOL MED, V8, P273, DOI 10.1007/BF03402153; Van de Bovenkamp JHB, 2005, DIGEST DIS SCI, V50, P1078, DOI 10.1007/s10620-005-2708-4; WILLIAMS AC, 1994, ONCOGENE, V9, P1479; Xu XD, 2003, CLIN CANCER RES, V9, P1764; Yio XY, 2005, CLIN EXP METASTAS, V22, P157, DOI 10.1007/s10585-005-6615-z; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200	44	23	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6628	6636		10.1038/sj.onc.1209665	http://dx.doi.org/10.1038/sj.onc.1209665			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16715141				2022-12-25	WOS:000241569700007
J	Paul, C; Lacroix, M; Iankova, I; Julien, E; Schafer, BW; Labalette, C; Wei, Y; Le Cam, A; Le Cam, L; Sardet, C				Paul, C.; Lacroix, M.; Iankova, I.; Julien, E.; Schaefer, B. W.; Labalette, C.; Wei, Y.; Le Cam, A.; Le Cam, L.; Sardet, C.			The LIM-only protein FHL2 is a negative regulator of E4F1	ONCOGENE			English	Article						FHL2; DRAL; E4F1; p53; proliferation; repression	TRANSCRIPTION FACTOR P120(E4F); DOMAIN PROTEIN; BETA-CATENIN; CELL-CYCLE; COACTIVATOR FHL2; INTERACTS; IDENTIFICATION; ACTIVATION; GENE; BINDING	The E1A-targeted transcription factor E4F1 is a key player in the control of mammalian embryonic and somatic cell proliferation and survival. Mouse embryos lacking E4F die at an early developmental stage, whereas enforced expression of E4F1 in various cell lines inhibits cell cycle progression. E4F1-antiproliferative effects have been shown to depend on its capacity to repress transcription and to interact with pRb and p53. Here we show that full-length E4F1 protein (p120(E4F1)) but not its E1A-activated and truncated form (p50(E4F1)), interacts directly in vitro and in vivo with the LIM-only protein FHL2, the product of the p53-responsive gene FHL2/DRAL (downregulated in rhabdomyosarcoma Lim protein). This E4F1-FHL2 association occurs in the nuclear compartment and inhibits the capacity of E4F1 to block cell proliferation. Consistent with this effect, ectopic expression of FHL2 inhibits E4F1 repressive effects on transcription and correlates with a reduction of nuclear E4F-p53 complexes. Overall, these results suggest that FHL2/DRAL is an inhibitor of E4F1 activity. Finally, we show that endogenous E4F1-FHL2 complexes form in U2OS cells upon UV-light-induced nuclear accumulation of FHL2.	CNRS, Inst Mol Genet, UMR 5535, IFR122, F-34293 Montpellier 5, France; Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, CH-8006 Zurich, Switzerland; Inst Pasteur, Unite Oncogenese & Virol Mol, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; University of Zurich; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Sardet, C (corresponding author), CNRS, Inst Mol Genet, UMR 5535, IFR122, 1919 Route Mende, F-34293 Montpellier 5, France.	claude.sardet@igmm.cnrs.fr	Le Cam, Laurent/O-1408-2016; Lacroix, Matthieu/O-1928-2018; Wei, Yu/A-7289-2016; JULIEN, ERIC/Y-5873-2019	Lacroix, Matthieu/0000-0002-1268-9058; JULIEN, ERIC/0000-0003-2976-666X; Schafer, Beat/0000-0001-5988-2915; LE CAM, Laurent/0000-0003-0325-878X				Ahmed-Choudhury J, 2005, CANCER RES, V65, P2690, DOI 10.1158/0008-5472.CAN-04-3593; Amaar YG, 2002, J BIOL CHEM, V277, P12053, DOI 10.1074/jbc.M110872200; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chan KK, 1998, GENE, V210, P345, DOI 10.1016/S0378-1119(97)00644-6; Chu PH, 2000, MOL CELL BIOL, V20, P7460, DOI 10.1128/MCB.20.20.7460-7462.2000; CHU PH, 2000, J MECH DEV, V95, P265; Colombo R, 2003, ONCOGENE, V22, P2541, DOI 10.1038/sj.onc.1206379; Dantonel JC, 2000, MOL CELL, V6, P715, DOI 10.1016/S1097-2765(00)00069-1; DU X, 2002, BIOCHIM BIOPHYS ACTA, V577, P93; Fajas L, 2001, MOL CELL BIOL, V21, P2956, DOI 10.1128/MCB.21.8.2956-2966.2001; Fajas L, 2000, P NATL ACAD SCI USA, V97, P7738, DOI 10.1073/pnas.130198397; Fenton SL, 2004, CANCER RES, V64, P102, DOI 10.1158/0008-5472.CAN-03-2622; Fernandes ER, 1999, MOL CELL BIOL, V19, P4739; Fernandes ER, 1997, MOL CELL BIOL, V17, P1890, DOI 10.1128/MCB.17.4.1890; Fernandes ER, 1998, MOL CELL BIOL, V18, P459, DOI 10.1128/MCB.18.1.459; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; FOGNANI C, 1993, EMBO J, V12, P4985, DOI 10.1002/j.1460-2075.1993.tb06192.x; Gabriel B, 2004, ANTICANCER RES, V24, P921; Genini M, 1997, DNA CELL BIOL, V16, P433, DOI 10.1089/dna.1997.16.433; Hill AA, 2004, MOL CELL BIOL, V24, P9835, DOI 10.1128/MCB.24.22.9835-9847.2004; Kang CM, 2003, RADIAT RES, V159, P312, DOI 10.1667/0033-7587(2003)159[0312:PBFIRE]2.0.CO;2; Kong YF, 2001, CIRCULATION, V103, P2731; Labalette C, 2004, MOL CELL BIOL, V24, P10689, DOI 10.1128/MCB.24.24.10689-10702.2004; Le Cam L, 2004, MOL CELL BIOL, V24, P6467, DOI 10.1128/MCB.24.14.6467-6475.2004; Li HY, 2001, CELL MOTIL CYTOSKEL, V48, P11, DOI 10.1002/1097-0169(200101)48:1<11::AID-CM2>3.0.CO;2-I; Martin B, 2002, J CELL BIOL, V159, P113, DOI 10.1083/jcb.200202075; McLoughlin P, 2002, J BIOL CHEM, V277, P37045, DOI 10.1074/jbc.M203336200; Morlon A, 2003, P NATL ACAD SCI USA, V100, P3977, DOI 10.1073/pnas.0735923100; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; Philippar U, 2004, MOL CELL, V16, P867, DOI 10.1016/j.molcel.2004.11.039; Purcell NH, 2004, MOL CELL BIOL, V24, P1081, DOI 10.1128/MCB.24.3.1081-1095.2004; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; Retaux S, 2002, MOL NEUROBIOL, V26, P269, DOI 10.1385/MN:26:2-3:269; Rizos H, 2003, J BIOL CHEM, V278, P4981, DOI 10.1074/jbc.M210978200; Sandy P, 2000, ONCOGENE, V19, P188, DOI 10.1038/sj.onc.1203250; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Scholl FA, 2000, J CELL BIOL, V151, P495, DOI 10.1083/jcb.151.3.495; Stilo R, 2002, FEBS LETT, V521, P165, DOI 10.1016/S0014-5793(02)02869-7; Tanahashi H, 2000, HUM MOL GENET, V9, P2281, DOI 10.1093/oxfordjournals.hmg.a018919; Tessari MA, 2003, MOL CELL BIOL, V23, P9104, DOI 10.1128/MCB.23.24.9104-9116.2003; Wei Y, 2003, J BIOL CHEM, V278, P5188, DOI 10.1074/jbc.M207216200; Wixler V, 2000, J BIOL CHEM, V275, P33669, DOI 10.1074/jbc.M002519200; Yang YH, 2005, EMBO J, V24, P1021, DOI 10.1038/sj.emboj.7600570	44	36	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2006	25	40					5475	5484		10.1038/sj.onc.1209567	http://dx.doi.org/10.1038/sj.onc.1209567			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16652157				2022-12-25	WOS:000240370400001
J	Hua, QX; Liu, M; Hu, SQ; Jia, WH; Arvan, P; Weiss, MA				Hua, Qing-xin; Liu, Ming; Hu, Shi-Quan; Jia, Wenhua; Arvan, Peter; Weiss, Michael A.			A conserved histidine in insulin is required for the foldability of human proinsulin - Structure and function of an Ala(B5) analog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; RECEPTOR-BINDING SURFACE; A-CHAIN; BIOLOGICAL-ACTIVITY; CRYSTAL-STRUCTURE; ALPHA-HELIX; SIDE-CHAIN; B CHAINS; MUTATIONAL ANALYSIS; CIRCULAR-DICHROISM	The insulins of eutherian mammals contain histidines at positions B5 and B10. The role of His(B10) is well defined: although not required in the mature hormone for receptor binding, in the islet beta cell this side chain functions in targeting proinsulin to glucose-regulated secretory granules and provides axial zinc-binding sites in storage hexamers. In contrast, the role of His(B5) is less well understood. Here, we demonstrate that its substitution with Ala markedly impairs insulin chain combination in vitro and blocks the folding and secretion of human proinsulin in a transfected mammalian cell line. The structure and stability of an Ala(B5)-insulin analog were investigated in an engineered monomer (DKP-insulin). Despite its impaired foldability, the structure of the Ala(B5) analog retains a native-like T-state conformation. At the site of substitution, interchain nuclear Overhauser effects are observed between the methyl resonance of AlaB5 and side chains in the A chain; these nuclear Overhauser effects resemble those characteristic of HisB5 in native insulin. Substantial receptor binding activity is retained (80 +/- 10% relative to the parent monomer). Although the thermodynamic stability of the Ala(B5) analog is decreased (Delta Delta G(u) = 1.7 +/- 0.1 kcal/mol), consistent with loss of His(B5)-related interchain packing and hydrogen bonds, control studies suggest that this decrement cannot account for its impaired foldability. We propose that nascent long-range interactions by His(B5) facilitate alignment of Cys(A7) and Cys(B7) in protein-folding intermediates; its conservation thus reflects mechanisms of oxidative folding rather than structure-function relationships in the native state.	Univ Michigan, Ctr Med, Div Metab Endocrinol & Diabet, Ann Arbor, MI 48109 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA	University of Michigan System; University of Michigan; Case Western Reserve University	Weiss, MA (corresponding author), Univ Michigan, Ctr Med, Div Metab Endocrinol & Diabet, Med Sci Res Bldg 2,Rm 5560,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	michael.weiss@case.edu			NIDDK NIH HHS [DK0697674, 5P60-DK20572] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAJAJ M, 1986, BIOCHEM J, V238, P345, DOI 10.1042/bj2380345; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BENTLEY G, 1976, NATURE, V261, P166, DOI 10.1038/261166a0; Betts S, 1999, STRUCT FOLD DES, V7, pR131, DOI 10.1016/S0969-2126(99)80078-1; BLUNDELL TL, 1971, NATURE, V231, P506, DOI 10.1038/231506a0; BRANGE J, 1988, NATURE, V333, P679, DOI 10.1038/333679a0; Brunger A. T, 1993, XPLOR MANUAL VERSION; Brzozowski AM, 2002, BIOCHEMISTRY-US, V41, P9389, DOI 10.1021/bi020084j; BURKE GT, 1990, BIOCHEM BIOPH RES CO, V173, P982, DOI 10.1016/S0006-291X(05)80882-4; CARROLL RJ, 1988, P NATL ACAD SCI USA, V85, P8943, DOI 10.1073/pnas.85.23.8943; Chance R. E., 1981, PEPTIDES SYNTHESIS S, P721; Dai Y, 1996, BBA-PROTEIN STRUCT M, V1296, P63, DOI 10.1016/0167-4838(96)00054-4; De Meyts P, 2002, NAT REV DRUG DISCOV, V1, P769, DOI 10.1038/nrd917; DEREWENDA U, 1989, NATURE, V338, P594, DOI 10.1038/338594a0; EIGENBROT C, 1991, J MOL BIOL, V221, P15, DOI 10.1016/0022-2836(91)90796-9; GEIGER R, 1981, H-S Z PHYSIOL CHEM, V362, P799, DOI 10.1515/bchm2.1981.362.1.799; Guo ZY, 2005, ACTA BIOCH BIOPH SIN, V37, P673, DOI 10.1111/j.1745-7270.2005.00093.x; HEATH WF, 1992, J BIOL CHEM, V267, P419; HELLMAN U, 1990, BIOCHEM BIOPH RES CO, V169, P571, DOI 10.1016/0006-291X(90)90369-X; HOBER S, 1992, BIOCHEMISTRY-US, V31, P1749, DOI 10.1021/bi00121a024; HU SQ, 1993, BIOCHEMISTRY-US, V32, P2631, DOI 10.1021/bi00061a022; HUA QX, 1991, BIOCHEMISTRY-US, V30, P5505, DOI 10.1021/bi00236a025; Hua QX, 2003, GENE DEV, V17, P826, DOI 10.1101/gad.1058003; Hua QX, 2002, J BIOL CHEM, V277, P43443, DOI 10.1074/jbc.M206107200; Hua QX, 1996, J MOL BIOL, V264, P390, DOI 10.1006/jmbi.1996.0648; HUA QX, 1991, NATURE, V354, P238, DOI 10.1038/354238a0; Hua QX, 2001, BIOCHEMISTRY-US, V40, P12299, DOI 10.1021/bi011021o; HUA QX, 1993, J MOL BIOL, V230, P387, DOI 10.1006/jmbi.1993.1156; HUANG GS, 1995, P NATL ACAD SCI USA, V92, P6878, DOI 10.1073/pnas.92.15.6878; Huang K, 2004, J MOL BIOL, V341, P529, DOI 10.1016/j.jmb.2004.05.023; HUANG XF, 1994, J BIOL CHEM, V269, P20838; KATSOYAN.PG, 1966, P NATL ACAD SCI USA, V55, P1554, DOI 10.1073/pnas.55.6.1554; KATSOYANNIS PG, 1966, SCIENCE, V154, P1509, DOI 10.1126/science.154.3756.1509; KITAGAWA K, 1984, BIOCHEMISTRY-US, V23, P1405, DOI 10.1021/bi00302a011; KOBAYASHI M, 1982, BIOCHEM BIOPH RES CO, V107, P329, DOI 10.1016/0006-291X(82)91708-9; Kristensen C, 1997, J BIOL CHEM, V272, P12978, DOI 10.1074/jbc.272.20.12978; LIANG DC, 1994, BIOPHYS CHEM, V50, P63, DOI 10.1016/0301-4622(94)85020-8; Liu M, 2005, J BIOL CHEM, V280, P13209, DOI 10.1074/jbc.C400475200; Liu M, 2003, J BIOL CHEM, V278, P14798, DOI 10.1074/jbc.M212070200; MARKI F, 1979, H-S Z PHYSIOL CHEM, V360, P1619, DOI 10.1515/bchm2.1979.360.2.1619; MARKUSSEN J, 1985, INT J PEPT PROT RES, V25, P431; MILLER JA, 1993, BIOCHEMISTRY-US, V32, P5203, DOI 10.1021/bi00070a032; MIRMIRA RG, 1991, J BIOL CHEM, V266, P1428; MIRMIRA RG, 1989, J BIOL CHEM, V264, P6349; Nakagawa SH, 2005, BIOCHEMISTRY-US, V44, P4984, DOI 10.1021/bi048025o; NAKAGAWA SH, 1986, J BIOL CHEM, V261, P7332; NAKAGAWA SH, 1992, BIOCHEMISTRY-US, V31, P3204, DOI 10.1021/bi00127a023; NAKAGAWA SH, 1991, J BIOL CHEM, V266, P11502; Nakagawa SH, 2000, BIOCHEMISTRY-US, V39, P15826, DOI 10.1021/bi001802+; NISHI M, 1990, MOL ENDOCRINOL, V4, P1192, DOI 10.1210/mend-4-8-1192; Olsen HB, 1996, BIOCHEMISTRY-US, V35, P8836, DOI 10.1021/bi960292+; PULLEN RA, 1976, NATURE, V259, P369, DOI 10.1038/259369a0; Qiao ZS, 2001, BIOCHEMISTRY-US, V40, P2662, DOI 10.1021/bi001613r; SCHWARTZ G, 1978, BIOCHEMISTRY-US, V17, P4550, DOI 10.1021/bi00614a029; SCHWARTZ GP, 1987, P NATL ACAD SCI USA, V84, P6408, DOI 10.1073/pnas.84.18.6408; SHOELSON SE, 1992, BIOCHEMISTRY-US, V31, P1757, DOI 10.1021/bi00121a025; Sosnick TR, 2000, METHOD ENZYMOL, V317, P393; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; STEINER DF, 1967, T NEW YORK ACAD SCI, V30, P60, DOI 10.1111/j.2164-0947.1967.tb02452.x; TANG JG, 1990, BIOCHEM J, V268, P429, DOI 10.1042/bj2680429; Vajdos FF, 2001, BIOCHEMISTRY-US, V40, P11022, DOI 10.1021/bi0109111; Wan ZL, 2005, BIOCHEMISTRY-US, V44, P5000, DOI 10.1021/bi047585k; Wan ZL, 2003, BIOCHEMISTRY-US, V42, P12770, DOI 10.1021/bi034430o; Wang J, 1999, J CLIN INVEST, V103, P27, DOI 10.1172/JCI4431; Weiss MA, 2002, BIOCHEMISTRY-US, V41, P809, DOI 10.1021/bi011839+; Weiss MA, 2000, BIOCHEMISTRY-US, V39, P15429, DOI 10.1021/bi001905s; Weiss MA, 2001, J BIOL CHEM, V276, P40018, DOI 10.1074/jbc.M104634200; WEISS MA, 1991, BIOCHEMISTRY-US, V30, P7373, DOI 10.1021/bi00244a004; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Xu B, 2002, J MOL BIOL, V316, P435, DOI 10.1006/jmbi.2001.5377; Xu B, 2002, PROTEIN SCI, V11, P104, DOI 10.1110/ps.ps.32102; Yan H, 2003, PROTEIN SCI, V12, P768, DOI 10.1110/ps.0237203; Zhang BY, 2003, J BIOL CHEM, V278, P3687, DOI 10.1074/jbc.M209474200; ZHANG YS, 2000, SHENG WU HUA XUE YU, V32, P1	75	36	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24889	24899		10.1074/jbc.M602617200	http://dx.doi.org/10.1074/jbc.M602617200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16728398	hybrid			2022-12-25	WOS:000239847800082
J	Shi, WJ; Wang, H; Pan, GJ; Geng, YJ; Guo, YQ; Pei, DQ				Shi, Wenjing; Wang, Hui; Pan, Guangjin; Geng, Yijie; Guo, Yunqian; Pei, Duanqing			Regulation of the pluripotency marker Rex-1 by Nanog and Sox2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; ZINC-FINGER GENE; RETINOIC ACID; SUSTAINING FACTOR; ES CELLS; EXPRESSION; OCTAMER; TRANSCRIPTION; BINDING; PROTEIN	Rex-1 (Zfp-42) is a known marker for undifferentiated embryonic stem cells and teratocarcinoma cells. However, the mechanism by which Rex-1 is regulated in pluripotent cells remains unresolved. Here we report that Nanog, an Nk-2 homeodomain protein known for its role in maintaining stem cell pluripotency, is a transcription activator for the Rex-1 promoter. Knockdown of Nanog in embryonic stem cells resulted in a reduction of Rex-1 expression, whereas forced expression of Nanog in P19 stimulated Rex-1 expression. Employing a Rex-1 reporter, we demonstrate that Nanog transactivates Rex-1 directly. Serial deletion studies mapped the Nanog-responsive element between -187 and -286 of the Rex-1 promoter. Although Oct-3/4 and Sox2 can both transactivate Rex-1 promoter, only Sox2 cooperates with Nanog in up-regulating Rex-1. Furthermore, we demonstrate that the C terminus of Nanog is responsible for transactivating the Rex-1 promoter, a function that can be substituted for by a viral transactivator Vp16 efficiently in NIH3T3 cells but less so in P19 cells. Taking these findings together, we conclude that Rex-1 is a direct target of Nanog, which is augmented by Sox2 and Oct-3/4.	Tsinghua Univ, Inst Pharmacol,Sch Med, Dept Biol Sci & Technol,Inst Biomed, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China	Tsinghua University	Pei, DQ (corresponding author), Guangzhou Inst Biomed & Hlth, Guangzhou 510663, Peoples R China.	pei_duanqing@gibh.ac.cn	Messier, Claude/A-2322-2008; Geng, Yijie/ABF-9498-2020; zhou, xingru/G-4442-2012; Guo, Yunqian/L-4716-2013	Messier, Claude/0000-0002-4791-1763; 				Ambrosetti DC, 1997, MOL CELL BIOL, V17, P6321, DOI 10.1128/MCB.17.11.6321; Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866; Bhattacharya B, 2004, BLOOD, V103, P2956, DOI 10.1182/blood-2003-09-3314; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chew JL, 2005, MOL CELL BIOL, V25, P6031, DOI 10.1128/MCB.25.14.6031-6046.2005; HOSLER BA, 1989, MOL CELL BIOL, V9, P5623, DOI 10.1128/MCB.9.12.5623; HOSLER BA, 1993, MOL CELL BIOL, V13, P2919, DOI 10.1128/MCB.13.5.2919; Kuroda T, 2005, MOL CELL BIOL, V25, P2475, DOI 10.1128/MCB.25.6.2475-2485.2005; LOH YH, 2006, NAT GENET; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Pan GJ, 2005, J BIOL CHEM, V280, P1401, DOI 10.1074/jbc.M407847200; Pan GJ, 2003, CELL RES, V13, P499, DOI 10.1038/sj.cr.7290193; PAN GJ, 2006, IN PRESS FASEB J; ROGERS MB, 1991, DEVELOPMENT, V113, P815; ROSFJORD E, 1994, BIOCHEM BIOPH RES CO, V203, P1795, DOI 10.1006/bbrc.1994.2395; Thompson JR, 2002, MOL CELL ENDOCRINOL, V195, P119, DOI 10.1016/S0303-7207(02)00180-6	16	135	153	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23319	23325		10.1074/jbc.M601811200	http://dx.doi.org/10.1074/jbc.M601811200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16714766	hybrid			2022-12-25	WOS:000239702900006
J	Yoshioka, M; Uchida, S; Mori, H; Komayama, K; Ohira, S; Morita, N; Nakanishi, T; Yamamoto, Y				Yoshioka, Miho; Uchida, Suguru; Mori, Hiroki; Komayama, Keisuke; Ohira, Satoshi; Morita, Noriko; Nakanishi, Tohru; Yamamoto, Yasusi			Quality control of photosystem II - Cleavage of reaction center D1 protein in spinach thylakoids by FtsH protease under moderate heat stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPAIR CYCLE; PHOTOSYNTHETIC MEMBRANES; CHLOROPLASTIC FTSH; OXYGEN EVOLUTION; HIGH-TEMPERATURE; PHOTOINHIBITION; PHOSPHORYLATION; LIGHT; DEGRADATION; HOMOLOG	When spinach thylakoids were subjected to moderate heat stress ( 40 degrees C for 30 min), oxygen evolution was inhibited, and cleavage of the reaction center-binding protein D1 of photosystem II took place, producing 23-kDa N-terminal fragments. The D1 cleavage was greatly facilitated by the addition of 0.15 mM ZnCl2 and 1 mM ATP and was completely inhibited by 1 mM EDTA, indicating the participation of an ATP-dependent metalloprotease(s) in the D1 cleavage. Herbicides 3-(3,4-dichlorophenyl)-1,1- dimethyl urea, bromoxynil, and ioxynil, all of which bind to the Q(B) site, inhibited the D1 cleavage, suggesting that the DE-loop of the D1 protein is the heat-sensitive cleavage site. We solubilized the protease by treating the thylakoids with 2 M KSCN and detected a protease activity in the supernatant by gelatin activity gel electrophoresis in the 70 - 80-kDa region. The antibodies against tobacco FtsH and Arabidopsis FtsH2 reacted with a 70 - 80-kDa band of the KSCN-solubilized fraction, which suggests the presence of FtsH in the fraction. In accordance with this finding, we identified the homolog to Arabidopsis FtsH8 in the 70 - 80-kDa region by matrix-assisted laser desorption ionization time-of-flight mass analysis of the thylakoids. The KSCN-solubilized fraction was successively reconstituted with thylakoids to show heat-induced cleavage of the D1 protein and production of the D1 fragment. These results strongly suggest that an FtsH protease( s) is involved in the primary cleavage of the D1 protein under moderate heat stress.	Okayama Univ, Grad Sch Nat Sci & Technol, Okayama 7008530, Japan; Shujitsu Univ, Sch Pharm, Okayama 7038516, Japan	Okayama University	Yamamoto, Y (corresponding author), Okayama Univ, Grad Sch Nat Sci & Technol, Okayama 7008530, Japan.	yasusiya@cc.okayama-u.ac.jp	Yoshioka-Nishimura, Miho/C-2745-2015; Yamamoto, Yasusi/B-2637-2011					Adam Z, 2002, TRENDS PLANT SCI, V7, P451, DOI 10.1016/S1360-1385(02)02326-9; Akiyama Y, 2002, P NATL ACAD SCI USA, V99, P8066, DOI 10.1073/pnas.122616899; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; Baena-Gonzalez E, 1999, PLANTA, V208, P196, DOI 10.1007/s004250050550; Bailey S, 2002, J BIOL CHEM, V277, P2006, DOI 10.1074/jbc.M105878200; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BERRY J, 1980, ANNU REV PLANT PHYS, V31, P491, DOI 10.1146/annurev.pp.31.060180.002423; DELASRIVAS J, 1992, FEBS LETT, V301, P246, DOI 10.1016/0014-5793(92)80250-K; DelasRivas J, 1997, BIOCHEMISTRY-US, V36, P8897, DOI 10.1021/bi970684w; GOUNARIS K, 1983, FEBS LETT, V153, P47, DOI 10.1016/0014-5793(83)80117-3; Haussuhl K, 2001, EMBO J, V20, P713, DOI 10.1093/emboj/20.4.713; HAVAUX M, 1994, PLANT CELL PHYSIOL, V35, P757, DOI 10.1093/oxfordjournals.pcp.a078654; Kamata T, 2005, PHOTOCH PHOTOBIO SCI, V4, P983, DOI 10.1039/b506068k; KYLE DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4070, DOI 10.1073/pnas.81.13.4070; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; Lindahl M, 1996, J BIOL CHEM, V271, P29329, DOI 10.1074/jbc.271.46.29329; Loll B, 2005, NATURE, V438, P1040, DOI 10.1038/nature04224; MacKinney G, 1941, J BIOL CHEM, V140, P315; Mann NH, 2000, FEBS LETT, V479, P72, DOI 10.1016/S0014-5793(00)01871-8; MULLET JE, 1983, METHOD ENZYMOL, V97, P502; NASH D, 1985, BIOCHIM BIOPHYS ACTA, V807, P127, DOI 10.1016/0005-2728(85)90115-X; Nixon PJ, 2005, J EXP BOT, V56, P357, DOI 10.1093/jxb/eri021; OHAD I, 1984, J CELL BIOL, V270, P14919; Pastenes C, 1996, PLANT PHYSIOL, V112, P1245, DOI 10.1104/pp.112.3.1245; Pursiheimo S, 2003, PLANT CELL ENVIRON, V26, P1995, DOI 10.1046/j.0016-8025.2003.01115.x; RINTAMAKI E, 1995, PHYSIOL PLANTARUM, V93, P191, DOI 10.1034/j.1399-3054.1995.930127.x; Rokka A, 2000, PLANT PHYSIOL, V123, P1525, DOI 10.1104/pp.123.4.1525; Sakamoto W, 2003, PLANT CELL, V15, P2843, DOI 10.1105/tpc.017319; Sakamoto W, 2002, GENES CELLS, V7, P769, DOI 10.1046/j.1365-2443.2002.00558.x; Sharkey TD, 2005, PLANT CELL ENVIRON, V28, P269, DOI 10.1111/j.1365-3040.2005.01324.x; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Silva P, 2003, PLANT CELL, V15, P2152, DOI 10.1105/tpc.012609; Singh AK, 1999, PHOTOSYNTHETICA, V36, P433, DOI 10.1023/A:1007080204112; Sinha P, 2001, PROTEOMICS, V1, P835, DOI 10.1002/1615-9861(200107)1:7<835::AID-PROT835>3.3.CO;2-U; SUNDBY C, 1986, BIOCHIM BIOPHYS ACTA, V851, P475, DOI 10.1016/0005-2728(86)90084-8; Vener AV, 2001, J BIOL CHEM, V276, P6959, DOI 10.1074/jbc.M009394200; Vener AV, 1999, BIOCHEMISTRY-US, V38, P14955, DOI 10.1021/bi990971v; VIERLING E, 1991, ANNU REV PLANT PHYS, V42, P579, DOI 10.1146/annurev.pp.42.060191.003051; Yamamoto Y, 2004, METH MOL B, V274, P29; Yamamoto Y, 2004, METH MOL B, V274, P217; Yamamoto Y, 2001, PLANT CELL PHYSIOL, V42, P121, DOI 10.1093/pcp/pce022; YAMAMOTO Y, 1995, BIOCHEMISTRY-US, V34, P9038, DOI 10.1021/bi00028a012	42	105	117	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21660	21669		10.1074/jbc.M602896200	http://dx.doi.org/10.1074/jbc.M602896200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16735503	Green Published, hybrid			2022-12-25	WOS:000239387100011
J	Takeuchi, H; Jin, SJ; Wang, JY; Zhang, GQ; Kawanokuchi, J; Kuno, R; Sonobe, Y; Mizuno, T; Suzumura, A				Takeuchi, Hideyuki; Jin, Shijie; Wang, Jinyan; Zhang, Guiqin; Kawanokuchi, Jun; Kuno, Reiko; Sonobe, Yoshifumi; Mizuno, Tetsuya; Suzumura, Akio			Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF-ALPHA; NEURONAL DEATH; IN-VITRO; NEURODEGENERATION; BRAIN; TRIGGERS; CELLS; GAMMA; DEGENERATION; STIMULATION	Glutamate released by activated microglia induces excitoneurotoxicity and may contribute to neuronal damage in neurodegenerative diseases, including Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. In addition, tumor necrosis factor-alpha (TNF-alpha) secreted from activated microglia may elicit neurodegeneration through caspase-dependent cascades and silencing cell survival signals. However, direct neurotoxicity of TNF-alpha is relatively weak, because TNF-alpha also increases production of neuroprotective factors. Accordingly, it is still controversial how TNF-alpha exerts neurotoxicity in neurodegenerative diseases. Here we have shown that TNF-alpha is the key cytokine that stimulates extensive microglial glutamate release in an autocrine manner by up-regulating glutaminase to cause excitoneurotoxicity. Further, we have demonstrated that the connexin 32 hemichannel of the gap junction is another main source of glutamate release from microglia besides glutamate transporters. Although pharmacological blockade of glutamate receptors is a promising therapeutic candidate for neurodegenerative diseases, the associated perturbation of physiological glutamate signals has severe adverse side effects. The unique mechanism of microglial glutamate release that we describe here is another potential therapeutic target. We rescued neuronal cell death in vitro by using a glutaminase inhibitor or hemichannel blockers to diminish microglial glutamate release without perturbing the physiological glutamate level. These drugs may give us a new therapeutic strategy against neurodegenerative diseases with minimum adverse side effects.	Nagoya Univ, Environm Med Res Inst, Dept Neuroimmunol, Chikusa Ku, Nagoya, Aichi 4648601, Japan	Nagoya University	Takeuchi, H (corresponding author), Nagoya Univ, Environm Med Res Inst, Dept Neuroimmunol, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.	htake@riem.nagoya-u.ac.jp		Takeuchi, Hideyuki/0000-0001-5912-7581; jin, shijie/0000-0001-5689-841X				Barger SW, 2001, J NEUROCHEM, V76, P846, DOI 10.1046/j.1471-4159.2001.00075.x; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Brown GC, 2003, MOL NEUROBIOL, V27, P325, DOI 10.1385/MN:27:3:325; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Ciesielski-Treska J, 2001, J BIOL CHEM, V276, P13113, DOI 10.1074/jbc.M009711200; De Vuyst E, 2006, EMBO J, V25, P34, DOI 10.1038/sj.emboj.7600908; Eugenin EA, 2001, P NATL ACAD SCI USA, V98, P4190, DOI 10.1073/pnas.051634298; Floden AM, 2005, J NEUROSCI, V25, P2566, DOI 10.1523/JNEUROSCI.4998-04.2005; Frucht DM, 2001, TRENDS IMMUNOL, V22, P556, DOI 10.1016/S1471-4906(01)02005-1; Ghezzi P, 2001, NEUROIMMUNOMODULAT, V9, P178, DOI 10.1159/000049024; Greig NH, 2004, ANN NY ACAD SCI, V1035, P290, DOI 10.1196/annals.1332.018; Illei GG, 2000, CURR OPIN IMMUNOL, V12, P712, DOI 10.1016/S0952-7915(00)00167-9; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kempermann G, 2003, SCIENCE, V302, P1689, DOI 10.1126/science.1092864; Kingham PJ, 1999, J NEUROCHEM, V73, P538, DOI 10.1046/j.1471-4159.1999.0730538.x; Kipnis J, 2004, P NATL ACAD SCI USA, V101, P14663, DOI 10.1073/pnas.0404842101; Koenigsknecht J, 2004, J NEUROSCI, V24, P9838, DOI 10.1523/JNEUROSCI.2557-04.2004; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kuno R, 2005, J NEUROIMMUNOL, V162, P89, DOI 10.1016/j.jneuroim.2005.01.015; McGeer PL, 2002, MUSCLE NERVE, V26, P459, DOI 10.1002/mus.10191; Mizuno T, 2003, BRAIN RES, V979, P65, DOI 10.1016/S0006-8993(03)02867-1; MIZUNO T, 1994, BRAIN RES, V656, P141, DOI 10.1016/0006-8993(94)91375-7; Nelson PT, 2002, ANN MED, V34, P491, DOI 10.1080/078538902321117698; Newsholme EA, 1997, NUTRITION, V13, P728, DOI 10.1016/S0899-9007(97)83034-1; NEWSHOLME P, 1989, BIOCHEM J, V261, P211, DOI 10.1042/bj2610211; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; Nissim I, 1999, AM J PHYSIOL-RENAL, V277, pF493, DOI 10.1152/ajprenal.1999.277.4.F493; Orr CF, 2002, PROG NEUROBIOL, V68, P325, DOI 10.1016/S0301-0082(02)00127-2; Parsons CG, 1999, NEUROPHARMACOLOGY, V38, P735, DOI 10.1016/S0028-3908(99)00019-2; PIANI D, 1994, J IMMUNOL, V152, P3578; Qin S, 2006, J NEUROSCI, V26, P3345, DOI 10.1523/JNEUROSCI.5186-05.2006; Saez JC, 2005, BBA-BIOMEMBRANES, V1711, P215, DOI 10.1016/j.bbamem.2005.01.014; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; Schwab JM, 2004, CELL DEATH DIFFER, V11, P1245, DOI 10.1038/sj.cdd.4401487; Schwartz M, 2003, TRENDS NEUROSCI, V26, P297, DOI 10.1016/S0166-2236(03)00126-7; Suzumura A, 1996, BRAIN RES, V713, P192, DOI 10.1016/0006-8993(95)01535-3; SUZUMURA A, 1987, J NEUROIMMUNOL, V15, P263, DOI 10.1016/0165-5728(87)90121-4; Takeuchi H, 2002, J BIOL CHEM, V277, P50966, DOI 10.1074/jbc.M209356200; Takeuchi H, 2005, J BIOL CHEM, V280, P10444, DOI 10.1074/jbc.M413863200; Taylor DL, 2005, J NEUROSCI, V25, P2952, DOI 10.1523/JNEUROSCI.4456-04.2005; Venters HD, 2000, TRENDS NEUROSCI, V23, P175, DOI 10.1016/S0166-2236(99)01533-7; Ye ZC, 2003, J NEUROSCI, V23, P3588, DOI 10.1523/jneurosci.23-09-03588.2003; Yudkoff M, 1997, GLIA, V21, P92, DOI 10.1002/(SICI)1098-1136(199709)21:1<92::AID-GLIA10>3.0.CO;2-W; Zietlow R, 1999, EUR J NEUROSCI, V11, P1657, DOI 10.1046/j.1460-9568.1999.00583.x; Zou JY, 2005, BRAIN RES, V1034, P11, DOI 10.1016/j.brainres.2004.11.014	45	539	559	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21362	21368		10.1074/jbc.M600504200	http://dx.doi.org/10.1074/jbc.M600504200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16720574	hybrid			2022-12-25	WOS:000239187300072
J	Behrens, M; Bartelt, J; Reichling, C; Winnig, M; Kuhn, C; Meyerhof, W				Behrens, Maik; Bartelt, Juliane; Reichling, Claudia; Winnig, Marcel; Kuhn, Christina; Meyerhof, Wolfgang			Members of RTP and REEP gene families influence functional bitter taste receptor expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; OLFACTORY RECEPTORS; PROTEIN; MEMBRANE; CELLS; ALPHA; TRAFFICKING; ASSOCIATION; ENDOSOMES; CONTAINS	Functional characterization of chemosensory receptors is usually achieved by heterologous expression in mammalian cell lines. However, many chemoreceptor genes, including bitter taste receptors (TAS2Rs), show only marginal cell surface expression. Usually, these problems are circumvented by using chimeric receptors consisting of "export tags" and the receptor sequence itself. It seems likely that chemoreceptor cells express factors for cell surface targeting of native receptor molecules in vivo. For TAS2Rs, however, such factors are still unknown. The present study investigates the influence of RTP and REEP proteins on the functional expression of human TAS2Rs in heterologous cells. We expressed hTAS2Rs in HEK 293T cells and observed dramatic differences in responsiveness to agonist stimulation. By immunocytochemistry we show accumulation of the bitter beta-glucopyranoside receptor hTAS2R16 in the Golgi compartment. Coexpression of RTP and REEP proteins changed the responses of some hTAS2Rs upon agonist stimulation, which is likely due to efficient cell surface localization as demonstrated by cell surface biotinylation experiments. The coimmunoprecipitation of hTAS2R16 and RTP3 or RTP4 suggests that the mechanism by which these cofactors influence hTAS2R16 function might involve direct protein-protein interaction. Finally, expression analyses demonstrate RTP and REEP gene expression in human circumvallate papillae and testis, both of which are sites of TAS2R gene expression.	German Inst Human Nutr Potsdam Rehbruecke, Dept Mol Genet, D-14558 Nuthetal, Germany	Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE)	Behrens, M (corresponding author), German Inst Human Nutr Potsdam Rehbruecke, Dept Mol Genet, Arthur Scheunert Allee 114-116, D-14558 Nuthetal, Germany.	behrens@mail.dife.de	Behrens, Maik/B-6753-2016	Behrens, Maik/0000-0003-2082-8860; Winnig, Marcel/0000-0002-5306-5778				[Anonymous], 1995, NEUROL DIS; Behrens M, 2004, BIOCHEM BIOPH RES CO, V319, P479, DOI 10.1016/j.bbrc.2004.05.019; Behrens M, 2000, EUR J NEUROSCI, V12, P1372, DOI 10.1046/j.1460-9568.2000.00032.x; Behrens M, 2004, CELL MOL LIFE SCI, V61, P2866, DOI 10.1007/s00018-004-4263-0; BEIDLER LM, 1965, J CELL BIOL, V27, P263, DOI 10.1083/jcb.27.2.263; Bhattacharya M, 2004, J NEUROSCI, V24, P8752, DOI 10.1523/JNEUROSCI.3155-04.2004; Bufe B, 2002, NAT GENET, V32, P397, DOI 10.1038/ng1014; Bufe B, 2005, CURR BIOL, V15, P322, DOI 10.1016/j.cub.2005.01.047; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; Erlich R, 1996, J BIOL CHEM, V271, P8328, DOI 10.1074/jbc.271.14.8328; Fang GW, 1999, NAT MED, V5, P239, DOI 10.1038/5607; Finger TE, 2003, P NATL ACAD SCI USA, V100, P8981, DOI 10.1073/pnas.1531172100; Gimelbrant AA, 2001, J BIOL CHEM, V276, P7285, DOI 10.1074/jbc.M005433200; Gimelbrant AA, 1999, J NEUROCHEM, V72, P2301, DOI 10.1046/j.1471-4159.1999.0722301.x; Hague C, 2004, P NATL ACAD SCI USA, V101, P13672, DOI 10.1073/pnas.0403854101; Kuhn C, 2004, J NEUROSCI, V24, P10260, DOI 10.1523/JNEUROSCI.1225-04.2004; Lindemann B, 2001, NATURE, V413, P219, DOI 10.1038/35093032; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; Loconto J, 2003, CELL, V112, P607, DOI 10.1016/S0092-8674(03)00153-3; McClintock TS, 1997, MOL BRAIN RES, V48, P270, DOI 10.1016/S0169-328X(97)00099-5; Meyerhof W, 2005, REV PHYSIOL BIOCH P, V154, P37, DOI 10.1007/s10254-005-0041-0; Morris DP, 2004, MOL PHARMACOL, V66, P843, DOI 10.1124/mol.104.000430; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Murrell JR, 1999, J NEUROSCI, V19, P8260; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Pronin AN, 2004, CHEM SENSES, V29, P583, DOI 10.1093/chemse/bjh064; Saito H, 2004, CELL, V119, P679, DOI 10.1016/j.cell.2004.11.021; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; Ueda T, 2003, J NEUROSCI, V23, P7376; van Vliet C, 2003, PROG BIOPHYS MOL BIO, V83, P1, DOI 10.1016/S0079-6107(03)00019-1; WADA I, 1991, J BIOL CHEM, V266, P19599; Winnig M, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-22; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; Wu SV, 2002, P NATL ACAD SCI USA, V99, P2392, DOI 10.1073/pnas.042617699	36	99	114	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20650	20659		10.1074/jbc.M513637200	http://dx.doi.org/10.1074/jbc.M513637200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16720576	hybrid			2022-12-25	WOS:000239038200086
J	Powlesland, AS; Ward, EM; Sadhu, SK; Guo, Y; Taylor, ME; Drickamer, K				Powlesland, Alex S.; Ward, Eliot M.; Sadhu, Sumon K.; Guo, Yuan; Taylor, Maureen E.; Drickamer, Kurt			Widely divergent biochemical properties of the complete set of mouse DC-SIGN-related proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE LECTIN; MARGINAL ZONE MACROPHAGES; CARBOHYDRATE-RECOGNITION; STREPTOCOCCUS-PNEUMONIAE; GLYCOPROTEIN RECEPTOR; MEDIATES UPTAKE; BINDING; INFECTION; LANGERIN; LIGAND	The mouse genome sequence has been examined to identify the complete set of proteins related to the human glycan-binding receptor, DC-SIGN. In addition to five SIGNR proteins previously described, a pseudogene, encoding a hypothetical SIGNR6, and a further two expressed proteins, SIGNR7 and SIGNR8, have been identified. The ligand-binding properties of these novel proteins and of the previously described mouse SIGNs have been systematically investigated in order to define the mouse proteins that most resemble human DC-SIGN and DC-SIGNR. Results from screening of a glycan array demonstrate that only mouse SIGNR3 shares with human DC-SIGN the ability to bind both high mannose and fucose-terminated glycans in this format and to mediate endocytosis. The finding that neither SIGNR1 nor SIGNR5 binds with high affinity to specific ligands in a large panel of mammalian glycans is consistent with the suggestion that these receptors bind surface polysaccharides on bacterial and fungal pathogens in a manner analogous to serum mannose-binding protein. The data also reveal that two of the mouse SIGNs have unusual binding specificities that have not been previously described for members of the C-type lectin family; the newly identified SIGNR7 binds preferentially to the 6-sulfo-sialyl Lewis(x) oligosaccharide, whereas SIGNR2 binds almost exclusively to glycans that bear terminal GlcNAc residues. The results presented demonstrate that the mouse homologs of DC-SIGN have a diverse set of ligand-binding and intracellular trafficking properties, some of which are distinct from the properties of any of the human receptors.	Univ London Imperial Coll Sci & Technol, Div Mol Biosci, London SW7 2AZ, England	Imperial College London	Drickamer, K (corresponding author), Univ London Imperial Coll Sci & Technol, Div Mol Biosci, Biochem Bldg, London SW7 2AZ, England.	k.drickamer@imperial.ac.uk	Guo, Yuan/B-1319-2018	Guo, Yuan/0000-0003-4607-7356; Taylor, Maureen/0000-0001-8300-4987	NIGMS NIH HHS [GM62116] Funding Source: Medline; Wellcome Trust [075565] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002; Appelmelk BJ, 2003, J IMMUNOL, V170, P1635, DOI 10.4049/jimmunol.170.4.1635; Bochner BS, 2005, J BIOL CHEM, V280, P4307, DOI 10.1074/jbc.M412378200; Chapman-Smith A, 1999, TRENDS BIOCHEM SCI, V24, P359, DOI 10.1016/S0968-0004(99)01438-3; Fadden AJ, 2003, GLYCOBIOLOGY, V13, P529, DOI 10.1093/glycob/cwg068; Feinberg H, 2005, J BIOL CHEM, V280, P1327, DOI 10.1074/jbc.M409925200; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; Galustian C, 2004, INT IMMUNOL, V16, P853, DOI 10.1093/intimm/dxh089; Gardner JP, 2003, P NATL ACAD SCI USA, V100, P4498, DOI 10.1073/pnas.0831128100; Geijtenbeek TBH, 2002, BLOOD, V100, P2908, DOI 10.1182/blood-2002-04-1044; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Guo Y, 2004, NAT STRUCT MOL BIOL, V11, P591, DOI 10.1038/nsmb784; Kang YS, 2003, INT IMMUNOL, V15, P177, DOI 10.1093/intimm/dxg019; Kang YS, 2004, P NATL ACAD SCI USA, V101, P215, DOI 10.1073/pnas.0307124101; KAWASAKI T, 1977, J BIOL CHEM, V252, P6536; Koppel EA, 2005, EUR J IMMUNOL, V35, P2962, DOI 10.1002/eji.200526216; Lanoue A, 2004, J EXP MED, V200, P1383, DOI 10.1084/jem.20040795; Matsushita M, 2001, IMMUNOL REV, V180, P78, DOI 10.1034/j.1600-065X.2001.1800107.x; MELLOW TE, 1988, J BIOL CHEM, V263, P5468; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; Park CG, 2001, INT IMMUNOL, V13, P1283, DOI 10.1093/intimm/13.10.1283; Pohlmann S, 2001, TRENDS IMMUNOL, V22, P643, DOI 10.1016/S1471-4906(01)02081-6; SCHATZ PJ, 1993, BIO-TECHNOL, V11, P1138, DOI 10.1038/nbt1093-1138; Soilleux EJ, 2003, CLIN SCI, V104, P437, DOI 10.1042/CS20020092; Stambach NS, 2003, GLYCOBIOLOGY, V13, P401, DOI 10.1093/glycob/cwg045; Takahara K, 2004, INT IMMUNOL, V16, P819, DOI 10.1093/intimm/dxh084; Tateno H, 2005, GLYCOBIOLOGY, V15, P1125, DOI 10.1093/glycob/cwi097	28	129	143	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20440	20449		10.1074/jbc.M601925200	http://dx.doi.org/10.1074/jbc.M601925200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16682406	hybrid			2022-12-25	WOS:000239038200067
J	Xie, J; Bogdanov, M; Heacock, P; Dowhan, W				Xie, Jun; Bogdanov, Mikhail; Heacock, Philip; Dowhan, William			Phosphatidylethanolamine and monoglucosyldiacylglycerol are interchangeable in supporting topogenesis and function of the polytopic membrane protein lactose permease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LIPID-COMPOSITION; TOPOLOGICAL ORGANIZATION; PHOSPHOLIPID-COMPOSITION; TRANSPORT PROTEINS; AMINO; RULE; DETERMINANTS; RECOGNITION; REQUIREMENT	To determine the specific role lipids play in membrane protein topogenesis in vivo, the orientation with respect to the membrane bilayer of Escherichia coli lactose permease ( LacY) transmembrane (TM) domains and their flanking extramembrane domains was compared after assembly in native membranes and membranes with genetically modified lipid content using the substituted cysteine accessibility method for determining TM domain mapping. LacY assembled in the absence of the major membrane lipid phosphatidylethanolamine ( PE) does not carry out uphill transport of substrate and displays an inverted orientation for the N-terminal six-TM domain helical bundle (Bogdanov, M., Heacock, P. N., and Dowhan, W. (2002) EMBO J. 21, 2107 - 2116). Strikingly, the replacement of PE in vivo by the foreign lipid monoglucosyldiacylglycerol (MGlcDAG), synthesized by the Acholeplasma laidlawii MGlcDAG synthase, restored uphill transport and supported the wild type TM topology of the N-terminal helical bundle of LacY. An interchangeable role in defining membrane protein TM domain orientation and supporting function is played by the two most abundant lipids, PE and MGlcDAG, in Gram-negative and Gram-positive bacteria, respectively. Therefore, these structurally diverse lipids endow the membrane with similar properties necessary for the proper organization of protein domains in LacY that are highly sensitive to lipids as topological determinants.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Grad Sch Biomed Sci, Houston, TX 77030 USA	University of Texas System	Dowhan, W (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, 6431 Fannin St,Suite 6-200, Houston, TX 77030 USA.	william.dowhan@uth.tmc.edu	Bogdanov, Mikhail/J-3695-2017	Xie, Jun/0000-0001-6943-0330	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020478, R37GM020478] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM020478, R37 GM020478, R37 GM20478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Abramson J, 2004, MOL MEMBR BIOL, V21, P227, DOI 10.1080/09687680410001716862; Adamian L, 2005, PROTEINS, V59, P496, DOI 10.1002/prot.20456; Berg S, 2001, J BIOL CHEM, V276, P22056, DOI 10.1074/jbc.M102576200; Bogdanov M, 2002, EMBO J, V21, P2107, DOI 10.1093/emboj/21.9.2107; Bogdanov M, 2005, METHODS, V36, P148, DOI 10.1016/j.ymeth.2004.11.002; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; BOGDANOV M, 1995, J BIOL CHEM, V270, P732, DOI 10.1074/jbc.270.2.732; BRABETZ W, 1993, J BACTERIOL, V175, P7488, DOI 10.1128/JB.175.22.7488-7491.1993; CHEN CC, 1984, J BIOL CHEM, V259, P150; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; Dogovski C, 2003, J BACTERIOL, V185, P6225, DOI 10.1128/JB.185.21.6225-6232.2003; Dormann P, 2002, TRENDS PLANT SCI, V7, P112, DOI 10.1016/S1360-1385(01)02216-6; Dowhan W, 2004, BBA-BIOMEMBRANES, V1666, P19, DOI 10.1016/j.bbamem.2004.04.010; DRIESSEN AJM, 1988, BIOCHEMISTRY-US, V27, P865, DOI 10.1021/bi00403a005; Ermolova NV, 2005, BIOCHEMISTRY-US, V44, P7669, DOI 10.1021/bi0502801; HOISCHEN C, 1990, J BACTERIOL, V172, P3409, DOI 10.1128/jb.172.6.3409-3416.1990; Jack DL, 2000, MICROBIOL-SGM, V146, P1797, DOI 10.1099/00221287-146-8-1797; KRISHTALIK LI, 1995, FEBS LETT, V369, P140, DOI 10.1016/0014-5793(95)00756-Y; NAVARRO J, 1985, BIOCHEMISTRY-US, V24, P4645, DOI 10.1021/bi00338a025; NAVARRO J, 1984, BIOCHEMISTRY-US, V23, P130, DOI 10.1021/bi00296a021; Nilsson J, 2005, PROTEINS, V60, P606, DOI 10.1002/prot.20583; OSTERBERG F, 1995, BBA-LIPID LIPID MET, V1257, P18, DOI 10.1016/0005-2760(95)00042-B; Ridder ANJA, 2001, EMBO REP, V2, P403; Rutz C, 1999, J BIOL CHEM, V274, P33757, DOI 10.1074/jbc.274.47.33757; SahinToth M, 1996, BIOCHEMISTRY-US, V35, P2016, DOI 10.1021/bi952496g; Saier MH, 2000, MOL MICROBIOL, V35, P699, DOI 10.1046/j.1365-2958.2000.01759.x; Schleiff E, 2001, MOL BIOL CELL, V12, P4090, DOI 10.1091/mbc.12.12.4090; Sun JZ, 1996, BIOCHEMISTRY-US, V35, P990, DOI 10.1021/bi952166w; vanKlompenburg W, 1997, EMBO J, V16, P4261, DOI 10.1093/emboj/16.14.4261; Vazquez-Ibar JL, 2004, J BIOL CHEM, V279, P49214, DOI 10.1074/jbc.M407408200; Vener AV, 2005, IUBMB LIFE, V57, P433, DOI 10.1080/15216540500138360; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wang XY, 2002, EMBO J, V21, P5673, DOI 10.1093/emboj/cdf571; Wikstrom M, 2004, J BIOL CHEM, V279, P10484, DOI 10.1074/jbc.M310183200; Zhang W, 2005, J BIOL CHEM, V280, P26032, DOI 10.1074/jbc.M504929200; Zhang W, 2003, J BIOL CHEM, V278, P50128, DOI 10.1074/jbc.M309840200	37	66	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19172	19178		10.1074/jbc.M602565200	http://dx.doi.org/10.1074/jbc.M602565200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16698795	Green Accepted, hybrid			2022-12-25	WOS:000238847000031
J	Valderrama, B; Garcia-Arellano, H; Giansanti, S; Baratto, MC; Pogni, R; Vazquez-Duhalt, R				Valderrama, Brenda; Garcia-Arellano, Humberto; Giansanti, Stefania; Baratto, M. Camilla; Pogni, Rebecca; Vazquez-Duhalt, Rafael			Oxidative stabilization of iso-1-cytochrome c by redox-inspired protein engineering	FASEB JOURNAL			English	Article						hemeproteins; peroxidase; oxidative inactivation; protein engineering	ELECTRON-PARAMAGNETIC-RESONANCE; CYTOCHROME-C; HYDROGEN-PEROXIDE; YEAST ISO-1-CYTOCHROME-C; HORSERADISH-PEROXIDASE; MANGANESE PEROXIDASE; CONSERVED TRYPTOPHAN; MOLECULAR-COMPLEXES; DIRECTED EVOLUTION; WATER MOLECULE	Iso-1-cytochrome c, as any other hemeprotein, is able to react with hydrogen peroxide and to engage in the peroxidase cycle. However, peroxidases are irreversibly inactivated by their substrate, hydrogen peroxide. The oxidative inactivation of hemeproteins is mechanism based and arises as the consequence of unproductive electron abstraction reactions. Protein elements, such as the porphyrin ring or the protein backbone, act as simultaneous and competing electron sources even in the presence of exogenous reducing substrates, leading to a decline in activity. It is hypothetically possible to alter the intramolecular electron transfer pathways by direct replacement of low redox potential residues around the active site; as a consequence, the inactivation process would be delayed or even suppressed. To demonstrate this hypothesis, a redox-inspired strategy was implemented until an iso-1-cytochrome c variant fully stable at catalytic concentrations of hydrogen peroxide was obtained. This variant, harboring the N52I,W59F,Y67F,K79A,F82G substitutions, preserved the catalytic performance of the parental protein but achieved a 15-fold higher total-turnover number. The phenotype of this variant was reflected in the stability of its electronic components, allowing identification of a protein-based radical intermediate mechanistically similar to Compound I of classical peroxidases. The results presented here clearly demonstrate that redox-inspired protein engineering is a useful tool for the rational modulation of intramolecular electron transfer networks.-Valderrama, B., Garcia-Arellano, H., Giansanti, S., Baratto, M. C., Pogni, R., Vazquez-Duhalt, R. Oxidative stabilization of iso-1-cytochrome c by redox-inspired protein engineering.	Natl Univ Mexico, Dept Cellular Engn & Biocatalysis, Inst Biotechnol, Cuernavaca, Morelos, Mexico; Univ Siena, Dept Chem, I-53100 Siena, Italy	Universidad Nacional Autonoma de Mexico; University of Siena	Valderrama, B (corresponding author), Univ Nacl Autonoma Mexico, Dept Med Mol & Bioproc, Inst Biotecnol, AP 510-3, Cuernavaca 62250, Morelos, Mexico.	brenda@ibt.unam.mx	Garcia-Arellano, Humberto/G-7516-2018; Vazquez-Duhalt, Rafael/AGO-6764-2022; Vazquez-Duhalt, Rafael/E-2751-2016	Garcia-Arellano, Humberto/0000-0002-7018-7080; Vazquez-Duhalt, Rafael/0000-0003-1612-2996; Vazquez-Duhalt, Rafael/0000-0003-1612-2996; Valderrama, Brenda/0000-0002-5510-9439				ALOISI GG, 1974, J CHEM SOC FARAD T 1, V70, P1908, DOI 10.1039/f19747001908; Ausubel F. M., 1999, SHORT PROTOCOLS MOL; BERGHUIS AM, 1994, J MOL BIOL, V235, P1326, DOI 10.1006/jmbi.1994.1086; BERGHUIS AM, 1994, J MOL BIOL, V236, P786, DOI 10.1006/jmbi.1994.1189; Black KM, 2001, BIOCHEM J, V359, P715, DOI 10.1042/0264-6021:3590715; BLUMBERG WE, 1968, J BIOL CHEM, V243, P1854; CAFFREY MS, 1993, ARCH BIOCHEM BIOPHYS, V304, P205, DOI 10.1006/abbi.1993.1340; Cherry JR, 1999, NAT BIOTECHNOL, V17, P379, DOI 10.1038/7939; Cutruzzola F, 1997, BIOCHEM J, V322, P35, DOI 10.1042/bj3220035; Davies M.J., 1997, RADICAL MEDIATED PRO; DAVIES MJ, 1988, BIOCHIM BIOPHYS ACTA, V964, P28, DOI 10.1016/0304-4165(88)90063-3; Estevam ML, 2004, J BIOL CHEM, V279, P39214, DOI 10.1074/jbc.M402093200; FOSTER R, 1960, TETRAHEDRON, V10, P96, DOI 10.1016/0040-4020(60)85012-0; Garcia-Arellano H, 2002, BIOCONJUGATE CHEM, V13, P1336, DOI 10.1021/bc025561p; GIBSON JF, 1958, NATURE, V181, P1398, DOI 10.1038/1811398a0; Hawkins CL, 2001, BBA-BIOENERGETICS, V1504, P196, DOI 10.1016/S0005-2728(00)00252-8; Hiner ANP, 2001, EUR J BIOCHEM, V268, P3091, DOI 10.1046/j.1432-1327.2001.02208.x; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; Ivancich A, 2001, BIOCHEMISTRY-US, V40, P6860, DOI 10.1021/bi002826j; Karuzina II, 1999, FREE RADICAL BIO MED, V26, P620, DOI 10.1016/S0891-5849(98)00252-4; KING NK, 1967, BIOCHIM BIOPHYS ACTA, V133, P65; Lett CM, 1996, J BIOL CHEM, V271, P29088, DOI 10.1074/jbc.271.46.29088; LOUIE GV, 1989, J MOL BIOL, V210, P313, DOI 10.1016/0022-2836(89)90333-1; LOUIE GV, 1988, BIOCHEMISTRY-US, V27, P7870, DOI 10.1021/bi00420a043; LOUIE GV, 1988, J MOL BIOL, V199, P295, DOI 10.1016/0022-2836(88)90315-4; MCARTHUR KM, 1993, BIOCHIM BIOPHYS ACTA, V1202, P173, DOI 10.1016/0167-4838(93)90002-9; MILLER VP, 1995, J BIOL CHEM, V270, P18413, DOI 10.1074/jbc.270.31.18413; Miyazaki C, 2001, FEBS LETT, V509, P111, DOI 10.1016/S0014-5793(01)03127-1; Miyazaki-Imamura C, 2003, PROTEIN ENG, V16, P423, DOI 10.1093/protein/gzg054; Morawski B, 2001, BIOTECHNOL BIOENG, V76, P99, DOI 10.1002/bit.1149; Ostdal H, 1999, ARCH BIOCHEM BIOPHYS, V362, P105, DOI 10.1006/abbi.1998.0988; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Page CC, 2003, CURR OPIN CHEM BIOL, V7, P551, DOI 10.1016/j.cbpa.2003.08.005; PIELAK GJ, 1985, NATURE, V313, P152, DOI 10.1038/313152a0; Pogni R, 2005, BIOCHEMISTRY-US, V44, P4267, DOI 10.1021/bi047474l; Pollock WBR, 1998, BIOCHEMISTRY-US, V37, P6124, DOI 10.1021/bi972188d; PRUTZ WA, 1990, NATO ADV SCI I A-LIF, V197, P389; Qian SY, 2002, BIOCHEM J, V363, P281, DOI 10.1042/0264-6021:3630281; SCHEJTER A, 1996, OXIDATION STATE DEPE, P335; SCHWEINGRUBER ME, 1979, J BIOL CHEM, V254, P4132; SCOTT RA, 1996, CYTOCHROME C MULTIDI; Stuchebrukhov AA, 2003, THEOR CHEM ACC, V110, P291, DOI 10.1007/s00214-003-0462-2; Valderrama B, 2005, J MOL CATAL B-ENZYM, V35, P41, DOI 10.1016/j.molcatb.2005.05.003; Valderrama B, 2002, CHEM BIOL, V9, P555, DOI 10.1016/S1074-5521(02)00149-7; Vazquez-Duhalt R, 1999, J MOL CATAL B-ENZYM, V7, P241, DOI 10.1016/S1381-1177(99)00033-8; Villegas JA, 2000, CHEM BIOL, V7, P237, DOI 10.1016/S1074-5521(00)00098-3; [No title captured]	47	31	32	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1233	+		10.1096/fj.05-4173fje	http://dx.doi.org/10.1096/fj.05-4173fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16720736				2022-12-25	WOS:000240210300036
J	Huang, D; Shi, FD; Jung, S; Pien, GC; Wang, J; Salazar-Mather, TP; He, TT; Weaver, JT; Ljunggren, HG; Biron, CA; Littman, DR; Ransohoff, RM				Huang, Deren; Shi, Fu-Dong; Jung, Steffen; Pien, Gary C.; Wang, Jintang; Salazar-Mather, Thais P.; He, Toby T.; Weaver, Jennifer T.; Ljunggren, Hans-Gustaf; Biron, Christine A.; Littman, Dan R.; Ransohoff, Richard M.			The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system	FASEB JOURNAL			English	Article						autoimmune disease; chemokine; chemokine receptor; NK; T cell	NATURAL-KILLER-CELLS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; FRACTALKINE RECEPTOR CX(3)CR1; T-CELLS; TARGETED DELETION; CUTTING EDGE; MICE LACKING; IFN-GAMMA; BRAIN; NATALIZUMAB	Leukocyte trafficking to the central nervous system (CNS), regulated in part by chemokines, determines severity of the demyelinating diseases multiple sclerosis ( MS) and experimental autoimmune encephalomyelitis ( EAE). To examine chemokine receptor CX3CR1 in EAE, we studied CX3CR1(GFP/GFP) mice, in which CX3CR1 targeting by insertion of Green Fluorescent Protein (GFP) allowed tracking of CX3CR1+ cells in CX3CR1(+/GFP) animals and cells destined to express CX3CR1 in CX3CR1(GFP/GFP) knockouts. NK cells were markedly reduced in the inflamed CNS of CX3CR1-deficient mice with EAE, whereas recruitment of T cells, NKT cells and monocyte/macrophages to the CNS during EAE did not require CX3CR1. Impaired recruitment of NK cells in CX3CR1(GFP/GFP) mice was associated with increased EAE-related mortality, nonremitting spastic paraplegia and hemorrhagic inflammatory lesions. The absence of CD1d did not affect the severity of EAE in CX3CR1(GFP/GFP) mice, arguing against a role for NKT cells. Accumulation of NK cells in livers of wild-type (WT) and CX3CR1(GFP/GFP) mice with cytomegalovirus hepatitis was equivalent, indicating that CX3CL1 mediated chemoattraction of NK cells was relatively specific for the CNS. These results are the first to define a chemokine that governs NK cell migration to the CNS, and the findings suggest novel therapeutic manipulation of CX3CR1+ NK cells.	Cleveland Clin Fdn, Neuroinflammat Res Ctr, Dept Neurosci NC30, Lerner Res Inst, Cleveland, OH 44195 USA; Barrow Neurol Inst, Phoenix, AZ 85013 USA; NYU, Med Ctr, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Med Ctr, Howard Hughes Med Inst, New York, NY 10016 USA; Brown Univ, Div Biol & Med, Dept Mol Microbiol & Immunol, Providence, RI 02912 USA; Huddinge Univ Hosp, Karolinska Inst, Dept Med, Ctr Infect Med, Stockholm, Sweden	Cleveland Clinic Foundation; Barrow Neurological Institute; New York University; Howard Hughes Medical Institute; New York University; Brown University; Karolinska Institutet	Ransohoff, RM (corresponding author), Cleveland Clin Fdn, Neuroinflammat Res Ctr, Dept Neurosci NC30, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	ransohr@ccf.org	Jung, Steffen/K-1409-2012	Jung, Steffen/0000-0003-4290-5716	NCI NIH HHS [R01 CA041268] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041268] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Bielekova B, 2004, J NEUROIMMUNOL, V154, P211; Campbell JJ, 2001, J IMMUNOL, V166, P6477, DOI 10.4049/jimmunol.166.11.6477; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Chapman GA, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-15-j0004.2000; Cook DN, 2001, MOL CELL BIOL, V21, P3159, DOI 10.1128/MCB.21.9.3159-3165.2001; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Engelhardt B, 2005, TRENDS IMMUNOL, V26, P485, DOI 10.1016/j.it.2005.07.004; Fife BT, 2000, J EXP MED, V192, P899, DOI 10.1084/jem.192.6.899; Fort MM, 1998, J IMMUNOL, V161, P3256; French AR, 2004, ARTHRITIS RES THER, V6, P8, DOI 10.1186/ar1034; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Haskell CA, 2001, J CLIN INVEST, V108, P679, DOI 10.1172/JCI12976; Hong SM, 1999, IMMUNOL REV, V169, P31, DOI 10.1111/j.1600-065X.1999.tb01304.x; Huang DR, 2000, IMMUNOL REV, V177, P52, DOI 10.1034/j.1600-065X.2000.17709.x; Huang DR, 2001, J EXP MED, V193, P713, DOI 10.1084/jem.193.6.713; Hughes PM, 2002, GLIA, V37, P314, DOI 10.1002/glia.10037; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Infante-Duarte C, 2005, FASEB J, V19, P1902, DOI 10.1096/fj.05-3832fje; Izikson L, 2000, J EXP MED, V192, P1075, DOI 10.1084/jem.192.7.1075; Jahng AW, 2001, J EXP MED, V194, P1789, DOI 10.1084/jem.194.12.1789; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kleinschmidt-DeMasters BK, 2005, NEW ENGL J MED, V353, P369, DOI 10.1056/NEJMoa051782; Korsgren M, 1999, J EXP MED, V189, P553, DOI 10.1084/jem.189.3.553; Langer-Gould A, 2005, NEW ENGL J MED, V353, P375, DOI 10.1056/NEJMoa051847; Lee IF, 2004, J IMMUNOL, V172, P937, DOI 10.4049/jimmunol.172.2.937; Li ZQ, 2005, J IMMUNOL, V174, P5187, DOI 10.4049/jimmunol.174.9.5187; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Matsuda JL, 2000, J EXP MED, V192, P741, DOI 10.1084/jem.192.5.741; Mendiratta SK, 1997, IMMUNITY, V6, P469, DOI 10.1016/S1074-7613(00)80290-3; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; Moatti D, 2001, BLOOD, V97, P1925, DOI 10.1182/blood.V97.7.1925; Niess JH, 2005, SCIENCE, V307, P254, DOI 10.1126/science.1102901; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Nishiyori A, 1998, FEBS LETT, V429, P167, DOI 10.1016/S0014-5793(98)00583-3; Ogasawara K, 2004, IMMUNITY, V20, P757, DOI 10.1016/j.immuni.2004.05.008; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Pien GC, 2000, J IMMUNOL, V165, P4787, DOI 10.4049/jimmunol.165.9.4787; Poirot L, 2004, P NATL ACAD SCI USA, V101, P8102, DOI 10.1073/pnas.0402065101; Ransohoff RM, 2005, NAT NEUROSCI, V8, P1275, DOI 10.1038/nn1005-1275; Salazar-Mather TP, 2000, J CLIN INVEST, V105, P985, DOI 10.1172/JCI9232; Salazar-Mather TP, 1998, J EXP MED, V187, P1, DOI 10.1084/jem.187.1.1; Sandborn WJ, 2005, NEW ENGL J MED, V353, P1912, DOI 10.1056/NEJMoa043335; Schwaeble WJ, 1998, FEBS LETT, V439, P203, DOI 10.1016/S0014-5793(98)01384-2; Shi FD, 2000, NAT IMMUNOL, V1, P245, DOI 10.1038/79792; Shi FD, 2000, J IMMUNOL, V165, P3099, DOI 10.4049/jimmunol.165.6.3099; Shi FD, 2001, TRENDS IMMUNOL, V22, P97, DOI 10.1016/S1471-4906(00)01821-4; Sunnemark D, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-17; Tsai HH, 2002, CELL, V110, P373, DOI 10.1016/S0092-8674(02)00838-3; Tsou CL, 2001, J BIOL CHEM, V276, P44622, DOI 10.1074/jbc.M107327200; Umehara H, 2001, TRENDS IMMUNOL, V22, P602, DOI 10.1016/S1471-4906(01)02051-8; Xu W, 2005, J NEUROIMMUNOL, V163, P24, DOI 10.1016/j.jneuroim.2005.02.011; Zhang BN, 1997, J EXP MED, V186, P1677, DOI 10.1084/jem.186.10.1677; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	55	222	229	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					896	905		10.1096/fj.05-5465com	http://dx.doi.org/10.1096/fj.05-5465com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675847				2022-12-25	WOS:000240157700012
J	Kamiyama, M; Pozzi, A; Yang, L; DeBusk, LM; Breyer, RM; Lin, PC				Kamiyama, M.; Pozzi, A.; Yang, L.; DeBusk, L. M.; Breyer, R. M.; Lin, P. C.			EP2, a receptor for PGE(2), regulates tumor angiogenesis through direct effects on endothelial cell motility and survival	ONCOGENE			English	Article						PGE2; EP2; endothelial cell; angiogenesis	PROSTANOID RECEPTORS; PROSTAGLANDIN; CYCLOOXYGENASE; EXPRESSION; CANCER; INHIBITION; SUBTYPE; PROTEIN; INFLAMMATION; MIGRATION	Prostaglandin E2 (PGE(2)), a major cyclooxygenase (COX) metabolite, plays important roles in tumor biology. We studied the role of EP2, a receptor for PGE2, in tumor angiogenesis using EP2 knockout mice. We found that deletion of the EP2 receptor impaired tumor angiogenesis and this finding was confirmed by an in vivo corneal angiogenesis model and an ex vivo aortic ring assay. To further characterize the cellular mechanisms of the EP2 receptor in angiogenesis, we isolated primary pulmonary endothelial cells (ECs) from wild-type (wt) and EP2(-/)-mice and observed that EP2(-/)-ECs exhibited defects in vascular branch formation when compared to wt ECs. In addition, EP2(-/)-ECs showed impaired cell motility on collagen-coated surface and they responded poorly to PGE(2)-induced cell migration compared to control cells. However, no difference in cell proliferation was observed between the EP2(-/)-and wt Ecs. In addition, EP2(-/)-ECs were more susceptible to apoptosis than wt cells under growth factor depletion conditions. Collectively, our data demonstrate that EP2 signaling in endothelium directly regulates tumor angiogenesis by contributing to cell survival and endothelial cell motility. Moreover, our finding suggests that EP2 is a major receptor in PGE(2)-mediated cell motility in ECs.	Vanderbilt Univ, Med Ctr, Dept Radiat Oncol, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Lin, PC (corresponding author), Vanderbilt Univ, Med Ctr, Dept Radiat Oncol, Vanderbilt Ingram Canc Ctr, 338 PRB,2220 Pierce Ave, Nashville, TN 37232 USA.	charles.lin@vanderbilt.edu			NATIONAL CANCER INSTITUTE [P30CA068485, T32CA009592, R01CA108856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045888] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA009592, CA108856, CA68485] Funding Source: Medline; NINDS NIH HHS [NS45888] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amano H, 2003, J EXP MED, V197, P221, DOI 10.1084/jem.20021408; Bradbury D, 2005, J BIOL CHEM, V280, P29993, DOI 10.1074/jbc.M414530200; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100; Chang SH, 2005, PROSTAG OTH LIPID M, V76, P48, DOI 10.1016/j.prostaglandins.2004.12.001; Dormond O, 2002, J BIOL CHEM, V277, P45838, DOI 10.1074/jbc.M209213200; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Elder DJE, 2002, INT J CANCER, V99, P323, DOI 10.1002/ijc.10330; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; Hida T, 1998, CANCER RES, V58, P3761; Huang LW, 1999, J BIOL CHEM, V274, P38183, DOI 10.1074/jbc.274.53.38183; Husain SS, 2001, LIFE SCI, V69, P3045, DOI 10.1016/S0024-3205(01)01411-4; Jiang HM, 2004, J BIOL CHEM, V279, P55905, DOI 10.1074/jbc.M406094200; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kennedy CRJ, 1999, NAT MED, V5, P217, DOI 10.1038/5583; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Klagsbrun M, 1999, CHEM BIOL, V6, pR217, DOI 10.1016/S1074-5521(99)80081-7; Kuwano T, 2004, FASEB J, V18, P300, DOI 10.1096/fj.03-0473com; Lin PN, 1997, J CLIN INVEST, V100, P2072, DOI 10.1172/JCI119740; Mutoh M, 2002, CANCER RES, V62, P28; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; Rozic JG, 2001, INT J CANCER, V93, P497, DOI 10.1002/ijc.1376; SANO H, 1995, CANCER RES, V55, P3785; Seno H, 2002, CANCER RES, V62, P506; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Tilley SL, 2001, J CLIN INVEST, V108, P15, DOI 10.1172/JCI200113416; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Watanabe K, 1999, CANCER RES, V59, P5093; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yang L, 2003, J CLIN INVEST, V111, P727, DOI 10.1172/JCI200316492	34	97	100	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7019	7028		10.1038/sj.onc.1209694	http://dx.doi.org/10.1038/sj.onc.1209694			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16732324				2022-12-25	WOS:000241910500002
J	Chen, H; Li, M; Campbell, RA; Burkhardt, K; Zhu, D; Li, SG; Lee, HJ; Wang, C; Zeng, Z; Gordon, MS; Bonavida, B; Berenson, JR				Chen, H.; Li, M.; Campbell, R. A.; Burkhardt, K.; Zhu, D.; Li, S. G.; Lee, H. J.; Wang, C.; Zeng, Z.; Gordon, M. S.; Bonavida, B.; Berenson, J. R.			Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis	ONCOGENE			English	Article						TRAF6; multiple myeloma; NF-kappa B; JNK; proliferation; apoptosis	TUMOR-NECROSIS-FACTOR; HUMAN MULTIPLE-MYELOMA; MARROW STROMAL CELLS; BONE-MARROW; DEFECTIVE INTERLEUKIN-1; INDUCE APOPTOSIS; ACTIVATION; MECHANISM; PATHWAYS; RECEPTOR	The tumor necrosis factor receptor (TNFR)-associated factor ( TRAF) family of six adaptor proteins (TRAF1-6) links the TNFR superfamily to the nuclear factor kappa B (NF-kappa B) and activator protein-1 (AP-1) transcriptional activators. Unlike other TRAFs, TRAF6 is also involved in Toll-like/interleukin (IL)-1 receptor (TIR) signal transduction. Thus, inhibition of TRAF6 function could interrupt both CD40 ( TNFR family) and IL-1 growth signals, pathways critical to myeloma proliferation. To block TRAF6-mediated IL-1 signaling, we constructed small interfering RNA ( siRNA) against TRAF6. We found that siRNA targeting the TRAF6 C-terminal (siTRAF6C) receptor interaction domain specifically reduced only TRAF6 protein expression, without affecting TRAF2 or 5 levels, and substantially interfered with IL-1-induced NF-kappa B and c-Jun/AP-1 activation. Inhibition by siTRAF6C was concentration-dependent. SiTRAF6C also significantly reduced myeloma proliferation and enhanced apoptosis in a similar dose-dependent fashion in vitro. More importantly, marked siTRAF6C growth inhibition was detected in vivo when these cells were implanted into the bone marrow of irradiated normal mice. In contrast, introduction of siRNA derived from the TRAF6 Zn-finger domain or an irrelevant siRNA construct failed to alter cell growth or cell death. These studies suggest that TRAF6 may be a new molecular target to block cell signal transduction important for the survival and proliferation of multiple myeloma cells.	Inst Myeloma & Bone Canc Res, W Hollywood, CA 90069 USA; Amgen Inc, Thousand Oaks, CA 91320 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA; Univ Calif Los Angeles, Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA USA; Cedars Sinai Med Ctr, Dept Neurosurg, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA USA	Amgen; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Berenson, JR (corresponding author), Inst Myeloma & Bone Canc Res, 9201 W Sunset Blvd,Ste 300, W Hollywood, CA 90069 USA.	jberenson@imbcr.org						Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200; Berenson JR, 2002, BLOOD, V99, P3163, DOI 10.1182/blood.V99.9.3163; Berenson JR, 2001, SEMIN ONCOL, V28, P626, DOI 10.1053/sonc.2001.29542; Bharti AC, 2004, J BIOL CHEM, V279, P6065, DOI 10.1074/jbc.M308062200; Callander NS, 2001, SEMIN HEMATOL, V38, P276, DOI 10.1053/shem.2001.26007; Cao Z, 1999, COLD SPRING HARB SYM, V64, P473, DOI 10.1101/sqb.1999.64.473; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chatterjee M, 2004, BLOOD, V104, P3712, DOI 10.1182/blood-2004-04-1670; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Chung JY, 2002, J CELL SCI, V115, P679; Corso A, 2005, CANCER, V104, P118, DOI 10.1002/cncr.21104; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Ma MH, 2003, CLIN CANCER RES, V9, P1136; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588; Pagnucco G, 2004, ANN NY ACAD SCI, V1028, P390, DOI 10.1196/annals.1322.047; Sanda T, 2005, CLIN CANCER RES, V11, P1974, DOI 10.1158/1078-0432.CCR-04-1936; Sinha SK, 2002, J BIOL CHEM, V277, P44953, DOI 10.1074/jbc.M207923200; Tai YT, 2005, CANCER RES, V65, P5898, DOI 10.1158/0008-5472.CAN-04-4125; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Teoh G, 2000, BLOOD, V95, P1039, DOI 10.1182/blood.V95.3.1039.003k02_1039_1046; Vincent T, 2005, LEUKEMIA LYMPHOMA, V46, P803, DOI 10.1080/10428190500051448; Yaccoby S, 2004, CANCER RES, V64, P2016, DOI 10.1158/0008-5472.CAN-03-1131; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888	29	31	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2006	25	49					6520	6527		10.1038/sj.onc.1209653	http://dx.doi.org/10.1038/sj.onc.1209653			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16702955				2022-12-25	WOS:000241395100008
J	Benzeno, S; Lu, F; Guo, M; Barbash, O; Zhang, F; Herman, JG; Klein, PS; Rustgi, A; Diehl, JA				Benzeno, S.; Lu, F.; Guo, M.; Barbash, O.; Zhang, F.; Herman, J. G.; Klein, P. S.; Rustgi, A.; Diehl, J. A.			Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1	ONCOGENE			English	Article						cyclin D1; GSK-3 beta; CDK4; nuclear export; cancer	GLYCOGEN-SYNTHASE KINASE-3; CDK INHIBITORS; CELL-CYCLE; ESTROGEN-RECEPTOR; SUBSTRATE-SPECIFICITY; BARRETTS-ESOPHAGUS; HUMAN CANCER; PROTEIN; GENE; RAS	Although cyclin D1 is overexpressed in a significant number of human cancers, overexpression alone is insufficient to promote tumorigenesis. In vitro studies have revealed that inhibition of cyclin D1 nuclear export unmasks its neoplastic potential. Cyclin D1 nuclear export depends upon phosphorylation of a C-terminal residue, threonine 286, (Thr-286) which in turn promotes association with the nuclear exportin, CRM1. Mutation of Thr-286 to a non-phosphorylatable residue results in a constitutively nuclear cyclin D1 protein with significantly increased oncogenic potential. To determine whether cyclin D1 is subject to mutations that inhibit its nuclear export in human cancer, we have sequenced exon 5 of cyclin D1 in primary esophageal carcinoma samples and in cell lines derived from esophageal cancer. Our work reveals that cyclin D1 is subject to mutations in primary human cancer. The mutations identified specifically disrupt phosphorylation of cyclin D1 at Thr-286, thereby enforcing nuclear accumulation of cyclin D1. Through characterization of these mutants, we also de. ne an acidic residue within the C-terminus of cyclin D1 that is necessary for recognition and phosphorylation of cyclin D1 by glycogen synthase kinase-3 beta. Finally, through construction of compound mutants, we demonstrate that cell transformation by the cancer-derived cyclin D1 alleles correlates with their ability to associate with and activate CDK4. Our data reveal that cyclin D1 is subject to mutations in primary human cancer that specifically disrupt phosphorylation-dependent nuclear export of cyclin D1 and suggest that such mutations contribute to the genesis and progression of neoplastic growth.	Univ Penn, Leonard & Madlyn Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Dept Hematol Oncol, Baltimore, MD 21205 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Johns Hopkins University; Johns Hopkins Medicine; University of Pennsylvania	Diehl, JA (corresponding author), Univ Penn, Leonard & Madlyn Abramson Family Canc Res Inst, Dept Canc Biol, 454 BRB II-III,421 Curie Blvd, Philadelphia, PA 19104 USA.	adiehl@mail.med.upenn.edu			NCI NIH HHS [R01 CA093237, CA111360, CA93237] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093237, R01CA111360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADELAIDE J, 1995, BRIT J CANCER, V71, P64, DOI 10.1038/bjc.1995.13; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alt JR, 2002, J BIOL CHEM, V277, P8517, DOI 10.1074/jbc.M108867200; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Arber N, 1996, CANCER EPIDEM BIOMAR, V5, P457; Bani-Hani K, 2000, J NATL CANCER I, V92, P1316, DOI 10.1093/jnci/92.16.1316; Bax B, 2001, STRUCTURE, V9, P1143, DOI 10.1016/S0969-2126(01)00679-7; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Benzeno S, 2004, J BIOL CHEM, V279, P56061, DOI 10.1074/jbc.M411910200; Benzeno S, 2004, CANCER RES, V64, P3885, DOI 10.1158/0008-5472.CAN-03-2818; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Calbo J, 2002, J BIOL CHEM, V277, P50263, DOI 10.1074/jbc.M209181200; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Collecchi P, 2000, CYTOMETRY, V42, P254; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Farkas T, 2002, J BIOL CHEM, V277, P26741, DOI 10.1074/jbc.M200381200; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Fraser E, 2002, J BIOL CHEM, V277, P2176, DOI 10.1074/jbc.M109462200; Fry DW, 2004, MOL CANCER THER, V3, P1427; Fry DW, 2001, J BIOL CHEM, V276, P16617, DOI 10.1074/jbc.M008867200; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; GLADDEN AB, 2005, ONCOGENE, V25, P1620; Hagen T, 2002, J BIOL CHEM, V277, P23330, DOI 10.1074/jbc.M201364200; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; Hedgepeth CM, 1999, MOL CELL BIOL, V19, P7147; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Hirai H, 1996, MOL CELL BIOL, V16, P6457; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lamb J, 2000, MOL CELL BIOL, V20, P8667, DOI 10.1128/MCB.20.23.8667-8675.2000; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Leng XH, 2002, MOL CELL BIOL, V22, P2242, DOI 10.1128/MCB.22.7.2242-2254.2002; Lin J, 2004, SEMIN ONCOL, V31, P476, DOI 10.1053/j.seminoncol.2004.04.019; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; Lu FM, 2003, CANCER RES, V63, P7056; LUKAS J, 1994, ONCOGENE, V9, P2159; Moreno-Bueno G, 2003, ONCOGENE, V22, P6115, DOI 10.1038/sj.onc.1206868; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; PARK IK, 1994, J BIOL CHEM, V269, P944; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Rimerman RA, 2000, J BIOL CHEM, V275, P14736, DOI 10.1074/jbc.M910241199; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Winston JT, 1996, ONCOGENE, V12, P127; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012; Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	75	99	100	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2006	25	47					6291	6303		10.1038/sj.onc.1209644	http://dx.doi.org/10.1038/sj.onc.1209644			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16732330				2022-12-25	WOS:000241218200006
J	Strozyk, E; Poppelmann, B; Schwarz, T; Kulms, D				Strozyk, E.; Poeppelmann, B.; Schwarz, T.; Kulms, D.			Differential effects of NF-kappa B on apoptosis induced by DNA-damaging agents: the type of DNA damage determines the final outcome	ONCOGENE			English	Article						apoptosis; DNA damage; NF-kappa B; TNF-alpha	PROTECTS TRANSFORMED KERATINOCYTES; RADIATION-INDUCED APOPTOSIS; GENE-EXPRESSION; HUMAN-CELLS; ACTIVATION; ALPHA; RECEPTOR; NUCLEAR; PHOSPHORYLATION; RECOGNITION	The transcription factor nuclear factor kappa-B ( NF-kB) is generally regarded as an antiapoptotic factor. Accordingly, NF-kB activation inhibits death ligand-induced apoptosis. In contrast, ultraviolet light B (UVB)-induced apoptosis is not inhibited but even enhanced upon NF-kappa B activation by interleukin-1 (IL-1). This study was performed to identify the molecular mechanisms underlying this switch of NF-kappa B. Enhancement of UVB-induced apoptosis was always associated with increased release of tumour necrosis factor-alpha (TNF-alpha), which was dependent on NF-kappa B activation. The same was observed when UVA and cisplatin were used, which like UVB induce base modi. cations. In contrast, apoptosis caused by DNA strand breaks was not enhanced by IL-1, indicating that the type of DNA damage is critical for switching the effect of NF-kappa B on apoptosis. Surprisingly, activated NF-kappa B induced TNF-alpha mRNA expression in the presence of all DNA damage-inducing agents. However, in the presence of DNA strand breaks, there was no release of the TNF-alpha protein, which is so crucial for enhancing apoptosis. Together, this indicates that induction of DNA damage may have a significant impact on biological effects but it is the type of DNA damage that determines the final outcome. This may have implications for the role of NF-kappa B in carcinogenesis and for the application of NF-kappa B inhibitors in anticancer therapy.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Univ Kiel, Dept Dermatol, D-2300 Kiel, Germany; Univ Munster, Dept Dermatol, D-4400 Munster, Germany	University of Stuttgart; University of Kiel; University of Munster	Kulms, D (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.	Dagmar.Kulms@izi.uni-stuttgart.de	Schwarz, Thomas/A-9148-2010; Kulms, Dagmar/H-1653-2014					Abdel-Raheem IT, 2005, BRIT J PHARMACOL, V145, P415, DOI 10.1038/sj.bjp.0706207; Armstrong BK, 2001, J PHOTOCH PHOTOBIO B, V63, P8, DOI 10.1016/S1011-1344(01)00198-1; Beissert S, 1999, J INVEST DERM SYMP P, V4, P61, DOI 10.1038/sj.jidsp.5640183; Besaratinia A, 2005, P NATL ACAD SCI USA, V102, P10058, DOI 10.1073/pnas.0502311102; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cornelis S, 2005, ONCOGENE, V24, P1552, DOI 10.1038/sj.onc.1208401; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Hailer MK, 2005, DNA REPAIR, V4, P41, DOI 10.1016/j.dnarep.2004.07.006; Ho WC, 2005, CANCER RES, V65, P4273, DOI 10.1158/0008-5472.CAN-04-3494; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hur GM, 2003, GENE DEV, V17, P873, DOI 10.1101/gad.1062403; Konemann S, 2005, APOPTOSIS, V10, P177, DOI 10.1007/s10495-005-6072-9; Kothny-Wilkes G, 1999, J BIOL CHEM, V274, P28916, DOI 10.1074/jbc.274.41.28916; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; Kulms D, 2002, ONCOGENE, V21, P5844, DOI 10.1038/sj.onc.1205743; Kulms D, 2002, BIOCHEM PHARMACOL, V64, P837, DOI 10.1016/S0006-2952(02)01146-2; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; Kulms D, 2000, J BIOL CHEM, V275, P15060, DOI 10.1074/jbc.M910113199; Lee JY, 2000, J BIOL CHEM, V275, P29290, DOI 10.1074/jbc.M000170200; Mezyk R, 2003, ACTA BIOCHIM POL, V50, P625; Nakajima S, 2004, J BIOL CHEM, V279, P46674, DOI 10.1074/jbc.M406070200; Panta GR, 2004, MOL CELL BIOL, V24, P1823, DOI 10.1128/MCB.24.5.1823-1835.2004; Poppelmann B, 2005, J BIOL CHEM, V280, P15635, DOI 10.1074/jbc.M413006200; Rosell Rafael, 2003, Cancer Control, V10, P297; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sclabas GM, 2005, CANCER-AM CANCER SOC, V103, P2485, DOI 10.1002/cncr.21075; Sordet Olivier, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P271, DOI 10.2174/1568011033482378; Sun NK, 1996, BIOCHEM J, V313, P441, DOI 10.1042/bj3130441; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; Thyss R, 2005, EMBO J, V24, P128, DOI 10.1038/sj.emboj.7600501; Wajant H, 2005, CYTOKINE GROWTH F R, V16, P55, DOI 10.1016/j.cytogfr.2004.12.001; Xu CJ, 2005, ONCOGENE, V24, P4486, DOI 10.1038/sj.onc.1208656; Zavrski I, 2005, ANTI-CANCER DRUG, V16, P475, DOI 10.1097/00001813-200506000-00002	38	46	47	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2006	25	47					6239	6251		10.1038/sj.onc.1209655	http://dx.doi.org/10.1038/sj.onc.1209655			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16702954				2022-12-25	WOS:000241218200002
J	Poulikakos, PI; Xiao, GH; Gallagher, R; Jablonski, S; Jhanwar, SC; Testa, JR				Poulikakos, P. I.; Xiao, G-H; Gallagher, R.; Jablonski, S.; Jhanwar, S. C.; Testa, J. R.			Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK	ONCOGENE			English	Article						NF2; merlin; invasion; FAK; mesothelioma	FOCAL-ADHESION KINASE; MEDIATES CONTACT INHIBITION; NEUROFIBROMATOSIS TYPE-2; MALIGNANT MESOTHELIOMA; GENE-PRODUCT; MERLIN PHOSPHORYLATION; MEMBRANE ORGANIZATION; PLASMA-MEMBRANE; UNITED-STATES; ERM PROTEINS	The neuro. bromatosis type 2 NF2 gene product, merlin, is a tumor suppressor frequently inactivated in malignant mesothelioma (MM). To investigate a possible correlation between merlin inactivation and MM invasiveness, we restored merlin expression in NF2-deficient MM cells. Re-expression of merlin markedly inhibited cell motility, spreading and invasiveness, properties connected with the malignant phenotype of MM cells. To test directly whether merlin inactivation promotes invasion in a nonmalignant system, we used small interfering RNA to silence Nf2 in mouse embryonic fibroblasts (MEFs) and found that downregulation of merlin resulted in enhanced cell spreading and invasion. To delineate signaling events connected with this phenotype, we investigated the effect of merlin expression on focal adhesion kinase (FAK), a key component of cellular pathways affecting migration and invasion. Expression of merlin attenuated FAK phosphorylation at the critical phosphorylation site Tyr397 and disrupted the interaction of FAK with its binding partners Src and p85, the regulatory subunit of phosphatidylinositol-3-kinase. In addition, NF2-null MM cells stably overexpressing FAK showed increased invasiveness, which decreased significantly when merlin expression was restored. Collectively, these findings suggest that merlin inactivation is a critical step in MM pathogenesis and is related, at least in part, with upregulation of FAK activity.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Cell Imaging Facil, Philadelphia, PA 19111 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA	Fox Chase Cancer Center; Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center	Testa, JR (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Joseph.Testa@fccc.edu			NCI NIH HHS [CA-06927, CA-114047, CA-45745] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA114047, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altomare DA, 2005, CANCER RES, V65, P8090, DOI 10.1158/0008-5472.CAN-05-2312; Baser ME, 2003, CURR OPIN NEUROL, V16, P27, DOI 10.1097/00019052-200302000-00004; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Brown MC, 2005, MOL BIOL CELL, V16, P4316, DOI 10.1091/mbc.E05-02-0131; Carbone M, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30227; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Cheng JQ, 1999, GENE CHROMOSOME CANC, V24, P238, DOI 10.1002/(SICI)1098-2264(199903)24:3<238::AID-GCC9>3.0.CO;2-M; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Fleury-Feith J, 2003, ONCOGENE, V22, P3799, DOI 10.1038/sj.onc.1206593; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; GUSELLA JF, 1999, BIOCHIM BIOPHYS ACTA, V1423, P29; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; Hirokawa Y, 2004, CANCER J, V10, P20, DOI 10.1097/00130404-200401000-00006; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; James MF, 2004, J CELL SCI, V117, P2951, DOI 10.1242/jcs.01156; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Lee WC, 1999, INT J ONCOL, V14, P181; Manchanda N, 2005, J BIOL CHEM, V280, P12517, DOI 10.1074/jbc.C400583200; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; Martin TA, 2003, CRIT REV ONCOL HEMAT, V46, P165, DOI 10.1016/S1040-8428(02)00172-5; McClatchey AI, 2005, GENE DEV, V19, P2265, DOI 10.1101/gad.1335605; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Muranen T, 2005, ONCOGENE, V24, P1150, DOI 10.1038/sj.onc.1208283; Okada T, 2005, J CELL BIOL, V171, P361, DOI 10.1083/jcb.200503165; OWENS LV, 1995, CANCER RES, V55, P2752; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Poullet P, 2001, J BIOL CHEM, V276, P37686, DOI 10.1074/jbc.M106175200; Price B, 2004, AM J EPIDEMIOL, V159, P107, DOI 10.1093/aje/kwh025; Price B, 1997, AM J EPIDEMIOL, V145, P211, DOI 10.1093/oxfordjournals.aje.a009093; Robinson BWS, 2005, NEW ENGL J MED, V353, P1591, DOI 10.1056/NEJMra050152; Rong R, 2004, ONCOGENE, V23, P8447, DOI 10.1038/sj.onc.1207794; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; SEKIDO Y, 1995, CANCER RES, V55, P1227; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Srivastava J, 2005, MOL BIOL CELL, V16, P1481, DOI 10.1091/mbc.e04-08-0721; Surace EI, 2004, ONCOGENE, V23, P580, DOI 10.1038/sj.onc.1207142; Watermann DO, 2005, BRIT J CANCER, V93, P694, DOI 10.1038/sj.bjc.6602744; Wells A, 2000, ADV CANCER RES, V78, P31; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200	51	130	132	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2006	25	44					5960	5968		10.1038/sj.onc.1209587	http://dx.doi.org/10.1038/sj.onc.1209587			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16652148				2022-12-25	WOS:000240826300005
J	Kaewsuwan, S; Cahoon, EB; Perroud, PF; Wiwat, C; Panvisavas, N; Quatrano, RS; Cove, DJ; Bunyapraphatsara, N				Kaewsuwan, Songsri; Cahoon, Edgar B.; Perroud, Pierre-Francois; Wiwat, Chanpen; Panvisavas, Nathinee; Quatrano, Ralph S.; Cove, David J.; Bunyapraphatsara, Nuntavan			Identification and functional characterization of the moss Physcomitrella patens Delta(5)-desaturase gene involved in arachidonic and eicosapentaenoic acid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROLOGOUS EXPRESSION; MICROSOMAL PREPARATIONS; DESATURASE GENE; FATTY-ACIDS; ENZYME; CYTOCHROME-B5; LEUKOTRIENES; MUTAGENESIS; COMPONENTS; MUTANTS	The moss Physcomitrella patens contains high levels of arachidonic acid and lesser amounts of eicosapentaenoic acid. Here we report the identification and characterization of a Delta(5)-desaturase from P. patens that is associated with the synthesis of these fatty acids. A full-length cDNA for this desaturase was identified by data base searches based on homology to sequences of known Delta(5)-desaturase cDNAs from fungal and algal species. The resulting P. patens cDNA encodes a 480-amino acid polypeptide that contains a predicted N-terminal cytochrome b(5)-like domain as well as three histidine-rich domains. Expression of the enzyme in Saccharomyces cerevisiae resulted in the production of the Delta(5)-containing fatty acid arachidonic acid in cells that were provided di-homo-gamma-linolenic acid. In addition, the expressed enzyme generated Delta(5)-desaturation products with the C20 substrates omega-6 eicosadienoic and omega-3 eicosatrienoic acids, but no products were detected with the C18 fatty acid linoleic and alpha-linolenic acids or with the C22 fatty acid adrenic and docosapentaenoic acids. When the corresponding P. patens genomic sequence was disrupted by replacement through homologous recombination, a dramatic alteration in the fatty acid composition was observed, i. e. an increase in di-homo-gamma-linolenic and eicosatetraenoic acids accompanied by a concomitant disappearance of the Delta(5)-fatty acid arachidonic and eicosapentaenoic acids. In addition, overexpression of the P. patens cDNA in protoplasts isolated from a disrupted line resulted in the restoration of arachidonic acid synthesis.	Mahidol Univ, Fac Pharm, Dept Pharmacognosy, Bangkok 10400, Thailand; Mahidol Univ, Fac Pharm, Dept Microbiol, Bangkok 10400, Thailand; Mahidol Univ, Fac Sci, Dept Plant Sci, Bangkok 10400, Thailand; USDA ARS, Plant Genet Res Unit, Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA; Washington Univ, Dept Biol, St Louis, MO 63130 USA	Mahidol University; Mahidol University; Mahidol University; Donald Danforth Plant Science Center; United States Department of Agriculture (USDA); Washington University (WUSTL)	Quatrano, RS (corresponding author), Mahidol Univ, Fac Pharm, Dept Pharmacognosy, 447 Sri Ayudhya Rd, Bangkok 10400, Thailand.	rsq@biology.wustl.edu; pynby@mahidol.ac.th						ACKMAN RG, 1968, J FISH RES BOARD CAN, V25, P1603, DOI 10.1139/f68-145; ASHTON NW, 1977, MOL GEN GENET, V154, P87, DOI 10.1007/BF00265581; Cahoon EB, 2000, PLANT PHYSIOL, V124, P243, DOI 10.1104/pp.124.1.243; Cove D, 2005, ANNU REV GENET, V39, P339, DOI 10.1146/annurev.genet.39.073003.110214; DAILEY HA, 1980, J BIOL CHEM, V255, P5184; DEMBITSKY VM, 1993, PROG LIPID RES, V32, P281, DOI 10.1016/0163-7827(93)90010-T; DORMERGUE F, 2002, EUR J BIOCHEM, V269, P4105; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Girke T, 1998, PLANT J, V15, P39, DOI 10.1046/j.1365-313X.1998.00178.x; Girod PA, 1999, PLANT CELL, V11, P1457; GRIMSLEY NH, 1981, PHYTOCHEMISTRY, V20, P1519, DOI 10.1016/S0031-9422(00)98523-6; Heinz Ernst, 1993, P33; Hornung E, 2005, BBA-MOL CELL BIOL L, V1686, P181, DOI 10.1016/j.bbalip.2004.11.001; Horrobin D.F., 1990, REV CONT PHYSL, V1, P1; HORROBIN DF, 1992, PROG LIPID RES, V31, P163, DOI 10.1016/0163-7827(92)90008-7; Horrocks LA, 1999, PHARMACOL RES, V40, P211, DOI 10.1006/phrs.1999.0495; Huang YS, 2004, BIOCHIMIE, V86, P793, DOI 10.1016/j.biochi.2004.09.019; Imaizumi T, 2002, PLANT CELL, V14, P373, DOI 10.1105/tpc.010388; JAMIESON GR, 1975, PHYTOCHEMISTRY, V14, P2229, DOI 10.1016/S0031-9422(00)91104-X; Jump DB, 2002, J BIOL CHEM, V277, P8755, DOI 10.1074/jbc.R100062200; Kajikawa M, 2004, PLANT MOL BIOL, V54, P335, DOI 10.1023/B:PLAN.0000036366.57794.ee; Kamisugi Y, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni172; Knight CD, 2002, PRACT APPROACH SER, V259, P285; Koprivova A, 2002, J BIOL CHEM, V277, P32195, DOI 10.1074/jbc.M204971200; LEDERER F, 1994, BIOCHIMIE, V76, P674, DOI 10.1016/0300-9084(94)90144-9; Michaelson LV, 1998, FEBS LETT, V439, P215, DOI 10.1016/S0014-5793(98)01385-4; Michaelson LV, 1998, J BIOL CHEM, V273, P19055, DOI 10.1074/jbc.273.30.19055; MITCHELL AG, 1995, J BIOL CHEM, V270, P29766; Napier JA, 1998, BIOCHEM J, V330, P611; Pereira SL, 2003, PROSTAG LEUKOTR ESS, V68, P97, DOI 10.1016/S0952-3278(02)00259-4; Roynette CE, 2004, CLIN NUTR, V23, P139, DOI 10.1016/j.clnu.2003.07.005; Saito T, 2000, EUR J BIOCHEM, V267, P1813, DOI 10.1046/j.1432-1327.2000.01180.x; Saito T, 1999, EUR J BIOCHEM, V265, P809, DOI 10.1046/j.1432-1327.1999.00789.x; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; Sayanova O, 1999, PLANT PHYSIOL, V121, P641, DOI 10.1104/pp.121.2.641; Sayanova O, 2001, J EXP BOT, V52, P1581, DOI 10.1093/jexbot/52.360.1581; Sayanova O, 2000, BIOCHEM SOC T, V28, P636, DOI 10.1042/BST0280636; Sayanova OV, 2004, PHYTOCHEMISTRY, V65, P147, DOI 10.1016/j.phytochem.2003.10.017; SCHAEFER D, 1991, MOL GEN GENET, V226, P418, DOI 10.1007/BF00260654; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; SMITH MA, 1990, BIOCHEM J, V272, P23, DOI 10.1042/bj2720023; SMITH MA, 1992, BIOCHEM J, V287, P141, DOI 10.1042/bj2870141; SPERLING P, 1995, EUR J BIOCHEM, V232, P798, DOI 10.1111/j.1432-1033.1995.0798a.x; Sperling P, 2001, EUR J LIPID SCI TECH, V103, P158, DOI 10.1002/1438-9312(200103)103:3<158::AID-EJLT158>3.0.CO;2-1; Uauy R, 2000, PEDIATR RES, V47, P127, DOI 10.1203/00006450-200001000-00022; Wallis JG, 2002, TRENDS BIOCHEM SCI, V27, P467, DOI 10.1016/S0968-0004(02)02168-0; Wolff RL, 2000, LIPIDS, V35, P1, DOI 10.1007/s11745-000-0489-y; ZANK T, 2005, Patent No. 2005012316; Zank TK, 2002, PLANT J, V31, P255, DOI 10.1046/j.1365-313X.2002.01354.x	49	36	41	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21988	21997		10.1074/jbc.M603022200	http://dx.doi.org/10.1074/jbc.M603022200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16728405	hybrid			2022-12-25	WOS:000239387100045
J	Lott, JS; Paget, B; Johnston, JM; Delbaere, LTJ; Sigrell-Simon, JA; Banfield, MJ; Baker, EN				Lott, J. Shaun; Paget, Blake; Johnston, Jodie M.; Delbaere, Louis T. J.; Sigrell-Simon, Jill A.; Banfield, Mark J.; Baker, Edward N.			The structure of an ancient conserved domain establishes a structural basis for stable histidine phosphorylation and identifies a new family of adenosine-specific kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-RESOLUTION STRUCTURE; CRYSTAL-STRUCTURE; PROTEINS; PHOSPHOHISTIDINE; MECHANISM; RESIDUES; DATABASE; MODEL; TOOL; CRYSTALLOGRAPHY	Phosphorylation of both small molecules and proteins plays a central role in many biological processes. In proteins, phosphorylation most commonly targets the oxygen atoms of Ser, Thr, and Tyr. In contrast, stably phosphorylated His residues are rarely found, due to the lability of the N-P bond, and histidine phosphorylation features most often in transient processes. Here we present the crystal structure of a protein of previously unknown function, which proves to contain a stably phosphorylated histidine residue. The protein is the product of open reading frame PAE2307, from the hyperthermophilic archaeon Pyrobaculum aerophilum, and is representative of a highly conserved protein family found in archaea and bacteria. The crystal structure of PAE2307, solved at 1.45-angstrom resolution (R = 0.208, R-free = 0.227), forms a remarkably tightly associated hexamer. The phosphorylated histidine at the proposed active site, pHis(85), occupies a cavity that is at the interface between two subunits and contains a number of fully conserved residues. Stable phosphorylation is attributed to favorable hydrogen bonding of the phosphoryl group and a salt bridge with pHis(85) that provides electronic stabilization. In silico modeling suggested that the protein may function as an adenosine kinase, a conclusion that is supported by in vitro assays of adenosine binding, using fluorescence spectroscopy, and crystallographic visualization of an adenosine complex of PAE2307 at 2.25-angstrom resolution.	Univ Auckland, Ctr Mol Biodiscovery, Struct Biol Lab, Auckland 1, New Zealand; Univ Auckland, Sch Biol Sci, Auckland 1, New Zealand; Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada; GE Healthcare, Dept Res & Dev, SE-75184 Uppsala, Sweden; Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of Auckland; University of Auckland; University of Saskatchewan; General Electric; Newcastle University - UK	Baker, EN (corresponding author), Univ Auckland, Ctr Mol Biodiscovery, Struct Biol Lab, 3A Symonds St,Private Bag 92-019, Auckland 1, New Zealand.	ted.baker@auckland.ac.nz	Banfield, Mark/C-7453-2013; Johnston, Jodie/D-4318-2009	Banfield, Mark/0000-0001-8921-3835; Baker, Edward/0000-0003-2456-7661; Lott, Shaun/0000-0003-3660-452X				ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Bond CS, 2001, J BIOL CHEM, V276, P3247, DOI 10.1074/jbc.M007318200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Dyguda E, 2004, INT J MOL SCI, V5, P141, DOI 10.3390/i5040141; Eftink MR, 1997, METHOD ENZYMOL, V278, P221; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fischer D, 1997, P NATL ACAD SCI USA, V94, P11929, DOI 10.1073/pnas.94.22.11929; Fitz-Gibbon ST, 2002, P NATL ACAD SCI USA, V99, P984, DOI 10.1073/pnas.241636498; Fraser ME, 2000, J MOL BIOL, V299, P1325, DOI 10.1006/jmbi.2000.3807; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Hopfner KP, 1999, P NATL ACAD SCI USA, V96, P3600, DOI 10.1073/pnas.96.7.3600; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM Y, 1995, BBA-MOL CELL RES, V1268, P221, DOI 10.1016/0167-4889(95)00062-W; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; Klumpp S, 2002, EUR J BIOCHEM, V269, P1067, DOI 10.1046/j.1432-1033.2002.02755.x; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lott JS, 2003, ACTA CRYSTALLOGR D, V59, P2242, DOI 10.1107/S0907444903020584; Mathews II, 1998, BIOCHEMISTRY-US, V37, P15607, DOI 10.1021/bi9815445; MATTHEWS HR, 1995, PHARMACOL THERAPEUT, V67, P323, DOI 10.1016/0163-7258(95)00020-8; MORERA S, 1995, BIOCHEMISTRY-US, V34, P11062, DOI 10.1021/bi00035a011; Mulder NJ, 2003, NUCLEIC ACIDS RES, V31, P315, DOI 10.1093/nar/gkg046; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Schauder S, 1998, J MOL BIOL, V276, P591, DOI 10.1006/jmbi.1997.1544; Schumacher MA, 2000, J MOL BIOL, V296, P549, DOI 10.1006/jmbi.1999.3474; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Sigrell JA, 1998, STRUCTURE, V6, P183, DOI 10.1016/S0969-2126(98)00020-3; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VANNULAND NAJ, 1995, J MOL BIOL, V246, P180, DOI 10.1006/jmbi.1994.0075; Verdonk ML, 2003, PROTEINS, V52, P609, DOI 10.1002/prot.10465; West AH, 2001, TRENDS BIOCHEM SCI, V26, P369, DOI 10.1016/S0968-0004(01)01852-7	40	7	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22131	22141		10.1074/jbc.M603062200	http://dx.doi.org/10.1074/jbc.M603062200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16737961	hybrid			2022-12-25	WOS:000239387100060
J	Nijman, SMB; Hijmans, EM; El Messaoudi, S; van Dongen, MMW; Sardet, C; Bernards, R				Nijman, Sebastian M. B.; Hijmans, E. Marielle; El Messaoudi, Selma; van Dongen, Miranda M. W.; Sardet, Claude; Bernards, Rene			A functional genetic screen identifies TFE3 as a gene that confers resistance to the anti-proliferative effects of the retinoblastoma protein and transforming growth factor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL-CELL CARCINOMAS; TRANSCRIPTION FACTOR; S-PHASE; TUMOR-SUPPRESSOR; CYCLIN-E; E2F; PROLIFERATION; ACTIVATION; REPRESSION; INHIBITION	The helix-loop-helix transcription factor TFE3 has been suggested to play a role in the control of cell growth by acting as a binding partner of transcriptional regulators such as E2F3, SMAD3, and LEF-1 ( 1 - 4). Furthermore, translocations/TFE3 fusions have been directly implicated in tumorigenesis ( 5 - 7). Surprisingly, however, a direct functional role for TFE3 in the regulation of proliferation has not been reported. By screening retroviral cDNA expression libraries to identify cDNAs that confer resistance to a pRB-induced proliferation arrest, we have found that TFE3 overrides a growth arrest in Rat1 cells induced by pRB and its upstream regulator p16(INK4A). In addition, TFE3 expression blocks the anti-mitogenic effects of TGF-beta in rodent and human cells. We provide data supporting a role for endogenous TFE3 in the direct regulation of CYCLIN E expression in an E2F3-dependent manner. These observations establish TFE3 as a functional regulator of proliferation and offer a potential mechanism for its involvement in cancer.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; CNRS, IFR24, UMR 5535, Inst Mol Genet, F-34293 Montpellier 5, France	Netherlands Cancer Institute; Netherlands Cancer Institute; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.bernards@nki.nl		Hijmans, Marielle/0000-0003-4847-9412; Bernards, Rene/0000-0001-8677-3423				Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Argani P, 2001, AM J PATHOL, V159, P179, DOI 10.1016/S0002-9440(10)61684-7; Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; Berns K, 2000, ONCOGENE, V19, P3330, DOI 10.1038/sj.onc.1203639; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Fabbrizio E, 2002, EMBO REP, V3, P641, DOI 10.1093/embo-reports/kvf136; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Giangrande PH, 2003, MOL CELL BIOL, V23, P3707, DOI 10.1128/MCB.23.11.3707-3720.2003; Giangrande PH, 2004, EMBO J, V23, P1336, DOI 10.1038/sj.emboj.7600134; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hauck L, 2002, MOL CELL BIOL, V22, P2147, DOI 10.1128/MCB.22.7.2147-2158.2002; Herrera RE, 1996, MOL BIOL CELL, V7, P1335, DOI 10.1091/mbc.7.9.1335; Hua XX, 2000, J BIOL CHEM, V275, P33205, DOI 10.1074/jbc.C000568200; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Humbert PO, 2000, GENE DEV, V14, P690; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; LEE GH, 1995, AM J PATHOL, V147, P1811; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Morrison AJ, 2002, MOL CELL BIOL, V22, P856, DOI 10.1128/MCB.22.3.856-865.2002; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Schlisio S, 2002, EMBO J, V21, P5775, DOI 10.1093/emboj/cdf577; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; Skalsky YM, 2001, ONCOGENE, V20, P178, DOI 10.1038/sj.onc.1204056; Tian G, 1999, MOL CELL BIOL, V19, P2946; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yasumoto K, 2002, EMBO J, V21, P2703, DOI 10.1093/emboj/21.11.2703; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	39	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21582	21587		10.1074/jbc.M602312200	http://dx.doi.org/10.1074/jbc.M602312200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16737956	Green Published, hybrid			2022-12-25	WOS:000239387100003
J	Xu, J; Liu, ZY; Clemens, TL; Messina, JL				Xu, Jie; Liu, Zhongyu; Clemens, Thomas L.; Messina, Joseph L.			Insulin reverses growth hormone-induced homologous desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ACUTE-PHASE RESPONSE; DEPENDENT DIABETES-MELLITUS; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN; SIGNAL-TRANSDUCTION; TRANSGENIC MICE; IN-VIVO; DIFFERENTIAL ACTIVATION; TRANSCRIPTION FACTOR	Growth hormone ( GH) is secreted in a pulsatile pattern to promote body growth and metabolism. GHexerts its function by activating several signaling pathways, including JAK2/STAT and MEK/ERK. ERK1/2 activation by GH plays important roles in gene expression, cell proliferation, and growth. We previously reported that in rat H4IIE hepatoma cells after an initial GH exposure, a second GH exposure induces STAT5 phosphorylation but not ERK1/2 phosphorylation ( Ji, S., Frank, S. J., and Messina, J. L. ( 2002) J. Biol. Chem. 277, 28384 - 28393). In this study the mechanisms underlying GH-induced homologous desensitization were investigated. A second GH exposure activated the signaling intermediates upstream of MEK/ERK, including JAK2, Ras, and Raf-1. This correlated with recovery of GH receptor levels, but was insufficient for GH-induced phosphorylation of MEK1/2 and ERK1/2. Insulin restored the ability of a second GH exposure to induce phosphorylation of MEK1/2 and ERK1/2 without altering GH receptor levels or GH-induced phosphorylation/activation of JAK2 and Raf-1. GH and insulin synergized in promoting cell proliferation. Further investigation suggested that insulin increased the amount of MEK bound to KSR (kinase suppressor of Ras) and restored GH-induced tyrosine phosphorylation of KSR. Previous GH exposure also induced desensitization of STAT1 and STAT3 phosphorylation, but this desensitization was not reversed by insulin. Thus, insulin-regulated resensitization of GH signaling may be necessary to reset the complete response to GH after a normal, physiologic pulse of GH.	Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Messina, JL (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Volker Hall,G019, Birmingham, AL 35294 USA.	messina@path.uab.edu			NIDDK NIH HHS [DK40456, DK62071] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040456, R01DK062071] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Alonzi T, 2001, MOL CELL BIOL, V21, P1621, DOI 10.1128/MCB.21.5.1621-1632.2001; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAXTER RC, 1980, ENDOCRINOLOGY, V107, P1176, DOI 10.1210/endo-107-4-1176; BEREKET A, 1995, J CLIN ENDOCR METAB, V80, P1312, DOI 10.1210/jc.80.4.1312; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; Chiarelli F, 2004, EUR J ENDOCRINOL, V151, pU109, DOI 10.1530/eje.0.151U109; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Coschigano KT, 2000, ENDOCRINOLOGY, V141, P2608, DOI 10.1210/en.141.7.2608; Davey HW, 1999, J BIOL CHEM, V274, P35331, DOI 10.1074/jbc.274.50.35331; Dhir RN, 2003, P NATL ACAD SCI USA, V100, P15224, DOI 10.1073/pnas.2434273100; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Donaghue KC, 2003, ARCH DIS CHILD, V88, P151, DOI 10.1136/adc.88.2.151; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; EDEN S, 1978, ACTA ENDOCRINOL-COP, V88, P676, DOI 10.1530/acta.0.0880676; EDEN S, 1978, ACTA PHYSIOL SCAND, P1; EVEN P, 1987, AM J PHYSIOL, V253, pR772, DOI 10.1152/ajpregu.1987.253.5.R772; Gebert CA, 1997, MOL ENDOCRINOL, V11, P400, DOI 10.1210/me.11.4.400; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; GUEST GM, 1953, DIABETES, V2, P415, DOI 10.2337/diab.2.5.415; Hackett RH, 1997, J BIOL CHEM, V272, P11128; Hansen LH, 1996, J BIOL CHEM, V271, P12669, DOI 10.1074/jbc.271.21.12669; Herrington J, 2000, ONCOGENE, V19, P2585, DOI 10.1038/sj.onc.1203526; HIKIDA RS, 1995, GROWTH DEVELOP AGING, V59, P121; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Huang Y, 2003, J BIOL CHEM, V278, P18902, DOI 10.1074/jbc.M300939200; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; JANSSON JO, 1985, ENDOCR REV, V6, P128, DOI 10.1210/edrv-6-2-128; Jarrar D, 1997, ARCH SURG-CHICAGO, V132, P1171; Ji SN, 2002, J BIOL CHEM, V277, P28384, DOI 10.1074/jbc.M111723200; Ji SN, 1999, J BIOL CHEM, V274, P13434, DOI 10.1074/jbc.274.19.13434; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; Kim SO, 1999, J BIOL CHEM, V274, P36015, DOI 10.1074/jbc.274.50.36015; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; KLARLUND JK, 1995, J BIOL CHEM, V270, P23421, DOI 10.1074/jbc.270.40.23421; Kolesnick R, 2004, J CLIN INVEST, V114, P1233, DOI 10.1172/JCI200423441; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Lewis MD, 2004, J CLIN ENDOCR METAB, V89, P1068, DOI 10.1210/jc.2003-030652; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liang L, 1999, ENDOCRINOLOGY, V140, P1972, DOI 10.1210/en.140.5.1972; Liang L, 2000, ENDOCRINOLOGY, V141, P3328, DOI 10.1210/en.141.9.3328; MENON RK, 1992, J CLIN ENDOCR METAB, V74, P934, DOI 10.1210/jc.74.4.934; MENON RK, 1994, J ENDOCRINOL, V142, P453, DOI 10.1677/joe.0.1420453; Metherell Louise A., 2001, American Journal of Human Genetics, V69, P641, DOI 10.1086/323266; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Nguyen A, 2002, MOL CELL BIOL, V22, P3035, DOI 10.1128/MCB.22.9.3035-3045.2002; Nguyen AP, 1996, ENDOCRINOLOGY, V137, P3659, DOI 10.1210/en.137.9.3659; Ory S, 2004, CURR BIOL, V14, pR277, DOI 10.1016/j.cub.2004.03.023; Pennisi PA, 2004, ENDOCRINOLOGY, V145, P4748, DOI 10.1210/en.2004-0655; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; Rogers RJ, 2000, BIOCHEM J, V347, P233, DOI 10.1042/0264-6021:3470233; Rowland JE, 2005, MOL CELL BIOL, V25, P66, DOI 10.1128/MCB.25.1.66-77.2005; SHEA BT, 1987, ENDOCRINOLOGY, V121, P1924, DOI 10.1210/endo-121-6-1924; SILVA CM, 1994, J BIOL CHEM, V269, P27532; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Snibson KJ, 1999, LIVER, V19, P242, DOI 10.1111/j.1478-3231.1999.tb00042.x; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; SOTIROPOULOS A, 1995, FEBS LETT, V369, P169, DOI 10.1016/0014-5793(95)00734-Q; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Stofega MR, 2000, J BIOL CHEM, V275, P28222; Stofega MR, 1998, J BIOL CHEM, V273, P7112, DOI 10.1074/jbc.273.12.7112; Stred SE, 2003, MOL CELL ENDOCRINOL, V204, P101, DOI 10.1016/S0303-7207(03)00149-7; TANNENBAUM GS, 1976, ENDOCRINOLOGY, V98, P562, DOI 10.1210/endo-98-3-562; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tiulpakov A, 2005, J CLIN ENDOCR METAB, V90, P542, DOI 10.1210/jc.2003-2133; Tollet-Egnell P, 1999, ENDOCRINOLOGY, V140, P3693, DOI 10.1210/en.140.8.3693; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Vanderkuur JA, 1997, ENDOCRINOLOGY, V138, P4301, DOI 10.1210/en.138.10.4301; Verma AS, 2005, MOL PHARMACOL, V67, P891, DOI 10.1124/mol.104.005454; Wang XZ, 1996, MOL ENDOCRINOL, V10, P1249, DOI 10.1210/me.10.10.1249; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; WANKE R, 1991, PEDIATR NEPHROL, V5, P513, DOI 10.1007/BF01453693; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Xu J, 2006, J BIOL CHEM, V281, P982, DOI 10.1074/jbc.M505484200; Xu L, 2005, J ENDOCRINOL, V184, P481, DOI 10.1677/joe.1.05977; Yi WS, 1996, MOL ENDOCRINOL, V10, P1425, DOI 10.1210/me.10.11.1425	85	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21594	21606		10.1074/jbc.M513612200	http://dx.doi.org/10.1074/jbc.M513612200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16717097	hybrid			2022-12-25	WOS:000239387100005
J	Ginder, ND; Binkowski, DJ; Fromm, HJ; Honzatko, RB				Ginder, Nathaniel D.; Binkowski, Daniel J.; Fromm, Herbert J.; Honzatko, Richard B.			Nucleotide complexes of Escherichia coli phosphoribosylaminoimidazole succinocarboxamide synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; ADENYLOSUCCINATE SYNTHETASE; SAICAR SYNTHASE; ENZYMATIC-SYNTHESIS; ACID 5-PHOSPHATE; BIOSYNTHESIS; MECHANISM; RIBONUCLEOTIDE; PURINES; GTP	Phosphoribosylaminoimidazole-succinocarboxamide synthetase ( SAICAR synthetase) converts 4-carboxy-5-aminoimidazole ribonucleotide ( CAIR) to 4-( N-succinylcarboxamide)-5-aminoimidazole ribonucleotide ( SAICAR). The enzyme is a target of natural products that impair cell growth. Reported here are the crystal structures of the ADP and the ADP (.) CAIR complexes of SAICAR synthetase from Escherichia coli, the latter being the first instance of a CAIR-ligated SAICAR synthetase. ADP and CAIR bind to the active site in association with three Mg2+, two of which coordinate the same oxygen atom of the 4- carboxyl group of CAIR; whereas, the third coordinates the alpha- and beta-phosphoryl groups of ADP. The ADP (.) CAIR complex is the basis for a transition state model of a phosphoryl transfer reaction involving CAIR and ATP, but also supports an alternative chemical pathway in which the nucleophilic attack of L-aspartate precedes the phosphoryl transfer reaction. The polypeptide fold for residues 204 - 221 of the E. coli structure differs significantly from those of the ligand-free SAICAR synthetase from Thermatoga maritima and the adenine nucleotide complexes of the synthetase from Saccharomyces cerevisiae. Conformational differences between the E. coli, T. maritima, and yeast synthetases suggest the possibility of selective inhibition of de novo purine nucleotide biosynthesis in microbial organisms.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Honzatko, RB (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.	honzatko@iastate.edu			NINDS NIH HHS [NS 10546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alenin V. V., 1992, Biokhimiya, V57, P845; Antonyuk SV, 2001, CRYSTALLOGR REP+, V46, P620, DOI 10.1134/1.1387127; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BASS MB, 1984, J BIOL CHEM, V259, P2330; Batova A, 1999, CANCER RES, V59, P1492; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN ZD, 1990, P NATL ACAD SCI USA, V87, P3097, DOI 10.1073/pnas.87.8.3097; Choe JY, 1999, BIOCHEMISTRY-US, V38, P6953, DOI 10.1021/bi990159s; COOPER BF, 1986, BIOCHEMISTRY-US, V25, P7323, DOI 10.1021/bi00371a013; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FIRESTINE SM, 1994, BIOCHEMISTRY-US, V33, P11917, DOI 10.1021/bi00205a030; FROMM HJ, 1958, BIOCHIM BIOPHYS ACTA, V29, P255, DOI 10.1016/0006-3002(58)90182-3; Groziak MP, 1997, J MED CHEM, V40, P3336, DOI 10.1021/jm970301s; GROZIAK MP, 1988, P NATL ACAD SCI USA, V85, P7174, DOI 10.1073/pnas.85.19.7174; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; Honzatko RB, 1999, ADV ENZYMOL RAMB, V73, P57, DOI 10.1002/9780470123195.ch3; Honzatko RB, 1999, ARCH BIOCHEM BIOPHYS, V370, P1, DOI 10.1006/abbi.1999.1383; Iancu CV, 2002, J BIOL CHEM, V277, P26779, DOI 10.1074/jbc.M203730200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levdikov VM, 1998, STRUCTURE, V6, P363, DOI 10.1016/S0969-2126(98)00038-0; LEVDIKOV VM, 1996, CRYSTALLOGR REP, V41, P275; LIEBERMAN I, 1956, J BIOL CHEM, V223, P327; LITCHFIELD GJ, 1971, J CHEM SOC B, P1474, DOI 10.1039/j29710001474; LUKENS LN, 1959, J BIOL CHEM, V234, P1791; MARKHAM GD, 1978, J BIOL CHEM, V253, P6184; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MEYER E, 1992, BIOCHEMISTRY-US, V31, P5022, DOI 10.1021/bi00136a016; MILLER RW, 1962, J BIOL CHEM, V237, P485; Nelson SW, 2005, BIOCHEMISTRY-US, V44, P766, DOI 10.1021/bi048191w; PATEY CAH, 1973, BIOCHEM J, V135, P543, DOI 10.1042/bj1350543; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Poland BW, 1997, J BIOL CHEM, V272, P15200, DOI 10.1074/jbc.272.24.15200; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; TERWILLIGER TC, 1999, ACTA CRYSTALLOGR D, V50, P760; TYAGI AK, 1980, CANCER RES, V40, P4390; Urusova DV, 2003, CRYSTALLOGR REP+, V48, P763, DOI 10.1134/1.1612597; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Zhang RG, 2006, ACTA CRYSTALLOGR F, V62, P335, DOI 10.1107/S1744309106009651	42	22	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20680	20688		10.1074/jbc.M602109200	http://dx.doi.org/10.1074/jbc.M602109200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16687397	hybrid			2022-12-25	WOS:000239187300005
J	Tomai, E; Butz, K; Lohrey, C; von Weizsacker, F; Zentgraf, H; Hoppe-Seyler, F				Tomai, Evangelia; Butz, Karin; Lohrey, Claudia; von Weizsaecker, Fritz; Zentgraf, Hanswalter; Hoppe-Seyler, Felix			Peptide aptamer-mediated inhibition of target proteins by sequestration into aggresomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC SELECTION; CORE-PROTEIN; TUMOR-CELLS; AGGREGATION; ONCOPROTEIN; APOPTOSIS; SIGNALS; DOMAIN; E6	Peptide aptamers (PAs) can be employed to block the intracellular function of target proteins. Little is known about the mechanism of PA-mediated protein inhibition. Here, we generated PAs that specifically bound to the duck hepatitis B virus (HBV) core protein. Among them, PA34 strongly blocked duck HBV replication by inhibiting viral capsid formation. We found that PA34 led to a dramatic intracellular redistribution of its target protein into perinuclear inclusion bodies, which exhibit the typical characteristics of aggresomes. As a result, the core protein is efficiently removed from the viral life cycle. Corresponding findings were obtained for bioactive PAs that bind to the HBV core protein or to the human papillomavirus-16 (HPV16) E6 protein, respectively. The observation that PAs induce the specific sequestration of bound proteins into aggresomes defines a novel mechanism as to how this new class of intracellular inhibitors blocks the function of their target proteins.	German Canc Res Ctr, Mol Therapy Virus Associated Canc Grp F065, D-69120 Heidelberg, Germany; German Canc Res Ctr, Electron Microcopy Grp F090, D-69120 Heidelberg, Germany; Univ Freiburg, Med Klin 2, D-79106 Freiburg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg; University of Hamburg; University Medical Center Hamburg-Eppendorf	Hoppe-Seyler, F (corresponding author), Deutsch Krebsforschungszentrum, F065,Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	hoppe-seyler@dkfz.de		Hoppe-Seyler, Felix/0000-0002-1864-300X				Baines IC, 2006, DRUG DISCOV TODAY, V11, P334, DOI 10.1016/j.drudis.2006.02.007; Borghouts C, 2005, EXPERT OPIN BIOL TH, V5, P783, DOI 10.1517/14712598.5.6.783; Buerger C, 2003, J BIOL CHEM, V278, P37610, DOI 10.1074/jbc.M301629200; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; Butz K, 2001, ONCOGENE, V20, P6579, DOI 10.1038/sj.onc.1204805; CALVERT J, 1994, J VIROL, V68, P2084, DOI 10.1128/JVI.68.4.2084-2090.1994; Chattopadhyay A, 2006, ONCOGENE, V25, P2223, DOI 10.1038/sj.onc.1209252; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Cohen BA, 1998, P NATL ACAD SCI USA, V95, P14272, DOI 10.1073/pnas.95.24.14272; Colas P, 2000, P NATL ACAD SCI USA, V97, P13720, DOI 10.1073/pnas.97.25.13720; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; CONDREAY LD, 1990, J VIROL, V64, P3249, DOI 10.1128/JVI.64.7.3249-3258.1990; Crawford Margaret, 2003, Briefings in Functional Genomics & Proteomics, V2, P72, DOI 10.1093/bfgp/2.1.72; Cui QQ, 2005, ONCOGENE, V24, P3864, DOI 10.1038/sj.onc.1208556; Fabbrizio E, 1999, ONCOGENE, V18, P4357, DOI 10.1038/sj.onc.1202825; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; Geyer CR, 2000, METHOD ENZYMOL, V328, P171, DOI 10.1016/S0076-6879(00)28398-5; Hoppe-Seyler F, 2004, CURR MOL MED, V4, P529, DOI 10.2174/1566524043360519; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kolonin MG, 1998, P NATL ACAD SCI USA, V95, P14266, DOI 10.1073/pnas.95.24.14266; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Mabit H, 2001, J VIROL, V75, P1968, DOI 10.1128/JVI.75.4.1968-1977.2001; Nagel-Wolfrum K, 2004, MOL CANCER RES, V2, P170; Norman TC, 1999, SCIENCE, V285, P591, DOI 10.1126/science.285.5427.591; Rajan RS, 2001, P NATL ACAD SCI USA, V98, P13060, DOI 10.1073/pnas.181479798; Tao MF, 2003, J VIROL, V77, P13232, DOI 10.1128/JVI.77.24.13232-13247.2003; Wyttenbach A, 2000, P NATL ACAD SCI USA, V97, P2898, DOI 10.1073/pnas.97.6.2898; Xu CW, 2002, ONCOGENE, V21, P5753, DOI 10.1038/sj.onc.1205680; ZENTGRAF H, 1995, NUCLEIC ACIDS RES, V23, P3347, DOI 10.1093/nar/23.16.3347; ZHOU S, 1992, P NATL ACAD SCI USA, V89, P10046, DOI 10.1073/pnas.89.21.10046	31	20	25	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21345	21352		10.1074/jbc.M604258200	http://dx.doi.org/10.1074/jbc.M604258200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16717089	hybrid			2022-12-25	WOS:000239187300070
J	Gardsvoll, H; Gilquin, B; Le Du, MH; Menez, A; Jorgensen, TJD; Ploug, M				Gardsvoll, Henrik; Gilquin, Bernard; Le Du, Marie Helene; Menez, Andre; Jorgensen, Thomas J. D.; Ploug, Michael			Characterization of the functional epitope on the urokinase receptor - Complete alanine scanning mutagenesis supplemented by chemical cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR RECEPTOR; LIGAND-BINDING; MASS-SPECTROMETRY; TUMOR-GROWTH; CELLULAR RECEPTOR; DOMAIN-II; PROTEIN; ANTAGONISTS; CANCER; IDENTIFICATION	The high affinity interaction between the serine protease urokinase-type plasminogen activator (uPA) and its glycolipid-anchored receptor (uPAR) represents one of the key regulatory steps in cell surface-associated plasminogen activation. On the basis on our crystal structure solved for uPAR in complex with a peptide antagonist, we recently proposed a model for the corresponding complex with the growth factor-like domain of uPA (Llinas et al. (2005) EMBO J. 24, 1655-1663). In the present study, we provide experimental evidence that consolidates and further develops this model using data from a comprehensive alanine scanning mutagenesis of uPAR combined with low resolution distance constraints defined within the complex using chemical cross-linkers as molecular rulers. The kinetic rate constants for the interaction between pro-uPA and 244 purified uPAR mutants with single-site replacements were determined by surface plasmon resonance. This complete alanine scanning of uPAR highlighted the involvement of 20 surface-exposed side chains in this interaction. Mutations causing Delta Delta G >= 1 kcal/mol for the uPA interaction are all located within or at the rim of the central cavity uniquely formed by the assembly of all three domains in uPAR, whereas none are found outside this crevice. Identification of specific cross-linking sites in uPAR and pro-uPA enabled us to build a model of the uPAR center dot uPA complex in which the kringle domain of uPA was positioned by the constraints established by the range of these cross-linkers. The nature of this interaction is predominantly hydrophobic and highly asymmetric, thus emphasizing the importance of the shape and size of the central cavity when designing low molecular mass antagonists of the uPAR/uPA interaction.	Rigshosp, Finsen Lab, DK-2100 Copenhagen O, Denmark; CE Saclay, CEA, Dept Ingn & Etudes Prot, F-91191 Gif Sur Yvette, France; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark	Rigshospitalet; CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Southern Denmark	Ploug, M (corresponding author), Rigshosp, Finsen Lab, Strandboulevarden 49, DK-2100 Copenhagen O, Denmark.	m-ploug@finsenlab.dk		Jorgensen, Thomas J.D./0000-0002-7149-316X; Ploug, Michael/0000-0003-2215-4265				Back JW, 2003, J MOL BIOL, V331, P303, DOI 10.1016/S0022-2836(03)00721-6; Back JW, 2002, ANAL CHEM, V74, P4417, DOI 10.1021/ac0257492; Baggio R, 2005, J BIOL CHEM, V280, P4188, DOI 10.1074/jbc.M410687200; BARKHOLT V, 1989, ANAL BIOCHEM, V177, P318, DOI 10.1016/0003-2697(89)90059-6; Bauer TW, 2005, CANCER RES, V65, P7775, DOI 10.1158/0008-5472.CAN-05-0946; Bdeir K, 2000, J BIOL CHEM, V275, P28532, DOI 10.1074/jbc.M001595200; Behrendt N, 1996, J BIOL CHEM, V271, P22885, DOI 10.1074/jbc.271.37.22885; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BROOKS CL, 1998, PROTEINS THEORETICAL; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; Eriksson MAL, 2002, BIOPHYS J, V83, P2595, DOI 10.1016/S0006-3495(02)75270-3; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; Gardsvoll H, 1999, J BIOL CHEM, V274, P37995, DOI 10.1074/jbc.274.53.37995; Gardsvoll H, 2004, PROTEIN EXPRES PURIF, V34, P284, DOI 10.1016/j.pep.2003.12.002; GEIGER T, 1987, J BIOL CHEM, V262, P785; GOODSON RJ, 1994, P NATL ACAD SCI USA, V91, P7129, DOI 10.1073/pnas.91.15.7129; HANSEN AP, 1994, BIOCHEMISTRY-US, V33, P4847, DOI 10.1021/bi00182a013; Huai Q, 2006, SCIENCE, V311, P656, DOI 10.1126/science.1121143; Jorgensen TJD, 2004, BIOCHEMISTRY-US, V43, P15044, DOI 10.1021/bi048706j; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; Le DM, 2003, J NEUROSCI, V23, P4034; Li Y, 2003, J BIOL CHEM, V278, P29925, DOI 10.1074/jbc.M300751200; Liang OD, 2001, J BIOL CHEM, V276, P28946, DOI 10.1074/jbc.M011437200; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Liu SH, 2003, P NATL ACAD SCI USA, V100, P657, DOI 10.1073/pnas.0236849100; Llinas P, 2005, EMBO J, V24, P1655, DOI 10.1038/sj.emboj.7600635; LOW BW, 1976, P NATL ACAD SCI USA, V73, P2991, DOI 10.1073/pnas.73.9.2991; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Magdolen V, 1996, EUR J BIOCHEM, V237, P743, DOI 10.1111/j.1432-1033.1996.0743p.x; Min HY, 1996, CANCER RES, V56, P2428; Netzel-Arnett S, 2002, J BIOL CHEM, V277, P45154, DOI 10.1074/jbc.M206354200; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; Oda M, 1998, EUR J BIOCHEM, V256, P411, DOI 10.1046/j.1432-1327.1998.2560411.x; PLOUG M, 1994, FEBS LETT, V349, P163, DOI 10.1016/0014-5793(94)00674-1; PLOUG M, 1994, BIOCHEMISTRY-US, V33, P8991, DOI 10.1021/bi00196a017; Ploug M, 2003, CURR PHARM DESIGN, V9, P1499, DOI 10.2174/1381612033454630; PLOUG M, 1995, BIOCHEMISTRY-US, V34, P12524, DOI 10.1021/bi00039a006; Ploug M, 2001, BIOCHEMISTRY-US, V40, P12157, DOI 10.1021/bi010662g; PLOUG M, 1993, J BIOL CHEM, V268, P17539; PLOUG M, 1991, J BIOL CHEM, V266, P1926; Ploug M, 1998, BIOCHEMISTRY-US, V37, P3612, DOI 10.1021/bi972787k; Pluskota E, 2003, BLOOD, V101, P1582, DOI 10.1182/blood-2002-06-1842; Pulukuri SM, 2005, J BIOL CHEM, V280, P36529, DOI 10.1074/jbc.M503111200; Rao JS, 2005, MOL CANCER THER, V4, P1399, DOI 10.1158/1535-7163.MCT-05-0082; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; Reuning U, 2003, CURR PHARM DESIGN, V9, P1529, DOI 10.2174/1381612033454612; Riittinen L, 1996, FEBS LETT, V381, P1, DOI 10.1016/0014-5793(96)00033-6; Rockway TW, 2003, CURR PHARM DESIGN, V9, P1483, DOI 10.2174/1381612033454649; Romer J, 2004, CURR PHARM DESIGN, V10, P2359, DOI 10.2174/1381612043383962; RONNE E, 1994, J IMMUNOL METHODS, V167, P91, DOI 10.1016/0022-1759(94)90078-7; Schmiedeberg N, 2002, J MED CHEM, V45, P4984, DOI 10.1021/jm020254q; Sinz A, 2003, J MASS SPECTROM, V38, P1225, DOI 10.1002/JMS.559; Stephens RW, 1999, JNCI-J NATL CANCER I, V91, P869, DOI 10.1093/jnci/91.10.869; Suckau D, 2003, ANAL BIOANAL CHEM, V376, P952, DOI 10.1007/s00216-003-2057-0; Vallera DA, 2002, J NATL CANCER I, V94, P597; Wei Y, 2005, J CELL BIOL, V168, P501, DOI 10.1083/jcb.200404112; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551	59	71	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19260	19272		10.1074/jbc.M513583200	http://dx.doi.org/10.1074/jbc.M513583200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16672229	hybrid			2022-12-25	WOS:000238847000040
J	Pieren, M; Prota, AE; Ruch, C; Kostrewa, D; Wagner, A; Biedermann, K; Winkler, FK; Ballmer-Hofer, K				Pieren, Michel; Prota, Andrea E.; Ruch, Claudia; Kostrewa, Dirk; Wagner, Armin; Biedermann, Katrin; Winkler, Fritz K.; Ballmer-Hofer, Kurt			Crystal structure of the Orf virus NZ2 variant of vascular endothelial growth factor-E - Implications for receptor specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE DOMAIN RECEPTOR; FACTOR VEGF; ANGSTROM RESOLUTION; FACTOR DETERMINANTS; BINDING; IDENTIFICATION; PERMEABILITY; SEQUENCE; PROTEIN; ENZYME	Mammalian vascular endothelial growth factors constitute a family of polypeptides, vascular endothelial growth factor (VEGF)-A, -B, -C, -D and placenta growth factor (PlGF), that regulate blood and lymphatic vessel development. VEGFs bind to three types of receptor tyrosine kinases, VEGF receptors 1, 2, and 3, that are predominantly expressed on endothelial and some hematopoietic cells. Pox viruses of the Orf family encode highly related proteins called VEGF-E that show only 25-35% amino acid identity with VEGF-A but bind with comparable affinity to VEGFR-2. The crystal structure of VEGF-E NZ2 described here reveals high similarity to the known structural homologs VEGF-A, PlGF, and the snake venoms Vammin and VR-1, which are all homodimers and contain the characteristic cysteine knot motif. Distinct conformational differences are observed in loop L1 and particularly in L3, which contains a highly flexible GS-rich motif that differs from all other structural homologs. Based on our structure, we created chimeric proteins by exchanging selected segments in L1 and L3 with the corresponding sequences from PlGF. Single loop mutants did not bind to either receptor, whereas a VEGF-E mutant in which both L1 and L3 were replaced gained affinity for VEGFR-1, illustrating the possibility to engineer receptor-specific chimeric VEGF molecules. In addition, changing arginine 46 to isoleucine in L1 significantly increased the affinity of VEGF-E for both VEGF receptors.	Paul Scherrer Inst, Lab Biomol Res, CH-5232 Villigen, Switzerland	Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Ballmer-Hofer, K (corresponding author), Paul Scherrer Inst, Lab Biomol Res, CH-5232 Villigen, Switzerland.	kurt.ballmer@psi.ch	Prota, Andrea Enrico/R-9526-2019	Prota, Andrea Enrico/0000-0003-0875-5339; Ballmer-Hofer, Kurt/0000-0002-3800-9129				Bellamy WT, 2002, CURR OPIN ONCOL, V14, P649, DOI 10.1097/00001622-200211000-00010; Brockington A, 2004, NEUROPATH APPL NEURO, V30, P427, DOI 10.1111/j.1365-2990.2004.00600.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Chow MA, 2004, BIOCHEMISTRY-US, V43, P12780, DOI 10.1021/bi0487544; Christinger HW, 2004, J BIOL CHEM, V279, P10382, DOI 10.1074/jbc.M313237200; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; Davis-Smyth T, 1998, J BIOL CHEM, V273, P3216, DOI 10.1074/jbc.273.6.3216; Demirovic AR, 2003, BIOL CHEM, V384, P1435, DOI 10.1515/BC.2003.159; Errico M, 2004, J BIOL CHEM, V279, P43929, DOI 10.1074/jbc.M401418200; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; Geiser M, 2001, BIOTECHNIQUES, V31, P88, DOI 10.2144/01311st05; GERBER PR, 1995, J COMPUT AID MOL DES, V9, P251, DOI 10.1007/BF00124456; Hiratsuka S, 2001, CANCER RES, V61, P1207; Ishida A, 2001, J CELL PHYSIOL, V188, P359, DOI 10.1002/jcp.1121; Iyer S, 2001, J BIOL CHEM, V276, P12153, DOI 10.1074/jbc.M008055200; Jun CD, 2001, J BIOL CHEM, V276, P29019, DOI 10.1074/jbc.M103394200; Junqueira-de-Azevedo IDL, 2004, TOXICON, V44, P571, DOI 10.1016/j.toxicon.2004.07.013; Kammerer RA, 1998, P NATL ACAD SCI USA, V95, P13419, DOI 10.1073/pnas.95.23.13419; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Kiba A, 2003, J BIOL CHEM, V278, P13453, DOI 10.1074/jbc.M210931200; Kiba A, 2003, BIOCHEM BIOPH RES CO, V301, P371, DOI 10.1016/S0006-291X(02)03033-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lodeiro S, 2005, J AM CHEM SOC, V127, P14132, DOI 10.1021/ja053791j; Luttun A, 2003, J CLIN INVEST, V111, P600, DOI 10.1172/JCI200318015; LYTTLE DJ, 1994, J VIROL, V68, P84, DOI 10.1128/JVI.68.1.84-92.1994; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; Mercer AA, 2002, J GEN VIROL, V83, P2845, DOI 10.1099/0022-1317-83-11-2845; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Muller YA, 2002, J BIOL CHEM, V277, P43410, DOI 10.1074/jbc.M206438200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; PAJUSOLA K, 1992, CANCER RES, V52, P5738; Robinson CJ, 2001, J CELL SCI, V114, P853; Ruhrberg C, 2003, BIOESSAYS, V25, P1052, DOI 10.1002/bies.10351; SAVINO R, 1994, EMBO J, V13, P1357, DOI 10.1002/j.1460-2075.1994.tb06389.x; Scheidegger P, 2001, BIOCHEM J, V353, P569, DOI 10.1042/0264-6021:3530569; Scheidegger P, 1999, BIOL CHEM, V380, P1449, DOI 10.1515/BC.1999.187; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; Siemeister G, 1998, P NATL ACAD SCI USA, V95, P4625, DOI 10.1073/pnas.95.8.4625; Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140; Suto K, 2005, J BIOL CHEM, V280, P2126, DOI 10.1074/jbc.M411395200; Takahashi H, 2004, J BIOL CHEM, V279, P46304, DOI 10.1074/jbc.M403687200; Tammela T, 2005, CARDIOVASC RES, V65, P550, DOI 10.1016/j.cardiores.2004.12.002; Tanaka T, 2004, BIOCHEM BIOPH RES CO, V323, P947, DOI 10.1016/j.bbrc.2004.08.191; TERMAN BI, 1991, ONCOGENE, V6, P1677; Toniatti C, 1996, EMBO J, V15, P2726, DOI 10.1002/j.1460-2075.1996.tb00633.x; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; Wise LM, 2003, J BIOL CHEM, V278, P38004, DOI 10.1074/jbc.M301194200; Yamazaki Y, 2003, J BIOL CHEM, V278, P51985, DOI 10.1074/jbc.C300454200	58	29	30	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19578	19587		10.1074/jbc.M601842200	http://dx.doi.org/10.1074/jbc.M601842200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16672228	Green Published, hybrid			2022-12-25	WOS:000238847000072
J	Tomiya, N; Narang, S; Park, J; Abdul-Rahman, B; Choi, O; Singh, S; Hiratake, J; Sakata, K; Betenbaugh, MJ; Palter, KB; Lee, YC				Tomiya, Noboru; Narang, Someet; Park, Jung; Abdul-Rahman, Badarulhisam; Choi, One; Singh, Sundeep; Hiratake, Jun; Sakata, Kanzo; Betenbaugh, Michael J.; Palter, Karen B.; Lee, Yuan C.			Purification, characterization, and cloning of a Spodoptera frugiperda Sf9 beta-N-acetylhexosaminidase that hydrolyzes terminal N-acetylglucosamine on the N-glycan core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAY-SACHS-DISEASE; ACID-SEQUENCE SIMILARITIES; ACETYL-D-GLUCOSAMINIDASE; NORMAL HUMAN-FIBROBLASTS; DROSOPHILA KC-CELLS; MANDUCA-SEXTA L; HEXOSAMINIDASE-B; INSECT CELLS; LYSOSOMAL-ENZYME; GLYCOSYL HYDROLASES	Paucimannosidic glycans are often predominant in N-glycans produced by insect cells. However, a beta-N-acetylhexosaminidase responsible for the generation of paucimannosidic glycans in lepidopteran insect cells has not been identified. We report the purification of a beta-N-acetylhexosaminidase from the culture medium of Spodoptera frugiperda Sf9 cells(Sfhex). The purified Sfhex protein showed 10 times higher activity for a terminal N-acetylglucosamine on the N-glycan core compared with tri-N-acetylchitotriose. Sfhex was found to be a homodimer of 110 kDa in solution, with a pH optimum of 5.5. With a biantennary N-glycan substrate, it exhibited a 5-fold preference for removal of the beta(1,2)-linked N-acetylglucosamine from the Man alpha(1,3) branch compared with the Man alpha(1,6) branch. We isolated two corresponding cDNA clones for Sfhex that encode proteins with > 99% amino acid identity. A phylogenetic analysis suggested that Sfhex is an ortholog of mammalian lysosomal beta-N-acetylhexosaminidases. Recombinant Sfhex expressed in Sf9 cells exhibited the same substrate specificity and pH optimum as the purified enzyme. Although a larger amount of newly synthesized Sfhex was secreted into the culture medium by Sf9 cells, a significant amount of Sfhex was also found to be intracellular. Under a confocal microscope, cellular Sfhex exhibited punctate staining throughout the cytoplasm, but did not colocalize with a Golgi marker. Because secretory glycoproteins and Sfhex are cotransported through the same secretory pathway and because Sfhex is active at the pH of the secretory compartments, this study suggests that Sfhex may play a role as a processing beta-N-acetylhexosaminidase acting on N-glycans from Sf9 cells.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; Temple Univ, Dept Biol, Philadelphia, PA 19122 USA; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan	Johns Hopkins University; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Korea Advanced Institute of Science & Technology (KAIST); Kyoto University	Tomiya, N (corresponding author), Johns Hopkins Univ, Dept Biol, 3400 Charles St, Baltimore, MD 21218 USA.	ntomiya1@jhu.edu	Park, Jung-Ki/C-1966-2011; Betenbaugh, Michael J./A-3252-2010	Betenbaugh, Michael J./0000-0002-6336-4659				Abdul-Rahman B, 2002, CARBOHYD RES, V337, P2181, DOI 10.1016/S0008-6215(02)00260-4; Ailor E, 2000, GLYCOBIOLOGY, V10, P837, DOI 10.1093/glycob/10.8.837; ALTMANN F, 1995, J BIOL CHEM, V270, P17344, DOI 10.1074/jbc.270.29.17344; Andersson SV, 2005, GLYCOBIOLOGY, V15, P211, DOI 10.1093/glycob/cwi006; Aumiller JJ, 2006, PROTEIN EXPRES PURIF, V47, P571, DOI 10.1016/j.pep.2005.11.026; BANERJEE P, 1991, BIOCHEM BIOPH RES CO, V181, P108, DOI 10.1016/S0006-291X(05)81388-9; Bartelsen O, 1998, J BIOTECHNOL, V63, P29, DOI 10.1016/S0168-1656(98)00070-4; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Boose J A, 1990, Protein Expr Purif, V1, P111, DOI 10.1016/1046-5928(90)90003-H; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Choi O, 2003, GLYCOBIOLOGY, V13, P539, DOI 10.1093/glycob/cwg071; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; Dennes A, 2005, J BIOL CHEM, V280, P12849, DOI 10.1074/jbc.M410626200; DZIADIKTURNER C, 1981, ARCH BIOCHEM BIOPHYS, V212, P546, DOI 10.1016/0003-9861(81)90398-2; DZIADIKTURNER C, 1981, INSECT BIOCHEM, V11, P215; Fabini G, 2001, J BIOL CHEM, V276, P28058, DOI 10.1074/jbc.M100573200; Filho BPD, 2002, INSECT BIOCHEM MOLEC, V32, P1723, DOI 10.1016/S0965-1748(02)00112-1; HASE S, 1986, J BIOCHEM-TOKYO, V99, P1725, DOI 10.1093/oxfordjournals.jbchem.a135649; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Hiratake J, 2003, METHOD ENZYMOL, V363, P421; Hou YM, 1996, BIOCHEMISTRY-US, V35, P3963, DOI 10.1021/bi9524575; HUBBES M, 1989, FEBS LETT, V249, P316, DOI 10.1016/0014-5793(89)80649-0; Inoue K, 2003, CARBOHYD RES, V338, P1477, DOI 10.1016/S0008-6215(03)00201-5; Kato M, 2005, BIOORGAN MED CHEM, V13, P1563, DOI 10.1016/j.bmc.2004.12.017; KIMURA S, 1974, COMP BIOCHEM PHYSIOL, V49, P345, DOI 10.1016/0305-0491(74)90169-2; KIMURA S, 1976, BIOCHIM BIOPHYS ACTA, V446, P399, DOI 10.1016/0005-2795(76)90006-4; KOGA D, 1983, COMP BIOCHEM PHYS B, V74, P515, DOI 10.1016/0305-0491(83)90220-1; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; KORNELUK RG, 1986, J BIOL CHEM, V261, P8407; KORNFELD S, 1990, BIOCHEM SOC T, V18, P367, DOI 10.1042/bst0180367; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KUBELKA V, 1994, ARCH BIOCHEM BIOPHYS, V308, P148, DOI 10.1006/abbi.1994.1021; KUROKI Y, 1995, BIOCHEM BIOPH RES CO, V212, P564, DOI 10.1006/bbrc.1995.2007; KYTZIA HJ, 1985, J BIOL CHEM, V260, P7568; Leonard R, 2006, J BIOL CHEM, V281, P4867, DOI 10.1074/jbc.M511023200; LICARI PJ, 1993, BIOTECHNOL PROGR, V9, P146, DOI 10.1021/bp00020a005; LITTLE LE, 1988, J BIOL CHEM, V263, P4288; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Luckow V. A, 1991, Recombinant DNA technology and applications., P97; LUCKOW VA, 1988, VIROLOGY, V167, P56, DOI 10.1016/0042-6822(88)90054-2; MAHURAN DJ, 1995, CLIN BIOCHEM, V28, P101, DOI 10.1016/0009-9120(95)00003-R; MAHURAN DJ, 1988, J BIOL CHEM, V263, P4612; MAHURAN DJ, 1990, J BIOL CHEM, V265, P6794; Maier T, 2003, J MOL BIOL, V328, P669, DOI 10.1016/S0022-2836(03)00311-5; MARCHINI D, 1989, INSECT BIOCHEM, V19, P549, DOI 10.1016/0020-1790(89)90020-6; Mark BL, 2003, J MOL BIOL, V327, P1093, DOI 10.1016/S0022-2836(03)00216-X; MYEROWITZ R, 1985, P NATL ACAD SCI USA, V82, P7830, DOI 10.1073/pnas.82.23.7830; NAGAMATSU Y, 1995, BIOSCI BIOTECH BIOCH, V59, P219, DOI 10.1271/bbb.59.219; NEOTE K, 1988, GENOMICS, V3, P279, DOI 10.1016/0888-7543(88)90116-4; ODOWD BF, 1985, P NATL ACAD SCI USA, V82, P1184, DOI 10.1073/pnas.82.4.1184; Okamoto Y, 1999, J BIOCHEM-TOKYO, V125, P537, DOI 10.1093/oxfordjournals.jbchem.a022318; QUON DVK, 1989, J BIOL CHEM, V264, P3380; Rouille Y, 2000, SEMIN CELL DEV BIOL, V11, P165, DOI 10.1006/scdb.2000.0168; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Schuette CG, 2001, GLYCOBIOLOGY, V11, P549, DOI 10.1093/glycob/11.7.549; SEKSEK O, 1995, J BIOL CHEM, V270, P4967, DOI 10.1074/jbc.270.10.4967; SOMMER U, 1991, ARCH INSECT BIOCHEM, V17, P3, DOI 10.1002/arch.940170103; SOMMER U, 1991, ARCH INSECT BIOCHEM, V18, P45, DOI 10.1002/arch.940180105; SONDERFELDFRESKO S, 1988, J BIOL CHEM, V263, P13463; STIRLING J, 1988, FEBS LETT, V231, P47, DOI 10.1016/0014-5793(88)80699-9; TAKAHASHI N, 1987, BIOCHEMISTRY-US, V26, P1137, DOI 10.1021/bi00378a023; Takahashi N, 1999, GLYCOCONJUGATE J, V16, P405, DOI 10.1023/A:1007082612019; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tomiya N, 2004, GLYCOCONJUGATE J, V21, P343, DOI 10.1023/B:GLYC.0000046275.28315.87; Urbe S, 1997, BIOCHEM J, V321, P65, DOI 10.1042/bj3210065; vanDie I, 1996, GLYCOBIOLOGY, V6, P157, DOI 10.1093/glycob/6.2.157; Wagner R, 1996, J VIROL, V70, P4103, DOI 10.1128/JVI.70.6.4103-4109.1996; Wendeler M, 2003, PROTEIN EXPRES PURIF, V27, P259, DOI 10.1016/S1046-5928(02)00599-5; Wu MM, 2001, J BIOL CHEM, V276, P33027, DOI 10.1074/jbc.M103917200; Zen KC, 1996, INSECT BIOCHEM MOLEC, V26, P435, DOI 10.1016/0965-1748(95)00111-5; Zhang WL, 2003, BIOCHEM J, V372, P53, DOI 10.1042/BJ20021931	75	44	46	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19545	19560		10.1074/jbc.M603312200	http://dx.doi.org/10.1074/jbc.M603312200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16684772	hybrid			2022-12-25	WOS:000238847000069
J	Bacabac, RG; Smit, TH; Van Loon, JJWA; Doulabi, BZ; Helder, M; Klein-Nulend, J				Bacabac, Rommel G.; Smit, Theo H.; Van Loon, Jack J. W. A.; Doulabi, Behrouz Zandieh; Helder, Marco; Klein-Nulend, Jenneke			Bone cell responses to high-frequency vibration stress: does the nucleus oscillate within the cytoplasm?	FASEB JOURNAL			English	Article						osteoblasts; mechanical loading; NO; prostaglandin; COX-2	NITRIC-OXIDE; SHEAR-STRESS; MECHANICAL STRAIN; LOW-MAGNITUDE; MECHANOTRANSDUCTION; EXERCISE; RATS; OSTEOPENIA	Mechanosensing by cells directs changes in bone mass and structure in response to the challenges of mechanical loading. Low-amplitude, high-frequency loading stimulates bone growth by enhancing bone formation and inhibiting disuse osteoporosis. However, how bone cells sense vibration stress is unknown. Hence, we investigated bone cell responses to vibration stress at a wide frequency range (5-100 Hz). We used NO and prostaglandin E(2) (PGE(2)) release, and COX-2 mRNA expression as parameters for bone cell response since these molecules regulate bone adaptation to mechanical loading. NO release positively correlated whereas PGE2 release negatively correlated to the maximum acceleration rate of the vibration stress. COX-2 mRNA expression increased in a frequency-dependent manner, which relates to increased NO release at high frequencies, confirming our previous results. The negatively correlated release of NO and PGE2 suggests that these signaling molecules play different roles in bone adaptation to high-frequency loading. The maximum acceleration rate is proportional to omega(3) (frequency = omega/2 pi), which is commensurate with the Stokes-Einstein relation for modeling cell nucleus motion within the cytoplasm due to vibration stress. Correlations of NO and PGE(2) with the maximum acceleration rate then relate to nucleus oscillations, providing a physical basis for cellular mechano-sensing of high-frequency loading.	Univ Amsterdam, ACTA, Dept Oral Cell Biol, NL-1081 BT Amsterdam, Netherlands; Vrije Univ Amsterdam, NL-1081 HV Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Phys & Med Technol, NL-1081 HV Amsterdam, Netherlands; Vrije Univ Amsterdam, Dutch Expt Support Ctr, NL-1081 HV Amsterdam, Netherlands	Academic Center for Dentistry Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Klein-Nulend, J (corresponding author), Univ Amsterdam, ACTA, Dept Oral Cell Biol, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	j.kleinnulend@vumc.nl	Smit, Theodoor H/C-5512-2009; van Loon, Jack JJWA/A-4250-2013; Smit, Theodoor/AAX-6657-2020; Smit, Theo/N-7534-2019; Bacabac, Rommel G./F-8605-2012	Smit, Theo/0000-0002-8906-7433; van Loon, Jack/0000-0001-9051-6016; Zandieh Doulabi, Behrouz/0000-0002-0290-3241; Bacabac, Rommel G./0000-0001-6148-6268				Bacabac RG, 2004, BIOCHEM BIOPH RES CO, V315, P823, DOI 10.1016/j.bbrc.2004.01.138; Bakker AD, 2001, J BIOMECH, V34, P671, DOI 10.1016/S0021-9290(00)00231-1; Burger EH, 1999, FASEB J, V13, pS101, DOI 10.1096/fasebj.13.9001.s101; Buttery L. D. K., 1995, Bone (New York), V17, P560, DOI 10.1016/8756-3282(96)87796-9; CHOW JWM, 1994, AM J PHYSIOL, V267, P287; Cook S D, 2001, Spine J, V1, P246, DOI 10.1016/S1529-9430(01)00086-9; Forwood MR, 1996, J BONE MINER RES, V11, P1688; Fox SW, 1996, AM J PHYSIOL-ENDOC M, V270, pE955, DOI 10.1152/ajpendo.1996.270.6.E955; Frost HM, 2003, ANAT REC PART A, V275A, P1081, DOI 10.1002/ar.a.10119; Guilak F, 2000, BIOCHEM BIOPH RES CO, V269, P781, DOI 10.1006/bbrc.2000.2360; Hara S, 2001, CALCIFIED TISSUE INT, V68, P23, DOI 10.1007/BF02684999; Honda A, 2003, J APPL PHYSIOL, V95, P1032, DOI 10.1152/japplphysiol.00781.2002; Huiskes R, 2000, NATURE, V405, P704, DOI 10.1038/35015116; JONES DB, 1991, BIOMATERIALS, V12, P101, DOI 10.1016/0142-9612(91)90186-E; Kamm RD, 2000, ASME INT C MECH BIOL, V242, P1; Karcher H, 2003, BIOPHYS J, V85, P3336, DOI 10.1016/S0006-3495(03)74753-5; Klein-Nulend J, 1998, BIOCHEM BIOPH RES CO, V250, P108, DOI 10.1006/bbrc.1998.9270; KleinNulend J, 1995, BIOCHEM BIOPH RES CO, V217, P640, DOI 10.1006/bbrc.1995.2822; Kodama HA., 1981, JPN J ORAL BIOL, V23, P899, DOI DOI 10.2330/JORALBIOSCI1965.23.899; Li J, 2002, CALCIFIED TISSUE INT, V70, P320, DOI 10.1007/s00223-001-1025-y; Mancini L, 1998, BIOCHEM BIOPH RES CO, V243, P785, DOI 10.1006/bbrc.1998.8175; Midura RJ, 2005, MED ENG PHYS, V27, P285, DOI 10.1016/j.medengphy.2004.12.014; Nagano T, 1999, LUMINESCENCE, V14, P283, DOI 10.1002/(SICI)1522-7243(199911/12)14:6<283::AID-BIO572>3.0.CO;2-G; Pitsillides AA, 1995, FASEB J, V9, P1614, DOI 10.1096/fasebj.9.15.8529841; Rubin C, 2001, FASEB J, V15, P2225, DOI 10.1096/fj.01-0166com; Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122; RUBIN CT, 1984, J BONE JOINT SURG AM, V66A, P397, DOI 10.2106/00004623-198466030-00012; Rubin CT, 2001, DRUG DISCOV TODAY, V6, P848, DOI 10.1016/S1359-6446(01)01872-4; Taaffe DR, 1997, J BONE MINER RES, V12, P255, DOI 10.1359/jbmr.1997.12.2.255; Tanaka SM, 2003, J BIOMECH, V36, P73, DOI 10.1016/S0021-9290(02)00245-2; Turner CH, 1996, AM J PHYSIOL-ENDOC M, V270, pE634, DOI 10.1152/ajpendo.1996.270.4.E634; TURNER CH, 1995, AM J PHYSIOL, V269, P438; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Warden SJ, 2004, BONE, V34, P261, DOI 10.1016/j.bone.2003.11.011; WEBSTER SSJ, 2001, BONE MECH HDB, P68; Wolff J, 1892, GESETZ TRANSFORMATIO	36	93	102	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					858	864		10.1096/fj.05-4966.com	http://dx.doi.org/10.1096/fj.05-4966.com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675843				2022-12-25	WOS:000240157700008
J	Martinelli, S; Kostylina, G; Niggli, V; Baumann, C; Fey, MF; Wendel, HG; Lowe, SW; Yousefi, S; Simon, HU				Martinelli, S.; Kostylina, G.; Niggli, V.; Baumann, C.; Fey, M. F.; Wendel, H-G; Lowe, S. W.; Yousefi, S.; Simon, H-U			Targeting survivin via PI3K but not c-akt/PKB by anticancer drugs in immature neutrophils	ONCOGENE			English	Article						apoptosis; cancer; chemotherapy; myelosuppression; neutrophils; survivin	CANCER-CELLS; INDUCED APOPTOSIS; ACTIVATION; PATHWAY; GENE; AKT; TRANSCRIPTION; INHIBITION; CYCLE; DEATH	Myelosuppression is the most common unwanted side effect associated with the administration of anticancer drugs, and infections remain a common cause of death in chemotherapy-treated patients. Several mechanisms of the cytotoxicity of these drugs have been proposed and may synergistically operate in a given cell. Survivin expression has been associated with cancer, but recent reports suggest that this molecule is also expressed in several immature and mature hematopoietic cells. Here, we provide evidence that treatment of immature neutrophils with anticancer drugs reduced endogenous survivin levels causing apoptosis. The anticancer drugs did not directly target survivin, instead they blocked the activity of phosphatidylinositol-3-OH kinase, which regulated survivin expression and apoptosis in these cells. Strikingly, and in contrast to other cells, this pathway did not involve the serine/threonine kinase c-akt/PKB. Moreover, in combination with anticancer drug therapy, rapamycin did not induce increased myelosuppression in an experimental lymphoma mouse model. These data suggest that drugs that block either c-akt/PKB or signaling molecules located distal to c-akt/PKB may preferentially induce apoptosis of cancer cells as they exhibit no cytotoxicity for immature neutrophils.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland; Univ Bern, Dept Pathol, CH-3010 Bern, Switzerland; Univ Bern, Inselspital, Inst Med Oncol, CH-3010 Bern, Switzerland; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	University of Bern; University of Bern; University of Bern; University Hospital of Bern; Cold Spring Harbor Laboratory	Simon, HU (corresponding author), Univ Bern, Dept Pharmacol, Friedbuhlstr 49, CH-3010 Bern, Switzerland.	hus@pki.unibe.ch	Yousefi, Shida/L-9689-2016; Yousefi, Shida/AAU-7986-2020; Simon, Hans-Uwe/AAU-5079-2020; Simon, Hans-Uwe/AAU-7410-2020	Yousefi, Shida/0000-0002-9855-4305; Yousefi, Shida/0000-0002-9855-4305; Simon, Hans-Uwe/0000-0002-9404-7736				Altznauer F, 2004, J EXP MED, V199, P1343, DOI 10.1084/jem.20032033; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Baumann R, 2003, FASEB J, V17, P2221, DOI 10.1096/fj.03-0110com; Belyanskaya LL, 2005, INT J CANCER, V117, P755, DOI 10.1002/ijc.21242; Beuvink I, 2005, CELL, V120, P747, DOI 10.1016/j.cell.2004.12.040; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Bruno A, 2005, J IMMUNOL, V174, P8090, DOI 10.4049/jimmunol.174.12.8090; BURERING BM, 1995, NATURE, V376, P599; Carter BZ, 2001, BLOOD, V97, P2784, DOI 10.1182/blood.V97.9.2784; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Conus S, 2005, J ALLERGY CLIN IMMUN, V116, P1228, DOI 10.1016/j.jaci.2005.09.003; Cowburn AS, 2002, BLOOD, V100, P2607, DOI 10.1182/blood-2001-11-0122; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Dale D, 2003, SEMIN ONCOL, V30, P3, DOI 10.1016/S0093-7754(03)00326-9; Daly C, 2004, GENE DEV, V18, P1060, DOI 10.1101/gad.1189704; Debatin KM, 2004, CANCER IMMUNOL IMMUN, V53, P153, DOI 10.1007/s00262-003-0474-8; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Fornaro M, 2003, J BIOL CHEM, V278, P50402, DOI 10.1074/jbc.M307627200; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Fukuda S, 2004, BLOOD, V103, P120, DOI 10.1182/blood-2003-05-1756; Fukuda S, 2002, BLOOD, V100, P2463, DOI 10.1182/blood.V100.7.2463; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Herr I, 2000, ONCOGENE, V19, P4255, DOI 10.1038/sj.onc.1203776; Hersey P, 2003, J CELL PHYSIOL, V196, P9, DOI 10.1002/jcp.10256; Kozikowski AP, 2003, J AM CHEM SOC, V125, P1144, DOI 10.1021/ja0285159; Martinelli S, 2004, J BIOL CHEM, V279, P44123, DOI 10.1074/jbc.M405883200; McCormick F, 2004, NATURE, V428, P267, DOI 10.1038/428267a; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Murphy BM, 2003, J EXP MED, V197, P625, DOI 10.1084/jem.20021862; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Sakai A, 1998, BLOOD, V92, P3410, DOI 10.1182/blood.V92.9.3410.421a06_3410_3415; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Scheel-Toellner D, 2002, EUR J IMMUNOL, V32, P486, DOI 10.1002/1521-4141(200202)32:2<486::AID-IMMU486>3.0.CO;2-U; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Straka C, 2004, BLOOD, V104, P1989, DOI 10.1182/blood-2004-02-0628; Suzuki J, 1997, ONCOGENE, V15, P1689, DOI 10.1038/sj.onc.1201333; Uruno A, 2005, CIRCULATION, V112, P727, DOI 10.1161/CIRCULATIONAHA.104.500959; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vong QP, 2005, SCIENCE, V310, P1499, DOI 10.1126/science.1120160; Wang Shulin, 2004, Cancer Treat Res, V119, P175; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Zangemeister-Wittke U, 2004, CELL CYCLE, V3, P1121	48	13	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	52					6915	6923		10.1038/sj.onc.1209692	http://dx.doi.org/10.1038/sj.onc.1209692			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16715127				2022-12-25	WOS:000241732300002
J	Wang, X; Zhou, YX; Qiao, W; Tominaga, Y; Ouchi, M; Ouchi, T; Deng, CX				Wang, X.; Zhou, Y-X; Qiao, W.; Tominaga, Y.; Ouchi, M.; Ouchi, T.; Deng, C-X			Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation	ONCOGENE			English	Article						cyclin D1; mTOR; centrosome; chromosome tetraploidization; premature sister chromatid segregation	SPINDLE ASSEMBLY CHECKPOINT; BREAST-CANCER; CENTROSOME AMPLIFICATION; MITOTIC SPINDLE; CHROMOSOME SEGREGATION; CELL-CYCLE; COLORECTAL CANCERS; AMPLIFIED KINASE; MAMMALIAN-CELLS; PROTEIN-KINASE	Aurora-A/ STK15/ BTAK, which encodes a centrosome-associated kinase, is amplified and overexpressed in multiple types of human tumors, including breast cancer. However, the causal relationship between overexpression of Aurora-A and tumorigenesis has not been fully established due to contradictory data obtained from different experimental systems. To investigate this, we generated a mouse strain that carries an MMTV-Aurora-A transgene. We showed that all the MMTV-Aurora-A mice displayed enhanced branch morphogenesis in the mammary gland and about 40% developed mammary tumors at 20 months of age. The tumor incidence was significantly increased in a p53(+/-) mutation background with about 70% MMTV-Aurora-A; p53(+/-) animals developed tumors at 18 months of age. Of note, overexpression of Aurora-A led to genetic instability, characterized by centrosome amplification, chromosome tetraploidization and premature sister chromatid segregation, at stages prior to tumor formation. Most notably, the severe chromosomal abnormality did not cause cell death owing to the activation of AKT pathway, including elevated levels of phosphorylated AKT and mammalian target of rapamycin, and nuclear accumulation of cyclin D1, which enabled continuous proliferation of the tetraploid cells. These data establish Aurora-A as an oncogene that causes malignant transformation through inducing genetic instability and activating oncogenic pathways such as AKT and its downstream signaling.	NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; NYU, Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Icahn School of Medicine at Mount Sinai; New York University	Deng, CX (corresponding author), NIDDK, Genet Dev & Dis Branch, NIH, 10-9N105,10 Ctr Dr, Bethesda, MD 20892 USA.	chuxiad@bdg10.niddk.nih.gov	deng, chuxia/N-6713-2016		Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056001, Z01DK056001, ZIADK056011, Z01DK056011, Z01DK056007] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Andreassen PR, 2003, MUTAT RES-FUND MOL M, V532, P245, DOI 10.1016/j.mrfmmm.2003.08.020; Aust DE, 2004, SCAND J GASTROENTERO, V39, P766, DOI 10.1080/00365520410003191; Berdnik D, 2002, CURR BIOL, V12, P640, DOI 10.1016/S0960-9822(02)00766-2; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Chiba S, 2000, EXP CELL RES, V258, P310, DOI 10.1006/excr.2000.4916; Colditz GA, 1998, JNCI-J NATL CANCER I, V90, P814, DOI 10.1093/jnci/90.11.814; Crane R, 2004, BIOL CELL, V96, P215, DOI 10.1016/j.biolcel.2003.09.008; Deng Chu-Xia, 2004, Methods Mol Biol, V280, P185; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Ducat D, 2004, EXP CELL RES, V301, P60, DOI 10.1016/j.yexcr.2004.08.016; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Gadducci A, 2005, GYNECOL ENDOCRINOL, V20, P343, DOI 10.1080/09513590500128492; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Gotoh J, 2003, CARCINOGENESIS, V24, P435, DOI 10.1093/carcin/24.3.435; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hu W, 2005, ONCOL RES, V15, P49, DOI 10.3727/096504005775082101; Kamada K, 2004, ONCOL REP, V12, P593; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Katayama Hiroshi, 2003, Cancer and Metastasis Reviews, V22, P451, DOI 10.1023/A:1023789416385; Kufer TA, 2003, CHROMOSOMA, V112, P159, DOI 10.1007/s00412-003-0265-1; Liu Q, 2004, J BIOL CHEM, V279, P18210, DOI 10.1074/jbc.M400678200; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Mita Monica M, 2003, Clin Breast Cancer, V4, P126, DOI 10.3816/CBC.2003.n.018; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Oikawa T, 2005, MOL CELL BIOL, V25, P4046, DOI 10.1128/MCB.25.10.4046-4061.2005; Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200; Prall OWJ, 1998, J STEROID BIOCHEM, V65, P169, DOI 10.1016/S0960-0760(98)00021-1; Satyamoorthy K, 2001, CANCER RES, V61, P7318; Sen S, 2002, JNCI-J NATL CANCER I, V94, P1320; Shah A, 2005, CLIN CANCER RES, V11, P2930, DOI 10.1158/1078-0432.CCR-04-1385; Stenoien DL, 2003, CELL MOTIL CYTOSKEL, V55, P134, DOI 10.1002/cm.10120; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Tanaka E, 2005, CLIN CANCER RES, V11, P1827, DOI 10.1158/1078-0432.CCR-04-1627; Tanaka T, 1999, CANCER RES, V59, P2041; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yoon DS, 2002, AM J PATHOL, V161, P391, DOI 10.1016/S0002-9440(10)64194-6; Zhang DW, 2004, ONCOGENE, V23, P8720, DOI 10.1038/sj.onc.1208153; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	51	192	197	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	54					7148	7158		10.1038/sj.onc.1209707	http://dx.doi.org/10.1038/sj.onc.1209707			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16715125				2022-12-25	WOS:000242046900004
J	Macip, S; Kosoy, A; Lee, SW; O'Connell, MJ; Aaronson, SA				Macip, S.; Kosoy, A.; Lee, S. W.; O'Connell, M. J.; Aaronson, S. A.			Oxidative stress induces a prolonged but reversible arrest in p53-null cancer cells, involving a Chk1-dependent G(2) checkpoint	ONCOGENE			English	Article						senescence; p53; ROS; Chk1; checkpoints	DNA-DAMAGE CHECKPOINT; LACKING FUNCTIONAL P53; STRAND BREAK REPAIR; HUMAN FIBROBLASTS; TUMOR-CELLS; REPLICATIVE SENESCENCE; GROWTH ARREST; IN-VIVO; PREMATURE SENESCENCE; CELLULAR SENESCENCE	Reactive oxygen species (ROS), the principal mediators of oxidative stress, induce responses suchas apoptosis or permanent growth arrest/senescence in normal cells. Moreover, p53 activation itself contributes to ROS accumulation. Here we show that treatment of p53-null cancer cells with sublethal concentrations of ROS triggered an arrest with some morphological similarities to cellular senescence. Different from a classical senescent arrest in G(1), the ROS-induced arrest was predominantly in the G(2) phase of the cell cycle, and its establishment depended at least in part on an intact Chk1-dependent checkpoint. Chk1 remained phosphorylated only during the repair of double strand DNA breaks, after which Chk1 was inactivated, the G2 arrest was suppressed, and some cells recovered their ability to proliferate. Inhibition of Chk1 by an RNAi approach resulted in an increase in cell death in p53-null cells, showing that the Chk1-dependent G2 checkpoint protected cells that lacked a functional p53 pathway from oxidative stress. It has been proposed that the induction of a senescent-like phenotype by antineoplastic agents can contribute therapeutic efficacy. Our results indicate that oxidative stress-induced growth arrest of p53-null tumor cells cannot be equated with effective therapy owing to its reversibility and supports the concept that targeting Chk1 may enhance the effects of DNA-damaging agents on cancer progression in such tumors.	Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Harvard Cutaneous Biol Res Ctr, Charlestown, MA USA	Icahn School of Medicine at Mount Sinai; Harvard University; Massachusetts General Hospital	Aaronson, SA (corresponding author), Mt Sinai Sch Med, Dept Oncol Sci, 1 Gustave L Levy Pl,Box 1130, New York, NY 10029 USA.	stuart.aaronson@mssm.edu	Macip, Salvador/K-5985-2014; Macip, Salvador/P-4233-2019; Macip, Salvador/S-6358-2019	Macip, Salvador/0000-0003-1963-8840; 	NCI NIH HHS [CA80058, CA78356, CA100076, CA82211, CA85214] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082211, R01CA078356, R01CA100076, R56CA100076, R01CA085214] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Aubry JP, 1999, CYTOMETRY, V37, P197, DOI 10.1002/(SICI)1097-0320(19991101)37:3<197::AID-CYTO6>3.0.CO;2-L; Bai JX, 2003, J BIOL CHEM, V278, P4660, DOI 10.1074/jbc.M206273200; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Bakondi E, 2003, J INVEST DERMATOL, V121, P88, DOI 10.1046/j.1523-1747.2003.12329.x; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkowiak D, 1999, CYTOMETRY, V37, P191, DOI 10.1002/(SICI)1097-0320(19991101)37:3<191::AID-CYTO5>3.0.CO;2-U; Barzilai A, 2004, DNA REPAIR, V3, P1109, DOI 10.1016/j.dnarep.2004.03.002; Caldini R, 1998, MECH AGEING DEV, V105, P137, DOI 10.1016/S0047-6374(98)00085-2; Campisi J, 2001, EXP GERONTOL, V36, P1619, DOI 10.1016/S0531-5565(01)00160-7; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chang BD, 1999, CANCER RES, V59, P3761; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Chiu CC, 2005, CANCER LETT, V223, P249, DOI 10.1016/j.canlet.2004.10.049; CLOPTON DA, 1995, BIOCHEM BIOPH RES CO, V210, P189, DOI 10.1006/bbrc.1995.1645; Curman D, 2001, J BIOL CHEM, V276, P17914, DOI 10.1074/jbc.M100728200; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; de Magalhaes JP, 2004, EXP GERONTOL, V39, P1379, DOI 10.1016/j.exger.2004.06.004; de Vries HI, 2005, J CELL SCI, V118, P1833, DOI 10.1242/jcs.02309; Dean RT, 1997, BIOCHEM J, V324, P1; den Elzen N, 2004, CELL CYCLE, V3, P529; den Elzen NR, 2004, EMBO J, V23, P908, DOI 10.1038/sj.emboj.7600105; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dumont P, 2000, FREE RADICAL BIO MED, V28, P361, DOI 10.1016/S0891-5849(99)00249-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang L, 1999, ONCOGENE, V18, P2789, DOI 10.1038/sj.onc.1202615; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Foster ER, 2005, FEBS J, V272, P3231, DOI 10.1111/j.1742-4658.2005.04741.x; Garber K, 2005, J NATL CANCER I, V97, P1026, DOI 10.1093/jnci/dji224; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hammond EM, 2003, J BIOL CHEM, V278, P12207, DOI 10.1074/jbc.M212360200; Hampton MB, 1998, TOXICOL LETT, V103, P355, DOI 10.1016/S0378-4274(98)00333-6; Hara E, 1996, MOL CELL BIOL, V16, P859; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Ho CC, 2005, EXP CELL RES, V304, P1, DOI 10.1016/j.yexcr.2004.10.016; Hwang ES, 2002, MECH AGEING DEV, V123, P1681, DOI 10.1016/S0047-6374(02)00102-1; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jackson JR, 2000, CANCER RES, V60, P566; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN WK, 1995, CANCER RES, V55, P7; Koniaras K, 2001, ONCOGENE, V20, P7453, DOI 10.1038/sj.onc.1204942; Latif C, 2004, J CELL SCI, V117, P3489, DOI 10.1242/jcs.01204; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu QH, 2000, GENE DEV, V14, P1448; Long H, 2003, CELL PHYSIOL BIOCHEM, V13, P401, DOI 10.1159/000075128; Macip S, 2003, MOL CELL BIOL, V23, P8576, DOI 10.1128/MCB.23.23.8576-8585.2003; Mason DX, 2004, ONCOGENE, V23, P9238, DOI 10.1038/sj.onc.1208172; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; O'Connell MJ, 2005, J CELL SCI, V118, P1, DOI 10.1242/jcs.01626; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Renschler MF, 2004, EUR J CANCER, V40, P1934, DOI 10.1016/j.ejca.2004.02.031; RILEY PA, 1994, INT J RADIAT BIOL, V65, P27, DOI 10.1080/09553009414550041; Roberson RS, 2005, CANCER RES, V65, P2795, DOI 10.1158/0008-5472.CAN-04-1270; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Roninson IB, 2003, CANCER RES, V63, P2705; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shackelford RE, 2001, J BIOL CHEM, V276, P21951, DOI 10.1074/jbc.M011303200; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; te Poele RH, 2002, CANCER RES, V62, P1876; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	81	32	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6037	6047		10.1038/sj.onc.1209629	http://dx.doi.org/10.1038/sj.onc.1209629			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16652144				2022-12-25	WOS:000241101200001
J	Peter, M; Rosty, C; Couturier, J; Radvanyi, F; Teshima, H; Sastre-Garau, X				Peter, M.; Rosty, C.; Couturier, J.; Radvanyi, F.; Teshima, H.; Sastre-Garau, X.			MYC activation associated with the integration of HPV DNA at the MYC locus in genital tumors	ONCOGENE			English	Article						MYC; HPV; integration; insertional mutagenesis; cervix	HUMAN-PAPILLOMAVIRUS TYPE-16; C-MYC; CERVICAL CARCINOMAS; HUMAN GENOME; PHYSICAL STATE; RAS GENE; SITES; AMPLIFICATION; SEQUENCES; ONCOGENES	To determine whether integration of human papillomavirus (HPV) DNA sequences could lead to the deregulation of genes implied in oncogenesis, we analysed the HPV integration sites in a series of nine cell lines derived from invasive genital carcinomas. Using in situ hybridization, HPV16 or 18 sequences were found at chromosome band 8q24, the localization of MYC, in IC1, IC2, IC3, IC6 and CAC-1 cells and at other sites in IC4, IC5, IC7 and IC8 cells. We then localized viral sequences at the molecular level and searched for alterations of MYC structure and expression in these cells. MYC genomic status and viral integration sites were also analysed in primary tumors from which IC1, IC2, IC3 and IC6 cells were derived. In IC1, IC2 and CAC-1 cells, HPV DNA was located within 58 kb of MYC, downstream, upstream, or within MYC. In IC3 and IC6 cells, HPV DNA was located 400-500 kb upstream of MYC. Amplification studies showed that, in IC1, IC2 and IC3, viral and MYC sequences were coamplified in an amplicon between less than 50 and 800 kb in size. MYC amplification was also observed in primary tumors, indicating that this genetic alteration, together with viral insertion at the MYC locus, had already taken place in vivo. MYC was not amplified in the other cell lines. MYC mRNA and protein overexpression was observed in the five cell lines in which the HPV DNA was inserted close to the MYC locus, but in none of the lines where the insertion had occurred at other sites. MYC activation, triggered by the insertion of HPV DNA sequences, can be an important genetic event in cervical oncogenesis.	Inst Curie, Serv Pathol, Dept Biol Tumeurs, F-75248 Paris 05, France; Inst Curie, UMR 144, CNRS, F-75248 Paris 05, France; Oita Prefectural Hosp, Dept Obstet & Gynaecol, Oita, Japan	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Sastre-Garau, X (corresponding author), Inst Curie, Serv Pathol, Dept Biol Tumeurs, 26 Rue Ulm, F-75248 Paris 05, France.	xavier.sastre@curie.net	Rosty, Christophe/F-1796-2010	Radvanyi, Francois/0000-0002-5696-6424; Rosty, Christophe/0000-0001-7671-2651; Sastre-Garau, Xavier/0000-0001-5992-2083				Alonso L, 2003, P NATL ACAD SCI USA, V100, P11830, DOI 10.1073/pnas.1734203100; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Bouallaga I, 2000, EMBO REP, V1, P422, DOI 10.1093/embo-reports/kvd091; Brink AATP, 2002, CANCER GENET CYTOGEN, V134, P145, DOI 10.1016/S0165-4608(01)00620-3; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; COUTURIER J, 1991, J VIROL, V65, P4534, DOI 10.1128/JVI.65.8.4534-4538.1991; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; Dang CV, 1999, MOL CELL BIOL, V19, P1; Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; Ferber MJ, 2003, ONCOGENE, V22, P7233, DOI 10.1038/sj.onc.1207006; Ferber MJ, 2003, ONCOGENE, V22, P3813, DOI 10.1038/sj.onc.1206528; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; Frye M, 2003, DEVELOPMENT, V130, P2793, DOI 10.1242/dev.00462; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HAYAKAWA O, 1988, Sapporo Medical Journal, V57, P603; HENGLEIN B, 1989, MOL CELL BIOL, V9, P2105, DOI 10.1128/MCB.9.5.2105; Herrick J, 2005, CANCER RES, V65, P1174, DOI 10.1158/0008-5472.CAN-04-2802; HORI T, 1991, JPN J CANCER RES, V82, P371, DOI 10.1111/j.1349-7006.1991.tb01857.x; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; JIKO K, 1994, INT J CANCER, V59, P601, DOI 10.1002/ijc.2910590505; JOOS S, 1992, CANCER RES, V52, P6547; Kalantari M, 2001, DIAGN MOL PATHOL, V10, P46, DOI 10.1097/00019606-200103000-00008; Klaes R, 1999, CANCER RES, V59, P6132; Klimov E, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-24; KRAUS I, 2005, 22 INT PAP C CLIN WO, V23, P157; LAZO PA, 1989, CANCER RES, V49, P4305; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lombard I, 1998, J CLIN ONCOL, V16, P2613, DOI 10.1200/JCO.1998.16.8.2613; Luft F, 2001, INT J CANCER, V92, P9, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1144>3.0.CO;2-L; Munger K, 2004, J VIROL, V78, P11451, DOI 10.1128/JVI.78.21.11451-11460.2004; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; NURNBERG W, 1995, CANCER RES, V55, P4432; PEI XF, 1993, VIROLOGY, V196, P855, DOI 10.1006/viro.1993.1546; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; POPESCU NC, 1987, CYTOGENET CELL GENET, V44, P58, DOI 10.1159/000132342; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; RIOU G, 1987, LANCET, V1, P761; RIOU G, 1988, ONCOGENE, V3, P329; Roix JJ, 2003, NAT GENET, V34, P287, DOI 10.1038/ng1177; ROSTY C, 2005, ONCOGENE; Rosty C, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-15; Sastre-Garau X, 2000, J GEN VIROL, V81, P1983, DOI 10.1099/0022-1317-81-8-1983; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Thorland EC, 2003, ONCOGENE, V22, P1225, DOI 10.1038/sj.onc.1206170; Thorland EC, 2000, CANCER RES, V60, P5916; Veldman T, 2003, P NATL ACAD SCI USA, V100, P8211, DOI 10.1073/pnas.1435900100; Waikel RL, 2001, NAT GENET, V28, P165, DOI 10.1038/88889; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wentzensen N, 2004, CANCER RES, V64, P3878, DOI 10.1158/0008-5472.CAN-04-0009; Wentzensen N, 2002, ONCOGENE, V21, P419, DOI 10.1038/sj.onc.1205104; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; ZEIDLER R, 1994, GENE CHROMOSOME CANC, V9, P282, DOI 10.1002/gcc.2870090408; Zhang A, 2002, INT J CANCER, V101, P427, DOI 10.1002/ijc.10627; Ziegert C, 2003, ONCOGENE, V22, P3977, DOI 10.1038/sj.onc.1206629	63	97	110	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2006	25	44					5985	5993		10.1038/sj.onc.1209625	http://dx.doi.org/10.1038/sj.onc.1209625			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16682952				2022-12-25	WOS:000240826300007
J	Shimura, T; Toyoshima, M; Adiga, SK; Kunoh, T; Nagai, H; Shimizu, N; Inoue, M; Niwa, O				Shimura, T.; Toyoshima, M.; Adiga, S. K.; Kunoh, T.; Nagai, H.; Shimizu, N.; Inoue, M.; Niwa, O.			Suppression of replication fork progression in low-dose-specic p53-dependent S-phase DNA damage checkpoint	ONCOGENE			English	Article						p53; PCNA; ATM; S-phase DNA damage checkpoint; replication fork progression	CELL NUCLEAR ANTIGEN; ATM GENE-PRODUCT; REPLICON INITIATION; IONIZING-RADIATION; BLM HELICASE; P53; PROTEIN; REPAIR; ACTIVATION; DYNAMICS	The S-phase DNA damage checkpoint is activated by DNA damage to delay DNA synthesis allowing time to resolve the replication block. We previously discovered the p53-dependent S-phase DNA damage checkpoint in mouse zygotes fertilized with irradiated sperm. Here, we report that the same p53 dependency holds in mouse embryonic fibroblasts (MEFs) at low doses of irradiation. DNA synthesis in p53 wild-type (WT) MEFs was suppressed in a biphasic manner in which a sharp decrease below 2.5 Gy was followed by a more moderate decrease up to 10 Gy. In contrast, p53-/- MEFs exhibited radioresistant DNA synthesis below 2.5 Gy whereas the cells retained the moderate suppression above 5 Gy. DNA fiber analysis revealed that 1 Gy irradiation suppressed replication fork progression in p53 WT MEFs, but not in p53-/- MEFs. Proliferating cell nuclear antigen (PCNA), clamp loader of DNA polymerase, was phosphorylated in WT MEFs after 1 Gy irradiation and redistributed to form foci in the nuclei. In contrast, PCNA was not phosphorylated and dissociated from chromatin in 1 Gy-irradiated p53-/- MEFs. These results demonstrate that the novel low-dosespecific p53-dependent S-phase DNA damage checkpoint is likely to regulate the replication fork movement through phosphorylation of PCNA.	Kyoto Univ, Dept Late Effect Studies, Radiat Biol Ctr, Sakyo Ku, Kyoto, Japan; Kyoto Univ, Dept Radiat Syst Biol, Radiat Biol Ctr, Sakyo Ku, Kyoto, Japan; Hiroshima Univ, Grad Sch Biosphere Sci, Hiroshima, Japan; Kanazawa Med Univ, Med Res Inst, Uchinada, Ishikawa 92002, Japan	Kyoto University; Kyoto University; Hiroshima University; Kanazawa Medical University	Shimura, T (corresponding author), NCI, Mol Pharmacol Lab, Canc Res Ctr, NIH Bldg 37,Rm 5056 37 Convent Dr, Bethesda, MD 20892 USA.	shimurat@mail.nih.gov	Kunoh, Tatsuki/AAQ-7881-2021; Kunoh, Tatsuki/K-7824-2019; Adiga, Satish Kumar/AAU-4386-2020	Kunoh, Tatsuki/0000-0002-8423-2903; Adiga, Satish Kumar/0000-0002-2897-4697				Agarwal ML, 1998, P NATL ACAD SCI USA, V95, P14775, DOI 10.1073/pnas.95.25.14775; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Balajee AS, 2001, NUCLEIC ACIDS RES, V29, P1341, DOI 10.1093/nar/29.6.1341; Boddy MN, 2001, CURR BIOL, V11, pR953, DOI 10.1016/S0960-9822(01)00572-3; Bohnke A, 2004, INT J RADIAT BIOL, V80, P53, DOI 10.1080/09553000310001642902; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; Brown KD, 2003, NAT GENET, V33, P80, DOI 10.1038/ng1052; Buscemi G, 2004, ONCOGENE, V23, P7691, DOI 10.1038/sj.onc.1207986; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Dimitrova DS, 1999, MOL CELL, V4, P983, DOI 10.1016/S1097-2765(00)80227-0; ELKIND MM, 1959, NATURE, V184, P1293, DOI 10.1038/1841293a0; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Henry-Mowatt J, 2003, MOL CELL, V11, P1109, DOI 10.1016/S1097-2765(03)00132-1; Hu T, 1999, MUTAT RES-FUND MOL M, V426, P51, DOI 10.1016/S0027-5107(99)00077-9; Jackson DA, 1998, J CELL BIOL, V140, P1285, DOI 10.1083/jcb.140.6.1285; Janz C, 2002, ONCOGENE, V21, P5929, DOI 10.1038/sj.onc.1205757; Karmakar P, 2001, MUTAGENESIS, V16, P225, DOI 10.1093/mutage/16.3.225; KEARSEY JM, 1995, SCIENCE, V270, P1004; Kim JM, 2002, EMBO J, V21, P2168, DOI 10.1093/emboj/21.9.2168; Laderoute MP, 1996, ANTICANCER RES, V16, P2825; Larner JM, 1999, NUCLEIC ACIDS RES, V27, P803, DOI 10.1093/nar/27.3.803; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ma H, 1998, J CELL BIOL, V143, P1415, DOI 10.1083/jcb.143.6.1415; MAKINO F, 1975, RADIAT RES, V62, P37, DOI 10.2307/3574182; Merrick CJ, 2004, J BIOL CHEM, V279, P20067, DOI 10.1074/jbc.M400022200; Miura M, 1996, RADIAT RES, V145, P75, DOI 10.2307/3579198; Nayak BK, 2002, ONCOGENE, V21, P7226, DOI 10.1038/sj.onc.1205889; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAINTER RB, 1975, RADIAT RES, V64, P648, DOI 10.2307/3574254; PAINTER RB, 1976, BIOCHIM BIOPHYS ACTA, V418, P146, DOI 10.1016/0005-2787(76)90063-0; Pilch DR, 2003, BIOCHEM CELL BIOL, V81, P123, DOI 10.1139/o03-042; PROSPERI E, 1993, EXP CELL RES, V205, P320, DOI 10.1006/excr.1993.1092; Rowley R, 1999, INT J RADIAT BIOL, V75, P267, DOI 10.1080/095530099140456; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Savio M, 1998, CARCINOGENESIS, V19, P591, DOI 10.1093/carcin/19.4.591; Sedelnikova OA, 2003, CANCER BIOL THER, V2, P233; Sengupta S, 2004, J CELL BIOL, V166, P801, DOI 10.1083/jcb.200405128; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Shimada K, 2002, GENE DEV, V16, P3236, DOI 10.1101/gad.239802; Shimura T, 2002, MOL CELL BIOL, V22, P2220, DOI 10.1128/MCB.22.7.2220-2228.2002; Shimura T, 2002, RADIAT RES, V158, P735, DOI 10.1667/0033-7587(2002)158[0735:TNSMOT]2.0.CO;2; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Solomon DA, 2004, J CELL BIOL, V166, P455, DOI 10.1083/jcb.200312048; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Storer RD, 1997, MUTAT RES-FUND MOL M, V373, P157, DOI 10.1016/S0027-5107(96)00227-8; Toyoshima M, 2005, ONCOGENE, V24, P3229, DOI 10.1038/sj.onc.1208514; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WATANABE I, 1974, RADIAT RES, V58, P541, DOI 10.2307/3573922; Xie GF, 1998, ONCOGENE, V16, P721, DOI 10.1038/sj.onc.1201793	57	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2006	25	44					5921	5932		10.1038/sj.onc.1209624	http://dx.doi.org/10.1038/sj.onc.1209624			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16682953				2022-12-25	WOS:000240826300001
J	Tauchi, T; Shin-ya, K; Sashida, G; Sumi, M; Okabe, S; Ohyashiki, JH; Ohyashiki, K				Tauchi, T.; Shin-ya, K.; Sashida, G.; Sumi, M.; Okabe, S.; Ohyashiki, J. H.; Ohyashiki, K.			Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia	ONCOGENE			English	Article						telomerase inhibition; p38 MAP kinase; MKK3/6; apoptosis; in vivo study	TYROSINE KINASE INHIBITOR; DNA; SENESCENCE; TARGET; CELLS; INVOLVEMENT; ARREST; PARP-2	The telomerase complex is responsible for telomere maintenance and represents a promising neoplasia therapeutic target. Recently, we have demonstrated that treatment with a G-quadruplex-interactive agent, telomestatin reproducibly inhibited telomerase activity in the BCR-ABL-positive leukemic cell lines. In the present study, we investigated the mechanisms of apoptosis induced by telomerase inhibition in acute leukemia. We have found the activation of caspase-3 and poly-(ADPribose) polymerase in telomestatin-treated U937 cells (PD20) and dominant-negative DN-hTERT-expressing U937 cells (PD25). Activation of p38 mitogen-activated protein (MAP) kinase and MKK3/6 was also found in telomestatin-treated U937 cells (PD20) and dominant-negative DN-hTERT-expressing U937 cells (PD25); however, activation of JNK and ASK1 was not detected in these cells. To examine the effect of p38 MAP kinase inhibition on growth properties and apoptosis in telomer-ase-inhibited cells, we cultured DN-hTERT-expressing U937 cells with or without SB203580. Dominant-negative-hTERT-expressing U937 cells stopped proliferation on PD25; however, a significant increase in growth rate was observed in the presence of SB203580. Treatment of SB203580 also reduced the induction of apoptosis in DN-hTERT-expressing U937 cells (PD25). These results suggest that p38 MAP kinase has a critical role for the induction of apoptosis in telomerase-inhibited leukemia cells. Further, we evaluated the effect of telomestatin on the growth of U937 cells in xenograft mouse model. Systemic intraperitoneal administration of telomestatin in U937 xenografts decreased tumor telomerase levels and reduced tumor volumes. Tumor tissue from telomestatin-treated animals exhibited marked apoptosis. None of the mice treated with telomestatin displayed any signs of toxicity. Taken together, these results lay the foundations for a program of drug development to achieve the dual aims of efficacy and selectivity in vivo.	Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, Tokyo 1600023, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo, Japan; Tokyo Med Univ, Intractable Dis Res Ctr, Shinjuku Ku, Tokyo 1600023, Japan	Tokyo Medical University; University of Tokyo; Tokyo Medical University	Tauchi, T (corresponding author), Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan.	tauchi@tokyo-med.ac.jp; kshin@iam.u-tokyo.ac.jp	Sashida, Goro/N-5259-2014	Sashida, Goro/0000-0003-2318-5987				Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Bearss DJ, 2000, ONCOGENE, V19, P6632, DOI 10.1038/sj.onc.1204092; Blackburn EH, 1995, TELOMERES; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Gomez D, 2004, J BIOL CHEM, V279, P41487, DOI 10.1074/jbc.M406123200; Gomez D, 2003, CANCER RES, V63, P6149; Gowan SM, 2002, MOL PHARMACOL, V61, P1154, DOI 10.1124/mol.61.5.1154; Gowan SM, 2001, MOL PHARMACOL, V60, P981, DOI 10.1124/mol.60.5.981; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; IZBICKA E, 1999, CANCER RES, V59, P369; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim MY, 2003, CANCER RES, V63, P3247; Kim MY, 2002, J AM CHEM SOC, V124, P2098, DOI 10.1021/ja017308q; Mergny JL, 1998, NAT MED, V4, P1366, DOI 10.1038/3949; Nakajima A, 2003, LEUKEMIA, V17, P560, DOI 10.1038/sj.leu.2402825; Nakajima A, 2001, LEUKEMIA, V15, P989, DOI 10.1038/sj.leu.2402137; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Ohyashiki JH, 2002, ONCOGENE, V21, P680, DOI 10.1038/sj.onc.1205075; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Riou JF, 2002, P NATL ACAD SCI USA, V99, P2672, DOI 10.1073/pnas.052698099; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Shammas MA, 2004, CLIN CANCER RES, V10, P770, DOI 10.1158/1078-0432.CCR-0793-03; Shin-ya K, 2001, J AM CHEM SOC, V123, P1262, DOI 10.1021/ja005780q; Sun DY, 1997, J MED CHEM, V40, P2113, DOI 10.1021/jm970199z; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; Tauchi T, 2003, ONCOGENE, V22, P5338, DOI 10.1038/sj.onc.1206833; Tauchi T, 2002, CLIN CANCER RES, V8, P3341; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Wheelhouse RT, 1998, J AM CHEM SOC, V120, P3261, DOI 10.1021/ja973792e; White LK, 2001, TRENDS BIOTECHNOL, V19, P114, DOI 10.1016/S0167-7799(00)01541-9; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0	32	182	189	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5719	5725		10.1038/sj.onc.1209577	http://dx.doi.org/10.1038/sj.onc.1209577			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16652154				2022-12-25	WOS:000240765800003
J	Bell, LA; O'Prey, J; Ryan, KM				Bell, L. A.; O'Prey, J.; Ryan, K. M.			DNA-binding independent cell death from a minimal proapoptotic region of E2F-1	ONCOGENE			English	Article						E2F; apoptosis; DNA binding	S-PHASE ENTRY; TRANSCRIPTION FACTORS E2F-1; RETINOBLASTOMA PROTEIN; E2F-DEPENDENT APOPTOSIS; E2F-1-INDUCED APOPTOSIS; P53-MEDIATED APOPTOSIS; MAMMALIAN-CELLS; MOUSE EMBRYOS; CYCLE ARREST; P53	The ability to induce cell cycle progression while evading cell death is a de. ning characteristic of cancer. Deregulation of E2F is a common event in most human cancers. Paradoxically, this can lead to both cell cycle progression and apoptosis. Although the way in which E2F causes cell cycle progression is well characterized, the pathways by which E2F induces cell death are less well defined. Many of the known mechanisms through which E2F induces apoptosis occur through regulation of E2F target genes. However, mutants of E2F-1 that lack the transactivation domain are still able to induce cell death. To further investigate this activity, we refined a transactivation independent mutant to identify a minimal apoptotic domain. This revealed that only 75 amino acids from within the DNA-binding domain of E2F-1 is sufficient for cell death and that this activity is also present in the DNA-binding domains of E2F-2 and E2F-3. However, analysis of this domain from E2F-1 revealed it does not bind DNA and is consequently unable to transactivate, repress or derepress E2F target genes. This provocative observation therefore defines a potential new mechanism of death from E2F and opens up new opportunities for inducing cell death in tumours for therapeutic gain.	Canc Res UK Beatson Labs, Tumour Cell Death Lab, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Ryan, KM (corresponding author), Canc Res UK Beatson Labs, Tumour Cell Death Lab, Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	k.ryan@beatson.gla.ac.uk		Ryan, Kevin M./0000-0002-1059-9681				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Bandara LR, 1997, NAT BIOTECHNOL, V15, P896, DOI 10.1038/nbt0997-896; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bell LA, 2004, CELL DEATH DIFFER, V11, P137, DOI 10.1038/sj.cdd.4401324; Berkovich E, 2003, ONCOGENE, V22, P161, DOI 10.1038/sj.onc.1206144; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Brooks LA, 2002, BRIT J CANCER, V86, P263, DOI 10.1038/sj.bjc.6600033; Chen D, 2005, CELL DEATH DIFFER, V12, P358, DOI 10.1038/sj.cdd.4401536; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Denchi EL, 2005, EMBO REP, V6, P661, DOI 10.1038/sj.embor.7400452; Ding Y, 1999, DNA Res, V6, P347, DOI 10.1093/dnares/6.5.347; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fogal V, 2005, CELL DEATH DIFFER, V12, P369, DOI 10.1038/sj.cdd.4401562; Furukawa Y, 2002, J BIOL CHEM, V277, P39760, DOI 10.1074/jbc.M200805200; Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1994, J VIROL, V68, P5027, DOI 10.1128/JVI.68.8.5027-5035.1994; Hershko T, 2005, CELL DEATH DIFFER, V12, P377, DOI 10.1038/sj.cdd.4401575; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; La Thangue NB, 2003, NAT CELL BIOL, V5, P587, DOI 10.1038/ncb0703-587; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Liu DX, 2001, NEURON, V32, P425, DOI 10.1016/S0896-6273(01)00495-0; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUELLE DE, 1995, CELL, V83, P993; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Ryan KM, 2004, CANCER RES, V64, P4415, DOI 10.1158/0008-5472.CAN-04-1474; Ryan KM, 1997, BIOCHEM J, V325, P79, DOI 10.1042/bj3250079; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Tsai KY, 2002, CURR BIOL, V12, P159, DOI 10.1016/S0960-9822(01)00659-5; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	64	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2006	25	41					5656	5663		10.1038/sj.onc.1209580	http://dx.doi.org/10.1038/sj.onc.1209580			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16652153				2022-12-25	WOS:000240599100007
J	Chen, SJ; Ning, HY; Ishida, W; Sodin-Semrl, S; Takagawa, S; Mori, Y; Varga, J				Chen, Shu-Jen; Ning, Hongyan; Ishida, Wataru; Sodin-Semrl, Snezna; Takagawa, Shinsuke; Mori, Yasuji; Varga, John			The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR EGR-1; ACTIVATED PROTEIN-KINASE; UNILATERAL URETERAL OBSTRUCTION; ANGIOTENSIN-CONVERTING ENZYME; RESPONSE FACTOR-I; TGF-BETA; SKIN FIBROBLASTS; PPAR-GAMMA; INDUCED PROLIFERATION; TARGETED DISRUPTION	Transforming growth factor-beta (TGF-beta) stimulates collagen synthesis and accumulation, and aberrant TGF-beta signaling is implicated in pathological organ fibrosis. Regulation of type I procollagen gene (COL1A2) transcription by TGF-beta involves the canonical Smad signaling pathway as well as additional protein and lipid kinases, coactivators, and DNA-binding transcription factors that constitute alternate non-Smad pathways. By using Affymetrix microarrays to detect cellular genes whose expression is regulated by Smad3, we identified early growth response factor-1 (EGR-1) as a novel Smad3-inducible gene. Previous studies implicated Egr-1 in cell growth, differentiation, and survival. We found that TGF-beta induced rapid and transient accumulation of Egr-1 protein and mRNA in human skin fibroblasts. In transient transfection assays, TGF-beta stimulated the activity of the Egr-1 gene promoter, as well as that of a minimal Egr-1-responsive reporter construct. Furthermore, TGF-beta enhanced endogenous Egr-1 interaction with a consensus Egr-1-binding site element and with GC-rich DNA sequences of the human COL1A2 promoter in vitro and in vivo. Forced expression of Egr-1 by itself caused dose-dependent up-regulation of COL1A2 promoter activity and further enhanced the stimulation induced by TGF-beta. In contrast, the TGF-beta response was abrogated when the Egr-1-binding sites of the COL1A2 promoter were mutated or deleted. Furthermore, Egr-1-deficient embryonic mouse fibroblasts showed attenuated TGF-beta responses despite intact Smad activation, and forced expression of ectopic EGR-1 in these cells could restore COL1A2 stimulation in a dose-dependent manner. Taken together, these findings identify Egr-1 as a novel intracellular TGF-beta target that is necessary for maximal stimulation of collagen gene expression in fibroblasts. The results therefore implicate Egr-1 in the profibrotic responses elicited by TGF-beta and suggest that Egr-1 may play a new and important role in the pathogenesis of fibrosis.	Northwestern Univ, Feinberg Sch Med, Div Rheumatol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Varga, J (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Rheumatol, M-300 McGaw,240 E Huron St, Chicago, IL 60611 USA.	j-varga@northwestern.edu	Sodin-Semrl, Snezna/AAJ-8954-2020; Varga, John/AAK-6472-2021		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049025, R01AR042309] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-42309, AR-49025] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Adamson ED, 2002, TUMOR BIOL, V23, P93, DOI 10.1159/000059711; Aicher WK, 2003, ARTHRITIS RHEUM, V48, P348, DOI 10.1002/art.10774; AICHER WK, 1994, J IMMUNOL, V152, P5940; Alexander D, 2002, BIOL CHEM, V383, P1845, DOI 10.1515/BC.2002.208; Baek SJ, 2003, J BIOL CHEM, V278, P5845, DOI 10.1074/jbc.M208394200; Bakin AV, 2002, J CELL SCI, V115, P3193; Banks MF, 2005, J APPL PHYSIOL, V98, P732, DOI 10.1152/japplphysiol.00821.2004; Bea F, 2003, ATHEROSCLEROSIS, V167, P187, DOI 10.1016/S0021-9150(02)00387-8; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bonniaud P, 2004, J IMMUNOL, V173, P2099, DOI 10.4049/jimmunol.173.3.2099; Bryant M, 2000, HUM GENE THER, V11, P2143, DOI 10.1089/104303400750001444; CAO XM, 1993, J BIOL CHEM, V268, P16949; Cesi V, 2005, EXP CELL RES, V305, P179, DOI 10.1016/j.yexcr.2004.12.015; Chambers RC, 2003, AM J PATHOL, V162, P533, DOI 10.1016/S0002-9440(10)63847-3; Chang BD, 1996, GENE, V183, P137, DOI 10.1016/S0378-1119(96)00532-X; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Cho SJ, 2006, J BIOL CHEM, V281, P8161, DOI 10.1074/jbc.M506770200; Day RM, 2004, J BIOL CHEM, V279, P8792, DOI 10.1074/jbc.M311140200; Day RM, 2001, AM J RESP CELL MOL, V25, P613, DOI 10.1165/ajrcmb.25.5.4521; de Belle I, 2000, BIOTECHNIQUES, V29, P162; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Delbridge GJ, 1997, CIRC RES, V81, P282, DOI 10.1161/01.RES.81.2.282; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Fang MA, 2001, J CELL BIOCHEM, V80, P550, DOI 10.1002/1097-4644(20010315)80:4<550::AID-JCB1009>3.3.CO;2-T; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Flanders KC, 2002, AM J PATHOL, V160, P1057, DOI 10.1016/S0002-9440(10)64926-7; Fu MG, 2003, BIOCHEM J, V370, P1019, DOI 10.1042/BJ20021503; Gaggioli C, 2005, ONCOGENE, V24, P1423, DOI 10.1038/sj.onc.1208318; Ghosh AK, 2002, EXP BIOL MED, V227, P301, DOI 10.1177/153537020222700502; Harja E, 2004, CIRC RES, V94, P333, DOI 10.1161/01.RES.0000112405.61577.95; Hayashida T, 2003, FASEB J, V17, P1576, DOI 10.1096/fj.03-0037fje; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; Inagaki Y, 2001, J BIOL CHEM, V276, P16573, DOI 10.1074/jbc.M010485200; ISHIDA W, 2006, IN PRESS J INVESTIG; Kaufmann K, 2002, J CELL BIOCHEM, V85, P381, DOI 10.1002/jcb.10145; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1998, J MOL MED-JMM, V76, P613, DOI 10.1007/s001090050258; KIM SJ, 1989, J BIOL CHEM, V264, P402; Lakos G, 2004, AM J PATHOL, V165, P203, DOI 10.1016/S0002-9440(10)63289-0; Lee CG, 2004, J EXP MED, V200, P377, DOI 10.1084/jem.20040104; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Liu CT, 2000, J BIOL CHEM, V275, P20315, DOI 10.1074/jbc.M909046199; Liu CT, 1999, J BIOL CHEM, V274, P4400, DOI 10.1074/jbc.274.7.4400; Maltzman JS, 1996, J EXP MED, V183, P1747, DOI 10.1084/jem.183.4.1747; Mauviel A, 2005, METH MOLEC MED, V117, P69; McCaffrey TA, 2000, J CLIN INVEST, V105, P653, DOI 10.1172/JCI8592; Mori Y, 2004, ARTHRITIS RHEUM-US, V50, P4008, DOI 10.1002/art.20658; Mori Y, 2000, EXP CELL RES, V258, P374, DOI 10.1006/excr.2000.4930; Mostecki J, 2005, J BIOL CHEM, V280, P2596, DOI 10.1074/jbc.M408938200; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Nakamura H, 2002, GENE THER, V9, P495, DOI 10.1038/sj.gt.3301681; Ning W, 2004, P NATL ACAD SCI USA, V101, P14895, DOI 10.1073/pnas.0401168101; Okada M, 2002, FASEB J, V16, P1861, DOI 10.1096/fj.02-0503com; Pendurthi UR, 2000, THROMB RES, V97, P179, DOI 10.1016/S0049-3848(99)00148-6; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; Renzoni EA, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-24; Roberts AB, 2003, ANN NY ACAD SCI, V995, P1, DOI 10.1111/j.1749-6632.2003.tb03205.x; Roberts AB, 2002, CYTOKINE GROWTH F R, V13, P3, DOI 10.1016/S1359-6101(01)00027-2; Roy S, 2004, WORLD J SURG, V28, P316, DOI 10.1007/s00268-003-7403-z; Runyan CE, 2004, J BIOL CHEM, V279, P2632, DOI 10.1074/jbc.M310412200; Saadane N, 2000, AM J PHYSIOL-HEART C, V278, pH796, DOI 10.1152/ajpheart.2000.278.3.H796; Sampson NS, 2001, J BIOL CHEM, V276, P34182, DOI 10.1074/jbc.M102859200; Sato M, 2003, J CLIN INVEST, V112, P1486, DOI 10.1172/JCI200319270; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; SHINGU T, 1994, J BIOL CHEM, V269, P32551; Takagawa S, 2003, J INVEST DERMATOL, V121, P41, DOI 10.1046/j.1523-1747.2003.12308.x; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; Tan FK, 2005, ARTHRITIS RHEUM-US, V52, P865, DOI 10.1002/art.20871; Tan LJ, 2003, J BIOL CHEM, V278, P17688, DOI 10.1074/jbc.M301676200; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Thiel G, 2000, BBA-GENE STRUCT EXPR, V1493, P289, DOI 10.1016/S0167-4781(00)00207-4; VARGA J, 2005, METHODS MOL MED, V117, P1; Verma A, 2002, J BIOL CHEM, V277, P7726, DOI 10.1074/jbc.M106640200; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Wilder PJ, 2002, MOL REPROD DEV, V63, P282, DOI 10.1002/mrd.10165; Yan SF, 2000, J CLIN INVEST, V105, P553, DOI 10.1172/JCI9513; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100; Yu JX, 2004, MOL CELL, V15, P83, DOI 10.1016/j.molcel.2004.06.030; YUFIT T, 1995, J INVEST DERMATOL, V105, P388, DOI 10.1111/1523-1747.ep12320990; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200	84	135	137	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21183	21197		10.1074/jbc.M603270200	http://dx.doi.org/10.1074/jbc.M603270200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16702209	hybrid			2022-12-25	WOS:000239187300054
J	Jakubiec, A; Tournier, V; Drugeon, G; Pflieger, S; Camborde, L; Vinh, J; Hericourt, F; Redeker, V; Jupin, I				Jakubiec, Anna; Tournier, Vincent; Drugeon, Gabriele; Pflieger, Stephanie; Camborde, Laurent; Vinh, Joelle; Hericourt, Francois; Redeker, Virginie; Jupin, Isabelle			Phosphorylation of viral RNA-dependent RNA polymerase and its role in replication of a plus-strand RNA virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YELLOW-MOSAIC-VIRUS; HEPATITIS-C VIRUS; VESICULAR STOMATITIS-VIRUS; FLIGHT MASS-SPECTROMETRY; IN-VITRO; MOVEMENT PROTEIN; CELL-CULTURE; ACTIVE-SITE; POLIOVIRUS; GENOME	Central to the process of plus-strand RNA virus genome amplification is the viral RNA-dependent RNA polymerase (RdRp). Understanding its regulation is of great importance given its essential function in viral replication and the common architecture and catalytic mechanism of polymerases. Here we show that Turnip yellow mosaic virus (TYMV) RdRp is phosphorylated, when expressed both individually and in the context of viral infection. Using a comprehensive biochemical approach, including metabolic labeling and mass spectrometry analyses, phosphorylation sites were mapped within an N-terminal PEST sequence and within the highly conserved palm subdomain of RNA polymerases. Systematic mutational analysis of the corresponding residues in a reverse genetic system demonstrated their importance for TYMV infectivity. Upon mutation of the phosphorylation sites, distinct steps of the viral cycle appeared affected, but in contrast to other plus-strand RNA viruses, the interaction between viral replication proteins was unaltered. Our results also highlighted the role of another TYMV-encoded replication protein as an antagonistic protein that may prevent the inhibitory effect of RdRp phosphorylation on viral infectivity. Based on these data, we propose that phosphorylation-dependent regulatory mechanisms are essential for viral RdRp function and virus replication.	Inst Jacques Monod, F-75251 Paris, France; Ecole Super Phys & Chim Ind Ville Paris, F-75005 Paris, France	UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	Jupin, I (corresponding author), Inst Jacques Monod, F-75251 Paris, France.	jupin@ccr.jussieu.fr	Hericourt, Francois/B-4717-2013; Redeker, Virginie/L-8929-2018; Vinh, Joelle/K-1347-2015	Redeker, Virginie/0000-0003-2694-8388; Vinh, Joelle/0000-0001-7184-2668; Tournier, Vincent/0000-0002-3971-1972				Ahlquist P, 2003, J VIROL, V77, P8181, DOI 10.1128/JVI.77.15.8181-8186.2003; Annan RS, 1996, ANAL CHEM, V68, P3413, DOI 10.1021/ac960221g; Arnold JJ, 2005, J BIOL CHEM, V280, P25706, DOI 10.1074/jbc.M503444200; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRANSOM KL, 1995, VIROLOGY, V206, P403, DOI 10.1016/S0042-6822(95)80056-5; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Buck KW, 1996, ADV VIRUS RES, V47, P159, DOI 10.1016/S0065-3527(08)60736-8; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; CHANG TLW, 1994, J VIROL, V68, P4980, DOI 10.1128/JVI.68.8.4980-4987.1994; CHATTOPADHYAY D, 1987, CELL, V49, P407, DOI 10.1016/0092-8674(87)90293-5; Cheney IW, 2002, VIROLOGY, V297, P298, DOI 10.1006/viro.2002.1461; De I, 2003, J VIROL, V77, P13106, DOI 10.1128/JVI.77.24.13106-13116.2003; DEAN AM, 1990, SCIENCE, V249, P1044, DOI 10.1126/science.2204110; DeGnore JP, 1998, J AM SOC MASS SPECTR, V9, P1175, DOI 10.1016/S1044-0305(98)00088-9; Dreher TW, 2004, MOL PLANT PATHOL, V5, P367, DOI 10.1111/j.1364-3703.2004.00236.X; Drugeon G, 2002, J GEN VIROL, V83, P3187, DOI 10.1099/0022-1317-83-12-3187; Evans MJ, 2004, P NATL ACAD SCI USA, V101, P13038, DOI 10.1073/pnas.0405152101; Fata CL, 2002, J VIROL, V76, P8632, DOI 10.1128/JVI.76.17.8632-8640.2002; Ferrer-Orta C, 2006, CURR OPIN STRUC BIOL, V16, P27, DOI 10.1016/j.sbi.2005.12.002; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gohara DW, 2000, J BIOL CHEM, V275, P25523, DOI 10.1074/jbc.M002671200; Gohara DW, 2004, BIOCHEMISTRY-US, V43, P5149, DOI 10.1021/bi035429s; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; Hericourt F, 2000, BIOCHEM J, V349, P417, DOI 10.1042/0264-6021:3490417; Jakubiec A, 2004, J VIROL, V78, P7945, DOI 10.1128/JVI.78.15.7945-7957.2004; Jia JH, 2004, NATURE, V432, P1045, DOI 10.1038/nature03179; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269; KAPOOR M, 1995, J BIOL CHEM, V270, P19100, DOI 10.1074/jbc.270.32.19100; Kim SH, 2002, EMBO J, V21, P2292, DOI 10.1093/emboj/21.9.2292; Kim SJ, 2004, J BIOL CHEM, V279, P50031, DOI 10.1074/jbc.M408617200; KOONIN EV, 1991, J GEN VIROL, V72, P2197, DOI 10.1099/0022-1317-72-9-2197; Kratzer R, 1998, ELECTROPHORESIS, V19, P1910, DOI 10.1002/elps.1150191109; Larsen Martin R, 2004, Methods Mol Biol, V251, P245; Larsen MR, 2001, PROTEOMICS, V1, P223; Loyet KM, 2005, MOL CELL PROTEOMICS, V4, P235, DOI 10.1074/mcp.R400011-MCP200; LUO KX, 1991, METHOD ENZYMOL, V201, P149; Ma YL, 2001, RAPID COMMUN MASS SP, V15, P1693, DOI 10.1002/rcm.426; Mann M, 2002, TRENDS BIOTECHNOL, V20, P261, DOI 10.1016/S0167-7799(02)01944-3; Michell BJ, 2002, J BIOL CHEM, V277, P42344, DOI 10.1074/jbc.M205144200; Neddermann P, 2004, J VIROL, V78, P13306, DOI 10.1128/JVI.78.23.13306-13314.2004; O'Reilly EK, 1998, VIROLOGY, V252, P287, DOI 10.1006/viro.1998.9463; Pattnaik AK, 1997, J VIROL, V71, P8167, DOI 10.1128/JVI.71.11.8167-8175.1997; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; Prod'homme D, 2003, J VIROL, V77, P9124, DOI 10.1128/JVI.77.17.9124-9135.2003; Prod'homme D, 2001, VIROLOGY, V281, P88, DOI 10.1006/viro.2000.0769; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Shapka N, 2005, VIROLOGY, V343, P65, DOI 10.1016/j.virol.2005.08.006; SWEENEY HL, 1994, P NATL ACAD SCI USA, V91, P1490, DOI 10.1073/pnas.91.4.1490; Thompson AA, 2004, EMBO J, V23, P3462, DOI 10.1038/sj.emboj.7600357; VANREGENMORTEL M, 2000, VIR TAX 7 REP INT CO; Waigmann E, 2000, EMBO J, V19, P4875, DOI 10.1093/emboj/19.18.4875; WEILAND JJ, 1993, P NATL ACAD SCI USA, V90, P6095, DOI 10.1073/pnas.90.13.6095; Xu X, 2003, NUCLEIC ACIDS RES, V31, P7117, DOI 10.1093/nar/gkg916	55	35	35	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21236	21249		10.1074/jbc.M600052200	http://dx.doi.org/10.1074/jbc.M600052200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16717096	hybrid			2022-12-25	WOS:000239187300059
J	Nakajima, J; Sato, Y; Hoshino, T; Yamazaki, M; Saito, K				Nakajima, Jun-ichiro; Sato, Yoshiharu; Hoshino, Tyuji; Yamazaki, Mami; Saito, Kazuki			Mechanistic study on the oxidation of anthocyanidin synthase by quantum mechanical calculation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVONOL SYNTHASE; 2-OXOGLUTARATE-DEPENDENT OXYGENASES; CONFORMATIONAL ENERGIES; AQUEOUS-SOLUTION; CROSS-LINKING; BIOSYNTHESIS; STEREOCHEMISTRY; BIOCHEMISTRY; SELECTIVITY; CHARGES	Anthocyanidin synthase (ANS), a member of the 2-oxo-glutarate-dependent dioxygenase family in flavonoid biosynthesis, catalyzes the conversion of leucoanthocyanidins ( e. g. 2R, 3S, 4S-cis-leucocyanidin, LCD) to flav-2-en-3,4-diols, a direct precursor of colored anthocyanidins via flavan-3,3,4-triols. The detailed oxygenation mechanism of 2R, 3S, 4S-cis-LCD to flav-2-en-3,4-diols was investigated using the density functional theory method. An initial model for the calculation was constructed from a structure obtained by a 100-ps molecular dynamics simulation of Arabidopsis ANS under physiological conditions. This model consisted of an LCD molecule as the substrate together with an iron atom, two histidine residues, an aspartic acid residue, a succinate, and an oxygen atom as ligands of the iron atom. The results of the calculation indicated that both the C-3 and C-4 positions of LCD can be oxidized, although C-4 oxidation is preferable. The C-3 oxidation required several steps to form flavan-3,3,4-triol:1) formation of Fe-III-OH and a substrate C-3 radical via hydrogen atom abstraction by Fe-IV=O, 2) formation of a C-3 ketone and a water molecule, 3) addition of OH- into the C-3 position of the ketone, and 4) addition of H+ to form flavan-3,3,4-triol. On the other hand, C-4 oxidation of 2R, 3S, 4S-cis-LCD resulted in the direct formation of 2R,3R-trans-dihydroquercetin. These results suggest that the oxidation at C-3 of LCD, a key reaction for coloring in anthocyanin biosynthesis, can be regarded as a "side reaction" from the viewpoint of quantum mechanics of enzymatic reactions. Molecular evolutional implications of ANS and related proteins are discussed in terms of reaction dynamics.	Chiba Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol & Biotechnol, Chiba 2638522, Japan; Tokiwa Phytochem Co Ltd, Chiba 2850801, Japan; Chiba Univ, Grad Sch Pharmaceut Sci, Dept Phys Chem, Chiba 2638522, Japan; JBIRC, Integrated Database Team, Tokyo 1350064, Japan; RIKEN, Plant Sci Ctr, Yokohama, Kanagawa 2300045, Japan	Chiba University; Chiba University; RIKEN	Saito, K (corresponding author), Chiba Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol & Biotechnol, Chiba 2638522, Japan.	ksaito@faculty.chiba-u.jp	Yamazaki, Mami/A-9050-2010; Saito, Kazuki/D-2670-2009	Yamazaki, Mami/0000-0001-6157-5287; Saito, Kazuki/0000-0001-6310-5342				Bach RD, 2006, J AM CHEM SOC, V128, P1474, DOI 10.1021/ja052111+; BAUSCHLICHER CW, 1995, J CHEM PHYS, V103, P1788, DOI 10.1063/1.469752; BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004; BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913; Borowski T, 2005, J AM CHEM SOC, V127, P17303, DOI 10.1021/ja054433j; Case D. A., 2002, AMBER 7; CIEPLAK P, 1995, J COMPUT CHEM, V16, P1357, DOI 10.1002/jcc.540161106; CORNELL WD, 1993, J AM CHEM SOC, V115, P9620, DOI 10.1021/ja00074a030; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Ensing B, 2004, J AM CHEM SOC, V126, P4355, DOI 10.1021/ja038865a; Foresman J. B, 1996, EXPLORING CHEM ELECT, V2nd; Friesner RA, 2005, ANNU REV PHYS CHEM, V56, P389, DOI 10.1146/annurev.physchem.55.091602.094410; Frisch G.W., 2016, GAUSSIAN 16 REVISION; Harborne JB, 2000, PHYTOCHEMISTRY, V55, P481, DOI 10.1016/S0031-9422(00)00235-1; Hata M, 2001, J AM CHEM SOC, V123, P6410, DOI 10.1021/ja000908p; Heller W., 1993, FLAVONOIDS ADV RES 1, P499; HOLTON TA, 1995, PLANT CELL, V7, P1071, DOI 10.1105/tpc.7.7.1071; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785; Lukacin R, 2003, PHYTOCHEMISTRY, V62, P287, DOI 10.1016/S0031-9422(02)00567-8; Martens S, 2003, FEBS LETT, V544, P93, DOI 10.1016/S0014-5793(03)00479-4; MENSSEN A, 1990, EMBO J, V9, P3051, DOI 10.1002/j.1460-2075.1990.tb07501.x; Nakajima J, 2001, J BIOL CHEM, V276, P25797, DOI 10.1074/jbc.M100744200; Nakanishi K., 1999, COMPREHENSIVE NATURA, V1, P713; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Prescott AG, 2002, PHYTOCHEMISTRY, V60, P589, DOI 10.1016/S0031-9422(02)00155-3; RiceEvans CA, 1997, TRENDS PLANT SCI, V2, P152, DOI 10.1016/S1360-1385(97)01018-2; Ryle MJ, 2002, CURR OPIN CHEM BIOL, V6, P193, DOI 10.1016/S1367-5931(02)00302-2; Saito K, 1999, PLANT J, V17, P181, DOI 10.1046/j.1365-313X.1999.00365.x; Saito K, 2002, NEW PHYTOL, V155, P9, DOI 10.1046/j.1469-8137.2002.00440.x; Schofield CJ, 1999, CURR OPIN STRUC BIOL, V9, P722, DOI 10.1016/S0959-440X(99)00036-6; Sobolewski AL, 2002, J PHYS CHEM A, V106, P4158, DOI 10.1021/jp013835k; Springob K, 2003, NAT PROD REP, V20, P288, DOI 10.1039/b109542k; TOMODA Y, 1961, J POLYM SCI, V54, P321, DOI 10.1002/pol.1961.1205416005; TOMODA Y, 1961, NATURE, V190, P905, DOI 10.1038/190905a0; Turnbull JJ, 2004, J BIOL CHEM, V279, P1206, DOI 10.1074/jbc.M309228200; Turnbull JJ, 2003, BIOORG MED CHEM LETT, V13, P3853, DOI 10.1016/S0960-894X(03)00711-X; Turnbull JJ, 2000, CHEM COMMUN, P2473, DOI 10.1039/b007594i; Valegard K, 1998, NATURE, V394, P805, DOI 10.1038/29575; Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F; Welford RWD, 2005, ORG BIOMOL CHEM, V3, P3117, DOI 10.1039/b507153d; Welford RWD, 2001, CHEM COMMUN, P1828, DOI 10.1039/b105576n; Wilmouth RC, 2002, STRUCTURE, V10, P93, DOI 10.1016/S0969-2126(01)00695-5; Xie DY, 2003, SCIENCE, V299, P396, DOI 10.1126/science.1078540; Yan YJ, 2005, APPL ENVIRON MICROB, V71, P3617, DOI 10.1128/AEM.71.7.3617-3623.2005; Zhang ZH, 2000, NAT STRUCT BIOL, V7, P127	46	16	19	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21387	21398		10.1074/jbc.M600303200	http://dx.doi.org/10.1074/jbc.M600303200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16702218	hybrid			2022-12-25	WOS:000239187300075
J	White, C; Yang, J; Monteiro, MJ; Foskett, JK				White, Carl; Yang, Jun; Monteiro, Mervyn J.; Foskett, J. Kevin			CIB1, a ubiquitously expressed Ca2+-binding protein ligand of the InsP(3) receptor Ca2+ release channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CALMODULIN-BINDING SITE; CALCIUM-BINDING; TRISPHOSPHATE RECEPTORS; PARTIAL INACTIVATION; RYANODINE RECEPTORS; CRYSTAL-STRUCTURE; RAPID ACTIVATION; KINASE; PHOSPHORYLATION	Afamily of Ca2+-binding proteins ( CaBPs) was shown to bind to the inositol 1,4,5-trisphosphate receptor ( InsP(3)R) Ca2+ release channel and gate it in the absence of InsP(3), establishing them as protein ligands ( Yang, J., McBride, S., Mak, D.-O.D., Vardi, N., Palczewski, K., Haeseleer, F., and Foskett, J. K. ( 2002) Proc. Natl. Acad. Sci. U. S. A. 99, 7711 - 7716). However, the neuronally restricted expression of CaBP and its inhibition of InsP(3)R-mediated Ca2+ signaling when overexpressed ( Kasri, N. N., Holmes, A. M., Bultynck, G., Parys, J. B., Bootman, M. D., Rietdorf, K., Missiaen, L., McDonald, F., De Smedt, H., Conway, S. J., Holmes, A. B., Berridge, M. J., and Roderick, H. L. ( 2004) EMBO J. 23, 312 - 321; Haynes, L. P., Tepikin, A. V., and Burgoyne, R. D. ( 2004) J. Biol. Chem. 279, 547 - 555) have raised questions regarding the functional implications of this regulation. We have discovered the Ca2+-binding protein CIB1 ( calmyrin) as a ubiquitously expressed ligand of the InsP3R. CIB1 binds to all mammalian InsP(3)R isoforms in a Ca2+-sensitive manner dependent on its two functional EF-hands and activates InsP(3)R channel gating in the absence of InsP3. In contrast, overexpression of CIB1 or CaBP1 attenuated InsP(3)R-dependent Ca2+ signaling, and in vitro pre-exposure to CIB1 reduced the number of channels available for subsequent stimulation by InsP3. These results establish CIB1 as a ubiquitously expressed activating and inhibiting protein ligand of the InsP3R.	Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA; Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Maryland, Inst Biotechnol, Baltimore, MD 21201 USA; Univ Maryland, Ctr Med Biotechnol, Baltimore, MD 21201 USA	University of Pennsylvania; University of Pennsylvania; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Foskett, JK (corresponding author), Univ Penn, Dept Physiol, B39 Anat Chem Bldg,414 Guardian Dr, Philadelphia, PA 19104 USA.	foskett@mail.med.upenn.edu	Monteiro, Mervyn J/H-3813-2011; Foskett, Kevin/R-2549-2019	White, Carl/0000-0002-0535-6968; Foskett, J. Kevin/0000-0002-8854-0268	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056328] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM056328, R01 GM056328] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adkins CE, 2000, BIOCHEM J, V352, P929, DOI 10.1042/0264-6021:3520929; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Blamey CJ, 2005, PROTEIN SCI, V14, P1214, DOI 10.1110/ps.041270805; Boehning D, 2001, BIOPHYS J, V81, P117, DOI 10.1016/S0006-3495(01)75685-8; Bosanac I, 2005, MOL CELL, V17, P193, DOI 10.1016/j.molcel.2004.11.047; Bosanac I, 2002, NATURE, V420, P696, DOI 10.1038/nature01268; Burgoyne RD, 2001, BIOCHEM J, V353, P1; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; Dufour JF, 1997, J BIOL CHEM, V272, P2675, DOI 10.1074/jbc.272.5.2675; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; Gentry HR, 2005, J BIOL CHEM, V280, P8407, DOI 10.1074/jbc.M411515200; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Haeseleer F, 2000, J BIOL CHEM, V275, P1247, DOI 10.1074/jbc.275.2.1247; Haeseleer F, 2002, BIOCHEM BIOPH RES CO, V290, P615, DOI 10.1006/bbrc.2001.6228; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; Haynes LP, 2004, J BIOL CHEM, V279, P547, DOI 10.1074/jbc.M309617200; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; Ionescu L, 2006, J PHYSIOL-LONDON, V573, P645, DOI 10.1113/jphysiol.2006.109504; Kasri NN, 2004, EMBO J, V23, P312, DOI 10.1038/sj.emboj.7600037; Kaznacheyeva E, 1998, J GEN PHYSIOL, V111, P847, DOI 10.1085/jgp.111.6.847; Lokuta AJ, 1997, J BIOL CHEM, V272, P25333, DOI 10.1074/jbc.272.40.25333; MAK DOD, 1994, J BIOL CHEM, V269, P29375; Mak DOD, 1997, J GEN PHYSIOL, V109, P571, DOI 10.1085/jgp.109.5.571; Mak DOD, 2003, J GEN PHYSIOL, V122, P569, DOI 10.1085/jgp.200308808; Mak DOD, 1999, J BIOL CHEM, V274, P22231, DOI 10.1074/jbc.274.32.22231; Mak DOD, 1998, P NATL ACAD SCI USA, V95, P15821, DOI 10.1073/pnas.95.26.15821; Mak DOD, 2001, J GEN PHYSIOL, V117, P447, DOI 10.1085/jgp.117.5.447; Marchant JS, 1998, BIOCHEMISTRY-US, V37, P11524, DOI 10.1021/bi980808k; MATTER N, 1993, J BIOL CHEM, V268, P732; Michikawa T, 1999, NEURON, V23, P799, DOI 10.1016/S0896-6273(01)80037-4; Missiaen L, 1999, J BIOL CHEM, V274, P13748, DOI 10.1074/jbc.274.20.13748; Nosyreva E, 2002, BIOCHEM J, V365, P659, DOI 10.1042/bj20011789; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Patterson RL, 2004, ANNU REV BIOCHEM, V73, P437, DOI 10.1146/annurev.biochem.73.071403.161303; Qin F, 2000, BIOPHYS J, V79, P1915, DOI 10.1016/S0006-3495(00)76441-1; Quadroni M, 1998, BIOCHEMISTRY-US, V37, P6523, DOI 10.1021/bi972930+; Shock DD, 1999, BIOCHEM J, V342, P729, DOI 10.1042/0264-6021:3420729; Stabler SM, 1999, J CELL BIOL, V145, P1277, DOI 10.1083/jcb.145.6.1277; Taylor CW, 1999, CELL CALCIUM, V26, P237, DOI 10.1054/ceca.1999.0090; Valdivia HH, 1998, TRENDS PHARMACOL SCI, V19, P479, DOI 10.1016/S0165-6147(98)01269-3; Vermassen E, 2004, BIOL CELL, V96, P3, DOI 10.1016/j.biolcel.2003.11.004; Wingard JN, 2005, J BIOL CHEM, V280, P37461, DOI 10.1074/jbc.M508541200; Wojcikiewicz RJH, 1998, J BIOL CHEM, V273, P5670, DOI 10.1074/jbc.273.10.5670; Yamaguchi K, 1999, J BIOL CHEM, V274, P3610, DOI 10.1074/jbc.274.6.3610; Yamniuk AP, 2004, BIOCHEMISTRY-US, V43, P2558, DOI 10.1021/bi035432b; Yang J, 2002, P NATL ACAD SCI USA, V99, P7711, DOI 10.1073/pnas.102006299; Zhang XC, 2001, BIOCHEM J, V360, P395, DOI 10.1042/0264-6021:3600395; Zhou W, 2004, NEURON, V41, P573, DOI 10.1016/S0896-6273(04)00045-5; Zhu JS, 2004, EXP CELL RES, V300, P440, DOI 10.1016/j.yexcr.2004.07.020	49	53	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20825	20833		10.1074/jbc.M602175200	http://dx.doi.org/10.1074/jbc.M602175200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16723353	hybrid			2022-12-25	WOS:000239187300019
J	Chai, L; Yang, JC; Di, CH; Cui, W; Kawakami, K; Lai, R; Ma, YP				Chai, Li; Yang, Jianchang; Di, Chunhui; Cui, Wei; Kawakami, Kiyoshi; Lai, Raymond; Ma, Yupo			Transcriptional activation of the SALL1 by the human SIX1 homeodomain during kidney development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOWNES-BROCKS-SYNDROME; HOMEOTIC GENE SPALT; ZINC-FINGER PROTEIN; DROSOPHILA EMBRYO; REGION; HEDGEHOG; HOMOLOG; MUTATIONS; ENCODES; CLONING	SALL1 is a member of the SAL gene family that encodes a group of putative developmental transcription factors. SALL1 plays a critical role during kidney development as mutations of the human SALL1 gene cause Townes-Brocks syndrome, which is associated with kidney malformation. Deletion of the mouse Sall1 gene results in renal agenesis or severe dysgenesis. To date, little is known about the molecular mechanisms controlling the regulation of SALL1 expression. This report describes the cloning and characterization of the human SALL1 gene promoter. Consensus binding sites were identified for several transcription factors, with multiple sites for WT1 and SIX1. In transient transfection assays, SALL1 promoter activity was higher in HEK-293 human kidney cells and COS-7 monkey kidney cells than in NIH-3T3 fibroblasts, consistent with its role in kidney development. Transcription from the SALL1 promoter was strikingly activated by the SIX1 protein. Utilizing a luciferase reporter gene assay, endogenous or exogenously added SIX1 activated the SALL1 promoter. Overexpression of SIX1 induced a significant increase in the endogenous SIX1 protein. In addition, co-expression of SIX1 and Eya1 resulted in a significant increase in the SALL1 promoter activity when compared with either SIX1 or Eya1 alone. Finally, we demonstrate that SIX1 was able to bind to the SALL1 promoter by retardation assays and that deletion of the putative element of SIX1 significantly diminishes the SALL1 promoter activity response to SIX1 stimulation. Our findings, when taken together, indicate that SALL1 is a likely target gene for SIX1 during kidney development.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Nevada Canc Inst, Div Lab Med, Las Vegas, NV 89135 USA; Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB T6G 2B7, Canada; Jichi Med Sch, Dept Biol, Tochigi 3290498, Japan	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of California System; University of California San Diego; University of Alberta; Jichi Medical University	Ma, YP (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.	yma@nvcancer.org		Chai, Li/0000-0003-1937-4750	NCI NIH HHS [K08 CA097185] Funding Source: Medline; NCRR NIH HHS [P20 RR016464] Funding Source: Medline; NIDDK NIH HHS [K08 DK063220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA097185] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK063220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Basson M, 1996, GENE DEV, V10, P1953, DOI 10.1101/gad.10.15.1953; deCelis JF, 1996, NATURE, V381, P421, DOI 10.1038/381421a0; DRESSLER GR, 1995, SEMIN NEPHROL, V15, P263; Dressler GR, 1999, DEV GENET, V24, P189, DOI 10.1002/(SICI)1520-6408(1999)24:3/4<189::AID-DVG1>3.0.CO;2-K; FERRAZ FG, 1989, ANN GENET-PARIS, V32, P120; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; FRAZIER GC, 1997, J BIOL CHEM, V272, P30678; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Hollemann T, 1996, MECH DEVELOP, V55, P19, DOI 10.1016/0925-4773(95)00485-8; Ikeda K, 2002, MOL CELL BIOL, V22, P6759, DOI 10.1128/MCB.22.19.6759-6766.2002; JURGENS G, 1988, EMBO J, V7, P189, DOI 10.1002/j.1460-2075.1988.tb02799.x; Kohlhase J, 1999, CYTOGENET CELL GENET, V84, P31, DOI 10.1159/000015206; Kohlhase J, 1999, AM J HUM GENET, V64, P435, DOI 10.1086/302238; Kohlhase J, 1998, NAT GENET, V18, P81, DOI 10.1038/ng0198-81; Kohlhase J, 1996, GENOMICS, V38, P291, DOI 10.1006/geno.1996.0631; Koster R, 1997, DEVELOPMENT, V124, P3147; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Kuhnlein RP, 1996, DEVELOPMENT, V122, P2215; KUHNLEIN RP, 1994, EMBO J, V13, P168, DOI 10.1002/j.1460-2075.1994.tb06246.x; Lechner MS, 1997, MECH DEVELOP, V62, P105, DOI 10.1016/S0925-4773(97)00667-9; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Ma YP, 2001, J BIOL CHEM, V276, P48223, DOI 10.1074/jbc.M106468200; Ma YP, 2001, PEDIATR NEPHROL, V16, P701, DOI 10.1007/s004670100624; Marlin S, 1999, HUM MUTAT, V14, P377, DOI 10.1002/(SICI)1098-1004(199911)14:5<377::AID-HUMU3>3.0.CO;2-A; Nishinakamura R, 2001, DEVELOPMENT, V128, P3105; Ohto H, 1999, MOL CELL BIOL, V19, P6815; Ott T, 1996, MECH DEVELOP, V56, P117, DOI 10.1016/0925-4773(96)00516-3; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; Roelink H, 1996, CURR OPIN NEUROBIOL, V6, P33, DOI 10.1016/S0959-4388(96)80006-7; Sato A, 2004, BIOCHEM BIOPH RES CO, V319, P103, DOI 10.1016/j.bbrc.2004.04.156; Sturtevant MA, 1997, DEVELOPMENT, V124, P21; TOWNES PL, 1972, J PEDIATR-US, V81, P321, DOI 10.1016/S0022-3476(72)80302-0; Xu PX, 2003, DEVELOPMENT, V130, P3085, DOI 10.1242/dev.00536	33	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					18918	18926		10.1074/jbc.M600180200	http://dx.doi.org/10.1074/jbc.M600180200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16670092	hybrid			2022-12-25	WOS:000238847000004
J	Fiala, KA; Duym, WW; Zhang, J; Suo, ZC				Fiala, Kevin A.; Duym, Wade W.; Zhang, Jun; Suo, Zucai			Up-regulation of the fidelity of human DNA polymerase lambda by its non-enzymatic proline-rich domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; POL LAMBDA; BETA; IDENTIFICATION; EXPRESSION; CORRECT; ENZYME; DAMAGE; FIT	DNA repair pathways are essential for maintaining genome stability. DNA polymerase beta plays a critical role in base-excision repair in vivo. DNA polymerase lambda, a recently identified X-family homolog of DNA polymerase beta, is hypothesized to be a second polymerase involved in base- excision repair. The full- length DNA polymerase lambda is comprised of three domains: a C-terminal DNA polymerase beta-like domain, an N-terminal BRCA1 C-terminal domain, and a previously uncharacterized proline- rich domain. Strikingly, pre-steady-state kinetic analyses reveal that, although human DNA polymerase lambda has almost identical fidelity to human DNA polymerase beta, the C-terminal DNA polymerase beta-like domain alone displays a dramatic, up to 100-fold loss in fidelity. We further demonstrate that the non-enzymatic pro-line-rich domain confers the increase in fidelity of DNA polymerase lambda by significantly lowering incorporation rate constants of incorrect nucleotides. Our studies illustrate a novel mechanism, in which the DNA polymerase fidelity is controlled not by an accessory protein or a proofreading exonuclease domain but by an internal regulatory domain.	Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA; Ohio State Univ, Biochem Program, Columbus, OH 43210 USA; Ohio State Univ, Biophys Program, Columbus, OH 43210 USA; Ohio State Univ, Mol Cellular & Dev Biol Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Suo, ZC (corresponding author), 740 Biol Sci,484 W 12th Ave, Columbus, OH 43210 USA.	suo.3@osu.edu			NIGMS NIH HHS [T32 GM08512-08] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008512] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o; Ahn JW, 1998, BIOCHEM J, V331, P79, DOI 10.1042/bj3310079; Aoufouchi S, 2000, NUCLEIC ACIDS RES, V28, P3684, DOI 10.1093/nar/28.18.3684; Beard WA, 2002, J BIOL CHEM, V277, P47393, DOI 10.1074/jbc.M210036200; Bebenek K, 2003, J BIOL CHEM, V278, P34685, DOI 10.1074/jbc.M305705200; Bertocci B, 2002, J IMMUNOL, V168, P3702, DOI 10.4049/jimmunol.168.8.3702; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Braithwaite EK, 2005, J BIOL CHEM, V280, P31641, DOI 10.1074/jbc.C500256200; Braithwaite EK, 2005, J BIOL CHEM, V280, P18469, DOI 10.1074/jbc.M411864200; Fan W, 2004, BIOCHEM BIOPH RES CO, V323, P1328, DOI 10.1016/j.bbrc.2004.09.002; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P6751, DOI 10.1021/bi049975c; Filee J, 2002, J MOL EVOL, V54, P763, DOI 10.1007/s00239-001-0078-x; Garcia-Diaz M, 2005, NAT STRUCT MOL BIOL, V12, P97, DOI 10.1038/nsmb876; Garcia-Diaz M, 2004, MOL CELL, V13, P561, DOI 10.1016/S1097-2765(04)00061-9; Garcia-Diaz M, 2002, J BIOL CHEM, V277, P13184, DOI 10.1074/jbc.M111601200; Garcia-Diaz M, 2001, J BIOL CHEM, V276, P34659, DOI 10.1074/jbc.M106336200; Garcia-Diaz M, 2000, J MOL BIOL, V301, P851, DOI 10.1006/jmbi.2000.4005; Goodman MF, 1997, P NATL ACAD SCI USA, V94, P10493, DOI 10.1073/pnas.94.20.10493; HIROSE F, 1989, EXP CELL RES, V181, P169, DOI 10.1016/0014-4827(89)90191-2; Johnson AA, 2001, J BIOL CHEM, V276, P38097; Johnson AA, 2001, J BIOL CHEM, V276, P38090; JOHNSON MD, 1992, PHYSICIAN SPORTSMED, V20, P60, DOI 10.1080/00913847.1992.11947449; Kobayashi Y, 2002, MOL CELL BIOL, V22, P2769, DOI 10.1128/MCB.22.8.2769-2776.2002; Kool ET, 2002, ANNU REV BIOCHEM, V71, P191, DOI 10.1146/annurev.biochem.71.110601.135453; Lee JW, 2004, J BIOL CHEM, V279, P805, DOI 10.1074/jbc.M307913200; Nagasawa K, 2000, J BIOL CHEM, V275, P31233, DOI 10.1074/jbc.M004263200; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PETRUSKA J, 1986, P NATL ACAD SCI USA, V83, P1559, DOI 10.1073/pnas.83.6.1559; Ramadan K, 2002, J BIOL CHEM, V277, P18454, DOI 10.1074/jbc.M200421200; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Shimazaki N, 2002, GENES CELLS, V7, P639, DOI 10.1046/j.1365-2443.2002.00547.x; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Uchiyama Y, 2004, EUR J BIOCHEM, V271, P2799, DOI 10.1111/j.1432-1033.2004.04214.x	34	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19038	19044		10.1074/jbc.M601178200	http://dx.doi.org/10.1074/jbc.M601178200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16675458	hybrid			2022-12-25	WOS:000238847000017
J	Schwer, B; Hausmann, S; Schneider, S; Shuman, S				Schwer, Beate; Hausmann, Stephane; Schneider, Susanne; Shuman, Stewart			Poxvirus mRNA cap methyltransferase - Bypass of the requirement for the stimulatory subunit by mutations in the catalytic subunit and evidence for intersubunit allostery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE N-7 METHYLTRANSFERASE; METHYL ACCEPTOR SITE; VACCINIA VIRUS; CAPPING ENZYME; ENCEPHALITOZOON-CUNICULI; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-ANALYSIS; GENETIC SYSTEM; (GUANINE-7-)METHYLTRANSFERASE; ASSOCIATION	The guanine-N7 methyltransferase domain of vaccinia virus mRNA capping enzyme is a heterodimer composed of a catalytic subunit vD1-(540-844) and a stimulatory subunit vD12. The poxvirus enzyme can function in vivo in Saccharomyces cerevisiae in lieu of the essential cellular cap methyltransferase Abd1. Coexpression of both poxvirus subunits is required to complement the growth of abd1 Delta cells. We performed a genetic screen for mutations in the catalytic subunit that bypassed the requirement for the stimulatory subunit in vivo. We thereby identified missense changes in vicinal residues Tyr-752 (to Ser, Cys, or His) and Asn-753 (to Ile), which are located in the cap guanine-binding pocket. Biochemical experiments illuminated a mechanism of intersubunit allostery, whereby the vD12 subunit enhances the affinity of the catalytic subunit for AdoMet and the cap guanine methyl acceptor by 6- and 14-fold, respectively, and increases k(cat) by a factor of 4. The bypass mutations elicited gains of function in both vD12-independent and vD12-dependent catalysis of cap methylation in vitro when compared with wild-type vD1-(540-844). These results highlight the power of yeast as a surrogate model for the genetic analysis of interacting poxvirus proteins and demonstrate that the activity of an RNA processing enzyme can be augmented through selection and protein engineering.	Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA; Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center	Schwer, B (corresponding author), Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA.	bschwer@med.cornell.edu			NIGMS NIH HHS [GM42498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARPENTER MS, 1991, J VIROL, V65, P4042, DOI 10.1128/JVI.65.8.4042-4050.1991; CONG PJ, 1992, J BIOL CHEM, V267, P16424; Fabrega C, 2004, MOL CELL, V13, P77, DOI 10.1016/S1097-2765(03)00522-7; Hall MP, 2006, RNA, V12, P488, DOI 10.1261/rna.2250606; Hausmann S, 2005, J BIOL CHEM, V280, P20404, DOI 10.1074/jbc.M501073200; Hausmann S, 2002, J BIOL CHEM, V277, P96, DOI 10.1074/jbc.M109649200; HIGMAN MA, 1994, J BIOL CHEM, V269, P14974; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; HIGMAN MA, 1994, J BIOL CHEM, V269, P14982; Ho CK, 2000, J VIROL, V74, P5486, DOI 10.1128/JVI.74.12.5486-5494.2000; MAO XD, 1994, J BIOL CHEM, V269, P24472; Mao XD, 1996, BIOCHEMISTRY-US, V35, P6900, DOI 10.1021/bi960221a; MAO XD, 1995, MOL CELL BIOL, V15, P4167; Mao XD, 1996, MOL CELL BIOL, V16, P475; MARTIN SA, 1975, J BIOL CHEM, V250, P9330; McCraith S, 2000, P NATL ACAD SCI USA, V97, P4879, DOI 10.1073/pnas.080078197; NILES EG, 1994, BIOCHEMISTRY-US, V33, P9898, DOI 10.1021/bi00199a011; Saha N, 1999, J BIOL CHEM, V274, P16553, DOI 10.1074/jbc.274.23.16553; Saha N, 2003, J VIROL, V77, P7300, DOI 10.1128/JVI.77.13.7300-7307.2003; Schwer B, 2000, GENETICS, V155, P1561; SCHWER B, 2006, IN PRESS VIROLOGY; VENKATESAN S, 1980, J BIOL CHEM, V255, P903; Wang SP, 1997, J BIOL CHEM, V272, P14683, DOI 10.1074/jbc.272.23.14683; Yamada-Okabe T, 1999, MICROBIOL-UK, V145, P3023, DOI 10.1099/00221287-145-11-3023	24	14	15	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					18953	18960		10.1074/jbc.M602867200	http://dx.doi.org/10.1074/jbc.M602867200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16707499	hybrid			2022-12-25	WOS:000238847000008
J	Wai, PY; Mi, ZY; Gao, C; Guo, H; Marroquin, C; Kuo, PC				Wai, Philip Y.; Mi, Zhiyong; Gao, Chengjiang; Guo, Hongtao; Marroquin, Carlos; Kuo, Paul C.			Ets-1 and Runx2 regulate transcription of a metastatic gene, osteopontin, in murine colorectal cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; IN-VIVO; OSTEOBLAST DIFFERENTIATION; BONE SIALOPROTEIN; ENDOTHELIAL-CELLS; AUTO-INHIBITION; EXPRESSION; COLON; INDUCTION; OVEREXPRESSION	Osteopontin (OPN) is a sialic acid-rich phosphoprotein secreted by a wide variety of cancers. We have shown previously that OPN is necessary for mediating hepatic metastasis in CT26 colorectal cancer cells. Although a variety of stimuli can induce OPN, the molecular mechanisms that regulate OPN gene transcription in colorectal cancer are unknown. We hypothesized that cis- and trans-regulatory elements determine OPN transcription in CT26 cells. OPN transcription was analyzed in CT26 cancer cells and compared withYAMC(young adult mouse colon) epithelial cells. Clonal deletion analysis of OPN promoter-luciferase constructs identified cis- regulatory regions. A specific promoter region, nucleotide (nt)-107 to -174, demonstrated a > 8.0-fold increase in luciferase activity in CT26 compared with YAMC. Gel-shift assays sublocalized two cis-regulatory regions, nt -101 to -123 and nt -121 to -145, which specifically bind CT26 nuclear proteins. Competition with unlabeled mutant oligonucleotides revealed that the regions nt -115 to -118 and nt -129 to -134 were essential for protein binding. Subsequent supershift and chromatin immunoprecipitation assays confirmed the corresponding nuclear proteins to be Ets-1 and Runx2. Functional relevance was demonstrated through mutations in the Ets-1 and Runx2 consensus binding sites resulting in > 60% decrease in OPN transcription. Ets-1 and Runx2 protein expression in CT26 was ablated using antisense oligonucleotides and resulted in a > 7-fold decrease in OPN protein expression. Ets-1 and Runx2 are critical transcriptional regulators of OPN expression in CT26 colorectal cancer cells. Suppression of these transcription factors results in significant down- regulation of the OPN metastasis protein.	Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA	Duke University	Wai, PY (corresponding author), Yale Univ, Sch Med, Dept Surg, 330 Cedar St,FMB102, New Haven, CT 06510 USA.	philip.wai@yale.edu		Gao, Chengjiang/0000-0002-9365-4497	NIAID NIH HHS [R01AI44629] Funding Source: Medline; NIGMS NIH HHS [R01GM65113] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065113] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal D, 2002, J NATL CANCER I, V94, P513; Anderson MK, 1999, DEVELOPMENT, V126, P3131; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Barnes GL, 2003, CANCER RES, V63, P2631; Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Chambers AF, 1996, LUNG CANCER-J IASLC, V15, P311, DOI 10.1016/0169-5002(95)00595-1; Coffman JA, 2003, CELL BIOL INT, V27, P315, DOI 10.1016/S1065-6995(03)00018-0; CORBETT TH, 1975, CANCER RES, V35, P2434; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; Denhardt DT, 1998, J CELL BIOCHEM, P92, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<92::AID-JCB13>3.0.CO;2-A; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; El-Tanani M, 2004, J BIOL CHEM, V279, P20794, DOI 10.1074/jbc.M311131200; Gao CJ, 2003, CARCINOGENESIS, V24, P1871, DOI 10.1093/carcin/bgg139; Gao CJ, 2004, J BIOL CHEM, V279, P11236, DOI 10.1074/jbc.M313385200; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Goodison S, 1999, J CLIN PATHOL-MOL PA, V52, P189; Gotoh M, 2002, PATHOL INT, V52, P19, DOI 10.1046/j.1440-1827.2002.01316.x; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; Hahne JC, 2005, ONCOGENE, V24, P5384, DOI 10.1038/sj.onc.1208761; HIJIYA N, 1994, BIOCHEM J, V303, P255, DOI 10.1042/bj3030255; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Ikubo A, 1999, CLIN EXP METASTAS, V17, P849, DOI 10.1023/A:1006730320248; Inman CK, 2003, J BIOL CHEM, V278, P48684, DOI 10.1074/jbc.M308001200; Irby R, 2004, CLIN EXP METASTAS, V21, P515, DOI 10.1007/s10585-004-2873-4; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Ito Y, 2002, ANTICANCER RES, V22, P1581; Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891-2905.2001; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Katagiri YU, 1999, CANCER RES, V59, P219; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; Mi ZY, 2004, J BIOL CHEM, V279, P46659, DOI 10.1074/jbc.M407952200; Naito S, 1998, AM J PHYSIOL-CELL PH, V274, pC472, DOI 10.1152/ajpcell.1998.274.2.C472; Nakayama T, 2001, MODERN PATHOL, V14, P415, DOI 10.1038/modpathol.3880328; Nam S, 2002, MOL CELL BIOL, V22, P547, DOI 10.1128/MCB.22.2.547-554.2002; O'Regan A, 2000, INT J EXP PATHOL, V81, P373, DOI 10.1046/j.1365-2613.2000.00163.x; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pan HW, 2003, CANCER-AM CANCER SOC, V98, P119, DOI 10.1002/cncr.11487; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; Pozzi A, 2004, J BIOL CHEM, V279, P29797, DOI 10.1074/jbc.M313989200; Qiao M, 2006, J BIOL CHEM, V281, P7118, DOI 10.1074/jbc.M508162200; Rangaswami H, 2005, J BIOL CHEM, V280, P19381, DOI 10.1074/jbc.M414204200; Sahin A, 2005, INT J MOL MED, V15, P771; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; SETH A, 1990, ONCOGENE, V5, P1761; Shijubo N, 1999, AM J RESP CRIT CARE, V160, P1269, DOI 10.1164/ajrccm.160.4.9807094; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Tanaka K, 1998, J CELL PHYSIOL, V176, P235, DOI 10.1002/(SICI)1097-4652(199808)176:2<235::AID-JCP2>3.0.CO;2-P; Thalmann GN, 1999, CLIN CANCER RES, V5, P2271; Tokuhara K, 2003, INT SURG, V88, P25; Tuck AB, 1999, ONCOGENE, V18, P4237, DOI 10.1038/sj.onc.1202799; Tuck AB, 1997, ARCH PATHOL LAB MED, V121, P578; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V; van Wijnen AJ, 2004, ONCOGENE, V23, P4209, DOI 10.1038/sj.onc.1207758; Vary CPH, 2000, EXP CELL RES, V257, P213, DOI 10.1006/excr.2000.4879; Wai PY, 2004, J SURG RES, V121, P228, DOI 10.1016/j.jss.2004.03.028; Wai PY, 2005, CARCINOGENESIS, V26, P741, DOI 10.1093/carcin/bgi027; Wang D, 2005, INT IMMUNOL, V17, P1179, DOI 10.1093/intimm/dxh295; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587; Yeatman TJ, 2003, CLIN EXP METASTAS, V20, P85, DOI 10.1023/A:1022502805474	72	67	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					18973	18982		10.1074/jbc.M511962200	http://dx.doi.org/10.1074/jbc.M511962200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16670084	hybrid			2022-12-25	WOS:000238847000010
J	Schindler, K; Winter, E				Schindler, Karen; Winter, Edward			Phosphorylation of Ime2 regulates meiotic progression in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MEIOSIS-SPECIFIC KINASE; BUDDING YEAST; CHROMOSOME SEGREGATION; DUAL PHOSPHORYLATION; DNA-REPLICATION; S PHASE; AUTOPHOSPHORYLATION; SPORULATION; ANAPHASE	Ime2p is a meiosis-specific protein kinase in Saccharomyces cerevisiae that controls multiple steps in meiosis. Although Ime2p is functionally related to the Cdc28p cyclin-dependent kinase (CDK), no cyclin binding partners that regulate its activities have been identified. The sequence of the Ime2p catalytic domain is similar to CDKs and mitogen-activated protein kinases (MAPKs). Ime2p is activated by phosphorylation of its activation loop in a Cak1p-dependent fashion and is subsequently phosphorylated on multiple residues as cells progress through meiosis. In this study, we show that Ime2p purified from meiotic cells is phosphorylated on Thr(242) and Tyr(244) in its activation loop and on Ser(520) and Ser(625) in its C terminus. Ime2p autophosphorylates on threonine in its activation loop in vitro consistent with autophosphorylation of Thr(242) playing a role in its activation. Moreover, autophosphorylation in cis is required for Ime2p to become hyperphosphorylated. Phosphorylation of the C-terminal serines is not essential to sporulation. However, Ime2p C-terminal phosphorylation site mutants genetically interact with components of the FEAR network that controls exit from meiosis I. These data suggest that Ime2p plays a role in controlling the exit from meiosis I and demonstrate that a phospho-mdification pathway regulates Ime2p during the different phases of meiotic development.	Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA	Jefferson University	Winter, E (corresponding author), Thomas Jefferson Univ, Dept Biochem & Mol Biol, 233 S 10th St, Philadelphia, PA 19107 USA.	edward.winter@jefferson.edu		Schindler, Karen/0000-0001-6113-1184	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061817] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM061817] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe MK, 2001, J BIOL CHEM, V276, P21272, DOI 10.1074/jbc.M100026200; Benjamin KR, 2003, GENE DEV, V17, P1524, DOI 10.1101/gad.1101503; Bolte M, 2002, P NATL ACAD SCI USA, V99, P4385, DOI 10.1073/pnas.072385099; BOWDISH KS, 1994, MOL CELL BIOL, V14, P7909, DOI 10.1128/MCB.14.12.7909; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Buonomo SBC, 2003, DEV CELL, V4, P727, DOI 10.1016/S1534-5807(03)00129-1; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Clifford DM, 2005, CELL CYCLE, V4, P1826, DOI 10.4161/cc.4.12.2214; Clifford DM, 2004, J BIOL CHEM, V279, P6163, DOI 10.1074/jbc.M306943200; Clyne RK, 2003, NAT CELL BIOL, V5, P480, DOI 10.1038/ncb977; Dirick L, 1998, SCIENCE, V281, P1854, DOI 10.1126/science.281.5384.1854; Donzeau M, 1999, MOL CELL BIOL, V19, P6110; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; Eyers PA, 2003, CURR BIOL, V13, P691, DOI 10.1016/S0960-9822(03)00166-0; Ferrell JE, 1997, J BIOL CHEM, V272, P19008, DOI 10.1074/jbc.272.30.19008; Fu Z, 2005, MOL CELL BIOL, V25, P6047, DOI 10.1128/MCB.25.14.6047-6064.2005; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Guttmann-Raviv N, 2002, MOL CELL BIOL, V22, P2047, DOI 10.1128/MCB.22.7.2047-2056.2002; Guttmann-Raviv N, 2001, GENETICS, V159, P1547; Honigberg SM, 2004, J CELL BIOCHEM, V92, P1025, DOI 10.1002/jcb.20131; Jaspersen SL, 1998, MOL BIOL CELL, V9, P2803, DOI 10.1091/mbc.9.10.2803; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; Kamieniecki RJ, 2005, CELL CYCLE, V4, P1093; Lee BH, 2003, SCIENCE, V300, P482, DOI 10.1126/science.1081846; Lochhead PA, 2005, CELL, V121, P925, DOI 10.1016/j.cell.2005.03.034; Marston AL, 2004, NAT REV MOL CELL BIO, V5, P983, DOI 10.1038/nrm1526; Marston AL, 2003, DEV CELL, V4, P711, DOI 10.1016/S1534-5807(03)00130-8; McDonald CM, 2005, GENETICS, V171, P901, DOI 10.1534/genetics.105.045567; MITCHELL AP, 1990, MOL CELL BIOL, V10, P2104, DOI 10.1128/MCB.10.5.2104; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024; Pak J, 2002, MOL CELL BIOL, V22, P6417, DOI 10.1128/MCB.22.18.6417-6429.2002; Purnapatre K, 2005, MOL CELL BIOL, V25, P440, DOI 10.1128/MCB.25.1.440-450.2005; Rice LM, 2005, EUKARYOT CELL, V4, P55, DOI 10.1128/EC.4.1.55-62.2005; Schaber M, 2002, MOL CELL BIOL, V22, P57, DOI 10.1128/MCB.22.1.57-68.2002; Schindler K, 2003, MOL CELL BIOL, V23, P8718, DOI 10.1128/MCB.23.23.8718-8728.2003; SIA RAL, 1995, MOL CELL BIOL, V15, P5279; Sopko R, 2002, MOL CELL BIOL, V22, P7024, DOI 10.1128/MCB.22.20.7024-7040.2002; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Strich R, 2004, GENETICS, V167, P1621, DOI 10.1534/genetics.104.029223; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191	42	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18307	18316		10.1074/jbc.M602349200	http://dx.doi.org/10.1074/jbc.M602349200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16684773	hybrid			2022-12-25	WOS:000238687300007
J	Ohmori, T; Mimuro, J; Takano, K; Madoiwa, S; Kashiwakura, Y; Ishiwata, A; Niimura, M; Mitomo, K; Tabata, T; Hasegawa, M; Ozawa, K; Sakata, Y				Ohmori, Tsukasa; Mimuro, Jun; Takano, Katsuhiro; Madoiwa, Seiji; Kashiwakura, Yuji; Ishiwata, Akira; Niimura, Masanori; Mitomo, Katsuyuki; Tabata, Toshiaki; Hasegawa, Mamoru; Ozawa, Keiya; Sakata, Yoichi			Efficient expression of a transgene in platelets using simian immunodeficiency virus-based vector harboring glycoprotein Ib alpha promoter: in vivo model for platelet-targeting gene therapy	FASEB JOURNAL			English	Article						hemophilia A; lentiviral vector; stem cell transplantation	FACTOR-VIII GENE; HEMATOPOIETIC STEM-CELLS; HEMOPHILIA-A; PLASMINOGEN-ACTIVATOR; PHENOTYPIC CORRECTION; CD34(+) CELLS; THROMBOPOIETIN; INDUCTION; INTEGRIN; TRANSDUCTION	Platelets release several mediators that modify vascular integrity and hemostasis. In the present study, we developed a technique for efficient transgene expression in platelets in vivo and examined whether this targeted-gene-product delivery system using a platelet release reaction could be exploited for clinical applications. Analysis of luciferase reporter gene constructs driven by platelet-specific promoters (the GPIIb, GPIb alpha, and GPVI) revealed that the GPIb alpha promoter was the most potent in the megakaryoblastic cell line UT-7/TPO and human CD34(+)-derived megakaryocytes. Transduction of UT-7/TPO; CD34(+)-derived megakaryocytes; and c-Kit(+), ScaI(+), and Lineage(-) (KSL) murine hematopoietic stem cells with a simian immunodeficiency virus (SIV)-based lentiviral vector carrying eGFP resulted in efficient, dose-dependent expression of eGFP, and the GPIb alpha promoter seemed to bestow megakaryocytic-specific expression. Transplantation of KSL cells transduced with SIV vector containing eGFP into mice showed that there was preferable expression of eGFP in platelets driven by the GPIb alpha promoter [7-11% for the cytomeglovirus (CMV) promoter, 16-27% for the GPIb alpha promoter]. Furthermore, transplantation of ex vivo-transduced KSL cells by SIV vector carrying human factorVIII (hFVIII) driven by the GPIb alpha promoter induced the production of detectable transcripts of the hFVIII gene and the hFVIII antigen in bone marrow and spleen for at least 90 days and partially corrected the hemophilia A phenotype. Platelet-targeting gene therapy using SIV vectors appears to be promising for gene therapy approaches toward not only inherited platelet diseases but also other hemorrhagic disorders such as hemophilia A.	Jichi Med Sch, Ctr Mol Med, Res Div Cell & Mol Med, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Div Hematol, Dept Med, Minami Kawachi, Tochigi 3290498, Japan; DNAVEC Corp, Ibaraki, Japan; Jichi Med Sch, Ctr Mol Med, Res Div Genet Therapeut, Minami Kawachi, Tochigi 3290498, Japan	Jichi Medical University; Jichi Medical University; DNAVEC Corporation; Jichi Medical University	Sakata, Y (corresponding author), Jichi Med Sch, Ctr Mol Med, Res Div Cell & Mol Med, Minami Kawachi, Tochigi 3290498, Japan.	yoisaka@jichi.ac.jp		OHMORI, TSUKASA/0000-0001-5082-6394				Afshar-Kharghan V, 1999, BLOOD, V94, P186, DOI 10.1182/blood.V94.1.186.413k19_186_191; BI L, 1995, NAT GENET, V10, P119, DOI 10.1038/ng0595-119; Fang J, 2005, BLOOD, V106, P2671, DOI 10.1182/blood-2004-12-4619; Flaumenhaft R, 2003, ARTERIOSCL THROM VAS, V23, P1152, DOI 10.1161/01.ATV.0000075965.88456.48; Haas DL, 2000, MOL THER, V2, P71, DOI 10.1006/mthe.2000.0094; Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314; HASHIMOTO Y, 1995, J BIOL CHEM, V270, P24532, DOI 10.1074/jbc.270.41.24532; High K, 2005, J THROMB HAEMOST, V3, P1682, DOI 10.1111/j.1538-7836.2005.01460.x; Hisano N, 1999, BLOOD, V93, P4293, DOI 10.1182/blood.V93.12.4293.412k26_4293_4299; Holmes ML, 2002, J BIOL CHEM, V277, P48333, DOI 10.1074/jbc.M206127200; HOYER LW, 1994, NEW ENGL J MED, V330, P38, DOI 10.1056/NEJM199401063300108; Kikuchi J, 2004, J GENE MED, V6, P1049, DOI 10.1002/jgm.609; Komatsu N, 1996, BLOOD, V87, P4552, DOI 10.1182/blood.V87.11.4552.bloodjournal87114552; KONKLE BA, 1990, J BIOL CHEM, V265, P19833; Kootstra NA, 2003, MOL THER, V7, P623, DOI 10.1016/S1525-0016(03)00073-X; Kufrin D, 2003, BLOOD, V102, P926, DOI 10.1182/blood-2003-01-0054; Lepage A, 2000, BLOOD, V96, P4169, DOI 10.1182/blood.V96.13.4169.h8004169_4169_4177; LIND P, 1995, EUR J BIOCHEM, V232, P19, DOI 10.1111/j.1432-1033.1995.tb20776.x; Lozier J, 2004, SEMIN HEMATOL, V41, P287, DOI 10.1053/j.seminhematol.2004.07.005; Madoiwa S, 2004, J THROMB HAEMOST, V2, P754, DOI 10.1111/j.1538-7933.2004.00671.x; Majka M, 1999, J CLIN INVEST, V104, P1739, DOI 10.1172/JCI7779; Mimuro J, 2001, GENE THER, V8, P1690, DOI 10.1038/sj.gt.3301579; Moayeri M, 2005, MOL THER, V12, P1034, DOI 10.1016/j.ymthe.2005.09.007; Moayeri M, 2004, MOL THER, V10, P892, DOI 10.1016/j.ymthe.2004.08.006; Mostoslavsky G, 2005, MOL THER, V11, P932, DOI 10.1016/j.ymthe.2005.01.005; Nakajima T, 2000, HUM GENE THER, V11, P1863, DOI 10.1089/10430340050129486; Nakauchi H, 2001, ANN NY ACAD SCI, V938, P18; PRANDINI MH, 1992, J BIOL CHEM, V267, P10370; Rendu F, 2001, PLATELETS, V12, P261, DOI 10.1080/09537100120068170; Sun B, 2003, PLATELETS, V14, P225, DOI 10.1080/0953710031000118858; Tropel P, 1997, BLOOD, V90, P2995, DOI 10.1182/blood.V90.8.2995; Ueda T, 2000, J CLIN INVEST, V105, P1013, DOI 10.1172/JCI8583; Wahlers A, 2001, GENE THER, V8, P477, DOI 10.1038/sj.gt.3301426; Wilcox DA, 2000, BLOOD, V95, P3645; Wilcox DA, 2003, J THROMB HAEMOST, V1, P2477, DOI 10.1111/j.1538-7836.2003.00534.x; Wilcox DA, 2003, J THROMB HAEMOST, V1, P2300, DOI 10.1046/j.1538-7836.2003.00476.x; Woods NB, 2002, LEUKEMIA, V16, P563, DOI 10.1038/sj.leu.2402447; Yarovoi HV, 2003, BLOOD, V102, P4006, DOI 10.1182/blood-2003-05-1519	38	43	45	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1522	+		10.1096/fj.05-5161fje	http://dx.doi.org/10.1096/fj.05-5161fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16723382				2022-12-25	WOS:000240266000038
J	Huang, L; Watanabe, M; Chikamori, M; Kido, Y; Yamamoto, T; Shibuya, M; Gotoh, N; Tsuchida, N				Huang, L.; Watanabe, M.; Chikamori, M.; Kido, Y.; Yamamoto, T.; Shibuya, M.; Gotoh, N.; Tsuchida, N.			Unique role of SNT-2/FRS2 beta/FRS3 docking/adaptor protein for negative regulation in EGF receptor tyrosine kinase signaling pathways	ONCOGENE			English	Article						SNT-2; FRS2 beta; FRS3; EGF; transformation; ERK2	GROWTH-FACTOR-RECEPTOR; MAP KINASE; PHOSPHORYLATION SITES; TRANSDUCTION PATHWAYS; DOCKING PROTEINS; PC12 CELLS; ACTIVATION; FRS2-ALPHA; FRS2; SHC	The membrane-linked docking protein SNT-2/FRS2b/FRS3 becomes tyrosine phosphorylated in response to fibroblast growth factors (FGFs) and neurotrophins and serves as a platform for recruitment of multiple signaling proteins, including Grb2 and Shp2, to FGF receptors or neurotrophin receptors. We previously reported that SNT-2 is not tyrosine phosphorylated significantly in response to epidermal growth factor (EGF) but that it inhibits ERK activation via EGF stimulation by forming a complex with ERK2. In the present report, we show that expression of SNT-2 suppressed EGF-induced cell transformation and proliferation, and expression level of SNT-2 is down-regulated in cancer. The activities of the major signaling molecules in EGF receptor ( EGFR) signal transduction pathways, including autophosphorylation of EGFR, were attenuated in cells expressing SNT-2 but not in cells expressing SNT-2 mutants lacking the ERK2-binding domain. Furthermore, SNT-2 constitutively bound to EGFR through the phosphotyrosine binding (PTB) domain both with and without EGF stimulation. Treatment of cells with MEK inhibitor U0126 partially restored the phosphorylation levels of MEK and EGFR in cells expressing SNT-2. On the basis of these findings, we propose a novel mechanism of negative control of EGFR tyrosine kinase activity with SNT-2 by recruiting ERK2, which is the site of negative-feedback loop from ERK, ultimately leading to inhibition of EGF-induced cell transformation and proliferation.	Univ Tokyo, Inst Med Sci, Div Genet, Minato Ku, Tokyo 1088639, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Mol Cellular Oncol & Microbiol, Bunkyo Ku, Tokyo, Japan; Univ Tokyo, Inst Med Sci, Div Oncol, Minato Ku, Tokyo, Japan; Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet & Digest & Kidney Dis,Chuo Ku, Kobe, Hyogo, Japan	University of Tokyo; Tokyo Medical & Dental University (TMDU); University of Tokyo; Kobe University	Gotoh, N (corresponding author), Univ Tokyo, Inst Med Sci, Div Genet, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	ngotoh@ims.u-tokyo.ac.jp; tsuchida.mcom@tmd.ac.jp	Huang, Lin/AAI-5740-2020; GOTOH, Noriko/D-8430-2015					BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Dhalluin C, 2000, MOL CELL, V6, P921, DOI 10.1016/S1097-2765(00)00089-7; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; Gotoh N, 2005, MOL CELL BIOL, V25, P4105, DOI 10.1128/MCB.25.10.4105-4116.2005; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Gotoh N, 2004, P NATL ACAD SCI USA, V101, P17144, DOI 10.1073/pnas.0407577101; Gotoh N, 2004, FEBS LETT, V564, P14, DOI 10.1016/S0014-5793(04)00287-X; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Gotoh N, 1995, ONCOGENE, V11, P2525; Habib AA, 2003, MOL CANCER RES, V1, P219; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Harada A, 2005, J BIOL CHEM, V280, P18418, DOI 10.1074/jbc.M411356200; Hirata A, 2005, CANCER RES, V65, P4253, DOI 10.1158/0008-5472.CAN-04-2748; Ho R, 2005, CANCER RES, V65, P9868, DOI 10.1158/0008-5472.CAN-04-2426; Huang L, 2004, BIOCHEM BIOPH RES CO, V324, P1011, DOI 10.1016/j.bbrc.2004.09.152; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Lax I, 2002, MOL CELL, V10, P709, DOI 10.1016/S1097-2765(02)00689-5; LEE M, 1992, JNCI-J NATL CANCER I, V13, P117; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Rubenstein M, 1999, METHOD FIND EXP CLIN, V21, P391, DOI 10.1358/mf.1999.21.6.541918; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Wu YJ, 2003, BIOL CHEM, V384, P1215, DOI 10.1515/BC.2003.134; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	36	24	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2006	25	49					6457	6466		10.1038/sj.onc.1209656	http://dx.doi.org/10.1038/sj.onc.1209656			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16702953				2022-12-25	WOS:000241395100002
J	Drose, S; Brandt, U; Hanley, PJ				Droese, Stefan; Brandt, Ulrich; Hanley, Peter J.			K+-independent actions of diazoxide question the role of inner membrane K-ATP channels in mitochondrial cytoprotective signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART-MITOCHONDRIA; POTASSIUM-TRANSPORT; HYDROGEN-PEROXIDE; BETA-OXIDATION; RABBIT HEARTS; CARDIOPROTECTION; 5-HYDROXYDECANOATE; INHIBITION; PROTECTION; OPENERS	Activation by diazoxide and inhibition by 5-hydroxydecanoate are the hallmarks of mitochondrial ATP-sensitive K+ (KATP) channels. Opening of these channels is thought to trigger cyto-protection (preconditioning) through the generation of reactive oxygen species. However, we found that diazoxide-induced oxidation of the widely used reactive oxygen species indicator 2',7'-dichlorodihydrofluorescein in isolated liver and heart mitochondria was observed in the absence of ATP or K+ and therefore independent of KATP channels. The response was blocked by stigmatellin, implying a role for the cytochrome bc(1) complex (complex III). Diazoxide, though, did not increase hydrogen peroxide (H2O2) production (quantitatively measured with Amplex Red) in intact mitochondria, submitochondrial particles, or purified cytochrome bc1 complex. We confirmed that diazoxide inhibited succinate oxidation, but it also weakly stimulated state 4 respiration even in K+-free buffer, excluding a role for KATP channels. Furthermore, we have shown previously that 5-hydroxydecanoate is partially metabolized, and we hypothesized that fatty acid metabolism may explain the ability of this putative mitochondrial KATP channel blocker to inhibit diazoxide-induced flavoprotein fluorescence, commonly used as an assay of KATP channel activity. Indeed, consistent with our hypothesis, we found that decanoate inhibited diazoxide-induced flavoprotein oxidation. Taken together, our data question the "mitochondrial KATP channel" hypothesis of preconditioning. Diazoxide did not evoke superoxide (which dismutates to H2O2) from the respiratory chain by a direct mechanism, and the stimulatory effects of this compound on mitochondrial respiration and 2',7'-dichlorodihydrofluorescein oxidation were not due to the opening of KATP channels.	Univ Frankfurt Klinikum, Zentrum Biol Chem Mol Bioenerget, D-60590 Frankfurt, Germany; Univ Marburg, Inst Normale & Pathol Physiol, D-35037 Marburg, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Philipps University Marburg	Drose, S (corresponding author), Univ Frankfurt Klinikum, Zentrum Biol Chem Mol Bioenerget, Haus 26,Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	droese@zbc.kgu.de	Hanley, Peter J/H-4915-2017; Brandt, Ulrich/C-4406-2008; Brandt, Ulrich/GLV-1242-2022; Dröse, Stefan/E-4903-2010	Brandt, Ulrich/0000-0003-1869-6811; Brandt, Ulrich/0000-0003-1869-6811; Dröse, Stefan/0000-0002-9361-9034				Ardehali H, 2005, J MOL CELL CARDIOL, V39, P7, DOI 10.1016/j.yjmcc.2004.12.003; BRANDT U, 1992, BIOCHIM BIOPHYS ACTA, V1101, P41, DOI 10.1016/0167-4838(92)90464-O; Burkitt MJ, 2001, BIOCHEM BIOPH RES CO, V282, P329, DOI 10.1006/bbrc.2001.4578; Costa ADT, 2006, AM J PHYSIOL-HEART C, V290, pH406, DOI 10.1152/ajpheart.00794.2005; ENGEL WD, 1983, H-S Z PHYSIOL CHEM, V364, P1753, DOI 10.1515/bchm2.1983.364.2.1753; Forbes RA, 2001, CIRC RES, V88, P802, DOI 10.1161/hh0801.089342; Garlid KD, 2000, BASIC RES CARDIOL, V95, P275, DOI 10.1007/s003950070046; Garlid KD, 2003, BBA-BIOENERGETICS, V1606, P1, DOI 10.1016/S0005-2728(03)00109-9; Garlid KD, 2003, BBA-BIOENERGETICS, V1606, P23, DOI 10.1016/S0005-2728(03)00108-7; Garlid KD, 1996, J BIOL CHEM, V271, P8796, DOI 10.1074/jbc.271.15.8796; Hanley PJ, 2005, J MOL CELL CARDIOL, V39, P17, DOI 10.1016/j.yjmcc.2005.04.002; Hanley PJ, 2005, J PHYSIOL-LONDON, V562, P307, DOI 10.1113/jphysiol.2004.073932; Hanley PJ, 2003, J PHYSIOL-LONDON, V547, P387, DOI 10.1113/jphysiol.2002.037044; Hanley PJ, 2002, J PHYSIOL-LONDON, V542, P735, DOI 10.1113/jphysiol.2002.023960; Hausenloy D, 2004, CIRCULATION, V109, P1714, DOI 10.1161/01.CIR.0000126294.81407.7D; Hempel SL, 1999, FREE RADICAL BIO MED, V27, P146, DOI 10.1016/S0891-5849(99)00061-1; Holmuhamedov EL, 2004, FEBS LETT, V568, P167, DOI 10.1016/j.febslet.2004.05.031; Jaburek M, 1998, J BIOL CHEM, V273, P13578; JACOBUS WE, 1982, ARCH BIOCHEM BIOPHYS, V219, P167, DOI 10.1016/0003-9861(82)90146-1; Kowaltowski AJ, 2001, AM J PHYSIOL-HEART C, V280, pH649, DOI 10.1152/ajpheart.2001.280.2.H649; Lim KHH, 2002, J PHYSIOL-LONDON, V545, P961, DOI 10.1113/jphysiol.2002.031484; Liu YG, 1998, CIRCULATION, V97, P2463, DOI 10.1161/01.CIR.97.24.2463; O'Rourke B, 2004, CIRC RES, V94, P420, DOI 10.1161/01.RES.0000117583.66950.43; Ohashi T, 2002, FEBS LETT, V511, P21, DOI 10.1016/S0014-5793(01)03262-8; Okun JG, 1999, J BIOL CHEM, V274, P2625, DOI 10.1074/jbc.274.5.2625; Oldenburg O, 2003, J MOL CELL CARDIOL, V35, P1035, DOI 10.1016/S0022-2828(03)00151-2; Pain T, 2000, CIRC RES, V87, P460; Ping PP, 1997, CIRC RES, V81, P404, DOI 10.1161/01.RES.81.3.404; PORTENHAUSER R, 1971, BIOCHEM PHARMACOL, V20, P2623, DOI 10.1016/0006-2952(71)90171-7; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; Tarpey MM, 2001, CIRC RES, V89, P224, DOI 10.1161/hh1501.094365; Wang S, 2001, AM J PHYSIOL-HEART C, V280, pH246, DOI 10.1152/ajpheart.2001.280.1.H246; Yellon DM, 2003, PHYSIOL REV, V83, P1113, DOI 10.1152/physrev.00009.2003; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391	34	91	92	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23733	23739		10.1074/jbc.M602570200	http://dx.doi.org/10.1074/jbc.M602570200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16709571	hybrid			2022-12-25	WOS:000239702900048
J	Oliveira, L; Henriques, AO; Tavares, P				Oliveira, Leonor; Henriques, Adriano O.; Tavares, Paulo			Modulation of the viral ATPase activity by the portal protein correlates with DNA packaging efficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO SYSTEM; BACTERIOPHAGE SPP1; ANGSTROM RESOLUTION; TERMINASE ENZYME; SMALL-SUBUNIT; ORGANIZATION; EXPRESSION; FORMS; MOTOR; GENE	DNA packaging in tailed bacteriophages and herpesviruses requires assembly of a complex molecular machine at a specific vertex of a preformed procapsid. As in all these viruses, the DNA translocation motor of bacteriophage SPP1 is composed of the portal protein (gp6) that provides a tunnel for DNA entry into the procapsid and of the viral ATPase (gp1-gp2 complex) that fuels DNA translocation. Here we studied the cross-talk between the components of the motor to control its ATP consumption and DNA encapsidation. We showed that gp6 embedded in the procapsid structure stimulated more than 10-fold the gp2 ATPase activity. This stimulation, which was significantly higher than the one conferred by isolated gp6, depended on the presence of gp1. Mutations in different regions of gp6 abolished or decreased the gp6-induced stimulation of the ATPase. This effect on gp2 activity was observed both in the presence and in the absence of DNA and showed a strict correlation with the efficiency of DNA packaging into procapsids containing the mutant portals. Our results demonstrated that the portal protein has an active control over the viral ATPase activity that correlates with the performance of the DNA packaging motor.	CNRS, Unite Virol Mol & Struct, UMR 2472, UMR 1157,INRA, F-91198 Gif Sur Yvette, France; Inst Federat Rech, F-91198 Gif Sur Yvette, France; Inst Tecnol Quim & Biol, Lab Microbial Dev, P-2781901 Oeiras, Portugal	Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay	Oliveira, L (corresponding author), CNRS, Unite Virol Mol & Struct, UMR 2472, UMR 1157,INRA, Batiment 14B,Ave Terrasse, F-91198 Gif Sur Yvette, France.	oliveira@vms.cnrs-gif.fr		Henriques, Adriano/0000-0003-4292-4802; Tavares, Paulo/0000-0002-2566-4546				Agirrezabala X, 2005, J MOL BIOL, V347, P895, DOI 10.1016/j.jmb.2005.02.005; Alonso JC, 1997, GENE, V204, P201, DOI 10.1016/S0378-1119(97)00547-7; BAZINET C, 1985, ANNU REV MICROBIOL, V39, P109; BLACK LW, 1989, ANNU REV MICROBIOL, V43, P267, DOI 10.1146/annurev.micro.43.1.267; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Camacho AG, 2003, J BIOL CHEM, V278, P23251, DOI 10.1074/jbc.M301805200; Casjens S, 1988, BACTERIOPHAGES, P15; Catalano Carlos Enrique, 2005, P1; CHAI S, 1992, J MOL BIOL, V224, P87, DOI 10.1016/0022-2836(92)90578-8; CHAI SH, 1995, J MOL BIOL, V252, P386, DOI 10.1006/jmbi.1995.0505; Chemla YR, 2005, CELL, V122, P683, DOI 10.1016/j.cell.2005.06.024; Droege Anja, 2005, P89; Droge A, 2000, J MOL BIOL, V296, P103, DOI 10.1006/jmbi.1999.3449; Droge A, 2000, J MOL BIOL, V296, P117, DOI 10.1006/jmbi.1999.3450; DUBE P, 1993, EMBO J, V12, P1303, DOI 10.1002/j.1460-2075.1993.tb05775.x; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; Gual A, 1998, VIROLOGY, V242, P279, DOI 10.1006/viro.1997.9017; Gual A, 2000, J BIOL CHEM, V275, P35311, DOI 10.1074/jbc.M004309200; GUO PX, 1987, J MOL BIOL, V197, P219, DOI 10.1016/0022-2836(87)90120-3; HAIMA P, 1987, MOL GEN GENET, V209, P335, DOI 10.1007/BF00329663; HAMADA K, 1987, VIROLOGY, V159, P244, DOI 10.1016/0042-6822(87)90461-2; Isidro A, 2004, VIROLOGY, V322, P253, DOI 10.1016/j.virol.2004.02.012; Isidro A, 2004, MOL MICROBIOL, V51, P949, DOI 10.1046/j.1365-2958.2003.03880.x; Jekow P, 1999, EUR J BIOCHEM, V264, P724, DOI 10.1046/j.1432-1327.1999.00601.x; Leffers G, 2000, J BIOL CHEM, V275, P37127, DOI 10.1074/jbc.M003357200; LEGRICE SFJ, 1990, METHOD ENZYMOL, V185, P201; LEONHARDT H, 1988, J GEN MICROBIOL, V134, P605; Lin HC, 1999, J MOL BIOL, V289, P249, DOI 10.1006/jmbi.1999.2781; Lurz R, 2001, J MOL BIOL, V310, P1027, DOI 10.1006/jmbi.2001.4800; MORITA M, 1993, VIROLOGY, V193, P748, DOI 10.1006/viro.1993.1183; Newcomb WW, 2001, J VIROL, V75, P10923, DOI 10.1128/JVI.75.22.10923-10932.2001; Oliveira L, 2005, J MOL BIOL, V353, P529, DOI 10.1016/j.jmb.2005.08.063; Orlova EV, 2003, EMBO J, V22, P1255, DOI 10.1093/emboj/cdg123; Orlova EV, 1999, NAT STRUCT BIOL, V6, P842; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Simpson AA, 2000, NATURE, V408, P745, DOI 10.1038/35047129; Smith DE, 2001, NATURE, V413, P748, DOI 10.1038/35099581; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TAVARES P, 1992, J MOL BIOL, V225, P81, DOI 10.1016/0022-2836(92)91027-M; VALPUESTA JM, 1994, Q REV BIOPHYS, V27, P107, DOI 10.1017/S0033583500004510; Yang G, 2003, VIROLOGY, V305, P276, DOI 10.1006/viro.2002.1602; YEO A, 1995, J MOL BIOL, V245, P141, DOI 10.1006/jmbi.1994.0013	42	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21914	21923		10.1074/jbc.M603314200	http://dx.doi.org/10.1074/jbc.M603314200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16735502	hybrid, Green Published			2022-12-25	WOS:000239387100038
J	Cestele, S; Yarov-Yarovoy, V; Qu, YS; Sampieri, F; Scheuer, T; Catterall, WA				Cestele, Sandrine; Yarov-Yarovoy, Vladimir; Qu, Yusheng; Sampieri, Francois; Scheuer, Todd; Catterall, William A.			Structure and function of the voltage sensor of sodium channels probed by a beta-scorpion toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER K+ CHANNEL; CENTRUROIDES-SUFFUSUS-SUFFUSUS; GATING MODIFIER TOXINS; SEA-ANEMONE TOXIN; POTASSIUM CHANNEL; STRUCTURE PREDICTION; TITYUS-SERRULATUS; ALPHA-SUBUNIT; RECEPTOR-SITE; S4 SEGMENT	Voltage sensing by voltage-gated sodium channels determines the electrical excitability of cells, but the molecular mechanism is unknown. beta-Scorpion toxins bind specifically to neurotoxin receptor site 4 and induce a negative shift in the voltage dependence of activation through a voltage sensor-trapping mechanism. Kinetic analysis showed that beta-scorpion toxin binds to the resting state, and subsequently the bound toxin traps the voltage sensor in the activated state in a voltage-dependent but concentration-independent manner. The rate of voltage sensor trapping can be fit by a two-step model, in which the first step is voltage-dependent and correlates with the outward gating movement of the IIS4 segment, whereas the second step is voltage-independent and results in shifted voltage dependence of activation of the channel. Mutations of Glu(779) in extracellular loop IIS1-S2 and both Glu(837) and Leu(840) in extracellular loop IIS3-S4 reduce the binding affinity of beta-scorpion toxin. Mutations of positively charged and hydrophobic amino acid residues in the IIS4 segment do not affect beta-scorpion toxin binding but alter voltage dependence of activation and enhance beta-scorpion toxin action. Structural modeling with the Rosetta algorithm yielded a three-dimensional model of the toxin-receptor complex with the IIS4 voltage sensor at the extracellular surface. Our results provide mechanistic and structural insight into the voltage sensor-trapping mode of scorpion toxin action, define the position of the voltage sensor in the resting state of the sodium channel, and favor voltage-sensing models in which the S4 segment spans the membrane in both resting and activated states.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Mediterranee, Fac Med Nord, F-13916 Marseille 20, France	University of Washington; University of Washington Seattle; UDICE-French Research Universities; Aix-Marseille Universite	Catterall, WA (corresponding author), Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA.	wcatt@u.washington.edu	Cestèle, Sandrine/O-7657-2016; Yarov-Yarovoy, Vladimir/ABE-5454-2020	Cestèle, Sandrine/0000-0002-5982-1562; Yarov-Yarovoy, Vladimir/0000-0002-2325-4834	NATIONAL INSTITUTE OF MENTAL HEALTH [K01MH067625] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015751] Funding Source: NIH RePORTER; NIMH NIH HHS [K01 MH067625-03, K01 MH067625, K01 MH067625-01, K01 MH067625-02, MH67625] Funding Source: Medline; NINDS NIH HHS [R01 NS015751, R01 NS15751] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahern CA, 2004, J GEN PHYSIOL, V123, P205, DOI 10.1085/jgp.200308993; ARMSTRONG CM, 1981, PHYSIOL REV, V61, P644, DOI 10.1152/physrev.1981.61.3.644; AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; Bezanilla F, 2005, TRENDS BIOCHEM SCI, V30, P166, DOI 10.1016/j.tibs.2005.02.006; Bourinet E, 1999, NAT NEUROSCI, V2, P407, DOI 10.1038/8070; Bradley P, 2005, SCIENCE, V309, P1868, DOI 10.1126/science.1113801; CAHALAN MD, 1975, J PHYSIOL-LONDON, V244, P511, DOI 10.1113/jphysiol.1975.sp010810; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; CATTERALL WA, 1978, J BIOL CHEM, V253, P7393; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; CATTERALL WA, 1979, J GEN PHYSIOL, V74, P375, DOI 10.1085/jgp.74.3.375; CATTERALL WA, 1977, J BIOL CHEM, V252, P8660; Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6; Cestele S, 2001, J GEN PHYSIOL, V118, P291, DOI 10.1085/jgp.118.3.291; Cestele S, 2000, BIOCHIMIE, V82, P883, DOI 10.1016/S0300-9084(00)01174-3; Cha A, 1999, NEURON, V22, P73, DOI 10.1016/S0896-6273(00)80680-7; Chanda B, 2002, J GEN PHYSIOL, V120, P629, DOI 10.1085/jgp.20028679; Chen LQ, 1996, J GEN PHYSIOL, V108, P549, DOI 10.1085/jgp.108.6.549; Chivian D, 2005, PROTEINS, V61, P157, DOI 10.1002/prot.20733; Cohen L, 2005, J BIOL CHEM, V280, P5045, DOI 10.1074/jbc.M408427200; Cohen L, 2004, J BIOL CHEM, V279, P8206, DOI 10.1074/jbc.M307531200; Cook WJ, 2002, PROTEIN SCI, V11, P479, DOI 10.1110/ps.39202; DARBON H, 1984, J BIOL CHEM, V259, P6074; Glaser F, 2001, PROTEINS, V43, P89, DOI 10.1002/1097-0134(20010501)43:2<89::AID-PROT1021>3.3.CO;2-8; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; Gray JJ, 2003, J MOL BIOL, V331, P281, DOI 10.1016/S0022-2836(03)00670-3; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; Hassani O, 1999, EUR J BIOCHEM, V260, P76, DOI 10.1046/j.1432-1327.1999.00152.x; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; JAIMOVICH E, 1982, P NATL ACAD SCI-BIOL, V79, P3896, DOI 10.1073/pnas.79.12.3896; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Jiang QX, 2004, NATURE, V430, P806, DOI 10.1038/nature02735; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; JONAS P, 1986, PFLUG ARCH EUR J PHY, V407, P92, DOI 10.1007/BF00580727; JOVER E, 1980, BIOCHEM BIOPH RES CO, V95, P1697; Jung HJ, 2005, BIOCHEMISTRY-US, V44, P6015, DOI 10.1021/bi0477034; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Laine M, 2003, NEURON, V39, P467, DOI 10.1016/S0896-6273(03)00468-9; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; Lee HC, 2003, NEURON, V40, P527, DOI 10.1016/S0896-6273(03)00636-6; Li-Smerin Y, 1998, P NATL ACAD SCI USA, V95, P8585, DOI 10.1073/pnas.95.15.8585; Li-Smerin Y, 2000, J GEN PHYSIOL, V115, P673, DOI 10.1085/jgp.115.6.673; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; MARTIN MF, 1987, J BIOL CHEM, V262, P4452; MEVES H, 1982, PFLUG ARCH EUR J PHY, V393, P56, DOI 10.1007/BF00582392; Morgan K, 2000, P NATL ACAD SCI USA, V97, P2308, DOI 10.1073/pnas.030362197; NICHOLSON GM, 1994, PFLUG ARCH EUR J PHY, V428, P400, DOI 10.1007/BF00724524; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; Phillips LR, 2005, NATURE, V436, P857, DOI 10.1038/nature03873; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; Rohl CA, 2004, PROTEINS, V55, P656, DOI 10.1002/prot.10629; Rohl CA, 2004, METHOD ENZYMOL, V383, P66; Ruta V, 2003, NATURE, V422, P180, DOI 10.1038/nature01473; Sato C, 2001, NATURE, V409, P1047, DOI 10.1038/35059098; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; Sheets MF, 1999, BIOPHYS J, V77, P747, DOI 10.1016/S0006-3495(99)76929-8; Simons KT, 1997, J MOL BIOL, V268, P209, DOI 10.1006/jmbi.1997.0959; Simons KT, 1999, PROTEINS, V34, P82, DOI 10.1002/(SICI)1097-0134(19990101)34:1<82::AID-PROT7>3.0.CO;2-A; Smith JJ, 2005, J BIOL CHEM, V280, P11127, DOI 10.1074/jbc.M412552200; Sokolov S, 2005, NEURON, V47, P183, DOI 10.1016/j.neuron.2005.06.012; Starace DM, 2004, NATURE, V427, P548, DOI 10.1038/nature02270; Starace DM, 2001, J GEN PHYSIOL, V117, P469, DOI 10.1085/jgp.117.5.469; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; Swartz KJ, 1997, NEURON, V18, P675, DOI 10.1016/S0896-6273(00)80307-4; TEJEDOR FJ, 1988, P NATL ACAD SCI USA, V85, P8742, DOI 10.1073/pnas.85.22.8742; THOMSEN WJ, 1989, P NATL ACAD SCI USA, V86, P10161, DOI 10.1073/pnas.86.24.10161; Tombola F, 2005, NEURON, V45, P379, DOI 10.1016/j.neuron.2004.12.047; VIJVERBERG HPM, 1984, PFLUG ARCH EUR J PHY, V401, P297; WANG GK, 1983, MOL PHARMACOL, V23, P519; Winterfield JR, 2000, J GEN PHYSIOL, V116, P637, DOI 10.1085/jgp.116.5.637; Yang NB, 1997, BIOPHYS J, V73, P2260, DOI 10.1016/S0006-3495(97)78258-4; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8; Yarov-Yarovoy V, 2006, PROTEINS, V62, P1010, DOI 10.1002/prot.20817; Yu FH, 2003, J NEUROSCI, V23, P7577; YU FH, 2004, SCI STKE 2004	80	118	118	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21332	21344		10.1074/jbc.M603814200	http://dx.doi.org/10.1074/jbc.M603814200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16679310	hybrid, Green Submitted, Green Accepted			2022-12-25	WOS:000239187300069
J	Hakulinen, J; Keski-Oja, J				Hakulinen, Juha; Keski-Oja, Jorma			ADAM10-mediated release of complement membrane cofactor protein during apoptosis of epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEVATED SERUM; CD46; ACTIVATION; CLEAVAGE; METALLOPROTEINASE; EXPRESSION; RECEPTOR; MCP; PURIFICATION; MECHANISM	Membrane cofactor protein CD46 controls complement activation on cells, is a receptor for several pathogens, and modulates immune responses by affecting CD8(+) T cells. Cells can release CD46 in an intact form on membrane vesicles and in a truncated form by a metalloproteolytic cleavage. The mechanism of shedding and its relationship to cell physiology has remained unclear. We have found using RNA interference analysis that a disintegrin and metalloproteinase (ADAM) 10 is responsible for the regulated shedding of the ectodomain of CD46 in apoptotic cells. The shedding of CD46 was initiated with staurosporine and UVB. Exposure of cell cultures to either UVB or staurosporine resulted in changes of cell morphology and detachment of cells from their matrices within 8 - 24 h. During this process CD46 was released both in apoptotic vesicles (vCD46) and proteolytically (sCD46) into the medium. Both the metalloproteinase inhibitor GM6001 and RNA interference of ADAM10 completely prevented the release of sCD46 and increased the expression of vCD46 on HaCaT cell vesicles, suggesting that ADAM10 releases sCD46 from the apoptotic vesicles. To explore whether the release of sCD46 is associated with apoptosis we analyzed the effects of caspase inhibitors. As expected, the inhibition of caspase activity attenuated the characteristic features of apoptosis and also decreased the release of sCD46. Our results reveal ADAM10 as an important regulator of CD46 expression during apoptosis. The ADAM10-mediated release of CD46 from apoptotic vesicles may represent a form of strategy to allow restricted complement activation to deal with modified self.	Univ Helsinki, Biomedicum, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Pathol, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Virol, Haartman Inst, FIN-00014 Helsinki, Finland; Helsinki Univ Hosp, Helsinki 00014, Finland	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Hakulinen, J (corresponding author), Univ Helsinki, Biomedicum, A506B,POB 63,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	Juha.Hakulinen@helsinki.fi						Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Astier A, 2000, J IMMUNOL, V164, P6091, DOI 10.4049/jimmunol.164.12.6091; Atkinson JP, 2005, ANN NY ACAD SCI, V1056, P144, DOI 10.1196/annals.1352.032; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BUICK RN, 1985, CANCER RES, V45, P3668; Duffy MJ, 2003, THROMB HAEMOSTASIS, V89, P622; Durrant L G, 2001, Curr Opin Investig Drugs, V2, P959; Fischer OM, 2004, MOL CELL BIOL, V24, P5172, DOI 10.1128/MCB.24.12.5172-5183.2004; Fishelson Z, 2003, MOL IMMUNOL, V40, P109, DOI 10.1016/S0161-5890(03)00112-3; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; Gaipl US, 2001, CELL DEATH DIFFER, V8, P327, DOI 10.1038/sj.cdd.4400826; Gescher A, 2000, CRIT REV ONCOL HEMAT, V34, P127, DOI 10.1016/S1040-8428(00)00058-5; Gutwein P, 2005, CLIN CANCER RES, V11, P2492, DOI 10.1158/1078-0432.CCR-04-1688; Guzman E, 2003, APOPTOSIS, V8, P315, DOI 10.1023/A:1024112231953; Hakulinen J, 2004, EUR J IMMUNOL, V34, P2620, DOI 10.1002/eji.200424969; Hara T, 1997, IMMUNOBIOLOGY, V196, P491, DOI 10.1016/S0171-2985(97)80066-6; Higashiyama S, 2005, BBA-PROTEINS PROTEOM, V1751, P110, DOI 10.1016/j.bbapap.2004.11.009; Ichihashi M, 2003, TOXICOLOGY, V189, P21, DOI 10.1016/S0300-483X(03)00150-1; Ilan N, 2001, FASEB J, V15, P362, DOI 10.1096/fj.00-0372com; Jones J, 1995, IMMUNOLOGY, V86, P651; Kallstrom H, 1998, J BIOL CHEM, V273, P21777, DOI 10.1074/jbc.273.34.21777; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; Kawano M, 1999, CLIN EXP IMMUNOL, V116, P542; Kemper C, 2003, NATURE, V421, P388, DOI 10.1038/nature01315; Latonen L, 2001, ONCOGENE, V20, P6784, DOI 10.1038/sj.onc.1204883; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Lindahl G, 2000, CURR OPIN IMMUNOL, V12, P44, DOI 10.1016/S0952-7915(99)00049-7; Liszewski MK, 2005, SPRINGER SEMIN IMMUN, V27, P345, DOI 10.1007/s00281-005-0002-3; Marie JC, 2002, NAT IMMUNOL, V3, P659, DOI 10.1038/ni810; Mevorach D, 1998, J EXP MED, V188, P2313, DOI 10.1084/jem.188.12.2313; Murai T, 2004, J BIOL CHEM, V279, P4541, DOI 10.1074/jbc.M307356200; Navratil JS, 2001, J IMMUNOL, V166, P3231, DOI 10.4049/jimmunol.166.5.3231; Reiss K, 2005, EMBO J, V24, P742, DOI 10.1038/sj.emboj.7600548; Riley-Vargas RC, 2005, J CLIN INVEST, V115, P1241, DOI 10.1172/JCI200523213; SAARI H, 1990, BIOCHEM BIOPH RES CO, V171, P979, DOI 10.1016/0006-291X(90)90780-Q; SBARBA PD, 2002, BIOL CHEM, V383, P69; SEYA T, 1995, INT IMMUNOL, V7, P727, DOI 10.1093/intimm/7.5.727; SEYA T, 1986, J EXP MED, V163, P837, DOI 10.1084/jem.163.4.837; Shimizu T, 2004, P NATL ACAD SCI USA, V101, P6770, DOI 10.1073/pnas.0401604101; Shoji T, 2000, CLIN IMMUNOL, V95, P163, DOI 10.1006/clim.2000.4847; Soldan SS, 2001, ANN NEUROL, V50, P486, DOI 10.1002/ana.1135; Solovyan VT, 2006, J CELL PHYSIOL, V207, P445, DOI 10.1002/jcp.20607; Sordet O, 2004, J BIOL CHEM, V279, P50499, DOI 10.1074/jbc.M410277200; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; Strey CW, 2003, J EXP MED, V198, P913, DOI 10.1084/jem.20030374; TSUJI S, 1994, J BIOCHEM-TOKYO, V116, P794, DOI 10.1093/oxfordjournals.jbchem.a124598; van den Berg CW, 2002, IMMUNOLOGY, V107, P102, DOI 10.1046/j.1365-2567.2002.01468.x; Vermes I, 2000, J IMMUNOL METHODS, V243, P167, DOI 10.1016/S0022-1759(00)00233-7; Wang GX, 2000, J IMMUNOL, V164, P1839, DOI 10.4049/jimmunol.164.4.1839; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Yoshimura T, 2002, J INFECT DIS, V185, P332, DOI 10.1086/338191	52	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21369	21376		10.1074/jbc.M602053200	http://dx.doi.org/10.1074/jbc.M602053200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16735514	hybrid			2022-12-25	WOS:000239187300073
J	Patwardhan, P; Shen, YQ; Goldberg, GS; Miller, WT				Patwardhan, Parag; Shen, Yongquan; Goldberg, Gary S.; Miller, W. Todd			Individual Cas phosphorylation sites are dispensable for processive phosphorylation by Src and anchorage-independent cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRK-ASSOCIATED SUBSTRATE; ADAPTER PROTEIN CAS; TRANSFORMED-CELLS; DUAL PHOSPHORYLATION; V-CRK; MIGRATION; P130(CAS); KINASE; APOPTOSIS; MOLECULE	Cas is a multidomain signaling protein that resides in focal adhesions. Cas possesses a large central substrate domain containing 15 repeats of the sequence YXXP, which are phosphorylated by Src. The phosphorylation sites are essential for the roles of Cas in cell migration and in regulation of the actin cytoskeleton. We showed previously that Src catalyzes the multisite phosphorylation of Cas via a processive mechanism. In this study, we created mutant forms of Cas to identify the determinants for processive phosphorylation. Mutants containing single or multiple YXXP mutations were phosphorylated processively by Src, suggesting that individual sites are dispensable. The results also suggest that there is no defined order to the Cas phosphorylation events. We also studied the effects of these mutations by reintroducing Cas into Cas-deficient fibroblasts. Mutants lacking some or all YXXP sites augment the ability of Src to promote anchorage-independent growth. On the other hand, deletion of YXXP sites compromises the ability of Cas to promote tumor cell migration.	SUNY Stony Brook, Dept Physiol & Biophys, Sch Med, Stony Brook, NY 11794 USA; Univ Med & Dent New Jersey, Dept Mol Biol, Stratford, NJ 08084 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Rutgers State University New Brunswick; Rutgers State University Medical Center	Miller, WT (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Sch Med, Stony Brook, NY 11794 USA.	todd.miller@stonybrook.edu	Patwardhan, Parag/G-1987-2011		NATIONAL CANCER INSTITUTE [R29CA058530, R01CA058530, R01CA088805] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R03EY014479] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA058530-12, CA88805, CA58530, R01 CA088805, R01 CA058530] Funding Source: Medline; NEI NIH HHS [R03 EY014479, EY014479] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alexander DB, 2004, CANCER RES, V64, P1347, DOI 10.1158/0008-5472.CAN-03-2558; Aubol BE, 2003, P NATL ACAD SCI USA, V100, P12601, DOI 10.1073/pnas.1635129100; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Brabek J, 2005, MOL CANCER RES, V3, P307, DOI 10.1158/1541-7786.MCR-05-0015; Brabek J, 2004, ONCOGENE, V23, P7406, DOI 10.1038/sj.onc.1207965; Burack WR, 1997, BIOCHEMISTRY-US, V36, P5929, DOI 10.1021/bi970535d; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Chodniewicz D, 2004, BBA-MOL CELL RES, V1692, P63, DOI 10.1016/j.bbamcr.2004.03.006; Ferrell JE, 1997, J BIOL CHEM, V272, P19008, DOI 10.1074/jbc.272.30.19008; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Goldberg GS, 2003, J BIOL CHEM, V278, P46533, DOI 10.1074/jbc.M307526200; Goldberg GS, 2001, CANCER RES, V61, P1334; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Huang JH, 2002, J BIOL CHEM, V277, P27265, DOI 10.1074/jbc.M203063200; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Pellicena P, 2001, J BIOL CHEM, V276, P28190, DOI 10.1074/jbc.M100055200; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; SAKAI R, 1994, J BIOL CHEM, V269, P32740; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Scott MP, 2000, BIOCHEMISTRY-US, V39, P14531, DOI 10.1021/bi001850u; Shen YQ, 2006, CANCER RES, V66, P1543, DOI 10.1158/0008-5472.CAN-05-3152; Shin NY, 2004, J BIOL CHEM, V279, P38331, DOI 10.1074/jbc.M404675200	29	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20689	20697		10.1074/jbc.M602311200	http://dx.doi.org/10.1074/jbc.M602311200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16707485	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000239187300006
J	Quillen, EE; Haslam, GC; Samra, HS; Amani-Taleshi, D; Knight, JA; Wyatt, DE; Bishop, SC; Colvert, KK; Richter, ML; Kitos, PA				Quillen, Ellen E.; Haslam, Gale C.; Samra, Hardeep S.; Amani-Taleshi, Darius; Knight, Jeffrey A.; Wyatt, Diane E.; Bishop, Stephanie C.; Colvert, Kim K.; Richter, Mark L.; Kitos, Paul A.			Ectoadenylate kinase and plasma membrane ATP synthase activities of human vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIABLE ANIMAL-CELLS; ADENYLATE KINASE; NUCLEOSIDE DIPHOSPHOKINASE; SURFACE; RELEASE; ANGIOSTATIN; INTERCONVERSION; INHIBITION; METABOLISM; MECHANISM	Formation of ATP from ADP on the external surface of vascular endothelial cells has been attributed to plasma membrane ATP synthase, ectoadenylate kinase ( ecto-AK), and/or ecto-nucleoside diphosphokinase. These enzymes or their catalytic products have been causatively linked to the elaboration of vascular networks and the regulation of capillary function. The amount of ATP generated extracellularly is small, requiring sensitive analytical methods for quantification. Human umbilical vein endothelial cells were used to revisit extracellular ATP synthesis using a reliable tetrazolium reduction assay and multiwell plate cultures. Test conditions compatible with AK stability were established. Extracellular AK activity was found to be < 1% of the total ( intracellular and extracellular), raising the possibility that the external enzyme could have leaked from living cells and/or a few dying cells. To determine whether AK inadvertently leaked from the cells, the activity of another cytoplasmic enzyme, glucose-6-phosphate dehydrogenase ( G6PD), was also measured. G6PD is present in the cytoplasm in similar abundance to AK. The activity ratio of G6PD ( extracellular/total) was found to be similar to that of AK. Because G6PD in the medium was probably due to leakage, other cytoplasmic macromolecules, including AK, should be released proportionately from the cells. The role of plasma membrane ATP synthase in extracellular ATP formation was examined using Hanks' balanced salt solution with and without selective inhibitors of AK and ATP synthase activities. With P-1, P-5-di( adenosine 5')-pentaphosphate ( inhibitor of AK activity), no extracellular ATP synthesis was detected, whereas with oligomycin, piceatannol, and aurovertin ( inhibitors of F1F0-ATP synthase and F-1-ATPase activities), no inhibition of extracellular ATP synthesis was observed. AK activity alone could account for the observed extracellular ATP synthesis. The possible impact of ADP impurity in the assays is discussed.	Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA; Ferris State Univ, Dept Phys Sci, Big Rapids, MI 49307 USA	University of Kansas	Richter, ML (corresponding author), Univ Kansas, Dept Mol Biosci, 1200 Sunnyside Ave, Lawrence, KS 66045 USA.	richter@ku.edu		Quillen, Ellen/0000-0003-2033-8693				Arakaki N, 2003, MOL CANCER RES, V1, P931; Boyer PD, 2000, BBA-BIOENERGETICS, V1458, P252, DOI 10.1016/S0005-2728(00)00077-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buckley KA, 2003, FASEB J, V17, P1401, DOI 10.1096/fj.02-0940com; Burrell HE, 2005, J BIOL CHEM, V280, P29667, DOI 10.1074/jbc.M505381200; Buxton ILO, 2001, AM J PHYSIOL-HEART C, V281, pH1657, DOI 10.1152/ajpheart.2001.281.4.H1657; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; Carrasco AJ, 2001, P NATL ACAD SCI USA, V98, P7623, DOI 10.1073/pnas.121038198; CHAHWALA SB, 1984, J BIOL CHEM, V259, P3717; Chi SL, 2006, CANCER RES, V66, P875, DOI 10.1158/0008-5472.CAN-05-2806; DAS B, 1994, J EXP MED, V180, P273, DOI 10.1084/jem.180.1.273; Dixon CJ, 2003, BRIT J PHARMACOL, V138, P272, DOI 10.1038/sj.bjp.0705016; Dixon CJ, 1999, BRIT J PHARMACOL, V127, P1680, DOI 10.1038/sj.bjp.0702653; Donaldson SH, 2002, AM J RESP CELL MOL, V26, P209, DOI 10.1165/ajrcmb.26.2.4650; DOUGLAS GC, 1993, J APPL PHYSIOL, V75, P1423, DOI 10.1152/jappl.1993.75.3.1423; Folkman J, 2000, JNCI-J NATL CANCER I, V92, P94, DOI 10.1093/jnci/92.2.94; FRESHNEY RI, 1983, CULTURE ANIMAL CELLS; Haslam G, 2000, CYTOTECHNOLOGY, V32, P63, DOI 10.1023/A:1008121125755; Haslam G, 2005, ANAL BIOCHEM, V336, P187, DOI 10.1016/j.ab.2004.10.008; KNOWLES AF, 1972, J BIOL CHEM, V247, P6617; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; Linnett P E, 1979, Methods Enzymol, V55, P472; Martinez LO, 2003, NATURE, V421, P75, DOI 10.1038/nature01250; Moser TL, 2001, P NATL ACAD SCI USA, V98, P6656, DOI 10.1073/pnas.131067798; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; Picher M, 2003, J BIOL CHEM, V278, P11256, DOI 10.1074/jbc.M208071200; ROZENGURT E, 1977, J BIOL CHEM, V252, P4584; Seow CJ, 2002, EUR J PHARMACOL, V443, P189, DOI 10.1016/S0014-2999(02)01534-0; Sinev MA, 1996, BIOCHEMISTRY-US, V35, P6425, DOI 10.1021/bi952687j; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TEUSCHER E, 1985, BIOMED BIOCHIM ACTA, V44, P493; vanRaaij MJ, 1996, P NATL ACAD SCI USA, V93, P6913, DOI 10.1073/pnas.93.14.6913; Yegutkin GG, 2001, FASEB J, V15, P251, DOI 10.1096/fj.00-0268com; Yegutkin GG, 2002, BIOCHEM J, V367, P121, DOI 10.1042/BJ20020439; Zheng JB, 2000, BRIT J PHARMACOL, V130, P1115, DOI 10.1038/sj.bjp.0703397; Zheng JB, 1999, BIOCHEM BIOPH RES CO, V261, P499, DOI 10.1006/bbrc.1999.1063	37	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20728	20737		10.1074/jbc.M513042200	http://dx.doi.org/10.1074/jbc.M513042200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16714292	hybrid			2022-12-25	WOS:000239187300009
J	Richardson, RT; Alekseev, OM; Grossman, G; Widgren, EE; Thresher, R; Wagner, EJ; Sullivan, KD; Marzluff, WF; O'Rand, MG				Richardson, Richard T.; Alekseev, Oleg M.; Grossman, Gail; Widgren, Esther E.; Thresher, Randy; Wagner, Eric J.; Sullivan, Kelly D.; Marzluff, William F.; O'Rand, Michael G.			Nuclear autoantigenic sperm protein (NASP), a linker histone chaperone that is required for cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME ASSEMBLY PATHWAYS; DNA-SYNTHESIS; CHROMATIN-STRUCTURE; BINDING-PROTEIN; MESSENGER-RNA; REPLICATION; H1; EXPRESSION; MOUSE; LOCALIZATION	A multichaperone nucleosome-remodeling complex that contains the H1 linker histone chaperone nuclear autoantigenic sperm protein ( NASP) has recently been described. Linker histones ( H1) are required for the proper completion of normal development, and NASP transports H1 histones into nuclei and exchanges H1 histones with DNA. Consequently, we investigated whether NASP is required for normal cell cycle progression and development. We now report that without sufficient NASP, HeLa cells and U2OS cells are unable to replicate their DNA and progress through the cell cycle and that the NASP(-/-) null mutation causes embryonic lethality. Although the null mutation NASP(-/-) caused embryonic lethality, null embryos survive until the blastocyst stage, which may be explained by the presence of stored NASP protein in the cytoplasm of oocytes. We conclude from this study that NASP and therefore the linker histones are key players in the assembly of chromatin after DNA replication.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	O'Rand, MG (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, CB 7090, Chapel Hill, NC 27599 USA.	morand@unc.edu	, UNC Flow Cytometry Core/AGU-9839-2022	SULLIVAN, KELLY/0000-0003-2725-0205	NICHD NIH HHS [U54HD35041] Funding Source: Medline; NIGMS NIH HHS [F32 GM070101-02] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD035041] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM070101] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ai X, 2004, MOL CELL, V14, P195, DOI 10.1016/S1097-2765(04)00184-4; Alekseev OM, 2005, J BIOL CHEM, V280, P2904, DOI 10.1074/jbc.M410397200; Alekseev OM, 2005, PROTEINS, V61, P1, DOI 10.1002/prot.20600; Alekseev OM, 2003, J BIOL CHEM, V278, P8846, DOI 10.1074/jbc.M210352200; Batova I, 1996, BIOL REPROD, V54, P1238, DOI 10.1095/biolreprod54.6.1238; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Bustin M, 2005, MOL CELL, V17, P617, DOI 10.1016/j.molcel.2005.02.019; Fan YH, 2005, CELL, V123, P1199, DOI 10.1016/j.cell.2005.10.028; Fan YH, 2003, MOL CELL BIOL, V23, P4559, DOI 10.1128/MCB.23.13.4559-4572.2003; Franco AA, 2005, GENE DEV, V19, P1365, DOI 10.1101/gad.1305005; Groth A, 2005, MOL CELL, V17, P301, DOI 10.1016/j.molcel.2004.12.018; Hoek M, 2003, P NATL ACAD SCI USA, V100, P12183, DOI 10.1073/pnas.1635158100; Johnson A, 2005, ANNU REV BIOCHEM, V74, P283, DOI 10.1146/annurev.biochem.73.011303.073859; Koike M, 2002, J RADIAT RES, V43, P223, DOI 10.1269/jrr.43.223; Lever MA, 2000, NATURE, V408, P873, DOI 10.1038/35048603; Lewis LK, 2005, NUCLEIC ACIDS RES, V33, P4928, DOI 10.1093/nar/gki806; Liang L, 2005, J BIOL CHEM, V280, P31442, DOI 10.1074/jbc.M503776200; MANSOUR SL, 1990, P NATL ACAD SCI USA, V87, P7688, DOI 10.1073/pnas.87.19.7688; Marzluff WF, 2005, CURR OPIN CELL BIOL, V17, P274, DOI 10.1016/j.ceb.2005.04.010; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Nakatani Y, 2004, COLD SPRING HARB SYM, V69, P273, DOI 10.1101/sqb.2004.69.273; Richardson RT, 2000, J BIOL CHEM, V275, P30378, DOI 10.1074/jbc.M003781200; Richardson RT, 2001, GENE, V274, P67, DOI 10.1016/S0378-1119(01)00605-9; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Schulz LL, 2006, FASEB J, V20, P488, DOI 10.1096/fj.05-5020fje; SCHWARZACHER T, 2000, PRACTICAL IN SITU HY, P126; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Tyler JK, 2002, EUR J BIOCHEM, V269, P2268, DOI 10.1046/j.1432-1033.2002.02890.x; Wagner EJ, 2005, BIOCHEM SOC T, V33, P471, DOI 10.1042/BST0330471; Wagner EJ, 2002, MOL CELL, V10, P943, DOI 10.1016/S1097-2765(02)00645-7; WELCH JE, 1990, BIOL REPROD, V43, P559, DOI 10.1095/biolreprod43.4.559; WELCH JE, 1990, BIOL REPROD, V43, P569, DOI 10.1095/biolreprod43.4.569; Whitfield ML, 2004, NUCLEIC ACIDS RES, V32, P4833, DOI 10.1093/nar/gkh798; Whitfield ML, 2000, MOL CELL BIOL, V20, P4188, DOI 10.1128/MCB.20.12.4188-4198.2000; Woodcock CL, 2006, CHROMOSOME RES, V14, P17, DOI 10.1007/s10577-005-1024-3; Ye XF, 2003, MOL CELL, V11, P341, DOI 10.1016/S1097-2765(03)00037-6; Zhao XJ, 2004, J CELL SCI, V117, P6043, DOI 10.1242/jcs.01523	38	86	93	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21526	21534		10.1074/jbc.M603816200	http://dx.doi.org/10.1074/jbc.M603816200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16728391	hybrid			2022-12-25	WOS:000239187300087
J	Cvetanovic, M; Mitchell, JE; Patel, V; Avner, BS; Su, Y; Van der Saag, PT; Witte, PL; Fiore, S; Levine, JS; Ucker, DS				Cvetanovic, Marija; Mitchell, Justin E.; Patel, Vimal; Avner, Benjamin S.; Su, Yan; Van der Saag, Paul T.; Witte, Pamela L.; Fiore, Stefano; Levine, Jerrold S.; Ucker, David S.			Specific recognition of apoptotic cells reveals a ubiquitous and unconventional innate immunity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROTIC CELLS; IN-VITRO; MACROPHAGE RECOGNITION; SIGNALING EVENTS; EPITHELIAL-CELLS; RECEPTOR; DEATH; PHAGOCYTOSIS; PHOSPHATIDYLSERINE	The purpose of physiological cell death is the noninflammatory clearance of cells that have become inappropriate or nonfunctional. Consistent with this function, the recognition of apoptotic cells by professional phagocytes, including macrophages and dendritic cells, triggers a set of potent anti-inflammatory responses manifest on multiple levels. The immediate-early inhibition of proinflammatory cytokine gene transcription in the phagocyte is a proximate consequence of recognition of the apoptotic corpse, independent of subsequent engulfment and soluble factor involvement. Here, we show that recognition is linked to a characteristic signature of responses, including MAPK signaling events and the ablation of proinflammatory transcription and cytokine secretion. Specific recognition and response occurs without regard to the origin ( species, tissue type, or suicidal stimulus) of the apoptotic cell and does not involve Toll-like receptor signaling. These features mark this as an innate immunity fundamentally distinct from the discrimination of "self" versus "other" considered to be the hallmark of conventional immunity. This profound unconventional innate immune discrimination of effete from live cells is as ubiquitous as apoptotic cell death itself, manifest by professional and nonprofessional phagocytes and nonphagocytic cell types alike. Innate apoptotic immunity provides an intrinsic anti-inflammatory circuit that attenuates proinflammatory responses dynamically and may act systemically as a powerful physiological regulator of immunity.	Univ Illinois, Coll Med, Dept Microbiol & Immunol MC 790, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Med, Nephrol Sect, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Med, Rheumatol Sect, Chicago, IL 60612 USA; Loyola Univ, Dept Cell Biol Neurol & Anat, Immunol & Aging Program, Maywood, IL 60153 USA; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Loyola University Chicago; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Ucker, DS (corresponding author), Univ Illinois, Coll Med, Dept Microbiol & Immunol MC 790, 835 S Wolcott, Chicago, IL 60612 USA.	duck@uic.edu			NIAID NIH HHS [T32 AI007343] Funding Source: Medline; NIA NIH HHS [AG024234] Funding Source: Medline; NIDDK NIH HHS [DK59793] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059793] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG024234] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Arur S, 2003, DEV CELL, V4, P587, DOI 10.1016/S1534-5807(03)00090-X; Bannister AJ, 1995, ONCOGENE, V11, P2509; Baumann NA, 2000, J BIOL CHEM, V275, P7378, DOI 10.1074/jbc.275.10.7378; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Benkoussa M, 2002, MOL CELL BIOL, V22, P4522, DOI 10.1128/MCB.22.13.4522-4534.2002; Byrne A, 2002, J IMMUNOL, V168, P1968, DOI 10.4049/jimmunol.168.4.1968; Chang SH, 2002, EXP CELL RES, V277, P15, DOI 10.1006/excr.2002.5539; Cocco RE, 2001, MOL BIOL CELL, V12, P919, DOI 10.1091/mbc.12.4.919; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Cvetanovic M, 2004, J IMMUNOL, V172, P880, DOI 10.4049/jimmunol.172.2.880; Fadok VA, 2001, J BIOL CHEM, V276, P1071, DOI 10.1074/jbc.M003649200; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; Harvey KJ, 2001, CYTOMETRY, V43, P273, DOI 10.1002/1097-0320(20010401)43:4<273::AID-CYTO1059>3.0.CO;2-3; Hoffmann PR, 2001, J CELL BIOL, V155, P649, DOI 10.1083/jcb.200108080; HOLOWKA D, 1983, BIOCHEMISTRY-US, V22, P3466, DOI 10.1021/bi00283a025; Hoshino K, 1999, J IMMUNOL, V162, P3749; Huang FP, 2000, J EXP MED, V191, P435, DOI 10.1084/jem.191.3.435; Hughes J, 1997, J IMMUNOL, V158, P4389; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim SJ, 2004, IMMUNITY, V21, P643, DOI 10.1016/j.immuni.2004.09.009; Kurt-Jones EA, 2004, J ENDOTOXIN RES, V10, P419, DOI 10.1179/096805104225006516; Lamioni A, 2005, TRANSPLANTATION, V79, P846, DOI 10.1097/01.TP.0000157278.02848.C7; Marguet D, 1999, NAT CELL BIOL, V1, P454, DOI 10.1038/15690; McDonald PP, 1999, J IMMUNOL, V163, P6164; MEAGHER LC, 1992, J LEUKOCYTE BIOL, V52, P269, DOI 10.1002/jlb.52.3.269; Mitchell JE, 2006, J BIOL CHEM, V281, P5718, DOI 10.1074/jbc.M509775200; Moffatt OD, 1999, J IMMUNOL, V162, P6800; Monks J, 2005, CELL DEATH DIFFER, V12, P107, DOI 10.1038/sj.cdd.4401517; Parnaik R, 2000, CURR BIOL, V10, P857, DOI 10.1016/S0960-9822(00)00598-4; Patel VA, 2006, J BIOL CHEM, V281, P4663, DOI 10.1074/jbc.M508342200; Reddy SM, 2002, J IMMUNOL, V169, P702, DOI 10.4049/jimmunol.169.2.702; ROBERTSON AMG, 1982, J EMBRYOL EXP MORPH, V67, P89; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Sodin-Semrl S, 2004, INT J IMMUNOPATH PH, V17, P145, DOI 10.1177/039463200401700206; Suchin KR, 1999, J AM ACAD DERMATOL, V41, P980, DOI 10.1016/S0190-9622(99)70257-4; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tosello-Trampont AC, 2001, J BIOL CHEM, V276, P13797, DOI 10.1074/jbc.M011238200; TUCKER KA, 1987, BLOOD, V70, P372; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wissink S, 1997, IMMUNOBIOLOGY, V198, P50, DOI 10.1016/S0171-2985(97)80026-5; Wood W, 2000, DEVELOPMENT, V127, P5245; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xiao YQ, 2002, J BIOL CHEM, V277, P14884, DOI 10.1074/jbc.M111718200	53	66	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20055	20067		10.1074/jbc.M603920200	http://dx.doi.org/10.1074/jbc.M603920200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16707494	hybrid			2022-12-25	WOS:000239038200030
J	Obreztchikova, M; Elouardighi, H; Ho, M; Wilson, BA; Gertsberg, Z; Steinberg, SF				Obreztchikova, Maria; Elouardighi, Hasnae; Ho, Mengfei; Wilson, Brenda A.; Gertsberg, Zoya; Steinberg, Susan F.			Distinct signaling functions for Shc isoforms in the heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PASTEURELLA-MULTOCIDA TOXIN; GROWTH-FACTOR RECEPTOR; CARDIAC FIBROBLASTS; KINASE ACTIVATION; DNA-SYNTHESIS; LIFE-SPAN; PATHWAY; PHOSPHORYLATION; APOPTOSIS; P66SHC	Thrombin activates protease-activated receptor-1 (PAR-1) and engages signaling pathways that influence the growth and survival of cardiomyocytes as well as extracellular matrix remodeling by cardiac fibroblasts. This study examines the role of Shc proteins in PAR-1-dependent signaling pathways that influence ventricular remodeling. We show that thrombin increases p46Shc/p52Shc phosphorylation at Tyr(239)/Tyr(240) and Tyr(317) (and p66Shc-Ser(36) phosphorylation) via a pertussis toxin-insensitive epidermal growth factor receptor (EGFR) transactivation pathway in cardiac fibroblasts; p66Shc-Ser(36) phosphorylation is via a MEK-dependent mechanism. In contrast, cardiac fibroblasts express beta(2)-adrenergic receptors that activate ERK through a pertussis toxin-sensitive EGFR transactivation pathway that does not involve Shc isoforms or lead to p66Shc-Ser(36) phosphorylation. In cardiomyocytes, thrombin triggers MEK-dependent p66Shc-Ser(36) phosphorylation, but this is not via EGFR transactivation (or associated with Shc-Tyr(239)/Tyr(240) and/or Tyr(317) phosphorylation). Importantly, p66Shc protein expression is detected in neonatal, but not adult, cardiomyocytes; p66Shc expression is induced ( via a mechanism that requires protein kinase C and MEK activity) by Pasteurella multocida toxin, a G alpha(q) agonist that promotes cardiomyocyte hypertrophy. These results identify novel regulation of individual Shc isoforms in receptor-dependent pathways leading to cardiac hypertrophy and the transition to heart failure. The observations that p66Shc expression is induced by a G alpha(q) agonist and that PAR-1 activation leads to p66Shc-Ser(36) phosphorylation identifies p66Shc as a novel candidate hypertrophy-induced mediator of cardiomyocyte apoptosis and heart failure.	Columbia Univ, Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	Columbia University; University of Illinois System; University of Illinois Urbana-Champaign	Steinberg, SF (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pharmacol, 630 W 168th St, New York, NY 10032 USA.	sfs1@columbia.edu	Ho, Mengfei/Q-6844-2019	Ho, Mengfei/0000-0002-8315-8158	NHLBI NIH HHS [HL77860, R01 HL077860, R01 HL064639, HL-64639] Funding Source: Medline; NIAID NIH HHS [R29 AI038396, AI038396, R01 AI038396] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064639, R01HL077860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI038396, R01AI038396] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams JW, 2000, CIRC RES, V87, P1180, DOI 10.1161/01.RES.87.12.1180; Bapat S, 2001, FEBS LETT, V499, P21, DOI 10.1016/S0014-5793(01)02511-X; Cesselli D, 2001, CIRC RES, V89, P279, DOI 10.1161/hh1501.094115; Collins LR, 1997, ONCOGENE, V15, P595, DOI 10.1038/sj.onc.1201220; Faisal A, 2002, J BIOL CHEM, V277, P30144, DOI 10.1074/jbc.M203229200; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Graiani G, 2005, HYPERTENSION, V46, P433, DOI 10.1161/01.HYP.0000174986.73346.ba; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; Jorgensen K, 2005, BIOCHEM BIOPH RES CO, V329, P266, DOI 10.1016/j.bbrc.2005.01.143; KHANDAY FA, 2005, MOL BIOL CELL; Kim J, 2002, J BIOL CHEM, V277, P32116, DOI 10.1074/jbc.M204895200; Kodama H, 2002, J MOL CELL CARDIOL, V34, P139, DOI 10.1006/jmcc.2001.1496; Le S, 2001, J BIOL CHEM, V276, P48332, DOI 10.1074/jbc.M106612200; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; Orsini F, 2004, J BIOL CHEM, V279, P25689, DOI 10.1074/jbc.M401844200; Pacini S, 2004, MOL CELL BIOL, V24, P1747, DOI 10.1128/MCB.24.4.1747-1757.2004; PELICCI G, 1995, ONCOGENE, V11, P899; Pellegrini M, 2005, APOPTOSIS, V10, P13, DOI 10.1007/s10495-005-6057-8; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Ricketts WA, 1999, MOL ENDOCRINOL, V13, P1988, DOI 10.1210/me.13.12.1988; Sabri A, 2002, CIRC RES, V90, P850, DOI 10.1161/01.RES.0000016165.23795.1F; Sabri A, 2002, CIRC RES, V91, P532, DOI 10.1161/01.RES.0000035242.96310.45; Suenaga A, 2004, J BIOL CHEM, V279, P4657, DOI 10.1074/jbc.M310598200; Tapinos N, 2005, P NATL ACAD SCI USA, V102, P9188, DOI 10.1073/pnas.0501196102; Trinei M, 2002, ONCOGENE, V21, P3872, DOI 10.1038/sj.onc.1205513; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Ventura A, 2002, J BIOL CHEM, V277, P22370, DOI 10.1074/jbc.M200280200; Wilson BA, 1999, INFECT IMMUN, V67, P80, DOI 10.1128/IAI.67.1.80-87.1999	31	30	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2006	281	29					20197	20204		10.1074/jbc.M601859200	http://dx.doi.org/10.1074/jbc.M601859200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	063RV	16699171	Green Accepted, hybrid			2022-12-25	WOS:000239038200044
J	Dreux, M; Pietschmann, T; Granier, C; Voisset, C; Ricard-Blum, S; Mangeot, PE; Keck, Z; Foung, S; Vu-Dac, N; Dubuisson, J; Bartenschlager, R; Lavillette, D; Cosset, FL				Dreux, Marlene; Pietschmann, Thomas; Granier, Christelle; Voisset, Cecile; Ricard-Blum, Sylvie; Mangeot, Philippe-Emmanuel; Keck, Zhenyong; Foung, Steven; Vu-Dac, Ngoc; Dubuisson, Jean; Bartenschlager, Ralf; Lavillette, Dimitri; Cosset, Francois-Loic			High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E2 ENVELOPE GLYCOPROTEIN; HUMAN MONOCLONAL-ANTIBODIES; HYPERVARIABLE REGION 1; VIRAL-INFECTION; IN-VITRO; VERY-LOW; RECOMBINANT VACCINIA; FUNCTIONAL-ANALYSIS; HYPERIMMUNE SERUM; MEMBRANE-FUSION	Hepatitis C virus (HCV) exploits serum-dependent mechanisms that inhibit neutralizing antibodies. Here we demonstrate that high density lipoprotein (HDL) is a key serum factor that attenuates neutralization by monoclonal and HCV patient-derived polyclonal antibodies of infectious pseudo-particles (HCVpp) harboring authentic E1E2 glycoproteins and cell culture-grown genuine HCV (HCVcc). Over 10-fold higher antibody concentrations are required to neutralize either HCV-enveloped particles in the presence of HDL or human serum, and less than 3-5-fold reduction of infectious titers are obtained at saturating antibody concentrations, in contrast to complete inhibition in serum-free conditions. We show that HDL interaction with the scavenger receptor BI (SR-BI), a proposed cell entry co-factor of HCV and a receptor mediating lipid transfer with HDL, strongly reduces neutralization of HCVpp and HCVcc. We found that HDL activation of target cells strongly stimulates cell entry of viral particles by accelerating their endocytosis, thereby suppressing a 1-h time lag during which cell-bound virions are not internalized and can be targeted by antibodies. Compounds that inhibit lipid transfer functions of SR-BI fully restore neutralization by antibodies in human serum. We demonstrate that this functional HDL/SR-BI interaction only interferes with antibodies blocking HCV-E2 binding to CD81, a major HCV receptor, reflecting its prominent role during the cell entry process. Moreover, we identify monoclonal antibodies targeted to epitopes in the E1E2 complex that are not inhibited by HDL. Consistently, we show that antibodies targeted to HCV-E1 efficiently neutralize HCVpp and HCVcc in the presence of human serum.	ENS Lyon, F-69007 Lyon, France; INSERM, U758, F-69007 Lyon, France; BioSci Lyon Gerland, IFR128, F-69007 Lyon, France; Univ Heidelberg, Dept Mol Virol, D-69120 Heidelberg, Germany; Inst Pasteur, CNRS, UPR2511, F-59021 Lille, France; UCB Lyon 1, UMR5086, IBCP, F-69007 Lyon, France; Epixis SA, F-69007 Lyon, France; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Ecole Normale Superieure de Lyon (ENS de LYON); Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Ruprecht Karls University Heidelberg; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Stanford University	Cosset, FL (corresponding author), ENS Lyon, 46 Allee Italie, F-69007 Lyon, France.	flcosset@neuf.fr	Cosset, François-Loïc/M-5862-2019; Pietschmann, Thomas/E-9241-2015; Dreux, Marlene/M-7295-2014; Voisset, Cecile/AAK-1636-2020; Bartenschlager, Ralf/L-2582-2015; Dubuisson, Jean/E-6813-2016	Cosset, François-Loïc/0000-0001-8842-3726; Pietschmann, Thomas/0000-0001-5138-6239; Dreux, Marlene/0000-0002-6607-4796; RICARD-BLUM, Sylvie/0000-0001-9263-1851; Foung, Steven/0000-0001-7149-6160; Bartenschlager, Ralf/0000-0001-5601-9307; Lavillette, Dimitri/0000-0002-4706-1519; Voisset, Cecile/0000-0001-7505-1927; Christelle, GRANIER/0000-0001-8987-0632; Dubuisson, Jean/0000-0003-1626-7693; MANGEOT, Philippe/0000-0003-3819-5440	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047355] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL079381] Funding Source: Medline; NIAID NIH HHS [AI47355] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; Andre P, 2002, J VIROL, V76, P6919, DOI 10.1128/JVI.76.14.6919-6928.2002; Barth H, 2005, J VIROL, V79, P5774, DOI 10.1128/JVI.79.9.5774-5785.2005; Bartosch B, 2006, VIROLOGY, V348, P1, DOI 10.1016/j.virol.2005.12.027; Bartosch B, 2005, J VIROL, V79, P8217, DOI 10.1128/JVI.79.13.8217-8229.2005; Bartosch B, 2003, J BIOL CHEM, V278, P41624, DOI 10.1074/jbc.M305289200; Bartosch B, 2003, P NATL ACAD SCI USA, V100, P14199, DOI 10.1073/pnas.2335981100; Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756; Baumert TF, 1998, J VIROL, V72, P3827, DOI 10.1128/JVI.72.5.3827-3836.1998; Bowen DG, 2005, NATURE, V436, P946, DOI 10.1038/nature04079; BRADLEY D, 1991, J MED VIROL, V34, P206, DOI 10.1002/jmv.1890340315; Burton DR, 2002, NAT REV IMMUNOL, V2, P706, DOI 10.1038/nri891; Calvo D, 1997, ARTERIOSCL THROM VAS, V17, P2341, DOI 10.1161/01.ATV.17.11.2341; Charrin S, 2003, EUR J IMMUNOL, V33, P2479, DOI 10.1002/eji.200323884; Chisholm JW, 2002, J LIPID RES, V43, P36; Cormier EG, 2004, P NATL ACAD SCI USA, V101, P7270, DOI 10.1073/pnas.0402253101; De Beeck AO, 2004, J VIROL, V78, P2994, DOI 10.1128/JVI.78.6.2994-3002.2004; Deleersnyder V, 1997, J VIROL, V71, P697, DOI 10.1128/JVI.71.1.697-704.1997; Drummer HE, 2003, FEBS LETT, V546, P385, DOI 10.1016/S0014-5793(03)00635-5; DUBUISSON J, 1994, J VIROL, V68, P6147, DOI 10.1128/JVI.68.10.6147-6160.1994; Farci P, 1996, P NATL ACAD SCI USA, V93, P15394, DOI 10.1073/pnas.93.26.15394; Farci P, 2000, SCIENCE, V288, P339, DOI 10.1126/science.288.5464.339; FARCI P, 1994, P NATL ACAD SCI USA, V91, P7792, DOI 10.1073/pnas.91.16.7792; Flint M, 1999, J VIROL, V73, P6782, DOI 10.1128/JVI.73.8.6782-6790.1999; Flint M, 1999, J VIROL, V73, P6235, DOI 10.1128/JVI.73.8.6235-6244.1999; Garry RF, 2003, VIROLOGY, V307, P255, DOI 10.1016/S0042-6822(02)00065-X; Hadlock KG, 2000, J VIROL, V74, P10407, DOI 10.1128/JVI.74.22.10407-10416.2000; Heo TH, 2004, J IMMUNOL, V173, P446, DOI 10.4049/jimmunol.173.1.446; HIJIKATA M, 1993, J VIROL, V67, P1953, DOI 10.1128/JVI.67.4.1953-1958.1993; Hsu M, 2003, P NATL ACAD SCI USA, V100, P7271, DOI 10.1073/pnas.0832180100; Ishii K, 1998, HEPATOLOGY, V28, P1117, DOI 10.1002/hep.510280429; KANTO T, 1995, J HEPATOL, V22, P440, DOI 10.1016/0168-8278(95)80107-3; Keck ZY, 2005, J VIROL, V79, P13199, DOI 10.1128/JVI.79.21.13199-13208.2005; Keck ZY, 2004, J VIROL, V78, P7257, DOI 10.1128/JVI.78.13.7257-7263.2004; Kizhatil K, 1997, J VIROL, V71, P7145, DOI 10.1128/JVI.71.10.7145-7156.1997; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Lagging LM, 1998, J VIROL, V72, P3539, DOI 10.1128/JVI.72.5.3539-3546.1998; Lavillette D, 2006, J BIOL CHEM, V281, P3909, DOI 10.1074/jbc.M509747200; Lavillette D, 2005, J VIROL, V79, P6023, DOI 10.1128/JVI.79.10.6023-6034.2005; Lavillette D, 2005, HEPATOLOGY, V41, P265, DOI 10.1002/hep.20542; Lavillette D, 2001, J VIROL, V75, P3685, DOI 10.1128/JVI.75.8.3685-3695.2001; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; LINDENBACH BD, 2001, FIELDS VIROLOGY, P991; Logvinoff C, 2004, P NATL ACAD SCI USA, V101, P10149, DOI 10.1073/pnas.0403519101; Lohmann V, 2003, J VIROL, V77, P3007, DOI 10.1128/JVI.77.5.3007-3019.2003; Maillard P, 2006, FASEB J, V20, P735, DOI 10.1096/fj.05-4728fje; McKeating JA, 2004, J VIROL, V78, P8496, DOI 10.1128/JVI.78.16.8496-8505.2004; Meunier JC, 2005, P NATL ACAD SCI USA, V102, P4560, DOI 10.1073/pnas.0501275102; Monazahian M, 2000, MED MICROBIOL IMMUN, V188, P177, DOI 10.1007/s004300000032; Nieland TJF, 2004, J LIPID RES, V45, P1256, DOI 10.1194/jlr.M300358-JLR200; Nielsen SU, 2006, J VIROL, V80, P2418, DOI 10.1128/JVI.80.5.2418-2428.2006; Orland JR, 2001, HEPATOLOGY, V33, P321, DOI 10.1053/jhep.2001.22112; Owsianka A, 2005, J VIROL, V79, P11095, DOI 10.1128/JVI.79.17.11095-11104.2005; Owsianka A, 2001, J GEN VIROL, V82, P1877, DOI 10.1099/0022-1317-82-8-1877; Pagler TA, 2006, J BIOL CHEM, V281, P11193, DOI 10.1074/jbc.M510261200; Patel AH, 2000, J GEN VIROL, V81, P2873, DOI 10.1099/0022-1317-81-12-2873; Peng Y, 2004, MOL BIOL CELL, V15, P384, DOI 10.1091/mbc.e03-06-0445; Penin F, 2001, J VIROL, V75, P5703, DOI 10.1128/JVI.75.12.5703-5710.2001; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Prince AM, 1996, J VIRAL HEPATITIS, V3, P11, DOI 10.1111/j.1365-2893.1996.tb00075.x; RALSTON R, 1993, J VIROL, V67, P6753, DOI 10.1128/JVI.67.11.6753-6761.1993; Ricard-Blum S, 2002, J BIOL CHEM, V277, P33864, DOI 10.1074/jbc.M205018200; Roingeard P, 2004, BIOL CELL, V96, P103, DOI 10.1016/j.biolcel.2003.11.006; Sandrin V, 2002, BLOOD, V100, P823, DOI 10.1182/blood-2001-11-0042; Scarselli E, 2002, EMBO J, V21, P5017, DOI 10.1093/emboj/cdf529; Schofield DJ, 2005, HEPATOLOGY, V42, P1055, DOI 10.1002/hep.20906; Seymour A, 2001, Manag Care, V10, P11; Shimizu YK, 1996, VIROLOGY, V223, P409, DOI 10.1006/viro.1996.0497; SHIMIZU YK, 1994, J VIROL, V68, P1494, DOI 10.1128/JVI.68.3.1494-1500.1994; THOMSSEN R, 1993, MED MICROBIOL IMMUN, V182, P329; Triyatni M, 2002, J VIROL, V76, P9335, DOI 10.1128/JVI.76.18.9335-9344.2002; Voisset C, 2005, J BIOL CHEM, V280, P7793, DOI 10.1074/jbc.M411600200; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Yu MYW, 2004, P NATL ACAD SCI USA, V101, P7705, DOI 10.1073/pnas.0402458101; Zhang J, 2004, J VIROL, V78, P1448, DOI 10.1128/JVI.78.3.1448-1455.2004; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102; Zimetti F, 2006, J LIPID RES, V47, P605, DOI 10.1194/jlr.M500466-JLR200; Zucchelli S, 2001, HEPATOLOGY, V33, P692, DOI 10.1053/jhep.2001.22175	78	173	182	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18285	18295		10.1074/jbc.M602706200	http://dx.doi.org/10.1074/jbc.M602706200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16675450	hybrid			2022-12-25	WOS:000238687300005
J	Van den Steen, PE; Van Aelst, I; Hvidberg, V; Piccard, H; Fiten, P; Jacobsen, C; Moestrup, SK; Fry, S; Royle, L; Wormald, MR; Wallis, R; Rudd, PM; Dwek, RA; Opdenakker, G				Van den Steen, Philippe E.; Van Aelst, Ilse; Hvidberg, Vibeke; Piccard, Helene; Fiten, Pierre; Jacobsen, Christian; Moestrup, Soren K.; Fry, Simon; Royle, Louise; Wormald, Mark R.; Wallis, Russell; Rudd, Pauline M.; Dwek, Raymond A.; Opdenakker, Ghislain			The hemopexin and O-glycosylated domains tune gelatinase B/MMP-9 bioavailability via inhibition and binding to cargo receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESORPTION/IONIZATION MASS-SPECTROMETRY; COLLAGEN TYPE-II; MATRIX METALLOPROTEINASES; NEUTROPHIL-GELATINASE; LINKED OLIGOSACCHARIDES; REMNANT EPITOPES; TISSUE INHIBITOR; TERMINAL DOMAIN; IV COLLAGENASE; PROTEIN	Gelatinase B/matrix metalloproteinase-9 (MMP-9), a key regulator and effector of immunity, contains a C-terminal hemopexin domain preceded by a unique linker sequence of similar to 64 amino acid residues. This linker sequence is demonstrated to be an extensively O-glycosylated (OG) domain with a compact three-dimensional structure. The OG and hemopexin domains have no influence on the cleavage efficiency of MMP-9 substrates. In contrast, the hemopexin domain contains a binding site for the cargo receptor low density lipoprotein receptor-related protein-1 (LRP-1). Furthermore, megalin/LRP-2 is identified as a new functional receptor for the hemopexin domain of MMP-9, able to mediate the endocytosis and catabolism of the enzyme. The OG domain is required to correctly orient the hemopexin domain for inhibition by TIMP-1 and internalization by LRP-1 and megalin. Therefore, the OG and hemopexin domains down-regulate the bioavailability of active MMP-9 and the interactions with the cargo receptors are proposed to be the original function of hemopexin domains in MMPs.	Katholieke Univ Leuven, Rega Inst Med Res, Immunobiol Lab, B-3000 Louvain, Belgium; Univ Aarhus, Dept Biochem Med, DK-8000 Aarhus C, Denmark; Univ Oxford, Oxford Glycobiol Inst, Oxford OX1 3QU, England; Univ Oxford, MRC, Immunochem Unit, Dept Biochem, Oxford OX1 3QU, England; Univ Leicester, Dept Infect Immun & Inflammat, Leicester LE1 9HN, Leics, England	KU Leuven; Aarhus University; University of Oxford; University of Oxford; University of Leicester	Opdenakker, G (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Immunobiol Lab, Minderbroedersstr 10, B-3000 Louvain, Belgium.	ghislain.opdenakker@rega.kuleuven.be	Moestrup, Søren Kragh/A-1403-2014; Wormald, Mark R/G-2785-2011; Opdenakker, Ghislain/Q-3130-2017; Van den Steen, Philippe E/K-5132-2012; Opdenakker, Ghislain/V-8562-2019; Moestrup, Søren Kragh/AAD-1735-2019	Moestrup, Søren Kragh/0000-0003-3862-2107; Wormald, Mark R/0000-0002-4853-2773; Opdenakker, Ghislain/0000-0003-1714-2294; Van den Steen, Philippe E/0000-0002-7334-9145; Opdenakker, Ghislain/0000-0003-1714-2294; Wallis, Russell/0000-0002-8705-5295				ALLAN JA, 1995, BIOCHEM J, V309, P299, DOI 10.1042/bj3090299; Barmina OY, 1999, J BIOL CHEM, V274, P30087, DOI 10.1074/jbc.274.42.30087; BIGGE JC, 1995, ANAL BIOCHEM, V230, P229, DOI 10.1006/abio.1995.1468; de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6; Descamps FJ, 2005, FASEB J, V19, P29, DOI 10.1096/fj.04-1837com; DESROCHERS PE, 1992, J BIOL CHEM, V267, P5005; Elkins PA, 2002, ACTA CRYSTALLOGR D, V58, P1182, DOI 10.1107/S0907444902007849; Emonard H, 2004, J BIOL CHEM, V279, P54944, DOI 10.1074/jbc.M406792200; Fiore E, 2002, ONCOGENE, V21, P5213, DOI 10.1038/sj.onc.1205684; Guile GR, 1996, ANAL BIOCHEM, V240, P210, DOI 10.1006/abio.1996.0351; Hahn-Dantona E, 2001, J BIOL CHEM, V276, P15498, DOI 10.1074/jbc.M100121200; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Huang YP, 2002, RAPID COMMUN MASS SP, V16, P1199, DOI 10.1002/rcm.701; Hvidberg V, 2005, BLOOD, V106, P2572, DOI 10.1182/blood-2005-03-1185; Hvidberg V, 2005, FEBS LETT, V579, P773, DOI 10.1016/j.febslet.2004.12.031; Julenius K, 2005, GLYCOBIOLOGY, V15, P153, DOI 10.1093/glycob/cwh151; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Kotra LP, 2002, BIOORG CHEM, V30, P356, DOI 10.1016/S0045-2068(02)00501-1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuster B, 1997, ANAL BIOCHEM, V250, P82, DOI 10.1006/abio.1997.2199; Lauer-Fields JL, 2002, BIOPOLYMERS, V66, P19, DOI 10.1002/bip.10201; Maskos K, 2003, MOL BIOTECHNOL, V25, P241, DOI 10.1385/MB:25:3:241; MASURE S, 1991, EUR J BIOCHEM, V198, P391, DOI 10.1111/j.1432-1033.1991.tb16027.x; Mattu TS, 2000, BIOCHEMISTRY-US, V39, P15695, DOI 10.1021/bi001367j; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; Moestrup SK, 2001, ANNU REV NUTR, V21, P407, DOI 10.1146/annurev.nutr.21.1.407; Monferran S, 2004, EMBO J, V23, P3758, DOI 10.1038/sj.emboj.7600403; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; OCHIENG J, 1994, BIOCHEMISTRY-US, V33, P14109, DOI 10.1021/bi00251a020; OCONNELL JP, 1994, J BIOL CHEM, V269, P14967; Opdenakker G, 2001, TRENDS IMMUNOL, V22, P571, DOI 10.1016/S1471-4906(01)02023-3; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; Petrescu AJ, 2004, GLYCOBIOLOGY, V14, P103, DOI 10.1093/glycob/cwh008; Royle L, 2002, ANAL BIOCHEM, V304, P70, DOI 10.1006/abio.2002.5619; Rudd PM, 1999, BIOCHEMISTRY-US, V38, P13937, DOI 10.1021/bi991162e; Sasaki T, 1997, J BIOL CHEM, V272, P9237; Sheu BC, 2001, CANCER RES, V61, P237; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; Van den Steen PE, 2004, BIOCHEMISTRY-US, V43, P10809, DOI 10.1021/bi0493665; Van den Steen PE, 2003, EUR J BIOCHEM, V270, P3739, DOI 10.1046/j.1432-1033.2003.03760.x; Van Den Steen PE, 2002, FASEB J, V16, DOI 10.1096/fj.01-0688com; Van den Steen PE, 2001, BBA-GEN SUBJECTS, V1528, P61, DOI 10.1016/S0304-4165(01)00190-8; Van den Steen PE, 2000, BLOOD, V96, P2673, DOI 10.1182/blood.V96.8.2673.h8002673_2673_2681; VANRANST M, 1991, CYTOKINE, V3, P231, DOI 10.1016/1043-4666(91)90021-5; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Wormald MR, 2002, CHEM REV, V102, P371, DOI 10.1021/cr990368i; Wu YI, 2004, J BIOL CHEM, V279, P8278, DOI 10.1074/jbc.M311870200; Yang ZT, 2001, J BIOL CHEM, V276, P8403, DOI 10.1074/jbc.M008925200	54	146	151	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18626	18637		10.1074/jbc.M512308200	http://dx.doi.org/10.1074/jbc.M512308200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16672230	hybrid			2022-12-25	WOS:000238687300042
J	Wirth, HP; Yang, MQ; Sanabria-Valentin, E; Berg, DE; Dubois, A; Blaser, MJ				Wirth, Hans-Peter; Yang, Manqiao; Sanabria-Valentin, Edgardo; Berg, Douglas E.; Dubois, Andre; Blaser, Martin J.			Host Lewis phenotype-dependent Helicobacter pylori Lewis antigen expression in rhesus monkeys	FASEB JOURNAL			English	Article						bacterial pathogenesis; evolution; genetics; colonization; phase variation	BLOOD-GROUP ANTIGENS; EXPERIMENTAL-INFECTION; MONOCLONAL-ANTIBODIES; FUCOSYL-TRANSFERASE; NONHUMAN-PRIMATES; GENETIC DIVERSITY; PHASE VARIATION; MOUSE MODEL; O ANTIGEN; LIPOPOLYSACCHARIDE	Both human and H. pylori populations are polymorphic for the expression of Lewis antigens. Using an experimental H. pylori challenge of rhesus monkeys of differing Lewis phenotypes, we aimed to determine whether H. pylori populations adapt their Lewis phenotypes to those of their hosts. After inoculation of four monkeys with a mixture of seven strains identified by RAPD-polymerase chain reaction, H. pylori Lewis expression was followed in 86 isolates obtained over 40 wk. Host Lewis(a/b) secretion status was characterized by immunological assays. Fingerprints of the predominating strain (J166) were identical in all four animals after 40 wk, but its Lewis phenotype had substantial variability in individual hosts. At 40 wk, J166 populations from two Lewis(a-b+) animals predominantly expressed Lewis(y). In contrast, J166 populations had switched to a Lewis(x) dominant phenotype in the two Lewis(a+b-) animals; a frame shift in futC, regulating conversion of Lewis(x) to Lewis(y), accounted for the phenotypic switch. The results indicate that individual cells in H. pylori populations can change Lewis phenotypes during long-term colonization of natural hosts to resemble those of their hosts, providing evidence for host selection for bacterial phenotypes.	NYU, Sch Med, Dept Med, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; VA Med Ctr, New York, NY 10016 USA; Univ Zurich, Sch Med, Div Gastroenterol, Zurich, Switzerland; Vanderbilt Univ, Sch Med, Div Infect Dis, Nashville, TN USA; VA Med Ctr, Nashville, TN USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO USA; Uniformed Serv Univ Hlth Sci, Dept Med, Div Digest Dis, Lab Gastrointestinal & Liver Studies, Bethesda, MD 20814 USA	New York University; New York University; University of Zurich; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Washington University (WUSTL); Washington University (WUSTL); Uniformed Services University of the Health Sciences - USA	Blaser, MJ (corresponding author), NYU, Sch Med, Dept Med, 550 1St Ave, New York, NY 10016 USA.	martin.blaser@med.nyu.edu			NCI NIH HHS [R01 CA082312-06, R01 CA082312, R01 CA82312] Funding Source: Medline; NIAID NIH HHS [AI38166] Funding Source: Medline; NIDDK NIH HHS [P30 DK052574, R01DK53707, P30DK52574, DK53727] Funding Source: Medline; NIGMS NIH HHS [GM63270, R01 GM063270] Funding Source: Medline; CGH CDC HHS [GH070098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053707, P30DK052574, R01DK053727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063270] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); CGH CDC HHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKOPYANZ N, 1992, NUCLEIC ACIDS RES, V20, P5137, DOI 10.1093/nar/20.19.5137; AKOPYANZ N, 1992, NUCLEIC ACIDS RES, V20, P6221, DOI 10.1093/nar/20.23.6221; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Amano K, 1997, CLIN DIAGN LAB IMMUN, V4, P540, DOI 10.1128/CDLI.4.5.540-544.1997; Appelmelk BJ, 1999, INFECT IMMUN, V67, P5361, DOI 10.1128/IAI.67.10.5361-5366.1999; Appelmelk BJ, 1998, INFECT IMMUN, V66, P70, DOI 10.1128/IAI.66.1.70-76.1998; Appelmelk BJ, 1996, INFECT IMMUN, V64, P2031, DOI 10.1128/IAI.64.6.2031-2040.1996; Aras RA, 2003, P NATL ACAD SCI USA, V100, P13579, DOI 10.1073/pnas.1735481100; Aras RA, 2003, J INFECT DIS, V188, P486, DOI 10.1086/377098; ASPINALL GO, 1994, CARBOHYDR LETT, V0001; Aspinall GO, 1996, BIOCHEMISTRY-US, V35, P2489, DOI 10.1021/bi951852s; Aspinall GO, 1996, BIOCHEMISTRY-US, V35, P2498, DOI 10.1021/bi951853k; Blaser MJ, 2004, J CLIN INVEST, V113, P321, DOI [10.1172/JCI200420925, 10.1172/JCI20925]; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; CHAN NWC, 1995, GLYCOBIOLOGY, V5, P683, DOI 10.1093/glycob/5.7.683; Claeys D, 1998, GASTROENTEROLOGY, V115, P340, DOI 10.1016/S0016-5085(98)70200-8; DAVIDSON JS, 1992, GASTROENTEROLOGY, V103, P1552, DOI 10.1016/0016-5085(92)91177-6; Dubois A, 1999, GASTROENTEROLOGY, V116, P90, DOI 10.1016/S0016-5085(99)70232-5; Dubois A, 1996, INFECT IMMUN, V64, P2885, DOI 10.1128/IAI.64.8.2885-2891.1996; Dubois A, 1998, J GASTROENTEROL, V33, P18, DOI 10.1007/PL00009961; FALK PG, 1995, P NATL ACAD SCI USA, V92, P1515, DOI 10.1073/pnas.92.5.1515; Falush D, 2001, P NATL ACAD SCI USA, V98, P15056, DOI 10.1073/pnas.251396098; Ge ZM, 1997, J BIOL CHEM, V272, P21357, DOI 10.1074/jbc.272.34.21357; Gibson JR, 1998, LETT APPL MICROBIOL, V26, P399, DOI 10.1046/j.1472-765X.1998.00361.x; Guruge JL, 1998, P NATL ACAD SCI USA, V95, P3925, DOI 10.1073/pnas.95.7.3925; HARRIS PA, 1991, MONOGRAPH DADE ED, P22; Heneghan MA, 2000, INFECT IMMUN, V68, P937, DOI 10.1128/IAI.68.2.937-941.2000; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; Israel DA, 2001, P NATL ACAD SCI USA, V98, P14625, DOI 10.1073/pnas.251551698; Kuipers EJ, 2000, J INFECT DIS, V181, P273, DOI 10.1086/315173; Kurtenkov O, 1999, FEMS IMMUNOL MED MIC, V24, P227, DOI 10.1111/j.1574-695X.1999.tb01287.x; LEVIN BR, 1981, GENETICS, V99, P1; Linden S, 2004, BIOCHEM J, V379, P765, DOI 10.1042/BJ20031557; Linden S, 2002, GASTROENTEROLOGY, V123, P1923, DOI 10.1053/gast.2002.37076; LINDEN S, 2003, GASTROENTEROLOGY, V124, pW885; Mahdavi J, 2002, SCIENCE, V297, P573, DOI 10.1126/science.1069076; Martin SL, 1997, J BIOL CHEM, V272, P21349, DOI 10.1074/jbc.272.34.21349; MOLLICONE R, 1985, LAB INVEST, V53, P219; Monteiro MA, 2000, EUR J BIOCHEM, V267, P305, DOI 10.1046/j.1432-1327.2000.01007.x; Monteiro MA, 1998, J BIOL CHEM, V273, P11533, DOI 10.1074/jbc.273.19.11533; MURATA K, 1992, AM J CLIN PATHOL, V98, P67, DOI 10.1093/ajcp/98.1.67; Negrini R, 1996, GASTROENTEROLOGY, V111, P655, DOI 10.1053/gast.1996.v111.pm8780570; ORIOL R, 1986, VOX SANG, V51, P161, DOI 10.1111/j.1423-0410.1986.tb01946.x; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Rasko DA, 2000, J BIOL CHEM, V275, P4988, DOI 10.1074/jbc.275.7.4988; SAKAMOTO J, 1989, CANCER RES, V49, P745; Salama N, 2000, P NATL ACAD SCI USA, V97, P14668, DOI 10.1073/pnas.97.26.14668; Salaun L, 2004, MICROBIOL-SGM, V150, P817, DOI 10.1099/mic.0.26993-0; SHERBURNE R, 1995, INFECT IMMUN, V63, P4564, DOI 10.1128/IAI.63.12.4564-4568.1995; SimoonsSmit IM, 1996, J CLIN MICROBIOL, V34, P2196, DOI 10.1128/JCM.34.9.2196-2200.1996; Socha WW, 1995, J MED PRIMATOL, V24, P282, DOI 10.1111/j.1600-0684.1995.tb00182.x; SOCHA WW, 1983, BLOOD GROUPS PRIMATE, P128; Solnick JV, 2004, P NATL ACAD SCI USA, V101, P2106, DOI 10.1073/pnas.0308573100; Solnick JV, 2001, INFECT IMMUN, V69, P6887, DOI 10.1128/IAI.69.11.6887-6892.2001; Takata T, 2002, INFECT IMMUN, V70, P3073, DOI 10.1128/IAI.70.6.3073-3079.2002; Taylor DE, 1998, GASTROENTEROLOGY, V115, P1113, DOI 10.1016/S0016-5085(98)70082-4; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TORRADO J, 1989, AM J CLIN PATHOL, V91, P249, DOI 10.1093/ajcp/91.3.249; Wang G, 1999, MOL MICROBIOL, V31, P1265, DOI 10.1046/j.1365-2958.1999.01268.x; Wang G, 2000, MOL MICROBIOL, V36, P1187, DOI 10.1046/j.1365-2958.2000.01934.x; Webb GF, 2002, P NATL ACAD SCI USA, V99, P3135, DOI 10.1073/pnas.042685799; Wirth HP, 1997, GASTROENTEROLOGY, V113, P1091, DOI 10.1053/gast.1997.v113.pm9322503; Wirth HP, 1996, INFECT IMMUN, V64, P4598, DOI 10.1128/IAI.64.11.4598-4605.1996; Wirth HP, 1998, INFECT IMMUN, V66, P4856, DOI 10.1128/IAI.66.10.4856-4866.1998; Wirth HP, 1999, J LAB CLIN MED, V133, P488, DOI 10.1016/S0022-2143(99)90026-4; Yokota SI, 1998, INFECT IMMUN, V66, P3006, DOI 10.1128/IAI.66.6.3006-3011.1998	66	28	32	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1534	+		10.1096/fj.05-5529fje	http://dx.doi.org/10.1096/fj.05-5529fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16720729	Green Accepted			2022-12-25	WOS:000240266000042
